Dossier zur Nutzenbewertung gemäß § 35a SGB V

Tezepelumab (Tezspire®)

AstraZeneca GmbH

Modul 4 A – Anhang 4-G-8

Add-on-Erhaltungstherapie bei Erwachsenen und Jugendlichen ab 12 Jahren mit schwerem Asthma, das trotz hochdosierter inhalativer Kortikosteroide plus eines weiteren Arzneimittels zur Erhaltungstherapie unzureichend kontrolliert ist

Zusätzlicher Datenschnitt

Studie NAVIGATOR

RCT mit dem zu bewertenden Arzneimittel

Stand: 11.11.2022

NT2FAC_IOMH0: Course of FEV1 Pre-BD - NAVIGATOR, DITT, DCO 2 4
NT2FAC_IOMC0: Change from baseline in FEV1 Pre-BD - MMRM results - NAVIGATOR, DITT, DCO 2 6
NF2FAC_IOMG0: Course of FEV1 Pre-BD - NAVIGATOR, DITT, DCO 2 7
NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups - NAVIGATOR, DITT, DCO 2 8
NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results - NAVIGATOR, DITT, DCO 2 86
NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups - NAVIGATOR, DITT, DCO 2 125
NT2FAC_IOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results - NAVIGATOR, DITT, DCO 2 185
NT2FAC_KOMH0: Course of FEV1 Pre-BD - NAVIGATOR, DITT-adolescent, DCO 2 215
NT2FAC_KOMC0: Change from baseline in FEV1 Pre-BD - MMRM results - NAVIGATOR, DITT-adolescent, DCO 2 217
NF2FAC_KOMG0: Course of FEV1 Pre-BD - NAVIGATOR, DITT-adolescent, DCO 2 218
NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups - NAVIGATOR, DITT-adolescent, DCO 2 219
NT2FAC_KOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results - NAVIGATOR, DITT-adolescent, DCO 2 293
NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups - NAVIGATOR, DITT-adolescent, DCO 2 319
NT2FAC_KOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results - NAVIGATOR, DITT-adolescent, DCO 2 373
NT2FAC_AOMH0: Course of FEV1 Pre-BD - NAVIGATOR, DITT-adult, DCO 2 391
NT2FAC_AOMC0: Change from baseline in FEV1 Pre-BD - MMRM results - NAVIGATOR, DITT-adult, DCO 2 393
NF2FAC_AOMG0: Course of FEV1 Pre-BD - NAVIGATOR, DITT-adult, DCO 2 394
NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups - NAVIGATOR, DITT-adult, DCO 2 395
NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results - NAVIGATOR, DITT-adult, DCO 2 473
NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups - NAVIGATOR, DITT-adult, DCO 2 509
NT2FAC_AOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results - NAVIGATOR, DITT-adult, DCO 2 563
NT2FAC_ILMH0: Course of FEV1 Pre-BD - NAVIGATOR, DITTL, DCO 2 590
NT2FAC_ILMC0: Change from baseline in FEV1 Pre-BD - MMRM results - NAVIGATOR, DITTL, DCO 2 592
NF2FAC_ILMG0: Course of FEV1 Pre-BD - NAVIGATOR, DITTL, DCO 2 593
NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups - NAVIGATOR, DITTL, DCO 2 594
NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results - NAVIGATOR, DITTL, DCO 2 668
NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups - NAVIGATOR, DITTL, DCO 2 705
NT2FAC_ILSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results - NAVIGATOR, DITTL, DCO 2 765
NF2FAC_ILSHK01: Course of FEV1 Pre-BD by sex - NAVIGATOR, DITTL, DCO 2 795
NF2FAC_ILSHK14: Course of FEV1 Pre-BD by baseline eosinophils - High - NAVIGATOR, DITTL, DCO 2 797

NF2FAC_ILSHK36: Course of FEV1 Pre-BD by OCS at baseline - NAVIGATOR, DITTL, DCO 2 799
NT2FAC_KLMH0: Course of FEV1 Pre-BD - NAVIGATOR, DITTL-adolescent, DCO 2 801
NT2FAC_KLMC0: Change from baseline in FEV1 Pre-BD - MMRM results - NAVIGATOR, DITTL-adolescent, DCO 2 803
NF2FAC_KLMG0: Course of FEV1 Pre-BD - NAVIGATOR, DITTL-adolescent, DCO 2 804
NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups - NAVIGATOR, DITTL-adolescent, DCO 2 805
NT2FAC_KLSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results - NAVIGATOR, DITTL-adolescent, DCO 2 875
NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups - NAVIGATOR, DITTL-adolescent, DCO 2 893
NT2FAC_KLSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results - NAVIGATOR, DITTL-adolescent, DCO 2 947
NT2FAC_ALMH0: Course of FEV1 Pre-BD - NAVIGATOR, DITTL-adult , DCO 2 954
NT2FAC_ALMC0: Change from baseline in FEV1 Pre-BD - MMRM results - NAVIGATOR, DITTL-adult , DCO 2 956
NF2FAC_ALMG0: Course of FEV1 Pre-BD - NAVIGATOR, DITTL-adult , DCO 2 957
NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups - NAVIGATOR, DITTL-adult , DCO 2 958
NT2FAC_ALSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results - NAVIGATOR, DITTL-adult , DCO 2 1032
NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups - NAVIGATOR, DITTL-adult , DCO 2 1066
NT2FAC_ALSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results - NAVIGATOR, DITTL-adult , DCO 2 1120
NF2FAC_ALSHK01: Course of FEV1 Pre-BD by sex - NAVIGATOR, DITTL-adult , DCO 2 1147
NF2FAC_ALSHK03: Course of FEV1 Pre-BD by age - NAVIGATOR, DITTL-adult , DCO 2 1149
NF2FAC_ALSHK14: Course of FEV1 Pre-BD by baseline eosinophils - High - NAVIGATOR, DITTL-adult , DCO 2 1151
NF2FAC_ALSHK36: Course of FEV1 Pre-BD by OCS at baseline - NAVIGATOR, DITTL-adult , DCO 2 1153
NF2FAC_ALSHN15: Course of FEV1 Pre-BD by baseline eosinophils (cat. N) - NAVIGATOR, DITTL-adult , DCO 2 1155
NT2FAC_IBMH0: Course of FEV1 Pre-BD - NAVIGATOR, DITTB, DCO 2 1159
NT2FAC_IBMC0: Change from baseline in FEV1 Pre-BD - MMRM results - NAVIGATOR, DITTB, DCO 2 1161
NF2FAC_IBMG0: Course of FEV1 Pre-BD - NAVIGATOR, DITTB, DCO 2 1162
NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups - NAVIGATOR, DITTB, DCO 2 1163
NT2FAC_IBSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results - NAVIGATOR, DITTB, DCO 2 1227
NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups - NAVIGATOR, DITTB, DCO 2 1252
NT2FAC_IBSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results - NAVIGATOR, DITTB, DCO 2 1296
NT2FAC_ABMH0: Course of FEV1 Pre-BD - NAVIGATOR, DITTB-adult, DCO 2 1308
NT2FAC_ABMC0: Change from baseline in FEV1 Pre-BD - MMRM results - NAVIGATOR, DITTB-adult, DCO 2 1310
NF2FAC_ABMG0: Course of FEV1 Pre-BD - NAVIGATOR, DITTB-adult, DCO 2 1311

NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups - NAVIGATOR, DITTB-adult, DCO 2 1312
NT2FAC_ABSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results - NAVIGATOR, DITTB-adult, DCO 2 1376
NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups - NAVIGATOR, DITTB-adult, DCO 2 1401
NT2FAC_ABSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results - NAVIGATOR, DITTB-adult, DCO 2 1439

Table NT2FAC_IOMH0: Course of FEV1 Pre-BD
DITT

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
FEV1 Pre-BD	Baseline	Tezepelumab	528	528 (100.0)	1.83 (0.72)	0.4	1.31	1.72	2.26	4.8	
		Placebo	531	531 (100.0)	1.85 (0.71)	0.4	1.36	1.73	2.23	4.9	
	Week 2	Tezepelumab	528	514 (97.3)	2.00 (0.73)	0.6	1.44	1.92	2.47	5.0	
		Placebo	531	507 (95.5)	1.92 (0.71)	0.4	1.39	1.80	2.36	4.7	
	Week 4	Tezepelumab	528	523 (99.1)	2.01 (0.74)	0.6	1.46	1.93	2.52	5.0	
		Placebo	531	516 (97.2)	1.92 (0.70)	0.4	1.44	1.83	2.33	4.8	
	Week 8	Tezepelumab	528	518 (98.1)	2.04 (0.75)	0.6	1.45	1.95	2.48	4.7	
		Placebo	531	517 (97.4)	1.95 (0.73)	0.4	1.41	1.85	2.35	4.9	
	Week 12	Tezepelumab	528	510 (96.6)	2.04 (0.75)	0.6	1.52	1.93	2.51	4.9	
		Placebo	531	514 (96.8)	1.95 (0.74)	0.5	1.42	1.81	2.37	5.0	
	Week 16	Tezepelumab	528	510 (96.6)	2.06 (0.77)	0.6	1.50	1.94	2.53	4.9	
		Placebo	531	509 (95.9)	1.95 (0.73)	0.5	1.43	1.82	2.35	5.2	
	Week 24	Tezepelumab	528	498 (94.3)	2.03 (0.74)	0.6	1.52	1.92	2.51	5.5	
		Placebo	531	491 (92.5)	1.94 (0.73)	0.6	1.43	1.83	2.28	5.1	
	Week 36	Tezepelumab	528	483 (91.5)	2.05 (0.76)	0.5	1.47	1.93	2.50	4.9	
		Placebo	531	475 (89.5)	1.97 (0.75)	0.6	1.43	1.82	2.35	5.3	
	Week 52	Tezepelumab	528	471 (89.2)	2.05 (0.77)	0.6	1.49	1.94	2.53	4.6	
		Placebo	531	453 (85.3)	1.96 (0.77)	0.6	1.39	1.81	2.40	5.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOMH0: Course of FEV1 Pre-BD
DITT

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in FEV1 Pre-BD	Week 2	Tezepelumab	528	514 (97.3)	0.17 (0.33)	-0.8	-0.01	0.11	0.29	1.9	0.33 [0.20, 0.45]
		Placebo	531	507 (95.5)	0.05 (0.36)	-1.8	-0.11	0.01	0.18	1.7	
	Week 4	Tezepelumab	528	523 (99.1)	0.19 (0.37)	-1.2	-0.04	0.12	0.33	1.8	0.28 [0.15, 0.40]
		Placebo	531	516 (97.2)	0.09 (0.38)	-1.8	-0.11	0.05	0.25	1.7	
	Week 8	Tezepelumab	528	518 (98.1)	0.22 (0.41)	-1.1	-0.04	0.14	0.39	1.9	0.31 [0.19, 0.43]
		Placebo	531	517 (97.4)	0.09 (0.38)	-1.7	-0.11	0.05	0.26	2.1	
	Week 12	Tezepelumab	528	510 (96.6)	0.22 (0.41)	-1.5	-0.03	0.17	0.40	2.2	0.31 [0.19, 0.44]
		Placebo	531	514 (96.8)	0.10 (0.40)	-1.5	-0.10	0.04	0.25	2.1	
	Week 16	Tezepelumab	528	510 (96.6)	0.23 (0.42)	-1.0	-0.03	0.15	0.40	2.1	0.34 [0.21, 0.46]
		Placebo	531	509 (95.9)	0.09 (0.38)	-1.6	-0.10	0.04	0.26	1.9	
	Week 24	Tezepelumab	528	498 (94.3)	0.21 (0.41)	-1.0	-0.06	0.15	0.40	2.1	0.34 [0.21, 0.46]
		Placebo	531	491 (92.5)	0.08 (0.38)	-1.4	-0.12	0.04	0.25	1.7	
	Week 36	Tezepelumab	528	483 (91.5)	0.22 (0.41)	-1.0	-0.05	0.15	0.42	1.8	0.27 [0.14, 0.39]
		Placebo	531	475 (89.5)	0.11 (0.41)	-1.7	-0.13	0.06	0.30	2.2	
	Week 52	Tezepelumab	528	471 (89.2)	0.22 (0.41)	-1.0	-0.04	0.15	0.44	1.7	0.32 [0.19, 0.45]
		Placebo	531	453 (85.3)	0.09 (0.40)	-1.4	-0.14	0.06	0.27	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOMC0: Change from baseline in FEV1 Pre-BD - MMRM results
DITT

Change from baseline in FEV1 Pre-BD				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Tezepelumab	528	514 (97.3)	0.17 (0.01)	(0.14, 0.19)	0.11 (0.02)	(0.07, 0.15)	<0.001 *
	Placebo	531	507 (95.5)	0.05 (0.01)	(0.02, 0.08)			
Week 4	Tezepelumab	528	523 (99.1)	0.19 (0.02)	(0.16, 0.22)	0.10 (0.02)	(0.06, 0.15)	<0.001 *
	Placebo	531	516 (97.2)	0.08 (0.02)	(0.05, 0.12)			
Week 8	Tezepelumab	528	518 (98.1)	0.21 (0.02)	(0.18, 0.25)	0.12 (0.02)	(0.07, 0.17)	<0.001 *
	Placebo	531	517 (97.4)	0.09 (0.02)	(0.06, 0.13)			
Week 12	Tezepelumab	528	510 (96.6)	0.22 (0.02)	(0.19, 0.25)	0.13 (0.02)	(0.08, 0.17)	<0.001 *
	Placebo	531	514 (96.8)	0.09 (0.02)	(0.06, 0.13)			
Week 16	Tezepelumab	528	510 (96.6)	0.23 (0.02)	(0.19, 0.26)	0.13 (0.02)	(0.09, 0.18)	<0.001 *
	Placebo	531	509 (95.9)	0.09 (0.02)	(0.06, 0.13)			
Week 24	Tezepelumab	528	498 (94.3)	0.21 (0.02)	(0.17, 0.24)	0.12 (0.02)	(0.08, 0.17)	<0.001 *
	Placebo	531	491 (92.5)	0.08 (0.02)	(0.05, 0.12)			
Week 36	Tezepelumab	528	483 (91.5)	0.22 (0.02)	(0.19, 0.26)	0.11 (0.03)	(0.07, 0.16)	<0.001 *
	Placebo	531	475 (89.5)	0.11 (0.02)	(0.07, 0.14)			
Week 52	Tezepelumab	528	471 (89.2)	0.23 (0.02)	(0.19, 0.27)	0.13 (0.03)	(0.08, 0.18)	<0.001 *
	Placebo	531	453 (85.3)	0.10 (0.02)	(0.06, 0.13)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Figure NF2FAC_IOMG0: Course of FEV1 Pre-BD
DITT



Note: DITT = Dossier Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source table: NT2FAC_IOMH0
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Absolute values	Baseline	Tezepelumab	193	193 (100.0)	2.21 (0.77)	0.6	1.62	2.15	2.79	4.8	
			Placebo	194	194 (100.0)	2.17 (0.79)	0.7	1.61	2.12	2.70	4.9	
		Week 2	Tezepelumab	193	189 (97.9)	2.40 (0.78)	0.7	1.81	2.41	2.91	5.0	
			Placebo	194	190 (97.9)	2.22 (0.76)	0.8	1.62	2.26	2.76	4.7	
		Week 4	Tezepelumab	193	191 (99.0)	2.43 (0.79)	0.7	1.90	2.45	2.97	5.0	
			Placebo	194	188 (96.9)	2.23 (0.75)	0.9	1.67	2.16	2.74	4.8	
		Week 8	Tezepelumab	193	187 (96.9)	2.43 (0.82)	0.7	1.76	2.41	2.95	4.7	
			Placebo	194	193 (99.5)	2.28 (0.79)	0.7	1.74	2.20	2.81	4.9	
		Week 12	Tezepelumab	193	184 (95.3)	2.44 (0.84)	0.7	1.79	2.44	3.03	4.9	
			Placebo	194	190 (97.9)	2.30 (0.80)	0.9	1.65	2.26	2.85	5.0	
		Week 16	Tezepelumab	193	186 (96.4)	2.48 (0.86)	0.6	1.83	2.48	3.10	4.9	
			Placebo	194	190 (97.9)	2.27 (0.82)	0.7	1.64	2.17	2.77	5.2	
		Week 24	Tezepelumab	193	176 (91.2)	2.45 (0.81)	0.6	1.80	2.45	2.94	5.5	
			Placebo	194	177 (91.2)	2.30 (0.81)	0.7	1.71	2.17	2.77	5.1	
		Week 36	Tezepelumab	193	175 (90.7)	2.46 (0.84)	0.5	1.84	2.41	3.05	4.9	
			Placebo	194	175 (90.2)	2.31 (0.83)	0.9	1.69	2.20	2.91	5.3	
		Week 52	Tezepelumab	193	170 (88.1)	2.48 (0.82)	0.8	1.79	2.42	3.10	4.6	
			Placebo	194	165 (85.1)	2.32 (0.86)	0.7	1.63	2.23	2.87	5.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Change from baseline	Week 2	Tezepelumab	193	189 (97.9)	0.20 (0.39)	-0.7	-0.03	0.12	0.34	1.9	0.40 [0.19, 0.60]
			Placebo	194	190 (97.9)	0.04 (0.41)	-1.3	-0.17	-0.01	0.19	1.7	
		Week 4	Tezepelumab	193	191 (99.0)	0.24 (0.43)	-0.9	-0.05	0.15	0.41	1.8	0.34 [0.14, 0.54]
			Placebo	194	188 (96.9)	0.09 (0.47)	-1.8	-0.15	0.02	0.33	1.7	
		Week 8	Tezepelumab	193	187 (96.9)	0.25 (0.48)	-1.1	-0.05	0.14	0.45	1.9	0.26 [0.05, 0.46]
			Placebo	194	193 (99.5)	0.12 (0.49)	-1.7	-0.13	0.07	0.33	2.1	
		Week 12	Tezepelumab	193	184 (95.3)	0.26 (0.49)	-0.8	-0.05	0.18	0.48	2.2	0.26 [0.05, 0.46]
			Placebo	194	190 (97.9)	0.14 (0.47)	-1.4	-0.11	0.05	0.36	2.1	
		Week 16	Tezepelumab	193	186 (96.4)	0.28 (0.51)	-0.8	-0.04	0.15	0.50	2.1	0.37 [0.17, 0.57]
			Placebo	194	190 (97.9)	0.10 (0.45)	-1.6	-0.15	0.03	0.33	1.9	
		Week 24	Tezepelumab	193	176 (91.2)	0.27 (0.47)	-0.5	-0.06	0.17	0.44	2.1	0.38 [0.16, 0.59]
			Placebo	194	177 (91.2)	0.09 (0.46)	-1.4	-0.17	0.07	0.32	1.7	
		Week 36	Tezepelumab	193	175 (90.7)	0.26 (0.49)	-0.8	-0.07	0.18	0.44	1.8	0.27 [0.06, 0.48]
			Placebo	194	175 (90.2)	0.13 (0.51)	-1.2	-0.19	0.08	0.38	2.2	
		Week 52	Tezepelumab	193	170 (88.1)	0.28 (0.49)	-1.0	-0.06	0.22	0.51	1.7	0.32 [0.11, 0.54]
			Placebo	194	165 (85.1)	0.12 (0.51)	-1.4	-0.17	0.05	0.33	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Absolute values	Baseline	Tezepelumab	335	335 (100.0)	1.61 (0.58)	0.4	1.20	1.55	1.96	4.1	
			Placebo	337	337 (100.0)	1.67 (0.58)	0.4	1.30	1.62	1.98	4.1	
		Week 2	Tezepelumab	335	325 (97.0)	1.77 (0.59)	0.6	1.32	1.69	2.17	3.7	
			Placebo	337	317 (94.1)	1.73 (0.61)	0.4	1.33	1.65	2.04	4.2	
		Week 4	Tezepelumab	335	332 (99.1)	1.77 (0.59)	0.6	1.33	1.69	2.16	3.8	
			Placebo	337	328 (97.3)	1.75 (0.60)	0.4	1.36	1.68	2.08	3.8	
		Week 8	Tezepelumab	335	331 (98.8)	1.81 (0.60)	0.6	1.33	1.77	2.22	3.9	
			Placebo	337	324 (96.1)	1.75 (0.61)	0.4	1.33	1.66	2.07	4.3	
		Week 12	Tezepelumab	335	326 (97.3)	1.81 (0.58)	0.6	1.40	1.75	2.16	3.6	
			Placebo	337	324 (96.1)	1.74 (0.61)	0.5	1.33	1.67	2.10	4.3	
		Week 16	Tezepelumab	335	324 (96.7)	1.81 (0.58)	0.6	1.37	1.77	2.17	3.8	
			Placebo	337	319 (94.7)	1.76 (0.60)	0.5	1.33	1.69	2.11	4.4	
		Week 24	Tezepelumab	335	322 (96.1)	1.80 (0.59)	0.6	1.38	1.77	2.16	3.8	
			Placebo	337	314 (93.2)	1.74 (0.60)	0.6	1.34	1.67	2.09	4.3	
		Week 36	Tezepelumab	335	308 (91.9)	1.81 (0.59)	0.6	1.37	1.78	2.22	3.7	
			Placebo	337	300 (89.0)	1.77 (0.62)	0.6	1.36	1.69	2.21	4.3	
		Week 52	Tezepelumab	335	301 (89.9)	1.81 (0.62)	0.6	1.38	1.74	2.20	4.0	
			Placebo	337	288 (85.5)	1.76 (0.63)	0.6	1.31	1.65	2.14	3.9	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Change from baseline	Week 2	Tezepelumab	335	325 (97.0)	0.15 (0.30)	-0.8	0.00	0.10	0.27	1.3	0.28 [0.12, 0.43]
			Placebo	337	317 (94.1)	0.06 (0.32)	-1.8	-0.07	0.03	0.17	1.2	
		Week 4	Tezepelumab	335	332 (99.1)	0.16 (0.32)	-1.2	-0.02	0.12	0.30	1.2	0.23 [0.08, 0.39]
			Placebo	337	328 (97.3)	0.09 (0.32)	-1.0	-0.08	0.05	0.23	1.2	
		Week 8	Tezepelumab	335	331 (98.8)	0.20 (0.36)	-0.8	-0.02	0.14	0.38	1.4	0.37 [0.21, 0.52]
			Placebo	337	324 (96.1)	0.08 (0.30)	-0.8	-0.10	0.03	0.22	1.6	
		Week 12	Tezepelumab	335	326 (97.3)	0.20 (0.35)	-1.5	-0.01	0.15	0.37	1.4	0.37 [0.21, 0.52]
			Placebo	337	324 (96.1)	0.07 (0.35)	-1.5	-0.09	0.04	0.21	1.7	
		Week 16	Tezepelumab	335	324 (96.7)	0.20 (0.35)	-1.0	-0.02	0.15	0.36	1.4	0.32 [0.17, 0.48]
			Placebo	337	319 (94.7)	0.09 (0.33)	-1.0	-0.07	0.04	0.22	1.8	
		Week 24	Tezepelumab	335	322 (96.1)	0.18 (0.37)	-1.0	-0.05	0.14	0.38	1.6	0.32 [0.16, 0.47]
			Placebo	337	314 (93.2)	0.07 (0.33)	-1.1	-0.11	0.03	0.22	1.7	
		Week 36	Tezepelumab	335	308 (91.9)	0.19 (0.36)	-1.0	-0.03	0.14	0.40	1.4	0.28 [0.12, 0.43]
			Placebo	337	300 (89.0)	0.10 (0.35)	-1.7	-0.11	0.05	0.27	1.7	
		Week 52	Tezepelumab	335	301 (89.9)	0.19 (0.36)	-1.0	-0.03	0.13	0.41	1.3	0.33 [0.17, 0.50]
			Placebo	337	288 (85.5)	0.08 (0.31)	-0.8	-0.11	0.06	0.26	1.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Absolute values	Baseline	Tezepelumab	432	432 (100.0)	1.92 (0.73)	0.4	1.41	1.83	2.36	4.8	
			Placebo	457	457 (100.0)	1.91 (0.72)	0.4	1.39	1.79	2.28	4.9	
		Week 2	Tezepelumab	432	421 (97.5)	2.10 (0.73)	0.6	1.55	2.04	2.57	5.0	
			Placebo	457	436 (95.4)	1.98 (0.72)	0.4	1.44	1.90	2.44	4.7	
		Week 4	Tezepelumab	432	430 (99.5)	2.12 (0.74)	0.7	1.60	2.05	2.60	5.0	
			Placebo	457	446 (97.6)	1.98 (0.70)	0.4	1.48	1.88	2.42	4.8	
		Week 8	Tezepelumab	432	424 (98.1)	2.14 (0.75)	0.6	1.60	2.10	2.58	4.7	
			Placebo	457	447 (97.8)	2.02 (0.74)	0.4	1.51	1.94	2.41	4.9	
		Week 12	Tezepelumab	432	417 (96.5)	2.14 (0.76)	0.6	1.61	2.06	2.63	4.9	
			Placebo	457	444 (97.2)	2.02 (0.75)	0.5	1.49	1.91	2.45	5.0	
		Week 16	Tezepelumab	432	418 (96.8)	2.16 (0.77)	0.6	1.60	2.06	2.62	4.9	
			Placebo	457	439 (96.1)	2.02 (0.75)	0.5	1.52	1.89	2.46	5.2	
		Week 24	Tezepelumab	432	409 (94.7)	2.14 (0.74)	0.6	1.65	2.05	2.59	5.5	
			Placebo	457	424 (92.8)	2.01 (0.74)	0.6	1.49	1.90	2.37	5.1	
		Week 36	Tezepelumab	432	396 (91.7)	2.15 (0.76)	0.5	1.57	2.11	2.59	4.9	
			Placebo	457	409 (89.5)	2.04 (0.76)	0.6	1.49	1.92	2.43	5.3	
		Week 52	Tezepelumab	432	387 (89.6)	2.16 (0.77)	0.6	1.63	2.08	2.68	4.6	
			Placebo	457	390 (85.3)	2.03 (0.78)	0.6	1.47	1.90	2.48	5.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Change from baseline	Week 2	Tezepelumab	432	421 (97.5)	0.18 (0.36)	-0.8	-0.02	0.13	0.32	1.9	0.35 [0.21, 0.48]
			Placebo	457	436 (95.4)	0.06 (0.37)	-1.8	-0.12	0.01	0.18	1.7	
		Week 4	Tezepelumab	432	430 (99.5)	0.21 (0.39)	-1.2	-0.04	0.14	0.37	1.8	0.31 [0.17, 0.44]
			Placebo	457	446 (97.6)	0.09 (0.40)	-1.8	-0.11	0.05	0.26	1.7	
		Week 8	Tezepelumab	432	424 (98.1)	0.23 (0.43)	-1.1	-0.04	0.15	0.45	1.9	0.33 [0.19, 0.46]
			Placebo	457	447 (97.8)	0.10 (0.39)	-1.7	-0.12	0.05	0.28	2.1	
		Week 12	Tezepelumab	432	417 (96.5)	0.24 (0.43)	-1.5	-0.03	0.16	0.44	2.2	0.31 [0.18, 0.45]
			Placebo	457	444 (97.2)	0.10 (0.42)	-1.5	-0.10	0.05	0.26	2.1	
		Week 16	Tezepelumab	432	418 (96.8)	0.25 (0.44)	-1.0	-0.02	0.16	0.43	2.1	0.35 [0.21, 0.48]
			Placebo	457	439 (96.1)	0.10 (0.40)	-1.6	-0.10	0.04	0.26	1.9	
		Week 24	Tezepelumab	432	409 (94.7)	0.23 (0.43)	-1.0	-0.05	0.15	0.43	2.1	0.36 [0.22, 0.50]
			Placebo	457	424 (92.8)	0.08 (0.40)	-1.4	-0.14	0.03	0.27	1.7	
		Week 36	Tezepelumab	432	396 (91.7)	0.24 (0.43)	-1.0	-0.05	0.18	0.46	1.8	0.28 [0.14, 0.42]
			Placebo	457	409 (89.5)	0.12 (0.43)	-1.7	-0.13	0.06	0.30	2.2	
		Week 52	Tezepelumab	432	387 (89.6)	0.25 (0.44)	-1.0	-0.03	0.19	0.48	1.7	0.34 [0.20, 0.48]
			Placebo	457	390 (85.3)	0.11 (0.40)	-1.4	-0.14	0.06	0.29	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Absolute values	Baseline	Tezepelumab	96	96 (100.0)	1.45 (0.54)	0.6	1.14	1.36	1.62	3.2	
			Placebo	74	74 (100.0)	1.48 (0.47)	0.7	1.12	1.42	1.77	2.6	
		Week 2	Tezepelumab	96	93 (96.9)	1.52 (0.51)	0.6	1.23	1.44	1.75	3.1	
			Placebo	74	71 (95.9)	1.52 (0.50)	0.7	1.14	1.45	1.78	3.1	
		Week 4	Tezepelumab	96	93 (96.9)	1.54 (0.51)	0.6	1.20	1.46	1.77	3.1	
			Placebo	74	70 (94.6)	1.54 (0.50)	0.7	1.21	1.46	1.81	3.1	
		Week 8	Tezepelumab	96	94 (97.9)	1.55 (0.51)	0.6	1.20	1.47	1.82	3.2	
			Placebo	74	70 (94.6)	1.52 (0.51)	0.7	1.16	1.43	1.76	3.2	
		Week 12	Tezepelumab	96	93 (96.9)	1.57 (0.49)	0.6	1.23	1.50	1.83	3.3	
			Placebo	74	70 (94.6)	1.50 (0.49)	0.7	1.19	1.44	1.69	3.1	
		Week 16	Tezepelumab	96	92 (95.8)	1.58 (0.53)	0.6	1.24	1.51	1.84	3.4	
			Placebo	74	70 (94.6)	1.52 (0.47)	0.7	1.19	1.46	1.77	3.0	
		Week 24	Tezepelumab	96	89 (92.7)	1.53 (0.51)	0.6	1.18	1.52	1.78	3.1	
			Placebo	74	67 (90.5)	1.51 (0.47)	0.6	1.24	1.45	1.83	3.0	
		Week 36	Tezepelumab	96	87 (90.6)	1.57 (0.53)	0.6	1.15	1.51	1.84	3.2	
			Placebo	74	66 (89.2)	1.54 (0.50)	0.7	1.21	1.41	1.80	3.2	
		Week 52	Tezepelumab	96	84 (87.5)	1.57 (0.54)	0.7	1.17	1.44	1.77	3.3	
			Placebo	74	63 (85.1)	1.51 (0.49)	0.7	1.18	1.48	1.76	2.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Change from baseline	Week 2	Tezepelumab	96	93 (96.9)	0.09 (0.19)	-0.4	-0.01	0.07	0.19	0.7	0.24 [-0.07, 0.55]
			Placebo	74	71 (95.9)	0.04 (0.23)	-0.6	-0.08	0.01	0.13	0.7	
		Week 4	Tezepelumab	96	93 (96.9)	0.11 (0.23)	-0.7	-0.04	0.09	0.23	0.8	0.09 [-0.22, 0.40]
			Placebo	74	70 (94.6)	0.08 (0.27)	-0.9	-0.03	0.06	0.18	0.9	
		Week 8	Tezepelumab	96	94 (97.9)	0.13 (0.27)	-0.6	-0.04	0.08	0.27	1.0	0.26 [-0.05, 0.57]
			Placebo	74	70 (94.6)	0.06 (0.27)	-0.9	-0.08	0.05	0.21	0.7	
		Week 12	Tezepelumab	96	93 (96.9)	0.16 (0.29)	-0.7	-0.01	0.19	0.34	1.2	0.43 [0.12, 0.74]
			Placebo	74	70 (94.6)	0.04 (0.26)	-1.1	-0.07	0.00	0.18	0.7	
		Week 16	Tezepelumab	96	92 (95.8)	0.15 (0.28)	-0.5	-0.04	0.11	0.34	1.2	0.34 [0.03, 0.66]
			Placebo	74	70 (94.6)	0.06 (0.25)	-1.0	-0.09	0.05	0.25	0.6	
		Week 24	Tezepelumab	96	89 (92.7)	0.12 (0.26)	-0.4	-0.07	0.12	0.29	1.0	0.25 [-0.06, 0.57]
			Placebo	74	67 (90.5)	0.05 (0.26)	-1.1	-0.07	0.06	0.19	0.7	
		Week 36	Tezepelumab	96	87 (90.6)	0.13 (0.27)	-0.6	-0.05	0.08	0.31	1.0	0.28 [-0.04, 0.60]
			Placebo	74	66 (89.2)	0.05 (0.27)	-0.6	-0.14	0.01	0.18	0.8	
		Week 52	Tezepelumab	96	84 (87.5)	0.11 (0.27)	-0.5	-0.04	0.07	0.26	0.9	0.33 [-0.00, 0.66]
			Placebo	74	63 (85.1)	0.02 (0.33)	-1.0	-0.17	0.04	0.22	0.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Absolute values	Baseline	Tezepelumab	310	310 (100.0)	1.87 (0.69)	0.4	1.35	1.80	2.30	4.1	
			Placebo	325	325 (100.0)	1.91 (0.71)	0.6	1.37	1.79	2.34	4.9	
		Week 2	Tezepelumab	310	304 (98.1)	2.03 (0.71)	0.6	1.48	1.99	2.50	4.3	
			Placebo	325	312 (96.0)	1.98 (0.71)	0.7	1.43	1.88	2.48	4.7	
		Week 4	Tezepelumab	310	307 (99.0)	2.05 (0.72)	0.6	1.54	1.97	2.54	4.3	
			Placebo	325	312 (96.0)	1.98 (0.70)	0.5	1.47	1.88	2.42	4.8	
		Week 8	Tezepelumab	310	303 (97.7)	2.07 (0.73)	0.6	1.52	2.01	2.48	4.7	
			Placebo	325	316 (97.2)	2.01 (0.75)	0.6	1.46	1.92	2.44	4.9	
		Week 12	Tezepelumab	310	300 (96.8)	2.05 (0.73)	0.6	1.53	1.95	2.52	4.7	
			Placebo	325	317 (97.5)	2.00 (0.76)	0.5	1.45	1.91	2.44	5.0	
		Week 16	Tezepelumab	310	301 (97.1)	2.07 (0.75)	0.6	1.54	1.97	2.55	4.9	
			Placebo	325	314 (96.6)	2.01 (0.77)	0.5	1.46	1.87	2.47	5.2	
		Week 24	Tezepelumab	310	292 (94.2)	2.06 (0.73)	0.6	1.56	1.95	2.55	4.4	
			Placebo	325	301 (92.6)	1.98 (0.76)	0.7	1.42	1.90	2.35	5.1	
		Week 36	Tezepelumab	310	287 (92.6)	2.06 (0.74)	0.6	1.51	1.98	2.50	4.5	
			Placebo	325	296 (91.1)	2.01 (0.78)	0.6	1.46	1.86	2.41	5.3	
		Week 52	Tezepelumab	310	279 (90.0)	2.06 (0.75)	0.6	1.51	1.99	2.57	4.2	
			Placebo	325	284 (87.4)	2.00 (0.79)	0.6	1.40	1.81	2.47	5.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Change from baseline	Week 2	Tezepelumab	310	304 (98.1)	0.16 (0.34)	-0.8	-0.02	0.11	0.29	1.9	0.28 [0.12, 0.44]
			Placebo	325	312 (96.0)	0.07 (0.34)	-0.8	-0.11	0.01	0.17	1.7	
		Week 4	Tezepelumab	310	307 (99.0)	0.18 (0.38)	-1.0	-0.05	0.11	0.33	1.8	0.23 [0.07, 0.39]
			Placebo	325	312 (96.0)	0.10 (0.37)	-1.0	-0.10	0.05	0.24	1.6	
		Week 8	Tezepelumab	310	303 (97.7)	0.20 (0.41)	-0.8	-0.05	0.14	0.38	1.8	0.25 [0.09, 0.41]
			Placebo	325	316 (97.2)	0.10 (0.38)	-1.0	-0.11	0.05	0.25	2.1	
		Week 12	Tezepelumab	310	300 (96.8)	0.20 (0.41)	-1.5	-0.04	0.14	0.39	1.9	0.24 [0.08, 0.40]
			Placebo	325	317 (97.5)	0.10 (0.41)	-1.5	-0.09	0.04	0.23	2.1	
		Week 16	Tezepelumab	310	301 (97.1)	0.21 (0.42)	-1.0	-0.04	0.15	0.39	2.0	0.27 [0.11, 0.43]
			Placebo	325	314 (96.6)	0.10 (0.39)	-1.2	-0.11	0.04	0.26	1.9	
		Week 24	Tezepelumab	310	292 (94.2)	0.19 (0.41)	-1.0	-0.07	0.13	0.38	2.1	0.28 [0.12, 0.44]
			Placebo	325	301 (92.6)	0.08 (0.41)	-1.1	-0.13	0.03	0.23	1.7	
		Week 36	Tezepelumab	310	287 (92.6)	0.21 (0.41)	-1.0	-0.07	0.12	0.43	1.8	0.22 [0.05, 0.38]
			Placebo	325	296 (91.1)	0.11 (0.43)	-1.7	-0.12	0.05	0.28	1.7	
		Week 52	Tezepelumab	310	279 (90.0)	0.19 (0.42)	-1.0	-0.07	0.13	0.37	1.7	0.21 [0.05, 0.38]
			Placebo	325	284 (87.4)	0.11 (0.41)	-1.0	-0.14	0.06	0.27	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Absolute values	Baseline	Tezepelumab	218	218 (100.0)	1.77 (0.75)	0.5	1.24	1.61	2.13	4.8	
			Placebo	206	206 (100.0)	1.76 (0.69)	0.4	1.35	1.67	2.10	4.5	
		Week 2	Tezepelumab	218	210 (96.3)	1.95 (0.76)	0.7	1.37	1.80	2.44	5.0	
			Placebo	206	195 (94.7)	1.81 (0.70)	0.4	1.36	1.73	2.24	4.2	
		Week 4	Tezepelumab	218	216 (99.1)	1.97 (0.76)	0.7	1.43	1.85	2.48	5.0	
			Placebo	206	204 (99.0)	1.84 (0.68)	0.4	1.41	1.72	2.25	4.2	
		Week 8	Tezepelumab	218	215 (98.6)	1.99 (0.76)	0.7	1.39	1.84	2.49	4.6	
			Placebo	206	201 (97.6)	1.85 (0.69)	0.4	1.36	1.76	2.19	4.3	
		Week 12	Tezepelumab	218	210 (96.3)	2.02 (0.78)	0.7	1.49	1.87	2.45	4.9	
			Placebo	206	197 (95.6)	1.86 (0.69)	0.6	1.40	1.73	2.24	4.3	
		Week 16	Tezepelumab	218	209 (95.9)	2.03 (0.80)	0.6	1.46	1.88	2.47	4.9	
			Placebo	206	195 (94.7)	1.84 (0.66)	0.7	1.36	1.75	2.18	4.3	
		Week 24	Tezepelumab	218	206 (94.5)	1.99 (0.76)	0.6	1.50	1.81	2.41	5.5	
			Placebo	206	190 (92.2)	1.88 (0.69)	0.6	1.45	1.73	2.20	4.8	
		Week 36	Tezepelumab	218	196 (89.9)	2.02 (0.79)	0.5	1.44	1.86	2.42	4.9	
			Placebo	206	179 (86.9)	1.92 (0.71)	0.7	1.41	1.79	2.26	4.6	
		Week 52	Tezepelumab	218	192 (88.1)	2.03 (0.80)	0.6	1.47	1.88	2.47	4.6	
			Placebo	206	169 (82.0)	1.91 (0.74)	0.7	1.38	1.81	2.30	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Change from baseline	Week 2	Tezepelumab	218	210 (96.3)	0.18 (0.33)	-0.6	0.00	0.11	0.31	1.4	0.39 [0.20, 0.59]
			Placebo	206	195 (94.7)	0.04 (0.39)	-1.8	-0.12	0.03	0.20	1.7	
		Week 4	Tezepelumab	218	216 (99.1)	0.20 (0.35)	-1.2	0.01	0.13	0.34	1.6	0.34 [0.15, 0.53]
			Placebo	206	204 (99.0)	0.07 (0.41)	-1.8	-0.11	0.03	0.26	1.7	
		Week 8	Tezepelumab	218	215 (98.6)	0.23 (0.40)	-1.1	-0.02	0.16	0.44	1.9	0.40 [0.21, 0.59]
			Placebo	206	201 (97.6)	0.08 (0.37)	-1.7	-0.12	0.05	0.28	2.0	
		Week 12	Tezepelumab	218	210 (96.3)	0.26 (0.41)	-0.8	0.02	0.19	0.44	2.2	0.43 [0.23, 0.63]
			Placebo	206	197 (95.6)	0.09 (0.38)	-1.2	-0.11	0.04	0.28	1.5	
		Week 16	Tezepelumab	218	209 (95.9)	0.25 (0.42)	-0.8	0.00	0.15	0.41	2.1	0.45 [0.25, 0.64]
			Placebo	206	195 (94.7)	0.08 (0.36)	-1.6	-0.10	0.03	0.26	1.6	
		Week 24	Tezepelumab	218	206 (94.5)	0.24 (0.41)	-1.0	-0.03	0.17	0.43	1.7	0.43 [0.23, 0.63]
			Placebo	206	190 (92.2)	0.08 (0.34)	-1.4	-0.12	0.06	0.28	1.1	
		Week 36	Tezepelumab	218	196 (89.9)	0.24 (0.40)	-0.6	-0.03	0.19	0.40	1.6	0.35 [0.14, 0.55]
			Placebo	206	179 (86.9)	0.10 (0.39)	-1.2	-0.15	0.06	0.34	2.2	
		Week 52	Tezepelumab	218	192 (88.1)	0.27 (0.41)	-0.8	-0.01	0.22	0.52	1.6	0.50 [0.29, 0.71]
			Placebo	206	169 (82.0)	0.07 (0.36)	-1.4	-0.14	0.06	0.26	1.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Absolute values	Baseline	Tezepelumab	332	332 (100.0)	1.89 (0.73)	0.6	1.34	1.77	2.30	4.8	
			Placebo	327	327 (100.0)	1.90 (0.78)	0.6	1.33	1.73	2.31	4.9	
		Week 2	Tezepelumab	332	325 (97.9)	2.07 (0.75)	0.7	1.48	1.96	2.57	5.0	
			Placebo	327	311 (95.1)	1.95 (0.78)	0.6	1.36	1.83	2.44	4.7	
		Week 4	Tezepelumab	332	329 (99.1)	2.08 (0.77)	0.7	1.48	1.98	2.60	5.0	
			Placebo	327	315 (96.3)	1.98 (0.76)	0.5	1.43	1.87	2.50	4.8	
		Week 8	Tezepelumab	332	329 (99.1)	2.09 (0.78)	0.7	1.43	2.01	2.59	4.7	
			Placebo	327	315 (96.3)	2.02 (0.80)	0.6	1.40	1.91	2.54	4.9	
		Week 12	Tezepelumab	332	319 (96.1)	2.10 (0.79)	0.8	1.52	1.96	2.64	4.9	
			Placebo	327	313 (95.7)	2.00 (0.82)	0.5	1.38	1.82	2.52	5.0	
		Week 16	Tezepelumab	332	320 (96.4)	2.13 (0.80)	0.7	1.51	2.02	2.65	4.9	
			Placebo	327	311 (95.1)	2.00 (0.82)	0.5	1.35	1.85	2.52	5.2	
		Week 24	Tezepelumab	332	313 (94.3)	2.09 (0.79)	0.7	1.52	1.97	2.57	5.5	
			Placebo	327	297 (90.8)	2.01 (0.82)	0.6	1.42	1.89	2.43	5.1	
		Week 36	Tezepelumab	332	300 (90.4)	2.11 (0.78)	0.7	1.48	2.06	2.56	4.9	
			Placebo	327	286 (87.5)	2.06 (0.83)	0.6	1.43	1.92	2.55	5.3	
		Week 52	Tezepelumab	332	291 (87.7)	2.12 (0.81)	0.6	1.50	2.04	2.69	4.6	
			Placebo	327	269 (82.3)	2.05 (0.86)	0.6	1.37	1.91	2.64	5.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Change from baseline	Week 2	Tezepelumab	332	325 (97.9)	0.17 (0.33)	-0.6	-0.01	0.12	0.29	1.9	0.39 [0.23, 0.55]
			Placebo	327	311 (95.1)	0.04 (0.39)	-1.8	-0.13	0.00	0.16	1.7	
		Week 4	Tezepelumab	332	329 (99.1)	0.18 (0.37)	-1.2	-0.05	0.12	0.33	1.7	0.24 [0.09, 0.40]
			Placebo	327	315 (96.3)	0.09 (0.40)	-1.8	-0.10	0.05	0.26	1.7	
		Week 8	Tezepelumab	332	329 (99.1)	0.21 (0.42)	-1.1	-0.05	0.13	0.41	1.9	0.26 [0.10, 0.41]
			Placebo	327	315 (96.3)	0.10 (0.41)	-1.7	-0.11	0.05	0.26	2.1	
		Week 12	Tezepelumab	332	319 (96.1)	0.21 (0.41)	-1.5	-0.04	0.14	0.40	2.2	0.27 [0.11, 0.42]
			Placebo	327	313 (95.7)	0.10 (0.43)	-1.5	-0.11	0.03	0.26	2.1	
		Week 16	Tezepelumab	332	320 (96.4)	0.24 (0.43)	-0.8	-0.02	0.15	0.39	2.1	0.34 [0.18, 0.49]
			Placebo	327	311 (95.1)	0.10 (0.41)	-1.6	-0.12	0.04	0.26	1.9	
		Week 24	Tezepelumab	332	313 (94.3)	0.21 (0.42)	-1.0	-0.07	0.14	0.40	2.1	0.29 [0.13, 0.45]
			Placebo	327	297 (90.8)	0.09 (0.39)	-1.4	-0.11	0.03	0.25	1.7	
		Week 36	Tezepelumab	332	300 (90.4)	0.21 (0.41)	-0.8	-0.07	0.16	0.40	1.8	0.19 [0.02, 0.35]
			Placebo	327	286 (87.5)	0.13 (0.44)	-1.2	-0.12	0.06	0.31	2.2	
		Week 52	Tezepelumab	332	291 (87.7)	0.22 (0.42)	-0.8	-0.05	0.15	0.43	1.7	0.22 [0.06, 0.39]
			Placebo	327	269 (82.3)	0.13 (0.43)	-1.4	-0.10	0.08	0.30	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Absolute values	Baseline	Tezepelumab	30	30 (100.0)	1.82 (0.81)	0.8	1.25	1.52	2.37	4.0	
			Placebo	31	31 (100.0)	1.75 (0.63)	0.8	1.22	1.77	2.13	3.2	
		Week 2	Tezepelumab	30	26 (86.7)	1.93 (0.79)	0.9	1.34	1.71	2.43	4.1	
			Placebo	31	31 (100.0)	1.90 (0.59)	0.9	1.47	1.90	2.28	3.1	
		Week 4	Tezepelumab	30	29 (96.7)	1.88 (0.78)	1.0	1.26	1.66	2.15	4.2	
			Placebo	31	31 (100.0)	1.85 (0.54)	1.0	1.33	1.91	2.28	3.1	
		Week 8	Tezepelumab	30	29 (96.7)	1.96 (0.74)	1.0	1.45	1.80	2.30	4.1	
			Placebo	31	31 (100.0)	1.77 (0.58)	0.8	1.36	1.69	2.19	3.4	
		Week 12	Tezepelumab	30	29 (96.7)	2.01 (0.79)	0.9	1.50	1.77	2.49	4.2	
			Placebo	31	31 (100.0)	1.82 (0.56)	1.0	1.35	1.74	2.10	3.3	
		Week 16	Tezepelumab	30	28 (93.3)	1.84 (0.77)	0.9	1.36	1.66	2.18	4.2	
			Placebo	31	30 (96.8)	1.85 (0.55)	0.8	1.54	1.86	2.16	3.1	
		Week 24	Tezepelumab	30	26 (86.7)	1.93 (0.76)	0.9	1.44	1.73	2.32	4.0	
			Placebo	31	29 (93.5)	1.75 (0.59)	0.7	1.30	1.74	2.09	3.3	
		Week 36	Tezepelumab	30	26 (86.7)	1.94 (0.84)	0.9	1.43	1.67	2.36	4.4	
			Placebo	31	30 (96.8)	1.83 (0.55)	1.0	1.38	1.92	2.17	3.3	
		Week 52	Tezepelumab	30	25 (83.3)	1.92 (0.77)	0.8	1.44	1.78	2.16	4.2	
			Placebo	31	27 (87.1)	1.82 (0.64)	0.7	1.24	1.85	2.33	3.1	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Change from baseline	Week 2	Tezepelumab	30	26 (86.7)	0.15 (0.44)	-0.8	-0.08	0.12	0.47	1.4	0.03 [-0.50, 0.55]
			Placebo	31	31 (100.0)	0.15 (0.28)	-0.3	-0.05	0.08	0.31	1.0	
		Week 4	Tezepelumab	30	29 (96.7)	0.11 (0.40)	-1.0	-0.13	0.16	0.33	1.1	0.05 [-0.45, 0.56]
			Placebo	31	31 (100.0)	0.09 (0.37)	-0.6	-0.13	-0.02	0.34	1.1	
		Week 8	Tezepelumab	30	29 (96.7)	0.19 (0.41)	-0.5	-0.08	0.17	0.39	1.1	0.47 [-0.05, 0.98]
			Placebo	31	31 (100.0)	0.02 (0.35)	-0.8	-0.19	0.01	0.29	0.9	
		Week 12	Tezepelumab	30	29 (96.7)	0.24 (0.38)	-0.4	0.02	0.18	0.43	1.5	0.48 [-0.03, 0.99]
			Placebo	31	31 (100.0)	0.06 (0.38)	-1.2	-0.09	0.03	0.21	1.0	
		Week 16	Tezepelumab	30	28 (93.3)	0.11 (0.45)	-1.0	-0.10	0.12	0.31	1.4	0.01 [-0.51, 0.52]
			Placebo	31	30 (96.8)	0.10 (0.37)	-0.7	-0.07	0.05	0.33	1.0	
		Week 24	Tezepelumab	30	26 (86.7)	0.20 (0.32)	-0.2	-0.06	0.16	0.39	1.1	0.54 [-0.00, 1.08]
			Placebo	31	29 (93.5)	0.01 (0.39)	-1.1	-0.19	0.00	0.22	1.1	
		Week 36	Tezepelumab	30	26 (86.7)	0.19 (0.31)	-0.2	-0.02	0.08	0.49	0.7	0.32 [-0.20, 0.85]
			Placebo	31	30 (96.8)	0.07 (0.41)	-1.7	-0.01	0.08	0.16	1.0	
		Week 52	Tezepelumab	30	25 (83.3)	0.23 (0.38)	-0.3	-0.07	0.13	0.55	1.1	0.55 [-0.01, 1.10]
			Placebo	31	27 (87.1)	0.03 (0.35)	-0.6	-0.14	0.01	0.21	1.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Absolute values	Baseline	Tezepelumab	146	146 (100.0)	1.70 (0.65)	0.4	1.24	1.64	2.15	4.1	
			Placebo	149	149 (100.0)	1.78 (0.56)	0.4	1.40	1.71	2.11	3.6	
		Week 2	Tezepelumab	146	144 (98.6)	1.86 (0.66)	0.6	1.31	1.80	2.30	4.3	
			Placebo	149	144 (96.6)	1.84 (0.60)	0.4	1.46	1.75	2.20	3.9	
		Week 4	Tezepelumab	146	146 (100.0)	1.92 (0.66)	0.7	1.46	1.85	2.37	3.7	
			Placebo	149	147 (98.7)	1.82 (0.58)	0.4	1.44	1.72	2.18	3.7	
		Week 8	Tezepelumab	146	141 (96.6)	1.95 (0.65)	0.6	1.49	1.89	2.35	4.7	
			Placebo	149	148 (99.3)	1.83 (0.59)	0.4	1.42	1.80	2.17	4.3	
		Week 12	Tezepelumab	146	143 (97.9)	1.94 (0.65)	0.6	1.50	1.92	2.29	3.8	
			Placebo	149	146 (98.0)	1.86 (0.59)	0.7	1.50	1.77	2.22	4.3	
		Week 16	Tezepelumab	146	144 (98.6)	1.95 (0.69)	0.6	1.52	1.85	2.38	4.7	
			Placebo	149	145 (97.3)	1.85 (0.57)	0.7	1.52	1.76	2.16	4.4	
		Week 24	Tezepelumab	146	142 (97.3)	1.95 (0.63)	0.6	1.56	1.82	2.32	4.0	
			Placebo	149	143 (96.0)	1.84 (0.57)	0.7	1.46	1.73	2.14	4.3	
		Week 36	Tezepelumab	146	139 (95.2)	1.95 (0.69)	0.5	1.51	1.82	2.38	4.4	
			Placebo	149	136 (91.3)	1.81 (0.61)	0.7	1.43	1.70	2.18	4.3	
		Week 52	Tezepelumab	146	137 (93.8)	1.96 (0.68)	0.6	1.50	1.82	2.39	4.2	
			Placebo	149	135 (90.6)	1.81 (0.58)	0.7	1.44	1.71	2.19	3.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Change from baseline	Week 2	Tezepelumab	146	144 (98.6)	0.16 (0.34)	-0.6	-0.01	0.09	0.25	1.3	0.28 [0.05, 0.52]
			Placebo	149	144 (96.6)	0.06 (0.31)	-0.7	-0.09	0.04	0.19	1.2	
		Week 4	Tezepelumab	146	146 (100.0)	0.21 (0.37)	-0.9	0.02	0.13	0.35	1.8	0.43 [0.20, 0.67]
			Placebo	149	147 (98.7)	0.06 (0.35)	-0.9	-0.12	0.01	0.20	1.1	
		Week 8	Tezepelumab	146	141 (96.6)	0.24 (0.40)	-0.8	0.03	0.16	0.44	1.7	0.48 [0.24, 0.71]
			Placebo	149	148 (99.3)	0.07 (0.33)	-0.9	-0.14	0.02	0.23	1.6	
		Week 12	Tezepelumab	146	143 (97.9)	0.26 (0.42)	-0.7	0.02	0.19	0.44	2.0	0.46 [0.22, 0.69]
			Placebo	149	146 (98.0)	0.08 (0.34)	-1.1	-0.07	0.03	0.19	1.7	
		Week 16	Tezepelumab	146	144 (98.6)	0.25 (0.41)	-0.6	-0.02	0.17	0.45	1.7	0.47 [0.24, 0.70]
			Placebo	149	145 (97.3)	0.08 (0.33)	-1.0	-0.10	0.02	0.22	1.8	
		Week 24	Tezepelumab	146	142 (97.3)	0.24 (0.40)	-1.0	-0.02	0.18	0.43	1.6	0.45 [0.22, 0.69]
			Placebo	149	143 (96.0)	0.07 (0.36)	-1.1	-0.13	0.07	0.22	1.7	
		Week 36	Tezepelumab	146	139 (95.2)	0.25 (0.43)	-1.0	0.00	0.22	0.44	1.5	0.50 [0.26, 0.74]
			Placebo	149	136 (91.3)	0.04 (0.38)	-1.0	-0.20	0.00	0.27	1.7	
		Week 52	Tezepelumab	146	137 (93.8)	0.24 (0.42)	-1.0	-0.02	0.23	0.47	1.6	0.56 [0.32, 0.80]
			Placebo	149	135 (90.6)	0.03 (0.33)	-1.0	-0.19	0.01	0.23	0.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Absolute values	Baseline	Tezepelumab	20	20 (100.0)	1.76 (0.72)	0.7	1.28	1.68	2.13	3.3	
			Placebo	24	24 (100.0)	1.81 (0.50)	1.1	1.38	1.77	2.14	3.0	
		Week 2	Tezepelumab	20	19 (95.0)	1.93 (0.76)	0.6	1.39	1.94	2.25	3.7	
			Placebo	24	21 (87.5)	1.94 (0.50)	1.2	1.66	1.87	2.29	3.2	
		Week 4	Tezepelumab	20	19 (95.0)	1.86 (0.68)	0.6	1.37	1.84	2.56	3.3	
			Placebo	24	23 (95.8)	1.97 (0.49)	1.1	1.63	1.93	2.29	3.3	
		Week 8	Tezepelumab	20	19 (95.0)	1.81 (0.69)	0.6	1.30	1.85	2.45	3.4	
			Placebo	24	23 (95.8)	2.01 (0.57)	1.1	1.57	1.98	2.42	3.3	
		Week 12	Tezepelumab	20	19 (95.0)	1.78 (0.69)	0.6	1.31	1.83	2.30	3.2	
			Placebo	24	24 (100.0)	2.00 (0.53)	1.0	1.60	2.05	2.32	3.4	
		Week 16	Tezepelumab	20	18 (90.0)	1.88 (0.66)	0.6	1.50	1.81	2.50	3.2	
			Placebo	24	23 (95.8)	2.00 (0.57)	1.0	1.56	2.09	2.38	3.3	
		Week 24	Tezepelumab	20	17 (85.0)	1.85 (0.69)	0.6	1.43	1.89	2.32	3.1	
			Placebo	24	22 (91.7)	1.91 (0.49)	0.9	1.57	2.01	2.26	2.7	
		Week 36	Tezepelumab	20	18 (90.0)	1.85 (0.67)	0.7	1.37	1.84	2.27	3.2	
			Placebo	24	23 (95.8)	2.02 (0.54)	1.0	1.64	2.02	2.35	3.3	
		Week 52	Tezepelumab	20	18 (90.0)	1.85 (0.66)	0.7	1.32	1.84	2.29	3.1	
			Placebo	24	22 (91.7)	1.98 (0.59)	1.0	1.61	1.87	2.30	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Change from baseline	Week 2	Tezepelumab	20	19 (95.0)	0.12 (0.23)	-0.3	-0.03	0.09	0.25	0.6	-0.01 [-0.63, 0.61]
			Placebo	24	21 (87.5)	0.12 (0.24)	-0.6	0.00	0.13	0.30	0.5	
		Week 4	Tezepelumab	20	19 (95.0)	0.18 (0.29)	-0.2	-0.04	0.11	0.29	1.1	0.05 [-0.55, 0.66]
			Placebo	24	23 (95.8)	0.16 (0.32)	-0.7	0.02	0.19	0.34	0.9	
		Week 8	Tezepelumab	20	19 (95.0)	0.13 (0.31)	-0.3	-0.05	0.10	0.21	1.2	-0.30 [-0.91, 0.31]
			Placebo	24	23 (95.8)	0.21 (0.25)	-0.5	0.07	0.23	0.40	0.6	
		Week 12	Tezepelumab	20	19 (95.0)	0.10 (0.30)	-0.2	-0.08	0.06	0.16	1.1	-0.32 [-0.93, 0.28]
			Placebo	24	24 (100.0)	0.19 (0.24)	-0.2	0.05	0.16	0.39	0.8	
		Week 16	Tezepelumab	20	18 (90.0)	0.14 (0.27)	-0.3	-0.05	0.09	0.21	1.1	-0.15 [-0.77, 0.47]
			Placebo	24	23 (95.8)	0.19 (0.30)	-0.4	-0.05	0.20	0.38	0.7	
		Week 24	Tezepelumab	20	17 (85.0)	0.11 (0.34)	-0.4	-0.05	0.13	0.21	1.2	-0.08 [-0.72, 0.55]
			Placebo	24	22 (91.7)	0.14 (0.40)	-0.7	-0.18	0.18	0.38	0.8	
		Week 36	Tezepelumab	20	18 (90.0)	0.12 (0.34)	-0.2	-0.04	0.06	0.14	1.3	-0.29 [-0.91, 0.33]
			Placebo	24	23 (95.8)	0.21 (0.32)	-0.5	-0.12	0.26	0.45	0.8	
		Week 52	Tezepelumab	20	18 (90.0)	0.11 (0.28)	-0.3	-0.03	0.06	0.23	0.8	-0.10 [-0.72, 0.52]
			Placebo	24	22 (91.7)	0.15 (0.39)	-0.6	-0.11	0.15	0.45	1.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Absolute values	Baseline	Tezepelumab	78	78 (100.0)	1.91 (0.69)	0.8	1.41	1.79	2.38	3.8	
			Placebo	74	74 (100.0)	1.87 (0.79)	0.7	1.26	1.76	2.34	4.2	
		Week 2	Tezepelumab	78	77 (98.7)	2.06 (0.74)	0.7	1.49	1.97	2.45	4.0	
			Placebo	74	71 (95.9)	1.97 (0.82)	0.6	1.36	1.85	2.49	4.0	
		Week 4	Tezepelumab	78	78 (100.0)	2.10 (0.74)	0.7	1.61	2.10	2.54	4.3	
			Placebo	74	73 (98.6)	1.94 (0.82)	0.7	1.33	1.88	2.49	4.2	
		Week 8	Tezepelumab	78	78 (100.0)	2.12 (0.77)	0.8	1.58	2.12	2.53	4.7	
			Placebo	74	69 (93.2)	2.02 (0.82)	0.7	1.35	2.05	2.63	4.3	
		Week 12	Tezepelumab	78	75 (96.2)	2.08 (0.78)	0.8	1.54	2.04	2.39	4.7	
			Placebo	74	70 (94.6)	1.93 (0.86)	0.6	1.25	1.73	2.54	4.3	
		Week 16	Tezepelumab	78	74 (94.9)	2.15 (0.77)	0.7	1.65	2.07	2.51	4.9	
			Placebo	74	70 (94.6)	1.91 (0.79)	0.7	1.31	1.77	2.40	4.1	
		Week 24	Tezepelumab	78	73 (93.6)	2.09 (0.70)	0.7	1.69	2.05	2.43	4.4	
			Placebo	74	63 (85.1)	1.95 (0.85)	0.6	1.25	2.02	2.31	4.8	
		Week 36	Tezepelumab	78	71 (91.0)	2.11 (0.73)	0.8	1.56	2.07	2.50	4.5	
			Placebo	74	60 (81.1)	2.07 (0.80)	0.8	1.46	2.02	2.56	4.6	
		Week 52	Tezepelumab	78	68 (87.2)	2.10 (0.74)	0.8	1.65	2.07	2.50	4.1	
			Placebo	74	59 (79.7)	2.10 (0.84)	0.7	1.34	1.99	2.64	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Change from baseline	Week 2	Tezepelumab	78	77 (98.7)	0.16 (0.30)	-0.6	0.00	0.13	0.29	1.1	0.23 [-0.09, 0.55]
			Placebo	74	71 (95.9)	0.08 (0.38)	-0.8	-0.12	0.01	0.22	1.7	
		Week 4	Tezepelumab	78	78 (100.0)	0.20 (0.36)	-0.7	-0.05	0.15	0.32	1.4	0.33 [0.01, 0.65]
			Placebo	74	73 (98.6)	0.08 (0.36)	-0.7	-0.11	0.03	0.25	1.4	
		Week 8	Tezepelumab	78	78 (100.0)	0.21 (0.43)	-0.6	-0.08	0.10	0.44	1.8	0.21 [-0.12, 0.53]
			Placebo	74	69 (93.2)	0.12 (0.45)	-0.8	-0.12	0.04	0.32	2.1	
		Week 12	Tezepelumab	78	75 (96.2)	0.18 (0.43)	-0.8	-0.09	0.12	0.38	1.9	0.27 [-0.06, 0.60]
			Placebo	74	70 (94.6)	0.07 (0.36)	-0.7	-0.11	0.02	0.24	1.2	
		Week 16	Tezepelumab	78	74 (94.9)	0.24 (0.44)	-0.8	-0.04	0.16	0.40	2.0	0.48 [0.15, 0.81]
			Placebo	74	70 (94.6)	0.03 (0.40)	-1.2	-0.16	0.02	0.18	1.4	
		Week 24	Tezepelumab	78	73 (93.6)	0.19 (0.38)	-0.5	-0.06	0.15	0.40	1.5	0.37 [0.03, 0.71]
			Placebo	74	63 (85.1)	0.05 (0.41)	-0.9	-0.15	-0.01	0.19	1.6	
		Week 36	Tezepelumab	78	71 (91.0)	0.19 (0.40)	-0.5	-0.08	0.12	0.46	1.7	0.15 [-0.20, 0.49]
			Placebo	74	60 (81.1)	0.13 (0.42)	-1.1	-0.08	0.14	0.38	1.5	
		Week 52	Tezepelumab	78	68 (87.2)	0.18 (0.38)	-0.6	-0.08	0.17	0.35	1.3	0.07 [-0.28, 0.42]
			Placebo	74	59 (79.7)	0.15 (0.39)	-0.8	-0.05	0.10	0.32	1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Absolute values	Baseline	Tezepelumab	198	198 (100.0)	1.94 (0.75)	0.6	1.38	1.78	2.40	4.8	
			Placebo	198	198 (100.0)	2.00 (0.79)	0.6	1.38	1.93	2.44	4.9	
		Week 2	Tezepelumab	198	192 (97.0)	2.12 (0.76)	0.8	1.54	1.99	2.65	5.0	
			Placebo	198	189 (95.5)	2.08 (0.76)	0.6	1.48	2.01	2.54	4.7	
		Week 4	Tezepelumab	198	194 (98.0)	2.10 (0.78)	0.7	1.51	1.97	2.66	5.0	
			Placebo	198	190 (96.0)	2.08 (0.74)	0.5	1.56	2.03	2.53	4.8	
		Week 8	Tezepelumab	198	193 (97.5)	2.11 (0.80)	0.7	1.45	1.99	2.60	4.6	
			Placebo	198	193 (97.5)	2.09 (0.80)	0.6	1.56	1.98	2.59	4.9	
		Week 12	Tezepelumab	198	189 (95.5)	2.13 (0.81)	0.8	1.56	1.96	2.71	4.9	
			Placebo	198	195 (98.5)	2.09 (0.79)	0.5	1.54	1.99	2.54	5.0	
		Week 16	Tezepelumab	198	190 (96.0)	2.14 (0.81)	0.8	1.53	2.00	2.63	4.9	
			Placebo	198	192 (97.0)	2.11 (0.82)	0.5	1.54	2.02	2.57	5.2	
		Week 24	Tezepelumab	198	183 (92.4)	2.11 (0.81)	0.7	1.51	1.96	2.66	5.5	
			Placebo	198	185 (93.4)	2.11 (0.80)	0.6	1.53	1.96	2.61	5.1	
		Week 36	Tezepelumab	198	178 (89.9)	2.14 (0.82)	0.7	1.47	2.10	2.72	4.9	
			Placebo	198	187 (94.4)	2.15 (0.83)	0.6	1.52	2.08	2.64	5.3	
		Week 52	Tezepelumab	198	172 (86.9)	2.15 (0.84)	0.6	1.57	2.04	2.76	4.6	
			Placebo	198	171 (86.4)	2.15 (0.87)	0.6	1.51	2.06	2.72	5.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Change from baseline	Week 2	Tezepelumab	198	192 (97.0)	0.18 (0.34)	-0.7	0.00	0.13	0.32	1.5	0.29 [0.09, 0.50]
			Placebo	198	189 (95.5)	0.07 (0.41)	-1.8	-0.10	0.01	0.20	1.7	
		Week 4	Tezepelumab	198	194 (98.0)	0.17 (0.36)	-1.2	-0.06	0.11	0.33	1.3	0.20 [-0.00, 0.40]
			Placebo	198	190 (96.0)	0.09 (0.42)	-1.8	-0.09	0.06	0.25	1.7	
		Week 8	Tezepelumab	198	193 (97.5)	0.19 (0.44)	-1.1	-0.05	0.11	0.38	1.9	0.26 [0.06, 0.46]
			Placebo	198	193 (97.5)	0.08 (0.38)	-1.7	-0.11	0.06	0.25	2.0	
		Week 12	Tezepelumab	198	189 (95.5)	0.20 (0.41)	-1.5	-0.01	0.11	0.39	2.2	0.26 [0.06, 0.46]
			Placebo	198	195 (98.5)	0.09 (0.46)	-1.5	-0.15	0.03	0.28	1.6	
		Week 16	Tezepelumab	198	190 (96.0)	0.21 (0.40)	-0.8	-0.04	0.14	0.35	2.1	0.27 [0.07, 0.47]
			Placebo	198	192 (97.0)	0.10 (0.41)	-1.6	-0.12	0.04	0.26	1.6	
		Week 24	Tezepelumab	198	183 (92.4)	0.20 (0.41)	-0.8	-0.07	0.13	0.38	1.8	0.28 [0.07, 0.48]
			Placebo	198	185 (93.4)	0.08 (0.40)	-1.4	-0.11	0.05	0.25	1.6	
		Week 36	Tezepelumab	198	178 (89.9)	0.22 (0.39)	-0.8	-0.04	0.16	0.40	1.7	0.19 [-0.02, 0.39]
			Placebo	198	187 (94.4)	0.14 (0.46)	-1.7	-0.12	0.06	0.29	2.2	
		Week 52	Tezepelumab	198	172 (86.9)	0.24 (0.43)	-0.8	-0.03	0.15	0.48	1.7	0.26 [0.04, 0.47]
			Placebo	198	171 (86.4)	0.13 (0.44)	-1.4	-0.15	0.08	0.30	2.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Absolute values	Baseline	Tezepelumab	133	133 (100.0)	1.73 (0.67)	0.4	1.26	1.71	2.17	4.1	
			Placebo	138	138 (100.0)	1.75 (0.55)	0.4	1.37	1.70	2.06	3.1	
		Week 2	Tezepelumab	133	131 (98.5)	1.88 (0.68)	0.6	1.31	1.80	2.31	4.3	
			Placebo	138	133 (96.4)	1.82 (0.60)	0.4	1.45	1.73	2.17	3.9	
		Week 4	Tezepelumab	133	133 (100.0)	1.95 (0.68)	0.7	1.46	1.93	2.41	3.7	
			Placebo	138	137 (99.3)	1.81 (0.58)	0.4	1.44	1.71	2.13	3.7	
		Week 8	Tezepelumab	133	129 (97.0)	1.99 (0.69)	0.6	1.48	1.93	2.41	4.7	
			Placebo	138	137 (99.3)	1.84 (0.61)	0.4	1.42	1.78	2.20	4.3	
		Week 12	Tezepelumab	133	130 (97.7)	1.98 (0.67)	0.6	1.50	1.93	2.38	3.8	
			Placebo	138	135 (97.8)	1.86 (0.61)	0.7	1.48	1.74	2.23	4.3	
		Week 16	Tezepelumab	133	131 (98.5)	2.00 (0.72)	0.6	1.52	1.88	2.47	4.7	
			Placebo	138	133 (96.4)	1.86 (0.59)	0.7	1.49	1.76	2.15	4.4	
		Week 24	Tezepelumab	133	130 (97.7)	1.96 (0.65)	0.7	1.56	1.82	2.34	4.0	
			Placebo	138	130 (94.2)	1.85 (0.58)	0.7	1.45	1.73	2.14	4.3	
		Week 36	Tezepelumab	133	125 (94.0)	1.97 (0.71)	0.6	1.51	1.81	2.44	4.4	
			Placebo	138	122 (88.4)	1.84 (0.62)	0.7	1.46	1.73	2.18	4.3	
		Week 52	Tezepelumab	133	125 (94.0)	1.97 (0.69)	0.6	1.50	1.82	2.37	4.2	
			Placebo	138	120 (87.0)	1.81 (0.58)	0.7	1.44	1.70	2.15	3.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Change from baseline	Week 2	Tezepelumab	133	131 (98.5)	0.16 (0.34)	-0.6	-0.01	0.09	0.25	1.3	0.30 [0.06, 0.54]
			Placebo	138	133 (96.4)	0.06 (0.32)	-0.7	-0.10	0.04	0.19	1.2	
		Week 4	Tezepelumab	133	133 (100.0)	0.21 (0.37)	-0.9	0.02	0.14	0.35	1.8	0.45 [0.21, 0.69]
			Placebo	138	137 (99.3)	0.05 (0.34)	-0.7	-0.13	0.01	0.20	1.1	
		Week 8	Tezepelumab	133	129 (97.0)	0.26 (0.42)	-0.8	0.03	0.17	0.49	1.7	0.46 [0.21, 0.70]
			Placebo	138	137 (99.3)	0.09 (0.33)	-0.7	-0.13	0.05	0.24	1.6	
		Week 12	Tezepelumab	133	130 (97.7)	0.27 (0.43)	-0.7	0.04	0.20	0.45	2.0	0.46 [0.21, 0.70]
			Placebo	138	135 (97.8)	0.09 (0.34)	-0.9	-0.07	0.03	0.19	1.7	
		Week 16	Tezepelumab	133	131 (98.5)	0.27 (0.42)	-0.6	0.00	0.20	0.45	1.7	0.47 [0.23, 0.71]
			Placebo	138	133 (96.4)	0.09 (0.33)	-0.8	-0.10	0.03	0.26	1.8	
		Week 24	Tezepelumab	133	130 (97.7)	0.24 (0.41)	-1.0	0.00	0.18	0.41	1.6	0.43 [0.19, 0.68]
			Placebo	138	130 (94.2)	0.07 (0.36)	-0.9	-0.14	0.07	0.22	1.7	
		Week 36	Tezepelumab	133	125 (94.0)	0.25 (0.44)	-1.0	0.00	0.21	0.42	1.5	0.44 [0.19, 0.69]
			Placebo	138	122 (88.4)	0.06 (0.39)	-1.0	-0.20	0.02	0.29	1.7	
		Week 52	Tezepelumab	133	125 (94.0)	0.24 (0.43)	-1.0	-0.02	0.17	0.47	1.6	0.52 [0.26, 0.77]
			Placebo	138	120 (87.0)	0.04 (0.32)	-1.0	-0.18	0.01	0.24	0.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Absolute values	Baseline	Tezepelumab	119	119 (100.0)	1.71 (0.70)	0.6	1.21	1.63	2.07	4.1	
			Placebo	121	121 (100.0)	1.70 (0.61)	0.8	1.28	1.58	1.98	4.0	
		Week 2	Tezepelumab	119	114 (95.8)	1.88 (0.70)	0.6	1.37	1.75	2.41	3.9	
			Placebo	121	114 (94.2)	1.72 (0.61)	0.7	1.28	1.63	2.04	3.6	
		Week 4	Tezepelumab	119	118 (99.2)	1.90 (0.73)	0.6	1.28	1.78	2.38	3.9	
			Placebo	121	116 (95.9)	1.80 (0.62)	0.7	1.35	1.67	2.11	4.1	
		Week 8	Tezepelumab	119	118 (99.2)	1.91 (0.69)	0.6	1.36	1.78	2.37	3.9	
			Placebo	121	118 (97.5)	1.79 (0.65)	0.7	1.36	1.69	2.13	4.7	
		Week 12	Tezepelumab	119	116 (97.5)	1.93 (0.71)	0.6	1.38	1.83	2.49	4.0	
			Placebo	121	114 (94.2)	1.81 (0.68)	0.6	1.35	1.65	2.21	4.6	
		Week 16	Tezepelumab	119	115 (96.6)	1.93 (0.73)	0.6	1.38	1.84	2.46	3.9	
			Placebo	121	114 (94.2)	1.81 (0.66)	0.8	1.33	1.70	2.18	4.7	
		Week 24	Tezepelumab	119	112 (94.1)	1.94 (0.75)	0.6	1.38	1.81	2.45	4.0	
			Placebo	121	113 (93.4)	1.77 (0.64)	0.7	1.37	1.65	2.12	4.6	
		Week 36	Tezepelumab	119	109 (91.6)	1.94 (0.71)	0.5	1.37	1.85	2.44	3.8	
			Placebo	121	106 (87.6)	1.76 (0.63)	0.8	1.36	1.65	2.19	4.3	
		Week 52	Tezepelumab	119	106 (89.1)	1.95 (0.75)	0.7	1.41	1.86	2.51	4.0	
			Placebo	121	103 (85.1)	1.75 (0.66)	0.8	1.27	1.62	2.12	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Change from baseline	Week 2	Tezepelumab	119	114 (95.8)	0.16 (0.35)	-0.8	-0.05	0.10	0.28	1.9	0.49 [0.23, 0.75]
			Placebo	121	114 (94.2)	0.01 (0.28)	-0.8	-0.12	0.01	0.13	1.0	
		Week 4	Tezepelumab	119	118 (99.2)	0.18 (0.39)	-1.0	-0.04	0.11	0.36	1.7	0.18 [-0.07, 0.44]
			Placebo	121	116 (95.9)	0.11 (0.38)	-1.0	-0.11	0.06	0.34	1.2	
		Week 8	Tezepelumab	119	118 (99.2)	0.22 (0.33)	-0.5	0.01	0.16	0.34	1.2	0.32 [0.06, 0.57]
			Placebo	121	118 (97.5)	0.10 (0.39)	-0.9	-0.09	0.03	0.23	1.8	
		Week 12	Tezepelumab	119	116 (97.5)	0.24 (0.36)	-0.5	-0.03	0.18	0.43	1.5	0.27 [0.01, 0.53]
			Placebo	121	114 (94.2)	0.13 (0.38)	-1.1	-0.06	0.05	0.23	2.1	
		Week 16	Tezepelumab	119	115 (96.6)	0.21 (0.43)	-1.0	-0.04	0.15	0.45	1.8	0.22 [-0.04, 0.48]
			Placebo	121	114 (94.2)	0.13 (0.36)	-1.0	-0.06	0.08	0.27	1.9	
		Week 24	Tezepelumab	119	112 (94.1)	0.22 (0.43)	-1.0	-0.05	0.13	0.41	2.1	0.32 [0.05, 0.58]
			Placebo	121	113 (93.4)	0.09 (0.36)	-1.1	-0.10	0.02	0.26	1.7	
		Week 36	Tezepelumab	119	109 (91.6)	0.20 (0.40)	-0.5	-0.07	0.11	0.40	1.8	0.29 [0.02, 0.55]
			Placebo	121	106 (87.6)	0.09 (0.36)	-0.9	-0.09	0.04	0.27	1.6	
		Week 52	Tezepelumab	119	106 (89.1)	0.22 (0.40)	-0.5	-0.07	0.14	0.38	1.5	0.37 [0.10, 0.65]
			Placebo	121	103 (85.1)	0.07 (0.39)	-1.0	-0.14	0.06	0.21	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
< 18.5 kg/m**2	Absolute values	Baseline	Tezepelumab	11	11 (100.0)	2.30 (0.63)	1.3	1.58	2.37	2.83	3.1	
			Placebo	11	11 (100.0)	2.61 (0.82)	1.0	2.24	2.70	3.15	4.0	
		Week 2	Tezepelumab	11	11 (100.0)	2.26 (0.68)	1.0	1.69	2.28	2.89	3.2	
			Placebo	11	11 (100.0)	2.56 (0.69)	1.1	2.27	2.70	3.15	3.4	
		Week 4	Tezepelumab	11	11 (100.0)	2.25 (0.70)	1.3	1.69	2.18	3.08	3.2	
			Placebo	11	11 (100.0)	2.45 (0.78)	1.2	1.65	2.59	3.18	3.3	
		Week 8	Tezepelumab	11	11 (100.0)	2.27 (0.76)	1.0	1.61	2.12	3.15	3.3	
			Placebo	11	11 (100.0)	2.52 (0.61)	1.5	2.31	2.43	3.06	3.4	
		Week 12	Tezepelumab	11	11 (100.0)	2.24 (0.88)	0.8	1.42	2.10	3.26	3.4	
			Placebo	11	11 (100.0)	2.49 (0.81)	1.0	1.72	2.59	3.07	3.6	
		Week 16	Tezepelumab	11	11 (100.0)	2.27 (0.64)	1.4	1.59	2.24	2.87	3.2	
			Placebo	11	11 (100.0)	2.43 (0.73)	1.1	1.79	2.46	3.06	3.3	
		Week 24	Tezepelumab	11	11 (100.0)	2.36 (0.69)	1.4	1.70	2.27	3.05	3.3	
			Placebo	11	10 (90.9)	2.56 (0.64)	1.3	2.10	2.68	3.14	3.2	
		Week 36	Tezepelumab	11	10 (90.9)	2.27 (0.76)	1.3	1.43	2.28	3.08	3.3	
			Placebo	11	9 (81.8)	2.65 (0.76)	1.3	2.45	2.90	3.04	3.5	
		Week 52	Tezepelumab	11	10 (90.9)	2.24 (0.72)	1.1	1.80	2.23	3.08	3.3	
			Placebo	11	7 (63.6)	2.90 (0.50)	2.0	2.67	2.93	3.22	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
< 18.5 kg/m**2	Change from baseline	Week 2	Tezepelumab	11	11 (100.0)	-0.04 (0.26)	-0.6	-0.09	0.05	0.10	0.3	0.04 [-0.80, 0.87]
			Placebo	11	11 (100.0)	-0.06 (0.53)	-1.3	-0.27	0.00	0.18	0.7	
		Week 4	Tezepelumab	11	11 (100.0)	-0.05 (0.32)	-0.9	-0.15	-0.04	0.11	0.4	0.31 [-0.53, 1.15]
			Placebo	11	11 (100.0)	-0.17 (0.44)	-1.0	-0.48	-0.11	0.21	0.4	
		Week 8	Tezepelumab	11	11 (100.0)	-0.03 (0.38)	-0.8	-0.22	0.02	0.24	0.6	0.13 [-0.71, 0.97]
			Placebo	11	11 (100.0)	-0.10 (0.59)	-1.7	-0.13	0.02	0.21	0.6	
		Week 12	Tezepelumab	11	11 (100.0)	-0.07 (0.40)	-0.7	-0.24	-0.09	0.17	0.5	0.11 [-0.73, 0.95]
			Placebo	11	11 (100.0)	-0.12 (0.54)	-1.0	-0.69	-0.09	0.39	0.8	
		Week 16	Tezepelumab	11	11 (100.0)	-0.03 (0.27)	-0.6	-0.10	0.01	0.11	0.4	0.32 [-0.52, 1.16]
			Placebo	11	11 (100.0)	-0.18 (0.59)	-1.6	-0.59	-0.03	0.22	0.5	
		Week 24	Tezepelumab	11	11 (100.0)	0.05 (0.29)	-0.6	-0.10	0.10	0.21	0.5	0.36 [-0.50, 1.22]
			Placebo	11	10 (90.9)	-0.09 (0.52)	-1.4	-0.26	0.03	0.23	0.3	
		Week 36	Tezepelumab	11	10 (90.9)	0.03 (0.35)	-0.7	-0.12	0.04	0.23	0.5	0.11 [-0.79, 1.02]
			Placebo	11	9 (81.8)	-0.02 (0.55)	-1.2	-0.21	0.04	0.30	0.6	
		Week 52	Tezepelumab	11	10 (90.9)	0.00 (0.43)	-1.0	-0.15	0.06	0.35	0.4	0.10 [-0.87, 1.07]
			Placebo	11	7 (63.6)	-0.05 (0.64)	-1.4	-0.29	0.23	0.30	0.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Absolute values	Baseline	Tezepelumab	157	157 (100.0)	1.83 (0.78)	0.4	1.29	1.68	2.25	4.8	
			Placebo	179	179 (100.0)	1.95 (0.74)	0.4	1.43	1.84	2.35	4.9	
		Week 2	Tezepelumab	157	153 (97.5)	2.03 (0.80)	0.6	1.43	1.97	2.53	5.0	
			Placebo	179	171 (95.5)	2.05 (0.72)	0.4	1.53	1.94	2.51	4.7	
		Week 4	Tezepelumab	157	157 (100.0)	2.05 (0.78)	0.7	1.51	1.94	2.54	5.0	
			Placebo	179	174 (97.2)	2.02 (0.71)	0.4	1.53	1.96	2.50	4.1	
		Week 8	Tezepelumab	157	155 (98.7)	2.09 (0.78)	0.6	1.47	2.01	2.62	4.6	
			Placebo	179	177 (98.9)	2.05 (0.76)	0.4	1.52	1.97	2.51	4.9	
		Week 12	Tezepelumab	157	156 (99.4)	2.10 (0.78)	0.6	1.56	1.93	2.65	4.9	
			Placebo	179	173 (96.6)	2.08 (0.77)	0.7	1.52	1.99	2.52	5.0	
		Week 16	Tezepelumab	157	150 (95.5)	2.14 (0.81)	0.6	1.55	1.98	2.67	4.9	
			Placebo	179	172 (96.1)	2.08 (0.77)	0.7	1.57	1.95	2.53	5.2	
		Week 24	Tezepelumab	157	151 (96.2)	2.06 (0.79)	0.7	1.54	1.87	2.56	5.5	
			Placebo	179	167 (93.3)	2.07 (0.75)	0.7	1.51	1.96	2.48	5.1	
		Week 36	Tezepelumab	157	145 (92.4)	2.13 (0.79)	0.6	1.58	1.96	2.67	4.9	
			Placebo	179	157 (87.7)	2.09 (0.82)	0.7	1.49	1.97	2.48	5.3	
		Week 52	Tezepelumab	157	137 (87.3)	2.12 (0.81)	0.8	1.56	1.88	2.69	4.6	
			Placebo	179	157 (87.7)	2.08 (0.82)	0.7	1.52	1.93	2.56	5.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Change from baseline	Week 2	Tezepelumab	157	153 (97.5)	0.20 (0.36)	-0.5	-0.01	0.13	0.33	1.4	0.36 [0.14, 0.58]
			Placebo	179	171 (95.5)	0.07 (0.37)	-1.1	-0.09	0.04	0.18	1.7	
		Week 4	Tezepelumab	157	157 (100.0)	0.22 (0.40)	-1.2	0.00	0.16	0.38	1.8	0.30 [0.08, 0.51]
			Placebo	179	174 (97.2)	0.10 (0.41)	-1.8	-0.10	0.05	0.28	1.7	
		Week 8	Tezepelumab	157	155 (98.7)	0.25 (0.46)	-1.1	-0.04	0.15	0.50	1.7	0.35 [0.13, 0.57]
			Placebo	179	177 (98.9)	0.10 (0.40)	-0.9	-0.12	0.03	0.28	2.1	
		Week 12	Tezepelumab	157	156 (99.4)	0.28 (0.45)	-1.5	0.01	0.21	0.46	2.0	0.34 [0.12, 0.56]
			Placebo	179	173 (96.6)	0.13 (0.39)	-1.1	-0.07	0.06	0.28	1.6	
		Week 16	Tezepelumab	157	150 (95.5)	0.31 (0.44)	-0.6	0.00	0.22	0.55	1.7	0.44 [0.22, 0.66]
			Placebo	179	172 (96.1)	0.12 (0.40)	-1.2	-0.08	0.07	0.33	1.6	
		Week 24	Tezepelumab	157	151 (96.2)	0.24 (0.45)	-1.0	-0.05	0.17	0.44	1.8	0.32 [0.10, 0.54]
			Placebo	179	167 (93.3)	0.10 (0.41)	-1.1	-0.12	0.07	0.31	1.6	
		Week 36	Tezepelumab	157	145 (92.4)	0.28 (0.45)	-1.0	-0.02	0.25	0.50	1.7	0.33 [0.10, 0.56]
			Placebo	179	157 (87.7)	0.13 (0.45)	-1.1	-0.11	0.09	0.30	2.2	
		Week 52	Tezepelumab	157	137 (87.3)	0.27 (0.41)	-0.7	-0.01	0.22	0.51	1.6	0.39 [0.16, 0.62]
			Placebo	179	157 (87.7)	0.11 (0.42)	-1.0	-0.12	0.08	0.31	1.9	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	178	178 (100.0)	1.88 (0.72)	0.6	1.35	1.77	2.30	4.1	
			Placebo	161	161 (100.0)	1.84 (0.69)	0.6	1.35	1.71	2.26	4.1	
		Week 2	Tezepelumab	178	176 (98.9)	2.05 (0.75)	0.7	1.49	1.96	2.49	4.3	
			Placebo	161	152 (94.4)	1.90 (0.70)	0.6	1.39	1.75	2.43	4.2	
		Week 4	Tezepelumab	178	175 (98.3)	2.07 (0.77)	0.7	1.48	1.99	2.60	4.3	
			Placebo	161	155 (96.3)	1.93 (0.71)	0.5	1.39	1.80	2.35	4.8	
		Week 8	Tezepelumab	178	174 (97.8)	2.11 (0.79)	0.7	1.51	2.00	2.55	4.7	
			Placebo	161	156 (96.9)	1.94 (0.76)	0.6	1.37	1.82	2.32	4.7	
		Week 12	Tezepelumab	178	171 (96.1)	2.11 (0.79)	0.7	1.52	1.99	2.64	4.7	
			Placebo	161	154 (95.7)	1.96 (0.75)	0.5	1.40	1.86	2.38	4.6	
		Week 16	Tezepelumab	178	173 (97.2)	2.12 (0.82)	0.6	1.52	2.04	2.62	4.9	
			Placebo	161	153 (95.0)	1.94 (0.76)	0.5	1.35	1.85	2.38	4.7	
		Week 24	Tezepelumab	178	166 (93.3)	2.10 (0.74)	0.6	1.61	2.03	2.55	4.4	
			Placebo	161	145 (90.1)	1.94 (0.76)	0.7	1.41	1.85	2.28	4.8	
		Week 36	Tezepelumab	178	162 (91.0)	2.09 (0.80)	0.5	1.52	2.06	2.50	4.5	
			Placebo	161	144 (89.4)	1.98 (0.75)	0.6	1.38	1.89	2.45	4.3	
		Week 52	Tezepelumab	178	161 (90.4)	2.12 (0.79)	0.6	1.60	2.06	2.61	4.3	
			Placebo	161	131 (81.4)	1.93 (0.74)	0.6	1.32	1.81	2.42	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Change from baseline	Week 2	Tezepelumab	178	176 (98.9)	0.17 (0.36)	-0.8	-0.03	0.11	0.29	1.9	0.35 [0.13, 0.57]
			Placebo	161	152 (94.4)	0.05 (0.34)	-0.7	-0.14	0.01	0.17	1.2	
		Week 4	Tezepelumab	178	175 (98.3)	0.20 (0.38)	-1.0	-0.03	0.12	0.33	1.7	0.26 [0.04, 0.48]
			Placebo	161	155 (96.3)	0.10 (0.38)	-0.7	-0.11	0.02	0.24	1.6	
		Week 8	Tezepelumab	178	174 (97.8)	0.24 (0.40)	-0.8	0.02	0.16	0.41	1.9	0.35 [0.13, 0.57]
			Placebo	161	156 (96.9)	0.10 (0.38)	-1.1	-0.10	0.07	0.24	1.8	
		Week 12	Tezepelumab	178	171 (96.1)	0.24 (0.42)	-0.6	-0.03	0.17	0.40	2.2	0.30 [0.08, 0.52]
			Placebo	161	154 (95.7)	0.12 (0.38)	-0.7	-0.11	0.03	0.25	1.8	
		Week 16	Tezepelumab	178	173 (97.2)	0.25 (0.45)	-1.0	-0.04	0.16	0.40	2.1	0.37 [0.15, 0.59]
			Placebo	161	153 (95.0)	0.10 (0.40)	-1.0	-0.14	0.00	0.24	1.9	
		Week 24	Tezepelumab	178	166 (93.3)	0.24 (0.40)	-0.7	-0.02	0.20	0.41	2.1	0.37 [0.15, 0.60]
			Placebo	161	145 (90.1)	0.10 (0.39)	-0.6	-0.14	0.03	0.27	1.7	
		Week 36	Tezepelumab	178	162 (91.0)	0.24 (0.42)	-0.8	-0.05	0.15	0.43	1.8	0.29 [0.07, 0.52]
			Placebo	161	144 (89.4)	0.12 (0.40)	-0.7	-0.15	0.04	0.31	1.7	
		Week 52	Tezepelumab	178	161 (90.4)	0.26 (0.42)	-0.8	-0.03	0.21	0.51	1.7	0.47 [0.24, 0.71]
			Placebo	161	131 (81.4)	0.06 (0.39)	-0.9	-0.17	0.01	0.23	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	182	182 (100.0)	1.75 (0.65)	0.6	1.28	1.63	2.12	4.0	
			Placebo	180	180 (100.0)	1.71 (0.64)	0.7	1.27	1.60	2.05	4.2	
		Week 2	Tezepelumab	182	174 (95.6)	1.90 (0.65)	0.6	1.39	1.82	2.41	4.1	
			Placebo	180	173 (96.1)	1.76 (0.66)	0.6	1.29	1.65	2.07	4.0	
		Week 4	Tezepelumab	182	180 (98.9)	1.91 (0.67)	0.6	1.39	1.82	2.39	4.2	
			Placebo	180	176 (97.8)	1.79 (0.64)	0.7	1.36	1.71	2.07	4.2	
		Week 8	Tezepelumab	182	178 (97.8)	1.91 (0.66)	0.6	1.34	1.85	2.37	4.1	
			Placebo	180	173 (96.1)	1.81 (0.66)	0.7	1.36	1.70	2.13	4.3	
		Week 12	Tezepelumab	182	172 (94.5)	1.90 (0.66)	0.6	1.38	1.83	2.32	4.6	
			Placebo	180	176 (97.8)	1.76 (0.66)	0.6	1.33	1.65	2.08	4.3	
		Week 16	Tezepelumab	182	176 (96.7)	1.91 (0.65)	0.6	1.39	1.86	2.31	4.2	
			Placebo	180	173 (96.1)	1.80 (0.64)	0.6	1.33	1.70	2.11	4.1	
		Week 24	Tezepelumab	182	170 (93.4)	1.91 (0.69)	0.6	1.40	1.79	2.40	4.0	
			Placebo	180	169 (93.9)	1.77 (0.65)	0.6	1.38	1.69	2.09	4.8	
		Week 36	Tezepelumab	182	166 (91.2)	1.92 (0.67)	0.7	1.42	1.81	2.34	4.4	
			Placebo	180	165 (91.7)	1.82 (0.65)	0.7	1.43	1.71	2.19	4.6	
		Week 52	Tezepelumab	182	163 (89.6)	1.92 (0.70)	0.6	1.36	1.84	2.33	4.2	
			Placebo	180	158 (87.8)	1.83 (0.70)	0.6	1.32	1.72	2.21	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Change from baseline	Week 2	Tezepelumab	182	174 (95.6)	0.15 (0.29)	-0.7	0.00	0.11	0.28	1.1	0.30 [0.09, 0.52]
			Placebo	180	173 (96.1)	0.05 (0.34)	-1.8	-0.11	-0.01	0.18	1.1	
		Week 4	Tezepelumab	182	180 (98.9)	0.16 (0.32)	-0.9	-0.04	0.11	0.32	1.1	0.28 [0.07, 0.49]
			Placebo	180	176 (97.8)	0.07 (0.34)	-1.0	-0.08	0.05	0.25	1.1	
		Week 8	Tezepelumab	182	178 (97.8)	0.17 (0.36)	-0.9	-0.05	0.11	0.34	1.4	0.25 [0.04, 0.46]
			Placebo	180	173 (96.1)	0.08 (0.35)	-0.8	-0.10	0.03	0.25	1.8	
		Week 12	Tezepelumab	182	172 (94.5)	0.17 (0.35)	-0.8	-0.03	0.12	0.34	1.3	0.32 [0.11, 0.53]
			Placebo	180	176 (97.8)	0.05 (0.41)	-1.5	-0.11	0.04	0.21	2.1	
		Week 16	Tezepelumab	182	176 (96.7)	0.15 (0.36)	-0.8	-0.04	0.12	0.30	1.4	0.22 [0.01, 0.43]
			Placebo	180	173 (96.1)	0.08 (0.32)	-0.8	-0.09	0.05	0.22	1.3	
		Week 24	Tezepelumab	182	170 (93.4)	0.17 (0.38)	-1.0	-0.09	0.08	0.35	1.7	0.32 [0.10, 0.53]
			Placebo	180	169 (93.9)	0.06 (0.33)	-1.1	-0.11	0.04	0.22	1.3	
		Week 36	Tezepelumab	182	166 (91.2)	0.16 (0.35)	-0.6	-0.09	0.08	0.35	1.6	0.20 [-0.02, 0.41]
			Placebo	180	165 (91.7)	0.09 (0.38)	-1.7	-0.14	0.05	0.28	1.6	
		Week 52	Tezepelumab	182	163 (89.6)	0.16 (0.40)	-1.0	-0.07	0.11	0.35	1.4	0.15 [-0.07, 0.37]
			Placebo	180	158 (87.8)	0.11 (0.37)	-0.8	-0.10	0.08	0.23	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Absolute values	Baseline	Tezepelumab	138	138 (100.0)	1.93 (0.73)	0.4	1.35	1.92	2.42	4.1	
			Placebo	138	138 (100.0)	1.84 (0.63)	0.8	1.41	1.80	2.18	4.9	
		Week 2	Tezepelumab	138	135 (97.8)	2.00 (0.74)	0.6	1.41	1.96	2.47	4.1	
			Placebo	138	132 (95.7)	1.89 (0.67)	0.8	1.41	1.78	2.25	4.7	
		Week 4	Tezepelumab	138	137 (99.3)	1.99 (0.78)	0.7	1.36	1.97	2.52	4.2	
			Placebo	138	134 (97.1)	1.88 (0.63)	0.7	1.42	1.83	2.32	3.6	
		Week 8	Tezepelumab	138	133 (96.4)	2.01 (0.73)	0.6	1.51	1.89	2.43	4.1	
			Placebo	138	134 (97.1)	1.92 (0.71)	0.7	1.41	1.86	2.34	4.9	
		Week 12	Tezepelumab	138	132 (95.7)	2.00 (0.73)	0.6	1.49	1.94	2.45	4.2	
			Placebo	138	132 (95.7)	1.91 (0.74)	0.7	1.38	1.81	2.29	5.0	
		Week 16	Tezepelumab	138	134 (97.1)	2.01 (0.78)	0.6	1.46	1.88	2.54	4.3	
			Placebo	138	133 (96.4)	1.90 (0.72)	0.6	1.36	1.78	2.31	5.2	
		Week 24	Tezepelumab	138	126 (91.3)	1.99 (0.70)	0.6	1.48	1.91	2.42	4.0	
			Placebo	138	127 (92.0)	1.91 (0.71)	0.7	1.38	1.80	2.28	5.1	
		Week 36	Tezepelumab	138	126 (91.3)	2.00 (0.75)	0.5	1.45	1.93	2.47	4.4	
			Placebo	138	123 (89.1)	1.94 (0.70)	0.8	1.41	1.85	2.34	5.3	
		Week 52	Tezepelumab	138	124 (89.9)	2.01 (0.74)	0.7	1.48	1.95	2.56	4.2	
			Placebo	138	121 (87.7)	1.92 (0.75)	0.7	1.36	1.78	2.41	5.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Change from baseline	Week 2	Tezepelumab	138	135 (97.8)	0.06 (0.29)	-0.8	-0.06	0.07	0.18	1.5	0.04 [-0.20, 0.28]
			Placebo	138	132 (95.7)	0.05 (0.34)	-1.8	-0.10	0.02	0.17	1.2	
		Week 4	Tezepelumab	138	137 (99.3)	0.07 (0.36)	-1.0	-0.11	0.03	0.20	1.7	0.01 [-0.23, 0.25]
			Placebo	138	134 (97.1)	0.06 (0.34)	-1.0	-0.06	0.05	0.22	1.1	
		Week 8	Tezepelumab	138	133 (96.4)	0.08 (0.35)	-0.9	-0.12	0.04	0.24	1.4	-0.04 [-0.28, 0.20]
			Placebo	138	134 (97.1)	0.09 (0.37)	-1.1	-0.10	0.05	0.28	1.8	
		Week 12	Tezepelumab	138	132 (95.7)	0.08 (0.33)	-0.8	-0.10	0.07	0.24	1.4	-0.01 [-0.26, 0.23]
			Placebo	138	132 (95.7)	0.09 (0.38)	-1.2	-0.08	0.03	0.24	1.8	
		Week 16	Tezepelumab	138	134 (97.1)	0.08 (0.40)	-1.0	-0.14	0.03	0.24	1.9	0.04 [-0.20, 0.28]
			Placebo	138	133 (96.4)	0.06 (0.37)	-1.0	-0.14	0.03	0.22	1.9	
		Week 24	Tezepelumab	138	126 (91.3)	0.08 (0.31)	-0.6	-0.10	0.03	0.22	1.1	0.02 [-0.23, 0.27]
			Placebo	138	127 (92.0)	0.07 (0.36)	-1.1	-0.11	0.04	0.23	1.7	
		Week 36	Tezepelumab	138	126 (91.3)	0.05 (0.34)	-0.7	-0.13	0.00	0.22	1.5	-0.10 [-0.35, 0.15]
			Placebo	138	123 (89.1)	0.09 (0.33)	-0.7	-0.13	0.06	0.28	1.5	
		Week 52	Tezepelumab	138	124 (89.9)	0.08 (0.36)	-1.0	-0.12	0.04	0.23	1.3	0.05 [-0.20, 0.30]
			Placebo	138	121 (87.7)	0.06 (0.39)	-1.0	-0.17	0.06	0.20	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Absolute values	Baseline	Tezepelumab	390	390 (100.0)	1.80 (0.71)	0.5	1.28	1.65	2.19	4.8	
			Placebo	393	393 (100.0)	1.86 (0.73)	0.4	1.35	1.71	2.26	4.5	
		Week 2	Tezepelumab	390	379 (97.2)	2.00 (0.73)	0.6	1.45	1.87	2.47	5.0	
			Placebo	393	375 (95.4)	1.92 (0.73)	0.4	1.38	1.80	2.37	4.2	
		Week 4	Tezepelumab	390	386 (99.0)	2.02 (0.73)	0.6	1.48	1.91	2.50	5.0	
			Placebo	393	382 (97.2)	1.94 (0.72)	0.4	1.44	1.83	2.33	4.8	
		Week 8	Tezepelumab	390	385 (98.7)	2.05 (0.75)	0.6	1.43	1.95	2.48	4.7	
			Placebo	393	383 (97.5)	1.96 (0.74)	0.4	1.41	1.85	2.35	4.6	
		Week 12	Tezepelumab	390	378 (96.9)	2.05 (0.76)	0.6	1.52	1.93	2.53	4.9	
			Placebo	393	382 (97.2)	1.96 (0.74)	0.5	1.45	1.82	2.40	4.6	
		Week 16	Tezepelumab	390	376 (96.4)	2.07 (0.76)	0.6	1.51	1.95	2.52	4.9	
			Placebo	393	376 (95.7)	1.97 (0.74)	0.5	1.46	1.84	2.37	4.7	
		Week 24	Tezepelumab	390	372 (95.4)	2.04 (0.76)	0.6	1.54	1.93	2.52	5.5	
			Placebo	393	364 (92.6)	1.95 (0.74)	0.6	1.44	1.84	2.28	4.8	
		Week 36	Tezepelumab	390	357 (91.5)	2.06 (0.76)	0.7	1.48	1.94	2.50	4.9	
			Placebo	393	352 (89.6)	1.99 (0.77)	0.6	1.44	1.82	2.37	4.6	
		Week 52	Tezepelumab	390	347 (89.0)	2.07 (0.78)	0.6	1.50	1.94	2.50	4.6	
			Placebo	393	332 (84.5)	1.98 (0.78)	0.6	1.41	1.82	2.38	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Change from baseline	Week 2	Tezepelumab	390	379 (97.2)	0.20 (0.34)	-0.7	0.00	0.13	0.34	1.9	0.42 [0.28, 0.57]
			Placebo	393	375 (95.4)	0.06 (0.36)	-1.3	-0.12	0.01	0.18	1.7	
		Week 4	Tezepelumab	390	386 (99.0)	0.23 (0.36)	-1.2	0.01	0.16	0.37	1.8	0.37 [0.23, 0.51]
			Placebo	393	382 (97.2)	0.09 (0.40)	-1.8	-0.11	0.05	0.27	1.7	
		Week 8	Tezepelumab	390	385 (98.7)	0.26 (0.42)	-1.1	0.02	0.17	0.45	1.9	0.42 [0.28, 0.56]
			Placebo	393	383 (97.5)	0.09 (0.38)	-1.7	-0.11	0.04	0.25	2.1	
		Week 12	Tezepelumab	390	378 (96.9)	0.27 (0.42)	-1.5	0.02	0.20	0.45	2.2	0.42 [0.27, 0.56]
			Placebo	393	382 (97.2)	0.10 (0.41)	-1.5	-0.11	0.04	0.26	2.1	
		Week 16	Tezepelumab	390	376 (96.4)	0.28 (0.41)	-0.6	0.01	0.20	0.46	2.1	0.45 [0.30, 0.59]
			Placebo	393	376 (95.7)	0.10 (0.38)	-1.6	-0.09	0.04	0.27	1.8	
		Week 24	Tezepelumab	390	372 (95.4)	0.26 (0.43)	-1.0	-0.02	0.21	0.44	2.1	0.43 [0.28, 0.57]
			Placebo	393	364 (92.6)	0.08 (0.39)	-1.4	-0.13	0.04	0.26	1.7	
		Week 36	Tezepelumab	390	357 (91.5)	0.28 (0.41)	-1.0	-0.01	0.22	0.49	1.8	0.38 [0.23, 0.52]
			Placebo	393	352 (89.6)	0.11 (0.44)	-1.7	-0.13	0.05	0.31	2.2	
		Week 52	Tezepelumab	390	347 (89.0)	0.28 (0.42)	-0.8	-0.01	0.22	0.52	1.7	0.41 [0.26, 0.57]
			Placebo	393	332 (84.5)	0.11 (0.40)	-1.4	-0.13	0.06	0.29	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Absolute values	Baseline	Tezepelumab	309	309 (100.0)	1.88 (0.72)	0.4	1.35	1.83	2.30	4.8	
			Placebo	309	309 (100.0)	1.85 (0.66)	0.7	1.40	1.73	2.18	4.9	
		Week 2	Tezepelumab	309	302 (97.7)	1.99 (0.74)	0.6	1.44	1.96	2.47	5.0	
			Placebo	309	297 (96.1)	1.89 (0.70)	0.6	1.39	1.75	2.29	4.7	
		Week 4	Tezepelumab	309	307 (99.4)	1.99 (0.75)	0.6	1.40	1.95	2.51	5.0	
			Placebo	309	300 (97.1)	1.88 (0.66)	0.7	1.43	1.79	2.27	4.8	
		Week 8	Tezepelumab	309	303 (98.1)	2.00 (0.73)	0.6	1.42	1.94	2.46	4.6	
			Placebo	309	299 (96.8)	1.94 (0.71)	0.7	1.43	1.82	2.31	4.9	
		Week 12	Tezepelumab	309	296 (95.8)	1.98 (0.74)	0.6	1.45	1.91	2.41	4.9	
			Placebo	309	297 (96.1)	1.90 (0.73)	0.6	1.40	1.74	2.29	5.0	
		Week 16	Tezepelumab	309	300 (97.1)	2.00 (0.75)	0.6	1.44	1.88	2.48	4.9	
			Placebo	309	297 (96.1)	1.91 (0.74)	0.6	1.40	1.76	2.31	5.2	
		Week 24	Tezepelumab	309	291 (94.2)	1.97 (0.74)	0.6	1.41	1.87	2.45	5.5	
			Placebo	309	287 (92.9)	1.89 (0.72)	0.6	1.40	1.74	2.24	5.1	
		Week 36	Tezepelumab	309	284 (91.9)	1.98 (0.74)	0.5	1.41	1.87	2.49	4.9	
			Placebo	309	277 (89.6)	1.91 (0.72)	0.7	1.41	1.74	2.27	5.3	
		Week 52	Tezepelumab	309	282 (91.3)	1.99 (0.76)	0.6	1.43	1.91	2.52	4.6	
			Placebo	309	264 (85.4)	1.92 (0.76)	0.7	1.39	1.73	2.32	5.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Change from baseline	Week 2	Tezepelumab	309	302 (97.7)	0.11 (0.28)	-0.8	-0.04	0.08	0.24	1.5	0.24 [0.08, 0.40]
			Placebo	309	297 (96.1)	0.03 (0.32)	-1.8	-0.11	0.00	0.16	1.2	
		Week 4	Tezepelumab	309	307 (99.4)	0.12 (0.33)	-1.0	-0.06	0.08	0.24	1.7	0.20 [0.04, 0.36]
			Placebo	309	300 (97.1)	0.05 (0.34)	-1.0	-0.11	0.04	0.20	1.6	
		Week 8	Tezepelumab	309	303 (98.1)	0.13 (0.35)	-0.9	-0.07	0.10	0.27	1.4	0.14 [-0.02, 0.30]
			Placebo	309	299 (96.8)	0.08 (0.34)	-1.1	-0.10	0.04	0.24	1.8	
		Week 12	Tezepelumab	309	296 (95.8)	0.12 (0.34)	-0.8	-0.07	0.09	0.25	2.0	0.17 [0.00, 0.33]
			Placebo	309	297 (96.1)	0.06 (0.37)	-1.5	-0.10	0.03	0.19	2.1	
		Week 16	Tezepelumab	309	300 (97.1)	0.12 (0.36)	-1.0	-0.08	0.08	0.26	1.9	0.17 [0.01, 0.33]
			Placebo	309	297 (96.1)	0.06 (0.35)	-1.2	-0.11	0.03	0.21	1.9	
		Week 24	Tezepelumab	309	291 (94.2)	0.10 (0.34)	-1.0	-0.11	0.06	0.27	1.3	0.17 [0.00, 0.33]
			Placebo	309	287 (92.9)	0.04 (0.34)	-1.1	-0.12	0.02	0.22	1.7	
		Week 36	Tezepelumab	309	284 (91.9)	0.10 (0.35)	-1.0	-0.11	0.04	0.27	1.5	0.13 [-0.04, 0.30]
			Placebo	309	277 (89.6)	0.05 (0.36)	-1.1	-0.17	0.03	0.25	1.6	
		Week 52	Tezepelumab	309	282 (91.3)	0.11 (0.36)	-1.0	-0.09	0.06	0.26	1.5	0.13 [-0.03, 0.30]
			Placebo	309	264 (85.4)	0.07 (0.36)	-1.0	-0.15	0.05	0.22	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Absolute values	Baseline	Tezepelumab	219	219 (100.0)	1.76 (0.72)	0.5	1.24	1.62	2.12	4.1	
			Placebo	222	222 (100.0)	1.85 (0.77)	0.4	1.30	1.70	2.27	4.5	
		Week 2	Tezepelumab	219	212 (96.8)	2.01 (0.73)	0.8	1.44	1.87	2.47	4.3	
			Placebo	222	210 (94.6)	1.96 (0.72)	0.4	1.40	1.92	2.46	4.2	
		Week 4	Tezepelumab	219	216 (98.6)	2.05 (0.73)	0.7	1.55	1.91	2.53	4.3	
			Placebo	222	216 (97.3)	1.98 (0.75)	0.4	1.44	1.90	2.50	4.2	
		Week 8	Tezepelumab	219	215 (98.2)	2.09 (0.77)	0.9	1.48	1.95	2.49	4.7	
			Placebo	222	218 (98.2)	1.96 (0.76)	0.4	1.34	1.92	2.41	4.3	
		Week 12	Tezepelumab	219	214 (97.7)	2.12 (0.77)	0.7	1.57	1.96	2.58	4.7	
			Placebo	222	217 (97.7)	2.01 (0.75)	0.5	1.46	1.95	2.44	4.3	
		Week 16	Tezepelumab	219	210 (95.9)	2.13 (0.79)	0.8	1.57	2.01	2.62	4.9	
			Placebo	222	212 (95.5)	2.00 (0.73)	0.5	1.51	1.91	2.46	4.4	
		Week 24	Tezepelumab	219	207 (94.5)	2.11 (0.74)	0.8	1.60	1.96	2.55	4.4	
			Placebo	222	204 (91.9)	2.01 (0.74)	0.7	1.48	1.91	2.38	4.8	
		Week 36	Tezepelumab	219	199 (90.9)	2.14 (0.77)	0.7	1.56	2.00	2.50	4.5	
			Placebo	222	198 (89.2)	2.06 (0.79)	0.6	1.48	1.97	2.43	4.6	
		Week 52	Tezepelumab	219	189 (86.3)	2.14 (0.78)	0.6	1.58	2.01	2.54	4.3	
			Placebo	222	189 (85.1)	2.02 (0.79)	0.6	1.40	1.98	2.45	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Change from baseline	Week 2	Tezepelumab	219	212 (96.8)	0.25 (0.38)	-0.6	0.03	0.17	0.41	1.9	0.43 [0.24, 0.63]
			Placebo	222	210 (94.6)	0.08 (0.40)	-1.3	-0.11	0.03	0.26	1.7	
		Week 4	Tezepelumab	219	216 (98.6)	0.29 (0.39)	-1.2	0.04	0.25	0.46	1.8	0.38 [0.19, 0.57]
			Placebo	222	216 (97.3)	0.14 (0.43)	-1.8	-0.11	0.06	0.35	1.7	
		Week 8	Tezepelumab	219	215 (98.2)	0.34 (0.46)	-1.1	0.05	0.27	0.59	1.9	0.51 [0.32, 0.70]
			Placebo	222	218 (98.2)	0.11 (0.43)	-1.7	-0.13	0.06	0.28	2.1	
		Week 12	Tezepelumab	219	214 (97.7)	0.37 (0.45)	-1.5	0.06	0.30	0.57	2.2	0.50 [0.31, 0.69]
			Placebo	222	217 (97.7)	0.15 (0.43)	-1.4	-0.10	0.07	0.36	1.7	
		Week 16	Tezepelumab	219	210 (95.9)	0.38 (0.45)	-0.5	0.08	0.31	0.59	2.1	0.57 [0.37, 0.76]
			Placebo	222	212 (95.5)	0.14 (0.41)	-1.6	-0.09	0.05	0.35	1.8	
		Week 24	Tezepelumab	219	207 (94.5)	0.37 (0.44)	-0.8	0.07	0.31	0.56	2.1	0.55 [0.35, 0.75]
			Placebo	222	204 (91.9)	0.13 (0.44)	-1.4	-0.13	0.07	0.34	1.7	
		Week 36	Tezepelumab	219	199 (90.9)	0.39 (0.42)	-0.5	0.08	0.35	0.56	1.8	0.45 [0.25, 0.65]
			Placebo	222	198 (89.2)	0.18 (0.47)	-1.7	-0.06	0.12	0.41	2.2	
		Week 52	Tezepelumab	219	189 (86.3)	0.39 (0.43)	-0.8	0.10	0.35	0.63	1.7	0.58 [0.38, 0.79]
			Placebo	222	189 (85.1)	0.13 (0.44)	-1.4	-0.10	0.07	0.34	2.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Absolute values	Baseline	Tezepelumab	213	213 (100.0)	1.78 (0.68)	0.4	1.28	1.63	2.20	4.1	
			Placebo	220	220 (100.0)	1.86 (0.71)	0.4	1.36	1.74	2.28	3.9	
		Week 2	Tezepelumab	213	206 (96.7)	1.92 (0.66)	0.6	1.38	1.86	2.42	4.1	
			Placebo	220	204 (92.7)	1.92 (0.71)	0.4	1.40	1.85	2.39	4.1	
		Week 4	Tezepelumab	213	210 (98.6)	1.90 (0.68)	0.6	1.39	1.83	2.39	4.2	
			Placebo	220	213 (96.8)	1.92 (0.70)	0.4	1.46	1.83	2.34	4.8	
		Week 8	Tezepelumab	213	208 (97.7)	1.92 (0.68)	0.6	1.41	1.85	2.36	4.1	
			Placebo	220	214 (97.3)	1.94 (0.71)	0.4	1.45	1.86	2.36	4.7	
		Week 12	Tezepelumab	213	205 (96.2)	1.91 (0.66)	0.6	1.45	1.86	2.30	4.2	
			Placebo	220	211 (95.9)	1.94 (0.74)	0.5	1.43	1.75	2.44	4.6	
		Week 16	Tezepelumab	213	205 (96.2)	1.93 (0.69)	0.6	1.40	1.84	2.39	4.2	
			Placebo	220	212 (96.4)	1.92 (0.73)	0.5	1.36	1.80	2.37	4.7	
		Week 24	Tezepelumab	213	202 (94.8)	1.90 (0.68)	0.6	1.40	1.81	2.32	4.0	
			Placebo	220	208 (94.5)	1.92 (0.73)	0.6	1.43	1.81	2.28	4.8	
		Week 36	Tezepelumab	213	192 (90.1)	1.89 (0.66)	0.5	1.41	1.83	2.33	4.4	
			Placebo	220	199 (90.5)	1.95 (0.73)	0.6	1.42	1.82	2.38	4.3	
		Week 52	Tezepelumab	213	192 (90.1)	1.90 (0.68)	0.7	1.43	1.82	2.27	4.2	
			Placebo	220	193 (87.7)	1.94 (0.76)	0.6	1.38	1.78	2.43	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Change from baseline	Week 2	Tezepelumab	213	206 (96.7)	0.13 (0.33)	-0.8	-0.03	0.08	0.23	1.9	0.27 [0.08, 0.47]
			Placebo	220	204 (92.7)	0.04 (0.29)	-0.8	-0.11	0.00	0.15	1.2	
		Week 4	Tezepelumab	213	210 (98.6)	0.13 (0.35)	-1.0	-0.06	0.07	0.28	1.7	0.19 [-0.00, 0.38]
			Placebo	220	213 (96.8)	0.07 (0.32)	-0.9	-0.09	0.03	0.20	1.6	
		Week 8	Tezepelumab	213	208 (97.7)	0.15 (0.36)	-0.9	-0.05	0.11	0.26	1.6	0.19 [-0.00, 0.38]
			Placebo	220	214 (97.3)	0.08 (0.36)	-1.0	-0.10	0.04	0.21	1.8	
		Week 12	Tezepelumab	213	205 (96.2)	0.15 (0.34)	-0.7	-0.04	0.10	0.28	1.5	0.19 [-0.00, 0.38]
			Placebo	220	211 (95.9)	0.08 (0.37)	-1.5	-0.08	0.03	0.20	2.1	
		Week 16	Tezepelumab	213	205 (96.2)	0.14 (0.37)	-1.0	-0.05	0.10	0.28	1.8	0.21 [0.02, 0.41]
			Placebo	220	212 (96.4)	0.06 (0.35)	-1.0	-0.11	0.02	0.19	1.9	
		Week 24	Tezepelumab	213	202 (94.8)	0.14 (0.38)	-1.0	-0.08	0.06	0.30	2.1	0.26 [0.06, 0.45]
			Placebo	220	208 (94.5)	0.04 (0.35)	-1.1	-0.13	0.03	0.17	1.7	
		Week 36	Tezepelumab	213	192 (90.1)	0.11 (0.36)	-1.0	-0.11	0.08	0.32	1.8	0.07 [-0.13, 0.27]
			Placebo	220	199 (90.5)	0.09 (0.33)	-0.8	-0.09	0.06	0.26	1.6	
		Week 52	Tezepelumab	213	192 (90.1)	0.14 (0.38)	-1.0	-0.06	0.10	0.32	1.5	0.14 [-0.06, 0.34]
			Placebo	220	193 (87.7)	0.08 (0.36)	-1.0	-0.12	0.05	0.22	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Absolute values	Baseline	Tezepelumab	309	309 (100.0)	1.88 (0.74)	0.5	1.35	1.77	2.29	4.8	
			Placebo	307	307 (100.0)	1.84 (0.71)	0.6	1.36	1.71	2.22	4.9	
		Week 2	Tezepelumab	309	302 (97.7)	2.07 (0.77)	0.7	1.52	1.96	2.53	5.0	
			Placebo	307	299 (97.4)	1.91 (0.72)	0.6	1.39	1.78	2.33	4.7	
		Week 4	Tezepelumab	309	308 (99.7)	2.10 (0.77)	0.7	1.51	2.00	2.64	5.0	
			Placebo	307	299 (97.4)	1.93 (0.70)	0.7	1.42	1.83	2.28	4.2	
		Week 8	Tezepelumab	309	304 (98.4)	2.13 (0.78)	0.8	1.52	2.08	2.59	4.7	
			Placebo	307	299 (97.4)	1.95 (0.75)	0.7	1.39	1.85	2.34	4.9	
		Week 12	Tezepelumab	309	299 (96.8)	2.14 (0.80)	0.7	1.55	1.96	2.65	4.9	
			Placebo	307	300 (97.7)	1.95 (0.74)	0.6	1.43	1.84	2.33	5.0	
		Week 16	Tezepelumab	309	299 (96.8)	2.16 (0.81)	0.7	1.59	2.02	2.62	4.9	
			Placebo	307	294 (95.8)	1.97 (0.74)	0.6	1.48	1.84	2.31	5.2	
		Week 24	Tezepelumab	309	290 (93.9)	2.13 (0.77)	0.7	1.61	2.00	2.60	5.5	
			Placebo	307	280 (91.2)	1.96 (0.74)	0.6	1.44	1.86	2.28	5.1	
		Week 36	Tezepelumab	309	285 (92.2)	2.16 (0.80)	0.6	1.57	2.06	2.67	4.9	
			Placebo	307	273 (88.9)	1.99 (0.77)	0.7	1.46	1.83	2.33	5.3	
		Week 52	Tezepelumab	309	274 (88.7)	2.17 (0.81)	0.6	1.59	2.06	2.70	4.6	
			Placebo	307	257 (83.7)	1.98 (0.78)	0.7	1.40	1.85	2.33	5.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Change from baseline	Week 2	Tezepelumab	309	302 (97.7)	0.20 (0.34)	-0.6	0.00	0.15	0.34	1.5	0.37 [0.21, 0.53]
			Placebo	307	299 (97.4)	0.06 (0.40)	-1.8	-0.11	0.02	0.21	1.7	
		Week 4	Tezepelumab	309	308 (99.7)	0.23 (0.37)	-1.2	0.01	0.16	0.38	1.8	0.33 [0.17, 0.49]
			Placebo	307	299 (97.4)	0.10 (0.42)	-1.8	-0.12	0.05	0.30	1.7	
		Week 8	Tezepelumab	309	304 (98.4)	0.27 (0.44)	-1.1	-0.01	0.18	0.50	1.9	0.38 [0.22, 0.55]
			Placebo	307	299 (97.4)	0.11 (0.40)	-1.7	-0.12	0.06	0.30	2.1	
		Week 12	Tezepelumab	309	299 (96.8)	0.28 (0.45)	-1.5	0.01	0.21	0.47	2.2	0.39 [0.22, 0.55]
			Placebo	307	300 (97.7)	0.11 (0.42)	-1.4	-0.12	0.06	0.31	1.7	
		Week 16	Tezepelumab	309	299 (96.8)	0.29 (0.44)	-0.8	0.00	0.22	0.49	2.1	0.41 [0.25, 0.58]
			Placebo	307	294 (95.8)	0.12 (0.40)	-1.6	-0.10	0.05	0.33	1.8	
		Week 24	Tezepelumab	309	290 (93.9)	0.27 (0.43)	-1.0	-0.03	0.23	0.47	1.8	0.38 [0.22, 0.55]
			Placebo	307	280 (91.2)	0.11 (0.41)	-1.4	-0.12	0.06	0.30	1.7	
		Week 36	Tezepelumab	309	285 (92.2)	0.29 (0.43)	-0.6	-0.02	0.22	0.53	1.7	0.37 [0.21, 0.54]
			Placebo	307	273 (88.9)	0.12 (0.47)	-1.7	-0.17	0.05	0.38	2.2	
		Week 52	Tezepelumab	309	274 (88.7)	0.29 (0.43)	-0.8	-0.03	0.24	0.54	1.7	0.44 [0.26, 0.61]
			Placebo	307	257 (83.7)	0.10 (0.42)	-1.4	-0.15	0.07	0.31	2.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	184	184 (100.0)	1.66 (0.66)	0.4	1.19	1.58	2.08	4.8	
			Placebo	177	177 (100.0)	1.69 (0.61)	0.6	1.30	1.64	1.97	4.2	
		Week 2	Tezepelumab	184	181 (98.4)	1.85 (0.67)	0.6	1.35	1.80	2.29	5.0	
			Placebo	177	169 (95.5)	1.73 (0.62)	0.6	1.35	1.63	1.98	4.0	
		Week 4	Tezepelumab	184	183 (99.5)	1.91 (0.69)	0.7	1.30	1.85	2.39	5.0	
			Placebo	177	171 (96.6)	1.78 (0.64)	0.7	1.32	1.68	2.13	4.2	
		Week 8	Tezepelumab	184	181 (98.4)	1.91 (0.68)	0.6	1.36	1.83	2.44	4.6	
			Placebo	177	171 (96.6)	1.78 (0.64)	0.7	1.34	1.67	2.06	4.3	
		Week 12	Tezepelumab	184	182 (98.9)	1.92 (0.70)	0.6	1.41	1.84	2.38	4.9	
			Placebo	177	172 (97.2)	1.78 (0.66)	0.6	1.32	1.65	2.12	4.3	
		Week 16	Tezepelumab	184	181 (98.4)	1.93 (0.71)	0.6	1.37	1.84	2.40	4.9	
			Placebo	177	169 (95.5)	1.78 (0.63)	0.7	1.32	1.71	2.15	4.2	
		Week 24	Tezepelumab	184	177 (96.2)	1.91 (0.71)	0.6	1.38	1.79	2.39	5.5	
			Placebo	177	157 (88.7)	1.77 (0.63)	0.7	1.38	1.66	2.11	4.8	
		Week 36	Tezepelumab	184	172 (93.5)	1.91 (0.70)	0.5	1.39	1.82	2.34	4.9	
			Placebo	177	155 (87.6)	1.81 (0.63)	0.8	1.36	1.70	2.21	4.6	
		Week 52	Tezepelumab	184	170 (92.4)	1.95 (0.70)	0.6	1.42	1.88	2.39	4.6	
			Placebo	177	148 (83.6)	1.72 (0.62)	0.6	1.30	1.62	2.08	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Change from baseline	Week 2	Tezepelumab	184	181 (98.4)	0.19 (0.30)	-0.4	0.02	0.12	0.29	1.1	0.54 [0.33, 0.76]
			Placebo	177	169 (95.5)	0.03 (0.27)	-0.7	-0.10	-0.01	0.13	1.0	
		Week 4	Tezepelumab	184	183 (99.5)	0.24 (0.35)	-0.7	0.01	0.17	0.39	1.7	0.46 [0.25, 0.67]
			Placebo	177	171 (96.6)	0.09 (0.32)	-1.0	-0.07	0.05	0.22	1.2	
		Week 8	Tezepelumab	184	181 (98.4)	0.26 (0.38)	-0.6	0.00	0.16	0.45	1.4	0.52 [0.31, 0.73]
			Placebo	177	171 (96.6)	0.09 (0.29)	-0.6	-0.11	0.05	0.24	1.2	
		Week 12	Tezepelumab	184	182 (98.9)	0.26 (0.38)	-0.7	0.01	0.21	0.45	1.4	0.48 [0.27, 0.69]
			Placebo	177	172 (97.2)	0.09 (0.33)	-0.7	-0.10	0.03	0.20	1.2	
		Week 16	Tezepelumab	184	181 (98.4)	0.27 (0.38)	-0.6	0.02	0.22	0.44	1.6	0.53 [0.32, 0.74]
			Placebo	177	169 (95.5)	0.09 (0.29)	-0.7	-0.08	0.04	0.26	1.2	
		Week 24	Tezepelumab	184	177 (96.2)	0.25 (0.38)	-0.5	-0.03	0.20	0.43	1.7	0.52 [0.30, 0.74]
			Placebo	177	157 (88.7)	0.07 (0.31)	-0.8	-0.11	0.05	0.22	1.2	
		Week 36	Tezepelumab	184	172 (93.5)	0.23 (0.39)	-0.6	-0.04	0.16	0.44	1.6	0.37 [0.15, 0.59]
			Placebo	177	155 (87.6)	0.10 (0.33)	-0.9	-0.11	0.06	0.29	1.3	
		Week 52	Tezepelumab	184	170 (92.4)	0.26 (0.40)	-0.6	-0.04	0.22	0.49	1.4	0.68 [0.45, 0.91]
			Placebo	177	148 (83.6)	0.01 (0.30)	-0.9	-0.18	0.04	0.19	0.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	339	339 (100.0)	1.92 (0.73)	0.5	1.41	1.80	2.39	4.1	
			Placebo	341	341 (100.0)	1.94 (0.74)	0.4	1.38	1.82	2.38	4.9	
		Week 2	Tezepelumab	339	329 (97.1)	2.08 (0.76)	0.6	1.50	1.99	2.59	4.3	
			Placebo	341	329 (96.5)	2.02 (0.74)	0.4	1.45	1.95	2.49	4.7	
		Week 4	Tezepelumab	339	337 (99.4)	2.07 (0.76)	0.6	1.50	1.97	2.60	4.3	
			Placebo	341	333 (97.7)	2.01 (0.72)	0.4	1.50	1.91	2.50	4.8	
		Week 8	Tezepelumab	339	333 (98.2)	2.10 (0.77)	0.6	1.52	2.01	2.54	4.7	
			Placebo	341	333 (97.7)	2.05 (0.77)	0.4	1.51	1.98	2.51	4.9	
		Week 12	Tezepelumab	339	324 (95.6)	2.10 (0.76)	0.6	1.58	1.96	2.62	4.7	
			Placebo	341	330 (96.8)	2.04 (0.77)	0.5	1.50	1.94	2.48	5.0	
		Week 16	Tezepelumab	339	325 (95.9)	2.12 (0.78)	0.6	1.55	1.98	2.59	4.9	
			Placebo	341	327 (95.9)	2.04 (0.78)	0.5	1.49	1.92	2.52	5.2	
		Week 24	Tezepelumab	339	317 (93.5)	2.09 (0.75)	0.6	1.58	1.97	2.58	4.4	
			Placebo	341	321 (94.1)	2.03 (0.78)	0.6	1.48	1.92	2.46	5.1	
		Week 36	Tezepelumab	339	307 (90.6)	2.12 (0.78)	0.6	1.51	2.02	2.57	4.5	
			Placebo	341	308 (90.3)	2.07 (0.80)	0.6	1.49	1.93	2.50	5.3	
		Week 52	Tezepelumab	339	298 (87.9)	2.11 (0.80)	0.6	1.54	1.97	2.61	4.3	
			Placebo	341	296 (86.8)	2.09 (0.81)	0.6	1.49	1.97	2.65	5.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Change from baseline	Week 2	Tezepelumab	339	329 (97.1)	0.16 (0.35)	-0.8	-0.03	0.10	0.29	1.9	0.23 [0.08, 0.39]
			Placebo	341	329 (96.5)	0.07 (0.39)	-1.8	-0.12	0.04	0.21	1.7	
		Week 4	Tezepelumab	339	337 (99.4)	0.16 (0.37)	-1.2	-0.05	0.10	0.30	1.8	0.18 [0.03, 0.33]
			Placebo	341	333 (97.7)	0.09 (0.41)	-1.8	-0.12	0.05	0.27	1.7	
		Week 8	Tezepelumab	339	333 (98.2)	0.19 (0.42)	-1.1	-0.05	0.12	0.38	1.8	0.20 [0.05, 0.35]
			Placebo	341	333 (97.7)	0.10 (0.42)	-1.7	-0.11	0.05	0.29	2.1	
		Week 12	Tezepelumab	339	324 (95.6)	0.19 (0.41)	-1.5	-0.04	0.12	0.36	2.0	0.23 [0.08, 0.38]
			Placebo	341	330 (96.8)	0.10 (0.44)	-1.5	-0.11	0.05	0.26	2.1	
		Week 16	Tezepelumab	339	325 (95.9)	0.20 (0.43)	-1.0	-0.05	0.13	0.37	2.0	0.23 [0.08, 0.39]
			Placebo	341	327 (95.9)	0.10 (0.42)	-1.6	-0.12	0.04	0.26	1.9	
		Week 24	Tezepelumab	339	317 (93.5)	0.18 (0.42)	-1.0	-0.07	0.12	0.38	2.1	0.24 [0.08, 0.39]
			Placebo	341	321 (94.1)	0.08 (0.42)	-1.4	-0.13	0.03	0.27	1.7	
		Week 36	Tezepelumab	339	307 (90.6)	0.21 (0.41)	-1.0	-0.05	0.14	0.40	1.8	0.20 [0.04, 0.35]
			Placebo	341	308 (90.3)	0.12 (0.45)	-1.7	-0.13	0.06	0.30	2.2	
		Week 52	Tezepelumab	339	298 (87.9)	0.20 (0.41)	-1.0	-0.04	0.13	0.41	1.7	0.14 [-0.02, 0.30]
			Placebo	341	296 (86.8)	0.14 (0.43)	-1.4	-0.11	0.09	0.33	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Absolute values	Baseline	Tezepelumab	158	158 (100.0)	1.72 (0.65)	0.4	1.23	1.64	2.05	4.1	
			Placebo	168	168 (100.0)	1.69 (0.58)	0.7	1.29	1.56	2.03	4.2	
		Week 2	Tezepelumab	158	155 (98.1)	1.83 (0.63)	0.6	1.38	1.70	2.28	3.8	
			Placebo	168	158 (94.0)	1.72 (0.61)	0.6	1.33	1.64	2.04	4.0	
		Week 4	Tezepelumab	158	158 (100.0)	1.87 (0.67)	0.7	1.34	1.74	2.33	3.8	
			Placebo	168	163 (97.0)	1.75 (0.60)	0.7	1.33	1.65	2.07	4.2	
		Week 8	Tezepelumab	158	154 (97.5)	1.88 (0.65)	0.6	1.36	1.76	2.35	3.9	
			Placebo	168	163 (97.0)	1.77 (0.61)	0.7	1.33	1.68	2.07	4.3	
		Week 12	Tezepelumab	158	153 (96.8)	1.88 (0.68)	0.6	1.43	1.77	2.28	4.6	
			Placebo	168	162 (96.4)	1.76 (0.63)	0.6	1.32	1.66	2.13	4.3	
		Week 16	Tezepelumab	158	155 (98.1)	1.89 (0.69)	0.6	1.36	1.79	2.31	3.8	
			Placebo	168	159 (94.6)	1.78 (0.61)	0.6	1.32	1.69	2.16	4.1	
		Week 24	Tezepelumab	158	153 (96.8)	1.85 (0.64)	0.6	1.38	1.80	2.29	3.8	
			Placebo	168	152 (90.5)	1.73 (0.60)	0.7	1.34	1.65	2.07	4.8	
		Week 36	Tezepelumab	158	147 (93.0)	1.86 (0.66)	0.5	1.38	1.77	2.20	3.7	
			Placebo	168	142 (84.5)	1.78 (0.60)	0.7	1.36	1.69	2.10	4.6	
		Week 52	Tezepelumab	158	147 (93.0)	1.87 (0.69)	0.6	1.38	1.75	2.27	4.0	
			Placebo	168	142 (84.5)	1.73 (0.62)	0.7	1.27	1.63	2.09	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Change from baseline	Week 2	Tezepelumab	158	155 (98.1)	0.11 (0.29)	-0.8	-0.01	0.09	0.26	1.1	0.29 [0.07, 0.51]
			Placebo	168	158 (94.0)	0.03 (0.29)	-0.7	-0.10	-0.00	0.12	1.1	
		Week 4	Tezepelumab	158	158 (100.0)	0.15 (0.39)	-1.0	-0.06	0.10	0.32	1.7	0.23 [0.01, 0.45]
			Placebo	168	163 (97.0)	0.07 (0.30)	-0.7	-0.07	0.05	0.18	1.1	
		Week 8	Tezepelumab	158	154 (97.5)	0.17 (0.36)	-0.8	-0.04	0.11	0.30	1.4	0.28 [0.06, 0.50]
			Placebo	168	163 (97.0)	0.08 (0.29)	-0.8	-0.09	0.04	0.20	1.2	
		Week 12	Tezepelumab	158	153 (96.8)	0.17 (0.38)	-0.8	-0.03	0.12	0.30	2.0	0.25 [0.03, 0.48]
			Placebo	168	162 (96.4)	0.08 (0.33)	-0.7	-0.10	0.03	0.20	1.2	
		Week 16	Tezepelumab	158	155 (98.1)	0.17 (0.38)	-1.0	-0.04	0.14	0.33	1.7	0.24 [0.02, 0.47]
			Placebo	168	159 (94.6)	0.08 (0.30)	-0.7	-0.07	0.04	0.26	1.0	
		Week 24	Tezepelumab	158	153 (96.8)	0.16 (0.33)	-0.6	-0.07	0.12	0.32	1.2	0.33 [0.10, 0.55]
			Placebo	168	152 (90.5)	0.05 (0.31)	-0.8	-0.11	0.03	0.19	1.2	
		Week 36	Tezepelumab	158	147 (93.0)	0.14 (0.34)	-0.7	-0.08	0.08	0.32	1.3	0.12 [-0.11, 0.36]
			Placebo	168	142 (84.5)	0.09 (0.33)	-1.1	-0.11	0.04	0.28	1.1	
		Week 52	Tezepelumab	158	147 (93.0)	0.14 (0.37)	-1.0	-0.09	0.11	0.34	1.5	0.33 [0.10, 0.56]
			Placebo	168	142 (84.5)	0.03 (0.31)	-0.7	-0.17	0.03	0.17	1.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Absolute values	Baseline	Tezepelumab	325	325 (100.0)	1.86 (0.75)	0.6	1.33	1.71	2.31	4.8	
			Placebo	303	303 (100.0)	1.92 (0.76)	0.4	1.36	1.78	2.38	4.9	
		Week 2	Tezepelumab	325	316 (97.2)	2.05 (0.77)	0.6	1.47	1.97	2.56	5.0	
			Placebo	303	291 (96.0)	1.96 (0.73)	0.4	1.42	1.90	2.43	4.7	
		Week 4	Tezepelumab	325	320 (98.5)	2.05 (0.77)	0.6	1.48	1.96	2.58	5.0	
			Placebo	303	293 (96.7)	1.97 (0.69)	0.4	1.48	1.87	2.41	4.1	
		Week 8	Tezepelumab	325	319 (98.2)	2.08 (0.77)	0.6	1.45	2.00	2.51	4.7	
			Placebo	303	294 (97.0)	2.00 (0.75)	0.4	1.42	1.94	2.39	4.9	
		Week 12	Tezepelumab	325	313 (96.3)	2.08 (0.77)	0.6	1.53	1.95	2.61	4.9	
			Placebo	303	294 (97.0)	1.99 (0.76)	0.6	1.48	1.87	2.41	5.0	
		Week 16	Tezepelumab	325	311 (95.7)	2.11 (0.79)	0.6	1.53	1.97	2.60	4.9	
			Placebo	303	292 (96.4)	1.99 (0.76)	0.7	1.46	1.86	2.41	5.2	
		Week 24	Tezepelumab	325	302 (92.9)	2.08 (0.77)	0.6	1.57	1.96	2.58	5.5	
			Placebo	303	282 (93.1)	2.01 (0.75)	0.6	1.48	1.90	2.36	5.1	
		Week 36	Tezepelumab	325	295 (90.8)	2.10 (0.79)	0.6	1.49	2.00	2.57	4.9	
			Placebo	303	274 (90.4)	2.03 (0.78)	0.8	1.47	1.90	2.46	5.3	
		Week 52	Tezepelumab	325	283 (87.1)	2.12 (0.80)	0.6	1.51	2.02	2.67	4.6	
			Placebo	303	259 (85.5)	2.04 (0.80)	0.6	1.46	1.91	2.47	5.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Change from baseline	Week 2	Tezepelumab	325	316 (97.2)	0.18 (0.34)	-0.5	-0.03	0.13	0.31	1.9	0.44 [0.28, 0.60]
			Placebo	303	291 (96.0)	0.03 (0.35)	-1.8	-0.12	0.01	0.17	1.2	
		Week 4	Tezepelumab	325	320 (98.5)	0.20 (0.33)	-0.9	-0.01	0.13	0.33	1.8	0.37 [0.21, 0.53]
			Placebo	303	293 (96.7)	0.07 (0.38)	-1.8	-0.11	0.04	0.25	1.4	
		Week 8	Tezepelumab	325	319 (98.2)	0.23 (0.41)	-1.1	-0.04	0.16	0.44	1.9	0.38 [0.22, 0.54]
			Placebo	303	294 (97.0)	0.08 (0.38)	-1.7	-0.12	0.04	0.25	1.8	
		Week 12	Tezepelumab	325	313 (96.3)	0.24 (0.41)	-1.5	-0.03	0.18	0.44	2.2	0.42 [0.26, 0.58]
			Placebo	303	294 (97.0)	0.07 (0.40)	-1.5	-0.11	0.03	0.22	2.1	
		Week 16	Tezepelumab	325	311 (95.7)	0.25 (0.42)	-0.8	-0.02	0.17	0.47	2.1	0.46 [0.30, 0.62]
			Placebo	303	292 (96.4)	0.07 (0.38)	-1.6	-0.15	0.03	0.23	1.9	
		Week 24	Tezepelumab	325	302 (92.9)	0.23 (0.43)	-1.0	-0.04	0.17	0.43	2.1	0.39 [0.23, 0.56]
			Placebo	303	282 (93.1)	0.07 (0.38)	-1.4	-0.13	0.04	0.25	1.7	
		Week 36	Tezepelumab	325	295 (90.8)	0.25 (0.42)	-1.0	-0.03	0.19	0.48	1.8	0.39 [0.22, 0.56]
			Placebo	303	274 (90.4)	0.09 (0.40)	-1.2	-0.15	0.05	0.29	1.7	
		Week 52	Tezepelumab	325	283 (87.1)	0.26 (0.43)	-1.0	-0.03	0.21	0.51	1.7	0.40 [0.23, 0.57]
			Placebo	303	259 (85.5)	0.10 (0.40)	-1.4	-0.14	0.07	0.29	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Absolute values	Baseline	Tezepelumab	45	45 (100.0)	2.00 (0.62)	0.8	1.58	1.99	2.28	3.8	
			Placebo	60	60 (100.0)	1.95 (0.65)	0.6	1.46	1.95	2.43	3.2	
		Week 2	Tezepelumab	45	43 (95.6)	2.23 (0.69)	1.0	1.72	2.24	2.57	3.8	
			Placebo	60	58 (96.7)	2.21 (0.75)	0.8	1.63	2.29	2.63	4.1	
		Week 4	Tezepelumab	45	45 (100.0)	2.25 (0.70)	0.9	1.76	2.23	2.54	4.3	
			Placebo	60	60 (100.0)	2.16 (0.84)	0.5	1.53	2.11	2.65	4.8	
		Week 8	Tezepelumab	45	45 (100.0)	2.29 (0.76)	1.0	1.73	2.20	2.66	4.7	
			Placebo	60	60 (100.0)	2.16 (0.83)	0.6	1.59	2.02	2.85	4.6	
		Week 12	Tezepelumab	45	44 (97.8)	2.31 (0.76)	1.2	1.71	2.21	2.63	4.7	
			Placebo	60	58 (96.7)	2.23 (0.82)	0.5	1.68	2.17	2.60	4.6	
		Week 16	Tezepelumab	45	44 (97.8)	2.28 (0.78)	0.9	1.76	2.18	2.57	4.9	
			Placebo	60	58 (96.7)	2.20 (0.82)	0.5	1.64	2.13	2.62	4.7	
		Week 24	Tezepelumab	45	43 (95.6)	2.29 (0.75)	0.9	1.74	2.27	2.57	4.4	
			Placebo	60	57 (95.0)	2.16 (0.83)	0.7	1.59	2.02	2.64	4.8	
		Week 36	Tezepelumab	45	41 (91.1)	2.31 (0.78)	0.9	1.77	2.37	2.59	4.5	
			Placebo	60	59 (98.3)	2.18 (0.87)	0.6	1.55	2.12	2.67	4.3	
		Week 52	Tezepelumab	45	41 (91.1)	2.27 (0.73)	0.9	1.69	2.23	2.63	4.0	
			Placebo	60	52 (86.7)	2.21 (0.87)	0.6	1.51	2.22	2.80	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Change from baseline	Week 2	Tezepelumab	45	43 (95.6)	0.23 (0.43)	-0.6	0.00	0.13	0.43	1.4	-0.00 [-0.40, 0.39]
			Placebo	60	58 (96.7)	0.23 (0.49)	-0.8	-0.07	0.13	0.48	1.7	
		Week 4	Tezepelumab	45	45 (100.0)	0.25 (0.48)	-1.2	-0.04	0.15	0.42	1.4	0.07 [-0.31, 0.46]
			Placebo	60	60 (100.0)	0.21 (0.54)	-0.8	-0.12	0.14	0.58	1.7	
		Week 8	Tezepelumab	45	45 (100.0)	0.29 (0.55)	-0.5	-0.07	0.14	0.53	1.8	0.14 [-0.24, 0.53]
			Placebo	60	60 (100.0)	0.21 (0.55)	-0.8	-0.12	0.09	0.49	2.1	
		Week 12	Tezepelumab	45	44 (97.8)	0.31 (0.49)	-0.3	0.01	0.19	0.49	1.9	0.04 [-0.35, 0.43]
			Placebo	60	58 (96.7)	0.29 (0.49)	-1.2	0.00	0.17	0.49	1.6	
		Week 16	Tezepelumab	45	44 (97.8)	0.27 (0.53)	-0.5	-0.02	0.11	0.50	2.0	0.03 [-0.36, 0.43]
			Placebo	60	58 (96.7)	0.26 (0.50)	-0.7	-0.05	0.07	0.49	1.6	
		Week 24	Tezepelumab	45	43 (95.6)	0.28 (0.51)	-0.4	-0.08	0.23	0.51	1.8	0.17 [-0.23, 0.56]
			Placebo	60	57 (95.0)	0.20 (0.51)	-1.1	-0.11	0.07	0.53	1.6	
		Week 36	Tezepelumab	45	41 (91.1)	0.30 (0.49)	-0.8	-0.03	0.24	0.53	1.7	0.11 [-0.29, 0.51]
			Placebo	60	59 (98.3)	0.24 (0.60)	-1.7	-0.11	0.14	0.57	2.2	
		Week 52	Tezepelumab	45	41 (91.1)	0.26 (0.41)	-0.8	0.00	0.18	0.46	1.3	-0.01 [-0.42, 0.40]
			Placebo	60	52 (86.7)	0.27 (0.52)	-0.7	-0.07	0.19	0.55	1.9	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Absolute values	Baseline	Tezepelumab	49	49 (100.0)	1.79 (0.73)	0.4	1.31	1.72	2.11	3.6	
			Placebo	51	51 (100.0)	1.81 (0.62)	0.8	1.43	1.75	2.16	3.7	
		Week 2	Tezepelumab	49	48 (98.0)	2.01 (0.74)	0.6	1.54	1.95	2.36	3.9	
			Placebo	51	49 (96.1)	1.81 (0.62)	0.8	1.36	1.74	2.24	3.7	
		Week 4	Tezepelumab	49	49 (100.0)	2.06 (0.75)	0.7	1.57	1.97	2.59	3.8	
			Placebo	51	49 (96.1)	1.84 (0.59)	0.7	1.50	1.76	2.06	4.0	
		Week 8	Tezepelumab	49	48 (98.0)	2.01 (0.72)	0.6	1.53	1.93	2.47	3.7	
			Placebo	51	50 (98.0)	1.86 (0.71)	0.7	1.34	1.78	2.20	3.9	
		Week 12	Tezepelumab	49	45 (91.8)	2.02 (0.79)	0.6	1.54	1.92	2.38	4.6	
			Placebo	51	47 (92.2)	1.88 (0.63)	0.7	1.48	1.81	2.13	3.6	
		Week 16	Tezepelumab	49	46 (93.9)	2.03 (0.76)	0.6	1.54	1.96	2.48	4.2	
			Placebo	51	44 (86.3)	1.83 (0.62)	0.9	1.45	1.77	2.12	3.6	
		Week 24	Tezepelumab	49	43 (87.8)	2.00 (0.67)	0.9	1.61	1.89	2.50	3.7	
			Placebo	51	36 (70.6)	1.81 (0.67)	0.9	1.32	1.80	2.19	4.2	
		Week 36	Tezepelumab	49	40 (81.6)	1.98 (0.71)	0.9	1.52	1.87	2.37	4.0	
			Placebo	51	39 (76.5)	1.90 (0.60)	0.8	1.46	1.82	2.16	3.6	
		Week 52	Tezepelumab	49	38 (77.6)	2.07 (0.71)	0.8	1.69	2.00	2.37	4.1	
			Placebo	51	35 (68.6)	1.89 (0.71)	0.9	1.30	1.73	2.31	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	49	48 (98.0)	0.22 (0.32)	-0.6	0.01	0.19	0.37	1.1	0.69 [0.28, 1.10]
			Placebo	51	49 (96.1)	-0.03 (0.41)	-1.8	-0.09	0.01	0.12	1.0	
		Week 4	Tezepelumab	49	49 (100.0)	0.27 (0.35)	-0.7	0.05	0.27	0.41	1.1	0.64 [0.24, 1.05]
			Placebo	51	49 (96.1)	0.02 (0.42)	-1.0	-0.17	0.02	0.22	1.4	
		Week 8	Tezepelumab	49	48 (98.0)	0.23 (0.38)	-0.4	0.00	0.21	0.39	1.2	0.49 [0.08, 0.89]
			Placebo	51	50 (98.0)	0.04 (0.41)	-0.6	-0.22	-0.01	0.20	1.3	
		Week 12	Tezepelumab	49	45 (91.8)	0.30 (0.44)	-0.8	0.12	0.23	0.50	1.3	0.54 [0.13, 0.96]
			Placebo	51	47 (92.2)	0.07 (0.43)	-1.2	-0.14	-0.02	0.31	1.2	
		Week 16	Tezepelumab	49	46 (93.9)	0.30 (0.37)	-0.8	0.07	0.29	0.51	1.2	0.82 [0.39, 1.25]
			Placebo	51	44 (86.3)	0.01 (0.35)	-0.8	-0.16	-0.03	0.19	1.0	
		Week 24	Tezepelumab	49	43 (87.8)	0.35 (0.39)	-0.2	0.04	0.29	0.63	1.3	1.00 [0.53, 1.47]
			Placebo	51	36 (70.6)	-0.06 (0.43)	-0.9	-0.37	-0.06	0.13	1.6	
		Week 36	Tezepelumab	49	40 (81.6)	0.27 (0.38)	-0.8	0.00	0.28	0.47	1.3	0.65 [0.20, 1.10]
			Placebo	51	39 (76.5)	0.01 (0.43)	-0.7	-0.25	-0.06	0.15	1.6	
		Week 52	Tezepelumab	49	38 (77.6)	0.29 (0.41)	-0.8	0.00	0.34	0.55	1.0	0.57 [0.10, 1.04]
			Placebo	51	35 (68.6)	0.03 (0.52)	-0.8	-0.29	0.01	0.19	2.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Absolute values	Baseline	Tezepelumab	479	479 (100.0)	1.84 (0.72)	0.5	1.31	1.72	2.26	4.8	
			Placebo	480	480 (100.0)	1.85 (0.71)	0.4	1.36	1.73	2.25	4.9	
		Week 2	Tezepelumab	479	466 (97.3)	2.00 (0.73)	0.6	1.44	1.90	2.48	5.0	
			Placebo	480	458 (95.4)	1.93 (0.72)	0.4	1.40	1.83	2.37	4.7	
		Week 4	Tezepelumab	479	474 (99.0)	2.01 (0.74)	0.6	1.46	1.92	2.51	5.0	
			Placebo	480	467 (97.3)	1.93 (0.71)	0.4	1.43	1.84	2.35	4.8	
		Week 8	Tezepelumab	479	470 (98.1)	2.04 (0.75)	0.6	1.44	1.95	2.49	4.7	
			Placebo	480	467 (97.3)	1.96 (0.73)	0.4	1.41	1.85	2.36	4.9	
		Week 12	Tezepelumab	479	465 (97.1)	2.04 (0.75)	0.6	1.52	1.93	2.51	4.9	
			Placebo	480	467 (97.3)	1.95 (0.75)	0.5	1.42	1.82	2.40	5.0	
		Week 16	Tezepelumab	479	464 (96.9)	2.06 (0.77)	0.6	1.50	1.93	2.54	4.9	
			Placebo	480	465 (96.9)	1.96 (0.74)	0.5	1.43	1.82	2.38	5.2	
		Week 24	Tezepelumab	479	455 (95.0)	2.03 (0.75)	0.6	1.52	1.92	2.52	5.5	
			Placebo	480	455 (94.8)	1.95 (0.74)	0.6	1.45	1.84	2.31	5.1	
		Week 36	Tezepelumab	479	443 (92.5)	2.05 (0.76)	0.5	1.47	1.94	2.50	4.9	
			Placebo	480	436 (90.8)	1.98 (0.76)	0.6	1.43	1.83	2.36	5.3	
		Week 52	Tezepelumab	479	433 (90.4)	2.05 (0.77)	0.6	1.48	1.93	2.56	4.6	
			Placebo	480	418 (87.1)	1.97 (0.78)	0.6	1.40	1.82	2.41	5.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Change from baseline	Week 2	Tezepelumab	479	466 (97.3)	0.16 (0.34)	-0.8	-0.02	0.10	0.29	1.9	0.29 [0.16, 0.42]
			Placebo	480	458 (95.4)	0.06 (0.35)	-1.3	-0.11	0.01	0.19	1.7	
		Week 4	Tezepelumab	479	474 (99.0)	0.18 (0.37)	-1.2	-0.04	0.11	0.33	1.8	0.24 [0.11, 0.37]
			Placebo	480	467 (97.3)	0.09 (0.38)	-1.8	-0.10	0.05	0.25	1.7	
		Week 8	Tezepelumab	479	470 (98.1)	0.21 (0.41)	-1.1	-0.04	0.14	0.40	1.9	0.29 [0.16, 0.42]
			Placebo	480	467 (97.3)	0.10 (0.38)	-1.7	-0.11	0.05	0.28	2.1	
		Week 12	Tezepelumab	479	465 (97.1)	0.21 (0.41)	-1.5	-0.03	0.15	0.39	2.2	0.29 [0.16, 0.42]
			Placebo	480	467 (97.3)	0.10 (0.40)	-1.5	-0.10	0.04	0.25	2.1	
		Week 16	Tezepelumab	479	464 (96.9)	0.22 (0.42)	-1.0	-0.04	0.14	0.37	2.1	0.30 [0.17, 0.43]
			Placebo	480	465 (96.9)	0.10 (0.38)	-1.6	-0.09	0.04	0.26	1.9	
		Week 24	Tezepelumab	479	455 (95.0)	0.20 (0.41)	-1.0	-0.06	0.14	0.38	2.1	0.28 [0.15, 0.41]
			Placebo	480	455 (94.8)	0.09 (0.38)	-1.4	-0.11	0.05	0.26	1.7	
		Week 36	Tezepelumab	479	443 (92.5)	0.21 (0.41)	-1.0	-0.05	0.14	0.40	1.8	0.23 [0.10, 0.37]
			Placebo	480	436 (90.8)	0.12 (0.41)	-1.7	-0.12	0.06	0.30	2.2	
		Week 52	Tezepelumab	479	433 (90.4)	0.22 (0.41)	-1.0	-0.04	0.14	0.42	1.7	0.30 [0.16, 0.43]
			Placebo	480	418 (87.1)	0.10 (0.38)	-1.4	-0.14	0.06	0.29	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
Medium/Low	Absolute values	Baseline	Tezepelumab	131	131 (100.0)	2.02 (0.76)	0.6	1.50	1.94	2.39	4.8	
			Placebo	133	133 (100.0)	1.90 (0.70)	0.7	1.40	1.79	2.31	4.1	
		Week 2	Tezepelumab	131	128 (97.7)	2.15 (0.76)	0.8	1.63	2.13	2.66	5.0	
			Placebo	133	128 (96.2)	1.94 (0.70)	0.7	1.40	1.78	2.42	4.2	
		Week 4	Tezepelumab	131	130 (99.2)	2.17 (0.75)	0.8	1.66	2.11	2.68	5.0	
			Placebo	133	128 (96.2)	1.99 (0.71)	0.8	1.48	1.84	2.41	4.1	
		Week 8	Tezepelumab	131	128 (97.7)	2.21 (0.75)	0.8	1.71	2.14	2.65	4.6	
			Placebo	133	130 (97.7)	2.01 (0.72)	0.7	1.50	1.91	2.44	4.7	
		Week 12	Tezepelumab	131	126 (96.2)	2.19 (0.78)	0.8	1.61	2.10	2.64	4.9	
			Placebo	133	130 (97.7)	1.98 (0.75)	0.6	1.49	1.82	2.34	4.6	
		Week 16	Tezepelumab	131	129 (98.5)	2.18 (0.81)	0.7	1.60	2.01	2.72	4.9	
			Placebo	133	132 (99.2)	2.02 (0.73)	0.7	1.52	1.90	2.47	4.7	
		Week 24	Tezepelumab	131	127 (96.9)	2.19 (0.79)	0.7	1.68	2.11	2.70	5.5	
			Placebo	133	127 (95.5)	1.99 (0.73)	0.7	1.48	1.87	2.36	4.6	
		Week 36	Tezepelumab	131	125 (95.4)	2.20 (0.75)	0.7	1.66	2.13	2.77	4.9	
			Placebo	133	123 (92.5)	2.03 (0.73)	0.9	1.49	1.87	2.41	4.3	
		Week 52	Tezepelumab	131	120 (91.6)	2.21 (0.78)	0.6	1.65	2.11	2.81	4.6	
			Placebo	133	121 (91.0)	2.07 (0.75)	0.8	1.53	1.92	2.69	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
Medium/Low	Change from baseline	Week 2	Tezepelumab	131	128 (97.7)	0.12 (0.33)	-0.8	-0.04	0.07	0.21	1.9	0.22 [-0.03, 0.47]
			Placebo	133	128 (96.2)	0.05 (0.33)	-0.8	-0.12	0.02	0.17	1.7	
		Week 4	Tezepelumab	131	130 (99.2)	0.14 (0.37)	-1.2	-0.07	0.07	0.30	1.4	0.13 [-0.11, 0.38]
			Placebo	133	128 (96.2)	0.09 (0.34)	-0.8	-0.08	0.05	0.24	1.1	
		Week 8	Tezepelumab	131	128 (97.7)	0.17 (0.39)	-0.9	-0.05	0.11	0.31	1.9	0.14 [-0.10, 0.39]
			Placebo	133	130 (97.7)	0.11 (0.41)	-1.1	-0.09	0.03	0.27	2.1	
		Week 12	Tezepelumab	131	126 (96.2)	0.19 (0.38)	-0.6	-0.03	0.12	0.31	2.2	0.22 [-0.02, 0.47]
			Placebo	133	130 (97.7)	0.10 (0.40)	-0.7	-0.10	0.03	0.21	2.1	
		Week 16	Tezepelumab	131	129 (98.5)	0.16 (0.44)	-1.0	-0.10	0.08	0.33	2.1	0.07 [-0.17, 0.31]
			Placebo	133	132 (99.2)	0.13 (0.36)	-0.7	-0.09	0.07	0.26	1.9	
		Week 24	Tezepelumab	131	127 (96.9)	0.15 (0.40)	-0.6	-0.09	0.09	0.33	2.1	0.17 [-0.07, 0.42]
			Placebo	133	127 (95.5)	0.09 (0.35)	-0.7	-0.11	0.04	0.22	1.7	
		Week 36	Tezepelumab	131	125 (95.4)	0.15 (0.38)	-0.6	-0.10	0.13	0.34	1.8	0.04 [-0.21, 0.29]
			Placebo	133	123 (92.5)	0.14 (0.40)	-0.6	-0.09	0.05	0.31	1.6	
		Week 52	Tezepelumab	131	120 (91.6)	0.16 (0.40)	-0.6	-0.10	0.12	0.37	1.5	0.02 [-0.23, 0.28]
			Placebo	133	121 (91.0)	0.15 (0.45)	-0.9	-0.09	0.07	0.31	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
High	Absolute values	Baseline	Tezepelumab	397	397 (100.0)	1.77 (0.69)	0.4	1.27	1.64	2.13	4.1	
			Placebo	398	398 (100.0)	1.83 (0.71)	0.4	1.35	1.71	2.22	4.9	
		Week 2	Tezepelumab	397	386 (97.2)	1.95 (0.72)	0.6	1.39	1.82	2.43	4.3	
			Placebo	398	379 (95.2)	1.91 (0.72)	0.4	1.39	1.80	2.33	4.7	
		Week 4	Tezepelumab	397	393 (99.0)	1.96 (0.73)	0.6	1.42	1.85	2.48	4.3	
			Placebo	398	388 (97.5)	1.90 (0.69)	0.4	1.43	1.83	2.30	4.8	
		Week 8	Tezepelumab	397	390 (98.2)	1.98 (0.74)	0.6	1.40	1.86	2.44	4.7	
			Placebo	398	387 (97.2)	1.93 (0.73)	0.4	1.40	1.83	2.34	4.9	
		Week 12	Tezepelumab	397	384 (96.7)	1.99 (0.74)	0.6	1.48	1.89	2.43	4.7	
			Placebo	398	384 (96.5)	1.93 (0.74)	0.5	1.40	1.81	2.38	5.0	
		Week 16	Tezepelumab	397	381 (96.0)	2.01 (0.75)	0.6	1.48	1.89	2.47	4.9	
			Placebo	398	377 (94.7)	1.92 (0.74)	0.5	1.37	1.79	2.32	5.2	
		Week 24	Tezepelumab	397	371 (93.5)	1.98 (0.72)	0.6	1.48	1.83	2.42	4.4	
			Placebo	398	364 (91.5)	1.92 (0.73)	0.6	1.41	1.80	2.25	5.1	
		Week 36	Tezepelumab	397	358 (90.2)	1.99 (0.76)	0.5	1.43	1.89	2.44	4.5	
			Placebo	398	352 (88.4)	1.95 (0.76)	0.6	1.42	1.82	2.33	5.3	
		Week 52	Tezepelumab	397	351 (88.4)	2.00 (0.76)	0.6	1.46	1.87	2.45	4.3	
			Placebo	398	332 (83.4)	1.92 (0.77)	0.6	1.35	1.77	2.31	5.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
High	Change from baseline	Week 2	Tezepelumab	397	386 (97.2)	0.18 (0.33)	-0.7	0.00	0.13	0.32	1.5	0.36 [0.22, 0.50]
			Placebo	398	379 (95.2)	0.06 (0.37)	-1.8	-0.11	0.01	0.18	1.7	
		Week 4	Tezepelumab	397	393 (99.0)	0.21 (0.36)	-0.9	-0.01	0.14	0.35	1.8	0.32 [0.18, 0.46]
			Placebo	398	388 (97.5)	0.08 (0.40)	-1.8	-0.11	0.04	0.25	1.7	
		Week 8	Tezepelumab	397	390 (98.2)	0.23 (0.42)	-1.1	-0.04	0.15	0.44	1.8	0.37 [0.22, 0.51]
			Placebo	398	387 (97.2)	0.09 (0.37)	-1.7	-0.11	0.05	0.26	2.0	
		Week 12	Tezepelumab	397	384 (96.7)	0.23 (0.42)	-1.5	-0.03	0.17	0.43	2.0	0.34 [0.20, 0.48]
			Placebo	398	384 (96.5)	0.10 (0.40)	-1.5	-0.10	0.05	0.26	1.7	
		Week 16	Tezepelumab	397	381 (96.0)	0.25 (0.41)	-0.8	0.00	0.17	0.42	2.0	0.43 [0.29, 0.58]
			Placebo	398	377 (94.7)	0.08 (0.39)	-1.6	-0.11	0.03	0.26	1.8	
		Week 24	Tezepelumab	397	371 (93.5)	0.23 (0.41)	-1.0	-0.05	0.18	0.43	1.8	0.39 [0.24, 0.54]
			Placebo	398	364 (91.5)	0.08 (0.40)	-1.4	-0.13	0.04	0.27	1.7	
		Week 36	Tezepelumab	397	358 (90.2)	0.24 (0.42)	-1.0	-0.04	0.17	0.46	1.7	0.34 [0.19, 0.49]
			Placebo	398	352 (88.4)	0.10 (0.42)	-1.7	-0.16	0.06	0.29	2.2	
		Week 52	Tezepelumab	397	351 (88.4)	0.24 (0.42)	-1.0	-0.02	0.18	0.49	1.7	0.44 [0.28, 0.59]
			Placebo	398	332 (83.4)	0.07 (0.37)	-1.4	-0.15	0.06	0.24	1.9	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	133	133 (100.0)	1.80 (0.75)	0.6	1.29	1.71	2.11	4.8	
			Placebo	127	127 (100.0)	1.83 (0.71)	0.4	1.36	1.71	2.19	4.2	
		Week 2	Tezepelumab	133	132 (99.2)	1.98 (0.78)	0.7	1.41	1.87	2.39	5.0	
			Placebo	127	124 (97.6)	1.87 (0.73)	0.4	1.36	1.80	2.32	4.2	
		Week 4	Tezepelumab	133	133 (100.0)	1.99 (0.78)	0.7	1.44	1.91	2.41	5.0	
			Placebo	127	126 (99.2)	1.88 (0.73)	0.4	1.42	1.76	2.35	4.2	
		Week 8	Tezepelumab	133	131 (98.5)	2.03 (0.80)	0.7	1.44	2.01	2.43	4.7	
			Placebo	127	122 (96.1)	1.91 (0.73)	0.4	1.45	1.80	2.33	4.3	
		Week 12	Tezepelumab	133	129 (97.0)	2.04 (0.82)	0.7	1.52	1.94	2.39	4.9	
			Placebo	127	122 (96.1)	1.85 (0.71)	0.6	1.37	1.73	2.25	4.3	
		Week 16	Tezepelumab	133	127 (95.5)	2.05 (0.84)	0.6	1.52	1.95	2.41	4.9	
			Placebo	127	119 (93.7)	1.88 (0.70)	0.7	1.36	1.75	2.26	4.1	
		Week 24	Tezepelumab	133	125 (94.0)	2.03 (0.81)	0.6	1.56	1.93	2.41	5.5	
			Placebo	127	116 (91.3)	1.88 (0.75)	0.6	1.37	1.74	2.25	4.8	
		Week 36	Tezepelumab	133	118 (88.7)	2.04 (0.83)	0.5	1.42	1.93	2.45	4.9	
			Placebo	127	111 (87.4)	1.96 (0.75)	0.7	1.43	1.81	2.36	4.6	
		Week 52	Tezepelumab	133	112 (84.2)	2.07 (0.83)	0.6	1.53	2.04	2.44	4.6	
			Placebo	127	106 (83.5)	1.92 (0.78)	0.7	1.31	1.79	2.31	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	133	132 (99.2)	0.18 (0.32)	-0.6	0.01	0.12	0.35	1.1	0.38 [0.13, 0.63]
			Placebo	127	124 (97.6)	0.05 (0.36)	-1.3	-0.14	0.02	0.18	1.7	
		Week 4	Tezepelumab	133	133 (100.0)	0.19 (0.34)	-0.7	0.01	0.15	0.30	1.6	0.40 [0.16, 0.65]
			Placebo	127	126 (99.2)	0.05 (0.37)	-1.0	-0.11	0.03	0.21	1.4	
		Week 8	Tezepelumab	133	131 (98.5)	0.23 (0.43)	-1.1	-0.02	0.17	0.44	1.8	0.39 [0.14, 0.64]
			Placebo	127	122 (96.1)	0.06 (0.42)	-1.7	-0.15	0.04	0.30	2.1	
		Week 12	Tezepelumab	133	129 (97.0)	0.25 (0.44)	-0.8	-0.03	0.16	0.45	2.0	0.55 [0.30, 0.80]
			Placebo	127	122 (96.1)	0.02 (0.38)	-1.5	-0.16	0.00	0.26	1.2	
		Week 16	Tezepelumab	133	127 (95.5)	0.25 (0.41)	-0.8	0.00	0.17	0.40	2.0	0.51 [0.25, 0.76]
			Placebo	127	119 (93.7)	0.04 (0.38)	-1.6	-0.13	0.01	0.26	1.4	
		Week 24	Tezepelumab	133	125 (94.0)	0.24 (0.38)	-0.7	-0.04	0.16	0.43	1.6	0.53 [0.27, 0.79]
			Placebo	127	116 (91.3)	0.03 (0.39)	-1.4	-0.15	0.01	0.22	1.6	
		Week 36	Tezepelumab	133	118 (88.7)	0.25 (0.39)	-0.6	-0.01	0.20	0.42	1.7	0.38 [0.12, 0.64]
			Placebo	127	111 (87.4)	0.10 (0.37)	-1.2	-0.16	0.05	0.36	1.5	
		Week 52	Tezepelumab	133	112 (84.2)	0.26 (0.41)	-0.8	-0.01	0.21	0.51	1.5	0.48 [0.21, 0.75]
			Placebo	127	106 (83.5)	0.06 (0.41)	-1.4	-0.16	0.07	0.24	1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Absolute values	Baseline	Tezepelumab	395	395 (100.0)	1.84 (0.71)	0.4	1.31	1.73	2.28	4.1	
			Placebo	404	404 (100.0)	1.86 (0.70)	0.6	1.36	1.73	2.26	4.9	
		Week 2	Tezepelumab	395	382 (96.7)	2.01 (0.72)	0.6	1.46	1.94	2.52	4.0	
			Placebo	404	383 (94.8)	1.93 (0.71)	0.6	1.40	1.80	2.37	4.7	
		Week 4	Tezepelumab	395	390 (98.7)	2.02 (0.73)	0.6	1.47	1.94	2.57	4.2	
			Placebo	404	390 (96.5)	1.94 (0.69)	0.5	1.44	1.85	2.32	4.8	
		Week 8	Tezepelumab	395	387 (98.0)	2.04 (0.73)	0.6	1.45	1.92	2.51	4.3	
			Placebo	404	395 (97.8)	1.96 (0.73)	0.6	1.40	1.89	2.37	4.9	
		Week 12	Tezepelumab	395	381 (96.5)	2.04 (0.73)	0.6	1.50	1.93	2.55	4.6	
			Placebo	404	392 (97.0)	1.98 (0.75)	0.5	1.46	1.86	2.41	5.0	
		Week 16	Tezepelumab	395	383 (97.0)	2.06 (0.74)	0.6	1.50	1.92	2.56	4.4	
			Placebo	404	390 (96.5)	1.97 (0.75)	0.5	1.44	1.84	2.36	5.2	
		Week 24	Tezepelumab	395	373 (94.4)	2.03 (0.72)	0.6	1.52	1.92	2.55	4.0	
			Placebo	404	375 (92.8)	1.96 (0.73)	0.6	1.45	1.86	2.32	5.1	
		Week 36	Tezepelumab	395	365 (92.4)	2.05 (0.73)	0.6	1.48	1.93	2.50	4.2	
			Placebo	404	364 (90.1)	1.98 (0.75)	0.6	1.44	1.84	2.35	5.3	
		Week 52	Tezepelumab	395	359 (90.9)	2.04 (0.75)	0.6	1.48	1.91	2.58	4.3	
			Placebo	404	347 (85.9)	1.97 (0.77)	0.6	1.43	1.82	2.42	5.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Change from baseline	Week 2	Tezepelumab	395	382 (96.7)	0.16 (0.34)	-0.8	-0.03	0.11	0.28	1.9	0.31 [0.17, 0.45]
			Placebo	404	383 (94.8)	0.06 (0.35)	-1.8	-0.11	0.01	0.18	1.7	
		Week 4	Tezepelumab	395	390 (98.7)	0.19 (0.37)	-1.2	-0.05	0.12	0.35	1.8	0.24 [0.10, 0.38]
			Placebo	404	390 (96.5)	0.10 (0.39)	-1.8	-0.11	0.05	0.26	1.7	
		Week 8	Tezepelumab	395	387 (98.0)	0.21 (0.40)	-0.9	-0.04	0.13	0.38	1.9	0.28 [0.14, 0.42]
			Placebo	404	395 (97.8)	0.10 (0.36)	-1.1	-0.10	0.05	0.25	2.0	
		Week 12	Tezepelumab	395	381 (96.5)	0.21 (0.40)	-1.5	-0.03	0.17	0.38	2.2	0.24 [0.10, 0.38]
			Placebo	404	392 (97.0)	0.12 (0.40)	-1.4	-0.09	0.05	0.25	2.1	
		Week 16	Tezepelumab	395	383 (97.0)	0.22 (0.42)	-1.0	-0.04	0.14	0.40	2.1	0.29 [0.14, 0.43]
			Placebo	404	390 (96.5)	0.11 (0.38)	-1.2	-0.09	0.04	0.26	1.9	
		Week 24	Tezepelumab	395	373 (94.4)	0.20 (0.42)	-1.0	-0.06	0.14	0.39	2.1	0.28 [0.13, 0.42]
			Placebo	404	375 (92.8)	0.09 (0.38)	-1.1	-0.11	0.04	0.26	1.7	
		Week 36	Tezepelumab	395	365 (92.4)	0.21 (0.42)	-1.0	-0.06	0.13	0.40	1.8	0.24 [0.09, 0.38]
			Placebo	404	364 (90.1)	0.11 (0.43)	-1.7	-0.13	0.06	0.29	2.2	
		Week 52	Tezepelumab	395	359 (90.9)	0.21 (0.42)	-1.0	-0.06	0.14	0.43	1.7	0.27 [0.12, 0.42]
			Placebo	404	347 (85.9)	0.10 (0.39)	-1.0	-0.13	0.06	0.29	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	124	124 (100.0)	1.81 (0.76)	0.7	1.29	1.73	2.12	4.8	
			Placebo	122	122 (100.0)	1.83 (0.72)	0.4	1.36	1.70	2.22	4.2	
		Week 2	Tezepelumab	124	123 (99.2)	1.99 (0.79)	0.7	1.42	1.87	2.39	5.0	
			Placebo	122	119 (97.5)	1.88 (0.74)	0.4	1.34	1.85	2.34	4.2	
		Week 4	Tezepelumab	124	124 (100.0)	2.00 (0.79)	0.7	1.45	1.91	2.42	5.0	
			Placebo	122	121 (99.2)	1.89 (0.74)	0.4	1.42	1.76	2.37	4.2	
		Week 8	Tezepelumab	124	122 (98.4)	2.05 (0.80)	0.8	1.45	2.03	2.40	4.7	
			Placebo	122	117 (95.9)	1.92 (0.73)	0.4	1.50	1.82	2.33	4.3	
		Week 12	Tezepelumab	124	120 (96.8)	2.05 (0.82)	0.8	1.53	1.93	2.40	4.9	
			Placebo	122	117 (95.9)	1.86 (0.72)	0.6	1.38	1.73	2.25	4.3	
		Week 16	Tezepelumab	124	119 (96.0)	2.07 (0.84)	0.7	1.52	1.97	2.41	4.9	
			Placebo	122	115 (94.3)	1.88 (0.71)	0.7	1.36	1.75	2.26	4.1	
		Week 24	Tezepelumab	124	117 (94.4)	2.06 (0.81)	0.7	1.57	1.93	2.42	5.5	
			Placebo	122	112 (91.8)	1.89 (0.76)	0.6	1.35	1.76	2.25	4.8	
		Week 36	Tezepelumab	124	110 (88.7)	2.06 (0.84)	0.7	1.44	1.93	2.46	4.9	
			Placebo	122	108 (88.5)	1.97 (0.75)	0.7	1.43	1.81	2.36	4.6	
		Week 52	Tezepelumab	124	104 (83.9)	2.10 (0.83)	0.6	1.55	2.04	2.46	4.6	
			Placebo	122	104 (85.2)	1.92 (0.79)	0.7	1.31	1.79	2.33	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	124	123 (99.2)	0.18 (0.32)	-0.6	0.00	0.11	0.35	1.1	0.36 [0.11, 0.61]
			Placebo	122	119 (97.5)	0.05 (0.37)	-1.3	-0.13	0.04	0.19	1.7	
		Week 4	Tezepelumab	124	124 (100.0)	0.19 (0.35)	-0.7	0.01	0.13	0.30	1.6	0.37 [0.12, 0.62]
			Placebo	122	121 (99.2)	0.06 (0.37)	-1.0	-0.10	0.03	0.22	1.4	
		Week 8	Tezepelumab	124	122 (98.4)	0.23 (0.44)	-1.1	-0.04	0.17	0.46	1.8	0.37 [0.12, 0.63]
			Placebo	122	117 (95.9)	0.07 (0.42)	-1.7	-0.13	0.05	0.30	2.1	
		Week 12	Tezepelumab	124	120 (96.8)	0.24 (0.46)	-0.8	-0.06	0.16	0.46	2.0	0.53 [0.27, 0.79]
			Placebo	122	117 (95.9)	0.02 (0.38)	-1.5	-0.14	0.00	0.26	1.2	
		Week 16	Tezepelumab	124	119 (96.0)	0.25 (0.42)	-0.8	0.00	0.17	0.42	2.0	0.52 [0.26, 0.78]
			Placebo	122	115 (94.3)	0.04 (0.39)	-1.6	-0.13	0.01	0.26	1.4	
		Week 24	Tezepelumab	124	117 (94.4)	0.24 (0.39)	-0.7	-0.04	0.16	0.43	1.6	0.52 [0.26, 0.78]
			Placebo	122	112 (91.8)	0.04 (0.39)	-1.4	-0.15	0.01	0.23	1.6	
		Week 36	Tezepelumab	124	110 (88.7)	0.25 (0.40)	-0.6	-0.01	0.20	0.42	1.7	0.38 [0.11, 0.64]
			Placebo	122	108 (88.5)	0.10 (0.37)	-1.2	-0.15	0.05	0.36	1.5	
		Week 52	Tezepelumab	124	104 (83.9)	0.25 (0.42)	-0.8	-0.01	0.21	0.51	1.5	0.48 [0.20, 0.75]
			Placebo	122	104 (85.2)	0.06 (0.41)	-1.4	-0.17	0.07	0.24	1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Absolute values	Baseline	Tezepelumab	404	404 (100.0)	1.84 (0.70)	0.4	1.31	1.72	2.28	4.1	
			Placebo	409	409 (100.0)	1.86 (0.70)	0.6	1.36	1.73	2.23	4.9	
		Week 2	Tezepelumab	404	391 (96.8)	2.00 (0.71)	0.6	1.44	1.93	2.52	4.0	
			Placebo	409	388 (94.9)	1.93 (0.70)	0.6	1.41	1.80	2.37	4.7	
		Week 4	Tezepelumab	404	399 (98.8)	2.02 (0.73)	0.6	1.46	1.94	2.57	4.2	
			Placebo	409	395 (96.6)	1.93 (0.68)	0.5	1.44	1.84	2.32	4.8	
		Week 8	Tezepelumab	404	396 (98.0)	2.03 (0.73)	0.6	1.45	1.93	2.51	4.3	
			Placebo	409	400 (97.8)	1.96 (0.73)	0.6	1.40	1.88	2.37	4.9	
		Week 12	Tezepelumab	404	390 (96.5)	2.04 (0.73)	0.6	1.50	1.93	2.55	4.6	
			Placebo	409	397 (97.1)	1.97 (0.74)	0.5	1.45	1.85	2.40	5.0	
		Week 16	Tezepelumab	404	391 (96.8)	2.05 (0.75)	0.6	1.50	1.92	2.56	4.4	
			Placebo	409	394 (96.3)	1.97 (0.74)	0.5	1.46	1.84	2.36	5.2	
		Week 24	Tezepelumab	404	381 (94.3)	2.02 (0.72)	0.6	1.52	1.92	2.54	4.0	
			Placebo	409	379 (92.7)	1.96 (0.73)	0.6	1.45	1.86	2.31	5.1	
		Week 36	Tezepelumab	404	373 (92.3)	2.04 (0.74)	0.5	1.48	1.93	2.50	4.2	
			Placebo	409	367 (89.7)	1.98 (0.75)	0.6	1.44	1.83	2.35	5.3	
		Week 52	Tezepelumab	404	367 (90.8)	2.04 (0.75)	0.6	1.48	1.91	2.57	4.3	
			Placebo	409	349 (85.3)	1.97 (0.77)	0.6	1.44	1.82	2.42	5.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Change from baseline	Week 2	Tezepelumab	404	391 (96.8)	0.16 (0.34)	-0.8	-0.02	0.11	0.28	1.9	0.32 [0.18, 0.46]
			Placebo	409	388 (94.9)	0.05 (0.35)	-1.8	-0.11	0.01	0.18	1.7	
		Week 4	Tezepelumab	404	399 (98.8)	0.19 (0.37)	-1.2	-0.04	0.12	0.35	1.8	0.25 [0.11, 0.39]
			Placebo	409	395 (96.6)	0.09 (0.39)	-1.8	-0.11	0.05	0.26	1.7	
		Week 8	Tezepelumab	404	396 (98.0)	0.21 (0.40)	-0.9	-0.04	0.13	0.38	1.9	0.29 [0.15, 0.43]
			Placebo	409	400 (97.8)	0.10 (0.37)	-1.1	-0.10	0.04	0.25	2.0	
		Week 12	Tezepelumab	404	390 (96.5)	0.22 (0.39)	-1.5	-0.02	0.17	0.39	2.2	0.25 [0.11, 0.39]
			Placebo	409	397 (97.1)	0.12 (0.40)	-1.4	-0.09	0.05	0.25	2.1	
		Week 16	Tezepelumab	404	391 (96.8)	0.22 (0.42)	-1.0	-0.04	0.14	0.39	2.1	0.28 [0.14, 0.42]
			Placebo	409	394 (96.3)	0.11 (0.38)	-1.2	-0.09	0.04	0.26	1.9	
		Week 24	Tezepelumab	404	381 (94.3)	0.20 (0.42)	-1.0	-0.06	0.14	0.39	2.1	0.28 [0.14, 0.43]
			Placebo	409	379 (92.7)	0.09 (0.38)	-1.1	-0.11	0.04	0.26	1.7	
		Week 36	Tezepelumab	404	373 (92.3)	0.21 (0.41)	-1.0	-0.06	0.14	0.40	1.8	0.24 [0.09, 0.38]
			Placebo	409	367 (89.7)	0.11 (0.43)	-1.7	-0.13	0.06	0.29	2.2	
		Week 52	Tezepelumab	404	367 (90.8)	0.22 (0.41)	-1.0	-0.06	0.14	0.43	1.7	0.27 [0.13, 0.42]
			Placebo	409	349 (85.3)	0.10 (0.39)	-1.0	-0.13	0.06	0.29	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	209	209 (100.0)	1.77 (0.72)	0.5	1.25	1.64	2.12	4.8	
			Placebo	197	197 (100.0)	1.87 (0.67)	0.6	1.40	1.79	2.22	4.1	
		Week 2	Tezepelumab	209	202 (96.7)	1.97 (0.74)	0.6	1.39	1.91	2.39	5.0	
			Placebo	197	188 (95.4)	1.94 (0.68)	0.7	1.48	1.83	2.40	4.2	
		Week 4	Tezepelumab	209	207 (99.0)	2.00 (0.76)	0.6	1.45	1.89	2.43	5.0	
			Placebo	197	192 (97.5)	1.96 (0.67)	0.7	1.51	1.85	2.35	4.0	
		Week 8	Tezepelumab	209	205 (98.1)	2.01 (0.76)	0.6	1.43	1.90	2.47	4.7	
			Placebo	197	193 (98.0)	1.98 (0.73)	0.7	1.53	1.91	2.36	4.7	
		Week 12	Tezepelumab	209	200 (95.7)	2.02 (0.77)	0.6	1.51	1.92	2.42	4.9	
			Placebo	197	196 (99.5)	1.95 (0.70)	0.7	1.48	1.82	2.32	4.6	
		Week 16	Tezepelumab	209	202 (96.7)	2.03 (0.78)	0.6	1.48	1.93	2.45	4.9	
			Placebo	197	192 (97.5)	1.97 (0.69)	0.7	1.52	1.85	2.35	4.7	
		Week 24	Tezepelumab	209	197 (94.3)	1.98 (0.73)	0.6	1.54	1.84	2.40	5.5	
			Placebo	197	187 (94.9)	1.94 (0.69)	0.6	1.44	1.86	2.31	4.6	
		Week 36	Tezepelumab	209	191 (91.4)	2.05 (0.78)	0.6	1.49	1.92	2.54	4.9	
			Placebo	197	181 (91.9)	1.95 (0.70)	0.7	1.46	1.82	2.38	4.3	
		Week 52	Tezepelumab	209	186 (89.0)	2.05 (0.78)	0.6	1.53	1.96	2.53	4.6	
			Placebo	197	168 (85.3)	1.96 (0.75)	0.7	1.41	1.81	2.41	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	209	202 (96.7)	0.20 (0.33)	-0.5	0.00	0.13	0.31	1.9	0.40 [0.20, 0.60]
			Placebo	197	188 (95.4)	0.06 (0.37)	-1.8	-0.10	0.04	0.20	1.2	
		Week 4	Tezepelumab	209	207 (99.0)	0.23 (0.37)	-0.9	0.01	0.12	0.36	1.7	0.39 [0.19, 0.59]
			Placebo	197	192 (97.5)	0.08 (0.41)	-1.0	-0.13	0.04	0.28	1.4	
		Week 8	Tezepelumab	209	205 (98.1)	0.25 (0.42)	-0.8	-0.04	0.17	0.46	1.8	0.36 [0.16, 0.56]
			Placebo	197	193 (98.0)	0.10 (0.41)	-1.7	-0.13	0.07	0.27	1.8	
		Week 12	Tezepelumab	209	200 (95.7)	0.27 (0.43)	-0.7	0.02	0.20	0.45	2.0	0.44 [0.24, 0.64]
			Placebo	197	196 (99.5)	0.08 (0.45)	-1.5	-0.12	0.03	0.26	2.1	
		Week 16	Tezepelumab	209	202 (96.7)	0.26 (0.43)	-0.6	-0.02	0.17	0.43	2.0	0.40 [0.20, 0.60]
			Placebo	197	192 (97.5)	0.09 (0.40)	-1.6	-0.11	0.06	0.27	1.9	
		Week 24	Tezepelumab	209	197 (94.3)	0.24 (0.43)	-1.0	-0.05	0.22	0.43	2.1	0.40 [0.20, 0.60]
			Placebo	197	187 (94.9)	0.08 (0.40)	-1.4	-0.13	0.05	0.27	1.7	
		Week 36	Tezepelumab	209	191 (91.4)	0.28 (0.42)	-1.0	0.01	0.23	0.51	1.8	0.48 [0.27, 0.68]
			Placebo	197	181 (91.9)	0.08 (0.42)	-1.2	-0.17	0.03	0.27	1.7	
		Week 52	Tezepelumab	209	186 (89.0)	0.28 (0.43)	-1.0	-0.02	0.23	0.53	1.6	0.47 [0.26, 0.68]
			Placebo	197	168 (85.3)	0.08 (0.40)	-1.4	-0.16	0.06	0.26	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Absolute values	Baseline	Tezepelumab	319	319 (100.0)	1.87 (0.71)	0.4	1.34	1.77	2.30	4.1	
			Placebo	334	334 (100.0)	1.84 (0.73)	0.4	1.34	1.71	2.23	4.9	
		Week 2	Tezepelumab	319	312 (97.8)	2.02 (0.73)	0.6	1.46	1.92	2.51	4.3	
			Placebo	334	319 (95.5)	1.90 (0.73)	0.4	1.36	1.78	2.32	4.7	
		Week 4	Tezepelumab	319	316 (99.1)	2.03 (0.73)	0.7	1.48	1.95	2.55	4.0	
			Placebo	334	324 (97.0)	1.90 (0.71)	0.4	1.41	1.81	2.31	4.8	
		Week 8	Tezepelumab	319	313 (98.1)	2.05 (0.74)	0.6	1.47	1.96	2.49	4.7	
			Placebo	334	324 (97.0)	1.93 (0.74)	0.4	1.38	1.81	2.34	4.9	
		Week 12	Tezepelumab	319	310 (97.2)	2.05 (0.74)	0.6	1.52	1.94	2.55	4.6	
			Placebo	334	318 (95.2)	1.94 (0.76)	0.5	1.38	1.81	2.40	5.0	
		Week 16	Tezepelumab	319	308 (96.6)	2.07 (0.76)	0.6	1.52	1.95	2.58	4.7	
			Placebo	334	317 (94.9)	1.94 (0.76)	0.5	1.35	1.79	2.35	5.2	
		Week 24	Tezepelumab	319	301 (94.4)	2.06 (0.75)	0.6	1.52	1.97	2.56	4.0	
			Placebo	334	304 (91.0)	1.94 (0.76)	0.7	1.43	1.81	2.27	5.1	
		Week 36	Tezepelumab	319	292 (91.5)	2.04 (0.75)	0.5	1.45	1.97	2.49	4.4	
			Placebo	334	294 (88.0)	1.99 (0.78)	0.6	1.43	1.83	2.34	5.3	
		Week 52	Tezepelumab	319	285 (89.3)	2.05 (0.76)	0.7	1.48	1.91	2.52	4.2	
			Placebo	334	285 (85.3)	1.97 (0.78)	0.6	1.37	1.82	2.37	5.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Change from baseline	Week 2	Tezepelumab	319	312 (97.8)	0.15 (0.34)	-0.8	-0.04	0.09	0.28	1.5	0.28 [0.12, 0.43]
			Placebo	334	319 (95.5)	0.05 (0.35)	-1.1	-0.12	0.00	0.17	1.7	
		Week 4	Tezepelumab	319	316 (99.1)	0.16 (0.36)	-1.2	-0.06	0.12	0.33	1.8	0.20 [0.04, 0.36]
			Placebo	334	324 (97.0)	0.09 (0.37)	-1.8	-0.10	0.05	0.24	1.7	
		Week 8	Tezepelumab	319	313 (98.1)	0.19 (0.40)	-1.1	-0.04	0.13	0.35	1.9	0.27 [0.12, 0.43]
			Placebo	334	324 (97.0)	0.09 (0.36)	-1.1	-0.10	0.04	0.26	2.1	
		Week 12	Tezepelumab	319	310 (97.2)	0.19 (0.39)	-1.5	-0.04	0.12	0.37	2.2	0.22 [0.06, 0.38]
			Placebo	334	318 (95.2)	0.11 (0.36)	-1.2	-0.09	0.05	0.25	1.6	
		Week 16	Tezepelumab	319	308 (96.6)	0.21 (0.41)	-1.0	-0.04	0.14	0.37	2.1	0.29 [0.13, 0.45]
			Placebo	334	317 (94.9)	0.09 (0.36)	-1.2	-0.10	0.02	0.23	1.6	
		Week 24	Tezepelumab	319	301 (94.4)	0.19 (0.40)	-0.8	-0.06	0.12	0.38	1.8	0.29 [0.13, 0.45]
			Placebo	334	304 (91.0)	0.08 (0.37)	-1.1	-0.12	0.04	0.25	1.6	
		Week 36	Tezepelumab	319	292 (91.5)	0.18 (0.39)	-0.8	-0.09	0.09	0.36	1.7	0.13 [-0.03, 0.29]
			Placebo	334	294 (88.0)	0.12 (0.41)	-1.7	-0.11	0.06	0.31	2.2	
		Week 52	Tezepelumab	319	285 (89.3)	0.19 (0.40)	-1.0	-0.06	0.12	0.36	1.7	0.22 [0.06, 0.39]
			Placebo	334	285 (85.3)	0.10 (0.39)	-1.0	-0.12	0.07	0.29	2.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Sex									0.062
Male	Week 2	Tezepelumab	193	189 (97.9)	0.20 (0.03)	(0.15, 0.25)	0.16 (0.04)	(0.09, 0.24)	<0.001 *
		Placebo	194	190 (97.9)	0.04 (0.03)	(-0.02, 0.09)			
	Week 4	Tezepelumab	193	191 (99.0)	0.24 (0.03)	(0.18, 0.30)	0.16 (0.04)	(0.08, 0.25)	<0.001 *
		Placebo	194	188 (96.9)	0.08 (0.03)	(0.02, 0.14)			
	Week 8	Tezepelumab	193	187 (96.9)	0.25 (0.03)	(0.18, 0.32)	0.13 (0.05)	(0.04, 0.23)	0.006 *
		Placebo	194	193 (99.5)	0.12 (0.03)	(0.05, 0.18)			
	Week 12	Tezepelumab	193	184 (95.3)	0.26 (0.03)	(0.19, 0.33)	0.13 (0.05)	(0.03, 0.22)	0.007 *
		Placebo	194	190 (97.9)	0.13 (0.03)	(0.07, 0.20)			
	Week 16	Tezepelumab	193	186 (96.4)	0.29 (0.03)	(0.22, 0.36)	0.19 (0.05)	(0.09, 0.28)	<0.001 *
		Placebo	194	190 (97.9)	0.10 (0.03)	(0.03, 0.17)			
	Week 24	Tezepelumab	193	176 (91.2)	0.27 (0.03)	(0.20, 0.33)	0.17 (0.05)	(0.08, 0.26)	<0.001 *
		Placebo	194	177 (91.2)	0.10 (0.03)	(0.03, 0.16)			
	Week 36	Tezepelumab	193	175 (90.7)	0.27 (0.04)	(0.20, 0.34)	0.16 (0.05)	(0.06, 0.26)	0.002 *
		Placebo	194	175 (90.2)	0.11 (0.04)	(0.05, 0.18)			
	Week 52	Tezepelumab	193	170 (88.1)	0.30 (0.04)	(0.23, 0.37)	0.19 (0.05)	(0.09, 0.29)	<0.001 *
		Placebo	194	165 (85.1)	0.10 (0.04)	(0.03, 0.17)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Female	Week 2	Tezepelumab	335	325 (97.0)	0.15 (0.02)	(0.11, 0.18)	0.08 (0.02)	(0.04, 0.13)	<0.001 *
		Placebo	337	317 (94.1)	0.06 (0.02)	(0.03, 0.10)			
	Week 4	Tezepelumab	335	332 (99.1)	0.16 (0.02)	(0.12, 0.19)	0.07 (0.02)	(0.02, 0.12)	0.003 *
		Placebo	337	328 (97.3)	0.09 (0.02)	(0.05, 0.12)			
	Week 8	Tezepelumab	335	331 (98.8)	0.19 (0.02)	(0.16, 0.23)	0.12 (0.03)	(0.07, 0.17)	<0.001 *
		Placebo	337	324 (96.1)	0.08 (0.02)	(0.04, 0.11)			
	Week 12	Tezepelumab	335	326 (97.3)	0.20 (0.02)	(0.16, 0.23)	0.13 (0.03)	(0.07, 0.18)	<0.001 *
		Placebo	337	324 (96.1)	0.07 (0.02)	(0.04, 0.11)			
	Week 16	Tezepelumab	335	324 (96.7)	0.19 (0.02)	(0.16, 0.23)	0.10 (0.03)	(0.05, 0.15)	<0.001 *
		Placebo	337	319 (94.7)	0.09 (0.02)	(0.05, 0.13)			
	Week 24	Tezepelumab	335	322 (96.1)	0.18 (0.02)	(0.14, 0.21)	0.10 (0.03)	(0.05, 0.15)	<0.001 *
		Placebo	337	314 (93.2)	0.07 (0.02)	(0.04, 0.11)			
	Week 36	Tezepelumab	335	308 (91.9)	0.19 (0.02)	(0.15, 0.23)	0.09 (0.03)	(0.04, 0.14)	<0.001 *
		Placebo	337	300 (89.0)	0.10 (0.02)	(0.06, 0.14)			
	Week 52	Tezepelumab	335	301 (89.9)	0.19 (0.02)	(0.15, 0.23)	0.10 (0.03)	(0.05, 0.16)	<0.001 *
		Placebo	337	288 (85.5)	0.09 (0.02)	(0.05, 0.13)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Age									0.108
< 65 years	Week 2	Tezepelumab	432	421 (97.5)	0.18 (0.02)	(0.15, 0.22)	0.13 (0.02)	(0.08, 0.18)	<0.001 *
		Placebo	457	436 (95.4)	0.05 (0.02)	(0.02, 0.09)			
	Week 4	Tezepelumab	432	430 (99.5)	0.21 (0.02)	(0.17, 0.24)	0.12 (0.03)	(0.07, 0.17)	<0.001 *
		Placebo	457	446 (97.6)	0.08 (0.02)	(0.05, 0.12)			
	Week 8	Tezepelumab	432	424 (98.1)	0.23 (0.02)	(0.20, 0.27)	0.14 (0.03)	(0.08, 0.19)	<0.001 *
		Placebo	457	447 (97.8)	0.10 (0.02)	(0.06, 0.13)			
	Week 12	Tezepelumab	432	417 (96.5)	0.24 (0.02)	(0.20, 0.28)	0.13 (0.03)	(0.08, 0.19)	<0.001 *
		Placebo	457	444 (97.2)	0.10 (0.02)	(0.06, 0.14)			
	Week 16	Tezepelumab	432	418 (96.8)	0.25 (0.02)	(0.21, 0.29)	0.15 (0.03)	(0.10, 0.20)	<0.001 *
		Placebo	457	439 (96.1)	0.10 (0.02)	(0.06, 0.14)			
	Week 24	Tezepelumab	432	409 (94.7)	0.23 (0.02)	(0.19, 0.27)	0.14 (0.03)	(0.09, 0.20)	<0.001 *
		Placebo	457	424 (92.8)	0.09 (0.02)	(0.05, 0.12)			
	Week 36	Tezepelumab	432	396 (91.7)	0.24 (0.02)	(0.20, 0.28)	0.13 (0.03)	(0.07, 0.19)	<0.001 *
		Placebo	457	409 (89.5)	0.11 (0.02)	(0.07, 0.15)			
	Week 52	Tezepelumab	432	387 (89.6)	0.25 (0.02)	(0.21, 0.29)	0.15 (0.03)	(0.09, 0.21)	<0.001 *
		Placebo	457	390 (85.3)	0.10 (0.02)	(0.07, 0.14)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 65 years	Week 2	Tezepelumab	96	93 (96.9)	0.09 (0.02)	(0.05, 0.13)	0.05 (0.03)	(-0.02, 0.11)	0.155
		Placebo	74	71 (95.9)	0.04 (0.02)	(-0.00, 0.09)			
	Week 4	Tezepelumab	96	93 (96.9)	0.11 (0.02)	(0.06, 0.16)	0.03 (0.04)	(-0.05, 0.10)	0.466
		Placebo	74	70 (94.6)	0.08 (0.03)	(0.02, 0.14)			
	Week 8	Tezepelumab	96	94 (97.9)	0.13 (0.03)	(0.08, 0.18)	0.07 (0.04)	(-0.01, 0.15)	0.107
		Placebo	74	70 (94.6)	0.06 (0.03)	(0.00, 0.13)			
	Week 12	Tezepelumab	96	93 (96.9)	0.15 (0.03)	(0.10, 0.21)	0.11 (0.04)	(0.03, 0.19)	0.009 *
		Placebo	74	70 (94.6)	0.04 (0.03)	(-0.02, 0.11)			
	Week 16	Tezepelumab	96	92 (95.8)	0.15 (0.03)	(0.10, 0.20)	0.08 (0.04)	(0.00, 0.17)	0.045 *
		Placebo	74	70 (94.6)	0.07 (0.03)	(0.00, 0.13)			
	Week 24	Tezepelumab	96	89 (92.7)	0.12 (0.03)	(0.06, 0.17)	0.06 (0.04)	(-0.02, 0.14)	0.159
		Placebo	74	67 (90.5)	0.06 (0.03)	(-0.00, 0.12)			
	Week 36	Tezepelumab	96	87 (90.6)	0.13 (0.03)	(0.07, 0.18)	0.07 (0.04)	(-0.02, 0.15)	0.113
		Placebo	74	66 (89.2)	0.06 (0.03)	(-0.00, 0.12)			
	Week 52	Tezepelumab	96	84 (87.5)	0.13 (0.03)	(0.07, 0.19)	0.10 (0.05)	(0.00, 0.19)	0.042 *
		Placebo	74	63 (85.1)	0.03 (0.04)	(-0.04, 0.10)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Exacerbations in the year before study									0.179
<= 2	Week 2	Tezepelumab	310	304 (98.1)	0.16 (0.02)	(0.12, 0.20)	0.09 (0.03)	(0.04, 0.14)	<0.001 *
		Placebo	325	312 (96.0)	0.07 (0.02)	(0.03, 0.10)			
	Week 4	Tezepelumab	310	307 (99.0)	0.18 (0.02)	(0.14, 0.22)	0.08 (0.03)	(0.03, 0.14)	0.004 *
		Placebo	325	312 (96.0)	0.10 (0.02)	(0.06, 0.14)			
	Week 8	Tezepelumab	310	303 (97.7)	0.20 (0.02)	(0.16, 0.25)	0.10 (0.03)	(0.04, 0.16)	0.002 *
		Placebo	325	316 (97.2)	0.10 (0.02)	(0.06, 0.15)			
	Week 12	Tezepelumab	310	300 (96.8)	0.20 (0.02)	(0.15, 0.24)	0.09 (0.03)	(0.03, 0.16)	0.004 *
		Placebo	325	317 (97.5)	0.10 (0.02)	(0.06, 0.15)			
	Week 16	Tezepelumab	310	301 (97.1)	0.21 (0.02)	(0.17, 0.26)	0.11 (0.03)	(0.04, 0.17)	0.001 *
		Placebo	325	314 (96.6)	0.11 (0.02)	(0.06, 0.15)			
	Week 24	Tezepelumab	310	292 (94.2)	0.19 (0.02)	(0.14, 0.23)	0.11 (0.03)	(0.05, 0.17)	<0.001 *
		Placebo	325	301 (92.6)	0.08 (0.02)	(0.04, 0.12)			
	Week 36	Tezepelumab	310	287 (92.6)	0.21 (0.02)	(0.16, 0.26)	0.10 (0.03)	(0.03, 0.17)	0.003 *
		Placebo	325	296 (91.1)	0.11 (0.02)	(0.06, 0.16)			
	Week 52	Tezepelumab	310	279 (90.0)	0.21 (0.02)	(0.16, 0.26)	0.10 (0.03)	(0.03, 0.17)	0.004 *
		Placebo	325	284 (87.4)	0.11 (0.02)	(0.06, 0.16)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
> 2	Week 2	Tezepelumab	218	210 (96.3)	0.18 (0.02)	(0.13, 0.22)	0.14 (0.03)	(0.08, 0.21)	<0.001 *
		Placebo	206	195 (94.7)	0.03 (0.02)	(-0.02, 0.08)			
	Week 4	Tezepelumab	218	216 (99.1)	0.20 (0.02)	(0.15, 0.25)	0.13 (0.04)	(0.06, 0.20)	<0.001 *
		Placebo	206	204 (99.0)	0.07 (0.03)	(0.02, 0.12)			
	Week 8	Tezepelumab	218	215 (98.6)	0.23 (0.03)	(0.18, 0.28)	0.16 (0.04)	(0.08, 0.23)	<0.001 *
		Placebo	206	201 (97.6)	0.07 (0.03)	(0.02, 0.13)			
	Week 12	Tezepelumab	218	210 (96.3)	0.26 (0.03)	(0.21, 0.31)	0.17 (0.04)	(0.10, 0.25)	<0.001 *
		Placebo	206	197 (95.6)	0.08 (0.03)	(0.03, 0.13)			
	Week 16	Tezepelumab	218	209 (95.9)	0.25 (0.03)	(0.20, 0.30)	0.18 (0.04)	(0.10, 0.25)	<0.001 *
		Placebo	206	195 (94.7)	0.07 (0.03)	(0.02, 0.13)			
	Week 24	Tezepelumab	218	206 (94.5)	0.23 (0.03)	(0.18, 0.28)	0.15 (0.04)	(0.07, 0.22)	<0.001 *
		Placebo	206	190 (92.2)	0.09 (0.03)	(0.04, 0.14)			
	Week 36	Tezepelumab	218	196 (89.9)	0.24 (0.03)	(0.18, 0.29)	0.14 (0.04)	(0.06, 0.21)	<0.001 *
		Placebo	206	179 (86.9)	0.10 (0.03)	(0.05, 0.15)			
	Week 52	Tezepelumab	218	192 (88.1)	0.26 (0.03)	(0.21, 0.32)	0.19 (0.04)	(0.11, 0.26)	<0.001 *
		Placebo	206	169 (82.0)	0.07 (0.03)	(0.02, 0.13)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Race									0.504
White	Week 2	Tezepelumab	332	325 (97.9)	0.17 (0.02)	(0.14, 0.21)	0.14 (0.03)	(0.09, 0.20)	<0.001 *
		Placebo	327	311 (95.1)	0.03 (0.02)	(-0.01, 0.07)			
	Week 4	Tezepelumab	332	329 (99.1)	0.18 (0.02)	(0.14, 0.22)	0.09 (0.03)	(0.04, 0.15)	0.001 *
		Placebo	327	315 (96.3)	0.09 (0.02)	(0.05, 0.13)			
	Week 8	Tezepelumab	332	329 (99.1)	0.21 (0.02)	(0.16, 0.25)	0.10 (0.03)	(0.04, 0.17)	0.001 *
		Placebo	327	315 (96.3)	0.10 (0.02)	(0.06, 0.15)			
	Week 12	Tezepelumab	332	319 (96.1)	0.21 (0.02)	(0.17, 0.26)	0.11 (0.03)	(0.05, 0.18)	<0.001 *
		Placebo	327	313 (95.7)	0.10 (0.02)	(0.05, 0.14)			
	Week 16	Tezepelumab	332	320 (96.4)	0.23 (0.02)	(0.19, 0.28)	0.14 (0.03)	(0.08, 0.20)	<0.001 *
		Placebo	327	311 (95.1)	0.09 (0.02)	(0.05, 0.14)			
	Week 24	Tezepelumab	332	313 (94.3)	0.20 (0.02)	(0.16, 0.25)	0.11 (0.03)	(0.05, 0.17)	<0.001 *
		Placebo	327	297 (90.8)	0.09 (0.02)	(0.05, 0.14)			
	Week 36	Tezepelumab	332	300 (90.4)	0.21 (0.02)	(0.17, 0.26)	0.09 (0.03)	(0.02, 0.15)	0.009 *
		Placebo	327	286 (87.5)	0.13 (0.02)	(0.08, 0.17)			
	Week 52	Tezepelumab	332	291 (87.7)	0.23 (0.02)	(0.18, 0.27)	0.10 (0.03)	(0.04, 0.17)	0.002 *
		Placebo	327	269 (82.3)	0.12 (0.02)	(0.07, 0.17)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Black or African American	Week 2	Tezepelumab	30	26 (86.7)	0.16 (0.06)	(0.03, 0.28)	0.01 (0.09)	(-0.16, 0.19)	0.896
		Placebo	31	31 (100.0)	0.15 (0.06)	(0.02, 0.27)			
	Week 4	Tezepelumab	30	29 (96.7)	0.12 (0.07)	(-0.02, 0.25)	0.02 (0.09)	(-0.16, 0.21)	0.802
		Placebo	31	31 (100.0)	0.09 (0.06)	(-0.04, 0.22)			
	Week 8	Tezepelumab	30	29 (96.7)	0.20 (0.07)	(0.07, 0.33)	0.18 (0.09)	(-0.00, 0.36)	0.054
		Placebo	31	31 (100.0)	0.02 (0.06)	(-0.11, 0.14)			
	Week 12	Tezepelumab	30	29 (96.7)	0.25 (0.07)	(0.11, 0.38)	0.18 (0.09)	(-0.00, 0.37)	0.051
		Placebo	31	31 (100.0)	0.06 (0.06)	(-0.07, 0.19)			
	Week 16	Tezepelumab	30	28 (93.3)	0.12 (0.07)	(-0.02, 0.27)	0.02 (0.10)	(-0.18, 0.22)	0.857
		Placebo	31	30 (96.8)	0.10 (0.07)	(-0.04, 0.24)			
	Week 24	Tezepelumab	30	26 (86.7)	0.20 (0.06)	(0.07, 0.32)	0.19 (0.09)	(0.02, 0.36)	0.031 *
		Placebo	31	29 (93.5)	0.01 (0.06)	(-0.11, 0.13)			
	Week 36	Tezepelumab	30	26 (86.7)	0.22 (0.07)	(0.08, 0.36)	0.15 (0.10)	(-0.05, 0.34)	0.135
		Placebo	31	30 (96.8)	0.07 (0.07)	(-0.06, 0.20)			
	Week 52	Tezepelumab	30	25 (83.3)	0.25 (0.07)	(0.11, 0.38)	0.18 (0.09)	(-0.01, 0.37)	0.061
		Placebo	31	27 (87.1)	0.07 (0.06)	(-0.06, 0.20)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Asian	Week 2	Tezepelumab	146	144 (98.6)	0.15 (0.03)	(0.10, 0.20)	0.08 (0.04)	(0.01, 0.16)	0.026 *
		Placebo	149	144 (96.6)	0.07 (0.03)	(0.02, 0.12)			
	Week 4	Tezepelumab	146	146 (100.0)	0.21 (0.03)	(0.15, 0.27)	0.15 (0.04)	(0.07, 0.23)	<0.001 *
		Placebo	149	147 (98.7)	0.06 (0.03)	(0.01, 0.12)			
	Week 8	Tezepelumab	146	141 (96.6)	0.24 (0.03)	(0.18, 0.30)	0.17 (0.04)	(0.09, 0.25)	<0.001 *
		Placebo	149	148 (99.3)	0.07 (0.03)	(0.01, 0.13)			
	Week 12	Tezepelumab	146	143 (97.9)	0.25 (0.03)	(0.19, 0.31)	0.17 (0.04)	(0.09, 0.26)	<0.001 *
		Placebo	149	146 (98.0)	0.08 (0.03)	(0.02, 0.14)			
	Week 16	Tezepelumab	146	144 (98.6)	0.25 (0.03)	(0.19, 0.30)	0.17 (0.04)	(0.08, 0.25)	<0.001 *
		Placebo	149	145 (97.3)	0.08 (0.03)	(0.02, 0.14)			
	Week 24	Tezepelumab	146	142 (97.3)	0.23 (0.03)	(0.17, 0.29)	0.16 (0.04)	(0.08, 0.25)	<0.001 *
		Placebo	149	143 (96.0)	0.07 (0.03)	(0.01, 0.13)			
	Week 36	Tezepelumab	146	139 (95.2)	0.25 (0.03)	(0.18, 0.31)	0.20 (0.05)	(0.10, 0.29)	<0.001 *
		Placebo	149	136 (91.3)	0.05 (0.03)	(-0.01, 0.12)			
	Week 52	Tezepelumab	146	137 (93.8)	0.25 (0.03)	(0.19, 0.31)	0.20 (0.05)	(0.11, 0.29)	<0.001 *
		Placebo	149	135 (90.6)	0.05 (0.03)	(-0.01, 0.11)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Other	Week 2	Tezepelumab	20	19 (95.0)	0.13 (0.05)	(0.02, 0.23)	0.01 (0.07)	(-0.14, 0.15)	0.943
		Placebo	24	21 (87.5)	0.12 (0.05)	(0.02, 0.22)			
	Week 4	Tezepelumab	20	19 (95.0)	0.20 (0.07)	(0.05, 0.34)	0.03 (0.10)	(-0.16, 0.23)	0.719
		Placebo	24	23 (95.8)	0.16 (0.06)	(0.03, 0.29)			
	Week 8	Tezepelumab	20	19 (95.0)	0.15 (0.07)	(0.01, 0.28)	-0.04 (0.09)	(-0.22, 0.14)	0.627
		Placebo	24	23 (95.8)	0.19 (0.06)	(0.07, 0.31)			
	Week 12	Tezepelumab	20	19 (95.0)	0.11 (0.06)	(-0.01, 0.24)	-0.07 (0.08)	(-0.24, 0.10)	0.383
		Placebo	24	24 (100.0)	0.19 (0.06)	(0.08, 0.30)			
	Week 16	Tezepelumab	20	18 (90.0)	0.16 (0.07)	(0.03, 0.29)	-0.02 (0.09)	(-0.20, 0.16)	0.828
		Placebo	24	23 (95.8)	0.18 (0.06)	(0.06, 0.30)			
	Week 24	Tezepelumab	20	17 (85.0)	0.14 (0.09)	(-0.03, 0.32)	0.02 (0.12)	(-0.21, 0.26)	0.831
		Placebo	24	22 (91.7)	0.12 (0.08)	(-0.04, 0.28)			
	Week 36	Tezepelumab	20	18 (90.0)	0.15 (0.08)	(-0.01, 0.30)	-0.05 (0.10)	(-0.26, 0.16)	0.623
		Placebo	24	23 (95.8)	0.20 (0.07)	(0.06, 0.34)			
	Week 52	Tezepelumab	20	18 (90.0)	0.14 (0.08)	(-0.02, 0.30)	-0.00 (0.11)	(-0.22, 0.21)	0.981
		Placebo	24	22 (91.7)	0.14 (0.07)	(-0.00, 0.29)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Region									0.860
Europe	Week 2	Tezepelumab	78	77 (98.7)	0.16 (0.04)	(0.08, 0.23)	0.09 (0.05)	(-0.02, 0.19)	0.119
		Placebo	74	71 (95.9)	0.07 (0.04)	(-0.01, 0.15)			
	Week 4	Tezepelumab	78	78 (100.0)	0.20 (0.04)	(0.12, 0.28)	0.12 (0.06)	(0.01, 0.24)	0.037 *
		Placebo	74	73 (98.6)	0.07 (0.04)	(-0.01, 0.16)			
	Week 8	Tezepelumab	78	78 (100.0)	0.21 (0.05)	(0.11, 0.31)	0.10 (0.07)	(-0.04, 0.24)	0.144
		Placebo	74	69 (93.2)	0.11 (0.05)	(0.01, 0.21)			
	Week 12	Tezepelumab	78	75 (96.2)	0.17 (0.05)	(0.08, 0.26)	0.10 (0.06)	(-0.03, 0.23)	0.137
		Placebo	74	70 (94.6)	0.07 (0.05)	(-0.02, 0.16)			
	Week 16	Tezepelumab	78	74 (94.9)	0.23 (0.05)	(0.13, 0.32)	0.20 (0.07)	(0.06, 0.33)	0.004 *
		Placebo	74	70 (94.6)	0.03 (0.05)	(-0.07, 0.13)			
	Week 24	Tezepelumab	78	73 (93.6)	0.18 (0.04)	(0.09, 0.27)	0.14 (0.06)	(0.01, 0.27)	0.033 *
		Placebo	74	63 (85.1)	0.04 (0.05)	(-0.05, 0.13)			
	Week 36	Tezepelumab	78	71 (91.0)	0.18 (0.05)	(0.09, 0.27)	0.05 (0.07)	(-0.08, 0.18)	0.443
		Placebo	74	60 (81.1)	0.13 (0.05)	(0.03, 0.22)			
	Week 52	Tezepelumab	78	68 (87.2)	0.17 (0.04)	(0.09, 0.26)	0.04 (0.06)	(-0.08, 0.17)	0.508
		Placebo	74	59 (79.7)	0.13 (0.05)	(0.04, 0.22)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
America	Week 2	Tezepelumab	198	192 (97.0)	0.17 (0.03)	(0.12, 0.22)	0.11 (0.04)	(0.04, 0.18)	0.003 *
		Placebo	198	189 (95.5)	0.07 (0.03)	(0.02, 0.12)			
	Week 4	Tezepelumab	198	194 (98.0)	0.17 (0.03)	(0.11, 0.22)	0.07 (0.04)	(-0.00, 0.15)	0.060
		Placebo	198	190 (96.0)	0.10 (0.03)	(0.04, 0.15)			
	Week 8	Tezepelumab	198	193 (97.5)	0.19 (0.03)	(0.13, 0.24)	0.10 (0.04)	(0.02, 0.18)	0.017 *
		Placebo	198	193 (97.5)	0.09 (0.03)	(0.03, 0.14)			
	Week 12	Tezepelumab	198	189 (95.5)	0.20 (0.03)	(0.14, 0.26)	0.11 (0.04)	(0.03, 0.20)	0.009 *
		Placebo	198	195 (98.5)	0.09 (0.03)	(0.03, 0.15)			
	Week 16	Tezepelumab	198	190 (96.0)	0.21 (0.03)	(0.15, 0.27)	0.11 (0.04)	(0.02, 0.19)	0.010 *
		Placebo	198	192 (97.0)	0.11 (0.03)	(0.05, 0.16)			
	Week 24	Tezepelumab	198	183 (92.4)	0.19 (0.03)	(0.13, 0.25)	0.09 (0.04)	(0.01, 0.18)	0.025 *
		Placebo	198	185 (93.4)	0.10 (0.03)	(0.04, 0.15)			
	Week 36	Tezepelumab	198	178 (89.9)	0.22 (0.03)	(0.16, 0.28)	0.09 (0.04)	(0.00, 0.17)	0.045 *
		Placebo	198	187 (94.4)	0.13 (0.03)	(0.07, 0.19)			
	Week 52	Tezepelumab	198	172 (86.9)	0.24 (0.03)	(0.18, 0.30)	0.11 (0.04)	(0.02, 0.20)	0.017 *
		Placebo	198	171 (86.4)	0.13 (0.03)	(0.07, 0.19)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Asia/Pacific	Week 2	Tezepelumab	133	131 (98.5)	0.16 (0.03)	(0.10, 0.21)	0.09 (0.04)	(0.02, 0.17)	0.018 *
		Placebo	138	133 (96.4)	0.06 (0.03)	(0.01, 0.12)			
	Week 4	Tezepelumab	133	133 (100.0)	0.21 (0.03)	(0.15, 0.27)	0.16 (0.04)	(0.08, 0.24)	<0.001 *
		Placebo	138	137 (99.3)	0.06 (0.03)	(-0.00, 0.11)			
	Week 8	Tezepelumab	133	129 (97.0)	0.26 (0.03)	(0.19, 0.32)	0.17 (0.04)	(0.08, 0.25)	<0.001 *
		Placebo	138	137 (99.3)	0.09 (0.03)	(0.03, 0.15)			
	Week 12	Tezepelumab	133	130 (97.7)	0.27 (0.03)	(0.20, 0.33)	0.18 (0.05)	(0.08, 0.27)	<0.001 *
		Placebo	138	135 (97.8)	0.09 (0.03)	(0.03, 0.15)			
	Week 16	Tezepelumab	133	131 (98.5)	0.27 (0.03)	(0.20, 0.33)	0.18 (0.05)	(0.09, 0.27)	<0.001 *
		Placebo	138	133 (96.4)	0.09 (0.03)	(0.03, 0.15)			
	Week 24	Tezepelumab	133	130 (97.7)	0.24 (0.03)	(0.17, 0.30)	0.16 (0.05)	(0.07, 0.25)	<0.001 *
		Placebo	138	130 (94.2)	0.08 (0.03)	(0.01, 0.14)			
	Week 36	Tezepelumab	133	125 (94.0)	0.25 (0.04)	(0.18, 0.32)	0.18 (0.05)	(0.08, 0.28)	<0.001 *
		Placebo	138	122 (88.4)	0.07 (0.04)	(0.00, 0.14)			
	Week 52	Tezepelumab	133	125 (94.0)	0.25 (0.03)	(0.18, 0.32)	0.19 (0.05)	(0.10, 0.29)	<0.001 *
		Placebo	138	120 (87.0)	0.06 (0.03)	(-0.01, 0.13)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Rest of the world	Week 2	Tezepelumab	119	114 (95.8)	0.17 (0.03)	(0.11, 0.22)	0.15 (0.04)	(0.08, 0.23)	<0.001 *
		Placebo	121	114 (94.2)	0.01 (0.03)	(-0.04, 0.07)			
	Week 4	Tezepelumab	119	118 (99.2)	0.19 (0.03)	(0.12, 0.26)	0.08 (0.05)	(-0.02, 0.17)	0.116
		Placebo	121	116 (95.9)	0.11 (0.03)	(0.04, 0.18)			
	Week 8	Tezepelumab	119	118 (99.2)	0.21 (0.03)	(0.15, 0.28)	0.12 (0.05)	(0.03, 0.21)	0.012 *
		Placebo	121	118 (97.5)	0.10 (0.03)	(0.03, 0.16)			
	Week 12	Tezepelumab	119	116 (97.5)	0.23 (0.03)	(0.17, 0.30)	0.11 (0.05)	(0.02, 0.20)	0.022 *
		Placebo	121	114 (94.2)	0.13 (0.03)	(0.06, 0.19)			
	Week 16	Tezepelumab	119	115 (96.6)	0.21 (0.04)	(0.14, 0.28)	0.09 (0.05)	(-0.01, 0.19)	0.070
		Placebo	121	114 (94.2)	0.12 (0.04)	(0.05, 0.19)			
	Week 24	Tezepelumab	119	112 (94.1)	0.22 (0.04)	(0.15, 0.29)	0.13 (0.05)	(0.03, 0.23)	0.010 *
		Placebo	121	113 (93.4)	0.09 (0.04)	(0.02, 0.16)			
	Week 36	Tezepelumab	119	109 (91.6)	0.21 (0.03)	(0.15, 0.28)	0.12 (0.05)	(0.03, 0.22)	0.013 *
		Placebo	121	106 (87.6)	0.09 (0.03)	(0.02, 0.16)			
	Week 52	Tezepelumab	119	106 (89.1)	0.23 (0.04)	(0.16, 0.31)	0.17 (0.05)	(0.06, 0.27)	0.002 *
		Placebo	121	103 (85.1)	0.07 (0.04)	(-0.00, 0.14)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
BMI									0.723
< 18.5 kg/m**2	Week 2	Tezepelumab	11	11 (100.0)	-0.06 (0.12)	(-0.31, 0.19)	-0.02 (0.17)	(-0.38, 0.33)	0.892
		Placebo	11	11 (100.0)	-0.04 (0.12)	(-0.29, 0.21)			
	Week 4	Tezepelumab	11	11 (100.0)	-0.07 (0.11)	(-0.31, 0.17)	0.08 (0.16)	(-0.26, 0.42)	0.634
		Placebo	11	11 (100.0)	-0.15 (0.11)	(-0.39, 0.09)			
	Week 8	Tezepelumab	11	11 (100.0)	-0.05 (0.14)	(-0.35, 0.24)	0.03 (0.20)	(-0.40, 0.45)	0.900
		Placebo	11	11 (100.0)	-0.08 (0.14)	(-0.38, 0.22)			
	Week 12	Tezepelumab	11	11 (100.0)	-0.09 (0.15)	(-0.39, 0.22)	0.01 (0.21)	(-0.42, 0.44)	0.947
		Placebo	11	11 (100.0)	-0.10 (0.15)	(-0.40, 0.20)			
	Week 16	Tezepelumab	11	11 (100.0)	-0.05 (0.13)	(-0.33, 0.22)	0.11 (0.19)	(-0.28, 0.50)	0.571
		Placebo	11	11 (100.0)	-0.16 (0.13)	(-0.43, 0.11)			
	Week 24	Tezepelumab	11	11 (100.0)	0.03 (0.12)	(-0.21, 0.28)	0.08 (0.17)	(-0.28, 0.43)	0.655
		Placebo	11	10 (90.9)	-0.04 (0.12)	(-0.29, 0.21)			
	Week 36	Tezepelumab	11	10 (90.9)	0.04 (0.14)	(-0.25, 0.33)	0.10 (0.20)	(-0.31, 0.52)	0.609
		Placebo	11	9 (81.8)	-0.06 (0.14)	(-0.36, 0.23)			
	Week 52	Tezepelumab	11	10 (90.9)	-0.00 (0.14)	(-0.30, 0.29)	-0.08 (0.21)	(-0.51, 0.36)	0.714
		Placebo	11	7 (63.6)	0.07 (0.15)	(-0.24, 0.39)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
18.5 - < 25.0 kg/m**2	Week 2	Tezepelumab	157	153 (97.5)	0.19 (0.03)	(0.14, 0.25)	0.12 (0.04)	(0.04, 0.19)	0.003 *
		Placebo	179	171 (95.5)	0.07 (0.03)	(0.02, 0.13)			
	Week 4	Tezepelumab	157	157 (100.0)	0.21 (0.03)	(0.15, 0.27)	0.11 (0.04)	(0.02, 0.19)	0.013 *
		Placebo	179	174 (97.2)	0.11 (0.03)	(0.05, 0.16)			
	Week 8	Tezepelumab	157	155 (98.7)	0.24 (0.03)	(0.18, 0.31)	0.13 (0.04)	(0.04, 0.22)	0.003 *
		Placebo	179	177 (98.9)	0.11 (0.03)	(0.05, 0.17)			
	Week 12	Tezepelumab	157	156 (99.4)	0.27 (0.03)	(0.20, 0.33)	0.13 (0.04)	(0.05, 0.22)	0.003 *
		Placebo	179	173 (96.6)	0.13 (0.03)	(0.07, 0.19)			
	Week 16	Tezepelumab	157	150 (95.5)	0.30 (0.03)	(0.24, 0.37)	0.18 (0.04)	(0.09, 0.27)	<0.001 *
		Placebo	179	172 (96.1)	0.12 (0.03)	(0.06, 0.18)			
	Week 24	Tezepelumab	157	151 (96.2)	0.23 (0.03)	(0.16, 0.29)	0.12 (0.05)	(0.02, 0.21)	0.013 *
		Placebo	179	167 (93.3)	0.11 (0.03)	(0.05, 0.17)			
	Week 36	Tezepelumab	157	145 (92.4)	0.28 (0.04)	(0.21, 0.35)	0.15 (0.05)	(0.06, 0.25)	0.002 *
		Placebo	179	157 (87.7)	0.13 (0.03)	(0.06, 0.20)			
	Week 52	Tezepelumab	157	137 (87.3)	0.29 (0.03)	(0.22, 0.35)	0.17 (0.05)	(0.08, 0.26)	<0.001 *
		Placebo	179	157 (87.7)	0.12 (0.03)	(0.06, 0.18)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
25.0 - < 30.0 kg/m**2	Week 2	Tezepelumab	178	176 (98.9)	0.17 (0.03)	(0.12, 0.22)	0.13 (0.04)	(0.06, 0.20)	<0.001 *
		Placebo	161	152 (94.4)	0.04 (0.03)	(-0.01, 0.10)			
	Week 4	Tezepelumab	178	175 (98.3)	0.20 (0.03)	(0.15, 0.26)	0.11 (0.04)	(0.03, 0.19)	0.008 *
		Placebo	161	155 (96.3)	0.09 (0.03)	(0.03, 0.15)			
	Week 8	Tezepelumab	178	174 (97.8)	0.24 (0.03)	(0.18, 0.30)	0.14 (0.04)	(0.06, 0.22)	0.001 *
		Placebo	161	156 (96.9)	0.10 (0.03)	(0.04, 0.16)			
	Week 12	Tezepelumab	178	171 (96.1)	0.24 (0.03)	(0.18, 0.30)	0.12 (0.04)	(0.04, 0.21)	0.006 *
		Placebo	161	154 (95.7)	0.12 (0.03)	(0.06, 0.18)			
	Week 16	Tezepelumab	178	173 (97.2)	0.26 (0.03)	(0.19, 0.32)	0.16 (0.05)	(0.07, 0.25)	<0.001 *
		Placebo	161	153 (95.0)	0.10 (0.03)	(0.03, 0.16)			
	Week 24	Tezepelumab	178	166 (93.3)	0.24 (0.03)	(0.18, 0.30)	0.15 (0.04)	(0.07, 0.24)	<0.001 *
		Placebo	161	145 (90.1)	0.09 (0.03)	(0.03, 0.15)			
	Week 36	Tezepelumab	178	162 (91.0)	0.24 (0.03)	(0.18, 0.30)	0.14 (0.05)	(0.05, 0.23)	0.002 *
		Placebo	161	144 (89.4)	0.11 (0.03)	(0.04, 0.17)			
	Week 52	Tezepelumab	178	161 (90.4)	0.26 (0.03)	(0.20, 0.32)	0.20 (0.05)	(0.11, 0.29)	<0.001 *
		Placebo	161	131 (81.4)	0.06 (0.03)	(-0.01, 0.12)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 30.0 kg/m**2	Week 2	Tezepelumab	182	174 (95.6)	0.15 (0.02)	(0.10, 0.19)	0.10 (0.03)	(0.03, 0.16)	0.003 *
		Placebo	180	173 (96.1)	0.05 (0.02)	(0.00, 0.09)			
	Week 4	Tezepelumab	182	180 (98.9)	0.17 (0.02)	(0.12, 0.21)	0.09 (0.03)	(0.03, 0.16)	0.006 *
		Placebo	180	176 (97.8)	0.07 (0.02)	(0.02, 0.12)			
	Week 8	Tezepelumab	182	178 (97.8)	0.18 (0.03)	(0.12, 0.23)	0.10 (0.04)	(0.02, 0.17)	0.010 *
		Placebo	180	173 (96.1)	0.08 (0.03)	(0.03, 0.13)			
	Week 12	Tezepelumab	182	172 (94.5)	0.18 (0.03)	(0.13, 0.23)	0.13 (0.04)	(0.05, 0.21)	<0.001 *
		Placebo	180	176 (97.8)	0.05 (0.03)	(-0.01, 0.10)			
	Week 16	Tezepelumab	182	176 (96.7)	0.15 (0.02)	(0.10, 0.20)	0.08 (0.03)	(0.01, 0.15)	0.030 *
		Placebo	180	173 (96.1)	0.08 (0.02)	(0.03, 0.13)			
	Week 24	Tezepelumab	182	170 (93.4)	0.17 (0.03)	(0.11, 0.22)	0.10 (0.04)	(0.03, 0.18)	0.006 *
		Placebo	180	169 (93.9)	0.06 (0.03)	(0.01, 0.11)			
	Week 36	Tezepelumab	182	166 (91.2)	0.16 (0.03)	(0.10, 0.21)	0.06 (0.04)	(-0.01, 0.14)	0.088
		Placebo	180	165 (91.7)	0.09 (0.03)	(0.04, 0.14)			
	Week 52	Tezepelumab	182	163 (89.6)	0.17 (0.03)	(0.11, 0.22)	0.05 (0.04)	(-0.03, 0.13)	0.208
		Placebo	180	158 (87.8)	0.11 (0.03)	(0.06, 0.17)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline eosinophils - Low									0.002 i
< 150 cells/uL	Week 2	Tezepelumab	138	135 (97.8)	0.07 (0.03)	(0.02, 0.12)	0.02 (0.04)	(-0.05, 0.09)	0.604
		Placebo	138	132 (95.7)	0.05 (0.03)	(-0.00, 0.10)			
	Week 4	Tezepelumab	138	137 (99.3)	0.07 (0.03)	(0.01, 0.13)	0.01 (0.04)	(-0.07, 0.09)	0.784
		Placebo	138	134 (97.1)	0.06 (0.03)	(0.00, 0.12)			
	Week 8	Tezepelumab	138	133 (96.4)	0.08 (0.03)	(0.03, 0.14)	-0.00 (0.04)	(-0.09, 0.08)	0.967
		Placebo	138	134 (97.1)	0.09 (0.03)	(0.03, 0.15)			
	Week 12	Tezepelumab	138	132 (95.7)	0.08 (0.03)	(0.02, 0.14)	-0.00 (0.04)	(-0.09, 0.08)	0.948
		Placebo	138	132 (95.7)	0.08 (0.03)	(0.02, 0.14)			
	Week 16	Tezepelumab	138	134 (97.1)	0.08 (0.03)	(0.02, 0.15)	0.03 (0.05)	(-0.07, 0.12)	0.579
		Placebo	138	133 (96.4)	0.06 (0.03)	(-0.01, 0.12)			
	Week 24	Tezepelumab	138	126 (91.3)	0.08 (0.03)	(0.02, 0.13)	0.01 (0.04)	(-0.07, 0.09)	0.800
		Placebo	138	127 (92.0)	0.07 (0.03)	(0.01, 0.12)			
	Week 36	Tezepelumab	138	126 (91.3)	0.06 (0.03)	(0.01, 0.12)	-0.03 (0.04)	(-0.11, 0.05)	0.508
		Placebo	138	123 (89.1)	0.09 (0.03)	(0.03, 0.15)			
	Week 52	Tezepelumab	138	124 (89.9)	0.09 (0.03)	(0.03, 0.15)	0.03 (0.05)	(-0.06, 0.12)	0.496
		Placebo	138	121 (87.7)	0.06 (0.03)	(-0.00, 0.12)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 150 cells/uL	Week 2	Tezepelumab	390	379 (97.2)	0.20 (0.02)	(0.16, 0.23)	0.14 (0.02)	(0.09, 0.19)	<0.001 *
		Placebo	393	375 (95.4)	0.06 (0.02)	(0.02, 0.09)			
	Week 4	Tezepelumab	390	386 (99.0)	0.23 (0.02)	(0.19, 0.27)	0.13 (0.03)	(0.08, 0.19)	<0.001 *
		Placebo	393	382 (97.2)	0.09 (0.02)	(0.06, 0.13)			
	Week 8	Tezepelumab	390	385 (98.7)	0.26 (0.02)	(0.22, 0.30)	0.16 (0.03)	(0.11, 0.22)	<0.001 *
		Placebo	393	383 (97.5)	0.10 (0.02)	(0.06, 0.14)			
	Week 12	Tezepelumab	390	378 (96.9)	0.27 (0.02)	(0.23, 0.31)	0.17 (0.03)	(0.11, 0.23)	<0.001 *
		Placebo	393	382 (97.2)	0.10 (0.02)	(0.06, 0.14)			
	Week 16	Tezepelumab	390	376 (96.4)	0.28 (0.02)	(0.24, 0.32)	0.17 (0.03)	(0.12, 0.23)	<0.001 *
		Placebo	393	376 (95.7)	0.11 (0.02)	(0.07, 0.15)			
	Week 24	Tezepelumab	390	372 (95.4)	0.25 (0.02)	(0.21, 0.29)	0.16 (0.03)	(0.11, 0.22)	<0.001 *
		Placebo	393	364 (92.6)	0.09 (0.02)	(0.05, 0.13)			
	Week 36	Tezepelumab	390	357 (91.5)	0.28 (0.02)	(0.23, 0.32)	0.17 (0.03)	(0.11, 0.22)	<0.001 *
		Placebo	393	352 (89.6)	0.11 (0.02)	(0.07, 0.15)			
	Week 52	Tezepelumab	390	347 (89.0)	0.28 (0.02)	(0.24, 0.32)	0.17 (0.03)	(0.11, 0.23)	<0.001 *
		Placebo	393	332 (84.5)	0.11 (0.02)	(0.07, 0.15)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline eosinophils - High									0.005 i
< 300 cells/uL	Week 2	Tezepelumab	309	302 (97.7)	0.11 (0.02)	(0.07, 0.14)	0.08 (0.02)	(0.03, 0.13)	0.001 *
		Placebo	309	297 (96.1)	0.03 (0.02)	(-0.00, 0.06)			
	Week 4	Tezepelumab	309	307 (99.4)	0.12 (0.02)	(0.08, 0.16)	0.07 (0.03)	(0.02, 0.12)	0.008 *
		Placebo	309	300 (97.1)	0.05 (0.02)	(0.01, 0.08)			
	Week 8	Tezepelumab	309	303 (98.1)	0.13 (0.02)	(0.09, 0.17)	0.05 (0.03)	(-0.00, 0.11)	0.056
		Placebo	309	299 (96.8)	0.08 (0.02)	(0.04, 0.11)			
	Week 12	Tezepelumab	309	296 (95.8)	0.12 (0.02)	(0.08, 0.16)	0.06 (0.03)	(0.00, 0.12)	0.034 *
		Placebo	309	297 (96.1)	0.06 (0.02)	(0.02, 0.10)			
	Week 16	Tezepelumab	309	300 (97.1)	0.13 (0.02)	(0.09, 0.17)	0.07 (0.03)	(0.01, 0.12)	0.023 *
		Placebo	309	297 (96.1)	0.06 (0.02)	(0.02, 0.10)			
	Week 24	Tezepelumab	309	291 (94.2)	0.10 (0.02)	(0.06, 0.14)	0.06 (0.03)	(0.00, 0.11)	0.034 *
		Placebo	309	287 (92.9)	0.04 (0.02)	(0.00, 0.08)			
	Week 36	Tezepelumab	309	284 (91.9)	0.11 (0.02)	(0.07, 0.15)	0.06 (0.03)	(-0.00, 0.11)	0.058
		Placebo	309	277 (89.6)	0.05 (0.02)	(0.01, 0.09)			
	Week 52	Tezepelumab	309	282 (91.3)	0.12 (0.02)	(0.08, 0.16)	0.07 (0.03)	(0.01, 0.13)	0.026 *
		Placebo	309	264 (85.4)	0.06 (0.02)	(0.01, 0.10)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 300 cells/uL	Week 2	Tezepelumab	219	212 (96.8)	0.24 (0.03)	(0.19, 0.29)	0.15 (0.04)	(0.08, 0.22)	<0.001 *
		Placebo	222	210 (94.6)	0.09 (0.03)	(0.04, 0.14)			
	Week 4	Tezepelumab	219	216 (98.6)	0.28 (0.03)	(0.23, 0.33)	0.14 (0.04)	(0.07, 0.22)	<0.001 *
		Placebo	222	216 (97.3)	0.14 (0.03)	(0.09, 0.19)			
	Week 8	Tezepelumab	219	215 (98.2)	0.33 (0.03)	(0.27, 0.39)	0.21 (0.04)	(0.13, 0.29)	<0.001 *
		Placebo	222	218 (98.2)	0.12 (0.03)	(0.06, 0.18)			
	Week 12	Tezepelumab	219	214 (97.7)	0.36 (0.03)	(0.30, 0.42)	0.21 (0.04)	(0.13, 0.29)	<0.001 *
		Placebo	222	217 (97.7)	0.15 (0.03)	(0.09, 0.21)			
	Week 16	Tezepelumab	219	210 (95.9)	0.37 (0.03)	(0.31, 0.43)	0.23 (0.04)	(0.15, 0.30)	<0.001 *
		Placebo	222	212 (95.5)	0.14 (0.03)	(0.09, 0.20)			
	Week 24	Tezepelumab	219	207 (94.5)	0.36 (0.03)	(0.30, 0.41)	0.21 (0.04)	(0.13, 0.29)	<0.001 *
		Placebo	222	204 (91.9)	0.14 (0.03)	(0.09, 0.20)			
	Week 36	Tezepelumab	219	199 (90.9)	0.38 (0.03)	(0.32, 0.44)	0.20 (0.04)	(0.11, 0.28)	<0.001 *
		Placebo	222	198 (89.2)	0.18 (0.03)	(0.13, 0.24)			
	Week 52	Tezepelumab	219	189 (86.3)	0.38 (0.03)	(0.32, 0.44)	0.22 (0.04)	(0.14, 0.31)	<0.001 *
		Placebo	222	189 (85.1)	0.15 (0.03)	(0.09, 0.21)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline FENO									0.032 i
< 25 ppb	Week 2	Tezepelumab	213	206 (96.7)	0.12 (0.02)	(0.08, 0.16)	0.08 (0.03)	(0.02, 0.13)	0.008 *
		Placebo	220	204 (92.7)	0.05 (0.02)	(0.01, 0.09)			
	Week 4	Tezepelumab	213	210 (98.6)	0.12 (0.02)	(0.08, 0.17)	0.06 (0.03)	(-0.01, 0.12)	0.082
		Placebo	220	213 (96.8)	0.07 (0.02)	(0.03, 0.11)			
	Week 8	Tezepelumab	213	208 (97.7)	0.14 (0.02)	(0.09, 0.19)	0.06 (0.03)	(-0.01, 0.12)	0.078
		Placebo	220	214 (97.3)	0.08 (0.02)	(0.03, 0.13)			
	Week 12	Tezepelumab	213	205 (96.2)	0.15 (0.02)	(0.10, 0.19)	0.07 (0.03)	(-0.00, 0.13)	0.052
		Placebo	220	211 (95.9)	0.08 (0.02)	(0.03, 0.13)			
	Week 16	Tezepelumab	213	205 (96.2)	0.13 (0.02)	(0.09, 0.18)	0.07 (0.03)	(0.00, 0.14)	0.043 *
		Placebo	220	212 (96.4)	0.06 (0.02)	(0.02, 0.11)			
	Week 24	Tezepelumab	213	202 (94.8)	0.12 (0.02)	(0.08, 0.17)	0.07 (0.03)	(0.01, 0.14)	0.034 *
		Placebo	220	208 (94.5)	0.05 (0.02)	(0.00, 0.10)			
	Week 36	Tezepelumab	213	192 (90.1)	0.12 (0.02)	(0.07, 0.17)	0.03 (0.03)	(-0.04, 0.10)	0.402
		Placebo	220	199 (90.5)	0.09 (0.02)	(0.05, 0.14)			
	Week 52	Tezepelumab	213	192 (90.1)	0.14 (0.03)	(0.09, 0.19)	0.05 (0.04)	(-0.02, 0.12)	0.161
		Placebo	220	193 (87.7)	0.09 (0.03)	(0.04, 0.14)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 25 ppb	Week 2	Tezepelumab	309	302 (97.7)	0.20 (0.02)	(0.16, 0.24)	0.14 (0.03)	(0.08, 0.20)	<0.001 *
		Placebo	307	299 (97.4)	0.06 (0.02)	(0.02, 0.10)			
	Week 4	Tezepelumab	309	308 (99.7)	0.23 (0.02)	(0.19, 0.28)	0.14 (0.03)	(0.08, 0.20)	<0.001 *
		Placebo	307	299 (97.4)	0.10 (0.02)	(0.05, 0.14)			
	Week 8	Tezepelumab	309	304 (98.4)	0.27 (0.02)	(0.22, 0.32)	0.17 (0.03)	(0.10, 0.23)	<0.001 *
		Placebo	307	299 (97.4)	0.10 (0.02)	(0.06, 0.15)			
	Week 12	Tezepelumab	309	299 (96.8)	0.28 (0.02)	(0.23, 0.32)	0.17 (0.03)	(0.10, 0.24)	<0.001 *
		Placebo	307	300 (97.7)	0.11 (0.02)	(0.06, 0.15)			
	Week 16	Tezepelumab	309	299 (96.8)	0.29 (0.02)	(0.25, 0.34)	0.18 (0.03)	(0.11, 0.24)	<0.001 *
		Placebo	307	294 (95.8)	0.12 (0.02)	(0.07, 0.16)			
	Week 24	Tezepelumab	309	290 (93.9)	0.27 (0.02)	(0.22, 0.31)	0.16 (0.03)	(0.09, 0.23)	<0.001 *
		Placebo	307	280 (91.2)	0.11 (0.02)	(0.06, 0.15)			
	Week 36	Tezepelumab	309	285 (92.2)	0.29 (0.03)	(0.24, 0.34)	0.17 (0.04)	(0.10, 0.24)	<0.001 *
		Placebo	307	273 (88.9)	0.12 (0.03)	(0.07, 0.17)			
	Week 52	Tezepelumab	309	274 (88.7)	0.30 (0.02)	(0.25, 0.34)	0.19 (0.04)	(0.12, 0.26)	<0.001 *
		Placebo	307	257 (83.7)	0.10 (0.03)	(0.05, 0.15)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline specific perennial FEIA status									0.053
All negative	Week 2	Tezepelumab	184	181 (98.4)	0.19 (0.02)	(0.14, 0.23)	0.15 (0.03)	(0.09, 0.21)	<0.001 *
		Placebo	177	169 (95.5)	0.03 (0.02)	(-0.01, 0.07)			
	Week 4	Tezepelumab	184	183 (99.5)	0.24 (0.02)	(0.19, 0.29)	0.15 (0.03)	(0.08, 0.22)	<0.001 *
		Placebo	177	171 (96.6)	0.09 (0.02)	(0.04, 0.14)			
	Week 8	Tezepelumab	184	181 (98.4)	0.26 (0.02)	(0.21, 0.31)	0.17 (0.03)	(0.11, 0.24)	<0.001 *
		Placebo	177	171 (96.6)	0.08 (0.02)	(0.04, 0.13)			
	Week 12	Tezepelumab	184	182 (98.9)	0.26 (0.03)	(0.21, 0.31)	0.17 (0.04)	(0.09, 0.24)	<0.001 *
		Placebo	177	172 (97.2)	0.09 (0.03)	(0.04, 0.14)			
	Week 16	Tezepelumab	184	181 (98.4)	0.26 (0.02)	(0.22, 0.31)	0.18 (0.04)	(0.11, 0.25)	<0.001 *
		Placebo	177	169 (95.5)	0.09 (0.03)	(0.03, 0.14)			
	Week 24	Tezepelumab	184	177 (96.2)	0.25 (0.03)	(0.20, 0.30)	0.17 (0.04)	(0.10, 0.24)	<0.001 *
		Placebo	177	157 (88.7)	0.08 (0.03)	(0.02, 0.13)			
	Week 36	Tezepelumab	184	172 (93.5)	0.23 (0.03)	(0.18, 0.29)	0.13 (0.04)	(0.06, 0.21)	<0.001 *
		Placebo	177	155 (87.6)	0.10 (0.03)	(0.05, 0.16)			
	Week 52	Tezepelumab	184	170 (92.4)	0.26 (0.03)	(0.21, 0.31)	0.23 (0.04)	(0.16, 0.31)	<0.001 *
		Placebo	177	148 (83.6)	0.03 (0.03)	(-0.03, 0.08)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Any positive	Week 2	Tezepelumab	339	329 (97.1)	0.16 (0.02)	(0.12, 0.19)	0.09 (0.03)	(0.03, 0.14)	0.002 *
		Placebo	341	329 (96.5)	0.07 (0.02)	(0.03, 0.11)			
	Week 4	Tezepelumab	339	337 (99.4)	0.16 (0.02)	(0.12, 0.20)	0.07 (0.03)	(0.01, 0.13)	0.017 *
		Placebo	341	333 (97.7)	0.09 (0.02)	(0.05, 0.13)			
	Week 8	Tezepelumab	339	333 (98.2)	0.18 (0.02)	(0.14, 0.23)	0.08 (0.03)	(0.02, 0.14)	0.009 *
		Placebo	341	333 (97.7)	0.10 (0.02)	(0.06, 0.15)			
	Week 12	Tezepelumab	339	324 (95.6)	0.19 (0.02)	(0.15, 0.24)	0.10 (0.03)	(0.04, 0.16)	0.002 *
		Placebo	341	330 (96.8)	0.10 (0.02)	(0.05, 0.14)			
	Week 16	Tezepelumab	339	325 (95.9)	0.20 (0.02)	(0.16, 0.25)	0.10 (0.03)	(0.04, 0.16)	0.002 *
		Placebo	341	327 (95.9)	0.10 (0.02)	(0.06, 0.15)			
	Week 24	Tezepelumab	339	317 (93.5)	0.18 (0.02)	(0.14, 0.23)	0.09 (0.03)	(0.03, 0.15)	0.004 *
		Placebo	341	321 (94.1)	0.09 (0.02)	(0.05, 0.13)			
	Week 36	Tezepelumab	339	307 (90.6)	0.21 (0.02)	(0.17, 0.26)	0.10 (0.03)	(0.03, 0.16)	0.003 *
		Placebo	341	308 (90.3)	0.11 (0.02)	(0.07, 0.16)			
	Week 52	Tezepelumab	339	298 (87.9)	0.21 (0.02)	(0.16, 0.26)	0.07 (0.03)	(0.01, 0.14)	0.030 *
		Placebo	341	296 (86.8)	0.14 (0.02)	(0.09, 0.18)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Total serum IgE									0.189
Low	Week 2	Tezepelumab	158	155 (98.1)	0.12 (0.02)	(0.07, 0.16)	0.09 (0.03)	(0.03, 0.15)	0.004 *
		Placebo	168	158 (94.0)	0.03 (0.02)	(-0.02, 0.07)			
	Week 4	Tezepelumab	158	158 (100.0)	0.15 (0.03)	(0.10, 0.21)	0.09 (0.04)	(0.01, 0.16)	0.023 *
		Placebo	168	163 (97.0)	0.07 (0.03)	(0.02, 0.12)			
	Week 8	Tezepelumab	158	154 (97.5)	0.17 (0.03)	(0.12, 0.22)	0.09 (0.04)	(0.02, 0.16)	0.010 *
		Placebo	168	163 (97.0)	0.08 (0.02)	(0.03, 0.13)			
	Week 12	Tezepelumab	158	153 (96.8)	0.17 (0.03)	(0.12, 0.22)	0.09 (0.04)	(0.02, 0.17)	0.017 *
		Placebo	168	162 (96.4)	0.08 (0.03)	(0.02, 0.13)			
	Week 16	Tezepelumab	158	155 (98.1)	0.17 (0.03)	(0.12, 0.22)	0.09 (0.04)	(0.01, 0.16)	0.019 *
		Placebo	168	159 (94.6)	0.08 (0.03)	(0.03, 0.13)			
	Week 24	Tezepelumab	158	153 (96.8)	0.15 (0.02)	(0.11, 0.20)	0.10 (0.03)	(0.03, 0.17)	0.003 *
		Placebo	168	152 (90.5)	0.05 (0.02)	(0.00, 0.10)			
	Week 36	Tezepelumab	158	147 (93.0)	0.14 (0.03)	(0.09, 0.20)	0.05 (0.04)	(-0.03, 0.12)	0.208
		Placebo	168	142 (84.5)	0.10 (0.03)	(0.04, 0.15)			
	Week 52	Tezepelumab	158	147 (93.0)	0.15 (0.03)	(0.09, 0.20)	0.11 (0.04)	(0.03, 0.19)	0.005 *
		Placebo	168	142 (84.5)	0.04 (0.03)	(-0.01, 0.09)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Normal	Week 2	Tezepelumab	325	316 (97.2)	0.18 (0.02)	(0.14, 0.22)	0.14 (0.03)	(0.09, 0.20)	<0.001 *
		Placebo	303	291 (96.0)	0.04 (0.02)	(-0.00, 0.07)			
	Week 4	Tezepelumab	325	320 (98.5)	0.19 (0.02)	(0.16, 0.23)	0.13 (0.03)	(0.07, 0.18)	<0.001 *
		Placebo	303	293 (96.7)	0.07 (0.02)	(0.03, 0.11)			
	Week 8	Tezepelumab	325	319 (98.2)	0.22 (0.02)	(0.18, 0.26)	0.14 (0.03)	(0.08, 0.20)	<0.001 *
		Placebo	303	294 (97.0)	0.08 (0.02)	(0.04, 0.12)			
	Week 12	Tezepelumab	325	313 (96.3)	0.23 (0.02)	(0.19, 0.28)	0.16 (0.03)	(0.10, 0.22)	<0.001 *
		Placebo	303	294 (97.0)	0.07 (0.02)	(0.03, 0.12)			
	Week 16	Tezepelumab	325	311 (95.7)	0.25 (0.02)	(0.20, 0.29)	0.18 (0.03)	(0.12, 0.24)	<0.001 *
		Placebo	303	292 (96.4)	0.07 (0.02)	(0.03, 0.11)			
	Week 24	Tezepelumab	325	302 (92.9)	0.22 (0.02)	(0.18, 0.26)	0.15 (0.03)	(0.08, 0.21)	<0.001 *
		Placebo	303	282 (93.1)	0.07 (0.02)	(0.03, 0.12)			
	Week 36	Tezepelumab	325	295 (90.8)	0.24 (0.02)	(0.20, 0.29)	0.16 (0.03)	(0.09, 0.22)	<0.001 *
		Placebo	303	274 (90.4)	0.08 (0.02)	(0.04, 0.13)			
	Week 52	Tezepelumab	325	283 (87.1)	0.26 (0.02)	(0.22, 0.31)	0.16 (0.03)	(0.09, 0.23)	<0.001 *
		Placebo	303	259 (85.5)	0.10 (0.02)	(0.05, 0.15)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
High	Week 2	Tezepelumab	45	43 (95.6)	0.23 (0.07)	(0.09, 0.36)	0.01 (0.09)	(-0.17, 0.19)	0.941
		Placebo	60	58 (96.7)	0.22 (0.06)	(0.10, 0.34)			
	Week 4	Tezepelumab	45	45 (100.0)	0.25 (0.08)	(0.10, 0.40)	0.04 (0.10)	(-0.16, 0.24)	0.689
		Placebo	60	60 (100.0)	0.21 (0.07)	(0.08, 0.34)			
	Week 8	Tezepelumab	45	45 (100.0)	0.29 (0.08)	(0.13, 0.45)	0.08 (0.11)	(-0.13, 0.30)	0.452
		Placebo	60	60 (100.0)	0.21 (0.07)	(0.07, 0.35)			
	Week 12	Tezepelumab	45	44 (97.8)	0.32 (0.07)	(0.17, 0.46)	0.04 (0.10)	(-0.15, 0.23)	0.668
		Placebo	60	58 (96.7)	0.27 (0.06)	(0.15, 0.40)			
	Week 16	Tezepelumab	45	44 (97.8)	0.29 (0.08)	(0.14, 0.44)	0.04 (0.10)	(-0.16, 0.24)	0.707
		Placebo	60	58 (96.7)	0.25 (0.07)	(0.12, 0.38)			
	Week 24	Tezepelumab	45	43 (95.6)	0.29 (0.08)	(0.13, 0.45)	0.07 (0.10)	(-0.14, 0.28)	0.490
		Placebo	60	57 (95.0)	0.22 (0.07)	(0.08, 0.35)			
	Week 36	Tezepelumab	45	41 (91.1)	0.34 (0.09)	(0.17, 0.51)	0.10 (0.11)	(-0.13, 0.32)	0.389
		Placebo	60	59 (98.3)	0.24 (0.07)	(0.10, 0.39)			
	Week 52	Tezepelumab	45	41 (91.1)	0.28 (0.07)	(0.14, 0.43)	0.05 (0.10)	(-0.15, 0.24)	0.637
		Placebo	60	52 (86.7)	0.24 (0.06)	(0.11, 0.36)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
OCS at baseline									0.019 i
Yes	Week 2	Tezepelumab	49	48 (98.0)	0.22 (0.05)	(0.12, 0.32)	0.25 (0.07)	(0.11, 0.39)	<0.001 *
		Placebo	51	49 (96.1)	-0.03 (0.05)	(-0.13, 0.07)			
	Week 4	Tezepelumab	49	49 (100.0)	0.27 (0.05)	(0.17, 0.38)	0.25 (0.07)	(0.10, 0.40)	0.001 *
		Placebo	51	49 (96.1)	0.03 (0.05)	(-0.08, 0.13)			
	Week 8	Tezepelumab	49	48 (98.0)	0.23 (0.05)	(0.12, 0.34)	0.19 (0.08)	(0.03, 0.34)	0.018 *
		Placebo	51	50 (98.0)	0.04 (0.05)	(-0.06, 0.15)			
	Week 12	Tezepelumab	49	45 (91.8)	0.28 (0.06)	(0.15, 0.40)	0.21 (0.09)	(0.04, 0.38)	0.016 *
		Placebo	51	47 (92.2)	0.06 (0.06)	(-0.05, 0.18)			
	Week 16	Tezepelumab	49	46 (93.9)	0.30 (0.05)	(0.19, 0.40)	0.28 (0.07)	(0.14, 0.43)	<0.001 *
		Placebo	51	44 (86.3)	0.01 (0.05)	(-0.09, 0.11)			
	Week 24	Tezepelumab	49	43 (87.8)	0.33 (0.06)	(0.21, 0.44)	0.36 (0.08)	(0.20, 0.53)	<0.001 *
		Placebo	51	36 (70.6)	-0.04 (0.06)	(-0.16, 0.08)			
	Week 36	Tezepelumab	49	40 (81.6)	0.24 (0.06)	(0.13, 0.36)	0.21 (0.08)	(0.05, 0.36)	0.012 *
		Placebo	51	39 (76.5)	0.04 (0.06)	(-0.07, 0.15)			
	Week 52	Tezepelumab	49	38 (77.6)	0.29 (0.07)	(0.15, 0.42)	0.27 (0.10)	(0.08, 0.46)	0.006 *
		Placebo	51	35 (68.6)	0.02 (0.07)	(-0.12, 0.15)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 2	Tezepelumab	479	466 (97.3)	0.16 (0.02)	(0.13, 0.19)	0.10 (0.02)	(0.05, 0.14)	<0.001 *
		Placebo	480	458 (95.4)	0.06 (0.02)	(0.03, 0.09)			
	Week 4	Tezepelumab	479	474 (99.0)	0.18 (0.02)	(0.15, 0.21)	0.09 (0.02)	(0.04, 0.13)	<0.001 *
		Placebo	480	467 (97.3)	0.09 (0.02)	(0.06, 0.12)			
	Week 8	Tezepelumab	479	470 (98.1)	0.21 (0.02)	(0.18, 0.25)	0.11 (0.03)	(0.06, 0.16)	<0.001 *
		Placebo	480	467 (97.3)	0.10 (0.02)	(0.06, 0.13)			
	Week 12	Tezepelumab	479	465 (97.1)	0.22 (0.02)	(0.18, 0.25)	0.12 (0.03)	(0.07, 0.17)	<0.001 *
		Placebo	480	467 (97.3)	0.10 (0.02)	(0.06, 0.13)			
	Week 16	Tezepelumab	479	464 (96.9)	0.22 (0.02)	(0.19, 0.26)	0.12 (0.03)	(0.07, 0.17)	<0.001 *
		Placebo	480	465 (96.9)	0.10 (0.02)	(0.07, 0.14)			
	Week 24	Tezepelumab	479	455 (95.0)	0.20 (0.02)	(0.16, 0.23)	0.10 (0.03)	(0.05, 0.15)	<0.001 *
		Placebo	480	455 (94.8)	0.09 (0.02)	(0.06, 0.13)			
	Week 36	Tezepelumab	479	443 (92.5)	0.22 (0.02)	(0.18, 0.25)	0.10 (0.03)	(0.05, 0.16)	<0.001 *
		Placebo	480	436 (90.8)	0.11 (0.02)	(0.08, 0.15)			
	Week 52	Tezepelumab	479	433 (90.4)	0.22 (0.02)	(0.19, 0.26)	0.12 (0.03)	(0.07, 0.17)	<0.001 *
		Placebo	480	418 (87.1)	0.10 (0.02)	(0.07, 0.14)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
ICS dose level (at study entry)									0.250
Medium/Low	Week 2	Tezepelumab	131	128 (97.7)	0.13 (0.03)	(0.07, 0.18)	0.09 (0.04)	(0.01, 0.17)	0.030 *
		Placebo	133	128 (96.2)	0.04 (0.03)	(-0.02, 0.10)			
	Week 4	Tezepelumab	131	130 (99.2)	0.15 (0.03)	(0.09, 0.21)	0.07 (0.04)	(-0.02, 0.15)	0.119
		Placebo	133	128 (96.2)	0.08 (0.03)	(0.02, 0.14)			
	Week 8	Tezepelumab	131	128 (97.7)	0.17 (0.03)	(0.11, 0.24)	0.07 (0.05)	(-0.02, 0.17)	0.120
		Placebo	133	130 (97.7)	0.10 (0.03)	(0.03, 0.17)			
	Week 12	Tezepelumab	131	126 (96.2)	0.19 (0.03)	(0.12, 0.26)	0.11 (0.05)	(0.01, 0.20)	0.026 *
		Placebo	133	130 (97.7)	0.09 (0.03)	(0.02, 0.15)			
	Week 16	Tezepelumab	131	129 (98.5)	0.16 (0.03)	(0.09, 0.23)	0.04 (0.05)	(-0.05, 0.14)	0.394
		Placebo	133	132 (99.2)	0.12 (0.03)	(0.05, 0.19)			
	Week 24	Tezepelumab	131	127 (96.9)	0.16 (0.03)	(0.09, 0.22)	0.08 (0.05)	(-0.01, 0.17)	0.083
		Placebo	133	127 (95.5)	0.08 (0.03)	(0.01, 0.14)			
	Week 36	Tezepelumab	131	125 (95.4)	0.16 (0.03)	(0.09, 0.23)	0.05 (0.05)	(-0.05, 0.14)	0.319
		Placebo	133	123 (92.5)	0.11 (0.03)	(0.05, 0.18)			
	Week 52	Tezepelumab	131	120 (91.6)	0.18 (0.04)	(0.10, 0.25)	0.05 (0.05)	(-0.05, 0.15)	0.338
		Placebo	133	121 (91.0)	0.13 (0.04)	(0.05, 0.20)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
High	Week 2	Tezepelumab	397	386 (97.2)	0.18 (0.02)	(0.14, 0.21)	0.12 (0.02)	(0.07, 0.17)	<0.001 *
		Placebo	398	379 (95.2)	0.06 (0.02)	(0.02, 0.09)			
	Week 4	Tezepelumab	397	393 (99.0)	0.20 (0.02)	(0.17, 0.24)	0.12 (0.03)	(0.06, 0.17)	<0.001 *
		Placebo	398	388 (97.5)	0.09 (0.02)	(0.05, 0.12)			
	Week 8	Tezepelumab	397	390 (98.2)	0.23 (0.02)	(0.19, 0.27)	0.14 (0.03)	(0.08, 0.19)	<0.001 *
		Placebo	398	387 (97.2)	0.09 (0.02)	(0.05, 0.13)			
	Week 12	Tezepelumab	397	384 (96.7)	0.23 (0.02)	(0.19, 0.27)	0.13 (0.03)	(0.08, 0.19)	<0.001 *
		Placebo	398	384 (96.5)	0.10 (0.02)	(0.06, 0.14)			
	Week 16	Tezepelumab	397	381 (96.0)	0.25 (0.02)	(0.21, 0.29)	0.17 (0.03)	(0.11, 0.22)	<0.001 *
		Placebo	398	377 (94.7)	0.09 (0.02)	(0.05, 0.12)			
	Week 24	Tezepelumab	397	371 (93.5)	0.23 (0.02)	(0.19, 0.26)	0.14 (0.03)	(0.08, 0.20)	<0.001 *
		Placebo	398	364 (91.5)	0.09 (0.02)	(0.05, 0.12)			
	Week 36	Tezepelumab	397	358 (90.2)	0.24 (0.02)	(0.20, 0.28)	0.14 (0.03)	(0.08, 0.20)	<0.001 *
		Placebo	398	352 (88.4)	0.10 (0.02)	(0.06, 0.14)			
	Week 52	Tezepelumab	397	351 (88.4)	0.25 (0.02)	(0.21, 0.29)	0.17 (0.03)	(0.11, 0.22)	<0.001 *
		Placebo	398	332 (83.4)	0.08 (0.02)	(0.04, 0.12)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
LAMA use at baseline									0.342
Yes	Week 2	Tezepelumab	133	132 (99.2)	0.18 (0.03)	(0.12, 0.23)	0.13 (0.04)	(0.05, 0.21)	0.002 *
		Placebo	127	124 (97.6)	0.05 (0.03)	(-0.01, 0.10)			
	Week 4	Tezepelumab	133	133 (100.0)	0.19 (0.03)	(0.13, 0.25)	0.14 (0.04)	(0.05, 0.22)	0.001 *
		Placebo	127	126 (99.2)	0.05 (0.03)	(-0.01, 0.11)			
	Week 8	Tezepelumab	133	131 (98.5)	0.23 (0.04)	(0.16, 0.30)	0.16 (0.05)	(0.06, 0.27)	0.002 *
		Placebo	127	122 (96.1)	0.06 (0.04)	(-0.01, 0.14)			
	Week 12	Tezepelumab	133	129 (97.0)	0.24 (0.04)	(0.17, 0.31)	0.22 (0.05)	(0.12, 0.32)	<0.001 *
		Placebo	127	122 (96.1)	0.02 (0.04)	(-0.05, 0.09)			
	Week 16	Tezepelumab	133	127 (95.5)	0.24 (0.03)	(0.17, 0.31)	0.20 (0.05)	(0.10, 0.30)	<0.001 *
		Placebo	127	119 (93.7)	0.04 (0.03)	(-0.03, 0.11)			
	Week 24	Tezepelumab	133	125 (94.0)	0.23 (0.03)	(0.16, 0.29)	0.19 (0.05)	(0.10, 0.29)	<0.001 *
		Placebo	127	116 (91.3)	0.04 (0.03)	(-0.03, 0.10)			
	Week 36	Tezepelumab	133	118 (88.7)	0.23 (0.03)	(0.17, 0.30)	0.13 (0.05)	(0.04, 0.23)	0.005 *
		Placebo	127	111 (87.4)	0.10 (0.03)	(0.03, 0.17)			
	Week 52	Tezepelumab	133	112 (84.2)	0.25 (0.04)	(0.18, 0.32)	0.20 (0.05)	(0.10, 0.30)	<0.001 *
		Placebo	127	106 (83.5)	0.05 (0.04)	(-0.03, 0.12)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 2	Tezepelumab	395	382 (96.7)	0.16 (0.02)	(0.13, 0.20)	0.11 (0.02)	(0.06, 0.15)	<0.001 *
		Placebo	404	383 (94.8)	0.06 (0.02)	(0.02, 0.09)			
	Week 4	Tezepelumab	395	390 (98.7)	0.19 (0.02)	(0.15, 0.22)	0.09 (0.03)	(0.04, 0.14)	<0.001 *
		Placebo	404	390 (96.5)	0.10 (0.02)	(0.06, 0.13)			
	Week 8	Tezepelumab	395	387 (98.0)	0.21 (0.02)	(0.17, 0.25)	0.11 (0.03)	(0.05, 0.16)	<0.001 *
		Placebo	404	395 (97.8)	0.10 (0.02)	(0.07, 0.14)			
	Week 12	Tezepelumab	395	381 (96.5)	0.22 (0.02)	(0.18, 0.25)	0.10 (0.03)	(0.04, 0.15)	<0.001 *
		Placebo	404	392 (97.0)	0.12 (0.02)	(0.08, 0.16)			
	Week 16	Tezepelumab	395	383 (97.0)	0.22 (0.02)	(0.19, 0.26)	0.11 (0.03)	(0.06, 0.17)	<0.001 *
		Placebo	404	390 (96.5)	0.11 (0.02)	(0.07, 0.15)			
	Week 24	Tezepelumab	395	373 (94.4)	0.20 (0.02)	(0.16, 0.24)	0.10 (0.03)	(0.05, 0.16)	<0.001 *
		Placebo	404	375 (92.8)	0.10 (0.02)	(0.06, 0.14)			
	Week 36	Tezepelumab	395	365 (92.4)	0.22 (0.02)	(0.18, 0.26)	0.11 (0.03)	(0.05, 0.17)	<0.001 *
		Placebo	404	364 (90.1)	0.11 (0.02)	(0.07, 0.15)			
	Week 52	Tezepelumab	395	359 (90.9)	0.22 (0.02)	(0.18, 0.26)	0.11 (0.03)	(0.06, 0.17)	<0.001 *
		Placebo	404	347 (85.9)	0.11 (0.02)	(0.07, 0.15)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Tiotropium use at baseline									0.415
Yes	Week 2	Tezepelumab	124	123 (99.2)	0.18 (0.03)	(0.12, 0.24)	0.13 (0.04)	(0.04, 0.21)	0.004 *
		Placebo	122	119 (97.5)	0.05 (0.03)	(-0.01, 0.11)			
	Week 4	Tezepelumab	124	124 (100.0)	0.19 (0.03)	(0.13, 0.25)	0.13 (0.05)	(0.04, 0.22)	0.004 *
		Placebo	122	121 (99.2)	0.06 (0.03)	(-0.01, 0.12)			
	Week 8	Tezepelumab	124	122 (98.4)	0.23 (0.04)	(0.15, 0.30)	0.16 (0.05)	(0.05, 0.26)	0.004 *
		Placebo	122	117 (95.9)	0.07 (0.04)	(-0.01, 0.14)			
	Week 12	Tezepelumab	124	120 (96.8)	0.23 (0.04)	(0.16, 0.31)	0.22 (0.05)	(0.11, 0.32)	<0.001 *
		Placebo	122	117 (95.9)	0.02 (0.04)	(-0.06, 0.09)			
	Week 16	Tezepelumab	124	119 (96.0)	0.24 (0.04)	(0.17, 0.31)	0.21 (0.05)	(0.11, 0.31)	<0.001 *
		Placebo	122	115 (94.3)	0.04 (0.04)	(-0.03, 0.11)			
	Week 24	Tezepelumab	124	117 (94.4)	0.23 (0.03)	(0.16, 0.30)	0.19 (0.05)	(0.09, 0.29)	<0.001 *
		Placebo	122	112 (91.8)	0.04 (0.04)	(-0.03, 0.11)			
	Week 36	Tezepelumab	124	110 (88.7)	0.24 (0.03)	(0.17, 0.30)	0.13 (0.05)	(0.04, 0.23)	0.007 *
		Placebo	122	108 (88.5)	0.10 (0.04)	(0.03, 0.17)			
	Week 52	Tezepelumab	124	104 (83.9)	0.25 (0.04)	(0.17, 0.32)	0.21 (0.05)	(0.10, 0.31)	<0.001 *
		Placebo	122	104 (85.2)	0.04 (0.04)	(-0.03, 0.12)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 2	Tezepelumab	404	391 (96.8)	0.16 (0.02)	(0.13, 0.20)	0.11 (0.02)	(0.06, 0.15)	<0.001 *
		Placebo	409	388 (94.9)	0.05 (0.02)	(0.02, 0.09)			
	Week 4	Tezepelumab	404	399 (98.8)	0.19 (0.02)	(0.15, 0.22)	0.09 (0.03)	(0.04, 0.14)	<0.001 *
		Placebo	409	395 (96.6)	0.09 (0.02)	(0.06, 0.13)			
	Week 8	Tezepelumab	404	396 (98.0)	0.21 (0.02)	(0.17, 0.25)	0.11 (0.03)	(0.06, 0.16)	<0.001 *
		Placebo	409	400 (97.8)	0.10 (0.02)	(0.06, 0.14)			
	Week 12	Tezepelumab	404	390 (96.5)	0.22 (0.02)	(0.18, 0.26)	0.10 (0.03)	(0.05, 0.15)	<0.001 *
		Placebo	409	397 (97.1)	0.12 (0.02)	(0.08, 0.16)			
	Week 16	Tezepelumab	404	391 (96.8)	0.22 (0.02)	(0.18, 0.26)	0.11 (0.03)	(0.06, 0.17)	<0.001 *
		Placebo	409	394 (96.3)	0.11 (0.02)	(0.07, 0.15)			
	Week 24	Tezepelumab	404	381 (94.3)	0.20 (0.02)	(0.16, 0.24)	0.11 (0.03)	(0.05, 0.16)	<0.001 *
		Placebo	409	379 (92.7)	0.10 (0.02)	(0.06, 0.13)			
	Week 36	Tezepelumab	404	373 (92.3)	0.22 (0.02)	(0.18, 0.26)	0.11 (0.03)	(0.05, 0.17)	<0.001 *
		Placebo	409	367 (89.7)	0.11 (0.02)	(0.07, 0.15)			
	Week 52	Tezepelumab	404	367 (90.8)	0.22 (0.02)	(0.18, 0.27)	0.11 (0.03)	(0.06, 0.17)	<0.001 *
		Placebo	409	349 (85.3)	0.11 (0.02)	(0.07, 0.15)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Montelukast/ Cromoglicic acid use at baseline									0.243
Yes	Week 2	Tezepelumab	209	202 (96.7)	0.19 (0.02)	(0.15, 0.24)	0.13 (0.03)	(0.07, 0.20)	<0.001 *
		Placebo	197	188 (95.4)	0.06 (0.02)	(0.01, 0.11)			
	Week 4	Tezepelumab	209	207 (99.0)	0.23 (0.03)	(0.18, 0.28)	0.14 (0.04)	(0.07, 0.21)	<0.001 *
		Placebo	197	192 (97.5)	0.09 (0.03)	(0.04, 0.14)			
	Week 8	Tezepelumab	209	205 (98.1)	0.24 (0.03)	(0.19, 0.30)	0.14 (0.04)	(0.06, 0.22)	<0.001 *
		Placebo	197	193 (98.0)	0.11 (0.03)	(0.05, 0.16)			
	Week 12	Tezepelumab	209	200 (95.7)	0.26 (0.03)	(0.20, 0.32)	0.17 (0.04)	(0.09, 0.26)	<0.001 *
		Placebo	197	196 (99.5)	0.09 (0.03)	(0.03, 0.15)			
	Week 16	Tezepelumab	209	202 (96.7)	0.25 (0.03)	(0.19, 0.30)	0.15 (0.04)	(0.07, 0.23)	<0.001 *
		Placebo	197	192 (97.5)	0.10 (0.03)	(0.04, 0.16)			
	Week 24	Tezepelumab	209	197 (94.3)	0.23 (0.03)	(0.17, 0.28)	0.15 (0.04)	(0.07, 0.22)	<0.001 *
		Placebo	197	187 (94.9)	0.08 (0.03)	(0.02, 0.14)			
	Week 36	Tezepelumab	209	191 (91.4)	0.27 (0.03)	(0.21, 0.33)	0.18 (0.04)	(0.10, 0.26)	<0.001 *
		Placebo	197	181 (91.9)	0.09 (0.03)	(0.03, 0.15)			
	Week 52	Tezepelumab	209	186 (89.0)	0.27 (0.03)	(0.21, 0.33)	0.17 (0.04)	(0.09, 0.26)	<0.001 *
		Placebo	197	168 (85.3)	0.10 (0.03)	(0.04, 0.16)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 2	Tezepelumab	319	312 (97.8)	0.15 (0.02)	(0.11, 0.18)	0.10 (0.03)	(0.05, 0.15)	<0.001 *
		Placebo	334	319 (95.5)	0.05 (0.02)	(0.01, 0.09)			
	Week 4	Tezepelumab	319	316 (99.1)	0.16 (0.02)	(0.12, 0.20)	0.08 (0.03)	(0.02, 0.13)	0.005 *
		Placebo	334	324 (97.0)	0.08 (0.02)	(0.04, 0.12)			
	Week 8	Tezepelumab	319	313 (98.1)	0.19 (0.02)	(0.15, 0.24)	0.11 (0.03)	(0.05, 0.17)	<0.001 *
		Placebo	334	324 (97.0)	0.09 (0.02)	(0.05, 0.13)			
	Week 12	Tezepelumab	319	310 (97.2)	0.19 (0.02)	(0.15, 0.24)	0.09 (0.03)	(0.04, 0.15)	0.002 *
		Placebo	334	318 (95.2)	0.10 (0.02)	(0.06, 0.14)			
	Week 16	Tezepelumab	319	308 (96.6)	0.21 (0.02)	(0.17, 0.26)	0.12 (0.03)	(0.06, 0.18)	<0.001 *
		Placebo	334	317 (94.9)	0.09 (0.02)	(0.05, 0.13)			
	Week 24	Tezepelumab	319	301 (94.4)	0.20 (0.02)	(0.15, 0.24)	0.11 (0.03)	(0.05, 0.17)	<0.001 *
		Placebo	334	304 (91.0)	0.08 (0.02)	(0.04, 0.13)			
	Week 36	Tezepelumab	319	292 (91.5)	0.19 (0.02)	(0.14, 0.23)	0.07 (0.03)	(0.01, 0.14)	0.024 *
		Placebo	334	294 (88.0)	0.12 (0.02)	(0.07, 0.16)			
	Week 52	Tezepelumab	319	285 (89.3)	0.20 (0.02)	(0.16, 0.25)	0.11 (0.03)	(0.05, 0.17)	<0.001 *
		Placebo	334	285 (85.3)	0.09 (0.02)	(0.05, 0.14)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age (cat. N)												
< 18 years	Absolute values	Baseline	Tezepelumab	41	41 (100.0)	2.68 (0.64)	1.4	2.20	2.78	3.06	4.1	
			Placebo	41	41 (100.0)	2.69 (0.77)	1.0	2.16	2.70	3.09	4.9	
		Week 2	Tezepelumab	41	40 (97.6)	2.82 (0.58)	1.7	2.42	2.82	3.20	4.0	
			Placebo	41	39 (95.1)	2.74 (0.62)	1.3	2.31	2.71	3.09	4.7	
		Week 4	Tezepelumab	41	40 (97.6)	2.75 (0.65)	1.3	2.27	2.75	3.19	4.0	
			Placebo	41	38 (92.7)	2.70 (0.58)	1.3	2.42	2.62	3.14	4.0	
		Week 8	Tezepelumab	41	40 (97.6)	2.73 (0.72)	1.0	2.26	2.80	3.28	3.9	
			Placebo	41	39 (95.1)	2.72 (0.67)	1.2	2.31	2.69	3.15	4.9	
		Week 12	Tezepelumab	41	37 (90.2)	2.76 (0.73)	0.8	2.21	2.81	3.34	4.0	
			Placebo	41	39 (95.1)	2.74 (0.71)	1.4	2.34	2.75	3.07	5.0	
		Week 16	Tezepelumab	41	39 (95.1)	2.78 (0.62)	1.5	2.28	2.86	3.24	3.9	
			Placebo	41	40 (97.6)	2.75 (0.68)	1.5	2.43	2.60	3.17	5.2	
		Week 24	Tezepelumab	41	38 (92.7)	2.80 (0.61)	1.6	2.32	2.89	3.23	3.9	
			Placebo	41	38 (92.7)	2.78 (0.68)	1.5	2.38	2.69	3.15	5.1	
		Week 36	Tezepelumab	41	37 (90.2)	2.89 (0.55)	1.4	2.47	2.93	3.26	4.0	
			Placebo	41	35 (85.4)	2.87 (0.82)	1.4	2.40	2.90	3.34	5.3	
		Week 52	Tezepelumab	41	34 (82.9)	2.99 (0.60)	1.9	2.47	3.05	3.44	4.2	
			Placebo	41	35 (85.4)	2.92 (0.76)	1.2	2.47	2.86	3.41	5.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age (cat. N)												
< 18 years	Change from baseline	Week 2	Tezepelumab	41	40 (97.6)	0.15 (0.36)	-0.5	-0.02	0.08	0.34	1.4	0.22 [-0.23, 0.66]
			Placebo	41	39 (95.1)	0.05 (0.48)	-1.3	-0.12	0.03	0.20	1.7	
		Week 4	Tezepelumab	41	40 (97.6)	0.09 (0.40)	-1.2	-0.15	0.06	0.33	1.2	0.00 [-0.44, 0.45]
			Placebo	41	38 (92.7)	0.08 (0.53)	-1.0	-0.19	-0.04	0.22	1.7	
		Week 8	Tezepelumab	41	40 (97.6)	0.07 (0.44)	-1.1	-0.18	0.10	0.28	1.6	0.04 [-0.40, 0.48]
			Placebo	41	39 (95.1)	0.05 (0.57)	-1.7	-0.20	0.01	0.14	2.0	
		Week 12	Tezepelumab	41	37 (90.2)	0.09 (0.49)	-1.5	-0.12	0.15	0.30	1.5	0.03 [-0.42, 0.48]
			Placebo	41	39 (95.1)	0.08 (0.57)	-1.2	-0.22	0.02	0.26	1.6	
		Week 16	Tezepelumab	41	39 (95.1)	0.13 (0.37)	-0.5	-0.12	0.10	0.36	1.4	0.08 [-0.36, 0.52]
			Placebo	41	40 (97.6)	0.09 (0.55)	-1.6	-0.15	0.04	0.21	1.6	
		Week 24	Tezepelumab	41	38 (92.7)	0.12 (0.42)	-0.8	-0.10	0.12	0.27	1.8	0.13 [-0.33, 0.58]
			Placebo	41	38 (92.7)	0.06 (0.52)	-1.4	-0.14	0.00	0.23	1.5	
		Week 36	Tezepelumab	41	37 (90.2)	0.22 (0.42)	-0.6	-0.02	0.23	0.40	1.7	0.08 [-0.38, 0.54]
			Placebo	41	35 (85.4)	0.17 (0.67)	-1.7	-0.09	0.15	0.42	2.2	
		Week 52	Tezepelumab	41	34 (82.9)	0.32 (0.41)	-0.6	0.02	0.39	0.59	1.3	0.25 [-0.22, 0.73]
			Placebo	41	35 (85.4)	0.19 (0.55)	-1.4	-0.02	0.23	0.38	1.9	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age (cat. N)												
18 - < 65 years	Absolute values	Baseline	Tezepelumab	391	391 (100.0)	1.84 (0.69)	0.4	1.35	1.75	2.21	4.8	
			Placebo	416	416 (100.0)	1.83 (0.67)	0.4	1.37	1.73	2.19	4.5	
		Week 2	Tezepelumab	391	381 (97.4)	2.03 (0.71)	0.6	1.52	1.97	2.45	5.0	
			Placebo	416	397 (95.4)	1.91 (0.69)	0.4	1.41	1.82	2.32	4.1	
		Week 4	Tezepelumab	391	390 (99.7)	2.05 (0.72)	0.7	1.57	2.00	2.52	5.0	
			Placebo	416	408 (98.1)	1.92 (0.68)	0.4	1.46	1.83	2.28	4.8	
		Week 8	Tezepelumab	391	384 (98.2)	2.08 (0.73)	0.6	1.57	2.03	2.49	4.7	
			Placebo	416	408 (98.1)	1.95 (0.71)	0.4	1.46	1.86	2.30	4.7	
		Week 12	Tezepelumab	391	380 (97.2)	2.08 (0.74)	0.6	1.58	1.99	2.52	4.9	
			Placebo	416	405 (97.4)	1.95 (0.72)	0.5	1.47	1.83	2.33	4.6	
		Week 16	Tezepelumab	391	379 (96.9)	2.10 (0.76)	0.6	1.56	1.99	2.55	4.9	
			Placebo	416	399 (95.9)	1.94 (0.71)	0.5	1.46	1.83	2.31	4.7	
		Week 24	Tezepelumab	391	371 (94.9)	2.07 (0.72)	0.6	1.61	1.97	2.52	5.5	
			Placebo	416	386 (92.8)	1.93 (0.71)	0.6	1.45	1.83	2.25	4.8	
		Week 36	Tezepelumab	391	359 (91.8)	2.08 (0.74)	0.5	1.52	1.98	2.49	4.9	
			Placebo	416	374 (89.9)	1.96 (0.71)	0.6	1.49	1.85	2.32	4.6	
		Week 52	Tezepelumab	391	353 (90.3)	2.08 (0.74)	0.6	1.58	2.00	2.52	4.6	
			Placebo	416	355 (85.3)	1.95 (0.73)	0.6	1.44	1.81	2.33	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age (cat. N)												
18 - < 65 years	Change from baseline	Week 2	Tezepelumab	391	381 (97.4)	0.19 (0.36)	-0.8	-0.02	0.13	0.32	1.9	0.37 [0.22, 0.51]
			Placebo	416	397 (95.4)	0.06 (0.36)	-1.8	-0.12	0.01	0.18	1.7	
		Week 4	Tezepelumab	391	390 (99.7)	0.22 (0.38)	-1.0	-0.01	0.15	0.37	1.8	0.35 [0.21, 0.49]
			Placebo	416	408 (98.1)	0.09 (0.38)	-1.8	-0.11	0.05	0.26	1.6	
		Week 8	Tezepelumab	391	384 (98.2)	0.25 (0.43)	-0.9	-0.03	0.16	0.46	1.9	0.37 [0.23, 0.51]
			Placebo	416	408 (98.1)	0.10 (0.37)	-1.1	-0.11	0.05	0.28	2.1	
		Week 12	Tezepelumab	391	380 (97.2)	0.25 (0.42)	-0.8	-0.03	0.17	0.45	2.2	0.35 [0.21, 0.49]
			Placebo	416	405 (97.4)	0.11 (0.40)	-1.5	-0.10	0.05	0.26	2.1	
		Week 16	Tezepelumab	391	379 (96.9)	0.26 (0.45)	-1.0	-0.02	0.17	0.44	2.1	0.38 [0.24, 0.52]
			Placebo	416	399 (95.9)	0.10 (0.38)	-1.2	-0.10	0.04	0.26	1.9	
		Week 24	Tezepelumab	391	371 (94.9)	0.24 (0.43)	-1.0	-0.05	0.16	0.44	2.1	0.39 [0.24, 0.53]
			Placebo	416	386 (92.8)	0.08 (0.39)	-0.9	-0.14	0.03	0.27	1.7	
		Week 36	Tezepelumab	391	359 (91.8)	0.24 (0.43)	-1.0	-0.05	0.17	0.48	1.8	0.31 [0.16, 0.45]
			Placebo	416	374 (89.9)	0.11 (0.41)	-1.1	-0.14	0.06	0.29	1.7	
		Week 52	Tezepelumab	391	353 (90.3)	0.24 (0.44)	-1.0	-0.03	0.17	0.47	1.7	0.35 [0.20, 0.50]
			Placebo	416	355 (85.3)	0.10 (0.39)	-1.0	-0.14	0.06	0.26	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age (cat. N)												
>= 65 years	Absolute values	Baseline	Tezepelumab	96	96 (100.0)	1.45 (0.54)	0.6	1.14	1.36	1.62	3.2	
			Placebo	74	74 (100.0)	1.48 (0.47)	0.7	1.12	1.42	1.77	2.6	
		Week 2	Tezepelumab	96	93 (96.9)	1.52 (0.51)	0.6	1.23	1.44	1.75	3.1	
			Placebo	74	71 (95.9)	1.52 (0.50)	0.7	1.14	1.45	1.78	3.1	
		Week 4	Tezepelumab	96	93 (96.9)	1.54 (0.51)	0.6	1.20	1.46	1.77	3.1	
			Placebo	74	70 (94.6)	1.54 (0.50)	0.7	1.21	1.46	1.81	3.1	
		Week 8	Tezepelumab	96	94 (97.9)	1.55 (0.51)	0.6	1.20	1.47	1.82	3.2	
			Placebo	74	70 (94.6)	1.52 (0.51)	0.7	1.16	1.43	1.76	3.2	
		Week 12	Tezepelumab	96	93 (96.9)	1.57 (0.49)	0.6	1.23	1.50	1.83	3.3	
			Placebo	74	70 (94.6)	1.50 (0.49)	0.7	1.19	1.44	1.69	3.1	
		Week 16	Tezepelumab	96	92 (95.8)	1.58 (0.53)	0.6	1.24	1.51	1.84	3.4	
			Placebo	74	70 (94.6)	1.52 (0.47)	0.7	1.19	1.46	1.77	3.0	
		Week 24	Tezepelumab	96	89 (92.7)	1.53 (0.51)	0.6	1.18	1.52	1.78	3.1	
			Placebo	74	67 (90.5)	1.51 (0.47)	0.6	1.24	1.45	1.83	3.0	
		Week 36	Tezepelumab	96	87 (90.6)	1.57 (0.53)	0.6	1.15	1.51	1.84	3.2	
			Placebo	74	66 (89.2)	1.54 (0.50)	0.7	1.21	1.41	1.80	3.2	
		Week 52	Tezepelumab	96	84 (87.5)	1.57 (0.54)	0.7	1.17	1.44	1.77	3.3	
			Placebo	74	63 (85.1)	1.51 (0.49)	0.7	1.18	1.48	1.76	2.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age (cat. N)												
>= 65 years	Change from baseline	Week 2	Tezepelumab	96	93 (96.9)	0.09 (0.19)	-0.4	-0.01	0.07	0.19	0.7	0.24 [-0.07, 0.55]
			Placebo	74	71 (95.9)	0.04 (0.23)	-0.6	-0.08	0.01	0.13	0.7	
		Week 4	Tezepelumab	96	93 (96.9)	0.11 (0.23)	-0.7	-0.04	0.09	0.23	0.8	0.09 [-0.22, 0.40]
			Placebo	74	70 (94.6)	0.08 (0.27)	-0.9	-0.03	0.06	0.18	0.9	
		Week 8	Tezepelumab	96	94 (97.9)	0.13 (0.27)	-0.6	-0.04	0.08	0.27	1.0	0.26 [-0.05, 0.57]
			Placebo	74	70 (94.6)	0.06 (0.27)	-0.9	-0.08	0.05	0.21	0.7	
		Week 12	Tezepelumab	96	93 (96.9)	0.16 (0.29)	-0.7	-0.01	0.19	0.34	1.2	0.43 [0.12, 0.74]
			Placebo	74	70 (94.6)	0.04 (0.26)	-1.1	-0.07	0.00	0.18	0.7	
		Week 16	Tezepelumab	96	92 (95.8)	0.15 (0.28)	-0.5	-0.04	0.11	0.34	1.2	0.34 [0.03, 0.66]
			Placebo	74	70 (94.6)	0.06 (0.25)	-1.0	-0.09	0.05	0.25	0.6	
		Week 24	Tezepelumab	96	89 (92.7)	0.12 (0.26)	-0.4	-0.07	0.12	0.29	1.0	0.25 [-0.06, 0.57]
			Placebo	74	67 (90.5)	0.05 (0.26)	-1.1	-0.07	0.06	0.19	0.7	
		Week 36	Tezepelumab	96	87 (90.6)	0.13 (0.27)	-0.6	-0.05	0.08	0.31	1.0	0.28 [-0.04, 0.60]
			Placebo	74	66 (89.2)	0.05 (0.27)	-0.6	-0.14	0.01	0.18	0.8	
		Week 52	Tezepelumab	96	84 (87.5)	0.11 (0.27)	-0.5	-0.04	0.07	0.26	0.9	0.33 [-0.00, 0.66]
			Placebo	74	63 (85.1)	0.02 (0.33)	-1.0	-0.17	0.04	0.22	0.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Western Europe	Absolute values	Baseline	Tezepelumab	86	86 (100.0)	1.91 (0.70)	0.7	1.36	1.79	2.39	3.8	
			Placebo	85	85 (100.0)	1.84 (0.76)	0.7	1.26	1.75	2.22	4.2	
		Week 2	Tezepelumab	86	84 (97.7)	2.06 (0.76)	0.7	1.42	1.98	2.50	4.0	
			Placebo	85	80 (94.1)	1.92 (0.79)	0.6	1.36	1.76	2.37	4.0	
		Week 4	Tezepelumab	86	86 (100.0)	2.10 (0.75)	0.7	1.59	2.10	2.54	4.3	
			Placebo	85	83 (97.6)	1.90 (0.78)	0.7	1.33	1.76	2.42	4.2	
		Week 8	Tezepelumab	86	86 (100.0)	2.13 (0.79)	0.8	1.56	2.13	2.56	4.7	
			Placebo	85	79 (92.9)	1.99 (0.79)	0.7	1.34	1.98	2.52	4.3	
		Week 12	Tezepelumab	86	82 (95.3)	2.09 (0.79)	0.8	1.52	2.06	2.42	4.7	
			Placebo	85	79 (92.9)	1.90 (0.83)	0.6	1.25	1.69	2.52	4.3	
		Week 16	Tezepelumab	86	81 (94.2)	2.17 (0.78)	0.7	1.65	2.07	2.54	4.9	
			Placebo	85	79 (92.9)	1.88 (0.76)	0.7	1.31	1.76	2.32	4.1	
		Week 24	Tezepelumab	86	80 (93.0)	2.09 (0.72)	0.7	1.66	2.08	2.46	4.4	
			Placebo	85	71 (83.5)	1.92 (0.81)	0.6	1.25	1.96	2.27	4.8	
		Week 36	Tezepelumab	86	77 (89.5)	2.10 (0.74)	0.8	1.53	2.07	2.50	4.5	
			Placebo	85	66 (77.6)	2.05 (0.77)	0.8	1.49	1.98	2.55	4.6	
		Week 52	Tezepelumab	86	75 (87.2)	2.09 (0.75)	0.7	1.58	2.07	2.54	4.1	
			Placebo	85	64 (75.3)	2.07 (0.82)	0.7	1.41	1.98	2.60	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Western Europe	Change from baseline	Week 2	Tezepelumab	86	84 (97.7)	0.16 (0.30)	-0.6	-0.01	0.12	0.32	1.1	0.29 [-0.02, 0.60]
			Placebo	85	80 (94.1)	0.06 (0.37)	-0.8	-0.13	-0.02	0.21	1.7	
		Week 4	Tezepelumab	86	86 (100.0)	0.19 (0.35)	-0.7	-0.04	0.15	0.32	1.4	0.38 [0.07, 0.68]
			Placebo	85	83 (97.6)	0.06 (0.35)	-0.7	-0.11	0.03	0.25	1.4	
		Week 8	Tezepelumab	86	86 (100.0)	0.22 (0.42)	-0.6	-0.07	0.13	0.45	1.8	0.23 [-0.08, 0.53]
			Placebo	85	79 (92.9)	0.12 (0.43)	-0.8	-0.12	0.05	0.32	2.1	
		Week 12	Tezepelumab	86	82 (95.3)	0.20 (0.43)	-0.8	-0.07	0.13	0.39	1.9	0.32 [0.01, 0.63]
			Placebo	85	79 (92.9)	0.07 (0.35)	-0.7	-0.11	0.02	0.25	1.2	
		Week 16	Tezepelumab	86	81 (94.2)	0.24 (0.43)	-0.8	-0.02	0.17	0.40	2.0	0.52 [0.20, 0.83]
			Placebo	85	79 (92.9)	0.03 (0.39)	-1.2	-0.16	0.01	0.19	1.4	
		Week 24	Tezepelumab	86	80 (93.0)	0.20 (0.37)	-0.5	-0.05	0.16	0.40	1.5	0.43 [0.10, 0.75]
			Placebo	85	71 (83.5)	0.03 (0.40)	-0.9	-0.16	-0.01	0.19	1.6	
		Week 36	Tezepelumab	86	77 (89.5)	0.20 (0.39)	-0.5	-0.07	0.12	0.44	1.7	0.18 [-0.15, 0.51]
			Placebo	85	66 (77.6)	0.12 (0.41)	-1.1	-0.15	0.13	0.39	1.5	
		Week 52	Tezepelumab	86	75 (87.2)	0.18 (0.37)	-0.6	-0.06	0.16	0.35	1.3	0.10 [-0.24, 0.43]
			Placebo	85	64 (75.3)	0.14 (0.38)	-0.8	-0.06	0.10	0.31	1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
North America	Absolute values	Baseline	Tezepelumab	111	111 (100.0)	1.88 (0.74)	0.6	1.35	1.73	2.27	4.8	
			Placebo	111	111 (100.0)	1.89 (0.66)	0.8	1.35	1.82	2.22	4.1	
		Week 2	Tezepelumab	111	105 (94.6)	2.11 (0.76)	0.8	1.56	1.99	2.61	5.0	
			Placebo	111	105 (94.6)	1.98 (0.63)	1.0	1.48	1.94	2.38	4.2	
		Week 4	Tezepelumab	111	108 (97.3)	2.09 (0.76)	0.7	1.60	1.97	2.59	5.0	
			Placebo	111	108 (97.3)	2.00 (0.61)	1.0	1.57	1.94	2.33	4.0	
		Week 8	Tezepelumab	111	107 (96.4)	2.11 (0.76)	0.8	1.54	2.01	2.52	4.6	
			Placebo	111	109 (98.2)	1.95 (0.64)	0.8	1.53	1.87	2.30	3.8	
		Week 12	Tezepelumab	111	106 (95.5)	2.14 (0.80)	0.9	1.56	2.01	2.65	4.9	
			Placebo	111	109 (98.2)	1.97 (0.66)	0.9	1.49	1.83	2.34	4.2	
		Week 16	Tezepelumab	111	106 (95.5)	2.12 (0.81)	0.9	1.56	2.00	2.63	4.9	
			Placebo	111	108 (97.3)	1.98 (0.61)	0.8	1.53	1.93	2.40	3.9	
		Week 24	Tezepelumab	111	100 (90.1)	2.09 (0.82)	0.8	1.50	1.94	2.65	5.5	
			Placebo	111	103 (92.8)	1.96 (0.62)	0.8	1.51	1.93	2.31	4.0	
		Week 36	Tezepelumab	111	96 (86.5)	2.14 (0.81)	0.9	1.50	2.06	2.61	4.9	
			Placebo	111	104 (93.7)	2.00 (0.64)	0.9	1.53	1.98	2.36	4.1	
		Week 52	Tezepelumab	111	92 (82.9)	2.14 (0.81)	0.7	1.58	2.04	2.76	4.6	
			Placebo	111	90 (81.1)	2.01 (0.70)	0.6	1.44	1.92	2.47	3.9	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
North America	Change from baseline	Week 2	Tezepelumab	111	105 (94.6)	0.24 (0.33)	-0.3	0.05	0.15	0.40	1.5	0.47 [0.20, 0.74]
			Placebo	111	105 (94.6)	0.08 (0.38)	-1.8	-0.07	0.03	0.26	1.1	
		Week 4	Tezepelumab	111	108 (97.3)	0.23 (0.35)	-0.9	-0.01	0.15	0.40	1.3	0.36 [0.09, 0.63]
			Placebo	111	108 (97.3)	0.10 (0.35)	-1.0	-0.05	0.06	0.25	1.0	
		Week 8	Tezepelumab	111	107 (96.4)	0.25 (0.44)	-0.9	0.02	0.14	0.44	1.9	0.50 [0.23, 0.77]
			Placebo	111	109 (98.2)	0.06 (0.33)	-1.7	-0.10	0.08	0.22	0.9	
		Week 12	Tezepelumab	111	106 (95.5)	0.27 (0.39)	-0.6	0.04	0.19	0.42	2.2	0.46 [0.19, 0.73]
			Placebo	111	109 (98.2)	0.08 (0.44)	-1.5	-0.10	0.03	0.29	1.3	
		Week 16	Tezepelumab	111	106 (95.5)	0.27 (0.42)	-0.8	0.01	0.16	0.42	2.1	0.44 [0.17, 0.71]
			Placebo	111	108 (97.3)	0.10 (0.35)	-1.6	-0.09	0.06	0.28	1.0	
		Week 24	Tezepelumab	111	100 (90.1)	0.25 (0.41)	-0.7	-0.02	0.21	0.47	1.6	0.44 [0.16, 0.72]
			Placebo	111	103 (92.8)	0.08 (0.35)	-1.4	-0.08	0.07	0.24	0.9	
		Week 36	Tezepelumab	111	96 (86.5)	0.28 (0.39)	-0.6	0.00	0.20	0.43	1.5	0.43 [0.15, 0.71]
			Placebo	111	104 (93.7)	0.11 (0.38)	-1.2	-0.08	0.06	0.25	1.6	
		Week 52	Tezepelumab	111	92 (82.9)	0.28 (0.44)	-0.5	-0.01	0.16	0.55	1.5	0.41 [0.12, 0.70]
			Placebo	111	90 (81.1)	0.11 (0.41)	-1.4	-0.11	0.06	0.23	2.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
South America	Absolute values	Baseline	Tezepelumab	87	87 (100.0)	2.02 (0.77)	0.8	1.44	1.97	2.62	3.9	
			Placebo	87	87 (100.0)	2.15 (0.92)	0.6	1.43	2.08	2.78	4.9	
		Week 2	Tezepelumab	87	87 (100.0)	2.12 (0.78)	0.9	1.47	1.98	2.79	4.0	
			Placebo	87	84 (96.6)	2.22 (0.88)	0.6	1.48	2.19	2.86	4.7	
		Week 4	Tezepelumab	87	86 (98.9)	2.11 (0.81)	0.8	1.46	1.95	2.78	4.2	
			Placebo	87	82 (94.3)	2.18 (0.87)	0.5	1.50	2.21	2.71	4.8	
		Week 8	Tezepelumab	87	86 (98.9)	2.12 (0.84)	0.7	1.36	1.96	2.76	4.2	
			Placebo	87	84 (96.6)	2.28 (0.93)	0.6	1.58	2.15	2.97	4.9	
		Week 12	Tezepelumab	87	83 (95.4)	2.13 (0.83)	0.8	1.56	1.91	2.74	4.3	
			Placebo	87	86 (98.9)	2.26 (0.90)	0.5	1.58	2.17	2.83	5.0	
		Week 16	Tezepelumab	87	84 (96.6)	2.15 (0.81)	0.8	1.52	2.01	2.76	4.3	
			Placebo	87	84 (96.6)	2.27 (1.00)	0.5	1.55	2.22	2.98	5.2	
		Week 24	Tezepelumab	87	83 (95.4)	2.14 (0.80)	0.7	1.54	2.03	2.78	3.7	
			Placebo	87	82 (94.3)	2.29 (0.97)	0.6	1.61	2.12	3.10	5.1	
		Week 36	Tezepelumab	87	82 (94.3)	2.15 (0.84)	0.7	1.41	2.13	2.82	4.2	
			Placebo	87	83 (95.4)	2.34 (1.00)	0.6	1.49	2.27	3.06	5.3	
		Week 52	Tezepelumab	87	80 (92.0)	2.17 (0.87)	0.6	1.52	2.03	2.74	4.3	
			Placebo	87	81 (93.1)	2.31 (1.00)	0.6	1.57	2.27	2.91	5.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
South America	Change from baseline	Week 2	Tezepelumab	87	87 (100.0)	0.10 (0.33)	-0.7	-0.09	0.10	0.26	1.4	0.11 [-0.19, 0.41]
			Placebo	87	84 (96.6)	0.06 (0.45)	-1.1	-0.16	-0.01	0.17	1.7	
		Week 4	Tezepelumab	87	86 (98.9)	0.10 (0.35)	-1.2	-0.11	0.07	0.22	1.3	0.04 [-0.26, 0.34]
			Placebo	87	82 (94.3)	0.08 (0.49)	-1.8	-0.13	0.03	0.25	1.7	
		Week 8	Tezepelumab	87	86 (98.9)	0.11 (0.42)	-1.1	-0.11	0.07	0.29	1.6	-0.02 [-0.32, 0.28]
			Placebo	87	84 (96.6)	0.11 (0.44)	-1.0	-0.11	0.06	0.28	2.0	
		Week 12	Tezepelumab	87	83 (95.4)	0.11 (0.41)	-1.5	-0.09	0.07	0.22	1.6	0.03 [-0.27, 0.34]
			Placebo	87	86 (98.9)	0.09 (0.49)	-1.2	-0.22	0.04	0.26	1.6	
		Week 16	Tezepelumab	87	84 (96.6)	0.14 (0.36)	-0.5	-0.08	0.10	0.27	1.5	0.08 [-0.22, 0.38]
			Placebo	87	84 (96.6)	0.10 (0.49)	-0.7	-0.18	0.00	0.25	1.6	
		Week 24	Tezepelumab	87	83 (95.4)	0.13 (0.41)	-0.8	-0.10	0.12	0.31	1.8	0.10 [-0.21, 0.40]
			Placebo	87	82 (94.3)	0.09 (0.46)	-1.1	-0.16	0.03	0.26	1.6	
		Week 36	Tezepelumab	87	82 (94.3)	0.14 (0.39)	-0.8	-0.10	0.05	0.35	1.7	-0.04 [-0.35, 0.26]
			Placebo	87	83 (95.4)	0.16 (0.55)	-1.7	-0.17	0.07	0.33	2.2	
		Week 52	Tezepelumab	87	80 (92.0)	0.18 (0.41)	-0.8	-0.06	0.11	0.40	1.7	0.09 [-0.22, 0.40]
			Placebo	87	81 (93.1)	0.14 (0.48)	-0.9	-0.16	0.11	0.35	1.9	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Central/Eastern Europe	Absolute values	Baseline	Tezepelumab	38	38 (100.0)	1.91 (0.74)	0.9	1.35	1.86	2.21	4.1	
			Placebo	39	39 (100.0)	1.68 (0.76)	0.8	1.10	1.45	2.22	4.0	
		Week 2	Tezepelumab	38	37 (97.4)	2.07 (0.74)	1.1	1.53	1.94	2.49	3.9	
			Placebo	39	37 (94.9)	1.68 (0.76)	0.7	1.14	1.40	2.21	3.6	
		Week 4	Tezepelumab	38	38 (100.0)	2.16 (0.78)	0.9	1.66	1.98	2.78	3.9	
			Placebo	39	38 (97.4)	1.79 (0.76)	0.7	1.27	1.53	2.19	4.1	
		Week 8	Tezepelumab	38	38 (100.0)	2.16 (0.77)	1.0	1.61	2.06	2.62	3.9	
			Placebo	39	38 (97.4)	1.83 (0.86)	0.7	1.33	1.67	2.10	4.7	
		Week 12	Tezepelumab	38	37 (97.4)	2.17 (0.74)	1.1	1.68	1.93	2.58	4.0	
			Placebo	39	37 (94.9)	1.83 (0.90)	0.6	1.31	1.54	2.16	4.6	
		Week 16	Tezepelumab	38	38 (100.0)	2.19 (0.76)	1.0	1.57	2.05	2.68	3.9	
			Placebo	39	39 (100.0)	1.85 (0.89)	0.9	1.25	1.63	2.35	4.7	
		Week 24	Tezepelumab	38	37 (97.4)	2.13 (0.77)	0.9	1.57	1.81	2.55	3.9	
			Placebo	39	39 (100.0)	1.83 (0.85)	0.8	1.34	1.62	2.24	4.6	
		Week 36	Tezepelumab	38	38 (100.0)	2.09 (0.73)	1.0	1.51	1.92	2.53	3.7	
			Placebo	39	38 (97.4)	1.82 (0.83)	0.8	1.26	1.62	2.27	4.3	
		Week 52	Tezepelumab	38	38 (100.0)	2.13 (0.82)	1.0	1.53	1.94	2.76	4.0	
			Placebo	39	39 (100.0)	1.77 (0.83)	0.8	1.24	1.52	2.43	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Central/Eastern Europe	Change from baseline	Week 2	Tezepelumab	38	37 (97.4)	0.18 (0.31)	-0.4	0.02	0.10	0.28	1.0	0.76 [0.29, 1.24]
			Placebo	39	37 (94.9)	-0.03 (0.23)	-0.8	-0.12	0.00	0.09	0.7	
		Week 4	Tezepelumab	38	38 (100.0)	0.24 (0.42)	-0.7	0.03	0.23	0.39	1.7	0.45 [-0.01, 0.90]
			Placebo	39	38 (97.4)	0.09 (0.28)	-0.4	-0.08	0.08	0.19	1.0	
		Week 8	Tezepelumab	38	38 (100.0)	0.25 (0.36)	-0.2	-0.05	0.21	0.37	1.2	0.30 [-0.15, 0.76]
			Placebo	39	38 (97.4)	0.13 (0.40)	-0.5	-0.07	0.03	0.24	1.8	
		Week 12	Tezepelumab	38	37 (97.4)	0.27 (0.37)	-0.5	0.01	0.25	0.44	1.4	0.30 [-0.16, 0.76]
			Placebo	39	37 (94.9)	0.16 (0.36)	-0.2	-0.05	0.06	0.23	1.8	
		Week 16	Tezepelumab	38	38 (100.0)	0.27 (0.46)	-0.6	0.04	0.22	0.56	1.6	0.25 [-0.20, 0.70]
			Placebo	39	39 (100.0)	0.17 (0.38)	-0.4	-0.05	0.11	0.22	1.9	
		Week 24	Tezepelumab	38	37 (97.4)	0.20 (0.43)	-1.0	-0.08	0.19	0.38	1.1	0.13 [-0.32, 0.59]
			Placebo	39	39 (100.0)	0.15 (0.37)	-0.4	-0.06	0.04	0.26	1.7	
		Week 36	Tezepelumab	38	38 (100.0)	0.17 (0.41)	-0.5	-0.12	0.07	0.48	1.1	0.15 [-0.30, 0.60]
			Placebo	39	38 (97.4)	0.12 (0.30)	-0.3	-0.04	0.06	0.17	1.5	
		Week 52	Tezepelumab	38	38 (100.0)	0.22 (0.43)	-0.5	-0.10	0.18	0.44	1.4	0.32 [-0.13, 0.77]
			Placebo	39	39 (100.0)	0.09 (0.36)	-0.9	-0.10	0.06	0.23	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Asia Pacific	Absolute values	Baseline	Tezepelumab	125	125 (100.0)	1.72 (0.66)	0.4	1.30	1.68	2.15	4.1	
			Placebo	127	127 (100.0)	1.76 (0.56)	0.4	1.37	1.70	2.11	3.1	
		Week 2	Tezepelumab	125	124 (99.2)	1.88 (0.67)	0.6	1.31	1.80	2.31	4.3	
			Placebo	127	124 (97.6)	1.84 (0.61)	0.4	1.45	1.73	2.19	3.9	
		Week 4	Tezepelumab	125	125 (100.0)	1.94 (0.66)	0.7	1.46	1.91	2.41	3.7	
			Placebo	127	127 (100.0)	1.83 (0.60)	0.4	1.44	1.72	2.18	3.7	
		Week 8	Tezepelumab	125	121 (96.8)	1.97 (0.66)	0.6	1.48	1.89	2.38	4.7	
			Placebo	127	127 (100.0)	1.85 (0.62)	0.4	1.42	1.79	2.20	4.3	
		Week 12	Tezepelumab	125	123 (98.4)	1.97 (0.65)	0.6	1.52	1.92	2.35	3.8	
			Placebo	127	126 (99.2)	1.87 (0.61)	0.7	1.48	1.75	2.23	4.3	
		Week 16	Tezepelumab	125	124 (99.2)	1.97 (0.70)	0.6	1.52	1.87	2.43	4.7	
			Placebo	127	124 (97.6)	1.87 (0.59)	0.7	1.52	1.77	2.17	4.4	
		Week 24	Tezepelumab	125	123 (98.4)	1.96 (0.63)	0.7	1.57	1.82	2.32	4.0	
			Placebo	127	122 (96.1)	1.86 (0.59)	0.7	1.45	1.75	2.14	4.3	
		Week 36	Tezepelumab	125	119 (95.2)	1.97 (0.70)	0.6	1.51	1.81	2.40	4.4	
			Placebo	127	116 (91.3)	1.84 (0.63)	0.7	1.46	1.73	2.18	4.3	
		Week 52	Tezepelumab	125	118 (94.4)	1.97 (0.68)	0.6	1.53	1.81	2.37	4.2	
			Placebo	127	115 (90.6)	1.82 (0.59)	0.7	1.44	1.70	2.19	3.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Asia Pacific	Change from baseline	Week 2	Tezepelumab	125	124 (99.2)	0.16 (0.34)	-0.6	-0.01	0.09	0.25	1.3	0.27 [0.02, 0.52]
			Placebo	127	124 (97.6)	0.07 (0.32)	-0.7	-0.09	0.04	0.19	1.2	
		Week 4	Tezepelumab	125	125 (100.0)	0.22 (0.37)	-0.9	0.02	0.14	0.35	1.8	0.43 [0.18, 0.68]
			Placebo	127	127 (100.0)	0.06 (0.34)	-0.7	-0.12	0.02	0.20	1.1	
		Week 8	Tezepelumab	125	121 (96.8)	0.26 (0.42)	-0.8	0.01	0.17	0.46	1.7	0.45 [0.20, 0.71]
			Placebo	127	127 (100.0)	0.09 (0.33)	-0.7	-0.13	0.04	0.24	1.6	
		Week 12	Tezepelumab	125	123 (98.4)	0.26 (0.44)	-0.7	0.04	0.19	0.45	2.0	0.43 [0.18, 0.68]
			Placebo	127	126 (99.2)	0.09 (0.34)	-0.9	-0.07	0.04	0.19	1.7	
		Week 16	Tezepelumab	125	124 (99.2)	0.26 (0.43)	-0.6	-0.00	0.20	0.45	1.7	0.44 [0.19, 0.69]
			Placebo	127	124 (97.6)	0.09 (0.33)	-0.8	-0.10	0.03	0.26	1.8	
		Week 24	Tezepelumab	125	123 (98.4)	0.24 (0.42)	-1.0	-0.01	0.18	0.41	1.6	0.40 [0.15, 0.65]
			Placebo	127	122 (96.1)	0.08 (0.37)	-0.9	-0.13	0.07	0.27	1.7	
		Week 36	Tezepelumab	125	119 (95.2)	0.25 (0.45)	-1.0	0.00	0.21	0.44	1.5	0.43 [0.17, 0.69]
			Placebo	127	116 (91.3)	0.07 (0.39)	-1.0	-0.20	0.02	0.29	1.7	
		Week 52	Tezepelumab	125	118 (94.4)	0.24 (0.44)	-1.0	-0.03	0.20	0.49	1.6	0.51 [0.25, 0.78]
			Placebo	127	115 (90.6)	0.04 (0.33)	-1.0	-0.19	0.01	0.24	0.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Rest of the world	Absolute values	Baseline	Tezepelumab	81	81 (100.0)	1.61 (0.66)	0.6	1.12	1.46	2.02	3.3	
			Placebo	82	82 (100.0)	1.71 (0.52)	0.8	1.38	1.64	1.98	3.6	
		Week 2	Tezepelumab	81	77 (95.1)	1.80 (0.67)	0.6	1.31	1.68	2.22	3.5	
			Placebo	82	77 (93.9)	1.73 (0.53)	0.8	1.35	1.70	2.03	3.2	
		Week 4	Tezepelumab	81	80 (98.8)	1.77 (0.68)	0.6	1.24	1.70	2.16	3.8	
			Placebo	82	78 (95.1)	1.80 (0.54)	0.9	1.38	1.76	2.07	3.4	
		Week 8	Tezepelumab	81	80 (98.8)	1.79 (0.63)	0.6	1.30	1.72	2.29	3.8	
			Placebo	82	80 (97.6)	1.77 (0.52)	0.7	1.36	1.70	2.14	3.3	
		Week 12	Tezepelumab	81	79 (97.5)	1.81 (0.67)	0.6	1.32	1.70	2.30	3.8	
			Placebo	82	77 (93.9)	1.80 (0.54)	0.7	1.42	1.74	2.21	3.4	
		Week 16	Tezepelumab	81	77 (95.1)	1.81 (0.69)	0.6	1.31	1.73	2.21	3.8	
			Placebo	82	75 (91.5)	1.79 (0.50)	0.8	1.44	1.71	2.17	3.3	
		Week 24	Tezepelumab	81	75 (92.6)	1.84 (0.72)	0.6	1.22	1.80	2.32	4.0	
			Placebo	82	74 (90.2)	1.73 (0.50)	0.7	1.38	1.66	2.11	3.1	
		Week 36	Tezepelumab	81	71 (87.7)	1.86 (0.70)	0.5	1.30	1.81	2.36	3.8	
			Placebo	82	68 (82.9)	1.73 (0.49)	0.9	1.39	1.67	2.17	3.3	
		Week 52	Tezepelumab	81	68 (84.0)	1.86 (0.69)	0.7	1.32	1.78	2.32	3.7	
			Placebo	82	64 (78.0)	1.73 (0.53)	0.8	1.32	1.66	2.01	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Rest of the world	Change from baseline	Week 2	Tezepelumab	81	77 (95.1)	0.16 (0.37)	-0.8	-0.06	0.10	0.29	1.9	0.38 [0.06, 0.70]
			Placebo	82	77 (93.9)	0.03 (0.30)	-0.7	-0.12	0.03	0.16	1.0	
		Week 4	Tezepelumab	81	80 (98.8)	0.16 (0.37)	-1.0	-0.06	0.07	0.35	1.4	0.07 [-0.24, 0.38]
			Placebo	82	78 (95.1)	0.13 (0.42)	-1.0	-0.12	0.06	0.37	1.2	
		Week 8	Tezepelumab	81	80 (98.8)	0.20 (0.31)	-0.5	0.01	0.15	0.34	1.1	0.32 [0.01, 0.63]
			Placebo	82	80 (97.6)	0.09 (0.38)	-0.9	-0.11	0.03	0.23	1.8	
		Week 12	Tezepelumab	81	79 (97.5)	0.22 (0.36)	-0.4	-0.03	0.16	0.41	1.5	0.26 [-0.05, 0.58]
			Placebo	82	77 (93.9)	0.12 (0.39)	-1.1	-0.07	0.05	0.22	2.1	
		Week 16	Tezepelumab	81	77 (95.1)	0.18 (0.42)	-1.0	-0.05	0.11	0.36	1.8	0.20 [-0.12, 0.52]
			Placebo	82	75 (91.5)	0.10 (0.34)	-1.0	-0.06	0.04	0.31	1.3	
		Week 24	Tezepelumab	81	75 (92.6)	0.23 (0.43)	-0.4	-0.05	0.09	0.41	2.1	0.41 [0.09, 0.74]
			Placebo	82	74 (90.2)	0.07 (0.35)	-1.1	-0.14	0.00	0.26	1.3	
		Week 36	Tezepelumab	81	71 (87.7)	0.22 (0.39)	-0.4	-0.04	0.11	0.38	1.8	0.35 [0.02, 0.69]
			Placebo	82	68 (82.9)	0.08 (0.38)	-0.9	-0.13	0.04	0.29	1.6	
		Week 52	Tezepelumab	81	68 (84.0)	0.22 (0.39)	-0.5	-0.05	0.13	0.36	1.5	0.40 [0.05, 0.74]
			Placebo	82	64 (78.0)	0.06 (0.41)	-1.0	-0.18	0.05	0.21	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
< 150 cells/uL	Absolute values	Baseline	Tezepelumab	138	138 (100.0)	1.93 (0.73)	0.4	1.35	1.92	2.42	4.1	
			Placebo	138	138 (100.0)	1.84 (0.63)	0.8	1.41	1.80	2.18	4.9	
		Week 2	Tezepelumab	138	135 (97.8)	2.00 (0.74)	0.6	1.41	1.96	2.47	4.1	
			Placebo	138	132 (95.7)	1.89 (0.67)	0.8	1.41	1.78	2.25	4.7	
		Week 4	Tezepelumab	138	137 (99.3)	1.99 (0.78)	0.7	1.36	1.97	2.52	4.2	
			Placebo	138	134 (97.1)	1.88 (0.63)	0.7	1.42	1.83	2.32	3.6	
		Week 8	Tezepelumab	138	133 (96.4)	2.01 (0.73)	0.6	1.51	1.89	2.43	4.1	
			Placebo	138	134 (97.1)	1.92 (0.71)	0.7	1.41	1.86	2.34	4.9	
		Week 12	Tezepelumab	138	132 (95.7)	2.00 (0.73)	0.6	1.49	1.94	2.45	4.2	
			Placebo	138	132 (95.7)	1.91 (0.74)	0.7	1.38	1.81	2.29	5.0	
		Week 16	Tezepelumab	138	134 (97.1)	2.01 (0.78)	0.6	1.46	1.88	2.54	4.3	
			Placebo	138	133 (96.4)	1.90 (0.72)	0.6	1.36	1.78	2.31	5.2	
		Week 24	Tezepelumab	138	126 (91.3)	1.99 (0.70)	0.6	1.48	1.91	2.42	4.0	
			Placebo	138	127 (92.0)	1.91 (0.71)	0.7	1.38	1.80	2.28	5.1	
		Week 36	Tezepelumab	138	126 (91.3)	2.00 (0.75)	0.5	1.45	1.93	2.47	4.4	
			Placebo	138	123 (89.1)	1.94 (0.70)	0.8	1.41	1.85	2.34	5.3	
		Week 52	Tezepelumab	138	124 (89.9)	2.01 (0.74)	0.7	1.48	1.95	2.56	4.2	
			Placebo	138	121 (87.7)	1.92 (0.75)	0.7	1.36	1.78	2.41	5.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
< 150 cells/uL	Change from baseline	Week 2	Tezepelumab	138	135 (97.8)	0.06 (0.29)	-0.8	-0.06	0.07	0.18	1.5	0.04 [-0.20, 0.28]
			Placebo	138	132 (95.7)	0.05 (0.34)	-1.8	-0.10	0.02	0.17	1.2	
		Week 4	Tezepelumab	138	137 (99.3)	0.07 (0.36)	-1.0	-0.11	0.03	0.20	1.7	0.01 [-0.23, 0.25]
			Placebo	138	134 (97.1)	0.06 (0.34)	-1.0	-0.06	0.05	0.22	1.1	
		Week 8	Tezepelumab	138	133 (96.4)	0.08 (0.35)	-0.9	-0.12	0.04	0.24	1.4	-0.04 [-0.28, 0.20]
			Placebo	138	134 (97.1)	0.09 (0.37)	-1.1	-0.10	0.05	0.28	1.8	
		Week 12	Tezepelumab	138	132 (95.7)	0.08 (0.33)	-0.8	-0.10	0.07	0.24	1.4	-0.01 [-0.26, 0.23]
			Placebo	138	132 (95.7)	0.09 (0.38)	-1.2	-0.08	0.03	0.24	1.8	
		Week 16	Tezepelumab	138	134 (97.1)	0.08 (0.40)	-1.0	-0.14	0.03	0.24	1.9	0.04 [-0.20, 0.28]
			Placebo	138	133 (96.4)	0.06 (0.37)	-1.0	-0.14	0.03	0.22	1.9	
		Week 24	Tezepelumab	138	126 (91.3)	0.08 (0.31)	-0.6	-0.10	0.03	0.22	1.1	0.02 [-0.23, 0.27]
			Placebo	138	127 (92.0)	0.07 (0.36)	-1.1	-0.11	0.04	0.23	1.7	
		Week 36	Tezepelumab	138	126 (91.3)	0.05 (0.34)	-0.7	-0.13	0.00	0.22	1.5	-0.10 [-0.35, 0.15]
			Placebo	138	123 (89.1)	0.09 (0.33)	-0.7	-0.13	0.06	0.28	1.5	
		Week 52	Tezepelumab	138	124 (89.9)	0.08 (0.36)	-1.0	-0.12	0.04	0.23	1.3	0.05 [-0.20, 0.30]
			Placebo	138	121 (87.7)	0.06 (0.39)	-1.0	-0.17	0.06	0.20	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
150 - < 300 cells/uL	Absolute values	Baseline	Tezepelumab	171	171 (100.0)	1.84 (0.70)	0.6	1.35	1.73	2.26	4.8	
			Placebo	171	171 (100.0)	1.86 (0.68)	0.7	1.39	1.71	2.18	4.1	
		Week 2	Tezepelumab	171	167 (97.7)	1.98 (0.74)	0.6	1.46	1.88	2.50	5.0	
			Placebo	171	165 (96.5)	1.88 (0.73)	0.6	1.38	1.72	2.29	4.1	
		Week 4	Tezepelumab	171	170 (99.4)	1.98 (0.73)	0.6	1.44	1.92	2.45	5.0	
			Placebo	171	166 (97.1)	1.89 (0.68)	0.7	1.45	1.75	2.25	4.8	
		Week 8	Tezepelumab	171	170 (99.4)	1.99 (0.73)	0.6	1.35	1.96	2.46	4.6	
			Placebo	171	165 (96.5)	1.95 (0.71)	0.7	1.43	1.78	2.30	4.6	
		Week 12	Tezepelumab	171	164 (95.9)	1.96 (0.74)	0.6	1.39	1.90	2.40	4.9	
			Placebo	171	165 (96.5)	1.90 (0.73)	0.6	1.42	1.74	2.29	4.6	
		Week 16	Tezepelumab	171	166 (97.1)	1.99 (0.72)	0.6	1.43	1.88	2.45	4.9	
			Placebo	171	164 (95.9)	1.93 (0.75)	0.7	1.42	1.76	2.27	4.7	
		Week 24	Tezepelumab	171	165 (96.5)	1.95 (0.76)	0.6	1.34	1.81	2.45	5.5	
			Placebo	171	160 (93.6)	1.87 (0.73)	0.6	1.41	1.69	2.15	4.8	
		Week 36	Tezepelumab	171	158 (92.4)	1.97 (0.74)	0.7	1.32	1.84	2.50	4.9	
			Placebo	171	154 (90.1)	1.90 (0.74)	0.7	1.41	1.67	2.25	4.3	
		Week 52	Tezepelumab	171	158 (92.4)	1.97 (0.77)	0.6	1.38	1.85	2.47	4.6	
			Placebo	171	143 (83.6)	1.92 (0.76)	0.7	1.42	1.71	2.23	4.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
150 - < 300 cells/uL	Change from baseline	Week 2	Tezepelumab	171	167 (97.7)	0.14 (0.28)	-0.7	-0.03	0.09	0.28	1.1	0.42 [0.20, 0.64]
			Placebo	171	165 (96.5)	0.02 (0.31)	-1.0	-0.12	0.00	0.13	1.1	
		Week 4	Tezepelumab	171	170 (99.4)	0.16 (0.30)	-0.5	-0.01	0.10	0.25	1.6	0.37 [0.16, 0.59]
			Placebo	171	166 (97.1)	0.04 (0.35)	-1.0	-0.12	0.03	0.19	1.6	
		Week 8	Tezepelumab	171	170 (99.4)	0.16 (0.34)	-0.8	-0.03	0.11	0.27	1.4	0.30 [0.08, 0.51]
			Placebo	171	165 (96.5)	0.07 (0.31)	-1.0	-0.10	0.03	0.18	1.8	
		Week 12	Tezepelumab	171	164 (95.9)	0.15 (0.34)	-0.7	-0.04	0.10	0.28	2.0	0.31 [0.09, 0.53]
			Placebo	171	165 (96.5)	0.04 (0.37)	-1.5	-0.11	0.02	0.17	2.1	
		Week 16	Tezepelumab	171	166 (97.1)	0.16 (0.33)	-0.6	-0.02	0.12	0.28	1.7	0.29 [0.08, 0.51]
			Placebo	171	164 (95.9)	0.06 (0.34)	-1.2	-0.08	0.02	0.19	1.4	
		Week 24	Tezepelumab	171	165 (96.5)	0.12 (0.37)	-1.0	-0.11	0.09	0.29	1.3	0.28 [0.06, 0.50]
			Placebo	171	160 (93.6)	0.02 (0.32)	-0.9	-0.13	-0.02	0.19	1.6	
		Week 36	Tezepelumab	171	158 (92.4)	0.14 (0.36)	-1.0	-0.08	0.08	0.29	1.3	0.30 [0.07, 0.52]
			Placebo	171	154 (90.1)	0.03 (0.38)	-1.1	-0.19	0.01	0.21	1.6	
		Week 52	Tezepelumab	171	158 (92.4)	0.14 (0.37)	-0.8	-0.06	0.08	0.29	1.5	0.21 [-0.02, 0.43]
			Placebo	171	143 (83.6)	0.07 (0.34)	-1.0	-0.15	0.04	0.22	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
300 - < 450 cells/uL	Absolute values	Baseline	Tezepelumab	99	99 (100.0)	1.75 (0.72)	0.5	1.20	1.64	2.05	4.1	
			Placebo	95	95 (100.0)	1.86 (0.79)	0.4	1.23	1.69	2.38	4.5	
		Week 2	Tezepelumab	99	95 (96.0)	1.93 (0.72)	0.9	1.37	1.79	2.44	4.3	
			Placebo	95	89 (93.7)	1.94 (0.71)	0.4	1.43	1.93	2.43	3.4	
		Week 4	Tezepelumab	99	96 (97.0)	1.96 (0.70)	0.9	1.46	1.83	2.35	4.3	
			Placebo	95	92 (96.8)	1.94 (0.72)	0.4	1.44	1.88	2.50	4.0	
		Week 8	Tezepelumab	99	97 (98.0)	2.01 (0.77)	0.9	1.41	1.90	2.42	4.7	
			Placebo	95	93 (97.9)	1.96 (0.72)	0.4	1.41	1.93	2.39	3.9	
		Week 12	Tezepelumab	99	95 (96.0)	2.05 (0.75)	0.7	1.52	1.93	2.54	4.7	
			Placebo	95	90 (94.7)	1.96 (0.73)	0.8	1.45	1.95	2.40	4.2	
		Week 16	Tezepelumab	99	95 (96.0)	2.05 (0.79)	1.0	1.47	1.91	2.51	4.9	
			Placebo	95	89 (93.7)	1.98 (0.73)	0.8	1.45	1.89	2.48	4.3	
		Week 24	Tezepelumab	99	95 (96.0)	2.04 (0.73)	0.9	1.49	1.94	2.52	4.4	
			Placebo	95	87 (91.6)	1.97 (0.72)	0.8	1.47	1.89	2.38	4.3	
		Week 36	Tezepelumab	99	89 (89.9)	2.06 (0.79)	0.7	1.44	1.91	2.47	4.5	
			Placebo	95	84 (88.4)	2.00 (0.77)	0.8	1.39	1.90	2.48	4.2	
		Week 52	Tezepelumab	99	87 (87.9)	2.07 (0.79)	0.6	1.46	1.99	2.54	4.2	
			Placebo	95	84 (88.4)	1.99 (0.79)	0.7	1.37	1.85	2.46	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
300 - < 450 cells/uL	Change from baseline	Week 2	Tezepelumab	99	95 (96.0)	0.20 (0.38)	-0.6	0.00	0.10	0.35	1.9	0.36 [0.07, 0.65]
			Placebo	95	89 (93.7)	0.06 (0.37)	-1.1	-0.10	0.05	0.20	1.7	
		Week 4	Tezepelumab	99	96 (97.0)	0.22 (0.39)	-1.2	-0.04	0.15	0.38	1.4	0.29 [0.01, 0.58]
			Placebo	95	92 (96.8)	0.10 (0.42)	-1.8	-0.10	0.06	0.29	1.7	
		Week 8	Tezepelumab	99	97 (98.0)	0.27 (0.43)	-0.6	0.01	0.19	0.50	1.8	0.43 [0.14, 0.71]
			Placebo	95	93 (97.9)	0.10 (0.36)	-0.6	-0.11	0.06	0.25	2.0	
		Week 12	Tezepelumab	99	95 (96.0)	0.30 (0.42)	-0.3	0.01	0.23	0.45	1.9	0.54 [0.25, 0.84]
			Placebo	95	90 (94.7)	0.08 (0.40)	-1.4	-0.13	0.01	0.29	1.5	
		Week 16	Tezepelumab	99	95 (96.0)	0.31 (0.44)	-0.4	0.01	0.23	0.47	2.0	0.47 [0.17, 0.76]
			Placebo	95	89 (93.7)	0.12 (0.37)	-1.0	-0.09	0.04	0.28	1.6	
		Week 24	Tezepelumab	99	95 (96.0)	0.31 (0.42)	-0.3	0.02	0.26	0.49	2.1	0.60 [0.30, 0.90]
			Placebo	95	87 (91.6)	0.08 (0.34)	-0.9	-0.13	0.07	0.27	1.1	
		Week 36	Tezepelumab	99	89 (89.9)	0.31 (0.42)	-0.3	0.01	0.31	0.52	1.8	0.45 [0.15, 0.75]
			Placebo	95	84 (88.4)	0.12 (0.43)	-0.8	-0.06	0.05	0.23	2.2	
		Week 52	Tezepelumab	99	87 (87.9)	0.32 (0.44)	-0.8	0.02	0.34	0.51	1.7	0.48 [0.18, 0.78]
			Placebo	95	84 (88.4)	0.11 (0.43)	-0.6	-0.16	0.05	0.29	2.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
>= 450 cells/uL	Absolute values	Baseline	Tezepelumab	120	120 (100.0)	1.78 (0.72)	0.6	1.30	1.61	2.13	3.8	
			Placebo	127	127 (100.0)	1.84 (0.76)	0.6	1.32	1.73	2.22	4.2	
		Week 2	Tezepelumab	120	117 (97.5)	2.07 (0.74)	0.8	1.52	1.92	2.53	4.0	
			Placebo	127	121 (95.3)	1.97 (0.73)	0.8	1.38	1.91	2.46	4.2	
		Week 4	Tezepelumab	120	120 (100.0)	2.13 (0.74)	0.7	1.58	1.98	2.65	4.2	
			Placebo	127	124 (97.6)	2.01 (0.77)	0.5	1.44	1.92	2.47	4.2	
		Week 8	Tezepelumab	120	118 (98.3)	2.15 (0.77)	0.9	1.61	2.01	2.61	4.3	
			Placebo	127	125 (98.4)	1.96 (0.79)	0.6	1.33	1.89	2.41	4.3	
		Week 12	Tezepelumab	120	119 (99.2)	2.19 (0.78)	0.9	1.64	1.98	2.65	4.6	
			Placebo	127	127 (100.0)	2.04 (0.76)	0.5	1.48	1.98	2.47	4.3	
		Week 16	Tezepelumab	120	115 (95.8)	2.21 (0.78)	0.8	1.63	2.05	2.67	4.4	
			Placebo	127	123 (96.9)	2.01 (0.73)	0.5	1.52	1.95	2.34	4.4	
		Week 24	Tezepelumab	120	112 (93.3)	2.17 (0.75)	0.8	1.67	1.98	2.57	4.0	
			Placebo	127	117 (92.1)	2.04 (0.76)	0.7	1.51	1.95	2.38	4.8	
		Week 36	Tezepelumab	120	110 (91.7)	2.20 (0.76)	0.8	1.64	2.06	2.50	4.2	
			Placebo	127	114 (89.8)	2.10 (0.80)	0.6	1.53	2.10	2.42	4.6	
		Week 52	Tezepelumab	120	102 (85.0)	2.21 (0.77)	0.9	1.66	2.04	2.63	4.3	
			Placebo	127	105 (82.7)	2.05 (0.78)	0.6	1.51	2.03	2.45	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
>= 450 cells/uL	Change from baseline	Week 2	Tezepelumab	120	117 (97.5)	0.30 (0.37)	-0.5	0.08	0.22	0.43	1.4	0.50 [0.24, 0.76]
			Placebo	127	121 (95.3)	0.10 (0.42)	-1.3	-0.12	0.01	0.28	1.7	
		Week 4	Tezepelumab	120	120 (100.0)	0.35 (0.37)	-0.4	0.09	0.32	0.51	1.8	0.46 [0.20, 0.71]
			Placebo	127	124 (97.6)	0.17 (0.43)	-1.0	-0.12	0.06	0.45	1.4	
		Week 8	Tezepelumab	120	118 (98.3)	0.39 (0.47)	-1.1	0.10	0.31	0.66	1.9	0.58 [0.32, 0.83]
			Placebo	127	125 (98.4)	0.12 (0.48)	-1.7	-0.15	0.07	0.31	2.1	
		Week 12	Tezepelumab	120	119 (99.2)	0.42 (0.47)	-1.5	0.09	0.37	0.62	2.2	0.49 [0.24, 0.75]
			Placebo	127	127 (100.0)	0.19 (0.44)	-1.2	-0.08	0.11	0.37	1.7	
		Week 16	Tezepelumab	120	115 (95.8)	0.44 (0.44)	-0.5	0.14	0.36	0.67	2.1	0.65 [0.39, 0.91]
			Placebo	127	123 (96.9)	0.15 (0.44)	-1.6	-0.10	0.05	0.43	1.8	
		Week 24	Tezepelumab	120	112 (93.3)	0.42 (0.46)	-0.8	0.14	0.38	0.64	1.8	0.54 [0.27, 0.80]
			Placebo	127	117 (92.1)	0.17 (0.49)	-1.4	-0.14	0.09	0.38	1.7	
		Week 36	Tezepelumab	120	110 (91.7)	0.44 (0.42)	-0.5	0.18	0.38	0.69	1.7	0.47 [0.20, 0.73]
			Placebo	127	114 (89.8)	0.23 (0.50)	-1.7	-0.04	0.15	0.51	1.7	
		Week 52	Tezepelumab	120	102 (85.0)	0.44 (0.42)	-0.6	0.22	0.43	0.73	1.6	0.68 [0.40, 0.96]
			Placebo	127	105 (82.7)	0.15 (0.45)	-1.4	-0.09	0.10	0.35	1.9	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q1: < 140 cells/uL	Absolute values	Baseline	Tezepelumab	125	125 (100.0)	1.92 (0.71)	0.4	1.35	1.92	2.40	4.0	
			Placebo	127	127 (100.0)	1.82 (0.64)	0.8	1.39	1.76	2.17	4.9	
		Week 2	Tezepelumab	125	122 (97.6)	2.00 (0.73)	0.6	1.40	1.97	2.47	4.1	
			Placebo	127	121 (95.3)	1.88 (0.67)	0.8	1.41	1.77	2.18	4.7	
		Week 4	Tezepelumab	125	124 (99.2)	1.99 (0.77)	0.7	1.34	1.98	2.54	4.2	
			Placebo	127	123 (96.9)	1.86 (0.64)	0.7	1.36	1.79	2.32	3.6	
		Week 8	Tezepelumab	125	121 (96.8)	2.01 (0.72)	0.6	1.51	1.91	2.43	4.1	
			Placebo	127	123 (96.9)	1.89 (0.71)	0.7	1.40	1.82	2.30	4.9	
		Week 12	Tezepelumab	125	120 (96.0)	1.99 (0.73)	0.6	1.51	1.95	2.43	4.2	
			Placebo	127	122 (96.1)	1.90 (0.75)	0.7	1.36	1.80	2.28	5.0	
		Week 16	Tezepelumab	125	122 (97.6)	2.01 (0.78)	0.6	1.46	1.88	2.54	4.3	
			Placebo	127	122 (96.1)	1.87 (0.73)	0.6	1.34	1.76	2.29	5.2	
		Week 24	Tezepelumab	125	115 (92.0)	2.00 (0.70)	0.6	1.48	1.93	2.42	4.0	
			Placebo	127	117 (92.1)	1.90 (0.72)	0.7	1.36	1.80	2.28	5.1	
		Week 36	Tezepelumab	125	115 (92.0)	2.01 (0.75)	0.5	1.47	1.94	2.48	4.4	
			Placebo	127	113 (89.0)	1.93 (0.72)	0.8	1.41	1.84	2.29	5.3	
		Week 52	Tezepelumab	125	113 (90.4)	2.02 (0.72)	0.7	1.51	1.97	2.59	4.2	
			Placebo	127	111 (87.4)	1.90 (0.76)	0.7	1.32	1.74	2.33	5.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q1: < 140 cells/uL	Change from baseline	Week 2	Tezepelumab	125	122 (97.6)	0.07 (0.28)	-0.8	-0.06	0.08	0.19	1.5	0.05 [-0.20, 0.30]
			Placebo	127	121 (95.3)	0.06 (0.30)	-0.7	-0.10	0.01	0.17	1.2	
		Week 4	Tezepelumab	125	124 (99.2)	0.08 (0.37)	-1.0	-0.09	0.05	0.26	1.7	0.03 [-0.22, 0.28]
			Placebo	127	123 (96.9)	0.07 (0.33)	-0.9	-0.06	0.05	0.22	1.1	
		Week 8	Tezepelumab	125	121 (96.8)	0.09 (0.36)	-0.9	-0.09	0.05	0.27	1.4	0.02 [-0.23, 0.27]
			Placebo	127	123 (96.9)	0.08 (0.37)	-1.1	-0.11	0.05	0.27	1.8	
		Week 12	Tezepelumab	125	120 (96.0)	0.09 (0.34)	-0.8	-0.10	0.08	0.25	1.4	-0.00 [-0.25, 0.25]
			Placebo	127	122 (96.1)	0.09 (0.36)	-1.1	-0.08	0.03	0.22	1.8	
		Week 16	Tezepelumab	125	122 (97.6)	0.09 (0.41)	-1.0	-0.13	0.03	0.25	1.9	0.07 [-0.18, 0.32]
			Placebo	127	122 (96.1)	0.06 (0.38)	-1.0	-0.14	0.04	0.22	1.9	
		Week 24	Tezepelumab	125	115 (92.0)	0.09 (0.32)	-0.6	-0.09	0.03	0.25	1.1	0.02 [-0.24, 0.27]
			Placebo	127	117 (92.1)	0.08 (0.35)	-1.1	-0.11	0.04	0.22	1.7	
		Week 36	Tezepelumab	125	115 (92.0)	0.07 (0.35)	-0.7	-0.12	0.01	0.24	1.5	-0.10 [-0.36, 0.16]
			Placebo	127	113 (89.0)	0.10 (0.32)	-0.7	-0.11	0.06	0.28	1.5	
		Week 52	Tezepelumab	125	113 (90.4)	0.09 (0.37)	-1.0	-0.09	0.05	0.24	1.3	0.09 [-0.17, 0.35]
			Placebo	127	111 (87.4)	0.06 (0.39)	-1.0	-0.17	0.06	0.20	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q2: 140 - < 250 cells/uL	Absolute values	Baseline	Tezepelumab	130	130 (100.0)	1.86 (0.67)	0.8	1.42	1.75	2.27	4.1	
			Placebo	136	136 (100.0)	1.91 (0.66)	0.7	1.42	1.77	2.29	4.1	
		Week 2	Tezepelumab	130	127 (97.7)	1.99 (0.68)	0.8	1.48	1.86	2.50	3.9	
			Placebo	136	132 (97.1)	1.90 (0.71)	0.7	1.37	1.73	2.31	4.0	
		Week 4	Tezepelumab	130	130 (100.0)	1.98 (0.69)	0.8	1.44	1.83	2.43	3.9	
			Placebo	136	131 (96.3)	1.92 (0.63)	0.8	1.46	1.83	2.26	3.7	
		Week 8	Tezepelumab	130	129 (99.2)	1.98 (0.70)	0.8	1.37	1.90	2.44	3.9	
			Placebo	136	134 (98.5)	1.98 (0.69)	0.7	1.45	1.85	2.36	4.1	
		Week 12	Tezepelumab	130	124 (95.4)	1.94 (0.71)	0.8	1.37	1.82	2.40	4.0	
			Placebo	136	131 (96.3)	1.92 (0.71)	0.6	1.49	1.74	2.40	4.1	
		Week 16	Tezepelumab	130	126 (96.9)	1.99 (0.69)	0.8	1.45	1.88	2.45	3.9	
			Placebo	136	132 (97.1)	1.96 (0.73)	0.7	1.47	1.77	2.40	4.1	
		Week 24	Tezepelumab	130	125 (96.2)	1.94 (0.72)	0.7	1.36	1.80	2.45	3.9	
			Placebo	136	128 (94.1)	1.92 (0.69)	0.6	1.45	1.74	2.25	4.0	
		Week 36	Tezepelumab	130	121 (93.1)	1.94 (0.70)	0.7	1.30	1.83	2.45	3.7	
			Placebo	136	123 (90.4)	1.93 (0.72)	0.8	1.44	1.71	2.28	4.1	
		Week 52	Tezepelumab	130	120 (92.3)	1.95 (0.75)	0.6	1.40	1.83	2.44	4.0	
			Placebo	136	115 (84.6)	1.96 (0.75)	0.7	1.44	1.75	2.36	4.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q2: 140 - < 250 cells/uL	Change from baseline	Week 2	Tezepelumab	130	127 (97.7)	0.12 (0.28)	-0.7	-0.03	0.08	0.24	1.1	0.46 [0.22, 0.71]
			Placebo	136	132 (97.1)	-0.02 (0.32)	-1.8	-0.12	0.00	0.13	1.1	
		Week 4	Tezepelumab	130	130 (100.0)	0.12 (0.27)	-0.5	-0.06	0.09	0.23	1.2	0.32 [0.07, 0.56]
			Placebo	136	131 (96.3)	0.02 (0.35)	-1.0	-0.13	0.04	0.19	1.1	
		Week 8	Tezepelumab	130	129 (99.2)	0.12 (0.32)	-0.8	-0.06	0.11	0.23	1.4	0.19 [-0.05, 0.43]
			Placebo	136	134 (98.5)	0.06 (0.31)	-1.0	-0.10	0.03	0.20	1.8	
		Week 12	Tezepelumab	130	124 (95.4)	0.10 (0.31)	-0.7	-0.06	0.08	0.20	1.4	0.22 [-0.02, 0.47]
			Placebo	136	131 (96.3)	0.02 (0.39)	-1.5	-0.12	0.01	0.17	2.1	
		Week 16	Tezepelumab	130	126 (96.9)	0.12 (0.28)	-0.6	-0.06	0.10	0.25	1.3	0.22 [-0.03, 0.46]
			Placebo	136	132 (97.1)	0.06 (0.30)	-0.8	-0.10	0.02	0.19	1.3	
		Week 24	Tezepelumab	130	125 (96.2)	0.08 (0.34)	-1.0	-0.12	0.08	0.24	1.3	0.19 [-0.05, 0.44]
			Placebo	136	128 (94.1)	0.02 (0.32)	-0.9	-0.11	0.01	0.22	1.3	
		Week 36	Tezepelumab	130	121 (93.1)	0.07 (0.32)	-0.8	-0.10	0.04	0.22	1.3	0.16 [-0.09, 0.41]
			Placebo	136	123 (90.4)	0.02 (0.38)	-1.1	-0.18	0.00	0.20	1.6	
		Week 52	Tezepelumab	130	120 (92.3)	0.09 (0.34)	-0.8	-0.11	0.03	0.23	1.3	0.06 [-0.20, 0.31]
			Placebo	136	115 (84.6)	0.07 (0.36)	-1.0	-0.16	0.02	0.22	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q3: 250 - < 430 cells/uL	Absolute values	Baseline	Tezepelumab	145	145 (100.0)	1.79 (0.77)	0.5	1.20	1.71	2.26	4.8	
			Placebo	130	130 (100.0)	1.81 (0.69)	0.4	1.30	1.69	2.28	3.7	
		Week 2	Tezepelumab	145	141 (97.2)	1.97 (0.77)	0.6	1.39	1.91	2.45	5.0	
			Placebo	130	123 (94.6)	1.90 (0.70)	0.4	1.43	1.85	2.34	4.1	
		Week 4	Tezepelumab	145	141 (97.2)	1.99 (0.77)	0.6	1.44	1.91	2.54	5.0	
			Placebo	130	127 (97.7)	1.89 (0.71)	0.4	1.45	1.80	2.35	4.8	
		Week 8	Tezepelumab	145	142 (97.9)	2.03 (0.80)	0.6	1.39	1.96	2.49	4.7	
			Placebo	130	124 (95.4)	1.94 (0.70)	0.4	1.46	1.91	2.31	4.6	
		Week 12	Tezepelumab	145	139 (95.9)	2.06 (0.78)	0.6	1.52	1.94	2.54	4.9	
			Placebo	130	123 (94.6)	1.92 (0.70)	0.6	1.43	1.86	2.32	4.6	
		Week 16	Tezepelumab	145	139 (95.9)	2.06 (0.81)	0.6	1.40	1.94	2.51	4.9	
			Placebo	130	121 (93.1)	1.93 (0.69)	0.7	1.45	1.85	2.28	4.7	
		Week 24	Tezepelumab	145	138 (95.2)	2.04 (0.80)	0.6	1.50	1.94	2.54	5.5	
			Placebo	130	118 (90.8)	1.88 (0.71)	0.6	1.42	1.76	2.24	4.8	
		Week 36	Tezepelumab	145	129 (89.0)	2.08 (0.82)	0.7	1.47	1.92	2.56	4.9	
			Placebo	130	114 (87.7)	1.93 (0.72)	0.7	1.40	1.74	2.34	4.3	
		Week 52	Tezepelumab	145	128 (88.3)	2.07 (0.82)	0.6	1.45	2.00	2.58	4.6	
			Placebo	130	111 (85.4)	1.94 (0.74)	0.7	1.40	1.73	2.29	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q3: 250 - < 430 cells/uL	Change from baseline	Week 2	Tezepelumab	145	141 (97.2)	0.18 (0.35)	-0.5	-0.04	0.10	0.32	1.9	0.25 [0.01, 0.49]
			Placebo	130	123 (94.6)	0.10 (0.35)	-0.8	-0.08	0.05	0.23	1.7	
		Week 4	Tezepelumab	145	141 (97.2)	0.21 (0.39)	-1.2	-0.03	0.12	0.37	1.6	0.30 [0.06, 0.54]
			Placebo	130	127 (97.7)	0.10 (0.35)	-0.8	-0.09	0.05	0.27	1.7	
		Week 8	Tezepelumab	145	142 (97.9)	0.25 (0.42)	-0.6	0.00	0.17	0.47	1.8	0.36 [0.12, 0.60]
			Placebo	130	124 (95.4)	0.12 (0.35)	-0.6	-0.07	0.05	0.28	2.0	
		Week 12	Tezepelumab	145	139 (95.9)	0.28 (0.41)	-0.6	0.01	0.21	0.45	2.0	0.45 [0.21, 0.70]
			Placebo	130	123 (94.6)	0.10 (0.37)	-0.7	-0.11	0.03	0.28	1.5	
		Week 16	Tezepelumab	145	139 (95.9)	0.27 (0.43)	-0.6	0.00	0.16	0.44	2.0	0.37 [0.13, 0.62]
			Placebo	130	121 (93.1)	0.12 (0.39)	-1.2	-0.06	0.06	0.28	1.6	
		Week 24	Tezepelumab	145	138 (95.2)	0.26 (0.42)	-1.0	-0.02	0.18	0.45	2.1	0.52 [0.27, 0.77]
			Placebo	130	118 (90.8)	0.06 (0.34)	-0.9	-0.13	0.03	0.24	1.6	
		Week 36	Tezepelumab	145	129 (89.0)	0.29 (0.42)	-1.0	0.02	0.24	0.51	1.8	0.45 [0.19, 0.70]
			Placebo	130	114 (87.7)	0.10 (0.44)	-0.8	-0.14	0.04	0.27	2.2	
		Week 52	Tezepelumab	145	128 (88.3)	0.28 (0.43)	-0.8	-0.00	0.24	0.48	1.7	0.42 [0.16, 0.67]
			Placebo	130	111 (85.4)	0.11 (0.40)	-0.6	-0.16	0.05	0.29	2.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q4: >= 430 cells/uL	Absolute values	Baseline	Tezepelumab	128	128 (100.0)	1.75 (0.71)	0.6	1.27	1.59	2.11	3.8	
			Placebo	138	138 (100.0)	1.86 (0.82)	0.6	1.30	1.71	2.23	4.5	
		Week 2	Tezepelumab	128	124 (96.9)	2.04 (0.74)	0.8	1.48	1.87	2.51	4.0	
			Placebo	138	131 (94.9)	1.98 (0.76)	0.8	1.37	1.91	2.48	4.2	
		Week 4	Tezepelumab	128	128 (100.0)	2.10 (0.73)	0.7	1.58	1.94	2.54	4.2	
			Placebo	138	135 (97.8)	2.01 (0.78)	0.5	1.42	1.93	2.53	4.2	
		Week 8	Tezepelumab	128	126 (98.4)	2.12 (0.76)	0.9	1.54	1.94	2.60	4.3	
			Placebo	138	136 (98.6)	1.98 (0.82)	0.6	1.31	1.86	2.47	4.3	
		Week 12	Tezepelumab	128	127 (99.2)	2.15 (0.77)	0.9	1.61	1.96	2.64	4.6	
			Placebo	138	138 (100.0)	2.03 (0.79)	0.5	1.44	1.95	2.47	4.3	
		Week 16	Tezepelumab	128	123 (96.1)	2.17 (0.78)	0.8	1.61	2.03	2.62	4.4	
			Placebo	138	134 (97.1)	2.02 (0.78)	0.5	1.48	1.93	2.44	4.4	
		Week 24	Tezepelumab	128	120 (93.8)	2.14 (0.74)	0.8	1.64	1.96	2.56	4.0	
			Placebo	138	128 (92.8)	2.05 (0.80)	0.7	1.46	1.95	2.41	4.8	
		Week 36	Tezepelumab	128	118 (92.2)	2.16 (0.75)	0.8	1.57	2.03	2.49	4.2	
			Placebo	138	125 (90.6)	2.10 (0.84)	0.6	1.49	2.06	2.43	4.6	
		Week 52	Tezepelumab	128	110 (85.9)	2.18 (0.76)	0.9	1.65	2.00	2.45	4.3	
			Placebo	138	116 (84.1)	2.05 (0.83)	0.6	1.38	2.03	2.47	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q4: >= 430 cells/uL	Change from baseline	Week 2	Tezepelumab	128	124 (96.9)	0.29 (0.38)	-0.6	0.06	0.21	0.42	1.4	0.51 [0.26, 0.76]
			Placebo	138	131 (94.9)	0.08 (0.43)	-1.3	-0.12	0.00	0.27	1.7	
		Week 4	Tezepelumab	128	128 (100.0)	0.35 (0.37)	-0.4	0.09	0.30	0.49	1.8	0.46 [0.21, 0.70]
			Placebo	138	135 (97.8)	0.15 (0.47)	-1.8	-0.12	0.06	0.45	1.4	
		Week 8	Tezepelumab	128	126 (98.4)	0.38 (0.47)	-1.1	0.09	0.28	0.66	1.9	0.59 [0.34, 0.83]
			Placebo	138	136 (98.6)	0.11 (0.47)	-1.7	-0.15	0.07	0.31	2.1	
		Week 12	Tezepelumab	128	127 (99.2)	0.41 (0.47)	-1.5	0.08	0.34	0.62	2.2	0.52 [0.27, 0.76]
			Placebo	138	138 (100.0)	0.17 (0.45)	-1.4	-0.09	0.11	0.37	1.7	
		Week 16	Tezepelumab	128	123 (96.1)	0.43 (0.44)	-0.5	0.13	0.35	0.67	2.1	0.67 [0.42, 0.92]
			Placebo	138	134 (97.1)	0.14 (0.43)	-1.6	-0.12	0.04	0.39	1.8	
		Week 24	Tezepelumab	128	120 (93.8)	0.41 (0.46)	-0.8	0.13	0.37	0.63	1.8	0.55 [0.29, 0.80]
			Placebo	138	128 (92.8)	0.15 (0.49)	-1.4	-0.14	0.09	0.38	1.7	
		Week 36	Tezepelumab	128	118 (92.2)	0.43 (0.42)	-0.5	0.16	0.38	0.66	1.7	0.49 [0.23, 0.74]
			Placebo	138	125 (90.6)	0.21 (0.48)	-1.7	-0.04	0.14	0.49	1.7	
		Week 52	Tezepelumab	128	110 (85.9)	0.44 (0.42)	-0.6	0.16	0.41	0.72	1.6	0.70 [0.43, 0.97]
			Placebo	138	116 (84.1)	0.14 (0.43)	-1.4	-0.10	0.09	0.34	1.9	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
< 25 ppb	Absolute values	Baseline	Tezepelumab	213	213 (100.0)	1.78 (0.68)	0.4	1.28	1.63	2.20	4.1	
			Placebo	220	220 (100.0)	1.86 (0.71)	0.4	1.36	1.74	2.28	3.9	
		Week 2	Tezepelumab	213	206 (96.7)	1.92 (0.66)	0.6	1.38	1.86	2.42	4.1	
			Placebo	220	204 (92.7)	1.92 (0.71)	0.4	1.40	1.85	2.39	4.1	
		Week 4	Tezepelumab	213	210 (98.6)	1.90 (0.68)	0.6	1.39	1.83	2.39	4.2	
			Placebo	220	213 (96.8)	1.92 (0.70)	0.4	1.46	1.83	2.34	4.8	
		Week 8	Tezepelumab	213	208 (97.7)	1.92 (0.68)	0.6	1.41	1.85	2.36	4.1	
			Placebo	220	214 (97.3)	1.94 (0.71)	0.4	1.45	1.86	2.36	4.7	
		Week 12	Tezepelumab	213	205 (96.2)	1.91 (0.66)	0.6	1.45	1.86	2.30	4.2	
			Placebo	220	211 (95.9)	1.94 (0.74)	0.5	1.43	1.75	2.44	4.6	
		Week 16	Tezepelumab	213	205 (96.2)	1.93 (0.69)	0.6	1.40	1.84	2.39	4.2	
			Placebo	220	212 (96.4)	1.92 (0.73)	0.5	1.36	1.80	2.37	4.7	
		Week 24	Tezepelumab	213	202 (94.8)	1.90 (0.68)	0.6	1.40	1.81	2.32	4.0	
			Placebo	220	208 (94.5)	1.92 (0.73)	0.6	1.43	1.81	2.28	4.8	
		Week 36	Tezepelumab	213	192 (90.1)	1.89 (0.66)	0.5	1.41	1.83	2.33	4.4	
			Placebo	220	199 (90.5)	1.95 (0.73)	0.6	1.42	1.82	2.38	4.3	
		Week 52	Tezepelumab	213	192 (90.1)	1.90 (0.68)	0.7	1.43	1.82	2.27	4.2	
			Placebo	220	193 (87.7)	1.94 (0.76)	0.6	1.38	1.78	2.43	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
< 25 ppb	Change from baseline	Week 2	Tezepelumab	213	206 (96.7)	0.13 (0.33)	-0.8	-0.03	0.08	0.23	1.9	0.27 [0.08, 0.47]
			Placebo	220	204 (92.7)	0.04 (0.29)	-0.8	-0.11	0.00	0.15	1.2	
		Week 4	Tezepelumab	213	210 (98.6)	0.13 (0.35)	-1.0	-0.06	0.07	0.28	1.7	0.19 [-0.00, 0.38]
			Placebo	220	213 (96.8)	0.07 (0.32)	-0.9	-0.09	0.03	0.20	1.6	
		Week 8	Tezepelumab	213	208 (97.7)	0.15 (0.36)	-0.9	-0.05	0.11	0.26	1.6	0.19 [-0.00, 0.38]
			Placebo	220	214 (97.3)	0.08 (0.36)	-1.0	-0.10	0.04	0.21	1.8	
		Week 12	Tezepelumab	213	205 (96.2)	0.15 (0.34)	-0.7	-0.04	0.10	0.28	1.5	0.19 [-0.00, 0.38]
			Placebo	220	211 (95.9)	0.08 (0.37)	-1.5	-0.08	0.03	0.20	2.1	
		Week 16	Tezepelumab	213	205 (96.2)	0.14 (0.37)	-1.0	-0.05	0.10	0.28	1.8	0.21 [0.02, 0.41]
			Placebo	220	212 (96.4)	0.06 (0.35)	-1.0	-0.11	0.02	0.19	1.9	
		Week 24	Tezepelumab	213	202 (94.8)	0.14 (0.38)	-1.0	-0.08	0.06	0.30	2.1	0.26 [0.06, 0.45]
			Placebo	220	208 (94.5)	0.04 (0.35)	-1.1	-0.13	0.03	0.17	1.7	
		Week 36	Tezepelumab	213	192 (90.1)	0.11 (0.36)	-1.0	-0.11	0.08	0.32	1.8	0.07 [-0.13, 0.27]
			Placebo	220	199 (90.5)	0.09 (0.33)	-0.8	-0.09	0.06	0.26	1.6	
		Week 52	Tezepelumab	213	192 (90.1)	0.14 (0.38)	-1.0	-0.06	0.10	0.32	1.5	0.14 [-0.06, 0.34]
			Placebo	220	193 (87.7)	0.08 (0.36)	-1.0	-0.12	0.05	0.22	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
25 - < 50 ppb	Absolute values	Baseline	Tezepelumab	158	158 (100.0)	1.77 (0.71)	0.5	1.23	1.67	2.21	3.9	
			Placebo	151	151 (100.0)	1.82 (0.75)	0.7	1.30	1.69	2.16	4.9	
		Week 2	Tezepelumab	158	157 (99.4)	1.94 (0.71)	0.7	1.38	1.82	2.45	4.0	
			Placebo	151	149 (98.7)	1.84 (0.75)	0.6	1.30	1.63	2.20	4.7	
		Week 4	Tezepelumab	158	158 (100.0)	1.99 (0.74)	0.7	1.37	1.85	2.59	4.2	
			Placebo	151	146 (96.7)	1.87 (0.69)	0.7	1.38	1.72	2.15	4.2	
		Week 8	Tezepelumab	158	156 (98.7)	1.97 (0.72)	0.8	1.36	1.86	2.47	4.2	
			Placebo	151	147 (97.4)	1.91 (0.77)	0.7	1.33	1.75	2.26	4.9	
		Week 12	Tezepelumab	158	153 (96.8)	1.99 (0.73)	0.7	1.47	1.89	2.51	4.3	
			Placebo	151	147 (97.4)	1.89 (0.77)	0.7	1.35	1.75	2.21	5.0	
		Week 16	Tezepelumab	158	156 (98.7)	1.99 (0.74)	0.7	1.46	1.87	2.47	4.3	
			Placebo	151	145 (96.0)	1.90 (0.79)	0.6	1.36	1.72	2.23	5.2	
		Week 24	Tezepelumab	158	149 (94.3)	1.96 (0.71)	0.7	1.44	1.79	2.46	3.8	
			Placebo	151	135 (89.4)	1.92 (0.77)	0.6	1.41	1.80	2.18	5.1	
		Week 36	Tezepelumab	158	147 (93.0)	2.00 (0.76)	0.6	1.37	1.89	2.53	4.2	
			Placebo	151	136 (90.1)	1.93 (0.79)	0.7	1.40	1.75	2.23	5.3	
		Week 52	Tezepelumab	158	143 (90.5)	2.00 (0.77)	0.6	1.40	1.85	2.53	4.3	
			Placebo	151	126 (83.4)	1.91 (0.80)	0.7	1.37	1.68	2.26	5.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
25 - < 50 ppb	Change from baseline	Week 2	Tezepelumab	158	157 (99.4)	0.17 (0.30)	-0.6	-0.02	0.12	0.29	1.3	0.43 [0.21, 0.66]
			Placebo	151	149 (98.7)	0.02 (0.39)	-1.8	-0.14	-0.01	0.17	1.7	
		Week 4	Tezepelumab	158	158 (100.0)	0.22 (0.31)	-0.5	0.02	0.14	0.37	1.3	0.42 [0.19, 0.64]
			Placebo	151	146 (96.7)	0.07 (0.40)	-1.8	-0.11	0.05	0.25	1.7	
		Week 8	Tezepelumab	158	156 (98.7)	0.21 (0.37)	-0.8	-0.03	0.14	0.39	1.5	0.31 [0.08, 0.54]
			Placebo	151	147 (97.4)	0.10 (0.35)	-1.1	-0.08	0.05	0.29	2.0	
		Week 12	Tezepelumab	158	153 (96.8)	0.24 (0.36)	-1.5	0.02	0.20	0.40	1.6	0.45 [0.22, 0.68]
			Placebo	151	147 (97.4)	0.07 (0.38)	-1.2	-0.13	0.03	0.25	1.5	
		Week 16	Tezepelumab	158	156 (98.7)	0.23 (0.38)	-0.6	0.00	0.20	0.40	1.5	0.42 [0.19, 0.65]
			Placebo	151	145 (96.0)	0.07 (0.36)	-1.2	-0.13	0.03	0.21	1.6	
		Week 24	Tezepelumab	158	149 (94.3)	0.21 (0.42)	-1.0	-0.06	0.14	0.40	1.6	0.28 [0.05, 0.52]
			Placebo	151	135 (89.4)	0.10 (0.37)	-1.1	-0.11	0.06	0.29	1.4	
		Week 36	Tezepelumab	158	147 (93.0)	0.23 (0.40)	-0.6	-0.03	0.12	0.42	1.6	0.32 [0.08, 0.55]
			Placebo	151	136 (90.1)	0.10 (0.46)	-1.7	-0.18	0.03	0.30	2.2	
		Week 52	Tezepelumab	158	143 (90.5)	0.25 (0.42)	-0.8	-0.06	0.17	0.52	1.7	0.49 [0.24, 0.73]
			Placebo	151	126 (83.4)	0.05 (0.39)	-1.0	-0.17	0.01	0.31	1.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
>= 50 ppb	Absolute values	Baseline	Tezepelumab	151	151 (100.0)	1.99 (0.76)	0.7	1.48	1.80	2.39	4.8	
			Placebo	156	156 (100.0)	1.86 (0.67)	0.6	1.38	1.77	2.23	4.1	
		Week 2	Tezepelumab	151	145 (96.0)	2.21 (0.81)	0.7	1.64	2.13	2.70	5.0	
			Placebo	156	150 (96.2)	1.98 (0.68)	0.6	1.51	1.89	2.47	4.2	
		Week 4	Tezepelumab	151	150 (99.3)	2.23 (0.78)	0.7	1.69	2.10	2.76	5.0	
			Placebo	156	153 (98.1)	1.98 (0.70)	0.7	1.44	1.88	2.43	4.0	
		Week 8	Tezepelumab	151	148 (98.0)	2.30 (0.81)	0.8	1.73	2.23	2.67	4.7	
			Placebo	156	152 (97.4)	1.99 (0.73)	0.7	1.49	1.94	2.42	4.3	
		Week 12	Tezepelumab	151	146 (96.7)	2.29 (0.84)	0.8	1.68	2.13	2.75	4.9	
			Placebo	156	153 (98.1)	2.01 (0.71)	0.6	1.50	1.90	2.41	4.3	
		Week 16	Tezepelumab	151	143 (94.7)	2.34 (0.83)	0.8	1.80	2.18	2.86	4.9	
			Placebo	156	149 (95.5)	2.04 (0.69)	0.8	1.57	1.91	2.45	4.4	
		Week 24	Tezepelumab	151	141 (93.4)	2.31 (0.80)	0.8	1.78	2.13	2.75	5.5	
			Placebo	156	145 (92.9)	1.99 (0.70)	0.8	1.46	1.87	2.41	4.3	
		Week 36	Tezepelumab	151	138 (91.4)	2.34 (0.81)	0.9	1.79	2.25	2.88	4.9	
			Placebo	156	137 (87.8)	2.04 (0.75)	0.8	1.49	1.95	2.38	4.3	
		Week 52	Tezepelumab	151	131 (86.8)	2.34 (0.82)	0.7	1.76	2.16	2.91	4.6	
			Placebo	156	131 (84.0)	2.05 (0.75)	0.7	1.47	1.97	2.49	3.9	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
>= 50 ppb	Change from baseline	Week 2	Tezepelumab	151	145 (96.0)	0.23 (0.37)	-0.6	0.03	0.18	0.38	1.5	0.33 [0.10, 0.56]
			Placebo	156	150 (96.2)	0.10 (0.40)	-1.3	-0.08	0.06	0.25	1.7	
		Week 4	Tezepelumab	151	150 (99.3)	0.24 (0.43)	-1.2	-0.01	0.20	0.39	1.8	0.27 [0.04, 0.50]
			Placebo	156	153 (98.1)	0.13 (0.44)	-1.0	-0.14	0.06	0.34	1.4	
		Week 8	Tezepelumab	151	148 (98.0)	0.33 (0.49)	-1.1	0.04	0.28	0.58	1.9	0.46 [0.23, 0.69]
			Placebo	156	152 (97.4)	0.11 (0.44)	-1.7	-0.14	0.07	0.32	2.1	
		Week 12	Tezepelumab	151	146 (96.7)	0.32 (0.52)	-0.8	-0.03	0.25	0.53	2.2	0.35 [0.12, 0.58]
			Placebo	156	153 (98.1)	0.15 (0.45)	-1.4	-0.10	0.10	0.37	1.7	
		Week 16	Tezepelumab	151	143 (94.7)	0.36 (0.49)	-0.8	0.02	0.29	0.61	2.1	0.43 [0.20, 0.66]
			Placebo	156	149 (95.5)	0.16 (0.43)	-1.6	-0.07	0.08	0.37	1.8	
		Week 24	Tezepelumab	151	141 (93.4)	0.33 (0.43)	-0.5	0.05	0.29	0.54	1.8	0.48 [0.25, 0.72]
			Placebo	156	145 (92.9)	0.12 (0.44)	-1.4	-0.14	0.06	0.34	1.7	
		Week 36	Tezepelumab	151	138 (91.4)	0.35 (0.45)	-0.5	0.01	0.32	0.60	1.7	0.44 [0.20, 0.68]
			Placebo	156	137 (87.8)	0.15 (0.48)	-1.2	-0.16	0.12	0.40	1.7	
		Week 52	Tezepelumab	151	131 (86.8)	0.33 (0.44)	-0.6	0.00	0.28	0.59	1.6	0.41 [0.16, 0.65]
			Placebo	156	131 (84.0)	0.15 (0.45)	-1.4	-0.11	0.11	0.34	2.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q1: < 16 ppb	Absolute values	Baseline	Tezepelumab	125	125 (100.0)	1.75 (0.68)	0.7	1.23	1.63	2.13	4.0	
			Placebo	122	122 (100.0)	1.81 (0.68)	0.4	1.34	1.69	2.31	3.5	
		Week 2	Tezepelumab	125	120 (96.0)	1.91 (0.68)	0.6	1.35	1.89	2.44	4.1	
			Placebo	122	110 (90.2)	1.89 (0.72)	0.4	1.36	1.83	2.43	4.1	
		Week 4	Tezepelumab	125	123 (98.4)	1.88 (0.69)	0.6	1.32	1.84	2.40	4.2	
			Placebo	122	119 (97.5)	1.87 (0.72)	0.4	1.32	1.83	2.35	4.8	
		Week 8	Tezepelumab	125	121 (96.8)	1.90 (0.66)	0.6	1.42	1.85	2.37	4.1	
			Placebo	122	119 (97.5)	1.90 (0.73)	0.4	1.37	1.86	2.31	4.7	
		Week 12	Tezepelumab	125	121 (96.8)	1.89 (0.66)	0.6	1.44	1.86	2.28	4.2	
			Placebo	122	117 (95.9)	1.93 (0.76)	0.5	1.39	1.76	2.44	4.6	
		Week 16	Tezepelumab	125	120 (96.0)	1.91 (0.69)	0.6	1.39	1.84	2.41	4.2	
			Placebo	122	117 (95.9)	1.90 (0.75)	0.5	1.32	1.79	2.36	4.7	
		Week 24	Tezepelumab	125	119 (95.2)	1.88 (0.66)	0.6	1.40	1.81	2.30	4.0	
			Placebo	122	115 (94.3)	1.89 (0.76)	0.6	1.30	1.85	2.28	4.8	
		Week 36	Tezepelumab	125	113 (90.4)	1.89 (0.68)	0.7	1.33	1.83	2.40	4.4	
			Placebo	122	111 (91.0)	1.92 (0.76)	0.6	1.34	1.82	2.36	4.3	
		Week 52	Tezepelumab	125	111 (88.8)	1.88 (0.65)	0.7	1.43	1.81	2.33	4.2	
			Placebo	122	105 (86.1)	1.91 (0.81)	0.6	1.31	1.70	2.43	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q1: < 16 ppb	Change from baseline	Week 2	Tezepelumab	125	120 (96.0)	0.15 (0.37)	-0.8	-0.02	0.08	0.24	1.9	0.27 [0.01, 0.53]
			Placebo	122	110 (90.2)	0.06 (0.31)	-0.8	-0.08	0.00	0.14	1.2	
		Week 4	Tezepelumab	125	123 (98.4)	0.15 (0.39)	-1.0	-0.05	0.08	0.28	1.7	0.23 [-0.02, 0.48]
			Placebo	122	119 (97.5)	0.07 (0.36)	-0.9	-0.08	0.02	0.18	1.6	
		Week 8	Tezepelumab	125	121 (96.8)	0.15 (0.35)	-0.9	-0.05	0.09	0.26	1.3	0.19 [-0.07, 0.44]
			Placebo	122	119 (97.5)	0.08 (0.38)	-1.0	-0.10	0.02	0.20	1.8	
		Week 12	Tezepelumab	125	121 (96.8)	0.16 (0.37)	-0.6	-0.04	0.10	0.28	1.5	0.13 [-0.13, 0.38]
			Placebo	122	117 (95.9)	0.11 (0.40)	-1.1	-0.05	0.03	0.22	2.1	
		Week 16	Tezepelumab	125	120 (96.0)	0.15 (0.39)	-1.0	-0.04	0.11	0.27	1.8	0.19 [-0.07, 0.45]
			Placebo	122	117 (95.9)	0.08 (0.38)	-1.0	-0.10	0.02	0.19	1.9	
		Week 24	Tezepelumab	125	119 (95.2)	0.13 (0.40)	-1.0	-0.07	0.03	0.29	2.1	0.18 [-0.07, 0.44]
			Placebo	122	115 (94.3)	0.06 (0.39)	-1.1	-0.11	0.03	0.17	1.7	
		Week 36	Tezepelumab	125	113 (90.4)	0.15 (0.39)	-1.0	-0.08	0.13	0.34	1.8	0.10 [-0.16, 0.36]
			Placebo	122	111 (91.0)	0.11 (0.35)	-0.8	-0.07	0.06	0.27	1.6	
		Week 52	Tezepelumab	125	111 (88.8)	0.14 (0.41)	-1.0	-0.06	0.10	0.31	1.5	0.07 [-0.19, 0.34]
			Placebo	122	105 (86.1)	0.11 (0.41)	-1.0	-0.07	0.06	0.23	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)											
Q2: 16 - < 30 ppb Absolute values	Baseline	Tezepelumab	128	128 (100.0)	1.80 (0.69)	0.4	1.28	1.65	2.26	4.1	
		Placebo	139	139 (100.0)	1.88 (0.77)	0.7	1.35	1.74	2.18	4.5	
	Week 2	Tezepelumab	128	126 (98.4)	1.92 (0.67)	0.6	1.38	1.79	2.44	3.8	
		Placebo	139	135 (97.1)	1.91 (0.70)	0.6	1.40	1.80	2.27	3.9	
	Week 4	Tezepelumab	128	127 (99.2)	1.94 (0.70)	0.7	1.37	1.81	2.50	3.8	
		Placebo	139	134 (96.4)	1.93 (0.68)	0.7	1.47	1.83	2.31	3.6	
	Week 8	Tezepelumab	128	127 (99.2)	1.94 (0.71)	0.6	1.36	1.82	2.37	3.9	
		Placebo	139	135 (97.1)	1.96 (0.72)	0.7	1.48	1.80	2.36	4.1	
	Week 12	Tezepelumab	128	121 (94.5)	1.94 (0.67)	0.6	1.47	1.83	2.38	3.6	
		Placebo	139	135 (97.1)	1.92 (0.74)	0.6	1.40	1.72	2.39	4.1	
	Week 16	Tezepelumab	128	125 (97.7)	1.96 (0.72)	0.6	1.38	1.88	2.48	3.8	
		Placebo	139	136 (97.8)	1.92 (0.74)	0.7	1.41	1.78	2.28	4.3	
	Week 24	Tezepelumab	128	120 (93.8)	1.95 (0.70)	0.6	1.37	1.79	2.43	3.8	
		Placebo	139	133 (95.7)	1.94 (0.72)	0.6	1.48	1.77	2.26	4.3	
	Week 36	Tezepelumab	128	118 (92.2)	1.91 (0.68)	0.5	1.37	1.85	2.33	3.7	
		Placebo	139	126 (90.6)	1.98 (0.70)	0.9	1.54	1.81	2.33	4.2	
	Week 52	Tezepelumab	128	119 (93.0)	1.96 (0.72)	0.7	1.39	1.84	2.33	4.0	
		Placebo	139	123 (88.5)	1.95 (0.74)	0.7	1.44	1.75	2.33	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q2: 16 - < 30 ppb	Change from baseline	Week 2	Tezepelumab	128	126 (98.4)	0.10 (0.27)	-0.7	-0.03	0.07	0.21	0.9	0.28 [0.03, 0.52]
			Placebo	139	135 (97.1)	0.03 (0.29)	-1.1	-0.13	0.00	0.17	0.9	
		Week 4	Tezepelumab	128	127 (99.2)	0.13 (0.29)	-0.9	-0.06	0.09	0.29	1.1	0.23 [-0.02, 0.47]
			Placebo	139	134 (96.4)	0.06 (0.34)	-1.8	-0.10	0.06	0.26	1.0	
		Week 8	Tezepelumab	128	127 (99.2)	0.15 (0.36)	-0.8	-0.06	0.10	0.25	1.6	0.20 [-0.05, 0.44]
			Placebo	139	135 (97.1)	0.08 (0.32)	-0.8	-0.11	0.06	0.30	1.2	
		Week 12	Tezepelumab	128	121 (94.5)	0.15 (0.30)	-0.7	-0.04	0.10	0.28	1.2	0.33 [0.08, 0.57]
			Placebo	139	135 (97.1)	0.05 (0.33)	-1.5	-0.10	0.03	0.19	1.2	
		Week 16	Tezepelumab	128	125 (97.7)	0.15 (0.35)	-0.6	-0.03	0.10	0.29	1.4	0.30 [0.05, 0.54]
			Placebo	139	136 (97.8)	0.05 (0.32)	-0.8	-0.13	0.04	0.19	1.0	
		Week 24	Tezepelumab	128	120 (93.8)	0.15 (0.34)	-0.6	-0.07	0.12	0.32	1.5	0.32 [0.07, 0.57]
			Placebo	139	133 (95.7)	0.05 (0.30)	-0.9	-0.13	0.03	0.22	0.8	
		Week 36	Tezepelumab	128	118 (92.2)	0.09 (0.35)	-0.7	-0.12	0.03	0.22	1.3	0.07 [-0.19, 0.32]
			Placebo	139	126 (90.6)	0.07 (0.36)	-1.0	-0.18	0.05	0.27	1.3	
		Week 52	Tezepelumab	128	119 (93.0)	0.15 (0.35)	-1.0	-0.05	0.13	0.32	1.3	0.36 [0.11, 0.61]
			Placebo	139	123 (88.5)	0.04 (0.32)	-1.0	-0.16	0.02	0.22	1.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)											
Q3: 30 - < 56 ppb Absolute values	Baseline	Tezepelumab	141	141 (100.0)	1.80 (0.71)	0.5	1.33	1.73	2.19	3.9	
		Placebo	127	127 (100.0)	1.85 (0.71)	0.8	1.32	1.69	2.17	4.9	
	Week 2	Tezepelumab	141	140 (99.3)	1.98 (0.70)	0.7	1.47	1.92	2.44	4.0	
		Placebo	127	124 (97.6)	1.89 (0.75)	0.8	1.33	1.64	2.30	4.7	
	Week 4	Tezepelumab	141	141 (100.0)	2.01 (0.73)	0.7	1.48	1.97	2.51	4.2	
		Placebo	127	122 (96.1)	1.90 (0.68)	0.7	1.40	1.75	2.26	4.2	
	Week 8	Tezepelumab	141	139 (98.6)	2.02 (0.71)	0.8	1.43	1.95	2.45	4.2	
		Placebo	127	124 (97.6)	1.95 (0.76)	0.7	1.35	1.88	2.29	4.9	
	Week 12	Tezepelumab	141	138 (97.9)	2.03 (0.72)	0.8	1.50	1.92	2.46	4.3	
		Placebo	127	123 (96.9)	1.91 (0.77)	0.7	1.37	1.79	2.29	5.0	
	Week 16	Tezepelumab	141	139 (98.6)	2.02 (0.73)	0.8	1.53	1.92	2.44	4.3	
		Placebo	127	120 (94.5)	1.91 (0.77)	0.6	1.38	1.75	2.33	5.2	
	Week 24	Tezepelumab	141	135 (95.7)	1.99 (0.70)	0.7	1.53	1.94	2.45	3.8	
		Placebo	127	111 (87.4)	1.95 (0.75)	0.9	1.42	1.80	2.25	5.1	
	Week 36	Tezepelumab	141	129 (91.5)	2.05 (0.75)	0.7	1.51	2.00	2.48	4.2	
		Placebo	127	115 (90.6)	1.93 (0.79)	0.7	1.39	1.72	2.34	5.3	
	Week 52	Tezepelumab	141	126 (89.4)	2.05 (0.77)	0.6	1.49	2.00	2.46	4.3	
		Placebo	127	107 (84.3)	1.92 (0.79)	0.7	1.34	1.74	2.29	5.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q3: 30 - < 56 ppb	Change from baseline	Week 2	Tezepelumab	141	140 (99.3)	0.17 (0.30)	-0.6	0.00	0.13	0.29	1.3	0.41 [0.17, 0.65]
			Placebo	127	124 (97.6)	0.03 (0.39)	-1.8	-0.11	0.01	0.17	1.7	
		Week 4	Tezepelumab	141	141 (100.0)	0.21 (0.32)	-0.5	0.01	0.15	0.36	1.3	0.36 [0.12, 0.61]
			Placebo	127	122 (96.1)	0.09 (0.36)	-1.0	-0.10	0.05	0.20	1.7	
		Week 8	Tezepelumab	141	139 (98.6)	0.22 (0.37)	-0.8	-0.02	0.17	0.41	1.5	0.31 [0.06, 0.55]
			Placebo	127	124 (97.6)	0.11 (0.35)	-1.1	-0.06	0.07	0.22	2.0	
		Week 12	Tezepelumab	141	138 (97.9)	0.23 (0.39)	-1.5	0.00	0.20	0.42	1.6	0.40 [0.16, 0.65]
			Placebo	127	123 (96.9)	0.07 (0.39)	-1.2	-0.13	0.03	0.22	1.5	
		Week 16	Tezepelumab	141	139 (98.6)	0.23 (0.39)	-0.6	-0.02	0.20	0.43	1.5	0.46 [0.21, 0.70]
			Placebo	127	120 (94.5)	0.06 (0.36)	-1.2	-0.14	0.00	0.21	1.6	
		Week 24	Tezepelumab	141	135 (95.7)	0.22 (0.43)	-1.0	-0.09	0.22	0.44	1.6	0.29 [0.03, 0.54]
			Placebo	127	111 (87.4)	0.11 (0.37)	-1.1	-0.11	0.07	0.30	1.4	
		Week 36	Tezepelumab	141	129 (91.5)	0.25 (0.39)	-0.5	-0.03	0.19	0.46	1.6	0.41 [0.15, 0.66]
			Placebo	127	115 (90.6)	0.08 (0.44)	-1.7	-0.18	0.02	0.27	2.2	
		Week 52	Tezepelumab	141	126 (89.4)	0.25 (0.43)	-0.8	-0.10	0.23	0.53	1.7	0.44 [0.18, 0.70]
			Placebo	127	107 (84.3)	0.07 (0.38)	-0.9	-0.17	0.01	0.31	1.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q4: >= 56 ppb	Absolute values	Baseline	Tezepelumab	128	128 (100.0)	1.99 (0.78)	0.7	1.46	1.78	2.40	4.8	
			Placebo	139	139 (100.0)	1.86 (0.67)	0.6	1.38	1.77	2.23	4.1	
		Week 2	Tezepelumab	128	122 (95.3)	2.23 (0.83)	0.7	1.64	2.13	2.81	5.0	
			Placebo	139	134 (96.4)	1.97 (0.68)	0.6	1.51	1.88	2.46	4.2	
		Week 4	Tezepelumab	128	127 (99.2)	2.24 (0.80)	0.7	1.68	2.10	2.78	5.0	
			Placebo	139	137 (98.6)	1.98 (0.70)	0.7	1.46	1.88	2.33	4.0	
		Week 8	Tezepelumab	128	125 (97.7)	2.32 (0.84)	0.8	1.72	2.26	2.75	4.7	
			Placebo	139	135 (97.1)	1.98 (0.74)	0.7	1.43	1.93	2.41	4.3	
		Week 12	Tezepelumab	128	124 (96.9)	2.32 (0.87)	0.8	1.68	2.13	2.85	4.9	
			Placebo	139	136 (97.8)	2.02 (0.71)	0.6	1.54	1.90	2.41	4.3	
		Week 16	Tezepelumab	128	120 (93.8)	2.37 (0.86)	0.8	1.77	2.19	2.86	4.9	
			Placebo	139	133 (95.7)	2.06 (0.69)	0.8	1.60	1.92	2.45	4.4	
		Week 24	Tezepelumab	128	118 (92.2)	2.34 (0.83)	0.8	1.76	2.16	2.77	5.5	
			Placebo	139	129 (92.8)	1.98 (0.70)	0.8	1.46	1.87	2.38	4.3	
		Week 36	Tezepelumab	128	117 (91.4)	2.36 (0.84)	0.9	1.79	2.29	2.91	4.9	
			Placebo	139	120 (86.3)	2.07 (0.76)	0.8	1.51	1.96	2.41	4.3	
		Week 52	Tezepelumab	128	110 (85.9)	2.37 (0.85)	0.7	1.72	2.17	3.04	4.6	
			Placebo	139	115 (82.7)	2.06 (0.75)	0.7	1.57	1.97	2.45	3.9	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q4: >= 56 ppb	Change from baseline	Week 2	Tezepelumab	128	122 (95.3)	0.25 (0.39)	-0.6	0.03	0.21	0.41	1.5	0.38 [0.13, 0.63]
			Placebo	139	134 (96.4)	0.09 (0.42)	-1.3	-0.10	0.05	0.25	1.7	
		Week 4	Tezepelumab	128	127 (99.2)	0.26 (0.44)	-1.2	0.00	0.20	0.43	1.8	0.30 [0.06, 0.55]
			Placebo	139	137 (98.6)	0.12 (0.46)	-1.0	-0.17	0.06	0.36	1.4	
		Week 8	Tezepelumab	128	125 (97.7)	0.35 (0.51)	-1.1	0.05	0.31	0.60	1.9	0.51 [0.26, 0.76]
			Placebo	139	135 (97.1)	0.10 (0.46)	-1.7	-0.16	0.04	0.32	2.1	
		Week 12	Tezepelumab	128	124 (96.9)	0.35 (0.52)	-0.8	0.01	0.28	0.57	2.2	0.40 [0.15, 0.64]
			Placebo	139	136 (97.8)	0.15 (0.47)	-1.4	-0.10	0.10	0.39	1.7	
		Week 16	Tezepelumab	128	120 (93.8)	0.39 (0.50)	-0.8	0.03	0.32	0.62	2.1	0.43 [0.18, 0.68]
			Placebo	139	133 (95.7)	0.19 (0.44)	-1.6	-0.05	0.11	0.42	1.8	
		Week 24	Tezepelumab	128	118 (92.2)	0.35 (0.44)	-0.5	0.05	0.29	0.62	1.8	0.53 [0.28, 0.79]
			Placebo	139	129 (92.8)	0.11 (0.46)	-1.4	-0.15	0.06	0.34	1.7	
		Week 36	Tezepelumab	128	117 (91.4)	0.38 (0.45)	-0.5	0.03	0.34	0.63	1.7	0.44 [0.18, 0.69]
			Placebo	139	120 (86.3)	0.17 (0.50)	-1.2	-0.16	0.15	0.48	1.7	
		Week 52	Tezepelumab	128	110 (85.9)	0.36 (0.44)	-0.6	0.03	0.29	0.61	1.6	0.43 [0.16, 0.69]
			Placebo	139	115 (82.7)	0.16 (0.47)	-1.4	-0.11	0.11	0.35	2.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q1: < 53.1 IU/ml	Absolute values	Baseline	Tezepelumab	129	129 (100.0)	1.70 (0.63)	0.4	1.20	1.61	2.05	3.3	
			Placebo	135	135 (100.0)	1.69 (0.59)	0.7	1.30	1.57	2.04	4.2	
		Week 2	Tezepelumab	129	126 (97.7)	1.80 (0.60)	0.6	1.36	1.70	2.23	3.3	
			Placebo	135	127 (94.1)	1.72 (0.61)	0.6	1.32	1.63	2.09	4.0	
		Week 4	Tezepelumab	129	129 (100.0)	1.83 (0.64)	0.7	1.30	1.73	2.32	3.3	
			Placebo	135	130 (96.3)	1.76 (0.62)	0.7	1.33	1.65	2.09	4.2	
		Week 8	Tezepelumab	129	126 (97.7)	1.85 (0.62)	0.6	1.38	1.75	2.30	3.3	
			Placebo	135	132 (97.8)	1.77 (0.60)	0.7	1.34	1.67	2.08	4.3	
		Week 12	Tezepelumab	129	126 (97.7)	1.84 (0.63)	0.6	1.38	1.77	2.24	3.6	
			Placebo	135	130 (96.3)	1.75 (0.62)	0.6	1.33	1.66	2.10	4.3	
		Week 16	Tezepelumab	129	127 (98.4)	1.86 (0.65)	0.6	1.38	1.78	2.28	3.5	
			Placebo	135	129 (95.6)	1.76 (0.60)	0.6	1.31	1.68	2.14	4.1	
		Week 24	Tezepelumab	129	125 (96.9)	1.81 (0.61)	0.6	1.26	1.77	2.28	3.3	
			Placebo	135	121 (89.6)	1.70 (0.59)	0.7	1.32	1.61	2.02	4.8	
		Week 36	Tezepelumab	129	120 (93.0)	1.82 (0.63)	0.5	1.39	1.75	2.19	3.3	
			Placebo	135	113 (83.7)	1.77 (0.59)	0.8	1.36	1.68	2.07	4.6	
		Week 52	Tezepelumab	129	121 (93.8)	1.84 (0.66)	0.6	1.38	1.74	2.23	3.6	
			Placebo	135	112 (83.0)	1.72 (0.61)	0.7	1.27	1.63	2.05	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q1: < 53.1 IU/ml	Change from baseline	Week 2	Tezepelumab	129	126 (97.7)	0.11 (0.28)	-0.8	-0.01	0.09	0.25	1.1	0.28 [0.03, 0.52]
			Placebo	135	127 (94.1)	0.03 (0.30)	-0.6	-0.10	0.00	0.11	1.1	
		Week 4	Tezepelumab	129	129 (100.0)	0.14 (0.36)	-1.0	-0.05	0.09	0.30	1.6	0.18 [-0.06, 0.42]
			Placebo	135	130 (96.3)	0.08 (0.28)	-0.7	-0.06	0.05	0.20	1.1	
		Week 8	Tezepelumab	129	126 (97.7)	0.17 (0.36)	-0.8	-0.03	0.11	0.29	1.4	0.29 [0.05, 0.54]
			Placebo	135	132 (97.8)	0.07 (0.28)	-0.8	-0.09	0.04	0.20	1.2	
		Week 12	Tezepelumab	129	126 (97.7)	0.15 (0.35)	-0.7	-0.03	0.12	0.28	2.0	0.24 [-0.00, 0.49]
			Placebo	135	130 (96.3)	0.07 (0.33)	-0.7	-0.10	0.02	0.19	1.2	
		Week 16	Tezepelumab	129	127 (98.4)	0.16 (0.35)	-1.0	-0.02	0.14	0.29	1.7	0.29 [0.04, 0.54]
			Placebo	135	129 (95.6)	0.07 (0.29)	-0.6	-0.07	0.02	0.18	1.0	
		Week 24	Tezepelumab	129	125 (96.9)	0.14 (0.31)	-0.6	-0.07	0.12	0.32	1.2	0.41 [0.15, 0.66]
			Placebo	135	121 (89.6)	0.02 (0.29)	-0.8	-0.13	0.03	0.13	1.1	
		Week 36	Tezepelumab	129	120 (93.0)	0.12 (0.33)	-0.7	-0.08	0.07	0.30	1.3	0.15 [-0.11, 0.41]
			Placebo	135	113 (83.7)	0.07 (0.29)	-0.5	-0.14	0.04	0.22	1.1	
		Week 52	Tezepelumab	129	121 (93.8)	0.13 (0.36)	-1.0	-0.09	0.11	0.30	1.5	0.35 [0.09, 0.61]
			Placebo	135	112 (83.0)	0.01 (0.31)	-0.7	-0.18	0.02	0.16	1.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q2: 53.1 - < 195.6 IU/ml	Absolute values	Baseline	Tezepelumab	136	136 (100.0)	1.78 (0.75)	0.6	1.27	1.63	2.18	4.8	
			Placebo	129	129 (100.0)	1.81 (0.64)	0.7	1.37	1.70	2.12	4.0	
		Week 2	Tezepelumab	136	134 (98.5)	1.95 (0.76)	0.8	1.34	1.80	2.42	5.0	
			Placebo	129	124 (96.1)	1.87 (0.66)	0.7	1.39	1.78	2.28	3.7	
		Week 4	Tezepelumab	136	133 (97.8)	2.00 (0.77)	0.8	1.41	1.92	2.44	5.0	
			Placebo	129	128 (99.2)	1.87 (0.63)	0.7	1.44	1.82	2.25	4.1	
		Week 8	Tezepelumab	136	132 (97.1)	2.00 (0.76)	0.8	1.36	1.82	2.48	4.6	
			Placebo	129	127 (98.4)	1.89 (0.66)	0.7	1.41	1.82	2.30	3.9	
		Week 12	Tezepelumab	136	132 (97.1)	2.03 (0.76)	0.8	1.50	1.90	2.51	4.9	
			Placebo	129	127 (98.4)	1.88 (0.65)	0.7	1.35	1.76	2.33	4.0	
		Week 16	Tezepelumab	136	130 (95.6)	2.02 (0.79)	0.7	1.35	1.87	2.54	4.9	
			Placebo	129	123 (95.3)	1.91 (0.68)	0.7	1.37	1.80	2.31	4.2	
		Week 24	Tezepelumab	136	129 (94.9)	2.03 (0.79)	0.7	1.44	1.92	2.52	5.5	
			Placebo	129	121 (93.8)	1.90 (0.62)	0.9	1.43	1.85	2.27	3.9	
		Week 36	Tezepelumab	136	127 (93.4)	2.05 (0.78)	0.7	1.42	1.90	2.53	4.9	
			Placebo	129	119 (92.2)	1.93 (0.69)	0.7	1.41	1.86	2.29	4.0	
		Week 52	Tezepelumab	136	118 (86.8)	2.06 (0.77)	0.8	1.48	1.97	2.61	4.6	
			Placebo	129	112 (86.8)	1.93 (0.68)	0.7	1.48	1.83	2.32	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q2: 53.1 - < 195.6 IU/ml	Change from baseline	Week 2	Tezepelumab	136	134 (98.5)	0.16 (0.33)	-0.6	-0.04	0.12	0.28	1.4	0.41 [0.17, 0.66]
			Placebo	129	124 (96.1)	0.04 (0.27)	-1.0	-0.11	0.01	0.17	1.0	
		Week 4	Tezepelumab	136	133 (97.8)	0.22 (0.37)	-0.9	0.00	0.16	0.35	1.7	0.45 [0.20, 0.69]
			Placebo	129	128 (99.2)	0.06 (0.33)	-0.7	-0.10	0.04	0.20	1.2	
		Week 8	Tezepelumab	136	132 (97.1)	0.22 (0.39)	-0.9	-0.06	0.14	0.43	1.2	0.42 [0.18, 0.67]
			Placebo	129	127 (98.4)	0.07 (0.30)	-1.1	-0.11	0.04	0.24	1.2	
		Week 12	Tezepelumab	136	132 (97.1)	0.24 (0.37)	-0.8	0.02	0.18	0.44	1.5	0.45 [0.21, 0.70]
			Placebo	129	127 (98.4)	0.07 (0.38)	-1.5	-0.14	0.05	0.28	1.3	
		Week 16	Tezepelumab	136	130 (95.6)	0.25 (0.43)	-0.8	-0.05	0.22	0.45	1.6	0.40 [0.15, 0.65]
			Placebo	129	123 (95.3)	0.09 (0.35)	-1.2	-0.14	0.04	0.29	1.2	
		Week 24	Tezepelumab	136	129 (94.9)	0.25 (0.40)	-0.5	-0.04	0.18	0.47	1.7	0.43 [0.18, 0.68]
			Placebo	129	121 (93.8)	0.09 (0.33)	-0.8	-0.11	0.06	0.27	1.2	
		Week 36	Tezepelumab	136	127 (93.4)	0.25 (0.38)	-0.6	-0.07	0.24	0.50	1.6	0.37 [0.11, 0.62]
			Placebo	129	119 (92.2)	0.11 (0.37)	-1.1	-0.15	0.05	0.39	1.3	
		Week 52	Tezepelumab	136	118 (86.8)	0.24 (0.42)	-0.6	-0.08	0.18	0.51	1.4	0.39 [0.13, 0.65]
			Placebo	129	112 (86.8)	0.10 (0.31)	-0.9	-0.09	0.07	0.27	1.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q3: 195.6 - < 572.4 IU/ml	Absolute values	Baseline	Tezepelumab	139	139 (100.0)	1.84 (0.71)	0.6	1.35	1.72	2.31	3.9	
			Placebo	126	126 (100.0)	1.96 (0.79)	0.6	1.35	1.79	2.43	4.5	
		Week 2	Tezepelumab	139	135 (97.1)	2.05 (0.74)	0.6	1.53	1.98	2.54	4.0	
			Placebo	126	118 (93.7)	1.96 (0.74)	0.7	1.44	1.81	2.48	4.2	
		Week 4	Tezepelumab	139	138 (99.3)	2.01 (0.73)	0.6	1.48	1.92	2.50	4.2	
			Placebo	126	119 (94.4)	1.99 (0.69)	0.7	1.46	1.88	2.43	3.8	
		Week 8	Tezepelumab	139	137 (98.6)	2.05 (0.74)	0.6	1.48	2.05	2.46	4.3	
			Placebo	126	122 (96.8)	2.03 (0.75)	0.7	1.48	1.96	2.44	4.7	
		Week 12	Tezepelumab	139	133 (95.7)	2.08 (0.79)	0.6	1.56	2.01	2.64	4.6	
			Placebo	126	121 (96.0)	2.03 (0.78)	0.7	1.49	1.81	2.45	4.6	
		Week 16	Tezepelumab	139	134 (96.4)	2.10 (0.77)	0.6	1.54	2.00	2.55	4.4	
			Placebo	126	123 (97.6)	2.00 (0.76)	0.8	1.46	1.83	2.47	4.7	
		Week 24	Tezepelumab	139	127 (91.4)	2.06 (0.71)	0.6	1.61	1.97	2.55	4.0	
			Placebo	126	116 (92.1)	2.03 (0.78)	0.6	1.48	1.90	2.46	4.6	
		Week 36	Tezepelumab	139	122 (87.8)	2.08 (0.73)	0.7	1.58	2.00	2.48	4.2	
			Placebo	126	111 (88.1)	2.05 (0.77)	0.8	1.48	1.88	2.49	4.3	
		Week 52	Tezepelumab	139	123 (88.5)	2.09 (0.76)	0.6	1.56	2.01	2.59	4.3	
			Placebo	126	107 (84.9)	2.11 (0.84)	0.7	1.49	1.93	2.56	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q3: 195.6 - < 572.4 IU/ml	Change from baseline	Week 2	Tezepelumab	139	135 (97.1)	0.22 (0.37)	-0.5	-0.03	0.16	0.35	1.9	0.60 [0.34, 0.85]
			Placebo	126	118 (93.7)	-0.01 (0.39)	-1.8	-0.14	0.00	0.13	1.2	
		Week 4	Tezepelumab	139	138 (99.3)	0.19 (0.32)	-0.5	-0.05	0.13	0.33	1.4	0.35 [0.10, 0.59]
			Placebo	126	119 (94.4)	0.06 (0.42)	-1.8	-0.11	0.05	0.29	1.0	
		Week 8	Tezepelumab	139	137 (98.6)	0.23 (0.41)	-0.8	-0.04	0.18	0.45	1.9	0.39 [0.14, 0.63]
			Placebo	126	122 (96.8)	0.08 (0.41)	-1.0	-0.13	0.03	0.24	1.8	
		Week 12	Tezepelumab	139	133 (95.7)	0.27 (0.46)	-1.5	-0.03	0.20	0.50	2.2	0.41 [0.16, 0.66]
			Placebo	126	121 (96.0)	0.09 (0.42)	-1.2	-0.09	0.03	0.22	2.1	
		Week 16	Tezepelumab	139	134 (96.4)	0.27 (0.45)	-0.6	-0.02	0.17	0.47	2.1	0.51 [0.26, 0.76]
			Placebo	126	123 (97.6)	0.05 (0.39)	-1.0	-0.19	0.02	0.21	1.9	
		Week 24	Tezepelumab	139	127 (91.4)	0.23 (0.46)	-1.0	-0.05	0.21	0.43	2.1	0.36 [0.11, 0.62]
			Placebo	126	116 (92.1)	0.07 (0.40)	-1.1	-0.14	0.02	0.27	1.7	
		Week 36	Tezepelumab	139	122 (87.8)	0.25 (0.46)	-1.0	-0.03	0.16	0.50	1.8	0.37 [0.11, 0.62]
			Placebo	126	111 (88.1)	0.09 (0.42)	-0.9	-0.13	0.04	0.27	1.6	
		Week 52	Tezepelumab	139	123 (88.5)	0.28 (0.46)	-1.0	0.01	0.22	0.59	1.6	0.29 [0.03, 0.55]
			Placebo	126	107 (84.9)	0.14 (0.46)	-1.0	-0.14	0.07	0.32	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q4: >= 572.4 IU/ml	Absolute values	Baseline	Tezepelumab	124	124 (100.0)	2.01 (0.74)	0.7	1.44	1.99	2.52	4.1	
			Placebo	141	141 (100.0)	1.95 (0.76)	0.4	1.39	1.94	2.41	4.9	
		Week 2	Tezepelumab	124	119 (96.0)	2.20 (0.77)	0.7	1.60	2.14	2.70	4.3	
			Placebo	141	138 (97.9)	2.11 (0.77)	0.4	1.53	2.10	2.58	4.7	
		Week 4	Tezepelumab	124	123 (99.2)	2.22 (0.77)	0.7	1.62	2.16	2.78	4.3	
			Placebo	141	139 (98.6)	2.07 (0.79)	0.4	1.50	1.98	2.57	4.8	
		Week 8	Tezepelumab	124	123 (99.2)	2.24 (0.81)	0.8	1.60	2.17	2.76	4.7	
			Placebo	141	136 (96.5)	2.11 (0.85)	0.4	1.52	1.99	2.68	4.9	
		Week 12	Tezepelumab	124	119 (96.0)	2.22 (0.77)	0.8	1.64	2.08	2.72	4.7	
			Placebo	141	136 (96.5)	2.12 (0.83)	0.5	1.50	2.04	2.56	5.0	
		Week 16	Tezepelumab	124	119 (96.0)	2.25 (0.80)	0.9	1.67	2.16	2.77	4.9	
			Placebo	141	134 (95.0)	2.12 (0.83)	0.5	1.58	2.05	2.52	5.2	
		Week 24	Tezepelumab	124	117 (94.4)	2.23 (0.79)	0.8	1.68	2.18	2.79	4.4	
			Placebo	141	133 (94.3)	2.11 (0.84)	0.6	1.57	1.95	2.53	5.1	
		Week 36	Tezepelumab	124	114 (91.9)	2.25 (0.83)	0.6	1.59	2.22	2.77	4.5	
			Placebo	141	132 (93.6)	2.12 (0.87)	0.6	1.52	1.92	2.56	5.3	
		Week 52	Tezepelumab	124	109 (87.9)	2.24 (0.84)	0.7	1.64	2.17	2.75	4.2	
			Placebo	141	122 (86.5)	2.09 (0.87)	0.6	1.40	1.93	2.67	5.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q4: >= 572.4 IU/ml	Change from baseline	Week 2	Tezepelumab	124	119 (96.0)	0.18 (0.34)	-0.6	0.00	0.13	0.32	1.4	0.08 [-0.16, 0.33]
			Placebo	141	138 (97.9)	0.15 (0.42)	-1.3	-0.09	0.06	0.35	1.7	
		Week 4	Tezepelumab	124	123 (99.2)	0.22 (0.40)	-1.2	-0.01	0.13	0.37	1.8	0.17 [-0.07, 0.42]
			Placebo	141	139 (98.6)	0.14 (0.46)	-1.0	-0.13	0.06	0.36	1.7	
		Week 8	Tezepelumab	124	123 (99.2)	0.24 (0.48)	-1.1	-0.04	0.15	0.44	1.8	0.19 [-0.05, 0.43]
			Placebo	141	136 (96.5)	0.15 (0.49)	-1.7	-0.12	0.06	0.33	2.1	
		Week 12	Tezepelumab	124	119 (96.0)	0.23 (0.44)	-0.6	-0.06	0.17	0.38	1.9	0.16 [-0.08, 0.41]
			Placebo	141	136 (96.5)	0.15 (0.45)	-1.2	-0.07	0.09	0.34	1.7	
		Week 16	Tezepelumab	124	119 (96.0)	0.24 (0.44)	-0.5	-0.02	0.13	0.43	2.0	0.17 [-0.07, 0.42]
			Placebo	141	134 (95.0)	0.16 (0.46)	-1.6	-0.07	0.06	0.36	1.8	
		Week 24	Tezepelumab	124	117 (94.4)	0.23 (0.45)	-0.7	-0.06	0.13	0.40	1.8	0.21 [-0.03, 0.46]
			Placebo	141	133 (94.3)	0.13 (0.47)	-1.4	-0.11	0.07	0.31	1.7	
		Week 36	Tezepelumab	124	114 (91.9)	0.25 (0.44)	-0.8	-0.02	0.19	0.42	1.7	0.21 [-0.04, 0.46]
			Placebo	141	132 (93.6)	0.15 (0.53)	-1.7	-0.11	0.11	0.36	2.2	
		Week 52	Tezepelumab	124	109 (87.9)	0.25 (0.40)	-0.8	-0.03	0.17	0.44	1.7	0.30 [0.04, 0.56]
			Placebo	141	122 (86.5)	0.12 (0.47)	-1.4	-0.15	0.07	0.33	1.9	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Nasal polyps last 2 years												
Yes	Absolute values	Baseline	Tezepelumab	42	42 (100.0)	2.01 (0.75)	0.8	1.44	1.91	2.48	3.7	
			Placebo	41	41 (100.0)	1.89 (0.66)	0.6	1.44	1.68	2.27	3.4	
		Week 2	Tezepelumab	42	41 (97.6)	2.18 (0.79)	0.9	1.60	2.13	2.61	4.0	
			Placebo	41	41 (100.0)	1.96 (0.71)	0.9	1.39	1.96	2.46	4.1	
		Week 4	Tezepelumab	42	42 (100.0)	2.24 (0.80)	0.9	1.64	2.02	2.82	4.2	
			Placebo	41	40 (97.6)	2.03 (0.77)	0.9	1.48	2.01	2.54	4.8	
		Week 8	Tezepelumab	42	42 (100.0)	2.32 (0.87)	1.0	1.65	2.13	3.01	4.3	
			Placebo	41	41 (100.0)	2.02 (0.79)	0.7	1.51	1.93	2.61	4.6	
		Week 12	Tezepelumab	42	39 (92.9)	2.33 (0.98)	0.9	1.55	2.07	3.13	4.6	
			Placebo	41	41 (100.0)	2.04 (0.70)	1.0	1.51	1.99	2.44	4.6	
		Week 16	Tezepelumab	42	40 (95.2)	2.34 (0.93)	0.9	1.54	2.12	2.95	4.4	
			Placebo	41	40 (97.6)	2.05 (0.76)	0.7	1.57	1.95	2.49	4.7	
		Week 24	Tezepelumab	42	39 (92.9)	2.20 (0.77)	0.9	1.71	1.88	2.77	4.0	
			Placebo	41	39 (95.1)	2.04 (0.70)	0.9	1.61	1.95	2.48	4.8	
		Week 36	Tezepelumab	42	39 (92.9)	2.33 (0.85)	0.9	1.54	2.19	3.05	4.2	
			Placebo	41	38 (92.7)	2.06 (0.65)	0.8	1.60	2.00	2.38	4.3	
		Week 52	Tezepelumab	42	38 (90.5)	2.30 (0.92)	0.6	1.58	2.27	2.80	4.3	
			Placebo	41	38 (92.7)	1.98 (0.65)	0.9	1.53	2.06	2.34	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Nasal polyps last 2 years												
Yes	Change from baseline	Week 2	Tezepelumab	42	41 (97.6)	0.19 (0.32)	-0.3	0.02	0.12	0.30	1.0	0.35 [-0.08, 0.79]
			Placebo	41	41 (100.0)	0.07 (0.35)	-0.5	-0.15	-0.02	0.17	1.0	
		Week 4	Tezepelumab	42	42 (100.0)	0.23 (0.36)	-0.5	0.06	0.19	0.36	1.8	0.21 [-0.22, 0.64]
			Placebo	41	40 (97.6)	0.14 (0.46)	-0.7	-0.10	0.05	0.27	1.6	
		Week 8	Tezepelumab	42	42 (100.0)	0.31 (0.47)	-0.3	0.03	0.20	0.48	1.9	0.37 [-0.07, 0.80]
			Placebo	41	41 (100.0)	0.14 (0.45)	-1.1	-0.13	0.08	0.31	1.4	
		Week 12	Tezepelumab	42	39 (92.9)	0.30 (0.51)	-0.5	-0.03	0.17	0.53	2.2	0.33 [-0.12, 0.77]
			Placebo	41	41 (100.0)	0.15 (0.41)	-0.5	-0.11	0.08	0.37	1.4	
		Week 16	Tezepelumab	42	40 (95.2)	0.32 (0.51)	-0.6	-0.02	0.26	0.61	2.1	0.31 [-0.13, 0.75]
			Placebo	41	40 (97.6)	0.17 (0.42)	-0.6	-0.14	0.09	0.42	1.4	
		Week 24	Tezepelumab	42	39 (92.9)	0.22 (0.47)	-1.0	-0.08	0.16	0.43	1.6	0.13 [-0.32, 0.57]
			Placebo	41	39 (95.1)	0.16 (0.44)	-0.5	-0.16	0.10	0.50	1.6	
		Week 36	Tezepelumab	42	39 (92.9)	0.31 (0.43)	-0.5	0.01	0.15	0.54	1.4	0.18 [-0.27, 0.63]
			Placebo	41	38 (92.7)	0.23 (0.41)	-0.4	-0.03	0.15	0.50	1.6	
		Week 52	Tezepelumab	42	38 (90.5)	0.29 (0.46)	-0.8	0.00	0.26	0.56	1.5	0.41 [-0.05, 0.86]
			Placebo	41	38 (92.7)	0.10 (0.50)	-0.7	-0.16	0.01	0.23	2.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Nasal polyps last 2 years												
No	Absolute values	Baseline	Tezepelumab	486	486 (100.0)	1.81 (0.71)	0.4	1.29	1.72	2.21	4.8	
			Placebo	490	490 (100.0)	1.85 (0.71)	0.4	1.35	1.73	2.22	4.9	
		Week 2	Tezepelumab	486	473 (97.3)	1.98 (0.73)	0.6	1.43	1.88	2.45	5.0	
			Placebo	490	466 (95.1)	1.91 (0.71)	0.4	1.39	1.80	2.32	4.7	
		Week 4	Tezepelumab	486	481 (99.0)	2.00 (0.73)	0.6	1.45	1.91	2.50	5.0	
			Placebo	490	476 (97.1)	1.91 (0.69)	0.4	1.44	1.83	2.32	4.2	
		Week 8	Tezepelumab	486	476 (97.9)	2.01 (0.73)	0.6	1.43	1.93	2.46	4.7	
			Placebo	490	476 (97.1)	1.94 (0.73)	0.4	1.41	1.85	2.34	4.9	
		Week 12	Tezepelumab	486	471 (96.9)	2.01 (0.73)	0.6	1.51	1.93	2.49	4.9	
			Placebo	490	473 (96.5)	1.94 (0.74)	0.5	1.41	1.79	2.34	5.0	
		Week 16	Tezepelumab	486	470 (96.7)	2.03 (0.75)	0.6	1.50	1.92	2.50	4.9	
			Placebo	490	469 (95.7)	1.94 (0.73)	0.5	1.41	1.81	2.33	5.2	
		Week 24	Tezepelumab	486	459 (94.4)	2.02 (0.74)	0.6	1.51	1.92	2.50	5.5	
			Placebo	490	452 (92.2)	1.93 (0.74)	0.6	1.43	1.80	2.28	5.1	
		Week 36	Tezepelumab	486	444 (91.4)	2.02 (0.75)	0.5	1.46	1.92	2.47	4.9	
			Placebo	490	437 (89.2)	1.97 (0.76)	0.6	1.41	1.82	2.35	5.3	
		Week 52	Tezepelumab	486	433 (89.1)	2.03 (0.75)	0.6	1.49	1.93	2.47	4.6	
			Placebo	490	415 (84.7)	1.96 (0.78)	0.6	1.38	1.81	2.41	5.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Nasal polyps last 2 years												
No	Change from baseline	Week 2	Tezepelumab	486	473 (97.3)	0.16 (0.34)	-0.8	-0.01	0.10	0.29	1.9	0.32 [0.20, 0.45]
			Placebo	490	466 (95.1)	0.05 (0.36)	-1.8	-0.11	0.02	0.18	1.7	
		Week 4	Tezepelumab	486	481 (99.0)	0.19 (0.37)	-1.2	-0.04	0.12	0.33	1.7	0.28 [0.16, 0.41]
			Placebo	490	476 (97.1)	0.08 (0.37)	-1.8	-0.11	0.05	0.25	1.7	
		Week 8	Tezepelumab	486	476 (97.9)	0.21 (0.40)	-1.1	-0.04	0.14	0.38	1.8	0.30 [0.18, 0.43]
			Placebo	490	476 (97.1)	0.09 (0.37)	-1.7	-0.11	0.04	0.25	2.1	
		Week 12	Tezepelumab	486	471 (96.9)	0.22 (0.40)	-1.5	-0.03	0.17	0.40	2.0	0.31 [0.18, 0.44]
			Placebo	490	473 (96.5)	0.09 (0.40)	-1.5	-0.10	0.04	0.24	2.1	
		Week 16	Tezepelumab	486	470 (96.7)	0.22 (0.41)	-1.0	-0.03	0.15	0.38	2.0	0.34 [0.21, 0.47]
			Placebo	490	469 (95.7)	0.09 (0.38)	-1.6	-0.10	0.04	0.24	1.9	
		Week 24	Tezepelumab	486	459 (94.4)	0.21 (0.41)	-1.0	-0.06	0.14	0.40	2.1	0.36 [0.23, 0.49]
			Placebo	490	452 (92.2)	0.07 (0.38)	-1.4	-0.12	0.03	0.24	1.7	
		Week 36	Tezepelumab	486	444 (91.4)	0.21 (0.41)	-1.0	-0.06	0.15	0.40	1.8	0.27 [0.14, 0.41]
			Placebo	490	437 (89.2)	0.10 (0.41)	-1.7	-0.14	0.04	0.29	2.2	
		Week 52	Tezepelumab	486	433 (89.1)	0.22 (0.41)	-1.0	-0.04	0.15	0.42	1.7	0.31 [0.18, 0.45]
			Placebo	490	415 (84.7)	0.09 (0.39)	-1.4	-0.13	0.06	0.27	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Age (cat. N)									0.180
< 18 years	Week 2	Tezepelumab	41	40 (97.6)	0.15 (0.06)	(0.04, 0.26)	0.10 (0.08)	(-0.06, 0.26)	0.213
		Placebo	41	39 (95.1)	0.05 (0.06)	(-0.06, 0.16)			
	Week 4	Tezepelumab	41	40 (97.6)	0.09 (0.07)	(-0.04, 0.22)	0.02 (0.09)	(-0.17, 0.20)	0.865
		Placebo	41	38 (92.7)	0.07 (0.07)	(-0.06, 0.21)			
	Week 8	Tezepelumab	41	40 (97.6)	0.07 (0.07)	(-0.07, 0.22)	0.04 (0.10)	(-0.17, 0.24)	0.726
		Placebo	41	39 (95.1)	0.04 (0.07)	(-0.11, 0.18)			
	Week 12	Tezepelumab	41	37 (90.2)	0.12 (0.08)	(-0.04, 0.27)	0.05 (0.11)	(-0.17, 0.27)	0.640
		Placebo	41	39 (95.1)	0.06 (0.08)	(-0.09, 0.22)			
	Week 16	Tezepelumab	41	39 (95.1)	0.14 (0.07)	(0.00, 0.27)	0.06 (0.09)	(-0.13, 0.24)	0.551
		Placebo	41	40 (97.6)	0.08 (0.07)	(-0.05, 0.21)			
	Week 24	Tezepelumab	41	38 (92.7)	0.14 (0.07)	(-0.00, 0.28)	0.03 (0.10)	(-0.17, 0.23)	0.737
		Placebo	41	38 (92.7)	0.10 (0.07)	(-0.04, 0.24)			
	Week 36	Tezepelumab	41	37 (90.2)	0.23 (0.08)	(0.07, 0.39)	0.09 (0.11)	(-0.14, 0.31)	0.450
		Placebo	41	35 (85.4)	0.14 (0.08)	(-0.02, 0.30)			
	Week 52	Tezepelumab	41	34 (82.9)	0.33 (0.07)	(0.18, 0.47)	0.15 (0.10)	(-0.05, 0.35)	0.129
		Placebo	41	35 (85.4)	0.17 (0.07)	(0.03, 0.31)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
18 - < 65 years	Week 2	Tezepelumab	391	381 (97.4)	0.19 (0.02)	(0.15, 0.22)	0.13 (0.02)	(0.08, 0.18)	<0.001 *
		Placebo	416	397 (95.4)	0.05 (0.02)	(0.02, 0.09)			
	Week 4	Tezepelumab	391	390 (99.7)	0.22 (0.02)	(0.18, 0.26)	0.13 (0.03)	(0.08, 0.18)	<0.001 *
		Placebo	416	408 (98.1)	0.09 (0.02)	(0.05, 0.12)			
	Week 8	Tezepelumab	391	384 (98.2)	0.25 (0.02)	(0.21, 0.29)	0.15 (0.03)	(0.09, 0.20)	<0.001 *
		Placebo	416	408 (98.1)	0.10 (0.02)	(0.06, 0.14)			
	Week 12	Tezepelumab	391	380 (97.2)	0.25 (0.02)	(0.21, 0.29)	0.14 (0.03)	(0.09, 0.20)	<0.001 *
		Placebo	416	405 (97.4)	0.11 (0.02)	(0.07, 0.14)			
	Week 16	Tezepelumab	391	379 (96.9)	0.26 (0.02)	(0.22, 0.30)	0.16 (0.03)	(0.10, 0.21)	<0.001 *
		Placebo	416	399 (95.9)	0.10 (0.02)	(0.06, 0.14)			
	Week 24	Tezepelumab	391	371 (94.9)	0.24 (0.02)	(0.20, 0.28)	0.15 (0.03)	(0.10, 0.21)	<0.001 *
		Placebo	416	386 (92.8)	0.08 (0.02)	(0.04, 0.12)			
	Week 36	Tezepelumab	391	359 (91.8)	0.24 (0.02)	(0.20, 0.28)	0.14 (0.03)	(0.08, 0.19)	<0.001 *
		Placebo	416	374 (89.9)	0.11 (0.02)	(0.07, 0.15)			
	Week 52	Tezepelumab	391	353 (90.3)	0.25 (0.02)	(0.21, 0.29)	0.15 (0.03)	(0.09, 0.21)	<0.001 *
		Placebo	416	355 (85.3)	0.10 (0.02)	(0.06, 0.14)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 65 years	Week 2	Tezepelumab	96	93 (96.9)	0.09 (0.02)	(0.05, 0.13)	0.05 (0.03)	(-0.02, 0.11)	0.155
		Placebo	74	71 (95.9)	0.04 (0.02)	(-0.00, 0.09)			
	Week 4	Tezepelumab	96	93 (96.9)	0.11 (0.02)	(0.06, 0.16)	0.03 (0.04)	(-0.05, 0.10)	0.466
		Placebo	74	70 (94.6)	0.08 (0.03)	(0.02, 0.14)			
	Week 8	Tezepelumab	96	94 (97.9)	0.13 (0.03)	(0.08, 0.18)	0.07 (0.04)	(-0.01, 0.15)	0.107
		Placebo	74	70 (94.6)	0.06 (0.03)	(0.00, 0.13)			
	Week 12	Tezepelumab	96	93 (96.9)	0.15 (0.03)	(0.10, 0.21)	0.11 (0.04)	(0.03, 0.19)	0.009 *
		Placebo	74	70 (94.6)	0.04 (0.03)	(-0.02, 0.11)			
	Week 16	Tezepelumab	96	92 (95.8)	0.15 (0.03)	(0.10, 0.20)	0.08 (0.04)	(0.00, 0.17)	0.045 *
		Placebo	74	70 (94.6)	0.07 (0.03)	(0.00, 0.13)			
	Week 24	Tezepelumab	96	89 (92.7)	0.12 (0.03)	(0.06, 0.17)	0.06 (0.04)	(-0.02, 0.14)	0.159
		Placebo	74	67 (90.5)	0.06 (0.03)	(-0.00, 0.12)			
	Week 36	Tezepelumab	96	87 (90.6)	0.13 (0.03)	(0.07, 0.18)	0.07 (0.04)	(-0.02, 0.15)	0.113
		Placebo	74	66 (89.2)	0.06 (0.03)	(-0.00, 0.12)			
	Week 52	Tezepelumab	96	84 (87.5)	0.13 (0.03)	(0.07, 0.19)	0.10 (0.05)	(0.00, 0.19)	0.042 *
		Placebo	74	63 (85.1)	0.03 (0.04)	(-0.04, 0.10)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Region (cat. N)									0.266
Western Europe	Week 2	Tezepelumab	86	84 (97.7)	0.16 (0.04)	(0.09, 0.23)	0.11 (0.05)	(0.01, 0.21)	0.037 *
		Placebo	85	80 (94.1)	0.06 (0.04)	(-0.02, 0.13)			
	Week 4	Tezepelumab	86	86 (100.0)	0.19 (0.04)	(0.12, 0.27)	0.14 (0.05)	(0.03, 0.24)	0.011 *
		Placebo	85	83 (97.6)	0.06 (0.04)	(-0.02, 0.13)			
	Week 8	Tezepelumab	86	86 (100.0)	0.22 (0.05)	(0.13, 0.31)	0.11 (0.06)	(-0.02, 0.24)	0.090
		Placebo	85	79 (92.9)	0.11 (0.05)	(0.02, 0.20)			
	Week 12	Tezepelumab	86	82 (95.3)	0.18 (0.04)	(0.10, 0.27)	0.12 (0.06)	(-0.00, 0.24)	0.053
		Placebo	85	79 (92.9)	0.07 (0.04)	(-0.02, 0.15)			
	Week 16	Tezepelumab	86	81 (94.2)	0.24 (0.04)	(0.15, 0.32)	0.21 (0.06)	(0.09, 0.34)	<0.001 *
		Placebo	85	79 (92.9)	0.02 (0.04)	(-0.06, 0.11)			
	Week 24	Tezepelumab	86	80 (93.0)	0.18 (0.04)	(0.10, 0.26)	0.15 (0.06)	(0.04, 0.27)	0.009 *
		Placebo	85	71 (83.5)	0.03 (0.04)	(-0.05, 0.11)			
	Week 36	Tezepelumab	86	77 (89.5)	0.19 (0.04)	(0.10, 0.27)	0.07 (0.06)	(-0.05, 0.19)	0.238
		Placebo	85	66 (77.6)	0.12 (0.04)	(0.03, 0.20)			
	Week 52	Tezepelumab	86	75 (87.2)	0.18 (0.04)	(0.10, 0.26)	0.06 (0.06)	(-0.05, 0.18)	0.294
		Placebo	85	64 (75.3)	0.12 (0.04)	(0.04, 0.20)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
North America	Week 2	Tezepelumab	111	105 (94.6)	0.24 (0.03)	(0.17, 0.30)	0.17 (0.05)	(0.08, 0.26)	<0.001 *
		Placebo	111	105 (94.6)	0.07 (0.03)	(0.01, 0.14)			
	Week 4	Tezepelumab	111	108 (97.3)	0.23 (0.03)	(0.17, 0.29)	0.13 (0.05)	(0.04, 0.21)	0.007 *
		Placebo	111	108 (97.3)	0.10 (0.03)	(0.04, 0.17)			
	Week 8	Tezepelumab	111	107 (96.4)	0.26 (0.04)	(0.18, 0.33)	0.19 (0.05)	(0.09, 0.29)	<0.001 *
		Placebo	111	109 (98.2)	0.06 (0.04)	(-0.01, 0.13)			
	Week 12	Tezepelumab	111	106 (95.5)	0.28 (0.04)	(0.20, 0.36)	0.20 (0.06)	(0.09, 0.31)	<0.001 *
		Placebo	111	109 (98.2)	0.08 (0.04)	(0.00, 0.16)			
	Week 16	Tezepelumab	111	106 (95.5)	0.27 (0.04)	(0.20, 0.35)	0.18 (0.05)	(0.07, 0.28)	<0.001 *
		Placebo	111	108 (97.3)	0.10 (0.04)	(0.03, 0.17)			
	Week 24	Tezepelumab	111	100 (90.1)	0.24 (0.04)	(0.17, 0.31)	0.16 (0.05)	(0.06, 0.26)	0.002 *
		Placebo	111	103 (92.8)	0.08 (0.04)	(0.01, 0.15)			
	Week 36	Tezepelumab	111	96 (86.5)	0.28 (0.04)	(0.21, 0.36)	0.17 (0.05)	(0.07, 0.27)	<0.001 *
		Placebo	111	104 (93.7)	0.11 (0.04)	(0.04, 0.18)			
	Week 52	Tezepelumab	111	92 (82.9)	0.28 (0.04)	(0.20, 0.36)	0.15 (0.06)	(0.04, 0.27)	0.011 *
		Placebo	111	90 (81.1)	0.13 (0.04)	(0.05, 0.21)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
South America	Week 2	Tezepelumab	87	87 (100.0)	0.10 (0.04)	(0.01, 0.18)	0.04 (0.06)	(-0.08, 0.15)	0.544
		Placebo	87	84 (96.6)	0.06 (0.04)	(-0.02, 0.14)			
	Week 4	Tezepelumab	87	86 (98.9)	0.09 (0.04)	(0.00, 0.18)	0.01 (0.06)	(-0.12, 0.13)	0.925
		Placebo	87	82 (94.3)	0.08 (0.05)	(-0.01, 0.17)			
	Week 8	Tezepelumab	87	86 (98.9)	0.10 (0.05)	(0.01, 0.19)	-0.02 (0.06)	(-0.15, 0.11)	0.726
		Placebo	87	84 (96.6)	0.12 (0.05)	(0.03, 0.21)			
	Week 12	Tezepelumab	87	83 (95.4)	0.10 (0.05)	(0.01, 0.20)	0.00 (0.07)	(-0.13, 0.13)	0.973
		Placebo	87	86 (98.9)	0.10 (0.05)	(0.01, 0.19)			
	Week 16	Tezepelumab	87	84 (96.6)	0.13 (0.05)	(0.04, 0.22)	0.02 (0.07)	(-0.11, 0.14)	0.812
		Placebo	87	84 (96.6)	0.12 (0.05)	(0.03, 0.21)			
	Week 24	Tezepelumab	87	83 (95.4)	0.13 (0.05)	(0.03, 0.22)	0.01 (0.07)	(-0.13, 0.14)	0.906
		Placebo	87	82 (94.3)	0.12 (0.05)	(0.02, 0.21)			
	Week 36	Tezepelumab	87	82 (94.3)	0.15 (0.05)	(0.04, 0.25)	-0.01 (0.07)	(-0.16, 0.13)	0.863
		Placebo	87	83 (95.4)	0.16 (0.05)	(0.05, 0.26)			
	Week 52	Tezepelumab	87	80 (92.0)	0.18 (0.05)	(0.08, 0.28)	0.05 (0.07)	(-0.09, 0.18)	0.511
		Placebo	87	81 (93.1)	0.14 (0.05)	(0.04, 0.23)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Central/Eastern Europe	Week 2	Tezepelumab	38	37 (97.4)	0.18 (0.05)	(0.09, 0.28)	0.21 (0.07)	(0.08, 0.34)	0.002 *
		Placebo	39	37 (94.9)	-0.03 (0.05)	(-0.12, 0.07)			
	Week 4	Tezepelumab	38	38 (100.0)	0.25 (0.06)	(0.14, 0.37)	0.18 (0.08)	(0.02, 0.34)	0.029 *
		Placebo	39	38 (97.4)	0.08 (0.06)	(-0.04, 0.19)			
	Week 8	Tezepelumab	38	38 (100.0)	0.26 (0.06)	(0.13, 0.38)	0.14 (0.09)	(-0.04, 0.31)	0.118
		Placebo	39	38 (97.4)	0.12 (0.06)	(-0.00, 0.24)			
	Week 12	Tezepelumab	38	37 (97.4)	0.28 (0.06)	(0.16, 0.40)	0.14 (0.08)	(-0.03, 0.31)	0.095
		Placebo	39	37 (94.9)	0.13 (0.06)	(0.02, 0.25)			
	Week 16	Tezepelumab	38	38 (100.0)	0.28 (0.07)	(0.15, 0.42)	0.13 (0.10)	(-0.07, 0.32)	0.195
		Placebo	39	39 (100.0)	0.16 (0.07)	(0.02, 0.29)			
	Week 24	Tezepelumab	38	37 (97.4)	0.21 (0.07)	(0.08, 0.34)	0.07 (0.09)	(-0.11, 0.26)	0.424
		Placebo	39	39 (100.0)	0.14 (0.06)	(0.01, 0.27)			
	Week 36	Tezepelumab	38	38 (100.0)	0.18 (0.06)	(0.07, 0.30)	0.08 (0.08)	(-0.09, 0.24)	0.349
		Placebo	39	38 (97.4)	0.11 (0.06)	(-0.01, 0.22)			
	Week 52	Tezepelumab	38	38 (100.0)	0.23 (0.06)	(0.10, 0.36)	0.15 (0.09)	(-0.03, 0.33)	0.108
		Placebo	39	39 (100.0)	0.08 (0.06)	(-0.04, 0.21)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Asia Pacific	Week 2	Tezepelumab	125	124 (99.2)	0.15 (0.03)	(0.10, 0.21)	0.08 (0.04)	(-0.00, 0.16)	0.053
		Placebo	127	124 (97.6)	0.07 (0.03)	(0.02, 0.13)			
	Week 4	Tezepelumab	125	125 (100.0)	0.22 (0.03)	(0.15, 0.28)	0.15 (0.04)	(0.06, 0.24)	<0.001 *
		Placebo	127	127 (100.0)	0.07 (0.03)	(0.01, 0.13)			
	Week 8	Tezepelumab	125	121 (96.8)	0.25 (0.03)	(0.19, 0.32)	0.16 (0.05)	(0.07, 0.26)	<0.001 *
		Placebo	127	127 (100.0)	0.09 (0.03)	(0.02, 0.15)			
	Week 12	Tezepelumab	125	123 (98.4)	0.26 (0.03)	(0.19, 0.33)	0.17 (0.05)	(0.07, 0.26)	<0.001 *
		Placebo	127	126 (99.2)	0.09 (0.03)	(0.03, 0.16)			
	Week 16	Tezepelumab	125	124 (99.2)	0.26 (0.03)	(0.19, 0.33)	0.16 (0.05)	(0.07, 0.25)	<0.001 *
		Placebo	127	124 (97.6)	0.10 (0.03)	(0.03, 0.16)			
	Week 24	Tezepelumab	125	123 (98.4)	0.24 (0.03)	(0.17, 0.30)	0.15 (0.05)	(0.06, 0.24)	0.002 *
		Placebo	127	122 (96.1)	0.08 (0.03)	(0.02, 0.15)			
	Week 36	Tezepelumab	125	119 (95.2)	0.25 (0.04)	(0.18, 0.32)	0.17 (0.05)	(0.07, 0.28)	0.001 *
		Placebo	127	116 (91.3)	0.07 (0.04)	(0.00, 0.15)			
	Week 52	Tezepelumab	125	118 (94.4)	0.25 (0.04)	(0.18, 0.32)	0.19 (0.05)	(0.09, 0.29)	<0.001 *
		Placebo	127	115 (90.6)	0.06 (0.04)	(-0.01, 0.13)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Rest of the world	Week 2	Tezepelumab	81	77 (95.1)	0.15 (0.04)	(0.08, 0.22)	0.12 (0.05)	(0.02, 0.22)	0.024 *
		Placebo	82	77 (93.9)	0.04 (0.04)	(-0.03, 0.11)			
	Week 4	Tezepelumab	81	80 (98.8)	0.15 (0.04)	(0.07, 0.24)	0.02 (0.06)	(-0.10, 0.14)	0.736
		Placebo	82	78 (95.1)	0.13 (0.04)	(0.05, 0.22)			
	Week 8	Tezepelumab	81	80 (98.8)	0.19 (0.04)	(0.12, 0.26)	0.10 (0.05)	(-0.01, 0.20)	0.065
		Placebo	82	80 (97.6)	0.09 (0.04)	(0.02, 0.17)			
	Week 12	Tezepelumab	81	79 (97.5)	0.21 (0.04)	(0.13, 0.29)	0.09 (0.06)	(-0.02, 0.20)	0.126
		Placebo	82	77 (93.9)	0.13 (0.04)	(0.05, 0.20)			
	Week 16	Tezepelumab	81	77 (95.1)	0.17 (0.04)	(0.09, 0.25)	0.07 (0.06)	(-0.05, 0.18)	0.237
		Placebo	82	75 (91.5)	0.10 (0.04)	(0.02, 0.18)			
	Week 24	Tezepelumab	81	75 (92.6)	0.22 (0.04)	(0.14, 0.31)	0.15 (0.06)	(0.03, 0.27)	0.012 *
		Placebo	82	74 (90.2)	0.07 (0.04)	(-0.01, 0.16)			
	Week 36	Tezepelumab	81	71 (87.7)	0.23 (0.04)	(0.14, 0.31)	0.14 (0.06)	(0.02, 0.26)	0.024 *
		Placebo	82	68 (82.9)	0.09 (0.04)	(0.00, 0.17)			
	Week 52	Tezepelumab	81	68 (84.0)	0.24 (0.04)	(0.15, 0.33)	0.17 (0.06)	(0.04, 0.30)	0.008 *
		Placebo	82	64 (78.0)	0.07 (0.05)	(-0.02, 0.16)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline eosinophils (cat. N)									0.004 i
< 150 cells/uL	Week 2	Tezepelumab	138	135 (97.8)	0.07 (0.03)	(0.02, 0.12)	0.02 (0.04)	(-0.05, 0.09)	0.604
		Placebo	138	132 (95.7)	0.05 (0.03)	(-0.00, 0.10)			
	Week 4	Tezepelumab	138	137 (99.3)	0.07 (0.03)	(0.01, 0.13)	0.01 (0.04)	(-0.07, 0.09)	0.784
		Placebo	138	134 (97.1)	0.06 (0.03)	(0.00, 0.12)			
	Week 8	Tezepelumab	138	133 (96.4)	0.08 (0.03)	(0.03, 0.14)	-0.00 (0.04)	(-0.09, 0.08)	0.967
		Placebo	138	134 (97.1)	0.09 (0.03)	(0.03, 0.15)			
	Week 12	Tezepelumab	138	132 (95.7)	0.08 (0.03)	(0.02, 0.14)	-0.00 (0.04)	(-0.09, 0.08)	0.948
		Placebo	138	132 (95.7)	0.08 (0.03)	(0.02, 0.14)			
	Week 16	Tezepelumab	138	134 (97.1)	0.08 (0.03)	(0.02, 0.15)	0.03 (0.05)	(-0.07, 0.12)	0.579
		Placebo	138	133 (96.4)	0.06 (0.03)	(-0.01, 0.12)			
	Week 24	Tezepelumab	138	126 (91.3)	0.08 (0.03)	(0.02, 0.13)	0.01 (0.04)	(-0.07, 0.09)	0.800
		Placebo	138	127 (92.0)	0.07 (0.03)	(0.01, 0.12)			
	Week 36	Tezepelumab	138	126 (91.3)	0.06 (0.03)	(0.01, 0.12)	-0.03 (0.04)	(-0.11, 0.05)	0.508
		Placebo	138	123 (89.1)	0.09 (0.03)	(0.03, 0.15)			
	Week 52	Tezepelumab	138	124 (89.9)	0.09 (0.03)	(0.03, 0.15)	0.03 (0.05)	(-0.06, 0.12)	0.496
		Placebo	138	121 (87.7)	0.06 (0.03)	(-0.00, 0.12)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
150 - < 300 cells/uL	Week 2	Tezepelumab	171	167 (97.7)	0.14 (0.02)	(0.10, 0.19)	0.13 (0.03)	(0.06, 0.19)	<0.001 *
		Placebo	171	165 (96.5)	0.02 (0.02)	(-0.03, 0.06)			
	Week 4	Tezepelumab	171	170 (99.4)	0.16 (0.02)	(0.11, 0.21)	0.12 (0.03)	(0.05, 0.19)	<0.001 *
		Placebo	171	166 (97.1)	0.04 (0.02)	(-0.01, 0.08)			
	Week 8	Tezepelumab	171	170 (99.4)	0.17 (0.02)	(0.12, 0.21)	0.10 (0.04)	(0.03, 0.17)	0.005 *
		Placebo	171	165 (96.5)	0.07 (0.02)	(0.02, 0.12)			
	Week 12	Tezepelumab	171	164 (95.9)	0.15 (0.03)	(0.10, 0.21)	0.11 (0.04)	(0.04, 0.19)	0.003 *
		Placebo	171	165 (96.5)	0.04 (0.03)	(-0.01, 0.09)			
	Week 16	Tezepelumab	171	166 (97.1)	0.16 (0.03)	(0.11, 0.21)	0.10 (0.04)	(0.03, 0.17)	0.006 *
		Placebo	171	164 (95.9)	0.06 (0.03)	(0.01, 0.11)			
	Week 24	Tezepelumab	171	165 (96.5)	0.12 (0.03)	(0.07, 0.17)	0.10 (0.04)	(0.03, 0.17)	0.008 *
		Placebo	171	160 (93.6)	0.02 (0.03)	(-0.03, 0.07)			
	Week 36	Tezepelumab	171	158 (92.4)	0.14 (0.03)	(0.09, 0.20)	0.12 (0.04)	(0.04, 0.20)	0.002 *
		Placebo	171	154 (90.1)	0.02 (0.03)	(-0.04, 0.07)			
	Week 52	Tezepelumab	171	158 (92.4)	0.15 (0.03)	(0.10, 0.21)	0.10 (0.04)	(0.02, 0.18)	0.013 *
		Placebo	171	143 (83.6)	0.05 (0.03)	(-0.00, 0.11)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
300 - < 450 cells/uL	Week 2	Tezepelumab	99	95 (96.0)	0.18 (0.04)	(0.11, 0.26)	0.12 (0.05)	(0.02, 0.22)	0.023 *
		Placebo	95	89 (93.7)	0.07 (0.04)	(-0.00, 0.14)			
	Week 4	Tezepelumab	99	96 (97.0)	0.21 (0.04)	(0.13, 0.28)	0.10 (0.06)	(-0.01, 0.21)	0.064
		Placebo	95	92 (96.8)	0.10 (0.04)	(0.03, 0.18)			
	Week 8	Tezepelumab	99	97 (98.0)	0.26 (0.04)	(0.18, 0.34)	0.15 (0.06)	(0.04, 0.26)	0.009 *
		Placebo	95	93 (97.9)	0.11 (0.04)	(0.03, 0.19)			
	Week 12	Tezepelumab	99	95 (96.0)	0.30 (0.04)	(0.22, 0.38)	0.22 (0.06)	(0.10, 0.33)	<0.001 *
		Placebo	95	90 (94.7)	0.08 (0.04)	(0.00, 0.16)			
	Week 16	Tezepelumab	99	95 (96.0)	0.29 (0.04)	(0.21, 0.37)	0.17 (0.06)	(0.05, 0.28)	0.005 *
		Placebo	95	89 (93.7)	0.12 (0.04)	(0.04, 0.20)			
	Week 24	Tezepelumab	99	95 (96.0)	0.29 (0.04)	(0.21, 0.37)	0.18 (0.06)	(0.07, 0.29)	0.002 *
		Placebo	95	87 (91.6)	0.11 (0.04)	(0.03, 0.19)			
	Week 36	Tezepelumab	99	89 (89.9)	0.31 (0.04)	(0.23, 0.40)	0.18 (0.06)	(0.06, 0.30)	0.004 *
		Placebo	95	84 (88.4)	0.13 (0.04)	(0.05, 0.22)			
	Week 52	Tezepelumab	99	87 (87.9)	0.30 (0.04)	(0.21, 0.39)	0.18 (0.06)	(0.06, 0.31)	0.004 *
		Placebo	95	84 (88.4)	0.12 (0.04)	(0.03, 0.21)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 450 cells/uL	Week 2	Tezepelumab	120	117 (97.5)	0.29 (0.04)	(0.22, 0.36)	0.18 (0.05)	(0.09, 0.28)	<0.001 *
		Placebo	127	121 (95.3)	0.11 (0.03)	(0.04, 0.17)			
	Week 4	Tezepelumab	120	120 (100.0)	0.34 (0.04)	(0.27, 0.42)	0.18 (0.05)	(0.08, 0.27)	<0.001 *
		Placebo	127	124 (97.6)	0.17 (0.03)	(0.10, 0.24)			
	Week 8	Tezepelumab	120	118 (98.3)	0.39 (0.04)	(0.31, 0.47)	0.26 (0.06)	(0.15, 0.38)	<0.001 *
		Placebo	127	125 (98.4)	0.13 (0.04)	(0.05, 0.21)			
	Week 12	Tezepelumab	120	119 (99.2)	0.41 (0.04)	(0.33, 0.49)	0.22 (0.06)	(0.10, 0.33)	<0.001 *
		Placebo	127	127 (100.0)	0.20 (0.04)	(0.12, 0.27)			
	Week 16	Tezepelumab	120	115 (95.8)	0.44 (0.04)	(0.36, 0.51)	0.28 (0.05)	(0.17, 0.38)	<0.001 *
		Placebo	127	123 (96.9)	0.16 (0.04)	(0.09, 0.24)			
	Week 24	Tezepelumab	120	112 (93.3)	0.41 (0.04)	(0.33, 0.49)	0.24 (0.06)	(0.13, 0.36)	<0.001 *
		Placebo	127	117 (92.1)	0.17 (0.04)	(0.09, 0.25)			
	Week 36	Tezepelumab	120	110 (91.7)	0.44 (0.04)	(0.35, 0.52)	0.21 (0.06)	(0.09, 0.32)	<0.001 *
		Placebo	127	114 (89.8)	0.23 (0.04)	(0.15, 0.31)			
	Week 52	Tezepelumab	120	102 (85.0)	0.44 (0.04)	(0.36, 0.52)	0.26 (0.06)	(0.14, 0.37)	<0.001 *
		Placebo	127	105 (82.7)	0.18 (0.04)	(0.10, 0.26)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline eosinophils (cat. Q)									0.006 i
Q1: < 140 cells/uL	Week 2	Tezepelumab	125	122 (97.6)	0.08 (0.03)	(0.03, 0.13)	0.02 (0.04)	(-0.05, 0.09)	0.573
		Placebo	127	121 (95.3)	0.06 (0.03)	(0.01, 0.11)			
	Week 4	Tezepelumab	125	124 (99.2)	0.08 (0.03)	(0.02, 0.14)	0.02 (0.04)	(-0.07, 0.10)	0.701
		Placebo	127	123 (96.9)	0.06 (0.03)	(0.00, 0.12)			
	Week 8	Tezepelumab	125	121 (96.8)	0.09 (0.03)	(0.03, 0.16)	0.02 (0.05)	(-0.07, 0.11)	0.680
		Placebo	127	123 (96.9)	0.08 (0.03)	(0.01, 0.14)			
	Week 12	Tezepelumab	125	120 (96.0)	0.09 (0.03)	(0.03, 0.15)	0.00 (0.04)	(-0.08, 0.09)	0.939
		Placebo	127	122 (96.1)	0.08 (0.03)	(0.02, 0.15)			
	Week 16	Tezepelumab	125	122 (97.6)	0.10 (0.04)	(0.03, 0.17)	0.04 (0.05)	(-0.06, 0.14)	0.433
		Placebo	127	122 (96.1)	0.06 (0.04)	(-0.01, 0.13)			
	Week 24	Tezepelumab	125	115 (92.0)	0.08 (0.03)	(0.03, 0.14)	0.01 (0.04)	(-0.07, 0.09)	0.798
		Placebo	127	117 (92.1)	0.07 (0.03)	(0.02, 0.13)			
	Week 36	Tezepelumab	125	115 (92.0)	0.08 (0.03)	(0.02, 0.14)	-0.02 (0.04)	(-0.11, 0.06)	0.582
		Placebo	127	113 (89.0)	0.10 (0.03)	(0.04, 0.16)			
	Week 52	Tezepelumab	125	113 (90.4)	0.10 (0.03)	(0.04, 0.17)	0.05 (0.05)	(-0.05, 0.14)	0.320
		Placebo	127	111 (87.4)	0.06 (0.03)	(-0.01, 0.12)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q2: 140 - < 250 cells/uL	Week 2	Tezepelumab	130	127 (97.7)	0.12 (0.03)	(0.07, 0.17)	0.14 (0.04)	(0.07, 0.21)	<0.001 *
		Placebo	136	132 (97.1)	-0.02 (0.03)	(-0.07, 0.03)			
	Week 4	Tezepelumab	130	130 (100.0)	0.12 (0.03)	(0.06, 0.17)	0.10 (0.04)	(0.02, 0.17)	0.011 *
		Placebo	136	131 (96.3)	0.02 (0.03)	(-0.03, 0.07)			
	Week 8	Tezepelumab	130	129 (99.2)	0.12 (0.03)	(0.07, 0.18)	0.05 (0.04)	(-0.02, 0.13)	0.153
		Placebo	136	134 (98.5)	0.07 (0.03)	(0.01, 0.12)			
	Week 12	Tezepelumab	130	124 (95.4)	0.10 (0.03)	(0.04, 0.16)	0.08 (0.04)	(-0.01, 0.16)	0.074
		Placebo	136	131 (96.3)	0.02 (0.03)	(-0.04, 0.08)			
	Week 16	Tezepelumab	130	126 (96.9)	0.12 (0.03)	(0.07, 0.17)	0.06 (0.04)	(-0.01, 0.13)	0.085
		Placebo	136	132 (97.1)	0.06 (0.03)	(0.01, 0.11)			
	Week 24	Tezepelumab	130	125 (96.2)	0.08 (0.03)	(0.02, 0.14)	0.06 (0.04)	(-0.02, 0.14)	0.139
		Placebo	136	128 (94.1)	0.02 (0.03)	(-0.04, 0.08)			
	Week 36	Tezepelumab	130	121 (93.1)	0.07 (0.03)	(0.01, 0.13)	0.06 (0.04)	(-0.03, 0.14)	0.197
		Placebo	136	123 (90.4)	0.02 (0.03)	(-0.04, 0.08)			
	Week 52	Tezepelumab	130	120 (92.3)	0.10 (0.03)	(0.03, 0.16)	0.03 (0.04)	(-0.05, 0.12)	0.456
		Placebo	136	115 (84.6)	0.06 (0.03)	(0.00, 0.13)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q3: 250 - < 430 cells/uL	Week 2	Tezepelumab	145	141 (97.2)	0.18 (0.03)	(0.13, 0.24)	0.09 (0.04)	(0.01, 0.18)	0.025 *
		Placebo	130	123 (94.6)	0.09 (0.03)	(0.03, 0.15)			
	Week 4	Tezepelumab	145	141 (97.2)	0.21 (0.03)	(0.15, 0.27)	0.11 (0.04)	(0.03, 0.20)	0.011 *
		Placebo	130	127 (97.7)	0.10 (0.03)	(0.03, 0.16)			
	Week 8	Tezepelumab	145	142 (97.9)	0.26 (0.03)	(0.19, 0.32)	0.14 (0.05)	(0.05, 0.23)	0.002 *
		Placebo	130	124 (95.4)	0.11 (0.03)	(0.05, 0.18)			
	Week 12	Tezepelumab	145	139 (95.9)	0.29 (0.03)	(0.22, 0.35)	0.19 (0.05)	(0.10, 0.28)	<0.001 *
		Placebo	130	123 (94.6)	0.10 (0.03)	(0.03, 0.16)			
	Week 16	Tezepelumab	145	139 (95.9)	0.26 (0.03)	(0.20, 0.33)	0.15 (0.05)	(0.06, 0.25)	0.002 *
		Placebo	130	121 (93.1)	0.11 (0.04)	(0.04, 0.18)			
	Week 24	Tezepelumab	145	138 (95.2)	0.26 (0.03)	(0.19, 0.32)	0.18 (0.05)	(0.09, 0.27)	<0.001 *
		Placebo	130	118 (90.8)	0.08 (0.03)	(0.01, 0.15)			
	Week 36	Tezepelumab	145	129 (89.0)	0.30 (0.04)	(0.23, 0.37)	0.21 (0.05)	(0.11, 0.31)	<0.001 *
		Placebo	130	114 (87.7)	0.09 (0.04)	(0.02, 0.17)			
	Week 52	Tezepelumab	145	128 (88.3)	0.28 (0.03)	(0.21, 0.35)	0.19 (0.05)	(0.09, 0.29)	<0.001 *
		Placebo	130	111 (85.4)	0.09 (0.04)	(0.02, 0.17)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q4: >= 430 cells/uL	Week 2	Tezepelumab	128	124 (96.9)	0.27 (0.03)	(0.21, 0.34)	0.18 (0.05)	(0.09, 0.28)	<0.001 *
		Placebo	138	131 (94.9)	0.09 (0.03)	(0.03, 0.16)			
	Week 4	Tezepelumab	128	128 (100.0)	0.34 (0.04)	(0.27, 0.41)	0.18 (0.05)	(0.08, 0.27)	<0.001 *
		Placebo	138	135 (97.8)	0.16 (0.03)	(0.09, 0.23)			
	Week 8	Tezepelumab	128	126 (98.4)	0.38 (0.04)	(0.30, 0.46)	0.26 (0.06)	(0.15, 0.37)	<0.001 *
		Placebo	138	136 (98.6)	0.12 (0.04)	(0.04, 0.20)			
	Week 12	Tezepelumab	128	127 (99.2)	0.40 (0.04)	(0.32, 0.48)	0.22 (0.05)	(0.12, 0.33)	<0.001 *
		Placebo	138	138 (100.0)	0.18 (0.04)	(0.10, 0.25)			
	Week 16	Tezepelumab	128	123 (96.1)	0.42 (0.04)	(0.35, 0.50)	0.27 (0.05)	(0.17, 0.38)	<0.001 *
		Placebo	138	134 (97.1)	0.15 (0.04)	(0.08, 0.22)			
	Week 24	Tezepelumab	128	120 (93.8)	0.40 (0.04)	(0.32, 0.48)	0.24 (0.06)	(0.13, 0.35)	<0.001 *
		Placebo	138	128 (92.8)	0.16 (0.04)	(0.08, 0.24)			
	Week 36	Tezepelumab	128	118 (92.2)	0.42 (0.04)	(0.34, 0.49)	0.21 (0.05)	(0.10, 0.31)	<0.001 *
		Placebo	138	125 (90.6)	0.21 (0.04)	(0.13, 0.29)			
	Week 52	Tezepelumab	128	110 (85.9)	0.43 (0.04)	(0.35, 0.51)	0.26 (0.06)	(0.15, 0.37)	<0.001 *
		Placebo	138	116 (84.1)	0.17 (0.04)	(0.10, 0.25)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline FENO (cat. N)									0.073
< 25 ppb	Week 2	Tezepelumab	213	206 (96.7)	0.12 (0.02)	(0.08, 0.16)	0.08 (0.03)	(0.02, 0.13)	0.008 *
		Placebo	220	204 (92.7)	0.05 (0.02)	(0.01, 0.09)			
	Week 4	Tezepelumab	213	210 (98.6)	0.12 (0.02)	(0.08, 0.17)	0.06 (0.03)	(-0.01, 0.12)	0.082
		Placebo	220	213 (96.8)	0.07 (0.02)	(0.03, 0.11)			
	Week 8	Tezepelumab	213	208 (97.7)	0.14 (0.02)	(0.09, 0.19)	0.06 (0.03)	(-0.01, 0.12)	0.078
		Placebo	220	214 (97.3)	0.08 (0.02)	(0.03, 0.13)			
	Week 12	Tezepelumab	213	205 (96.2)	0.15 (0.02)	(0.10, 0.19)	0.07 (0.03)	(-0.00, 0.13)	0.052
		Placebo	220	211 (95.9)	0.08 (0.02)	(0.03, 0.13)			
	Week 16	Tezepelumab	213	205 (96.2)	0.13 (0.02)	(0.09, 0.18)	0.07 (0.03)	(0.00, 0.14)	0.043 *
		Placebo	220	212 (96.4)	0.06 (0.02)	(0.02, 0.11)			
	Week 24	Tezepelumab	213	202 (94.8)	0.12 (0.02)	(0.08, 0.17)	0.07 (0.03)	(0.01, 0.14)	0.034 *
		Placebo	220	208 (94.5)	0.05 (0.02)	(0.00, 0.10)			
	Week 36	Tezepelumab	213	192 (90.1)	0.12 (0.02)	(0.07, 0.17)	0.03 (0.03)	(-0.04, 0.10)	0.402
		Placebo	220	199 (90.5)	0.09 (0.02)	(0.05, 0.14)			
	Week 52	Tezepelumab	213	192 (90.1)	0.14 (0.03)	(0.09, 0.19)	0.05 (0.04)	(-0.02, 0.12)	0.161
		Placebo	220	193 (87.7)	0.09 (0.03)	(0.04, 0.14)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
25 - < 50 ppb	Week 2	Tezepelumab	158	157 (99.4)	0.16 (0.03)	(0.11, 0.22)	0.14 (0.04)	(0.07, 0.22)	<0.001 *
		Placebo	151	149 (98.7)	0.02 (0.03)	(-0.03, 0.07)			
	Week 4	Tezepelumab	158	158 (100.0)	0.22 (0.03)	(0.16, 0.27)	0.14 (0.04)	(0.07, 0.22)	<0.001 *
		Placebo	151	146 (96.7)	0.07 (0.03)	(0.02, 0.13)			
	Week 8	Tezepelumab	158	156 (98.7)	0.21 (0.03)	(0.15, 0.26)	0.11 (0.04)	(0.03, 0.19)	0.007 *
		Placebo	151	147 (97.4)	0.10 (0.03)	(0.04, 0.16)			
	Week 12	Tezepelumab	158	153 (96.8)	0.23 (0.03)	(0.17, 0.29)	0.16 (0.04)	(0.08, 0.24)	<0.001 *
		Placebo	151	147 (97.4)	0.07 (0.03)	(0.01, 0.13)			
	Week 16	Tezepelumab	158	156 (98.7)	0.23 (0.03)	(0.17, 0.28)	0.15 (0.04)	(0.07, 0.23)	<0.001 *
		Placebo	151	145 (96.0)	0.08 (0.03)	(0.02, 0.14)			
	Week 24	Tezepelumab	158	149 (94.3)	0.21 (0.03)	(0.15, 0.27)	0.10 (0.05)	(0.01, 0.19)	0.024 *
		Placebo	151	135 (89.4)	0.11 (0.03)	(0.04, 0.17)			
	Week 36	Tezepelumab	158	147 (93.0)	0.22 (0.03)	(0.16, 0.29)	0.13 (0.05)	(0.03, 0.22)	0.008 *
		Placebo	151	136 (90.1)	0.10 (0.03)	(0.03, 0.16)			
	Week 52	Tezepelumab	158	143 (90.5)	0.24 (0.03)	(0.18, 0.31)	0.18 (0.05)	(0.09, 0.28)	<0.001 *
		Placebo	151	126 (83.4)	0.06 (0.03)	(-0.01, 0.13)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 50 ppb	Week 2	Tezepelumab	151	145 (96.0)	0.24 (0.03)	(0.17, 0.30)	0.14 (0.04)	(0.06, 0.23)	0.001 *
		Placebo	156	150 (96.2)	0.09 (0.03)	(0.03, 0.15)			
	Week 4	Tezepelumab	151	150 (99.3)	0.25 (0.03)	(0.18, 0.32)	0.14 (0.05)	(0.04, 0.23)	0.006 *
		Placebo	156	153 (98.1)	0.12 (0.03)	(0.05, 0.18)			
	Week 8	Tezepelumab	151	148 (98.0)	0.33 (0.04)	(0.26, 0.41)	0.23 (0.05)	(0.13, 0.33)	<0.001 *
		Placebo	156	152 (97.4)	0.10 (0.04)	(0.03, 0.18)			
	Week 12	Tezepelumab	151	146 (96.7)	0.32 (0.04)	(0.25, 0.40)	0.19 (0.05)	(0.08, 0.29)	<0.001 *
		Placebo	156	153 (98.1)	0.14 (0.04)	(0.06, 0.21)			
	Week 16	Tezepelumab	151	143 (94.7)	0.37 (0.04)	(0.30, 0.44)	0.21 (0.05)	(0.11, 0.32)	<0.001 *
		Placebo	156	149 (95.5)	0.15 (0.04)	(0.08, 0.23)			
	Week 24	Tezepelumab	151	141 (93.4)	0.33 (0.04)	(0.26, 0.40)	0.22 (0.05)	(0.12, 0.32)	<0.001 *
		Placebo	156	145 (92.9)	0.11 (0.03)	(0.04, 0.18)			
	Week 36	Tezepelumab	151	138 (91.4)	0.36 (0.04)	(0.29, 0.43)	0.23 (0.05)	(0.12, 0.33)	<0.001 *
		Placebo	156	137 (87.8)	0.13 (0.04)	(0.06, 0.20)			
	Week 52	Tezepelumab	151	131 (86.8)	0.35 (0.04)	(0.27, 0.42)	0.21 (0.05)	(0.10, 0.31)	<0.001 *
		Placebo	156	131 (84.0)	0.14 (0.04)	(0.07, 0.21)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline FENO (cat. Q)									0.086
Q1: < 16 ppb	Week 2	Tezepelumab	125	120 (96.0)	0.15 (0.03)	(0.09, 0.21)	0.09 (0.04)	(0.00, 0.17)	0.041 *
		Placebo	122	110 (90.2)	0.06 (0.03)	(0.00, 0.12)			
	Week 4	Tezepelumab	125	123 (98.4)	0.15 (0.03)	(0.08, 0.21)	0.08 (0.05)	(-0.01, 0.17)	0.094
		Placebo	122	119 (97.5)	0.07 (0.03)	(0.00, 0.13)			
	Week 8	Tezepelumab	125	121 (96.8)	0.14 (0.03)	(0.08, 0.21)	0.06 (0.05)	(-0.03, 0.15)	0.184
		Placebo	122	119 (97.5)	0.08 (0.03)	(0.02, 0.15)			
	Week 12	Tezepelumab	125	121 (96.8)	0.15 (0.03)	(0.09, 0.22)	0.04 (0.05)	(-0.05, 0.14)	0.373
		Placebo	122	117 (95.9)	0.11 (0.03)	(0.04, 0.18)			
	Week 16	Tezepelumab	125	120 (96.0)	0.15 (0.03)	(0.08, 0.21)	0.07 (0.05)	(-0.03, 0.16)	0.168
		Placebo	122	117 (95.9)	0.08 (0.03)	(0.01, 0.15)			
	Week 24	Tezepelumab	125	119 (95.2)	0.12 (0.03)	(0.06, 0.19)	0.06 (0.05)	(-0.04, 0.16)	0.208
		Placebo	122	115 (94.3)	0.06 (0.04)	(-0.01, 0.13)			
	Week 36	Tezepelumab	125	113 (90.4)	0.15 (0.03)	(0.08, 0.21)	0.04 (0.05)	(-0.06, 0.13)	0.444
		Placebo	122	111 (91.0)	0.11 (0.03)	(0.04, 0.18)			
	Week 52	Tezepelumab	125	111 (88.8)	0.14 (0.04)	(0.06, 0.21)	0.03 (0.05)	(-0.07, 0.14)	0.510
		Placebo	122	105 (86.1)	0.10 (0.04)	(0.03, 0.17)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q2: 16 - < 30 ppb	Week 2	Tezepelumab	128	126 (98.4)	0.10 (0.02)	(0.05, 0.15)	0.07 (0.03)	(0.01, 0.14)	0.029 *
		Placebo	139	135 (97.1)	0.03 (0.02)	(-0.02, 0.07)			
	Week 4	Tezepelumab	128	127 (99.2)	0.13 (0.03)	(0.08, 0.18)	0.06 (0.04)	(-0.01, 0.14)	0.084
		Placebo	139	134 (96.4)	0.06 (0.03)	(0.01, 0.12)			
	Week 8	Tezepelumab	128	127 (99.2)	0.14 (0.03)	(0.09, 0.20)	0.06 (0.04)	(-0.02, 0.14)	0.145
		Placebo	139	135 (97.1)	0.09 (0.03)	(0.03, 0.14)			
	Week 12	Tezepelumab	128	121 (94.5)	0.15 (0.03)	(0.10, 0.21)	0.10 (0.04)	(0.03, 0.18)	0.007 *
		Placebo	139	135 (97.1)	0.05 (0.03)	(-0.00, 0.10)			
	Week 16	Tezepelumab	128	125 (97.7)	0.15 (0.03)	(0.09, 0.21)	0.09 (0.04)	(0.02, 0.17)	0.019 *
		Placebo	139	136 (97.8)	0.06 (0.03)	(0.00, 0.11)			
	Week 24	Tezepelumab	128	120 (93.8)	0.14 (0.03)	(0.08, 0.19)	0.08 (0.04)	(0.00, 0.15)	0.047 *
		Placebo	139	133 (95.7)	0.06 (0.03)	(0.01, 0.11)			
	Week 36	Tezepelumab	128	118 (92.2)	0.11 (0.03)	(0.05, 0.17)	0.03 (0.04)	(-0.05, 0.12)	0.486
		Placebo	139	126 (90.6)	0.08 (0.03)	(0.02, 0.14)			
	Week 52	Tezepelumab	128	119 (93.0)	0.16 (0.03)	(0.10, 0.22)	0.11 (0.04)	(0.03, 0.20)	0.009 *
		Placebo	139	123 (88.5)	0.05 (0.03)	(-0.01, 0.11)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q3: 30 - < 56 ppb	Week 2	Tezepelumab	141	140 (99.3)	0.17 (0.03)	(0.12, 0.23)	0.14 (0.04)	(0.06, 0.22)	<0.001 *
		Placebo	127	124 (97.6)	0.04 (0.03)	(-0.02, 0.09)			
	Week 4	Tezepelumab	141	141 (100.0)	0.21 (0.03)	(0.15, 0.26)	0.12 (0.04)	(0.04, 0.20)	0.003 *
		Placebo	127	122 (96.1)	0.09 (0.03)	(0.03, 0.15)			
	Week 8	Tezepelumab	141	139 (98.6)	0.22 (0.03)	(0.16, 0.28)	0.11 (0.04)	(0.03, 0.20)	0.010 *
		Placebo	127	124 (97.6)	0.11 (0.03)	(0.05, 0.17)			
	Week 12	Tezepelumab	141	138 (97.9)	0.23 (0.03)	(0.16, 0.29)	0.15 (0.05)	(0.06, 0.25)	0.001 *
		Placebo	127	123 (96.9)	0.07 (0.03)	(0.00, 0.14)			
	Week 16	Tezepelumab	141	139 (98.6)	0.23 (0.03)	(0.17, 0.29)	0.17 (0.05)	(0.08, 0.25)	<0.001 *
		Placebo	127	120 (94.5)	0.06 (0.03)	(-0.00, 0.13)			
	Week 24	Tezepelumab	141	135 (95.7)	0.22 (0.03)	(0.15, 0.29)	0.12 (0.05)	(0.02, 0.21)	0.022 *
		Placebo	127	111 (87.4)	0.11 (0.04)	(0.03, 0.18)			
	Week 36	Tezepelumab	141	129 (91.5)	0.25 (0.03)	(0.18, 0.31)	0.17 (0.05)	(0.07, 0.27)	<0.001 *
		Placebo	127	115 (90.6)	0.08 (0.04)	(0.01, 0.15)			
	Week 52	Tezepelumab	141	126 (89.4)	0.25 (0.03)	(0.18, 0.32)	0.18 (0.05)	(0.08, 0.27)	<0.001 *
		Placebo	127	107 (84.3)	0.07 (0.04)	(-0.00, 0.15)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q4: >= 56 ppb	Week 2	Tezepelumab	128	122 (95.3)	0.25 (0.04)	(0.18, 0.32)	0.17 (0.05)	(0.07, 0.26)	<0.001 *
		Placebo	139	134 (96.4)	0.08 (0.03)	(0.02, 0.15)			
	Week 4	Tezepelumab	128	127 (99.2)	0.27 (0.04)	(0.19, 0.35)	0.16 (0.05)	(0.05, 0.26)	0.004 *
		Placebo	139	137 (98.6)	0.11 (0.04)	(0.04, 0.19)			
	Week 8	Tezepelumab	128	125 (97.7)	0.36 (0.04)	(0.28, 0.44)	0.26 (0.06)	(0.15, 0.38)	<0.001 *
		Placebo	139	135 (97.1)	0.10 (0.04)	(0.02, 0.18)			
	Week 12	Tezepelumab	128	124 (96.9)	0.36 (0.04)	(0.27, 0.44)	0.21 (0.06)	(0.10, 0.33)	<0.001 *
		Placebo	139	136 (97.8)	0.15 (0.04)	(0.07, 0.23)			
	Week 16	Tezepelumab	128	120 (93.8)	0.39 (0.04)	(0.31, 0.48)	0.22 (0.06)	(0.11, 0.33)	<0.001 *
		Placebo	139	133 (95.7)	0.18 (0.04)	(0.10, 0.25)			
	Week 24	Tezepelumab	128	118 (92.2)	0.35 (0.04)	(0.27, 0.43)	0.25 (0.05)	(0.14, 0.36)	<0.001 *
		Placebo	139	129 (92.8)	0.10 (0.04)	(0.03, 0.18)			
	Week 36	Tezepelumab	128	117 (91.4)	0.39 (0.04)	(0.30, 0.47)	0.23 (0.06)	(0.12, 0.35)	<0.001 *
		Placebo	139	120 (86.3)	0.15 (0.04)	(0.07, 0.23)			
	Week 52	Tezepelumab	128	110 (85.9)	0.38 (0.04)	(0.30, 0.46)	0.22 (0.06)	(0.11, 0.34)	<0.001 *
		Placebo	139	115 (82.7)	0.15 (0.04)	(0.07, 0.23)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Total serum IgE (cat. N)									0.242
Q1: < 53.1 IU/ml	Week 2	Tezepelumab	129	126 (97.7)	0.11 (0.02)	(0.06, 0.16)	0.09 (0.03)	(0.02, 0.15)	0.013 *
		Placebo	135	127 (94.1)	0.02 (0.02)	(-0.03, 0.07)			
	Week 4	Tezepelumab	129	129 (100.0)	0.14 (0.03)	(0.08, 0.19)	0.06 (0.04)	(-0.02, 0.14)	0.120
		Placebo	135	130 (96.3)	0.08 (0.03)	(0.02, 0.13)			
	Week 8	Tezepelumab	129	126 (97.7)	0.16 (0.03)	(0.11, 0.22)	0.09 (0.04)	(0.02, 0.17)	0.017 *
		Placebo	135	132 (97.8)	0.07 (0.03)	(0.02, 0.13)			
	Week 12	Tezepelumab	129	126 (97.7)	0.15 (0.03)	(0.10, 0.21)	0.08 (0.04)	(0.00, 0.16)	0.041 *
		Placebo	135	130 (96.3)	0.07 (0.03)	(0.01, 0.12)			
	Week 16	Tezepelumab	129	127 (98.4)	0.16 (0.03)	(0.11, 0.22)	0.09 (0.04)	(0.02, 0.17)	0.017 *
		Placebo	135	129 (95.6)	0.07 (0.03)	(0.02, 0.12)			
	Week 24	Tezepelumab	129	125 (96.9)	0.14 (0.03)	(0.09, 0.19)	0.12 (0.04)	(0.04, 0.19)	0.002 *
		Placebo	135	121 (89.6)	0.02 (0.03)	(-0.03, 0.07)			
	Week 36	Tezepelumab	129	120 (93.0)	0.13 (0.03)	(0.07, 0.18)	0.05 (0.04)	(-0.03, 0.13)	0.188
		Placebo	135	113 (83.7)	0.08 (0.03)	(0.02, 0.13)			
	Week 52	Tezepelumab	129	121 (93.8)	0.14 (0.03)	(0.08, 0.20)	0.11 (0.04)	(0.02, 0.20)	0.012 *
		Placebo	135	112 (83.0)	0.03 (0.03)	(-0.03, 0.09)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q2: 53.1 - < 195.6 IU/ml	Week 2	Tezepelumab	136	134 (98.5)	0.16 (0.03)	(0.11, 0.21)	0.12 (0.04)	(0.05, 0.19)	0.001 *
		Placebo	129	124 (96.1)	0.04 (0.03)	(-0.01, 0.09)			
	Week 4	Tezepelumab	136	133 (97.8)	0.21 (0.03)	(0.16, 0.27)	0.15 (0.04)	(0.07, 0.24)	<0.001 *
		Placebo	129	128 (99.2)	0.06 (0.03)	(0.00, 0.12)			
	Week 8	Tezepelumab	136	132 (97.1)	0.22 (0.03)	(0.16, 0.27)	0.14 (0.04)	(0.06, 0.22)	<0.001 *
		Placebo	129	127 (98.4)	0.07 (0.03)	(0.02, 0.13)			
	Week 12	Tezepelumab	136	132 (97.1)	0.24 (0.03)	(0.17, 0.30)	0.17 (0.05)	(0.08, 0.26)	<0.001 *
		Placebo	129	127 (98.4)	0.07 (0.03)	(0.00, 0.13)			
	Week 16	Tezepelumab	136	130 (95.6)	0.24 (0.03)	(0.18, 0.31)	0.15 (0.05)	(0.06, 0.25)	0.001 *
		Placebo	129	123 (95.3)	0.09 (0.03)	(0.02, 0.16)			
	Week 24	Tezepelumab	136	129 (94.9)	0.24 (0.03)	(0.18, 0.30)	0.16 (0.04)	(0.07, 0.25)	<0.001 *
		Placebo	129	121 (93.8)	0.08 (0.03)	(0.02, 0.15)			
	Week 36	Tezepelumab	136	127 (93.4)	0.24 (0.03)	(0.18, 0.31)	0.14 (0.05)	(0.05, 0.23)	0.003 *
		Placebo	129	119 (92.2)	0.11 (0.03)	(0.04, 0.17)			
	Week 52	Tezepelumab	136	118 (86.8)	0.24 (0.03)	(0.18, 0.31)	0.14 (0.05)	(0.05, 0.23)	0.003 *
		Placebo	129	112 (86.8)	0.10 (0.03)	(0.04, 0.17)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q3: 195.6 - < 572.4 IU/ml	Week 2	Tezepelumab	139	135 (97.1)	0.21 (0.03)	(0.15, 0.27)	0.20 (0.05)	(0.12, 0.29)	<0.001 *
		Placebo	126	118 (93.7)	0.00 (0.03)	(-0.06, 0.07)			
	Week 4	Tezepelumab	139	138 (99.3)	0.18 (0.03)	(0.12, 0.24)	0.11 (0.04)	(0.03, 0.20)	0.010 *
		Placebo	126	119 (94.4)	0.06 (0.03)	(0.00, 0.13)			
	Week 8	Tezepelumab	139	137 (98.6)	0.23 (0.03)	(0.16, 0.29)	0.15 (0.05)	(0.05, 0.24)	0.003 *
		Placebo	126	122 (96.8)	0.08 (0.04)	(0.01, 0.15)			
	Week 12	Tezepelumab	139	133 (95.7)	0.25 (0.04)	(0.18, 0.33)	0.16 (0.05)	(0.05, 0.26)	0.003 *
		Placebo	126	121 (96.0)	0.10 (0.04)	(0.02, 0.17)			
	Week 16	Tezepelumab	139	134 (96.4)	0.26 (0.04)	(0.19, 0.33)	0.19 (0.05)	(0.09, 0.29)	<0.001 *
		Placebo	126	123 (97.6)	0.06 (0.04)	(-0.01, 0.14)			
	Week 24	Tezepelumab	139	127 (91.4)	0.21 (0.04)	(0.14, 0.28)	0.13 (0.05)	(0.02, 0.23)	0.016 *
		Placebo	126	116 (92.1)	0.09 (0.04)	(0.01, 0.16)			
	Week 36	Tezepelumab	139	122 (87.8)	0.24 (0.04)	(0.17, 0.31)	0.15 (0.05)	(0.05, 0.25)	0.005 *
		Placebo	126	111 (88.1)	0.09 (0.04)	(0.02, 0.17)			
	Week 52	Tezepelumab	139	123 (88.5)	0.27 (0.04)	(0.19, 0.34)	0.13 (0.06)	(0.02, 0.24)	0.025 *
		Placebo	126	107 (84.9)	0.14 (0.04)	(0.06, 0.22)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q4: >= 572.4 IU/ml	Week 2	Tezepelumab	124	119 (96.0)	0.19 (0.03)	(0.12, 0.25)	0.04 (0.05)	(-0.05, 0.13)	0.375
		Placebo	141	138 (97.9)	0.14 (0.03)	(0.08, 0.21)			
	Week 4	Tezepelumab	124	123 (99.2)	0.22 (0.04)	(0.14, 0.30)	0.08 (0.05)	(-0.02, 0.19)	0.119
		Placebo	141	139 (98.6)	0.14 (0.04)	(0.07, 0.21)			
	Week 8	Tezepelumab	124	123 (99.2)	0.24 (0.04)	(0.16, 0.33)	0.10 (0.06)	(-0.02, 0.22)	0.091
		Placebo	141	136 (96.5)	0.14 (0.04)	(0.06, 0.22)			
	Week 12	Tezepelumab	124	119 (96.0)	0.24 (0.04)	(0.16, 0.31)	0.09 (0.05)	(-0.02, 0.20)	0.103
		Placebo	141	136 (96.5)	0.15 (0.04)	(0.07, 0.22)			
	Week 16	Tezepelumab	124	119 (96.0)	0.24 (0.04)	(0.16, 0.32)	0.09 (0.06)	(-0.02, 0.20)	0.107
		Placebo	141	134 (95.0)	0.15 (0.04)	(0.08, 0.23)			
	Week 24	Tezepelumab	124	117 (94.4)	0.23 (0.04)	(0.15, 0.32)	0.10 (0.06)	(-0.02, 0.21)	0.098
		Placebo	141	133 (94.3)	0.14 (0.04)	(0.06, 0.21)			
	Week 36	Tezepelumab	124	114 (91.9)	0.27 (0.04)	(0.18, 0.36)	0.12 (0.06)	(0.00, 0.24)	0.045 *
		Placebo	141	132 (93.6)	0.15 (0.04)	(0.06, 0.23)			
	Week 52	Tezepelumab	124	109 (87.9)	0.27 (0.04)	(0.19, 0.35)	0.15 (0.06)	(0.04, 0.26)	0.007 *
		Placebo	141	122 (86.5)	0.12 (0.04)	(0.04, 0.19)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Nasal polyps last 2 years									0.871
Yes	Week 2	Tezepelumab	42	41 (97.6)	0.19 (0.05)	(0.09, 0.29)	0.12 (0.07)	(-0.03, 0.27)	0.103
		Placebo	41	41 (100.0)	0.07 (0.05)	(-0.03, 0.17)			
	Week 4	Tezepelumab	42	42 (100.0)	0.23 (0.06)	(0.10, 0.36)	0.09 (0.09)	(-0.09, 0.28)	0.301
		Placebo	41	40 (97.6)	0.14 (0.06)	(0.01, 0.26)			
	Week 8	Tezepelumab	42	42 (100.0)	0.31 (0.07)	(0.17, 0.45)	0.18 (0.10)	(-0.03, 0.38)	0.087
		Placebo	41	41 (100.0)	0.13 (0.07)	(-0.01, 0.28)			
	Week 12	Tezepelumab	42	39 (92.9)	0.30 (0.07)	(0.15, 0.44)	0.15 (0.10)	(-0.06, 0.35)	0.156
		Placebo	41	41 (100.0)	0.15 (0.07)	(0.01, 0.29)			
	Week 16	Tezepelumab	42	40 (95.2)	0.30 (0.07)	(0.16, 0.45)	0.14 (0.10)	(-0.07, 0.34)	0.193
		Placebo	41	40 (97.6)	0.17 (0.07)	(0.02, 0.31)			
	Week 24	Tezepelumab	42	39 (92.9)	0.21 (0.07)	(0.07, 0.35)	0.04 (0.10)	(-0.16, 0.24)	0.669
		Placebo	41	39 (95.1)	0.17 (0.07)	(0.03, 0.31)			
	Week 36	Tezepelumab	42	39 (92.9)	0.30 (0.06)	(0.17, 0.43)	0.08 (0.09)	(-0.10, 0.26)	0.365
		Placebo	41	38 (92.7)	0.22 (0.06)	(0.09, 0.35)			
	Week 52	Tezepelumab	42	38 (90.5)	0.31 (0.08)	(0.15, 0.46)	0.19 (0.11)	(-0.03, 0.41)	0.090
		Placebo	41	38 (92.7)	0.12 (0.08)	(-0.03, 0.27)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 2	Tezepelumab	486	473 (97.3)	0.16 (0.02)	(0.13, 0.19)	0.11 (0.02)	(0.07, 0.15)	<0.001 *
		Placebo	490	466 (95.1)	0.05 (0.02)	(0.02, 0.08)			
	Week 4	Tezepelumab	486	481 (99.0)	0.18 (0.02)	(0.15, 0.22)	0.10 (0.02)	(0.06, 0.15)	<0.001 *
		Placebo	490	476 (97.1)	0.08 (0.02)	(0.05, 0.11)			
	Week 8	Tezepelumab	486	476 (97.9)	0.21 (0.02)	(0.17, 0.24)	0.12 (0.02)	(0.07, 0.16)	<0.001 *
		Placebo	490	476 (97.1)	0.09 (0.02)	(0.06, 0.12)			
	Week 12	Tezepelumab	486	471 (96.9)	0.21 (0.02)	(0.18, 0.25)	0.12 (0.03)	(0.07, 0.17)	<0.001 *
		Placebo	490	473 (96.5)	0.09 (0.02)	(0.06, 0.13)			
	Week 16	Tezepelumab	486	470 (96.7)	0.22 (0.02)	(0.19, 0.26)	0.13 (0.02)	(0.08, 0.18)	<0.001 *
		Placebo	490	469 (95.7)	0.09 (0.02)	(0.05, 0.12)			
	Week 24	Tezepelumab	486	459 (94.4)	0.21 (0.02)	(0.17, 0.24)	0.13 (0.02)	(0.08, 0.18)	<0.001 *
		Placebo	490	452 (92.2)	0.08 (0.02)	(0.04, 0.11)			
	Week 36	Tezepelumab	486	444 (91.4)	0.21 (0.02)	(0.18, 0.25)	0.12 (0.03)	(0.07, 0.17)	<0.001 *
		Placebo	490	437 (89.2)	0.10 (0.02)	(0.06, 0.13)			
	Week 52	Tezepelumab	486	433 (89.1)	0.22 (0.02)	(0.19, 0.26)	0.13 (0.03)	(0.08, 0.18)	<0.001 *
		Placebo	490	415 (84.7)	0.09 (0.02)	(0.06, 0.13)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOMH0: Course of FEV1 Pre-BD
DITT - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
FEV1 Pre-BD	Baseline	Tezepelumab	41	41 (100.0)	2.68 (0.64)	1.4	2.20	2.78	3.06	4.1	
		Placebo	41	41 (100.0)	2.69 (0.77)	1.0	2.16	2.70	3.09	4.9	
	Week 2	Tezepelumab	41	40 (97.6)	2.82 (0.58)	1.7	2.42	2.82	3.20	4.0	
		Placebo	41	39 (95.1)	2.74 (0.62)	1.3	2.31	2.71	3.09	4.7	
	Week 4	Tezepelumab	41	40 (97.6)	2.75 (0.65)	1.3	2.27	2.75	3.19	4.0	
		Placebo	41	38 (92.7)	2.70 (0.58)	1.3	2.42	2.62	3.14	4.0	
	Week 8	Tezepelumab	41	40 (97.6)	2.73 (0.72)	1.0	2.26	2.80	3.28	3.9	
		Placebo	41	39 (95.1)	2.72 (0.67)	1.2	2.31	2.69	3.15	4.9	
	Week 12	Tezepelumab	41	37 (90.2)	2.76 (0.73)	0.8	2.21	2.81	3.34	4.0	
		Placebo	41	39 (95.1)	2.74 (0.71)	1.4	2.34	2.75	3.07	5.0	
	Week 16	Tezepelumab	41	39 (95.1)	2.78 (0.62)	1.5	2.28	2.86	3.24	3.9	
		Placebo	41	40 (97.6)	2.75 (0.68)	1.5	2.43	2.60	3.17	5.2	
	Week 24	Tezepelumab	41	38 (92.7)	2.80 (0.61)	1.6	2.32	2.89	3.23	3.9	
		Placebo	41	38 (92.7)	2.78 (0.68)	1.5	2.38	2.69	3.15	5.1	
	Week 36	Tezepelumab	41	37 (90.2)	2.89 (0.55)	1.4	2.47	2.93	3.26	4.0	
		Placebo	41	35 (85.4)	2.87 (0.82)	1.4	2.40	2.90	3.34	5.3	
	Week 52	Tezepelumab	41	34 (82.9)	2.99 (0.60)	1.9	2.47	3.05	3.44	4.2	
		Placebo	41	35 (85.4)	2.92 (0.76)	1.2	2.47	2.86	3.41	5.3	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOMH0: Course of FEV1 Pre-BD
DITT - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in FEV1 Pre-BD	Week 2	Tezepelumab	41	40 (97.6)	0.15 (0.36)	-0.5	-0.02	0.08	0.34	1.4	0.22 [-0.23, 0.66]
		Placebo	41	39 (95.1)	0.05 (0.48)	-1.3	-0.12	0.03	0.20	1.7	
	Week 4	Tezepelumab	41	40 (97.6)	0.09 (0.40)	-1.2	-0.15	0.06	0.33	1.2	0.00 [-0.44, 0.45]
		Placebo	41	38 (92.7)	0.08 (0.53)	-1.0	-0.19	-0.04	0.22	1.7	
	Week 8	Tezepelumab	41	40 (97.6)	0.07 (0.44)	-1.1	-0.18	0.10	0.28	1.6	0.04 [-0.40, 0.48]
		Placebo	41	39 (95.1)	0.05 (0.57)	-1.7	-0.20	0.01	0.14	2.0	
	Week 12	Tezepelumab	41	37 (90.2)	0.09 (0.49)	-1.5	-0.12	0.15	0.30	1.5	0.03 [-0.42, 0.48]
		Placebo	41	39 (95.1)	0.08 (0.57)	-1.2	-0.22	0.02	0.26	1.6	
	Week 16	Tezepelumab	41	39 (95.1)	0.13 (0.37)	-0.5	-0.12	0.10	0.36	1.4	0.08 [-0.36, 0.52]
		Placebo	41	40 (97.6)	0.09 (0.55)	-1.6	-0.15	0.04	0.21	1.6	
	Week 24	Tezepelumab	41	38 (92.7)	0.12 (0.42)	-0.8	-0.10	0.12	0.27	1.8	0.13 [-0.33, 0.58]
		Placebo	41	38 (92.7)	0.06 (0.52)	-1.4	-0.14	0.00	0.23	1.5	
	Week 36	Tezepelumab	41	37 (90.2)	0.22 (0.42)	-0.6	-0.02	0.23	0.40	1.7	0.08 [-0.38, 0.54]
		Placebo	41	35 (85.4)	0.17 (0.67)	-1.7	-0.09	0.15	0.42	2.2	
	Week 52	Tezepelumab	41	34 (82.9)	0.32 (0.41)	-0.6	0.02	0.39	0.59	1.3	0.25 [-0.22, 0.73]
		Placebo	41	35 (85.4)	0.19 (0.55)	-1.4	-0.02	0.23	0.38	1.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOMC0: Change from baseline in FEV1 Pre-BD - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Tezepelumab	41	40 (97.6)	0.15 (0.06)	(0.04, 0.26)	0.10 (0.08)	(-0.06, 0.26)	0.213
	Placebo	41	39 (95.1)	0.05 (0.06)	(-0.06, 0.16)			
Week 4	Tezepelumab	41	40 (97.6)	0.09 (0.07)	(-0.04, 0.22)	0.02 (0.09)	(-0.17, 0.20)	0.865
	Placebo	41	38 (92.7)	0.07 (0.07)	(-0.06, 0.21)			
Week 8	Tezepelumab	41	40 (97.6)	0.07 (0.07)	(-0.07, 0.22)	0.04 (0.10)	(-0.17, 0.24)	0.726
	Placebo	41	39 (95.1)	0.04 (0.07)	(-0.11, 0.18)			
Week 12	Tezepelumab	41	37 (90.2)	0.12 (0.08)	(-0.04, 0.27)	0.05 (0.11)	(-0.17, 0.27)	0.640
	Placebo	41	39 (95.1)	0.06 (0.08)	(-0.09, 0.22)			
Week 16	Tezepelumab	41	39 (95.1)	0.14 (0.07)	(0.00, 0.27)	0.06 (0.09)	(-0.13, 0.24)	0.551
	Placebo	41	40 (97.6)	0.08 (0.07)	(-0.05, 0.21)			
Week 24	Tezepelumab	41	38 (92.7)	0.14 (0.07)	(-0.00, 0.28)	0.03 (0.10)	(-0.17, 0.23)	0.737
	Placebo	41	38 (92.7)	0.10 (0.07)	(-0.04, 0.24)			
Week 36	Tezepelumab	41	37 (90.2)	0.23 (0.08)	(0.07, 0.39)	0.09 (0.11)	(-0.14, 0.31)	0.450
	Placebo	41	35 (85.4)	0.14 (0.08)	(-0.02, 0.30)			
Week 52	Tezepelumab	41	34 (82.9)	0.33 (0.07)	(0.18, 0.47)	0.15 (0.10)	(-0.05, 0.35)	0.129
	Placebo	41	35 (85.4)	0.17 (0.07)	(0.03, 0.31)			

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Figure NF2FAC_KOMG0: Course of FEV1 Pre-BD
DITT - adolescents



Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source table: NT2FAC_KOMH0
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Absolute values	Baseline	Tezepelumab	20	20 (100.0)	2.77 (0.68)	1.4	2.25	2.88	3.16	3.9	
			Placebo	18	18 (100.0)	2.79 (0.92)	1.0	2.24	2.86	3.15	4.9	
		Week 2	Tezepelumab	20	19 (95.0)	2.91 (0.71)	1.7	2.29	2.98	3.36	4.0	
			Placebo	18	18 (100.0)	2.82 (0.63)	1.3	2.60	2.75	3.11	4.7	
		Week 4	Tezepelumab	20	19 (95.0)	2.84 (0.76)	1.3	2.36	2.94	3.45	4.0	
			Placebo	18	16 (88.9)	2.80 (0.59)	1.4	2.59	2.69	3.13	4.0	
		Week 8	Tezepelumab	20	19 (95.0)	2.84 (0.84)	1.0	1.96	3.20	3.43	3.7	
			Placebo	18	17 (94.4)	2.92 (0.72)	1.5	2.52	2.84	3.28	4.9	
		Week 12	Tezepelumab	20	18 (90.0)	2.93 (0.86)	0.8	2.51	3.19	3.51	4.0	
			Placebo	18	17 (94.4)	2.96 (0.81)	1.4	2.49	2.90	3.38	5.0	
		Week 16	Tezepelumab	20	18 (90.0)	2.91 (0.74)	1.5	2.41	3.16	3.39	3.9	
			Placebo	18	17 (94.4)	2.97 (0.81)	1.5	2.52	2.67	3.34	5.2	
		Week 24	Tezepelumab	20	17 (85.0)	2.98 (0.69)	1.7	2.70	3.16	3.51	3.9	
			Placebo	18	15 (83.3)	3.01 (0.82)	1.5	2.61	3.05	3.33	5.1	
		Week 36	Tezepelumab	20	16 (80.0)	3.06 (0.66)	1.4	2.66	3.19	3.55	4.0	
			Placebo	18	15 (83.3)	3.23 (0.82)	1.4	2.81	3.22	3.54	5.3	
		Week 52	Tezepelumab	20	13 (65.0)	3.25 (0.65)	1.9	3.08	3.29	3.60	4.2	
			Placebo	18	14 (77.8)	3.16 (0.89)	1.5	2.67	3.05	3.65	5.3	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Change from baseline	Week 2	Tezepelumab	20	19 (95.0)	0.14 (0.37)	-0.5	0.00	0.07	0.26	1.4	0.21 [-0.44, 0.85]
			Placebo	18	18 (100.0)	0.03 (0.67)	-1.3	-0.19	-0.07	0.04	1.7	
		Week 4	Tezepelumab	20	19 (95.0)	0.09 (0.33)	-0.3	-0.12	0.07	0.15	1.2	-0.19 [-0.85, 0.48]
			Placebo	18	16 (88.9)	0.19 (0.69)	-1.0	-0.19	-0.04	0.56	1.7	
		Week 8	Tezepelumab	20	19 (95.0)	0.09 (0.52)	-1.1	-0.17	0.11	0.24	1.6	-0.12 [-0.78, 0.53]
			Placebo	18	17 (94.4)	0.17 (0.79)	-1.7	-0.13	0.09	0.32	2.0	
		Week 12	Tezepelumab	20	18 (90.0)	0.19 (0.46)	-0.6	-0.01	0.19	0.32	1.5	-0.04 [-0.71, 0.62]
			Placebo	18	17 (94.4)	0.21 (0.74)	-1.0	-0.24	0.01	0.40	1.6	
		Week 16	Tezepelumab	20	18 (90.0)	0.19 (0.37)	-0.2	0.00	0.12	0.24	1.4	-0.06 [-0.72, 0.61]
			Placebo	18	17 (94.4)	0.22 (0.76)	-1.6	-0.09	0.08	0.34	1.6	
		Week 24	Tezepelumab	20	17 (85.0)	0.19 (0.48)	-0.5	0.06	0.12	0.25	1.8	0.14 [-0.55, 0.84]
			Placebo	18	15 (83.3)	0.11 (0.69)	-1.4	-0.26	0.07	0.35	1.5	
		Week 36	Tezepelumab	20	16 (80.0)	0.29 (0.49)	-0.5	0.04	0.23	0.40	1.7	-0.26 [-0.97, 0.45]
			Placebo	18	15 (83.3)	0.45 (0.79)	-1.2	0.00	0.31	0.96	2.2	
		Week 52	Tezepelumab	20	13 (65.0)	0.45 (0.42)	-0.4	0.15	0.42	0.59	1.3	0.15 [-0.61, 0.91]
			Placebo	18	14 (77.8)	0.36 (0.77)	-1.4	-0.01	0.32	0.63	1.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Absolute values	Baseline	Tezepelumab	21	21 (100.0)	2.59 (0.60)	1.4	2.14	2.39	2.94	4.1	
			Placebo	23	23 (100.0)	2.60 (0.65)	1.3	2.11	2.57	3.08	4.1	
		Week 2	Tezepelumab	21	21 (100.0)	2.74 (0.44)	2.1	2.43	2.59	3.06	3.7	
			Placebo	23	21 (91.3)	2.67 (0.62)	1.7	2.25	2.61	3.04	4.2	
		Week 4	Tezepelumab	21	21 (100.0)	2.67 (0.53)	1.8	2.22	2.67	3.06	3.8	
			Placebo	23	22 (95.7)	2.63 (0.59)	1.3	2.32	2.55	3.14	3.8	
		Week 8	Tezepelumab	21	21 (100.0)	2.63 (0.60)	1.0	2.36	2.58	2.93	3.9	
			Placebo	23	22 (95.7)	2.58 (0.61)	1.2	2.20	2.61	3.02	3.8	
		Week 12	Tezepelumab	21	19 (90.5)	2.60 (0.56)	1.4	2.16	2.57	3.06	3.6	
			Placebo	23	22 (95.7)	2.58 (0.59)	1.5	2.21	2.55	2.96	3.9	
		Week 16	Tezepelumab	21	21 (100.0)	2.66 (0.49)	1.9	2.28	2.51	2.94	3.8	
			Placebo	23	23 (100.0)	2.59 (0.53)	1.6	2.26	2.59	3.03	3.7	
		Week 24	Tezepelumab	21	21 (100.0)	2.65 (0.50)	1.6	2.27	2.60	2.95	3.8	
			Placebo	23	23 (100.0)	2.64 (0.55)	1.7	2.19	2.60	3.11	4.0	
		Week 36	Tezepelumab	21	21 (100.0)	2.75 (0.42)	2.2	2.46	2.71	2.99	3.7	
			Placebo	23	20 (87.0)	2.60 (0.73)	1.4	2.28	2.63	3.04	3.8	
		Week 52	Tezepelumab	21	21 (100.0)	2.82 (0.51)	2.2	2.37	2.80	3.24	4.0	
			Placebo	23	21 (91.3)	2.75 (0.64)	1.2	2.43	2.72	3.09	3.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Change from baseline	Week 2	Tezepelumab	21	21 (100.0)	0.15 (0.37)	-0.5	-0.04	0.16	0.41	0.8	0.24 [-0.36, 0.85]
			Placebo	23	21 (91.3)	0.08 (0.25)	-0.5	-0.04	0.09	0.21	0.6	
		Week 4	Tezepelumab	21	21 (100.0)	0.08 (0.46)	-1.2	-0.18	-0.01	0.39	1.0	0.17 [-0.43, 0.77]
			Placebo	23	22 (95.7)	0.01 (0.38)	-0.8	-0.19	-0.05	0.22	1.0	
		Week 8	Tezepelumab	21	21 (100.0)	0.04 (0.36)	-0.8	-0.19	0.04	0.38	0.6	0.28 [-0.32, 0.88]
			Placebo	23	22 (95.7)	-0.05 (0.30)	-0.8	-0.22	-0.04	0.05	0.7	
		Week 12	Tezepelumab	21	19 (90.5)	0.01 (0.50)	-1.5	-0.17	0.01	0.27	0.8	0.07 [-0.55, 0.68]
			Placebo	23	22 (95.7)	-0.02 (0.38)	-1.2	-0.22	0.04	0.25	0.4	
		Week 16	Tezepelumab	21	21 (100.0)	0.07 (0.37)	-0.5	-0.17	-0.02	0.36	0.8	0.25 [-0.34, 0.84]
			Placebo	23	23 (100.0)	-0.01 (0.30)	-0.7	-0.19	0.00	0.20	0.6	
		Week 24	Tezepelumab	21	21 (100.0)	0.07 (0.38)	-0.8	-0.16	0.09	0.34	0.8	0.09 [-0.51, 0.68]
			Placebo	23	23 (100.0)	0.03 (0.38)	-1.1	-0.14	-0.01	0.22	0.7	
		Week 36	Tezepelumab	21	21 (100.0)	0.16 (0.36)	-0.6	-0.12	0.23	0.42	0.8	0.48 [-0.14, 1.10]
			Placebo	23	20 (87.0)	-0.04 (0.48)	-1.7	-0.17	0.03	0.18	0.6	
		Week 52	Tezepelumab	21	21 (100.0)	0.24 (0.40)	-0.6	-0.10	0.37	0.48	0.9	0.42 [-0.19, 1.03]
			Placebo	23	21 (91.3)	0.09 (0.31)	-0.7	-0.02	0.11	0.31	0.5	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Absolute values	Baseline	Tezepelumab	26	26 (100.0)	2.71 (0.68)	1.4	2.25	2.84	3.08	4.1	
			Placebo	26	26 (100.0)	2.81 (0.65)	1.4	2.43	2.76	3.09	4.9	
		Week 2	Tezepelumab	26	26 (100.0)	2.88 (0.53)	2.0	2.50	2.92	3.16	3.9	
			Placebo	26	24 (92.3)	2.82 (0.60)	1.3	2.54	2.74	3.10	4.7	
		Week 4	Tezepelumab	26	26 (100.0)	2.85 (0.61)	1.7	2.57	2.81	3.19	4.0	
			Placebo	26	23 (88.5)	2.74 (0.58)	1.4	2.50	2.66	3.15	4.0	
		Week 8	Tezepelumab	26	26 (100.0)	2.81 (0.67)	1.0	2.36	2.91	3.30	3.9	
			Placebo	26	24 (92.3)	2.82 (0.66)	1.5	2.35	2.78	3.20	4.9	
		Week 12	Tezepelumab	26	25 (96.2)	2.84 (0.70)	1.4	2.21	3.03	3.43	4.0	
			Placebo	26	24 (92.3)	2.79 (0.77)	1.4	2.31	2.71	3.07	5.0	
		Week 16	Tezepelumab	26	25 (96.2)	2.84 (0.64)	1.6	2.40	2.87	3.30	3.9	
			Placebo	26	25 (96.2)	2.84 (0.74)	1.5	2.49	2.63	3.16	5.2	
		Week 24	Tezepelumab	26	24 (92.3)	2.84 (0.63)	1.6	2.30	2.83	3.28	3.9	
			Placebo	26	24 (92.3)	2.82 (0.75)	1.5	2.29	2.70	3.19	5.1	
		Week 36	Tezepelumab	26	23 (88.5)	2.95 (0.49)	2.2	2.50	2.95	3.26	3.8	
			Placebo	26	21 (80.8)	2.95 (0.88)	1.4	2.56	2.93	3.51	5.3	
		Week 52	Tezepelumab	26	22 (84.6)	3.02 (0.59)	2.2	2.37	3.18	3.45	4.0	
			Placebo	26	21 (80.8)	3.03 (0.78)	1.5	2.69	3.01	3.27	5.3	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Change from baseline	Week 2	Tezepelumab	26	26 (100.0)	0.17 (0.38)	-0.4	-0.04	0.08	0.24	1.4	0.43 [-0.13, 1.00]
			Placebo	26	24 (92.3)	0.00 (0.38)	-0.8	-0.11	-0.02	0.08	1.3	
		Week 4	Tezepelumab	26	26 (100.0)	0.14 (0.35)	-0.3	-0.12	0.07	0.37	1.2	0.32 [-0.24, 0.89]
			Placebo	26	23 (88.5)	0.03 (0.38)	-0.8	-0.12	-0.04	0.22	1.0	
		Week 8	Tezepelumab	26	26 (100.0)	0.10 (0.43)	-0.8	-0.17	0.11	0.25	1.6	0.21 [-0.35, 0.76]
			Placebo	26	24 (92.3)	0.02 (0.40)	-0.8	-0.17	0.02	0.13	1.4	
		Week 12	Tezepelumab	26	25 (96.2)	0.14 (0.54)	-1.5	-0.09	0.17	0.32	1.5	0.24 [-0.32, 0.80]
			Placebo	26	24 (92.3)	0.01 (0.54)	-1.2	-0.24	-0.00	0.15	1.6	
		Week 16	Tezepelumab	26	25 (96.2)	0.14 (0.42)	-0.5	-0.12	0.08	0.36	1.4	0.19 [-0.37, 0.74]
			Placebo	26	25 (96.2)	0.06 (0.45)	-0.7	-0.15	0.01	0.20	1.6	
		Week 24	Tezepelumab	26	24 (92.3)	0.11 (0.48)	-0.8	-0.11	0.09	0.22	1.8	0.17 [-0.40, 0.73]
			Placebo	26	24 (92.3)	0.03 (0.48)	-1.1	-0.13	-0.01	0.20	1.5	
		Week 36	Tezepelumab	26	23 (88.5)	0.22 (0.48)	-0.5	-0.12	0.21	0.42	1.7	0.19 [-0.40, 0.79]
			Placebo	26	21 (80.8)	0.11 (0.60)	-1.7	-0.03	0.14	0.30	1.6	
		Week 52	Tezepelumab	26	22 (84.6)	0.29 (0.45)	-0.6	-0.03	0.34	0.59	1.3	0.20 [-0.40, 0.80]
			Placebo	26	21 (80.8)	0.19 (0.54)	-0.7	-0.01	0.23	0.34	1.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Absolute values	Baseline	Tezepelumab	15	15 (100.0)	2.62 (0.58)	1.4	2.12	2.69	3.03	3.7	
			Placebo	15	15 (100.0)	2.48 (0.94)	1.0	2.06	2.11	3.23	4.1	
		Week 2	Tezepelumab	15	14 (93.3)	2.71 (0.68)	1.7	2.29	2.64	3.24	4.0	
			Placebo	15	15 (100.0)	2.61 (0.65)	1.7	2.22	2.60	2.94	4.2	
		Week 4	Tezepelumab	15	14 (93.3)	2.55 (0.69)	1.3	1.98	2.49	3.16	3.8	
			Placebo	15	15 (100.0)	2.65 (0.61)	1.3	2.32	2.53	3.14	3.8	
		Week 8	Tezepelumab	15	14 (93.3)	2.57 (0.81)	1.0	2.12	2.64	3.23	3.7	
			Placebo	15	15 (100.0)	2.57 (0.68)	1.2	2.14	2.62	3.09	3.8	
		Week 12	Tezepelumab	15	12 (80.0)	2.59 (0.78)	0.8	2.31	2.66	3.23	3.6	
			Placebo	15	15 (100.0)	2.67 (0.61)	1.5	2.34	2.76	3.07	3.9	
		Week 16	Tezepelumab	15	14 (93.3)	2.67 (0.60)	1.5	2.22	2.62	3.23	3.8	
			Placebo	15	15 (100.0)	2.61 (0.56)	1.6	2.31	2.52	3.17	3.7	
		Week 24	Tezepelumab	15	14 (93.3)	2.73 (0.58)	1.7	2.41	2.89	3.16	3.6	
			Placebo	15	14 (93.3)	2.71 (0.58)	1.7	2.38	2.68	3.11	4.0	
		Week 36	Tezepelumab	15	14 (93.3)	2.79 (0.65)	1.4	2.39	2.62	3.34	4.0	
			Placebo	15	14 (93.3)	2.76 (0.74)	1.4	2.34	2.77	3.33	3.8	
		Week 52	Tezepelumab	15	12 (80.0)	2.93 (0.64)	1.9	2.50	2.93	3.33	4.2	
			Placebo	15	14 (93.3)	2.74 (0.74)	1.2	2.27	2.66	3.41	3.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Change from baseline	Week 2	Tezepelumab	15	14 (93.3)	0.11 (0.34)	-0.5	0.00	0.14	0.41	0.5	-0.06 [-0.79, 0.67]
			Placebo	15	15 (100.0)	0.13 (0.62)	-1.3	-0.12	0.14	0.31	1.7	
		Week 4	Tezepelumab	15	14 (93.3)	-0.02 (0.47)	-1.2	-0.19	-0.01	0.15	1.0	-0.32 [-1.06, 0.41]
			Placebo	15	15 (100.0)	0.17 (0.71)	-1.0	-0.24	-0.02	0.40	1.7	
		Week 8	Tezepelumab	15	14 (93.3)	-0.00 (0.45)	-1.1	-0.34	0.04	0.38	0.7	-0.15 [-0.88, 0.58]
			Placebo	15	15 (100.0)	0.09 (0.79)	-1.7	-0.24	-0.06	0.49	2.0	
		Week 12	Tezepelumab	15	12 (80.0)	0.01 (0.36)	-0.6	-0.16	0.01	0.24	0.6	-0.36 [-1.13, 0.40]
			Placebo	15	15 (100.0)	0.20 (0.62)	-1.0	-0.21	0.19	0.41	1.5	
		Week 16	Tezepelumab	15	14 (93.3)	0.09 (0.26)	-0.3	-0.10	0.10	0.23	0.6	-0.07 [-0.79, 0.66]
			Placebo	15	15 (100.0)	0.13 (0.71)	-1.6	-0.19	0.15	0.37	1.6	
		Week 24	Tezepelumab	15	14 (93.3)	0.15 (0.32)	-0.5	-0.06	0.17	0.34	0.8	0.05 [-0.69, 0.79]
			Placebo	15	14 (93.3)	0.13 (0.60)	-1.4	-0.16	0.16	0.54	1.1	
		Week 36	Tezepelumab	15	14 (93.3)	0.21 (0.32)	-0.6	0.00	0.28	0.40	0.8	-0.08 [-0.82, 0.66]
			Placebo	15	14 (93.3)	0.26 (0.77)	-1.2	-0.09	0.20	0.47	2.2	
		Week 52	Tezepelumab	15	12 (80.0)	0.36 (0.36)	-0.3	0.18	0.42	0.56	0.9	0.34 [-0.44, 1.11]
			Placebo	15	14 (93.3)	0.20 (0.59)	-1.4	-0.02	0.26	0.53	1.3	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Absolute values	Baseline	Tezepelumab	28	28 (100.0)	2.82 (0.62)	1.4	2.31	2.87	3.11	4.1	
			Placebo	30	30 (100.0)	2.81 (0.76)	1.0	2.24	2.76	3.23	4.9	
		Week 2	Tezepelumab	28	27 (96.4)	2.93 (0.59)	1.7	2.59	2.98	3.29	4.0	
			Placebo	30	29 (96.7)	2.85 (0.58)	2.2	2.40	2.74	3.09	4.7	
		Week 4	Tezepelumab	28	28 (100.0)	2.88 (0.65)	1.3	2.49	2.92	3.25	4.0	
			Placebo	30	29 (96.7)	2.81 (0.53)	1.7	2.50	2.66	3.15	4.0	
		Week 8	Tezepelumab	28	28 (100.0)	2.87 (0.70)	1.0	2.55	3.01	3.37	3.9	
			Placebo	30	29 (96.7)	2.91 (0.58)	2.0	2.54	2.79	3.15	4.9	
		Week 12	Tezepelumab	28	26 (92.9)	2.90 (0.75)	0.8	2.57	3.04	3.43	4.0	
			Placebo	30	29 (96.7)	2.93 (0.65)	1.7	2.52	2.86	3.07	5.0	
		Week 16	Tezepelumab	28	27 (96.4)	2.93 (0.56)	1.5	2.50	2.87	3.31	3.9	
			Placebo	30	30 (100.0)	2.90 (0.65)	1.8	2.49	2.70	3.21	5.2	
		Week 24	Tezepelumab	28	27 (96.4)	2.91 (0.59)	1.7	2.45	2.95	3.31	3.9	
			Placebo	30	28 (93.3)	3.00 (0.64)	2.1	2.61	2.99	3.28	5.1	
		Week 36	Tezepelumab	28	26 (92.9)	2.96 (0.57)	1.4	2.55	3.04	3.34	4.0	
			Placebo	30	26 (86.7)	3.14 (0.67)	1.9	2.76	3.07	3.54	5.3	
		Week 52	Tezepelumab	28	24 (85.7)	3.13 (0.58)	1.9	2.73	3.23	3.50	4.2	
			Placebo	30	26 (86.7)	3.09 (0.71)	2.1	2.65	3.04	3.46	5.3	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Change from baseline	Week 2	Tezepelumab	28	27 (96.4)	0.11 (0.40)	-0.5	-0.06	0.08	0.26	1.4	0.13 [-0.40, 0.65]
			Placebo	30	29 (96.7)	0.05 (0.54)	-1.3	-0.12	0.00	0.14	1.7	
		Week 4	Tezepelumab	28	28 (100.0)	0.06 (0.44)	-1.2	-0.17	0.02	0.30	1.2	-0.01 [-0.53, 0.51]
			Placebo	30	29 (96.7)	0.07 (0.56)	-1.0	-0.24	-0.07	0.22	1.7	
		Week 8	Tezepelumab	28	28 (100.0)	0.05 (0.49)	-1.1	-0.20	0.07	0.28	1.6	-0.03 [-0.55, 0.49]
			Placebo	30	29 (96.7)	0.07 (0.64)	-1.7	-0.20	-0.06	0.17	2.0	
		Week 12	Tezepelumab	28	26 (92.9)	0.05 (0.55)	-1.5	-0.17	0.03	0.27	1.5	-0.10 [-0.63, 0.43]
			Placebo	30	29 (96.7)	0.11 (0.61)	-1.0	-0.23	0.02	0.26	1.6	
		Week 16	Tezepelumab	28	27 (96.4)	0.13 (0.39)	-0.5	-0.12	0.10	0.35	1.4	0.07 [-0.45, 0.59]
			Placebo	30	30 (100.0)	0.09 (0.61)	-1.6	-0.19	0.00	0.22	1.6	
		Week 24	Tezepelumab	28	27 (96.4)	0.10 (0.48)	-0.8	-0.21	0.12	0.34	1.8	0.02 [-0.51, 0.55]
			Placebo	30	28 (93.3)	0.09 (0.54)	-1.4	-0.15	-0.00	0.30	1.5	
		Week 36	Tezepelumab	28	26 (92.9)	0.16 (0.45)	-0.6	-0.13	0.22	0.40	1.7	-0.17 [-0.72, 0.37]
			Placebo	30	26 (86.7)	0.26 (0.67)	-1.2	-0.09	0.18	0.43	2.2	
		Week 52	Tezepelumab	28	24 (85.7)	0.31 (0.45)	-0.6	-0.04	0.40	0.53	1.3	0.15 [-0.40, 0.71]
			Placebo	30	26 (86.7)	0.23 (0.61)	-1.4	-0.02	0.24	0.38	1.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	2.63 (0.58)	2.0	1.98	2.84	3.08	3.1	
			Placebo	4	4 (100.0)	2.05 (0.84)	1.3	1.37	1.93	2.73	3.1	
		Week 2	Tezepelumab	3	3 (100.0)	2.88 (0.29)	2.6	2.58	2.91	3.16	3.2	
			Placebo	4	4 (100.0)	2.25 (0.61)	1.7	1.76	2.13	2.75	3.0	
		Week 4	Tezepelumab	3	3 (100.0)	2.93 (0.45)	2.7	2.66	2.68	3.45	3.5	
			Placebo	4	4 (100.0)	2.18 (0.61)	1.3	1.78	2.43	2.57	2.6	
		Week 8	Tezepelumab	3	3 (100.0)	2.97 (0.42)	2.6	2.56	2.95	3.39	3.4	
			Placebo	4	4 (100.0)	1.82 (0.61)	1.2	1.29	1.83	2.35	2.4	
		Week 12	Tezepelumab	3	3 (100.0)	2.99 (0.58)	2.4	2.37	3.08	3.51	3.5	
			Placebo	4	4 (100.0)	1.82 (0.30)	1.5	1.59	1.81	2.06	2.2	
		Week 16	Tezepelumab	3	3 (100.0)	3.05 (0.62)	2.4	2.40	3.10	3.64	3.6	
			Placebo	4	4 (100.0)	2.11 (0.47)	1.6	1.73	2.15	2.50	2.6	
		Week 24	Tezepelumab	3	3 (100.0)	3.08 (0.54)	2.7	2.66	2.90	3.69	3.7	
			Placebo	4	4 (100.0)	2.00 (0.28)	1.7	1.82	1.97	2.19	2.4	
		Week 36	Tezepelumab	3	3 (100.0)	3.18 (0.54)	2.7	2.72	3.05	3.77	3.8	
			Placebo	4	4 (100.0)	1.64 (0.51)	1.4	1.38	1.39	1.90	2.4	
		Week 52	Tezepelumab	3	2 (66.7)	3.24 (0.62)	2.8	2.80	3.24	3.67	3.7	
			Placebo	4	3 (75.0)	2.13 (0.85)	1.2	1.15	2.51	2.72	2.7	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Change from baseline	Week 2	Tezepelumab	3	3 (100.0)	0.25 (0.30)	0.1	0.07	0.08	0.60	0.6	0.17 [-1.33, 1.67]
			Placebo	4	4 (100.0)	0.21 (0.24)	-0.1	0.01	0.21	0.40	0.5	
		Week 4	Tezepelumab	3	3 (100.0)	0.30 (0.42)	-0.2	-0.16	0.37	0.68	0.7	0.29 [-1.22, 1.80]
			Placebo	4	4 (100.0)	0.13 (0.66)	-0.5	-0.35	0.00	0.60	1.0	
		Week 8	Tezepelumab	3	3 (100.0)	0.33 (0.24)	0.1	0.11	0.31	0.58	0.6	1.66 [-0.15, 3.48]
			Placebo	4	4 (100.0)	-0.23 (0.39)	-0.8	-0.51	-0.11	0.05	0.1	
		Week 12	Tezepelumab	3	3 (100.0)	0.35 (0.10)	0.2	0.24	0.39	0.43	0.4	1.11 [-0.54, 2.76]
			Placebo	4	4 (100.0)	-0.23 (0.67)	-1.2	-0.67	-0.08	0.22	0.4	
		Week 16	Tezepelumab	3	3 (100.0)	0.41 (0.15)	0.3	0.26	0.42	0.56	0.6	0.81 [-0.77, 2.39]
			Placebo	4	4 (100.0)	0.07 (0.54)	-0.7	-0.29	0.15	0.42	0.6	
		Week 24	Tezepelumab	3	3 (100.0)	0.45 (0.34)	0.1	0.06	0.61	0.68	0.7	0.80 [-0.78, 2.37]
			Placebo	4	4 (100.0)	-0.05 (0.75)	-1.1	-0.55	0.11	0.46	0.7	
		Week 36	Tezepelumab	3	3 (100.0)	0.55 (0.29)	0.2	0.21	0.69	0.74	0.7	1.39 [-0.34, 3.12]
			Placebo	4	4 (100.0)	-0.41 (0.85)	-1.7	-0.89	-0.04	0.07	0.1	
		Week 52	Tezepelumab	3	2 (66.7)	0.70 (0.16)	0.6	0.59	0.70	0.82	0.8	2.14 [-0.34, 4.61]
			Placebo	4	3 (75.0)	-0.11 (0.46)	-0.6	-0.57	-0.11	0.34	0.3	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Absolute values	Baseline	Tezepelumab	8	8 (100.0)	2.19 (0.57)	1.4	1.75	2.17	2.58	3.1	
			Placebo	6	6 (100.0)	2.41 (0.71)	1.4	2.10	2.36	2.70	3.6	
		Week 2	Tezepelumab	8	8 (100.0)	2.34 (0.39)	2.0	2.07	2.25	2.46	3.2	
			Placebo	6	5 (83.3)	2.37 (0.72)	1.3	1.93	2.71	2.74	3.1	
		Week 4	Tezepelumab	8	8 (100.0)	2.24 (0.49)	1.7	1.89	2.14	2.47	3.2	
			Placebo	6	4 (66.7)	2.28 (0.59)	1.4	1.88	2.48	2.68	2.7	
		Week 8	Tezepelumab	8	8 (100.0)	2.16 (0.69)	1.0	1.91	2.10	2.52	3.3	
			Placebo	6	5 (83.3)	2.27 (0.50)	1.5	2.14	2.20	2.62	2.8	
		Week 12	Tezepelumab	8	7 (87.5)	2.24 (0.48)	2.0	2.01	2.07	2.21	3.3	
			Placebo	6	5 (83.3)	2.27 (0.52)	1.4	2.21	2.29	2.66	2.8	
		Week 16	Tezepelumab	8	8 (100.0)	2.18 (0.52)	1.6	1.85	2.01	2.45	3.2	
			Placebo	6	5 (83.3)	2.24 (0.45)	1.5	2.23	2.31	2.55	2.6	
		Week 24	Tezepelumab	8	7 (87.5)	2.32 (0.53)	1.6	1.95	2.27	2.70	3.3	
			Placebo	6	5 (83.3)	2.23 (0.47)	1.5	2.19	2.25	2.58	2.7	
		Week 36	Tezepelumab	8	7 (87.5)	2.49 (0.37)	2.2	2.25	2.31	2.77	3.2	
			Placebo	6	4 (66.7)	2.25 (0.62)	1.4	1.80	2.46	2.70	2.7	
		Week 52	Tezepelumab	8	7 (87.5)	2.47 (0.44)	2.2	2.17	2.23	2.93	3.3	
			Placebo	6	5 (83.3)	2.33 (0.53)	1.5	2.21	2.43	2.69	2.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Change from baseline	Week 2	Tezepelumab	8	8 (100.0)	0.15 (0.31)	-0.1	-0.05	0.04	0.25	0.8	0.81 [-0.36, 1.98]
			Placebo	6	5 (83.3)	-0.09 (0.24)	-0.4	-0.17	-0.07	0.04	0.2	
		Week 4	Tezepelumab	8	8 (100.0)	0.04 (0.19)	-0.3	-0.05	0.07	0.10	0.4	-0.32 [-1.53, 0.89]
			Placebo	6	4 (66.7)	0.10 (0.14)	-0.1	-0.02	0.12	0.22	0.2	
		Week 8	Tezepelumab	8	8 (100.0)	-0.03 (0.24)	-0.5	-0.21	0.07	0.14	0.2	-0.58 [-1.73, 0.56]
			Placebo	6	5 (83.3)	0.08 (0.07)	-0.0	0.04	0.12	0.13	0.1	
		Week 12	Tezepelumab	8	7 (87.5)	0.13 (0.30)	-0.2	-0.16	0.15	0.32	0.6	0.18 [-0.97, 1.33]
			Placebo	6	5 (83.3)	0.08 (0.13)	-0.0	-0.01	0.03	0.19	0.3	
		Week 16	Tezepelumab	8	8 (100.0)	-0.01 (0.30)	-0.4	-0.18	-0.06	0.10	0.6	-0.26 [-1.38, 0.86]
			Placebo	6	5 (83.3)	0.05 (0.14)	-0.2	0.01	0.08	0.12	0.2	
		Week 24	Tezepelumab	8	7 (87.5)	0.05 (0.11)	-0.1	-0.08	0.09	0.12	0.2	-0.00 [-1.15, 1.15]
			Placebo	6	5 (83.3)	0.05 (0.12)	-0.1	-0.03	0.07	0.15	0.2	
		Week 36	Tezepelumab	8	7 (87.5)	0.22 (0.31)	-0.1	-0.01	0.21	0.35	0.8	0.26 [-0.98, 1.49]
			Placebo	6	4 (66.7)	0.14 (0.31)	-0.0	-0.02	0.00	0.30	0.6	
		Week 52	Tezepelumab	8	7 (87.5)	0.20 (0.28)	-0.1	-0.03	0.15	0.31	0.7	0.20 [-0.95, 1.36]
			Placebo	6	5 (83.3)	0.15 (0.18)	-0.0	-0.01	0.08	0.33	0.4	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Absolute values	Baseline	Tezepelumab	2	2 (100.0)	2.68 (0.76)	2.1	2.14	2.68	3.22	3.2	
			Placebo	1	1 (100.0)	3.00	3.0	3.00	3.00	3.00	3.0	
		Week 2	Tezepelumab	2	2 (100.0)	3.10 (0.85)	2.5	2.50	3.10	3.70	3.7	
			Placebo	1	1 (100.0)	3.16	3.2	3.16	3.16	3.16	3.2	
		Week 4	Tezepelumab	2	1 (50.0)	2.57	2.6	2.57	2.57	2.57	2.6	
			Placebo	1	1 (100.0)	3.34	3.3	3.34	3.34	3.34	3.3	
		Week 8	Tezepelumab	2	1 (50.0)	2.58	2.6	2.58	2.58	2.58	2.6	
			Placebo	1	1 (100.0)	3.32	3.3	3.32	3.32	3.32	3.3	
		Week 12	Tezepelumab	2	1 (50.0)	2.30	2.3	2.30	2.30	2.30	2.3	
			Placebo	1	1 (100.0)	3.40	3.4	3.40	3.40	3.40	3.4	
		Week 16	Tezepelumab	2	1 (50.0)	2.50	2.5	2.50	2.50	2.50	2.5	
			Placebo	1	1 (100.0)	3.34	3.3	3.34	3.34	3.34	3.3	
		Week 24	Tezepelumab	2	1 (50.0)	2.32	2.3	2.32	2.32	2.32	2.3	
			Placebo	1	1 (100.0)	2.74	2.7	2.74	2.74	2.74	2.7	
		Week 36	Tezepelumab	2	1 (50.0)	2.71	2.7	2.71	2.71	2.71	2.7	
			Placebo	1	1 (100.0)	3.30	3.3	3.30	3.30	3.30	3.3	
		Week 52	Tezepelumab	2	1 (50.0)	2.79	2.8	2.79	2.79	2.79	2.8	
			Placebo	1	1 (100.0)	3.56	3.6	3.56	3.56	3.56	3.6	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Change from baseline	Week 2	Tezepelumab	2	2 (100.0)	0.42 (0.08)	0.4	0.36	0.42	0.48	0.5	NE
			Placebo	1	1 (100.0)	0.16	0.2	0.16	0.16	0.16	0.2	
		Week 4	Tezepelumab	2	1 (50.0)	0.43	0.4	0.43	0.43	0.43	0.4	NE
			Placebo	1	1 (100.0)	0.34	0.3	0.34	0.34	0.34	0.3	
		Week 8	Tezepelumab	2	1 (50.0)	0.44	0.4	0.44	0.44	0.44	0.4	NE
			Placebo	1	1 (100.0)	0.32	0.3	0.32	0.32	0.32	0.3	
		Week 12	Tezepelumab	2	1 (50.0)	0.16	0.2	0.16	0.16	0.16	0.2	NE
			Placebo	1	1 (100.0)	0.40	0.4	0.40	0.40	0.40	0.4	
		Week 16	Tezepelumab	2	1 (50.0)	0.36	0.4	0.36	0.36	0.36	0.4	NE
			Placebo	1	1 (100.0)	0.34	0.3	0.34	0.34	0.34	0.3	
		Week 24	Tezepelumab	2	1 (50.0)	0.18	0.2	0.18	0.18	0.18	0.2	NE
			Placebo	1	1 (100.0)	-0.26	-0.3	-0.26	-0.26	-0.26	-0.3	
		Week 36	Tezepelumab	2	1 (50.0)	0.57	0.6	0.57	0.57	0.57	0.6	NE
			Placebo	1	1 (100.0)	0.30	0.3	0.30	0.30	0.30	0.3	
		Week 52	Tezepelumab	2	1 (50.0)	0.65	0.7	0.65	0.65	0.65	0.7	NE
			Placebo	1	1 (100.0)	0.56	0.6	0.56	0.56	0.56	0.6	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	3.18	3.2	3.18	3.18	3.18	3.2	
			Placebo	1	1 (100.0)	2.11	2.1	2.11	2.11	2.11	2.1	
		Week 2	Tezepelumab	1	1 (100.0)	3.26	3.3	3.26	3.26	3.26	3.3	
			Placebo	1	1 (100.0)	2.37	2.4	2.37	2.37	2.37	2.4	
		Week 4	Tezepelumab	1	1 (100.0)	3.51	3.5	3.51	3.51	3.51	3.5	
			Placebo	1	1 (100.0)	2.09	2.1	2.09	2.09	2.09	2.1	
		Week 8	Tezepelumab	1	1 (100.0)	3.43	3.4	3.43	3.43	3.43	3.4	
			Placebo	1	1 (100.0)	2.76	2.8	2.76	2.76	2.76	2.8	
		Week 12	Tezepelumab	1	1 (100.0)	3.48	3.5	3.48	3.48	3.48	3.5	
			Placebo	1	1 (100.0)	2.52	2.5	2.52	2.52	2.52	2.5	
		Week 16	Placebo	1	1 (100.0)	2.48	2.5	2.48	2.48	2.48	2.5	
		Week 24	Placebo	1	1 (100.0)	2.71	2.7	2.71	2.71	2.71	2.7	
		Week 52	Placebo	1	1 (100.0)	2.14	2.1	2.14	2.14	2.14	2.1	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Change from baseline	Week 2	Tezepelumab	1	1 (100.0)	0.08	0.1	0.08	0.08	0.08	0.1	NE
			Placebo	1	1 (100.0)	0.26	0.3	0.26	0.26	0.26	0.3	
		Week 4	Tezepelumab	1	1 (100.0)	0.33	0.3	0.33	0.33	0.33	0.3	NE
			Placebo	1	1 (100.0)	-0.02	-0.0	-0.02	-0.02	-0.02	-0.0	
		Week 8	Tezepelumab	1	1 (100.0)	0.25	0.3	0.25	0.25	0.25	0.3	NE
			Placebo	1	1 (100.0)	0.65	0.7	0.65	0.65	0.65	0.7	
		Week 12	Tezepelumab	1	1 (100.0)	0.30	0.3	0.30	0.30	0.30	0.3	NE
			Placebo	1	1 (100.0)	0.41	0.4	0.41	0.41	0.41	0.4	
		Week 16	Placebo	1	1 (100.0)	0.37	0.4	0.37	0.37	0.37	0.4	
		Week 24	Placebo	1	1 (100.0)	0.60	0.6	0.60	0.60	0.60	0.6	
		Week 52	Placebo	1	1 (100.0)	0.03	0.0	0.03	0.03	0.03	0.0	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Absolute values	Baseline	Tezepelumab	28	28 (100.0)	2.71 (0.57)	1.4	2.23	2.85	3.05	3.9	
			Placebo	29	29 (100.0)	2.77 (0.82)	1.0	2.24	2.74	3.23	4.9	
		Week 2	Tezepelumab	28	28 (100.0)	2.87 (0.56)	1.7	2.53	2.92	3.20	4.0	
			Placebo	29	28 (96.6)	2.83 (0.61)	1.7	2.44	2.72	3.03	4.7	
		Week 4	Tezepelumab	28	27 (96.4)	2.78 (0.61)	1.3	2.36	2.81	3.19	4.0	
			Placebo	29	28 (96.6)	2.80 (0.52)	1.7	2.50	2.63	3.15	4.0	
		Week 8	Tezepelumab	28	27 (96.4)	2.75 (0.67)	1.0	2.42	2.81	3.23	3.7	
			Placebo	29	28 (96.6)	2.83 (0.65)	1.4	2.40	2.73	3.20	4.9	
		Week 12	Tezepelumab	28	25 (89.3)	2.77 (0.73)	0.8	2.51	2.87	3.29	4.0	
			Placebo	29	29 (100.0)	2.83 (0.72)	1.7	2.44	2.84	3.07	5.0	
		Week 16	Tezepelumab	28	27 (96.4)	2.83 (0.55)	1.5	2.41	2.86	3.24	3.8	
			Placebo	29	29 (100.0)	2.85 (0.69)	1.8	2.46	2.63	3.21	5.2	
		Week 24	Tezepelumab	28	27 (96.4)	2.83 (0.56)	1.7	2.41	2.90	3.23	3.7	
			Placebo	29	27 (93.1)	2.91 (0.70)	2.0	2.38	2.76	3.33	5.1	
		Week 36	Tezepelumab	28	26 (92.9)	2.91 (0.57)	1.4	2.50	2.97	3.30	4.0	
			Placebo	29	26 (89.7)	3.01 (0.83)	1.4	2.55	2.95	3.54	5.3	
		Week 52	Tezepelumab	28	23 (82.1)	3.02 (0.56)	1.9	2.53	3.12	3.44	4.2	
			Placebo	29	25 (86.2)	3.02 (0.81)	1.2	2.63	3.01	3.46	5.3	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Change from baseline	Week 2	Tezepelumab	28	28 (100.0)	0.16 (0.39)	-0.5	-0.02	0.08	0.37	1.4	0.17 [-0.35, 0.69]
			Placebo	29	28 (96.6)	0.07 (0.55)	-1.3	-0.11	0.01	0.17	1.7	
		Week 4	Tezepelumab	28	27 (96.4)	0.09 (0.45)	-1.2	-0.15	0.06	0.32	1.2	-0.03 [-0.56, 0.49]
			Placebo	29	28 (96.6)	0.11 (0.60)	-1.0	-0.21	-0.06	0.35	1.7	
		Week 8	Tezepelumab	28	27 (96.4)	0.06 (0.49)	-1.1	-0.13	0.09	0.31	1.6	0.04 [-0.49, 0.57]
			Placebo	29	28 (96.6)	0.04 (0.65)	-1.7	-0.21	-0.04	0.09	2.0	
		Week 12	Tezepelumab	28	25 (89.3)	0.06 (0.55)	-1.5	-0.12	0.02	0.26	1.5	-0.00 [-0.54, 0.53]
			Placebo	29	29 (100.0)	0.06 (0.66)	-1.2	-0.24	0.01	0.26	1.6	
		Week 16	Tezepelumab	28	27 (96.4)	0.14 (0.38)	-0.5	-0.12	0.10	0.35	1.4	0.10 [-0.42, 0.63]
			Placebo	29	29 (100.0)	0.08 (0.64)	-1.6	-0.21	0.00	0.22	1.6	
		Week 24	Tezepelumab	28	27 (96.4)	0.14 (0.49)	-0.8	-0.16	0.12	0.34	1.8	0.15 [-0.38, 0.69]
			Placebo	29	27 (93.1)	0.06 (0.60)	-1.4	-0.26	-0.01	0.35	1.5	
		Week 36	Tezepelumab	28	26 (92.9)	0.23 (0.42)	-0.6	-0.02	0.24	0.40	1.7	0.04 [-0.51, 0.58]
			Placebo	29	26 (89.7)	0.20 (0.76)	-1.7	-0.04	0.18	0.43	2.2	
		Week 52	Tezepelumab	28	23 (82.1)	0.34 (0.45)	-0.6	0.02	0.41	0.59	1.3	0.24 [-0.33, 0.81]
			Placebo	29	25 (86.2)	0.21 (0.64)	-1.4	-0.11	0.25	0.38	1.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Absolute values	Baseline	Tezepelumab	4	4 (100.0)	2.30 (0.70)	1.4	1.85	2.32	2.75	3.1	
			Placebo	4	4 (100.0)	2.18 (0.57)	1.4	1.76	2.30	2.60	2.7	
		Week 2	Tezepelumab	4	4 (100.0)	2.49 (0.45)	2.2	2.25	2.27	2.72	3.2	
			Placebo	4	4 (100.0)	2.18 (0.67)	1.3	1.64	2.32	2.73	2.7	
		Week 4	Tezepelumab	4	4 (100.0)	2.33 (0.60)	1.8	1.96	2.16	2.71	3.2	
			Placebo	4	4 (100.0)	2.28 (0.59)	1.4	1.88	2.48	2.68	2.7	
		Week 8	Tezepelumab	4	4 (100.0)	2.12 (0.95)	1.0	1.52	2.11	2.73	3.3	
			Placebo	4	4 (100.0)	2.29 (0.58)	1.5	1.84	2.38	2.73	2.8	
		Week 12	Tezepelumab	4	4 (100.0)	2.40 (0.61)	2.0	2.05	2.14	2.76	3.3	
			Placebo	4	4 (100.0)	2.29 (0.60)	1.4	1.87	2.48	2.71	2.8	
		Week 16	Tezepelumab	4	4 (100.0)	2.36 (0.58)	1.9	1.99	2.14	2.73	3.2	
			Placebo	4	4 (100.0)	2.24 (0.52)	1.5	1.90	2.43	2.59	2.6	
		Week 24	Tezepelumab	4	4 (100.0)	2.35 (0.68)	1.6	1.94	2.27	2.76	3.3	
			Placebo	4	4 (100.0)	2.24 (0.54)	1.5	1.87	2.42	2.62	2.7	
		Week 36	Tezepelumab	4	4 (100.0)	2.54 (0.45)	2.3	2.25	2.36	2.84	3.2	
			Placebo	4	3 (75.0)	2.26 (0.76)	1.4	1.38	2.70	2.70	2.7	
		Week 52	Tezepelumab	4	4 (100.0)	2.47 (0.53)	2.2	2.20	2.23	2.75	3.3	
			Placebo	4	4 (100.0)	2.37 (0.61)	1.5	1.96	2.56	2.77	2.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Change from baseline	Week 2	Tezepelumab	4	4 (100.0)	0.19 (0.42)	-0.1	-0.05	0.02	0.42	0.8	0.58 [-0.84, 2.01]
			Placebo	4	4 (100.0)	0.00 (0.16)	-0.2	-0.12	-0.01	0.13	0.2	
		Week 4	Tezepelumab	4	4 (100.0)	0.04 (0.27)	-0.3	-0.15	0.01	0.23	0.4	-0.30 [-1.69, 1.10]
			Placebo	4	4 (100.0)	0.10 (0.14)	-0.1	-0.02	0.12	0.22	0.2	
		Week 8	Tezepelumab	4	4 (100.0)	-0.18 (0.26)	-0.5	-0.34	-0.21	-0.01	0.2	-1.51 [-3.14, 0.11]
			Placebo	4	4 (100.0)	0.11 (0.05)	0.0	0.08	0.13	0.13	0.1	
		Week 12	Tezepelumab	4	4 (100.0)	0.10 (0.40)	-0.2	-0.20	0.00	0.41	0.6	-0.02 [-1.40, 1.37]
			Placebo	4	4 (100.0)	0.11 (0.14)	-0.0	-0.01	0.11	0.22	0.3	
		Week 16	Tezepelumab	4	4 (100.0)	0.06 (0.42)	-0.4	-0.22	0.03	0.34	0.6	-0.02 [-1.41, 1.36]
			Placebo	4	4 (100.0)	0.06 (0.15)	-0.2	-0.04	0.10	0.17	0.2	
		Week 24	Tezepelumab	4	4 (100.0)	0.05 (0.12)	-0.1	-0.04	0.07	0.15	0.2	-0.10 [-1.49, 1.29]
			Placebo	4	4 (100.0)	0.07 (0.13)	-0.1	-0.03	0.11	0.16	0.2	
		Week 36	Tezepelumab	4	4 (100.0)	0.25 (0.41)	-0.1	-0.02	0.14	0.52	0.8	0.14 [-1.36, 1.64]
			Placebo	4	3 (75.0)	0.19 (0.36)	-0.0	-0.03	0.00	0.60	0.6	
		Week 52	Tezepelumab	4	4 (100.0)	0.18 (0.40)	-0.1	-0.09	0.06	0.44	0.7	-0.04 [-1.43, 1.35]
			Placebo	4	4 (100.0)	0.19 (0.18)	-0.0	0.03	0.21	0.34	0.4	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Absolute values	Baseline	Tezepelumab	8	8 (100.0)	2.68 (0.88)	1.6	2.00	2.59	3.26	4.1	
			Placebo	7	7 (100.0)	2.71 (0.69)	1.5	2.22	2.96	3.15	3.6	
		Week 2	Tezepelumab	8	7 (87.5)	2.77 (0.75)	2.0	2.01	2.63	3.74	3.9	
			Placebo	7	6 (85.7)	2.76 (0.59)	1.8	2.25	3.10	3.15	3.2	
		Week 4	Tezepelumab	8	8 (100.0)	2.74 (0.77)	1.7	2.22	2.64	3.31	3.9	
			Placebo	7	5 (71.4)	2.59 (0.83)	1.3	2.30	2.88	3.15	3.3	
		Week 8	Tezepelumab	8	8 (100.0)	2.86 (0.75)	1.9	2.27	2.79	3.50	3.9	
			Placebo	7	6 (85.7)	2.52 (0.80)	1.2	2.17	2.63	3.15	3.3	
		Week 12	Tezepelumab	8	7 (87.5)	2.84 (0.82)	2.0	2.01	2.66	3.62	4.0	
			Placebo	7	5 (71.4)	2.65 (0.78)	1.5	2.21	3.06	3.07	3.4	
		Week 16	Tezepelumab	8	8 (100.0)	2.81 (0.85)	1.6	2.13	2.76	3.58	3.9	
			Placebo	7	6 (85.7)	2.66 (0.67)	1.6	2.23	2.83	3.16	3.3	
		Week 24	Tezepelumab	8	7 (87.5)	2.93 (0.72)	2.0	2.32	2.76	3.79	3.9	
			Placebo	7	6 (85.7)	2.59 (0.58)	1.7	2.19	2.64	3.15	3.2	
		Week 36	Tezepelumab	8	7 (87.5)	2.99 (0.52)	2.2	2.71	2.79	3.55	3.7	
			Placebo	7	6 (85.7)	2.60 (0.72)	1.4	2.22	2.80	3.10	3.3	
		Week 52	Tezepelumab	8	7 (87.5)	3.16 (0.67)	2.2	2.79	2.93	3.82	4.0	
			Placebo	7	5 (71.4)	2.97 (0.52)	2.2	2.71	3.09	3.27	3.6	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Change from baseline	Week 2	Tezepelumab	8	7 (87.5)	0.10 (0.28)	-0.4	-0.14	0.15	0.36	0.4	0.47 [-0.64, 1.58]
			Placebo	7	6 (85.7)	-0.04 (0.31)	-0.4	-0.40	0.06	0.16	0.3	
		Week 4	Tezepelumab	8	8 (100.0)	0.05 (0.28)	-0.3	-0.19	0.09	0.25	0.4	0.38 [-0.75, 1.51]
			Placebo	7	5 (71.4)	-0.06 (0.30)	-0.4	-0.27	-0.19	0.19	0.3	
		Week 8	Tezepelumab	8	8 (100.0)	0.18 (0.29)	-0.2	-0.04	0.16	0.38	0.7	0.80 [-0.31, 1.90]
			Placebo	7	6 (85.7)	-0.05 (0.29)	-0.5	-0.24	-0.05	0.19	0.3	
		Week 12	Tezepelumab	8	7 (87.5)	0.17 (0.34)	-0.5	0.15	0.25	0.32	0.6	0.31 [-0.85, 1.46]
			Placebo	7	5 (71.4)	0.09 (0.19)	-0.1	-0.01	0.02	0.11	0.4	
		Week 16	Tezepelumab	8	8 (100.0)	0.12 (0.35)	-0.4	-0.18	0.14	0.41	0.6	0.14 [-0.92, 1.20]
			Placebo	7	6 (85.7)	0.08 (0.16)	-0.1	-0.05	0.05	0.20	0.3	
		Week 24	Tezepelumab	8	7 (87.5)	0.10 (0.26)	-0.3	-0.08	0.12	0.37	0.4	0.39 [-0.72, 1.49]
			Placebo	7	6 (85.7)	0.01 (0.20)	-0.3	-0.12	-0.02	0.22	0.3	
		Week 36	Tezepelumab	8	7 (87.5)	0.16 (0.49)	-0.5	-0.47	0.35	0.57	0.8	0.36 [-0.74, 1.46]
			Placebo	7	6 (85.7)	0.03 (0.16)	-0.1	-0.09	-0.04	0.14	0.3	
		Week 52	Tezepelumab	8	7 (87.5)	0.33 (0.32)	-0.1	0.08	0.31	0.65	0.8	0.53 [-0.64, 1.70]
			Placebo	7	5 (71.4)	0.17 (0.26)	-0.1	-0.01	0.06	0.31	0.6	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
< 18.5 kg/m**2	Absolute values	Baseline	Tezepelumab	7	7 (100.0)	2.41 (0.57)	1.4	2.08	2.37	2.91	3.1	
			Placebo	7	7 (100.0)	2.93 (0.58)	2.2	2.44	2.97	3.15	4.0	
		Week 2	Tezepelumab	7	7 (100.0)	2.46 (0.52)	1.7	2.13	2.28	2.98	3.2	
			Placebo	7	7 (100.0)	2.81 (0.32)	2.3	2.62	2.76	3.15	3.2	
		Week 4	Tezepelumab	7	7 (100.0)	2.40 (0.67)	1.3	2.10	2.22	3.19	3.2	
			Placebo	7	7 (100.0)	2.69 (0.60)	1.7	2.17	2.88	3.18	3.3	
		Week 8	Tezepelumab	7	7 (100.0)	2.36 (0.77)	1.0	2.07	2.15	3.15	3.3	
			Placebo	7	7 (100.0)	2.68 (0.39)	2.3	2.35	2.52	3.06	3.3	
		Week 12	Tezepelumab	7	7 (100.0)	2.37 (0.90)	0.8	2.02	2.21	3.30	3.4	
			Placebo	7	7 (100.0)	2.68 (0.61)	1.7	2.00	2.90	3.07	3.4	
		Week 16	Tezepelumab	7	7 (100.0)	2.36 (0.60)	1.5	1.94	2.24	2.87	3.2	
			Placebo	7	7 (100.0)	2.66 (0.52)	1.8	2.44	2.49	3.06	3.3	
		Week 24	Tezepelumab	7	7 (100.0)	2.52 (0.56)	1.7	2.18	2.27	3.05	3.3	
			Placebo	7	6 (85.7)	2.80 (0.41)	2.1	2.61	2.90	3.14	3.2	
		Week 36	Tezepelumab	7	6 (85.7)	2.46 (0.64)	1.4	2.25	2.39	3.08	3.2	
			Placebo	7	5 (71.4)	3.12 (0.30)	2.8	2.90	3.04	3.30	3.5	
		Week 52	Tezepelumab	7	6 (85.7)	2.49 (0.55)	1.9	2.22	2.27	3.08	3.3	
			Placebo	7	5 (71.4)	3.09 (0.33)	2.7	2.93	3.09	3.22	3.6	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
< 18.5 kg/m**2	Change from baseline	Week 2	Tezepelumab	7	7 (100.0)	0.05 (0.11)	-0.1	0.00	0.05	0.07	0.3	0.42 [-0.65, 1.48]
			Placebo	7	7 (100.0)	-0.12 (0.57)	-1.3	-0.27	0.00	0.16	0.6	
		Week 4	Tezepelumab	7	7 (100.0)	-0.01 (0.18)	-0.3	-0.15	-0.04	0.10	0.3	0.61 [-0.47, 1.69]
			Placebo	7	7 (100.0)	-0.24 (0.49)	-1.0	-0.79	-0.11	0.21	0.3	
		Week 8	Tezepelumab	7	7 (100.0)	-0.05 (0.23)	-0.4	-0.22	0.02	0.17	0.2	0.40 [-0.66, 1.46]
			Placebo	7	7 (100.0)	-0.25 (0.68)	-1.7	-0.45	-0.09	0.17	0.3	
		Week 12	Tezepelumab	7	7 (100.0)	-0.04 (0.36)	-0.6	-0.24	0.02	0.17	0.5	0.51 [-0.56, 1.57]
			Placebo	7	7 (100.0)	-0.26 (0.48)	-1.0	-0.72	-0.24	0.20	0.4	
		Week 16	Tezepelumab	7	7 (100.0)	-0.05 (0.18)	-0.4	-0.10	-0.02	0.08	0.1	0.46 [-0.60, 1.53]
			Placebo	7	7 (100.0)	-0.28 (0.66)	-1.6	-0.65	-0.09	0.22	0.3	
		Week 24	Tezepelumab	7	7 (100.0)	0.11 (0.12)	-0.1	0.01	0.12	0.21	0.3	0.82 [-0.32, 1.97]
			Placebo	7	6 (85.7)	-0.25 (0.63)	-1.4	-0.34	-0.13	0.17	0.3	
		Week 36	Tezepelumab	7	6 (85.7)	0.13 (0.18)	-0.1	0.00	0.14	0.23	0.4	0.38 [-0.82, 1.58]
			Placebo	7	5 (71.4)	-0.05 (0.70)	-1.2	-0.11	0.20	0.30	0.6	
		Week 52	Tezepelumab	7	6 (85.7)	0.17 (0.23)	-0.1	-0.03	0.19	0.39	0.4	0.46 [-0.75, 1.67]
			Placebo	7	5 (71.4)	-0.08 (0.75)	-1.4	-0.06	0.23	0.25	0.6	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Absolute values	Baseline	Tezepelumab	20	20 (100.0)	2.84 (0.72)	1.4	2.32	2.87	3.17	4.1	
			Placebo	26	26 (100.0)	2.56 (0.79)	1.0	2.10	2.54	3.02	4.9	
		Week 2	Tezepelumab	20	20 (100.0)	2.99 (0.62)	1.7	2.61	3.03	3.33	4.0	
			Placebo	26	25 (96.2)	2.66 (0.66)	1.3	2.30	2.60	2.99	4.7	
		Week 4	Tezepelumab	20	20 (100.0)	2.92 (0.70)	1.7	2.59	2.86	3.48	4.0	
			Placebo	26	24 (92.3)	2.63 (0.60)	1.3	2.41	2.58	2.90	4.0	
		Week 8	Tezepelumab	20	20 (100.0)	2.85 (0.81)	1.0	2.63	2.94	3.48	3.9	
			Placebo	26	25 (96.2)	2.73 (0.73)	1.2	2.30	2.62	3.15	4.9	
		Week 12	Tezepelumab	20	19 (95.0)	2.94 (0.75)	1.4	2.57	3.06	3.51	4.0	
			Placebo	26	25 (96.2)	2.76 (0.74)	1.4	2.41	2.66	2.96	5.0	
		Week 16	Tezepelumab	20	19 (95.0)	3.00 (0.62)	1.8	2.50	3.06	3.64	3.9	
			Placebo	26	26 (100.0)	2.76 (0.75)	1.5	2.36	2.60	3.21	5.2	
		Week 24	Tezepelumab	20	18 (90.0)	2.93 (0.70)	1.6	2.45	2.93	3.59	3.9	
			Placebo	26	25 (96.2)	2.78 (0.75)	1.5	2.38	2.66	3.22	5.1	
		Week 36	Tezepelumab	20	18 (90.0)	3.06 (0.52)	2.3	2.67	3.02	3.55	4.0	
			Placebo	26	23 (88.5)	2.89 (0.88)	1.4	2.34	2.72	3.51	5.3	
		Week 52	Tezepelumab	20	16 (80.0)	3.21 (0.58)	2.2	2.83	3.27	3.61	4.2	
			Placebo	26	23 (88.5)	2.96 (0.80)	1.5	2.43	2.85	3.46	5.3	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Change from baseline	Week 2	Tezepelumab	20	20 (100.0)	0.15 (0.47)	-0.5	-0.17	0.09	0.34	1.4	0.13 [-0.46, 0.72]
			Placebo	26	25 (96.2)	0.08 (0.49)	-0.8	-0.12	0.04	0.20	1.7	
		Week 4	Tezepelumab	20	20 (100.0)	0.08 (0.47)	-1.2	-0.17	0.09	0.35	1.2	-0.15 [-0.74, 0.45]
			Placebo	26	24 (92.3)	0.15 (0.46)	-0.4	-0.17	0.04	0.28	1.7	
		Week 8	Tezepelumab	20	20 (100.0)	0.01 (0.55)	-1.1	-0.29	0.07	0.28	1.6	-0.26 [-0.85, 0.33]
			Placebo	26	25 (96.2)	0.15 (0.53)	-0.5	-0.12	0.03	0.14	2.0	
		Week 12	Tezepelumab	20	19 (95.0)	0.10 (0.62)	-1.5	-0.12	0.19	0.32	1.5	-0.17 [-0.77, 0.43]
			Placebo	26	25 (96.2)	0.20 (0.52)	-0.4	-0.04	0.09	0.26	1.6	
		Week 16	Tezepelumab	20	19 (95.0)	0.18 (0.46)	-0.5	-0.21	0.12	0.47	1.4	-0.03 [-0.63, 0.56]
			Placebo	26	26 (100.0)	0.20 (0.48)	-0.4	-0.07	0.09	0.21	1.6	
		Week 24	Tezepelumab	20	18 (90.0)	0.04 (0.55)	-0.8	-0.35	0.02	0.18	1.8	-0.22 [-0.83, 0.38]
			Placebo	26	25 (96.2)	0.15 (0.42)	-0.7	-0.06	0.13	0.23	1.5	
		Week 36	Tezepelumab	20	18 (90.0)	0.17 (0.54)	-0.6	-0.17	0.20	0.40	1.7	-0.25 [-0.87, 0.37]
			Placebo	26	23 (88.5)	0.32 (0.58)	-0.4	-0.03	0.15	0.43	2.2	
		Week 52	Tezepelumab	20	16 (80.0)	0.28 (0.51)	-0.6	-0.13	0.38	0.59	1.3	-0.17 [-0.81, 0.47]
			Placebo	26	23 (88.5)	0.36 (0.48)	-0.4	0.03	0.31	0.38	1.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	2.53 (0.50)	1.9	2.14	2.33	3.01	3.2	
			Placebo	7	7 (100.0)	2.85 (0.94)	1.3	2.06	2.94	3.55	4.1	
		Week 2	Tezepelumab	9	8 (88.9)	2.67 (0.53)	2.0	2.36	2.49	2.98	3.7	
			Placebo	7	6 (85.7)	2.93 (0.78)	1.7	2.74	2.91	3.11	4.2	
		Week 4	Tezepelumab	9	8 (88.9)	2.45 (0.44)	1.9	2.14	2.42	2.76	3.2	
			Placebo	7	6 (85.7)	3.03 (0.54)	2.3	2.66	3.01	3.46	3.8	
		Week 8	Tezepelumab	9	8 (88.9)	2.64 (0.58)	2.0	2.16	2.50	3.22	3.4	
			Placebo	7	6 (85.7)	2.83 (0.80)	1.4	2.76	3.01	3.09	3.8	
		Week 12	Tezepelumab	9	8 (88.9)	2.59 (0.46)	2.0	2.23	2.53	2.93	3.4	
			Placebo	7	6 (85.7)	2.91 (0.75)	1.7	2.56	2.99	3.38	3.9	
		Week 16	Tezepelumab	9	8 (88.9)	2.66 (0.61)	1.6	2.35	2.51	3.27	3.4	
			Placebo	7	6 (85.7)	2.90 (0.61)	1.9	2.63	2.99	3.17	3.7	
		Week 24	Tezepelumab	9	8 (88.9)	2.65 (0.51)	2.0	2.27	2.51	3.19	3.3	
			Placebo	7	6 (85.7)	2.93 (0.68)	2.0	2.52	3.02	3.11	4.0	
		Week 36	Tezepelumab	9	8 (88.9)	2.78 (0.53)	2.2	2.34	2.63	3.30	3.6	
			Placebo	7	6 (85.7)	2.85 (0.81)	1.4	2.76	2.95	3.22	3.8	
		Week 52	Tezepelumab	9	7 (77.8)	2.86 (0.61)	2.2	2.20	2.79	3.57	3.6	
			Placebo	7	6 (85.7)	2.65 (0.95)	1.2	2.09	2.84	3.05	3.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Change from baseline	Week 2	Tezepelumab	9	8 (88.9)	0.18 (0.23)	-0.2	0.03	0.12	0.40	0.5	0.09 [-0.97, 1.15]
			Placebo	7	6 (85.7)	0.15 (0.41)	-0.4	-0.04	0.08	0.48	0.7	
		Week 4	Tezepelumab	9	8 (88.9)	0.01 (0.23)	-0.3	-0.16	0.03	0.13	0.4	-0.57 [-1.66, 0.51]
			Placebo	7	6 (85.7)	0.30 (0.72)	-0.3	-0.12	-0.08	1.02	1.4	
		Week 8	Tezepelumab	9	8 (88.9)	0.20 (0.30)	-0.3	0.06	0.18	0.41	0.7	0.27 [-0.80, 1.33]
			Placebo	7	6 (85.7)	0.10 (0.48)	-0.3	-0.23	0.02	0.09	1.0	
		Week 12	Tezepelumab	9	8 (88.9)	0.15 (0.29)	-0.2	-0.09	0.15	0.36	0.6	-0.06 [-1.12, 1.00]
			Placebo	7	6 (85.7)	0.18 (0.61)	-0.2	-0.22	-0.09	0.42	1.3	
		Week 16	Tezepelumab	9	8 (88.9)	0.22 (0.27)	-0.2	0.03	0.24	0.41	0.6	0.11 [-0.95, 1.17]
			Placebo	7	6 (85.7)	0.17 (0.57)	-0.3	-0.22	-0.07	0.63	1.1	
		Week 24	Tezepelumab	9	8 (88.9)	0.21 (0.20)	-0.1	0.11	0.19	0.32	0.6	0.01 [-1.05, 1.07]
			Placebo	7	6 (85.7)	0.21 (0.53)	-0.3	-0.14	-0.05	0.69	1.1	
		Week 36	Tezepelumab	9	8 (88.9)	0.35 (0.27)	-0.1	0.19	0.38	0.50	0.8	0.53 [-0.54, 1.61]
			Placebo	7	6 (85.7)	0.12 (0.57)	-0.5	-0.25	0.08	0.15	1.2	
		Week 52	Tezepelumab	9	7 (77.8)	0.50 (0.35)	-0.1	0.31	0.54	0.79	0.9	1.51 [0.25, 2.77]
			Placebo	7	6 (85.7)	-0.08 (0.42)	-0.7	-0.22	-0.13	0.11	0.6	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	5	5 (100.0)	2.67 (0.61)	2.0	2.12	2.78	3.03	3.4	
			Placebo	1	1 (100.0)	3.08	3.1	3.08	3.08	3.08	3.1	
		Week 2	Tezepelumab	5	5 (100.0)	2.89 (0.39)	2.6	2.59	2.64	3.24	3.4	
			Placebo	1	1 (100.0)	3.01	3.0	3.01	3.01	3.01	3.0	
		Week 4	Tezepelumab	5	5 (100.0)	3.02 (0.32)	2.7	2.71	3.08	3.29	3.4	
			Placebo	1	1 (100.0)	2.57	2.6	2.57	2.57	2.57	2.6	
		Week 8	Tezepelumab	5	5 (100.0)	2.90 (0.35)	2.5	2.56	2.88	3.20	3.3	
			Placebo	1	1 (100.0)	2.30	2.3	2.30	2.30	2.30	2.3	
		Week 12	Tezepelumab	5	3 (60.0)	3.00 (0.55)	2.4	2.37	3.29	3.34	3.3	
			Placebo	1	1 (100.0)	1.93	1.9	1.93	1.93	1.93	1.9	
		Week 16	Tezepelumab	5	5 (100.0)	2.69 (0.42)	2.2	2.40	2.65	2.86	3.3	
			Placebo	1	1 (100.0)	2.41	2.4	2.41	2.41	2.41	2.4	
		Week 24	Tezepelumab	5	5 (100.0)	2.96 (0.31)	2.7	2.70	2.88	3.19	3.4	
			Placebo	1	1 (100.0)	1.99	2.0	1.99	1.99	1.99	2.0	
		Week 36	Tezepelumab	5	5 (100.0)	2.94 (0.36)	2.6	2.72	2.77	3.30	3.3	
			Placebo	1	1 (100.0)	1.40	1.4	1.40	1.40	1.40	1.4	
		Week 52	Tezepelumab	5	5 (100.0)	3.05 (0.37)	2.6	2.80	2.93	3.44	3.5	
			Placebo	1	1 (100.0)	2.51	2.5	2.51	2.51	2.51	2.5	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Change from baseline	Week 2	Tezepelumab	5	5 (100.0)	0.22 (0.32)	-0.1	-0.04	0.21	0.47	0.6	NE
			Placebo	1	1 (100.0)	-0.07	-0.1	-0.07	-0.07	-0.07	-0.1	
		Week 4	Tezepelumab	5	5 (100.0)	0.35 (0.47)	-0.1	-0.07	0.32	0.68	1.0	NE
			Placebo	1	1 (100.0)	-0.51	-0.5	-0.51	-0.51	-0.51	-0.5	
		Week 8	Tezepelumab	5	5 (100.0)	0.23 (0.28)	-0.1	0.10	0.17	0.42	0.6	NE
			Placebo	1	1 (100.0)	-0.78	-0.8	-0.78	-0.78	-0.78	-0.8	
		Week 12	Tezepelumab	5	3 (60.0)	0.19 (0.25)	-0.1	-0.09	0.26	0.39	0.4	NE
			Placebo	1	1 (100.0)	-1.15	-1.2	-1.15	-1.15	-1.15	-1.2	
		Week 16	Tezepelumab	5	5 (100.0)	0.02 (0.25)	-0.2	-0.13	-0.12	0.10	0.4	NE
			Placebo	1	1 (100.0)	-0.67	-0.7	-0.67	-0.67	-0.67	-0.7	
		Week 24	Tezepelumab	5	5 (100.0)	0.29 (0.45)	-0.2	-0.08	0.34	0.68	0.8	NE
			Placebo	1	1 (100.0)	-1.09	-1.1	-1.09	-1.09	-1.09	-1.1	
		Week 36	Tezepelumab	5	5 (100.0)	0.27 (0.35)	-0.1	-0.01	0.31	0.44	0.7	NE
			Placebo	1	1 (100.0)	-1.68	-1.7	-1.68	-1.68	-1.68	-1.7	
		Week 52	Tezepelumab	5	5 (100.0)	0.38 (0.31)	0.0	0.15	0.41	0.52	0.8	NE
			Placebo	1	1 (100.0)	-0.57	-0.6	-0.57	-0.57	-0.57	-0.6	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Absolute values	Baseline	Tezepelumab	8	8 (100.0)	3.00 (0.74)	2.0	2.51	2.90	3.53	4.1	
			Placebo	6	6 (100.0)	2.71 (1.17)	1.4	2.10	2.58	2.70	4.9	
		Week 2	Tezepelumab	8	8 (100.0)	2.99 (0.57)	2.4	2.51	2.86	3.45	3.9	
			Placebo	6	6 (100.0)	2.61 (1.15)	1.3	1.93	2.48	2.74	4.7	
		Week 4	Tezepelumab	8	8 (100.0)	3.05 (0.61)	2.3	2.59	2.94	3.51	4.0	
			Placebo	6	5 (83.3)	2.28 (0.51)	1.4	2.30	2.32	2.64	2.7	
		Week 8	Tezepelumab	8	8 (100.0)	3.05 (0.55)	2.4	2.56	3.06	3.43	3.9	
			Placebo	6	6 (100.0)	2.70 (1.17)	1.5	2.14	2.40	2.84	4.9	
		Week 12	Tezepelumab	8	7 (87.5)	2.98 (0.68)	2.2	2.37	2.81	3.62	4.0	
			Placebo	6	5 (83.3)	2.82 (1.31)	1.4	2.29	2.66	2.75	5.0	
		Week 16	Tezepelumab	8	8 (100.0)	2.96 (0.60)	2.3	2.42	2.93	3.48	3.8	
			Placebo	6	6 (100.0)	2.80 (1.26)	1.5	2.31	2.58	2.62	5.2	
		Week 24	Tezepelumab	8	8 (100.0)	2.98 (0.54)	2.2	2.60	2.96	3.38	3.8	
			Placebo	6	6 (100.0)	2.77 (1.23)	1.5	2.25	2.56	2.66	5.1	
		Week 36	Tezepelumab	8	8 (100.0)	3.02 (0.51)	2.2	2.70	2.99	3.48	3.7	
			Placebo	6	5 (83.3)	2.93 (1.44)	1.4	2.56	2.70	2.70	5.3	
		Week 52	Tezepelumab	8	7 (87.5)	3.05 (0.63)	2.2	2.53	2.93	3.55	4.0	
			Placebo	6	6 (100.0)	2.91 (1.25)	1.5	2.43	2.70	2.85	5.3	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Change from baseline	Week 2	Tezepelumab	8	8 (100.0)	-0.01 (0.30)	-0.4	-0.21	-0.01	0.08	0.6	0.32 [-0.75, 1.39]
			Placebo	6	6 (100.0)	-0.10 (0.21)	-0.4	-0.19	-0.12	0.04	0.2	
		Week 4	Tezepelumab	8	8 (100.0)	0.05 (0.29)	-0.3	-0.13	0.02	0.11	0.7	0.14 [-0.98, 1.26]
			Placebo	6	5 (83.3)	0.01 (0.24)	-0.4	-0.06	0.02	0.22	0.2	
		Week 8	Tezepelumab	8	8 (100.0)	0.05 (0.29)	-0.4	-0.17	0.06	0.20	0.6	0.19 [-0.87, 1.25]
			Placebo	6	6 (100.0)	-0.00 (0.24)	-0.5	0.03	0.08	0.13	0.1	
		Week 12	Tezepelumab	8	7 (87.5)	-0.05 (0.30)	-0.5	-0.20	-0.12	0.17	0.4	-0.65 [-1.83, 0.54]
			Placebo	6	5 (83.3)	0.10 (0.12)	-0.0	0.03	0.09	0.19	0.3	
		Week 16	Tezepelumab	8	8 (100.0)	-0.04 (0.27)	-0.4	-0.23	-0.09	0.16	0.4	-0.55 [-1.63, 0.54]
			Placebo	6	6 (100.0)	0.09 (0.17)	-0.2	-0.05	0.10	0.21	0.3	
		Week 24	Tezepelumab	8	8 (100.0)	-0.01 (0.35)	-0.4	-0.25	-0.09	0.16	0.7	-0.27 [-1.33, 0.80]
			Placebo	6	6 (100.0)	0.06 (0.15)	-0.1	-0.12	0.11	0.16	0.2	
		Week 36	Tezepelumab	8	8 (100.0)	0.03 (0.39)	-0.5	-0.25	-0.01	0.24	0.7	-0.42 [-1.55, 0.71]
			Placebo	6	5 (83.3)	0.18 (0.31)	-0.1	-0.03	0.00	0.42	0.6	
		Week 52	Tezepelumab	8	7 (87.5)	0.05 (0.38)	-0.4	-0.16	-0.10	0.15	0.8	-0.48 [-1.59, 0.63]
			Placebo	6	6 (100.0)	0.20 (0.17)	-0.0	0.06	0.21	0.35	0.4	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Absolute values	Baseline	Tezepelumab	33	33 (100.0)	2.60 (0.60)	1.4	2.14	2.78	3.03	3.7	
			Placebo	35	35 (100.0)	2.68 (0.71)	1.0	2.16	2.74	3.15	4.1	
		Week 2	Tezepelumab	33	32 (97.0)	2.78 (0.59)	1.7	2.29	2.82	3.20	4.0	
			Placebo	35	33 (94.3)	2.76 (0.50)	1.7	2.40	2.74	3.09	4.2	
		Week 4	Tezepelumab	33	32 (97.0)	2.67 (0.64)	1.3	2.14	2.73	3.19	3.9	
			Placebo	35	33 (94.3)	2.77 (0.58)	1.3	2.50	2.66	3.15	4.0	
		Week 8	Tezepelumab	33	32 (97.0)	2.65 (0.75)	1.0	2.14	2.78	3.23	3.7	
			Placebo	35	33 (94.3)	2.73 (0.57)	1.2	2.39	2.76	3.15	3.8	
		Week 12	Tezepelumab	33	30 (90.9)	2.71 (0.74)	0.8	2.10	2.81	3.34	4.0	
			Placebo	35	34 (97.1)	2.73 (0.61)	1.5	2.41	2.80	3.07	4.2	
		Week 16	Tezepelumab	33	31 (93.9)	2.73 (0.63)	1.5	2.22	2.86	3.23	3.9	
			Placebo	35	34 (97.1)	2.74 (0.55)	1.6	2.44	2.62	3.17	3.9	
		Week 24	Tezepelumab	33	30 (90.9)	2.75 (0.62)	1.6	2.27	2.89	3.19	3.9	
			Placebo	35	32 (91.4)	2.79 (0.56)	1.7	2.38	2.74	3.19	4.0	
		Week 36	Tezepelumab	33	29 (87.9)	2.85 (0.56)	1.4	2.46	2.93	3.26	4.0	
			Placebo	35	30 (85.7)	2.86 (0.71)	1.4	2.40	2.95	3.34	4.1	
		Week 52	Tezepelumab	33	27 (81.8)	2.97 (0.60)	1.9	2.37	3.08	3.44	4.2	
			Placebo	35	29 (82.9)	2.92 (0.66)	1.2	2.51	3.01	3.41	3.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Change from baseline	Week 2	Tezepelumab	33	32 (97.0)	0.19 (0.37)	-0.5	0.02	0.13	0.36	1.4	0.23 [-0.26, 0.72]
			Placebo	35	33 (94.3)	0.08 (0.51)	-1.3	-0.08	0.04	0.20	1.7	
		Week 4	Tezepelumab	33	32 (97.0)	0.09 (0.42)	-1.2	-0.15	0.09	0.33	1.2	-0.00 [-0.49, 0.48]
			Placebo	35	33 (94.3)	0.10 (0.56)	-1.0	-0.19	-0.04	0.34	1.7	
		Week 8	Tezepelumab	33	32 (97.0)	0.07 (0.47)	-1.1	-0.18	0.11	0.31	1.6	0.02 [-0.46, 0.51]
			Placebo	35	33 (94.3)	0.06 (0.61)	-1.7	-0.20	-0.02	0.17	2.0	
		Week 12	Tezepelumab	33	30 (90.9)	0.13 (0.52)	-1.5	-0.09	0.17	0.32	1.5	0.09 [-0.40, 0.58]
			Placebo	35	34 (97.1)	0.08 (0.61)	-1.2	-0.23	0.01	0.38	1.6	
		Week 16	Tezepelumab	33	31 (93.9)	0.17 (0.38)	-0.5	-0.10	0.11	0.36	1.4	0.16 [-0.33, 0.65]
			Placebo	35	34 (97.1)	0.09 (0.60)	-1.6	-0.19	0.02	0.22	1.6	
		Week 24	Tezepelumab	33	30 (90.9)	0.16 (0.44)	-0.8	-0.03	0.13	0.34	1.8	0.19 [-0.31, 0.69]
			Placebo	35	32 (91.4)	0.06 (0.56)	-1.4	-0.21	-0.00	0.30	1.5	
		Week 36	Tezepelumab	33	29 (87.9)	0.27 (0.42)	-0.6	0.00	0.26	0.42	1.7	0.17 [-0.35, 0.68]
			Placebo	35	30 (85.7)	0.17 (0.71)	-1.7	-0.09	0.15	0.33	2.2	
		Week 52	Tezepelumab	33	27 (81.8)	0.39 (0.40)	-0.6	0.13	0.42	0.59	1.3	0.38 [-0.15, 0.91]
			Placebo	35	29 (82.9)	0.19 (0.60)	-1.4	-0.06	0.23	0.38	1.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Absolute values	Baseline	Tezepelumab	23	23 (100.0)	2.80 (0.72)	1.4	2.14	2.86	3.22	4.1	
			Placebo	14	14 (100.0)	2.71 (0.85)	1.4	2.43	2.68	3.15	4.9	
		Week 2	Tezepelumab	23	23 (100.0)	2.93 (0.63)	1.7	2.50	2.91	3.39	4.0	
			Placebo	14	13 (92.9)	2.69 (0.84)	1.3	2.25	2.71	3.04	4.7	
		Week 4	Tezepelumab	23	22 (95.7)	2.86 (0.69)	1.3	2.57	2.81	3.21	4.0	
			Placebo	14	13 (92.9)	2.43 (0.64)	1.3	2.30	2.64	2.86	3.3	
		Week 8	Tezepelumab	23	22 (95.7)	2.86 (0.67)	1.0	2.56	2.92	3.30	3.9	
			Placebo	14	14 (100.0)	2.63 (0.87)	1.2	2.17	2.58	3.02	4.9	
		Week 12	Tezepelumab	23	19 (82.6)	2.80 (0.79)	0.8	2.30	2.81	3.34	4.0	
			Placebo	14	13 (92.9)	2.62 (0.90)	1.4	2.29	2.66	2.96	5.0	
		Week 16	Tezepelumab	23	22 (95.7)	2.83 (0.69)	1.5	2.40	2.84	3.30	3.9	
			Placebo	14	14 (100.0)	2.68 (0.91)	1.5	2.31	2.61	3.03	5.2	
		Week 24	Tezepelumab	23	21 (91.3)	2.90 (0.58)	1.7	2.53	2.90	3.25	3.9	
			Placebo	14	14 (100.0)	2.69 (0.88)	1.5	2.10	2.62	3.11	5.1	
		Week 36	Tezepelumab	23	21 (91.3)	2.92 (0.58)	1.4	2.67	3.05	3.26	4.0	
			Placebo	14	11 (78.6)	2.84 (1.06)	1.4	2.56	2.76	3.04	5.3	
		Week 52	Tezepelumab	23	19 (82.6)	3.08 (0.64)	1.9	2.64	3.08	3.55	4.2	
			Placebo	14	10 (71.4)	3.01 (0.95)	1.5	2.69	2.94	3.09	5.3	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Change from baseline	Week 2	Tezepelumab	23	23 (100.0)	0.13 (0.25)	-0.4	-0.04	0.10	0.36	0.6	0.40 [-0.29, 1.08]
			Placebo	14	13 (92.9)	0.03 (0.25)	-0.4	-0.12	0.00	0.14	0.6	
		Week 4	Tezepelumab	23	22 (95.7)	0.08 (0.30)	-0.3	-0.13	0.02	0.13	1.0	0.64 [-0.07, 1.34]
			Placebo	14	13 (92.9)	-0.11 (0.26)	-0.8	-0.19	-0.06	0.02	0.2	
		Week 8	Tezepelumab	23	22 (95.7)	0.07 (0.25)	-0.4	-0.13	0.10	0.22	0.6	0.66 [-0.03, 1.35]
			Placebo	14	14 (100.0)	-0.08 (0.18)	-0.5	-0.20	-0.08	0.05	0.1	
		Week 12	Tezepelumab	23	19 (82.6)	-0.02 (0.27)	-0.6	-0.17	0.01	0.17	0.4	0.28 [-0.43, 0.99]
			Placebo	14	13 (92.9)	-0.09 (0.26)	-0.7	-0.23	0.01	0.03	0.3	
		Week 16	Tezepelumab	23	22 (95.7)	0.05 (0.22)	-0.4	-0.12	0.09	0.23	0.4	0.32 [-0.35, 1.00]
			Placebo	14	14 (100.0)	-0.02 (0.23)	-0.7	-0.09	0.00	0.09	0.3	
		Week 24	Tezepelumab	23	21 (91.3)	0.06 (0.30)	-0.4	-0.11	0.09	0.20	0.8	0.26 [-0.42, 0.94]
			Placebo	14	14 (100.0)	-0.02 (0.25)	-0.7	-0.12	0.04	0.16	0.2	
		Week 36	Tezepelumab	23	21 (91.3)	0.08 (0.36)	-0.6	-0.13	0.07	0.35	0.7	-0.03 [-0.76, 0.70]
			Placebo	14	11 (78.6)	0.09 (0.32)	-0.5	-0.09	0.00	0.42	0.6	
		Week 52	Tezepelumab	23	19 (82.6)	0.25 (0.31)	-0.4	0.02	0.31	0.52	0.8	0.45 [-0.33, 1.22]
			Placebo	14	10 (71.4)	0.12 (0.20)	-0.2	-0.01	0.09	0.33	0.4	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Absolute values	Baseline	Tezepelumab	18	18 (100.0)	2.51 (0.50)	1.4	2.20	2.38	2.98	3.2	
			Placebo	27	27 (100.0)	2.67 (0.75)	1.0	2.11	2.71	3.09	4.1	
		Week 2	Tezepelumab	18	17 (94.4)	2.67 (0.48)	1.7	2.28	2.63	3.06	3.4	
			Placebo	27	26 (96.3)	2.76 (0.50)	1.7	2.37	2.72	3.09	4.2	
		Week 4	Tezepelumab	18	18 (100.0)	2.61 (0.59)	1.8	2.10	2.57	3.18	3.5	
			Placebo	27	25 (92.6)	2.84 (0.52)	2.1	2.50	2.60	3.15	4.0	
		Week 8	Tezepelumab	18	18 (100.0)	2.57 (0.77)	1.0	2.12	2.75	3.20	3.5	
			Placebo	27	25 (92.6)	2.78 (0.54)	1.4	2.41	2.76	3.24	3.8	
		Week 12	Tezepelumab	18	18 (100.0)	2.73 (0.68)	1.4	2.10	2.85	3.37	3.5	
			Placebo	27	26 (96.3)	2.81 (0.60)	1.7	2.49	2.80	3.16	4.2	
		Week 16	Tezepelumab	18	17 (94.4)	2.70 (0.53)	1.9	2.24	2.86	3.06	3.6	
			Placebo	27	26 (96.3)	2.79 (0.53)	1.9	2.44	2.60	3.21	3.9	
		Week 24	Tezepelumab	18	17 (94.4)	2.68 (0.64)	1.6	2.27	2.60	3.16	3.7	
			Placebo	27	24 (88.9)	2.84 (0.55)	2.0	2.45	2.74	3.22	4.0	
		Week 36	Tezepelumab	18	16 (88.9)	2.84 (0.52)	2.3	2.43	2.67	3.30	3.8	
			Placebo	27	24 (88.9)	2.89 (0.72)	1.4	2.37	3.02	3.43	4.1	
		Week 52	Tezepelumab	18	15 (83.3)	2.87 (0.54)	2.2	2.31	2.84	3.32	3.7	
			Placebo	27	25 (92.6)	2.88 (0.70)	1.2	2.47	2.86	3.41	3.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Change from baseline	Week 2	Tezepelumab	18	17 (94.4)	0.17 (0.48)	-0.5	0.00	0.08	0.24	1.4	0.19 [-0.42, 0.80]
			Placebo	27	26 (96.3)	0.07 (0.57)	-1.3	-0.10	0.03	0.20	1.7	
		Week 4	Tezepelumab	18	18 (100.0)	0.10 (0.50)	-1.2	-0.27	0.16	0.37	1.2	-0.15 [-0.76, 0.45]
			Placebo	27	25 (92.6)	0.18 (0.61)	-1.0	-0.18	0.19	0.36	1.7	
		Week 8	Tezepelumab	18	18 (100.0)	0.06 (0.60)	-1.1	-0.34	0.13	0.31	1.6	-0.09 [-0.70, 0.52]
			Placebo	27	25 (92.6)	0.12 (0.70)	-1.7	-0.12	0.03	0.32	2.0	
		Week 12	Tezepelumab	18	18 (100.0)	0.21 (0.63)	-1.5	0.01	0.27	0.52	1.5	0.07 [-0.53, 0.67]
			Placebo	27	26 (96.3)	0.17 (0.66)	-1.2	-0.22	0.12	0.40	1.6	
		Week 16	Tezepelumab	18	17 (94.4)	0.23 (0.49)	-0.5	-0.10	0.12	0.56	1.4	0.13 [-0.48, 0.74]
			Placebo	27	26 (96.3)	0.15 (0.66)	-1.6	-0.19	0.10	0.34	1.6	
		Week 24	Tezepelumab	18	17 (94.4)	0.20 (0.54)	-0.8	0.01	0.14	0.38	1.8	0.16 [-0.46, 0.78]
			Placebo	27	24 (88.9)	0.11 (0.62)	-1.4	-0.21	-0.01	0.53	1.5	
		Week 36	Tezepelumab	18	16 (88.9)	0.39 (0.44)	-0.2	0.20	0.28	0.56	1.7	0.28 [-0.36, 0.91]
			Placebo	27	24 (88.9)	0.21 (0.78)	-1.7	-0.02	0.15	0.39	2.2	
		Week 52	Tezepelumab	18	15 (83.3)	0.41 (0.51)	-0.6	-0.03	0.43	0.79	1.3	0.31 [-0.34, 0.95]
			Placebo	27	25 (92.6)	0.22 (0.64)	-1.4	-0.02	0.28	0.53	1.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Absolute values	Baseline	Tezepelumab	11	11 (100.0)	2.67 (0.69)	1.6	2.14	2.78	3.01	4.1	
			Placebo	16	16 (100.0)	2.74 (0.56)	1.4	2.44	2.72	3.19	3.6	
		Week 2	Tezepelumab	11	11 (100.0)	2.72 (0.52)	2.0	2.26	2.74	3.07	3.7	
			Placebo	16	14 (87.5)	2.71 (0.59)	1.3	2.40	2.78	3.11	3.5	
		Week 4	Tezepelumab	11	11 (100.0)	2.70 (0.60)	1.7	2.22	2.71	3.16	3.8	
			Placebo	16	14 (87.5)	2.59 (0.60)	1.4	2.32	2.59	2.88	3.7	
		Week 8	Tezepelumab	11	11 (100.0)	2.78 (0.63)	1.9	2.07	2.88	3.20	3.9	
			Placebo	16	15 (93.8)	2.58 (0.47)	1.5	2.20	2.62	3.02	3.2	
		Week 12	Tezepelumab	11	10 (90.9)	2.66 (0.59)	2.0	2.02	2.69	3.05	3.6	
			Placebo	16	14 (87.5)	2.60 (0.56)	1.4	2.29	2.80	2.96	3.5	
		Week 16	Tezepelumab	11	11 (100.0)	2.69 (0.65)	1.6	2.24	2.73	3.24	3.8	
			Placebo	16	15 (93.8)	2.59 (0.49)	1.5	2.31	2.60	3.03	3.2	
		Week 24	Tezepelumab	11	10 (90.9)	2.84 (0.55)	2.0	2.32	2.91	3.21	3.8	
			Placebo	16	15 (93.8)	2.65 (0.55)	1.5	2.19	2.74	3.11	3.4	
		Week 36	Tezepelumab	11	9 (81.8)	2.94 (0.46)	2.2	2.71	2.93	3.18	3.7	
			Placebo	16	13 (81.3)	2.82 (0.60)	1.4	2.70	2.76	3.04	3.7	
		Week 52	Tezepelumab	11	8 (72.7)	3.02 (0.64)	2.2	2.51	3.01	3.46	4.0	
			Placebo	16	12 (75.0)	2.89 (0.63)	1.5	2.57	2.98	3.28	3.7	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Change from baseline	Week 2	Tezepelumab	11	11 (100.0)	0.05 (0.23)	-0.4	-0.14	0.06	0.19	0.4	0.35 [-0.45, 1.14]
			Placebo	16	14 (87.5)	-0.03 (0.25)	-0.4	-0.12	-0.05	0.06	0.6	
		Week 4	Tezepelumab	11	11 (100.0)	0.03 (0.21)	-0.3	-0.12	-0.04	0.15	0.4	0.64 [-0.17, 1.45]
			Placebo	16	14 (87.5)	-0.13 (0.27)	-0.8	-0.27	-0.08	0.02	0.2	
		Week 8	Tezepelumab	11	11 (100.0)	0.11 (0.19)	-0.2	0.02	0.14	0.22	0.4	1.20 [0.35, 2.05]
			Placebo	16	15 (93.8)	-0.10 (0.17)	-0.5	-0.22	-0.09	0.05	0.1	
		Week 12	Tezepelumab	11	10 (90.9)	-0.01 (0.31)	-0.5	-0.24	0.02	0.16	0.5	0.29 [-0.53, 1.10]
			Placebo	16	14 (87.5)	-0.09 (0.26)	-0.7	-0.23	-0.00	0.06	0.2	
		Week 16	Tezepelumab	11	11 (100.0)	0.02 (0.21)	-0.4	-0.13	0.00	0.23	0.4	0.51 [-0.28, 1.31]
			Placebo	16	15 (93.8)	-0.09 (0.23)	-0.7	-0.22	-0.05	0.08	0.2	
		Week 24	Tezepelumab	11	10 (90.9)	0.06 (0.18)	-0.3	-0.03	0.11	0.20	0.3	0.43 [-0.38, 1.24]
			Placebo	16	15 (93.8)	-0.04 (0.25)	-0.7	-0.14	-0.01	0.15	0.3	
		Week 36	Tezepelumab	11	9 (81.8)	0.17 (0.31)	-0.5	-0.01	0.21	0.39	0.6	0.19 [-0.67, 1.04]
			Placebo	16	13 (81.3)	0.12 (0.28)	-0.5	-0.03	0.15	0.31	0.6	
		Week 52	Tezepelumab	11	8 (72.7)	0.29 (0.26)	-0.1	0.06	0.34	0.47	0.7	0.52 [-0.39, 1.43]
			Placebo	16	12 (75.0)	0.16 (0.22)	-0.2	0.02	0.17	0.29	0.6	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Absolute values	Baseline	Tezepelumab	30	30 (100.0)	2.68 (0.64)	1.4	2.20	2.81	3.13	3.9	
			Placebo	25	25 (100.0)	2.65 (0.90)	1.0	2.10	2.70	3.08	4.9	
		Week 2	Tezepelumab	30	29 (96.7)	2.86 (0.61)	1.7	2.43	2.91	3.26	4.0	
			Placebo	25	25 (100.0)	2.75 (0.65)	1.7	2.31	2.71	3.01	4.7	
		Week 4	Tezepelumab	30	29 (96.7)	2.77 (0.67)	1.3	2.32	2.78	3.21	4.0	
			Placebo	25	24 (96.0)	2.77 (0.58)	1.3	2.50	2.65	3.15	4.0	
		Week 8	Tezepelumab	30	29 (96.7)	2.71 (0.76)	1.0	2.36	2.79	3.30	3.7	
			Placebo	25	24 (96.0)	2.81 (0.77)	1.2	2.40	2.76	3.29	4.9	
		Week 12	Tezepelumab	30	27 (90.0)	2.80 (0.78)	0.8	2.21	3.03	3.37	4.0	
			Placebo	25	25 (100.0)	2.82 (0.78)	1.5	2.49	2.66	3.16	5.0	
		Week 16	Tezepelumab	30	28 (93.3)	2.81 (0.62)	1.5	2.34	2.86	3.27	3.9	
			Placebo	25	25 (100.0)	2.85 (0.76)	1.6	2.44	2.59	3.28	5.2	
		Week 24	Tezepelumab	30	28 (93.3)	2.78 (0.63)	1.6	2.31	2.82	3.24	3.9	
			Placebo	25	23 (92.0)	2.87 (0.76)	1.7	2.38	2.66	3.22	5.1	
		Week 36	Tezepelumab	30	28 (93.3)	2.87 (0.58)	1.4	2.43	2.87	3.28	4.0	
			Placebo	25	22 (88.0)	2.91 (0.94)	1.4	2.34	3.02	3.51	5.3	
		Week 52	Tezepelumab	30	26 (86.7)	2.98 (0.60)	1.9	2.47	3.07	3.44	4.2	
			Placebo	25	23 (92.0)	2.93 (0.84)	1.2	2.47	2.72	3.41	5.3	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Change from baseline	Week 2	Tezepelumab	30	29 (96.7)	0.18 (0.40)	-0.5	0.00	0.10	0.41	1.4	0.16 [-0.37, 0.70]
			Placebo	25	25 (100.0)	0.10 (0.57)	-1.3	-0.10	0.09	0.23	1.7	
		Week 4	Tezepelumab	30	29 (96.7)	0.11 (0.45)	-1.2	-0.16	0.07	0.33	1.2	-0.19 [-0.74, 0.35]
			Placebo	25	24 (96.0)	0.21 (0.61)	-1.0	-0.19	0.19	0.38	1.7	
		Week 8	Tezepelumab	30	29 (96.7)	0.05 (0.50)	-1.1	-0.22	0.04	0.31	1.6	-0.15 [-0.69, 0.39]
			Placebo	25	24 (96.0)	0.14 (0.70)	-1.7	-0.10	0.06	0.40	2.0	
		Week 12	Tezepelumab	30	27 (90.0)	0.13 (0.54)	-1.5	-0.10	0.19	0.39	1.5	-0.07 [-0.61, 0.47]
			Placebo	25	25 (100.0)	0.17 (0.67)	-1.2	-0.22	0.11	0.40	1.6	
		Week 16	Tezepelumab	30	28 (93.3)	0.17 (0.41)	-0.5	-0.12	0.11	0.44	1.4	-0.05 [-0.59, 0.48]
			Placebo	25	25 (100.0)	0.20 (0.66)	-1.6	-0.10	0.18	0.34	1.6	
		Week 24	Tezepelumab	30	28 (93.3)	0.14 (0.48)	-0.8	-0.14	0.12	0.38	1.8	0.03 [-0.52, 0.58]
			Placebo	25	23 (92.0)	0.13 (0.63)	-1.4	-0.16	0.16	0.54	1.5	
		Week 36	Tezepelumab	30	28 (93.3)	0.23 (0.45)	-0.6	-0.07	0.24	0.42	1.7	0.04 [-0.52, 0.60]
			Placebo	25	22 (88.0)	0.20 (0.82)	-1.7	-0.09	0.15	0.47	2.2	
		Week 52	Tezepelumab	30	26 (86.7)	0.33 (0.45)	-0.6	0.02	0.42	0.59	1.3	0.21 [-0.35, 0.77]
			Placebo	25	23 (92.0)	0.21 (0.66)	-1.4	-0.11	0.31	0.53	1.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	5	5 (100.0)	2.44 (0.62)	1.4	2.33	2.69	2.69	3.1	
			Placebo	3	3 (100.0)	2.38 (0.85)	1.4	1.41	2.78	2.96	3.0	
		Week 2	Tezepelumab	5	5 (100.0)	2.54 (0.27)	2.2	2.41	2.43	2.74	2.9	
			Placebo	3	3 (100.0)	2.39 (0.93)	1.3	1.34	2.74	3.09	3.1	
		Week 4	Tezepelumab	5	5 (100.0)	2.44 (0.41)	1.8	2.32	2.51	2.61	2.9	
			Placebo	3	3 (100.0)	2.41 (0.89)	1.4	1.43	2.66	3.15	3.2	
		Week 8	Tezepelumab	5	5 (100.0)	2.36 (0.84)	1.0	2.36	2.56	2.71	3.2	
			Placebo	3	3 (100.0)	2.48 (0.84)	1.5	1.54	2.76	3.15	3.2	
		Week 12	Tezepelumab	5	5 (100.0)	2.52 (0.41)	2.1	2.16	2.57	2.74	3.1	
			Placebo	3	3 (100.0)	2.36 (0.83)	1.4	1.44	2.56	3.07	3.1	
		Week 16	Tezepelumab	5	5 (100.0)	2.55 (0.49)	2.0	2.28	2.43	2.73	3.3	
			Placebo	3	3 (100.0)	2.43 (0.85)	1.5	1.49	2.63	3.16	3.2	
		Week 24	Tezepelumab	5	5 (100.0)	2.51 (0.65)	1.6	2.22	2.53	2.90	3.3	
			Placebo	3	3 (100.0)	2.41 (0.88)	1.5	1.48	2.52	3.22	3.2	
		Week 36	Tezepelumab	5	5 (100.0)	2.68 (0.45)	2.2	2.25	2.67	3.08	3.2	
			Placebo	3	3 (100.0)	2.47 (0.95)	1.4	1.38	2.93	3.10	3.1	
		Week 52	Tezepelumab	5	5 (100.0)	2.72 (0.62)	2.2	2.20	2.53	3.08	3.6	
			Placebo	3	3 (100.0)	2.28 (0.91)	1.5	1.49	2.09	3.27	3.3	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Change from baseline	Week 2	Tezepelumab	5	5 (100.0)	0.10 (0.43)	-0.3	-0.17	0.05	0.10	0.8	0.27 [-1.17, 1.71]
			Placebo	3	3 (100.0)	0.01 (0.11)	-0.1	-0.07	-0.04	0.13	0.1	
		Week 4	Tezepelumab	5	5 (100.0)	0.00 (0.23)	-0.2	-0.12	-0.08	-0.01	0.4	-0.15 [-1.58, 1.29]
			Placebo	3	3 (100.0)	0.03 (0.16)	-0.1	-0.12	0.02	0.19	0.2	
		Week 8	Tezepelumab	5	5 (100.0)	-0.08 (0.23)	-0.5	-0.13	0.02	0.03	0.1	-0.90 [-2.42, 0.62]
			Placebo	3	3 (100.0)	0.10 (0.11)	-0.0	-0.02	0.13	0.19	0.2	
		Week 12	Tezepelumab	5	5 (100.0)	0.08 (0.33)	-0.2	-0.12	-0.01	0.05	0.6	0.37 [-1.08, 1.81]
			Placebo	3	3 (100.0)	-0.03 (0.17)	-0.2	-0.22	0.03	0.11	0.1	
		Week 16	Tezepelumab	5	5 (100.0)	0.11 (0.33)	-0.3	-0.05	0.04	0.24	0.6	0.25 [-1.19, 1.69]
			Placebo	3	3 (100.0)	0.04 (0.18)	-0.1	-0.15	0.08	0.20	0.2	
		Week 24	Tezepelumab	5	5 (100.0)	0.07 (0.19)	-0.2	-0.11	0.18	0.21	0.3	0.23 [-1.21, 1.67]
			Placebo	3	3 (100.0)	0.02 (0.26)	-0.3	-0.26	0.07	0.26	0.3	
		Week 36	Tezepelumab	5	5 (100.0)	0.24 (0.38)	-0.1	-0.02	0.12	0.39	0.8	0.47 [-0.98, 1.93]
			Placebo	3	3 (100.0)	0.09 (0.10)	-0.0	-0.03	0.14	0.15	0.2	
		Week 52	Tezepelumab	5	5 (100.0)	0.28 (0.40)	-0.2	-0.13	0.39	0.54	0.7	0.84 [-0.67, 2.35]
			Placebo	3	3 (100.0)	-0.10 (0.52)	-0.7	-0.69	0.08	0.31	0.3	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	36	36 (100.0)	2.71 (0.65)	1.4	2.17	2.84	3.11	4.1	
			Placebo	38	38 (100.0)	2.71 (0.78)	1.0	2.16	2.70	3.15	4.9	
		Week 2	Tezepelumab	36	35 (97.2)	2.86 (0.61)	1.7	2.48	2.93	3.26	4.0	
			Placebo	38	36 (94.7)	2.77 (0.60)	1.7	2.34	2.71	3.08	4.7	
		Week 4	Tezepelumab	36	35 (97.2)	2.79 (0.67)	1.3	2.22	2.80	3.21	4.0	
			Placebo	38	35 (92.1)	2.73 (0.56)	1.3	2.42	2.60	3.14	4.0	
		Week 8	Tezepelumab	36	35 (97.2)	2.78 (0.70)	1.0	2.15	2.88	3.30	3.9	
			Placebo	38	36 (94.7)	2.74 (0.67)	1.2	2.33	2.66	3.12	4.9	
		Week 12	Tezepelumab	36	32 (88.9)	2.80 (0.76)	0.8	2.26	2.95	3.40	4.0	
			Placebo	38	36 (94.7)	2.78 (0.70)	1.5	2.38	2.76	3.07	5.0	
		Week 16	Tezepelumab	36	34 (94.4)	2.81 (0.64)	1.5	2.40	2.86	3.24	3.9	
			Placebo	38	37 (97.4)	2.78 (0.67)	1.6	2.44	2.60	3.17	5.2	
		Week 24	Tezepelumab	36	33 (91.7)	2.84 (0.60)	1.7	2.34	2.90	3.23	3.9	
			Placebo	38	35 (92.1)	2.82 (0.67)	1.7	2.38	2.71	3.15	5.1	
		Week 36	Tezepelumab	36	32 (88.9)	2.92 (0.56)	1.4	2.49	2.94	3.32	4.0	
			Placebo	38	32 (84.2)	2.91 (0.82)	1.4	2.47	2.86	3.43	5.3	
		Week 52	Tezepelumab	36	29 (80.6)	3.03 (0.59)	1.9	2.64	3.12	3.44	4.2	
			Placebo	38	32 (84.2)	2.98 (0.74)	1.2	2.57	2.90	3.44	5.3	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Change from baseline	Week 2	Tezepelumab	36	35 (97.2)	0.15 (0.36)	-0.5	0.00	0.08	0.36	1.4	0.22 [-0.25, 0.68]
			Placebo	38	36 (94.7)	0.06 (0.50)	-1.3	-0.12	0.03	0.20	1.7	
		Week 4	Tezepelumab	36	35 (97.2)	0.10 (0.42)	-1.2	-0.15	0.08	0.33	1.2	0.02 [-0.45, 0.48]
			Placebo	38	35 (92.1)	0.09 (0.55)	-1.0	-0.24	-0.04	0.34	1.7	
		Week 8	Tezepelumab	36	35 (97.2)	0.09 (0.46)	-1.1	-0.19	0.11	0.31	1.6	0.08 [-0.38, 0.55]
			Placebo	38	36 (94.7)	0.04 (0.59)	-1.7	-0.21	-0.00	0.13	2.0	
		Week 12	Tezepelumab	36	32 (88.9)	0.10 (0.51)	-1.5	-0.13	0.16	0.31	1.5	0.01 [-0.46, 0.49]
			Placebo	38	36 (94.7)	0.09 (0.59)	-1.2	-0.22	0.02	0.32	1.6	
		Week 16	Tezepelumab	36	34 (94.4)	0.13 (0.38)	-0.5	-0.12	0.10	0.36	1.4	0.07 [-0.39, 0.54]
			Placebo	38	37 (97.4)	0.09 (0.57)	-1.6	-0.15	0.04	0.22	1.6	
		Week 24	Tezepelumab	36	33 (91.7)	0.13 (0.45)	-0.8	-0.08	0.12	0.34	1.8	0.13 [-0.35, 0.60]
			Placebo	38	35 (92.1)	0.07 (0.54)	-1.4	-0.14	0.00	0.23	1.5	
		Week 36	Tezepelumab	36	32 (88.9)	0.21 (0.43)	-0.6	-0.02	0.24	0.41	1.7	0.06 [-0.43, 0.55]
			Placebo	38	32 (84.2)	0.18 (0.70)	-1.7	-0.09	0.15	0.43	2.2	
		Week 52	Tezepelumab	36	29 (80.6)	0.33 (0.42)	-0.6	0.08	0.38	0.59	1.3	0.21 [-0.29, 0.71]
			Placebo	38	32 (84.2)	0.22 (0.55)	-1.4	-0.02	0.24	0.38	1.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Absolute values	Baseline	Tezepelumab	5	5 (100.0)	3.07 (0.68)	2.3	2.69	3.06	3.13	4.1	
			Placebo	5	5 (100.0)	2.26 (0.56)	1.4	2.11	2.24	2.74	2.8	
		Week 2	Tezepelumab	5	5 (100.0)	2.99 (0.49)	2.4	2.74	2.89	3.16	3.7	
			Placebo	5	5 (100.0)	2.27 (0.55)	1.3	2.27	2.37	2.62	2.7	
		Week 4	Tezepelumab	5	5 (100.0)	2.98 (0.58)	2.3	2.61	2.94	3.19	3.8	
			Placebo	5	5 (100.0)	2.21 (0.52)	1.4	2.09	2.17	2.66	2.7	
		Week 8	Tezepelumab	5	5 (100.0)	3.10 (0.60)	2.4	2.71	3.20	3.30	3.9	
			Placebo	5	5 (100.0)	2.40 (0.50)	1.5	2.41	2.54	2.76	2.8	
		Week 12	Tezepelumab	5	5 (100.0)	2.97 (0.56)	2.2	2.74	3.05	3.30	3.6	
			Placebo	5	5 (100.0)	2.19 (0.47)	1.4	2.00	2.41	2.52	2.6	
		Week 16	Tezepelumab	5	5 (100.0)	3.06 (0.57)	2.3	2.73	3.21	3.30	3.8	
			Placebo	5	5 (100.0)	2.35 (0.49)	1.5	2.46	2.48	2.63	2.7	
		Week 24	Tezepelumab	5	5 (100.0)	3.09 (0.58)	2.2	2.90	3.25	3.31	3.8	
			Placebo	5	4 (80.0)	2.20 (0.55)	1.5	1.78	2.30	2.62	2.7	
		Week 36	Tezepelumab	5	5 (100.0)	3.07 (0.54)	2.2	3.08	3.18	3.20	3.7	
			Placebo	5	2 (40.0)	2.16 (1.10)	1.4	1.38	2.16	2.93	2.9	
		Week 52	Tezepelumab	5	5 (100.0)	3.24 (0.69)	2.2	3.08	3.27	3.60	4.0	
			Placebo	5	3 (60.0)	1.91 (0.36)	1.5	1.49	2.09	2.14	2.1	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Change from baseline	Week 2	Tezepelumab	5	5 (100.0)	-0.08 (0.21)	-0.4	-0.17	0.03	0.05	0.1	-0.50 [-1.76, 0.76]
			Placebo	5	5 (100.0)	0.01 (0.15)	-0.1	-0.07	-0.04	0.03	0.3	
		Week 4	Tezepelumab	5	5 (100.0)	-0.09 (0.14)	-0.3	-0.12	-0.08	-0.01	0.1	-0.45 [-1.71, 0.81]
			Placebo	5	5 (100.0)	-0.04 (0.05)	-0.1	-0.07	-0.03	-0.02	0.0	
		Week 8	Tezepelumab	5	5 (100.0)	0.03 (0.15)	-0.2	0.02	0.03	0.14	0.2	-0.47 [-1.73, 0.79]
			Placebo	5	5 (100.0)	0.15 (0.32)	-0.2	-0.02	0.13	0.17	0.7	
		Week 12	Tezepelumab	5	5 (100.0)	-0.10 (0.27)	-0.5	-0.17	-0.01	0.05	0.2	-0.09 [-1.33, 1.15]
			Placebo	5	5 (100.0)	-0.07 (0.30)	-0.3	-0.24	-0.22	0.03	0.4	
		Week 16	Tezepelumab	5	5 (100.0)	-0.01 (0.23)	-0.4	-0.05	0.04	0.08	0.2	-0.47 [-1.73, 0.79]
			Placebo	5	5 (100.0)	0.09 (0.21)	-0.1	-0.07	0.08	0.22	0.4	
		Week 24	Tezepelumab	5	5 (100.0)	0.02 (0.25)	-0.3	-0.11	0.12	0.21	0.3	0.22 [-1.10, 1.54]
			Placebo	5	4 (80.0)	-0.07 (0.54)	-0.7	-0.47	-0.09	0.34	0.6	
		Week 36	Tezepelumab	5	5 (100.0)	-0.00 (0.32)	-0.5	-0.13	0.07	0.12	0.4	-0.22 [-1.86, 1.43]
			Placebo	5	2 (40.0)	0.06 (0.13)	-0.0	-0.03	0.06	0.15	0.2	
		Week 52	Tezepelumab	5	5 (100.0)	0.17 (0.30)	-0.1	-0.10	0.14	0.39	0.5	1.04 [-0.51, 2.59]
			Placebo	5	3 (60.0)	-0.19 (0.43)	-0.7	-0.69	0.03	0.08	0.1	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Absolute values	Baseline	Tezepelumab	29	29 (100.0)	2.64 (0.66)	1.4	2.14	2.78	3.01	3.9	
			Placebo	25	25 (100.0)	2.96 (0.73)	1.5	2.44	2.96	3.38	4.9	
		Week 2	Tezepelumab	29	28 (96.6)	2.80 (0.64)	1.7	2.35	2.78	3.21	4.0	
			Placebo	25	23 (92.0)	2.93 (0.65)	1.8	2.60	2.94	3.16	4.7	
		Week 4	Tezepelumab	29	28 (96.6)	2.72 (0.69)	1.3	2.14	2.70	3.20	4.0	
			Placebo	25	22 (88.0)	2.78 (0.58)	1.3	2.50	2.79	3.15	3.8	
		Week 8	Tezepelumab	29	28 (96.6)	2.67 (0.78)	1.0	2.15	2.85	3.28	3.7	
			Placebo	25	23 (92.0)	2.86 (0.71)	1.2	2.35	2.84	3.24	4.9	
		Week 12	Tezepelumab	29	26 (89.7)	2.69 (0.79)	0.8	2.10	2.65	3.37	4.0	
			Placebo	25	24 (96.0)	2.86 (0.70)	1.5	2.49	2.88	3.07	5.0	
		Week 16	Tezepelumab	29	27 (93.1)	2.75 (0.68)	1.5	2.20	2.86	3.24	3.9	
			Placebo	25	24 (96.0)	2.84 (0.73)	1.6	2.47	2.67	3.22	5.2	
		Week 24	Tezepelumab	29	26 (89.7)	2.72 (0.63)	1.6	2.27	2.73	3.19	3.9	
			Placebo	25	24 (96.0)	2.89 (0.70)	1.7	2.48	2.75	3.22	5.1	
		Week 36	Tezepelumab	29	25 (86.2)	2.83 (0.59)	1.4	2.39	2.77	3.26	4.0	
			Placebo	25	22 (88.0)	3.01 (0.78)	1.4	2.70	2.94	3.34	5.3	
		Week 52	Tezepelumab	29	22 (75.9)	2.93 (0.63)	1.9	2.37	2.87	3.45	4.2	
			Placebo	25	21 (84.0)	3.16 (0.66)	2.2	2.72	3.03	3.46	5.3	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Change from baseline	Week 2	Tezepelumab	29	28 (96.6)	0.16 (0.31)	-0.5	0.00	0.13	0.36	0.8	0.64 [0.07, 1.20]
			Placebo	25	23 (92.0)	-0.05 (0.37)	-1.3	-0.12	0.04	0.13	0.6	
		Week 4	Tezepelumab	29	28 (96.6)	0.09 (0.29)	-0.3	-0.15	0.10	0.33	0.7	0.63 [0.06, 1.20]
			Placebo	25	22 (88.0)	-0.10 (0.34)	-1.0	-0.27	-0.08	0.19	0.3	
		Week 8	Tezepelumab	29	28 (96.6)	0.05 (0.41)	-1.1	-0.15	0.11	0.31	0.7	0.39 [-0.16, 0.95]
			Placebo	25	23 (92.0)	-0.11 (0.38)	-1.7	-0.22	-0.02	0.05	0.3	
		Week 12	Tezepelumab	29	26 (89.7)	0.08 (0.48)	-1.5	-0.12	0.17	0.39	0.8	0.38 [-0.18, 0.94]
			Placebo	25	24 (96.0)	-0.07 (0.32)	-1.0	-0.21	-0.00	0.15	0.4	
		Week 16	Tezepelumab	29	27 (93.1)	0.15 (0.33)	-0.5	-0.12	0.12	0.42	0.8	0.67 [0.10, 1.23]
			Placebo	25	24 (96.0)	-0.10 (0.40)	-1.6	-0.22	0.00	0.14	0.3	
		Week 24	Tezepelumab	29	26 (89.7)	0.08 (0.33)	-0.8	-0.08	0.11	0.27	0.7	0.38 [-0.18, 0.94]
			Placebo	25	24 (96.0)	-0.04 (0.34)	-1.4	-0.13	-0.01	0.17	0.3	
		Week 36	Tezepelumab	29	25 (86.2)	0.20 (0.38)	-0.6	-0.02	0.23	0.42	0.8	0.44 [-0.14, 1.02]
			Placebo	25	22 (88.0)	0.04 (0.38)	-1.2	-0.09	0.09	0.30	0.6	
		Week 52	Tezepelumab	29	22 (75.9)	0.31 (0.39)	-0.6	0.08	0.40	0.59	0.9	0.50 [-0.11, 1.11]
			Placebo	25	21 (84.0)	0.10 (0.42)	-1.4	-0.01	0.23	0.33	0.6	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Absolute values	Baseline	Tezepelumab	7	7 (100.0)	2.53 (0.48)	2.0	2.12	2.29	3.03	3.2	
			Placebo	11	11 (100.0)	2.26 (0.72)	1.0	1.89	2.10	2.97	3.1	
		Week 2	Tezepelumab	7	7 (100.0)	2.76 (0.43)	2.3	2.29	2.68	3.24	3.4	
			Placebo	11	11 (100.0)	2.55 (0.43)	1.7	2.25	2.60	2.99	3.2	
		Week 4	Tezepelumab	7	7 (100.0)	2.71 (0.53)	2.0	2.22	2.80	3.18	3.4	
			Placebo	11	11 (100.0)	2.78 (0.55)	2.3	2.44	2.57	3.18	4.0	
		Week 8	Tezepelumab	7	7 (100.0)	2.69 (0.57)	2.0	2.07	2.76	3.20	3.5	
			Placebo	11	11 (100.0)	2.58 (0.63)	1.4	2.17	2.59	3.09	3.6	
		Week 12	Tezepelumab	7	6 (85.7)	2.90 (0.55)	2.0	2.51	3.02	3.29	3.5	
			Placebo	11	10 (90.9)	2.74 (0.75)	1.7	2.34	2.54	3.38	4.2	
		Week 16	Tezepelumab	7	7 (100.0)	2.67 (0.41)	2.2	2.24	2.74	2.86	3.4	
			Placebo	11	11 (100.0)	2.75 (0.60)	1.9	2.36	2.52	3.17	3.9	
		Week 24	Tezepelumab	7	7 (100.0)	2.87 (0.54)	2.3	2.41	2.88	3.37	3.7	
			Placebo	11	10 (90.9)	2.76 (0.62)	2.0	2.38	2.62	3.14	3.9	
		Week 36	Tezepelumab	7	7 (100.0)	2.96 (0.45)	2.5	2.55	2.99	3.34	3.6	
			Placebo	11	11 (100.0)	2.73 (0.86)	1.4	2.33	2.56	3.51	4.1	
		Week 52	Tezepelumab	7	7 (100.0)	2.98 (0.43)	2.2	2.64	3.21	3.29	3.4	
			Placebo	11	11 (100.0)	2.73 (0.79)	1.2	2.27	2.65	3.22	3.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Change from baseline	Week 2	Tezepelumab	7	7 (100.0)	0.24 (0.58)	-0.5	0.00	0.07	0.47	1.4	-0.09 [-1.04, 0.86]
			Placebo	11	11 (100.0)	0.30 (0.69)	-0.5	-0.27	0.20	0.74	1.7	
		Week 4	Tezepelumab	7	7 (100.0)	0.18 (0.78)	-1.2	-0.06	0.07	0.96	1.2	-0.46 [-1.42, 0.50]
			Placebo	11	11 (100.0)	0.52 (0.71)	-0.5	-0.18	0.40	1.02	1.7	
		Week 8	Tezepelumab	7	7 (100.0)	0.16 (0.67)	-0.4	-0.34	-0.10	0.42	1.6	-0.21 [-1.16, 0.74]
			Placebo	11	11 (100.0)	0.33 (0.85)	-0.8	-0.45	0.09	1.03	2.0	
		Week 12	Tezepelumab	7	6 (85.7)	0.30 (0.63)	-0.2	0.01	0.12	0.26	1.5	-0.28 [-1.30, 0.74]
			Placebo	11	10 (90.9)	0.52 (0.89)	-1.2	0.13	0.41	1.32	1.6	
		Week 16	Tezepelumab	7	7 (100.0)	0.14 (0.56)	-0.3	-0.17	-0.02	0.12	1.4	-0.51 [-1.48, 0.45]
			Placebo	11	11 (100.0)	0.49 (0.74)	-0.7	-0.05	0.26	1.11	1.6	
		Week 24	Tezepelumab	7	7 (100.0)	0.34 (0.73)	-0.4	-0.21	0.12	0.76	1.8	-0.05 [-1.02, 0.92]
			Placebo	11	10 (90.9)	0.38 (0.75)	-1.1	-0.12	0.53	0.82	1.5	
		Week 36	Tezepelumab	7	7 (100.0)	0.43 (0.58)	-0.2	0.21	0.28	0.44	1.7	-0.05 [-0.99, 0.90]
			Placebo	11	11 (100.0)	0.47 (1.03)	-1.7	-0.09	0.47	1.16	2.2	
		Week 52	Tezepelumab	7	7 (100.0)	0.46 (0.55)	-0.3	-0.03	0.41	0.92	1.3	-0.02 [-0.97, 0.92]
			Placebo	11	11 (100.0)	0.47 (0.70)	-0.6	-0.02	0.38	0.82	1.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	3.18	3.2	3.18	3.18	3.18	3.2	
		Week 2	Tezepelumab	1	1 (100.0)	3.26	3.3	3.26	3.26	3.26	3.3	
		Week 4	Tezepelumab	1	1 (100.0)	3.51	3.5	3.51	3.51	3.51	3.5	
		Week 8	Tezepelumab	1	1 (100.0)	3.43	3.4	3.43	3.43	3.43	3.4	
		Week 12	Tezepelumab	1	1 (100.0)	3.48	3.5	3.48	3.48	3.48	3.5	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	1	1 (100.0)	0.08	0.1	0.08	0.08	0.08	0.1	NE
		Week 4	Tezepelumab	1	1 (100.0)	0.33	0.3	0.33	0.33	0.33	0.3	NE
		Week 8	Tezepelumab	1	1 (100.0)	0.25	0.3	0.25	0.25	0.25	0.3	NE
		Week 12	Tezepelumab	1	1 (100.0)	0.30	0.3	0.30	0.30	0.30	0.3	NE

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Absolute values	Baseline	Tezepelumab	40	40 (100.0)	2.66 (0.64)	1.4	2.17	2.78	3.05	4.1	
			Placebo	41	41 (100.0)	2.69 (0.77)	1.0	2.16	2.70	3.09	4.9	
		Week 2	Tezepelumab	40	39 (97.5)	2.81 (0.59)	1.7	2.41	2.74	3.16	4.0	
			Placebo	41	39 (95.1)	2.74 (0.62)	1.3	2.31	2.71	3.09	4.7	
		Week 4	Tezepelumab	40	39 (97.5)	2.73 (0.64)	1.3	2.22	2.71	3.19	4.0	
			Placebo	41	38 (92.7)	2.70 (0.58)	1.3	2.42	2.62	3.14	4.0	
		Week 8	Tezepelumab	40	39 (97.5)	2.71 (0.72)	1.0	2.15	2.79	3.26	3.9	
			Placebo	41	39 (95.1)	2.72 (0.67)	1.2	2.31	2.69	3.15	4.9	
		Week 12	Tezepelumab	40	36 (90.0)	2.74 (0.73)	0.8	2.19	2.78	3.32	4.0	
			Placebo	41	39 (95.1)	2.74 (0.71)	1.4	2.34	2.75	3.07	5.0	
		Week 16	Tezepelumab	40	39 (97.5)	2.78 (0.62)	1.5	2.28	2.86	3.24	3.9	
			Placebo	41	40 (97.6)	2.75 (0.68)	1.5	2.43	2.60	3.17	5.2	
		Week 24	Tezepelumab	40	38 (95.0)	2.80 (0.61)	1.6	2.32	2.89	3.23	3.9	
			Placebo	41	38 (92.7)	2.78 (0.68)	1.5	2.38	2.69	3.15	5.1	
		Week 36	Tezepelumab	40	37 (92.5)	2.89 (0.55)	1.4	2.47	2.93	3.26	4.0	
			Placebo	41	35 (85.4)	2.87 (0.82)	1.4	2.40	2.90	3.34	5.3	
		Week 52	Tezepelumab	40	34 (85.0)	2.99 (0.60)	1.9	2.47	3.05	3.44	4.2	
			Placebo	41	35 (85.4)	2.92 (0.76)	1.2	2.47	2.86	3.41	5.3	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Change from baseline	Week 2	Tezepelumab	40	39 (97.5)	0.15 (0.37)	-0.5	-0.04	0.08	0.36	1.4	0.22 [-0.23, 0.66]
			Placebo	41	39 (95.1)	0.05 (0.48)	-1.3	-0.12	0.03	0.20	1.7	
		Week 4	Tezepelumab	40	39 (97.5)	0.08 (0.40)	-1.2	-0.15	0.06	0.32	1.2	-0.01 [-0.46, 0.43]
			Placebo	41	38 (92.7)	0.08 (0.53)	-1.0	-0.19	-0.04	0.22	1.7	
		Week 8	Tezepelumab	40	39 (97.5)	0.06 (0.44)	-1.1	-0.19	0.10	0.31	1.6	0.03 [-0.42, 0.47]
			Placebo	41	39 (95.1)	0.05 (0.57)	-1.7	-0.20	0.01	0.14	2.0	
		Week 12	Tezepelumab	40	36 (90.0)	0.09 (0.49)	-1.5	-0.14	0.12	0.30	1.5	0.02 [-0.44, 0.47]
			Placebo	41	39 (95.1)	0.08 (0.57)	-1.2	-0.22	0.02	0.26	1.6	
		Week 16	Tezepelumab	40	39 (97.5)	0.13 (0.37)	-0.5	-0.12	0.10	0.36	1.4	0.08 [-0.36, 0.52]
			Placebo	41	40 (97.6)	0.09 (0.55)	-1.6	-0.15	0.04	0.21	1.6	
		Week 24	Tezepelumab	40	38 (95.0)	0.12 (0.42)	-0.8	-0.10	0.12	0.27	1.8	0.13 [-0.33, 0.58]
			Placebo	41	38 (92.7)	0.06 (0.52)	-1.4	-0.14	0.00	0.23	1.5	
		Week 36	Tezepelumab	40	37 (92.5)	0.22 (0.42)	-0.6	-0.02	0.23	0.40	1.7	0.08 [-0.38, 0.54]
			Placebo	41	35 (85.4)	0.17 (0.67)	-1.7	-0.09	0.15	0.42	2.2	
		Week 52	Tezepelumab	40	34 (85.0)	0.32 (0.41)	-0.6	0.02	0.39	0.59	1.3	0.25 [-0.22, 0.73]
			Placebo	41	35 (85.4)	0.19 (0.55)	-1.4	-0.02	0.23	0.38	1.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
Medium/Low	Absolute values	Baseline	Tezepelumab	26	26 (100.0)	2.73 (0.62)	1.6	2.26	2.84	3.06	4.1	
			Placebo	21	21 (100.0)	2.84 (0.57)	1.5	2.50	2.74	3.23	4.1	
		Week 2	Tezepelumab	26	26 (100.0)	2.83 (0.53)	2.0	2.43	2.90	3.16	3.9	
			Placebo	21	19 (90.5)	2.80 (0.56)	1.8	2.48	2.74	3.15	4.2	
		Week 4	Tezepelumab	26	26 (100.0)	2.79 (0.64)	1.7	2.22	2.79	3.19	4.0	
			Placebo	21	19 (90.5)	2.79 (0.66)	1.3	2.42	2.72	3.16	4.0	
		Week 8	Tezepelumab	26	26 (100.0)	2.81 (0.57)	1.9	2.36	2.85	3.23	3.9	
			Placebo	21	20 (95.2)	2.77 (0.61)	1.2	2.35	2.73	3.23	3.8	
		Week 12	Tezepelumab	26	24 (92.3)	2.86 (0.62)	2.0	2.29	2.95	3.30	4.0	
			Placebo	21	19 (90.5)	2.78 (0.65)	1.5	2.29	2.84	3.07	4.2	
		Week 16	Tezepelumab	26	26 (100.0)	2.82 (0.62)	1.6	2.40	2.86	3.23	3.9	
			Placebo	21	20 (95.2)	2.82 (0.60)	1.6	2.54	2.70	3.26	3.9	
		Week 24	Tezepelumab	26	25 (96.2)	2.88 (0.54)	2.0	2.41	2.90	3.25	3.9	
			Placebo	21	20 (95.2)	2.78 (0.62)	1.7	2.32	2.70	3.22	4.0	
		Week 36	Tezepelumab	26	24 (92.3)	2.89 (0.49)	2.2	2.47	2.89	3.26	3.8	
			Placebo	21	17 (81.0)	2.92 (0.67)	1.4	2.56	2.76	3.34	4.1	
		Week 52	Tezepelumab	26	22 (84.6)	3.01 (0.57)	2.2	2.47	3.07	3.44	4.0	
			Placebo	21	17 (81.0)	3.07 (0.48)	2.2	2.72	3.03	3.41	3.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
Medium/Low	Change from baseline	Week 2	Tezepelumab	26	26 (100.0)	0.10 (0.27)	-0.5	0.00	0.07	0.21	0.8	0.50 [-0.11, 1.10]
			Placebo	21	19 (90.5)	-0.04 (0.32)	-0.8	-0.17	0.04	0.14	0.6	
		Week 4	Tezepelumab	26	26 (100.0)	0.06 (0.35)	-1.2	-0.07	0.07	0.28	0.7	0.29 [-0.31, 0.88]
			Placebo	21	19 (90.5)	-0.04 (0.36)	-0.8	-0.27	-0.09	0.19	1.0	
		Week 8	Tezepelumab	26	26 (100.0)	0.08 (0.27)	-0.4	-0.17	0.11	0.24	0.6	0.46 [-0.13, 1.05]
			Placebo	21	20 (95.2)	-0.03 (0.22)	-0.5	-0.17	-0.05	0.09	0.5	
		Week 12	Tezepelumab	26	24 (92.3)	0.15 (0.29)	-0.5	-0.00	0.18	0.30	0.8	0.53 [-0.09, 1.14]
			Placebo	21	19 (90.5)	-0.03 (0.38)	-0.7	-0.23	-0.04	0.19	1.1	
		Week 16	Tezepelumab	26	26 (100.0)	0.10 (0.31)	-0.4	-0.13	0.10	0.35	0.8	0.26 [-0.33, 0.84]
			Placebo	21	20 (95.2)	0.02 (0.30)	-0.7	-0.13	0.00	0.18	0.8	
		Week 24	Tezepelumab	26	25 (96.2)	0.11 (0.29)	-0.4	-0.08	0.12	0.25	0.7	0.44 [-0.15, 1.04]
			Placebo	21	20 (95.2)	-0.02 (0.30)	-0.7	-0.15	-0.05	0.16	0.8	
		Week 36	Tezepelumab	26	24 (92.3)	0.13 (0.35)	-0.6	-0.13	0.22	0.37	0.7	0.14 [-0.48, 0.76]
			Placebo	21	17 (81.0)	0.08 (0.35)	-0.5	-0.09	0.00	0.15	1.0	
		Week 52	Tezepelumab	26	22 (84.6)	0.26 (0.36)	-0.4	-0.03	0.27	0.48	0.9	0.28 [-0.36, 0.91]
			Placebo	21	17 (81.0)	0.17 (0.30)	-0.4	-0.01	0.23	0.34	0.8	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
High	Absolute values	Baseline	Tezepelumab	15	15 (100.0)	2.59 (0.68)	1.4	2.12	2.69	3.18	3.7	
			Placebo	20	20 (100.0)	2.53 (0.93)	1.0	2.07	2.34	3.00	4.9	
		Week 2	Tezepelumab	15	14 (93.3)	2.80 (0.70)	1.7	2.41	2.67	3.36	4.0	
			Placebo	20	20 (100.0)	2.67 (0.68)	1.3	2.31	2.66	2.98	4.7	
		Week 4	Tezepelumab	15	14 (93.3)	2.68 (0.68)	1.3	2.47	2.64	3.18	3.8	
			Placebo	20	19 (95.0)	2.62 (0.50)	1.4	2.39	2.59	2.86	3.7	
		Week 8	Tezepelumab	15	14 (93.3)	2.58 (0.95)	1.0	2.15	2.65	3.43	3.7	
			Placebo	20	19 (95.0)	2.67 (0.75)	1.4	2.30	2.69	2.99	4.9	
		Week 12	Tezepelumab	15	13 (86.7)	2.58 (0.89)	0.8	2.07	2.64	3.37	3.6	
			Placebo	20	20 (100.0)	2.71 (0.77)	1.4	2.39	2.55	3.02	5.0	
		Week 16	Tezepelumab	15	13 (86.7)	2.68 (0.64)	1.5	2.22	2.50	3.31	3.8	
			Placebo	20	20 (100.0)	2.69 (0.75)	1.5	2.39	2.51	2.98	5.2	
		Week 24	Tezepelumab	15	13 (86.7)	2.65 (0.71)	1.6	2.20	2.88	3.16	3.7	
			Placebo	20	18 (90.0)	2.79 (0.77)	1.5	2.52	2.69	3.11	5.1	
		Week 36	Tezepelumab	15	13 (86.7)	2.88 (0.67)	1.4	2.56	2.93	3.30	4.0	
			Placebo	20	18 (90.0)	2.83 (0.96)	1.4	2.34	2.92	3.33	5.3	
		Week 52	Tezepelumab	15	12 (80.0)	2.94 (0.68)	1.9	2.45	2.94	3.38	4.2	
			Placebo	20	18 (90.0)	2.77 (0.95)	1.2	2.14	2.64	3.22	5.3	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
High	Change from baseline	Week 2	Tezepelumab	15	14 (93.3)	0.23 (0.49)	-0.5	-0.04	0.23	0.47	1.4	0.15 [-0.54, 0.83]
			Placebo	20	20 (100.0)	0.15 (0.59)	-1.3	-0.08	0.01	0.25	1.7	
		Week 4	Tezepelumab	15	14 (93.3)	0.13 (0.48)	-0.3	-0.18	-0.11	0.39	1.2	-0.14 [-0.83, 0.55]
			Placebo	20	19 (95.0)	0.21 (0.64)	-1.0	-0.11	0.02	0.40	1.7	
		Week 8	Tezepelumab	15	14 (93.3)	0.03 (0.66)	-1.1	-0.40	0.03	0.42	1.6	-0.13 [-0.82, 0.56]
			Placebo	20	19 (95.0)	0.13 (0.79)	-1.7	-0.22	0.05	0.49	2.0	
		Week 12	Tezepelumab	15	13 (86.7)	-0.00 (0.73)	-1.5	-0.30	-0.09	0.30	1.5	-0.26 [-0.96, 0.44]
			Placebo	20	20 (100.0)	0.18 (0.70)	-1.2	-0.19	0.07	0.40	1.6	
		Week 16	Tezepelumab	15	13 (86.7)	0.19 (0.47)	-0.5	0.00	0.10	0.36	1.4	0.05 [-0.65, 0.74]
			Placebo	20	20 (100.0)	0.16 (0.72)	-1.6	-0.18	0.08	0.35	1.6	
		Week 24	Tezepelumab	15	13 (86.7)	0.15 (0.62)	-0.8	-0.16	0.18	0.27	1.8	-0.01 [-0.72, 0.70]
			Placebo	20	18 (90.0)	0.16 (0.68)	-1.4	-0.06	0.20	0.54	1.5	
		Week 36	Tezepelumab	15	13 (86.7)	0.38 (0.50)	-0.1	-0.01	0.32	0.57	1.7	0.16 [-0.55, 0.88]
			Placebo	20	18 (90.0)	0.26 (0.87)	-1.7	0.03	0.22	0.47	2.2	
		Week 52	Tezepelumab	15	12 (80.0)	0.42 (0.49)	-0.6	0.20	0.47	0.70	1.3	0.31 [-0.42, 1.05]
			Placebo	20	18 (90.0)	0.22 (0.72)	-1.4	-0.02	0.24	0.53	1.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	5	5 (100.0)	2.71 (0.63)	2.1	2.20	2.69	2.91	3.7	
			Placebo	7	7 (100.0)	2.72 (1.14)	1.3	1.41	2.97	4.03	4.1	
		Week 2	Tezepelumab	5	5 (100.0)	2.63 (0.88)	1.7	2.13	2.41	2.98	4.0	
			Placebo	7	7 (100.0)	2.56 (0.92)	1.3	1.74	2.70	2.94	4.2	
		Week 4	Tezepelumab	5	5 (100.0)	2.71 (0.77)	1.9	2.18	2.51	3.19	3.8	
			Placebo	7	7 (100.0)	2.63 (0.76)	1.4	2.17	2.59	3.18	3.8	
		Week 8	Tezepelumab	5	5 (100.0)	2.52 (1.00)	1.1	2.12	2.56	3.15	3.7	
			Placebo	7	7 (100.0)	2.37 (0.79)	1.4	1.54	2.41	2.69	3.8	
		Week 12	Tezepelumab	5	5 (100.0)	2.67 (0.82)	1.7	2.10	2.57	3.43	3.6	
			Placebo	7	7 (100.0)	2.50 (0.85)	1.4	1.68	2.59	3.07	3.9	
		Week 16	Tezepelumab	5	5 (100.0)	2.65 (0.70)	2.0	2.20	2.43	2.87	3.8	
			Placebo	7	7 (100.0)	2.52 (0.73)	1.5	1.89	2.46	3.01	3.7	
		Week 24	Tezepelumab	5	5 (100.0)	2.61 (0.74)	1.7	2.18	2.53	3.05	3.6	
			Placebo	7	6 (85.7)	2.65 (0.88)	1.5	1.95	2.69	3.14	4.0	
		Week 36	Tezepelumab	5	4 (80.0)	2.84 (0.77)	2.3	2.35	2.53	3.32	4.0	
			Placebo	7	6 (85.7)	2.71 (1.08)	1.4	1.38	3.07	3.54	3.8	
		Week 52	Tezepelumab	5	3 (60.0)	3.03 (1.06)	2.3	2.31	2.53	4.24	4.2	
			Placebo	7	6 (85.7)	2.69 (1.15)	1.2	1.49	2.95	3.65	3.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	5	5 (100.0)	-0.07 (0.33)	-0.5	-0.28	0.05	0.07	0.3	0.18 [-0.97, 1.33]
			Placebo	7	7 (100.0)	-0.16 (0.54)	-1.3	-0.27	-0.07	0.09	0.5	
		Week 4	Tezepelumab	5	5 (100.0)	0.01 (0.24)	-0.3	-0.18	0.10	0.13	0.3	0.17 [-0.98, 1.32]
			Placebo	7	7 (100.0)	-0.08 (0.62)	-1.0	-0.43	-0.07	0.21	1.0	
		Week 8	Tezepelumab	5	5 (100.0)	-0.19 (0.54)	-1.1	-0.13	0.04	0.04	0.2	0.26 [-0.90, 1.41]
			Placebo	7	7 (100.0)	-0.34 (0.64)	-1.7	-0.45	-0.33	0.13	0.2	
		Week 12	Tezepelumab	5	5 (100.0)	-0.04 (0.37)	-0.5	-0.12	-0.10	0.02	0.5	0.43 [-0.73, 1.60]
			Placebo	7	7 (100.0)	-0.21 (0.42)	-1.0	-0.38	-0.21	0.03	0.4	
		Week 16	Tezepelumab	5	5 (100.0)	-0.06 (0.13)	-0.3	-0.10	-0.04	0.00	0.1	0.25 [-0.91, 1.40]
			Placebo	7	7 (100.0)	-0.20 (0.71)	-1.6	-0.42	0.04	0.22	0.6	
		Week 24	Tezepelumab	5	5 (100.0)	-0.10 (0.26)	-0.5	-0.16	-0.06	0.10	0.1	0.08 [-1.11, 1.27]
			Placebo	7	6 (85.7)	-0.14 (0.70)	-1.4	-0.26	-0.02	0.17	0.7	
		Week 36	Tezepelumab	5	4 (80.0)	0.18 (0.14)	-0.0	0.08	0.21	0.28	0.3	0.53 [-0.77, 1.82]
			Placebo	7	6 (85.7)	-0.08 (0.62)	-1.2	-0.25	0.04	0.31	0.6	
		Week 52	Tezepelumab	5	3 (60.0)	0.22 (0.38)	-0.2	-0.16	0.23	0.59	0.6	0.54 [-0.87, 1.96]
			Placebo	7	6 (85.7)	-0.11 (0.67)	-1.4	-0.14	-0.02	0.25	0.6	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Absolute values	Baseline	Tezepelumab	36	36 (100.0)	2.67 (0.65)	1.4	2.20	2.81	3.07	4.1	
			Placebo	34	34 (100.0)	2.68 (0.70)	1.0	2.16	2.70	3.09	4.9	
		Week 2	Tezepelumab	36	35 (97.2)	2.85 (0.54)	1.7	2.48	2.89	3.24	3.9	
			Placebo	34	32 (94.1)	2.78 (0.55)	1.8	2.39	2.73	3.10	4.7	
		Week 4	Tezepelumab	36	35 (97.2)	2.75 (0.64)	1.3	2.32	2.78	3.19	4.0	
			Placebo	34	31 (91.2)	2.72 (0.55)	1.3	2.44	2.64	3.14	4.0	
		Week 8	Tezepelumab	36	35 (97.2)	2.76 (0.69)	1.0	2.36	2.81	3.30	3.9	
			Placebo	34	32 (94.1)	2.80 (0.63)	1.2	2.35	2.78	3.15	4.9	
		Week 12	Tezepelumab	36	32 (88.9)	2.78 (0.72)	0.8	2.26	2.84	3.32	4.0	
			Placebo	34	32 (94.1)	2.80 (0.68)	1.5	2.43	2.76	3.07	5.0	
		Week 16	Tezepelumab	36	34 (94.4)	2.79 (0.62)	1.5	2.40	2.86	3.24	3.9	
			Placebo	34	33 (97.1)	2.80 (0.67)	1.6	2.48	2.62	3.17	5.2	
		Week 24	Tezepelumab	36	33 (91.7)	2.83 (0.59)	1.6	2.34	2.90	3.23	3.9	
			Placebo	34	32 (94.1)	2.81 (0.65)	1.7	2.38	2.69	3.19	5.1	
		Week 36	Tezepelumab	36	33 (91.7)	2.89 (0.53)	1.4	2.50	2.95	3.26	3.8	
			Placebo	34	29 (85.3)	2.91 (0.78)	1.4	2.55	2.90	3.30	5.3	
		Week 52	Tezepelumab	36	31 (86.1)	2.98 (0.56)	1.9	2.47	3.08	3.44	4.0	
			Placebo	34	29 (85.3)	2.96 (0.68)	2.1	2.51	2.86	3.27	5.3	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Change from baseline	Week 2	Tezepelumab	36	35 (97.2)	0.18 (0.36)	-0.5	0.00	0.10	0.36	1.4	0.19 [-0.29, 0.67]
			Placebo	34	32 (94.1)	0.10 (0.46)	-0.8	-0.11	0.04	0.20	1.7	
		Week 4	Tezepelumab	36	35 (97.2)	0.10 (0.42)	-1.2	-0.14	0.06	0.33	1.2	-0.06 [-0.54, 0.43]
			Placebo	34	31 (91.2)	0.12 (0.51)	-0.8	-0.18	-0.03	0.34	1.7	
		Week 8	Tezepelumab	36	35 (97.2)	0.10 (0.42)	-0.8	-0.19	0.11	0.31	1.6	-0.06 [-0.54, 0.41]
			Placebo	34	32 (94.1)	0.13 (0.53)	-0.8	-0.13	0.02	0.16	2.0	
		Week 12	Tezepelumab	36	32 (88.9)	0.12 (0.50)	-1.5	-0.13	0.16	0.31	1.5	-0.05 [-0.54, 0.44]
			Placebo	34	32 (94.1)	0.15 (0.59)	-1.2	-0.20	0.07	0.32	1.6	
		Week 16	Tezepelumab	36	34 (94.4)	0.15 (0.38)	-0.5	-0.12	0.12	0.36	1.4	0.01 [-0.47, 0.49]
			Placebo	34	33 (97.1)	0.15 (0.50)	-0.7	-0.10	0.04	0.21	1.6	
		Week 24	Tezepelumab	36	33 (91.7)	0.16 (0.44)	-0.8	-0.08	0.12	0.34	1.8	0.12 [-0.37, 0.60]
			Placebo	34	32 (94.1)	0.10 (0.48)	-1.1	-0.13	0.00	0.25	1.5	
		Week 36	Tezepelumab	36	33 (91.7)	0.22 (0.44)	-0.6	-0.03	0.25	0.42	1.7	-0.01 [-0.51, 0.49]
			Placebo	34	29 (85.3)	0.23 (0.67)	-1.7	-0.04	0.15	0.42	2.2	
		Week 52	Tezepelumab	36	31 (86.1)	0.33 (0.42)	-0.6	0.02	0.39	0.59	1.3	0.15 [-0.36, 0.66]
			Placebo	34	29 (85.3)	0.26 (0.51)	-0.7	-0.01	0.28	0.38	1.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	5	5 (100.0)	2.71 (0.63)	2.1	2.20	2.69	2.91	3.7	
			Placebo	7	7 (100.0)	2.72 (1.14)	1.3	1.41	2.97	4.03	4.1	
		Week 2	Tezepelumab	5	5 (100.0)	2.63 (0.88)	1.7	2.13	2.41	2.98	4.0	
			Placebo	7	7 (100.0)	2.56 (0.92)	1.3	1.74	2.70	2.94	4.2	
		Week 4	Tezepelumab	5	5 (100.0)	2.71 (0.77)	1.9	2.18	2.51	3.19	3.8	
			Placebo	7	7 (100.0)	2.63 (0.76)	1.4	2.17	2.59	3.18	3.8	
		Week 8	Tezepelumab	5	5 (100.0)	2.52 (1.00)	1.1	2.12	2.56	3.15	3.7	
			Placebo	7	7 (100.0)	2.37 (0.79)	1.4	1.54	2.41	2.69	3.8	
		Week 12	Tezepelumab	5	5 (100.0)	2.67 (0.82)	1.7	2.10	2.57	3.43	3.6	
			Placebo	7	7 (100.0)	2.50 (0.85)	1.4	1.68	2.59	3.07	3.9	
		Week 16	Tezepelumab	5	5 (100.0)	2.65 (0.70)	2.0	2.20	2.43	2.87	3.8	
			Placebo	7	7 (100.0)	2.52 (0.73)	1.5	1.89	2.46	3.01	3.7	
		Week 24	Tezepelumab	5	5 (100.0)	2.61 (0.74)	1.7	2.18	2.53	3.05	3.6	
			Placebo	7	6 (85.7)	2.65 (0.88)	1.5	1.95	2.69	3.14	4.0	
		Week 36	Tezepelumab	5	4 (80.0)	2.84 (0.77)	2.3	2.35	2.53	3.32	4.0	
			Placebo	7	6 (85.7)	2.71 (1.08)	1.4	1.38	3.07	3.54	3.8	
		Week 52	Tezepelumab	5	3 (60.0)	3.03 (1.06)	2.3	2.31	2.53	4.24	4.2	
			Placebo	7	6 (85.7)	2.69 (1.15)	1.2	1.49	2.95	3.65	3.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	5	5 (100.0)	-0.07 (0.33)	-0.5	-0.28	0.05	0.07	0.3	0.18 [-0.97, 1.33]
			Placebo	7	7 (100.0)	-0.16 (0.54)	-1.3	-0.27	-0.07	0.09	0.5	
		Week 4	Tezepelumab	5	5 (100.0)	0.01 (0.24)	-0.3	-0.18	0.10	0.13	0.3	0.17 [-0.98, 1.32]
			Placebo	7	7 (100.0)	-0.08 (0.62)	-1.0	-0.43	-0.07	0.21	1.0	
		Week 8	Tezepelumab	5	5 (100.0)	-0.19 (0.54)	-1.1	-0.13	0.04	0.04	0.2	0.26 [-0.90, 1.41]
			Placebo	7	7 (100.0)	-0.34 (0.64)	-1.7	-0.45	-0.33	0.13	0.2	
		Week 12	Tezepelumab	5	5 (100.0)	-0.04 (0.37)	-0.5	-0.12	-0.10	0.02	0.5	0.43 [-0.73, 1.60]
			Placebo	7	7 (100.0)	-0.21 (0.42)	-1.0	-0.38	-0.21	0.03	0.4	
		Week 16	Tezepelumab	5	5 (100.0)	-0.06 (0.13)	-0.3	-0.10	-0.04	0.00	0.1	0.25 [-0.91, 1.40]
			Placebo	7	7 (100.0)	-0.20 (0.71)	-1.6	-0.42	0.04	0.22	0.6	
		Week 24	Tezepelumab	5	5 (100.0)	-0.10 (0.26)	-0.5	-0.16	-0.06	0.10	0.1	0.08 [-1.11, 1.27]
			Placebo	7	6 (85.7)	-0.14 (0.70)	-1.4	-0.26	-0.02	0.17	0.7	
		Week 36	Tezepelumab	5	4 (80.0)	0.18 (0.14)	-0.0	0.08	0.21	0.28	0.3	0.53 [-0.77, 1.82]
			Placebo	7	6 (85.7)	-0.08 (0.62)	-1.2	-0.25	0.04	0.31	0.6	
		Week 52	Tezepelumab	5	3 (60.0)	0.22 (0.38)	-0.2	-0.16	0.23	0.59	0.6	0.54 [-0.87, 1.96]
			Placebo	7	6 (85.7)	-0.11 (0.67)	-1.4	-0.14	-0.02	0.25	0.6	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Absolute values	Baseline	Tezepelumab	36	36 (100.0)	2.67 (0.65)	1.4	2.20	2.81	3.07	4.1	
			Placebo	34	34 (100.0)	2.68 (0.70)	1.0	2.16	2.70	3.09	4.9	
		Week 2	Tezepelumab	36	35 (97.2)	2.85 (0.54)	1.7	2.48	2.89	3.24	3.9	
			Placebo	34	32 (94.1)	2.78 (0.55)	1.8	2.39	2.73	3.10	4.7	
		Week 4	Tezepelumab	36	35 (97.2)	2.75 (0.64)	1.3	2.32	2.78	3.19	4.0	
			Placebo	34	31 (91.2)	2.72 (0.55)	1.3	2.44	2.64	3.14	4.0	
		Week 8	Tezepelumab	36	35 (97.2)	2.76 (0.69)	1.0	2.36	2.81	3.30	3.9	
			Placebo	34	32 (94.1)	2.80 (0.63)	1.2	2.35	2.78	3.15	4.9	
		Week 12	Tezepelumab	36	32 (88.9)	2.78 (0.72)	0.8	2.26	2.84	3.32	4.0	
			Placebo	34	32 (94.1)	2.80 (0.68)	1.5	2.43	2.76	3.07	5.0	
		Week 16	Tezepelumab	36	34 (94.4)	2.79 (0.62)	1.5	2.40	2.86	3.24	3.9	
			Placebo	34	33 (97.1)	2.80 (0.67)	1.6	2.48	2.62	3.17	5.2	
		Week 24	Tezepelumab	36	33 (91.7)	2.83 (0.59)	1.6	2.34	2.90	3.23	3.9	
			Placebo	34	32 (94.1)	2.81 (0.65)	1.7	2.38	2.69	3.19	5.1	
		Week 36	Tezepelumab	36	33 (91.7)	2.89 (0.53)	1.4	2.50	2.95	3.26	3.8	
			Placebo	34	29 (85.3)	2.91 (0.78)	1.4	2.55	2.90	3.30	5.3	
		Week 52	Tezepelumab	36	31 (86.1)	2.98 (0.56)	1.9	2.47	3.08	3.44	4.0	
			Placebo	34	29 (85.3)	2.96 (0.68)	2.1	2.51	2.86	3.27	5.3	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Change from baseline	Week 2	Tezepelumab	36	35 (97.2)	0.18 (0.36)	-0.5	0.00	0.10	0.36	1.4	0.19 [-0.29, 0.67]
			Placebo	34	32 (94.1)	0.10 (0.46)	-0.8	-0.11	0.04	0.20	1.7	
		Week 4	Tezepelumab	36	35 (97.2)	0.10 (0.42)	-1.2	-0.14	0.06	0.33	1.2	-0.06 [-0.54, 0.43]
			Placebo	34	31 (91.2)	0.12 (0.51)	-0.8	-0.18	-0.03	0.34	1.7	
		Week 8	Tezepelumab	36	35 (97.2)	0.10 (0.42)	-0.8	-0.19	0.11	0.31	1.6	-0.06 [-0.54, 0.41]
			Placebo	34	32 (94.1)	0.13 (0.53)	-0.8	-0.13	0.02	0.16	2.0	
		Week 12	Tezepelumab	36	32 (88.9)	0.12 (0.50)	-1.5	-0.13	0.16	0.31	1.5	-0.05 [-0.54, 0.44]
			Placebo	34	32 (94.1)	0.15 (0.59)	-1.2	-0.20	0.07	0.32	1.6	
		Week 16	Tezepelumab	36	34 (94.4)	0.15 (0.38)	-0.5	-0.12	0.12	0.36	1.4	0.01 [-0.47, 0.49]
			Placebo	34	33 (97.1)	0.15 (0.50)	-0.7	-0.10	0.04	0.21	1.6	
		Week 24	Tezepelumab	36	33 (91.7)	0.16 (0.44)	-0.8	-0.08	0.12	0.34	1.8	0.12 [-0.37, 0.60]
			Placebo	34	32 (94.1)	0.10 (0.48)	-1.1	-0.13	0.00	0.25	1.5	
		Week 36	Tezepelumab	36	33 (91.7)	0.22 (0.44)	-0.6	-0.03	0.25	0.42	1.7	-0.01 [-0.51, 0.49]
			Placebo	34	29 (85.3)	0.23 (0.67)	-1.7	-0.04	0.15	0.42	2.2	
		Week 52	Tezepelumab	36	31 (86.1)	0.33 (0.42)	-0.6	0.02	0.39	0.59	1.3	0.15 [-0.36, 0.66]
			Placebo	34	29 (85.3)	0.26 (0.51)	-0.7	-0.01	0.28	0.38	1.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	14	14 (100.0)	2.45 (0.48)	1.4	2.12	2.49	2.84	3.1	
			Placebo	13	13 (100.0)	2.60 (0.83)	1.3	2.16	2.50	3.00	4.1	
		Week 2	Tezepelumab	14	14 (100.0)	2.62 (0.35)	2.1	2.29	2.59	2.91	3.2	
			Placebo	13	13 (100.0)	2.58 (0.68)	1.3	2.37	2.62	2.76	4.2	
		Week 4	Tezepelumab	14	14 (100.0)	2.62 (0.41)	1.8	2.36	2.64	2.80	3.4	
			Placebo	13	13 (100.0)	2.61 (0.57)	1.4	2.39	2.59	2.72	3.8	
		Week 8	Tezepelumab	14	14 (100.0)	2.51 (0.59)	1.0	2.12	2.57	2.88	3.3	
			Placebo	13	12 (92.3)	2.56 (0.66)	1.4	2.33	2.66	2.82	3.8	
		Week 12	Tezepelumab	14	12 (85.7)	2.60 (0.46)	2.0	2.20	2.54	2.98	3.3	
			Placebo	13	13 (100.0)	2.64 (0.65)	1.4	2.44	2.66	2.90	3.9	
		Week 16	Tezepelumab	14	14 (100.0)	2.54 (0.37)	2.0	2.24	2.47	2.74	3.2	
			Placebo	13	13 (100.0)	2.53 (0.57)	1.5	2.44	2.52	2.60	3.7	
		Week 24	Tezepelumab	14	14 (100.0)	2.60 (0.46)	1.6	2.32	2.60	2.90	3.4	
			Placebo	13	13 (100.0)	2.59 (0.58)	1.5	2.38	2.66	2.74	4.0	
		Week 36	Tezepelumab	14	14 (100.0)	2.77 (0.34)	2.3	2.55	2.72	3.08	3.3	
			Placebo	13	11 (84.6)	2.60 (0.79)	1.4	1.86	2.76	3.30	3.8	
		Week 52	Tezepelumab	14	13 (92.9)	2.82 (0.42)	2.2	2.53	2.80	3.21	3.4	
			Placebo	13	12 (92.3)	2.69 (0.83)	1.2	2.31	2.71	3.25	3.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	14	14 (100.0)	0.16 (0.30)	-0.3	0.00	0.06	0.36	0.8	0.50 [-0.26, 1.27]
			Placebo	13	13 (100.0)	-0.01 (0.41)	-1.3	-0.07	0.04	0.16	0.5	
		Week 4	Tezepelumab	14	14 (100.0)	0.17 (0.34)	-0.2	-0.07	0.06	0.39	1.0	0.40 [-0.37, 1.16]
			Placebo	13	13 (100.0)	0.01 (0.47)	-1.0	-0.11	-0.02	0.22	1.0	
		Week 8	Tezepelumab	14	14 (100.0)	0.06 (0.29)	-0.5	-0.13	0.07	0.17	0.6	0.31 [-0.47, 1.08]
			Placebo	13	12 (92.3)	-0.08 (0.57)	-1.7	-0.23	0.09	0.13	0.7	
		Week 12	Tezepelumab	14	12 (85.7)	0.15 (0.23)	-0.2	0.02	0.16	0.25	0.6	0.34 [-0.45, 1.13]
			Placebo	13	13 (100.0)	0.04 (0.38)	-1.0	-0.16	0.03	0.38	0.4	
		Week 16	Tezepelumab	14	14 (100.0)	0.08 (0.25)	-0.3	-0.12	0.06	0.26	0.6	0.38 [-0.39, 1.14]
			Placebo	13	13 (100.0)	-0.07 (0.54)	-1.6	-0.21	0.08	0.21	0.6	
		Week 24	Tezepelumab	14	14 (100.0)	0.15 (0.30)	-0.4	0.01	0.12	0.21	0.8	0.37 [-0.39, 1.13]
			Placebo	13	13 (100.0)	-0.01 (0.52)	-1.4	-0.12	0.00	0.23	0.7	
		Week 36	Tezepelumab	14	14 (100.0)	0.32 (0.25)	-0.0	0.21	0.27	0.44	0.8	1.06 [0.21, 1.90]
			Placebo	13	11 (84.6)	-0.05 (0.44)	-1.2	-0.25	0.02	0.30	0.3	
		Week 52	Tezepelumab	14	13 (92.9)	0.40 (0.33)	-0.2	0.15	0.39	0.65	0.9	0.75 [-0.06, 1.56]
			Placebo	13	12 (92.3)	0.08 (0.51)	-1.4	-0.06	0.16	0.35	0.6	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Absolute values	Baseline	Tezepelumab	27	27 (100.0)	2.79 (0.69)	1.4	2.25	2.91	3.18	4.1	
			Placebo	28	28 (100.0)	2.73 (0.76)	1.0	2.16	2.76	3.19	4.9	
		Week 2	Tezepelumab	27	26 (96.3)	2.93 (0.66)	1.7	2.48	3.03	3.36	4.0	
			Placebo	28	26 (92.9)	2.81 (0.59)	1.8	2.31	2.77	3.11	4.7	
		Week 4	Tezepelumab	27	26 (96.3)	2.81 (0.74)	1.3	2.10	2.92	3.29	4.0	
			Placebo	28	25 (89.3)	2.75 (0.60)	1.3	2.44	2.66	3.15	4.0	
		Week 8	Tezepelumab	27	26 (96.3)	2.84 (0.77)	1.0	2.36	3.12	3.43	3.9	
			Placebo	28	27 (96.4)	2.80 (0.67)	1.2	2.31	2.76	3.15	4.9	
		Week 12	Tezepelumab	27	25 (92.6)	2.84 (0.82)	0.8	2.21	3.05	3.48	4.0	
			Placebo	28	26 (92.9)	2.80 (0.74)	1.5	2.34	2.80	3.07	5.0	
		Week 16	Tezepelumab	27	25 (92.6)	2.91 (0.70)	1.5	2.50	3.06	3.35	3.9	
			Placebo	28	27 (96.4)	2.86 (0.71)	1.6	2.41	2.72	3.21	5.2	
		Week 24	Tezepelumab	27	24 (88.9)	2.91 (0.66)	1.7	2.31	3.03	3.41	3.9	
			Placebo	28	25 (89.3)	2.88 (0.72)	1.7	2.38	2.93	3.22	5.1	
		Week 36	Tezepelumab	27	23 (85.2)	2.96 (0.64)	1.4	2.39	2.99	3.55	4.0	
			Placebo	28	24 (85.7)	3.00 (0.82)	1.4	2.56	3.01	3.53	5.3	
		Week 52	Tezepelumab	27	21 (77.8)	3.09 (0.67)	1.9	2.47	3.29	3.57	4.2	
			Placebo	28	23 (82.1)	3.03 (0.72)	2.1	2.51	3.03	3.41	5.3	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Change from baseline	Week 2	Tezepelumab	27	26 (96.3)	0.14 (0.40)	-0.5	-0.06	0.11	0.32	1.4	0.10 [-0.44, 0.65]
			Placebo	28	26 (92.9)	0.09 (0.52)	-0.8	-0.17	0.01	0.20	1.7	
		Week 4	Tezepelumab	27	26 (96.3)	0.04 (0.42)	-1.2	-0.19	0.07	0.28	1.2	-0.17 [-0.72, 0.38]
			Placebo	28	25 (89.3)	0.12 (0.56)	-0.8	-0.19	-0.07	0.22	1.7	
		Week 8	Tezepelumab	27	26 (96.3)	0.07 (0.50)	-1.1	-0.22	0.12	0.31	1.6	-0.06 [-0.60, 0.48]
			Placebo	28	27 (96.4)	0.10 (0.57)	-0.8	-0.20	-0.02	0.17	2.0	
		Week 12	Tezepelumab	27	25 (92.6)	0.07 (0.57)	-1.5	-0.17	0.09	0.32	1.5	-0.05 [-0.60, 0.50]
			Placebo	28	26 (92.9)	0.10 (0.65)	-1.2	-0.24	0.02	0.19	1.6	
		Week 16	Tezepelumab	27	25 (92.6)	0.15 (0.42)	-0.5	-0.12	0.11	0.36	1.4	-0.03 [-0.58, 0.51]
			Placebo	28	27 (96.4)	0.16 (0.55)	-0.7	-0.10	0.04	0.22	1.6	
		Week 24	Tezepelumab	27	24 (88.9)	0.11 (0.49)	-0.8	-0.16	0.10	0.32	1.8	0.01 [-0.55, 0.57]
			Placebo	28	25 (89.3)	0.10 (0.52)	-1.1	-0.14	0.00	0.23	1.5	
		Week 36	Tezepelumab	27	23 (85.2)	0.15 (0.49)	-0.6	-0.13	0.12	0.40	1.7	-0.19 [-0.77, 0.38]
			Placebo	28	24 (85.7)	0.27 (0.73)	-1.7	-0.06	0.15	0.52	2.2	
		Week 52	Tezepelumab	27	21 (77.8)	0.27 (0.46)	-0.6	-0.10	0.37	0.54	1.3	0.03 [-0.57, 0.62]
			Placebo	28	23 (82.1)	0.26 (0.57)	-0.7	-0.02	0.25	0.38	1.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Sex									0.969
Male	Week 2	Tezepelumab	20	19 (95.0)	0.14 (0.10)	(-0.06, 0.35)	0.11 (0.14)	(-0.18, 0.40)	0.457
		Placebo	18	18 (100.0)	0.04 (0.10)	(-0.18, 0.25)			
	Week 4	Tezepelumab	20	19 (95.0)	0.11 (0.11)	(-0.11, 0.33)	-0.05 (0.16)	(-0.37, 0.27)	0.741
		Placebo	18	16 (88.9)	0.16 (0.11)	(-0.07, 0.39)			
	Week 8	Tezepelumab	20	19 (95.0)	0.12 (0.13)	(-0.16, 0.39)	-0.04 (0.19)	(-0.43, 0.36)	0.851
		Placebo	18	17 (94.4)	0.15 (0.14)	(-0.13, 0.44)			
	Week 12	Tezepelumab	20	18 (90.0)	0.21 (0.13)	(-0.06, 0.47)	0.01 (0.19)	(-0.37, 0.39)	0.957
		Placebo	18	17 (94.4)	0.20 (0.14)	(-0.08, 0.47)			
	Week 16	Tezepelumab	20	18 (90.0)	0.22 (0.12)	(-0.03, 0.46)	0.01 (0.18)	(-0.34, 0.37)	0.946
		Placebo	18	17 (94.4)	0.20 (0.13)	(-0.05, 0.46)			
	Week 24	Tezepelumab	20	17 (85.0)	0.22 (0.13)	(-0.03, 0.48)	0.03 (0.18)	(-0.35, 0.40)	0.889
		Placebo	18	15 (83.3)	0.20 (0.13)	(-0.07, 0.47)			
	Week 36	Tezepelumab	20	16 (80.0)	0.30 (0.13)	(0.05, 0.56)	-0.10 (0.18)	(-0.47, 0.27)	0.586
		Placebo	18	15 (83.3)	0.40 (0.13)	(0.14, 0.67)			
	Week 52	Tezepelumab	20	13 (65.0)	0.47 (0.12)	(0.22, 0.71)	0.14 (0.17)	(-0.21, 0.49)	0.420
		Placebo	18	14 (77.8)	0.33 (0.12)	(0.08, 0.58)			

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Female	Week 2	Tezepelumab	21	21 (100.0)	0.15 (0.06)	(0.03, 0.27)	0.08 (0.08)	(-0.09, 0.24)	0.347
		Placebo	23	21 (91.3)	0.07 (0.06)	(-0.05, 0.19)			
	Week 4	Tezepelumab	21	21 (100.0)	0.07 (0.08)	(-0.09, 0.24)	0.07 (0.11)	(-0.16, 0.29)	0.547
		Placebo	23	22 (95.7)	0.01 (0.08)	(-0.15, 0.16)			
	Week 8	Tezepelumab	21	21 (100.0)	0.04 (0.07)	(-0.10, 0.18)	0.08 (0.10)	(-0.11, 0.28)	0.386
		Placebo	23	22 (95.7)	-0.05 (0.07)	(-0.18, 0.09)			
	Week 12	Tezepelumab	21	19 (90.5)	0.03 (0.09)	(-0.15, 0.20)	0.05 (0.12)	(-0.19, 0.29)	0.672
		Placebo	23	22 (95.7)	-0.02 (0.08)	(-0.19, 0.14)			
	Week 16	Tezepelumab	21	21 (100.0)	0.07 (0.06)	(-0.05, 0.19)	0.08 (0.08)	(-0.09, 0.25)	0.342
		Placebo	23	23 (100.0)	-0.01 (0.06)	(-0.13, 0.10)			
	Week 24	Tezepelumab	21	21 (100.0)	0.06 (0.07)	(-0.08, 0.20)	0.03 (0.10)	(-0.17, 0.22)	0.775
		Placebo	23	23 (100.0)	0.03 (0.07)	(-0.10, 0.17)			
	Week 36	Tezepelumab	21	21 (100.0)	0.16 (0.09)	(-0.01, 0.33)	0.22 (0.12)	(-0.03, 0.46)	0.084
		Placebo	23	20 (87.0)	-0.06 (0.09)	(-0.23, 0.12)			
	Week 52	Tezepelumab	21	21 (100.0)	0.23 (0.08)	(0.08, 0.38)	0.17 (0.11)	(-0.04, 0.39)	0.109
		Placebo	23	21 (91.3)	0.06 (0.07)	(-0.09, 0.21)			

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Exacerbations in the year before study									0.552
<= 2	Week 2	Tezepelumab	26	26 (100.0)	0.16 (0.06)	(0.03, 0.29)	0.15 (0.09)	(-0.03, 0.33)	0.104
		Placebo	26	24 (92.3)	0.01 (0.07)	(-0.12, 0.14)			
	Week 4	Tezepelumab	26	26 (100.0)	0.13 (0.07)	(-0.00, 0.27)	0.11 (0.10)	(-0.09, 0.30)	0.277
		Placebo	26	23 (88.5)	0.03 (0.07)	(-0.11, 0.17)			
	Week 8	Tezepelumab	26	26 (100.0)	0.09 (0.08)	(-0.06, 0.25)	0.08 (0.11)	(-0.15, 0.30)	0.497
		Placebo	26	24 (92.3)	0.02 (0.08)	(-0.14, 0.18)			
	Week 12	Tezepelumab	26	25 (96.2)	0.12 (0.10)	(-0.08, 0.32)	0.13 (0.14)	(-0.15, 0.42)	0.354
		Placebo	26	24 (92.3)	-0.02 (0.10)	(-0.22, 0.19)			
	Week 16	Tezepelumab	26	25 (96.2)	0.14 (0.08)	(-0.02, 0.31)	0.08 (0.12)	(-0.15, 0.32)	0.486
		Placebo	26	25 (96.2)	0.06 (0.08)	(-0.11, 0.23)			
	Week 24	Tezepelumab	26	24 (92.3)	0.11 (0.09)	(-0.07, 0.29)	0.08 (0.13)	(-0.17, 0.33)	0.528
		Placebo	26	24 (92.3)	0.03 (0.09)	(-0.15, 0.21)			
	Week 36	Tezepelumab	26	23 (88.5)	0.21 (0.10)	(0.01, 0.42)	0.15 (0.15)	(-0.14, 0.44)	0.307
		Placebo	26	21 (80.8)	0.06 (0.10)	(-0.15, 0.27)			
	Week 52	Tezepelumab	26	22 (84.6)	0.29 (0.09)	(0.12, 0.47)	0.13 (0.13)	(-0.12, 0.39)	0.300
		Placebo	26	21 (80.8)	0.16 (0.09)	(-0.02, 0.34)			

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
> 2	Week 2	Tezepelumab	15	14 (93.3)	0.15 (0.11)	(-0.08, 0.38)	0.04 (0.16)	(-0.28, 0.37)	0.778
		Placebo	15	15 (100.0)	0.11 (0.11)	(-0.12, 0.33)			
	Week 4	Tezepelumab	15	14 (93.3)	0.03 (0.13)	(-0.24, 0.30)	-0.12 (0.19)	(-0.50, 0.26)	0.528
		Placebo	15	15 (100.0)	0.15 (0.13)	(-0.12, 0.41)			
	Week 8	Tezepelumab	15	14 (93.3)	0.06 (0.15)	(-0.25, 0.38)	-0.00 (0.22)	(-0.45, 0.44)	0.982
		Placebo	15	15 (100.0)	0.07 (0.15)	(-0.24, 0.38)			
	Week 12	Tezepelumab	15	12 (80.0)	0.09 (0.12)	(-0.16, 0.34)	-0.08 (0.17)	(-0.42, 0.27)	0.659
		Placebo	15	15 (100.0)	0.17 (0.12)	(-0.07, 0.41)			
	Week 16	Tezepelumab	15	14 (93.3)	0.14 (0.11)	(-0.08, 0.36)	0.04 (0.15)	(-0.27, 0.35)	0.794
		Placebo	15	15 (100.0)	0.10 (0.11)	(-0.12, 0.32)			
	Week 24	Tezepelumab	15	14 (93.3)	0.21 (0.11)	(-0.02, 0.44)	-0.01 (0.16)	(-0.34, 0.32)	0.944
		Placebo	15	14 (93.3)	0.22 (0.11)	(-0.01, 0.45)			
	Week 36	Tezepelumab	15	14 (93.3)	0.26 (0.13)	(-0.01, 0.54)	0.02 (0.19)	(-0.37, 0.40)	0.925
		Placebo	15	14 (93.3)	0.25 (0.13)	(-0.03, 0.52)			
	Week 52	Tezepelumab	15	12 (80.0)	0.41 (0.12)	(0.16, 0.66)	0.24 (0.17)	(-0.11, 0.59)	0.167
		Placebo	15	14 (93.3)	0.17 (0.12)	(-0.07, 0.41)			

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Race				N<10 any level					NE

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Region				N<10 any level					NE

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
BMI				N<10 any level					NE

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline eosinophils - Low									0.971
< 150 cells/uL	Week 2	Tezepelumab	8	8 (100.0)	-0.02 (0.10)	(-0.25, 0.22)	0.07 (0.16)	(-0.29, 0.43)	0.664
		Placebo	6	6 (100.0)	-0.09 (0.12)	(-0.36, 0.18)			
	Week 4	Tezepelumab	8	8 (100.0)	0.04 (0.10)	(-0.19, 0.27)	0.02 (0.16)	(-0.33, 0.37)	0.916
		Placebo	6	5 (83.3)	0.02 (0.12)	(-0.24, 0.29)			
	Week 8	Tezepelumab	8	8 (100.0)	0.04 (0.11)	(-0.20, 0.28)	0.04 (0.16)	(-0.33, 0.40)	0.818
		Placebo	6	6 (100.0)	0.00 (0.12)	(-0.27, 0.28)			
	Week 12	Tezepelumab	8	7 (87.5)	-0.10 (0.10)	(-0.32, 0.11)	-0.19 (0.15)	(-0.52, 0.15)	0.235
		Placebo	6	5 (83.3)	0.09 (0.11)	(-0.17, 0.34)			
	Week 16	Tezepelumab	8	8 (100.0)	-0.04 (0.09)	(-0.24, 0.15)	-0.14 (0.13)	(-0.44, 0.16)	0.322
		Placebo	6	6 (100.0)	0.10 (0.10)	(-0.13, 0.32)			
	Week 24	Tezepelumab	8	8 (100.0)	-0.02 (0.11)	(-0.26, 0.22)	-0.09 (0.17)	(-0.46, 0.28)	0.600
		Placebo	6	6 (100.0)	0.07 (0.12)	(-0.21, 0.35)			
	Week 36	Tezepelumab	8	8 (100.0)	0.02 (0.13)	(-0.27, 0.31)	-0.18 (0.20)	(-0.62, 0.27)	0.395
		Placebo	6	5 (83.3)	0.20 (0.15)	(-0.14, 0.54)			
	Week 52	Tezepelumab	8	7 (87.5)	0.08 (0.11)	(-0.17, 0.33)	-0.13 (0.17)	(-0.51, 0.26)	0.482
		Placebo	6	6 (100.0)	0.21 (0.13)	(-0.08, 0.49)			

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 150 cells/uL	Week 2	Tezepelumab	33	32 (97.0)	0.18 (0.06)	(0.05, 0.30)	0.08 (0.09)	(-0.09, 0.26)	0.352
		Placebo	35	33 (94.3)	0.09 (0.06)	(-0.03, 0.22)			
	Week 4	Tezepelumab	33	32 (97.0)	0.09 (0.08)	(-0.07, 0.24)	-0.01 (0.11)	(-0.23, 0.20)	0.891
		Placebo	35	33 (94.3)	0.10 (0.08)	(-0.05, 0.25)			
	Week 8	Tezepelumab	33	32 (97.0)	0.07 (0.09)	(-0.11, 0.24)	0.01 (0.12)	(-0.24, 0.25)	0.948
		Placebo	35	33 (94.3)	0.06 (0.09)	(-0.11, 0.23)			
	Week 12	Tezepelumab	33	30 (90.9)	0.14 (0.09)	(-0.04, 0.32)	0.06 (0.13)	(-0.19, 0.31)	0.638
		Placebo	35	34 (97.1)	0.08 (0.09)	(-0.09, 0.26)			
	Week 16	Tezepelumab	33	31 (93.9)	0.16 (0.08)	(0.01, 0.32)	0.07 (0.11)	(-0.14, 0.28)	0.506
		Placebo	35	34 (97.1)	0.09 (0.07)	(-0.06, 0.24)			
	Week 24	Tezepelumab	33	30 (90.9)	0.16 (0.08)	(-0.01, 0.32)	0.04 (0.12)	(-0.19, 0.27)	0.757
		Placebo	35	32 (91.4)	0.12 (0.08)	(-0.04, 0.28)			
	Week 36	Tezepelumab	33	29 (87.9)	0.26 (0.09)	(0.08, 0.45)	0.12 (0.13)	(-0.14, 0.38)	0.378
		Placebo	35	30 (85.7)	0.15 (0.09)	(-0.03, 0.33)			
	Week 52	Tezepelumab	33	27 (81.8)	0.37 (0.08)	(0.21, 0.54)	0.20 (0.12)	(-0.04, 0.43)	0.095
		Placebo	35	29 (82.9)	0.18 (0.08)	(0.02, 0.34)			

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline eosinophils - High									0.525
< 300 cells/uL	Week 2	Tezepelumab	23	23 (100.0)	0.13 (0.05)	(0.03, 0.23)	0.10 (0.08)	(-0.06, 0.27)	0.212
		Placebo	14	13 (92.9)	0.03 (0.07)	(-0.10, 0.16)			
	Week 4	Tezepelumab	23	22 (95.7)	0.08 (0.06)	(-0.04, 0.21)	0.17 (0.10)	(-0.03, 0.38)	0.091
		Placebo	14	13 (92.9)	-0.09 (0.08)	(-0.25, 0.07)			
	Week 8	Tezepelumab	23	22 (95.7)	0.08 (0.05)	(-0.02, 0.18)	0.16 (0.08)	(0.01, 0.32)	0.040 *
		Placebo	14	14 (100.0)	-0.08 (0.06)	(-0.20, 0.04)			
	Week 12	Tezepelumab	23	19 (82.6)	0.03 (0.06)	(-0.11, 0.16)	0.14 (0.10)	(-0.07, 0.35)	0.173
		Placebo	14	13 (92.9)	-0.12 (0.08)	(-0.27, 0.04)			
	Week 16	Tezepelumab	23	22 (95.7)	0.05 (0.05)	(-0.05, 0.15)	0.08 (0.08)	(-0.08, 0.24)	0.307
		Placebo	14	14 (100.0)	-0.03 (0.06)	(-0.15, 0.10)			
	Week 24	Tezepelumab	23	21 (91.3)	0.07 (0.06)	(-0.05, 0.19)	0.09 (0.09)	(-0.10, 0.28)	0.334
		Placebo	14	14 (100.0)	-0.02 (0.07)	(-0.17, 0.13)			
	Week 36	Tezepelumab	23	21 (91.3)	0.08 (0.08)	(-0.07, 0.24)	0.03 (0.13)	(-0.22, 0.29)	0.789
		Placebo	14	11 (78.6)	0.05 (0.10)	(-0.16, 0.26)			
	Week 52	Tezepelumab	23	19 (82.6)	0.29 (0.06)	(0.16, 0.41)	0.20 (0.10)	(-0.00, 0.40)	0.053
		Placebo	14	10 (71.4)	0.09 (0.08)	(-0.07, 0.25)			

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 300 cells/uL	Week 2	Tezepelumab	18	17 (94.4)	0.13 (0.09)	(-0.06, 0.32)	0.02 (0.12)	(-0.22, 0.27)	0.857
		Placebo	27	26 (96.3)	0.11 (0.08)	(-0.05, 0.26)			
	Week 4	Tezepelumab	18	18 (100.0)	0.05 (0.11)	(-0.16, 0.26)	-0.15 (0.14)	(-0.43, 0.12)	0.269
		Placebo	27	25 (92.6)	0.20 (0.09)	(0.03, 0.38)			
	Week 8	Tezepelumab	18	18 (100.0)	0.01 (0.13)	(-0.26, 0.28)	-0.12 (0.17)	(-0.47, 0.23)	0.482
		Placebo	27	25 (92.6)	0.13 (0.11)	(-0.09, 0.35)			
	Week 12	Tezepelumab	18	18 (100.0)	0.17 (0.13)	(-0.10, 0.43)	-0.02 (0.17)	(-0.36, 0.32)	0.893
		Placebo	27	26 (96.3)	0.19 (0.11)	(-0.03, 0.41)			
	Week 16	Tezepelumab	18	17 (94.4)	0.18 (0.11)	(-0.04, 0.41)	0.01 (0.14)	(-0.27, 0.30)	0.923
		Placebo	27	26 (96.3)	0.17 (0.09)	(-0.01, 0.35)			
	Week 24	Tezepelumab	18	17 (94.4)	0.17 (0.12)	(-0.08, 0.41)	-0.04 (0.16)	(-0.36, 0.28)	0.810
		Placebo	27	24 (88.9)	0.20 (0.10)	(-0.00, 0.41)			
	Week 36	Tezepelumab	18	16 (88.9)	0.34 (0.13)	(0.07, 0.61)	0.10 (0.17)	(-0.25, 0.45)	0.559
		Placebo	27	24 (88.9)	0.24 (0.11)	(0.02, 0.46)			
	Week 52	Tezepelumab	18	15 (83.3)	0.33 (0.13)	(0.07, 0.59)	0.09 (0.17)	(-0.24, 0.43)	0.582
		Placebo	27	25 (92.6)	0.24 (0.10)	(0.03, 0.45)			

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline FENO									0.996
< 25 ppb	Week 2	Tezepelumab	11	11 (100.0)	0.05 (0.07)	(-0.09, 0.18)	0.09 (0.09)	(-0.09, 0.28)	0.295
		Placebo	16	14 (87.5)	-0.05 (0.06)	(-0.17, 0.07)			
	Week 4	Tezepelumab	11	11 (100.0)	0.02 (0.07)	(-0.12, 0.17)	0.14 (0.09)	(-0.05, 0.34)	0.149
		Placebo	16	14 (87.5)	-0.12 (0.06)	(-0.25, 0.01)			
	Week 8	Tezepelumab	11	11 (100.0)	0.11 (0.05)	(0.01, 0.21)	0.22 (0.06)	(0.08, 0.35)	0.003 *
		Placebo	16	15 (93.8)	-0.11 (0.04)	(-0.20, -0.02)			
	Week 12	Tezepelumab	11	10 (90.9)	-0.01 (0.08)	(-0.18, 0.16)	0.09 (0.11)	(-0.13, 0.31)	0.397
		Placebo	16	14 (87.5)	-0.10 (0.07)	(-0.25, 0.04)			
	Week 16	Tezepelumab	11	11 (100.0)	0.02 (0.06)	(-0.11, 0.15)	0.11 (0.08)	(-0.06, 0.28)	0.203
		Placebo	16	15 (93.8)	-0.09 (0.05)	(-0.20, 0.02)			
	Week 24	Tezepelumab	11	10 (90.9)	0.08 (0.07)	(-0.06, 0.22)	0.12 (0.09)	(-0.06, 0.30)	0.183
		Placebo	16	15 (93.8)	-0.04 (0.06)	(-0.16, 0.08)			
	Week 36	Tezepelumab	11	9 (81.8)	0.24 (0.10)	(0.03, 0.44)	0.19 (0.13)	(-0.09, 0.46)	0.164
		Placebo	16	13 (81.3)	0.05 (0.08)	(-0.13, 0.22)			
	Week 52	Tezepelumab	11	8 (72.7)	0.34 (0.09)	(0.16, 0.52)	0.19 (0.11)	(-0.04, 0.42)	0.098
		Placebo	16	12 (75.0)	0.15 (0.07)	(0.00, 0.30)			

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 25 ppb	Week 2	Tezepelumab	30	29 (96.7)	0.20 (0.07)	(0.05, 0.34)	0.10 (0.11)	(-0.12, 0.31)	0.378
		Placebo	25	25 (100.0)	0.10 (0.08)	(-0.06, 0.26)			
	Week 4	Tezepelumab	30	29 (96.7)	0.12 (0.09)	(-0.05, 0.29)	-0.08 (0.13)	(-0.33, 0.18)	0.550
		Placebo	25	24 (96.0)	0.20 (0.09)	(0.01, 0.39)			
	Week 8	Tezepelumab	30	29 (96.7)	0.07 (0.10)	(-0.14, 0.27)	-0.06 (0.15)	(-0.37, 0.24)	0.673
		Placebo	25	24 (96.0)	0.13 (0.11)	(-0.09, 0.35)			
	Week 12	Tezepelumab	30	27 (90.0)	0.17 (0.10)	(-0.04, 0.38)	0.00 (0.15)	(-0.31, 0.31)	0.998
		Placebo	25	25 (100.0)	0.17 (0.11)	(-0.05, 0.40)			
	Week 16	Tezepelumab	30	28 (93.3)	0.19 (0.09)	(0.01, 0.36)	-0.01 (0.13)	(-0.27, 0.25)	0.953
		Placebo	25	25 (100.0)	0.19 (0.09)	(0.00, 0.38)			
	Week 24	Tezepelumab	30	28 (93.3)	0.17 (0.09)	(-0.02, 0.36)	-0.03 (0.14)	(-0.31, 0.25)	0.834
		Placebo	25	23 (92.0)	0.20 (0.10)	(-0.01, 0.40)			
	Week 36	Tezepelumab	30	28 (93.3)	0.25 (0.11)	(0.04, 0.46)	0.04 (0.16)	(-0.27, 0.35)	0.793
		Placebo	25	22 (88.0)	0.21 (0.12)	(-0.02, 0.44)			
	Week 52	Tezepelumab	30	26 (86.7)	0.34 (0.09)	(0.15, 0.53)	0.14 (0.14)	(-0.14, 0.41)	0.332
		Placebo	25	23 (92.0)	0.20 (0.10)	(0.00, 0.41)			

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline specific perennial FEIA status				N<10 any level					NE

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Total serum IgE									0.430
Low	Week 2	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	5	5 (100.0)					
	Week 4	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	5	5 (100.0)					
	Week 8	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	5	5 (100.0)					
	Week 12	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	5	5 (100.0)					
	Week 16	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	5	5 (100.0)					
	Week 24	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	5	4 (80.0)					
	Week 36	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	5	2 (40.0)					
	Week 52	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	5	3 (60.0)					

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Normal	Week 2	Tezepelumab	29	28 (96.6)	0.15 (0.06)	(0.04, 0.27)	0.19 (0.09)	(0.01, 0.36)	0.039 *
		Placebo	25	23 (92.0)	-0.03 (0.06)	(-0.16, 0.10)			
	Week 4	Tezepelumab	29	28 (96.6)	0.08 (0.06)	(-0.04, 0.19)	0.15 (0.09)	(-0.02, 0.33)	0.083
		Placebo	25	22 (88.0)	-0.08 (0.06)	(-0.21, 0.05)			
	Week 8	Tezepelumab	29	28 (96.6)	0.04 (0.07)	(-0.11, 0.19)	0.12 (0.11)	(-0.10, 0.34)	0.280
		Placebo	25	23 (92.0)	-0.08 (0.08)	(-0.25, 0.08)			
	Week 12	Tezepelumab	29	26 (89.7)	0.08 (0.08)	(-0.08, 0.24)	0.14 (0.11)	(-0.09, 0.37)	0.230
		Placebo	25	24 (96.0)	-0.06 (0.08)	(-0.23, 0.11)			
	Week 16	Tezepelumab	29	27 (93.1)	0.14 (0.07)	(0.00, 0.28)	0.22 (0.10)	(0.02, 0.42)	0.030 *
		Placebo	25	24 (96.0)	-0.08 (0.07)	(-0.23, 0.06)			
	Week 24	Tezepelumab	29	26 (89.7)	0.08 (0.06)	(-0.05, 0.20)	0.11 (0.09)	(-0.07, 0.29)	0.243
		Placebo	25	24 (96.0)	-0.03 (0.07)	(-0.16, 0.10)			
	Week 36	Tezepelumab	29	25 (86.2)	0.18 (0.07)	(0.04, 0.33)	0.14 (0.10)	(-0.07, 0.35)	0.184
		Placebo	25	22 (88.0)	0.04 (0.08)	(-0.11, 0.19)			
	Week 52	Tezepelumab	29	22 (75.9)	0.28 (0.07)	(0.13, 0.42)	0.15 (0.11)	(-0.06, 0.36)	0.160
		Placebo	25	21 (84.0)	0.13 (0.08)	(-0.02, 0.28)			

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
High	Week 2	Tezepelumab	7	7 (100.0)	NE		NE		
		Placebo	11	11 (100.0)					
	Week 4	Tezepelumab	7	7 (100.0)	NE		NE		
		Placebo	11	11 (100.0)					
	Week 8	Tezepelumab	7	7 (100.0)	NE		NE		
		Placebo	11	11 (100.0)					
	Week 12	Tezepelumab	7	6 (85.7)	NE		NE		
		Placebo	11	10 (90.9)					
	Week 16	Tezepelumab	7	7 (100.0)	NE		NE		
		Placebo	11	11 (100.0)					
	Week 24	Tezepelumab	7	7 (100.0)	NE		NE		
		Placebo	11	10 (90.9)					
	Week 36	Tezepelumab	7	7 (100.0)	NE		NE		
		Placebo	11	11 (100.0)					
	Week 52	Tezepelumab	7	7 (100.0)	NE		NE		
		Placebo	11	11 (100.0)					

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
OCS at baseline				N<10 any level					NE

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
ICS dose level (at study entry)									0.760
Medium/Low	Week 2	Tezepelumab	26	26 (100.0)	0.09 (0.05)	(-0.01, 0.20)	0.12 (0.08)	(-0.04, 0.28)	0.135
		Placebo	21	19 (90.5)	-0.03 (0.06)	(-0.15, 0.09)			
	Week 4	Tezepelumab	26	26 (100.0)	0.05 (0.07)	(-0.09, 0.19)	0.10 (0.11)	(-0.12, 0.31)	0.362
		Placebo	21	19 (90.5)	-0.05 (0.08)	(-0.21, 0.11)			
	Week 8	Tezepelumab	26	26 (100.0)	0.07 (0.05)	(-0.02, 0.17)	0.11 (0.07)	(-0.04, 0.25)	0.157
		Placebo	21	20 (95.2)	-0.03 (0.05)	(-0.14, 0.08)			
	Week 12	Tezepelumab	26	24 (92.3)	0.14 (0.07)	(0.01, 0.27)	0.18 (0.10)	(-0.02, 0.38)	0.078
		Placebo	21	19 (90.5)	-0.03 (0.07)	(-0.18, 0.11)			
	Week 16	Tezepelumab	26	26 (100.0)	0.09 (0.06)	(-0.03, 0.21)	0.07 (0.09)	(-0.11, 0.25)	0.456
		Placebo	21	20 (95.2)	0.02 (0.07)	(-0.12, 0.15)			
	Week 24	Tezepelumab	26	25 (96.2)	0.10 (0.06)	(-0.01, 0.22)	0.12 (0.09)	(-0.05, 0.30)	0.155
		Placebo	21	20 (95.2)	-0.02 (0.06)	(-0.15, 0.11)			
	Week 36	Tezepelumab	26	24 (92.3)	0.12 (0.07)	(-0.02, 0.26)	0.09 (0.11)	(-0.13, 0.30)	0.409
		Placebo	21	17 (81.0)	0.03 (0.08)	(-0.13, 0.20)			
	Week 52	Tezepelumab	26	22 (84.6)	0.26 (0.07)	(0.13, 0.40)	0.13 (0.10)	(-0.07, 0.33)	0.181
		Placebo	21	17 (81.0)	0.13 (0.07)	(-0.02, 0.28)			

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
High	Week 2	Tezepelumab	15	14 (93.3)	0.26 (0.12)	(0.02, 0.50)	0.12 (0.15)	(-0.20, 0.43)	0.446
		Placebo	20	20 (100.0)	0.14 (0.10)	(-0.06, 0.35)			
	Week 4	Tezepelumab	15	14 (93.3)	0.16 (0.12)	(-0.09, 0.41)	-0.02 (0.16)	(-0.35, 0.31)	0.895
		Placebo	20	19 (95.0)	0.18 (0.11)	(-0.03, 0.40)			
	Week 8	Tezepelumab	15	14 (93.3)	0.08 (0.17)	(-0.27, 0.43)	-0.03 (0.23)	(-0.50, 0.43)	0.880
		Placebo	20	19 (95.0)	0.11 (0.15)	(-0.19, 0.41)			
	Week 12	Tezepelumab	15	13 (86.7)	0.08 (0.17)	(-0.27, 0.42)	-0.10 (0.22)	(-0.55, 0.34)	0.636
		Placebo	20	20 (100.0)	0.18 (0.14)	(-0.11, 0.47)			
	Week 16	Tezepelumab	15	13 (86.7)	0.23 (0.14)	(-0.05, 0.51)	0.07 (0.18)	(-0.30, 0.44)	0.692
		Placebo	20	20 (100.0)	0.16 (0.12)	(-0.08, 0.40)			
	Week 24	Tezepelumab	15	13 (86.7)	0.21 (0.15)	(-0.11, 0.52)	-0.03 (0.20)	(-0.45, 0.38)	0.871
		Placebo	20	18 (90.0)	0.24 (0.13)	(-0.03, 0.51)			
	Week 36	Tezepelumab	15	13 (86.7)	0.44 (0.17)	(0.08, 0.79)	0.17 (0.23)	(-0.29, 0.63)	0.464
		Placebo	20	18 (90.0)	0.27 (0.15)	(-0.03, 0.57)			
	Week 52	Tezepelumab	15	12 (80.0)	0.41 (0.16)	(0.09, 0.73)	0.20 (0.21)	(-0.22, 0.62)	0.339
		Placebo	20	18 (90.0)	0.21 (0.13)	(-0.06, 0.48)			

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
LAMA use at baseline									0.933
Yes	Week 2	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 4	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 8	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 12	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 16	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 24	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	7	6 (85.7)					
	Week 36	Tezepelumab	5	4 (80.0)	NE		NE		
		Placebo	7	6 (85.7)					
	Week 52	Tezepelumab	5	3 (60.0)	NE		NE		
		Placebo	7	6 (85.7)					

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 2	Tezepelumab	36	35 (97.2)	0.18 (0.06)	(0.07, 0.29)	0.09 (0.08)	(-0.07, 0.25)	0.279
		Placebo	34	32 (94.1)	0.10 (0.06)	(-0.02, 0.21)			
	Week 4	Tezepelumab	36	35 (97.2)	0.10 (0.07)	(-0.04, 0.25)	-0.00 (0.10)	(-0.21, 0.21)	0.989
		Placebo	34	31 (91.2)	0.11 (0.08)	(-0.04, 0.26)			
	Week 8	Tezepelumab	36	35 (97.2)	0.11 (0.07)	(-0.04, 0.26)	-0.01 (0.11)	(-0.22, 0.21)	0.951
		Placebo	34	32 (94.1)	0.12 (0.08)	(-0.03, 0.27)			
	Week 12	Tezepelumab	36	32 (88.9)	0.14 (0.09)	(-0.03, 0.31)	0.01 (0.12)	(-0.23, 0.26)	0.921
		Placebo	34	32 (94.1)	0.12 (0.09)	(-0.05, 0.30)			
	Week 16	Tezepelumab	36	34 (94.4)	0.17 (0.07)	(0.03, 0.31)	0.03 (0.10)	(-0.17, 0.23)	0.786
		Placebo	34	33 (97.1)	0.14 (0.07)	(-0.00, 0.28)			
	Week 24	Tezepelumab	36	33 (91.7)	0.17 (0.08)	(0.02, 0.32)	0.03 (0.11)	(-0.19, 0.24)	0.802
		Placebo	34	32 (94.1)	0.15 (0.08)	(-0.01, 0.30)			
	Week 36	Tezepelumab	36	33 (91.7)	0.23 (0.09)	(0.06, 0.41)	0.06 (0.13)	(-0.19, 0.31)	0.651
		Placebo	34	29 (85.3)	0.18 (0.09)	(-0.00, 0.36)			
	Week 52	Tezepelumab	36	31 (86.1)	0.34 (0.07)	(0.20, 0.48)	0.12 (0.10)	(-0.08, 0.33)	0.241
		Placebo	34	29 (85.3)	0.22 (0.07)	(0.07, 0.37)			

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Tiotropium use at baseline									0.933
Yes	Week 2	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 4	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 8	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 12	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 16	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 24	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	7	6 (85.7)					
	Week 36	Tezepelumab	5	4 (80.0)	NE		NE		
		Placebo	7	6 (85.7)					
	Week 52	Tezepelumab	5	3 (60.0)	NE		NE		
		Placebo	7	6 (85.7)					

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 2	Tezepelumab	36	35 (97.2)	0.18 (0.06)	(0.07, 0.29)	0.09 (0.08)	(-0.07, 0.25)	0.279
		Placebo	34	32 (94.1)	0.10 (0.06)	(-0.02, 0.21)			
	Week 4	Tezepelumab	36	35 (97.2)	0.10 (0.07)	(-0.04, 0.25)	-0.00 (0.10)	(-0.21, 0.21)	0.989
		Placebo	34	31 (91.2)	0.11 (0.08)	(-0.04, 0.26)			
	Week 8	Tezepelumab	36	35 (97.2)	0.11 (0.07)	(-0.04, 0.26)	-0.01 (0.11)	(-0.22, 0.21)	0.951
		Placebo	34	32 (94.1)	0.12 (0.08)	(-0.03, 0.27)			
	Week 12	Tezepelumab	36	32 (88.9)	0.14 (0.09)	(-0.03, 0.31)	0.01 (0.12)	(-0.23, 0.26)	0.921
		Placebo	34	32 (94.1)	0.12 (0.09)	(-0.05, 0.30)			
	Week 16	Tezepelumab	36	34 (94.4)	0.17 (0.07)	(0.03, 0.31)	0.03 (0.10)	(-0.17, 0.23)	0.786
		Placebo	34	33 (97.1)	0.14 (0.07)	(-0.00, 0.28)			
	Week 24	Tezepelumab	36	33 (91.7)	0.17 (0.08)	(0.02, 0.32)	0.03 (0.11)	(-0.19, 0.24)	0.802
		Placebo	34	32 (94.1)	0.15 (0.08)	(-0.01, 0.30)			
	Week 36	Tezepelumab	36	33 (91.7)	0.23 (0.09)	(0.06, 0.41)	0.06 (0.13)	(-0.19, 0.31)	0.651
		Placebo	34	29 (85.3)	0.18 (0.09)	(-0.00, 0.36)			
	Week 52	Tezepelumab	36	31 (86.1)	0.34 (0.07)	(0.20, 0.48)	0.12 (0.10)	(-0.08, 0.33)	0.241
		Placebo	34	29 (85.3)	0.22 (0.07)	(0.07, 0.37)			

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Montelukast/ Cromoglicic acid use at baseline									0.555
Yes	Week 2	Tezepelumab	14	14 (100.0)	0.14 (0.08)	(-0.02, 0.29)	0.12 (0.11)	(-0.10, 0.35)	0.273
		Placebo	13	13 (100.0)	0.01 (0.08)	(-0.15, 0.18)			
	Week 4	Tezepelumab	14	14 (100.0)	0.15 (0.08)	(-0.02, 0.31)	0.11 (0.12)	(-0.13, 0.35)	0.368
		Placebo	13	13 (100.0)	0.04 (0.08)	(-0.13, 0.21)			
	Week 8	Tezepelumab	14	14 (100.0)	0.03 (0.11)	(-0.19, 0.25)	0.09 (0.16)	(-0.24, 0.41)	0.583
		Placebo	13	12 (92.3)	-0.06 (0.11)	(-0.29, 0.18)			
	Week 12	Tezepelumab	14	12 (85.7)	0.13 (0.07)	(-0.02, 0.29)	0.06 (0.11)	(-0.15, 0.28)	0.549
		Placebo	13	13 (100.0)	0.07 (0.07)	(-0.08, 0.22)			
	Week 16	Tezepelumab	14	14 (100.0)	0.06 (0.08)	(-0.11, 0.22)	0.10 (0.12)	(-0.14, 0.34)	0.386
		Placebo	13	13 (100.0)	-0.05 (0.08)	(-0.22, 0.13)			
	Week 24	Tezepelumab	14	14 (100.0)	0.12 (0.09)	(-0.06, 0.30)	0.10 (0.13)	(-0.16, 0.36)	0.432
		Placebo	13	13 (100.0)	0.02 (0.09)	(-0.17, 0.21)			
	Week 36	Tezepelumab	14	14 (100.0)	0.29 (0.08)	(0.13, 0.46)	0.27 (0.12)	(0.03, 0.51)	0.029 *
		Placebo	13	11 (84.6)	0.02 (0.08)	(-0.15, 0.20)			
	Week 52	Tezepelumab	14	13 (92.9)	0.37 (0.11)	(0.14, 0.59)	0.24 (0.15)	(-0.08, 0.56)	0.139
		Placebo	13	12 (92.3)	0.13 (0.11)	(-0.10, 0.36)			

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 2	Tezepelumab	27	26 (96.3)	0.16 (0.08)	(0.00, 0.31)	0.08 (0.11)	(-0.13, 0.30)	0.439
		Placebo	28	26 (92.9)	0.07 (0.07)	(-0.08, 0.22)			
	Week 4	Tezepelumab	27	26 (96.3)	0.06 (0.09)	(-0.13, 0.24)	-0.03 (0.13)	(-0.29, 0.23)	0.792
		Placebo	28	25 (89.3)	0.09 (0.09)	(-0.09, 0.28)			
	Week 8	Tezepelumab	27	26 (96.3)	0.09 (0.10)	(-0.10, 0.29)	0.02 (0.14)	(-0.25, 0.29)	0.888
		Placebo	28	27 (96.4)	0.07 (0.10)	(-0.12, 0.27)			
	Week 12	Tezepelumab	27	25 (92.6)	0.11 (0.11)	(-0.12, 0.33)	0.05 (0.16)	(-0.27, 0.37)	0.753
		Placebo	28	26 (92.9)	0.06 (0.11)	(-0.16, 0.28)			
	Week 16	Tezepelumab	27	25 (92.6)	0.18 (0.09)	(0.00, 0.36)	0.04 (0.12)	(-0.21, 0.29)	0.764
		Placebo	28	27 (96.4)	0.14 (0.09)	(-0.03, 0.31)			
	Week 24	Tezepelumab	27	24 (88.9)	0.14 (0.10)	(-0.05, 0.33)	-0.00 (0.14)	(-0.27, 0.27)	0.991
		Placebo	28	25 (89.3)	0.14 (0.09)	(-0.05, 0.33)			
	Week 36	Tezepelumab	27	23 (85.2)	0.18 (0.12)	(-0.06, 0.41)	-0.01 (0.16)	(-0.34, 0.32)	0.955
		Placebo	28	24 (85.7)	0.19 (0.11)	(-0.04, 0.41)			
	Week 52	Tezepelumab	27	21 (77.8)	0.29 (0.09)	(0.10, 0.47)	0.09 (0.13)	(-0.18, 0.35)	0.512
		Placebo	28	23 (82.1)	0.20 (0.09)	(0.02, 0.38)			

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Western Europe	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	3.18	3.2	3.18	3.18	3.18	3.2	
			Placebo	1	1 (100.0)	2.11	2.1	2.11	2.11	2.11	2.1	
		Week 2	Tezepelumab	1	1 (100.0)	3.26	3.3	3.26	3.26	3.26	3.3	
			Placebo	1	1 (100.0)	2.37	2.4	2.37	2.37	2.37	2.4	
		Week 4	Tezepelumab	1	1 (100.0)	3.51	3.5	3.51	3.51	3.51	3.5	
			Placebo	1	1 (100.0)	2.09	2.1	2.09	2.09	2.09	2.1	
		Week 8	Tezepelumab	1	1 (100.0)	3.43	3.4	3.43	3.43	3.43	3.4	
			Placebo	1	1 (100.0)	2.76	2.8	2.76	2.76	2.76	2.8	
		Week 12	Tezepelumab	1	1 (100.0)	3.48	3.5	3.48	3.48	3.48	3.5	
			Placebo	1	1 (100.0)	2.52	2.5	2.52	2.52	2.52	2.5	
		Week 16	Placebo	1	1 (100.0)	2.48	2.5	2.48	2.48	2.48	2.5	
		Week 24	Placebo	1	1 (100.0)	2.71	2.7	2.71	2.71	2.71	2.7	
		Week 52	Placebo	1	1 (100.0)	2.14	2.1	2.14	2.14	2.14	2.1	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Western Europe	Change from baseline	Week 2	Tezepelumab	1	1 (100.0)	0.08	0.1	0.08	0.08	0.08	0.1	NE
			Placebo	1	1 (100.0)	0.26	0.3	0.26	0.26	0.26	0.3	
		Week 4	Tezepelumab	1	1 (100.0)	0.33	0.3	0.33	0.33	0.33	0.3	NE
			Placebo	1	1 (100.0)	-0.02	-0.0	-0.02	-0.02	-0.02	-0.0	
		Week 8	Tezepelumab	1	1 (100.0)	0.25	0.3	0.25	0.25	0.25	0.3	NE
			Placebo	1	1 (100.0)	0.65	0.7	0.65	0.65	0.65	0.7	
		Week 12	Tezepelumab	1	1 (100.0)	0.30	0.3	0.30	0.30	0.30	0.3	NE
			Placebo	1	1 (100.0)	0.41	0.4	0.41	0.41	0.41	0.4	
		Week 16	Placebo	1	1 (100.0)	0.37	0.4	0.37	0.37	0.37	0.4	
		Week 24	Placebo	1	1 (100.0)	0.60	0.6	0.60	0.60	0.60	0.6	
		Week 52	Placebo	1	1 (100.0)	0.03	0.0	0.03	0.03	0.03	0.0	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
North America	Absolute values	Baseline	Tezepelumab	8	8 (100.0)	2.65 (0.48)	2.0	2.17	2.77	3.06	3.2	
			Placebo	9	9 (100.0)	2.80 (0.89)	1.3	2.38	2.70	3.09	4.1	
		Week 2	Tezepelumab	8	8 (100.0)	2.94 (0.47)	2.1	2.66	2.99	3.20	3.7	
			Placebo	9	9 (100.0)	2.71 (0.67)	1.7	2.40	2.62	2.94	4.2	
		Week 4	Tezepelumab	8	7 (87.5)	2.83 (0.44)	2.2	2.61	2.68	3.35	3.5	
			Placebo	9	9 (100.0)	2.82 (0.66)	2.2	2.39	2.59	3.04	4.0	
		Week 8	Tezepelumab	8	7 (87.5)	2.82 (0.42)	2.1	2.56	2.81	3.20	3.4	
			Placebo	9	9 (100.0)	2.62 (0.72)	1.4	2.35	2.41	2.79	3.8	
		Week 12	Tezepelumab	8	7 (87.5)	2.88 (0.50)	2.1	2.37	3.06	3.29	3.5	
			Placebo	9	9 (100.0)	2.80 (0.83)	1.7	2.19	2.86	3.07	4.2	
		Week 16	Tezepelumab	8	7 (87.5)	2.82 (0.53)	2.0	2.40	2.86	3.10	3.6	
			Placebo	9	9 (100.0)	2.74 (0.66)	1.9	2.46	2.52	2.60	3.9	
		Week 24	Tezepelumab	8	7 (87.5)	2.86 (0.54)	2.2	2.34	2.90	3.37	3.7	
			Placebo	9	8 (88.9)	2.91 (0.71)	2.0	2.50	2.71	3.48	4.0	
		Week 36	Tezepelumab	8	7 (87.5)	2.97 (0.50)	2.3	2.50	3.05	3.34	3.8	
			Placebo	9	8 (88.9)	2.93 (0.84)	1.4	2.58	2.86	3.58	4.1	
		Week 52	Tezepelumab	8	6 (75.0)	3.07 (0.48)	2.3	2.80	3.10	3.44	3.7	
			Placebo	9	7 (77.8)	3.00 (0.98)	1.2	2.67	2.93	3.91	3.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
North America	Change from baseline	Week 2	Tezepelumab	8	8 (100.0)	0.29 (0.30)	0.0	0.06	0.15	0.54	0.8	0.97 [-0.04, 1.98]
			Placebo	9	9 (100.0)	-0.10 (0.47)	-1.3	-0.08	-0.03	0.09	0.5	
		Week 4	Tezepelumab	8	7 (87.5)	0.27 (0.33)	-0.2	-0.08	0.32	0.65	0.7	0.47 [-0.54, 1.47]
			Placebo	9	9 (100.0)	0.02 (0.64)	-1.0	-0.33	-0.07	0.19	1.0	
		Week 8	Tezepelumab	8	7 (87.5)	0.26 (0.24)	0.0	0.04	0.17	0.56	0.6	0.89 [-0.15, 1.93]
			Placebo	9	9 (100.0)	-0.18 (0.62)	-1.7	-0.33	0.01	0.09	0.5	
		Week 12	Tezepelumab	8	7 (87.5)	0.31 (0.27)	0.0	0.05	0.26	0.43	0.8	0.71 [-0.31, 1.74]
			Placebo	9	9 (100.0)	-0.01 (0.55)	-1.0	-0.21	-0.16	0.20	1.1	
		Week 16	Tezepelumab	8	7 (87.5)	0.26 (0.36)	-0.2	-0.10	0.26	0.56	0.8	0.55 [-0.46, 1.56]
			Placebo	9	9 (100.0)	-0.06 (0.71)	-1.6	-0.34	0.09	0.22	0.8	
		Week 24	Tezepelumab	8	7 (87.5)	0.30 (0.26)	0.1	0.09	0.21	0.61	0.7	0.48 [-0.55, 1.51]
			Placebo	9	8 (88.9)	0.04 (0.70)	-1.4	-0.18	0.12	0.52	0.8	
		Week 36	Tezepelumab	8	7 (87.5)	0.40 (0.22)	0.2	0.23	0.31	0.69	0.7	0.72 [-0.33, 1.77]
			Placebo	9	8 (88.9)	0.06 (0.62)	-1.2	-0.12	0.16	0.32	1.0	
		Week 52	Tezepelumab	8	6 (75.0)	0.55 (0.25)	0.2	0.39	0.50	0.82	0.9	0.88 [-0.27, 2.04]
			Placebo	9	7 (77.8)	0.06 (0.72)	-1.4	-0.14	0.23	0.63	0.8	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
South America	Absolute values	Baseline	Tezepelumab	20	20 (100.0)	2.74 (0.61)	1.4	2.25	2.87	3.04	3.9	
			Placebo	20	20 (100.0)	2.75 (0.81)	1.0	2.13	2.76	3.24	4.9	
		Week 2	Tezepelumab	20	20 (100.0)	2.84 (0.60)	1.7	2.46	2.91	3.21	4.0	
			Placebo	20	19 (95.0)	2.88 (0.59)	2.2	2.60	2.74	3.18	4.7	
		Week 4	Tezepelumab	20	20 (100.0)	2.77 (0.67)	1.3	2.34	2.88	3.19	4.0	
			Placebo	20	19 (95.0)	2.79 (0.47)	1.7	2.50	2.66	3.16	3.7	
		Week 8	Tezepelumab	20	20 (100.0)	2.73 (0.75)	1.0	2.39	2.86	3.25	3.7	
			Placebo	20	19 (95.0)	2.93 (0.62)	2.0	2.54	2.93	3.24	4.9	
		Week 12	Tezepelumab	20	18 (90.0)	2.73 (0.81)	0.8	2.51	2.84	3.34	4.0	
			Placebo	20	20 (100.0)	2.85 (0.68)	1.7	2.49	2.80	3.09	5.0	
		Week 16	Tezepelumab	20	20 (100.0)	2.83 (0.57)	1.5	2.42	2.87	3.27	3.8	
			Placebo	20	20 (100.0)	2.90 (0.72)	1.8	2.47	2.83	3.22	5.2	
		Week 24	Tezepelumab	20	20 (100.0)	2.82 (0.58)	1.7	2.43	2.93	3.22	3.7	
			Placebo	20	19 (95.0)	2.91 (0.72)	2.0	2.38	2.93	3.33	5.1	
		Week 36	Tezepelumab	20	19 (95.0)	2.89 (0.60)	1.4	2.46	2.95	3.30	4.0	
			Placebo	20	18 (90.0)	3.04 (0.85)	1.4	2.55	3.04	3.54	5.3	
		Week 52	Tezepelumab	20	17 (85.0)	3.01 (0.60)	1.9	2.53	3.21	3.32	4.2	
			Placebo	20	18 (90.0)	3.04 (0.76)	2.1	2.51	3.02	3.41	5.3	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
South America	Change from baseline	Week 2	Tezepelumab	20	20 (100.0)	0.10 (0.42)	-0.5	-0.12	0.07	0.29	1.4	-0.11 [-0.74, 0.52]
			Placebo	20	19 (95.0)	0.15 (0.58)	-0.8	-0.12	0.04	0.23	1.7	
		Week 4	Tezepelumab	20	20 (100.0)	0.03 (0.48)	-1.2	-0.17	-0.04	0.19	1.2	-0.23 [-0.86, 0.40]
			Placebo	20	19 (95.0)	0.15 (0.60)	-0.8	-0.18	-0.03	0.36	1.7	
		Week 8	Tezepelumab	20	20 (100.0)	-0.01 (0.54)	-1.1	-0.35	0.03	0.23	1.6	-0.25 [-0.88, 0.38]
			Placebo	20	19 (95.0)	0.14 (0.66)	-0.8	-0.20	-0.06	0.05	2.0	
		Week 12	Tezepelumab	20	18 (90.0)	-0.03 (0.60)	-1.5	-0.20	-0.05	0.19	1.5	-0.20 [-0.84, 0.44]
			Placebo	20	20 (100.0)	0.10 (0.71)	-1.2	-0.36	0.04	0.32	1.6	
		Week 16	Tezepelumab	20	20 (100.0)	0.09 (0.38)	-0.5	-0.12	0.05	0.24	1.4	-0.11 [-0.73, 0.52]
			Placebo	20	20 (100.0)	0.15 (0.62)	-0.7	-0.17	0.00	0.22	1.6	
		Week 24	Tezepelumab	20	20 (100.0)	0.08 (0.54)	-0.8	-0.23	0.05	0.26	1.8	0.04 [-0.59, 0.67]
			Placebo	20	19 (95.0)	0.06 (0.57)	-1.1	-0.26	-0.01	0.23	1.5	
		Week 36	Tezepelumab	20	19 (95.0)	0.16 (0.46)	-0.6	-0.13	0.12	0.40	1.7	-0.16 [-0.81, 0.48]
			Placebo	20	18 (90.0)	0.27 (0.83)	-1.7	-0.04	0.18	0.47	2.2	
		Week 52	Tezepelumab	20	17 (85.0)	0.27 (0.49)	-0.6	-0.13	0.38	0.52	1.3	0.00 [-0.66, 0.67]
			Placebo	20	18 (90.0)	0.26 (0.62)	-0.7	-0.02	0.27	0.38	1.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Central/Eastern Europe	Absolute values	Baseline	Tezepelumab	4	4 (100.0)	3.26 (0.81)	2.4	2.59	3.26	3.94	4.1	
			Placebo	3	3 (100.0)	2.92 (0.25)	2.7	2.65	2.96	3.15	3.2	
		Week 2	Tezepelumab	4	3 (75.0)	3.41 (0.67)	2.6	2.63	3.74	3.85	3.9	
			Placebo	3	3 (100.0)	2.83 (0.50)	2.3	2.25	3.09	3.15	3.2	
		Week 4	Tezepelumab	4	4 (100.0)	3.23 (0.71)	2.5	2.63	3.31	3.84	3.9	
			Placebo	3	3 (100.0)	2.78 (0.43)	2.3	2.30	2.88	3.15	3.2	
		Week 8	Tezepelumab	4	4 (100.0)	3.41 (0.51)	2.7	3.07	3.50	3.75	3.9	
			Placebo	3	3 (100.0)	2.79 (0.54)	2.2	2.17	3.06	3.15	3.2	
		Week 12	Tezepelumab	4	4 (100.0)	3.41 (0.56)	2.7	3.02	3.50	3.81	4.0	
			Placebo	3	2 (66.7)	3.07 (0.01)	3.1	3.06	3.07	3.07	3.1	
		Week 16	Tezepelumab	4	4 (100.0)	3.48 (0.46)	2.9	3.13	3.58	3.83	3.9	
			Placebo	3	3 (100.0)	2.94 (0.30)	2.6	2.60	3.06	3.16	3.2	
		Week 24	Tezepelumab	4	4 (100.0)	3.39 (0.53)	2.8	2.96	3.48	3.83	3.9	
			Placebo	3	3 (100.0)	2.97 (0.38)	2.5	2.53	3.15	3.22	3.2	
		Week 36	Tezepelumab	4	4 (100.0)	3.32 (0.39)	2.8	3.03	3.41	3.61	3.7	
			Placebo	3	3 (100.0)	2.90 (0.30)	2.6	2.56	3.04	3.10	3.1	
		Week 52	Tezepelumab	4	4 (100.0)	3.56 (0.54)	2.8	3.19	3.70	3.93	4.0	
			Placebo	3	3 (100.0)	3.02 (0.29)	2.7	2.71	3.09	3.27	3.3	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Central/Eastern Europe	Change from baseline	Week 2	Tezepelumab	4	3 (75.0)	-0.02 (0.34)	-0.4	-0.40	0.11	0.24	0.2	0.24 [-1.37, 1.85]
			Placebo	3	3 (100.0)	-0.09 (0.28)	-0.4	-0.40	0.00	0.13	0.1	
		Week 4	Tezepelumab	4	4 (100.0)	-0.03 (0.34)	-0.3	-0.31	-0.10	0.25	0.4	0.35 [-1.16, 1.86]
			Placebo	3	3 (100.0)	-0.14 (0.29)	-0.4	-0.35	-0.27	0.19	0.2	
		Week 8	Tezepelumab	4	4 (100.0)	0.14 (0.41)	-0.2	-0.20	0.07	0.48	0.7	0.70 [-0.86, 2.26]
			Placebo	3	3 (100.0)	-0.13 (0.34)	-0.5	-0.48	-0.09	0.19	0.2	
		Week 12	Tezepelumab	4	4 (100.0)	0.15 (0.47)	-0.5	-0.13	0.26	0.43	0.6	0.33 [-1.38, 2.04]
			Placebo	3	2 (66.7)	0.01 (0.14)	-0.1	-0.09	0.01	0.11	0.1	
		Week 16	Tezepelumab	4	4 (100.0)	0.22 (0.43)	-0.4	-0.11	0.31	0.54	0.6	0.56 [-0.98, 2.09]
			Placebo	3	3 (100.0)	0.02 (0.16)	-0.1	-0.09	-0.05	0.20	0.2	
		Week 24	Tezepelumab	4	4 (100.0)	0.13 (0.34)	-0.3	-0.12	0.24	0.38	0.4	0.29 [-1.22, 1.79]
			Placebo	3	3 (100.0)	0.05 (0.19)	-0.1	-0.12	0.00	0.26	0.3	
		Week 36	Tezepelumab	4	4 (100.0)	0.05 (0.63)	-0.5	-0.48	-0.03	0.59	0.8	0.15 [-1.35, 1.65]
			Placebo	3	3 (100.0)	-0.02 (0.14)	-0.1	-0.11	-0.09	0.14	0.1	
		Week 52	Tezepelumab	4	4 (100.0)	0.30 (0.39)	-0.1	-0.01	0.25	0.61	0.8	0.59 [-0.95, 2.14]
			Placebo	3	3 (100.0)	0.10 (0.19)	-0.1	-0.06	0.06	0.31	0.3	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Asia Pacific	Absolute values	Baseline	Tezepelumab	4	4 (100.0)	2.30 (0.70)	1.4	1.85	2.32	2.75	3.1	
			Placebo	4	4 (100.0)	2.18 (0.57)	1.4	1.76	2.30	2.60	2.7	
		Week 2	Tezepelumab	4	4 (100.0)	2.49 (0.45)	2.2	2.25	2.27	2.72	3.2	
			Placebo	4	4 (100.0)	2.18 (0.67)	1.3	1.64	2.32	2.73	2.7	
		Week 4	Tezepelumab	4	4 (100.0)	2.33 (0.60)	1.8	1.96	2.16	2.71	3.2	
			Placebo	4	4 (100.0)	2.28 (0.59)	1.4	1.88	2.48	2.68	2.7	
		Week 8	Tezepelumab	4	4 (100.0)	2.12 (0.95)	1.0	1.52	2.11	2.73	3.3	
			Placebo	4	4 (100.0)	2.29 (0.58)	1.5	1.84	2.38	2.73	2.8	
		Week 12	Tezepelumab	4	4 (100.0)	2.40 (0.61)	2.0	2.05	2.14	2.76	3.3	
			Placebo	4	4 (100.0)	2.29 (0.60)	1.4	1.87	2.48	2.71	2.8	
		Week 16	Tezepelumab	4	4 (100.0)	2.36 (0.58)	1.9	1.99	2.14	2.73	3.2	
			Placebo	4	4 (100.0)	2.24 (0.52)	1.5	1.90	2.43	2.59	2.6	
		Week 24	Tezepelumab	4	4 (100.0)	2.35 (0.68)	1.6	1.94	2.27	2.76	3.3	
			Placebo	4	4 (100.0)	2.24 (0.54)	1.5	1.87	2.42	2.62	2.7	
		Week 36	Tezepelumab	4	4 (100.0)	2.54 (0.45)	2.3	2.25	2.36	2.84	3.2	
			Placebo	4	3 (75.0)	2.26 (0.76)	1.4	1.38	2.70	2.70	2.7	
		Week 52	Tezepelumab	4	4 (100.0)	2.47 (0.53)	2.2	2.20	2.23	2.75	3.3	
			Placebo	4	4 (100.0)	2.37 (0.61)	1.5	1.96	2.56	2.77	2.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Asia Pacific	Change from baseline	Week 2	Tezepelumab	4	4 (100.0)	0.19 (0.42)	-0.1	-0.05	0.02	0.42	0.8	0.58 [-0.84, 2.01]
			Placebo	4	4 (100.0)	0.00 (0.16)	-0.2	-0.12	-0.01	0.13	0.2	
		Week 4	Tezepelumab	4	4 (100.0)	0.04 (0.27)	-0.3	-0.15	0.01	0.23	0.4	-0.30 [-1.69, 1.10]
			Placebo	4	4 (100.0)	0.10 (0.14)	-0.1	-0.02	0.12	0.22	0.2	
		Week 8	Tezepelumab	4	4 (100.0)	-0.18 (0.26)	-0.5	-0.34	-0.21	-0.01	0.2	-1.51 [-3.14, 0.11]
			Placebo	4	4 (100.0)	0.11 (0.05)	0.0	0.08	0.13	0.13	0.1	
		Week 12	Tezepelumab	4	4 (100.0)	0.10 (0.40)	-0.2	-0.20	0.00	0.41	0.6	-0.02 [-1.40, 1.37]
			Placebo	4	4 (100.0)	0.11 (0.14)	-0.0	-0.01	0.11	0.22	0.3	
		Week 16	Tezepelumab	4	4 (100.0)	0.06 (0.42)	-0.4	-0.22	0.03	0.34	0.6	-0.02 [-1.41, 1.36]
			Placebo	4	4 (100.0)	0.06 (0.15)	-0.2	-0.04	0.10	0.17	0.2	
		Week 24	Tezepelumab	4	4 (100.0)	0.05 (0.12)	-0.1	-0.04	0.07	0.15	0.2	-0.10 [-1.49, 1.29]
			Placebo	4	4 (100.0)	0.07 (0.13)	-0.1	-0.03	0.11	0.16	0.2	
		Week 36	Tezepelumab	4	4 (100.0)	0.25 (0.41)	-0.1	-0.02	0.14	0.52	0.8	0.14 [-1.36, 1.64]
			Placebo	4	3 (75.0)	0.19 (0.36)	-0.0	-0.03	0.00	0.60	0.6	
		Week 52	Tezepelumab	4	4 (100.0)	0.18 (0.40)	-0.1	-0.09	0.06	0.44	0.7	-0.04 [-1.43, 1.35]
			Placebo	4	4 (100.0)	0.19 (0.18)	-0.0	0.03	0.21	0.34	0.4	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Rest of the world	Absolute values	Baseline	Tezepelumab	4	4 (100.0)	2.10 (0.50)	1.6	1.75	2.00	2.46	2.8	
			Placebo	4	4 (100.0)	2.56 (0.91)	1.5	1.85	2.61	3.28	3.6	
		Week 2	Tezepelumab	4	4 (100.0)	2.29 (0.33)	2.0	2.00	2.26	2.57	2.6	
			Placebo	4	3 (75.0)	2.68 (0.78)	1.8	1.78	3.11	3.16	3.2	
		Week 4	Tezepelumab	4	4 (100.0)	2.24 (0.48)	1.7	1.84	2.27	2.64	2.7	
			Placebo	4	2 (50.0)	2.31 (1.46)	1.3	1.28	2.31	3.34	3.3	
		Week 8	Tezepelumab	4	4 (100.0)	2.32 (0.49)	1.9	1.91	2.27	2.73	2.9	
			Placebo	4	3 (75.0)	2.25 (1.05)	1.2	1.23	2.20	3.32	3.3	
		Week 12	Tezepelumab	4	3 (75.0)	2.09 (0.19)	2.0	1.95	2.01	2.30	2.3	
			Placebo	4	3 (75.0)	2.37 (0.96)	1.5	1.49	2.21	3.40	3.4	
		Week 16	Tezepelumab	4	4 (100.0)	2.14 (0.51)	1.6	1.70	2.13	2.58	2.7	
			Placebo	4	3 (75.0)	2.38 (0.90)	1.6	1.56	2.23	3.34	3.3	
		Week 24	Tezepelumab	4	3 (75.0)	2.32 (0.38)	2.0	1.95	2.32	2.70	2.7	
			Placebo	4	3 (75.0)	2.21 (0.53)	1.7	1.69	2.19	2.74	2.7	
		Week 36	Tezepelumab	4	3 (75.0)	2.56 (0.31)	2.2	2.21	2.71	2.77	2.8	
			Placebo	4	3 (75.0)	2.30 (0.96)	1.4	1.38	2.22	3.30	3.3	
		Week 52	Tezepelumab	4	3 (75.0)	2.63 (0.40)	2.2	2.17	2.79	2.93	2.9	
			Placebo	4	2 (50.0)	2.89 (0.95)	2.2	2.21	2.89	3.56	3.6	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Rest of the world	Change from baseline	Week 2	Tezepelumab	4	4 (100.0)	0.18 (0.24)	-0.1	0.01	0.25	0.36	0.4	0.55 [-0.98, 2.09]
			Placebo	4	3 (75.0)	0.01 (0.40)	-0.4	-0.44	0.16	0.31	0.3	
		Week 4	Tezepelumab	4	4 (100.0)	0.13 (0.21)	-0.1	0.01	0.09	0.26	0.4	0.23 [-1.48, 1.93]
			Placebo	4	2 (50.0)	0.07 (0.37)	-0.2	-0.19	0.07	0.34	0.3	
		Week 8	Tezepelumab	4	4 (100.0)	0.22 (0.16)	0.1	0.10	0.16	0.33	0.4	0.90 [-0.70, 2.49]
			Placebo	4	3 (75.0)	0.02 (0.28)	-0.2	-0.24	-0.02	0.32	0.3	
		Week 12	Tezepelumab	4	3 (75.0)	0.21 (0.10)	0.1	0.15	0.16	0.32	0.3	0.42 [-1.21, 2.05]
			Placebo	4	3 (75.0)	0.14 (0.23)	-0.0	-0.01	0.02	0.40	0.4	
		Week 16	Tezepelumab	4	4 (100.0)	0.03 (0.26)	-0.2	-0.18	-0.00	0.24	0.4	-0.50 [-2.02, 1.03]
			Placebo	4	3 (75.0)	0.15 (0.17)	0.0	0.01	0.09	0.34	0.3	
		Week 24	Tezepelumab	4	3 (75.0)	0.06 (0.13)	-0.1	-0.08	0.09	0.18	0.2	0.45 [-1.18, 2.08]
			Placebo	4	3 (75.0)	-0.02 (0.24)	-0.3	-0.26	-0.03	0.22	0.2	
		Week 36	Tezepelumab	4	3 (75.0)	0.30 (0.29)	-0.0	-0.01	0.35	0.57	0.6	0.92 [-0.80, 2.65]
			Placebo	4	3 (75.0)	0.07 (0.20)	-0.1	-0.09	0.00	0.30	0.3	
		Week 52	Tezepelumab	4	3 (75.0)	0.37 (0.26)	0.2	0.15	0.31	0.65	0.7	0.30 [-1.50, 2.11]
			Placebo	4	2 (50.0)	0.27 (0.40)	-0.0	-0.01	0.27	0.56	0.6	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
< 150 cells/uL	Absolute values	Baseline	Tezepelumab	8	8 (100.0)	3.00 (0.74)	2.0	2.51	2.90	3.53	4.1	
			Placebo	6	6 (100.0)	2.71 (1.17)	1.4	2.10	2.58	2.70	4.9	
		Week 2	Tezepelumab	8	8 (100.0)	2.99 (0.57)	2.4	2.51	2.86	3.45	3.9	
			Placebo	6	6 (100.0)	2.61 (1.15)	1.3	1.93	2.48	2.74	4.7	
		Week 4	Tezepelumab	8	8 (100.0)	3.05 (0.61)	2.3	2.59	2.94	3.51	4.0	
			Placebo	6	5 (83.3)	2.28 (0.51)	1.4	2.30	2.32	2.64	2.7	
		Week 8	Tezepelumab	8	8 (100.0)	3.05 (0.55)	2.4	2.56	3.06	3.43	3.9	
			Placebo	6	6 (100.0)	2.70 (1.17)	1.5	2.14	2.40	2.84	4.9	
		Week 12	Tezepelumab	8	7 (87.5)	2.98 (0.68)	2.2	2.37	2.81	3.62	4.0	
			Placebo	6	5 (83.3)	2.82 (1.31)	1.4	2.29	2.66	2.75	5.0	
		Week 16	Tezepelumab	8	8 (100.0)	2.96 (0.60)	2.3	2.42	2.93	3.48	3.8	
			Placebo	6	6 (100.0)	2.80 (1.26)	1.5	2.31	2.58	2.62	5.2	
		Week 24	Tezepelumab	8	8 (100.0)	2.98 (0.54)	2.2	2.60	2.96	3.38	3.8	
			Placebo	6	6 (100.0)	2.77 (1.23)	1.5	2.25	2.56	2.66	5.1	
		Week 36	Tezepelumab	8	8 (100.0)	3.02 (0.51)	2.2	2.70	2.99	3.48	3.7	
			Placebo	6	5 (83.3)	2.93 (1.44)	1.4	2.56	2.70	2.70	5.3	
		Week 52	Tezepelumab	8	7 (87.5)	3.05 (0.63)	2.2	2.53	2.93	3.55	4.0	
			Placebo	6	6 (100.0)	2.91 (1.25)	1.5	2.43	2.70	2.85	5.3	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
< 150 cells/uL	Change from baseline	Week 2	Tezepelumab	8	8 (100.0)	-0.01 (0.30)	-0.4	-0.21	-0.01	0.08	0.6	0.32 [-0.75, 1.39]
			Placebo	6	6 (100.0)	-0.10 (0.21)	-0.4	-0.19	-0.12	0.04	0.2	
		Week 4	Tezepelumab	8	8 (100.0)	0.05 (0.29)	-0.3	-0.13	0.02	0.11	0.7	0.14 [-0.98, 1.26]
			Placebo	6	5 (83.3)	0.01 (0.24)	-0.4	-0.06	0.02	0.22	0.2	
		Week 8	Tezepelumab	8	8 (100.0)	0.05 (0.29)	-0.4	-0.17	0.06	0.20	0.6	0.19 [-0.87, 1.25]
			Placebo	6	6 (100.0)	-0.00 (0.24)	-0.5	0.03	0.08	0.13	0.1	
		Week 12	Tezepelumab	8	7 (87.5)	-0.05 (0.30)	-0.5	-0.20	-0.12	0.17	0.4	-0.65 [-1.83, 0.54]
			Placebo	6	5 (83.3)	0.10 (0.12)	-0.0	0.03	0.09	0.19	0.3	
		Week 16	Tezepelumab	8	8 (100.0)	-0.04 (0.27)	-0.4	-0.23	-0.09	0.16	0.4	-0.55 [-1.63, 0.54]
			Placebo	6	6 (100.0)	0.09 (0.17)	-0.2	-0.05	0.10	0.21	0.3	
		Week 24	Tezepelumab	8	8 (100.0)	-0.01 (0.35)	-0.4	-0.25	-0.09	0.16	0.7	-0.27 [-1.33, 0.80]
			Placebo	6	6 (100.0)	0.06 (0.15)	-0.1	-0.12	0.11	0.16	0.2	
		Week 36	Tezepelumab	8	8 (100.0)	0.03 (0.39)	-0.5	-0.25	-0.01	0.24	0.7	-0.42 [-1.55, 0.71]
			Placebo	6	5 (83.3)	0.18 (0.31)	-0.1	-0.03	0.00	0.42	0.6	
		Week 52	Tezepelumab	8	7 (87.5)	0.05 (0.38)	-0.4	-0.16	-0.10	0.15	0.8	-0.48 [-1.59, 0.63]
			Placebo	6	6 (100.0)	0.20 (0.17)	-0.0	0.06	0.21	0.35	0.4	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
150 - < 300 cells/uL	Absolute values	Baseline	Tezepelumab	15	15 (100.0)	2.70 (0.72)	1.4	2.12	2.86	3.22	3.7	
			Placebo	8	8 (100.0)	2.71 (0.60)	1.5	2.44	2.84	3.19	3.3	
		Week 2	Tezepelumab	15	15 (100.0)	2.91 (0.68)	1.7	2.50	2.91	3.39	4.0	
			Placebo	8	7 (87.5)	2.77 (0.54)	1.8	2.40	3.01	3.15	3.4	
		Week 4	Tezepelumab	15	14 (93.3)	2.76 (0.73)	1.3	2.57	2.81	3.21	3.9	
			Placebo	8	8 (100.0)	2.53 (0.72)	1.3	2.02	2.79	3.02	3.3	
		Week 8	Tezepelumab	15	14 (93.3)	2.75 (0.73)	1.0	2.54	2.86	3.26	3.7	
			Placebo	8	8 (100.0)	2.58 (0.64)	1.2	2.31	2.77	3.04	3.2	
		Week 12	Tezepelumab	15	12 (80.0)	2.69 (0.85)	0.8	2.16	2.81	3.21	4.0	
			Placebo	8	8 (100.0)	2.49 (0.60)	1.5	2.07	2.64	2.99	3.1	
		Week 16	Tezepelumab	15	14 (93.3)	2.76 (0.75)	1.5	2.22	2.84	3.30	3.9	
			Placebo	8	8 (100.0)	2.60 (0.62)	1.6	2.16	2.81	3.05	3.2	
		Week 24	Tezepelumab	15	13 (86.7)	2.84 (0.61)	1.7	2.45	2.90	3.19	3.9	
			Placebo	8	8 (100.0)	2.63 (0.61)	1.7	2.09	2.80	3.13	3.4	
		Week 36	Tezepelumab	15	13 (86.7)	2.86 (0.63)	1.4	2.56	3.05	3.18	4.0	
			Placebo	8	6 (75.0)	2.76 (0.75)	1.4	2.76	2.87	3.04	3.7	
		Week 52	Tezepelumab	15	12 (80.0)	3.10 (0.67)	1.9	2.72	3.16	3.53	4.2	
			Placebo	8	4 (50.0)	3.16 (0.20)	3.0	3.04	3.07	3.28	3.5	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
150 - < 300 cells/uL	Change from baseline	Week 2	Tezepelumab	15	15 (100.0)	0.21 (0.19)	-0.2	0.07	0.19	0.36	0.5	0.32 [-0.58, 1.22]
			Placebo	8	7 (87.5)	0.14 (0.25)	-0.1	-0.03	0.07	0.31	0.6	
		Week 4	Tezepelumab	15	14 (93.3)	0.09 (0.31)	-0.2	-0.13	0.01	0.13	1.0	0.91 [-0.00, 1.83]
			Placebo	8	8 (100.0)	-0.18 (0.27)	-0.8	-0.23	-0.08	-0.04	0.1	
		Week 8	Tezepelumab	15	14 (93.3)	0.09 (0.24)	-0.4	-0.10	0.11	0.22	0.4	1.09 [0.16, 2.02]
			Placebo	8	8 (100.0)	-0.13 (0.10)	-0.2	-0.22	-0.13	-0.08	0.1	
		Week 12	Tezepelumab	15	12 (80.0)	0.00 (0.27)	-0.6	-0.10	0.03	0.20	0.3	0.82 [-0.12, 1.75]
			Placebo	8	8 (100.0)	-0.21 (0.26)	-0.7	-0.36	-0.16	0.01	0.0	
		Week 16	Tezepelumab	15	14 (93.3)	0.10 (0.17)	-0.2	0.00	0.11	0.24	0.4	1.02 [0.10, 1.94]
			Placebo	8	8 (100.0)	-0.11 (0.24)	-0.7	-0.16	-0.04	0.04	0.1	
		Week 24	Tezepelumab	15	13 (86.7)	0.10 (0.28)	-0.4	-0.03	0.12	0.21	0.8	0.60 [-0.30, 1.51]
			Placebo	8	8 (100.0)	-0.07 (0.31)	-0.7	-0.24	-0.00	0.17	0.2	
		Week 36	Tezepelumab	15	13 (86.7)	0.11 (0.35)	-0.6	-0.01	0.21	0.35	0.6	0.29 [-0.69, 1.26]
			Placebo	8	6 (75.0)	0.02 (0.33)	-0.5	-0.11	-0.03	0.33	0.4	
		Week 52	Tezepelumab	15	12 (80.0)	0.37 (0.20)	0.0	0.22	0.39	0.53	0.7	1.75 [0.45, 3.05]
			Placebo	8	4 (50.0)	0.01 (0.20)	-0.2	-0.14	0.02	0.17	0.2	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
300 - < 450 cells/uL	Absolute values	Baseline	Tezepelumab	6	6 (100.0)	2.42 (0.38)	2.0	2.26	2.33	2.39	3.2	
			Placebo	12	12 (100.0)	2.40 (0.75)	1.0	2.09	2.47	2.98	3.6	
		Week 2	Tezepelumab	6	6 (100.0)	2.44 (0.19)	2.3	2.28	2.39	2.63	2.7	
			Placebo	12	12 (100.0)	2.62 (0.42)	1.7	2.34	2.61	3.04	3.2	
		Week 4	Tezepelumab	6	6 (100.0)	2.22 (0.33)	1.9	1.98	2.16	2.36	2.8	
			Placebo	12	11 (91.7)	2.73 (0.56)	2.1	2.42	2.57	3.15	4.0	
		Week 8	Tezepelumab	6	6 (100.0)	2.35 (0.35)	2.0	2.07	2.29	2.70	2.8	
			Placebo	12	11 (91.7)	2.68 (0.62)	1.4	2.39	2.76	3.15	3.6	
		Week 12	Tezepelumab	6	6 (100.0)	2.52 (0.40)	2.0	2.21	2.53	2.66	3.2	
			Placebo	12	11 (91.7)	2.73 (0.66)	1.7	2.34	2.52	3.07	4.2	
		Week 16	Tezepelumab	6	6 (100.0)	2.47 (0.36)	1.9	2.24	2.46	2.86	2.9	
			Placebo	12	11 (91.7)	2.70 (0.57)	1.9	2.36	2.52	3.16	3.9	
		Week 24	Tezepelumab	6	6 (100.0)	2.54 (0.28)	2.3	2.27	2.51	2.76	3.0	
			Placebo	12	10 (83.3)	2.79 (0.52)	2.0	2.60	2.73	3.05	3.9	
		Week 36	Tezepelumab	6	6 (100.0)	2.59 (0.26)	2.3	2.46	2.51	2.79	3.0	
			Placebo	12	10 (83.3)	2.78 (0.70)	1.4	2.40	2.81	3.10	4.1	
		Week 52	Tezepelumab	6	6 (100.0)	2.63 (0.39)	2.2	2.23	2.64	2.84	3.2	
			Placebo	12	11 (91.7)	2.68 (0.77)	1.2	2.14	2.72	3.27	3.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
300 - < 450 cells/uL	Change from baseline	Week 2	Tezepelumab	6	6 (100.0)	0.02 (0.31)	-0.5	-0.09	0.00	0.24	0.4	-0.44 [-1.43, 0.55]
			Placebo	12	12 (100.0)	0.22 (0.50)	-0.4	-0.02	0.15	0.25	1.7	
		Week 4	Tezepelumab	6	6 (100.0)	-0.20 (0.53)	-1.2	-0.27	-0.11	0.07	0.4	-1.17 [-2.25, -0.09]
			Placebo	12	11 (91.7)	0.44 (0.55)	-0.1	-0.02	0.34	0.95	1.7	
		Week 8	Tezepelumab	6	6 (100.0)	-0.07 (0.33)	-0.4	-0.34	-0.21	0.31	0.4	-0.91 [-1.96, 0.13]
			Placebo	12	11 (91.7)	0.39 (0.57)	-0.1	0.05	0.19	0.49	2.0	
		Week 12	Tezepelumab	6	6 (100.0)	0.10 (0.28)	-0.2	-0.16	0.11	0.27	0.5	-0.80 [-1.83, 0.24]
			Placebo	12	11 (91.7)	0.44 (0.48)	-0.2	0.19	0.39	0.42	1.5	
		Week 16	Tezepelumab	6	6 (100.0)	0.05 (0.38)	-0.4	-0.30	0.05	0.47	0.5	-0.82 [-1.86, 0.22]
			Placebo	12	11 (91.7)	0.41 (0.47)	-0.2	0.18	0.26	0.63	1.6	
		Week 24	Tezepelumab	6	6 (100.0)	0.13 (0.29)	-0.2	-0.10	0.07	0.37	0.6	-0.77 [-1.82, 0.29]
			Placebo	12	10 (83.3)	0.37 (0.33)	-0.3	0.17	0.43	0.60	0.8	
		Week 36	Tezepelumab	6	6 (100.0)	0.17 (0.25)	-0.2	-0.12	0.24	0.40	0.4	-0.57 [-1.61, 0.46]
			Placebo	12	10 (83.3)	0.48 (0.65)	0.0	0.14	0.22	0.47	2.2	
		Week 52	Tezepelumab	6	6 (100.0)	0.21 (0.46)	-0.3	-0.15	0.20	0.43	0.9	-0.42 [-1.42, 0.59]
			Placebo	12	11 (91.7)	0.39 (0.41)	-0.1	0.03	0.31	0.56	1.3	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
>= 450 cells/uL	Absolute values	Baseline	Tezepelumab	12	12 (100.0)	2.56 (0.55)	1.4	2.14	2.81	3.01	3.2	
			Placebo	15	15 (100.0)	2.90 (0.69)	1.9	2.22	2.97	3.39	4.1	
		Week 2	Tezepelumab	12	11 (91.7)	2.79 (0.55)	1.7	2.24	3.00	3.24	3.4	
			Placebo	15	14 (93.3)	2.88 (0.54)	2.2	2.60	2.78	3.18	4.2	
		Week 4	Tezepelumab	12	12 (100.0)	2.81 (0.59)	1.8	2.33	2.98	3.27	3.5	
			Placebo	15	14 (93.3)	2.93 (0.48)	2.2	2.57	2.85	3.18	3.8	
		Week 8	Tezepelumab	12	12 (100.0)	2.68 (0.91)	1.0	2.14	3.04	3.41	3.5	
			Placebo	15	14 (93.3)	2.85 (0.49)	2.2	2.41	2.73	3.28	3.8	
		Week 12	Tezepelumab	12	12 (100.0)	2.83 (0.78)	1.4	2.09	3.18	3.46	3.5	
			Placebo	15	15 (100.0)	2.87 (0.57)	1.9	2.54	2.86	3.38	3.9	
		Week 16	Tezepelumab	12	11 (91.7)	2.83 (0.57)	2.0	2.20	2.87	3.35	3.6	
			Placebo	15	15 (100.0)	2.85 (0.52)	2.1	2.44	2.63	3.28	3.7	
		Week 24	Tezepelumab	12	11 (91.7)	2.75 (0.77)	1.6	2.18	3.05	3.37	3.7	
			Placebo	15	14 (93.3)	2.87 (0.58)	2.0	2.38	2.94	3.33	4.0	
		Week 36	Tezepelumab	12	10 (83.3)	3.00 (0.59)	2.3	2.39	3.11	3.55	3.8	
			Placebo	15	14 (93.3)	2.97 (0.74)	1.4	2.33	3.28	3.54	3.8	
		Week 52	Tezepelumab	12	9 (75.0)	3.03 (0.58)	2.2	2.37	3.29	3.44	3.7	
			Placebo	15	14 (93.3)	3.04 (0.62)	2.1	2.51	3.05	3.65	3.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
>= 450 cells/uL	Change from baseline	Week 2	Tezepelumab	12	11 (91.7)	0.25 (0.55)	-0.5	0.05	0.08	0.81	1.4	0.54 [-0.26, 1.35]
			Placebo	15	14 (93.3)	-0.07 (0.60)	-1.3	-0.27	-0.05	0.06	1.3	
		Week 4	Tezepelumab	12	12 (100.0)	0.25 (0.43)	-0.3	-0.10	0.30	0.38	1.2	0.50 [-0.28, 1.29]
			Placebo	15	14 (93.3)	-0.02 (0.59)	-1.0	-0.33	-0.15	0.22	1.4	
		Week 8	Tezepelumab	12	12 (100.0)	0.12 (0.70)	-1.1	-0.21	0.21	0.44	1.6	0.31 [-0.47, 1.09]
			Placebo	15	14 (93.3)	-0.10 (0.72)	-1.7	-0.33	-0.10	0.03	1.4	
		Week 12	Tezepelumab	12	12 (100.0)	0.27 (0.75)	-1.5	0.11	0.36	0.62	1.5	0.41 [-0.36, 1.18]
			Placebo	15	15 (100.0)	-0.03 (0.72)	-1.2	-0.38	-0.21	0.13	1.6	
		Week 16	Tezepelumab	12	11 (91.7)	0.32 (0.53)	-0.5	-0.10	0.36	0.61	1.4	0.56 [-0.23, 1.36]
			Placebo	15	15 (100.0)	-0.05 (0.72)	-1.6	-0.34	-0.10	0.04	1.6	
		Week 24	Tezepelumab	12	11 (91.7)	0.25 (0.64)	-0.8	0.09	0.18	0.39	1.8	0.47 [-0.34, 1.27]
			Placebo	15	14 (93.3)	-0.08 (0.72)	-1.4	-0.26	-0.08	-0.01	1.5	
		Week 36	Tezepelumab	12	10 (83.3)	0.53 (0.48)	-0.0	0.23	0.37	0.77	1.7	0.72 [-0.12, 1.55]
			Placebo	15	14 (93.3)	0.02 (0.84)	-1.7	-0.30	0.07	0.31	1.6	
		Week 52	Tezepelumab	12	9 (75.0)	0.53 (0.53)	-0.6	0.41	0.59	0.79	1.3	0.65 [-0.21, 1.51]
			Placebo	15	14 (93.3)	0.09 (0.76)	-1.4	-0.38	0.14	0.38	1.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q1: < 140 cells/uL	Absolute values	Baseline	Tezepelumab	6	6 (100.0)	2.86 (0.68)	2.0	2.33	2.90	3.13	3.9	
			Placebo	6	6 (100.0)	2.71 (1.17)	1.4	2.10	2.58	2.70	4.9	
		Week 2	Tezepelumab	6	6 (100.0)	2.96 (0.53)	2.4	2.58	2.86	3.16	3.9	
			Placebo	6	6 (100.0)	2.61 (1.15)	1.3	1.93	2.48	2.74	4.7	
		Week 4	Tezepelumab	6	6 (100.0)	3.00 (0.58)	2.3	2.66	2.94	3.19	4.0	
			Placebo	6	5 (83.3)	2.28 (0.51)	1.4	2.30	2.32	2.64	2.7	
		Week 8	Tezepelumab	6	6 (100.0)	2.98 (0.46)	2.4	2.56	3.06	3.30	3.6	
			Placebo	6	6 (100.0)	2.70 (1.17)	1.5	2.14	2.40	2.84	4.9	
		Week 12	Tezepelumab	6	5 (83.3)	2.93 (0.75)	2.2	2.37	2.81	3.30	4.0	
			Placebo	6	5 (83.3)	2.82 (1.31)	1.4	2.29	2.66	2.75	5.0	
		Week 16	Tezepelumab	6	6 (100.0)	2.92 (0.56)	2.3	2.40	2.93	3.24	3.7	
			Placebo	6	6 (100.0)	2.80 (1.26)	1.5	2.31	2.58	2.62	5.2	
		Week 24	Tezepelumab	6	6 (100.0)	2.93 (0.48)	2.2	2.66	2.96	3.25	3.5	
			Placebo	6	6 (100.0)	2.77 (1.23)	1.5	2.25	2.56	2.66	5.1	
		Week 36	Tezepelumab	6	6 (100.0)	2.98 (0.51)	2.2	2.72	2.99	3.41	3.6	
			Placebo	6	5 (83.3)	2.93 (1.44)	1.4	2.56	2.70	2.70	5.3	
		Week 52	Tezepelumab	6	5 (83.3)	2.95 (0.51)	2.2	2.80	2.93	3.27	3.6	
			Placebo	6	6 (100.0)	2.91 (1.25)	1.5	2.43	2.70	2.85	5.3	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q1: < 140 cells/uL	Change from baseline	Week 2	Tezepelumab	6	6 (100.0)	0.10 (0.26)	-0.1	-0.06	0.05	0.10	0.6	0.82 [-0.36, 2.01]
			Placebo	6	6 (100.0)	-0.10 (0.21)	-0.4	-0.19	-0.12	0.04	0.2	
		Week 4	Tezepelumab	6	6 (100.0)	0.15 (0.27)	-0.1	-0.01	0.06	0.15	0.7	0.53 [-0.69, 1.74]
			Placebo	6	5 (83.3)	0.01 (0.24)	-0.4	-0.06	0.02	0.22	0.2	
		Week 8	Tezepelumab	6	6 (100.0)	0.12 (0.30)	-0.4	0.03	0.14	0.22	0.6	0.46 [-0.69, 1.61]
			Placebo	6	6 (100.0)	-0.00 (0.24)	-0.5	0.03	0.08	0.13	0.1	
		Week 12	Tezepelumab	6	5 (83.3)	0.06 (0.25)	-0.2	-0.17	0.09	0.17	0.4	-0.25 [-1.49, 1.00]
			Placebo	6	5 (83.3)	0.10 (0.12)	-0.0	0.03	0.09	0.19	0.3	
		Week 16	Tezepelumab	6	6 (100.0)	0.06 (0.24)	-0.2	-0.13	0.01	0.23	0.4	-0.16 [-1.29, 0.97]
			Placebo	6	6 (100.0)	0.09 (0.17)	-0.2	-0.05	0.10	0.21	0.3	
		Week 24	Tezepelumab	6	6 (100.0)	0.07 (0.37)	-0.4	-0.11	0.02	0.20	0.7	0.02 [-1.11, 1.15]
			Placebo	6	6 (100.0)	0.06 (0.15)	-0.1	-0.12	0.11	0.16	0.2	
		Week 36	Tezepelumab	6	6 (100.0)	0.12 (0.40)	-0.4	-0.13	0.03	0.40	0.7	-0.18 [-1.37, 1.01]
			Placebo	6	5 (83.3)	0.18 (0.31)	-0.1	-0.03	0.00	0.42	0.6	
		Week 52	Tezepelumab	6	5 (83.3)	0.12 (0.45)	-0.4	-0.13	0.14	0.15	0.8	-0.24 [-1.43, 0.96]
			Placebo	6	6 (100.0)	0.20 (0.17)	-0.0	0.06	0.21	0.35	0.4	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q2: 140 - < 250 cells/uL	Absolute values	Baseline	Tezepelumab	13	13 (100.0)	2.82 (0.73)	1.4	2.69	2.86	3.06	4.1	
			Placebo	6	6 (100.0)	2.66 (0.65)	1.5	2.43	2.84	3.15	3.2	
		Week 2	Tezepelumab	13	13 (100.0)	2.88 (0.63)	1.7	2.50	2.91	3.29	3.9	
			Placebo	6	6 (100.0)	2.72 (0.58)	1.8	2.40	2.82	3.15	3.4	
		Week 4	Tezepelumab	13	13 (100.0)	2.80 (0.69)	1.3	2.57	2.80	3.21	3.9	
			Placebo	6	6 (100.0)	2.57 (0.70)	1.3	2.39	2.79	2.88	3.3	
		Week 8	Tezepelumab	13	13 (100.0)	2.84 (0.74)	1.0	2.58	2.95	3.26	3.9	
			Placebo	6	6 (100.0)	2.55 (0.72)	1.2	2.30	2.77	3.06	3.2	
		Week 12	Tezepelumab	13	12 (92.3)	2.75 (0.83)	0.8	2.43	2.81	3.21	4.0	
			Placebo	6	6 (100.0)	2.53 (0.58)	1.5	2.41	2.64	2.96	3.1	
		Week 16	Tezepelumab	13	13 (100.0)	2.86 (0.71)	1.5	2.50	2.94	3.30	3.9	
			Placebo	6	6 (100.0)	2.66 (0.60)	1.6	2.52	2.81	3.06	3.2	
		Week 24	Tezepelumab	13	13 (100.0)	2.83 (0.64)	1.7	2.45	2.90	3.19	3.9	
			Placebo	6	6 (100.0)	2.64 (0.65)	1.7	2.07	2.80	3.15	3.4	
		Week 36	Tezepelumab	13	13 (100.0)	2.84 (0.58)	1.4	2.67	3.05	3.18	3.7	
			Placebo	6	5 (83.3)	2.76 (0.84)	1.4	2.76	2.97	3.04	3.7	
		Week 52	Tezepelumab	13	12 (92.3)	3.07 (0.65)	1.9	2.66	3.16	3.53	4.0	
			Placebo	6	3 (50.0)	3.20 (0.23)	3.1	3.05	3.09	3.46	3.5	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q2: 140 - < 250 cells/uL	Change from baseline	Week 2	Tezepelumab	13	13 (100.0)	0.06 (0.24)	-0.4	-0.04	0.07	0.19	0.4	-0.01 [-0.98, 0.96]
			Placebo	6	6 (100.0)	0.06 (0.15)	-0.1	-0.03	0.03	0.14	0.3	
		Week 4	Tezepelumab	13	13 (100.0)	-0.03 (0.21)	-0.3	-0.15	-0.12	0.10	0.4	0.33 [-0.65, 1.30]
			Placebo	6	6 (100.0)	-0.09 (0.12)	-0.3	-0.19	-0.06	-0.03	0.1	
		Week 8	Tezepelumab	13	13 (100.0)	0.01 (0.24)	-0.4	-0.13	0.02	0.14	0.4	0.62 [-0.37, 1.61]
			Placebo	6	6 (100.0)	-0.12 (0.10)	-0.2	-0.20	-0.11	-0.08	0.1	
		Week 12	Tezepelumab	13	12 (92.3)	-0.07 (0.29)	-0.6	-0.21	0.00	0.15	0.3	0.22 [-0.76, 1.21]
			Placebo	6	6 (100.0)	-0.13 (0.19)	-0.4	-0.33	-0.04	0.02	0.0	
		Week 16	Tezepelumab	13	13 (100.0)	0.03 (0.24)	-0.4	-0.12	0.04	0.24	0.4	0.14 [-0.83, 1.11]
			Placebo	6	6 (100.0)	0.00 (0.08)	-0.1	-0.07	0.00	0.09	0.1	
		Week 24	Tezepelumab	13	13 (100.0)	0.01 (0.23)	-0.4	-0.16	0.09	0.18	0.3	0.10 [-0.87, 1.07]
			Placebo	6	6 (100.0)	-0.02 (0.34)	-0.7	-0.01	0.06	0.22	0.2	
		Week 36	Tezepelumab	13	13 (100.0)	0.02 (0.36)	-0.6	-0.13	0.00	0.28	0.6	-0.30 [-1.34, 0.74]
			Placebo	6	5 (83.3)	0.12 (0.25)	-0.1	-0.09	0.03	0.33	0.4	
		Week 52	Tezepelumab	13	12 (92.3)	0.25 (0.25)	-0.2	0.05	0.34	0.41	0.7	0.66 [-0.63, 1.95]
			Placebo	6	3 (50.0)	0.09 (0.15)	-0.1	-0.06	0.11	0.23	0.2	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q3: 250 - < 430 cells/uL	Absolute values	Baseline	Tezepelumab	10	10 (100.0)	2.51 (0.63)	1.6	2.12	2.33	3.16	3.7	
			Placebo	13	13 (100.0)	2.55 (0.67)	1.0	2.11	2.57	3.00	3.6	
		Week 2	Tezepelumab	10	10 (100.0)	2.69 (0.64)	2.0	2.28	2.54	2.68	4.0	
			Placebo	13	12 (92.3)	2.72 (0.33)	2.3	2.43	2.62	3.07	3.2	
		Week 4	Tezepelumab	10	9 (90.0)	2.43 (0.67)	1.7	1.98	2.22	2.78	3.8	
			Placebo	13	12 (92.3)	2.71 (0.63)	1.7	2.43	2.58	3.16	4.0	
		Week 8	Tezepelumab	10	9 (90.0)	2.46 (0.57)	1.9	2.07	2.42	2.70	3.7	
			Placebo	13	12 (92.3)	2.79 (0.44)	2.0	2.49	2.78	3.09	3.6	
		Week 12	Tezepelumab	10	8 (80.0)	2.58 (0.55)	2.0	2.12	2.53	2.92	3.6	
			Placebo	13	12 (92.3)	2.75 (0.63)	1.7	2.42	2.64	3.05	4.2	
		Week 16	Tezepelumab	10	9 (90.0)	2.50 (0.60)	1.8	2.22	2.41	2.86	3.8	
			Placebo	13	12 (92.3)	2.72 (0.57)	1.8	2.42	2.56	3.10	3.9	
		Week 24	Tezepelumab	10	8 (80.0)	2.72 (0.44)	2.3	2.34	2.68	2.92	3.6	
			Placebo	13	11 (84.6)	2.84 (0.48)	2.1	2.60	2.74	3.11	3.9	
		Week 36	Tezepelumab	10	8 (80.0)	2.76 (0.54)	2.3	2.47	2.56	2.89	4.0	
			Placebo	13	10 (76.9)	2.92 (0.51)	2.3	2.55	2.83	3.10	4.1	
		Week 52	Tezepelumab	10	8 (80.0)	2.83 (0.66)	2.2	2.35	2.73	3.03	4.2	
			Placebo	13	11 (84.6)	2.85 (0.58)	2.1	2.27	2.86	3.27	3.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q3: 250 - < 430 cells/uL	Change from baseline	Week 2	Tezepelumab	10	10 (100.0)	0.17 (0.31)	-0.5	0.00	0.28	0.44	0.5	-0.13 [-0.97, 0.71]
			Placebo	13	12 (92.3)	0.23 (0.51)	-0.4	-0.02	0.15	0.25	1.7	
		Week 4	Tezepelumab	10	9 (90.0)	-0.01 (0.57)	-1.2	-0.19	0.07	0.13	1.0	-0.42 [-1.29, 0.45]
			Placebo	13	12 (92.3)	0.24 (0.61)	-0.8	-0.10	0.19	0.38	1.7	
		Week 8	Tezepelumab	10	9 (90.0)	0.03 (0.32)	-0.4	-0.22	0.04	0.31	0.4	-0.60 [-1.48, 0.29]
			Placebo	13	12 (92.3)	0.32 (0.59)	-0.2	-0.02	0.14	0.49	2.0	
		Week 12	Tezepelumab	10	8 (80.0)	0.10 (0.26)	-0.2	-0.13	0.11	0.30	0.5	-0.38 [-1.28, 0.53]
			Placebo	13	12 (92.3)	0.29 (0.58)	-0.7	-0.04	0.23	0.41	1.5	
		Week 16	Tezepelumab	10	9 (90.0)	0.07 (0.30)	-0.4	-0.02	0.10	0.12	0.5	-0.39 [-1.27, 0.48]
			Placebo	13	12 (92.3)	0.25 (0.55)	-0.7	-0.03	0.21	0.36	1.6	
		Week 24	Tezepelumab	10	8 (80.0)	0.18 (0.35)	-0.2	-0.08	0.07	0.46	0.8	-0.13 [-1.04, 0.78]
			Placebo	13	11 (84.6)	0.23 (0.38)	-0.3	-0.14	0.26	0.54	0.8	
		Week 36	Tezepelumab	10	8 (80.0)	0.22 (0.24)	-0.2	0.05	0.29	0.41	0.4	-0.35 [-1.29, 0.59]
			Placebo	13	10 (76.9)	0.41 (0.71)	-0.5	0.14	0.22	0.47	2.2	
		Week 52	Tezepelumab	10	8 (80.0)	0.30 (0.42)	-0.3	-0.09	0.43	0.56	0.9	-0.20 [-1.11, 0.72]
			Placebo	13	11 (84.6)	0.38 (0.43)	-0.2	0.03	0.31	0.56	1.3	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q4: >= 430 cells/uL	Absolute values	Baseline	Tezepelumab	12	12 (100.0)	2.56 (0.55)	1.4	2.14	2.81	3.01	3.2	
			Placebo	16	16 (100.0)	2.80 (0.78)	1.3	2.19	2.88	3.39	4.1	
		Week 2	Tezepelumab	12	11 (91.7)	2.79 (0.55)	1.7	2.24	3.00	3.24	3.4	
			Placebo	16	15 (93.8)	2.80 (0.60)	1.7	2.27	2.76	3.18	4.2	
		Week 4	Tezepelumab	12	12 (100.0)	2.81 (0.59)	1.8	2.33	2.98	3.27	3.5	
			Placebo	16	15 (93.8)	2.89 (0.49)	2.2	2.53	2.66	3.18	3.8	
		Week 8	Tezepelumab	12	12 (100.0)	2.68 (0.91)	1.0	2.14	3.04	3.41	3.5	
			Placebo	16	15 (93.8)	2.75 (0.61)	1.4	2.35	2.69	3.28	3.8	
		Week 12	Tezepelumab	12	12 (100.0)	2.83 (0.78)	1.4	2.09	3.18	3.46	3.5	
			Placebo	16	16 (100.0)	2.79 (0.63)	1.7	2.38	2.85	3.27	3.9	
		Week 16	Tezepelumab	12	11 (91.7)	2.83 (0.57)	2.0	2.20	2.87	3.35	3.6	
			Placebo	16	16 (100.0)	2.79 (0.55)	1.9	2.43	2.62	3.25	3.7	
		Week 24	Tezepelumab	12	11 (91.7)	2.75 (0.77)	1.6	2.18	3.05	3.37	3.7	
			Placebo	16	15 (93.8)	2.81 (0.61)	2.0	2.19	2.76	3.33	4.0	
		Week 36	Tezepelumab	12	10 (83.3)	3.00 (0.59)	2.3	2.39	3.11	3.55	3.8	
			Placebo	16	15 (93.8)	2.86 (0.83)	1.4	2.22	3.22	3.54	3.8	
		Week 52	Tezepelumab	12	9 (75.0)	3.03 (0.58)	2.2	2.37	3.29	3.44	3.7	
			Placebo	16	15 (93.8)	2.91 (0.77)	1.2	2.47	3.01	3.65	3.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q4: >= 430 cells/uL	Change from baseline	Week 2	Tezepelumab	12	11 (91.7)	0.25 (0.55)	-0.5	0.05	0.08	0.81	1.4	0.48 [-0.31, 1.27]
			Placebo	16	15 (93.8)	-0.03 (0.60)	-1.3	-0.27	-0.04	0.09	1.3	
		Week 4	Tezepelumab	12	12 (100.0)	0.25 (0.43)	-0.3	-0.10	0.30	0.38	1.2	0.35 [-0.41, 1.12]
			Placebo	16	15 (93.8)	0.05 (0.63)	-1.0	-0.33	-0.12	0.34	1.4	
		Week 8	Tezepelumab	12	12 (100.0)	0.12 (0.70)	-1.1	-0.21	0.21	0.44	1.6	0.30 [-0.47, 1.06]
			Placebo	16	15 (93.8)	-0.09 (0.70)	-1.7	-0.33	-0.08	0.09	1.4	
		Week 12	Tezepelumab	12	12 (100.0)	0.27 (0.75)	-1.5	0.11	0.36	0.62	1.5	0.37 [-0.38, 1.13]
			Placebo	16	16 (100.0)	-0.00 (0.71)	-1.2	-0.31	-0.19	0.25	1.6	
		Week 16	Tezepelumab	12	11 (91.7)	0.32 (0.53)	-0.5	-0.10	0.36	0.61	1.4	0.50 [-0.28, 1.28]
			Placebo	16	16 (100.0)	-0.01 (0.72)	-1.6	-0.29	-0.09	0.13	1.6	
		Week 24	Tezepelumab	12	11 (91.7)	0.25 (0.64)	-0.8	0.09	0.18	0.39	1.8	0.39 [-0.40, 1.18]
			Placebo	16	15 (93.8)	-0.02 (0.72)	-1.4	-0.26	-0.06	0.17	1.5	
		Week 36	Tezepelumab	12	10 (83.3)	0.53 (0.48)	-0.0	0.23	0.37	0.77	1.7	0.72 [-0.10, 1.55]
			Placebo	16	15 (93.8)	0.03 (0.81)	-1.7	-0.30	0.12	0.31	1.6	
		Week 52	Tezepelumab	12	9 (75.0)	0.53 (0.53)	-0.6	0.41	0.59	0.79	1.3	0.68 [-0.17, 1.53]
			Placebo	16	15 (93.8)	0.08 (0.74)	-1.4	-0.38	0.03	0.38	1.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
< 25 ppb	Absolute values	Baseline	Tezepelumab	11	11 (100.0)	2.67 (0.69)	1.6	2.14	2.78	3.01	4.1	
			Placebo	16	16 (100.0)	2.74 (0.56)	1.4	2.44	2.72	3.19	3.6	
		Week 2	Tezepelumab	11	11 (100.0)	2.72 (0.52)	2.0	2.26	2.74	3.07	3.7	
			Placebo	16	14 (87.5)	2.71 (0.59)	1.3	2.40	2.78	3.11	3.5	
		Week 4	Tezepelumab	11	11 (100.0)	2.70 (0.60)	1.7	2.22	2.71	3.16	3.8	
			Placebo	16	14 (87.5)	2.59 (0.60)	1.4	2.32	2.59	2.88	3.7	
		Week 8	Tezepelumab	11	11 (100.0)	2.78 (0.63)	1.9	2.07	2.88	3.20	3.9	
			Placebo	16	15 (93.8)	2.58 (0.47)	1.5	2.20	2.62	3.02	3.2	
		Week 12	Tezepelumab	11	10 (90.9)	2.66 (0.59)	2.0	2.02	2.69	3.05	3.6	
			Placebo	16	14 (87.5)	2.60 (0.56)	1.4	2.29	2.80	2.96	3.5	
		Week 16	Tezepelumab	11	11 (100.0)	2.69 (0.65)	1.6	2.24	2.73	3.24	3.8	
			Placebo	16	15 (93.8)	2.59 (0.49)	1.5	2.31	2.60	3.03	3.2	
		Week 24	Tezepelumab	11	10 (90.9)	2.84 (0.55)	2.0	2.32	2.91	3.21	3.8	
			Placebo	16	15 (93.8)	2.65 (0.55)	1.5	2.19	2.74	3.11	3.4	
		Week 36	Tezepelumab	11	9 (81.8)	2.94 (0.46)	2.2	2.71	2.93	3.18	3.7	
			Placebo	16	13 (81.3)	2.82 (0.60)	1.4	2.70	2.76	3.04	3.7	
		Week 52	Tezepelumab	11	8 (72.7)	3.02 (0.64)	2.2	2.51	3.01	3.46	4.0	
			Placebo	16	12 (75.0)	2.89 (0.63)	1.5	2.57	2.98	3.28	3.7	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
< 25 ppb	Change from baseline	Week 2	Tezepelumab	11	11 (100.0)	0.05 (0.23)	-0.4	-0.14	0.06	0.19	0.4	0.35 [-0.45, 1.14]
			Placebo	16	14 (87.5)	-0.03 (0.25)	-0.4	-0.12	-0.05	0.06	0.6	
		Week 4	Tezepelumab	11	11 (100.0)	0.03 (0.21)	-0.3	-0.12	-0.04	0.15	0.4	0.64 [-0.17, 1.45]
			Placebo	16	14 (87.5)	-0.13 (0.27)	-0.8	-0.27	-0.08	0.02	0.2	
		Week 8	Tezepelumab	11	11 (100.0)	0.11 (0.19)	-0.2	0.02	0.14	0.22	0.4	1.20 [0.35, 2.05]
			Placebo	16	15 (93.8)	-0.10 (0.17)	-0.5	-0.22	-0.09	0.05	0.1	
		Week 12	Tezepelumab	11	10 (90.9)	-0.01 (0.31)	-0.5	-0.24	0.02	0.16	0.5	0.29 [-0.53, 1.10]
			Placebo	16	14 (87.5)	-0.09 (0.26)	-0.7	-0.23	-0.00	0.06	0.2	
		Week 16	Tezepelumab	11	11 (100.0)	0.02 (0.21)	-0.4	-0.13	0.00	0.23	0.4	0.51 [-0.28, 1.31]
			Placebo	16	15 (93.8)	-0.09 (0.23)	-0.7	-0.22	-0.05	0.08	0.2	
		Week 24	Tezepelumab	11	10 (90.9)	0.06 (0.18)	-0.3	-0.03	0.11	0.20	0.3	0.43 [-0.38, 1.24]
			Placebo	16	15 (93.8)	-0.04 (0.25)	-0.7	-0.14	-0.01	0.15	0.3	
		Week 36	Tezepelumab	11	9 (81.8)	0.17 (0.31)	-0.5	-0.01	0.21	0.39	0.6	0.19 [-0.67, 1.04]
			Placebo	16	13 (81.3)	0.12 (0.28)	-0.5	-0.03	0.15	0.31	0.6	
		Week 52	Tezepelumab	11	8 (72.7)	0.29 (0.26)	-0.1	0.06	0.34	0.47	0.7	0.52 [-0.39, 1.43]
			Placebo	16	12 (75.0)	0.16 (0.22)	-0.2	0.02	0.17	0.29	0.6	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
25 - < 50 ppb	Absolute values	Baseline	Tezepelumab	12	12 (100.0)	2.78 (0.52)	2.0	2.31	2.84	3.06	3.9	
			Placebo	10	10 (100.0)	2.60 (1.00)	1.0	2.16	2.44	2.96	4.9	
		Week 2	Tezepelumab	12	12 (100.0)	2.90 (0.46)	2.3	2.51	2.96	3.21	3.9	
			Placebo	10	10 (100.0)	2.81 (0.72)	2.2	2.37	2.66	3.01	4.7	
		Week 4	Tezepelumab	12	12 (100.0)	2.92 (0.49)	2.3	2.59	2.79	3.20	4.0	
			Placebo	10	9 (90.0)	2.56 (0.31)	2.1	2.50	2.57	2.66	3.2	
		Week 8	Tezepelumab	12	12 (100.0)	2.82 (0.52)	2.0	2.46	2.87	3.28	3.6	
			Placebo	10	9 (90.0)	2.91 (0.80)	2.3	2.41	2.76	2.93	4.9	
		Week 12	Tezepelumab	12	11 (91.7)	2.82 (0.70)	1.4	2.37	3.03	3.30	4.0	
			Placebo	10	10 (100.0)	2.70 (0.87)	1.9	2.19	2.53	2.75	5.0	
		Week 16	Tezepelumab	12	11 (91.7)	2.87 (0.48)	2.3	2.41	3.06	3.21	3.7	
			Placebo	10	10 (100.0)	2.82 (0.88)	2.1	2.46	2.56	2.63	5.2	
		Week 24	Tezepelumab	12	11 (91.7)	2.75 (0.46)	2.2	2.34	2.66	3.23	3.5	
			Placebo	10	8 (80.0)	2.84 (0.99)	2.0	2.27	2.59	2.97	5.1	
		Week 36	Tezepelumab	12	11 (91.7)	2.81 (0.42)	2.2	2.50	2.72	3.20	3.6	
			Placebo	10	7 (70.0)	2.87 (1.25)	1.4	1.86	2.93	3.10	5.3	
		Week 52	Tezepelumab	12	10 (83.3)	2.94 (0.45)	2.2	2.53	3.07	3.27	3.6	
			Placebo	10	9 (90.0)	2.84 (0.98)	2.1	2.27	2.51	2.85	5.3	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
25 - < 50 ppb	Change from baseline	Week 2	Tezepelumab	12	12 (100.0)	0.13 (0.34)	-0.4	-0.03	0.07	0.29	0.8	-0.19 [-1.03, 0.66]
			Placebo	10	10 (100.0)	0.21 (0.52)	-0.2	-0.04	0.06	0.21	1.7	
		Week 4	Tezepelumab	12	12 (100.0)	0.15 (0.31)	-0.3	-0.08	0.06	0.33	0.7	-0.14 [-1.00, 0.73]
			Placebo	10	9 (90.0)	0.21 (0.60)	-0.5	-0.07	0.19	0.22	1.7	
		Week 8	Tezepelumab	12	12 (100.0)	0.04 (0.41)	-0.8	-0.24	0.10	0.32	0.6	-0.38 [-1.25, 0.49]
			Placebo	10	9 (90.0)	0.26 (0.74)	-0.8	0.01	0.12	0.19	2.0	
		Week 12	Tezepelumab	12	11 (91.7)	0.05 (0.59)	-1.5	-0.12	0.19	0.30	0.8	-0.07 [-0.93, 0.79]
			Placebo	10	10 (100.0)	0.10 (0.68)	-1.2	-0.22	0.10	0.38	1.5	
		Week 16	Tezepelumab	12	11 (91.7)	0.13 (0.37)	-0.5	-0.21	0.12	0.36	0.8	-0.18 [-1.04, 0.68]
			Placebo	10	10 (100.0)	0.21 (0.57)	-0.7	-0.07	0.21	0.33	1.6	
		Week 24	Tezepelumab	12	11 (91.7)	0.01 (0.39)	-0.8	-0.16	0.09	0.13	0.7	0.06 [-0.85, 0.97]
			Placebo	10	8 (80.0)	-0.01 (0.50)	-1.1	-0.14	0.08	0.25	0.6	
		Week 36	Tezepelumab	12	11 (91.7)	0.08 (0.36)	-0.6	-0.13	0.07	0.26	0.7	-0.07 [-1.02, 0.88]
			Placebo	10	7 (70.0)	0.13 (1.13)	-1.7	-0.30	0.14	0.42	2.2	
		Week 52	Tezepelumab	12	10 (83.3)	0.21 (0.54)	-0.6	-0.16	0.14	0.82	0.9	0.02 [-0.88, 0.92]
			Placebo	10	9 (90.0)	0.20 (0.59)	-0.7	0.03	0.31	0.35	1.3	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
>= 50 ppb	Absolute values	Baseline	Tezepelumab	18	18 (100.0)	2.61 (0.71)	1.4	2.08	2.59	3.16	3.7	
			Placebo	15	15 (100.0)	2.68 (0.86)	1.3	2.06	2.71	3.38	4.1	
		Week 2	Tezepelumab	18	17 (94.4)	2.82 (0.71)	1.7	2.28	2.68	3.36	4.0	
			Placebo	15	15 (100.0)	2.71 (0.62)	1.7	2.30	2.74	3.16	4.2	
		Week 4	Tezepelumab	18	17 (94.4)	2.66 (0.77)	1.3	1.98	2.78	3.29	3.9	
			Placebo	15	15 (100.0)	2.89 (0.67)	1.3	2.50	3.04	3.34	4.0	
		Week 8	Tezepelumab	18	17 (94.4)	2.63 (0.91)	1.0	2.15	2.76	3.39	3.7	
			Placebo	15	15 (100.0)	2.75 (0.77)	1.2	2.35	2.84	3.32	3.8	
		Week 12	Tezepelumab	18	16 (88.9)	2.79 (0.85)	0.8	2.16	3.02	3.44	4.0	
			Placebo	15	15 (100.0)	2.91 (0.74)	1.5	2.49	2.96	3.40	4.2	
		Week 16	Tezepelumab	18	17 (94.4)	2.77 (0.71)	1.5	2.20	2.86	3.35	3.9	
			Placebo	15	15 (100.0)	2.87 (0.70)	1.6	2.36	3.01	3.43	3.9	
		Week 24	Tezepelumab	18	17 (94.4)	2.81 (0.74)	1.6	2.27	2.88	3.37	3.9	
			Placebo	15	15 (100.0)	2.88 (0.64)	1.7	2.58	2.74	3.33	4.0	
		Week 36	Tezepelumab	18	17 (94.4)	2.91 (0.68)	1.4	2.39	2.99	3.34	4.0	
			Placebo	15	15 (100.0)	2.92 (0.81)	1.4	2.34	3.22	3.54	4.1	
		Week 52	Tezepelumab	18	16 (88.9)	3.00 (0.69)	1.9	2.39	3.04	3.51	4.2	
			Placebo	15	14 (93.3)	2.99 (0.77)	1.2	2.65	3.05	3.56	3.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
>= 50 ppb	Change from baseline	Week 2	Tezepelumab	18	17 (94.4)	0.22 (0.45)	-0.5	0.05	0.21	0.44	1.4	0.36 [-0.34, 1.06]
			Placebo	15	15 (100.0)	0.03 (0.61)	-1.3	-0.27	0.09	0.31	1.3	
		Week 4	Tezepelumab	18	17 (94.4)	0.08 (0.53)	-1.2	-0.19	0.10	0.37	1.2	-0.22 [-0.92, 0.47]
			Placebo	15	15 (100.0)	0.21 (0.63)	-1.0	-0.24	0.21	0.77	1.4	
		Week 8	Tezepelumab	18	17 (94.4)	0.05 (0.57)	-1.1	-0.22	0.04	0.31	1.6	-0.02 [-0.72, 0.67]
			Placebo	15	15 (100.0)	0.07 (0.69)	-1.7	-0.24	0.03	0.49	1.4	
		Week 12	Tezepelumab	18	16 (88.9)	0.19 (0.51)	-0.6	-0.10	0.14	0.46	1.5	-0.06 [-0.77, 0.64]
			Placebo	15	15 (100.0)	0.23 (0.69)	-1.0	-0.22	0.13	0.42	1.6	
		Week 16	Tezepelumab	18	17 (94.4)	0.19 (0.44)	-0.4	-0.12	0.10	0.47	1.4	0.01 [-0.68, 0.71]
			Placebo	15	15 (100.0)	0.19 (0.73)	-1.6	-0.15	0.09	0.63	1.6	
		Week 24	Tezepelumab	18	17 (94.4)	0.23 (0.53)	-0.5	-0.10	0.18	0.38	1.8	0.04 [-0.65, 0.74]
			Placebo	15	15 (100.0)	0.20 (0.70)	-1.4	-0.16	0.17	0.69	1.5	
		Week 36	Tezepelumab	18	17 (94.4)	0.33 (0.49)	-0.5	0.00	0.31	0.44	1.7	0.15 [-0.54, 0.85]
			Placebo	15	15 (100.0)	0.24 (0.68)	-1.2	-0.09	0.15	0.57	1.6	
		Week 52	Tezepelumab	18	16 (88.9)	0.40 (0.39)	-0.3	0.15	0.42	0.59	1.3	0.32 [-0.40, 1.04]
			Placebo	15	14 (93.3)	0.22 (0.73)	-1.4	-0.11	0.14	0.56	1.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q1: < 16 ppb	Absolute values	Baseline	Tezepelumab	5	5 (100.0)	2.42 (0.63)	1.6	1.86	2.69	2.91	3.0	
			Placebo	10	10 (100.0)	2.70 (0.43)	2.1	2.43	2.68	3.02	3.5	
		Week 2	Tezepelumab	5	5 (100.0)	2.56 (0.52)	2.0	2.01	2.74	2.98	3.1	
			Placebo	10	9 (90.0)	2.74 (0.52)	1.9	2.40	2.62	3.04	3.5	
		Week 4	Tezepelumab	5	5 (100.0)	2.53 (0.68)	1.7	1.96	2.61	3.16	3.2	
			Placebo	10	9 (90.0)	2.61 (0.59)	1.7	2.32	2.59	2.71	3.7	
		Week 8	Tezepelumab	5	5 (100.0)	2.58 (0.65)	1.9	1.96	2.71	3.15	3.2	
			Placebo	10	10 (100.0)	2.55 (0.40)	2.1	2.20	2.43	2.79	3.2	
		Week 12	Tezepelumab	5	5 (100.0)	2.59 (0.62)	2.0	2.01	2.74	2.81	3.4	
			Placebo	10	9 (90.0)	2.58 (0.52)	1.7	2.29	2.44	2.86	3.5	
		Week 16	Tezepelumab	5	5 (100.0)	2.45 (0.71)	1.6	1.75	2.73	2.87	3.2	
			Placebo	10	10 (100.0)	2.57 (0.43)	1.8	2.31	2.56	2.67	3.2	
		Week 24	Tezepelumab	5	4 (80.0)	2.78 (0.57)	2.0	2.43	2.98	3.13	3.2	
			Placebo	10	10 (100.0)	2.64 (0.50)	2.1	2.19	2.60	3.05	3.4	
		Week 36	Tezepelumab	5	3 (60.0)	2.90 (0.62)	2.2	2.21	3.08	3.41	3.4	
			Placebo	10	8 (80.0)	2.97 (0.53)	2.2	2.63	2.83	3.50	3.7	
		Week 52	Tezepelumab	5	2 (40.0)	2.63 (0.64)	2.2	2.17	2.63	3.08	3.1	
			Placebo	10	7 (70.0)	3.02 (0.61)	2.2	2.43	2.93	3.65	3.7	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q1: < 16 ppb	Change from baseline	Week 2	Tezepelumab	5	5 (100.0)	0.14 (0.13)	0.1	0.06	0.07	0.15	0.4	0.62 [-0.50, 1.74]
			Placebo	10	9 (90.0)	-0.01 (0.27)	-0.4	-0.12	-0.08	0.06	0.6	
		Week 4	Tezepelumab	5	5 (100.0)	0.11 (0.13)	-0.1	0.08	0.10	0.15	0.3	0.87 [-0.28, 2.02]
			Placebo	10	9 (90.0)	-0.14 (0.33)	-0.8	-0.35	-0.04	0.07	0.2	
		Week 8	Tezepelumab	5	5 (100.0)	0.16 (0.10)	0.0	0.10	0.22	0.22	0.2	2.01 [0.69, 3.33]
			Placebo	10	10 (100.0)	-0.15 (0.17)	-0.5	-0.22	-0.13	-0.02	0.1	
		Week 12	Tezepelumab	5	5 (100.0)	0.17 (0.27)	-0.2	0.05	0.15	0.32	0.5	1.01 [-0.16, 2.17]
			Placebo	10	9 (90.0)	-0.13 (0.30)	-0.7	-0.33	-0.01	0.06	0.2	
		Week 16	Tezepelumab	5	5 (100.0)	0.03 (0.17)	-0.2	-0.04	0.04	0.12	0.2	0.69 [-0.42, 1.79]
			Placebo	10	10 (100.0)	-0.13 (0.26)	-0.7	-0.25	-0.06	0.01	0.2	
		Week 24	Tezepelumab	5	4 (80.0)	0.16 (0.06)	0.1	0.11	0.17	0.21	0.2	0.84 [-0.37, 2.05]
			Placebo	10	10 (100.0)	-0.06 (0.30)	-0.7	-0.26	-0.05	0.15	0.3	
		Week 36	Tezepelumab	5	3 (60.0)	0.38 (0.03)	0.3	0.35	0.39	0.40	0.4	0.67 [-0.69, 2.04]
			Placebo	10	8 (80.0)	0.25 (0.22)	-0.1	0.10	0.26	0.38	0.6	
		Week 52	Tezepelumab	5	2 (40.0)	0.35 (0.06)	0.3	0.31	0.35	0.39	0.4	0.52 [-1.08, 2.11]
			Placebo	10	7 (70.0)	0.25 (0.21)	-0.0	0.06	0.23	0.33	0.6	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)											
Q2: 16 - < 30 ppb Absolute values	Baseline	Tezepelumab	10	10 (100.0)	2.76 (0.64)	2.0	2.25	2.83	3.06	4.1	
		Placebo	7	7 (100.0)	2.72 (0.74)	1.4	2.16	2.94	3.25	3.6	
	Week 2	Tezepelumab	10	10 (100.0)	2.93 (0.44)	2.3	2.58	2.98	3.16	3.7	
		Placebo	7	6 (85.7)	2.56 (0.71)	1.3	2.16	2.81	3.11	3.2	
	Week 4	Tezepelumab	10	10 (100.0)	2.90 (0.44)	2.2	2.66	2.86	3.19	3.8	
		Placebo	7	6 (85.7)	2.54 (0.61)	1.4	2.42	2.68	2.88	3.2	
	Week 8	Tezepelumab	10	10 (100.0)	2.97 (0.51)	2.1	2.58	2.98	3.26	3.9	
		Placebo	7	5 (71.4)	2.65 (0.64)	1.5	2.62	2.99	3.02	3.1	
	Week 12	Tezepelumab	10	8 (80.0)	2.80 (0.55)	2.0	2.34	2.85	3.18	3.6	
		Placebo	7	6 (85.7)	2.63 (0.61)	1.4	2.54	2.86	3.02	3.1	
	Week 16	Tezepelumab	10	10 (100.0)	2.93 (0.48)	2.2	2.50	3.00	3.23	3.8	
		Placebo	7	6 (85.7)	2.56 (0.63)	1.5	2.09	2.83	3.03	3.1	
	Week 24	Tezepelumab	10	10 (100.0)	2.86 (0.50)	2.3	2.34	2.81	3.25	3.8	
		Placebo	7	6 (85.7)	2.59 (0.66)	1.5	2.15	2.84	3.11	3.2	
	Week 36	Tezepelumab	10	10 (100.0)	2.85 (0.41)	2.3	2.50	2.75	3.18	3.7	
		Placebo	7	6 (85.7)	2.46 (0.68)	1.4	1.86	2.74	2.97	3.0	
	Week 52	Tezepelumab	10	10 (100.0)	3.11 (0.49)	2.2	2.80	3.07	3.31	4.0	
		Placebo	7	6 (85.7)	2.67 (0.62)	1.5	2.47	2.95	3.05	3.1	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q2: 16 - < 30 ppb	Change from baseline	Week 2	Tezepelumab	10	10 (100.0)	0.17 (0.38)	-0.4	-0.14	0.11	0.41	0.8	0.73 [-0.32, 1.78]
			Placebo	7	6 (85.7)	-0.07 (0.19)	-0.4	-0.07	0.00	0.04	0.1	
		Week 4	Tezepelumab	10	10 (100.0)	0.15 (0.35)	-0.3	-0.12	0.01	0.43	0.7	0.61 [-0.43, 1.65]
			Placebo	7	6 (85.7)	-0.04 (0.21)	-0.3	-0.15	-0.08	0.02	0.3	
		Week 8	Tezepelumab	10	10 (100.0)	0.21 (0.28)	-0.2	0.10	0.16	0.44	0.6	0.92 [-0.21, 2.06]
			Placebo	7	5 (71.4)	-0.02 (0.14)	-0.2	-0.09	0.05	0.05	0.1	
		Week 12	Tezepelumab	10	8 (80.0)	0.06 (0.42)	-0.5	-0.27	0.07	0.28	0.8	0.02 [-1.04, 1.08]
			Placebo	7	6 (85.7)	0.05 (0.21)	-0.2	-0.09	0.03	0.19	0.4	
		Week 16	Tezepelumab	10	10 (100.0)	0.17 (0.33)	-0.4	-0.02	0.16	0.36	0.8	0.71 [-0.33, 1.76]
			Placebo	7	6 (85.7)	-0.02 (0.13)	-0.2	-0.09	-0.04	0.08	0.2	
		Week 24	Tezepelumab	10	10 (100.0)	0.10 (0.26)	-0.3	-0.03	0.11	0.18	0.7	0.39 [-0.63, 1.42]
			Placebo	7	6 (85.7)	0.01 (0.10)	-0.1	-0.01	-0.00	0.07	0.2	
		Week 36	Tezepelumab	10	10 (100.0)	0.09 (0.40)	-0.6	-0.01	0.10	0.25	0.7	0.61 [-0.43, 1.65]
			Placebo	7	6 (85.7)	-0.12 (0.23)	-0.5	-0.30	-0.07	0.03	0.2	
		Week 52	Tezepelumab	10	10 (100.0)	0.35 (0.35)	-0.1	0.13	0.26	0.65	0.9	0.88 [-0.18, 1.94]
			Placebo	7	6 (85.7)	0.08 (0.20)	-0.2	-0.06	0.09	0.29	0.3	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)											
Q3: 30 - < 56 ppb Absolute values	Baseline	Tezepelumab	11	11 (100.0)	2.83 (0.58)	2.0	2.33	2.84	3.18	3.9	
		Placebo	10	10 (100.0)	2.60 (1.00)	1.0	2.11	2.44	2.96	4.9	
	Week 2	Tezepelumab	11	11 (100.0)	2.86 (0.61)	2.3	2.41	2.59	3.26	4.0	
		Placebo	10	10 (100.0)	2.83 (0.71)	2.3	2.37	2.66	3.01	4.7	
	Week 4	Tezepelumab	11	11 (100.0)	2.80 (0.70)	1.9	2.32	2.67	3.51	4.0	
		Placebo	10	9 (90.0)	2.56 (0.31)	2.1	2.50	2.57	2.66	3.2	
	Week 8	Tezepelumab	11	11 (100.0)	2.74 (0.61)	2.0	2.15	2.56	3.43	3.7	
		Placebo	10	10 (100.0)	2.88 (0.76)	2.3	2.41	2.69	2.93	4.9	
	Week 12	Tezepelumab	11	11 (100.0)	2.78 (0.74)	1.4	2.21	2.57	3.48	4.0	
		Placebo	10	10 (100.0)	2.70 (0.87)	1.9	2.19	2.51	2.75	5.0	
	Week 16	Tezepelumab	11	10 (90.9)	2.78 (0.62)	1.9	2.41	2.51	3.20	3.8	
		Placebo	10	10 (100.0)	2.84 (0.86)	2.4	2.46	2.56	2.63	5.2	
	Week 24	Tezepelumab	11	10 (90.9)	2.75 (0.53)	2.2	2.27	2.57	3.23	3.6	
		Placebo	10	8 (80.0)	2.90 (0.96)	2.0	2.45	2.65	2.97	5.1	
	Week 36	Tezepelumab	11	10 (90.9)	2.89 (0.58)	2.2	2.46	2.81	3.26	4.0	
		Placebo	10	7 (70.0)	2.94 (1.20)	1.4	2.34	2.93	3.10	5.3	
	Week 52	Tezepelumab	11	9 (81.8)	2.90 (0.71)	2.2	2.37	2.53	3.32	4.2	
		Placebo	10	9 (90.0)	2.86 (0.97)	2.1	2.27	2.63	2.85	5.3	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q3: 30 - < 56 ppb	Change from baseline	Week 2	Tezepelumab	11	11 (100.0)	0.03 (0.24)	-0.4	-0.09	0.07	0.16	0.4	-0.49 [-1.36, 0.38]
			Placebo	10	10 (100.0)	0.23 (0.52)	-0.2	-0.04	0.12	0.21	1.7	
		Week 4	Tezepelumab	11	11 (100.0)	-0.03 (0.21)	-0.3	-0.19	-0.01	0.13	0.3	-0.57 [-1.47, 0.33]
			Placebo	10	9 (90.0)	0.21 (0.60)	-0.5	-0.07	0.19	0.22	1.7	
		Week 8	Tezepelumab	11	11 (100.0)	-0.09 (0.34)	-0.8	-0.34	0.03	0.11	0.4	-0.69 [-1.57, 0.20]
			Placebo	10	10 (100.0)	0.28 (0.70)	-0.8	0.01	0.15	0.49	2.0	
		Week 12	Tezepelumab	11	11 (100.0)	-0.05 (0.54)	-1.5	-0.16	0.09	0.24	0.5	-0.24 [-1.10, 0.62]
			Placebo	10	10 (100.0)	0.10 (0.68)	-1.2	-0.22	0.10	0.39	1.5	
		Week 16	Tezepelumab	11	10 (90.9)	-0.01 (0.33)	-0.5	-0.26	0.02	0.26	0.5	-0.56 [-1.46, 0.33]
			Placebo	10	10 (100.0)	0.25 (0.56)	-0.7	0.12	0.21	0.33	1.6	
		Week 24	Tezepelumab	11	10 (90.9)	-0.05 (0.38)	-0.8	-0.16	-0.08	0.12	0.6	-0.23 [-1.16, 0.70]
			Placebo	10	8 (80.0)	0.06 (0.54)	-1.1	-0.13	0.20	0.40	0.6	
		Week 36	Tezepelumab	11	10 (90.9)	0.10 (0.27)	-0.4	-0.12	0.09	0.32	0.4	-0.15 [-1.12, 0.82]
			Placebo	10	7 (70.0)	0.21 (1.11)	-1.7	0.02	0.15	0.42	2.2	
		Week 52	Tezepelumab	11	9 (81.8)	0.11 (0.51)	-0.6	-0.16	-0.13	0.48	0.9	-0.20 [-1.13, 0.73]
			Placebo	10	9 (90.0)	0.22 (0.60)	-0.7	0.03	0.34	0.38	1.3	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q4: >= 56 ppb	Absolute values	Baseline	Tezepelumab	15	15 (100.0)	2.60 (0.71)	1.4	2.08	2.78	3.16	3.7	
			Placebo	14	14 (100.0)	2.72 (0.88)	1.3	2.06	2.84	3.38	4.1	
		Week 2	Tezepelumab	15	14 (93.3)	2.81 (0.69)	1.7	2.24	2.81	3.36	3.9	
			Placebo	14	14 (100.0)	2.74 (0.63)	1.7	2.31	2.75	3.16	4.2	
		Week 4	Tezepelumab	15	14 (93.3)	2.67 (0.75)	1.3	1.98	2.79	3.29	3.9	
			Placebo	14	14 (100.0)	2.92 (0.69)	1.3	2.53	3.06	3.34	4.0	
		Week 8	Tezepelumab	15	14 (93.3)	2.60 (0.95)	1.0	2.12	2.78	3.39	3.6	
			Placebo	14	14 (100.0)	2.76 (0.79)	1.2	2.35	2.97	3.32	3.8	
		Week 12	Tezepelumab	15	13 (86.7)	2.80 (0.90)	0.8	2.10	3.17	3.37	4.0	
			Placebo	14	14 (100.0)	2.94 (0.75)	1.5	2.59	3.02	3.40	4.2	
		Week 16	Tezepelumab	15	14 (93.3)	2.78 (0.70)	1.5	2.20	2.86	3.35	3.9	
			Placebo	14	14 (100.0)	2.90 (0.71)	1.6	2.44	3.09	3.43	3.9	
		Week 24	Tezepelumab	15	14 (93.3)	2.80 (0.77)	1.6	2.18	2.92	3.37	3.9	
			Placebo	14	14 (100.0)	2.90 (0.67)	1.7	2.58	2.93	3.33	4.0	
		Week 36	Tezepelumab	15	14 (93.3)	2.91 (0.66)	1.4	2.39	3.07	3.34	3.8	
			Placebo	14	14 (100.0)	2.96 (0.83)	1.4	2.55	3.26	3.54	4.1	
		Week 52	Tezepelumab	15	13 (86.7)	3.01 (0.62)	1.9	2.64	3.24	3.45	3.8	
			Placebo	14	13 (92.9)	3.01 (0.79)	1.2	2.67	3.09	3.56	3.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q4: >= 56 ppb	Change from baseline	Week 2	Tezepelumab	15	14 (93.3)	0.22 (0.48)	-0.5	0.05	0.16	0.47	1.4	0.36 [-0.39, 1.11]
			Placebo	14	14 (100.0)	0.02 (0.63)	-1.3	-0.27	0.06	0.31	1.3	
		Week 4	Tezepelumab	15	14 (93.3)	0.12 (0.58)	-1.2	-0.15	0.11	0.39	1.2	-0.12 [-0.86, 0.62]
			Placebo	14	14 (100.0)	0.20 (0.65)	-1.0	-0.24	0.07	0.77	1.4	
		Week 8	Tezepelumab	15	14 (93.3)	0.05 (0.62)	-1.1	-0.37	-0.03	0.31	1.6	0.02 [-0.72, 0.76]
			Placebo	14	14 (100.0)	0.04 (0.71)	-1.7	-0.24	-0.02	0.32	1.4	
		Week 12	Tezepelumab	15	13 (86.7)	0.21 (0.55)	-0.6	0.01	0.25	0.43	1.5	-0.00 [-0.76, 0.75]
			Placebo	14	14 (100.0)	0.21 (0.72)	-1.0	-0.22	0.07	0.42	1.6	
		Week 16	Tezepelumab	15	14 (93.3)	0.23 (0.45)	-0.3	-0.12	0.11	0.56	1.4	0.07 [-0.67, 0.81]
			Placebo	14	14 (100.0)	0.18 (0.76)	-1.6	-0.15	0.07	0.63	1.6	
		Week 24	Tezepelumab	15	14 (93.3)	0.25 (0.57)	-0.5	-0.21	0.23	0.38	1.8	0.11 [-0.63, 0.85]
			Placebo	14	14 (100.0)	0.18 (0.71)	-1.4	-0.16	0.05	0.69	1.5	
		Week 36	Tezepelumab	15	14 (93.3)	0.36 (0.53)	-0.5	0.00	0.30	0.69	1.7	0.19 [-0.55, 0.93]
			Placebo	14	14 (100.0)	0.24 (0.70)	-1.2	-0.09	0.13	0.57	1.6	
		Week 52	Tezepelumab	15	13 (86.7)	0.43 (0.40)	-0.3	0.23	0.42	0.59	1.3	0.39 [-0.39, 1.16]
			Placebo	14	13 (92.9)	0.20 (0.75)	-1.4	-0.11	0.03	0.56	1.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q1: < 53.1 IU/ml	Absolute values	Baseline	Tezepelumab	4	4 (100.0)	2.80 (0.37)	2.3	2.51	2.88	3.10	3.1	
			Placebo	4	4 (100.0)	2.29 (0.64)	1.4	1.83	2.49	2.76	2.8	
		Week 2	Tezepelumab	4	4 (100.0)	2.81 (0.30)	2.4	2.59	2.82	3.03	3.2	
			Placebo	4	4 (100.0)	2.24 (0.63)	1.3	1.81	2.45	2.68	2.7	
		Week 4	Tezepelumab	4	4 (100.0)	2.77 (0.38)	2.3	2.47	2.78	3.07	3.2	
			Placebo	4	4 (100.0)	2.24 (0.59)	1.4	1.80	2.42	2.69	2.7	
		Week 8	Tezepelumab	4	4 (100.0)	2.89 (0.44)	2.4	2.54	2.96	3.25	3.3	
			Placebo	4	4 (100.0)	2.31 (0.53)	1.5	1.98	2.48	2.65	2.8	
		Week 12	Tezepelumab	4	4 (100.0)	2.81 (0.49)	2.2	2.45	2.90	3.18	3.3	
			Placebo	4	4 (100.0)	2.10 (0.50)	1.4	1.72	2.21	2.49	2.6	
		Week 16	Tezepelumab	4	4 (100.0)	2.88 (0.47)	2.3	2.51	2.97	3.26	3.3	
			Placebo	4	4 (100.0)	2.31 (0.56)	1.5	1.98	2.55	2.65	2.7	
		Week 24	Tezepelumab	4	4 (100.0)	2.92 (0.50)	2.2	2.56	3.08	3.28	3.3	
			Placebo	4	3 (75.0)	2.02 (0.52)	1.5	1.48	2.07	2.52	2.5	
		Week 36	Tezepelumab	4	4 (100.0)	2.92 (0.48)	2.2	2.64	3.13	3.19	3.2	
			Placebo	4	2 (50.0)	2.16 (1.10)	1.4	1.38	2.16	2.93	2.9	
		Week 52	Tezepelumab	4	4 (100.0)	3.04 (0.60)	2.2	2.64	3.18	3.44	3.6	
			Placebo	4	2 (50.0)	1.79 (0.42)	1.5	1.49	1.79	2.09	2.1	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q1: < 53.1 IU/ml	Change from baseline	Week 2	Tezepelumab	4	4 (100.0)	0.00 (0.12)	-0.2	-0.07	0.04	0.08	0.1	0.55 [-0.87, 1.97]
			Placebo	4	4 (100.0)	-0.05 (0.06)	-0.1	-0.09	-0.05	-0.00	0.0	
		Week 4	Tezepelumab	4	4 (100.0)	-0.04 (0.08)	-0.1	-0.10	-0.05	0.02	0.1	0.18 [-1.21, 1.57]
			Placebo	4	4 (100.0)	-0.05 (0.06)	-0.1	-0.09	-0.05	-0.01	0.0	
		Week 8	Tezepelumab	4	4 (100.0)	0.09 (0.08)	0.0	0.02	0.08	0.16	0.2	0.54 [-0.88, 1.96]
			Placebo	4	4 (100.0)	0.02 (0.17)	-0.2	-0.11	0.06	0.15	0.2	
		Week 12	Tezepelumab	4	4 (100.0)	0.01 (0.14)	-0.2	-0.09	0.02	0.11	0.2	1.35 [-0.23, 2.93]
			Placebo	4	4 (100.0)	-0.19 (0.15)	-0.3	-0.29	-0.23	-0.09	0.0	
		Week 16	Tezepelumab	4	4 (100.0)	0.08 (0.12)	-0.1	-0.01	0.06	0.16	0.2	0.40 [-1.01, 1.80]
			Placebo	4	4 (100.0)	0.02 (0.16)	-0.1	-0.11	0.00	0.15	0.2	
		Week 24	Tezepelumab	4	4 (100.0)	0.12 (0.16)	-0.1	0.01	0.17	0.23	0.3	1.52 [-0.25, 3.29]
			Placebo	4	3 (75.0)	-0.29 (0.37)	-0.7	-0.67	-0.26	0.07	0.1	
		Week 36	Tezepelumab	4	4 (100.0)	0.11 (0.21)	-0.1	-0.03	0.10	0.26	0.4	0.27 [-1.44, 1.98]
			Placebo	4	2 (50.0)	0.06 (0.13)	-0.0	-0.03	0.06	0.15	0.2	
		Week 52	Tezepelumab	4	4 (100.0)	0.24 (0.29)	-0.1	0.01	0.27	0.47	0.5	1.45 [-0.52, 3.42]
			Placebo	4	2 (50.0)	-0.30 (0.54)	-0.7	-0.69	-0.30	0.08	0.1	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q2: 53.1 - < 195.6 IU/ml	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	3.07 (0.94)	2.4	2.37	2.69	4.14	4.1	
			Placebo	4	4 (100.0)	2.94 (0.59)	2.1	2.54	3.10	3.35	3.5	
		Week 2	Tezepelumab	3	3 (100.0)	2.81 (0.81)	2.3	2.28	2.41	3.74	3.7	
			Placebo	4	4 (100.0)	3.09 (0.51)	2.4	2.73	3.23	3.45	3.5	
		Week 4	Tezepelumab	3	3 (100.0)	2.81 (0.90)	2.1	2.10	2.51	3.83	3.8	
			Placebo	4	4 (100.0)	3.06 (0.68)	2.1	2.62	3.23	3.49	3.7	
		Week 8	Tezepelumab	3	3 (100.0)	2.88 (0.93)	2.2	2.15	2.56	3.92	3.9	
			Placebo	4	4 (100.0)	3.08 (0.21)	2.8	2.96	3.15	3.20	3.2	
		Week 12	Tezepelumab	3	3 (100.0)	2.80 (0.73)	2.2	2.21	2.57	3.62	3.6	
			Placebo	4	4 (100.0)	2.99 (0.42)	2.5	2.68	2.96	3.30	3.5	
		Week 16	Tezepelumab	3	3 (100.0)	2.71 (0.95)	1.9	1.94	2.43	3.77	3.8	
			Placebo	4	4 (100.0)	3.02 (0.36)	2.5	2.82	3.19	3.22	3.2	
		Week 24	Tezepelumab	3	3 (100.0)	2.86 (0.81)	2.3	2.27	2.53	3.79	3.8	
			Placebo	4	4 (100.0)	3.17 (0.32)	2.7	2.97	3.29	3.38	3.4	
		Week 36	Tezepelumab	3	3 (100.0)	2.86 (0.73)	2.3	2.25	2.67	3.67	3.7	
			Placebo	4	3 (75.0)	3.47 (0.32)	3.1	3.10	3.66	3.66	3.7	
		Week 52	Tezepelumab	3	3 (100.0)	2.93 (0.97)	2.2	2.22	2.53	4.04	4.0	
			Placebo	4	4 (100.0)	3.15 (0.70)	2.1	2.71	3.37	3.60	3.7	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q2: 53.1 - < 195.6 IU/ml	Change from baseline	Week 2	Tezepelumab	3	3 (100.0)	-0.26 (0.16)	-0.4	-0.40	-0.28	-0.09	-0.1	-3.43 [-6.03, -0.83]
			Placebo	4	4 (100.0)	0.15 (0.08)	0.1	0.09	0.14	0.20	0.3	
		Week 4	Tezepelumab	3	3 (100.0)	-0.25 (0.07)	-0.3	-0.31	-0.27	-0.18	-0.2	-3.85 [-6.67, -1.03]
			Placebo	4	4 (100.0)	0.12 (0.11)	-0.0	0.02	0.13	0.21	0.2	
		Week 8	Tezepelumab	3	3 (100.0)	-0.19 (0.05)	-0.2	-0.22	-0.22	-0.13	-0.1	-1.09 [-2.73, 0.55]
			Placebo	4	4 (100.0)	0.14 (0.38)	-0.2	-0.15	0.05	0.42	0.7	
		Week 12	Tezepelumab	3	3 (100.0)	-0.27 (0.22)	-0.5	-0.52	-0.16	-0.12	-0.1	-1.08 [-2.72, 0.56]
			Placebo	4	4 (100.0)	0.05 (0.33)	-0.4	-0.17	0.08	0.26	0.4	
		Week 16	Tezepelumab	3	3 (100.0)	-0.35 (0.09)	-0.4	-0.43	-0.37	-0.26	-0.3	-2.03 [-3.98, -0.07]
			Placebo	4	4 (100.0)	0.08 (0.27)	-0.3	-0.13	0.10	0.29	0.4	
		Week 24	Tezepelumab	3	3 (100.0)	-0.20 (0.13)	-0.3	-0.35	-0.16	-0.10	-0.1	-1.89 [-3.79, 0.01]
			Placebo	4	4 (100.0)	0.23 (0.28)	-0.1	0.03	0.20	0.43	0.6	
		Week 36	Tezepelumab	3	3 (100.0)	-0.20 (0.24)	-0.5	-0.47	-0.12	-0.02	-0.0	-2.31 [-4.57, -0.05]
			Placebo	4	3 (75.0)	0.26 (0.15)	0.1	0.14	0.20	0.43	0.4	
		Week 52	Tezepelumab	3	3 (100.0)	-0.14 (0.03)	-0.2	-0.16	-0.15	-0.10	-0.1	-3.50 [-6.14, -0.86]
			Placebo	4	4 (100.0)	0.21 (0.13)	0.0	0.13	0.26	0.30	0.3	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q3: 195.6 - < 572.4 IU/ml	Absolute values	Baseline	Tezepelumab	14	14 (100.0)	2.63 (0.71)	1.4	2.08	2.59	3.08	3.9	
			Placebo	10	10 (100.0)	2.90 (0.59)	2.2	2.43	2.79	3.25	4.1	
		Week 2	Tezepelumab	14	13 (92.9)	2.90 (0.59)	2.1	2.50	2.63	3.16	3.9	
			Placebo	10	8 (80.0)	2.95 (0.57)	2.4	2.55	2.83	3.14	4.2	
		Week 4	Tezepelumab	14	13 (92.9)	2.76 (0.67)	1.8	2.47	2.67	2.90	4.0	
			Placebo	10	8 (80.0)	2.87 (0.49)	2.4	2.50	2.66	3.25	3.8	
		Week 8	Tezepelumab	14	13 (92.9)	2.71 (0.73)	1.0	2.42	2.70	3.39	3.6	
			Placebo	10	9 (90.0)	2.77 (0.51)	2.2	2.39	2.62	3.02	3.8	
		Week 12	Tezepelumab	14	13 (92.9)	2.81 (0.78)	1.4	2.30	2.66	3.37	4.0	
			Placebo	10	9 (90.0)	2.83 (0.55)	2.2	2.44	2.76	3.02	3.9	
		Week 16	Tezepelumab	14	13 (92.9)	2.89 (0.63)	2.0	2.50	2.86	3.39	3.9	
			Placebo	10	9 (90.0)	2.82 (0.47)	2.2	2.59	2.62	3.03	3.7	
		Week 24	Tezepelumab	14	13 (92.9)	2.75 (0.66)	1.6	2.32	2.66	3.16	3.9	
			Placebo	10	9 (90.0)	2.80 (0.51)	2.2	2.66	2.74	2.76	4.0	
		Week 36	Tezepelumab	14	13 (92.9)	2.91 (0.50)	2.3	2.50	2.79	3.26	3.8	
			Placebo	10	8 (80.0)	2.92 (0.53)	2.2	2.56	2.76	3.32	3.8	
		Week 52	Tezepelumab	14	12 (85.7)	2.95 (0.58)	2.2	2.42	2.81	3.56	3.8	
			Placebo	10	8 (80.0)	3.10 (0.57)	2.2	2.79	2.95	3.61	3.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q3: 195.6 - < 572.4 IU/ml	Change from baseline	Week 2	Tezepelumab	14	13 (92.9)	0.28 (0.35)	-0.4	0.07	0.24	0.48	0.8	0.89 [-0.04, 1.81]
			Placebo	10	8 (80.0)	0.01 (0.20)	-0.4	-0.06	0.06	0.13	0.2	
		Week 4	Tezepelumab	14	13 (92.9)	0.17 (0.34)	-0.3	-0.16	0.11	0.39	0.7	0.65 [-0.26, 1.55]
			Placebo	10	8 (80.0)	-0.04 (0.27)	-0.4	-0.24	-0.06	0.21	0.3	
		Week 8	Tezepelumab	14	13 (92.9)	0.12 (0.46)	-0.8	-0.17	0.31	0.44	0.7	0.48 [-0.39, 1.34]
			Placebo	10	9 (90.0)	-0.06 (0.22)	-0.3	-0.23	-0.02	0.05	0.3	
		Week 12	Tezepelumab	14	13 (92.9)	0.22 (0.58)	-1.5	0.16	0.27	0.50	0.8	0.46 [-0.41, 1.32]
			Placebo	10	9 (90.0)	0.01 (0.23)	-0.2	-0.19	-0.01	0.19	0.4	
		Week 16	Tezepelumab	14	13 (92.9)	0.30 (0.37)	-0.5	0.15	0.42	0.56	0.8	0.93 [0.03, 1.83]
			Placebo	10	9 (90.0)	-0.01 (0.26)	-0.4	-0.22	0.09	0.15	0.3	
		Week 24	Tezepelumab	14	13 (92.9)	0.16 (0.40)	-0.8	0.09	0.18	0.38	0.7	0.57 [-0.30, 1.44]
			Placebo	10	9 (90.0)	-0.03 (0.18)	-0.3	-0.14	-0.03	0.16	0.2	
		Week 36	Tezepelumab	14	13 (92.9)	0.32 (0.42)	-0.5	0.21	0.40	0.69	0.8	0.74 [-0.17, 1.65]
			Placebo	10	8 (80.0)	0.05 (0.29)	-0.5	-0.13	0.09	0.30	0.3	
		Week 52	Tezepelumab	14	12 (85.7)	0.39 (0.48)	-0.6	0.15	0.51	0.77	0.9	0.38 [-0.52, 1.29]
			Placebo	10	8 (80.0)	0.23 (0.32)	-0.2	-0.08	0.32	0.46	0.6	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q4: >= 572.4 IU/ml	Absolute values	Baseline	Tezepelumab	20	20 (100.0)	2.62 (0.61)	1.4	2.16	2.85	3.02	3.7	
			Placebo	23	23 (100.0)	2.62 (0.88)	1.0	2.08	2.70	3.09	4.9	
		Week 2	Tezepelumab	20	20 (100.0)	2.77 (0.62)	1.7	2.28	2.96	3.25	4.0	
			Placebo	23	23 (100.0)	2.69 (0.62)	1.7	2.25	2.70	3.01	4.7	
		Week 4	Tezepelumab	20	20 (100.0)	2.73 (0.68)	1.3	2.10	2.94	3.20	3.8	
			Placebo	23	22 (95.7)	2.66 (0.57)	1.3	2.44	2.60	3.04	4.0	
		Week 8	Tezepelumab	20	20 (100.0)	2.69 (0.78)	1.0	2.02	2.91	3.25	3.7	
			Placebo	23	22 (95.7)	2.72 (0.78)	1.2	2.30	2.69	3.09	4.9	
		Week 12	Tezepelumab	20	17 (85.0)	2.71 (0.79)	0.8	2.02	2.87	3.34	3.6	
			Placebo	23	22 (95.7)	2.78 (0.80)	1.5	2.34	2.75	3.07	5.0	
		Week 16	Tezepelumab	20	19 (95.0)	2.68 (0.62)	1.5	2.22	2.86	3.23	3.8	
			Placebo	23	23 (100.0)	2.75 (0.79)	1.6	2.31	2.52	3.17	5.2	
		Week 24	Tezepelumab	20	18 (90.0)	2.79 (0.60)	1.7	2.41	2.93	3.21	3.7	
			Placebo	23	22 (95.7)	2.81 (0.76)	1.7	2.25	2.63	3.15	5.1	
		Week 36	Tezepelumab	20	17 (85.0)	2.86 (0.62)	1.4	2.47	2.93	3.30	4.0	
			Placebo	23	22 (95.7)	2.84 (0.91)	1.4	2.34	2.86	3.34	5.3	
		Week 52	Tezepelumab	20	15 (75.0)	3.01 (0.60)	1.9	2.64	3.21	3.32	4.2	
			Placebo	23	21 (91.3)	2.91 (0.80)	1.2	2.51	2.71	3.09	5.3	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q4: >= 572.4 IU/ml	Change from baseline	Week 2	Tezepelumab	20	20 (100.0)	0.15 (0.38)	-0.5	0.00	0.11	0.29	1.4	0.15 [-0.45, 0.75]
			Placebo	23	23 (100.0)	0.07 (0.62)	-1.3	-0.19	0.00	0.31	1.7	
		Week 4	Tezepelumab	20	20 (100.0)	0.11 (0.47)	-1.2	-0.10	0.09	0.30	1.2	-0.07 [-0.68, 0.53]
			Placebo	23	22 (95.7)	0.15 (0.67)	-1.0	-0.27	-0.07	0.40	1.7	
		Week 8	Tezepelumab	20	20 (100.0)	0.06 (0.50)	-1.1	-0.16	0.10	0.23	1.6	-0.03 [-0.63, 0.58]
			Placebo	23	22 (95.7)	0.08 (0.73)	-1.7	-0.13	0.03	0.14	2.0	
		Week 12	Tezepelumab	20	17 (85.0)	0.08 (0.48)	-0.6	-0.20	0.01	0.26	1.5	-0.13 [-0.76, 0.50]
			Placebo	23	22 (95.7)	0.17 (0.73)	-1.2	-0.22	0.11	0.39	1.6	
		Week 16	Tezepelumab	20	19 (95.0)	0.09 (0.36)	-0.3	-0.12	0.00	0.12	1.4	-0.08 [-0.69, 0.53]
			Placebo	23	23 (100.0)	0.14 (0.70)	-1.6	-0.15	0.04	0.33	1.6	
		Week 24	Tezepelumab	20	18 (90.0)	0.15 (0.50)	-0.5	-0.08	0.11	0.27	1.8	0.05 [-0.57, 0.68]
			Placebo	23	22 (95.7)	0.12 (0.64)	-1.4	-0.12	0.07	0.52	1.5	
		Week 36	Tezepelumab	20	17 (85.0)	0.23 (0.45)	-0.6	-0.01	0.26	0.35	1.7	0.02 [-0.61, 0.65]
			Placebo	23	22 (95.7)	0.22 (0.82)	-1.7	-0.09	0.13	0.57	2.2	
		Week 52	Tezepelumab	20	15 (75.0)	0.38 (0.39)	-0.3	0.13	0.38	0.52	1.3	0.27 [-0.40, 0.93]
			Placebo	23	21 (91.3)	0.23 (0.66)	-1.4	-0.02	0.23	0.38	1.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Nasal polyps last 2 years												
Yes	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	2.78	2.8	2.78	2.78	2.78	2.8	
			Placebo	2	2 (100.0)	2.45 (0.47)	2.1	2.11	2.45	2.78	2.8	
		Week 2	Placebo	2	2 (100.0)	2.56 (0.26)	2.4	2.37	2.56	2.74	2.7	
		Week 4	Tezepelumab	1	1 (100.0)	2.47	2.5	2.47	2.47	2.47	2.5	
			Placebo	2	2 (100.0)	2.38 (0.40)	2.1	2.09	2.38	2.66	2.7	
		Week 8	Tezepelumab	1	1 (100.0)	3.43	3.4	3.43	3.43	3.43	3.4	
			Placebo	2	2 (100.0)	2.76 (0.00)	2.8	2.76	2.76	2.76	2.8	
		Week 12	Tezepelumab	1	1 (100.0)	3.37	3.4	3.37	3.37	3.37	3.4	
			Placebo	2	2 (100.0)	2.54 (0.03)	2.5	2.52	2.54	2.56	2.6	
		Week 16	Tezepelumab	1	1 (100.0)	3.39	3.4	3.39	3.39	3.39	3.4	
			Placebo	2	2 (100.0)	2.56 (0.11)	2.5	2.48	2.56	2.63	2.6	
		Week 24	Tezepelumab	1	1 (100.0)	3.16	3.2	3.16	3.16	3.16	3.2	
			Placebo	2	2 (100.0)	2.62 (0.13)	2.5	2.52	2.62	2.71	2.7	
		Week 36	Tezepelumab	1	1 (100.0)	3.55	3.6	3.55	3.55	3.55	3.6	
			Placebo	2	1 (50.0)	2.93	2.9	2.93	2.93	2.93	2.9	
		Week 52	Tezepelumab	1	1 (100.0)	3.57	3.6	3.57	3.57	3.57	3.6	
			Placebo	2	2 (100.0)	2.12 (0.04)	2.1	2.09	2.12	2.14	2.1	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Nasal polyps last 2 years												
Yes	Change from baseline	Week 2	Placebo	2	2 (100.0)	0.11 (0.21)	-0.0	-0.04	0.11	0.26	0.3	
		Week 4	Tezepelumab	1	1 (100.0)	-0.31	-0.3	-0.31	-0.31	-0.31	-0.3	NE
			Placebo	2	2 (100.0)	-0.07 (0.07)	-0.1	-0.12	-0.07	-0.02	-0.0	
		Week 8	Tezepelumab	1	1 (100.0)	0.65	0.7	0.65	0.65	0.65	0.7	NE
			Placebo	2	2 (100.0)	0.32 (0.47)	-0.0	-0.02	0.32	0.65	0.7	
		Week 12	Tezepelumab	1	1 (100.0)	0.59	0.6	0.59	0.59	0.59	0.6	NE
			Placebo	2	2 (100.0)	0.10 (0.45)	-0.2	-0.22	0.10	0.41	0.4	
		Week 16	Tezepelumab	1	1 (100.0)	0.61	0.6	0.61	0.61	0.61	0.6	NE
			Placebo	2	2 (100.0)	0.11 (0.37)	-0.1	-0.15	0.11	0.37	0.4	
		Week 24	Tezepelumab	1	1 (100.0)	0.38	0.4	0.38	0.38	0.38	0.4	NE
			Placebo	2	2 (100.0)	0.17 (0.61)	-0.3	-0.26	0.17	0.60	0.6	
		Week 36	Tezepelumab	1	1 (100.0)	0.77	0.8	0.77	0.77	0.77	0.8	NE
			Placebo	2	1 (50.0)	0.15	0.2	0.15	0.15	0.15	0.2	
		Week 52	Tezepelumab	1	1 (100.0)	0.79	0.8	0.79	0.79	0.79	0.8	NE
			Placebo	2	2 (100.0)	-0.33 (0.51)	-0.7	-0.69	-0.33	0.03	0.0	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Nasal polyps last 2 years												
No	Absolute values	Baseline	Tezepelumab	40	40 (100.0)	2.67 (0.65)	1.4	2.17	2.81	3.07	4.1	
			Placebo	39	39 (100.0)	2.70 (0.79)	1.0	2.16	2.70	3.15	4.9	
		Week 2	Tezepelumab	40	40 (100.0)	2.82 (0.58)	1.7	2.42	2.82	3.20	4.0	
			Placebo	39	37 (94.9)	2.75 (0.63)	1.3	2.31	2.71	3.09	4.7	
		Week 4	Tezepelumab	40	39 (97.5)	2.75 (0.65)	1.3	2.22	2.78	3.19	4.0	
			Placebo	39	36 (92.3)	2.72 (0.59)	1.3	2.43	2.62	3.15	4.0	
		Week 8	Tezepelumab	40	39 (97.5)	2.71 (0.72)	1.0	2.15	2.79	3.26	3.9	
			Placebo	39	37 (94.9)	2.72 (0.69)	1.2	2.31	2.62	3.15	4.9	
		Week 12	Tezepelumab	40	36 (90.0)	2.75 (0.73)	0.8	2.19	2.78	3.32	4.0	
			Placebo	39	37 (94.9)	2.76 (0.73)	1.4	2.34	2.76	3.07	5.0	
		Week 16	Tezepelumab	40	38 (95.0)	2.76 (0.62)	1.5	2.28	2.80	3.23	3.9	
			Placebo	39	38 (97.4)	2.76 (0.69)	1.5	2.41	2.60	3.17	5.2	
		Week 24	Tezepelumab	40	37 (92.5)	2.79 (0.61)	1.6	2.32	2.88	3.23	3.9	
			Placebo	39	36 (92.3)	2.79 (0.70)	1.5	2.32	2.70	3.19	5.1	
		Week 36	Tezepelumab	40	36 (90.0)	2.87 (0.55)	1.4	2.47	2.86	3.26	4.0	
			Placebo	39	34 (87.2)	2.87 (0.84)	1.4	2.40	2.86	3.34	5.3	
		Week 52	Tezepelumab	40	33 (82.5)	2.97 (0.60)	1.9	2.47	3.01	3.32	4.2	
			Placebo	39	33 (84.6)	2.96 (0.76)	1.2	2.63	2.93	3.41	5.3	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Nasal polyps last 2 years												
No	Change from baseline	Week 2	Tezepelumab	40	40 (100.0)	0.15 (0.36)	-0.5	-0.02	0.08	0.34	1.4	0.22 [-0.23, 0.67]
			Placebo	39	37 (94.9)	0.05 (0.49)	-1.3	-0.12	0.03	0.16	1.7	
		Week 4	Tezepelumab	40	39 (97.5)	0.10 (0.40)	-1.2	-0.14	0.07	0.33	1.2	0.00 [-0.45, 0.46]
			Placebo	39	36 (92.3)	0.09 (0.54)	-1.0	-0.21	-0.04	0.28	1.7	
		Week 8	Tezepelumab	40	39 (97.5)	0.05 (0.43)	-1.1	-0.19	0.10	0.25	1.6	0.04 [-0.41, 0.49]
			Placebo	39	37 (94.9)	0.03 (0.58)	-1.7	-0.20	0.01	0.13	2.0	
		Week 12	Tezepelumab	40	36 (90.0)	0.08 (0.49)	-1.5	-0.14	0.12	0.28	1.5	0.00 [-0.46, 0.46]
			Placebo	39	37 (94.9)	0.08 (0.58)	-1.2	-0.22	0.02	0.25	1.6	
		Week 16	Tezepelumab	40	38 (95.0)	0.11 (0.36)	-0.5	-0.12	0.09	0.35	1.4	0.06 [-0.39, 0.51]
			Placebo	39	38 (97.4)	0.09 (0.56)	-1.6	-0.15	0.04	0.21	1.6	
		Week 24	Tezepelumab	40	37 (92.5)	0.12 (0.43)	-0.8	-0.10	0.12	0.25	1.8	0.12 [-0.34, 0.58]
			Placebo	39	36 (92.3)	0.06 (0.52)	-1.4	-0.13	0.00	0.23	1.5	
		Week 36	Tezepelumab	40	36 (90.0)	0.20 (0.42)	-0.6	-0.02	0.22	0.40	1.7	0.05 [-0.42, 0.52]
			Placebo	39	34 (87.2)	0.17 (0.68)	-1.7	-0.09	0.15	0.42	2.2	
		Week 52	Tezepelumab	40	33 (82.5)	0.30 (0.41)	-0.6	0.02	0.38	0.54	1.3	0.16 [-0.32, 0.65]
			Placebo	39	33 (84.6)	0.23 (0.54)	-1.4	-0.01	0.25	0.38	1.9	

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Region (cat. N)				N<10 any level					NE

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline eosinophils (cat. N)									0.144
< 150 cells/uL	Week 2	Tezepelumab	8	8 (100.0)	-0.02 (0.10)	(-0.25, 0.22)	0.07 (0.16)	(-0.29, 0.43)	0.664
		Placebo	6	6 (100.0)	-0.09 (0.12)	(-0.36, 0.18)			
	Week 4	Tezepelumab	8	8 (100.0)	0.04 (0.10)	(-0.19, 0.27)	0.02 (0.16)	(-0.33, 0.37)	0.916
		Placebo	6	5 (83.3)	0.02 (0.12)	(-0.24, 0.29)			
	Week 8	Tezepelumab	8	8 (100.0)	0.04 (0.11)	(-0.20, 0.28)	0.04 (0.16)	(-0.33, 0.40)	0.818
		Placebo	6	6 (100.0)	0.00 (0.12)	(-0.27, 0.28)			
	Week 12	Tezepelumab	8	7 (87.5)	-0.10 (0.10)	(-0.32, 0.11)	-0.19 (0.15)	(-0.52, 0.15)	0.235
		Placebo	6	5 (83.3)	0.09 (0.11)	(-0.17, 0.34)			
	Week 16	Tezepelumab	8	8 (100.0)	-0.04 (0.09)	(-0.24, 0.15)	-0.14 (0.13)	(-0.44, 0.16)	0.322
		Placebo	6	6 (100.0)	0.10 (0.10)	(-0.13, 0.32)			
	Week 24	Tezepelumab	8	8 (100.0)	-0.02 (0.11)	(-0.26, 0.22)	-0.09 (0.17)	(-0.46, 0.28)	0.600
		Placebo	6	6 (100.0)	0.07 (0.12)	(-0.21, 0.35)			
	Week 36	Tezepelumab	8	8 (100.0)	0.02 (0.13)	(-0.27, 0.31)	-0.18 (0.20)	(-0.62, 0.27)	0.395
		Placebo	6	5 (83.3)	0.20 (0.15)	(-0.14, 0.54)			
	Week 52	Tezepelumab	8	7 (87.5)	0.08 (0.11)	(-0.17, 0.33)	-0.13 (0.17)	(-0.51, 0.26)	0.482
		Placebo	6	6 (100.0)	0.21 (0.13)	(-0.08, 0.49)			

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
150 - < 300 cells/uL	Week 2	Tezepelumab	15	15 (100.0)	0.21 (0.05)	(0.10, 0.31)	0.04 (0.09)	(-0.15, 0.24)	0.642
		Placebo	8	7 (87.5)	0.16 (0.08)	(0.00, 0.32)			
	Week 4	Tezepelumab	15	14 (93.3)	0.09 (0.08)	(-0.07, 0.26)	0.27 (0.13)	(-0.00, 0.55)	0.053
		Placebo	8	8 (100.0)	-0.18 (0.11)	(-0.40, 0.04)			
	Week 8	Tezepelumab	15	14 (93.3)	0.09 (0.06)	(-0.03, 0.20)	0.22 (0.09)	(0.03, 0.41)	0.026 *
		Placebo	8	8 (100.0)	-0.13 (0.07)	(-0.28, 0.02)			
	Week 12	Tezepelumab	15	12 (80.0)	0.07 (0.09)	(-0.11, 0.26)	0.29 (0.14)	(-0.01, 0.58)	0.057
		Placebo	8	8 (100.0)	-0.21 (0.11)	(-0.45, 0.02)			
	Week 16	Tezepelumab	15	14 (93.3)	0.09 (0.06)	(-0.03, 0.21)	0.20 (0.09)	(0.00, 0.39)	0.047 *
		Placebo	8	8 (100.0)	-0.11 (0.07)	(-0.26, 0.05)			
	Week 24	Tezepelumab	15	13 (86.7)	0.11 (0.08)	(-0.05, 0.27)	0.18 (0.12)	(-0.08, 0.44)	0.158
		Placebo	8	8 (100.0)	-0.07 (0.10)	(-0.27, 0.13)			
	Week 36	Tezepelumab	15	13 (86.7)	0.08 (0.10)	(-0.16, 0.32)	0.07 (0.19)	(-0.36, 0.49)	0.726
		Placebo	8	6 (75.0)	0.01 (0.15)	(-0.34, 0.37)			
	Week 52	Tezepelumab	15	12 (80.0)	0.36 (0.06)	(0.23, 0.49)	0.33 (0.11)	(0.09, 0.57)	0.012 *
		Placebo	8	4 (50.0)	0.03 (0.09)	(-0.16, 0.23)			

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
300 - < 450 cells/uL	Week 2	Tezepelumab	6	6 (100.0)	0.06 (0.10)	(-0.16, 0.27)	-0.19 (0.12)	(-0.45, 0.07)	0.149
		Placebo	12	12 (100.0)	0.24 (0.07)	(0.09, 0.40)			
	Week 4	Tezepelumab	6	6 (100.0)	-0.16 (0.17)	(-0.53, 0.21)	-0.57 (0.21)	(-1.02, -0.11)	0.018 *
		Placebo	12	11 (91.7)	0.40 (0.13)	(0.13, 0.67)			
	Week 8	Tezepelumab	6	6 (100.0)	-0.03 (0.18)	(-0.41, 0.35)	-0.39 (0.22)	(-0.86, 0.07)	0.094
		Placebo	12	11 (91.7)	0.36 (0.13)	(0.09, 0.63)			
	Week 12	Tezepelumab	6	6 (100.0)	0.14 (0.18)	(-0.25, 0.53)	-0.26 (0.22)	(-0.74, 0.22)	0.259
		Placebo	12	11 (91.7)	0.40 (0.13)	(0.12, 0.68)			
	Week 16	Tezepelumab	6	6 (100.0)	0.09 (0.16)	(-0.25, 0.43)	-0.29 (0.19)	(-0.70, 0.13)	0.159
		Placebo	12	11 (91.7)	0.38 (0.11)	(0.14, 0.62)			
	Week 24	Tezepelumab	6	6 (100.0)	0.16 (0.14)	(-0.13, 0.46)	-0.29 (0.17)	(-0.66, 0.08)	0.113
		Placebo	12	10 (83.3)	0.45 (0.10)	(0.23, 0.67)			
	Week 36	Tezepelumab	6	6 (100.0)	0.21 (0.19)	(-0.20, 0.61)	-0.23 (0.24)	(-0.73, 0.28)	0.355
		Placebo	12	10 (83.3)	0.43 (0.14)	(0.14, 0.73)			
	Week 52	Tezepelumab	6	6 (100.0)	0.25 (0.21)	(-0.20, 0.70)	-0.11 (0.26)	(-0.66, 0.45)	0.686
		Placebo	12	11 (91.7)	0.36 (0.15)	(0.03, 0.69)			

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 450 cells/uL	Week 2	Tezepelumab	12	11 (91.7)	0.14 (0.14)	(-0.14, 0.42)	0.12 (0.19)	(-0.27, 0.50)	0.534
		Placebo	15	14 (93.3)	0.02 (0.12)	(-0.23, 0.27)			
	Week 4	Tezepelumab	12	12 (100.0)	0.14 (0.13)	(-0.12, 0.40)	0.06 (0.17)	(-0.30, 0.42)	0.728
		Placebo	15	14 (93.3)	0.08 (0.11)	(-0.16, 0.31)			
	Week 8	Tezepelumab	12	12 (100.0)	0.01 (0.18)	(-0.37, 0.39)	0.02 (0.25)	(-0.49, 0.54)	0.928
		Placebo	15	14 (93.3)	-0.01 (0.17)	(-0.35, 0.33)			
	Week 12	Tezepelumab	12	12 (100.0)	0.16 (0.18)	(-0.22, 0.54)	0.12 (0.25)	(-0.39, 0.63)	0.644
		Placebo	15	15 (100.0)	0.05 (0.16)	(-0.29, 0.38)			
	Week 16	Tezepelumab	12	11 (91.7)	0.21 (0.15)	(-0.10, 0.52)	0.18 (0.20)	(-0.24, 0.60)	0.379
		Placebo	15	15 (100.0)	0.03 (0.13)	(-0.24, 0.30)			
	Week 24	Tezepelumab	12	11 (91.7)	0.15 (0.18)	(-0.21, 0.51)	0.14 (0.24)	(-0.34, 0.63)	0.553
		Placebo	15	14 (93.3)	0.01 (0.16)	(-0.31, 0.33)			
	Week 36	Tezepelumab	12	10 (83.3)	0.39 (0.18)	(0.01, 0.77)	0.28 (0.25)	(-0.23, 0.78)	0.269
		Placebo	15	14 (93.3)	0.11 (0.16)	(-0.22, 0.44)			
	Week 52	Tezepelumab	12	9 (75.0)	0.34 (0.17)	(-0.01, 0.69)	0.16 (0.23)	(-0.30, 0.63)	0.477
		Placebo	15	14 (93.3)	0.18 (0.14)	(-0.12, 0.48)			

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline eosinophils (cat. Q)									0.594
Q1: < 140 cells/uL	Week 2	Tezepelumab	6	6 (100.0)	NE		NE		
		Placebo	6	6 (100.0)					
	Week 4	Tezepelumab	6	6 (100.0)	NE		NE		
		Placebo	6	5 (83.3)					
	Week 8	Tezepelumab	6	6 (100.0)	NE		NE		
		Placebo	6	6 (100.0)					
	Week 12	Tezepelumab	6	5 (83.3)	NE		NE		
		Placebo	6	5 (83.3)					
	Week 16	Tezepelumab	6	6 (100.0)	NE		NE		
		Placebo	6	6 (100.0)					
	Week 24	Tezepelumab	6	6 (100.0)	NE		NE		
		Placebo	6	6 (100.0)					
	Week 36	Tezepelumab	6	6 (100.0)	NE		NE		
		Placebo	6	5 (83.3)					
	Week 52	Tezepelumab	6	5 (83.3)	NE		NE		
		Placebo	6	6 (100.0)					

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q2: 140 - < 250 cells/uL	Week 2	Tezepelumab	13	13 (100.0)	0.07 (0.05)	(-0.04, 0.17)	0.02 (0.09)	(-0.17, 0.22)	0.790
		Placebo	6	6 (100.0)	0.04 (0.07)	(-0.12, 0.20)			
	Week 4	Tezepelumab	13	13 (100.0)	-0.02 (0.06)	(-0.14, 0.10)	0.09 (0.10)	(-0.13, 0.31)	0.399
		Placebo	6	6 (100.0)	-0.11 (0.08)	(-0.29, 0.07)			
	Week 8	Tezepelumab	13	13 (100.0)	0.02 (0.07)	(-0.12, 0.16)	0.15 (0.12)	(-0.10, 0.41)	0.208
		Placebo	6	6 (100.0)	-0.13 (0.10)	(-0.34, 0.07)			
	Week 12	Tezepelumab	13	12 (92.3)	-0.02 (0.09)	(-0.21, 0.18)	0.13 (0.16)	(-0.21, 0.47)	0.417
		Placebo	6	6 (100.0)	-0.15 (0.13)	(-0.43, 0.13)			
	Week 16	Tezepelumab	13	13 (100.0)	0.04 (0.06)	(-0.08, 0.16)	0.06 (0.10)	(-0.16, 0.27)	0.600
		Placebo	6	6 (100.0)	-0.02 (0.08)	(-0.20, 0.16)			
	Week 24	Tezepelumab	13	13 (100.0)	0.02 (0.07)	(-0.13, 0.16)	0.05 (0.12)	(-0.20, 0.31)	0.671
		Placebo	6	6 (100.0)	-0.04 (0.10)	(-0.25, 0.17)			
	Week 36	Tezepelumab	13	13 (100.0)	0.03 (0.08)	(-0.15, 0.20)	-0.09 (0.17)	(-0.44, 0.26)	0.599
		Placebo	6	5 (83.3)	0.11 (0.14)	(-0.19, 0.42)			
	Week 52	Tezepelumab	13	12 (92.3)	0.28 (0.06)	(0.16, 0.41)	0.20 (0.12)	(-0.05, 0.45)	0.115
		Placebo	6	3 (50.0)	0.08 (0.11)	(-0.14, 0.30)			

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q3: 250 - < 430 cells/uL	Week 2	Tezepelumab	10	10 (100.0)	0.18 (0.11)	(-0.04, 0.41)	-0.01 (0.15)	(-0.32, 0.29)	0.920
		Placebo	13	12 (92.3)	0.20 (0.10)	(-0.00, 0.40)			
	Week 4	Tezepelumab	10	9 (90.0)	0.02 (0.18)	(-0.36, 0.40)	-0.20 (0.24)	(-0.70, 0.30)	0.408
		Placebo	13	12 (92.3)	0.22 (0.16)	(-0.11, 0.55)			
	Week 8	Tezepelumab	10	9 (90.0)	0.06 (0.13)	(-0.22, 0.34)	-0.23 (0.18)	(-0.60, 0.13)	0.199
		Placebo	13	12 (92.3)	0.30 (0.12)	(0.05, 0.54)			
	Week 12	Tezepelumab	10	8 (80.0)	0.10 (0.14)	(-0.20, 0.41)	-0.17 (0.19)	(-0.56, 0.23)	0.395
		Placebo	13	12 (92.3)	0.27 (0.12)	(0.01, 0.53)			
	Week 16	Tezepelumab	10	9 (90.0)	0.08 (0.14)	(-0.21, 0.38)	-0.15 (0.18)	(-0.53, 0.24)	0.427
		Placebo	13	12 (92.3)	0.23 (0.12)	(-0.02, 0.49)			
	Week 24	Tezepelumab	10	8 (80.0)	0.22 (0.13)	(-0.06, 0.50)	-0.12 (0.17)	(-0.49, 0.25)	0.505
		Placebo	13	11 (84.6)	0.34 (0.11)	(0.10, 0.58)			
	Week 36	Tezepelumab	10	8 (80.0)	0.27 (0.15)	(-0.04, 0.59)	-0.06 (0.20)	(-0.48, 0.36)	0.784
		Placebo	13	10 (76.9)	0.33 (0.13)	(0.05, 0.61)			
	Week 52	Tezepelumab	10	8 (80.0)	0.33 (0.15)	(0.02, 0.64)	0.03 (0.19)	(-0.38, 0.44)	0.893
		Placebo	13	11 (84.6)	0.30 (0.13)	(0.03, 0.57)			

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q4: >= 430 cells/uL	Week 2	Tezepelumab	12	11 (91.7)	0.18 (0.13)	(-0.10, 0.46)	0.15 (0.18)	(-0.21, 0.52)	0.399
		Placebo	16	15 (93.8)	0.03 (0.12)	(-0.21, 0.26)			
	Week 4	Tezepelumab	12	12 (100.0)	0.17 (0.12)	(-0.08, 0.42)	0.06 (0.16)	(-0.27, 0.40)	0.701
		Placebo	16	15 (93.8)	0.11 (0.11)	(-0.11, 0.33)			
	Week 8	Tezepelumab	12	12 (100.0)	0.05 (0.18)	(-0.33, 0.43)	0.08 (0.24)	(-0.42, 0.59)	0.738
		Placebo	16	15 (93.8)	-0.03 (0.16)	(-0.36, 0.30)			
	Week 12	Tezepelumab	12	12 (100.0)	0.20 (0.18)	(-0.17, 0.57)	0.15 (0.24)	(-0.34, 0.64)	0.530
		Placebo	16	16 (100.0)	0.05 (0.16)	(-0.27, 0.37)			
	Week 16	Tezepelumab	12	11 (91.7)	0.25 (0.15)	(-0.05, 0.55)	0.20 (0.19)	(-0.19, 0.60)	0.302
		Placebo	16	16 (100.0)	0.04 (0.13)	(-0.21, 0.30)			
	Week 24	Tezepelumab	12	11 (91.7)	0.19 (0.17)	(-0.16, 0.54)	0.16 (0.23)	(-0.31, 0.62)	0.488
		Placebo	16	15 (93.8)	0.03 (0.15)	(-0.28, 0.33)			
	Week 36	Tezepelumab	12	10 (83.3)	0.43 (0.19)	(0.05, 0.81)	0.34 (0.24)	(-0.16, 0.84)	0.169
		Placebo	16	15 (93.8)	0.09 (0.16)	(-0.23, 0.41)			
	Week 52	Tezepelumab	12	9 (75.0)	0.37 (0.18)	(0.00, 0.74)	0.24 (0.23)	(-0.24, 0.72)	0.323
		Placebo	16	15 (93.8)	0.13 (0.15)	(-0.17, 0.44)			

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline FENO (cat. N)									0.901
< 25 ppb	Week 2	Tezepelumab	11	11 (100.0)	0.05 (0.07)	(-0.09, 0.18)	0.09 (0.09)	(-0.09, 0.28)	0.295
		Placebo	16	14 (87.5)	-0.05 (0.06)	(-0.17, 0.07)			
	Week 4	Tezepelumab	11	11 (100.0)	0.02 (0.07)	(-0.12, 0.17)	0.14 (0.09)	(-0.05, 0.34)	0.149
		Placebo	16	14 (87.5)	-0.12 (0.06)	(-0.25, 0.01)			
	Week 8	Tezepelumab	11	11 (100.0)	0.11 (0.05)	(0.01, 0.21)	0.22 (0.06)	(0.08, 0.35)	0.003 *
		Placebo	16	15 (93.8)	-0.11 (0.04)	(-0.20, -0.02)			
	Week 12	Tezepelumab	11	10 (90.9)	-0.01 (0.08)	(-0.18, 0.16)	0.09 (0.11)	(-0.13, 0.31)	0.397
		Placebo	16	14 (87.5)	-0.10 (0.07)	(-0.25, 0.04)			
	Week 16	Tezepelumab	11	11 (100.0)	0.02 (0.06)	(-0.11, 0.15)	0.11 (0.08)	(-0.06, 0.28)	0.203
		Placebo	16	15 (93.8)	-0.09 (0.05)	(-0.20, 0.02)			
	Week 24	Tezepelumab	11	10 (90.9)	0.08 (0.07)	(-0.06, 0.22)	0.12 (0.09)	(-0.06, 0.30)	0.183
		Placebo	16	15 (93.8)	-0.04 (0.06)	(-0.16, 0.08)			
	Week 36	Tezepelumab	11	9 (81.8)	0.24 (0.10)	(0.03, 0.44)	0.19 (0.13)	(-0.09, 0.46)	0.164
		Placebo	16	13 (81.3)	0.05 (0.08)	(-0.13, 0.22)			
	Week 52	Tezepelumab	11	8 (72.7)	0.34 (0.09)	(0.16, 0.52)	0.19 (0.11)	(-0.04, 0.42)	0.098
		Placebo	16	12 (75.0)	0.15 (0.07)	(0.00, 0.30)			

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
25 - < 50 ppb	Week 2	Tezepelumab	12	12 (100.0)	0.15 (0.10)	(-0.05, 0.36)	-0.03 (0.15)	(-0.33, 0.28)	0.856
		Placebo	10	10 (100.0)	0.18 (0.11)	(-0.05, 0.40)			
	Week 4	Tezepelumab	12	12 (100.0)	0.17 (0.11)	(-0.05, 0.39)	0.03 (0.16)	(-0.31, 0.36)	0.862
		Placebo	10	9 (90.0)	0.14 (0.12)	(-0.11, 0.39)			
	Week 8	Tezepelumab	12	12 (100.0)	0.07 (0.14)	(-0.23, 0.36)	-0.12 (0.21)	(-0.56, 0.31)	0.559
		Placebo	10	9 (90.0)	0.19 (0.15)	(-0.13, 0.51)			
	Week 12	Tezepelumab	12	11 (91.7)	0.14 (0.17)	(-0.22, 0.51)	0.07 (0.26)	(-0.46, 0.61)	0.774
		Placebo	10	10 (100.0)	0.07 (0.19)	(-0.33, 0.46)			
	Week 16	Tezepelumab	12	11 (91.7)	0.16 (0.12)	(-0.09, 0.41)	-0.02 (0.18)	(-0.40, 0.35)	0.904
		Placebo	10	10 (100.0)	0.18 (0.13)	(-0.09, 0.46)			
	Week 24	Tezepelumab	12	11 (91.7)	0.07 (0.14)	(-0.24, 0.37)	-0.09 (0.22)	(-0.55, 0.36)	0.665
		Placebo	10	8 (80.0)	0.16 (0.16)	(-0.17, 0.50)			
	Week 36	Tezepelumab	12	11 (91.7)	0.15 (0.19)	(-0.24, 0.55)	0.01 (0.29)	(-0.59, 0.60)	0.986
		Placebo	10	7 (70.0)	0.15 (0.22)	(-0.30, 0.59)			
	Week 52	Tezepelumab	12	10 (83.3)	0.24 (0.15)	(-0.06, 0.55)	0.08 (0.21)	(-0.36, 0.53)	0.697
		Placebo	10	9 (90.0)	0.16 (0.16)	(-0.16, 0.48)			

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 50 ppb	Week 2	Tezepelumab	18	17 (94.4)	0.22 (0.11)	(0.01, 0.44)	0.17 (0.16)	(-0.15, 0.49)	0.286
		Placebo	15	15 (100.0)	0.05 (0.11)	(-0.18, 0.29)			
	Week 4	Tezepelumab	18	17 (94.4)	0.08 (0.13)	(-0.18, 0.34)	-0.15 (0.18)	(-0.53, 0.23)	0.428
		Placebo	15	15 (100.0)	0.23 (0.14)	(-0.05, 0.51)			
	Week 8	Tezepelumab	18	17 (94.4)	0.06 (0.15)	(-0.24, 0.36)	-0.03 (0.22)	(-0.47, 0.42)	0.904
		Placebo	15	15 (100.0)	0.09 (0.16)	(-0.24, 0.41)			
	Week 12	Tezepelumab	18	16 (88.9)	0.21 (0.14)	(-0.07, 0.49)	-0.04 (0.20)	(-0.44, 0.37)	0.857
		Placebo	15	15 (100.0)	0.24 (0.15)	(-0.05, 0.54)			
	Week 16	Tezepelumab	18	17 (94.4)	0.20 (0.12)	(-0.06, 0.45)	-0.01 (0.18)	(-0.38, 0.37)	0.963
		Placebo	15	15 (100.0)	0.20 (0.13)	(-0.07, 0.48)			
	Week 24	Tezepelumab	18	17 (94.4)	0.23 (0.13)	(-0.02, 0.49)	0.01 (0.19)	(-0.37, 0.39)	0.951
		Placebo	15	15 (100.0)	0.22 (0.14)	(-0.06, 0.50)			
	Week 36	Tezepelumab	18	17 (94.4)	0.33 (0.13)	(0.07, 0.59)	0.07 (0.19)	(-0.31, 0.46)	0.701
		Placebo	15	15 (100.0)	0.26 (0.14)	(-0.02, 0.54)			
	Week 52	Tezepelumab	18	16 (88.9)	0.38 (0.13)	(0.12, 0.64)	0.15 (0.19)	(-0.24, 0.54)	0.431
		Placebo	15	14 (93.3)	0.23 (0.14)	(-0.06, 0.51)			

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline FENO (cat. Q)									0.478
Q1: < 16 ppb	Week 2	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	10	9 (90.0)					
	Week 4	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	10	9 (90.0)					
	Week 8	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	10	10 (100.0)					
	Week 12	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	10	9 (90.0)					
	Week 16	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	10	10 (100.0)					
	Week 24	Tezepelumab	5	4 (80.0)	NE		NE		
		Placebo	10	10 (100.0)					
	Week 36	Tezepelumab	5	3 (60.0)	NE		NE		
		Placebo	10	8 (80.0)					
	Week 52	Tezepelumab	5	2 (40.0)	NE		NE		
		Placebo	10	7 (70.0)					

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q2: 16 - < 30 ppb	Week 2	Tezepelumab	10	10 (100.0)	0.18 (0.08)	(0.01, 0.35)	0.25 (0.13)	(-0.02, 0.52)	0.070
		Placebo	7	6 (85.7)	-0.06 (0.10)	(-0.27, 0.15)			
	Week 4	Tezepelumab	10	10 (100.0)	0.16 (0.07)	(0.01, 0.32)	0.25 (0.12)	(0.00, 0.49)	0.048 *
		Placebo	7	6 (85.7)	-0.09 (0.09)	(-0.28, 0.11)			
	Week 8	Tezepelumab	10	10 (100.0)	0.23 (0.07)	(0.06, 0.39)	0.17 (0.12)	(-0.10, 0.43)	0.195
		Placebo	7	5 (71.4)	0.06 (0.10)	(-0.15, 0.27)			
	Week 12	Tezepelumab	10	8 (80.0)	0.10 (0.10)	(-0.13, 0.33)	0.11 (0.17)	(-0.25, 0.47)	0.533
		Placebo	7	6 (85.7)	-0.00 (0.13)	(-0.28, 0.27)			
	Week 16	Tezepelumab	10	10 (100.0)	0.19 (0.07)	(0.04, 0.34)	0.26 (0.11)	(0.03, 0.50)	0.031 *
		Placebo	7	6 (85.7)	-0.07 (0.09)	(-0.25, 0.11)			
	Week 24	Tezepelumab	10	10 (100.0)	0.12 (0.06)	(-0.01, 0.24)	0.14 (0.09)	(-0.06, 0.34)	0.163
		Placebo	7	6 (85.7)	-0.02 (0.07)	(-0.18, 0.14)			
	Week 36	Tezepelumab	10	10 (100.0)	0.11 (0.09)	(-0.09, 0.30)	0.26 (0.15)	(-0.05, 0.58)	0.093
		Placebo	7	6 (85.7)	-0.16 (0.12)	(-0.41, 0.09)			
	Week 52	Tezepelumab	10	10 (100.0)	0.37 (0.08)	(0.20, 0.54)	0.33 (0.13)	(0.06, 0.60)	0.021 *
		Placebo	7	6 (85.7)	0.04 (0.10)	(-0.17, 0.25)			

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q3: 30 - < 56 ppb	Week 2	Tezepelumab	11	11 (100.0)	0.06 (0.10)	(-0.15, 0.27)	-0.13 (0.15)	(-0.44, 0.17)	0.366
		Placebo	10	10 (100.0)	0.20 (0.10)	(-0.02, 0.42)			
	Week 4	Tezepelumab	11	11 (100.0)	0.00 (0.12)	(-0.25, 0.25)	-0.16 (0.18)	(-0.53, 0.21)	0.376
		Placebo	10	9 (90.0)	0.16 (0.13)	(-0.11, 0.43)			
	Week 8	Tezepelumab	11	11 (100.0)	-0.06 (0.14)	(-0.36, 0.24)	-0.31 (0.21)	(-0.74, 0.12)	0.146
		Placebo	10	10 (100.0)	0.25 (0.15)	(-0.06, 0.56)			
	Week 12	Tezepelumab	11	11 (100.0)	-0.02 (0.17)	(-0.38, 0.34)	-0.09 (0.25)	(-0.61, 0.43)	0.728
		Placebo	10	10 (100.0)	0.07 (0.18)	(-0.31, 0.44)			
	Week 16	Tezepelumab	11	10 (90.9)	0.04 (0.13)	(-0.22, 0.31)	-0.17 (0.18)	(-0.56, 0.22)	0.371
		Placebo	10	10 (100.0)	0.21 (0.13)	(-0.06, 0.49)			
	Week 24	Tezepelumab	11	10 (90.9)	0.02 (0.15)	(-0.29, 0.33)	-0.17 (0.21)	(-0.62, 0.28)	0.430
		Placebo	10	8 (80.0)	0.19 (0.15)	(-0.13, 0.52)			
	Week 36	Tezepelumab	11	10 (90.9)	0.19 (0.20)	(-0.22, 0.60)	0.01 (0.29)	(-0.59, 0.62)	0.960
		Placebo	10	7 (70.0)	0.18 (0.21)	(-0.27, 0.62)			
	Week 52	Tezepelumab	11	9 (81.8)	0.15 (0.16)	(-0.19, 0.48)	-0.02 (0.23)	(-0.51, 0.46)	0.924
		Placebo	10	9 (90.0)	0.17 (0.16)	(-0.18, 0.51)			

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q4: >= 56 ppb	Week 2	Tezepelumab	15	14 (93.3)	0.21 (0.12)	(-0.04, 0.46)	0.15 (0.17)	(-0.21, 0.51)	0.394
		Placebo	14	14 (100.0)	0.06 (0.12)	(-0.20, 0.31)			
	Week 4	Tezepelumab	15	14 (93.3)	0.11 (0.14)	(-0.19, 0.40)	-0.12 (0.20)	(-0.55, 0.30)	0.549
		Placebo	14	14 (100.0)	0.23 (0.15)	(-0.07, 0.53)			
	Week 8	Tezepelumab	15	14 (93.3)	0.05 (0.18)	(-0.31, 0.41)	-0.02 (0.25)	(-0.54, 0.49)	0.923
		Placebo	14	14 (100.0)	0.07 (0.18)	(-0.30, 0.44)			
	Week 12	Tezepelumab	15	13 (86.7)	0.23 (0.16)	(-0.11, 0.56)	-0.02 (0.23)	(-0.50, 0.45)	0.926
		Placebo	14	14 (100.0)	0.25 (0.16)	(-0.09, 0.59)			
	Week 16	Tezepelumab	15	14 (93.3)	0.21 (0.14)	(-0.08, 0.51)	-0.00 (0.20)	(-0.42, 0.41)	0.995
		Placebo	14	14 (100.0)	0.22 (0.14)	(-0.08, 0.51)			
	Week 24	Tezepelumab	15	14 (93.3)	0.24 (0.15)	(-0.06, 0.55)	0.03 (0.21)	(-0.41, 0.46)	0.892
		Placebo	14	14 (100.0)	0.21 (0.15)	(-0.10, 0.52)			
	Week 36	Tezepelumab	15	14 (93.3)	0.35 (0.15)	(0.04, 0.65)	0.07 (0.21)	(-0.37, 0.51)	0.743
		Placebo	14	14 (100.0)	0.28 (0.15)	(-0.04, 0.59)			
	Week 52	Tezepelumab	15	13 (86.7)	0.39 (0.15)	(0.08, 0.69)	0.16 (0.21)	(-0.27, 0.60)	0.442
		Placebo	14	13 (92.9)	0.22 (0.15)	(-0.09, 0.53)			

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Total serum IgE (cat. N)				N<10 any level					NE

DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Nasal polyps last 2 years				N<10 any level					NE

Note: DITT - adolescents = Dossier Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOMH0: Course of FEV1 Pre-BD
DITT - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
FEV1 Pre-BD	Baseline	Tezepelumab	487	487 (100.0)	1.76 (0.68)	0.4	1.28	1.64	2.13	4.8	
		Placebo	490	490 (100.0)	1.78 (0.65)	0.4	1.34	1.69	2.14	4.5	
	Week 2	Tezepelumab	487	474 (97.3)	1.93 (0.70)	0.6	1.39	1.83	2.39	5.0	
		Placebo	490	468 (95.5)	1.85 (0.68)	0.4	1.37	1.75	2.26	4.1	
	Week 4	Tezepelumab	487	483 (99.2)	1.95 (0.72)	0.6	1.44	1.85	2.42	5.0	
		Placebo	490	478 (97.6)	1.86 (0.67)	0.4	1.41	1.79	2.23	4.8	
	Week 8	Tezepelumab	487	478 (98.2)	1.98 (0.72)	0.6	1.43	1.88	2.43	4.7	
		Placebo	490	478 (97.6)	1.89 (0.70)	0.4	1.39	1.78	2.23	4.7	
	Week 12	Tezepelumab	487	473 (97.1)	1.98 (0.73)	0.6	1.49	1.88	2.41	4.9	
		Placebo	490	475 (96.9)	1.88 (0.70)	0.5	1.38	1.75	2.27	4.6	
	Week 16	Tezepelumab	487	471 (96.7)	2.00 (0.75)	0.6	1.46	1.88	2.44	4.9	
		Placebo	490	469 (95.7)	1.88 (0.70)	0.5	1.37	1.76	2.23	4.7	
	Week 24	Tezepelumab	487	460 (94.5)	1.97 (0.72)	0.6	1.48	1.84	2.42	5.5	
		Placebo	490	453 (92.4)	1.87 (0.69)	0.6	1.41	1.76	2.21	4.8	
	Week 36	Tezepelumab	487	446 (91.6)	1.98 (0.73)	0.5	1.44	1.86	2.40	4.9	
		Placebo	490	440 (89.8)	1.90 (0.70)	0.6	1.42	1.79	2.27	4.6	
	Week 52	Tezepelumab	487	437 (89.7)	1.98 (0.73)	0.6	1.47	1.84	2.41	4.6	
		Placebo	490	418 (85.3)	1.88 (0.72)	0.6	1.37	1.74	2.28	4.5	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOMH0: Course of FEV1 Pre-BD
DITT - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in FEV1 Pre-BD	Week 2	Tezepelumab	487	474 (97.3)	0.17 (0.33)	-0.8	-0.01	0.12	0.29	1.9	0.34 [0.21, 0.47]
		Placebo	490	468 (95.5)	0.05 (0.34)	-1.8	-0.11	0.01	0.18	1.7	
	Week 4	Tezepelumab	487	483 (99.2)	0.20 (0.36)	-1.0	-0.02	0.13	0.34	1.8	0.31 [0.18, 0.43]
		Placebo	490	478 (97.6)	0.09 (0.37)	-1.8	-0.10	0.05	0.25	1.6	
	Week 8	Tezepelumab	487	478 (98.2)	0.23 (0.40)	-0.9	-0.04	0.15	0.41	1.9	0.34 [0.21, 0.47]
		Placebo	490	478 (97.6)	0.10 (0.36)	-1.1	-0.11	0.05	0.28	2.1	
	Week 12	Tezepelumab	487	473 (97.1)	0.23 (0.40)	-0.8	-0.02	0.17	0.40	2.2	0.35 [0.22, 0.47]
		Placebo	490	475 (96.9)	0.10 (0.38)	-1.5	-0.10	0.04	0.25	2.1	
	Week 16	Tezepelumab	487	471 (96.7)	0.24 (0.42)	-1.0	-0.02	0.16	0.40	2.1	0.36 [0.24, 0.49]
		Placebo	490	469 (95.7)	0.09 (0.36)	-1.2	-0.10	0.04	0.26	1.9	
	Week 24	Tezepelumab	487	460 (94.5)	0.22 (0.41)	-1.0	-0.05	0.16	0.41	2.1	0.36 [0.23, 0.49]
		Placebo	490	453 (92.4)	0.08 (0.37)	-1.1	-0.12	0.04	0.25	1.7	
	Week 36	Tezepelumab	487	446 (91.6)	0.22 (0.41)	-1.0	-0.05	0.14	0.42	1.8	0.29 [0.16, 0.42]
		Placebo	490	440 (89.8)	0.10 (0.39)	-1.1	-0.14	0.05	0.29	1.7	
	Week 52	Tezepelumab	487	437 (89.7)	0.22 (0.41)	-1.0	-0.04	0.14	0.43	1.7	0.33 [0.19, 0.46]
		Placebo	490	418 (85.3)	0.09 (0.38)	-1.0	-0.14	0.06	0.24	2.3	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOMC0: Change from baseline in FEV1 Pre-BD - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Tezepelumab	487	474 (97.3)	0.17 (0.02)	(0.14, 0.20)	0.11 (0.02)	(0.07, 0.15)	<0.001 *
	Placebo	490	468 (95.5)	0.05 (0.02)	(0.02, 0.08)			
Week 4	Tezepelumab	487	483 (99.2)	0.20 (0.02)	(0.16, 0.23)	0.11 (0.02)	(0.07, 0.16)	<0.001 *
	Placebo	490	478 (97.6)	0.09 (0.02)	(0.05, 0.12)			
Week 8	Tezepelumab	487	478 (98.2)	0.23 (0.02)	(0.19, 0.26)	0.13 (0.02)	(0.08, 0.18)	<0.001 *
	Placebo	490	478 (97.6)	0.10 (0.02)	(0.06, 0.13)			
Week 12	Tezepelumab	487	473 (97.1)	0.23 (0.02)	(0.20, 0.26)	0.13 (0.02)	(0.08, 0.18)	<0.001 *
	Placebo	490	475 (96.9)	0.10 (0.02)	(0.06, 0.13)			
Week 16	Tezepelumab	487	471 (96.7)	0.24 (0.02)	(0.20, 0.27)	0.14 (0.03)	(0.09, 0.19)	<0.001 *
	Placebo	490	469 (95.7)	0.09 (0.02)	(0.06, 0.13)			
Week 24	Tezepelumab	487	460 (94.5)	0.21 (0.02)	(0.18, 0.25)	0.13 (0.02)	(0.08, 0.18)	<0.001 *
	Placebo	490	453 (92.4)	0.08 (0.02)	(0.05, 0.12)			
Week 36	Tezepelumab	487	446 (91.6)	0.22 (0.02)	(0.18, 0.26)	0.12 (0.03)	(0.07, 0.17)	<0.001 *
	Placebo	490	440 (89.8)	0.10 (0.02)	(0.07, 0.14)			
Week 52	Tezepelumab	487	437 (89.7)	0.22 (0.02)	(0.19, 0.26)	0.13 (0.03)	(0.08, 0.18)	<0.001 *
	Placebo	490	418 (85.3)	0.09 (0.02)	(0.05, 0.13)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Figure NF2FAC_AOMG0: Course of FEV1 Pre-BD
DITT - adult



Note: DITT - adult = Dossier Intent-to-Treat - adult.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source table: NT2FAC_AOMH0
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Absolute values	Baseline	Tezepelumab	173	173 (100.0)	2.14 (0.76)	0.6	1.56	2.12	2.62	4.8	
			Placebo	176	176 (100.0)	2.10 (0.75)	0.7	1.54	2.09	2.60	4.5	
		Week 2	Tezepelumab	173	170 (98.3)	2.34 (0.77)	0.7	1.77	2.38	2.83	5.0	
			Placebo	176	172 (97.7)	2.16 (0.75)	0.8	1.57	2.17	2.69	4.1	
		Week 4	Tezepelumab	173	172 (99.4)	2.39 (0.78)	0.7	1.88	2.42	2.92	5.0	
			Placebo	176	172 (97.7)	2.17 (0.74)	0.9	1.65	2.08	2.68	4.8	
		Week 8	Tezepelumab	173	168 (97.1)	2.38 (0.81)	0.7	1.74	2.38	2.84	4.7	
			Placebo	176	176 (100.0)	2.22 (0.77)	0.7	1.71	2.09	2.69	4.7	
		Week 12	Tezepelumab	173	166 (96.0)	2.39 (0.83)	0.7	1.77	2.37	2.84	4.9	
			Placebo	176	173 (98.3)	2.24 (0.78)	0.9	1.64	2.16	2.78	4.6	
		Week 16	Tezepelumab	173	168 (97.1)	2.44 (0.86)	0.6	1.80	2.41	2.97	4.9	
			Placebo	176	173 (98.3)	2.20 (0.79)	0.7	1.60	2.11	2.69	4.7	
		Week 24	Tezepelumab	173	159 (91.9)	2.39 (0.81)	0.6	1.76	2.42	2.81	5.5	
			Placebo	176	162 (92.0)	2.23 (0.78)	0.7	1.68	2.11	2.73	4.8	
		Week 36	Tezepelumab	173	159 (91.9)	2.40 (0.84)	0.5	1.80	2.38	3.00	4.9	
			Placebo	176	160 (90.9)	2.23 (0.78)	0.9	1.66	2.17	2.69	4.6	
		Week 52	Tezepelumab	173	157 (90.8)	2.41 (0.81)	0.8	1.77	2.39	2.93	4.6	
			Placebo	176	151 (85.8)	2.24 (0.81)	0.7	1.59	2.17	2.79	4.5	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Change from baseline	Week 2	Tezepelumab	173	170 (98.3)	0.20 (0.39)	-0.7	-0.03	0.14	0.35	1.9	0.43 [0.21, 0.64]
			Placebo	176	172 (97.7)	0.04 (0.38)	-1.1	-0.17	-0.01	0.19	1.7	
		Week 4	Tezepelumab	173	172 (99.4)	0.25 (0.44)	-0.9	-0.04	0.18	0.44	1.8	0.40 [0.19, 0.62]
			Placebo	176	172 (97.7)	0.08 (0.45)	-1.8	-0.15	0.02	0.32	1.6	
		Week 8	Tezepelumab	173	168 (97.1)	0.26 (0.48)	-0.9	-0.05	0.15	0.46	1.9	0.32 [0.10, 0.53]
			Placebo	176	176 (100.0)	0.12 (0.45)	-1.1	-0.13	0.07	0.33	2.1	
		Week 12	Tezepelumab	173	166 (96.0)	0.27 (0.50)	-0.8	-0.05	0.18	0.48	2.2	0.30 [0.08, 0.51]
			Placebo	176	173 (98.3)	0.13 (0.44)	-1.4	-0.10	0.05	0.34	2.1	
		Week 16	Tezepelumab	173	168 (97.1)	0.29 (0.53)	-0.8	-0.04	0.17	0.51	2.1	0.43 [0.21, 0.64]
			Placebo	176	173 (98.3)	0.09 (0.41)	-1.2	-0.15	0.01	0.31	1.9	
		Week 24	Tezepelumab	173	159 (91.9)	0.28 (0.47)	-0.5	-0.07	0.18	0.47	2.1	0.41 [0.19, 0.63]
			Placebo	176	162 (92.0)	0.09 (0.44)	-1.1	-0.17	0.06	0.32	1.7	
		Week 36	Tezepelumab	173	159 (91.9)	0.26 (0.49)	-0.8	-0.07	0.16	0.46	1.8	0.34 [0.12, 0.56]
			Placebo	176	160 (90.9)	0.10 (0.46)	-1.1	-0.20	0.04	0.35	1.6	
		Week 52	Tezepelumab	173	157 (90.8)	0.27 (0.50)	-1.0	-0.07	0.19	0.50	1.7	0.35 [0.12, 0.57]
			Placebo	176	151 (85.8)	0.10 (0.48)	-1.0	-0.18	0.03	0.30	2.3	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Absolute values	Baseline	Tezepelumab	314	314 (100.0)	1.55 (0.52)	0.4	1.19	1.51	1.88	3.2	
			Placebo	314	314 (100.0)	1.60 (0.51)	0.4	1.27	1.56	1.88	3.6	
		Week 2	Tezepelumab	314	304 (96.8)	1.70 (0.54)	0.6	1.30	1.64	2.06	3.4	
			Placebo	314	296 (94.3)	1.67 (0.55)	0.4	1.31	1.61	1.97	4.0	
		Week 4	Tezepelumab	314	311 (99.0)	1.71 (0.54)	0.6	1.28	1.66	2.07	3.2	
			Placebo	314	306 (97.5)	1.69 (0.55)	0.4	1.32	1.65	1.99	3.7	
		Week 8	Tezepelumab	314	310 (98.7)	1.76 (0.56)	0.6	1.31	1.72	2.14	3.4	
			Placebo	314	302 (96.2)	1.69 (0.57)	0.4	1.32	1.63	1.99	4.3	
		Week 12	Tezepelumab	314	307 (97.8)	1.76 (0.55)	0.6	1.37	1.69	2.10	3.5	
			Placebo	314	302 (96.2)	1.68 (0.57)	0.5	1.31	1.64	2.00	4.3	
		Week 16	Tezepelumab	314	303 (96.5)	1.75 (0.54)	0.6	1.35	1.69	2.08	3.5	
			Placebo	314	296 (94.3)	1.69 (0.56)	0.5	1.32	1.65	2.02	4.4	
		Week 24	Tezepelumab	314	301 (95.9)	1.74 (0.54)	0.6	1.32	1.73	2.07	3.4	
			Placebo	314	291 (92.7)	1.67 (0.54)	0.6	1.32	1.63	1.97	4.3	
		Week 36	Tezepelumab	314	287 (91.4)	1.74 (0.54)	0.6	1.32	1.69	2.12	3.3	
			Placebo	314	280 (89.2)	1.72 (0.57)	0.6	1.34	1.64	2.08	4.3	
		Week 52	Tezepelumab	314	280 (89.2)	1.74 (0.56)	0.6	1.37	1.70	2.09	3.4	
			Placebo	314	267 (85.0)	1.68 (0.56)	0.6	1.30	1.61	1.97	3.9	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Change from baseline	Week 2	Tezepelumab	314	304 (96.8)	0.15 (0.29)	-0.8	0.00	0.10	0.26	1.3	0.28 [0.12, 0.44]
			Placebo	314	296 (94.3)	0.06 (0.32)	-1.8	-0.08	0.03	0.17	1.2	
		Week 4	Tezepelumab	314	311 (99.0)	0.17 (0.31)	-1.0	-0.01	0.12	0.30	1.2	0.24 [0.08, 0.40]
			Placebo	314	306 (97.5)	0.09 (0.32)	-1.0	-0.07	0.06	0.24	1.2	
		Week 8	Tezepelumab	314	310 (98.7)	0.21 (0.36)	-0.8	-0.01	0.15	0.38	1.4	0.37 [0.21, 0.53]
			Placebo	314	302 (96.2)	0.09 (0.30)	-0.8	-0.08	0.04	0.23	1.6	
		Week 12	Tezepelumab	314	307 (97.8)	0.21 (0.34)	-0.7	0.00	0.16	0.37	1.4	0.39 [0.23, 0.55]
			Placebo	314	302 (96.2)	0.08 (0.35)	-1.5	-0.08	0.04	0.21	1.7	
		Week 16	Tezepelumab	314	303 (96.5)	0.21 (0.35)	-1.0	-0.01	0.15	0.36	1.4	0.33 [0.17, 0.49]
			Placebo	314	296 (94.3)	0.10 (0.33)	-1.0	-0.07	0.04	0.23	1.8	
		Week 24	Tezepelumab	314	301 (95.9)	0.19 (0.37)	-1.0	-0.05	0.14	0.38	1.6	0.33 [0.17, 0.49]
			Placebo	314	291 (92.7)	0.07 (0.33)	-0.9	-0.10	0.03	0.22	1.7	
		Week 36	Tezepelumab	314	287 (91.4)	0.20 (0.36)	-1.0	-0.03	0.13	0.40	1.4	0.26 [0.09, 0.42]
			Placebo	314	280 (89.2)	0.11 (0.34)	-0.8	-0.11	0.06	0.27	1.7	
		Week 52	Tezepelumab	314	280 (89.2)	0.19 (0.36)	-1.0	-0.03	0.13	0.38	1.3	0.33 [0.16, 0.50]
			Placebo	314	267 (85.0)	0.08 (0.31)	-0.8	-0.11	0.06	0.23	1.2	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Absolute values	Baseline	Tezepelumab	391	391 (100.0)	1.84 (0.69)	0.4	1.35	1.75	2.21	4.8	
			Placebo	416	416 (100.0)	1.83 (0.67)	0.4	1.37	1.73	2.19	4.5	
		Week 2	Tezepelumab	391	381 (97.4)	2.03 (0.71)	0.6	1.52	1.97	2.45	5.0	
			Placebo	416	397 (95.4)	1.91 (0.69)	0.4	1.41	1.82	2.32	4.1	
		Week 4	Tezepelumab	391	390 (99.7)	2.05 (0.72)	0.7	1.57	2.00	2.52	5.0	
			Placebo	416	408 (98.1)	1.92 (0.68)	0.4	1.46	1.83	2.28	4.8	
		Week 8	Tezepelumab	391	384 (98.2)	2.08 (0.73)	0.6	1.57	2.03	2.49	4.7	
			Placebo	416	408 (98.1)	1.95 (0.71)	0.4	1.46	1.86	2.30	4.7	
		Week 12	Tezepelumab	391	380 (97.2)	2.08 (0.74)	0.6	1.58	1.99	2.52	4.9	
			Placebo	416	405 (97.4)	1.95 (0.72)	0.5	1.47	1.83	2.33	4.6	
		Week 16	Tezepelumab	391	379 (96.9)	2.10 (0.76)	0.6	1.56	1.99	2.55	4.9	
			Placebo	416	399 (95.9)	1.94 (0.71)	0.5	1.46	1.83	2.31	4.7	
		Week 24	Tezepelumab	391	371 (94.9)	2.07 (0.72)	0.6	1.61	1.97	2.52	5.5	
			Placebo	416	386 (92.8)	1.93 (0.71)	0.6	1.45	1.83	2.25	4.8	
		Week 36	Tezepelumab	391	359 (91.8)	2.08 (0.74)	0.5	1.52	1.98	2.49	4.9	
			Placebo	416	374 (89.9)	1.96 (0.71)	0.6	1.49	1.85	2.32	4.6	
		Week 52	Tezepelumab	391	353 (90.3)	2.08 (0.74)	0.6	1.58	2.00	2.52	4.6	
			Placebo	416	355 (85.3)	1.95 (0.73)	0.6	1.44	1.81	2.33	4.5	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Change from baseline	Week 2	Tezepelumab	391	381 (97.4)	0.19 (0.36)	-0.8	-0.02	0.13	0.32	1.9	0.37 [0.22, 0.51]
			Placebo	416	397 (95.4)	0.06 (0.36)	-1.8	-0.12	0.01	0.18	1.7	
		Week 4	Tezepelumab	391	390 (99.7)	0.22 (0.38)	-1.0	-0.01	0.15	0.37	1.8	0.35 [0.21, 0.49]
			Placebo	416	408 (98.1)	0.09 (0.38)	-1.8	-0.11	0.05	0.26	1.6	
		Week 8	Tezepelumab	391	384 (98.2)	0.25 (0.43)	-0.9	-0.03	0.16	0.46	1.9	0.37 [0.23, 0.51]
			Placebo	416	408 (98.1)	0.10 (0.37)	-1.1	-0.11	0.05	0.28	2.1	
		Week 12	Tezepelumab	391	380 (97.2)	0.25 (0.42)	-0.8	-0.03	0.17	0.45	2.2	0.35 [0.21, 0.49]
			Placebo	416	405 (97.4)	0.11 (0.40)	-1.5	-0.10	0.05	0.26	2.1	
		Week 16	Tezepelumab	391	379 (96.9)	0.26 (0.45)	-1.0	-0.02	0.17	0.44	2.1	0.38 [0.24, 0.52]
			Placebo	416	399 (95.9)	0.10 (0.38)	-1.2	-0.10	0.04	0.26	1.9	
		Week 24	Tezepelumab	391	371 (94.9)	0.24 (0.43)	-1.0	-0.05	0.16	0.44	2.1	0.39 [0.24, 0.53]
			Placebo	416	386 (92.8)	0.08 (0.39)	-0.9	-0.14	0.03	0.27	1.7	
		Week 36	Tezepelumab	391	359 (91.8)	0.24 (0.43)	-1.0	-0.05	0.17	0.48	1.8	0.31 [0.16, 0.45]
			Placebo	416	374 (89.9)	0.11 (0.41)	-1.1	-0.14	0.06	0.29	1.7	
		Week 52	Tezepelumab	391	353 (90.3)	0.24 (0.44)	-1.0	-0.03	0.17	0.47	1.7	0.35 [0.20, 0.50]
			Placebo	416	355 (85.3)	0.10 (0.39)	-1.0	-0.14	0.06	0.26	2.3	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Absolute values	Baseline	Tezepelumab	96	96 (100.0)	1.45 (0.54)	0.6	1.14	1.36	1.62	3.2	
			Placebo	74	74 (100.0)	1.48 (0.47)	0.7	1.12	1.42	1.77	2.6	
		Week 2	Tezepelumab	96	93 (96.9)	1.52 (0.51)	0.6	1.23	1.44	1.75	3.1	
			Placebo	74	71 (95.9)	1.52 (0.50)	0.7	1.14	1.45	1.78	3.1	
		Week 4	Tezepelumab	96	93 (96.9)	1.54 (0.51)	0.6	1.20	1.46	1.77	3.1	
			Placebo	74	70 (94.6)	1.54 (0.50)	0.7	1.21	1.46	1.81	3.1	
		Week 8	Tezepelumab	96	94 (97.9)	1.55 (0.51)	0.6	1.20	1.47	1.82	3.2	
			Placebo	74	70 (94.6)	1.52 (0.51)	0.7	1.16	1.43	1.76	3.2	
		Week 12	Tezepelumab	96	93 (96.9)	1.57 (0.49)	0.6	1.23	1.50	1.83	3.3	
			Placebo	74	70 (94.6)	1.50 (0.49)	0.7	1.19	1.44	1.69	3.1	
		Week 16	Tezepelumab	96	92 (95.8)	1.58 (0.53)	0.6	1.24	1.51	1.84	3.4	
			Placebo	74	70 (94.6)	1.52 (0.47)	0.7	1.19	1.46	1.77	3.0	
		Week 24	Tezepelumab	96	89 (92.7)	1.53 (0.51)	0.6	1.18	1.52	1.78	3.1	
			Placebo	74	67 (90.5)	1.51 (0.47)	0.6	1.24	1.45	1.83	3.0	
		Week 36	Tezepelumab	96	87 (90.6)	1.57 (0.53)	0.6	1.15	1.51	1.84	3.2	
			Placebo	74	66 (89.2)	1.54 (0.50)	0.7	1.21	1.41	1.80	3.2	
		Week 52	Tezepelumab	96	84 (87.5)	1.57 (0.54)	0.7	1.17	1.44	1.77	3.3	
			Placebo	74	63 (85.1)	1.51 (0.49)	0.7	1.18	1.48	1.76	2.8	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Change from baseline	Week 2	Tezepelumab	96	93 (96.9)	0.09 (0.19)	-0.4	-0.01	0.07	0.19	0.7	0.24 [-0.07, 0.55]
			Placebo	74	71 (95.9)	0.04 (0.23)	-0.6	-0.08	0.01	0.13	0.7	
		Week 4	Tezepelumab	96	93 (96.9)	0.11 (0.23)	-0.7	-0.04	0.09	0.23	0.8	0.09 [-0.22, 0.40]
			Placebo	74	70 (94.6)	0.08 (0.27)	-0.9	-0.03	0.06	0.18	0.9	
		Week 8	Tezepelumab	96	94 (97.9)	0.13 (0.27)	-0.6	-0.04	0.08	0.27	1.0	0.26 [-0.05, 0.57]
			Placebo	74	70 (94.6)	0.06 (0.27)	-0.9	-0.08	0.05	0.21	0.7	
		Week 12	Tezepelumab	96	93 (96.9)	0.16 (0.29)	-0.7	-0.01	0.19	0.34	1.2	0.43 [0.12, 0.74]
			Placebo	74	70 (94.6)	0.04 (0.26)	-1.1	-0.07	0.00	0.18	0.7	
		Week 16	Tezepelumab	96	92 (95.8)	0.15 (0.28)	-0.5	-0.04	0.11	0.34	1.2	0.34 [0.03, 0.66]
			Placebo	74	70 (94.6)	0.06 (0.25)	-1.0	-0.09	0.05	0.25	0.6	
		Week 24	Tezepelumab	96	89 (92.7)	0.12 (0.26)	-0.4	-0.07	0.12	0.29	1.0	0.25 [-0.06, 0.57]
			Placebo	74	67 (90.5)	0.05 (0.26)	-1.1	-0.07	0.06	0.19	0.7	
		Week 36	Tezepelumab	96	87 (90.6)	0.13 (0.27)	-0.6	-0.05	0.08	0.31	1.0	0.28 [-0.04, 0.60]
			Placebo	74	66 (89.2)	0.05 (0.27)	-0.6	-0.14	0.01	0.18	0.8	
		Week 52	Tezepelumab	96	84 (87.5)	0.11 (0.27)	-0.5	-0.04	0.07	0.26	0.9	0.33 [-0.00, 0.66]
			Placebo	74	63 (85.1)	0.02 (0.33)	-1.0	-0.17	0.04	0.22	0.7	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Absolute values	Baseline	Tezepelumab	284	284 (100.0)	1.79 (0.64)	0.4	1.32	1.75	2.17	4.1	
			Placebo	299	299 (100.0)	1.83 (0.66)	0.6	1.33	1.73	2.22	4.1	
		Week 2	Tezepelumab	284	278 (97.9)	1.95 (0.68)	0.6	1.44	1.89	2.40	4.3	
			Placebo	299	288 (96.3)	1.91 (0.68)	0.7	1.42	1.79	2.32	4.1	
		Week 4	Tezepelumab	284	281 (98.9)	1.98 (0.69)	0.6	1.46	1.91	2.43	4.3	
			Placebo	299	289 (96.7)	1.92 (0.68)	0.5	1.45	1.84	2.30	4.8	
		Week 8	Tezepelumab	284	277 (97.5)	2.00 (0.70)	0.6	1.45	1.95	2.41	4.7	
			Placebo	299	292 (97.7)	1.94 (0.72)	0.6	1.41	1.85	2.35	4.7	
		Week 12	Tezepelumab	284	275 (96.8)	1.98 (0.69)	0.6	1.50	1.91	2.45	4.7	
			Placebo	299	293 (98.0)	1.94 (0.73)	0.5	1.40	1.82	2.38	4.6	
		Week 16	Tezepelumab	284	276 (97.2)	2.00 (0.72)	0.6	1.50	1.90	2.48	4.9	
			Placebo	299	289 (96.7)	1.94 (0.73)	0.5	1.41	1.83	2.33	4.7	
		Week 24	Tezepelumab	284	268 (94.4)	1.99 (0.70)	0.6	1.49	1.89	2.48	4.4	
			Placebo	299	277 (92.6)	1.91 (0.71)	0.7	1.39	1.83	2.26	4.8	
		Week 36	Tezepelumab	284	264 (93.0)	1.99 (0.71)	0.6	1.47	1.91	2.45	4.5	
			Placebo	299	275 (92.0)	1.94 (0.72)	0.6	1.43	1.81	2.33	4.3	
		Week 52	Tezepelumab	284	257 (90.5)	1.98 (0.71)	0.6	1.48	1.87	2.45	4.2	
			Placebo	299	263 (88.0)	1.91 (0.73)	0.6	1.37	1.74	2.30	4.4	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Change from baseline	Week 2	Tezepelumab	284	278 (97.9)	0.16 (0.34)	-0.8	-0.02	0.12	0.29	1.9	0.27 [0.10, 0.43]
			Placebo	299	288 (96.3)	0.07 (0.33)	-0.8	-0.11	0.01	0.17	1.7	
		Week 4	Tezepelumab	284	281 (98.9)	0.19 (0.38)	-1.0	-0.05	0.12	0.33	1.8	0.23 [0.06, 0.39]
			Placebo	299	289 (96.7)	0.10 (0.36)	-1.0	-0.10	0.06	0.25	1.6	
		Week 8	Tezepelumab	284	277 (97.5)	0.21 (0.41)	-0.8	-0.05	0.14	0.39	1.8	0.26 [0.09, 0.42]
			Placebo	299	292 (97.7)	0.11 (0.38)	-1.0	-0.10	0.05	0.27	2.1	
		Week 12	Tezepelumab	284	275 (96.8)	0.20 (0.40)	-0.7	-0.04	0.13	0.39	1.9	0.24 [0.08, 0.41]
			Placebo	299	293 (98.0)	0.11 (0.40)	-1.5	-0.09	0.05	0.25	2.1	
		Week 16	Tezepelumab	284	276 (97.2)	0.22 (0.42)	-1.0	-0.04	0.15	0.40	2.0	0.28 [0.11, 0.44]
			Placebo	299	289 (96.7)	0.11 (0.39)	-1.2	-0.11	0.04	0.26	1.9	
		Week 24	Tezepelumab	284	268 (94.4)	0.20 (0.41)	-1.0	-0.07	0.14	0.40	2.1	0.29 [0.12, 0.46]
			Placebo	299	277 (92.6)	0.08 (0.40)	-0.9	-0.13	0.03	0.24	1.7	
		Week 36	Tezepelumab	284	264 (93.0)	0.20 (0.41)	-1.0	-0.07	0.12	0.43	1.8	0.22 [0.05, 0.39]
			Placebo	299	275 (92.0)	0.11 (0.42)	-1.1	-0.14	0.05	0.28	1.7	
		Week 52	Tezepelumab	284	257 (90.5)	0.19 (0.41)	-1.0	-0.07	0.13	0.35	1.7	0.21 [0.04, 0.39]
			Placebo	299	263 (88.0)	0.10 (0.40)	-1.0	-0.14	0.05	0.26	2.3	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Absolute values	Baseline	Tezepelumab	203	203 (100.0)	1.71 (0.73)	0.5	1.21	1.56	2.05	4.8	
			Placebo	191	191 (100.0)	1.71 (0.64)	0.4	1.35	1.62	2.06	4.5	
		Week 2	Tezepelumab	203	196 (96.6)	1.90 (0.74)	0.7	1.35	1.78	2.33	5.0	
			Placebo	191	180 (94.2)	1.75 (0.66)	0.4	1.35	1.66	2.11	4.0	
		Week 4	Tezepelumab	203	202 (99.5)	1.92 (0.75)	0.7	1.39	1.75	2.37	5.0	
			Placebo	191	189 (99.0)	1.77 (0.64)	0.4	1.39	1.68	2.08	4.2	
		Week 8	Tezepelumab	203	201 (99.0)	1.95 (0.75)	0.7	1.39	1.79	2.45	4.6	
			Placebo	191	186 (97.4)	1.80 (0.66)	0.4	1.34	1.72	2.09	4.3	
		Week 12	Tezepelumab	203	198 (97.5)	1.98 (0.77)	0.7	1.49	1.82	2.38	4.9	
			Placebo	191	182 (95.3)	1.79 (0.65)	0.6	1.37	1.70	2.13	4.3	
		Week 16	Tezepelumab	203	195 (96.1)	1.99 (0.79)	0.6	1.45	1.83	2.36	4.9	
			Placebo	191	180 (94.2)	1.78 (0.63)	0.7	1.34	1.72	2.12	4.3	
		Week 24	Tezepelumab	203	192 (94.6)	1.94 (0.74)	0.6	1.45	1.79	2.32	5.5	
			Placebo	191	176 (92.1)	1.81 (0.65)	0.6	1.43	1.71	2.09	4.8	
		Week 36	Tezepelumab	203	182 (89.7)	1.96 (0.77)	0.5	1.41	1.81	2.34	4.9	
			Placebo	191	165 (86.4)	1.84 (0.66)	0.7	1.41	1.75	2.21	4.6	
		Week 52	Tezepelumab	203	180 (88.7)	1.97 (0.77)	0.6	1.42	1.83	2.37	4.6	
			Placebo	191	155 (81.2)	1.83 (0.70)	0.7	1.34	1.73	2.26	4.5	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Change from baseline	Week 2	Tezepelumab	203	196 (96.6)	0.18 (0.33)	-0.6	-0.00	0.11	0.30	1.4	0.45 [0.24, 0.65]
			Placebo	191	180 (94.2)	0.03 (0.36)	-1.8	-0.11	0.02	0.19	1.0	
		Week 4	Tezepelumab	203	202 (99.5)	0.21 (0.33)	-0.9	0.02	0.15	0.36	1.6	0.43 [0.23, 0.63]
			Placebo	191	189 (99.0)	0.06 (0.37)	-1.8	-0.11	0.03	0.26	1.1	
		Week 8	Tezepelumab	203	201 (99.0)	0.25 (0.40)	-0.9	-0.02	0.16	0.44	1.9	0.48 [0.28, 0.68]
			Placebo	191	186 (97.4)	0.08 (0.32)	-1.1	-0.12	0.05	0.28	1.2	
		Week 12	Tezepelumab	203	198 (97.5)	0.27 (0.41)	-0.8	0.03	0.19	0.44	2.2	0.51 [0.30, 0.71]
			Placebo	191	182 (95.3)	0.08 (0.35)	-1.2	-0.10	0.04	0.28	1.2	
		Week 16	Tezepelumab	203	195 (96.1)	0.26 (0.42)	-0.8	0.00	0.18	0.43	2.1	0.51 [0.30, 0.71]
			Placebo	191	180 (94.2)	0.07 (0.32)	-1.0	-0.09	0.02	0.24	1.0	
		Week 24	Tezepelumab	203	192 (94.6)	0.24 (0.41)	-1.0	-0.03	0.17	0.44	1.7	0.47 [0.26, 0.67]
			Placebo	191	176 (92.1)	0.07 (0.31)	-1.1	-0.12	0.05	0.27	0.9	
		Week 36	Tezepelumab	203	182 (89.7)	0.24 (0.41)	-0.6	-0.04	0.16	0.40	1.6	0.41 [0.19, 0.62]
			Placebo	191	165 (86.4)	0.08 (0.34)	-0.8	-0.15	0.05	0.30	1.0	
		Week 52	Tezepelumab	203	180 (88.7)	0.26 (0.41)	-0.8	-0.01	0.20	0.51	1.6	0.52 [0.30, 0.74]
			Placebo	191	155 (81.2)	0.06 (0.34)	-1.0	-0.16	0.06	0.23	1.1	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Absolute values	Baseline	Tezepelumab	304	304 (100.0)	1.81 (0.68)	0.6	1.30	1.70	2.13	4.8	
			Placebo	297	297 (100.0)	1.80 (0.72)	0.6	1.30	1.67	2.19	4.5	
		Week 2	Tezepelumab	304	298 (98.0)	1.99 (0.71)	0.7	1.44	1.89	2.47	5.0	
			Placebo	297	282 (94.9)	1.86 (0.74)	0.6	1.32	1.73	2.31	4.1	
		Week 4	Tezepelumab	304	301 (99.0)	2.00 (0.74)	0.7	1.44	1.90	2.50	5.0	
			Placebo	297	286 (96.3)	1.89 (0.73)	0.5	1.36	1.80	2.26	4.8	
		Week 8	Tezepelumab	304	301 (99.0)	2.02 (0.75)	0.7	1.41	1.93	2.48	4.7	
			Placebo	297	286 (96.3)	1.93 (0.77)	0.6	1.34	1.78	2.32	4.7	
		Week 12	Tezepelumab	304	293 (96.4)	2.03 (0.75)	0.8	1.49	1.92	2.45	4.9	
			Placebo	297	284 (95.6)	1.90 (0.78)	0.5	1.35	1.73	2.37	4.6	
		Week 16	Tezepelumab	304	293 (96.4)	2.06 (0.78)	0.7	1.45	1.94	2.56	4.9	
			Placebo	297	281 (94.6)	1.90 (0.78)	0.5	1.31	1.76	2.32	4.7	
		Week 24	Tezepelumab	304	286 (94.1)	2.01 (0.76)	0.7	1.41	1.90	2.48	5.5	
			Placebo	297	269 (90.6)	1.90 (0.77)	0.6	1.38	1.77	2.25	4.8	
		Week 36	Tezepelumab	304	274 (90.1)	2.03 (0.75)	0.7	1.43	1.95	2.46	4.9	
			Placebo	297	260 (87.5)	1.95 (0.77)	0.6	1.40	1.82	2.34	4.6	
		Week 52	Tezepelumab	304	267 (87.8)	2.03 (0.77)	0.6	1.47	1.96	2.46	4.6	
			Placebo	297	243 (81.8)	1.94 (0.80)	0.6	1.31	1.79	2.36	4.5	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Change from baseline	Week 2	Tezepelumab	304	298 (98.0)	0.18 (0.32)	-0.6	0.00	0.13	0.30	1.9	0.43 [0.26, 0.59]
			Placebo	297	282 (94.9)	0.03 (0.37)	-1.8	-0.13	-0.01	0.16	1.7	
		Week 4	Tezepelumab	304	301 (99.0)	0.20 (0.36)	-0.9	-0.04	0.12	0.34	1.7	0.28 [0.11, 0.44]
			Placebo	297	286 (96.3)	0.09 (0.38)	-1.8	-0.09	0.06	0.26	1.6	
		Week 8	Tezepelumab	304	301 (99.0)	0.22 (0.41)	-0.9	-0.04	0.14	0.42	1.9	0.30 [0.13, 0.46]
			Placebo	297	286 (96.3)	0.11 (0.38)	-1.1	-0.10	0.06	0.28	2.1	
		Week 12	Tezepelumab	304	293 (96.4)	0.23 (0.39)	-0.8	-0.03	0.16	0.41	2.2	0.32 [0.15, 0.48]
			Placebo	297	284 (95.6)	0.10 (0.41)	-1.5	-0.11	0.04	0.26	2.1	
		Week 16	Tezepelumab	304	293 (96.4)	0.25 (0.43)	-0.8	0.00	0.16	0.40	2.1	0.37 [0.20, 0.53]
			Placebo	297	281 (94.6)	0.10 (0.38)	-1.2	-0.12	0.04	0.26	1.9	
		Week 24	Tezepelumab	304	286 (94.1)	0.22 (0.42)	-1.0	-0.06	0.15	0.42	2.1	0.33 [0.16, 0.49]
			Placebo	297	269 (90.6)	0.09 (0.38)	-0.9	-0.11	0.03	0.25	1.7	
		Week 36	Tezepelumab	304	274 (90.1)	0.22 (0.41)	-0.8	-0.07	0.15	0.43	1.8	0.24 [0.07, 0.41]
			Placebo	297	260 (87.5)	0.12 (0.41)	-1.1	-0.12	0.04	0.30	1.6	
		Week 52	Tezepelumab	304	267 (87.8)	0.21 (0.42)	-0.8	-0.05	0.13	0.40	1.7	0.24 [0.06, 0.41]
			Placebo	297	243 (81.8)	0.12 (0.40)	-0.9	-0.12	0.07	0.27	2.3	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Absolute values	Baseline	Tezepelumab	27	27 (100.0)	1.73 (0.78)	0.8	1.21	1.43	2.28	4.0	
			Placebo	27	27 (100.0)	1.71 (0.60)	0.8	1.22	1.77	2.10	3.2	
		Week 2	Tezepelumab	27	23 (85.2)	1.80 (0.75)	0.9	1.27	1.57	2.15	4.1	
			Placebo	27	27 (100.0)	1.85 (0.58)	0.9	1.40	1.90	2.22	3.1	
		Week 4	Tezepelumab	27	26 (96.3)	1.76 (0.72)	1.0	1.26	1.65	2.06	4.2	
			Placebo	27	27 (100.0)	1.80 (0.52)	1.0	1.33	1.87	2.09	3.1	
		Week 8	Tezepelumab	27	26 (96.3)	1.85 (0.68)	1.0	1.30	1.73	2.11	4.1	
			Placebo	27	27 (100.0)	1.76 (0.59)	0.8	1.38	1.69	2.16	3.4	
		Week 12	Tezepelumab	27	26 (96.3)	1.90 (0.74)	0.9	1.50	1.71	2.45	4.2	
			Placebo	27	27 (100.0)	1.81 (0.59)	1.0	1.23	1.74	2.10	3.3	
		Week 16	Tezepelumab	27	25 (92.6)	1.69 (0.66)	0.9	1.34	1.64	1.91	4.2	
			Placebo	27	26 (96.3)	1.81 (0.55)	0.8	1.38	1.81	2.09	3.1	
		Week 24	Tezepelumab	27	23 (85.2)	1.78 (0.65)	0.9	1.34	1.63	2.11	4.0	
			Placebo	27	25 (92.6)	1.71 (0.62)	0.7	1.28	1.69	2.09	3.3	
		Week 36	Tezepelumab	27	23 (85.2)	1.77 (0.74)	0.9	1.35	1.61	2.16	4.4	
			Placebo	27	26 (96.3)	1.85 (0.56)	1.0	1.37	2.02	2.17	3.3	
		Week 52	Tezepelumab	27	23 (85.2)	1.80 (0.68)	0.8	1.38	1.76	2.10	4.2	
			Placebo	27	24 (88.9)	1.78 (0.62)	0.7	1.25	1.82	2.25	3.1	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Change from baseline	Week 2	Tezepelumab	27	23 (85.2)	0.14 (0.46)	-0.8	-0.13	0.13	0.47	1.4	0.02 [-0.54, 0.57]
			Placebo	27	27 (100.0)	0.14 (0.29)	-0.3	-0.05	0.01	0.31	1.0	
		Week 4	Tezepelumab	27	26 (96.3)	0.09 (0.40)	-1.0	-0.13	0.14	0.30	1.1	0.01 [-0.53, 0.55]
			Placebo	27	27 (100.0)	0.09 (0.33)	-0.6	-0.11	-0.02	0.34	1.1	
		Week 8	Tezepelumab	27	26 (96.3)	0.18 (0.43)	-0.5	-0.19	0.14	0.39	1.1	0.32 [-0.22, 0.87]
			Placebo	27	27 (100.0)	0.05 (0.33)	-0.8	-0.17	0.01	0.32	0.9	
		Week 12	Tezepelumab	27	26 (96.3)	0.23 (0.40)	-0.4	0.01	0.16	0.45	1.5	0.35 [-0.19, 0.90]
			Placebo	27	27 (100.0)	0.10 (0.32)	-0.4	-0.08	0.03	0.21	1.0	
		Week 16	Tezepelumab	27	25 (92.6)	0.07 (0.46)	-1.0	-0.11	0.01	0.23	1.4	-0.10 [-0.65, 0.45]
			Placebo	27	26 (96.3)	0.11 (0.35)	-0.6	-0.07	0.03	0.33	1.0	
		Week 24	Tezepelumab	27	23 (85.2)	0.17 (0.31)	-0.2	-0.08	0.13	0.38	1.1	0.48 [-0.10, 1.05]
			Placebo	27	25 (92.6)	0.02 (0.33)	-0.5	-0.19	-0.02	0.15	1.1	
		Week 36	Tezepelumab	27	23 (85.2)	0.14 (0.28)	-0.2	-0.12	0.04	0.45	0.7	-0.01 [-0.57, 0.55]
			Placebo	27	26 (96.3)	0.14 (0.25)	-0.2	0.02	0.09	0.16	1.0	
		Week 52	Tezepelumab	27	23 (85.2)	0.19 (0.37)	-0.3	-0.08	0.13	0.39	1.1	0.40 [-0.18, 0.97]
			Placebo	27	24 (88.9)	0.05 (0.34)	-0.5	-0.14	0.02	0.21	1.2	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Absolute values	Baseline	Tezepelumab	138	138 (100.0)	1.67 (0.65)	0.4	1.21	1.63	2.13	4.1	
			Placebo	143	143 (100.0)	1.75 (0.54)	0.4	1.37	1.71	2.06	3.1	
		Week 2	Tezepelumab	138	136 (98.6)	1.83 (0.66)	0.6	1.31	1.78	2.30	4.3	
			Placebo	143	139 (97.2)	1.83 (0.59)	0.4	1.46	1.73	2.18	3.9	
		Week 4	Tezepelumab	138	138 (100.0)	1.90 (0.66)	0.7	1.45	1.79	2.37	3.7	
			Placebo	143	143 (100.0)	1.81 (0.58)	0.4	1.44	1.72	2.13	3.7	
		Week 8	Tezepelumab	138	133 (96.4)	1.94 (0.65)	0.6	1.48	1.84	2.35	4.7	
			Placebo	143	143 (100.0)	1.82 (0.59)	0.4	1.41	1.78	2.13	4.3	
		Week 12	Tezepelumab	138	136 (98.6)	1.93 (0.65)	0.6	1.50	1.89	2.31	3.8	
			Placebo	143	141 (98.6)	1.84 (0.59)	0.7	1.50	1.76	2.19	4.3	
		Week 16	Tezepelumab	138	136 (98.6)	1.94 (0.70)	0.6	1.51	1.83	2.38	4.7	
			Placebo	143	140 (97.9)	1.84 (0.57)	0.7	1.52	1.76	2.14	4.4	
		Week 24	Tezepelumab	138	135 (97.8)	1.93 (0.63)	0.6	1.54	1.82	2.32	4.0	
			Placebo	143	138 (96.5)	1.83 (0.57)	0.7	1.45	1.73	2.10	4.3	
		Week 36	Tezepelumab	138	132 (95.7)	1.92 (0.70)	0.5	1.51	1.80	2.35	4.4	
			Placebo	143	132 (92.3)	1.80 (0.60)	0.7	1.43	1.69	2.13	4.3	
		Week 52	Tezepelumab	138	130 (94.2)	1.93 (0.68)	0.6	1.49	1.77	2.39	4.2	
			Placebo	143	130 (90.9)	1.79 (0.57)	0.7	1.44	1.70	2.12	3.4	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Change from baseline	Week 2	Tezepelumab	138	136 (98.6)	0.16 (0.34)	-0.6	-0.01	0.10	0.25	1.3	0.27 [0.03, 0.51]
			Placebo	143	139 (97.2)	0.07 (0.31)	-0.7	-0.09	0.04	0.19	1.2	
		Week 4	Tezepelumab	138	138 (100.0)	0.22 (0.37)	-0.9	0.02	0.15	0.37	1.8	0.46 [0.22, 0.70]
			Placebo	143	143 (100.0)	0.06 (0.35)	-0.9	-0.13	0.01	0.20	1.1	
		Week 8	Tezepelumab	138	133 (96.4)	0.26 (0.41)	-0.8	0.03	0.17	0.44	1.7	0.52 [0.28, 0.76]
			Placebo	143	143 (100.0)	0.07 (0.33)	-0.9	-0.15	0.02	0.24	1.6	
		Week 12	Tezepelumab	138	136 (98.6)	0.26 (0.43)	-0.7	0.04	0.20	0.45	2.0	0.47 [0.23, 0.71]
			Placebo	143	141 (98.6)	0.08 (0.35)	-1.1	-0.07	0.03	0.19	1.7	
		Week 16	Tezepelumab	138	136 (98.6)	0.27 (0.41)	-0.6	-0.00	0.20	0.46	1.7	0.51 [0.27, 0.74]
			Placebo	143	140 (97.9)	0.08 (0.34)	-1.0	-0.11	0.02	0.24	1.8	
		Week 24	Tezepelumab	138	135 (97.8)	0.25 (0.41)	-1.0	-0.02	0.20	0.43	1.6	0.47 [0.23, 0.71]
			Placebo	143	138 (96.5)	0.07 (0.36)	-1.1	-0.14	0.07	0.22	1.7	
		Week 36	Tezepelumab	138	132 (95.7)	0.25 (0.44)	-1.0	0.00	0.22	0.47	1.5	0.51 [0.26, 0.75]
			Placebo	143	132 (92.3)	0.04 (0.38)	-1.0	-0.21	0.01	0.27	1.7	
		Week 52	Tezepelumab	138	130 (94.2)	0.25 (0.42)	-1.0	-0.02	0.25	0.47	1.6	0.57 [0.32, 0.82]
			Placebo	143	130 (90.9)	0.03 (0.33)	-1.0	-0.20	0.01	0.23	0.8	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Absolute values	Baseline	Tezepelumab	18	18 (100.0)	1.66 (0.66)	0.7	1.26	1.64	2.04	3.3	
			Placebo	23	23 (100.0)	1.76 (0.44)	1.1	1.35	1.73	2.12	2.6	
		Week 2	Tezepelumab	18	17 (94.4)	1.79 (0.65)	0.6	1.39	1.71	2.13	3.3	
			Placebo	23	20 (87.0)	1.88 (0.43)	1.2	1.62	1.86	2.18	2.7	
		Week 4	Tezepelumab	18	18 (100.0)	1.82 (0.67)	0.6	1.37	1.76	2.18	3.3	
			Placebo	23	22 (95.7)	1.90 (0.40)	1.1	1.63	1.92	2.27	2.6	
		Week 8	Tezepelumab	18	18 (100.0)	1.77 (0.69)	0.6	1.30	1.85	2.17	3.4	
			Placebo	23	22 (95.7)	1.95 (0.50)	1.1	1.57	1.90	2.37	2.9	
		Week 12	Tezepelumab	18	18 (100.0)	1.76 (0.69)	0.6	1.31	1.80	2.16	3.2	
			Placebo	23	23 (100.0)	1.94 (0.44)	1.0	1.51	2.04	2.27	2.6	
		Week 16	Tezepelumab	18	17 (94.4)	1.84 (0.66)	0.6	1.50	1.80	2.21	3.2	
			Placebo	23	22 (95.7)	1.94 (0.50)	1.0	1.56	2.07	2.32	2.7	
		Week 24	Tezepelumab	18	16 (88.9)	1.82 (0.70)	0.6	1.30	1.85	2.39	3.1	
			Placebo	23	21 (91.3)	1.87 (0.46)	0.9	1.57	1.97	2.15	2.7	
		Week 36	Tezepelumab	18	17 (94.4)	1.80 (0.65)	0.7	1.37	1.83	2.12	3.2	
			Placebo	23	22 (95.7)	1.96 (0.48)	1.0	1.64	2.00	2.33	2.8	
		Week 52	Tezepelumab	18	17 (94.4)	1.79 (0.64)	0.7	1.32	1.79	2.23	3.1	
			Placebo	23	21 (91.3)	1.90 (0.48)	1.0	1.61	1.82	2.23	2.9	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Change from baseline	Week 2	Tezepelumab	18	17 (94.4)	0.08 (0.22)	-0.3	-0.03	0.05	0.12	0.6	-0.15 [-0.80, 0.50]
			Placebo	23	20 (87.0)	0.12 (0.24)	-0.6	-0.01	0.12	0.32	0.5	
		Week 4	Tezepelumab	18	18 (100.0)	0.16 (0.30)	-0.2	-0.04	0.08	0.29	1.1	0.03 [-0.59, 0.66]
			Placebo	23	22 (95.7)	0.15 (0.33)	-0.7	0.02	0.17	0.32	0.9	
		Week 8	Tezepelumab	18	18 (100.0)	0.11 (0.31)	-0.3	-0.05	0.09	0.19	1.2	-0.34 [-0.97, 0.29]
			Placebo	23	22 (95.7)	0.21 (0.25)	-0.5	0.07	0.22	0.40	0.6	
		Week 12	Tezepelumab	18	18 (100.0)	0.10 (0.31)	-0.2	-0.08	0.06	0.14	1.1	-0.30 [-0.92, 0.32]
			Placebo	23	23 (100.0)	0.18 (0.25)	-0.2	0.04	0.12	0.37	0.8	
		Week 16	Tezepelumab	18	17 (94.4)	0.13 (0.28)	-0.3	-0.05	0.09	0.18	1.1	-0.17 [-0.80, 0.47]
			Placebo	23	22 (95.7)	0.18 (0.30)	-0.4	-0.05	0.14	0.38	0.7	
		Week 24	Tezepelumab	18	16 (88.9)	0.10 (0.35)	-0.4	-0.10	0.08	0.22	1.2	-0.14 [-0.80, 0.51]
			Placebo	23	21 (91.3)	0.16 (0.40)	-0.7	-0.16	0.22	0.38	0.8	
		Week 36	Tezepelumab	18	17 (94.4)	0.09 (0.33)	-0.2	-0.04	0.03	0.13	1.3	-0.36 [-1.00, 0.28]
			Placebo	23	22 (95.7)	0.21 (0.33)	-0.5	-0.12	0.24	0.45	0.8	
		Week 52	Tezepelumab	18	17 (94.4)	0.08 (0.25)	-0.3	-0.03	0.06	0.19	0.8	-0.14 [-0.78, 0.50]
			Placebo	23	21 (91.3)	0.13 (0.39)	-0.6	-0.11	0.12	0.26	1.0	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Absolute values	Baseline	Tezepelumab	77	77 (100.0)	1.89 (0.68)	0.8	1.41	1.79	2.30	3.8	
			Placebo	73	73 (100.0)	1.86 (0.80)	0.7	1.26	1.75	2.34	4.2	
		Week 2	Tezepelumab	77	76 (98.7)	2.05 (0.73)	0.7	1.46	1.97	2.45	4.0	
			Placebo	73	70 (95.9)	1.96 (0.82)	0.6	1.36	1.82	2.49	4.0	
		Week 4	Tezepelumab	77	77 (100.0)	2.08 (0.73)	0.7	1.61	2.09	2.53	4.3	
			Placebo	73	72 (98.6)	1.94 (0.82)	0.7	1.32	1.85	2.53	4.2	
		Week 8	Tezepelumab	77	77 (100.0)	2.10 (0.76)	0.8	1.58	2.11	2.53	4.7	
			Placebo	73	68 (93.2)	2.01 (0.82)	0.7	1.34	2.04	2.57	4.3	
		Week 12	Tezepelumab	77	74 (96.1)	2.06 (0.77)	0.8	1.54	2.03	2.39	4.7	
			Placebo	73	69 (94.5)	1.92 (0.87)	0.6	1.25	1.70	2.54	4.3	
		Week 16	Tezepelumab	77	74 (96.1)	2.15 (0.77)	0.7	1.65	2.07	2.51	4.9	
			Placebo	73	69 (94.5)	1.90 (0.79)	0.7	1.31	1.77	2.32	4.1	
		Week 24	Tezepelumab	77	73 (94.8)	2.09 (0.70)	0.7	1.69	2.05	2.43	4.4	
			Placebo	73	62 (84.9)	1.93 (0.85)	0.6	1.25	2.02	2.28	4.8	
		Week 36	Tezepelumab	77	71 (92.2)	2.11 (0.73)	0.8	1.56	2.07	2.50	4.5	
			Placebo	73	60 (82.2)	2.07 (0.80)	0.8	1.46	2.02	2.56	4.6	
		Week 52	Tezepelumab	77	68 (88.3)	2.10 (0.74)	0.8	1.65	2.07	2.50	4.1	
			Placebo	73	58 (79.5)	2.10 (0.85)	0.7	1.34	1.99	2.64	4.4	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Change from baseline	Week 2	Tezepelumab	77	76 (98.7)	0.16 (0.30)	-0.6	-0.01	0.13	0.32	1.1	0.24 [-0.09, 0.57]
			Placebo	73	70 (95.9)	0.08 (0.38)	-0.8	-0.12	0.00	0.20	1.7	
		Week 4	Tezepelumab	77	77 (100.0)	0.19 (0.36)	-0.7	-0.05	0.14	0.31	1.4	0.32 [-0.00, 0.65]
			Placebo	73	72 (98.6)	0.08 (0.36)	-0.7	-0.11	0.03	0.26	1.4	
		Week 8	Tezepelumab	77	77 (100.0)	0.21 (0.44)	-0.6	-0.08	0.10	0.44	1.8	0.22 [-0.10, 0.55]
			Placebo	73	68 (93.2)	0.11 (0.45)	-0.8	-0.12	0.04	0.32	2.1	
		Week 12	Tezepelumab	77	74 (96.1)	0.18 (0.44)	-0.8	-0.09	0.12	0.38	1.9	0.28 [-0.05, 0.61]
			Placebo	73	69 (94.5)	0.07 (0.36)	-0.7	-0.11	0.02	0.22	1.2	
		Week 16	Tezepelumab	77	74 (96.1)	0.24 (0.44)	-0.8	-0.04	0.16	0.40	2.0	0.49 [0.16, 0.82]
			Placebo	73	69 (94.5)	0.03 (0.40)	-1.2	-0.16	0.01	0.18	1.4	
		Week 24	Tezepelumab	77	73 (94.8)	0.19 (0.38)	-0.5	-0.06	0.15	0.40	1.5	0.39 [0.05, 0.73]
			Placebo	73	62 (84.9)	0.04 (0.41)	-0.9	-0.15	-0.03	0.19	1.6	
		Week 36	Tezepelumab	77	71 (92.2)	0.19 (0.40)	-0.5	-0.08	0.12	0.46	1.7	0.15 [-0.20, 0.49]
			Placebo	73	60 (82.2)	0.13 (0.42)	-1.1	-0.08	0.14	0.38	1.5	
		Week 52	Tezepelumab	77	68 (88.3)	0.18 (0.38)	-0.6	-0.08	0.17	0.35	1.3	0.06 [-0.29, 0.42]
			Placebo	73	58 (79.5)	0.15 (0.40)	-0.8	-0.05	0.11	0.32	1.6	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Absolute values	Baseline	Tezepelumab	170	170 (100.0)	1.81 (0.70)	0.6	1.33	1.64	2.12	4.8	
			Placebo	169	169 (100.0)	1.87 (0.71)	0.6	1.34	1.79	2.23	4.5	
		Week 2	Tezepelumab	170	164 (96.5)	1.99 (0.72)	0.8	1.46	1.83	2.48	5.0	
			Placebo	169	161 (95.3)	1.96 (0.71)	0.6	1.42	1.93	2.32	4.1	
		Week 4	Tezepelumab	170	167 (98.2)	1.99 (0.75)	0.7	1.46	1.89	2.50	5.0	
			Placebo	169	162 (95.9)	1.95 (0.70)	0.5	1.45	1.92	2.29	4.8	
		Week 8	Tezepelumab	170	166 (97.6)	2.01 (0.77)	0.7	1.41	1.88	2.45	4.6	
			Placebo	169	165 (97.6)	1.97 (0.75)	0.6	1.47	1.87	2.28	4.6	
		Week 12	Tezepelumab	170	164 (96.5)	2.04 (0.78)	0.8	1.54	1.87	2.46	4.9	
			Placebo	169	166 (98.2)	1.97 (0.73)	0.5	1.43	1.89	2.40	4.6	
		Week 16	Tezepelumab	170	163 (95.9)	2.02 (0.79)	0.8	1.48	1.84	2.48	4.9	
			Placebo	169	163 (96.4)	1.98 (0.77)	0.5	1.38	1.88	2.43	4.7	
		Week 24	Tezepelumab	170	156 (91.8)	1.99 (0.78)	0.7	1.41	1.82	2.53	5.5	
			Placebo	169	158 (93.5)	1.97 (0.74)	0.6	1.46	1.90	2.28	4.8	
		Week 36	Tezepelumab	170	152 (89.4)	2.01 (0.79)	0.7	1.44	1.87	2.36	4.9	
			Placebo	169	161 (95.3)	2.01 (0.75)	0.6	1.44	1.98	2.35	4.3	
		Week 52	Tezepelumab	170	149 (87.6)	2.02 (0.79)	0.6	1.43	1.84	2.41	4.6	
			Placebo	169	146 (86.4)	2.00 (0.79)	0.6	1.40	1.92	2.41	4.5	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Change from baseline	Week 2	Tezepelumab	170	164 (96.5)	0.18 (0.33)	-0.7	0.00	0.13	0.31	1.5	0.32 [0.11, 0.54]
			Placebo	169	161 (95.3)	0.07 (0.38)	-1.8	-0.10	0.01	0.21	1.1	
		Week 4	Tezepelumab	170	167 (98.2)	0.18 (0.34)	-0.9	-0.05	0.12	0.34	1.3	0.26 [0.04, 0.47]
			Placebo	169	162 (95.9)	0.09 (0.38)	-1.8	-0.07	0.06	0.25	1.6	
		Week 8	Tezepelumab	170	166 (97.6)	0.21 (0.43)	-0.9	-0.05	0.11	0.39	1.9	0.31 [0.10, 0.53]
			Placebo	169	165 (97.6)	0.09 (0.32)	-1.1	-0.10	0.09	0.28	1.4	
		Week 12	Tezepelumab	170	164 (96.5)	0.22 (0.38)	-0.6	0.00	0.14	0.40	2.2	0.33 [0.11, 0.55]
			Placebo	169	166 (98.2)	0.09 (0.42)	-1.5	-0.10	0.05	0.28	1.4	
		Week 16	Tezepelumab	170	163 (95.9)	0.22 (0.40)	-0.8	-0.02	0.15	0.35	2.1	0.31 [0.09, 0.53]
			Placebo	169	163 (96.4)	0.10 (0.36)	-0.7	-0.11	0.05	0.27	1.5	
		Week 24	Tezepelumab	170	156 (91.8)	0.21 (0.40)	-0.7	-0.07	0.13	0.38	1.6	0.31 [0.09, 0.53]
			Placebo	169	158 (93.5)	0.09 (0.36)	-0.9	-0.11	0.05	0.25	1.6	
		Week 36	Tezepelumab	170	152 (89.4)	0.21 (0.39)	-0.8	-0.05	0.15	0.39	1.6	0.23 [0.01, 0.45]
			Placebo	169	161 (95.3)	0.12 (0.39)	-0.8	-0.12	0.04	0.27	1.6	
		Week 52	Tezepelumab	170	149 (87.6)	0.22 (0.42)	-0.8	-0.03	0.12	0.46	1.7	0.27 [0.04, 0.50]
			Placebo	169	146 (86.4)	0.11 (0.40)	-0.9	-0.15	0.05	0.27	2.0	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Absolute values	Baseline	Tezepelumab	129	129 (100.0)	1.71 (0.67)	0.4	1.24	1.68	2.15	4.1	
			Placebo	134	134 (100.0)	1.74 (0.55)	0.4	1.37	1.69	2.06	3.1	
		Week 2	Tezepelumab	129	127 (98.4)	1.87 (0.68)	0.6	1.30	1.79	2.31	4.3	
			Placebo	134	129 (96.3)	1.81 (0.60)	0.4	1.45	1.71	2.13	3.9	
		Week 4	Tezepelumab	129	129 (100.0)	1.93 (0.68)	0.7	1.45	1.91	2.41	3.7	
			Placebo	134	133 (99.3)	1.79 (0.58)	0.4	1.44	1.69	2.07	3.7	
		Week 8	Tezepelumab	129	125 (96.9)	1.99 (0.68)	0.6	1.48	1.89	2.41	4.7	
			Placebo	134	133 (99.3)	1.83 (0.61)	0.4	1.41	1.78	2.13	4.3	
		Week 12	Tezepelumab	129	126 (97.7)	1.96 (0.67)	0.6	1.50	1.92	2.38	3.8	
			Placebo	134	131 (97.8)	1.84 (0.61)	0.7	1.48	1.73	2.21	4.3	
		Week 16	Tezepelumab	129	127 (98.4)	1.99 (0.72)	0.6	1.52	1.86	2.47	4.7	
			Placebo	134	129 (96.3)	1.85 (0.59)	0.7	1.49	1.76	2.14	4.4	
		Week 24	Tezepelumab	129	126 (97.7)	1.95 (0.64)	0.7	1.56	1.82	2.34	4.0	
			Placebo	134	126 (94.0)	1.84 (0.58)	0.7	1.45	1.73	2.11	4.3	
		Week 36	Tezepelumab	129	121 (93.8)	1.95 (0.71)	0.6	1.51	1.80	2.40	4.4	
			Placebo	134	119 (88.8)	1.83 (0.62)	0.7	1.46	1.71	2.13	4.3	
		Week 52	Tezepelumab	129	121 (93.8)	1.95 (0.69)	0.6	1.49	1.77	2.37	4.2	
			Placebo	134	116 (86.6)	1.79 (0.58)	0.7	1.43	1.69	2.10	3.4	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Change from baseline	Week 2	Tezepelumab	129	127 (98.4)	0.16 (0.34)	-0.6	-0.01	0.09	0.25	1.3	0.29 [0.05, 0.54]
			Placebo	134	129 (96.3)	0.06 (0.32)	-0.7	-0.10	0.04	0.19	1.2	
		Week 4	Tezepelumab	129	129 (100.0)	0.22 (0.37)	-0.9	0.02	0.14	0.35	1.8	0.47 [0.22, 0.71]
			Placebo	134	133 (99.3)	0.05 (0.34)	-0.7	-0.13	0.01	0.20	1.1	
		Week 8	Tezepelumab	129	125 (96.9)	0.27 (0.41)	-0.8	0.03	0.17	0.50	1.7	0.49 [0.25, 0.74]
			Placebo	134	133 (99.3)	0.09 (0.33)	-0.7	-0.13	0.04	0.25	1.6	
		Week 12	Tezepelumab	129	126 (97.7)	0.27 (0.44)	-0.7	0.05	0.20	0.45	2.0	0.47 [0.22, 0.71]
			Placebo	134	131 (97.8)	0.09 (0.34)	-0.9	-0.07	0.03	0.19	1.7	
		Week 16	Tezepelumab	129	127 (98.4)	0.27 (0.42)	-0.6	0.00	0.20	0.45	1.7	0.48 [0.23, 0.73]
			Placebo	134	129 (96.3)	0.09 (0.34)	-0.8	-0.10	0.02	0.26	1.8	
		Week 24	Tezepelumab	129	126 (97.7)	0.25 (0.41)	-1.0	0.00	0.19	0.43	1.6	0.44 [0.19, 0.69]
			Placebo	134	126 (94.0)	0.07 (0.36)	-0.9	-0.14	0.07	0.27	1.7	
		Week 36	Tezepelumab	129	121 (93.8)	0.25 (0.44)	-1.0	0.00	0.21	0.42	1.5	0.45 [0.19, 0.70]
			Placebo	134	119 (88.8)	0.06 (0.39)	-1.0	-0.20	0.02	0.29	1.7	
		Week 52	Tezepelumab	129	121 (93.8)	0.24 (0.43)	-1.0	-0.01	0.19	0.47	1.6	0.53 [0.27, 0.79]
			Placebo	134	116 (86.6)	0.04 (0.33)	-1.0	-0.19	0.01	0.23	0.8	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Absolute values	Baseline	Tezepelumab	111	111 (100.0)	1.64 (0.63)	0.6	1.19	1.56	2.01	3.5	
			Placebo	114	114 (100.0)	1.64 (0.54)	0.8	1.26	1.54	1.88	4.0	
		Week 2	Tezepelumab	111	107 (96.4)	1.83 (0.66)	0.6	1.34	1.68	2.26	3.8	
			Placebo	114	108 (94.7)	1.66 (0.56)	0.7	1.25	1.60	1.98	3.6	
		Week 4	Tezepelumab	111	110 (99.1)	1.83 (0.69)	0.6	1.27	1.72	2.26	3.8	
			Placebo	114	111 (97.4)	1.76 (0.59)	0.7	1.33	1.67	2.07	4.1	
		Week 8	Tezepelumab	111	110 (99.1)	1.84 (0.64)	0.6	1.35	1.73	2.30	3.8	
			Placebo	114	112 (98.2)	1.75 (0.62)	0.7	1.35	1.68	2.02	4.7	
		Week 12	Tezepelumab	111	109 (98.2)	1.87 (0.66)	0.6	1.35	1.82	2.45	3.8	
			Placebo	114	109 (95.6)	1.77 (0.65)	0.6	1.33	1.63	2.14	4.6	
		Week 16	Tezepelumab	111	107 (96.4)	1.87 (0.68)	0.6	1.34	1.80	2.33	3.8	
			Placebo	114	108 (94.7)	1.76 (0.63)	0.8	1.30	1.69	2.13	4.7	
		Week 24	Tezepelumab	111	105 (94.6)	1.87 (0.70)	0.6	1.38	1.78	2.38	4.0	
			Placebo	114	107 (93.9)	1.72 (0.62)	0.7	1.34	1.62	2.10	4.6	
		Week 36	Tezepelumab	111	102 (91.9)	1.86 (0.67)	0.5	1.33	1.82	2.36	3.8	
			Placebo	114	100 (87.7)	1.71 (0.59)	0.8	1.34	1.63	2.07	4.3	
		Week 52	Tezepelumab	111	99 (89.2)	1.87 (0.68)	0.7	1.37	1.77	2.37	3.7	
			Placebo	114	98 (86.0)	1.68 (0.60)	0.8	1.27	1.60	1.97	4.4	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Change from baseline	Week 2	Tezepelumab	111	107 (96.4)	0.17 (0.36)	-0.8	-0.05	0.10	0.28	1.9	0.49 [0.22, 0.76]
			Placebo	114	108 (94.7)	0.01 (0.28)	-0.8	-0.12	0.01	0.12	1.0	
		Week 4	Tezepelumab	111	110 (99.1)	0.19 (0.39)	-1.0	-0.04	0.12	0.36	1.7	0.19 [-0.08, 0.45]
			Placebo	114	111 (97.4)	0.12 (0.38)	-1.0	-0.09	0.06	0.35	1.2	
		Week 8	Tezepelumab	111	110 (99.1)	0.22 (0.33)	-0.5	0.01	0.16	0.34	1.2	0.30 [0.03, 0.56]
			Placebo	114	112 (98.2)	0.11 (0.39)	-0.9	-0.08	0.03	0.24	1.8	
		Week 12	Tezepelumab	111	109 (98.2)	0.24 (0.36)	-0.4	-0.03	0.17	0.44	1.5	0.28 [0.01, 0.54]
			Placebo	114	109 (95.6)	0.14 (0.39)	-1.1	-0.06	0.05	0.23	2.1	
		Week 16	Tezepelumab	111	107 (96.4)	0.22 (0.44)	-1.0	-0.04	0.15	0.45	1.8	0.22 [-0.05, 0.49]
			Placebo	114	108 (94.7)	0.13 (0.36)	-1.0	-0.06	0.08	0.29	1.9	
		Week 24	Tezepelumab	111	105 (94.6)	0.23 (0.44)	-1.0	-0.05	0.14	0.43	2.1	0.32 [0.05, 0.59]
			Placebo	114	107 (93.9)	0.10 (0.37)	-1.1	-0.10	0.04	0.27	1.7	
		Week 36	Tezepelumab	111	102 (91.9)	0.20 (0.39)	-0.4	-0.07	0.10	0.39	1.8	0.28 [0.00, 0.56]
			Placebo	114	100 (87.7)	0.10 (0.36)	-0.9	-0.09	0.05	0.28	1.6	
		Week 52	Tezepelumab	111	99 (89.2)	0.21 (0.41)	-0.5	-0.08	0.13	0.37	1.5	0.36 [0.08, 0.64]
			Placebo	114	98 (86.0)	0.07 (0.40)	-1.0	-0.14	0.05	0.21	2.3	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
< 18.5 kg/m**2	Absolute values	Baseline	Tezepelumab	4	4 (100.0)	2.11 (0.78)	1.3	1.45	2.16	2.78	2.8	
			Placebo	4	4 (100.0)	2.05 (0.95)	1.0	1.32	2.04	2.79	3.2	
		Week 2	Tezepelumab	4	4 (100.0)	1.91 (0.87)	1.0	1.20	1.89	2.63	2.9	
			Placebo	4	4 (100.0)	2.11 (0.97)	1.1	1.38	1.98	2.84	3.4	
		Week 4	Tezepelumab	4	4 (100.0)	2.01 (0.77)	1.3	1.48	1.84	2.53	3.1	
			Placebo	4	4 (100.0)	2.02 (0.95)	1.2	1.27	1.82	2.77	3.2	
		Week 8	Tezepelumab	4	4 (100.0)	2.11 (0.82)	1.5	1.57	1.81	2.65	3.3	
			Placebo	4	4 (100.0)	2.23 (0.87)	1.5	1.55	2.00	2.91	3.4	
		Week 12	Tezepelumab	4	4 (100.0)	2.00 (0.92)	1.2	1.32	1.76	2.68	3.3	
			Placebo	4	4 (100.0)	2.17 (1.10)	1.0	1.35	2.08	3.00	3.6	
		Week 16	Tezepelumab	4	4 (100.0)	2.11 (0.79)	1.4	1.51	1.93	2.71	3.2	
			Placebo	4	4 (100.0)	2.04 (0.96)	1.1	1.28	1.93	2.81	3.2	
		Week 24	Tezepelumab	4	4 (100.0)	2.08 (0.90)	1.4	1.39	1.82	2.76	3.3	
			Placebo	4	4 (100.0)	2.19 (0.81)	1.3	1.58	2.19	2.81	3.1	
		Week 36	Tezepelumab	4	4 (100.0)	1.99 (0.94)	1.3	1.29	1.73	2.70	3.3	
			Placebo	4	4 (100.0)	2.07 (0.77)	1.3	1.43	2.00	2.71	3.0	
		Week 52	Tezepelumab	4	4 (100.0)	1.86 (0.86)	1.1	1.29	1.63	2.44	3.1	
			Placebo	4	2 (50.0)	2.43 (0.64)	2.0	1.97	2.43	2.88	2.9	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
< 18.5 kg/m**2	Change from baseline	Week 2	Tezepelumab	4	4 (100.0)	-0.20 (0.39)	-0.6	-0.54	-0.19	0.13	0.2	-0.57 [-1.99, 0.85]
			Placebo	4	4 (100.0)	0.06 (0.51)	-0.5	-0.32	0.05	0.43	0.7	
		Week 4	Tezepelumab	4	4 (100.0)	-0.11 (0.52)	-0.9	-0.45	0.03	0.23	0.4	-0.16 [-1.55, 1.23]
			Placebo	4	4 (100.0)	-0.04 (0.36)	-0.5	-0.30	-0.03	0.22	0.4	
		Week 8	Tezepelumab	4	4 (100.0)	-0.01 (0.61)	-0.8	-0.45	0.12	0.44	0.6	-0.38 [-1.78, 1.03]
			Placebo	4	4 (100.0)	0.18 (0.30)	-0.1	-0.04	0.12	0.40	0.6	
		Week 12	Tezepelumab	4	4 (100.0)	-0.11 (0.52)	-0.7	-0.45	-0.13	0.22	0.5	-0.41 [-1.82, 1.00]
			Placebo	4	4 (100.0)	0.12 (0.61)	-0.7	-0.33	0.21	0.57	0.8	
		Week 16	Tezepelumab	4	4 (100.0)	-0.00 (0.42)	-0.6	-0.28	0.06	0.28	0.4	0.02 [-1.37, 1.40]
			Placebo	4	4 (100.0)	-0.01 (0.46)	-0.6	-0.31	0.01	0.29	0.5	
		Week 24	Tezepelumab	4	4 (100.0)	-0.04 (0.48)	-0.6	-0.40	-0.06	0.32	0.5	-0.50 [-1.91, 0.91]
			Placebo	4	4 (100.0)	0.14 (0.15)	-0.0	0.02	0.15	0.26	0.3	
		Week 36	Tezepelumab	4	4 (100.0)	-0.12 (0.52)	-0.7	-0.48	-0.16	0.24	0.5	-0.29 [-1.68, 1.11]
			Placebo	4	4 (100.0)	0.02 (0.41)	-0.3	-0.28	-0.08	0.31	0.6	
		Week 52	Tezepelumab	4	4 (100.0)	-0.25 (0.57)	-1.0	-0.62	-0.16	0.12	0.4	-0.47 [-2.20, 1.26]
			Placebo	4	2 (50.0)	0.01 (0.42)	-0.3	-0.29	0.01	0.30	0.3	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Absolute values	Baseline	Tezepelumab	137	137 (100.0)	1.69 (0.68)	0.4	1.23	1.61	1.99	4.8	
			Placebo	153	153 (100.0)	1.84 (0.68)	0.4	1.40	1.75	2.18	4.5	
		Week 2	Tezepelumab	137	133 (97.1)	1.89 (0.72)	0.6	1.34	1.80	2.30	5.0	
			Placebo	153	146 (95.4)	1.94 (0.68)	0.4	1.44	1.86	2.40	3.9	
		Week 4	Tezepelumab	137	137 (100.0)	1.93 (0.70)	0.7	1.46	1.81	2.35	5.0	
			Placebo	153	150 (98.0)	1.93 (0.68)	0.4	1.49	1.83	2.26	4.1	
		Week 8	Tezepelumab	137	135 (98.5)	1.98 (0.72)	0.6	1.43	1.84	2.44	4.6	
			Placebo	153	152 (99.3)	1.94 (0.70)	0.4	1.42	1.86	2.34	4.1	
		Week 12	Tezepelumab	137	137 (100.0)	1.99 (0.71)	0.6	1.54	1.83	2.41	4.9	
			Placebo	153	148 (96.7)	1.97 (0.71)	0.7	1.47	1.82	2.40	4.1	
		Week 16	Tezepelumab	137	131 (95.6)	2.01 (0.76)	0.6	1.52	1.87	2.51	4.9	
			Placebo	153	146 (95.4)	1.95 (0.70)	0.7	1.51	1.82	2.28	4.3	
		Week 24	Tezepelumab	137	133 (97.1)	1.95 (0.73)	0.7	1.51	1.80	2.39	5.5	
			Placebo	153	142 (92.8)	1.95 (0.68)	0.7	1.45	1.86	2.27	4.3	
		Week 36	Tezepelumab	137	127 (92.7)	1.99 (0.73)	0.6	1.50	1.86	2.47	4.9	
			Placebo	153	134 (87.6)	1.95 (0.73)	0.7	1.44	1.83	2.33	4.2	
		Week 52	Tezepelumab	137	121 (88.3)	1.97 (0.72)	0.8	1.50	1.76	2.39	4.6	
			Placebo	153	134 (87.6)	1.93 (0.73)	0.7	1.46	1.76	2.29	4.5	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Change from baseline	Week 2	Tezepelumab	137	133 (97.1)	0.21 (0.34)	-0.4	-0.01	0.13	0.33	1.4	0.41 [0.17, 0.65]
			Placebo	153	146 (95.4)	0.07 (0.35)	-1.1	-0.08	0.04	0.18	1.7	
		Week 4	Tezepelumab	137	137 (100.0)	0.24 (0.38)	-0.7	0.01	0.18	0.41	1.8	0.38 [0.14, 0.61]
			Placebo	153	150 (98.0)	0.09 (0.41)	-1.8	-0.10	0.05	0.28	1.4	
		Week 8	Tezepelumab	137	135 (98.5)	0.29 (0.43)	-0.6	0.00	0.17	0.52	1.7	0.48 [0.24, 0.71]
			Placebo	153	152 (99.3)	0.10 (0.37)	-0.9	-0.13	0.04	0.29	2.1	
		Week 12	Tezepelumab	137	137 (100.0)	0.30 (0.42)	-0.6	0.02	0.21	0.47	2.0	0.45 [0.22, 0.69]
			Placebo	153	148 (96.7)	0.12 (0.37)	-1.1	-0.07	0.05	0.30	1.2	
		Week 16	Tezepelumab	137	131 (95.6)	0.33 (0.44)	-0.6	0.02	0.22	0.59	1.7	0.53 [0.29, 0.77]
			Placebo	153	146 (95.4)	0.11 (0.38)	-1.2	-0.09	0.06	0.34	1.5	
		Week 24	Tezepelumab	137	133 (97.1)	0.26 (0.43)	-1.0	-0.03	0.19	0.49	1.6	0.41 [0.17, 0.65]
			Placebo	153	142 (92.8)	0.09 (0.41)	-1.1	-0.13	0.05	0.32	1.6	
		Week 36	Tezepelumab	137	127 (92.7)	0.29 (0.43)	-1.0	0.00	0.26	0.53	1.5	0.46 [0.21, 0.70]
			Placebo	153	134 (87.6)	0.10 (0.42)	-1.1	-0.15	0.07	0.27	1.5	
		Week 52	Tezepelumab	137	121 (88.3)	0.27 (0.40)	-0.7	0.00	0.22	0.49	1.6	0.51 [0.26, 0.76]
			Placebo	153	134 (87.6)	0.07 (0.39)	-1.0	-0.14	0.06	0.26	1.6	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	169	169 (100.0)	1.85 (0.72)	0.6	1.34	1.76	2.27	4.1	
			Placebo	154	154 (100.0)	1.80 (0.64)	0.6	1.35	1.70	2.19	4.1	
		Week 2	Tezepelumab	169	168 (99.4)	2.02 (0.75)	0.7	1.47	1.89	2.47	4.3	
			Placebo	154	146 (94.8)	1.86 (0.67)	0.6	1.38	1.73	2.34	4.1	
		Week 4	Tezepelumab	169	167 (98.8)	2.05 (0.78)	0.7	1.48	1.97	2.60	4.3	
			Placebo	154	149 (96.8)	1.88 (0.68)	0.5	1.38	1.74	2.32	4.8	
		Week 8	Tezepelumab	169	166 (98.2)	2.08 (0.79)	0.7	1.50	1.97	2.51	4.7	
			Placebo	154	150 (97.4)	1.91 (0.74)	0.6	1.36	1.79	2.28	4.7	
		Week 12	Tezepelumab	169	163 (96.4)	2.08 (0.80)	0.7	1.52	1.96	2.64	4.7	
			Placebo	154	148 (96.1)	1.92 (0.72)	0.5	1.40	1.84	2.34	4.6	
		Week 16	Tezepelumab	169	165 (97.6)	2.09 (0.83)	0.6	1.50	1.97	2.62	4.9	
			Placebo	154	147 (95.5)	1.90 (0.74)	0.5	1.33	1.83	2.29	4.7	
		Week 24	Tezepelumab	169	158 (93.5)	2.07 (0.74)	0.6	1.60	2.00	2.55	4.4	
			Placebo	154	139 (90.3)	1.90 (0.73)	0.7	1.40	1.80	2.25	4.8	
		Week 36	Tezepelumab	169	154 (91.1)	2.06 (0.80)	0.5	1.51	2.00	2.49	4.5	
			Placebo	154	138 (89.6)	1.94 (0.73)	0.6	1.37	1.85	2.40	4.3	
		Week 52	Tezepelumab	169	154 (91.1)	2.08 (0.78)	0.6	1.58	2.00	2.52	4.3	
			Placebo	154	125 (81.2)	1.90 (0.71)	0.6	1.32	1.79	2.33	4.4	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Change from baseline	Week 2	Tezepelumab	169	168 (99.4)	0.17 (0.36)	-0.8	-0.03	0.11	0.29	1.9	0.36 [0.14, 0.59]
			Placebo	154	146 (94.8)	0.04 (0.34)	-0.7	-0.14	0.01	0.17	1.2	
		Week 4	Tezepelumab	169	167 (98.8)	0.21 (0.38)	-1.0	-0.03	0.14	0.34	1.7	0.31 [0.09, 0.53]
			Placebo	154	149 (96.8)	0.09 (0.36)	-0.7	-0.11	0.04	0.23	1.6	
		Week 8	Tezepelumab	169	166 (98.2)	0.24 (0.41)	-0.8	0.01	0.16	0.41	1.9	0.35 [0.13, 0.57]
			Placebo	154	150 (97.4)	0.11 (0.37)	-1.1	-0.10	0.08	0.24	1.8	
		Week 12	Tezepelumab	169	163 (96.4)	0.25 (0.43)	-0.6	-0.03	0.17	0.40	2.2	0.32 [0.09, 0.54]
			Placebo	154	148 (96.1)	0.12 (0.37)	-0.7	-0.10	0.04	0.25	1.8	
		Week 16	Tezepelumab	169	165 (97.6)	0.26 (0.45)	-1.0	-0.04	0.16	0.40	2.1	0.38 [0.16, 0.61]
			Placebo	154	147 (95.5)	0.09 (0.39)	-1.0	-0.14	0.01	0.24	1.9	
		Week 24	Tezepelumab	169	158 (93.5)	0.25 (0.41)	-0.7	-0.02	0.20	0.41	2.1	0.39 [0.16, 0.62]
			Placebo	154	139 (90.3)	0.09 (0.39)	-0.6	-0.14	0.03	0.27	1.7	
		Week 36	Tezepelumab	169	154 (91.1)	0.23 (0.43)	-0.8	-0.05	0.14	0.43	1.8	0.28 [0.05, 0.51]
			Placebo	154	138 (89.6)	0.11 (0.40)	-0.7	-0.14	0.04	0.31	1.7	
		Week 52	Tezepelumab	169	154 (91.1)	0.25 (0.43)	-0.8	-0.04	0.19	0.47	1.7	0.43 [0.19, 0.67]
			Placebo	154	125 (81.2)	0.07 (0.39)	-0.9	-0.17	0.01	0.23	1.5	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	177	177 (100.0)	1.72 (0.63)	0.6	1.27	1.61	2.09	4.0	
			Placebo	179	179 (100.0)	1.70 (0.63)	0.7	1.26	1.59	2.04	4.2	
		Week 2	Tezepelumab	177	169 (95.5)	1.87 (0.63)	0.6	1.39	1.80	2.37	4.1	
			Placebo	179	172 (96.1)	1.75 (0.66)	0.6	1.28	1.65	2.07	4.0	
		Week 4	Tezepelumab	177	175 (98.9)	1.88 (0.65)	0.6	1.37	1.80	2.35	4.2	
			Placebo	179	175 (97.8)	1.78 (0.64)	0.7	1.33	1.71	2.07	4.2	
		Week 8	Tezepelumab	177	173 (97.7)	1.88 (0.64)	0.6	1.33	1.82	2.35	4.1	
			Placebo	179	172 (96.1)	1.81 (0.66)	0.7	1.36	1.70	2.12	4.3	
		Week 12	Tezepelumab	177	169 (95.5)	1.88 (0.65)	0.6	1.37	1.81	2.31	4.6	
			Placebo	179	175 (97.8)	1.76 (0.66)	0.6	1.33	1.64	2.08	4.3	
		Week 16	Tezepelumab	177	171 (96.6)	1.89 (0.64)	0.6	1.38	1.83	2.30	4.2	
			Placebo	179	172 (96.1)	1.79 (0.64)	0.6	1.33	1.70	2.11	4.1	
		Week 24	Tezepelumab	177	165 (93.2)	1.88 (0.67)	0.6	1.38	1.78	2.35	4.0	
			Placebo	179	168 (93.9)	1.77 (0.65)	0.6	1.38	1.69	2.11	4.8	
		Week 36	Tezepelumab	177	161 (91.0)	1.88 (0.66)	0.7	1.39	1.79	2.30	4.4	
			Placebo	179	164 (91.6)	1.82 (0.65)	0.7	1.44	1.71	2.20	4.6	
		Week 52	Tezepelumab	177	158 (89.3)	1.89 (0.68)	0.6	1.36	1.83	2.29	4.2	
			Placebo	179	157 (87.7)	1.82 (0.71)	0.6	1.32	1.71	2.18	4.4	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Change from baseline	Week 2	Tezepelumab	177	169 (95.5)	0.14 (0.29)	-0.7	0.00	0.10	0.28	1.1	0.29 [0.08, 0.51]
			Placebo	179	172 (96.1)	0.05 (0.34)	-1.8	-0.11	-0.01	0.18	1.1	
		Week 4	Tezepelumab	177	175 (98.9)	0.16 (0.31)	-0.9	-0.04	0.11	0.31	1.1	0.25 [0.04, 0.46]
			Placebo	179	175 (97.8)	0.08 (0.34)	-1.0	-0.08	0.05	0.25	1.1	
		Week 8	Tezepelumab	177	173 (97.7)	0.17 (0.37)	-0.9	-0.05	0.11	0.33	1.4	0.23 [0.02, 0.45]
			Placebo	179	172 (96.1)	0.09 (0.34)	-0.8	-0.10	0.03	0.25	1.8	
		Week 12	Tezepelumab	177	169 (95.5)	0.17 (0.35)	-0.8	-0.03	0.12	0.33	1.3	0.31 [0.09, 0.52]
			Placebo	179	175 (97.8)	0.06 (0.40)	-1.5	-0.11	0.04	0.21	2.1	
		Week 16	Tezepelumab	177	171 (96.6)	0.16 (0.36)	-0.8	-0.04	0.13	0.31	1.4	0.22 [0.00, 0.43]
			Placebo	179	172 (96.1)	0.09 (0.32)	-0.8	-0.08	0.05	0.23	1.3	
		Week 24	Tezepelumab	177	165 (93.2)	0.17 (0.38)	-1.0	-0.09	0.08	0.34	1.7	0.29 [0.08, 0.51]
			Placebo	179	168 (93.9)	0.06 (0.32)	-0.9	-0.10	0.04	0.22	1.3	
		Week 36	Tezepelumab	177	161 (91.0)	0.15 (0.35)	-0.6	-0.09	0.08	0.34	1.6	0.16 [-0.06, 0.38]
			Placebo	179	164 (91.6)	0.10 (0.35)	-0.9	-0.13	0.05	0.28	1.6	
		Week 52	Tezepelumab	177	158 (89.3)	0.16 (0.40)	-1.0	-0.07	0.10	0.34	1.4	0.12 [-0.10, 0.34]
			Placebo	179	157 (87.7)	0.11 (0.37)	-0.8	-0.10	0.08	0.23	2.3	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Absolute values	Baseline	Tezepelumab	130	130 (100.0)	1.86 (0.68)	0.4	1.34	1.87	2.28	4.0	
			Placebo	132	132 (100.0)	1.80 (0.58)	0.8	1.38	1.75	2.17	3.4	
		Week 2	Tezepelumab	130	127 (97.7)	1.94 (0.70)	0.6	1.38	1.92	2.41	4.1	
			Placebo	132	126 (95.5)	1.86 (0.63)	0.8	1.40	1.77	2.20	3.5	
		Week 4	Tezepelumab	130	129 (99.2)	1.93 (0.74)	0.7	1.30	1.89	2.48	4.2	
			Placebo	132	129 (97.7)	1.86 (0.63)	0.7	1.40	1.81	2.26	3.6	
		Week 8	Tezepelumab	130	125 (96.2)	1.94 (0.69)	0.6	1.45	1.87	2.37	4.1	
			Placebo	132	128 (97.0)	1.89 (0.66)	0.7	1.41	1.83	2.29	4.7	
		Week 12	Tezepelumab	130	125 (96.2)	1.94 (0.70)	0.6	1.46	1.86	2.35	4.2	
			Placebo	132	127 (96.2)	1.87 (0.69)	0.7	1.36	1.79	2.27	4.6	
		Week 16	Tezepelumab	130	126 (96.9)	1.95 (0.76)	0.6	1.38	1.83	2.47	4.3	
			Placebo	132	127 (96.2)	1.85 (0.67)	0.6	1.34	1.76	2.26	4.7	
		Week 24	Tezepelumab	130	118 (90.8)	1.93 (0.66)	0.6	1.44	1.87	2.35	4.0	
			Placebo	132	121 (91.7)	1.87 (0.65)	0.7	1.36	1.77	2.25	4.6	
		Week 36	Tezepelumab	130	118 (90.8)	1.93 (0.71)	0.5	1.40	1.90	2.38	4.4	
			Placebo	132	118 (89.4)	1.89 (0.63)	0.8	1.41	1.84	2.28	4.3	
		Week 52	Tezepelumab	130	117 (90.0)	1.95 (0.70)	0.7	1.44	1.84	2.39	4.2	
			Placebo	132	115 (87.1)	1.87 (0.69)	0.7	1.34	1.73	2.33	4.4	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Change from baseline	Week 2	Tezepelumab	130	127 (97.7)	0.07 (0.29)	-0.8	-0.06	0.07	0.19	1.5	0.03 [-0.22, 0.28]
			Placebo	132	126 (95.5)	0.06 (0.34)	-1.8	-0.09	0.02	0.17	1.2	
		Week 4	Tezepelumab	130	129 (99.2)	0.07 (0.37)	-1.0	-0.11	0.03	0.22	1.7	0.00 [-0.24, 0.25]
			Placebo	132	129 (97.7)	0.07 (0.34)	-1.0	-0.06	0.05	0.22	1.1	
		Week 8	Tezepelumab	130	125 (96.2)	0.08 (0.35)	-0.9	-0.11	0.04	0.27	1.4	-0.04 [-0.29, 0.20]
			Placebo	132	128 (97.0)	0.10 (0.37)	-1.1	-0.10	0.05	0.28	1.8	
		Week 12	Tezepelumab	130	125 (96.2)	0.09 (0.33)	-0.8	-0.09	0.07	0.25	1.4	0.01 [-0.24, 0.26]
			Placebo	132	127 (96.2)	0.08 (0.39)	-1.2	-0.09	0.03	0.25	1.8	
		Week 16	Tezepelumab	130	126 (96.9)	0.09 (0.41)	-1.0	-0.13	0.03	0.24	1.9	0.06 [-0.19, 0.31]
			Placebo	132	127 (96.2)	0.06 (0.38)	-1.0	-0.14	0.03	0.23	1.9	
		Week 24	Tezepelumab	130	118 (90.8)	0.08 (0.31)	-0.6	-0.08	0.03	0.22	1.1	0.04 [-0.22, 0.29]
			Placebo	132	121 (91.7)	0.07 (0.36)	-1.1	-0.11	0.03	0.24	1.7	
		Week 36	Tezepelumab	130	118 (90.8)	0.06 (0.34)	-0.7	-0.12	0.01	0.22	1.5	-0.09 [-0.34, 0.17]
			Placebo	132	118 (89.4)	0.08 (0.33)	-0.7	-0.14	0.06	0.27	1.5	
		Week 52	Tezepelumab	130	117 (90.0)	0.08 (0.36)	-1.0	-0.10	0.05	0.23	1.3	0.07 [-0.19, 0.33]
			Placebo	132	115 (87.1)	0.06 (0.39)	-1.0	-0.18	0.06	0.19	1.5	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Absolute values	Baseline	Tezepelumab	357	357 (100.0)	1.72 (0.68)	0.5	1.23	1.61	2.05	4.8	
			Placebo	358	358 (100.0)	1.77 (0.68)	0.4	1.32	1.68	2.13	4.5	
		Week 2	Tezepelumab	357	347 (97.2)	1.92 (0.70)	0.6	1.39	1.80	2.38	5.0	
			Placebo	358	342 (95.5)	1.84 (0.69)	0.4	1.36	1.74	2.27	4.1	
		Week 4	Tezepelumab	357	354 (99.2)	1.96 (0.71)	0.6	1.46	1.85	2.40	5.0	
			Placebo	358	349 (97.5)	1.86 (0.68)	0.4	1.42	1.77	2.22	4.8	
		Week 8	Tezepelumab	357	353 (98.9)	1.99 (0.73)	0.6	1.41	1.89	2.44	4.7	
			Placebo	358	350 (97.8)	1.89 (0.71)	0.4	1.36	1.78	2.22	4.6	
		Week 12	Tezepelumab	357	348 (97.5)	2.00 (0.73)	0.6	1.50	1.89	2.43	4.9	
			Placebo	358	348 (97.2)	1.88 (0.71)	0.5	1.40	1.75	2.26	4.6	
		Week 16	Tezepelumab	357	345 (96.6)	2.01 (0.75)	0.6	1.49	1.88	2.40	4.9	
			Placebo	358	342 (95.5)	1.89 (0.71)	0.5	1.40	1.77	2.21	4.7	
		Week 24	Tezepelumab	357	342 (95.8)	1.98 (0.74)	0.6	1.49	1.83	2.43	5.5	
			Placebo	358	332 (92.7)	1.87 (0.71)	0.6	1.42	1.76	2.19	4.8	
		Week 36	Tezepelumab	357	328 (91.9)	1.99 (0.74)	0.7	1.44	1.85	2.41	4.9	
			Placebo	358	322 (89.9)	1.90 (0.72)	0.6	1.42	1.75	2.27	4.6	
		Week 52	Tezepelumab	357	320 (89.6)	1.99 (0.75)	0.6	1.47	1.85	2.42	4.6	
			Placebo	358	303 (84.6)	1.89 (0.73)	0.6	1.37	1.74	2.27	4.5	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Change from baseline	Week 2	Tezepelumab	357	347 (97.2)	0.21 (0.34)	-0.7	0.00	0.13	0.33	1.9	0.45 [0.30, 0.60]
			Placebo	358	342 (95.5)	0.05 (0.35)	-1.1	-0.12	0.01	0.18	1.7	
		Week 4	Tezepelumab	357	354 (99.2)	0.24 (0.35)	-0.5	0.01	0.17	0.38	1.8	0.42 [0.27, 0.57]
			Placebo	358	349 (97.5)	0.09 (0.38)	-1.8	-0.11	0.05	0.27	1.6	
		Week 8	Tezepelumab	357	353 (98.9)	0.28 (0.41)	-0.8	0.03	0.18	0.50	1.9	0.48 [0.33, 0.63]
			Placebo	358	350 (97.8)	0.10 (0.36)	-1.0	-0.11	0.05	0.26	2.1	
		Week 12	Tezepelumab	357	348 (97.5)	0.28 (0.41)	-0.7	0.02	0.20	0.46	2.2	0.46 [0.31, 0.61]
			Placebo	358	348 (97.2)	0.10 (0.38)	-1.5	-0.10	0.05	0.26	2.1	
		Week 16	Tezepelumab	357	345 (96.6)	0.29 (0.41)	-0.6	0.02	0.21	0.47	2.1	0.48 [0.33, 0.64]
			Placebo	358	342 (95.5)	0.11 (0.36)	-1.2	-0.09	0.04	0.28	1.8	
		Week 24	Tezepelumab	357	342 (95.8)	0.27 (0.43)	-1.0	-0.02	0.23	0.47	2.1	0.46 [0.30, 0.61]
			Placebo	358	332 (92.7)	0.08 (0.37)	-0.9	-0.13	0.05	0.26	1.7	
		Week 36	Tezepelumab	357	328 (91.9)	0.28 (0.41)	-1.0	-0.01	0.21	0.50	1.8	0.41 [0.25, 0.56]
			Placebo	358	322 (89.9)	0.11 (0.41)	-1.1	-0.14	0.04	0.30	1.7	
		Week 52	Tezepelumab	357	320 (89.6)	0.27 (0.42)	-0.8	-0.02	0.21	0.50	1.7	0.42 [0.26, 0.58]
			Placebo	358	303 (84.6)	0.10 (0.38)	-1.0	-0.14	0.06	0.26	2.3	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Absolute values	Baseline	Tezepelumab	286	286 (100.0)	1.80 (0.66)	0.4	1.32	1.75	2.20	4.8	
			Placebo	295	295 (100.0)	1.81 (0.62)	0.7	1.37	1.71	2.13	4.1	
		Week 2	Tezepelumab	286	279 (97.6)	1.91 (0.69)	0.6	1.39	1.86	2.39	5.0	
			Placebo	295	284 (96.3)	1.85 (0.68)	0.6	1.38	1.72	2.21	4.1	
		Week 4	Tezepelumab	286	285 (99.7)	1.92 (0.71)	0.6	1.37	1.85	2.42	5.0	
			Placebo	295	287 (97.3)	1.86 (0.65)	0.7	1.43	1.77	2.23	4.8	
		Week 8	Tezepelumab	286	281 (98.3)	1.93 (0.69)	0.6	1.37	1.88	2.40	4.6	
			Placebo	295	285 (96.6)	1.91 (0.69)	0.7	1.41	1.78	2.28	4.7	
		Week 12	Tezepelumab	286	277 (96.9)	1.92 (0.70)	0.6	1.41	1.84	2.35	4.9	
			Placebo	295	284 (96.3)	1.87 (0.71)	0.6	1.38	1.74	2.23	4.6	
		Week 16	Tezepelumab	286	278 (97.2)	1.94 (0.71)	0.6	1.38	1.85	2.40	4.9	
			Placebo	295	283 (95.9)	1.87 (0.71)	0.6	1.36	1.75	2.23	4.7	
		Week 24	Tezepelumab	286	270 (94.4)	1.90 (0.70)	0.6	1.38	1.81	2.38	5.5	
			Placebo	295	273 (92.5)	1.85 (0.69)	0.6	1.38	1.72	2.17	4.8	
		Week 36	Tezepelumab	286	263 (92.0)	1.91 (0.70)	0.5	1.36	1.83	2.38	4.9	
			Placebo	295	266 (90.2)	1.88 (0.68)	0.7	1.41	1.72	2.25	4.3	
		Week 52	Tezepelumab	286	263 (92.0)	1.91 (0.70)	0.6	1.41	1.81	2.37	4.6	
			Placebo	295	254 (86.1)	1.88 (0.72)	0.7	1.37	1.71	2.26	4.4	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Change from baseline	Week 2	Tezepelumab	286	279 (97.6)	0.10 (0.29)	-0.8	-0.04	0.07	0.24	1.5	0.23 [0.07, 0.40]
			Placebo	295	284 (96.3)	0.03 (0.32)	-1.8	-0.11	0.00	0.16	1.2	
		Week 4	Tezepelumab	286	285 (99.7)	0.12 (0.34)	-1.0	-0.06	0.08	0.25	1.7	0.19 [0.03, 0.35]
			Placebo	295	287 (97.3)	0.06 (0.34)	-1.0	-0.10	0.05	0.20	1.6	
		Week 8	Tezepelumab	286	281 (98.3)	0.13 (0.35)	-0.9	-0.07	0.09	0.27	1.4	0.13 [-0.04, 0.29]
			Placebo	295	285 (96.6)	0.09 (0.34)	-1.1	-0.09	0.04	0.25	1.8	
		Week 12	Tezepelumab	286	277 (96.9)	0.13 (0.34)	-0.8	-0.06	0.10	0.26	2.0	0.17 [0.01, 0.34]
			Placebo	295	284 (96.3)	0.07 (0.38)	-1.5	-0.09	0.03	0.20	2.1	
		Week 16	Tezepelumab	286	278 (97.2)	0.13 (0.37)	-1.0	-0.08	0.08	0.27	1.9	0.17 [0.00, 0.34]
			Placebo	295	283 (95.9)	0.07 (0.36)	-1.2	-0.11	0.03	0.22	1.9	
		Week 24	Tezepelumab	286	270 (94.4)	0.10 (0.35)	-1.0	-0.10	0.05	0.29	1.3	0.17 [-0.00, 0.33]
			Placebo	295	273 (92.5)	0.05 (0.34)	-1.1	-0.11	0.02	0.22	1.7	
		Week 36	Tezepelumab	286	263 (92.0)	0.10 (0.35)	-1.0	-0.10	0.04	0.25	1.5	0.14 [-0.03, 0.31]
			Placebo	295	266 (90.2)	0.05 (0.36)	-1.1	-0.18	0.03	0.24	1.6	
		Week 52	Tezepelumab	286	263 (92.0)	0.10 (0.37)	-1.0	-0.09	0.05	0.25	1.5	0.11 [-0.06, 0.29]
			Placebo	295	254 (86.1)	0.06 (0.37)	-1.0	-0.16	0.04	0.22	2.3	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Absolute values	Baseline	Tezepelumab	201	201 (100.0)	1.70 (0.70)	0.5	1.20	1.55	2.00	4.1	
			Placebo	195	195 (100.0)	1.74 (0.70)	0.4	1.24	1.66	2.17	4.5	
		Week 2	Tezepelumab	201	195 (97.0)	1.95 (0.72)	0.8	1.39	1.80	2.41	4.3	
			Placebo	195	184 (94.4)	1.84 (0.68)	0.4	1.36	1.81	2.28	4.0	
		Week 4	Tezepelumab	201	198 (98.5)	2.00 (0.72)	0.7	1.49	1.87	2.42	4.3	
			Placebo	195	191 (97.9)	1.87 (0.70)	0.4	1.38	1.82	2.25	4.2	
		Week 8	Tezepelumab	201	197 (98.0)	2.04 (0.76)	0.9	1.48	1.89	2.46	4.7	
			Placebo	195	193 (99.0)	1.86 (0.72)	0.4	1.31	1.78	2.20	4.3	
		Week 12	Tezepelumab	201	196 (97.5)	2.07 (0.75)	0.7	1.56	1.93	2.53	4.7	
			Placebo	195	191 (97.9)	1.90 (0.70)	0.5	1.40	1.85	2.30	4.3	
		Week 16	Tezepelumab	201	193 (96.0)	2.08 (0.79)	0.8	1.52	1.95	2.53	4.9	
			Placebo	195	186 (95.4)	1.89 (0.68)	0.5	1.40	1.81	2.21	4.4	
		Week 24	Tezepelumab	201	190 (94.5)	2.06 (0.73)	0.8	1.59	1.94	2.52	4.4	
			Placebo	195	180 (92.3)	1.90 (0.70)	0.7	1.45	1.85	2.23	4.8	
		Week 36	Tezepelumab	201	183 (91.0)	2.07 (0.76)	0.7	1.50	1.92	2.44	4.5	
			Placebo	195	174 (89.2)	1.94 (0.73)	0.6	1.44	1.88	2.31	4.6	
		Week 52	Tezepelumab	201	174 (86.6)	2.08 (0.77)	0.6	1.56	1.89	2.45	4.3	
			Placebo	195	164 (84.1)	1.89 (0.71)	0.6	1.36	1.82	2.29	4.5	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Change from baseline	Week 2	Tezepelumab	201	195 (97.0)	0.26 (0.37)	-0.6	0.04	0.18	0.41	1.9	0.47 [0.26, 0.67]
			Placebo	195	184 (94.4)	0.09 (0.37)	-1.1	-0.12	0.03	0.27	1.7	
		Week 4	Tezepelumab	201	198 (98.5)	0.31 (0.37)	-0.4	0.05	0.25	0.47	1.8	0.46 [0.26, 0.66]
			Placebo	195	191 (97.9)	0.13 (0.40)	-1.8	-0.10	0.06	0.33	1.4	
		Week 8	Tezepelumab	201	197 (98.0)	0.36 (0.44)	-0.6	0.06	0.27	0.60	1.9	0.61 [0.41, 0.82]
			Placebo	195	193 (99.0)	0.11 (0.39)	-0.8	-0.13	0.07	0.28	2.1	
		Week 12	Tezepelumab	201	196 (97.5)	0.38 (0.43)	-0.3	0.06	0.30	0.57	2.2	0.58 [0.37, 0.78]
			Placebo	195	191 (97.9)	0.14 (0.39)	-1.4	-0.10	0.07	0.34	1.7	
		Week 16	Tezepelumab	201	193 (96.0)	0.40 (0.44)	-0.4	0.11	0.31	0.59	2.1	0.64 [0.43, 0.84]
			Placebo	195	186 (95.4)	0.14 (0.37)	-1.0	-0.09	0.05	0.36	1.8	
		Week 24	Tezepelumab	201	190 (94.5)	0.38 (0.43)	-0.5	0.08	0.32	0.60	2.1	0.60 [0.39, 0.81]
			Placebo	195	180 (92.3)	0.13 (0.41)	-0.9	-0.13	0.07	0.34	1.7	
		Week 36	Tezepelumab	201	183 (91.0)	0.39 (0.42)	-0.5	0.08	0.35	0.56	1.8	0.49 [0.28, 0.70]
			Placebo	195	174 (89.2)	0.18 (0.41)	-0.8	-0.06	0.11	0.41	1.7	
		Week 52	Tezepelumab	201	174 (86.6)	0.39 (0.43)	-0.8	0.10	0.35	0.61	1.7	0.64 [0.43, 0.86]
			Placebo	195	164 (84.1)	0.12 (0.40)	-0.9	-0.11	0.06	0.32	2.0	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Absolute values	Baseline	Tezepelumab	202	202 (100.0)	1.73 (0.65)	0.4	1.26	1.61	2.13	4.0	
			Placebo	204	204 (100.0)	1.79 (0.67)	0.4	1.35	1.71	2.17	3.9	
		Week 2	Tezepelumab	202	195 (96.5)	1.87 (0.64)	0.6	1.37	1.80	2.31	4.1	
			Placebo	204	190 (93.1)	1.86 (0.68)	0.4	1.38	1.77	2.28	4.1	
		Week 4	Tezepelumab	202	199 (98.5)	1.86 (0.66)	0.6	1.34	1.79	2.26	4.2	
			Placebo	204	199 (97.5)	1.87 (0.68)	0.4	1.43	1.82	2.29	4.8	
		Week 8	Tezepelumab	202	197 (97.5)	1.87 (0.65)	0.6	1.39	1.80	2.30	4.1	
			Placebo	204	199 (97.5)	1.90 (0.70)	0.4	1.40	1.81	2.30	4.7	
		Week 12	Tezepelumab	202	195 (96.5)	1.88 (0.65)	0.6	1.43	1.83	2.24	4.2	
			Placebo	204	197 (96.6)	1.89 (0.73)	0.5	1.41	1.74	2.34	4.6	
		Week 16	Tezepelumab	202	194 (96.0)	1.89 (0.67)	0.6	1.38	1.83	2.31	4.2	
			Placebo	204	197 (96.6)	1.87 (0.72)	0.5	1.33	1.78	2.28	4.7	
		Week 24	Tezepelumab	202	192 (95.0)	1.85 (0.65)	0.6	1.38	1.78	2.30	4.0	
			Placebo	204	193 (94.6)	1.86 (0.71)	0.6	1.40	1.77	2.23	4.8	
		Week 36	Tezepelumab	202	183 (90.6)	1.84 (0.63)	0.5	1.33	1.80	2.24	4.4	
			Placebo	204	186 (91.2)	1.89 (0.70)	0.6	1.41	1.79	2.29	4.3	
		Week 52	Tezepelumab	202	184 (91.1)	1.86 (0.64)	0.7	1.41	1.76	2.23	4.2	
			Placebo	204	181 (88.7)	1.88 (0.73)	0.6	1.36	1.73	2.32	4.4	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Change from baseline	Week 2	Tezepelumab	202	195 (96.5)	0.13 (0.33)	-0.8	-0.03	0.08	0.24	1.9	0.27 [0.07, 0.47]
			Placebo	204	190 (93.1)	0.05 (0.29)	-0.8	-0.11	0.01	0.16	1.2	
		Week 4	Tezepelumab	202	199 (98.5)	0.14 (0.36)	-1.0	-0.06	0.08	0.29	1.7	0.16 [-0.03, 0.36]
			Placebo	204	199 (97.5)	0.08 (0.32)	-0.9	-0.07	0.04	0.20	1.6	
		Week 8	Tezepelumab	202	197 (97.5)	0.15 (0.36)	-0.9	-0.05	0.10	0.26	1.6	0.15 [-0.04, 0.35]
			Placebo	204	199 (97.5)	0.09 (0.36)	-1.0	-0.09	0.04	0.24	1.8	
		Week 12	Tezepelumab	202	195 (96.5)	0.16 (0.34)	-0.7	-0.04	0.10	0.28	1.5	0.18 [-0.02, 0.38]
			Placebo	204	197 (96.6)	0.09 (0.38)	-1.5	-0.07	0.03	0.21	2.1	
		Week 16	Tezepelumab	202	194 (96.0)	0.15 (0.38)	-1.0	-0.05	0.11	0.28	1.8	0.20 [-0.00, 0.39]
			Placebo	204	197 (96.6)	0.07 (0.36)	-1.0	-0.10	0.03	0.20	1.9	
		Week 24	Tezepelumab	202	192 (95.0)	0.14 (0.38)	-1.0	-0.08	0.06	0.32	2.1	0.25 [0.05, 0.45]
			Placebo	204	193 (94.6)	0.05 (0.35)	-1.1	-0.12	0.03	0.20	1.7	
		Week 36	Tezepelumab	202	183 (90.6)	0.11 (0.36)	-1.0	-0.11	0.07	0.32	1.8	0.07 [-0.14, 0.27]
			Placebo	204	186 (91.2)	0.09 (0.33)	-0.8	-0.10	0.06	0.22	1.6	
		Week 52	Tezepelumab	202	184 (91.1)	0.13 (0.38)	-1.0	-0.07	0.08	0.31	1.5	0.14 [-0.07, 0.34]
			Placebo	204	181 (88.7)	0.08 (0.37)	-1.0	-0.14	0.04	0.21	2.3	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Absolute values	Baseline	Tezepelumab	279	279 (100.0)	1.79 (0.70)	0.5	1.32	1.70	2.13	4.8	
			Placebo	282	282 (100.0)	1.77 (0.64)	0.6	1.33	1.68	2.11	4.5	
		Week 2	Tezepelumab	279	273 (97.8)	1.99 (0.74)	0.7	1.45	1.86	2.42	5.0	
			Placebo	282	274 (97.2)	1.83 (0.67)	0.6	1.37	1.73	2.21	4.0	
		Week 4	Tezepelumab	279	279 (100.0)	2.03 (0.75)	0.7	1.48	1.93	2.54	5.0	
			Placebo	282	275 (97.5)	1.85 (0.66)	0.7	1.40	1.75	2.19	4.2	
		Week 8	Tezepelumab	279	275 (98.6)	2.07 (0.76)	0.8	1.48	1.96	2.48	4.7	
			Placebo	282	275 (97.5)	1.88 (0.70)	0.7	1.36	1.74	2.20	4.3	
		Week 12	Tezepelumab	279	272 (97.5)	2.07 (0.77)	0.7	1.52	1.93	2.53	4.9	
			Placebo	282	275 (97.5)	1.87 (0.69)	0.6	1.38	1.76	2.23	4.3	
		Week 16	Tezepelumab	279	271 (97.1)	2.09 (0.79)	0.7	1.53	1.95	2.53	4.9	
			Placebo	282	269 (95.4)	1.89 (0.69)	0.6	1.44	1.75	2.19	4.4	
		Week 24	Tezepelumab	279	262 (93.9)	2.06 (0.76)	0.7	1.57	1.94	2.51	5.5	
			Placebo	282	257 (91.1)	1.88 (0.68)	0.6	1.41	1.75	2.15	4.8	
		Week 36	Tezepelumab	279	257 (92.1)	2.08 (0.78)	0.6	1.52	1.97	2.50	4.9	
			Placebo	282	251 (89.0)	1.91 (0.70)	0.7	1.43	1.79	2.25	4.6	
		Week 52	Tezepelumab	279	248 (88.9)	2.08 (0.79)	0.6	1.56	1.96	2.53	4.6	
			Placebo	282	234 (83.0)	1.88 (0.71)	0.7	1.37	1.75	2.26	4.5	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Change from baseline	Week 2	Tezepelumab	279	273 (97.8)	0.20 (0.33)	-0.6	0.00	0.15	0.33	1.5	0.40 [0.23, 0.57]
			Placebo	282	274 (97.2)	0.06 (0.38)	-1.8	-0.11	0.02	0.20	1.7	
		Week 4	Tezepelumab	279	279 (100.0)	0.24 (0.36)	-0.7	0.01	0.17	0.39	1.8	0.40 [0.24, 0.57]
			Placebo	282	275 (97.5)	0.09 (0.40)	-1.8	-0.11	0.05	0.29	1.4	
		Week 8	Tezepelumab	279	275 (98.6)	0.29 (0.43)	-0.6	0.02	0.19	0.50	1.9	0.47 [0.31, 0.64]
			Placebo	282	275 (97.5)	0.10 (0.36)	-1.1	-0.12	0.06	0.30	2.1	
		Week 12	Tezepelumab	279	272 (97.5)	0.29 (0.43)	-0.8	0.01	0.21	0.48	2.2	0.45 [0.28, 0.62]
			Placebo	282	275 (97.5)	0.10 (0.39)	-1.4	-0.11	0.06	0.29	1.7	
		Week 16	Tezepelumab	279	271 (97.1)	0.31 (0.44)	-0.8	0.01	0.23	0.50	2.1	0.48 [0.31, 0.65]
			Placebo	282	269 (95.4)	0.11 (0.37)	-1.2	-0.10	0.04	0.33	1.8	
		Week 24	Tezepelumab	279	262 (93.9)	0.28 (0.42)	-1.0	-0.01	0.23	0.47	1.7	0.43 [0.26, 0.61]
			Placebo	282	257 (91.1)	0.11 (0.38)	-0.9	-0.11	0.06	0.30	1.7	
		Week 36	Tezepelumab	279	257 (92.1)	0.30 (0.42)	-0.6	-0.01	0.22	0.54	1.7	0.43 [0.25, 0.60]
			Placebo	282	251 (89.0)	0.12 (0.43)	-1.1	-0.18	0.05	0.37	1.7	
		Week 52	Tezepelumab	279	248 (88.9)	0.28 (0.43)	-0.8	-0.03	0.23	0.53	1.7	0.47 [0.29, 0.65]
			Placebo	282	234 (83.0)	0.09 (0.39)	-1.0	-0.15	0.06	0.30	2.0	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	179	179 (100.0)	1.64 (0.65)	0.4	1.18	1.53	2.02	4.8	
			Placebo	174	174 (100.0)	1.68 (0.60)	0.6	1.28	1.63	1.97	4.2	
		Week 2	Tezepelumab	179	176 (98.3)	1.83 (0.67)	0.6	1.33	1.79	2.26	5.0	
			Placebo	174	166 (95.4)	1.72 (0.61)	0.6	1.35	1.63	1.98	4.0	
		Week 4	Tezepelumab	179	178 (99.4)	1.89 (0.69)	0.7	1.28	1.85	2.35	5.0	
			Placebo	174	168 (96.6)	1.77 (0.63)	0.7	1.32	1.68	2.10	4.2	
		Week 8	Tezepelumab	179	176 (98.3)	1.90 (0.68)	0.6	1.36	1.81	2.41	4.6	
			Placebo	174	168 (96.6)	1.77 (0.63)	0.7	1.34	1.67	2.04	4.3	
		Week 12	Tezepelumab	179	177 (98.9)	1.91 (0.70)	0.6	1.40	1.83	2.37	4.9	
			Placebo	174	169 (97.1)	1.77 (0.66)	0.6	1.31	1.65	2.10	4.3	
		Week 16	Tezepelumab	179	176 (98.3)	1.91 (0.70)	0.6	1.36	1.83	2.40	4.9	
			Placebo	174	166 (95.4)	1.77 (0.63)	0.7	1.32	1.71	2.12	4.2	
		Week 24	Tezepelumab	179	172 (96.1)	1.90 (0.71)	0.6	1.38	1.78	2.38	5.5	
			Placebo	174	154 (88.5)	1.76 (0.62)	0.7	1.38	1.66	2.09	4.8	
		Week 36	Tezepelumab	179	167 (93.3)	1.88 (0.69)	0.5	1.37	1.80	2.33	4.9	
			Placebo	174	152 (87.4)	1.80 (0.62)	0.8	1.36	1.70	2.21	4.6	
		Week 52	Tezepelumab	179	165 (92.2)	1.92 (0.69)	0.6	1.41	1.85	2.35	4.6	
			Placebo	174	145 (83.3)	1.71 (0.61)	0.6	1.29	1.61	2.05	4.4	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Change from baseline	Week 2	Tezepelumab	179	176 (98.3)	0.19 (0.30)	-0.4	0.02	0.12	0.30	1.1	0.55 [0.33, 0.77]
			Placebo	174	166 (95.4)	0.03 (0.27)	-0.7	-0.10	-0.01	0.16	1.0	
		Week 4	Tezepelumab	179	178 (99.4)	0.25 (0.35)	-0.7	0.03	0.19	0.40	1.7	0.48 [0.26, 0.69]
			Placebo	174	168 (96.6)	0.09 (0.32)	-1.0	-0.07	0.05	0.23	1.2	
		Week 8	Tezepelumab	179	176 (98.3)	0.27 (0.38)	-0.6	0.00	0.18	0.46	1.4	0.55 [0.33, 0.76]
			Placebo	174	168 (96.6)	0.09 (0.29)	-0.6	-0.11	0.05	0.24	1.2	
		Week 12	Tezepelumab	179	177 (98.9)	0.26 (0.38)	-0.7	0.02	0.21	0.45	1.4	0.48 [0.27, 0.70]
			Placebo	174	169 (97.1)	0.09 (0.33)	-0.7	-0.09	0.03	0.20	1.2	
		Week 16	Tezepelumab	179	176 (98.3)	0.27 (0.38)	-0.6	0.02	0.23	0.44	1.6	0.54 [0.32, 0.75]
			Placebo	174	166 (95.4)	0.09 (0.29)	-0.7	-0.08	0.04	0.26	1.2	
		Week 24	Tezepelumab	179	172 (96.1)	0.26 (0.39)	-0.5	-0.02	0.21	0.44	1.7	0.53 [0.30, 0.75]
			Placebo	174	154 (88.5)	0.07 (0.31)	-0.8	-0.11	0.05	0.22	1.2	
		Week 36	Tezepelumab	179	167 (93.3)	0.23 (0.40)	-0.6	-0.05	0.16	0.44	1.6	0.37 [0.14, 0.59]
			Placebo	174	152 (87.4)	0.10 (0.34)	-0.9	-0.11	0.05	0.29	1.3	
		Week 52	Tezepelumab	179	165 (92.2)	0.26 (0.41)	-0.6	-0.03	0.22	0.47	1.4	0.67 [0.45, 0.90]
			Placebo	174	145 (83.3)	0.02 (0.29)	-0.9	-0.17	0.04	0.19	0.7	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	303	303 (100.0)	1.83 (0.68)	0.5	1.36	1.69	2.18	4.1	
			Placebo	303	303 (100.0)	1.84 (0.68)	0.4	1.36	1.74	2.23	4.5	
		Week 2	Tezepelumab	303	294 (97.0)	1.99 (0.72)	0.6	1.46	1.87	2.45	4.3	
			Placebo	303	293 (96.7)	1.93 (0.70)	0.4	1.40	1.88	2.38	4.1	
		Week 4	Tezepelumab	303	302 (99.7)	1.99 (0.73)	0.6	1.46	1.88	2.44	4.3	
			Placebo	303	298 (98.3)	1.92 (0.69)	0.4	1.45	1.85	2.31	4.8	
		Week 8	Tezepelumab	303	298 (98.3)	2.02 (0.73)	0.6	1.46	1.93	2.43	4.7	
			Placebo	303	297 (98.0)	1.96 (0.74)	0.4	1.42	1.91	2.34	4.7	
		Week 12	Tezepelumab	303	292 (96.4)	2.02 (0.72)	0.6	1.55	1.92	2.45	4.7	
			Placebo	303	294 (97.0)	1.95 (0.73)	0.5	1.46	1.82	2.34	4.6	
		Week 16	Tezepelumab	303	291 (96.0)	2.04 (0.76)	0.6	1.52	1.91	2.48	4.9	
			Placebo	303	290 (95.7)	1.95 (0.74)	0.5	1.43	1.83	2.35	4.7	
		Week 24	Tezepelumab	303	284 (93.7)	2.00 (0.72)	0.6	1.52	1.89	2.47	4.4	
			Placebo	303	286 (94.4)	1.94 (0.73)	0.6	1.42	1.86	2.28	4.8	
		Week 36	Tezepelumab	303	275 (90.8)	2.03 (0.75)	0.6	1.48	1.91	2.46	4.5	
			Placebo	303	276 (91.1)	1.97 (0.74)	0.6	1.48	1.84	2.36	4.3	
		Week 52	Tezepelumab	303	269 (88.8)	2.01 (0.75)	0.6	1.49	1.84	2.43	4.3	
			Placebo	303	264 (87.1)	1.99 (0.76)	0.6	1.45	1.85	2.42	4.5	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Change from baseline	Week 2	Tezepelumab	303	294 (97.0)	0.16 (0.35)	-0.8	-0.03	0.10	0.29	1.9	0.24 [0.07, 0.40]
			Placebo	303	293 (96.7)	0.07 (0.38)	-1.8	-0.12	0.04	0.22	1.7	
		Week 4	Tezepelumab	303	302 (99.7)	0.17 (0.37)	-1.0	-0.04	0.10	0.30	1.8	0.20 [0.04, 0.36]
			Placebo	303	298 (98.3)	0.09 (0.39)	-1.8	-0.11	0.05	0.27	1.6	
		Week 8	Tezepelumab	303	298 (98.3)	0.20 (0.41)	-0.9	-0.05	0.13	0.39	1.8	0.22 [0.06, 0.38]
			Placebo	303	297 (98.0)	0.11 (0.40)	-1.1	-0.10	0.05	0.30	2.1	
		Week 12	Tezepelumab	303	292 (96.4)	0.21 (0.40)	-0.8	-0.04	0.12	0.37	2.0	0.26 [0.10, 0.43]
			Placebo	303	294 (97.0)	0.10 (0.42)	-1.5	-0.10	0.05	0.26	2.1	
		Week 16	Tezepelumab	303	291 (96.0)	0.21 (0.43)	-1.0	-0.04	0.14	0.37	2.0	0.25 [0.09, 0.42]
			Placebo	303	290 (95.7)	0.10 (0.40)	-1.2	-0.11	0.04	0.28	1.9	
		Week 24	Tezepelumab	303	284 (93.7)	0.19 (0.41)	-1.0	-0.07	0.13	0.38	2.1	0.25 [0.09, 0.42]
			Placebo	303	286 (94.4)	0.09 (0.40)	-1.1	-0.13	0.03	0.27	1.7	
		Week 36	Tezepelumab	303	275 (90.8)	0.20 (0.41)	-1.0	-0.05	0.12	0.40	1.8	0.22 [0.05, 0.39]
			Placebo	303	276 (91.1)	0.11 (0.42)	-1.1	-0.15	0.06	0.30	1.7	
		Week 52	Tezepelumab	303	269 (88.8)	0.19 (0.41)	-1.0	-0.04	0.12	0.36	1.7	0.14 [-0.03, 0.31]
			Placebo	303	264 (87.1)	0.13 (0.42)	-1.0	-0.12	0.07	0.31	2.3	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Absolute values	Baseline	Tezepelumab	153	153 (100.0)	1.68 (0.61)	0.4	1.22	1.61	2.02	3.3	
			Placebo	163	163 (100.0)	1.67 (0.57)	0.7	1.26	1.55	1.98	4.2	
		Week 2	Tezepelumab	153	150 (98.0)	1.79 (0.60)	0.6	1.37	1.70	2.21	3.8	
			Placebo	163	153 (93.9)	1.70 (0.60)	0.6	1.32	1.63	1.98	4.0	
		Week 4	Tezepelumab	153	153 (100.0)	1.84 (0.64)	0.7	1.32	1.69	2.29	3.8	
			Placebo	163	158 (96.9)	1.73 (0.60)	0.7	1.32	1.65	2.03	4.2	
		Week 8	Tezepelumab	153	149 (97.4)	1.84 (0.61)	0.6	1.35	1.74	2.30	3.7	
			Placebo	163	158 (96.9)	1.75 (0.61)	0.7	1.33	1.67	2.06	4.3	
		Week 12	Tezepelumab	153	148 (96.7)	1.85 (0.65)	0.6	1.39	1.75	2.24	4.6	
			Placebo	163	157 (96.3)	1.74 (0.63)	0.6	1.31	1.66	2.10	4.3	
		Week 16	Tezepelumab	153	150 (98.0)	1.85 (0.66)	0.6	1.34	1.75	2.27	3.7	
			Placebo	163	154 (94.5)	1.76 (0.61)	0.6	1.32	1.68	2.10	4.1	
		Week 24	Tezepelumab	153	148 (96.7)	1.81 (0.60)	0.6	1.29	1.78	2.25	3.7	
			Placebo	163	148 (90.8)	1.72 (0.60)	0.7	1.31	1.64	2.03	4.8	
		Week 36	Tezepelumab	153	142 (92.8)	1.81 (0.62)	0.5	1.37	1.75	2.18	3.7	
			Placebo	163	140 (85.9)	1.78 (0.60)	0.7	1.36	1.69	2.09	4.6	
		Week 52	Tezepelumab	153	142 (92.8)	1.82 (0.64)	0.6	1.37	1.73	2.21	3.6	
			Placebo	163	139 (85.3)	1.73 (0.62)	0.7	1.27	1.62	2.08	4.4	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Change from baseline	Week 2	Tezepelumab	153	150 (98.0)	0.12 (0.29)	-0.8	0.00	0.09	0.26	1.1	0.31 [0.08, 0.54]
			Placebo	163	153 (93.9)	0.03 (0.29)	-0.7	-0.10	0.00	0.12	1.1	
		Week 4	Tezepelumab	153	153 (100.0)	0.16 (0.39)	-1.0	-0.05	0.11	0.33	1.7	0.24 [0.02, 0.46]
			Placebo	163	158 (96.9)	0.08 (0.30)	-0.7	-0.07	0.05	0.20	1.1	
		Week 8	Tezepelumab	153	149 (97.4)	0.18 (0.37)	-0.8	-0.04	0.11	0.31	1.4	0.30 [0.07, 0.52]
			Placebo	163	158 (96.9)	0.08 (0.29)	-0.8	-0.09	0.04	0.20	1.2	
		Week 12	Tezepelumab	153	148 (96.7)	0.18 (0.38)	-0.8	-0.02	0.13	0.32	2.0	0.27 [0.04, 0.49]
			Placebo	163	157 (96.3)	0.08 (0.34)	-0.7	-0.10	0.03	0.20	1.2	
		Week 16	Tezepelumab	153	150 (98.0)	0.17 (0.38)	-1.0	-0.04	0.15	0.33	1.7	0.26 [0.03, 0.49]
			Placebo	163	154 (94.5)	0.08 (0.31)	-0.7	-0.07	0.04	0.26	1.0	
		Week 24	Tezepelumab	153	148 (96.7)	0.16 (0.33)	-0.6	-0.07	0.12	0.33	1.2	0.33 [0.10, 0.56]
			Placebo	163	148 (90.8)	0.05 (0.31)	-0.8	-0.11	0.03	0.19	1.2	
		Week 36	Tezepelumab	153	142 (92.8)	0.14 (0.34)	-0.7	-0.08	0.08	0.32	1.3	0.14 [-0.10, 0.37]
			Placebo	163	140 (85.9)	0.10 (0.33)	-1.1	-0.11	0.04	0.29	1.1	
		Week 52	Tezepelumab	153	142 (92.8)	0.14 (0.37)	-1.0	-0.09	0.11	0.34	1.5	0.32 [0.08, 0.55]
			Placebo	163	139 (85.3)	0.03 (0.30)	-0.7	-0.17	0.03	0.18	1.2	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Absolute values	Baseline	Tezepelumab	296	296 (100.0)	1.78 (0.72)	0.6	1.29	1.64	2.19	4.8	
			Placebo	278	278 (100.0)	1.83 (0.70)	0.4	1.35	1.73	2.22	4.5	
		Week 2	Tezepelumab	296	288 (97.3)	1.97 (0.74)	0.6	1.42	1.86	2.44	5.0	
			Placebo	278	268 (96.4)	1.88 (0.68)	0.4	1.40	1.79	2.28	3.9	
		Week 4	Tezepelumab	296	292 (98.6)	1.99 (0.74)	0.6	1.44	1.90	2.43	5.0	
			Placebo	278	271 (97.5)	1.91 (0.66)	0.4	1.45	1.83	2.29	4.1	
		Week 8	Tezepelumab	296	291 (98.3)	2.02 (0.75)	0.6	1.43	1.91	2.44	4.7	
			Placebo	278	271 (97.5)	1.93 (0.71)	0.4	1.40	1.88	2.33	4.7	
		Week 12	Tezepelumab	296	287 (97.0)	2.02 (0.75)	0.6	1.52	1.92	2.46	4.9	
			Placebo	278	270 (97.1)	1.92 (0.71)	0.6	1.41	1.76	2.30	4.6	
		Week 16	Tezepelumab	296	284 (95.9)	2.05 (0.77)	0.6	1.51	1.92	2.53	4.9	
			Placebo	278	268 (96.4)	1.92 (0.71)	0.7	1.40	1.80	2.26	4.7	
		Week 24	Tezepelumab	296	276 (93.2)	2.02 (0.76)	0.6	1.52	1.86	2.52	5.5	
			Placebo	278	258 (92.8)	1.93 (0.70)	0.6	1.45	1.86	2.24	4.6	
		Week 36	Tezepelumab	296	270 (91.2)	2.04 (0.77)	0.6	1.45	1.92	2.46	4.9	
			Placebo	278	252 (90.6)	1.94 (0.72)	0.8	1.43	1.81	2.31	4.3	
		Week 52	Tezepelumab	296	261 (88.2)	2.05 (0.77)	0.6	1.49	1.94	2.50	4.6	
			Placebo	278	238 (85.6)	1.94 (0.73)	0.6	1.44	1.84	2.33	4.5	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Change from baseline	Week 2	Tezepelumab	296	288 (97.3)	0.19 (0.34)	-0.5	-0.03	0.13	0.30	1.9	0.43 [0.26, 0.60]
			Placebo	278	268 (96.4)	0.04 (0.35)	-1.8	-0.12	0.01	0.18	1.2	
		Week 4	Tezepelumab	296	292 (98.6)	0.21 (0.33)	-0.9	-0.01	0.14	0.33	1.8	0.36 [0.19, 0.52]
			Placebo	278	271 (97.5)	0.08 (0.38)	-1.8	-0.11	0.05	0.26	1.4	
		Week 8	Tezepelumab	296	291 (98.3)	0.24 (0.40)	-0.9	-0.02	0.16	0.44	1.9	0.39 [0.22, 0.55]
			Placebo	278	271 (97.5)	0.09 (0.38)	-1.1	-0.12	0.06	0.28	1.8	
		Week 12	Tezepelumab	296	287 (97.0)	0.25 (0.40)	-0.7	-0.03	0.18	0.45	2.2	0.42 [0.25, 0.59]
			Placebo	278	270 (97.1)	0.08 (0.41)	-1.5	-0.10	0.03	0.25	2.1	
		Week 16	Tezepelumab	296	284 (95.9)	0.26 (0.42)	-0.8	-0.01	0.17	0.47	2.1	0.45 [0.28, 0.62]
			Placebo	278	268 (96.4)	0.08 (0.38)	-1.2	-0.15	0.04	0.24	1.9	
		Week 24	Tezepelumab	296	276 (93.2)	0.24 (0.44)	-1.0	-0.04	0.18	0.45	2.1	0.40 [0.23, 0.57]
			Placebo	278	258 (92.8)	0.08 (0.39)	-1.1	-0.13	0.05	0.27	1.7	
		Week 36	Tezepelumab	296	270 (91.2)	0.25 (0.43)	-1.0	-0.04	0.19	0.49	1.8	0.39 [0.21, 0.56]
			Placebo	278	252 (90.6)	0.09 (0.41)	-1.0	-0.16	0.05	0.28	1.7	
		Week 52	Tezepelumab	296	261 (88.2)	0.26 (0.44)	-1.0	-0.03	0.19	0.49	1.7	0.39 [0.21, 0.57]
			Placebo	278	238 (85.6)	0.09 (0.40)	-1.0	-0.14	0.06	0.26	2.3	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Absolute values	Baseline	Tezepelumab	38	38 (100.0)	1.90 (0.59)	0.8	1.55	1.87	2.13	3.8	
			Placebo	49	49 (100.0)	1.88 (0.62)	0.6	1.45	1.80	2.26	3.2	
		Week 2	Tezepelumab	38	36 (94.7)	2.12 (0.69)	1.0	1.62	2.13	2.49	3.8	
			Placebo	49	47 (95.9)	2.12 (0.79)	0.8	1.49	2.24	2.58	4.1	
		Week 4	Tezepelumab	38	38 (100.0)	2.17 (0.70)	0.9	1.64	2.16	2.52	4.3	
			Placebo	49	49 (100.0)	2.02 (0.83)	0.5	1.45	1.96	2.37	4.8	
		Week 8	Tezepelumab	38	38 (100.0)	2.22 (0.78)	1.0	1.60	2.11	2.57	4.7	
			Placebo	49	49 (100.0)	2.06 (0.84)	0.6	1.56	1.94	2.77	4.6	
		Week 12	Tezepelumab	38	38 (100.0)	2.21 (0.75)	1.2	1.64	2.19	2.52	4.7	
			Placebo	49	48 (98.0)	2.12 (0.80)	0.5	1.60	2.05	2.58	4.6	
		Week 16	Tezepelumab	38	37 (97.4)	2.21 (0.81)	0.9	1.67	2.10	2.39	4.9	
			Placebo	49	47 (95.9)	2.07 (0.82)	0.5	1.52	2.06	2.53	4.7	
		Week 24	Tezepelumab	38	36 (94.7)	2.18 (0.74)	0.9	1.67	2.11	2.53	4.4	
			Placebo	49	47 (95.9)	2.03 (0.82)	0.7	1.43	1.87	2.48	4.8	
		Week 36	Tezepelumab	38	34 (89.5)	2.17 (0.77)	0.9	1.59	2.01	2.50	4.5	
			Placebo	49	48 (98.0)	2.06 (0.83)	0.6	1.54	1.83	2.40	4.3	
		Week 52	Tezepelumab	38	34 (89.5)	2.12 (0.69)	0.9	1.63	1.93	2.42	4.0	
			Placebo	49	41 (83.7)	2.07 (0.85)	0.6	1.44	1.84	2.68	4.0	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Change from baseline	Week 2	Tezepelumab	38	36 (94.7)	0.23 (0.40)	-0.6	-0.01	0.14	0.42	1.3	0.03 [-0.40, 0.46]
			Placebo	49	47 (95.9)	0.22 (0.44)	-0.8	-0.06	0.09	0.48	1.7	
		Week 4	Tezepelumab	38	38 (100.0)	0.26 (0.42)	-0.4	0.01	0.18	0.42	1.4	0.27 [-0.16, 0.69]
			Placebo	49	49 (100.0)	0.14 (0.47)	-0.8	-0.12	0.05	0.49	1.6	
		Week 8	Tezepelumab	38	38 (100.0)	0.31 (0.53)	-0.5	-0.04	0.16	0.54	1.8	0.26 [-0.16, 0.69]
			Placebo	49	49 (100.0)	0.19 (0.46)	-0.6	-0.08	0.08	0.39	2.1	
		Week 12	Tezepelumab	38	38 (100.0)	0.31 (0.47)	-0.3	0.01	0.19	0.54	1.9	0.17 [-0.26, 0.60]
			Placebo	49	48 (98.0)	0.24 (0.36)	-0.2	-0.01	0.13	0.39	1.4	
		Week 16	Tezepelumab	38	37 (97.4)	0.30 (0.53)	-0.5	0.00	0.15	0.56	2.0	0.21 [-0.22, 0.64]
			Placebo	49	47 (95.9)	0.20 (0.41)	-0.4	-0.07	0.04	0.45	1.4	
		Week 24	Tezepelumab	38	36 (94.7)	0.27 (0.46)	-0.4	-0.08	0.23	0.48	1.5	0.24 [-0.19, 0.68]
			Placebo	49	47 (95.9)	0.16 (0.45)	-0.8	-0.11	0.05	0.45	1.6	
		Week 36	Tezepelumab	38	34 (89.5)	0.28 (0.47)	-0.8	-0.05	0.16	0.54	1.7	0.19 [-0.25, 0.63]
			Placebo	49	48 (98.0)	0.19 (0.45)	-0.6	-0.12	0.08	0.38	1.5	
		Week 52	Tezepelumab	38	34 (89.5)	0.22 (0.38)	-0.8	0.00	0.14	0.44	1.2	0.02 [-0.43, 0.48]
			Placebo	49	41 (83.7)	0.21 (0.45)	-0.7	-0.08	0.15	0.45	1.6	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Absolute values	Baseline	Tezepelumab	48	48 (100.0)	1.76 (0.71)	0.4	1.28	1.72	2.10	3.6	
			Placebo	51	51 (100.0)	1.81 (0.62)	0.8	1.43	1.75	2.16	3.7	
		Week 2	Tezepelumab	48	47 (97.9)	1.99 (0.72)	0.6	1.53	1.93	2.32	3.9	
			Placebo	51	49 (96.1)	1.81 (0.62)	0.8	1.36	1.74	2.24	3.7	
		Week 4	Tezepelumab	48	48 (100.0)	2.03 (0.73)	0.7	1.53	1.96	2.58	3.8	
			Placebo	51	49 (96.1)	1.84 (0.59)	0.7	1.50	1.76	2.06	4.0	
		Week 8	Tezepelumab	48	47 (97.9)	1.98 (0.70)	0.6	1.50	1.90	2.46	3.7	
			Placebo	51	50 (98.0)	1.86 (0.71)	0.7	1.34	1.78	2.20	3.9	
		Week 12	Tezepelumab	48	44 (91.7)	1.99 (0.77)	0.6	1.52	1.91	2.35	4.6	
			Placebo	51	47 (92.2)	1.88 (0.63)	0.7	1.48	1.81	2.13	3.6	
		Week 16	Tezepelumab	48	46 (95.8)	2.03 (0.76)	0.6	1.54	1.96	2.48	4.2	
			Placebo	51	44 (86.3)	1.83 (0.62)	0.9	1.45	1.77	2.12	3.6	
		Week 24	Tezepelumab	48	43 (89.6)	2.00 (0.67)	0.9	1.61	1.89	2.50	3.7	
			Placebo	51	36 (70.6)	1.81 (0.67)	0.9	1.32	1.80	2.19	4.2	
		Week 36	Tezepelumab	48	40 (83.3)	1.98 (0.71)	0.9	1.52	1.87	2.37	4.0	
			Placebo	51	39 (76.5)	1.90 (0.60)	0.8	1.46	1.82	2.16	3.6	
		Week 52	Tezepelumab	48	38 (79.2)	2.07 (0.71)	0.8	1.69	2.00	2.37	4.1	
			Placebo	51	35 (68.6)	1.89 (0.71)	0.9	1.30	1.73	2.31	3.7	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	48	47 (97.9)	0.23 (0.32)	-0.6	0.01	0.19	0.38	1.1	0.70 [0.29, 1.11]
			Placebo	51	49 (96.1)	-0.03 (0.41)	-1.8	-0.09	0.01	0.12	1.0	
		Week 4	Tezepelumab	48	48 (100.0)	0.27 (0.36)	-0.7	0.04	0.26	0.42	1.1	0.64 [0.23, 1.04]
			Placebo	51	49 (96.1)	0.02 (0.42)	-1.0	-0.17	0.02	0.22	1.4	
		Week 8	Tezepelumab	48	47 (97.9)	0.23 (0.38)	-0.4	0.00	0.20	0.39	1.2	0.48 [0.08, 0.89]
			Placebo	51	50 (98.0)	0.04 (0.41)	-0.6	-0.22	-0.01	0.20	1.3	
		Week 12	Tezepelumab	48	44 (91.7)	0.30 (0.45)	-0.8	0.11	0.22	0.51	1.3	0.54 [0.12, 0.96]
			Placebo	51	47 (92.2)	0.07 (0.43)	-1.2	-0.14	-0.02	0.31	1.2	
		Week 16	Tezepelumab	48	46 (95.8)	0.30 (0.37)	-0.8	0.07	0.29	0.51	1.2	0.82 [0.39, 1.25]
			Placebo	51	44 (86.3)	0.01 (0.35)	-0.8	-0.16	-0.03	0.19	1.0	
		Week 24	Tezepelumab	48	43 (89.6)	0.35 (0.39)	-0.2	0.04	0.29	0.63	1.3	1.00 [0.53, 1.47]
			Placebo	51	36 (70.6)	-0.06 (0.43)	-0.9	-0.37	-0.06	0.13	1.6	
		Week 36	Tezepelumab	48	40 (83.3)	0.27 (0.38)	-0.8	0.00	0.28	0.47	1.3	0.65 [0.20, 1.10]
			Placebo	51	39 (76.5)	0.01 (0.43)	-0.7	-0.25	-0.06	0.15	1.6	
		Week 52	Tezepelumab	48	38 (79.2)	0.29 (0.41)	-0.8	0.00	0.34	0.55	1.0	0.57 [0.10, 1.04]
			Placebo	51	35 (68.6)	0.03 (0.52)	-0.8	-0.29	0.01	0.19	2.0	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Absolute values	Baseline	Tezepelumab	439	439 (100.0)	1.76 (0.68)	0.5	1.28	1.64	2.13	4.8	
			Placebo	439	439 (100.0)	1.78 (0.66)	0.4	1.34	1.69	2.14	4.5	
		Week 2	Tezepelumab	439	427 (97.3)	1.92 (0.70)	0.6	1.39	1.81	2.40	5.0	
			Placebo	439	419 (95.4)	1.85 (0.68)	0.4	1.37	1.75	2.26	4.1	
		Week 4	Tezepelumab	439	435 (99.1)	1.95 (0.71)	0.6	1.42	1.85	2.41	5.0	
			Placebo	439	429 (97.7)	1.86 (0.68)	0.4	1.40	1.79	2.25	4.8	
		Week 8	Tezepelumab	439	431 (98.2)	1.98 (0.72)	0.6	1.42	1.88	2.41	4.7	
			Placebo	439	428 (97.5)	1.89 (0.70)	0.4	1.39	1.78	2.24	4.7	
		Week 12	Tezepelumab	439	429 (97.7)	1.98 (0.72)	0.6	1.49	1.87	2.42	4.9	
			Placebo	439	428 (97.5)	1.88 (0.71)	0.5	1.38	1.75	2.27	4.6	
		Week 16	Tezepelumab	439	425 (96.8)	1.99 (0.75)	0.6	1.46	1.86	2.43	4.9	
			Placebo	439	425 (96.8)	1.88 (0.71)	0.5	1.37	1.76	2.23	4.7	
		Week 24	Tezepelumab	439	417 (95.0)	1.96 (0.72)	0.6	1.47	1.83	2.41	5.5	
			Placebo	439	417 (95.0)	1.87 (0.69)	0.6	1.42	1.76	2.22	4.8	
		Week 36	Tezepelumab	439	406 (92.5)	1.98 (0.73)	0.5	1.44	1.86	2.41	4.9	
			Placebo	439	401 (91.3)	1.90 (0.71)	0.6	1.41	1.79	2.27	4.6	
		Week 52	Tezepelumab	439	399 (90.9)	1.97 (0.73)	0.6	1.44	1.83	2.43	4.6	
			Placebo	439	383 (87.2)	1.88 (0.72)	0.6	1.37	1.74	2.28	4.5	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Change from baseline	Week 2	Tezepelumab	439	427 (97.3)	0.16 (0.33)	-0.8	-0.02	0.10	0.28	1.9	0.29 [0.16, 0.43]
			Placebo	439	419 (95.4)	0.06 (0.34)	-1.1	-0.11	0.01	0.19	1.7	
		Week 4	Tezepelumab	439	435 (99.1)	0.19 (0.36)	-1.0	-0.03	0.12	0.33	1.8	0.27 [0.13, 0.40]
			Placebo	439	429 (97.7)	0.09 (0.36)	-1.8	-0.10	0.05	0.25	1.6	
		Week 8	Tezepelumab	439	431 (98.2)	0.23 (0.41)	-0.9	-0.04	0.14	0.42	1.9	0.32 [0.19, 0.46]
			Placebo	439	428 (97.5)	0.10 (0.35)	-1.1	-0.10	0.06	0.28	2.1	
		Week 12	Tezepelumab	439	429 (97.7)	0.23 (0.40)	-0.7	-0.03	0.16	0.40	2.2	0.32 [0.19, 0.46]
			Placebo	439	428 (97.5)	0.10 (0.38)	-1.5	-0.09	0.05	0.25	2.1	
		Week 16	Tezepelumab	439	425 (96.8)	0.23 (0.43)	-1.0	-0.02	0.15	0.38	2.1	0.32 [0.19, 0.46]
			Placebo	439	425 (96.8)	0.10 (0.36)	-1.2	-0.09	0.04	0.26	1.9	
		Week 24	Tezepelumab	439	417 (95.0)	0.21 (0.41)	-1.0	-0.06	0.14	0.39	2.1	0.30 [0.16, 0.43]
			Placebo	439	417 (95.0)	0.09 (0.36)	-1.1	-0.11	0.05	0.26	1.7	
		Week 36	Tezepelumab	439	406 (92.5)	0.21 (0.41)	-1.0	-0.06	0.13	0.40	1.8	0.25 [0.11, 0.39]
			Placebo	439	401 (91.3)	0.11 (0.38)	-1.1	-0.12	0.06	0.29	1.7	
		Week 52	Tezepelumab	439	399 (90.9)	0.21 (0.41)	-1.0	-0.04	0.13	0.38	1.7	0.30 [0.16, 0.44]
			Placebo	439	383 (87.2)	0.09 (0.37)	-1.0	-0.14	0.06	0.26	2.3	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
Medium/Low	Absolute values	Baseline	Tezepelumab	105	105 (100.0)	1.85 (0.69)	0.6	1.36	1.80	2.21	4.8	
			Placebo	112	112 (100.0)	1.73 (0.58)	0.7	1.36	1.69	2.02	4.0	
		Week 2	Tezepelumab	105	102 (97.1)	1.98 (0.72)	0.8	1.51	1.93	2.37	5.0	
			Placebo	112	109 (97.3)	1.79 (0.60)	0.7	1.33	1.73	2.09	3.6	
		Week 4	Tezepelumab	105	104 (99.0)	2.01 (0.70)	0.8	1.54	1.95	2.41	5.0	
			Placebo	112	109 (97.3)	1.85 (0.63)	0.8	1.41	1.77	2.23	4.1	
		Week 8	Tezepelumab	105	102 (97.1)	2.06 (0.71)	0.8	1.62	1.93	2.48	4.6	
			Placebo	112	110 (98.2)	1.87 (0.66)	0.7	1.40	1.77	2.13	4.7	
		Week 12	Tezepelumab	105	102 (97.1)	2.04 (0.73)	0.8	1.52	1.93	2.53	4.9	
			Placebo	112	111 (99.1)	1.85 (0.68)	0.6	1.41	1.71	2.13	4.6	
		Week 16	Tezepelumab	105	103 (98.1)	2.02 (0.77)	0.7	1.50	1.89	2.48	4.9	
			Placebo	112	112 (100.0)	1.88 (0.65)	0.7	1.49	1.77	2.22	4.7	
		Week 24	Tezepelumab	105	102 (97.1)	2.02 (0.75)	0.7	1.54	1.89	2.45	5.5	
			Placebo	112	107 (95.5)	1.85 (0.65)	0.7	1.43	1.77	2.16	4.6	
		Week 36	Tezepelumab	105	101 (96.2)	2.03 (0.71)	0.7	1.51	1.88	2.45	4.9	
			Placebo	112	106 (94.6)	1.88 (0.63)	0.9	1.45	1.75	2.25	4.3	
		Week 52	Tezepelumab	105	98 (93.3)	2.03 (0.71)	0.6	1.56	1.92	2.45	4.6	
			Placebo	112	104 (92.9)	1.91 (0.66)	0.8	1.48	1.75	2.29	4.4	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
Medium/Low	Change from baseline	Week 2	Tezepelumab	105	102 (97.1)	0.12 (0.35)	-0.8	-0.05	0.07	0.20	1.9	0.18 [-0.09, 0.45]
			Placebo	112	109 (97.3)	0.06 (0.33)	-0.8	-0.10	0.01	0.18	1.7	
		Week 4	Tezepelumab	105	104 (99.0)	0.16 (0.38)	-1.0	-0.07	0.07	0.32	1.4	0.12 [-0.15, 0.39]
			Placebo	112	109 (97.3)	0.12 (0.33)	-0.7	-0.06	0.08	0.26	1.1	
		Week 8	Tezepelumab	105	102 (97.1)	0.19 (0.41)	-0.9	-0.05	0.11	0.32	1.9	0.12 [-0.15, 0.39]
			Placebo	112	110 (98.2)	0.14 (0.44)	-1.1	-0.09	0.04	0.29	2.1	
		Week 12	Tezepelumab	105	102 (97.1)	0.19 (0.40)	-0.6	-0.03	0.10	0.31	2.2	0.19 [-0.08, 0.46]
			Placebo	112	111 (99.1)	0.12 (0.40)	-0.5	-0.09	0.03	0.25	2.1	
		Week 16	Tezepelumab	105	103 (98.1)	0.17 (0.46)	-1.0	-0.08	0.07	0.33	2.1	0.06 [-0.21, 0.32]
			Placebo	112	112 (100.0)	0.15 (0.36)	-0.6	-0.08	0.09	0.34	1.9	
		Week 24	Tezepelumab	105	102 (97.1)	0.16 (0.42)	-0.6	-0.09	0.07	0.33	2.1	0.14 [-0.13, 0.41]
			Placebo	112	107 (95.5)	0.11 (0.35)	-0.6	-0.10	0.06	0.25	1.7	
		Week 36	Tezepelumab	105	101 (96.2)	0.16 (0.39)	-0.6	-0.09	0.11	0.34	1.8	0.03 [-0.24, 0.30]
			Placebo	112	106 (94.6)	0.15 (0.41)	-0.6	-0.09	0.06	0.31	1.6	
		Week 52	Tezepelumab	105	98 (93.3)	0.14 (0.41)	-0.6	-0.12	0.11	0.35	1.5	-0.02 [-0.30, 0.25]
			Placebo	112	104 (92.9)	0.15 (0.47)	-0.9	-0.10	0.07	0.30	2.3	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
High	Absolute values	Baseline	Tezepelumab	382	382 (100.0)	1.73 (0.67)	0.4	1.26	1.62	2.11	4.1	
			Placebo	378	378 (100.0)	1.80 (0.67)	0.4	1.33	1.69	2.18	4.5	
		Week 2	Tezepelumab	382	372 (97.4)	1.91 (0.70)	0.6	1.39	1.80	2.39	4.3	
			Placebo	378	359 (95.0)	1.86 (0.70)	0.4	1.38	1.75	2.29	4.1	
		Week 4	Tezepelumab	382	379 (99.2)	1.94 (0.72)	0.6	1.41	1.84	2.42	4.3	
			Placebo	378	369 (97.6)	1.87 (0.68)	0.4	1.42	1.79	2.23	4.8	
		Week 8	Tezepelumab	382	376 (98.4)	1.96 (0.72)	0.6	1.40	1.84	2.41	4.7	
			Placebo	378	368 (97.4)	1.89 (0.71)	0.4	1.39	1.80	2.27	4.6	
		Week 12	Tezepelumab	382	371 (97.1)	1.97 (0.72)	0.6	1.47	1.85	2.41	4.7	
			Placebo	378	364 (96.3)	1.89 (0.71)	0.5	1.38	1.76	2.29	4.6	
		Week 16	Tezepelumab	382	368 (96.3)	1.99 (0.74)	0.6	1.46	1.87	2.42	4.9	
			Placebo	378	357 (94.4)	1.88 (0.71)	0.5	1.35	1.76	2.23	4.7	
		Week 24	Tezepelumab	382	358 (93.7)	1.95 (0.71)	0.6	1.44	1.82	2.39	4.4	
			Placebo	378	346 (91.5)	1.88 (0.70)	0.6	1.40	1.76	2.22	4.8	
		Week 36	Tezepelumab	382	345 (90.3)	1.96 (0.74)	0.5	1.42	1.85	2.39	4.5	
			Placebo	378	334 (88.4)	1.91 (0.72)	0.6	1.41	1.79	2.28	4.6	
		Week 52	Tezepelumab	382	339 (88.7)	1.96 (0.74)	0.6	1.43	1.84	2.40	4.3	
			Placebo	378	314 (83.1)	1.87 (0.73)	0.6	1.32	1.73	2.28	4.5	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
High	Change from baseline	Week 2	Tezepelumab	382	372 (97.4)	0.18 (0.33)	-0.7	0.00	0.13	0.31	1.5	0.38 [0.24, 0.53]
			Placebo	378	359 (95.0)	0.05 (0.35)	-1.8	-0.11	0.01	0.18	1.2	
		Week 4	Tezepelumab	382	379 (99.2)	0.21 (0.36)	-0.9	0.00	0.14	0.35	1.8	0.36 [0.21, 0.50]
			Placebo	378	369 (97.6)	0.08 (0.38)	-1.8	-0.11	0.05	0.24	1.6	
		Week 8	Tezepelumab	382	376 (98.4)	0.24 (0.40)	-0.8	-0.04	0.16	0.44	1.8	0.41 [0.27, 0.56]
			Placebo	378	368 (97.4)	0.09 (0.33)	-0.9	-0.11	0.05	0.25	1.6	
		Week 12	Tezepelumab	382	371 (97.1)	0.24 (0.40)	-0.8	-0.01	0.18	0.43	2.0	0.39 [0.25, 0.54]
			Placebo	378	364 (96.3)	0.09 (0.38)	-1.5	-0.10	0.05	0.26	1.7	
		Week 16	Tezepelumab	382	368 (96.3)	0.26 (0.41)	-0.8	0.00	0.17	0.42	2.0	0.46 [0.32, 0.61]
			Placebo	378	357 (94.4)	0.08 (0.36)	-1.2	-0.11	0.03	0.24	1.8	
		Week 24	Tezepelumab	382	358 (93.7)	0.24 (0.40)	-1.0	-0.04	0.18	0.43	1.7	0.42 [0.27, 0.57]
			Placebo	378	346 (91.5)	0.07 (0.38)	-1.1	-0.14	0.03	0.26	1.7	
		Week 36	Tezepelumab	382	345 (90.3)	0.23 (0.41)	-1.0	-0.04	0.16	0.46	1.7	0.37 [0.22, 0.52]
			Placebo	378	334 (88.4)	0.09 (0.38)	-1.1	-0.16	0.04	0.28	1.7	
		Week 52	Tezepelumab	382	339 (88.7)	0.24 (0.41)	-1.0	-0.02	0.17	0.47	1.7	0.46 [0.30, 0.61]
			Placebo	378	314 (83.1)	0.06 (0.34)	-1.0	-0.15	0.05	0.23	1.2	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	128	128 (100.0)	1.76 (0.74)	0.6	1.28	1.69	2.08	4.8	
			Placebo	120	120 (100.0)	1.77 (0.65)	0.4	1.36	1.69	2.17	4.2	
		Week 2	Tezepelumab	128	127 (99.2)	1.95 (0.77)	0.7	1.40	1.86	2.35	5.0	
			Placebo	120	117 (97.5)	1.83 (0.70)	0.4	1.35	1.76	2.31	4.0	
		Week 4	Tezepelumab	128	128 (100.0)	1.96 (0.77)	0.7	1.43	1.87	2.39	5.0	
			Placebo	120	119 (99.2)	1.83 (0.71)	0.4	1.36	1.73	2.22	4.2	
		Week 8	Tezepelumab	128	126 (98.4)	2.02 (0.79)	0.7	1.44	1.96	2.38	4.7	
			Placebo	120	115 (95.8)	1.88 (0.72)	0.4	1.42	1.76	2.28	4.3	
		Week 12	Tezepelumab	128	124 (96.9)	2.01 (0.81)	0.7	1.52	1.91	2.36	4.9	
			Placebo	120	115 (95.8)	1.81 (0.69)	0.6	1.36	1.72	2.21	4.3	
		Week 16	Tezepelumab	128	122 (95.3)	2.02 (0.84)	0.6	1.49	1.92	2.39	4.9	
			Placebo	120	112 (93.3)	1.84 (0.68)	0.7	1.35	1.71	2.21	4.1	
		Week 24	Tezepelumab	128	120 (93.8)	2.01 (0.80)	0.6	1.52	1.90	2.38	5.5	
			Placebo	120	110 (91.7)	1.84 (0.72)	0.6	1.34	1.73	2.22	4.8	
		Week 36	Tezepelumab	128	114 (89.1)	2.01 (0.82)	0.5	1.39	1.88	2.42	4.9	
			Placebo	120	105 (87.5)	1.92 (0.71)	0.7	1.43	1.80	2.31	4.6	
		Week 52	Tezepelumab	128	109 (85.2)	2.05 (0.81)	0.6	1.51	2.01	2.42	4.6	
			Placebo	120	100 (83.3)	1.88 (0.74)	0.7	1.31	1.77	2.26	4.4	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	128	127 (99.2)	0.19 (0.31)	-0.6	0.01	0.12	0.36	1.1	0.38 [0.13, 0.64]
			Placebo	120	117 (97.5)	0.06 (0.35)	-1.0	-0.13	0.04	0.19	1.7	
		Week 4	Tezepelumab	128	128 (100.0)	0.20 (0.34)	-0.7	0.02	0.16	0.30	1.6	0.41 [0.16, 0.66]
			Placebo	120	119 (99.2)	0.06 (0.35)	-0.7	-0.11	0.03	0.22	1.4	
		Week 8	Tezepelumab	128	126 (98.4)	0.25 (0.41)	-0.6	-0.02	0.19	0.46	1.8	0.39 [0.14, 0.65]
			Placebo	120	115 (95.8)	0.09 (0.39)	-0.8	-0.13	0.05	0.31	2.1	
		Week 12	Tezepelumab	128	124 (96.9)	0.26 (0.44)	-0.8	0.01	0.17	0.46	2.0	0.55 [0.29, 0.80]
			Placebo	120	115 (95.8)	0.03 (0.37)	-1.5	-0.13	0.00	0.26	1.2	
		Week 16	Tezepelumab	128	122 (95.3)	0.26 (0.41)	-0.8	0.00	0.20	0.42	2.0	0.52 [0.26, 0.78]
			Placebo	120	112 (93.3)	0.06 (0.35)	-1.0	-0.12	0.01	0.26	1.4	
		Week 24	Tezepelumab	128	120 (93.8)	0.25 (0.38)	-0.7	-0.03	0.18	0.43	1.6	0.56 [0.30, 0.82]
			Placebo	120	110 (91.7)	0.04 (0.36)	-0.9	-0.14	0.01	0.22	1.6	
		Week 36	Tezepelumab	128	114 (89.1)	0.25 (0.39)	-0.6	-0.01	0.20	0.46	1.7	0.36 [0.09, 0.63]
			Placebo	120	105 (87.5)	0.11 (0.35)	-1.0	-0.14	0.05	0.36	1.5	
		Week 52	Tezepelumab	128	109 (85.2)	0.26 (0.41)	-0.8	-0.01	0.21	0.51	1.5	0.46 [0.19, 0.74]
			Placebo	120	100 (83.3)	0.07 (0.39)	-1.0	-0.17	0.07	0.24	1.6	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Absolute values	Baseline	Tezepelumab	359	359 (100.0)	1.76 (0.66)	0.4	1.28	1.64	2.14	3.8	
			Placebo	370	370 (100.0)	1.78 (0.66)	0.6	1.34	1.69	2.14	4.5	
		Week 2	Tezepelumab	359	347 (96.7)	1.92 (0.68)	0.6	1.39	1.81	2.41	4.0	
			Placebo	370	351 (94.9)	1.85 (0.67)	0.6	1.38	1.73	2.23	4.1	
		Week 4	Tezepelumab	359	355 (98.9)	1.95 (0.69)	0.6	1.44	1.85	2.44	4.2	
			Placebo	370	359 (97.0)	1.87 (0.65)	0.5	1.42	1.82	2.25	4.8	
		Week 8	Tezepelumab	359	352 (98.1)	1.96 (0.69)	0.6	1.43	1.86	2.44	4.3	
			Placebo	370	363 (98.1)	1.89 (0.70)	0.6	1.38	1.78	2.23	4.7	
		Week 12	Tezepelumab	359	349 (97.2)	1.97 (0.69)	0.6	1.48	1.86	2.45	4.6	
			Placebo	370	360 (97.3)	1.90 (0.71)	0.5	1.41	1.76	2.28	4.6	
		Week 16	Tezepelumab	359	349 (97.2)	1.99 (0.72)	0.6	1.45	1.87	2.48	4.4	
			Placebo	370	357 (96.5)	1.89 (0.70)	0.5	1.39	1.77	2.23	4.7	
		Week 24	Tezepelumab	359	340 (94.7)	1.95 (0.69)	0.6	1.46	1.83	2.43	4.0	
			Placebo	370	343 (92.7)	1.88 (0.68)	0.6	1.43	1.78	2.21	4.8	
		Week 36	Tezepelumab	359	332 (92.5)	1.97 (0.70)	0.6	1.44	1.86	2.39	4.2	
			Placebo	370	335 (90.5)	1.90 (0.70)	0.6	1.41	1.79	2.26	4.3	
		Week 52	Tezepelumab	359	328 (91.4)	1.96 (0.71)	0.6	1.45	1.84	2.40	4.3	
			Placebo	370	318 (85.9)	1.88 (0.71)	0.6	1.38	1.74	2.28	4.5	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Change from baseline	Week 2	Tezepelumab	359	347 (96.7)	0.16 (0.34)	-0.8	-0.03	0.11	0.28	1.9	0.32 [0.17, 0.47]
			Placebo	370	351 (94.9)	0.05 (0.34)	-1.8	-0.11	0.01	0.18	1.2	
		Week 4	Tezepelumab	359	355 (98.9)	0.20 (0.37)	-1.0	-0.04	0.12	0.36	1.8	0.27 [0.13, 0.42]
			Placebo	370	359 (97.0)	0.09 (0.38)	-1.8	-0.10	0.05	0.26	1.6	
		Week 8	Tezepelumab	359	352 (98.1)	0.22 (0.40)	-0.9	-0.04	0.13	0.40	1.9	0.32 [0.17, 0.47]
			Placebo	370	363 (98.1)	0.10 (0.35)	-1.1	-0.10	0.05	0.26	1.8	
		Week 12	Tezepelumab	359	349 (97.2)	0.22 (0.39)	-0.7	-0.03	0.17	0.39	2.2	0.28 [0.13, 0.42]
			Placebo	370	360 (97.3)	0.12 (0.38)	-1.4	-0.08	0.05	0.25	2.1	
		Week 16	Tezepelumab	359	349 (97.2)	0.23 (0.43)	-1.0	-0.03	0.15	0.40	2.1	0.32 [0.17, 0.46]
			Placebo	370	357 (96.5)	0.11 (0.36)	-1.2	-0.09	0.05	0.26	1.9	
		Week 24	Tezepelumab	359	340 (94.7)	0.21 (0.42)	-1.0	-0.06	0.14	0.41	2.1	0.29 [0.14, 0.45]
			Placebo	370	343 (92.7)	0.09 (0.37)	-1.1	-0.11	0.05	0.26	1.7	
		Week 36	Tezepelumab	359	332 (92.5)	0.21 (0.41)	-1.0	-0.06	0.13	0.40	1.8	0.27 [0.11, 0.42]
			Placebo	370	335 (90.5)	0.10 (0.40)	-1.1	-0.14	0.04	0.28	1.7	
		Week 52	Tezepelumab	359	328 (91.4)	0.20 (0.41)	-1.0	-0.06	0.13	0.40	1.7	0.29 [0.13, 0.44]
			Placebo	370	318 (85.9)	0.09 (0.38)	-1.0	-0.14	0.05	0.24	2.3	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	119	119 (100.0)	1.77 (0.75)	0.7	1.29	1.69	2.09	4.8	
			Placebo	115	115 (100.0)	1.78 (0.66)	0.4	1.33	1.69	2.17	4.2	
		Week 2	Tezepelumab	119	118 (99.2)	1.96 (0.78)	0.7	1.40	1.86	2.35	5.0	
			Placebo	115	112 (97.4)	1.84 (0.71)	0.4	1.33	1.79	2.32	4.0	
		Week 4	Tezepelumab	119	119 (100.0)	1.97 (0.78)	0.7	1.44	1.84	2.40	5.0	
			Placebo	115	114 (99.1)	1.84 (0.72)	0.4	1.34	1.74	2.26	4.2	
		Week 8	Tezepelumab	119	117 (98.3)	2.03 (0.79)	0.8	1.45	1.95	2.38	4.7	
			Placebo	115	110 (95.7)	1.89 (0.72)	0.4	1.46	1.80	2.28	4.3	
		Week 12	Tezepelumab	119	115 (96.6)	2.02 (0.82)	0.8	1.52	1.89	2.38	4.9	
			Placebo	115	110 (95.7)	1.82 (0.70)	0.6	1.36	1.73	2.21	4.3	
		Week 16	Tezepelumab	119	114 (95.8)	2.04 (0.84)	0.7	1.52	1.93	2.39	4.9	
			Placebo	115	108 (93.9)	1.84 (0.69)	0.7	1.32	1.71	2.21	4.1	
		Week 24	Tezepelumab	119	112 (94.1)	2.03 (0.80)	0.7	1.54	1.90	2.41	5.5	
			Placebo	115	106 (92.2)	1.84 (0.73)	0.6	1.34	1.73	2.24	4.8	
		Week 36	Tezepelumab	119	106 (89.1)	2.03 (0.83)	0.7	1.42	1.88	2.45	4.9	
			Placebo	115	102 (88.7)	1.92 (0.71)	0.7	1.43	1.81	2.31	4.6	
		Week 52	Tezepelumab	119	101 (84.9)	2.07 (0.82)	0.6	1.54	2.01	2.43	4.6	
			Placebo	115	98 (85.2)	1.88 (0.74)	0.7	1.30	1.77	2.28	4.4	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	119	118 (99.2)	0.19 (0.32)	-0.6	0.00	0.12	0.36	1.1	0.36 [0.10, 0.62]
			Placebo	115	112 (97.4)	0.06 (0.35)	-1.0	-0.13	0.04	0.19	1.7	
		Week 4	Tezepelumab	119	119 (100.0)	0.20 (0.35)	-0.7	0.01	0.16	0.30	1.6	0.38 [0.12, 0.64]
			Placebo	115	114 (99.1)	0.07 (0.35)	-0.7	-0.10	0.03	0.23	1.4	
		Week 8	Tezepelumab	119	117 (98.3)	0.25 (0.42)	-0.6	-0.02	0.18	0.46	1.8	0.37 [0.11, 0.63]
			Placebo	115	110 (95.7)	0.10 (0.39)	-0.7	-0.13	0.06	0.31	2.1	
		Week 12	Tezepelumab	119	115 (96.6)	0.25 (0.46)	-0.8	-0.03	0.17	0.46	2.0	0.52 [0.26, 0.79]
			Placebo	115	110 (95.7)	0.04 (0.37)	-1.5	-0.12	0.01	0.26	1.2	
		Week 16	Tezepelumab	119	114 (95.8)	0.27 (0.42)	-0.8	0.02	0.20	0.44	2.0	0.53 [0.27, 0.80]
			Placebo	115	108 (93.9)	0.06 (0.36)	-1.0	-0.12	0.01	0.26	1.4	
		Week 24	Tezepelumab	119	112 (94.1)	0.26 (0.39)	-0.7	-0.03	0.18	0.43	1.6	0.55 [0.28, 0.82]
			Placebo	115	106 (92.2)	0.05 (0.37)	-0.9	-0.14	0.01	0.23	1.6	
		Week 36	Tezepelumab	119	106 (89.1)	0.25 (0.40)	-0.6	-0.01	0.20	0.46	1.7	0.36 [0.08, 0.63]
			Placebo	115	102 (88.7)	0.12 (0.36)	-1.0	-0.14	0.05	0.36	1.5	
		Week 52	Tezepelumab	119	101 (84.9)	0.26 (0.42)	-0.8	-0.01	0.19	0.51	1.5	0.46 [0.18, 0.74]
			Placebo	115	98 (85.2)	0.07 (0.39)	-1.0	-0.18	0.07	0.23	1.6	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Absolute values	Baseline	Tezepelumab	368	368 (100.0)	1.75 (0.65)	0.4	1.28	1.64	2.14	3.8	
			Placebo	375	375 (100.0)	1.78 (0.65)	0.6	1.34	1.69	2.13	4.5	
		Week 2	Tezepelumab	368	356 (96.7)	1.92 (0.68)	0.6	1.39	1.81	2.41	4.0	
			Placebo	375	356 (94.9)	1.85 (0.66)	0.6	1.39	1.74	2.22	4.1	
		Week 4	Tezepelumab	368	364 (98.9)	1.95 (0.69)	0.6	1.43	1.86	2.43	4.2	
			Placebo	375	364 (97.1)	1.87 (0.65)	0.5	1.43	1.81	2.23	4.8	
		Week 8	Tezepelumab	368	361 (98.1)	1.96 (0.70)	0.6	1.42	1.87	2.44	4.3	
			Placebo	375	368 (98.1)	1.89 (0.69)	0.6	1.38	1.78	2.23	4.7	
		Week 12	Tezepelumab	368	358 (97.3)	1.97 (0.69)	0.6	1.47	1.87	2.45	4.6	
			Placebo	375	365 (97.3)	1.90 (0.71)	0.5	1.41	1.75	2.27	4.6	
		Week 16	Tezepelumab	368	357 (97.0)	1.98 (0.72)	0.6	1.45	1.86	2.48	4.4	
			Placebo	375	361 (96.3)	1.89 (0.70)	0.5	1.40	1.77	2.23	4.7	
		Week 24	Tezepelumab	368	348 (94.6)	1.95 (0.69)	0.6	1.45	1.83	2.43	4.0	
			Placebo	375	347 (92.5)	1.88 (0.68)	0.6	1.43	1.77	2.21	4.8	
		Week 36	Tezepelumab	368	340 (92.4)	1.96 (0.70)	0.5	1.44	1.86	2.39	4.2	
			Placebo	375	338 (90.1)	1.90 (0.70)	0.6	1.41	1.79	2.26	4.3	
		Week 52	Tezepelumab	368	336 (91.3)	1.95 (0.70)	0.6	1.44	1.84	2.39	4.3	
			Placebo	375	320 (85.3)	1.88 (0.71)	0.6	1.38	1.74	2.28	4.5	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Change from baseline	Week 2	Tezepelumab	368	356 (96.7)	0.16 (0.34)	-0.8	-0.02	0.11	0.28	1.9	0.33 [0.18, 0.48]
			Placebo	375	356 (94.9)	0.05 (0.34)	-1.8	-0.11	0.01	0.18	1.2	
		Week 4	Tezepelumab	368	364 (98.9)	0.20 (0.36)	-1.0	-0.03	0.13	0.36	1.8	0.28 [0.14, 0.43]
			Placebo	375	364 (97.1)	0.09 (0.37)	-1.8	-0.10	0.05	0.26	1.6	
		Week 8	Tezepelumab	368	361 (98.1)	0.22 (0.40)	-0.9	-0.04	0.13	0.40	1.9	0.33 [0.18, 0.48]
			Placebo	375	368 (98.1)	0.10 (0.35)	-1.1	-0.10	0.05	0.25	1.8	
		Week 12	Tezepelumab	368	358 (97.3)	0.23 (0.38)	-0.7	-0.02	0.17	0.40	2.2	0.29 [0.14, 0.43]
			Placebo	375	365 (97.3)	0.12 (0.38)	-1.4	-0.09	0.05	0.25	2.1	
		Week 16	Tezepelumab	368	357 (97.0)	0.23 (0.42)	-1.0	-0.03	0.15	0.39	2.1	0.31 [0.17, 0.46]
			Placebo	375	361 (96.3)	0.11 (0.36)	-1.2	-0.09	0.05	0.26	1.9	
		Week 24	Tezepelumab	368	348 (94.6)	0.21 (0.41)	-1.0	-0.06	0.14	0.41	2.1	0.30 [0.15, 0.45]
			Placebo	375	347 (92.5)	0.09 (0.37)	-1.1	-0.11	0.05	0.26	1.7	
		Week 36	Tezepelumab	368	340 (92.4)	0.21 (0.41)	-1.0	-0.06	0.13	0.40	1.8	0.27 [0.12, 0.42]
			Placebo	375	338 (90.1)	0.10 (0.40)	-1.1	-0.14	0.04	0.28	1.7	
		Week 52	Tezepelumab	368	336 (91.3)	0.20 (0.41)	-1.0	-0.06	0.13	0.40	1.7	0.29 [0.13, 0.44]
			Placebo	375	320 (85.3)	0.09 (0.38)	-1.0	-0.14	0.05	0.25	2.3	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	195	195 (100.0)	1.72 (0.71)	0.5	1.21	1.61	2.04	4.8	
			Placebo	184	184 (100.0)	1.82 (0.63)	0.6	1.37	1.74	2.13	4.1	
		Week 2	Tezepelumab	195	188 (96.4)	1.92 (0.74)	0.6	1.38	1.81	2.33	5.0	
			Placebo	184	175 (95.1)	1.89 (0.65)	0.7	1.46	1.80	2.29	3.9	
		Week 4	Tezepelumab	195	193 (99.0)	1.95 (0.76)	0.6	1.42	1.82	2.38	5.0	
			Placebo	184	179 (97.3)	1.91 (0.65)	0.7	1.48	1.83	2.27	4.0	
		Week 8	Tezepelumab	195	191 (97.9)	1.98 (0.76)	0.6	1.41	1.85	2.43	4.7	
			Placebo	184	181 (98.4)	1.94 (0.72)	0.7	1.50	1.85	2.30	4.7	
		Week 12	Tezepelumab	195	188 (96.4)	1.98 (0.77)	0.6	1.50	1.85	2.38	4.9	
			Placebo	184	183 (99.5)	1.90 (0.68)	0.7	1.47	1.79	2.24	4.6	
		Week 16	Tezepelumab	195	188 (96.4)	1.99 (0.78)	0.6	1.45	1.83	2.36	4.9	
			Placebo	184	179 (97.3)	1.93 (0.68)	0.7	1.51	1.81	2.24	4.7	
		Week 24	Tezepelumab	195	183 (93.8)	1.93 (0.73)	0.6	1.48	1.80	2.32	5.5	
			Placebo	184	174 (94.6)	1.89 (0.67)	0.6	1.42	1.81	2.22	4.6	
		Week 36	Tezepelumab	195	177 (90.8)	2.00 (0.78)	0.6	1.47	1.83	2.37	4.9	
			Placebo	184	170 (92.4)	1.91 (0.68)	0.7	1.43	1.80	2.29	4.3	
		Week 52	Tezepelumab	195	173 (88.7)	2.00 (0.77)	0.6	1.49	1.87	2.39	4.6	
			Placebo	184	156 (84.8)	1.90 (0.71)	0.7	1.40	1.74	2.27	4.4	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	195	188 (96.4)	0.20 (0.33)	-0.5	0.00	0.14	0.31	1.9	0.40 [0.19, 0.60]
			Placebo	184	175 (95.1)	0.06 (0.37)	-1.8	-0.11	0.04	0.20	1.2	
		Week 4	Tezepelumab	195	193 (99.0)	0.24 (0.37)	-0.9	0.01	0.13	0.36	1.7	0.39 [0.18, 0.59]
			Placebo	184	179 (97.3)	0.09 (0.40)	-1.0	-0.14	0.05	0.28	1.4	
		Week 8	Tezepelumab	195	191 (97.9)	0.26 (0.42)	-0.8	-0.03	0.19	0.50	1.8	0.37 [0.17, 0.58]
			Placebo	184	181 (98.4)	0.11 (0.40)	-0.7	-0.13	0.07	0.29	1.8	
		Week 12	Tezepelumab	195	188 (96.4)	0.28 (0.44)	-0.7	0.02	0.21	0.46	2.0	0.45 [0.24, 0.65]
			Placebo	184	183 (99.5)	0.08 (0.46)	-1.5	-0.12	0.02	0.25	2.1	
		Week 16	Tezepelumab	195	188 (96.4)	0.28 (0.44)	-0.6	-0.01	0.18	0.45	2.0	0.41 [0.20, 0.61]
			Placebo	184	179 (97.3)	0.11 (0.39)	-1.0	-0.11	0.06	0.28	1.9	
		Week 24	Tezepelumab	195	183 (93.8)	0.25 (0.43)	-1.0	-0.05	0.23	0.45	2.1	0.40 [0.19, 0.61]
			Placebo	184	174 (94.6)	0.09 (0.39)	-0.9	-0.13	0.05	0.27	1.7	
		Week 36	Tezepelumab	195	177 (90.8)	0.28 (0.43)	-1.0	0.00	0.22	0.51	1.8	0.44 [0.23, 0.66]
			Placebo	184	170 (92.4)	0.09 (0.42)	-1.1	-0.17	0.03	0.27	1.7	
		Week 52	Tezepelumab	195	173 (88.7)	0.27 (0.44)	-1.0	-0.03	0.23	0.53	1.6	0.45 [0.23, 0.66]
			Placebo	184	156 (84.8)	0.08 (0.40)	-1.0	-0.17	0.05	0.24	2.3	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Absolute values	Baseline	Tezepelumab	292	292 (100.0)	1.79 (0.65)	0.4	1.31	1.70	2.20	4.1	
			Placebo	306	306 (100.0)	1.76 (0.67)	0.4	1.30	1.68	2.16	4.5	
		Week 2	Tezepelumab	292	286 (97.9)	1.94 (0.68)	0.6	1.43	1.84	2.42	4.3	
			Placebo	306	293 (95.8)	1.82 (0.69)	0.4	1.33	1.70	2.24	4.1	
		Week 4	Tezepelumab	292	290 (99.3)	1.96 (0.69)	0.7	1.44	1.90	2.48	3.8	
			Placebo	306	299 (97.7)	1.83 (0.67)	0.4	1.36	1.74	2.19	4.8	
		Week 8	Tezepelumab	292	287 (98.3)	1.98 (0.70)	0.6	1.43	1.89	2.41	4.7	
			Placebo	306	297 (97.1)	1.85 (0.69)	0.4	1.35	1.72	2.23	4.6	
		Week 12	Tezepelumab	292	285 (97.6)	1.98 (0.70)	0.6	1.49	1.91	2.45	4.6	
			Placebo	306	292 (95.4)	1.87 (0.72)	0.5	1.36	1.74	2.29	4.6	
		Week 16	Tezepelumab	292	283 (96.9)	2.00 (0.72)	0.6	1.49	1.89	2.51	4.7	
			Placebo	306	290 (94.8)	1.85 (0.71)	0.5	1.32	1.73	2.21	4.7	
		Week 24	Tezepelumab	292	277 (94.9)	1.99 (0.71)	0.6	1.48	1.89	2.48	4.0	
			Placebo	306	279 (91.2)	1.86 (0.71)	0.7	1.40	1.72	2.20	4.8	
		Week 36	Tezepelumab	292	269 (92.1)	1.96 (0.70)	0.5	1.43	1.89	2.41	4.4	
			Placebo	306	270 (88.2)	1.90 (0.71)	0.6	1.40	1.79	2.26	4.6	
		Week 52	Tezepelumab	292	264 (90.4)	1.97 (0.71)	0.7	1.44	1.84	2.42	4.2	
			Placebo	306	262 (85.6)	1.87 (0.72)	0.6	1.34	1.73	2.28	4.5	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Change from baseline	Week 2	Tezepelumab	292	286 (97.9)	0.15 (0.33)	-0.8	-0.03	0.09	0.28	1.5	0.30 [0.13, 0.46]
			Placebo	306	293 (95.8)	0.05 (0.33)	-1.1	-0.11	0.00	0.16	1.7	
		Week 4	Tezepelumab	292	290 (99.3)	0.17 (0.35)	-1.0	-0.04	0.13	0.33	1.8	0.25 [0.09, 0.41]
			Placebo	306	299 (97.7)	0.08 (0.35)	-1.8	-0.09	0.05	0.24	1.6	
		Week 8	Tezepelumab	292	287 (98.3)	0.20 (0.39)	-0.9	-0.04	0.13	0.36	1.9	0.32 [0.15, 0.48]
			Placebo	306	297 (97.1)	0.09 (0.34)	-1.1	-0.10	0.04	0.27	2.1	
		Week 12	Tezepelumab	292	285 (97.6)	0.20 (0.37)	-0.8	-0.04	0.12	0.37	2.2	0.27 [0.10, 0.43]
			Placebo	306	292 (95.4)	0.11 (0.33)	-1.1	-0.08	0.05	0.25	1.4	
		Week 16	Tezepelumab	292	283 (96.9)	0.21 (0.41)	-1.0	-0.03	0.14	0.37	2.1	0.33 [0.17, 0.50]
			Placebo	306	290 (94.8)	0.09 (0.34)	-1.2	-0.10	0.02	0.24	1.5	
		Week 24	Tezepelumab	292	277 (94.9)	0.20 (0.39)	-0.7	-0.05	0.13	0.38	1.7	0.33 [0.16, 0.49]
			Placebo	306	279 (91.2)	0.08 (0.36)	-1.1	-0.12	0.04	0.25	1.6	
		Week 36	Tezepelumab	292	269 (92.1)	0.18 (0.39)	-0.8	-0.09	0.09	0.35	1.6	0.18 [0.01, 0.35]
			Placebo	306	270 (88.2)	0.11 (0.37)	-0.9	-0.12	0.06	0.30	1.6	
		Week 52	Tezepelumab	292	264 (90.4)	0.18 (0.39)	-1.0	-0.06	0.12	0.35	1.7	0.25 [0.08, 0.42]
			Placebo	306	262 (85.6)	0.09 (0.37)	-1.0	-0.13	0.06	0.24	2.0	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Sex									0.041 i
Male	Week 2	Tezepelumab	173	170 (98.3)	0.21 (0.03)	(0.15, 0.26)	0.17 (0.04)	(0.09, 0.25)	<0.001 *
		Placebo	176	172 (97.7)	0.04 (0.03)	(-0.02, 0.09)			
	Week 4	Tezepelumab	173	172 (99.4)	0.26 (0.03)	(0.19, 0.32)	0.18 (0.05)	(0.09, 0.27)	<0.001 *
		Placebo	176	172 (97.7)	0.07 (0.03)	(0.01, 0.14)			
	Week 8	Tezepelumab	173	168 (97.1)	0.26 (0.03)	(0.20, 0.33)	0.15 (0.05)	(0.05, 0.24)	0.002 *
		Placebo	176	176 (100.0)	0.11 (0.03)	(0.05, 0.18)			
	Week 12	Tezepelumab	173	166 (96.0)	0.27 (0.04)	(0.20, 0.34)	0.14 (0.05)	(0.04, 0.24)	0.004 *
		Placebo	176	173 (98.3)	0.13 (0.03)	(0.06, 0.19)			
	Week 16	Tezepelumab	173	168 (97.1)	0.30 (0.04)	(0.23, 0.37)	0.21 (0.05)	(0.11, 0.30)	<0.001 *
		Placebo	176	173 (98.3)	0.09 (0.04)	(0.02, 0.16)			
	Week 24	Tezepelumab	173	159 (91.9)	0.27 (0.03)	(0.20, 0.34)	0.18 (0.05)	(0.09, 0.27)	<0.001 *
		Placebo	176	162 (92.0)	0.09 (0.03)	(0.03, 0.16)			
	Week 36	Tezepelumab	173	159 (91.9)	0.27 (0.04)	(0.20, 0.34)	0.18 (0.05)	(0.08, 0.28)	<0.001 *
		Placebo	176	160 (90.9)	0.09 (0.04)	(0.02, 0.16)			
	Week 52	Tezepelumab	173	157 (90.8)	0.29 (0.04)	(0.22, 0.36)	0.20 (0.05)	(0.10, 0.30)	<0.001 *
		Placebo	176	151 (85.8)	0.09 (0.04)	(0.01, 0.16)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Female	Week 2	Tezepelumab	314	304 (96.8)	0.15 (0.02)	(0.11, 0.18)	0.08 (0.02)	(0.04, 0.13)	<0.001 *
		Placebo	314	296 (94.3)	0.06 (0.02)	(0.03, 0.10)			
	Week 4	Tezepelumab	314	311 (99.0)	0.16 (0.02)	(0.13, 0.20)	0.07 (0.02)	(0.02, 0.12)	0.004 *
		Placebo	314	306 (97.5)	0.09 (0.02)	(0.06, 0.13)			
	Week 8	Tezepelumab	314	310 (98.7)	0.21 (0.02)	(0.17, 0.24)	0.12 (0.03)	(0.07, 0.17)	<0.001 *
		Placebo	314	302 (96.2)	0.09 (0.02)	(0.05, 0.12)			
	Week 12	Tezepelumab	314	307 (97.8)	0.21 (0.02)	(0.17, 0.25)	0.13 (0.03)	(0.08, 0.18)	<0.001 *
		Placebo	314	302 (96.2)	0.08 (0.02)	(0.04, 0.12)			
	Week 16	Tezepelumab	314	303 (96.5)	0.20 (0.02)	(0.17, 0.24)	0.10 (0.03)	(0.05, 0.16)	<0.001 *
		Placebo	314	296 (94.3)	0.10 (0.02)	(0.06, 0.13)			
	Week 24	Tezepelumab	314	301 (95.9)	0.18 (0.02)	(0.15, 0.22)	0.11 (0.03)	(0.05, 0.16)	<0.001 *
		Placebo	314	291 (92.7)	0.08 (0.02)	(0.04, 0.11)			
	Week 36	Tezepelumab	314	287 (91.4)	0.19 (0.02)	(0.15, 0.23)	0.08 (0.03)	(0.03, 0.14)	0.003 *
		Placebo	314	280 (89.2)	0.11 (0.02)	(0.07, 0.15)			
	Week 52	Tezepelumab	314	280 (89.2)	0.19 (0.02)	(0.15, 0.23)	0.10 (0.03)	(0.04, 0.15)	<0.001 *
		Placebo	314	267 (85.0)	0.09 (0.02)	(0.05, 0.13)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Age									0.083
< 65 years	Week 2	Tezepelumab	391	381 (97.4)	0.19 (0.02)	(0.15, 0.22)	0.13 (0.02)	(0.08, 0.18)	<0.001 *
		Placebo	416	397 (95.4)	0.05 (0.02)	(0.02, 0.09)			
	Week 4	Tezepelumab	391	390 (99.7)	0.22 (0.02)	(0.18, 0.26)	0.13 (0.03)	(0.08, 0.18)	<0.001 *
		Placebo	416	408 (98.1)	0.09 (0.02)	(0.05, 0.12)			
	Week 8	Tezepelumab	391	384 (98.2)	0.25 (0.02)	(0.21, 0.29)	0.15 (0.03)	(0.09, 0.20)	<0.001 *
		Placebo	416	408 (98.1)	0.10 (0.02)	(0.06, 0.14)			
	Week 12	Tezepelumab	391	380 (97.2)	0.25 (0.02)	(0.21, 0.29)	0.14 (0.03)	(0.09, 0.20)	<0.001 *
		Placebo	416	405 (97.4)	0.11 (0.02)	(0.07, 0.14)			
	Week 16	Tezepelumab	391	379 (96.9)	0.26 (0.02)	(0.22, 0.30)	0.16 (0.03)	(0.10, 0.21)	<0.001 *
		Placebo	416	399 (95.9)	0.10 (0.02)	(0.06, 0.14)			
	Week 24	Tezepelumab	391	371 (94.9)	0.24 (0.02)	(0.20, 0.28)	0.15 (0.03)	(0.10, 0.21)	<0.001 *
		Placebo	416	386 (92.8)	0.08 (0.02)	(0.04, 0.12)			
	Week 36	Tezepelumab	391	359 (91.8)	0.24 (0.02)	(0.20, 0.28)	0.14 (0.03)	(0.08, 0.19)	<0.001 *
		Placebo	416	374 (89.9)	0.11 (0.02)	(0.07, 0.15)			
	Week 52	Tezepelumab	391	353 (90.3)	0.25 (0.02)	(0.21, 0.29)	0.15 (0.03)	(0.09, 0.21)	<0.001 *
		Placebo	416	355 (85.3)	0.10 (0.02)	(0.06, 0.14)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 65 years	Week 2	Tezepelumab	96	93 (96.9)	0.09 (0.02)	(0.05, 0.13)	0.05 (0.03)	(-0.02, 0.11)	0.155
		Placebo	74	71 (95.9)	0.04 (0.02)	(-0.00, 0.09)			
	Week 4	Tezepelumab	96	93 (96.9)	0.11 (0.02)	(0.06, 0.16)	0.03 (0.04)	(-0.05, 0.10)	0.466
		Placebo	74	70 (94.6)	0.08 (0.03)	(0.02, 0.14)			
	Week 8	Tezepelumab	96	94 (97.9)	0.13 (0.03)	(0.08, 0.18)	0.07 (0.04)	(-0.01, 0.15)	0.107
		Placebo	74	70 (94.6)	0.06 (0.03)	(0.00, 0.13)			
	Week 12	Tezepelumab	96	93 (96.9)	0.15 (0.03)	(0.10, 0.21)	0.11 (0.04)	(0.03, 0.19)	0.009 *
		Placebo	74	70 (94.6)	0.04 (0.03)	(-0.02, 0.11)			
	Week 16	Tezepelumab	96	92 (95.8)	0.15 (0.03)	(0.10, 0.20)	0.08 (0.04)	(0.00, 0.17)	0.045 *
		Placebo	74	70 (94.6)	0.07 (0.03)	(0.00, 0.13)			
	Week 24	Tezepelumab	96	89 (92.7)	0.12 (0.03)	(0.06, 0.17)	0.06 (0.04)	(-0.02, 0.14)	0.159
		Placebo	74	67 (90.5)	0.06 (0.03)	(-0.00, 0.12)			
	Week 36	Tezepelumab	96	87 (90.6)	0.13 (0.03)	(0.07, 0.18)	0.07 (0.04)	(-0.02, 0.15)	0.113
		Placebo	74	66 (89.2)	0.06 (0.03)	(-0.00, 0.12)			
	Week 52	Tezepelumab	96	84 (87.5)	0.13 (0.03)	(0.07, 0.19)	0.10 (0.05)	(0.00, 0.19)	0.042 *
		Placebo	74	63 (85.1)	0.03 (0.04)	(-0.04, 0.10)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Exacerbations in the year before study									0.078
<= 2	Week 2	Tezepelumab	284	278 (97.9)	0.16 (0.02)	(0.12, 0.20)	0.09 (0.03)	(0.03, 0.14)	0.002 *
		Placebo	299	288 (96.3)	0.07 (0.02)	(0.03, 0.11)			
	Week 4	Tezepelumab	284	281 (98.9)	0.18 (0.02)	(0.14, 0.23)	0.08 (0.03)	(0.02, 0.14)	0.008 *
		Placebo	299	289 (96.7)	0.10 (0.02)	(0.06, 0.14)			
	Week 8	Tezepelumab	284	277 (97.5)	0.21 (0.02)	(0.17, 0.26)	0.10 (0.03)	(0.04, 0.16)	0.002 *
		Placebo	299	292 (97.7)	0.11 (0.02)	(0.07, 0.16)			
	Week 12	Tezepelumab	284	275 (96.8)	0.20 (0.02)	(0.16, 0.25)	0.09 (0.03)	(0.02, 0.15)	0.007 *
		Placebo	299	293 (98.0)	0.11 (0.02)	(0.07, 0.16)			
	Week 16	Tezepelumab	284	276 (97.2)	0.22 (0.02)	(0.17, 0.27)	0.11 (0.03)	(0.04, 0.17)	0.001 *
		Placebo	299	289 (96.7)	0.11 (0.02)	(0.07, 0.16)			
	Week 24	Tezepelumab	284	268 (94.4)	0.20 (0.02)	(0.15, 0.24)	0.11 (0.03)	(0.05, 0.18)	<0.001 *
		Placebo	299	277 (92.6)	0.08 (0.02)	(0.04, 0.13)			
	Week 36	Tezepelumab	284	264 (93.0)	0.21 (0.02)	(0.16, 0.26)	0.09 (0.03)	(0.03, 0.16)	0.006 *
		Placebo	299	275 (92.0)	0.11 (0.02)	(0.07, 0.16)			
	Week 52	Tezepelumab	284	257 (90.5)	0.20 (0.03)	(0.15, 0.25)	0.09 (0.04)	(0.03, 0.16)	0.008 *
		Placebo	299	263 (88.0)	0.11 (0.02)	(0.06, 0.15)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
> 2	Week 2	Tezepelumab	203	196 (96.6)	0.18 (0.02)	(0.13, 0.23)	0.16 (0.03)	(0.09, 0.22)	<0.001 *
		Placebo	191	180 (94.2)	0.02 (0.02)	(-0.03, 0.07)			
	Week 4	Tezepelumab	203	202 (99.5)	0.21 (0.02)	(0.16, 0.26)	0.15 (0.03)	(0.09, 0.22)	<0.001 *
		Placebo	191	189 (99.0)	0.06 (0.03)	(0.01, 0.11)			
	Week 8	Tezepelumab	203	201 (99.0)	0.25 (0.02)	(0.20, 0.30)	0.17 (0.04)	(0.10, 0.24)	<0.001 *
		Placebo	191	186 (97.4)	0.07 (0.03)	(0.02, 0.12)			
	Week 12	Tezepelumab	203	198 (97.5)	0.27 (0.03)	(0.22, 0.32)	0.20 (0.04)	(0.12, 0.27)	<0.001 *
		Placebo	191	182 (95.3)	0.07 (0.03)	(0.02, 0.13)			
	Week 16	Tezepelumab	203	195 (96.1)	0.26 (0.03)	(0.21, 0.31)	0.19 (0.04)	(0.12, 0.26)	<0.001 *
		Placebo	191	180 (94.2)	0.07 (0.03)	(0.02, 0.12)			
	Week 24	Tezepelumab	203	192 (94.6)	0.24 (0.03)	(0.19, 0.29)	0.16 (0.04)	(0.09, 0.23)	<0.001 *
		Placebo	191	176 (92.1)	0.08 (0.03)	(0.02, 0.13)			
	Week 36	Tezepelumab	203	182 (89.7)	0.24 (0.03)	(0.18, 0.29)	0.15 (0.04)	(0.07, 0.23)	<0.001 *
		Placebo	191	165 (86.4)	0.09 (0.03)	(0.03, 0.14)			
	Week 52	Tezepelumab	203	180 (88.7)	0.26 (0.03)	(0.20, 0.31)	0.19 (0.04)	(0.11, 0.27)	<0.001 *
		Placebo	191	155 (81.2)	0.07 (0.03)	(0.01, 0.12)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Race									0.249
White	Week 2	Tezepelumab	304	298 (98.0)	0.18 (0.02)	(0.14, 0.22)	0.15 (0.03)	(0.09, 0.20)	<0.001 *
		Placebo	297	282 (94.9)	0.03 (0.02)	(-0.01, 0.07)			
	Week 4	Tezepelumab	304	301 (99.0)	0.20 (0.02)	(0.15, 0.24)	0.10 (0.03)	(0.05, 0.16)	<0.001 *
		Placebo	297	286 (96.3)	0.09 (0.02)	(0.05, 0.13)			
	Week 8	Tezepelumab	304	301 (99.0)	0.22 (0.02)	(0.18, 0.27)	0.12 (0.03)	(0.05, 0.18)	<0.001 *
		Placebo	297	286 (96.3)	0.11 (0.02)	(0.06, 0.15)			
	Week 12	Tezepelumab	304	293 (96.4)	0.22 (0.02)	(0.18, 0.27)	0.13 (0.03)	(0.06, 0.19)	<0.001 *
		Placebo	297	284 (95.6)	0.10 (0.02)	(0.05, 0.14)			
	Week 16	Tezepelumab	304	293 (96.4)	0.24 (0.02)	(0.20, 0.29)	0.15 (0.03)	(0.08, 0.21)	<0.001 *
		Placebo	297	281 (94.6)	0.09 (0.02)	(0.05, 0.14)			
	Week 24	Tezepelumab	304	286 (94.1)	0.21 (0.02)	(0.17, 0.26)	0.12 (0.03)	(0.06, 0.19)	<0.001 *
		Placebo	297	269 (90.6)	0.09 (0.02)	(0.04, 0.13)			
	Week 36	Tezepelumab	304	274 (90.1)	0.22 (0.02)	(0.17, 0.26)	0.10 (0.03)	(0.04, 0.17)	0.002 *
		Placebo	297	260 (87.5)	0.12 (0.02)	(0.07, 0.16)			
	Week 52	Tezepelumab	304	267 (87.8)	0.22 (0.02)	(0.17, 0.27)	0.11 (0.03)	(0.04, 0.17)	0.002 *
		Placebo	297	243 (81.8)	0.11 (0.02)	(0.06, 0.16)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Black or African American	Week 2	Tezepelumab	27	23 (85.2)	0.14 (0.07)	(-0.00, 0.28)	-0.00 (0.10)	(-0.20, 0.19)	0.992
		Placebo	27	27 (100.0)	0.14 (0.07)	(0.00, 0.28)			
	Week 4	Tezepelumab	27	26 (96.3)	0.09 (0.07)	(-0.04, 0.22)	-0.00 (0.09)	(-0.19, 0.19)	0.993
		Placebo	27	27 (100.0)	0.09 (0.07)	(-0.04, 0.22)			
	Week 8	Tezepelumab	27	26 (96.3)	0.18 (0.07)	(0.04, 0.32)	0.12 (0.10)	(-0.08, 0.32)	0.234
		Placebo	27	27 (100.0)	0.06 (0.07)	(-0.08, 0.20)			
	Week 12	Tezepelumab	27	26 (96.3)	0.23 (0.07)	(0.09, 0.36)	0.12 (0.09)	(-0.07, 0.31)	0.207
		Placebo	27	27 (100.0)	0.11 (0.07)	(-0.03, 0.24)			
	Week 16	Tezepelumab	27	25 (92.6)	0.08 (0.08)	(-0.07, 0.23)	-0.03 (0.11)	(-0.24, 0.18)	0.769
		Placebo	27	26 (96.3)	0.11 (0.07)	(-0.04, 0.26)			
	Week 24	Tezepelumab	27	23 (85.2)	0.16 (0.06)	(0.04, 0.28)	0.14 (0.08)	(-0.02, 0.31)	0.087
		Placebo	27	25 (92.6)	0.02 (0.06)	(-0.10, 0.13)			
	Week 36	Tezepelumab	27	23 (85.2)	0.17 (0.06)	(0.05, 0.28)	0.02 (0.08)	(-0.14, 0.18)	0.800
		Placebo	27	26 (96.3)	0.15 (0.05)	(0.04, 0.25)			
	Week 52	Tezepelumab	27	23 (85.2)	0.21 (0.07)	(0.07, 0.34)	0.13 (0.09)	(-0.05, 0.32)	0.159
		Placebo	27	24 (88.9)	0.07 (0.07)	(-0.06, 0.20)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Asian	Week 2	Tezepelumab	138	136 (98.6)	0.15 (0.03)	(0.10, 0.21)	0.08 (0.04)	(0.00, 0.15)	0.044 *
		Placebo	143	139 (97.2)	0.07 (0.03)	(0.02, 0.13)			
	Week 4	Tezepelumab	138	138 (100.0)	0.22 (0.03)	(0.16, 0.28)	0.16 (0.04)	(0.07, 0.24)	<0.001 *
		Placebo	143	143 (100.0)	0.06 (0.03)	(0.00, 0.12)			
	Week 8	Tezepelumab	138	133 (96.4)	0.25 (0.03)	(0.19, 0.32)	0.18 (0.04)	(0.10, 0.27)	<0.001 *
		Placebo	143	143 (100.0)	0.07 (0.03)	(0.01, 0.13)			
	Week 12	Tezepelumab	138	136 (98.6)	0.26 (0.03)	(0.20, 0.32)	0.18 (0.05)	(0.09, 0.27)	<0.001 *
		Placebo	143	141 (98.6)	0.08 (0.03)	(0.02, 0.15)			
	Week 16	Tezepelumab	138	136 (98.6)	0.26 (0.03)	(0.20, 0.32)	0.18 (0.04)	(0.09, 0.26)	<0.001 *
		Placebo	143	140 (97.9)	0.08 (0.03)	(0.02, 0.14)			
	Week 24	Tezepelumab	138	135 (97.8)	0.24 (0.03)	(0.18, 0.31)	0.17 (0.04)	(0.08, 0.26)	<0.001 *
		Placebo	143	138 (96.5)	0.07 (0.03)	(0.01, 0.13)			
	Week 36	Tezepelumab	138	132 (95.7)	0.25 (0.03)	(0.18, 0.32)	0.20 (0.05)	(0.10, 0.29)	<0.001 *
		Placebo	143	132 (92.3)	0.05 (0.03)	(-0.02, 0.12)			
	Week 52	Tezepelumab	138	130 (94.2)	0.25 (0.03)	(0.19, 0.32)	0.21 (0.05)	(0.11, 0.30)	<0.001 *
		Placebo	143	130 (90.9)	0.05 (0.03)	(-0.02, 0.11)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Other	Week 2	Tezepelumab	18	17 (94.4)	0.09 (0.05)	(-0.02, 0.20)	-0.03 (0.07)	(-0.18, 0.12)	0.678
		Placebo	23	20 (87.0)	0.12 (0.05)	(0.02, 0.22)			
	Week 4	Tezepelumab	18	18 (100.0)	0.16 (0.07)	(0.02, 0.30)	0.00 (0.10)	(-0.19, 0.20)	0.972
		Placebo	23	22 (95.7)	0.16 (0.06)	(0.03, 0.29)			
	Week 8	Tezepelumab	18	18 (100.0)	0.11 (0.07)	(-0.03, 0.25)	-0.07 (0.09)	(-0.26, 0.11)	0.439
		Placebo	23	22 (95.7)	0.18 (0.06)	(0.06, 0.31)			
	Week 12	Tezepelumab	18	18 (100.0)	0.09 (0.06)	(-0.04, 0.22)	-0.09 (0.09)	(-0.26, 0.09)	0.315
		Placebo	23	23 (100.0)	0.18 (0.06)	(0.07, 0.30)			
	Week 16	Tezepelumab	18	17 (94.4)	0.13 (0.07)	(-0.01, 0.27)	-0.04 (0.09)	(-0.23, 0.14)	0.625
		Placebo	23	22 (95.7)	0.18 (0.06)	(0.06, 0.30)			
	Week 24	Tezepelumab	18	16 (88.9)	0.12 (0.09)	(-0.06, 0.29)	-0.02 (0.12)	(-0.26, 0.22)	0.866
		Placebo	23	21 (91.3)	0.14 (0.08)	(-0.02, 0.29)			
	Week 36	Tezepelumab	18	17 (94.4)	0.10 (0.08)	(-0.06, 0.25)	-0.10 (0.10)	(-0.31, 0.11)	0.337
		Placebo	23	22 (95.7)	0.20 (0.07)	(0.06, 0.34)			
	Week 52	Tezepelumab	18	17 (94.4)	0.09 (0.08)	(-0.07, 0.24)	-0.04 (0.10)	(-0.25, 0.17)	0.706
		Placebo	23	21 (91.3)	0.12 (0.07)	(-0.01, 0.26)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Region									0.913
Europe	Week 2	Tezepelumab	77	76 (98.7)	0.16 (0.04)	(0.08, 0.23)	0.09 (0.06)	(-0.02, 0.20)	0.111
		Placebo	73	70 (95.9)	0.07 (0.04)	(-0.01, 0.15)			
	Week 4	Tezepelumab	77	77 (100.0)	0.19 (0.04)	(0.11, 0.27)	0.12 (0.06)	(0.00, 0.23)	0.045 *
		Placebo	73	72 (98.6)	0.08 (0.04)	(-0.01, 0.16)			
	Week 8	Tezepelumab	77	77 (100.0)	0.21 (0.05)	(0.11, 0.31)	0.11 (0.07)	(-0.03, 0.25)	0.124
		Placebo	73	68 (93.2)	0.10 (0.05)	(-0.00, 0.20)			
	Week 12	Tezepelumab	77	74 (96.1)	0.17 (0.05)	(0.08, 0.26)	0.10 (0.07)	(-0.03, 0.23)	0.131
		Placebo	73	69 (94.5)	0.07 (0.05)	(-0.03, 0.16)			
	Week 16	Tezepelumab	77	74 (96.1)	0.23 (0.05)	(0.13, 0.32)	0.20 (0.07)	(0.07, 0.34)	0.004 *
		Placebo	73	69 (94.5)	0.03 (0.05)	(-0.07, 0.12)			
	Week 24	Tezepelumab	77	73 (94.8)	0.18 (0.04)	(0.09, 0.27)	0.15 (0.06)	(0.02, 0.27)	0.025 *
		Placebo	73	62 (84.9)	0.03 (0.05)	(-0.06, 0.12)			
	Week 36	Tezepelumab	77	71 (92.2)	0.18 (0.05)	(0.09, 0.27)	0.05 (0.07)	(-0.08, 0.18)	0.431
		Placebo	73	60 (82.2)	0.12 (0.05)	(0.03, 0.22)			
	Week 52	Tezepelumab	77	68 (88.3)	0.17 (0.04)	(0.09, 0.26)	0.04 (0.06)	(-0.09, 0.17)	0.552
		Placebo	73	58 (79.5)	0.13 (0.05)	(0.04, 0.23)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
America	Week 2	Tezepelumab	170	164 (96.5)	0.18 (0.03)	(0.13, 0.23)	0.11 (0.04)	(0.04, 0.19)	0.003 *
		Placebo	169	161 (95.3)	0.06 (0.03)	(0.01, 0.12)			
	Week 4	Tezepelumab	170	167 (98.2)	0.18 (0.03)	(0.13, 0.23)	0.09 (0.04)	(0.01, 0.16)	0.023 *
		Placebo	169	162 (95.9)	0.09 (0.03)	(0.04, 0.14)			
	Week 8	Tezepelumab	170	166 (97.6)	0.21 (0.03)	(0.15, 0.26)	0.11 (0.04)	(0.03, 0.19)	0.007 *
		Placebo	169	165 (97.6)	0.09 (0.03)	(0.04, 0.15)			
	Week 12	Tezepelumab	170	164 (96.5)	0.22 (0.03)	(0.16, 0.28)	0.13 (0.04)	(0.04, 0.21)	0.003 *
		Placebo	169	166 (98.2)	0.09 (0.03)	(0.03, 0.15)			
	Week 16	Tezepelumab	170	163 (95.9)	0.22 (0.03)	(0.16, 0.28)	0.11 (0.04)	(0.03, 0.20)	0.007 *
		Placebo	169	163 (96.4)	0.11 (0.03)	(0.05, 0.17)			
	Week 24	Tezepelumab	170	156 (91.8)	0.20 (0.03)	(0.14, 0.26)	0.11 (0.04)	(0.02, 0.19)	0.012 *
		Placebo	169	158 (93.5)	0.09 (0.03)	(0.03, 0.15)			
	Week 36	Tezepelumab	170	152 (89.4)	0.22 (0.03)	(0.16, 0.28)	0.09 (0.04)	(0.01, 0.18)	0.033 *
		Placebo	169	161 (95.3)	0.13 (0.03)	(0.07, 0.19)			
	Week 52	Tezepelumab	170	149 (87.6)	0.22 (0.03)	(0.16, 0.29)	0.10 (0.05)	(0.01, 0.19)	0.029 *
		Placebo	169	146 (86.4)	0.12 (0.03)	(0.06, 0.19)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Asia/Pacific	Week 2	Tezepelumab	129	127 (98.4)	0.15 (0.03)	(0.10, 0.21)	0.09 (0.04)	(0.01, 0.17)	0.025 *
		Placebo	134	129 (96.3)	0.06 (0.03)	(0.01, 0.12)			
	Week 4	Tezepelumab	129	129 (100.0)	0.22 (0.03)	(0.16, 0.28)	0.16 (0.04)	(0.08, 0.25)	<0.001 *
		Placebo	134	133 (99.3)	0.05 (0.03)	(-0.00, 0.11)			
	Week 8	Tezepelumab	129	125 (96.9)	0.27 (0.03)	(0.21, 0.33)	0.18 (0.05)	(0.09, 0.27)	<0.001 *
		Placebo	134	133 (99.3)	0.09 (0.03)	(0.03, 0.15)			
	Week 12	Tezepelumab	129	126 (97.7)	0.27 (0.03)	(0.20, 0.34)	0.18 (0.05)	(0.09, 0.27)	<0.001 *
		Placebo	134	131 (97.8)	0.09 (0.03)	(0.02, 0.15)			
	Week 16	Tezepelumab	129	127 (98.4)	0.27 (0.03)	(0.21, 0.34)	0.18 (0.05)	(0.09, 0.27)	<0.001 *
		Placebo	134	129 (96.3)	0.09 (0.03)	(0.03, 0.16)			
	Week 24	Tezepelumab	129	126 (97.7)	0.24 (0.03)	(0.18, 0.31)	0.16 (0.05)	(0.07, 0.26)	<0.001 *
		Placebo	134	126 (94.0)	0.08 (0.03)	(0.01, 0.14)			
	Week 36	Tezepelumab	129	121 (93.8)	0.25 (0.04)	(0.18, 0.32)	0.19 (0.05)	(0.09, 0.29)	<0.001 *
		Placebo	134	119 (88.8)	0.07 (0.04)	(-0.01, 0.14)			
	Week 52	Tezepelumab	129	121 (93.8)	0.25 (0.03)	(0.18, 0.32)	0.20 (0.05)	(0.10, 0.29)	<0.001 *
		Placebo	134	116 (86.6)	0.05 (0.03)	(-0.01, 0.12)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Rest of the world	Week 2	Tezepelumab	111	107 (96.4)	0.17 (0.03)	(0.11, 0.23)	0.15 (0.04)	(0.07, 0.24)	<0.001 *
		Placebo	114	108 (94.7)	0.01 (0.03)	(-0.04, 0.07)			
	Week 4	Tezepelumab	111	110 (99.1)	0.20 (0.04)	(0.13, 0.27)	0.07 (0.05)	(-0.03, 0.17)	0.150
		Placebo	114	111 (97.4)	0.12 (0.04)	(0.05, 0.19)			
	Week 8	Tezepelumab	111	110 (99.1)	0.21 (0.03)	(0.15, 0.28)	0.11 (0.05)	(0.01, 0.20)	0.028 *
		Placebo	114	112 (98.2)	0.11 (0.03)	(0.04, 0.18)			
	Week 12	Tezepelumab	111	109 (98.2)	0.24 (0.04)	(0.17, 0.31)	0.11 (0.05)	(0.01, 0.20)	0.032 *
		Placebo	114	109 (95.6)	0.13 (0.03)	(0.06, 0.20)			
	Week 16	Tezepelumab	111	107 (96.4)	0.22 (0.04)	(0.14, 0.29)	0.09 (0.05)	(-0.01, 0.20)	0.085
		Placebo	114	108 (94.7)	0.12 (0.04)	(0.05, 0.20)			
	Week 24	Tezepelumab	111	105 (94.6)	0.23 (0.04)	(0.16, 0.30)	0.13 (0.05)	(0.03, 0.23)	0.015 *
		Placebo	114	107 (93.9)	0.10 (0.04)	(0.03, 0.17)			
	Week 36	Tezepelumab	111	102 (91.9)	0.21 (0.04)	(0.14, 0.29)	0.12 (0.05)	(0.02, 0.22)	0.022 *
		Placebo	114	100 (87.7)	0.10 (0.04)	(0.03, 0.17)			
	Week 52	Tezepelumab	111	99 (89.2)	0.23 (0.04)	(0.15, 0.30)	0.16 (0.05)	(0.05, 0.26)	0.004 *
		Placebo	114	98 (86.0)	0.07 (0.04)	(-0.01, 0.14)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
BMI				N<10 any level					NE

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline eosinophils - Low									<0.001 i
< 150 cells/uL	Week 2	Tezepelumab	130	127 (97.7)	0.07 (0.03)	(0.02, 0.12)	0.01 (0.04)	(-0.06, 0.09)	0.708
		Placebo	132	126 (95.5)	0.06 (0.03)	(0.00, 0.11)			
	Week 4	Tezepelumab	130	129 (99.2)	0.07 (0.03)	(0.01, 0.13)	0.01 (0.04)	(-0.08, 0.09)	0.847
		Placebo	132	129 (97.7)	0.06 (0.03)	(0.00, 0.12)			
	Week 8	Tezepelumab	130	125 (96.2)	0.09 (0.03)	(0.02, 0.15)	-0.01 (0.04)	(-0.09, 0.08)	0.886
		Placebo	132	128 (97.0)	0.09 (0.03)	(0.03, 0.15)			
	Week 12	Tezepelumab	130	125 (96.2)	0.08 (0.03)	(0.02, 0.14)	0.00 (0.04)	(-0.09, 0.09)	0.998
		Placebo	132	127 (96.2)	0.08 (0.03)	(0.02, 0.14)			
	Week 16	Tezepelumab	130	126 (96.9)	0.09 (0.03)	(0.02, 0.16)	0.03 (0.05)	(-0.06, 0.13)	0.504
		Placebo	132	127 (96.2)	0.06 (0.03)	(-0.01, 0.13)			
	Week 24	Tezepelumab	130	118 (90.8)	0.08 (0.03)	(0.02, 0.14)	0.01 (0.04)	(-0.07, 0.09)	0.756
		Placebo	132	121 (91.7)	0.07 (0.03)	(0.01, 0.12)			
	Week 36	Tezepelumab	130	118 (90.8)	0.06 (0.03)	(0.00, 0.12)	-0.02 (0.04)	(-0.10, 0.06)	0.592
		Placebo	132	118 (89.4)	0.08 (0.03)	(0.03, 0.14)			
	Week 52	Tezepelumab	130	117 (90.0)	0.09 (0.03)	(0.02, 0.16)	0.04 (0.05)	(-0.06, 0.13)	0.446
		Placebo	132	115 (87.1)	0.05 (0.03)	(-0.01, 0.12)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 150 cells/uL	Week 2	Tezepelumab	357	347 (97.2)	0.20 (0.02)	(0.17, 0.24)	0.15 (0.03)	(0.10, 0.20)	<0.001 *
		Placebo	358	342 (95.5)	0.05 (0.02)	(0.02, 0.09)			
	Week 4	Tezepelumab	357	354 (99.2)	0.24 (0.02)	(0.20, 0.28)	0.15 (0.03)	(0.09, 0.20)	<0.001 *
		Placebo	358	349 (97.5)	0.09 (0.02)	(0.06, 0.13)			
	Week 8	Tezepelumab	357	353 (98.9)	0.28 (0.02)	(0.24, 0.32)	0.18 (0.03)	(0.12, 0.23)	<0.001 *
		Placebo	358	350 (97.8)	0.10 (0.02)	(0.06, 0.14)			
	Week 12	Tezepelumab	357	348 (97.5)	0.28 (0.02)	(0.24, 0.32)	0.18 (0.03)	(0.12, 0.24)	<0.001 *
		Placebo	358	348 (97.2)	0.10 (0.02)	(0.06, 0.14)			
	Week 16	Tezepelumab	357	345 (96.6)	0.29 (0.02)	(0.25, 0.33)	0.18 (0.03)	(0.12, 0.24)	<0.001 *
		Placebo	358	342 (95.5)	0.11 (0.02)	(0.07, 0.15)			
	Week 24	Tezepelumab	357	342 (95.8)	0.26 (0.02)	(0.22, 0.30)	0.17 (0.03)	(0.12, 0.23)	<0.001 *
		Placebo	358	332 (92.7)	0.09 (0.02)	(0.05, 0.13)			
	Week 36	Tezepelumab	357	328 (91.9)	0.28 (0.02)	(0.23, 0.32)	0.17 (0.03)	(0.11, 0.23)	<0.001 *
		Placebo	358	322 (89.9)	0.11 (0.02)	(0.07, 0.15)			
	Week 52	Tezepelumab	357	320 (89.6)	0.27 (0.02)	(0.23, 0.31)	0.17 (0.03)	(0.11, 0.23)	<0.001 *
		Placebo	358	303 (84.6)	0.10 (0.02)	(0.06, 0.15)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline eosinophils - High									<0.001 i
< 300 cells/uL	Week 2	Tezepelumab	286	279 (97.6)	0.10 (0.02)	(0.07, 0.14)	0.07 (0.03)	(0.02, 0.12)	0.004 *
		Placebo	295	284 (96.3)	0.03 (0.02)	(-0.00, 0.07)			
	Week 4	Tezepelumab	286	285 (99.7)	0.12 (0.02)	(0.08, 0.16)	0.06 (0.03)	(0.01, 0.12)	0.021 *
		Placebo	295	287 (97.3)	0.05 (0.02)	(0.02, 0.09)			
	Week 8	Tezepelumab	286	281 (98.3)	0.13 (0.02)	(0.09, 0.17)	0.05 (0.03)	(-0.01, 0.10)	0.105
		Placebo	295	285 (96.6)	0.08 (0.02)	(0.05, 0.12)			
	Week 12	Tezepelumab	286	277 (96.9)	0.12 (0.02)	(0.08, 0.17)	0.06 (0.03)	(-0.00, 0.12)	0.053
		Placebo	295	284 (96.3)	0.07 (0.02)	(0.03, 0.11)			
	Week 16	Tezepelumab	286	278 (97.2)	0.13 (0.02)	(0.09, 0.17)	0.06 (0.03)	(0.01, 0.12)	0.033 *
		Placebo	295	283 (95.9)	0.06 (0.02)	(0.02, 0.11)			
	Week 24	Tezepelumab	286	270 (94.4)	0.10 (0.02)	(0.06, 0.14)	0.06 (0.03)	(-0.00, 0.11)	0.051
		Placebo	295	273 (92.5)	0.05 (0.02)	(0.01, 0.08)			
	Week 36	Tezepelumab	286	263 (92.0)	0.11 (0.02)	(0.06, 0.15)	0.05 (0.03)	(-0.01, 0.11)	0.073
		Placebo	295	266 (90.2)	0.05 (0.02)	(0.01, 0.09)			
	Week 52	Tezepelumab	286	263 (92.0)	0.11 (0.02)	(0.07, 0.15)	0.05 (0.03)	(-0.01, 0.11)	0.082
		Placebo	295	254 (86.1)	0.06 (0.02)	(0.01, 0.10)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 300 cells/uL	Week 2	Tezepelumab	201	195 (97.0)	0.25 (0.03)	(0.20, 0.30)	0.17 (0.04)	(0.09, 0.24)	<0.001 *
		Placebo	195	184 (94.4)	0.09 (0.03)	(0.04, 0.14)			
	Week 4	Tezepelumab	201	198 (98.5)	0.30 (0.03)	(0.25, 0.36)	0.17 (0.04)	(0.10, 0.25)	<0.001 *
		Placebo	195	191 (97.9)	0.13 (0.03)	(0.08, 0.19)			
	Week 8	Tezepelumab	201	197 (98.0)	0.36 (0.03)	(0.30, 0.42)	0.24 (0.04)	(0.16, 0.32)	<0.001 *
		Placebo	195	193 (99.0)	0.12 (0.03)	(0.06, 0.18)			
	Week 12	Tezepelumab	201	196 (97.5)	0.38 (0.03)	(0.32, 0.44)	0.24 (0.04)	(0.16, 0.32)	<0.001 *
		Placebo	195	191 (97.9)	0.14 (0.03)	(0.09, 0.20)			
	Week 16	Tezepelumab	201	193 (96.0)	0.39 (0.03)	(0.33, 0.44)	0.25 (0.04)	(0.17, 0.33)	<0.001 *
		Placebo	195	186 (95.4)	0.14 (0.03)	(0.08, 0.20)			
	Week 24	Tezepelumab	201	190 (94.5)	0.37 (0.03)	(0.32, 0.43)	0.24 (0.04)	(0.15, 0.32)	<0.001 *
		Placebo	195	180 (92.3)	0.14 (0.03)	(0.08, 0.20)			
	Week 36	Tezepelumab	201	183 (91.0)	0.38 (0.03)	(0.33, 0.44)	0.21 (0.04)	(0.12, 0.29)	<0.001 *
		Placebo	195	174 (89.2)	0.18 (0.03)	(0.12, 0.24)			
	Week 52	Tezepelumab	201	174 (86.6)	0.38 (0.03)	(0.32, 0.44)	0.24 (0.04)	(0.16, 0.33)	<0.001 *
		Placebo	195	164 (84.1)	0.14 (0.03)	(0.08, 0.20)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline FENO									0.013 i
< 25 ppb	Week 2	Tezepelumab	202	195 (96.5)	0.13 (0.02)	(0.09, 0.17)	0.08 (0.03)	(0.02, 0.14)	0.011 *
		Placebo	204	190 (93.1)	0.05 (0.02)	(0.01, 0.09)			
	Week 4	Tezepelumab	202	199 (98.5)	0.13 (0.02)	(0.08, 0.18)	0.05 (0.03)	(-0.02, 0.11)	0.154
		Placebo	204	199 (97.5)	0.08 (0.02)	(0.04, 0.13)			
	Week 8	Tezepelumab	202	197 (97.5)	0.14 (0.02)	(0.09, 0.19)	0.05 (0.04)	(-0.02, 0.12)	0.175
		Placebo	204	199 (97.5)	0.09 (0.02)	(0.05, 0.14)			
	Week 12	Tezepelumab	202	195 (96.5)	0.16 (0.03)	(0.11, 0.20)	0.06 (0.04)	(-0.01, 0.13)	0.077
		Placebo	204	197 (96.6)	0.09 (0.02)	(0.04, 0.14)			
	Week 16	Tezepelumab	202	194 (96.0)	0.14 (0.03)	(0.09, 0.19)	0.06 (0.04)	(-0.01, 0.14)	0.072
		Placebo	204	197 (96.6)	0.08 (0.03)	(0.03, 0.13)			
	Week 24	Tezepelumab	202	192 (95.0)	0.13 (0.03)	(0.08, 0.18)	0.07 (0.04)	(-0.00, 0.14)	0.051
		Placebo	204	193 (94.6)	0.06 (0.03)	(0.01, 0.11)			
	Week 36	Tezepelumab	202	183 (90.6)	0.12 (0.02)	(0.07, 0.17)	0.02 (0.04)	(-0.04, 0.09)	0.488
		Placebo	204	186 (91.2)	0.09 (0.02)	(0.05, 0.14)			
	Week 52	Tezepelumab	202	184 (91.1)	0.13 (0.03)	(0.08, 0.18)	0.05 (0.04)	(-0.03, 0.12)	0.225
		Placebo	204	181 (88.7)	0.08 (0.03)	(0.03, 0.14)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 25 ppb	Week 2	Tezepelumab	279	273 (97.8)	0.20 (0.02)	(0.16, 0.24)	0.14 (0.03)	(0.09, 0.20)	<0.001 *
		Placebo	282	274 (97.2)	0.05 (0.02)	(0.01, 0.10)			
	Week 4	Tezepelumab	279	279 (100.0)	0.24 (0.02)	(0.20, 0.29)	0.16 (0.03)	(0.10, 0.22)	<0.001 *
		Placebo	282	275 (97.5)	0.09 (0.02)	(0.04, 0.13)			
	Week 8	Tezepelumab	279	275 (98.6)	0.29 (0.02)	(0.24, 0.34)	0.19 (0.03)	(0.13, 0.26)	<0.001 *
		Placebo	282	275 (97.5)	0.10 (0.02)	(0.05, 0.15)			
	Week 12	Tezepelumab	279	272 (97.5)	0.29 (0.02)	(0.24, 0.33)	0.19 (0.03)	(0.12, 0.25)	<0.001 *
		Placebo	282	275 (97.5)	0.10 (0.02)	(0.05, 0.15)			
	Week 16	Tezepelumab	279	271 (97.1)	0.30 (0.02)	(0.26, 0.35)	0.19 (0.03)	(0.13, 0.26)	<0.001 *
		Placebo	282	269 (95.4)	0.11 (0.02)	(0.06, 0.16)			
	Week 24	Tezepelumab	279	262 (93.9)	0.28 (0.02)	(0.23, 0.32)	0.18 (0.03)	(0.11, 0.24)	<0.001 *
		Placebo	282	257 (91.1)	0.10 (0.02)	(0.05, 0.15)			
	Week 36	Tezepelumab	279	257 (92.1)	0.29 (0.03)	(0.24, 0.34)	0.19 (0.04)	(0.11, 0.26)	<0.001 *
		Placebo	282	251 (89.0)	0.11 (0.03)	(0.06, 0.16)			
	Week 52	Tezepelumab	279	248 (88.9)	0.29 (0.03)	(0.24, 0.34)	0.20 (0.04)	(0.13, 0.27)	<0.001 *
		Placebo	282	234 (83.0)	0.09 (0.03)	(0.04, 0.14)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline specific perennial FEIA status									0.055
All negative	Week 2	Tezepelumab	179	176 (98.3)	0.19 (0.02)	(0.15, 0.23)	0.16 (0.03)	(0.10, 0.21)	<0.001 *
		Placebo	174	166 (95.4)	0.03 (0.02)	(-0.01, 0.08)			
	Week 4	Tezepelumab	179	178 (99.4)	0.25 (0.02)	(0.20, 0.30)	0.16 (0.04)	(0.09, 0.23)	<0.001 *
		Placebo	174	168 (96.6)	0.09 (0.03)	(0.04, 0.14)			
	Week 8	Tezepelumab	179	176 (98.3)	0.27 (0.02)	(0.22, 0.32)	0.18 (0.04)	(0.11, 0.25)	<0.001 *
		Placebo	174	168 (96.6)	0.08 (0.03)	(0.03, 0.13)			
	Week 12	Tezepelumab	179	177 (98.9)	0.26 (0.03)	(0.21, 0.31)	0.17 (0.04)	(0.09, 0.24)	<0.001 *
		Placebo	174	169 (97.1)	0.09 (0.03)	(0.04, 0.15)			
	Week 16	Tezepelumab	179	176 (98.3)	0.27 (0.03)	(0.22, 0.32)	0.18 (0.04)	(0.11, 0.25)	<0.001 *
		Placebo	174	166 (95.4)	0.09 (0.03)	(0.04, 0.14)			
	Week 24	Tezepelumab	179	172 (96.1)	0.25 (0.03)	(0.20, 0.30)	0.17 (0.04)	(0.10, 0.25)	<0.001 *
		Placebo	174	154 (88.5)	0.08 (0.03)	(0.03, 0.13)			
	Week 36	Tezepelumab	179	167 (93.3)	0.23 (0.03)	(0.18, 0.29)	0.13 (0.04)	(0.05, 0.21)	<0.001 *
		Placebo	174	152 (87.4)	0.10 (0.03)	(0.05, 0.16)			
	Week 52	Tezepelumab	179	165 (92.2)	0.26 (0.03)	(0.21, 0.31)	0.23 (0.04)	(0.15, 0.30)	<0.001 *
		Placebo	174	145 (83.3)	0.03 (0.03)	(-0.02, 0.09)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Any positive	Week 2	Tezepelumab	303	294 (97.0)	0.16 (0.02)	(0.11, 0.20)	0.09 (0.03)	(0.03, 0.14)	0.003 *
		Placebo	303	293 (96.7)	0.07 (0.02)	(0.03, 0.11)			
	Week 4	Tezepelumab	303	302 (99.7)	0.17 (0.02)	(0.12, 0.21)	0.08 (0.03)	(0.02, 0.14)	0.013 *
		Placebo	303	298 (98.3)	0.09 (0.02)	(0.05, 0.13)			
	Week 8	Tezepelumab	303	298 (98.3)	0.20 (0.02)	(0.15, 0.24)	0.09 (0.03)	(0.02, 0.15)	0.008 *
		Placebo	303	297 (98.0)	0.11 (0.02)	(0.06, 0.15)			
	Week 12	Tezepelumab	303	292 (96.4)	0.20 (0.02)	(0.16, 0.25)	0.10 (0.03)	(0.04, 0.17)	0.001 *
		Placebo	303	294 (97.0)	0.10 (0.02)	(0.05, 0.14)			
	Week 16	Tezepelumab	303	291 (96.0)	0.21 (0.02)	(0.16, 0.26)	0.11 (0.03)	(0.04, 0.17)	0.002 *
		Placebo	303	290 (95.7)	0.10 (0.02)	(0.06, 0.15)			
	Week 24	Tezepelumab	303	284 (93.7)	0.19 (0.02)	(0.14, 0.23)	0.10 (0.03)	(0.03, 0.16)	0.003 *
		Placebo	303	286 (94.4)	0.09 (0.02)	(0.04, 0.13)			
	Week 36	Tezepelumab	303	275 (90.8)	0.21 (0.02)	(0.16, 0.26)	0.10 (0.03)	(0.03, 0.17)	0.003 *
		Placebo	303	276 (91.1)	0.11 (0.02)	(0.06, 0.16)			
	Week 52	Tezepelumab	303	269 (88.8)	0.20 (0.02)	(0.15, 0.24)	0.07 (0.03)	(-0.00, 0.13)	0.056
		Placebo	303	264 (87.1)	0.13 (0.02)	(0.08, 0.18)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Total serum IgE									0.391
Low	Week 2	Tezepelumab	153	150 (98.0)	0.12 (0.02)	(0.08, 0.17)	0.09 (0.03)	(0.03, 0.16)	0.004 *
		Placebo	163	153 (93.9)	0.03 (0.02)	(-0.02, 0.07)			
	Week 4	Tezepelumab	153	153 (100.0)	0.16 (0.03)	(0.11, 0.21)	0.09 (0.04)	(0.01, 0.16)	0.025 *
		Placebo	163	158 (96.9)	0.07 (0.03)	(0.02, 0.13)			
	Week 8	Tezepelumab	153	149 (97.4)	0.17 (0.03)	(0.12, 0.23)	0.10 (0.04)	(0.02, 0.17)	0.009 *
		Placebo	163	158 (96.9)	0.08 (0.03)	(0.03, 0.13)			
	Week 12	Tezepelumab	153	148 (96.7)	0.18 (0.03)	(0.12, 0.23)	0.09 (0.04)	(0.02, 0.17)	0.018 *
		Placebo	163	157 (96.3)	0.08 (0.03)	(0.03, 0.14)			
	Week 16	Tezepelumab	153	150 (98.0)	0.17 (0.03)	(0.12, 0.23)	0.09 (0.04)	(0.02, 0.17)	0.018 *
		Placebo	163	154 (94.5)	0.08 (0.03)	(0.03, 0.13)			
	Week 24	Tezepelumab	153	148 (96.7)	0.16 (0.03)	(0.11, 0.21)	0.10 (0.04)	(0.03, 0.17)	0.005 *
		Placebo	163	148 (90.8)	0.06 (0.02)	(0.01, 0.10)			
	Week 36	Tezepelumab	153	142 (92.8)	0.15 (0.03)	(0.09, 0.20)	0.05 (0.04)	(-0.03, 0.12)	0.220
		Placebo	163	140 (85.9)	0.10 (0.03)	(0.05, 0.15)			
	Week 52	Tezepelumab	153	142 (92.8)	0.14 (0.03)	(0.09, 0.20)	0.10 (0.04)	(0.02, 0.17)	0.014 *
		Placebo	163	139 (85.3)	0.05 (0.03)	(-0.01, 0.10)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Normal	Week 2	Tezepelumab	296	288 (97.3)	0.18 (0.02)	(0.14, 0.22)	0.14 (0.03)	(0.08, 0.19)	<0.001 *
		Placebo	278	268 (96.4)	0.04 (0.02)	(0.00, 0.08)			
	Week 4	Tezepelumab	296	292 (98.6)	0.20 (0.02)	(0.17, 0.24)	0.12 (0.03)	(0.06, 0.18)	<0.001 *
		Placebo	278	271 (97.5)	0.08 (0.02)	(0.04, 0.12)			
	Week 8	Tezepelumab	296	291 (98.3)	0.24 (0.02)	(0.20, 0.28)	0.15 (0.03)	(0.08, 0.21)	<0.001 *
		Placebo	278	271 (97.5)	0.09 (0.02)	(0.05, 0.14)			
	Week 12	Tezepelumab	296	287 (97.0)	0.25 (0.02)	(0.20, 0.29)	0.16 (0.03)	(0.10, 0.23)	<0.001 *
		Placebo	278	270 (97.1)	0.08 (0.02)	(0.04, 0.13)			
	Week 16	Tezepelumab	296	284 (95.9)	0.26 (0.02)	(0.21, 0.30)	0.17 (0.03)	(0.11, 0.24)	<0.001 *
		Placebo	278	268 (96.4)	0.08 (0.02)	(0.04, 0.13)			
	Week 24	Tezepelumab	296	276 (93.2)	0.23 (0.02)	(0.19, 0.28)	0.15 (0.03)	(0.08, 0.22)	<0.001 *
		Placebo	278	258 (92.8)	0.08 (0.02)	(0.04, 0.13)			
	Week 36	Tezepelumab	296	270 (91.2)	0.24 (0.02)	(0.20, 0.29)	0.16 (0.03)	(0.09, 0.22)	<0.001 *
		Placebo	278	252 (90.6)	0.09 (0.02)	(0.04, 0.14)			
	Week 52	Tezepelumab	296	261 (88.2)	0.26 (0.02)	(0.21, 0.31)	0.16 (0.04)	(0.09, 0.23)	<0.001 *
		Placebo	278	238 (85.6)	0.10 (0.03)	(0.05, 0.15)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
High	Week 2	Tezepelumab	38	36 (94.7)	0.22 (0.07)	(0.08, 0.36)	0.02 (0.09)	(-0.17, 0.20)	0.850
		Placebo	49	47 (95.9)	0.20 (0.06)	(0.08, 0.32)			
	Week 4	Tezepelumab	38	38 (100.0)	0.26 (0.07)	(0.12, 0.41)	0.12 (0.10)	(-0.07, 0.31)	0.225
		Placebo	49	49 (100.0)	0.14 (0.06)	(0.02, 0.27)			
	Week 8	Tezepelumab	38	38 (100.0)	0.31 (0.08)	(0.15, 0.47)	0.13 (0.11)	(-0.08, 0.34)	0.234
		Placebo	49	49 (100.0)	0.19 (0.07)	(0.05, 0.33)			
	Week 12	Tezepelumab	38	38 (100.0)	0.31 (0.07)	(0.18, 0.44)	0.08 (0.09)	(-0.10, 0.25)	0.393
		Placebo	49	48 (98.0)	0.23 (0.06)	(0.12, 0.35)			
	Week 16	Tezepelumab	38	37 (97.4)	0.32 (0.08)	(0.17, 0.47)	0.12 (0.10)	(-0.08, 0.32)	0.247
		Placebo	49	47 (95.9)	0.20 (0.07)	(0.07, 0.33)			
	Week 24	Tezepelumab	38	36 (94.7)	0.28 (0.08)	(0.13, 0.43)	0.12 (0.10)	(-0.08, 0.32)	0.229
		Placebo	49	47 (95.9)	0.16 (0.07)	(0.03, 0.29)			
	Week 36	Tezepelumab	38	34 (89.5)	0.32 (0.08)	(0.16, 0.47)	0.12 (0.10)	(-0.08, 0.33)	0.236
		Placebo	49	48 (98.0)	0.19 (0.07)	(0.06, 0.33)			
	Week 52	Tezepelumab	38	34 (89.5)	0.25 (0.07)	(0.11, 0.40)	0.07 (0.10)	(-0.12, 0.26)	0.445
		Placebo	49	41 (83.7)	0.18 (0.06)	(0.05, 0.31)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
OCS at baseline									0.022 i
Yes	Week 2	Tezepelumab	48	47 (97.9)	0.22 (0.05)	(0.12, 0.33)	0.25 (0.07)	(0.10, 0.39)	<0.001 *
		Placebo	51	49 (96.1)	-0.03 (0.05)	(-0.13, 0.07)			
	Week 4	Tezepelumab	48	48 (100.0)	0.27 (0.05)	(0.16, 0.38)	0.24 (0.08)	(0.09, 0.39)	0.002 *
		Placebo	51	49 (96.1)	0.03 (0.05)	(-0.08, 0.13)			
	Week 8	Tezepelumab	48	47 (97.9)	0.23 (0.06)	(0.12, 0.34)	0.18 (0.08)	(0.03, 0.34)	0.022 *
		Placebo	51	50 (98.0)	0.05 (0.05)	(-0.06, 0.15)			
	Week 12	Tezepelumab	48	44 (91.7)	0.27 (0.06)	(0.15, 0.40)	0.21 (0.09)	(0.03, 0.38)	0.019 *
		Placebo	51	47 (92.2)	0.07 (0.06)	(-0.05, 0.19)			
	Week 16	Tezepelumab	48	46 (95.8)	0.29 (0.05)	(0.19, 0.39)	0.28 (0.07)	(0.14, 0.42)	<0.001 *
		Placebo	51	44 (86.3)	0.01 (0.05)	(-0.09, 0.11)			
	Week 24	Tezepelumab	48	43 (89.6)	0.32 (0.06)	(0.21, 0.44)	0.36 (0.08)	(0.19, 0.53)	<0.001 *
		Placebo	51	36 (70.6)	-0.04 (0.06)	(-0.16, 0.08)			
	Week 36	Tezepelumab	48	40 (83.3)	0.24 (0.06)	(0.13, 0.35)	0.20 (0.08)	(0.04, 0.36)	0.014 *
		Placebo	51	39 (76.5)	0.04 (0.06)	(-0.07, 0.15)			
	Week 52	Tezepelumab	48	38 (79.2)	0.29 (0.07)	(0.15, 0.42)	0.27 (0.10)	(0.07, 0.46)	0.007 *
		Placebo	51	35 (68.6)	0.02 (0.07)	(-0.12, 0.16)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 2	Tezepelumab	439	427 (97.3)	0.16 (0.02)	(0.13, 0.19)	0.10 (0.02)	(0.05, 0.14)	<0.001 *
		Placebo	439	419 (95.4)	0.06 (0.02)	(0.03, 0.09)			
	Week 4	Tezepelumab	439	435 (99.1)	0.19 (0.02)	(0.15, 0.22)	0.09 (0.02)	(0.05, 0.14)	<0.001 *
		Placebo	439	429 (97.7)	0.09 (0.02)	(0.06, 0.13)			
	Week 8	Tezepelumab	439	431 (98.2)	0.23 (0.02)	(0.19, 0.26)	0.12 (0.03)	(0.07, 0.17)	<0.001 *
		Placebo	439	428 (97.5)	0.10 (0.02)	(0.07, 0.14)			
	Week 12	Tezepelumab	439	429 (97.7)	0.23 (0.02)	(0.19, 0.26)	0.12 (0.03)	(0.07, 0.18)	<0.001 *
		Placebo	439	428 (97.5)	0.10 (0.02)	(0.06, 0.14)			
	Week 16	Tezepelumab	439	425 (96.8)	0.23 (0.02)	(0.19, 0.27)	0.13 (0.03)	(0.07, 0.18)	<0.001 *
		Placebo	439	425 (96.8)	0.10 (0.02)	(0.07, 0.14)			
	Week 24	Tezepelumab	439	417 (95.0)	0.20 (0.02)	(0.17, 0.24)	0.11 (0.03)	(0.06, 0.16)	<0.001 *
		Placebo	439	417 (95.0)	0.09 (0.02)	(0.06, 0.13)			
	Week 36	Tezepelumab	439	406 (92.5)	0.22 (0.02)	(0.18, 0.25)	0.11 (0.03)	(0.05, 0.16)	<0.001 *
		Placebo	439	401 (91.3)	0.11 (0.02)	(0.07, 0.15)			
	Week 52	Tezepelumab	439	399 (90.9)	0.21 (0.02)	(0.18, 0.25)	0.12 (0.03)	(0.06, 0.17)	<0.001 *
		Placebo	439	383 (87.2)	0.10 (0.02)	(0.06, 0.14)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
ICS dose level (at study entry)									0.141
Medium/Low	Week 2	Tezepelumab	105	102 (97.1)	0.13 (0.03)	(0.07, 0.19)	0.07 (0.05)	(-0.02, 0.16)	0.114
		Placebo	112	109 (97.3)	0.06 (0.03)	(-0.00, 0.12)			
	Week 4	Tezepelumab	105	104 (99.0)	0.17 (0.03)	(0.10, 0.23)	0.06 (0.05)	(-0.03, 0.15)	0.212
		Placebo	112	109 (97.3)	0.11 (0.03)	(0.04, 0.17)			
	Week 8	Tezepelumab	105	102 (97.1)	0.19 (0.04)	(0.11, 0.27)	0.07 (0.06)	(-0.04, 0.18)	0.239
		Placebo	112	110 (98.2)	0.13 (0.04)	(0.05, 0.20)			
	Week 12	Tezepelumab	105	102 (97.1)	0.20 (0.04)	(0.12, 0.27)	0.09 (0.05)	(-0.02, 0.19)	0.108
		Placebo	112	111 (99.1)	0.11 (0.04)	(0.04, 0.18)			
	Week 16	Tezepelumab	105	103 (98.1)	0.17 (0.04)	(0.09, 0.25)	0.03 (0.06)	(-0.08, 0.14)	0.573
		Placebo	112	112 (100.0)	0.14 (0.04)	(0.06, 0.22)			
	Week 24	Tezepelumab	105	102 (97.1)	0.16 (0.04)	(0.09, 0.24)	0.07 (0.05)	(-0.04, 0.17)	0.218
		Placebo	112	107 (95.5)	0.10 (0.04)	(0.03, 0.17)			
	Week 36	Tezepelumab	105	101 (96.2)	0.16 (0.04)	(0.09, 0.24)	0.03 (0.05)	(-0.07, 0.14)	0.526
		Placebo	112	106 (94.6)	0.13 (0.04)	(0.06, 0.20)			
	Week 52	Tezepelumab	105	98 (93.3)	0.15 (0.04)	(0.07, 0.23)	0.02 (0.06)	(-0.10, 0.13)	0.758
		Placebo	112	104 (92.9)	0.13 (0.04)	(0.05, 0.21)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
High	Week 2	Tezepelumab	382	372 (97.4)	0.18 (0.02)	(0.14, 0.21)	0.13 (0.02)	(0.08, 0.17)	<0.001 *
		Placebo	378	359 (95.0)	0.05 (0.02)	(0.02, 0.09)			
	Week 4	Tezepelumab	382	379 (99.2)	0.20 (0.02)	(0.17, 0.24)	0.12 (0.03)	(0.07, 0.18)	<0.001 *
		Placebo	378	369 (97.6)	0.08 (0.02)	(0.04, 0.12)			
	Week 8	Tezepelumab	382	376 (98.4)	0.23 (0.02)	(0.20, 0.27)	0.15 (0.03)	(0.09, 0.20)	<0.001 *
		Placebo	378	368 (97.4)	0.09 (0.02)	(0.05, 0.13)			
	Week 12	Tezepelumab	382	371 (97.1)	0.24 (0.02)	(0.20, 0.28)	0.15 (0.03)	(0.09, 0.20)	<0.001 *
		Placebo	378	364 (96.3)	0.09 (0.02)	(0.05, 0.13)			
	Week 16	Tezepelumab	382	368 (96.3)	0.25 (0.02)	(0.21, 0.29)	0.17 (0.03)	(0.12, 0.23)	<0.001 *
		Placebo	378	357 (94.4)	0.08 (0.02)	(0.04, 0.12)			
	Week 24	Tezepelumab	382	358 (93.7)	0.23 (0.02)	(0.19, 0.27)	0.15 (0.03)	(0.10, 0.21)	<0.001 *
		Placebo	378	346 (91.5)	0.08 (0.02)	(0.04, 0.12)			
	Week 36	Tezepelumab	382	345 (90.3)	0.24 (0.02)	(0.20, 0.28)	0.14 (0.03)	(0.08, 0.20)	<0.001 *
		Placebo	378	334 (88.4)	0.09 (0.02)	(0.05, 0.13)			
	Week 52	Tezepelumab	382	339 (88.7)	0.24 (0.02)	(0.20, 0.28)	0.17 (0.03)	(0.11, 0.22)	<0.001 *
		Placebo	378	314 (83.1)	0.08 (0.02)	(0.03, 0.12)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
LAMA use at baseline									0.405
Yes	Week 2	Tezepelumab	128	127 (99.2)	0.19 (0.03)	(0.13, 0.24)	0.13 (0.04)	(0.05, 0.21)	0.002 *
		Placebo	120	117 (97.5)	0.06 (0.03)	(-0.00, 0.12)			
	Week 4	Tezepelumab	128	128 (100.0)	0.20 (0.03)	(0.14, 0.26)	0.14 (0.04)	(0.05, 0.23)	0.001 *
		Placebo	120	119 (99.2)	0.06 (0.03)	(-0.00, 0.12)			
	Week 8	Tezepelumab	128	126 (98.4)	0.24 (0.04)	(0.17, 0.31)	0.16 (0.05)	(0.06, 0.26)	0.002 *
		Placebo	120	115 (95.8)	0.09 (0.04)	(0.01, 0.16)			
	Week 12	Tezepelumab	128	124 (96.9)	0.25 (0.04)	(0.18, 0.32)	0.22 (0.05)	(0.12, 0.32)	<0.001 *
		Placebo	120	115 (95.8)	0.03 (0.04)	(-0.04, 0.10)			
	Week 16	Tezepelumab	128	122 (95.3)	0.25 (0.03)	(0.19, 0.32)	0.20 (0.05)	(0.10, 0.30)	<0.001 *
		Placebo	120	112 (93.3)	0.05 (0.04)	(-0.02, 0.12)			
	Week 24	Tezepelumab	128	120 (93.8)	0.24 (0.03)	(0.18, 0.31)	0.20 (0.05)	(0.10, 0.29)	<0.001 *
		Placebo	120	110 (91.7)	0.04 (0.03)	(-0.02, 0.11)			
	Week 36	Tezepelumab	128	114 (89.1)	0.24 (0.03)	(0.17, 0.30)	0.13 (0.05)	(0.03, 0.22)	0.008 *
		Placebo	120	105 (87.5)	0.11 (0.03)	(0.04, 0.18)			
	Week 52	Tezepelumab	128	109 (85.2)	0.25 (0.04)	(0.18, 0.32)	0.20 (0.05)	(0.09, 0.30)	<0.001 *
		Placebo	120	100 (83.3)	0.06 (0.04)	(-0.02, 0.13)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 2	Tezepelumab	359	347 (96.7)	0.16 (0.02)	(0.13, 0.19)	0.11 (0.02)	(0.06, 0.16)	<0.001 *
		Placebo	370	351 (94.9)	0.05 (0.02)	(0.02, 0.09)			
	Week 4	Tezepelumab	359	355 (98.9)	0.19 (0.02)	(0.16, 0.23)	0.10 (0.03)	(0.05, 0.15)	<0.001 *
		Placebo	370	359 (97.0)	0.09 (0.02)	(0.06, 0.13)			
	Week 8	Tezepelumab	359	352 (98.1)	0.22 (0.02)	(0.18, 0.26)	0.12 (0.03)	(0.06, 0.17)	<0.001 *
		Placebo	370	363 (98.1)	0.10 (0.02)	(0.06, 0.14)			
	Week 12	Tezepelumab	359	349 (97.2)	0.22 (0.02)	(0.18, 0.26)	0.10 (0.03)	(0.05, 0.16)	<0.001 *
		Placebo	370	360 (97.3)	0.12 (0.02)	(0.08, 0.16)			
	Week 16	Tezepelumab	359	349 (97.2)	0.23 (0.02)	(0.19, 0.27)	0.12 (0.03)	(0.06, 0.18)	<0.001 *
		Placebo	370	357 (96.5)	0.11 (0.02)	(0.07, 0.15)			
	Week 24	Tezepelumab	359	340 (94.7)	0.20 (0.02)	(0.16, 0.24)	0.11 (0.03)	(0.05, 0.17)	<0.001 *
		Placebo	370	343 (92.7)	0.09 (0.02)	(0.05, 0.13)			
	Week 36	Tezepelumab	359	332 (92.5)	0.21 (0.02)	(0.17, 0.26)	0.11 (0.03)	(0.05, 0.17)	<0.001 *
		Placebo	370	335 (90.5)	0.10 (0.02)	(0.06, 0.14)			
	Week 52	Tezepelumab	359	328 (91.4)	0.21 (0.02)	(0.17, 0.25)	0.11 (0.03)	(0.05, 0.17)	<0.001 *
		Placebo	370	318 (85.9)	0.10 (0.02)	(0.06, 0.14)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Tiotropium use at baseline									0.494
Yes	Week 2	Tezepelumab	119	118 (99.2)	0.19 (0.03)	(0.13, 0.25)	0.13 (0.04)	(0.04, 0.21)	0.005 *
		Placebo	115	112 (97.4)	0.06 (0.03)	(-0.00, 0.12)			
	Week 4	Tezepelumab	119	119 (100.0)	0.20 (0.03)	(0.14, 0.26)	0.13 (0.05)	(0.04, 0.22)	0.004 *
		Placebo	115	114 (99.1)	0.07 (0.03)	(0.00, 0.13)			
	Week 8	Tezepelumab	119	117 (98.3)	0.24 (0.04)	(0.17, 0.32)	0.15 (0.05)	(0.05, 0.25)	0.005 *
		Placebo	115	110 (95.7)	0.09 (0.04)	(0.02, 0.17)			
	Week 12	Tezepelumab	119	115 (96.6)	0.25 (0.04)	(0.17, 0.32)	0.21 (0.05)	(0.11, 0.32)	<0.001 *
		Placebo	115	110 (95.7)	0.03 (0.04)	(-0.05, 0.11)			
	Week 16	Tezepelumab	119	114 (95.8)	0.26 (0.04)	(0.19, 0.33)	0.21 (0.05)	(0.11, 0.31)	<0.001 *
		Placebo	115	108 (93.9)	0.05 (0.04)	(-0.02, 0.12)			
	Week 24	Tezepelumab	119	112 (94.1)	0.24 (0.03)	(0.18, 0.31)	0.20 (0.05)	(0.10, 0.30)	<0.001 *
		Placebo	115	106 (92.2)	0.05 (0.04)	(-0.02, 0.12)			
	Week 36	Tezepelumab	119	106 (89.1)	0.24 (0.04)	(0.17, 0.31)	0.13 (0.05)	(0.03, 0.23)	0.012 *
		Placebo	115	102 (88.7)	0.11 (0.04)	(0.04, 0.18)			
	Week 52	Tezepelumab	119	101 (84.9)	0.25 (0.04)	(0.18, 0.33)	0.20 (0.05)	(0.09, 0.31)	<0.001 *
		Placebo	115	98 (85.2)	0.05 (0.04)	(-0.03, 0.13)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 2	Tezepelumab	368	356 (96.7)	0.16 (0.02)	(0.13, 0.19)	0.11 (0.02)	(0.06, 0.16)	<0.001 *
		Placebo	375	356 (94.9)	0.05 (0.02)	(0.02, 0.09)			
	Week 4	Tezepelumab	368	364 (98.9)	0.19 (0.02)	(0.16, 0.23)	0.10 (0.03)	(0.05, 0.15)	<0.001 *
		Placebo	375	364 (97.1)	0.09 (0.02)	(0.06, 0.13)			
	Week 8	Tezepelumab	368	361 (98.1)	0.22 (0.02)	(0.18, 0.26)	0.12 (0.03)	(0.07, 0.17)	<0.001 *
		Placebo	375	368 (98.1)	0.10 (0.02)	(0.06, 0.14)			
	Week 12	Tezepelumab	368	358 (97.3)	0.22 (0.02)	(0.19, 0.26)	0.11 (0.03)	(0.05, 0.16)	<0.001 *
		Placebo	375	365 (97.3)	0.12 (0.02)	(0.08, 0.16)			
	Week 16	Tezepelumab	368	357 (97.0)	0.23 (0.02)	(0.19, 0.27)	0.12 (0.03)	(0.06, 0.18)	<0.001 *
		Placebo	375	361 (96.3)	0.11 (0.02)	(0.07, 0.15)			
	Week 24	Tezepelumab	368	348 (94.6)	0.20 (0.02)	(0.16, 0.24)	0.11 (0.03)	(0.06, 0.17)	<0.001 *
		Placebo	375	347 (92.5)	0.09 (0.02)	(0.05, 0.13)			
	Week 36	Tezepelumab	368	340 (92.4)	0.21 (0.02)	(0.17, 0.26)	0.11 (0.03)	(0.06, 0.17)	<0.001 *
		Placebo	375	338 (90.1)	0.10 (0.02)	(0.06, 0.14)			
	Week 52	Tezepelumab	368	336 (91.3)	0.21 (0.02)	(0.17, 0.26)	0.11 (0.03)	(0.05, 0.17)	<0.001 *
		Placebo	375	320 (85.3)	0.10 (0.02)	(0.06, 0.14)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Montelukast/ Cromoglicic acid use at baseline									0.324
Yes	Week 2	Tezepelumab	195	188 (96.4)	0.20 (0.02)	(0.15, 0.24)	0.13 (0.04)	(0.06, 0.20)	<0.001 *
		Placebo	184	175 (95.1)	0.06 (0.03)	(0.01, 0.11)			
	Week 4	Tezepelumab	195	193 (99.0)	0.23 (0.03)	(0.18, 0.29)	0.14 (0.04)	(0.06, 0.22)	<0.001 *
		Placebo	184	179 (97.3)	0.09 (0.03)	(0.04, 0.15)			
	Week 8	Tezepelumab	195	191 (97.9)	0.26 (0.03)	(0.20, 0.31)	0.14 (0.04)	(0.06, 0.22)	<0.001 *
		Placebo	184	181 (98.4)	0.12 (0.03)	(0.06, 0.17)			
	Week 12	Tezepelumab	195	188 (96.4)	0.27 (0.03)	(0.21, 0.33)	0.18 (0.05)	(0.09, 0.27)	<0.001 *
		Placebo	184	183 (99.5)	0.09 (0.03)	(0.02, 0.15)			
	Week 16	Tezepelumab	195	188 (96.4)	0.26 (0.03)	(0.20, 0.32)	0.15 (0.04)	(0.07, 0.23)	<0.001 *
		Placebo	184	179 (97.3)	0.11 (0.03)	(0.05, 0.17)			
	Week 24	Tezepelumab	195	183 (93.8)	0.23 (0.03)	(0.18, 0.29)	0.15 (0.04)	(0.07, 0.23)	<0.001 *
		Placebo	184	174 (94.6)	0.09 (0.03)	(0.03, 0.14)			
	Week 36	Tezepelumab	195	177 (90.8)	0.27 (0.03)	(0.21, 0.32)	0.17 (0.04)	(0.09, 0.26)	<0.001 *
		Placebo	184	170 (92.4)	0.09 (0.03)	(0.03, 0.16)			
	Week 52	Tezepelumab	195	173 (88.7)	0.26 (0.03)	(0.20, 0.32)	0.16 (0.04)	(0.08, 0.25)	<0.001 *
		Placebo	184	156 (84.8)	0.10 (0.03)	(0.03, 0.16)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 2	Tezepelumab	292	286 (97.9)	0.15 (0.02)	(0.11, 0.18)	0.10 (0.03)	(0.05, 0.15)	<0.001 *
		Placebo	306	293 (95.8)	0.05 (0.02)	(0.01, 0.08)			
	Week 4	Tezepelumab	292	290 (99.3)	0.17 (0.02)	(0.13, 0.21)	0.09 (0.03)	(0.03, 0.14)	0.002 *
		Placebo	306	299 (97.7)	0.08 (0.02)	(0.04, 0.12)			
	Week 8	Tezepelumab	292	287 (98.3)	0.20 (0.02)	(0.16, 0.25)	0.12 (0.03)	(0.06, 0.18)	<0.001 *
		Placebo	306	297 (97.1)	0.09 (0.02)	(0.05, 0.13)			
	Week 12	Tezepelumab	292	285 (97.6)	0.20 (0.02)	(0.16, 0.24)	0.10 (0.03)	(0.04, 0.16)	<0.001 *
		Placebo	306	292 (95.4)	0.10 (0.02)	(0.06, 0.14)			
	Week 16	Tezepelumab	292	283 (96.9)	0.22 (0.02)	(0.17, 0.26)	0.13 (0.03)	(0.07, 0.19)	<0.001 *
		Placebo	306	290 (94.8)	0.08 (0.02)	(0.04, 0.13)			
	Week 24	Tezepelumab	292	277 (94.9)	0.20 (0.02)	(0.16, 0.24)	0.12 (0.03)	(0.06, 0.18)	<0.001 *
		Placebo	306	279 (91.2)	0.08 (0.02)	(0.04, 0.12)			
	Week 36	Tezepelumab	292	269 (92.1)	0.19 (0.02)	(0.15, 0.23)	0.08 (0.03)	(0.02, 0.14)	0.009 *
		Placebo	306	270 (88.2)	0.11 (0.02)	(0.06, 0.15)			
	Week 52	Tezepelumab	292	264 (90.4)	0.20 (0.02)	(0.15, 0.24)	0.11 (0.03)	(0.05, 0.18)	<0.001 *
		Placebo	306	262 (85.6)	0.09 (0.02)	(0.04, 0.13)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Western Europe	Absolute values	Baseline	Tezepelumab	85	85 (100.0)	1.89 (0.70)	0.7	1.36	1.79	2.38	3.8	
			Placebo	84	84 (100.0)	1.84 (0.76)	0.7	1.26	1.73	2.23	4.2	
		Week 2	Tezepelumab	85	83 (97.6)	2.04 (0.75)	0.7	1.42	1.97	2.47	4.0	
			Placebo	84	79 (94.0)	1.92 (0.79)	0.6	1.36	1.74	2.37	4.0	
		Week 4	Tezepelumab	85	85 (100.0)	2.08 (0.74)	0.7	1.59	2.09	2.54	4.3	
			Placebo	84	82 (97.6)	1.90 (0.79)	0.7	1.33	1.76	2.42	4.2	
		Week 8	Tezepelumab	85	85 (100.0)	2.11 (0.78)	0.8	1.56	2.12	2.55	4.7	
			Placebo	84	78 (92.9)	1.98 (0.79)	0.7	1.34	1.98	2.51	4.3	
		Week 12	Tezepelumab	85	81 (95.3)	2.07 (0.78)	0.8	1.52	2.04	2.39	4.7	
			Placebo	84	78 (92.9)	1.90 (0.84)	0.6	1.25	1.67	2.52	4.3	
		Week 16	Tezepelumab	85	81 (95.3)	2.17 (0.78)	0.7	1.65	2.07	2.54	4.9	
			Placebo	84	78 (92.9)	1.87 (0.77)	0.7	1.31	1.74	2.28	4.1	
		Week 24	Tezepelumab	85	80 (94.1)	2.09 (0.72)	0.7	1.66	2.08	2.46	4.4	
			Placebo	84	70 (83.3)	1.91 (0.81)	0.6	1.25	1.90	2.25	4.8	
		Week 36	Tezepelumab	85	77 (90.6)	2.10 (0.74)	0.8	1.53	2.07	2.50	4.5	
			Placebo	84	66 (78.6)	2.05 (0.77)	0.8	1.49	1.98	2.55	4.6	
		Week 52	Tezepelumab	85	75 (88.2)	2.09 (0.75)	0.7	1.58	2.07	2.54	4.1	
			Placebo	84	63 (75.0)	2.07 (0.82)	0.7	1.37	1.97	2.64	4.4	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Western Europe	Change from baseline	Week 2	Tezepelumab	85	83 (97.6)	0.16 (0.30)	-0.6	-0.01	0.12	0.34	1.1	0.30 [-0.01, 0.61]
			Placebo	84	79 (94.0)	0.06 (0.37)	-0.8	-0.13	-0.03	0.20	1.7	
		Week 4	Tezepelumab	85	85 (100.0)	0.19 (0.35)	-0.7	-0.04	0.14	0.31	1.4	0.37 [0.06, 0.67]
			Placebo	84	82 (97.6)	0.06 (0.36)	-0.7	-0.11	0.03	0.25	1.4	
		Week 8	Tezepelumab	85	85 (100.0)	0.22 (0.43)	-0.6	-0.07	0.11	0.45	1.8	0.24 [-0.07, 0.55]
			Placebo	84	78 (92.9)	0.11 (0.43)	-0.8	-0.12	0.05	0.32	2.1	
		Week 12	Tezepelumab	85	81 (95.3)	0.19 (0.43)	-0.8	-0.07	0.12	0.39	1.9	0.33 [0.01, 0.64]
			Placebo	84	78 (92.9)	0.07 (0.35)	-0.7	-0.11	0.02	0.24	1.2	
		Week 16	Tezepelumab	85	81 (95.3)	0.24 (0.43)	-0.8	-0.02	0.17	0.40	2.0	0.53 [0.21, 0.84]
			Placebo	84	78 (92.9)	0.03 (0.39)	-1.2	-0.16	0.01	0.18	1.4	
		Week 24	Tezepelumab	85	80 (94.1)	0.20 (0.37)	-0.5	-0.05	0.16	0.40	1.5	0.45 [0.13, 0.77]
			Placebo	84	70 (83.3)	0.03 (0.40)	-0.9	-0.16	-0.03	0.18	1.6	
		Week 36	Tezepelumab	85	77 (90.6)	0.20 (0.39)	-0.5	-0.07	0.12	0.44	1.7	0.18 [-0.15, 0.51]
			Placebo	84	66 (78.6)	0.12 (0.41)	-1.1	-0.15	0.13	0.39	1.5	
		Week 52	Tezepelumab	85	75 (88.2)	0.18 (0.37)	-0.6	-0.06	0.16	0.35	1.3	0.09 [-0.24, 0.43]
			Placebo	84	63 (75.0)	0.14 (0.39)	-0.8	-0.07	0.10	0.32	1.6	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
North America	Absolute values	Baseline	Tezepelumab	103	103 (100.0)	1.82 (0.72)	0.6	1.33	1.63	2.12	4.8	
			Placebo	102	102 (100.0)	1.81 (0.57)	0.8	1.34	1.74	2.13	3.3	
		Week 2	Tezepelumab	103	97 (94.2)	2.05 (0.74)	0.8	1.54	1.85	2.55	5.0	
			Placebo	102	96 (94.1)	1.91 (0.58)	1.0	1.43	1.93	2.20	3.4	
		Week 4	Tezepelumab	103	101 (98.1)	2.04 (0.75)	0.7	1.58	1.92	2.50	5.0	
			Placebo	102	99 (97.1)	1.92 (0.56)	1.0	1.50	1.88	2.29	3.4	
		Week 8	Tezepelumab	103	100 (97.1)	2.06 (0.76)	0.8	1.49	1.95	2.46	4.6	
			Placebo	102	100 (98.0)	1.89 (0.60)	0.8	1.51	1.85	2.16	3.7	
		Week 12	Tezepelumab	103	99 (96.1)	2.09 (0.79)	0.9	1.55	1.95	2.46	4.9	
			Placebo	102	100 (98.0)	1.89 (0.60)	0.9	1.41	1.79	2.26	3.6	
		Week 16	Tezepelumab	103	99 (96.1)	2.07 (0.81)	0.9	1.50	1.86	2.53	4.9	
			Placebo	102	99 (97.1)	1.91 (0.56)	0.8	1.46	1.88	2.31	3.2	
		Week 24	Tezepelumab	103	93 (90.3)	2.04 (0.81)	0.8	1.47	1.89	2.57	5.5	
			Placebo	102	95 (93.1)	1.88 (0.54)	0.8	1.49	1.88	2.22	3.3	
		Week 36	Tezepelumab	103	89 (86.4)	2.07 (0.79)	0.9	1.48	1.90	2.39	4.9	
			Placebo	102	96 (94.1)	1.92 (0.56)	0.9	1.51	1.92	2.29	3.4	
		Week 52	Tezepelumab	103	86 (83.5)	2.07 (0.79)	0.7	1.56	1.98	2.53	4.6	
			Placebo	102	83 (81.4)	1.92 (0.61)	0.6	1.43	1.90	2.33	3.6	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
North America	Change from baseline	Week 2	Tezepelumab	103	97 (94.2)	0.24 (0.33)	-0.3	0.04	0.15	0.40	1.5	0.42 [0.13, 0.70]
			Placebo	102	96 (94.1)	0.09 (0.37)	-1.8	-0.07	0.03	0.27	1.1	
		Week 4	Tezepelumab	103	101 (98.1)	0.23 (0.35)	-0.9	0.00	0.15	0.39	1.3	0.34 [0.06, 0.62]
			Placebo	102	99 (97.1)	0.11 (0.32)	-1.0	-0.04	0.08	0.25	1.0	
		Week 8	Tezepelumab	103	100 (97.1)	0.25 (0.45)	-0.9	-0.02	0.13	0.43	1.9	0.46 [0.18, 0.74]
			Placebo	102	100 (98.0)	0.08 (0.29)	-1.1	-0.09	0.09	0.24	0.9	
		Week 12	Tezepelumab	103	99 (96.1)	0.27 (0.40)	-0.6	0.04	0.18	0.42	2.2	0.44 [0.16, 0.72]
			Placebo	102	100 (98.0)	0.09 (0.43)	-1.5	-0.09	0.05	0.31	1.3	
		Week 16	Tezepelumab	103	99 (96.1)	0.27 (0.43)	-0.8	0.01	0.16	0.41	2.1	0.43 [0.15, 0.71]
			Placebo	102	99 (97.1)	0.11 (0.29)	-0.6	-0.08	0.06	0.28	1.0	
		Week 24	Tezepelumab	103	93 (90.3)	0.24 (0.42)	-0.7	-0.05	0.20	0.47	1.6	0.44 [0.15, 0.73]
			Placebo	102	95 (93.1)	0.08 (0.32)	-0.9	-0.07	0.07	0.24	0.9	
		Week 36	Tezepelumab	103	89 (86.4)	0.27 (0.40)	-0.6	-0.01	0.18	0.40	1.5	0.40 [0.11, 0.69]
			Placebo	102	96 (94.1)	0.12 (0.36)	-0.5	-0.08	0.06	0.23	1.6	
		Week 52	Tezepelumab	103	86 (83.5)	0.26 (0.44)	-0.5	-0.01	0.14	0.52	1.5	0.37 [0.06, 0.67]
			Placebo	102	83 (81.4)	0.11 (0.38)	-0.7	-0.09	0.05	0.22	2.0	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
South America	Absolute values	Baseline	Tezepelumab	67	67 (100.0)	1.80 (0.68)	0.8	1.33	1.64	2.13	3.8	
			Placebo	67	67 (100.0)	1.97 (0.88)	0.6	1.22	1.92	2.56	4.5	
		Week 2	Tezepelumab	67	67 (100.0)	1.91 (0.69)	0.9	1.39	1.79	2.39	4.0	
			Placebo	67	65 (97.0)	2.02 (0.86)	0.6	1.38	1.90	2.54	4.1	
		Week 4	Tezepelumab	67	66 (98.5)	1.91 (0.74)	0.8	1.36	1.75	2.35	4.2	
			Placebo	67	63 (94.0)	1.99 (0.88)	0.5	1.27	2.03	2.51	4.8	
		Week 8	Tezepelumab	67	66 (98.5)	1.93 (0.79)	0.7	1.28	1.77	2.41	4.2	
			Placebo	67	65 (97.0)	2.09 (0.92)	0.6	1.41	1.95	2.69	4.6	
		Week 12	Tezepelumab	67	65 (97.0)	1.96 (0.76)	0.8	1.49	1.76	2.45	4.3	
			Placebo	67	66 (98.5)	2.08 (0.89)	0.5	1.48	2.05	2.58	4.6	
		Week 16	Tezepelumab	67	64 (95.5)	1.94 (0.76)	0.8	1.41	1.78	2.33	4.3	
			Placebo	67	64 (95.5)	2.08 (1.00)	0.5	1.28	1.92	2.62	4.7	
		Week 24	Tezepelumab	67	63 (94.0)	1.92 (0.74)	0.7	1.32	1.74	2.46	3.7	
			Placebo	67	63 (94.0)	2.10 (0.96)	0.6	1.40	1.90	2.79	4.8	
		Week 36	Tezepelumab	67	63 (94.0)	1.92 (0.77)	0.7	1.31	1.85	2.31	4.2	
			Placebo	67	65 (97.0)	2.14 (0.95)	0.6	1.41	2.12	2.78	4.3	
		Week 52	Tezepelumab	67	63 (94.0)	1.95 (0.79)	0.6	1.38	1.79	2.33	4.3	
			Placebo	67	63 (94.0)	2.10 (0.97)	0.6	1.31	2.07	2.76	4.5	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
South America	Change from baseline	Week 2	Tezepelumab	67	67 (100.0)	0.10 (0.31)	-0.7	-0.09	0.10	0.25	1.3	0.20 [-0.14, 0.54]
			Placebo	67	65 (97.0)	0.03 (0.41)	-1.1	-0.17	-0.02	0.16	1.1	
		Week 4	Tezepelumab	67	66 (98.5)	0.12 (0.31)	-0.5	-0.08	0.08	0.22	1.3	0.15 [-0.19, 0.50]
			Placebo	67	63 (94.0)	0.06 (0.46)	-1.8	-0.12	0.03	0.23	1.6	
		Week 8	Tezepelumab	67	66 (98.5)	0.14 (0.38)	-0.6	-0.08	0.08	0.31	1.6	0.10 [-0.25, 0.44]
			Placebo	67	65 (97.0)	0.11 (0.36)	-1.0	-0.11	0.09	0.29	1.4	
		Week 12	Tezepelumab	67	65 (97.0)	0.14 (0.34)	-0.4	-0.07	0.08	0.24	1.6	0.15 [-0.19, 0.49]
			Placebo	67	66 (98.5)	0.09 (0.40)	-0.7	-0.13	0.04	0.26	1.4	
		Week 16	Tezepelumab	67	64 (95.5)	0.15 (0.35)	-0.5	-0.06	0.14	0.28	1.5	0.15 [-0.19, 0.50]
			Placebo	67	64 (95.5)	0.09 (0.45)	-0.7	-0.18	0.00	0.26	1.5	
		Week 24	Tezepelumab	67	63 (94.0)	0.15 (0.36)	-0.7	-0.08	0.12	0.31	1.5	0.13 [-0.22, 0.48]
			Placebo	67	63 (94.0)	0.10 (0.43)	-0.8	-0.13	0.03	0.29	1.6	
		Week 36	Tezepelumab	67	63 (94.0)	0.14 (0.37)	-0.8	-0.10	0.05	0.35	1.6	0.01 [-0.34, 0.35]
			Placebo	67	65 (97.0)	0.13 (0.44)	-0.8	-0.17	0.03	0.29	1.3	
		Week 52	Tezepelumab	67	63 (94.0)	0.16 (0.39)	-0.8	-0.06	0.08	0.36	1.7	0.13 [-0.22, 0.48]
			Placebo	67	63 (94.0)	0.11 (0.43)	-0.9	-0.16	0.03	0.35	1.2	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Central/Eastern Europe	Absolute values	Baseline	Tezepelumab	34	34 (100.0)	1.75 (0.55)	0.9	1.32	1.71	1.99	3.5	
			Placebo	36	36 (100.0)	1.58 (0.70)	0.8	1.10	1.40	1.78	4.0	
		Week 2	Tezepelumab	34	34 (100.0)	1.95 (0.62)	1.1	1.52	1.83	2.44	3.8	
			Placebo	36	34 (94.4)	1.58 (0.69)	0.7	1.11	1.39	1.90	3.6	
		Week 4	Tezepelumab	34	34 (100.0)	2.03 (0.69)	0.9	1.57	1.90	2.42	3.7	
			Placebo	36	35 (97.2)	1.70 (0.72)	0.7	1.26	1.48	2.09	4.1	
		Week 8	Tezepelumab	34	34 (100.0)	2.01 (0.65)	1.0	1.61	1.85	2.48	3.7	
			Placebo	36	35 (97.2)	1.75 (0.84)	0.7	1.25	1.59	1.95	4.7	
		Week 12	Tezepelumab	34	33 (97.1)	2.02 (0.60)	1.1	1.58	1.91	2.52	3.6	
			Placebo	36	35 (97.2)	1.75 (0.87)	0.6	1.30	1.51	2.10	4.6	
		Week 16	Tezepelumab	34	34 (100.0)	2.04 (0.63)	1.0	1.56	1.93	2.59	3.3	
			Placebo	36	36 (100.0)	1.76 (0.87)	0.9	1.25	1.55	2.12	4.7	
		Week 24	Tezepelumab	34	33 (97.1)	1.98 (0.65)	0.9	1.57	1.78	2.47	3.8	
			Placebo	36	36 (100.0)	1.74 (0.81)	0.8	1.32	1.59	2.01	4.6	
		Week 36	Tezepelumab	34	34 (100.0)	1.94 (0.62)	1.0	1.48	1.90	2.44	3.5	
			Placebo	36	35 (97.2)	1.72 (0.79)	0.8	1.26	1.60	1.93	4.3	
		Week 52	Tezepelumab	34	34 (100.0)	1.97 (0.68)	1.0	1.48	1.86	2.63	3.5	
			Placebo	36	36 (100.0)	1.67 (0.77)	0.8	1.22	1.46	1.92	4.4	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Central/Eastern Europe	Change from baseline	Week 2	Tezepelumab	34	34 (100.0)	0.20 (0.31)	-0.3	0.02	0.10	0.28	1.0	0.81 [0.32, 1.31]
			Placebo	36	34 (94.4)	-0.03 (0.23)	-0.8	-0.12	-0.01	0.09	0.7	
		Week 4	Tezepelumab	34	34 (100.0)	0.28 (0.42)	-0.7	0.09	0.24	0.39	1.7	0.49 [0.01, 0.97]
			Placebo	36	35 (97.2)	0.11 (0.27)	-0.3	-0.07	0.08	0.23	1.0	
		Week 8	Tezepelumab	34	34 (100.0)	0.26 (0.36)	-0.2	-0.05	0.21	0.37	1.2	0.28 [-0.20, 0.75]
			Placebo	36	35 (97.2)	0.15 (0.40)	-0.4	-0.07	0.03	0.28	1.8	
		Week 12	Tezepelumab	34	33 (97.1)	0.28 (0.36)	-0.3	0.01	0.24	0.44	1.4	0.32 [-0.16, 0.80]
			Placebo	36	35 (97.2)	0.17 (0.37)	-0.2	-0.05	0.06	0.26	1.8	
		Week 16	Tezepelumab	34	34 (100.0)	0.28 (0.47)	-0.6	0.04	0.22	0.56	1.6	0.23 [-0.24, 0.70]
			Placebo	36	36 (100.0)	0.18 (0.39)	-0.4	-0.03	0.12	0.26	1.9	
		Week 24	Tezepelumab	34	33 (97.1)	0.21 (0.44)	-1.0	-0.08	0.19	0.48	1.1	0.13 [-0.34, 0.60]
			Placebo	36	36 (100.0)	0.16 (0.39)	-0.4	-0.05	0.05	0.30	1.7	
		Week 36	Tezepelumab	34	34 (100.0)	0.19 (0.39)	-0.4	-0.09	0.07	0.48	1.1	0.16 [-0.31, 0.63]
			Placebo	36	35 (97.2)	0.13 (0.31)	-0.3	-0.02	0.06	0.17	1.5	
		Week 52	Tezepelumab	34	34 (100.0)	0.21 (0.44)	-0.5	-0.10	0.18	0.44	1.4	0.29 [-0.18, 0.77]
			Placebo	36	36 (100.0)	0.09 (0.37)	-0.9	-0.10	0.04	0.22	1.5	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Asia Pacific	Absolute values	Baseline	Tezepelumab	121	121 (100.0)	1.70 (0.65)	0.4	1.26	1.66	2.13	4.1	
			Placebo	123	123 (100.0)	1.75 (0.56)	0.4	1.37	1.69	2.06	3.1	
		Week 2	Tezepelumab	121	120 (99.2)	1.86 (0.66)	0.6	1.31	1.79	2.31	4.3	
			Placebo	123	120 (97.6)	1.83 (0.61)	0.4	1.45	1.72	2.17	3.9	
		Week 4	Tezepelumab	121	121 (100.0)	1.92 (0.66)	0.7	1.46	1.79	2.41	3.7	
			Placebo	123	123 (100.0)	1.81 (0.60)	0.4	1.44	1.72	2.13	3.7	
		Week 8	Tezepelumab	121	117 (96.7)	1.97 (0.66)	0.6	1.48	1.89	2.38	4.7	
			Placebo	123	123 (100.0)	1.83 (0.62)	0.4	1.41	1.78	2.20	4.3	
		Week 12	Tezepelumab	121	119 (98.3)	1.95 (0.65)	0.6	1.50	1.91	2.35	3.8	
			Placebo	123	122 (99.2)	1.85 (0.61)	0.7	1.48	1.74	2.21	4.3	
		Week 16	Tezepelumab	121	120 (99.2)	1.96 (0.70)	0.6	1.52	1.83	2.43	4.7	
			Placebo	123	120 (97.6)	1.86 (0.59)	0.7	1.52	1.76	2.15	4.4	
		Week 24	Tezepelumab	121	119 (98.3)	1.94 (0.63)	0.7	1.56	1.82	2.32	4.0	
			Placebo	123	118 (95.9)	1.85 (0.59)	0.7	1.45	1.73	2.11	4.3	
		Week 36	Tezepelumab	121	115 (95.0)	1.95 (0.70)	0.6	1.51	1.80	2.38	4.4	
			Placebo	123	113 (91.9)	1.83 (0.63)	0.7	1.46	1.71	2.13	4.3	
		Week 52	Tezepelumab	121	114 (94.2)	1.95 (0.67)	0.6	1.50	1.77	2.37	4.2	
			Placebo	123	111 (90.2)	1.80 (0.59)	0.7	1.42	1.70	2.13	3.4	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Asia Pacific	Change from baseline	Week 2	Tezepelumab	121	120 (99.2)	0.16 (0.34)	-0.6	-0.01	0.09	0.25	1.3	0.26 [0.00, 0.51]
			Placebo	123	120 (97.6)	0.07 (0.32)	-0.7	-0.09	0.04	0.19	1.2	
		Week 4	Tezepelumab	121	121 (100.0)	0.23 (0.38)	-0.9	0.02	0.14	0.35	1.8	0.45 [0.19, 0.70]
			Placebo	123	123 (100.0)	0.06 (0.35)	-0.7	-0.13	0.01	0.20	1.1	
		Week 8	Tezepelumab	121	117 (96.7)	0.27 (0.42)	-0.8	0.03	0.17	0.49	1.7	0.49 [0.24, 0.75]
			Placebo	123	123 (100.0)	0.08 (0.34)	-0.7	-0.14	0.03	0.25	1.6	
		Week 12	Tezepelumab	121	119 (98.3)	0.27 (0.44)	-0.7	0.04	0.19	0.45	2.0	0.44 [0.18, 0.70]
			Placebo	123	122 (99.2)	0.09 (0.35)	-0.9	-0.07	0.04	0.19	1.7	
		Week 16	Tezepelumab	121	120 (99.2)	0.27 (0.43)	-0.6	0.00	0.20	0.45	1.7	0.45 [0.20, 0.71]
			Placebo	123	120 (97.6)	0.10 (0.34)	-0.8	-0.10	0.03	0.26	1.8	
		Week 24	Tezepelumab	121	119 (98.3)	0.24 (0.42)	-1.0	-0.01	0.19	0.43	1.6	0.41 [0.15, 0.67]
			Placebo	123	118 (95.9)	0.08 (0.37)	-0.9	-0.14	0.07	0.28	1.7	
		Week 36	Tezepelumab	121	115 (95.0)	0.25 (0.45)	-1.0	0.00	0.22	0.44	1.5	0.44 [0.18, 0.70]
			Placebo	123	113 (91.9)	0.06 (0.39)	-1.0	-0.20	0.02	0.28	1.7	
		Week 52	Tezepelumab	121	114 (94.2)	0.24 (0.44)	-1.0	-0.02	0.22	0.49	1.6	0.53 [0.26, 0.80]
			Placebo	123	111 (90.2)	0.03 (0.33)	-1.0	-0.20	0.01	0.23	0.8	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Rest of the world	Absolute values	Baseline	Tezepelumab	77	77 (100.0)	1.58 (0.66)	0.6	1.12	1.44	2.02	3.3	
			Placebo	78	78 (100.0)	1.67 (0.46)	0.8	1.37	1.61	1.90	3.0	
		Week 2	Tezepelumab	77	73 (94.8)	1.77 (0.68)	0.6	1.30	1.64	2.22	3.5	
			Placebo	78	74 (94.9)	1.69 (0.48)	0.8	1.31	1.65	1.99	2.7	
		Week 4	Tezepelumab	77	76 (98.7)	1.75 (0.68)	0.6	1.22	1.67	2.14	3.8	
			Placebo	78	76 (97.4)	1.79 (0.52)	0.9	1.39	1.76	2.05	3.4	
		Week 8	Tezepelumab	77	76 (98.7)	1.76 (0.62)	0.6	1.30	1.69	2.27	3.8	
			Placebo	78	77 (98.7)	1.75 (0.50)	0.7	1.36	1.69	2.09	3.0	
		Week 12	Tezepelumab	77	76 (98.7)	1.80 (0.68)	0.6	1.32	1.68	2.28	3.8	
			Placebo	78	74 (94.9)	1.78 (0.52)	0.7	1.40	1.72	2.15	3.2	
		Week 16	Tezepelumab	77	73 (94.8)	1.79 (0.70)	0.6	1.28	1.67	2.18	3.8	
			Placebo	78	72 (92.3)	1.76 (0.48)	0.8	1.40	1.71	2.13	3.1	
		Week 24	Tezepelumab	77	72 (93.5)	1.82 (0.73)	0.6	1.21	1.78	2.29	4.0	
			Placebo	78	71 (91.0)	1.71 (0.50)	0.7	1.37	1.64	2.10	3.1	
		Week 36	Tezepelumab	77	68 (88.3)	1.83 (0.69)	0.5	1.30	1.79	2.30	3.8	
			Placebo	78	65 (83.3)	1.71 (0.46)	0.9	1.39	1.65	2.11	2.8	
		Week 52	Tezepelumab	77	65 (84.4)	1.82 (0.68)	0.7	1.31	1.77	2.23	3.7	
			Placebo	78	62 (79.5)	1.69 (0.48)	0.8	1.31	1.65	1.97	3.3	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Rest of the world	Change from baseline	Week 2	Tezepelumab	77	73 (94.8)	0.16 (0.38)	-0.8	-0.06	0.09	0.28	1.9	0.37 [0.05, 0.70]
			Placebo	78	74 (94.9)	0.03 (0.30)	-0.7	-0.12	0.02	0.16	1.0	
		Week 4	Tezepelumab	77	76 (98.7)	0.16 (0.38)	-1.0	-0.06	0.06	0.35	1.4	0.07 [-0.25, 0.39]
			Placebo	78	76 (97.4)	0.13 (0.43)	-1.0	-0.12	0.06	0.39	1.2	
		Week 8	Tezepelumab	77	76 (98.7)	0.20 (0.32)	-0.5	0.01	0.15	0.34	1.1	0.31 [-0.01, 0.63]
			Placebo	78	77 (98.7)	0.09 (0.39)	-0.9	-0.10	0.03	0.22	1.8	
		Week 12	Tezepelumab	77	76 (98.7)	0.22 (0.37)	-0.4	-0.04	0.16	0.43	1.5	0.26 [-0.06, 0.58]
			Placebo	78	74 (94.9)	0.12 (0.39)	-1.1	-0.08	0.05	0.22	2.1	
		Week 16	Tezepelumab	77	73 (94.8)	0.19 (0.43)	-1.0	-0.05	0.11	0.40	1.8	0.22 [-0.10, 0.55]
			Placebo	78	72 (92.3)	0.10 (0.35)	-1.0	-0.06	0.04	0.29	1.3	
		Week 24	Tezepelumab	77	72 (93.5)	0.23 (0.44)	-0.4	-0.05	0.09	0.42	2.1	0.41 [0.08, 0.74]
			Placebo	78	71 (91.0)	0.07 (0.35)	-1.1	-0.14	0.02	0.27	1.3	
		Week 36	Tezepelumab	77	68 (88.3)	0.21 (0.40)	-0.4	-0.06	0.10	0.37	1.8	0.34 [-0.01, 0.68]
			Placebo	78	65 (83.3)	0.08 (0.39)	-0.9	-0.14	0.04	0.29	1.6	
		Week 52	Tezepelumab	77	65 (84.4)	0.21 (0.40)	-0.5	-0.06	0.13	0.35	1.5	0.40 [0.04, 0.75]
			Placebo	78	62 (79.5)	0.05 (0.41)	-1.0	-0.18	0.05	0.21	2.3	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
< 150 cells/uL	Absolute values	Baseline	Tezepelumab	130	130 (100.0)	1.86 (0.68)	0.4	1.34	1.87	2.28	4.0	
			Placebo	132	132 (100.0)	1.80 (0.58)	0.8	1.38	1.75	2.17	3.4	
		Week 2	Tezepelumab	130	127 (97.7)	1.94 (0.70)	0.6	1.38	1.92	2.41	4.1	
			Placebo	132	126 (95.5)	1.86 (0.63)	0.8	1.40	1.77	2.20	3.5	
		Week 4	Tezepelumab	130	129 (99.2)	1.93 (0.74)	0.7	1.30	1.89	2.48	4.2	
			Placebo	132	129 (97.7)	1.86 (0.63)	0.7	1.40	1.81	2.26	3.6	
		Week 8	Tezepelumab	130	125 (96.2)	1.94 (0.69)	0.6	1.45	1.87	2.37	4.1	
			Placebo	132	128 (97.0)	1.89 (0.66)	0.7	1.41	1.83	2.29	4.7	
		Week 12	Tezepelumab	130	125 (96.2)	1.94 (0.70)	0.6	1.46	1.86	2.35	4.2	
			Placebo	132	127 (96.2)	1.87 (0.69)	0.7	1.36	1.79	2.27	4.6	
		Week 16	Tezepelumab	130	126 (96.9)	1.95 (0.76)	0.6	1.38	1.83	2.47	4.3	
			Placebo	132	127 (96.2)	1.85 (0.67)	0.6	1.34	1.76	2.26	4.7	
		Week 24	Tezepelumab	130	118 (90.8)	1.93 (0.66)	0.6	1.44	1.87	2.35	4.0	
			Placebo	132	121 (91.7)	1.87 (0.65)	0.7	1.36	1.77	2.25	4.6	
		Week 36	Tezepelumab	130	118 (90.8)	1.93 (0.71)	0.5	1.40	1.90	2.38	4.4	
			Placebo	132	118 (89.4)	1.89 (0.63)	0.8	1.41	1.84	2.28	4.3	
		Week 52	Tezepelumab	130	117 (90.0)	1.95 (0.70)	0.7	1.44	1.84	2.39	4.2	
			Placebo	132	115 (87.1)	1.87 (0.69)	0.7	1.34	1.73	2.33	4.4	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
< 150 cells/uL	Change from baseline	Week 2	Tezepelumab	130	127 (97.7)	0.07 (0.29)	-0.8	-0.06	0.07	0.19	1.5	0.03 [-0.22, 0.28]
			Placebo	132	126 (95.5)	0.06 (0.34)	-1.8	-0.09	0.02	0.17	1.2	
		Week 4	Tezepelumab	130	129 (99.2)	0.07 (0.37)	-1.0	-0.11	0.03	0.22	1.7	0.00 [-0.24, 0.25]
			Placebo	132	129 (97.7)	0.07 (0.34)	-1.0	-0.06	0.05	0.22	1.1	
		Week 8	Tezepelumab	130	125 (96.2)	0.08 (0.35)	-0.9	-0.11	0.04	0.27	1.4	-0.04 [-0.29, 0.20]
			Placebo	132	128 (97.0)	0.10 (0.37)	-1.1	-0.10	0.05	0.28	1.8	
		Week 12	Tezepelumab	130	125 (96.2)	0.09 (0.33)	-0.8	-0.09	0.07	0.25	1.4	0.01 [-0.24, 0.26]
			Placebo	132	127 (96.2)	0.08 (0.39)	-1.2	-0.09	0.03	0.25	1.8	
		Week 16	Tezepelumab	130	126 (96.9)	0.09 (0.41)	-1.0	-0.13	0.03	0.24	1.9	0.06 [-0.19, 0.31]
			Placebo	132	127 (96.2)	0.06 (0.38)	-1.0	-0.14	0.03	0.23	1.9	
		Week 24	Tezepelumab	130	118 (90.8)	0.08 (0.31)	-0.6	-0.08	0.03	0.22	1.1	0.04 [-0.22, 0.29]
			Placebo	132	121 (91.7)	0.07 (0.36)	-1.1	-0.11	0.03	0.24	1.7	
		Week 36	Tezepelumab	130	118 (90.8)	0.06 (0.34)	-0.7	-0.12	0.01	0.22	1.5	-0.09 [-0.34, 0.17]
			Placebo	132	118 (89.4)	0.08 (0.33)	-0.7	-0.14	0.06	0.27	1.5	
		Week 52	Tezepelumab	130	117 (90.0)	0.08 (0.36)	-1.0	-0.10	0.05	0.23	1.3	0.07 [-0.19, 0.33]
			Placebo	132	115 (87.1)	0.06 (0.39)	-1.0	-0.18	0.06	0.19	1.5	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
150 - < 300 cells/uL	Absolute values	Baseline	Tezepelumab	156	156 (100.0)	1.75 (0.65)	0.6	1.28	1.67	2.13	4.8	
			Placebo	163	163 (100.0)	1.82 (0.66)	0.7	1.37	1.69	2.10	4.1	
		Week 2	Tezepelumab	156	152 (97.4)	1.89 (0.68)	0.6	1.39	1.79	2.38	5.0	
			Placebo	163	158 (96.9)	1.84 (0.71)	0.6	1.37	1.69	2.25	4.1	
		Week 4	Tezepelumab	156	156 (100.0)	1.91 (0.69)	0.6	1.40	1.83	2.40	5.0	
			Placebo	163	158 (96.9)	1.86 (0.66)	0.7	1.44	1.74	2.18	4.8	
		Week 8	Tezepelumab	156	156 (100.0)	1.92 (0.70)	0.6	1.34	1.89	2.43	4.6	
			Placebo	163	157 (96.3)	1.92 (0.71)	0.7	1.43	1.76	2.28	4.6	
		Week 12	Tezepelumab	156	152 (97.4)	1.90 (0.70)	0.6	1.35	1.83	2.35	4.9	
			Placebo	163	157 (96.3)	1.87 (0.72)	0.6	1.41	1.73	2.15	4.6	
		Week 16	Tezepelumab	156	152 (97.4)	1.92 (0.68)	0.6	1.37	1.86	2.35	4.9	
			Placebo	163	156 (95.7)	1.89 (0.74)	0.7	1.40	1.73	2.22	4.7	
		Week 24	Tezepelumab	156	152 (97.4)	1.88 (0.73)	0.6	1.31	1.77	2.40	5.5	
			Placebo	163	152 (93.3)	1.83 (0.72)	0.6	1.40	1.67	2.09	4.8	
		Week 36	Tezepelumab	156	145 (92.9)	1.89 (0.70)	0.7	1.30	1.81	2.38	4.9	
			Placebo	163	148 (90.8)	1.86 (0.72)	0.7	1.41	1.63	2.21	4.3	
		Week 52	Tezepelumab	156	146 (93.6)	1.88 (0.70)	0.6	1.38	1.81	2.33	4.6	
			Placebo	163	139 (85.3)	1.89 (0.75)	0.7	1.40	1.70	2.21	4.3	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
150 - < 300 cells/uL	Change from baseline	Week 2	Tezepelumab	156	152 (97.4)	0.13 (0.29)	-0.7	-0.03	0.08	0.26	1.1	0.41 [0.19, 0.64]
			Placebo	163	158 (96.9)	0.01 (0.31)	-1.0	-0.12	0.00	0.13	1.1	
		Week 4	Tezepelumab	156	156 (100.0)	0.16 (0.30)	-0.5	-0.01	0.10	0.25	1.6	0.36 [0.14, 0.58]
			Placebo	163	158 (96.9)	0.05 (0.35)	-1.0	-0.11	0.04	0.20	1.6	
		Week 8	Tezepelumab	156	156 (100.0)	0.17 (0.35)	-0.8	-0.03	0.11	0.27	1.4	0.28 [0.06, 0.50]
			Placebo	163	157 (96.3)	0.08 (0.31)	-1.0	-0.08	0.03	0.20	1.8	
		Week 12	Tezepelumab	156	152 (97.4)	0.16 (0.35)	-0.7	-0.03	0.10	0.28	2.0	0.31 [0.08, 0.53]
			Placebo	163	157 (96.3)	0.05 (0.37)	-1.5	-0.10	0.03	0.18	2.1	
		Week 16	Tezepelumab	156	152 (97.4)	0.16 (0.34)	-0.6	-0.02	0.13	0.30	1.7	0.28 [0.05, 0.50]
			Placebo	163	156 (95.7)	0.07 (0.34)	-1.2	-0.07	0.03	0.21	1.4	
		Week 24	Tezepelumab	156	152 (97.4)	0.12 (0.37)	-1.0	-0.12	0.08	0.30	1.3	0.26 [0.04, 0.49]
			Placebo	163	152 (93.3)	0.03 (0.32)	-0.9	-0.12	-0.02	0.19	1.6	
		Week 36	Tezepelumab	156	145 (92.9)	0.14 (0.36)	-1.0	-0.08	0.07	0.28	1.3	0.30 [0.07, 0.53]
			Placebo	163	148 (90.8)	0.03 (0.39)	-1.1	-0.19	0.01	0.21	1.6	
		Week 52	Tezepelumab	156	146 (93.6)	0.12 (0.37)	-0.8	-0.08	0.05	0.25	1.5	0.15 [-0.08, 0.38]
			Placebo	163	139 (85.3)	0.07 (0.34)	-1.0	-0.15	0.04	0.22	2.3	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
300 - < 450 cells/uL	Absolute values	Baseline	Tezepelumab	93	93 (100.0)	1.70 (0.71)	0.5	1.19	1.58	2.01	4.1	
			Placebo	83	83 (100.0)	1.79 (0.76)	0.4	1.21	1.68	2.28	4.5	
		Week 2	Tezepelumab	93	89 (95.7)	1.89 (0.73)	0.9	1.35	1.70	2.37	4.3	
			Placebo	83	77 (92.8)	1.84 (0.69)	0.4	1.38	1.85	2.28	3.4	
		Week 4	Tezepelumab	93	90 (96.8)	1.94 (0.72)	0.9	1.44	1.78	2.33	4.3	
			Placebo	83	81 (97.6)	1.84 (0.67)	0.4	1.30	1.82	2.31	3.5	
		Week 8	Tezepelumab	93	91 (97.8)	1.99 (0.79)	0.9	1.39	1.78	2.38	4.7	
			Placebo	83	82 (98.8)	1.86 (0.68)	0.4	1.34	1.84	2.22	3.9	
		Week 12	Tezepelumab	93	89 (95.7)	2.01 (0.75)	0.7	1.49	1.87	2.49	4.7	
			Placebo	83	79 (95.2)	1.86 (0.68)	0.8	1.40	1.76	2.30	4.0	
		Week 16	Tezepelumab	93	89 (95.7)	2.02 (0.80)	1.0	1.45	1.75	2.48	4.9	
			Placebo	83	78 (94.0)	1.88 (0.70)	0.8	1.35	1.84	2.33	4.3	
		Week 24	Tezepelumab	93	89 (95.7)	2.01 (0.74)	0.9	1.45	1.92	2.43	4.4	
			Placebo	83	77 (92.8)	1.87 (0.68)	0.8	1.45	1.77	2.23	4.3	
		Week 36	Tezepelumab	93	83 (89.2)	2.02 (0.80)	0.7	1.37	1.82	2.37	4.5	
			Placebo	83	74 (89.2)	1.90 (0.72)	0.8	1.37	1.76	2.31	4.2	
		Week 52	Tezepelumab	93	81 (87.1)	2.02 (0.80)	0.6	1.43	1.83	2.48	4.2	
			Placebo	83	73 (88.0)	1.88 (0.75)	0.7	1.34	1.68	2.28	4.5	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
300 - < 450 cells/uL	Change from baseline	Week 2	Tezepelumab	93	89 (95.7)	0.21 (0.39)	-0.6	0.02	0.11	0.35	1.9	0.47 [0.16, 0.78]
			Placebo	83	77 (92.8)	0.04 (0.34)	-1.1	-0.12	0.04	0.18	0.9	
		Week 4	Tezepelumab	93	90 (96.8)	0.25 (0.37)	-0.4	-0.01	0.15	0.39	1.4	0.52 [0.21, 0.82]
			Placebo	83	81 (97.6)	0.05 (0.38)	-1.8	-0.10	0.04	0.25	1.1	
		Week 8	Tezepelumab	93	91 (97.8)	0.29 (0.43)	-0.6	0.02	0.21	0.51	1.8	0.61 [0.31, 0.92]
			Placebo	83	82 (98.8)	0.06 (0.31)	-0.6	-0.12	0.04	0.22	1.1	
		Week 12	Tezepelumab	93	89 (95.7)	0.32 (0.42)	-0.3	0.04	0.23	0.45	1.9	0.72 [0.41, 1.03]
			Placebo	83	79 (95.2)	0.03 (0.36)	-1.4	-0.14	-0.01	0.25	1.0	
		Week 16	Tezepelumab	93	89 (95.7)	0.32 (0.44)	-0.4	0.03	0.24	0.46	2.0	0.63 [0.32, 0.94]
			Placebo	83	78 (94.0)	0.07 (0.34)	-1.0	-0.09	0.03	0.19	1.0	
		Week 24	Tezepelumab	93	89 (95.7)	0.32 (0.42)	-0.3	0.03	0.27	0.49	2.1	0.74 [0.42, 1.05]
			Placebo	83	77 (92.8)	0.04 (0.33)	-0.9	-0.13	0.03	0.19	1.1	
		Week 36	Tezepelumab	93	83 (89.2)	0.32 (0.43)	-0.3	0.01	0.31	0.54	1.8	0.62 [0.30, 0.94]
			Placebo	83	74 (89.2)	0.07 (0.37)	-0.8	-0.10	0.03	0.18	1.6	
		Week 52	Tezepelumab	93	81 (87.1)	0.33 (0.44)	-0.8	0.02	0.34	0.51	1.7	0.60 [0.28, 0.92]
			Placebo	83	73 (88.0)	0.07 (0.42)	-0.6	-0.19	0.01	0.23	2.0	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
>= 450 cells/uL	Absolute values	Baseline	Tezepelumab	108	108 (100.0)	1.69 (0.69)	0.6	1.22	1.55	1.94	3.8	
			Placebo	112	112 (100.0)	1.70 (0.65)	0.6	1.29	1.59	2.09	4.2	
		Week 2	Tezepelumab	108	106 (98.1)	2.00 (0.72)	0.8	1.47	1.86	2.41	4.0	
			Placebo	112	107 (95.5)	1.85 (0.67)	0.8	1.35	1.80	2.27	4.0	
		Week 4	Tezepelumab	108	108 (100.0)	2.05 (0.72)	0.7	1.57	1.91	2.51	4.2	
			Placebo	112	110 (98.2)	1.89 (0.72)	0.5	1.41	1.81	2.22	4.2	
		Week 8	Tezepelumab	108	106 (98.1)	2.09 (0.73)	0.9	1.59	1.92	2.48	4.3	
			Placebo	112	111 (99.1)	1.85 (0.75)	0.6	1.30	1.70	2.16	4.3	
		Week 12	Tezepelumab	108	107 (99.1)	2.11 (0.75)	0.9	1.63	1.96	2.53	4.6	
			Placebo	112	112 (100.0)	1.92 (0.71)	0.5	1.40	1.87	2.32	4.3	
		Week 16	Tezepelumab	108	104 (96.3)	2.14 (0.78)	0.8	1.61	2.00	2.55	4.4	
			Placebo	112	108 (96.4)	1.90 (0.67)	0.5	1.43	1.79	2.18	4.4	
		Week 24	Tezepelumab	108	101 (93.5)	2.11 (0.72)	0.8	1.64	1.96	2.53	4.0	
			Placebo	112	103 (92.0)	1.93 (0.71)	0.7	1.43	1.89	2.22	4.8	
		Week 36	Tezepelumab	108	100 (92.6)	2.12 (0.73)	0.8	1.58	2.00	2.47	4.2	
			Placebo	112	100 (89.3)	1.98 (0.74)	0.6	1.51	1.95	2.32	4.6	
		Week 52	Tezepelumab	108	93 (86.1)	2.13 (0.74)	0.9	1.65	1.90	2.43	4.3	
			Placebo	112	91 (81.3)	1.89 (0.69)	0.6	1.37	1.90	2.30	4.4	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
>= 450 cells/uL	Change from baseline	Week 2	Tezepelumab	108	106 (98.1)	0.31 (0.35)	-0.3	0.10	0.23	0.43	1.3	0.49 [0.22, 0.76]
			Placebo	112	107 (95.5)	0.12 (0.39)	-0.6	-0.11	0.02	0.33	1.7	
		Week 4	Tezepelumab	108	108 (100.0)	0.36 (0.36)	-0.4	0.10	0.32	0.52	1.8	0.45 [0.18, 0.72]
			Placebo	112	110 (98.2)	0.19 (0.41)	-0.5	-0.09	0.07	0.47	1.4	
		Week 8	Tezepelumab	108	106 (98.1)	0.43 (0.43)	-0.4	0.12	0.33	0.69	1.9	0.64 [0.37, 0.91]
			Placebo	112	111 (99.1)	0.15 (0.43)	-0.8	-0.13	0.09	0.33	2.1	
		Week 12	Tezepelumab	108	107 (99.1)	0.44 (0.44)	-0.3	0.09	0.37	0.62	2.2	0.52 [0.25, 0.79]
			Placebo	112	112 (100.0)	0.22 (0.39)	-0.5	-0.04	0.13	0.40	1.7	
		Week 16	Tezepelumab	108	104 (96.3)	0.46 (0.43)	-0.4	0.15	0.36	0.68	2.1	0.67 [0.39, 0.95]
			Placebo	112	108 (96.4)	0.18 (0.38)	-0.5	-0.08	0.08	0.43	1.8	
		Week 24	Tezepelumab	108	101 (93.5)	0.44 (0.44)	-0.5	0.16	0.39	0.64	1.7	0.55 [0.27, 0.83]
			Placebo	112	103 (92.0)	0.20 (0.45)	-0.8	-0.13	0.11	0.41	1.7	
		Week 36	Tezepelumab	108	100 (92.6)	0.44 (0.41)	-0.5	0.17	0.38	0.66	1.6	0.42 [0.14, 0.70]
			Placebo	112	100 (89.3)	0.26 (0.43)	-0.5	-0.03	0.16	0.51	1.7	
		Week 52	Tezepelumab	108	93 (86.1)	0.43 (0.41)	-0.6	0.21	0.39	0.72	1.6	0.70 [0.40, 1.00]
			Placebo	112	91 (81.3)	0.16 (0.38)	-0.9	-0.09	0.10	0.35	1.6	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q1: < 140 cells/uL	Absolute values	Baseline	Tezepelumab	119	119 (100.0)	1.87 (0.68)	0.4	1.34	1.88	2.30	4.0	
			Placebo	121	121 (100.0)	1.77 (0.57)	0.8	1.37	1.73	2.13	3.4	
		Week 2	Tezepelumab	119	116 (97.5)	1.95 (0.71)	0.6	1.35	1.95	2.42	4.1	
			Placebo	121	115 (95.0)	1.85 (0.63)	0.8	1.40	1.75	2.16	3.5	
		Week 4	Tezepelumab	119	118 (99.2)	1.94 (0.74)	0.7	1.30	1.96	2.48	4.2	
			Placebo	121	118 (97.5)	1.84 (0.64)	0.7	1.34	1.78	2.26	3.6	
		Week 8	Tezepelumab	119	115 (96.6)	1.96 (0.70)	0.6	1.45	1.88	2.38	4.1	
			Placebo	121	117 (96.7)	1.85 (0.66)	0.7	1.40	1.77	2.26	4.7	
		Week 12	Tezepelumab	119	115 (96.6)	1.95 (0.70)	0.6	1.47	1.92	2.37	4.2	
			Placebo	121	117 (96.7)	1.86 (0.70)	0.7	1.34	1.75	2.25	4.6	
		Week 16	Tezepelumab	119	116 (97.5)	1.97 (0.76)	0.6	1.38	1.84	2.48	4.3	
			Placebo	121	116 (95.9)	1.83 (0.67)	0.6	1.33	1.73	2.21	4.7	
		Week 24	Tezepelumab	119	109 (91.6)	1.95 (0.67)	0.6	1.47	1.89	2.36	4.0	
			Placebo	121	111 (91.7)	1.86 (0.66)	0.7	1.33	1.76	2.25	4.6	
		Week 36	Tezepelumab	119	109 (91.6)	1.96 (0.72)	0.5	1.45	1.91	2.40	4.4	
			Placebo	121	108 (89.3)	1.88 (0.64)	0.8	1.41	1.83	2.28	4.3	
		Week 52	Tezepelumab	119	108 (90.8)	1.98 (0.71)	0.7	1.46	1.93	2.52	4.2	
			Placebo	121	105 (86.8)	1.84 (0.69)	0.7	1.32	1.70	2.26	4.4	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q1: < 140 cells/uL	Change from baseline	Week 2	Tezepelumab	119	116 (97.5)	0.07 (0.29)	-0.8	-0.06	0.08	0.20	1.5	0.01 [-0.24, 0.27]
			Placebo	121	115 (95.0)	0.07 (0.31)	-0.7	-0.10	0.02	0.17	1.2	
		Week 4	Tezepelumab	119	118 (99.2)	0.07 (0.37)	-1.0	-0.11	0.04	0.26	1.7	0.01 [-0.25, 0.26]
			Placebo	121	118 (97.5)	0.07 (0.33)	-0.9	-0.06	0.05	0.22	1.1	
		Week 8	Tezepelumab	119	115 (96.6)	0.09 (0.36)	-0.9	-0.11	0.04	0.27	1.4	0.00 [-0.25, 0.26]
			Placebo	121	117 (96.7)	0.09 (0.37)	-1.1	-0.11	0.05	0.28	1.8	
		Week 12	Tezepelumab	119	115 (96.6)	0.09 (0.34)	-0.8	-0.09	0.08	0.25	1.4	0.01 [-0.25, 0.26]
			Placebo	121	117 (96.7)	0.09 (0.37)	-1.1	-0.09	0.03	0.22	1.8	
		Week 16	Tezepelumab	119	116 (97.5)	0.09 (0.42)	-1.0	-0.13	0.03	0.26	1.9	0.07 [-0.18, 0.33]
			Placebo	121	116 (95.9)	0.06 (0.39)	-1.0	-0.15	0.03	0.22	1.9	
		Week 24	Tezepelumab	119	109 (91.6)	0.09 (0.31)	-0.6	-0.08	0.03	0.25	1.1	0.02 [-0.25, 0.28]
			Placebo	121	111 (91.7)	0.08 (0.36)	-1.1	-0.11	0.03	0.24	1.7	
		Week 36	Tezepelumab	119	109 (91.6)	0.07 (0.35)	-0.7	-0.12	0.01	0.24	1.5	-0.10 [-0.36, 0.17]
			Placebo	121	108 (89.3)	0.10 (0.32)	-0.7	-0.12	0.06	0.28	1.5	
		Week 52	Tezepelumab	119	108 (90.8)	0.09 (0.37)	-1.0	-0.09	0.05	0.24	1.3	0.11 [-0.16, 0.38]
			Placebo	121	105 (86.8)	0.05 (0.40)	-1.0	-0.18	0.05	0.19	1.5	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q2: 140 - < 250 cells/uL	Absolute values	Baseline	Tezepelumab	117	117 (100.0)	1.76 (0.57)	0.8	1.33	1.68	2.11	3.5	
			Placebo	130	130 (100.0)	1.87 (0.64)	0.7	1.42	1.77	2.18	4.1	
		Week 2	Tezepelumab	117	114 (97.4)	1.89 (0.61)	0.8	1.42	1.77	2.38	3.8	
			Placebo	130	126 (96.9)	1.86 (0.69)	0.7	1.36	1.71	2.28	4.0	
		Week 4	Tezepelumab	117	117 (100.0)	1.89 (0.63)	0.8	1.41	1.76	2.38	3.7	
			Placebo	130	125 (96.2)	1.89 (0.61)	0.8	1.46	1.82	2.23	3.7	
		Week 8	Tezepelumab	117	116 (99.1)	1.88 (0.63)	0.8	1.36	1.78	2.36	3.7	
			Placebo	130	128 (98.5)	1.95 (0.68)	0.7	1.44	1.81	2.31	4.1	
		Week 12	Tezepelumab	117	112 (95.7)	1.86 (0.64)	0.8	1.34	1.74	2.32	3.6	
			Placebo	130	125 (96.2)	1.89 (0.70)	0.6	1.49	1.73	2.29	4.1	
		Week 16	Tezepelumab	117	113 (96.6)	1.89 (0.62)	0.8	1.40	1.84	2.31	3.5	
			Placebo	130	126 (96.9)	1.93 (0.72)	0.7	1.46	1.76	2.35	4.1	
		Week 24	Tezepelumab	117	112 (95.7)	1.84 (0.65)	0.7	1.32	1.77	2.28	3.8	
			Placebo	130	122 (93.8)	1.89 (0.68)	0.6	1.44	1.73	2.18	4.0	
		Week 36	Tezepelumab	117	108 (92.3)	1.83 (0.63)	0.7	1.27	1.77	2.33	3.5	
			Placebo	130	118 (90.8)	1.89 (0.69)	0.8	1.44	1.69	2.25	4.1	
		Week 52	Tezepelumab	117	108 (92.3)	1.82 (0.65)	0.6	1.36	1.76	2.29	3.5	
			Placebo	130	112 (86.2)	1.93 (0.73)	0.7	1.44	1.74	2.30	4.3	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q2: 140 - < 250 cells/uL	Change from baseline	Week 2	Tezepelumab	117	114 (97.4)	0.12 (0.28)	-0.7	-0.01	0.08	0.24	1.1	0.49 [0.23, 0.75]
			Placebo	130	126 (96.9)	-0.02 (0.33)	-1.8	-0.12	0.00	0.12	1.1	
		Week 4	Tezepelumab	117	117 (100.0)	0.13 (0.27)	-0.5	-0.03	0.10	0.24	1.2	0.35 [0.09, 0.60]
			Placebo	130	125 (96.2)	0.02 (0.36)	-1.0	-0.13	0.05	0.20	1.1	
		Week 8	Tezepelumab	117	116 (99.1)	0.14 (0.32)	-0.8	-0.05	0.11	0.23	1.4	0.20 [-0.05, 0.45]
			Placebo	130	128 (98.5)	0.07 (0.31)	-1.0	-0.10	0.04	0.20	1.8	
		Week 12	Tezepelumab	117	112 (95.7)	0.11 (0.30)	-0.7	-0.05	0.09	0.20	1.4	0.25 [-0.01, 0.51]
			Placebo	130	125 (96.2)	0.03 (0.39)	-1.5	-0.11	0.01	0.17	2.1	
		Week 16	Tezepelumab	117	113 (96.6)	0.13 (0.29)	-0.6	-0.04	0.10	0.25	1.3	0.24 [-0.02, 0.49]
			Placebo	130	126 (96.9)	0.06 (0.31)	-0.8	-0.10	0.02	0.20	1.3	
		Week 24	Tezepelumab	117	112 (95.7)	0.09 (0.35)	-1.0	-0.12	0.08	0.25	1.3	0.21 [-0.05, 0.47]
			Placebo	130	122 (93.8)	0.02 (0.32)	-0.9	-0.12	0.01	0.22	1.3	
		Week 36	Tezepelumab	117	108 (92.3)	0.08 (0.32)	-0.8	-0.10	0.04	0.22	1.3	0.19 [-0.08, 0.45]
			Placebo	130	118 (90.8)	0.02 (0.38)	-1.1	-0.19	-0.01	0.18	1.6	
		Week 52	Tezepelumab	117	108 (92.3)	0.07 (0.34)	-0.8	-0.11	0.02	0.19	1.3	0.01 [-0.26, 0.27]
			Placebo	130	112 (86.2)	0.07 (0.36)	-1.0	-0.16	0.02	0.22	2.3	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q3: 250 - < 430 cells/uL	Absolute values	Baseline	Tezepelumab	135	135 (100.0)	1.74 (0.76)	0.5	1.19	1.64	2.07	4.8	
			Placebo	117	117 (100.0)	1.73 (0.65)	0.4	1.27	1.68	2.08	3.7	
		Week 2	Tezepelumab	135	131 (97.0)	1.91 (0.76)	0.6	1.37	1.80	2.37	5.0	
			Placebo	117	111 (94.9)	1.82 (0.67)	0.4	1.40	1.78	2.26	4.1	
		Week 4	Tezepelumab	135	132 (97.8)	1.96 (0.77)	0.6	1.40	1.88	2.52	5.0	
			Placebo	117	115 (98.3)	1.81 (0.67)	0.4	1.43	1.74	2.19	4.8	
		Week 8	Tezepelumab	135	133 (98.5)	2.00 (0.80)	0.6	1.36	1.94	2.48	4.7	
			Placebo	117	112 (95.7)	1.85 (0.67)	0.4	1.41	1.79	2.20	4.6	
		Week 12	Tezepelumab	135	131 (97.0)	2.03 (0.79)	0.6	1.48	1.91	2.50	4.9	
			Placebo	117	111 (94.9)	1.83 (0.65)	0.6	1.40	1.76	2.16	4.6	
		Week 16	Tezepelumab	135	130 (96.3)	2.02 (0.81)	0.6	1.37	1.88	2.48	4.9	
			Placebo	117	109 (93.2)	1.84 (0.65)	0.7	1.42	1.76	2.16	4.7	
		Week 24	Tezepelumab	135	130 (96.3)	2.00 (0.80)	0.6	1.45	1.88	2.43	5.5	
			Placebo	117	107 (91.5)	1.78 (0.65)	0.6	1.41	1.67	2.17	4.8	
		Week 36	Tezepelumab	135	121 (89.6)	2.03 (0.82)	0.7	1.44	1.85	2.52	4.9	
			Placebo	117	104 (88.9)	1.83 (0.67)	0.7	1.38	1.69	2.21	4.3	
		Week 52	Tezepelumab	135	120 (88.9)	2.02 (0.81)	0.6	1.39	1.84	2.50	4.6	
			Placebo	117	100 (85.5)	1.84 (0.68)	0.7	1.37	1.68	2.23	4.0	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q3: 250 - < 430 cells/uL	Change from baseline	Week 2	Tezepelumab	135	131 (97.0)	0.19 (0.36)	-0.5	-0.04	0.10	0.32	1.9	0.30 [0.04, 0.55]
			Placebo	117	111 (94.9)	0.08 (0.33)	-0.8	-0.09	0.05	0.22	1.0	
		Week 4	Tezepelumab	135	132 (97.8)	0.23 (0.37)	-0.5	-0.01	0.13	0.38	1.6	0.40 [0.15, 0.66]
			Placebo	117	115 (98.3)	0.08 (0.32)	-0.8	-0.09	0.04	0.25	1.6	
		Week 8	Tezepelumab	135	133 (98.5)	0.27 (0.42)	-0.6	0.01	0.17	0.50	1.8	0.47 [0.22, 0.73]
			Placebo	117	112 (95.7)	0.09 (0.31)	-0.6	-0.07	0.04	0.26	1.4	
		Week 12	Tezepelumab	135	131 (97.0)	0.29 (0.42)	-0.6	0.02	0.21	0.45	2.0	0.54 [0.29, 0.80]
			Placebo	117	111 (94.9)	0.08 (0.34)	-0.7	-0.11	0.03	0.26	1.4	
		Week 16	Tezepelumab	135	130 (96.3)	0.28 (0.43)	-0.6	0.00	0.19	0.44	2.0	0.45 [0.19, 0.71]
			Placebo	117	109 (93.2)	0.10 (0.36)	-1.2	-0.06	0.04	0.26	1.4	
		Week 24	Tezepelumab	135	130 (96.3)	0.27 (0.42)	-1.0	-0.01	0.19	0.45	2.1	0.58 [0.32, 0.84]
			Placebo	117	107 (91.5)	0.04 (0.33)	-0.9	-0.13	0.00	0.19	1.6	
		Week 36	Tezepelumab	135	121 (89.6)	0.30 (0.43)	-1.0	0.02	0.23	0.52	1.8	0.55 [0.28, 0.82]
			Placebo	117	104 (88.9)	0.07 (0.39)	-0.8	-0.15	0.03	0.26	1.6	
		Week 52	Tezepelumab	135	120 (88.9)	0.28 (0.43)	-0.8	0.00	0.23	0.47	1.7	0.49 [0.22, 0.76]
			Placebo	117	100 (85.5)	0.08 (0.38)	-0.6	-0.18	0.04	0.23	2.0	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q4: >= 430 cells/uL	Absolute values	Baseline	Tezepelumab	116	116 (100.0)	1.67 (0.67)	0.6	1.22	1.54	1.89	3.8	
			Placebo	122	122 (100.0)	1.74 (0.74)	0.6	1.24	1.59	2.16	4.5	
		Week 2	Tezepelumab	116	113 (97.4)	1.96 (0.72)	0.8	1.45	1.84	2.34	4.0	
			Placebo	122	116 (95.1)	1.87 (0.71)	0.8	1.33	1.80	2.32	4.0	
		Week 4	Tezepelumab	116	116 (100.0)	2.03 (0.71)	0.7	1.56	1.90	2.45	4.2	
			Placebo	122	120 (98.4)	1.91 (0.75)	0.5	1.38	1.84	2.26	4.2	
		Week 8	Tezepelumab	116	114 (98.3)	2.06 (0.72)	0.9	1.52	1.90	2.46	4.3	
			Placebo	122	121 (99.2)	1.88 (0.79)	0.6	1.28	1.70	2.20	4.3	
		Week 12	Tezepelumab	116	115 (99.1)	2.08 (0.74)	0.9	1.58	1.94	2.53	4.6	
			Placebo	122	122 (100.0)	1.93 (0.76)	0.5	1.37	1.87	2.37	4.3	
		Week 16	Tezepelumab	116	112 (96.6)	2.11 (0.77)	0.8	1.59	1.97	2.54	4.4	
			Placebo	122	118 (96.7)	1.91 (0.74)	0.5	1.37	1.79	2.21	4.4	
		Week 24	Tezepelumab	116	109 (94.0)	2.08 (0.71)	0.8	1.61	1.94	2.52	4.0	
			Placebo	122	113 (92.6)	1.95 (0.77)	0.7	1.43	1.89	2.22	4.8	
		Week 36	Tezepelumab	116	108 (93.1)	2.08 (0.72)	0.8	1.54	1.98	2.43	4.2	
			Placebo	122	110 (90.2)	1.99 (0.78)	0.6	1.48	1.95	2.33	4.6	
		Week 52	Tezepelumab	116	101 (87.1)	2.10 (0.73)	0.9	1.64	1.89	2.42	4.3	
			Placebo	122	101 (82.8)	1.93 (0.77)	0.6	1.32	1.90	2.30	4.5	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q4: >= 430 cells/uL	Change from baseline	Week 2	Tezepelumab	116	113 (97.4)	0.29 (0.36)	-0.6	0.06	0.22	0.41	1.3	0.51 [0.25, 0.78]
			Placebo	122	116 (95.1)	0.10 (0.40)	-1.1	-0.12	0.00	0.28	1.7	
		Week 4	Tezepelumab	116	116 (100.0)	0.36 (0.36)	-0.4	0.10	0.30	0.51	1.8	0.47 [0.21, 0.73]
			Placebo	122	120 (98.4)	0.17 (0.44)	-1.8	-0.11	0.06	0.46	1.4	
		Week 8	Tezepelumab	116	114 (98.3)	0.41 (0.43)	-0.4	0.10	0.31	0.67	1.9	0.64 [0.38, 0.91]
			Placebo	122	121 (99.2)	0.14 (0.43)	-0.8	-0.15	0.08	0.33	2.1	
		Week 12	Tezepelumab	116	115 (99.1)	0.42 (0.43)	-0.3	0.08	0.34	0.62	2.2	0.55 [0.29, 0.81]
			Placebo	122	122 (100.0)	0.19 (0.41)	-1.4	-0.06	0.12	0.37	1.7	
		Week 16	Tezepelumab	116	112 (96.6)	0.44 (0.43)	-0.4	0.14	0.35	0.67	2.1	0.70 [0.44, 0.97]
			Placebo	122	118 (96.7)	0.16 (0.38)	-0.5	-0.09	0.07	0.42	1.8	
		Week 24	Tezepelumab	116	109 (94.0)	0.43 (0.44)	-0.5	0.14	0.38	0.64	1.7	0.57 [0.30, 0.84]
			Placebo	122	113 (92.6)	0.18 (0.45)	-0.8	-0.13	0.10	0.38	1.7	
		Week 36	Tezepelumab	116	108 (93.1)	0.42 (0.41)	-0.5	0.15	0.38	0.65	1.6	0.45 [0.18, 0.72]
			Placebo	122	110 (90.2)	0.23 (0.42)	-0.5	-0.04	0.15	0.50	1.7	
		Week 52	Tezepelumab	116	101 (87.1)	0.43 (0.41)	-0.6	0.15	0.39	0.72	1.6	0.72 [0.43, 1.00]
			Placebo	122	101 (82.8)	0.15 (0.37)	-0.9	-0.09	0.09	0.34	1.6	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
< 25 ppb	Absolute values	Baseline	Tezepelumab	202	202 (100.0)	1.73 (0.65)	0.4	1.26	1.61	2.13	4.0	
			Placebo	204	204 (100.0)	1.79 (0.67)	0.4	1.35	1.71	2.17	3.9	
		Week 2	Tezepelumab	202	195 (96.5)	1.87 (0.64)	0.6	1.37	1.80	2.31	4.1	
			Placebo	204	190 (93.1)	1.86 (0.68)	0.4	1.38	1.77	2.28	4.1	
		Week 4	Tezepelumab	202	199 (98.5)	1.86 (0.66)	0.6	1.34	1.79	2.26	4.2	
			Placebo	204	199 (97.5)	1.87 (0.68)	0.4	1.43	1.82	2.29	4.8	
		Week 8	Tezepelumab	202	197 (97.5)	1.87 (0.65)	0.6	1.39	1.80	2.30	4.1	
			Placebo	204	199 (97.5)	1.90 (0.70)	0.4	1.40	1.81	2.30	4.7	
		Week 12	Tezepelumab	202	195 (96.5)	1.88 (0.65)	0.6	1.43	1.83	2.24	4.2	
			Placebo	204	197 (96.6)	1.89 (0.73)	0.5	1.41	1.74	2.34	4.6	
		Week 16	Tezepelumab	202	194 (96.0)	1.89 (0.67)	0.6	1.38	1.83	2.31	4.2	
			Placebo	204	197 (96.6)	1.87 (0.72)	0.5	1.33	1.78	2.28	4.7	
		Week 24	Tezepelumab	202	192 (95.0)	1.85 (0.65)	0.6	1.38	1.78	2.30	4.0	
			Placebo	204	193 (94.6)	1.86 (0.71)	0.6	1.40	1.77	2.23	4.8	
		Week 36	Tezepelumab	202	183 (90.6)	1.84 (0.63)	0.5	1.33	1.80	2.24	4.4	
			Placebo	204	186 (91.2)	1.89 (0.70)	0.6	1.41	1.79	2.29	4.3	
		Week 52	Tezepelumab	202	184 (91.1)	1.86 (0.64)	0.7	1.41	1.76	2.23	4.2	
			Placebo	204	181 (88.7)	1.88 (0.73)	0.6	1.36	1.73	2.32	4.4	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
< 25 ppb	Change from baseline	Week 2	Tezepelumab	202	195 (96.5)	0.13 (0.33)	-0.8	-0.03	0.08	0.24	1.9	0.27 [0.07, 0.47]
			Placebo	204	190 (93.1)	0.05 (0.29)	-0.8	-0.11	0.01	0.16	1.2	
		Week 4	Tezepelumab	202	199 (98.5)	0.14 (0.36)	-1.0	-0.06	0.08	0.29	1.7	0.16 [-0.03, 0.36]
			Placebo	204	199 (97.5)	0.08 (0.32)	-0.9	-0.07	0.04	0.20	1.6	
		Week 8	Tezepelumab	202	197 (97.5)	0.15 (0.36)	-0.9	-0.05	0.10	0.26	1.6	0.15 [-0.04, 0.35]
			Placebo	204	199 (97.5)	0.09 (0.36)	-1.0	-0.09	0.04	0.24	1.8	
		Week 12	Tezepelumab	202	195 (96.5)	0.16 (0.34)	-0.7	-0.04	0.10	0.28	1.5	0.18 [-0.02, 0.38]
			Placebo	204	197 (96.6)	0.09 (0.38)	-1.5	-0.07	0.03	0.21	2.1	
		Week 16	Tezepelumab	202	194 (96.0)	0.15 (0.38)	-1.0	-0.05	0.11	0.28	1.8	0.20 [-0.00, 0.39]
			Placebo	204	197 (96.6)	0.07 (0.36)	-1.0	-0.10	0.03	0.20	1.9	
		Week 24	Tezepelumab	202	192 (95.0)	0.14 (0.38)	-1.0	-0.08	0.06	0.32	2.1	0.25 [0.05, 0.45]
			Placebo	204	193 (94.6)	0.05 (0.35)	-1.1	-0.12	0.03	0.20	1.7	
		Week 36	Tezepelumab	202	183 (90.6)	0.11 (0.36)	-1.0	-0.11	0.07	0.32	1.8	0.07 [-0.14, 0.27]
			Placebo	204	186 (91.2)	0.09 (0.33)	-0.8	-0.10	0.06	0.22	1.6	
		Week 52	Tezepelumab	202	184 (91.1)	0.13 (0.38)	-1.0	-0.07	0.08	0.31	1.5	0.14 [-0.07, 0.34]
			Placebo	204	181 (88.7)	0.08 (0.37)	-1.0	-0.14	0.04	0.21	2.3	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
25 - < 50 ppb	Absolute values	Baseline	Tezepelumab	146	146 (100.0)	1.69 (0.65)	0.5	1.20	1.60	2.04	3.7	
			Placebo	141	141 (100.0)	1.76 (0.70)	0.7	1.28	1.66	2.06	4.5	
		Week 2	Tezepelumab	146	145 (99.3)	1.86 (0.67)	0.7	1.31	1.78	2.38	4.0	
			Placebo	141	139 (98.6)	1.77 (0.70)	0.6	1.27	1.59	2.11	4.0	
		Week 4	Tezepelumab	146	146 (100.0)	1.91 (0.71)	0.7	1.34	1.77	2.42	4.2	
			Placebo	141	137 (97.2)	1.82 (0.69)	0.7	1.36	1.68	2.09	4.2	
		Week 8	Tezepelumab	146	144 (98.6)	1.90 (0.69)	0.8	1.35	1.78	2.40	4.2	
			Placebo	141	138 (97.9)	1.85 (0.72)	0.7	1.31	1.71	2.16	4.3	
		Week 12	Tezepelumab	146	142 (97.3)	1.93 (0.69)	0.7	1.46	1.80	2.35	4.3	
			Placebo	141	137 (97.2)	1.83 (0.73)	0.7	1.34	1.66	2.10	4.3	
		Week 16	Tezepelumab	146	145 (99.3)	1.92 (0.72)	0.7	1.45	1.77	2.30	4.3	
			Placebo	141	135 (95.7)	1.83 (0.74)	0.6	1.32	1.65	2.09	4.3	
		Week 24	Tezepelumab	146	138 (94.5)	1.89 (0.69)	0.7	1.40	1.77	2.41	3.8	
			Placebo	141	127 (90.1)	1.87 (0.73)	0.6	1.40	1.72	2.09	4.8	
		Week 36	Tezepelumab	146	136 (93.2)	1.93 (0.74)	0.6	1.36	1.82	2.42	4.2	
			Placebo	141	129 (91.5)	1.88 (0.74)	0.7	1.38	1.72	2.19	4.6	
		Week 52	Tezepelumab	146	133 (91.1)	1.93 (0.75)	0.6	1.39	1.79	2.40	4.3	
			Placebo	141	117 (83.0)	1.83 (0.75)	0.7	1.33	1.62	2.08	4.5	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
25 - < 50 ppb	Change from baseline	Week 2	Tezepelumab	146	145 (99.3)	0.17 (0.30)	-0.6	-0.02	0.12	0.29	1.3	0.49 [0.26, 0.73]
			Placebo	141	139 (98.6)	0.00 (0.37)	-1.8	-0.16	-0.01	0.17	1.1	
		Week 4	Tezepelumab	146	146 (100.0)	0.22 (0.31)	-0.5	0.02	0.14	0.37	1.3	0.47 [0.23, 0.71]
			Placebo	141	137 (97.2)	0.06 (0.38)	-1.8	-0.11	0.05	0.25	1.0	
		Week 8	Tezepelumab	146	144 (98.6)	0.22 (0.37)	-0.6	-0.02	0.15	0.40	1.5	0.40 [0.17, 0.64]
			Placebo	141	138 (97.9)	0.09 (0.31)	-1.1	-0.09	0.05	0.29	0.9	
		Week 12	Tezepelumab	146	142 (97.3)	0.25 (0.34)	-0.4	0.02	0.20	0.42	1.6	0.53 [0.29, 0.77]
			Placebo	141	137 (97.2)	0.07 (0.36)	-1.2	-0.13	0.03	0.22	1.2	
		Week 16	Tezepelumab	146	145 (99.3)	0.24 (0.38)	-0.6	0.00	0.20	0.40	1.5	0.48 [0.24, 0.72]
			Placebo	141	135 (95.7)	0.06 (0.34)	-1.2	-0.13	0.02	0.19	1.5	
		Week 24	Tezepelumab	146	138 (94.5)	0.23 (0.42)	-1.0	-0.05	0.18	0.42	1.6	0.31 [0.07, 0.55]
			Placebo	141	127 (90.1)	0.11 (0.36)	-0.9	-0.11	0.06	0.30	1.4	
		Week 36	Tezepelumab	146	136 (93.2)	0.24 (0.40)	-0.6	-0.02	0.12	0.46	1.6	0.37 [0.13, 0.62]
			Placebo	141	129 (91.5)	0.09 (0.40)	-1.0	-0.18	0.02	0.29	1.3	
		Week 52	Tezepelumab	146	133 (91.1)	0.26 (0.41)	-0.8	-0.04	0.19	0.50	1.7	0.54 [0.29, 0.79]
			Placebo	141	117 (83.0)	0.04 (0.37)	-1.0	-0.17	0.00	0.23	1.2	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
>= 50 ppb	Absolute values	Baseline	Tezepelumab	133	133 (100.0)	1.91 (0.74)	0.7	1.47	1.75	2.26	4.8	
			Placebo	141	141 (100.0)	1.77 (0.58)	0.6	1.37	1.69	2.18	3.3	
		Week 2	Tezepelumab	133	128 (96.2)	2.13 (0.79)	0.7	1.60	2.01	2.45	5.0	
			Placebo	141	135 (95.7)	1.90 (0.64)	0.6	1.44	1.85	2.38	3.9	
		Week 4	Tezepelumab	133	133 (100.0)	2.17 (0.76)	0.7	1.66	2.03	2.56	5.0	
			Placebo	141	138 (97.9)	1.88 (0.63)	0.7	1.44	1.82	2.25	4.0	
		Week 8	Tezepelumab	133	131 (98.5)	2.26 (0.79)	0.8	1.71	2.20	2.60	4.7	
			Placebo	141	137 (97.2)	1.91 (0.68)	0.7	1.46	1.82	2.22	4.3	
		Week 12	Tezepelumab	133	130 (97.7)	2.23 (0.82)	0.9	1.66	2.05	2.67	4.9	
			Placebo	141	138 (97.9)	1.92 (0.64)	0.6	1.48	1.85	2.29	4.3	
		Week 16	Tezepelumab	133	126 (94.7)	2.28 (0.84)	0.8	1.72	2.15	2.67	4.9	
			Placebo	141	134 (95.0)	1.94 (0.63)	0.8	1.53	1.85	2.23	4.4	
		Week 24	Tezepelumab	133	124 (93.2)	2.25 (0.79)	0.8	1.77	2.04	2.62	5.5	
			Placebo	141	130 (92.2)	1.89 (0.63)	0.8	1.44	1.81	2.22	4.3	
		Week 36	Tezepelumab	133	121 (91.0)	2.26 (0.80)	0.9	1.74	2.10	2.64	4.9	
			Placebo	141	122 (86.5)	1.94 (0.67)	0.8	1.48	1.86	2.27	4.3	
		Week 52	Tezepelumab	133	115 (86.5)	2.25 (0.80)	0.7	1.72	2.06	2.72	4.6	
			Placebo	141	117 (83.0)	1.94 (0.67)	0.7	1.44	1.89	2.30	3.7	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
>= 50 ppb	Change from baseline	Week 2	Tezepelumab	133	128 (96.2)	0.23 (0.36)	-0.6	0.02	0.18	0.38	1.5	0.33 [0.08, 0.57]
			Placebo	141	135 (95.7)	0.11 (0.38)	-0.7	-0.07	0.06	0.25	1.7	
		Week 4	Tezepelumab	133	133 (100.0)	0.26 (0.41)	-0.7	0.01	0.21	0.41	1.8	0.36 [0.12, 0.60]
			Placebo	141	138 (97.9)	0.12 (0.42)	-0.8	-0.13	0.06	0.31	1.4	
		Week 8	Tezepelumab	133	131 (98.5)	0.36 (0.47)	-0.6	0.06	0.29	0.60	1.9	0.55 [0.31, 0.80]
			Placebo	141	137 (97.2)	0.12 (0.41)	-0.6	-0.14	0.08	0.30	2.1	
		Week 12	Tezepelumab	133	130 (97.7)	0.33 (0.52)	-0.8	-0.03	0.25	0.54	2.2	0.41 [0.17, 0.66]
			Placebo	141	138 (97.9)	0.14 (0.42)	-1.4	-0.09	0.10	0.36	1.7	
		Week 16	Tezepelumab	133	126 (94.7)	0.38 (0.50)	-0.8	0.06	0.31	0.63	2.1	0.51 [0.26, 0.75]
			Placebo	141	134 (95.0)	0.16 (0.38)	-1.0	-0.07	0.08	0.37	1.8	
		Week 24	Tezepelumab	133	124 (93.2)	0.34 (0.42)	-0.5	0.05	0.29	0.55	1.7	0.57 [0.32, 0.82]
			Placebo	141	130 (92.2)	0.11 (0.41)	-0.8	-0.14	0.06	0.30	1.7	
		Week 36	Tezepelumab	133	121 (91.0)	0.36 (0.44)	-0.5	0.02	0.32	0.60	1.7	0.49 [0.23, 0.75]
			Placebo	141	122 (86.5)	0.14 (0.45)	-1.1	-0.17	0.11	0.39	1.7	
		Week 52	Tezepelumab	133	115 (86.5)	0.32 (0.45)	-0.6	-0.02	0.26	0.56	1.6	0.42 [0.16, 0.68]
			Placebo	141	117 (83.0)	0.14 (0.41)	-0.9	-0.11	0.11	0.31	2.0	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q1: < 16 ppb	Absolute values	Baseline	Tezepelumab	120	120 (100.0)	1.72 (0.67)	0.7	1.23	1.61	2.11	4.0	
			Placebo	112	112 (100.0)	1.73 (0.65)	0.4	1.24	1.63	2.20	3.3	
		Week 2	Tezepelumab	120	115 (95.8)	1.88 (0.67)	0.6	1.32	1.86	2.42	4.1	
			Placebo	112	101 (90.2)	1.82 (0.69)	0.4	1.31	1.68	2.29	4.1	
		Week 4	Tezepelumab	120	118 (98.3)	1.86 (0.68)	0.6	1.28	1.80	2.35	4.2	
			Placebo	112	110 (98.2)	1.81 (0.70)	0.4	1.27	1.76	2.29	4.8	
		Week 8	Tezepelumab	120	116 (96.7)	1.87 (0.64)	0.6	1.40	1.81	2.36	4.1	
			Placebo	112	109 (97.3)	1.84 (0.72)	0.4	1.35	1.78	2.20	4.7	
		Week 12	Tezepelumab	120	116 (96.7)	1.86 (0.65)	0.6	1.44	1.83	2.23	4.2	
			Placebo	112	108 (96.4)	1.88 (0.75)	0.5	1.33	1.74	2.34	4.6	
		Week 16	Tezepelumab	120	115 (95.8)	1.89 (0.68)	0.6	1.38	1.83	2.39	4.2	
			Placebo	112	107 (95.5)	1.83 (0.74)	0.5	1.29	1.73	2.28	4.7	
		Week 24	Tezepelumab	120	115 (95.8)	1.85 (0.64)	0.6	1.40	1.78	2.30	4.0	
			Placebo	112	105 (93.8)	1.82 (0.75)	0.6	1.26	1.78	2.23	4.8	
		Week 36	Tezepelumab	120	110 (91.7)	1.87 (0.66)	0.7	1.33	1.83	2.33	4.4	
			Placebo	112	103 (92.0)	1.83 (0.72)	0.6	1.27	1.75	2.28	4.3	
		Week 52	Tezepelumab	120	109 (90.8)	1.87 (0.65)	0.7	1.43	1.79	2.25	4.2	
			Placebo	112	98 (87.5)	1.83 (0.76)	0.6	1.24	1.66	2.33	4.4	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q1: < 16 ppb	Change from baseline	Week 2	Tezepelumab	120	115 (95.8)	0.15 (0.37)	-0.8	-0.03	0.08	0.24	1.9	0.25 [-0.02, 0.52]
			Placebo	112	101 (90.2)	0.06 (0.31)	-0.8	-0.07	0.00	0.15	1.2	
		Week 4	Tezepelumab	120	118 (98.3)	0.15 (0.40)	-1.0	-0.05	0.07	0.29	1.7	0.19 [-0.07, 0.45]
			Placebo	112	110 (98.2)	0.08 (0.35)	-0.9	-0.07	0.03	0.18	1.6	
		Week 8	Tezepelumab	120	116 (96.7)	0.15 (0.36)	-0.9	-0.05	0.08	0.28	1.3	0.13 [-0.14, 0.39]
			Placebo	112	109 (97.3)	0.10 (0.39)	-1.0	-0.08	0.04	0.21	1.8	
		Week 12	Tezepelumab	120	116 (96.7)	0.16 (0.37)	-0.6	-0.04	0.10	0.28	1.5	0.07 [-0.19, 0.34]
			Placebo	112	108 (96.4)	0.13 (0.40)	-1.1	-0.04	0.04	0.26	2.1	
		Week 16	Tezepelumab	120	115 (95.8)	0.16 (0.40)	-1.0	-0.05	0.11	0.28	1.8	0.15 [-0.11, 0.41]
			Placebo	112	107 (95.5)	0.10 (0.39)	-1.0	-0.09	0.03	0.22	1.9	
		Week 24	Tezepelumab	120	115 (95.8)	0.13 (0.41)	-1.0	-0.07	0.03	0.29	2.1	0.15 [-0.11, 0.42]
			Placebo	112	105 (93.8)	0.07 (0.40)	-1.1	-0.11	0.04	0.17	1.7	
		Week 36	Tezepelumab	120	110 (91.7)	0.14 (0.39)	-1.0	-0.08	0.12	0.34	1.8	0.11 [-0.16, 0.38]
			Placebo	112	103 (92.0)	0.10 (0.35)	-0.8	-0.07	0.05	0.26	1.6	
		Week 52	Tezepelumab	120	109 (90.8)	0.14 (0.41)	-1.0	-0.06	0.08	0.28	1.5	0.09 [-0.18, 0.36]
			Placebo	112	98 (87.5)	0.10 (0.42)	-1.0	-0.09	0.06	0.21	2.3	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)											
Q2: 16 - < 30 ppb Absolute values	Baseline	Tezepelumab	118	118 (100.0)	1.72 (0.63)	0.4	1.26	1.61	2.17	3.5	
		Placebo	132	132 (100.0)	1.84 (0.75)	0.7	1.34	1.73	2.15	4.5	
	Week 2	Tezepelumab	118	116 (98.3)	1.83 (0.62)	0.6	1.34	1.73	2.27	3.8	
		Placebo	132	129 (97.7)	1.88 (0.69)	0.6	1.40	1.78	2.20	3.9	
	Week 4	Tezepelumab	118	117 (99.2)	1.86 (0.65)	0.7	1.36	1.74	2.26	3.7	
		Placebo	132	128 (97.0)	1.90 (0.67)	0.7	1.47	1.82	2.24	3.6	
	Week 8	Tezepelumab	118	117 (99.2)	1.86 (0.66)	0.6	1.34	1.78	2.30	3.7	
		Placebo	132	130 (98.5)	1.93 (0.72)	0.7	1.47	1.79	2.30	4.1	
	Week 12	Tezepelumab	118	113 (95.8)	1.88 (0.64)	0.6	1.46	1.77	2.31	3.6	
		Placebo	132	129 (97.7)	1.89 (0.73)	0.6	1.40	1.71	2.27	4.1	
	Week 16	Tezepelumab	118	115 (97.5)	1.88 (0.67)	0.6	1.36	1.79	2.30	3.5	
		Placebo	132	130 (98.5)	1.89 (0.73)	0.7	1.36	1.77	2.21	4.3	
	Week 24	Tezepelumab	118	110 (93.2)	1.86 (0.66)	0.6	1.32	1.76	2.35	3.8	
		Placebo	132	127 (96.2)	1.91 (0.71)	0.6	1.47	1.77	2.24	4.3	
	Week 36	Tezepelumab	118	108 (91.5)	1.83 (0.63)	0.5	1.33	1.81	2.17	3.5	
		Placebo	132	120 (90.9)	1.96 (0.70)	0.9	1.54	1.80	2.27	4.2	
	Week 52	Tezepelumab	118	109 (92.4)	1.85 (0.64)	0.7	1.37	1.75	2.23	3.5	
		Placebo	132	117 (88.6)	1.91 (0.73)	0.7	1.43	1.73	2.23	4.5	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q2: 16 - < 30 ppb	Change from baseline	Week 2	Tezepelumab	118	116 (98.3)	0.10 (0.26)	-0.7	-0.03	0.07	0.19	0.9	0.25 [-0.01, 0.50]
			Placebo	132	129 (97.7)	0.03 (0.30)	-1.1	-0.13	0.01	0.17	0.9	
		Week 4	Tezepelumab	118	117 (99.2)	0.13 (0.29)	-0.9	-0.06	0.09	0.27	1.1	0.21 [-0.04, 0.46]
			Placebo	132	128 (97.0)	0.07 (0.34)	-1.8	-0.10	0.07	0.27	1.0	
		Week 8	Tezepelumab	118	117 (99.2)	0.15 (0.37)	-0.8	-0.06	0.09	0.24	1.6	0.17 [-0.08, 0.42]
			Placebo	132	130 (98.5)	0.09 (0.32)	-0.8	-0.11	0.06	0.31	1.2	
		Week 12	Tezepelumab	118	113 (95.8)	0.16 (0.29)	-0.7	-0.04	0.10	0.28	1.2	0.35 [0.10, 0.60]
			Placebo	132	129 (97.7)	0.05 (0.34)	-1.5	-0.10	0.03	0.19	1.2	
		Week 16	Tezepelumab	118	115 (97.5)	0.15 (0.35)	-0.6	-0.04	0.10	0.29	1.4	0.28 [0.03, 0.53]
			Placebo	132	130 (98.5)	0.06 (0.32)	-0.8	-0.13	0.04	0.20	1.0	
		Week 24	Tezepelumab	118	110 (93.2)	0.15 (0.35)	-0.6	-0.08	0.12	0.32	1.5	0.32 [0.06, 0.58]
			Placebo	132	127 (96.2)	0.05 (0.30)	-0.9	-0.13	0.03	0.22	0.8	
		Week 36	Tezepelumab	118	108 (91.5)	0.09 (0.35)	-0.7	-0.12	0.02	0.22	1.3	0.04 [-0.22, 0.30]
			Placebo	132	120 (90.9)	0.08 (0.36)	-1.0	-0.17	0.06	0.28	1.3	
		Week 52	Tezepelumab	118	109 (92.4)	0.14 (0.34)	-1.0	-0.06	0.09	0.31	1.3	0.31 [0.05, 0.57]
			Placebo	132	117 (88.6)	0.03 (0.32)	-1.0	-0.16	0.00	0.21	1.0	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)											
Q3: 30 - < 56 ppb Absolute values	Baseline	Tezepelumab	130	130 (100.0)	1.71 (0.65)	0.5	1.28	1.64	2.11	3.7	
		Placebo	117	117 (100.0)	1.78 (0.64)	0.8	1.30	1.68	2.10	4.2	
	Week 2	Tezepelumab	130	129 (99.2)	1.90 (0.66)	0.7	1.44	1.84	2.39	4.0	
		Placebo	117	114 (97.4)	1.80 (0.70)	0.8	1.30	1.60	2.17	4.0	
	Week 4	Tezepelumab	130	130 (100.0)	1.95 (0.70)	0.7	1.44	1.88	2.42	4.2	
		Placebo	117	113 (96.6)	1.85 (0.68)	0.7	1.38	1.67	2.13	4.2	
	Week 8	Tezepelumab	130	128 (98.5)	1.95 (0.68)	0.8	1.39	1.90	2.42	4.2	
		Placebo	117	114 (97.4)	1.87 (0.70)	0.7	1.33	1.74	2.22	4.3	
	Week 12	Tezepelumab	130	127 (97.7)	1.96 (0.69)	0.8	1.50	1.88	2.38	4.3	
		Placebo	117	113 (96.6)	1.84 (0.72)	0.7	1.35	1.65	2.21	4.3	
	Week 16	Tezepelumab	130	129 (99.2)	1.96 (0.70)	0.8	1.51	1.87	2.30	4.3	
		Placebo	117	110 (94.0)	1.83 (0.70)	0.6	1.33	1.69	2.12	4.2	
	Week 24	Tezepelumab	130	125 (96.2)	1.93 (0.67)	0.7	1.49	1.85	2.41	3.8	
		Placebo	117	103 (88.0)	1.87 (0.69)	0.9	1.41	1.73	2.18	4.8	
	Week 36	Tezepelumab	130	119 (91.5)	1.98 (0.72)	0.7	1.42	1.90	2.38	4.2	
		Placebo	117	108 (92.3)	1.86 (0.71)	0.7	1.37	1.69	2.23	4.6	
	Week 52	Tezepelumab	130	117 (90.0)	1.98 (0.73)	0.6	1.47	1.93	2.40	4.3	
		Placebo	117	98 (83.8)	1.84 (0.72)	0.7	1.32	1.64	2.26	4.4	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q3: 30 - < 56 ppb	Change from baseline	Week 2	Tezepelumab	130	129 (99.2)	0.19 (0.30)	-0.6	0.01	0.15	0.29	1.3	0.51 [0.25, 0.76]
			Placebo	117	114 (97.4)	0.02 (0.37)	-1.8	-0.12	0.00	0.17	1.1	
		Week 4	Tezepelumab	130	130 (100.0)	0.23 (0.32)	-0.5	0.02	0.17	0.38	1.3	0.47 [0.21, 0.72]
			Placebo	117	113 (96.6)	0.08 (0.34)	-1.0	-0.10	0.05	0.20	1.1	
		Week 8	Tezepelumab	130	128 (98.5)	0.24 (0.36)	-0.6	-0.01	0.19	0.45	1.5	0.46 [0.20, 0.72]
			Placebo	117	114 (97.4)	0.09 (0.30)	-1.1	-0.07	0.06	0.21	0.9	
		Week 12	Tezepelumab	130	127 (97.7)	0.25 (0.37)	-0.7	0.02	0.20	0.44	1.6	0.51 [0.25, 0.76]
			Placebo	117	113 (96.6)	0.07 (0.36)	-1.2	-0.11	0.03	0.20	1.2	
		Week 16	Tezepelumab	130	129 (99.2)	0.25 (0.39)	-0.6	0.00	0.22	0.44	1.5	0.57 [0.31, 0.83]
			Placebo	117	110 (94.0)	0.04 (0.33)	-1.2	-0.14	-0.00	0.18	1.5	
		Week 24	Tezepelumab	130	125 (96.2)	0.24 (0.42)	-1.0	-0.06	0.23	0.44	1.6	0.34 [0.07, 0.60]
			Placebo	117	103 (88.0)	0.11 (0.36)	-0.9	-0.11	0.07	0.30	1.4	
		Week 36	Tezepelumab	130	119 (91.5)	0.26 (0.40)	-0.5	-0.02	0.19	0.48	1.6	0.49 [0.23, 0.76]
			Placebo	117	108 (92.3)	0.07 (0.36)	-0.6	-0.18	0.01	0.26	1.3	
		Week 52	Tezepelumab	130	117 (90.0)	0.26 (0.42)	-0.8	-0.07	0.23	0.53	1.7	0.52 [0.25, 0.79]
			Placebo	117	98 (83.8)	0.06 (0.36)	-0.9	-0.17	-0.01	0.23	1.2	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q4: >= 56 ppb	Absolute values	Baseline	Tezepelumab	113	113 (100.0)	1.91 (0.76)	0.7	1.44	1.75	2.30	4.8	
			Placebo	125	125 (100.0)	1.76 (0.57)	0.6	1.37	1.70	2.13	3.3	
		Week 2	Tezepelumab	113	108 (95.6)	2.16 (0.82)	0.7	1.60	2.01	2.54	5.0	
			Placebo	125	120 (96.0)	1.88 (0.63)	0.6	1.46	1.84	2.32	3.9	
		Week 4	Tezepelumab	113	113 (100.0)	2.19 (0.79)	0.7	1.65	2.04	2.64	5.0	
			Placebo	125	123 (98.4)	1.87 (0.62)	0.7	1.44	1.81	2.25	4.0	
		Week 8	Tezepelumab	113	111 (98.2)	2.29 (0.82)	0.8	1.71	2.22	2.64	4.7	
			Placebo	125	121 (96.8)	1.89 (0.67)	0.7	1.43	1.82	2.20	4.3	
		Week 12	Tezepelumab	113	111 (98.2)	2.27 (0.85)	0.9	1.67	2.12	2.71	4.9	
			Placebo	125	122 (97.6)	1.91 (0.62)	0.6	1.50	1.85	2.24	4.3	
		Week 16	Tezepelumab	113	106 (93.8)	2.31 (0.87)	0.8	1.70	2.15	2.69	4.9	
			Placebo	125	119 (95.2)	1.96 (0.62)	0.8	1.57	1.88	2.22	4.4	
		Week 24	Tezepelumab	113	104 (92.0)	2.27 (0.82)	0.8	1.76	2.08	2.66	5.5	
			Placebo	125	115 (92.0)	1.87 (0.62)	0.8	1.44	1.81	2.13	4.3	
		Week 36	Tezepelumab	113	103 (91.2)	2.28 (0.84)	0.9	1.69	2.10	2.72	4.9	
			Placebo	125	106 (84.8)	1.95 (0.67)	0.8	1.49	1.87	2.27	4.3	
		Week 52	Tezepelumab	113	97 (85.8)	2.28 (0.84)	0.7	1.69	2.09	2.78	4.6	
			Placebo	125	102 (81.6)	1.94 (0.66)	0.7	1.56	1.90	2.28	3.7	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q4: >= 56 ppb	Change from baseline	Week 2	Tezepelumab	113	108 (95.6)	0.25 (0.37)	-0.6	0.03	0.21	0.41	1.5	0.39 [0.13, 0.65]
			Placebo	125	120 (96.0)	0.10 (0.39)	-0.7	-0.08	0.05	0.25	1.7	
		Week 4	Tezepelumab	113	113 (100.0)	0.28 (0.42)	-0.7	0.01	0.20	0.44	1.8	0.38 [0.12, 0.64]
			Placebo	125	123 (98.4)	0.11 (0.43)	-0.8	-0.15	0.06	0.32	1.4	
		Week 8	Tezepelumab	113	111 (98.2)	0.39 (0.49)	-0.6	0.10	0.33	0.66	1.9	0.61 [0.35, 0.87]
			Placebo	125	121 (96.8)	0.11 (0.42)	-0.6	-0.15	0.04	0.31	2.1	
		Week 12	Tezepelumab	113	111 (98.2)	0.37 (0.52)	-0.8	0.02	0.29	0.57	2.2	0.46 [0.20, 0.72]
			Placebo	125	122 (97.6)	0.15 (0.43)	-1.4	-0.09	0.10	0.37	1.7	
		Week 16	Tezepelumab	113	106 (93.8)	0.41 (0.51)	-0.8	0.06	0.34	0.66	2.1	0.50 [0.23, 0.77]
			Placebo	125	119 (95.2)	0.19 (0.39)	-1.0	-0.04	0.11	0.42	1.8	
		Week 24	Tezepelumab	113	104 (92.0)	0.36 (0.42)	-0.3	0.06	0.29	0.63	1.7	0.62 [0.35, 0.89]
			Placebo	125	115 (92.0)	0.10 (0.43)	-0.8	-0.15	0.06	0.33	1.7	
		Week 36	Tezepelumab	113	103 (91.2)	0.38 (0.44)	-0.4	0.03	0.34	0.63	1.7	0.48 [0.21, 0.76]
			Placebo	125	106 (84.8)	0.16 (0.47)	-1.1	-0.17	0.15	0.45	1.7	
		Week 52	Tezepelumab	113	97 (85.8)	0.35 (0.45)	-0.6	0.00	0.26	0.61	1.6	0.44 [0.15, 0.72]
			Placebo	125	102 (81.6)	0.16 (0.42)	-0.9	-0.07	0.11	0.34	2.0	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q1: < 53.1 IU/ml	Absolute values	Baseline	Tezepelumab	125	125 (100.0)	1.66 (0.61)	0.4	1.19	1.60	2.02	3.3	
			Placebo	131	131 (100.0)	1.67 (0.58)	0.7	1.27	1.55	1.98	4.2	
		Week 2	Tezepelumab	125	122 (97.6)	1.77 (0.58)	0.6	1.35	1.69	2.18	3.3	
			Placebo	131	123 (93.9)	1.70 (0.60)	0.6	1.31	1.61	2.04	4.0	
		Week 4	Tezepelumab	125	125 (100.0)	1.80 (0.63)	0.7	1.28	1.68	2.26	3.3	
			Placebo	131	126 (96.2)	1.74 (0.61)	0.7	1.32	1.64	2.05	4.2	
		Week 8	Tezepelumab	125	122 (97.6)	1.82 (0.59)	0.6	1.36	1.72	2.22	3.3	
			Placebo	131	128 (97.7)	1.75 (0.60)	0.7	1.33	1.66	2.07	4.3	
		Week 12	Tezepelumab	125	122 (97.6)	1.81 (0.61)	0.6	1.37	1.74	2.23	3.6	
			Placebo	131	126 (96.2)	1.74 (0.62)	0.6	1.31	1.65	2.10	4.3	
		Week 16	Tezepelumab	125	123 (98.4)	1.83 (0.63)	0.6	1.37	1.74	2.26	3.5	
			Placebo	131	125 (95.4)	1.74 (0.60)	0.6	1.31	1.68	2.10	4.1	
		Week 24	Tezepelumab	125	121 (96.8)	1.77 (0.58)	0.6	1.26	1.75	2.24	3.3	
			Placebo	131	118 (90.1)	1.69 (0.59)	0.7	1.30	1.60	1.98	4.8	
		Week 36	Tezepelumab	125	116 (92.8)	1.78 (0.60)	0.5	1.38	1.70	2.16	3.3	
			Placebo	131	111 (84.7)	1.76 (0.58)	0.8	1.35	1.68	2.07	4.6	
		Week 52	Tezepelumab	125	117 (93.6)	1.80 (0.62)	0.6	1.37	1.71	2.20	3.3	
			Placebo	131	110 (84.0)	1.72 (0.61)	0.7	1.27	1.63	2.03	4.4	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q1: < 53.1 IU/ml	Change from baseline	Week 2	Tezepelumab	125	122 (97.6)	0.11 (0.29)	-0.8	-0.01	0.09	0.26	1.1	0.28 [0.02, 0.53]
			Placebo	131	123 (93.9)	0.03 (0.30)	-0.6	-0.10	0.00	0.11	1.1	
		Week 4	Tezepelumab	125	125 (100.0)	0.14 (0.37)	-1.0	-0.05	0.10	0.31	1.6	0.18 [-0.07, 0.43]
			Placebo	131	126 (96.2)	0.08 (0.28)	-0.7	-0.06	0.05	0.20	1.1	
		Week 8	Tezepelumab	125	122 (97.6)	0.17 (0.36)	-0.8	-0.04	0.11	0.30	1.4	0.29 [0.04, 0.54]
			Placebo	131	128 (97.7)	0.07 (0.29)	-0.8	-0.09	0.04	0.20	1.2	
		Week 12	Tezepelumab	125	122 (97.6)	0.15 (0.35)	-0.7	-0.03	0.13	0.30	2.0	0.23 [-0.02, 0.48]
			Placebo	131	126 (96.2)	0.08 (0.33)	-0.7	-0.10	0.02	0.19	1.2	
		Week 16	Tezepelumab	125	123 (98.4)	0.17 (0.36)	-1.0	-0.02	0.15	0.29	1.7	0.29 [0.04, 0.54]
			Placebo	131	125 (95.4)	0.07 (0.29)	-0.6	-0.07	0.02	0.18	1.0	
		Week 24	Tezepelumab	125	121 (96.8)	0.14 (0.31)	-0.6	-0.07	0.11	0.33	1.2	0.38 [0.13, 0.64]
			Placebo	131	118 (90.1)	0.03 (0.29)	-0.8	-0.11	0.03	0.14	1.1	
		Week 36	Tezepelumab	125	116 (92.8)	0.12 (0.34)	-0.7	-0.08	0.07	0.30	1.3	0.15 [-0.11, 0.41]
			Placebo	131	111 (84.7)	0.07 (0.29)	-0.5	-0.14	0.04	0.25	1.1	
		Week 52	Tezepelumab	125	117 (93.6)	0.13 (0.36)	-1.0	-0.09	0.10	0.29	1.5	0.32 [0.06, 0.58]
			Placebo	131	110 (84.0)	0.02 (0.31)	-0.7	-0.18	0.02	0.17	1.2	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q2: 53.1 - < 195.6 IU/ml	Absolute values	Baseline	Tezepelumab	133	133 (100.0)	1.75 (0.72)	0.6	1.26	1.61	2.10	4.8	
			Placebo	125	125 (100.0)	1.78 (0.61)	0.7	1.35	1.69	2.11	4.0	
		Week 2	Tezepelumab	133	131 (98.5)	1.93 (0.75)	0.8	1.32	1.79	2.42	5.0	
			Placebo	125	120 (96.0)	1.83 (0.62)	0.7	1.38	1.74	2.20	3.7	
		Week 4	Tezepelumab	133	130 (97.7)	1.98 (0.76)	0.8	1.41	1.89	2.43	5.0	
			Placebo	125	124 (99.2)	1.83 (0.59)	0.7	1.44	1.80	2.20	4.1	
		Week 8	Tezepelumab	133	129 (97.0)	1.98 (0.75)	0.8	1.34	1.78	2.44	4.6	
			Placebo	125	123 (98.4)	1.85 (0.63)	0.7	1.40	1.80	2.22	3.9	
		Week 12	Tezepelumab	133	129 (97.0)	2.01 (0.76)	0.8	1.50	1.85	2.48	4.9	
			Placebo	125	123 (98.4)	1.85 (0.63)	0.7	1.34	1.75	2.25	4.0	
		Week 16	Tezepelumab	133	127 (95.5)	2.00 (0.79)	0.7	1.34	1.86	2.54	4.9	
			Placebo	125	119 (95.2)	1.87 (0.66)	0.7	1.36	1.78	2.23	4.2	
		Week 24	Tezepelumab	133	126 (94.7)	2.01 (0.79)	0.7	1.44	1.86	2.51	5.5	
			Placebo	125	117 (93.6)	1.86 (0.58)	0.9	1.43	1.81	2.22	3.9	
		Week 36	Tezepelumab	133	124 (93.2)	2.03 (0.78)	0.7	1.42	1.87	2.53	4.9	
			Placebo	125	116 (92.8)	1.89 (0.65)	0.7	1.41	1.85	2.28	4.0	
		Week 52	Tezepelumab	133	115 (86.5)	2.04 (0.76)	0.8	1.43	1.91	2.61	4.6	
			Placebo	125	108 (86.4)	1.88 (0.64)	0.7	1.47	1.81	2.28	3.6	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q2: 53.1 - < 195.6 IU/ml	Change from baseline	Week 2	Tezepelumab	133	131 (98.5)	0.17 (0.33)	-0.6	-0.03	0.12	0.29	1.4	0.46 [0.21, 0.71]
			Placebo	125	120 (96.0)	0.03 (0.27)	-1.0	-0.12	-0.00	0.17	1.0	
		Week 4	Tezepelumab	133	130 (97.7)	0.23 (0.37)	-0.9	0.01	0.17	0.36	1.7	0.48 [0.23, 0.73]
			Placebo	125	124 (99.2)	0.06 (0.34)	-0.7	-0.11	0.03	0.20	1.2	
		Week 8	Tezepelumab	133	129 (97.0)	0.23 (0.39)	-0.9	0.00	0.15	0.44	1.2	0.46 [0.21, 0.71]
			Placebo	125	123 (98.4)	0.07 (0.30)	-1.1	-0.11	0.04	0.24	1.2	
		Week 12	Tezepelumab	133	129 (97.0)	0.25 (0.37)	-0.8	0.02	0.18	0.44	1.5	0.49 [0.23, 0.74]
			Placebo	125	123 (98.4)	0.07 (0.39)	-1.5	-0.14	0.03	0.28	1.3	
		Week 16	Tezepelumab	133	127 (95.5)	0.26 (0.42)	-0.8	-0.03	0.22	0.48	1.6	0.44 [0.18, 0.69]
			Placebo	125	119 (95.2)	0.09 (0.35)	-1.2	-0.14	0.04	0.29	1.2	
		Week 24	Tezepelumab	133	126 (94.7)	0.26 (0.40)	-0.5	-0.04	0.19	0.47	1.7	0.47 [0.22, 0.73]
			Placebo	125	117 (93.6)	0.09 (0.34)	-0.8	-0.11	0.03	0.27	1.2	
		Week 36	Tezepelumab	133	124 (93.2)	0.26 (0.38)	-0.6	-0.05	0.26	0.51	1.6	0.40 [0.15, 0.66]
			Placebo	125	116 (92.8)	0.10 (0.37)	-1.1	-0.15	0.03	0.38	1.3	
		Week 52	Tezepelumab	133	115 (86.5)	0.25 (0.42)	-0.6	-0.05	0.21	0.52	1.4	0.42 [0.16, 0.69]
			Placebo	125	108 (86.4)	0.10 (0.31)	-0.9	-0.09	0.07	0.27	1.0	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q3: 195.6 - < 572.4 IU/ml	Absolute values	Baseline	Tezepelumab	125	125 (100.0)	1.75 (0.66)	0.6	1.33	1.64	2.08	3.7	
			Placebo	116	116 (100.0)	1.87 (0.75)	0.6	1.32	1.73	2.23	4.5	
		Week 2	Tezepelumab	125	122 (97.6)	1.96 (0.70)	0.6	1.46	1.87	2.39	4.0	
			Placebo	116	110 (94.8)	1.88 (0.70)	0.7	1.38	1.76	2.26	3.9	
		Week 4	Tezepelumab	125	125 (100.0)	1.94 (0.70)	0.6	1.46	1.89	2.38	4.2	
			Placebo	116	111 (95.7)	1.92 (0.66)	0.7	1.45	1.85	2.33	3.6	
		Week 8	Tezepelumab	125	124 (99.2)	1.99 (0.71)	0.6	1.45	1.95	2.40	4.3	
			Placebo	116	113 (97.4)	1.97 (0.74)	0.7	1.43	1.89	2.34	4.7	
		Week 12	Tezepelumab	125	120 (96.0)	2.00 (0.75)	0.6	1.52	1.91	2.45	4.6	
			Placebo	116	112 (96.6)	1.97 (0.77)	0.7	1.46	1.75	2.39	4.6	
		Week 16	Tezepelumab	125	121 (96.8)	2.02 (0.74)	0.6	1.52	1.95	2.44	4.4	
			Placebo	116	114 (98.3)	1.93 (0.75)	0.8	1.45	1.73	2.35	4.7	
		Week 24	Tezepelumab	125	114 (91.2)	1.98 (0.67)	0.6	1.58	1.88	2.48	4.0	
			Placebo	116	107 (92.2)	1.97 (0.77)	0.6	1.46	1.86	2.36	4.6	
		Week 36	Tezepelumab	125	109 (87.2)	1.98 (0.69)	0.7	1.52	1.94	2.35	4.2	
			Placebo	116	103 (88.8)	1.99 (0.75)	0.8	1.48	1.79	2.41	4.3	
		Week 52	Tezepelumab	125	111 (88.8)	1.99 (0.72)	0.6	1.50	1.90	2.44	4.3	
			Placebo	116	99 (85.3)	2.02 (0.80)	0.7	1.45	1.89	2.46	4.5	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q3: 195.6 - < 572.4 IU/ml	Change from baseline	Week 2	Tezepelumab	125	122 (97.6)	0.21 (0.37)	-0.5	-0.04	0.15	0.33	1.9	0.57 [0.31, 0.83]
			Placebo	116	110 (94.8)	-0.01 (0.40)	-1.8	-0.15	-0.01	0.13	1.2	
		Week 4	Tezepelumab	125	125 (100.0)	0.19 (0.32)	-0.5	-0.03	0.13	0.32	1.4	0.33 [0.07, 0.59]
			Placebo	116	111 (95.7)	0.06 (0.43)	-1.8	-0.11	0.05	0.30	1.0	
		Week 8	Tezepelumab	125	124 (99.2)	0.25 (0.40)	-0.6	-0.04	0.18	0.46	1.9	0.39 [0.13, 0.65]
			Placebo	116	113 (97.4)	0.09 (0.42)	-1.0	-0.12	0.04	0.26	1.8	
		Week 12	Tezepelumab	125	120 (96.0)	0.27 (0.45)	-0.7	-0.04	0.17	0.52	2.2	0.41 [0.15, 0.67]
			Placebo	116	112 (96.6)	0.09 (0.43)	-1.2	-0.09	0.04	0.22	2.1	
		Week 16	Tezepelumab	125	121 (96.8)	0.26 (0.46)	-0.6	-0.02	0.16	0.45	2.1	0.48 [0.22, 0.74]
			Placebo	116	114 (98.3)	0.06 (0.40)	-1.0	-0.19	0.02	0.21	1.9	
		Week 24	Tezepelumab	125	114 (91.2)	0.24 (0.47)	-1.0	-0.05	0.22	0.43	2.1	0.35 [0.09, 0.62]
			Placebo	116	107 (92.2)	0.08 (0.41)	-1.1	-0.14	0.03	0.31	1.7	
		Week 36	Tezepelumab	125	109 (87.2)	0.24 (0.46)	-1.0	-0.04	0.11	0.48	1.8	0.33 [0.06, 0.60]
			Placebo	116	103 (88.8)	0.09 (0.43)	-0.9	-0.13	0.04	0.26	1.6	
		Week 52	Tezepelumab	125	111 (88.8)	0.26 (0.46)	-1.0	-0.01	0.20	0.47	1.6	0.27 [0.00, 0.54]
			Placebo	116	99 (85.3)	0.14 (0.47)	-1.0	-0.14	0.06	0.31	2.3	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q4: >= 572.4 IU/ml	Absolute values	Baseline	Tezepelumab	104	104 (100.0)	1.90 (0.71)	0.7	1.41	1.78	2.25	4.1	
			Placebo	118	118 (100.0)	1.81 (0.66)	0.4	1.37	1.80	2.23	3.6	
		Week 2	Tezepelumab	104	99 (95.2)	2.08 (0.75)	0.7	1.51	1.99	2.53	4.3	
			Placebo	118	115 (97.5)	1.99 (0.74)	0.4	1.44	1.94	2.40	4.1	
		Week 4	Tezepelumab	104	103 (99.0)	2.12 (0.75)	0.7	1.57	2.09	2.54	4.3	
			Placebo	118	117 (99.2)	1.96 (0.78)	0.4	1.44	1.89	2.27	4.8	
		Week 8	Tezepelumab	104	103 (99.0)	2.16 (0.80)	0.8	1.52	2.07	2.53	4.7	
			Placebo	118	114 (96.6)	1.99 (0.81)	0.4	1.42	1.88	2.36	4.6	
		Week 12	Tezepelumab	104	102 (98.1)	2.13 (0.74)	0.8	1.59	2.01	2.46	4.7	
			Placebo	118	114 (96.6)	1.99 (0.78)	0.5	1.48	1.98	2.40	4.6	
		Week 16	Tezepelumab	104	100 (96.2)	2.17 (0.81)	0.9	1.65	2.07	2.47	4.9	
			Placebo	118	111 (94.1)	1.99 (0.77)	0.5	1.48	1.91	2.26	4.7	
		Week 24	Tezepelumab	104	99 (95.2)	2.13 (0.78)	0.8	1.60	2.00	2.57	4.4	
			Placebo	118	111 (94.1)	1.97 (0.78)	0.6	1.43	1.87	2.22	4.8	
		Week 36	Tezepelumab	104	97 (93.3)	2.14 (0.82)	0.6	1.55	2.05	2.50	4.5	
			Placebo	118	110 (93.2)	1.97 (0.79)	0.6	1.50	1.83	2.27	4.3	
		Week 52	Tezepelumab	104	94 (90.4)	2.11 (0.81)	0.7	1.53	1.98	2.47	4.2	
			Placebo	118	101 (85.6)	1.92 (0.78)	0.6	1.37	1.82	2.28	4.0	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q4: >= 572.4 IU/ml	Change from baseline	Week 2	Tezepelumab	104	99 (95.2)	0.19 (0.34)	-0.6	0.00	0.13	0.32	1.3	0.07 [-0.20, 0.34]
			Placebo	118	115 (97.5)	0.17 (0.37)	-0.8	-0.07	0.09	0.36	1.7	
		Week 4	Tezepelumab	104	103 (99.0)	0.24 (0.38)	-0.4	0.01	0.14	0.39	1.8	0.25 [-0.02, 0.51]
			Placebo	118	117 (99.2)	0.14 (0.41)	-0.8	-0.11	0.06	0.36	1.6	
		Week 8	Tezepelumab	104	103 (99.0)	0.27 (0.47)	-0.8	-0.02	0.16	0.47	1.8	0.25 [-0.02, 0.52]
			Placebo	118	114 (96.6)	0.16 (0.42)	-0.7	-0.09	0.09	0.33	2.1	
		Week 12	Tezepelumab	104	102 (98.1)	0.25 (0.43)	-0.4	-0.04	0.17	0.44	1.9	0.24 [-0.03, 0.51]
			Placebo	118	114 (96.6)	0.15 (0.38)	-0.9	-0.06	0.08	0.29	1.7	
		Week 16	Tezepelumab	104	100 (96.2)	0.26 (0.45)	-0.5	0.00	0.15	0.49	2.0	0.24 [-0.03, 0.51]
			Placebo	118	111 (94.1)	0.16 (0.40)	-0.8	-0.05	0.08	0.38	1.8	
		Week 24	Tezepelumab	104	99 (95.2)	0.24 (0.44)	-0.7	-0.06	0.14	0.44	1.6	0.25 [-0.02, 0.53]
			Placebo	118	111 (94.1)	0.13 (0.43)	-0.9	-0.11	0.07	0.31	1.7	
		Week 36	Tezepelumab	104	97 (93.3)	0.26 (0.44)	-0.8	-0.03	0.18	0.46	1.7	0.27 [-0.01, 0.54]
			Placebo	118	110 (93.2)	0.14 (0.45)	-1.0	-0.14	0.10	0.31	1.7	
		Week 52	Tezepelumab	104	94 (90.4)	0.23 (0.40)	-0.8	-0.03	0.16	0.41	1.7	0.32 [0.04, 0.61]
			Placebo	118	101 (85.6)	0.10 (0.41)	-1.0	-0.15	0.06	0.31	1.6	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Nasal polyps last 2 years												
Yes	Absolute values	Baseline	Tezepelumab	41	41 (100.0)	1.99 (0.75)	0.8	1.44	1.89	2.46	3.7	
			Placebo	39	39 (100.0)	1.86 (0.66)	0.6	1.42	1.67	2.27	3.4	
		Week 2	Tezepelumab	41	41 (100.0)	2.18 (0.79)	0.9	1.60	2.13	2.61	4.0	
			Placebo	39	39 (100.0)	1.93 (0.71)	0.9	1.38	1.85	2.46	4.1	
		Week 4	Tezepelumab	41	41 (100.0)	2.23 (0.81)	0.9	1.64	2.01	2.82	4.2	
			Placebo	39	38 (97.4)	2.01 (0.79)	0.9	1.42	2.00	2.52	4.8	
		Week 8	Tezepelumab	41	41 (100.0)	2.29 (0.86)	1.0	1.65	2.09	2.72	4.3	
			Placebo	39	39 (100.0)	1.98 (0.79)	0.7	1.50	1.89	2.46	4.6	
		Week 12	Tezepelumab	41	38 (92.7)	2.30 (0.97)	0.9	1.55	2.01	2.97	4.6	
			Placebo	39	39 (100.0)	2.02 (0.71)	1.0	1.48	1.95	2.37	4.6	
		Week 16	Tezepelumab	41	39 (95.1)	2.31 (0.93)	0.9	1.53	2.08	2.92	4.4	
			Placebo	39	38 (97.4)	2.03 (0.77)	0.7	1.55	1.85	2.47	4.7	
		Week 24	Tezepelumab	41	38 (92.7)	2.17 (0.77)	0.9	1.71	1.85	2.76	4.0	
			Placebo	39	37 (94.9)	2.01 (0.70)	0.9	1.61	1.93	2.24	4.8	
		Week 36	Tezepelumab	41	38 (92.7)	2.30 (0.84)	0.9	1.54	2.13	3.04	4.2	
			Placebo	39	37 (94.9)	2.03 (0.65)	0.8	1.60	1.93	2.31	4.3	
		Week 52	Tezepelumab	41	37 (90.2)	2.26 (0.91)	0.6	1.58	2.24	2.78	4.3	
			Placebo	39	36 (92.3)	1.97 (0.67)	0.9	1.51	1.98	2.37	4.0	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Nasal polyps last 2 years												
Yes	Change from baseline	Week 2	Tezepelumab	41	41 (100.0)	0.19 (0.32)	-0.3	0.02	0.12	0.30	1.0	0.36 [-0.09, 0.80]
			Placebo	39	39 (100.0)	0.07 (0.35)	-0.5	-0.15	-0.02	0.17	1.0	
		Week 4	Tezepelumab	41	41 (100.0)	0.24 (0.36)	-0.5	0.06	0.19	0.36	1.8	0.21 [-0.23, 0.66]
			Placebo	39	38 (97.4)	0.15 (0.47)	-0.7	-0.10	0.05	0.30	1.6	
		Week 8	Tezepelumab	41	41 (100.0)	0.30 (0.47)	-0.3	0.03	0.19	0.46	1.9	0.37 [-0.07, 0.81]
			Placebo	39	39 (100.0)	0.13 (0.45)	-1.1	-0.13	0.08	0.31	1.4	
		Week 12	Tezepelumab	41	38 (92.7)	0.30 (0.52)	-0.5	-0.03	0.17	0.46	2.2	0.30 [-0.15, 0.75]
			Placebo	39	39 (100.0)	0.16 (0.41)	-0.5	-0.11	0.08	0.37	1.4	
		Week 16	Tezepelumab	41	39 (95.1)	0.31 (0.51)	-0.6	-0.05	0.26	0.60	2.1	0.28 [-0.17, 0.73]
			Placebo	39	38 (97.4)	0.18 (0.43)	-0.6	-0.13	0.09	0.43	1.4	
		Week 24	Tezepelumab	41	38 (92.7)	0.21 (0.47)	-1.0	-0.08	0.16	0.43	1.6	0.12 [-0.33, 0.57]
			Placebo	39	37 (94.9)	0.16 (0.44)	-0.5	-0.14	0.10	0.49	1.6	
		Week 36	Tezepelumab	41	38 (92.7)	0.29 (0.43)	-0.5	0.01	0.14	0.53	1.4	0.14 [-0.31, 0.60]
			Placebo	39	37 (94.9)	0.23 (0.41)	-0.4	-0.03	0.15	0.50	1.6	
		Week 52	Tezepelumab	41	37 (90.2)	0.28 (0.46)	-0.8	0.00	0.23	0.52	1.5	0.33 [-0.13, 0.79]
			Placebo	39	36 (92.3)	0.12 (0.49)	-0.6	-0.15	0.01	0.28	2.0	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Nasal polyps last 2 years												
No	Absolute values	Baseline	Tezepelumab	446	446 (100.0)	1.74 (0.67)	0.4	1.26	1.64	2.12	4.8	
			Placebo	451	451 (100.0)	1.77 (0.65)	0.4	1.33	1.69	2.13	4.5	
		Week 2	Tezepelumab	446	433 (97.1)	1.90 (0.69)	0.6	1.39	1.81	2.37	5.0	
			Placebo	451	429 (95.1)	1.84 (0.67)	0.4	1.37	1.74	2.23	4.0	
		Week 4	Tezepelumab	446	442 (99.1)	1.93 (0.70)	0.6	1.41	1.84	2.40	5.0	
			Placebo	451	440 (97.6)	1.85 (0.66)	0.4	1.41	1.79	2.20	4.2	
		Week 8	Tezepelumab	446	437 (98.0)	1.95 (0.70)	0.6	1.41	1.87	2.38	4.7	
			Placebo	451	439 (97.3)	1.88 (0.69)	0.4	1.39	1.78	2.23	4.7	
		Week 12	Tezepelumab	446	435 (97.5)	1.95 (0.69)	0.6	1.48	1.87	2.39	4.9	
			Placebo	451	436 (96.7)	1.87 (0.70)	0.5	1.38	1.74	2.25	4.6	
		Week 16	Tezepelumab	446	432 (96.9)	1.97 (0.72)	0.6	1.45	1.86	2.40	4.9	
			Placebo	451	431 (95.6)	1.87 (0.69)	0.5	1.36	1.75	2.21	4.7	
		Week 24	Tezepelumab	446	422 (94.6)	1.95 (0.71)	0.6	1.45	1.84	2.39	5.5	
			Placebo	451	416 (92.2)	1.86 (0.69)	0.6	1.40	1.74	2.20	4.8	
		Week 36	Tezepelumab	446	408 (91.5)	1.95 (0.72)	0.5	1.42	1.85	2.37	4.9	
			Placebo	451	403 (89.4)	1.89 (0.70)	0.6	1.40	1.78	2.26	4.6	
		Week 52	Tezepelumab	446	400 (89.7)	1.95 (0.71)	0.6	1.46	1.83	2.37	4.6	
			Placebo	451	382 (84.7)	1.87 (0.72)	0.6	1.36	1.74	2.27	4.5	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Nasal polyps last 2 years												
No	Change from baseline	Week 2	Tezepelumab	446	433 (97.1)	0.17 (0.33)	-0.8	-0.01	0.11	0.29	1.9	0.34 [0.20, 0.47]
			Placebo	451	429 (95.1)	0.05 (0.34)	-1.8	-0.11	0.01	0.18	1.7	
		Week 4	Tezepelumab	446	442 (99.1)	0.19 (0.36)	-1.0	-0.03	0.13	0.33	1.7	0.32 [0.18, 0.45]
			Placebo	451	440 (97.6)	0.08 (0.36)	-1.8	-0.10	0.05	0.25	1.4	
		Week 8	Tezepelumab	446	437 (98.0)	0.22 (0.40)	-0.9	-0.04	0.14	0.39	1.8	0.34 [0.20, 0.47]
			Placebo	451	439 (97.3)	0.09 (0.35)	-1.0	-0.10	0.05	0.27	2.1	
		Week 12	Tezepelumab	446	435 (97.5)	0.23 (0.39)	-0.8	-0.02	0.17	0.40	2.0	0.35 [0.22, 0.49]
			Placebo	451	436 (96.7)	0.09 (0.38)	-1.5	-0.09	0.04	0.24	2.1	
		Week 16	Tezepelumab	446	432 (96.9)	0.23 (0.41)	-1.0	-0.02	0.15	0.39	2.0	0.37 [0.24, 0.51]
			Placebo	451	431 (95.6)	0.09 (0.35)	-1.2	-0.10	0.04	0.24	1.9	
		Week 24	Tezepelumab	446	422 (94.6)	0.22 (0.40)	-1.0	-0.05	0.15	0.41	2.1	0.38 [0.25, 0.52]
			Placebo	451	416 (92.2)	0.07 (0.36)	-1.1	-0.11	0.04	0.24	1.7	
		Week 36	Tezepelumab	446	408 (91.5)	0.21 (0.41)	-1.0	-0.06	0.14	0.40	1.8	0.30 [0.17, 0.44]
			Placebo	451	403 (89.4)	0.09 (0.38)	-1.1	-0.15	0.04	0.28	1.7	
		Week 52	Tezepelumab	446	400 (89.7)	0.21 (0.41)	-1.0	-0.04	0.14	0.40	1.7	0.33 [0.19, 0.47]
			Placebo	451	382 (84.7)	0.08 (0.37)	-1.0	-0.14	0.06	0.24	2.3	

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Region (cat. N)									0.652
Western Europe	Week 2	Tezepelumab	85	83 (97.6)	0.16 (0.04)	(0.09, 0.23)	0.11 (0.05)	(0.01, 0.21)	0.035 *
		Placebo	84	79 (94.0)	0.05 (0.04)	(-0.02, 0.13)			
	Week 4	Tezepelumab	85	85 (100.0)	0.19 (0.04)	(0.12, 0.26)	0.13 (0.05)	(0.03, 0.24)	0.015 *
		Placebo	84	82 (97.6)	0.06 (0.04)	(-0.02, 0.13)			
	Week 8	Tezepelumab	85	85 (100.0)	0.22 (0.05)	(0.13, 0.31)	0.12 (0.07)	(-0.01, 0.24)	0.076
		Placebo	84	78 (92.9)	0.10 (0.05)	(0.01, 0.19)			
	Week 12	Tezepelumab	85	81 (95.3)	0.18 (0.04)	(0.10, 0.27)	0.12 (0.06)	(-0.00, 0.24)	0.051
		Placebo	84	78 (92.9)	0.06 (0.04)	(-0.02, 0.15)			
	Week 16	Tezepelumab	85	81 (95.3)	0.24 (0.04)	(0.15, 0.32)	0.22 (0.06)	(0.09, 0.34)	<0.001 *
		Placebo	84	78 (92.9)	0.02 (0.04)	(-0.07, 0.11)			
	Week 24	Tezepelumab	85	80 (94.1)	0.18 (0.04)	(0.10, 0.26)	0.16 (0.06)	(0.04, 0.28)	0.007 *
		Placebo	84	70 (83.3)	0.02 (0.04)	(-0.06, 0.10)			
	Week 36	Tezepelumab	85	77 (90.6)	0.19 (0.04)	(0.10, 0.27)	0.07 (0.06)	(-0.05, 0.20)	0.229
		Placebo	84	66 (78.6)	0.11 (0.04)	(0.02, 0.20)			
	Week 52	Tezepelumab	85	75 (88.2)	0.18 (0.04)	(0.10, 0.26)	0.06 (0.06)	(-0.06, 0.17)	0.327
		Placebo	84	63 (75.0)	0.12 (0.04)	(0.04, 0.21)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
North America	Week 2	Tezepelumab	103	97 (94.2)	0.24 (0.03)	(0.17, 0.30)	0.15 (0.05)	(0.06, 0.24)	0.002 *
		Placebo	102	96 (94.1)	0.09 (0.03)	(0.02, 0.15)			
	Week 4	Tezepelumab	103	101 (98.1)	0.23 (0.03)	(0.16, 0.29)	0.12 (0.05)	(0.03, 0.21)	0.011 *
		Placebo	102	99 (97.1)	0.11 (0.03)	(0.04, 0.17)			
	Week 8	Tezepelumab	103	100 (97.1)	0.26 (0.04)	(0.18, 0.33)	0.17 (0.05)	(0.07, 0.28)	0.001 *
		Placebo	102	100 (98.0)	0.08 (0.04)	(0.01, 0.16)			
	Week 12	Tezepelumab	103	99 (96.1)	0.28 (0.04)	(0.20, 0.36)	0.19 (0.06)	(0.08, 0.31)	0.001 *
		Placebo	102	100 (98.0)	0.09 (0.04)	(0.01, 0.17)			
	Week 16	Tezepelumab	103	99 (96.1)	0.27 (0.04)	(0.20, 0.35)	0.16 (0.05)	(0.06, 0.27)	0.002 *
		Placebo	102	99 (97.1)	0.11 (0.04)	(0.04, 0.18)			
	Week 24	Tezepelumab	103	93 (90.3)	0.24 (0.04)	(0.16, 0.31)	0.16 (0.05)	(0.05, 0.26)	0.003 *
		Placebo	102	95 (93.1)	0.08 (0.04)	(0.01, 0.15)			
	Week 36	Tezepelumab	103	89 (86.4)	0.27 (0.04)	(0.20, 0.35)	0.16 (0.05)	(0.06, 0.27)	0.003 *
		Placebo	102	96 (94.1)	0.11 (0.04)	(0.04, 0.19)			
	Week 52	Tezepelumab	103	86 (83.5)	0.26 (0.04)	(0.18, 0.35)	0.13 (0.06)	(0.02, 0.25)	0.026 *
		Placebo	102	83 (81.4)	0.13 (0.04)	(0.05, 0.21)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
South America	Week 2	Tezepelumab	67	67 (100.0)	0.10 (0.04)	(0.01, 0.18)	0.07 (0.06)	(-0.05, 0.19)	0.276
		Placebo	67	65 (97.0)	0.03 (0.04)	(-0.06, 0.12)			
	Week 4	Tezepelumab	67	66 (98.5)	0.11 (0.05)	(0.02, 0.20)	0.05 (0.07)	(-0.09, 0.18)	0.489
		Placebo	67	63 (94.0)	0.06 (0.05)	(-0.03, 0.16)			
	Week 8	Tezepelumab	67	66 (98.5)	0.13 (0.05)	(0.04, 0.22)	0.02 (0.06)	(-0.11, 0.15)	0.728
		Placebo	67	65 (97.0)	0.11 (0.05)	(0.02, 0.20)			
	Week 12	Tezepelumab	67	65 (97.0)	0.14 (0.05)	(0.05, 0.23)	0.04 (0.06)	(-0.09, 0.16)	0.561
		Placebo	67	66 (98.5)	0.10 (0.05)	(0.01, 0.19)			
	Week 16	Tezepelumab	67	64 (95.5)	0.15 (0.05)	(0.05, 0.25)	0.04 (0.07)	(-0.10, 0.18)	0.570
		Placebo	67	64 (95.5)	0.11 (0.05)	(0.01, 0.21)			
	Week 24	Tezepelumab	67	63 (94.0)	0.14 (0.05)	(0.05, 0.24)	0.04 (0.07)	(-0.10, 0.17)	0.594
		Placebo	67	63 (94.0)	0.11 (0.05)	(0.01, 0.20)			
	Week 36	Tezepelumab	67	63 (94.0)	0.14 (0.05)	(0.04, 0.24)	-0.00 (0.07)	(-0.15, 0.14)	0.959
		Placebo	67	65 (97.0)	0.14 (0.05)	(0.04, 0.25)			
	Week 52	Tezepelumab	67	63 (94.0)	0.16 (0.05)	(0.06, 0.27)	0.05 (0.07)	(-0.10, 0.19)	0.512
		Placebo	67	63 (94.0)	0.11 (0.05)	(0.01, 0.22)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Central/Eastern Europe	Week 2	Tezepelumab	34	34 (100.0)	0.20 (0.05)	(0.10, 0.29)	0.21 (0.07)	(0.07, 0.35)	0.003 *
		Placebo	36	34 (94.4)	-0.01 (0.05)	(-0.11, 0.08)			
	Week 4	Tezepelumab	34	34 (100.0)	0.28 (0.06)	(0.16, 0.40)	0.18 (0.08)	(0.01, 0.34)	0.041 *
		Placebo	36	35 (97.2)	0.10 (0.06)	(-0.01, 0.22)			
	Week 8	Tezepelumab	34	34 (100.0)	0.26 (0.07)	(0.13, 0.39)	0.11 (0.09)	(-0.07, 0.30)	0.222
		Placebo	36	35 (97.2)	0.15 (0.06)	(0.02, 0.28)			
	Week 12	Tezepelumab	34	33 (97.1)	0.28 (0.06)	(0.16, 0.41)	0.13 (0.09)	(-0.05, 0.30)	0.157
		Placebo	36	35 (97.2)	0.16 (0.06)	(0.03, 0.28)			
	Week 16	Tezepelumab	34	34 (100.0)	0.28 (0.07)	(0.14, 0.43)	0.10 (0.10)	(-0.10, 0.31)	0.316
		Placebo	36	36 (100.0)	0.18 (0.07)	(0.04, 0.32)			
	Week 24	Tezepelumab	34	33 (97.1)	0.21 (0.07)	(0.07, 0.35)	0.06 (0.10)	(-0.14, 0.25)	0.564
		Placebo	36	36 (100.0)	0.15 (0.07)	(0.02, 0.29)			
	Week 36	Tezepelumab	34	34 (100.0)	0.19 (0.06)	(0.07, 0.31)	0.06 (0.08)	(-0.11, 0.23)	0.453
		Placebo	36	35 (97.2)	0.13 (0.06)	(0.01, 0.24)			
	Week 52	Tezepelumab	34	34 (100.0)	0.21 (0.07)	(0.07, 0.35)	0.12 (0.10)	(-0.07, 0.32)	0.208
		Placebo	36	36 (100.0)	0.09 (0.07)	(-0.05, 0.22)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Asia Pacific	Week 2	Tezepelumab	121	120 (99.2)	0.15 (0.03)	(0.09, 0.21)	0.08 (0.04)	(-0.01, 0.16)	0.072
		Placebo	123	120 (97.6)	0.08 (0.03)	(0.02, 0.13)			
	Week 4	Tezepelumab	121	121 (100.0)	0.22 (0.03)	(0.16, 0.28)	0.16 (0.05)	(0.07, 0.24)	<0.001 *
		Placebo	123	123 (100.0)	0.07 (0.03)	(0.00, 0.13)			
	Week 8	Tezepelumab	121	117 (96.7)	0.27 (0.03)	(0.20, 0.33)	0.18 (0.05)	(0.09, 0.27)	<0.001 *
		Placebo	123	123 (100.0)	0.09 (0.03)	(0.02, 0.15)			
	Week 12	Tezepelumab	121	119 (98.3)	0.27 (0.04)	(0.20, 0.33)	0.17 (0.05)	(0.07, 0.27)	<0.001 *
		Placebo	123	122 (99.2)	0.09 (0.03)	(0.03, 0.16)			
	Week 16	Tezepelumab	121	120 (99.2)	0.27 (0.03)	(0.20, 0.33)	0.17 (0.05)	(0.07, 0.26)	<0.001 *
		Placebo	123	120 (97.6)	0.10 (0.03)	(0.03, 0.17)			
	Week 24	Tezepelumab	121	119 (98.3)	0.24 (0.03)	(0.17, 0.31)	0.16 (0.05)	(0.06, 0.25)	0.002 *
		Placebo	123	118 (95.9)	0.09 (0.03)	(0.02, 0.15)			
	Week 36	Tezepelumab	121	115 (95.0)	0.25 (0.04)	(0.17, 0.32)	0.18 (0.05)	(0.07, 0.28)	<0.001 *
		Placebo	123	113 (91.9)	0.07 (0.04)	(-0.00, 0.14)			
	Week 52	Tezepelumab	121	114 (94.2)	0.25 (0.04)	(0.18, 0.32)	0.20 (0.05)	(0.09, 0.30)	<0.001 *
		Placebo	123	111 (90.2)	0.06 (0.04)	(-0.02, 0.13)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Rest of the world	Week 2	Tezepelumab	77	73 (94.8)	0.15 (0.04)	(0.08, 0.23)	0.12 (0.05)	(0.01, 0.22)	0.031 *
		Placebo	78	74 (94.9)	0.04 (0.04)	(-0.04, 0.11)			
	Week 4	Tezepelumab	77	76 (98.7)	0.16 (0.04)	(0.07, 0.24)	0.02 (0.06)	(-0.11, 0.14)	0.797
		Placebo	78	76 (97.4)	0.14 (0.04)	(0.05, 0.23)			
	Week 8	Tezepelumab	77	76 (98.7)	0.19 (0.04)	(0.11, 0.27)	0.09 (0.05)	(-0.02, 0.20)	0.095
		Placebo	78	77 (98.7)	0.10 (0.04)	(0.02, 0.17)			
	Week 12	Tezepelumab	77	76 (98.7)	0.22 (0.04)	(0.13, 0.30)	0.09 (0.06)	(-0.03, 0.21)	0.138
		Placebo	78	74 (94.9)	0.13 (0.04)	(0.04, 0.21)			
	Week 16	Tezepelumab	77	73 (94.8)	0.18 (0.04)	(0.09, 0.26)	0.08 (0.06)	(-0.04, 0.20)	0.211
		Placebo	78	72 (92.3)	0.10 (0.04)	(0.02, 0.19)			
	Week 24	Tezepelumab	77	72 (93.5)	0.23 (0.04)	(0.14, 0.32)	0.15 (0.06)	(0.03, 0.28)	0.016 *
		Placebo	78	71 (91.0)	0.08 (0.04)	(-0.01, 0.16)			
	Week 36	Tezepelumab	77	68 (88.3)	0.22 (0.04)	(0.13, 0.31)	0.13 (0.06)	(0.01, 0.26)	0.040 *
		Placebo	78	65 (83.3)	0.09 (0.04)	(0.00, 0.18)			
	Week 52	Tezepelumab	77	65 (84.4)	0.23 (0.05)	(0.14, 0.32)	0.16 (0.06)	(0.03, 0.29)	0.013 *
		Placebo	78	62 (79.5)	0.07 (0.05)	(-0.02, 0.16)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline eosinophils (cat. N)									0.001 i
< 150 cells/uL	Week 2	Tezepelumab	130	127 (97.7)	0.07 (0.03)	(0.02, 0.12)	0.01 (0.04)	(-0.06, 0.09)	0.708
		Placebo	132	126 (95.5)	0.06 (0.03)	(0.00, 0.11)			
	Week 4	Tezepelumab	130	129 (99.2)	0.07 (0.03)	(0.01, 0.13)	0.01 (0.04)	(-0.08, 0.09)	0.847
		Placebo	132	129 (97.7)	0.06 (0.03)	(0.00, 0.12)			
	Week 8	Tezepelumab	130	125 (96.2)	0.09 (0.03)	(0.02, 0.15)	-0.01 (0.04)	(-0.09, 0.08)	0.886
		Placebo	132	128 (97.0)	0.09 (0.03)	(0.03, 0.15)			
	Week 12	Tezepelumab	130	125 (96.2)	0.08 (0.03)	(0.02, 0.14)	0.00 (0.04)	(-0.09, 0.09)	0.998
		Placebo	132	127 (96.2)	0.08 (0.03)	(0.02, 0.14)			
	Week 16	Tezepelumab	130	126 (96.9)	0.09 (0.03)	(0.02, 0.16)	0.03 (0.05)	(-0.06, 0.13)	0.504
		Placebo	132	127 (96.2)	0.06 (0.03)	(-0.01, 0.13)			
	Week 24	Tezepelumab	130	118 (90.8)	0.08 (0.03)	(0.02, 0.14)	0.01 (0.04)	(-0.07, 0.09)	0.756
		Placebo	132	121 (91.7)	0.07 (0.03)	(0.01, 0.12)			
	Week 36	Tezepelumab	130	118 (90.8)	0.06 (0.03)	(0.00, 0.12)	-0.02 (0.04)	(-0.10, 0.06)	0.592
		Placebo	132	118 (89.4)	0.08 (0.03)	(0.03, 0.14)			
	Week 52	Tezepelumab	130	117 (90.0)	0.09 (0.03)	(0.02, 0.16)	0.04 (0.05)	(-0.06, 0.13)	0.446
		Placebo	132	115 (87.1)	0.05 (0.03)	(-0.01, 0.12)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
150 - < 300 cells/uL	Week 2	Tezepelumab	156	152 (97.4)	0.13 (0.02)	(0.09, 0.18)	0.12 (0.03)	(0.06, 0.19)	<0.001 *
		Placebo	163	158 (96.9)	0.01 (0.02)	(-0.03, 0.06)			
	Week 4	Tezepelumab	156	156 (100.0)	0.16 (0.03)	(0.11, 0.21)	0.11 (0.04)	(0.04, 0.19)	0.002 *
		Placebo	163	158 (96.9)	0.05 (0.03)	(-0.00, 0.10)			
	Week 8	Tezepelumab	156	156 (100.0)	0.17 (0.03)	(0.12, 0.22)	0.09 (0.04)	(0.02, 0.17)	0.013 *
		Placebo	163	157 (96.3)	0.08 (0.03)	(0.03, 0.13)			
	Week 12	Tezepelumab	156	152 (97.4)	0.16 (0.03)	(0.10, 0.22)	0.11 (0.04)	(0.03, 0.18)	0.008 *
		Placebo	163	157 (96.3)	0.05 (0.03)	(-0.00, 0.11)			
	Week 16	Tezepelumab	156	152 (97.4)	0.16 (0.03)	(0.11, 0.22)	0.09 (0.04)	(0.02, 0.17)	0.014 *
		Placebo	163	156 (95.7)	0.07 (0.03)	(0.02, 0.12)			
	Week 24	Tezepelumab	156	152 (97.4)	0.12 (0.03)	(0.07, 0.18)	0.09 (0.04)	(0.02, 0.17)	0.017 *
		Placebo	163	152 (93.3)	0.03 (0.03)	(-0.03, 0.08)			
	Week 36	Tezepelumab	156	145 (92.9)	0.14 (0.03)	(0.08, 0.20)	0.12 (0.04)	(0.04, 0.20)	0.005 *
		Placebo	163	148 (90.8)	0.02 (0.03)	(-0.03, 0.08)			
	Week 52	Tezepelumab	156	146 (93.6)	0.13 (0.03)	(0.07, 0.19)	0.07 (0.04)	(-0.01, 0.16)	0.074
		Placebo	163	139 (85.3)	0.06 (0.03)	(0.00, 0.12)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
300 - < 450 cells/uL	Week 2	Tezepelumab	93	89 (95.7)	0.20 (0.04)	(0.13, 0.27)	0.16 (0.05)	(0.05, 0.26)	0.003 *
		Placebo	83	77 (92.8)	0.04 (0.04)	(-0.04, 0.12)			
	Week 4	Tezepelumab	93	90 (96.8)	0.24 (0.04)	(0.16, 0.31)	0.18 (0.05)	(0.07, 0.28)	0.001 *
		Placebo	83	81 (97.6)	0.06 (0.04)	(-0.02, 0.13)			
	Week 8	Tezepelumab	93	91 (97.8)	0.28 (0.04)	(0.21, 0.36)	0.21 (0.06)	(0.10, 0.32)	<0.001 *
		Placebo	83	82 (98.8)	0.07 (0.04)	(-0.01, 0.15)			
	Week 12	Tezepelumab	93	89 (95.7)	0.32 (0.04)	(0.24, 0.39)	0.28 (0.06)	(0.16, 0.39)	<0.001 *
		Placebo	83	79 (95.2)	0.04 (0.04)	(-0.05, 0.12)			
	Week 16	Tezepelumab	93	89 (95.7)	0.31 (0.04)	(0.23, 0.39)	0.22 (0.06)	(0.11, 0.34)	<0.001 *
		Placebo	83	78 (94.0)	0.08 (0.04)	(-0.00, 0.17)			
	Week 24	Tezepelumab	93	89 (95.7)	0.30 (0.04)	(0.23, 0.38)	0.24 (0.06)	(0.13, 0.35)	<0.001 *
		Placebo	83	77 (92.8)	0.06 (0.04)	(-0.02, 0.14)			
	Week 36	Tezepelumab	93	83 (89.2)	0.32 (0.04)	(0.24, 0.41)	0.24 (0.06)	(0.11, 0.36)	<0.001 *
		Placebo	83	74 (89.2)	0.09 (0.04)	(-0.00, 0.18)			
	Week 52	Tezepelumab	93	81 (87.1)	0.31 (0.04)	(0.22, 0.40)	0.23 (0.06)	(0.10, 0.36)	<0.001 *
		Placebo	83	73 (88.0)	0.08 (0.05)	(-0.01, 0.18)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 450 cells/uL	Week 2	Tezepelumab	108	106 (98.1)	0.30 (0.04)	(0.23, 0.37)	0.18 (0.05)	(0.08, 0.27)	<0.001 *
		Placebo	112	107 (95.5)	0.12 (0.03)	(0.06, 0.19)			
	Week 4	Tezepelumab	108	108 (100.0)	0.36 (0.04)	(0.29, 0.43)	0.17 (0.05)	(0.07, 0.27)	<0.001 *
		Placebo	112	110 (98.2)	0.19 (0.04)	(0.12, 0.26)			
	Week 8	Tezepelumab	108	106 (98.1)	0.43 (0.04)	(0.34, 0.51)	0.27 (0.06)	(0.16, 0.39)	<0.001 *
		Placebo	112	111 (99.1)	0.15 (0.04)	(0.07, 0.23)			
	Week 12	Tezepelumab	108	107 (99.1)	0.43 (0.04)	(0.36, 0.51)	0.21 (0.06)	(0.10, 0.32)	<0.001 *
		Placebo	112	112 (100.0)	0.22 (0.04)	(0.15, 0.30)			
	Week 16	Tezepelumab	108	104 (96.3)	0.45 (0.04)	(0.38, 0.53)	0.27 (0.05)	(0.16, 0.38)	<0.001 *
		Placebo	112	108 (96.4)	0.18 (0.04)	(0.11, 0.26)			
	Week 24	Tezepelumab	108	101 (93.5)	0.43 (0.04)	(0.35, 0.52)	0.24 (0.06)	(0.12, 0.36)	<0.001 *
		Placebo	112	103 (92.0)	0.20 (0.04)	(0.11, 0.28)			
	Week 36	Tezepelumab	108	100 (92.6)	0.43 (0.04)	(0.35, 0.51)	0.18 (0.06)	(0.07, 0.30)	0.002 *
		Placebo	112	100 (89.3)	0.25 (0.04)	(0.17, 0.33)			
	Week 52	Tezepelumab	108	93 (86.1)	0.44 (0.04)	(0.36, 0.52)	0.26 (0.06)	(0.15, 0.38)	<0.001 *
		Placebo	112	91 (81.3)	0.18 (0.04)	(0.10, 0.26)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline eosinophils (cat. Q)									0.004 i
Q1: < 140 cells/uL	Week 2	Tezepelumab	119	116 (97.5)	0.08 (0.03)	(0.02, 0.13)	0.01 (0.04)	(-0.06, 0.09)	0.770
		Placebo	121	115 (95.0)	0.07 (0.03)	(0.01, 0.12)			
	Week 4	Tezepelumab	119	118 (99.2)	0.08 (0.03)	(0.01, 0.14)	0.01 (0.05)	(-0.08, 0.10)	0.811
		Placebo	121	118 (97.5)	0.07 (0.03)	(0.00, 0.13)			
	Week 8	Tezepelumab	119	115 (96.6)	0.09 (0.03)	(0.03, 0.16)	0.01 (0.05)	(-0.08, 0.10)	0.786
		Placebo	121	117 (96.7)	0.08 (0.03)	(0.01, 0.14)			
	Week 12	Tezepelumab	119	115 (96.6)	0.09 (0.03)	(0.03, 0.15)	0.00 (0.05)	(-0.09, 0.09)	0.953
		Placebo	121	117 (96.7)	0.09 (0.03)	(0.02, 0.15)			
	Week 16	Tezepelumab	119	116 (97.5)	0.10 (0.04)	(0.03, 0.17)	0.04 (0.05)	(-0.06, 0.15)	0.412
		Placebo	121	116 (95.9)	0.06 (0.04)	(-0.02, 0.13)			
	Week 24	Tezepelumab	119	109 (91.6)	0.08 (0.03)	(0.02, 0.14)	0.01 (0.04)	(-0.07, 0.09)	0.810
		Placebo	121	111 (91.7)	0.07 (0.03)	(0.01, 0.13)			
	Week 36	Tezepelumab	119	109 (91.6)	0.08 (0.03)	(0.01, 0.14)	-0.02 (0.04)	(-0.11, 0.07)	0.631
		Placebo	121	108 (89.3)	0.10 (0.03)	(0.04, 0.16)			
	Week 52	Tezepelumab	119	108 (90.8)	0.10 (0.04)	(0.03, 0.17)	0.05 (0.05)	(-0.04, 0.15)	0.282
		Placebo	121	105 (86.8)	0.05 (0.04)	(-0.02, 0.12)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q2: 140 - < 250 cells/uL	Week 2	Tezepelumab	117	114 (97.4)	0.12 (0.03)	(0.07, 0.18)	0.14 (0.04)	(0.07, 0.22)	<0.001 *
		Placebo	130	126 (96.9)	-0.02 (0.03)	(-0.08, 0.03)			
	Week 4	Tezepelumab	117	117 (100.0)	0.13 (0.03)	(0.07, 0.19)	0.10 (0.04)	(0.02, 0.18)	0.010 *
		Placebo	130	125 (96.2)	0.03 (0.03)	(-0.03, 0.08)			
	Week 8	Tezepelumab	117	116 (99.1)	0.13 (0.03)	(0.07, 0.19)	0.06 (0.04)	(-0.02, 0.14)	0.174
		Placebo	130	128 (98.5)	0.08 (0.03)	(0.02, 0.13)			
	Week 12	Tezepelumab	117	112 (95.7)	0.11 (0.03)	(0.05, 0.18)	0.08 (0.05)	(-0.01, 0.17)	0.070
		Placebo	130	125 (96.2)	0.03 (0.03)	(-0.03, 0.09)			
	Week 16	Tezepelumab	117	113 (96.6)	0.13 (0.03)	(0.07, 0.18)	0.07 (0.04)	(-0.01, 0.14)	0.085
		Placebo	130	126 (96.9)	0.06 (0.03)	(0.01, 0.11)			
	Week 24	Tezepelumab	117	112 (95.7)	0.09 (0.03)	(0.02, 0.15)	0.06 (0.04)	(-0.02, 0.15)	0.144
		Placebo	130	122 (93.8)	0.02 (0.03)	(-0.03, 0.08)			
	Week 36	Tezepelumab	117	108 (92.3)	0.08 (0.03)	(0.01, 0.14)	0.06 (0.05)	(-0.03, 0.15)	0.179
		Placebo	130	118 (90.8)	0.02 (0.03)	(-0.04, 0.08)			
	Week 52	Tezepelumab	117	108 (92.3)	0.08 (0.03)	(0.01, 0.14)	0.01 (0.05)	(-0.08, 0.10)	0.810
		Placebo	130	112 (86.2)	0.07 (0.03)	(0.00, 0.13)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q3: 250 - < 430 cells/uL	Week 2	Tezepelumab	135	131 (97.0)	0.19 (0.03)	(0.13, 0.24)	0.11 (0.04)	(0.03, 0.19)	0.010 *
		Placebo	117	111 (94.9)	0.08 (0.03)	(0.01, 0.14)			
	Week 4	Tezepelumab	135	132 (97.8)	0.22 (0.03)	(0.17, 0.28)	0.14 (0.04)	(0.06, 0.23)	0.001 *
		Placebo	117	115 (98.3)	0.08 (0.03)	(0.02, 0.14)			
	Week 8	Tezepelumab	135	133 (98.5)	0.27 (0.03)	(0.21, 0.33)	0.18 (0.05)	(0.09, 0.27)	<0.001 *
		Placebo	117	112 (95.7)	0.09 (0.03)	(0.02, 0.16)			
	Week 12	Tezepelumab	135	131 (97.0)	0.30 (0.03)	(0.23, 0.36)	0.22 (0.05)	(0.12, 0.31)	<0.001 *
		Placebo	117	111 (94.9)	0.08 (0.04)	(0.01, 0.15)			
	Week 16	Tezepelumab	135	130 (96.3)	0.28 (0.03)	(0.21, 0.34)	0.18 (0.05)	(0.08, 0.28)	<0.001 *
		Placebo	117	109 (93.2)	0.10 (0.04)	(0.03, 0.17)			
	Week 24	Tezepelumab	135	130 (96.3)	0.26 (0.03)	(0.20, 0.33)	0.21 (0.05)	(0.12, 0.31)	<0.001 *
		Placebo	117	107 (91.5)	0.05 (0.04)	(-0.02, 0.12)			
	Week 36	Tezepelumab	135	121 (89.6)	0.31 (0.04)	(0.24, 0.38)	0.24 (0.05)	(0.13, 0.34)	<0.001 *
		Placebo	117	104 (88.9)	0.07 (0.04)	(-0.01, 0.15)			
	Week 52	Tezepelumab	135	120 (88.9)	0.28 (0.04)	(0.21, 0.35)	0.21 (0.05)	(0.10, 0.31)	<0.001 *
		Placebo	117	100 (85.5)	0.07 (0.04)	(-0.00, 0.15)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q4: >= 430 cells/uL	Week 2	Tezepelumab	116	113 (97.4)	0.28 (0.03)	(0.22, 0.35)	0.18 (0.05)	(0.08, 0.27)	<0.001 *
		Placebo	122	116 (95.1)	0.10 (0.03)	(0.04, 0.17)			
	Week 4	Tezepelumab	116	116 (100.0)	0.35 (0.04)	(0.28, 0.42)	0.18 (0.05)	(0.08, 0.28)	<0.001 *
		Placebo	122	120 (98.4)	0.17 (0.04)	(0.10, 0.24)			
	Week 8	Tezepelumab	116	114 (98.3)	0.41 (0.04)	(0.33, 0.49)	0.27 (0.06)	(0.16, 0.38)	<0.001 *
		Placebo	122	121 (99.2)	0.14 (0.04)	(0.07, 0.22)			
	Week 12	Tezepelumab	116	115 (99.1)	0.42 (0.04)	(0.34, 0.49)	0.22 (0.05)	(0.12, 0.33)	<0.001 *
		Placebo	122	122 (100.0)	0.19 (0.04)	(0.12, 0.27)			
	Week 16	Tezepelumab	116	112 (96.6)	0.44 (0.04)	(0.36, 0.51)	0.27 (0.05)	(0.17, 0.38)	<0.001 *
		Placebo	122	118 (96.7)	0.16 (0.04)	(0.09, 0.24)			
	Week 24	Tezepelumab	116	109 (94.0)	0.42 (0.04)	(0.34, 0.50)	0.24 (0.06)	(0.13, 0.35)	<0.001 *
		Placebo	122	113 (92.6)	0.18 (0.04)	(0.10, 0.26)			
	Week 36	Tezepelumab	116	108 (93.1)	0.41 (0.04)	(0.34, 0.49)	0.18 (0.05)	(0.08, 0.29)	<0.001 *
		Placebo	122	110 (90.2)	0.23 (0.04)	(0.15, 0.30)			
	Week 52	Tezepelumab	116	101 (87.1)	0.43 (0.04)	(0.36, 0.51)	0.26 (0.06)	(0.15, 0.37)	<0.001 *
		Placebo	122	101 (82.8)	0.17 (0.04)	(0.10, 0.25)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline FENO (cat. N)									0.033 i
< 25 ppb	Week 2	Tezepelumab	202	195 (96.5)	0.13 (0.02)	(0.09, 0.17)	0.08 (0.03)	(0.02, 0.14)	0.011 *
		Placebo	204	190 (93.1)	0.05 (0.02)	(0.01, 0.09)			
	Week 4	Tezepelumab	202	199 (98.5)	0.13 (0.02)	(0.08, 0.18)	0.05 (0.03)	(-0.02, 0.11)	0.154
		Placebo	204	199 (97.5)	0.08 (0.02)	(0.04, 0.13)			
	Week 8	Tezepelumab	202	197 (97.5)	0.14 (0.02)	(0.09, 0.19)	0.05 (0.04)	(-0.02, 0.12)	0.175
		Placebo	204	199 (97.5)	0.09 (0.02)	(0.05, 0.14)			
	Week 12	Tezepelumab	202	195 (96.5)	0.16 (0.03)	(0.11, 0.20)	0.06 (0.04)	(-0.01, 0.13)	0.077
		Placebo	204	197 (96.6)	0.09 (0.02)	(0.04, 0.14)			
	Week 16	Tezepelumab	202	194 (96.0)	0.14 (0.03)	(0.09, 0.19)	0.06 (0.04)	(-0.01, 0.14)	0.072
		Placebo	204	197 (96.6)	0.08 (0.03)	(0.03, 0.13)			
	Week 24	Tezepelumab	202	192 (95.0)	0.13 (0.03)	(0.08, 0.18)	0.07 (0.04)	(-0.00, 0.14)	0.051
		Placebo	204	193 (94.6)	0.06 (0.03)	(0.01, 0.11)			
	Week 36	Tezepelumab	202	183 (90.6)	0.12 (0.02)	(0.07, 0.17)	0.02 (0.04)	(-0.04, 0.09)	0.488
		Placebo	204	186 (91.2)	0.09 (0.02)	(0.05, 0.14)			
	Week 52	Tezepelumab	202	184 (91.1)	0.13 (0.03)	(0.08, 0.18)	0.05 (0.04)	(-0.03, 0.12)	0.225
		Placebo	204	181 (88.7)	0.08 (0.03)	(0.03, 0.14)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
25 - < 50 ppb	Week 2	Tezepelumab	146	145 (99.3)	0.17 (0.03)	(0.11, 0.22)	0.16 (0.04)	(0.08, 0.24)	<0.001 *
		Placebo	141	139 (98.6)	0.01 (0.03)	(-0.05, 0.06)			
	Week 4	Tezepelumab	146	146 (100.0)	0.22 (0.03)	(0.16, 0.28)	0.16 (0.04)	(0.08, 0.24)	<0.001 *
		Placebo	141	137 (97.2)	0.06 (0.03)	(0.01, 0.12)			
	Week 8	Tezepelumab	146	144 (98.6)	0.22 (0.03)	(0.17, 0.28)	0.13 (0.04)	(0.05, 0.21)	<0.001 *
		Placebo	141	138 (97.9)	0.09 (0.03)	(0.03, 0.14)			
	Week 12	Tezepelumab	146	142 (97.3)	0.24 (0.03)	(0.19, 0.30)	0.17 (0.04)	(0.09, 0.25)	<0.001 *
		Placebo	141	137 (97.2)	0.07 (0.03)	(0.01, 0.13)			
	Week 16	Tezepelumab	146	145 (99.3)	0.23 (0.03)	(0.17, 0.29)	0.16 (0.04)	(0.08, 0.25)	<0.001 *
		Placebo	141	135 (95.7)	0.07 (0.03)	(0.01, 0.13)			
	Week 24	Tezepelumab	146	138 (94.5)	0.22 (0.03)	(0.16, 0.28)	0.12 (0.05)	(0.03, 0.21)	0.009 *
		Placebo	141	127 (90.1)	0.10 (0.03)	(0.04, 0.17)			
	Week 36	Tezepelumab	146	136 (93.2)	0.23 (0.03)	(0.17, 0.30)	0.14 (0.05)	(0.05, 0.24)	0.003 *
		Placebo	141	129 (91.5)	0.09 (0.03)	(0.03, 0.16)			
	Week 52	Tezepelumab	146	133 (91.1)	0.25 (0.03)	(0.18, 0.31)	0.19 (0.05)	(0.10, 0.29)	<0.001 *
		Placebo	141	117 (83.0)	0.05 (0.03)	(-0.01, 0.12)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 50 ppb	Week 2	Tezepelumab	133	128 (96.2)	0.24 (0.03)	(0.17, 0.30)	0.13 (0.04)	(0.05, 0.22)	0.003 *
		Placebo	141	135 (95.7)	0.10 (0.03)	(0.04, 0.16)			
	Week 4	Tezepelumab	133	133 (100.0)	0.27 (0.04)	(0.20, 0.34)	0.16 (0.05)	(0.07, 0.26)	0.001 *
		Placebo	141	138 (97.9)	0.11 (0.03)	(0.04, 0.18)			
	Week 8	Tezepelumab	133	131 (98.5)	0.37 (0.04)	(0.29, 0.44)	0.26 (0.05)	(0.15, 0.36)	<0.001 *
		Placebo	141	137 (97.2)	0.11 (0.04)	(0.04, 0.18)			
	Week 12	Tezepelumab	133	130 (97.7)	0.34 (0.04)	(0.26, 0.42)	0.21 (0.06)	(0.10, 0.32)	<0.001 *
		Placebo	141	138 (97.9)	0.13 (0.04)	(0.06, 0.21)			
	Week 16	Tezepelumab	133	126 (94.7)	0.39 (0.04)	(0.31, 0.46)	0.23 (0.05)	(0.13, 0.34)	<0.001 *
		Placebo	141	134 (95.0)	0.15 (0.04)	(0.08, 0.23)			
	Week 24	Tezepelumab	133	124 (93.2)	0.34 (0.04)	(0.27, 0.41)	0.24 (0.05)	(0.14, 0.34)	<0.001 *
		Placebo	141	130 (92.2)	0.10 (0.03)	(0.03, 0.17)			
	Week 36	Tezepelumab	133	121 (91.0)	0.36 (0.04)	(0.28, 0.43)	0.24 (0.05)	(0.13, 0.34)	<0.001 *
		Placebo	141	122 (86.5)	0.12 (0.04)	(0.05, 0.20)			
	Week 52	Tezepelumab	133	115 (86.5)	0.34 (0.04)	(0.26, 0.42)	0.21 (0.05)	(0.10, 0.31)	<0.001 *
		Placebo	141	117 (83.0)	0.13 (0.04)	(0.06, 0.21)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline FENO (cat. Q)									0.020 i
Q1: < 16 ppb	Week 2	Tezepelumab	120	115 (95.8)	0.15 (0.03)	(0.09, 0.21)	0.09 (0.04)	(-0.00, 0.18)	0.050
		Placebo	112	101 (90.2)	0.06 (0.03)	(-0.00, 0.13)			
	Week 4	Tezepelumab	120	118 (98.3)	0.15 (0.03)	(0.08, 0.22)	0.07 (0.05)	(-0.03, 0.16)	0.161
		Placebo	112	110 (98.2)	0.08 (0.03)	(0.01, 0.15)			
	Week 8	Tezepelumab	120	116 (96.7)	0.14 (0.03)	(0.08, 0.21)	0.05 (0.05)	(-0.05, 0.14)	0.348
		Placebo	112	109 (97.3)	0.10 (0.03)	(0.03, 0.17)			
	Week 12	Tezepelumab	120	116 (96.7)	0.16 (0.04)	(0.09, 0.23)	0.03 (0.05)	(-0.07, 0.13)	0.606
		Placebo	112	108 (96.4)	0.13 (0.04)	(0.06, 0.20)			
	Week 16	Tezepelumab	120	115 (95.8)	0.15 (0.04)	(0.08, 0.22)	0.06 (0.05)	(-0.04, 0.16)	0.253
		Placebo	112	107 (95.5)	0.09 (0.04)	(0.02, 0.17)			
	Week 24	Tezepelumab	120	115 (95.8)	0.13 (0.04)	(0.05, 0.20)	0.06 (0.05)	(-0.05, 0.16)	0.289
		Placebo	112	105 (93.8)	0.07 (0.04)	(-0.00, 0.14)			
	Week 36	Tezepelumab	120	110 (91.7)	0.14 (0.03)	(0.07, 0.21)	0.04 (0.05)	(-0.06, 0.14)	0.441
		Placebo	112	103 (92.0)	0.10 (0.04)	(0.03, 0.17)			
	Week 52	Tezepelumab	120	109 (90.8)	0.13 (0.04)	(0.06, 0.21)	0.04 (0.05)	(-0.07, 0.14)	0.475
		Placebo	112	98 (87.5)	0.09 (0.04)	(0.02, 0.17)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q2: 16 - < 30 ppb	Week 2	Tezepelumab	118	116 (98.3)	0.09 (0.02)	(0.04, 0.14)	0.06 (0.03)	(-0.01, 0.12)	0.096
		Placebo	132	129 (97.7)	0.03 (0.02)	(-0.01, 0.08)			
	Week 4	Tezepelumab	118	117 (99.2)	0.12 (0.03)	(0.07, 0.18)	0.05 (0.04)	(-0.03, 0.13)	0.192
		Placebo	132	128 (97.0)	0.07 (0.03)	(0.02, 0.13)			
	Week 8	Tezepelumab	118	117 (99.2)	0.14 (0.03)	(0.08, 0.20)	0.04 (0.04)	(-0.04, 0.13)	0.310
		Placebo	132	130 (98.5)	0.09 (0.03)	(0.04, 0.15)			
	Week 12	Tezepelumab	118	113 (95.8)	0.16 (0.03)	(0.10, 0.21)	0.10 (0.04)	(0.03, 0.18)	0.009 *
		Placebo	132	129 (97.7)	0.05 (0.03)	(0.00, 0.11)			
	Week 16	Tezepelumab	118	115 (97.5)	0.15 (0.03)	(0.09, 0.20)	0.08 (0.04)	(-0.00, 0.16)	0.052
		Placebo	132	130 (98.5)	0.06 (0.03)	(0.01, 0.12)			
	Week 24	Tezepelumab	118	110 (93.2)	0.14 (0.03)	(0.08, 0.20)	0.07 (0.04)	(-0.01, 0.15)	0.084
		Placebo	132	127 (96.2)	0.07 (0.03)	(0.01, 0.12)			
	Week 36	Tezepelumab	118	108 (91.5)	0.11 (0.03)	(0.04, 0.17)	0.01 (0.04)	(-0.07, 0.10)	0.744
		Placebo	132	120 (90.9)	0.09 (0.03)	(0.03, 0.15)			
	Week 52	Tezepelumab	118	109 (92.4)	0.14 (0.03)	(0.08, 0.20)	0.09 (0.04)	(0.00, 0.18)	0.040 *
		Placebo	132	117 (88.6)	0.05 (0.03)	(-0.01, 0.11)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q3: 30 - < 56 ppb	Week 2	Tezepelumab	130	129 (99.2)	0.19 (0.03)	(0.13, 0.24)	0.17 (0.04)	(0.08, 0.25)	<0.001 *
		Placebo	117	114 (97.4)	0.02 (0.03)	(-0.04, 0.08)			
	Week 4	Tezepelumab	130	130 (100.0)	0.23 (0.03)	(0.17, 0.29)	0.15 (0.04)	(0.07, 0.23)	<0.001 *
		Placebo	117	113 (96.6)	0.08 (0.03)	(0.02, 0.14)			
	Week 8	Tezepelumab	130	128 (98.5)	0.24 (0.03)	(0.19, 0.30)	0.15 (0.04)	(0.07, 0.23)	<0.001 *
		Placebo	117	114 (97.4)	0.09 (0.03)	(0.03, 0.15)			
	Week 12	Tezepelumab	130	127 (97.7)	0.25 (0.03)	(0.19, 0.31)	0.18 (0.05)	(0.09, 0.27)	<0.001 *
		Placebo	117	113 (96.6)	0.07 (0.03)	(0.00, 0.13)			
	Week 16	Tezepelumab	130	129 (99.2)	0.25 (0.03)	(0.18, 0.31)	0.20 (0.05)	(0.11, 0.29)	<0.001 *
		Placebo	117	110 (94.0)	0.05 (0.03)	(-0.02, 0.11)			
	Week 24	Tezepelumab	130	125 (96.2)	0.24 (0.03)	(0.17, 0.31)	0.15 (0.05)	(0.05, 0.25)	0.004 *
		Placebo	117	103 (88.0)	0.10 (0.04)	(0.02, 0.17)			
	Week 36	Tezepelumab	130	119 (91.5)	0.26 (0.03)	(0.19, 0.32)	0.19 (0.05)	(0.09, 0.28)	<0.001 *
		Placebo	117	108 (92.3)	0.07 (0.04)	(-0.00, 0.14)			
	Week 52	Tezepelumab	130	117 (90.0)	0.26 (0.04)	(0.19, 0.32)	0.19 (0.05)	(0.09, 0.30)	<0.001 *
		Placebo	117	98 (83.8)	0.06 (0.04)	(-0.01, 0.14)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q4: >= 56 ppb	Week 2	Tezepelumab	113	108 (95.6)	0.26 (0.04)	(0.19, 0.33)	0.16 (0.05)	(0.07, 0.26)	0.001 *
		Placebo	125	120 (96.0)	0.09 (0.03)	(0.03, 0.16)			
	Week 4	Tezepelumab	113	113 (100.0)	0.28 (0.04)	(0.21, 0.36)	0.18 (0.05)	(0.07, 0.29)	0.001 *
		Placebo	125	123 (98.4)	0.11 (0.04)	(0.03, 0.18)			
	Week 8	Tezepelumab	113	111 (98.2)	0.40 (0.04)	(0.31, 0.48)	0.29 (0.06)	(0.17, 0.41)	<0.001 *
		Placebo	125	121 (96.8)	0.10 (0.04)	(0.02, 0.18)			
	Week 12	Tezepelumab	113	111 (98.2)	0.37 (0.04)	(0.28, 0.46)	0.23 (0.06)	(0.11, 0.35)	<0.001 *
		Placebo	125	122 (97.6)	0.14 (0.04)	(0.06, 0.22)			
	Week 16	Tezepelumab	113	106 (93.8)	0.41 (0.04)	(0.33, 0.50)	0.24 (0.06)	(0.12, 0.35)	<0.001 *
		Placebo	125	119 (95.2)	0.18 (0.04)	(0.10, 0.26)			
	Week 24	Tezepelumab	113	104 (92.0)	0.36 (0.04)	(0.28, 0.44)	0.26 (0.06)	(0.16, 0.37)	<0.001 *
		Placebo	125	115 (92.0)	0.09 (0.04)	(0.02, 0.17)			
	Week 36	Tezepelumab	113	103 (91.2)	0.39 (0.04)	(0.30, 0.47)	0.24 (0.06)	(0.12, 0.36)	<0.001 *
		Placebo	125	106 (84.8)	0.14 (0.04)	(0.06, 0.22)			
	Week 52	Tezepelumab	113	97 (85.8)	0.37 (0.04)	(0.29, 0.46)	0.22 (0.06)	(0.10, 0.34)	<0.001 *
		Placebo	125	102 (81.6)	0.15 (0.04)	(0.07, 0.23)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Total serum IgE (cat. N)									0.295
Q1: < 53.1 IU/ml	Week 2	Tezepelumab	125	122 (97.6)	0.11 (0.03)	(0.06, 0.16)	0.09 (0.04)	(0.02, 0.16)	0.017 *
		Placebo	131	123 (93.9)	0.02 (0.03)	(-0.02, 0.07)			
	Week 4	Tezepelumab	125	125 (100.0)	0.14 (0.03)	(0.09, 0.20)	0.06 (0.04)	(-0.02, 0.14)	0.134
		Placebo	131	126 (96.2)	0.08 (0.03)	(0.03, 0.14)			
	Week 8	Tezepelumab	125	122 (97.6)	0.17 (0.03)	(0.11, 0.22)	0.09 (0.04)	(0.01, 0.17)	0.023 *
		Placebo	131	128 (97.7)	0.07 (0.03)	(0.02, 0.13)			
	Week 12	Tezepelumab	125	122 (97.6)	0.16 (0.03)	(0.10, 0.21)	0.08 (0.04)	(-0.00, 0.16)	0.063
		Placebo	131	126 (96.2)	0.08 (0.03)	(0.02, 0.14)			
	Week 16	Tezepelumab	125	123 (98.4)	0.16 (0.03)	(0.11, 0.22)	0.09 (0.04)	(0.01, 0.17)	0.022 *
		Placebo	131	125 (95.4)	0.07 (0.03)	(0.02, 0.13)			
	Week 24	Tezepelumab	125	121 (96.8)	0.14 (0.03)	(0.09, 0.19)	0.11 (0.04)	(0.03, 0.18)	0.004 *
		Placebo	131	118 (90.1)	0.03 (0.03)	(-0.02, 0.08)			
	Week 36	Tezepelumab	125	116 (92.8)	0.13 (0.03)	(0.07, 0.18)	0.05 (0.04)	(-0.03, 0.12)	0.245
		Placebo	131	111 (84.7)	0.08 (0.03)	(0.03, 0.14)			
	Week 52	Tezepelumab	125	117 (93.6)	0.13 (0.03)	(0.07, 0.19)	0.09 (0.04)	(0.01, 0.18)	0.033 *
		Placebo	131	110 (84.0)	0.04 (0.03)	(-0.02, 0.10)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q2: 53.1 - < 195.6 IU/ml	Week 2	Tezepelumab	133	131 (98.5)	0.17 (0.03)	(0.12, 0.22)	0.13 (0.04)	(0.06, 0.21)	<0.001 *
		Placebo	125	120 (96.0)	0.03 (0.03)	(-0.02, 0.09)			
	Week 4	Tezepelumab	133	130 (97.7)	0.22 (0.03)	(0.17, 0.28)	0.17 (0.04)	(0.08, 0.25)	<0.001 *
		Placebo	125	124 (99.2)	0.06 (0.03)	(-0.00, 0.12)			
	Week 8	Tezepelumab	133	129 (97.0)	0.23 (0.03)	(0.17, 0.28)	0.15 (0.04)	(0.07, 0.24)	<0.001 *
		Placebo	125	123 (98.4)	0.07 (0.03)	(0.01, 0.13)			
	Week 12	Tezepelumab	133	129 (97.0)	0.25 (0.03)	(0.19, 0.31)	0.18 (0.05)	(0.09, 0.27)	<0.001 *
		Placebo	125	123 (98.4)	0.07 (0.03)	(0.00, 0.13)			
	Week 16	Tezepelumab	133	127 (95.5)	0.26 (0.03)	(0.19, 0.32)	0.17 (0.05)	(0.07, 0.26)	<0.001 *
		Placebo	125	119 (95.2)	0.09 (0.03)	(0.02, 0.16)			
	Week 24	Tezepelumab	133	126 (94.7)	0.25 (0.03)	(0.19, 0.32)	0.18 (0.05)	(0.09, 0.27)	<0.001 *
		Placebo	125	117 (93.6)	0.08 (0.03)	(0.01, 0.14)			
	Week 36	Tezepelumab	133	124 (93.2)	0.25 (0.03)	(0.19, 0.32)	0.16 (0.05)	(0.06, 0.25)	0.001 *
		Placebo	125	116 (92.8)	0.10 (0.03)	(0.03, 0.17)			
	Week 52	Tezepelumab	133	115 (86.5)	0.25 (0.03)	(0.19, 0.32)	0.15 (0.05)	(0.06, 0.24)	0.002 *
		Placebo	125	108 (86.4)	0.10 (0.03)	(0.03, 0.17)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q3: 195.6 - < 572.4 IU/ml	Week 2	Tezepelumab	125	122 (97.6)	0.20 (0.03)	(0.13, 0.26)	0.20 (0.05)	(0.10, 0.29)	<0.001 *
		Placebo	116	110 (94.8)	0.00 (0.03)	(-0.07, 0.07)			
	Week 4	Tezepelumab	125	125 (100.0)	0.18 (0.03)	(0.11, 0.24)	0.10 (0.05)	(0.01, 0.19)	0.028 *
		Placebo	116	111 (95.7)	0.07 (0.03)	(0.01, 0.14)			
	Week 8	Tezepelumab	125	124 (99.2)	0.24 (0.04)	(0.17, 0.31)	0.14 (0.05)	(0.04, 0.24)	0.006 *
		Placebo	116	113 (97.4)	0.10 (0.04)	(0.02, 0.17)			
	Week 12	Tezepelumab	125	120 (96.0)	0.26 (0.04)	(0.18, 0.33)	0.15 (0.06)	(0.04, 0.26)	0.008 *
		Placebo	116	112 (96.6)	0.10 (0.04)	(0.03, 0.18)			
	Week 16	Tezepelumab	125	121 (96.8)	0.25 (0.04)	(0.18, 0.33)	0.18 (0.05)	(0.07, 0.29)	0.001 *
		Placebo	116	114 (98.3)	0.07 (0.04)	(-0.00, 0.15)			
	Week 24	Tezepelumab	125	114 (91.2)	0.22 (0.04)	(0.14, 0.29)	0.12 (0.06)	(0.01, 0.23)	0.036 *
		Placebo	116	107 (92.2)	0.10 (0.04)	(0.02, 0.18)			
	Week 36	Tezepelumab	125	109 (87.2)	0.23 (0.04)	(0.15, 0.30)	0.13 (0.06)	(0.02, 0.24)	0.019 *
		Placebo	116	103 (88.8)	0.10 (0.04)	(0.02, 0.18)			
	Week 52	Tezepelumab	125	111 (88.8)	0.25 (0.04)	(0.17, 0.33)	0.12 (0.06)	(0.00, 0.24)	0.047 *
		Placebo	116	99 (85.3)	0.13 (0.04)	(0.05, 0.22)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q4: >= 572.4 IU/ml	Week 2	Tezepelumab	104	99 (95.2)	0.19 (0.04)	(0.12, 0.26)	0.03 (0.05)	(-0.06, 0.13)	0.514
		Placebo	118	115 (97.5)	0.16 (0.03)	(0.10, 0.22)			
	Week 4	Tezepelumab	104	103 (99.0)	0.24 (0.04)	(0.16, 0.32)	0.10 (0.05)	(-0.00, 0.21)	0.059
		Placebo	118	117 (99.2)	0.14 (0.04)	(0.07, 0.21)			
	Week 8	Tezepelumab	104	103 (99.0)	0.27 (0.04)	(0.19, 0.36)	0.12 (0.06)	(-0.00, 0.24)	0.052
		Placebo	118	114 (96.6)	0.16 (0.04)	(0.08, 0.24)			
	Week 12	Tezepelumab	104	102 (98.1)	0.26 (0.04)	(0.18, 0.34)	0.11 (0.05)	(0.00, 0.22)	0.046 *
		Placebo	118	114 (96.6)	0.15 (0.04)	(0.07, 0.22)			
	Week 16	Tezepelumab	104	100 (96.2)	0.27 (0.04)	(0.19, 0.35)	0.11 (0.06)	(-0.00, 0.22)	0.054
		Placebo	118	111 (94.1)	0.16 (0.04)	(0.08, 0.24)			
	Week 24	Tezepelumab	104	99 (95.2)	0.24 (0.04)	(0.16, 0.33)	0.12 (0.06)	(0.00, 0.23)	0.049 *
		Placebo	118	111 (94.1)	0.13 (0.04)	(0.05, 0.21)			
	Week 36	Tezepelumab	104	97 (93.3)	0.27 (0.04)	(0.19, 0.36)	0.13 (0.06)	(0.01, 0.25)	0.029 *
		Placebo	118	110 (93.2)	0.14 (0.04)	(0.06, 0.22)			
	Week 52	Tezepelumab	104	94 (90.4)	0.25 (0.04)	(0.17, 0.34)	0.15 (0.06)	(0.04, 0.27)	0.009 *
		Placebo	118	101 (85.6)	0.10 (0.04)	(0.02, 0.18)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Nasal polyps last 2 years									0.945
Yes	Week 2	Tezepelumab	41	41 (100.0)	0.20 (0.05)	(0.09, 0.30)	0.13 (0.08)	(-0.02, 0.28)	0.098
		Placebo	39	39 (100.0)	0.07 (0.05)	(-0.04, 0.18)			
	Week 4	Tezepelumab	41	41 (100.0)	0.24 (0.06)	(0.11, 0.37)	0.10 (0.09)	(-0.09, 0.28)	0.300
		Placebo	39	38 (97.4)	0.15 (0.07)	(0.01, 0.28)			
	Week 8	Tezepelumab	41	41 (100.0)	0.30 (0.07)	(0.16, 0.45)	0.18 (0.10)	(-0.03, 0.39)	0.093
		Placebo	39	39 (100.0)	0.12 (0.07)	(-0.03, 0.27)			
	Week 12	Tezepelumab	41	38 (92.7)	0.29 (0.07)	(0.14, 0.44)	0.14 (0.10)	(-0.07, 0.35)	0.197
		Placebo	39	39 (100.0)	0.15 (0.07)	(0.01, 0.30)			
	Week 16	Tezepelumab	41	39 (95.1)	0.30 (0.07)	(0.15, 0.45)	0.13 (0.11)	(-0.09, 0.34)	0.244
		Placebo	39	38 (97.4)	0.17 (0.08)	(0.02, 0.32)			
	Week 24	Tezepelumab	41	38 (92.7)	0.21 (0.07)	(0.07, 0.35)	0.04 (0.10)	(-0.17, 0.24)	0.706
		Placebo	39	37 (94.9)	0.17 (0.07)	(0.02, 0.32)			
	Week 36	Tezepelumab	41	38 (92.7)	0.29 (0.06)	(0.16, 0.42)	0.07 (0.09)	(-0.11, 0.26)	0.441
		Placebo	39	37 (94.9)	0.22 (0.07)	(0.09, 0.35)			
	Week 52	Tezepelumab	41	37 (90.2)	0.29 (0.08)	(0.14, 0.45)	0.15 (0.11)	(-0.07, 0.37)	0.178
		Placebo	39	36 (92.3)	0.14 (0.08)	(-0.01, 0.30)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_AOSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 2	Tezepelumab	446	433 (97.1)	0.16 (0.02)	(0.13, 0.19)	0.11 (0.02)	(0.07, 0.15)	<0.001 *
		Placebo	451	429 (95.1)	0.05 (0.02)	(0.02, 0.08)			
	Week 4	Tezepelumab	446	442 (99.1)	0.19 (0.02)	(0.16, 0.22)	0.11 (0.02)	(0.06, 0.16)	<0.001 *
		Placebo	451	440 (97.6)	0.08 (0.02)	(0.05, 0.11)			
	Week 8	Tezepelumab	446	437 (98.0)	0.22 (0.02)	(0.18, 0.25)	0.12 (0.02)	(0.07, 0.17)	<0.001 *
		Placebo	451	439 (97.3)	0.10 (0.02)	(0.06, 0.13)			
	Week 12	Tezepelumab	446	435 (97.5)	0.22 (0.02)	(0.19, 0.26)	0.13 (0.03)	(0.08, 0.18)	<0.001 *
		Placebo	451	436 (96.7)	0.09 (0.02)	(0.06, 0.13)			
	Week 16	Tezepelumab	446	432 (96.9)	0.23 (0.02)	(0.19, 0.26)	0.14 (0.03)	(0.09, 0.19)	<0.001 *
		Placebo	451	431 (95.6)	0.09 (0.02)	(0.05, 0.12)			
	Week 24	Tezepelumab	446	422 (94.6)	0.21 (0.02)	(0.18, 0.25)	0.14 (0.03)	(0.09, 0.19)	<0.001 *
		Placebo	451	416 (92.2)	0.07 (0.02)	(0.04, 0.11)			
	Week 36	Tezepelumab	446	408 (91.5)	0.21 (0.02)	(0.18, 0.25)	0.12 (0.03)	(0.07, 0.17)	<0.001 *
		Placebo	451	403 (89.4)	0.09 (0.02)	(0.06, 0.13)			
	Week 52	Tezepelumab	446	400 (89.7)	0.22 (0.02)	(0.18, 0.25)	0.13 (0.03)	(0.08, 0.18)	<0.001 *
		Placebo	451	382 (84.7)	0.09 (0.02)	(0.05, 0.12)			

Note: DITT - adult = Dossier Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILMH0: Course of FEV1 Pre-BD
DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
FEV1 Pre-BD	Baseline	Tezepelumab	395	395 (100.0)	1.77 (0.69)	0.4	1.27	1.64	2.14	4.1	
		Placebo	391	391 (100.0)	1.84 (0.71)	0.4	1.34	1.71	2.22	4.9	
	Week 2	Tezepelumab	395	384 (97.2)	1.95 (0.72)	0.6	1.40	1.83	2.43	4.3	
		Placebo	391	373 (95.4)	1.91 (0.72)	0.4	1.38	1.80	2.33	4.7	
	Week 4	Tezepelumab	395	391 (99.0)	1.97 (0.73)	0.6	1.42	1.86	2.48	4.3	
		Placebo	391	382 (97.7)	1.90 (0.69)	0.4	1.43	1.82	2.28	4.8	
	Week 8	Tezepelumab	395	388 (98.2)	1.98 (0.74)	0.6	1.41	1.87	2.44	4.7	
		Placebo	391	380 (97.2)	1.93 (0.74)	0.4	1.40	1.83	2.35	4.9	
	Week 12	Tezepelumab	395	382 (96.7)	1.99 (0.74)	0.6	1.49	1.89	2.44	4.7	
		Placebo	391	377 (96.4)	1.94 (0.74)	0.5	1.40	1.81	2.38	5.0	
	Week 16	Tezepelumab	395	380 (96.2)	2.02 (0.75)	0.6	1.48	1.90	2.48	4.9	
		Placebo	391	370 (94.6)	1.93 (0.74)	0.5	1.36	1.80	2.32	5.2	
	Week 24	Tezepelumab	395	369 (93.4)	1.98 (0.72)	0.6	1.49	1.84	2.42	4.4	
		Placebo	391	357 (91.3)	1.92 (0.74)	0.6	1.41	1.80	2.24	5.1	
	Week 36	Tezepelumab	395	356 (90.1)	2.00 (0.75)	0.5	1.43	1.90	2.45	4.5	
		Placebo	391	346 (88.5)	1.96 (0.76)	0.6	1.42	1.83	2.33	5.3	
	Week 52	Tezepelumab	395	349 (88.4)	2.00 (0.76)	0.6	1.48	1.87	2.45	4.3	
		Placebo	391	326 (83.4)	1.92 (0.78)	0.6	1.34	1.77	2.32	5.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILMH0: Course of FEV1 Pre-BD
DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in FEV1 Pre-BD	Week 2	Tezepelumab	395	384 (97.2)	0.18 (0.33)	-0.7	-0.00	0.13	0.32	1.5	0.37 [0.23, 0.51]
		Placebo	391	373 (95.4)	0.05 (0.37)	-1.8	-0.11	0.01	0.18	1.7	
	Week 4	Tezepelumab	395	391 (99.0)	0.21 (0.36)	-0.9	-0.01	0.14	0.35	1.8	0.33 [0.19, 0.47]
		Placebo	391	382 (97.7)	0.08 (0.39)	-1.8	-0.11	0.04	0.25	1.7	
	Week 8	Tezepelumab	395	388 (98.2)	0.23 (0.42)	-1.1	-0.04	0.15	0.44	1.8	0.37 [0.23, 0.51]
		Placebo	391	380 (97.2)	0.09 (0.37)	-1.7	-0.12	0.05	0.25	2.0	
	Week 12	Tezepelumab	395	382 (96.7)	0.24 (0.42)	-1.5	-0.03	0.17	0.43	2.0	0.34 [0.20, 0.49]
		Placebo	391	377 (96.4)	0.09 (0.40)	-1.5	-0.10	0.05	0.26	1.7	
	Week 16	Tezepelumab	395	380 (96.2)	0.25 (0.41)	-0.8	0.00	0.17	0.42	2.0	0.43 [0.29, 0.58]
		Placebo	391	370 (94.6)	0.08 (0.39)	-1.6	-0.11	0.03	0.26	1.8	
	Week 24	Tezepelumab	395	369 (93.4)	0.23 (0.41)	-1.0	-0.05	0.18	0.43	1.8	0.40 [0.25, 0.54]
		Placebo	391	357 (91.3)	0.07 (0.40)	-1.4	-0.13	0.04	0.26	1.7	
	Week 36	Tezepelumab	395	356 (90.1)	0.24 (0.42)	-1.0	-0.04	0.17	0.46	1.7	0.34 [0.19, 0.49]
		Placebo	391	346 (88.5)	0.10 (0.42)	-1.7	-0.16	0.06	0.29	2.2	
	Week 52	Tezepelumab	395	349 (88.4)	0.25 (0.42)	-1.0	-0.02	0.18	0.49	1.7	0.44 [0.28, 0.59]
		Placebo	391	326 (83.4)	0.07 (0.37)	-1.4	-0.14	0.06	0.23	1.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILMC0: Change from baseline in FEV1 Pre-BD - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Tezepelumab	395	384 (97.2)	0.18 (0.02)	(0.15, 0.21)	0.12 (0.02)	(0.08, 0.17)	<0.001 *
	Placebo	391	373 (95.4)	0.05 (0.02)	(0.02, 0.09)			
Week 4	Tezepelumab	395	391 (99.0)	0.20 (0.02)	(0.17, 0.24)	0.12 (0.03)	(0.07, 0.17)	<0.001 *
	Placebo	391	382 (97.7)	0.08 (0.02)	(0.05, 0.12)			
Week 8	Tezepelumab	395	388 (98.2)	0.23 (0.02)	(0.19, 0.27)	0.14 (0.03)	(0.08, 0.19)	<0.001 *
	Placebo	391	380 (97.2)	0.09 (0.02)	(0.05, 0.13)			
Week 12	Tezepelumab	395	382 (96.7)	0.23 (0.02)	(0.19, 0.27)	0.13 (0.03)	(0.08, 0.19)	<0.001 *
	Placebo	391	377 (96.4)	0.10 (0.02)	(0.06, 0.14)			
Week 16	Tezepelumab	395	380 (96.2)	0.25 (0.02)	(0.21, 0.29)	0.17 (0.03)	(0.11, 0.22)	<0.001 *
	Placebo	391	370 (94.6)	0.08 (0.02)	(0.04, 0.12)			
Week 24	Tezepelumab	395	369 (93.4)	0.23 (0.02)	(0.19, 0.27)	0.14 (0.03)	(0.09, 0.20)	<0.001 *
	Placebo	391	357 (91.3)	0.08 (0.02)	(0.04, 0.12)			
Week 36	Tezepelumab	395	356 (90.1)	0.24 (0.02)	(0.20, 0.28)	0.14 (0.03)	(0.08, 0.20)	<0.001 *
	Placebo	391	346 (88.5)	0.10 (0.02)	(0.06, 0.14)			
Week 52	Tezepelumab	395	349 (88.4)	0.25 (0.02)	(0.21, 0.29)	0.17 (0.03)	(0.11, 0.23)	<0.001 *
	Placebo	391	326 (83.4)	0.08 (0.02)	(0.04, 0.12)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Figure NF2FAC_ILMG0: Course of FEV1 Pre-BD
DITTL



Note: DITTL = Dossier Label Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source table: NT2FAC_ILMH0
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Absolute values	Baseline	Tezepelumab	143	143 (100.0)	2.12 (0.76)	0.6	1.55	2.10	2.72	4.1	
			Placebo	147	147 (100.0)	2.15 (0.80)	0.8	1.54	2.10	2.62	4.9	
		Week 2	Tezepelumab	143	140 (97.9)	2.33 (0.79)	0.7	1.71	2.36	2.88	4.3	
			Placebo	147	143 (97.3)	2.21 (0.77)	0.8	1.61	2.21	2.72	4.7	
		Week 4	Tezepelumab	143	141 (98.6)	2.37 (0.79)	0.7	1.84	2.41	2.93	4.3	
			Placebo	147	143 (97.3)	2.18 (0.74)	0.9	1.65	2.09	2.68	4.8	
		Week 8	Tezepelumab	143	137 (95.8)	2.36 (0.83)	0.7	1.68	2.38	2.87	4.7	
			Placebo	147	147 (100.0)	2.24 (0.79)	0.7	1.70	2.13	2.69	4.9	
		Week 12	Tezepelumab	143	136 (95.1)	2.36 (0.85)	0.7	1.70	2.34	2.92	4.7	
			Placebo	147	145 (98.6)	2.27 (0.79)	0.9	1.65	2.22	2.80	5.0	
		Week 16	Tezepelumab	143	136 (95.1)	2.42 (0.86)	0.6	1.75	2.40	2.98	4.9	
			Placebo	147	144 (98.0)	2.23 (0.83)	0.7	1.60	2.13	2.74	5.2	
		Week 24	Tezepelumab	143	127 (88.8)	2.37 (0.81)	0.6	1.73	2.39	2.80	4.4	
			Placebo	147	133 (90.5)	2.26 (0.82)	0.9	1.67	2.14	2.76	5.1	
		Week 36	Tezepelumab	143	127 (88.8)	2.39 (0.87)	0.5	1.75	2.34	3.05	4.5	
			Placebo	147	132 (89.8)	2.28 (0.84)	0.9	1.64	2.16	2.86	5.3	
		Week 52	Tezepelumab	143	125 (87.4)	2.41 (0.84)	0.8	1.77	2.39	3.08	4.3	
			Placebo	147	122 (83.0)	2.26 (0.89)	0.7	1.53	2.15	2.78	5.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Change from baseline	Week 2	Tezepelumab	143	140 (97.9)	0.21 (0.40)	-0.7	-0.02	0.16	0.36	1.5	0.45 [0.21, 0.68]
			Placebo	147	143 (97.3)	0.04 (0.40)	-1.3	-0.17	-0.02	0.19	1.7	
		Week 4	Tezepelumab	143	141 (98.6)	0.26 (0.44)	-0.7	-0.04	0.17	0.43	1.8	0.46 [0.22, 0.70]
			Placebo	147	143 (97.3)	0.05 (0.48)	-1.8	-0.20	0.00	0.21	1.7	
		Week 8	Tezepelumab	143	137 (95.8)	0.28 (0.50)	-1.1	-0.05	0.15	0.52	1.8	0.41 [0.17, 0.64]
			Placebo	147	147 (100.0)	0.08 (0.44)	-1.7	-0.16	0.05	0.28	2.0	
		Week 12	Tezepelumab	143	136 (95.1)	0.27 (0.50)	-0.8	-0.09	0.17	0.51	2.0	0.33 [0.10, 0.57]
			Placebo	147	145 (98.6)	0.11 (0.44)	-1.4	-0.11	0.04	0.29	1.6	
		Week 16	Tezepelumab	143	136 (95.1)	0.31 (0.50)	-0.8	0.00	0.16	0.51	2.0	0.51 [0.27, 0.75]
			Placebo	147	144 (98.0)	0.07 (0.44)	-1.6	-0.15	0.01	0.26	1.6	
		Week 24	Tezepelumab	143	127 (88.8)	0.29 (0.46)	-0.5	-0.06	0.21	0.47	1.8	0.48 [0.23, 0.72]
			Placebo	147	133 (90.5)	0.07 (0.45)	-1.4	-0.21	0.07	0.31	1.6	
		Week 36	Tezepelumab	143	127 (88.8)	0.28 (0.49)	-0.8	-0.06	0.19	0.48	1.7	0.40 [0.15, 0.64]
			Placebo	147	132 (89.8)	0.08 (0.49)	-1.2	-0.20	0.05	0.34	2.2	
		Week 52	Tezepelumab	143	125 (87.4)	0.31 (0.49)	-1.0	-0.02	0.23	0.56	1.7	0.52 [0.26, 0.77]
			Placebo	147	122 (83.0)	0.06 (0.45)	-1.4	-0.18	0.04	0.23	1.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Absolute values	Baseline	Tezepelumab	252	252 (100.0)	1.57 (0.56)	0.4	1.20	1.48	1.90	3.4	
			Placebo	244	244 (100.0)	1.64 (0.57)	0.4	1.26	1.59	2.01	3.6	
		Week 2	Tezepelumab	252	244 (96.8)	1.74 (0.57)	0.6	1.31	1.64	2.13	3.4	
			Placebo	244	230 (94.3)	1.71 (0.62)	0.4	1.30	1.63	2.07	4.0	
		Week 4	Tezepelumab	252	250 (99.2)	1.74 (0.58)	0.6	1.28	1.66	2.12	3.3	
			Placebo	244	239 (98.0)	1.73 (0.61)	0.4	1.31	1.68	2.09	3.7	
		Week 8	Tezepelumab	252	251 (99.6)	1.78 (0.59)	0.6	1.31	1.71	2.19	3.4	
			Placebo	244	233 (95.5)	1.74 (0.63)	0.4	1.31	1.62	2.07	4.3	
		Week 12	Tezepelumab	252	246 (97.6)	1.79 (0.57)	0.6	1.40	1.70	2.12	3.5	
			Placebo	244	232 (95.1)	1.73 (0.63)	0.5	1.31	1.66	2.09	4.3	
		Week 16	Tezepelumab	252	244 (96.8)	1.79 (0.57)	0.6	1.37	1.70	2.16	3.5	
			Placebo	244	226 (92.6)	1.73 (0.61)	0.5	1.31	1.68	2.09	4.4	
		Week 24	Tezepelumab	252	242 (96.0)	1.78 (0.57)	0.6	1.34	1.73	2.13	3.4	
			Placebo	244	224 (91.8)	1.72 (0.60)	0.6	1.31	1.68	2.09	4.3	
		Week 36	Tezepelumab	252	229 (90.9)	1.78 (0.58)	0.6	1.32	1.71	2.17	3.3	
			Placebo	244	214 (87.7)	1.76 (0.64)	0.6	1.34	1.68	2.21	4.3	
		Week 52	Tezepelumab	252	224 (88.9)	1.78 (0.60)	0.6	1.37	1.72	2.17	3.5	
			Placebo	244	204 (83.6)	1.73 (0.63)	0.6	1.27	1.64	2.14	3.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Change from baseline	Week 2	Tezepelumab	252	244 (96.8)	0.17 (0.29)	-0.6	0.00	0.12	0.29	1.3	0.32 [0.14, 0.50]
			Placebo	244	230 (94.3)	0.06 (0.34)	-1.8	-0.07	0.03	0.18	1.2	
		Week 4	Tezepelumab	252	250 (99.2)	0.17 (0.31)	-0.9	-0.01	0.13	0.31	1.2	0.24 [0.06, 0.42]
			Placebo	244	239 (98.0)	0.10 (0.33)	-1.0	-0.08	0.06	0.25	1.2	
		Week 8	Tezepelumab	252	251 (99.6)	0.21 (0.37)	-0.8	-0.02	0.16	0.41	1.4	0.35 [0.17, 0.53]
			Placebo	244	233 (95.5)	0.09 (0.32)	-0.8	-0.10	0.05	0.24	1.6	
		Week 12	Tezepelumab	252	246 (97.6)	0.22 (0.36)	-1.5	0.00	0.17	0.39	1.4	0.36 [0.18, 0.54]
			Placebo	244	232 (95.1)	0.09 (0.38)	-1.5	-0.09	0.05	0.26	1.7	
		Week 16	Tezepelumab	252	244 (96.8)	0.22 (0.35)	-0.6	0.00	0.17	0.38	1.4	0.39 [0.20, 0.57]
			Placebo	244	226 (92.6)	0.09 (0.35)	-1.0	-0.07	0.04	0.26	1.8	
		Week 24	Tezepelumab	252	242 (96.0)	0.20 (0.38)	-1.0	-0.04	0.17	0.40	1.6	0.35 [0.16, 0.53]
			Placebo	244	224 (91.8)	0.08 (0.36)	-1.1	-0.11	0.03	0.22	1.7	
		Week 36	Tezepelumab	252	229 (90.9)	0.22 (0.37)	-1.0	-0.02	0.16	0.46	1.4	0.30 [0.11, 0.49]
			Placebo	244	214 (87.7)	0.11 (0.37)	-1.7	-0.12	0.06	0.27	1.7	
		Week 52	Tezepelumab	252	224 (88.9)	0.21 (0.37)	-1.0	-0.01	0.16	0.46	1.3	0.39 [0.20, 0.58]
			Placebo	244	204 (83.6)	0.08 (0.32)	-0.8	-0.11	0.06	0.24	1.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Absolute values	Baseline	Tezepelumab	319	319 (100.0)	1.85 (0.71)	0.4	1.33	1.74	2.27	4.1	
			Placebo	338	338 (100.0)	1.90 (0.72)	0.4	1.37	1.77	2.26	4.9	
		Week 2	Tezepelumab	319	310 (97.2)	2.05 (0.72)	0.6	1.51	1.98	2.53	4.3	
			Placebo	338	323 (95.6)	1.97 (0.73)	0.4	1.42	1.90	2.43	4.7	
		Week 4	Tezepelumab	319	317 (99.4)	2.07 (0.74)	0.7	1.54	2.00	2.56	4.3	
			Placebo	338	332 (98.2)	1.96 (0.70)	0.4	1.45	1.88	2.35	4.8	
		Week 8	Tezepelumab	319	314 (98.4)	2.09 (0.75)	0.6	1.52	2.04	2.53	4.7	
			Placebo	338	330 (97.6)	1.99 (0.75)	0.4	1.46	1.94	2.39	4.9	
		Week 12	Tezepelumab	319	309 (96.9)	2.09 (0.76)	0.6	1.58	2.00	2.53	4.7	
			Placebo	338	327 (96.7)	2.00 (0.75)	0.5	1.47	1.91	2.44	5.0	
		Week 16	Tezepelumab	319	307 (96.2)	2.12 (0.76)	0.6	1.57	2.04	2.55	4.9	
			Placebo	338	321 (95.0)	1.99 (0.75)	0.5	1.45	1.88	2.41	5.2	
		Week 24	Tezepelumab	319	299 (93.7)	2.08 (0.73)	0.6	1.61	2.00	2.53	4.4	
			Placebo	338	309 (91.4)	1.99 (0.75)	0.6	1.46	1.89	2.32	5.1	
		Week 36	Tezepelumab	319	288 (90.3)	2.10 (0.77)	0.5	1.51	2.06	2.53	4.5	
			Placebo	338	298 (88.2)	2.03 (0.78)	0.6	1.49	1.92	2.43	5.3	
		Week 52	Tezepelumab	319	282 (88.4)	2.10 (0.77)	0.6	1.58	2.04	2.57	4.3	
			Placebo	338	281 (83.1)	2.00 (0.79)	0.6	1.40	1.84	2.42	5.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Change from baseline	Week 2	Tezepelumab	319	310 (97.2)	0.21 (0.36)	-0.7	0.00	0.15	0.37	1.5	0.41 [0.25, 0.57]
			Placebo	338	323 (95.6)	0.05 (0.38)	-1.8	-0.12	0.01	0.19	1.7	
		Week 4	Tezepelumab	319	317 (99.4)	0.23 (0.39)	-0.9	-0.01	0.15	0.38	1.8	0.38 [0.22, 0.54]
			Placebo	338	332 (98.2)	0.08 (0.41)	-1.8	-0.12	0.04	0.25	1.7	
		Week 8	Tezepelumab	319	314 (98.4)	0.25 (0.44)	-1.1	-0.04	0.17	0.50	1.8	0.41 [0.25, 0.56]
			Placebo	338	330 (97.6)	0.09 (0.38)	-1.7	-0.13	0.05	0.26	2.0	
		Week 12	Tezepelumab	319	309 (96.9)	0.25 (0.44)	-1.5	-0.03	0.17	0.45	2.0	0.35 [0.19, 0.51]
			Placebo	338	327 (96.7)	0.10 (0.42)	-1.5	-0.10	0.05	0.28	1.7	
		Week 16	Tezepelumab	319	307 (96.2)	0.28 (0.43)	-0.8	0.00	0.20	0.47	2.0	0.46 [0.30, 0.62]
			Placebo	338	321 (95.0)	0.08 (0.40)	-1.6	-0.12	0.02	0.26	1.8	
		Week 24	Tezepelumab	319	299 (93.7)	0.25 (0.44)	-1.0	-0.05	0.21	0.48	1.8	0.42 [0.26, 0.58]
			Placebo	338	309 (91.4)	0.08 (0.41)	-1.4	-0.15	0.03	0.27	1.7	
		Week 36	Tezepelumab	319	288 (90.3)	0.26 (0.44)	-1.0	-0.04	0.21	0.53	1.7	0.35 [0.19, 0.51]
			Placebo	338	298 (88.2)	0.11 (0.44)	-1.7	-0.16	0.06	0.30	2.2	
		Week 52	Tezepelumab	319	282 (88.4)	0.27 (0.45)	-1.0	-0.01	0.23	0.53	1.7	0.46 [0.29, 0.63]
			Placebo	338	281 (83.1)	0.08 (0.38)	-1.4	-0.14	0.06	0.25	1.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Absolute values	Baseline	Tezepelumab	76	76 (100.0)	1.45 (0.50)	0.7	1.16	1.40	1.58	3.2	
			Placebo	53	53 (100.0)	1.45 (0.48)	0.7	1.08	1.38	1.70	2.6	
		Week 2	Tezepelumab	76	74 (97.4)	1.52 (0.48)	0.6	1.23	1.44	1.70	3.1	
			Placebo	53	50 (94.3)	1.52 (0.50)	0.7	1.11	1.45	1.68	3.1	
		Week 4	Tezepelumab	76	74 (97.4)	1.54 (0.49)	0.6	1.20	1.49	1.76	3.1	
			Placebo	53	50 (94.3)	1.53 (0.50)	0.7	1.18	1.46	1.79	3.1	
		Week 8	Tezepelumab	76	74 (97.4)	1.55 (0.47)	0.6	1.23	1.50	1.82	2.9	
			Placebo	53	50 (94.3)	1.53 (0.50)	0.7	1.23	1.53	1.76	3.2	
		Week 12	Tezepelumab	76	73 (96.1)	1.57 (0.45)	0.6	1.24	1.52	1.80	2.7	
			Placebo	53	50 (94.3)	1.49 (0.49)	0.7	1.18	1.48	1.69	3.1	
		Week 16	Tezepelumab	76	73 (96.1)	1.59 (0.51)	0.6	1.26	1.52	1.84	3.4	
			Placebo	53	49 (92.5)	1.50 (0.46)	0.8	1.19	1.44	1.68	3.0	
		Week 24	Tezepelumab	76	70 (92.1)	1.54 (0.48)	0.6	1.19	1.53	1.78	2.8	
			Placebo	53	48 (90.6)	1.49 (0.46)	0.6	1.18	1.45	1.74	3.0	
		Week 36	Tezepelumab	76	68 (89.5)	1.57 (0.52)	0.6	1.16	1.52	1.86	3.2	
			Placebo	53	48 (90.6)	1.50 (0.47)	0.7	1.17	1.41	1.77	3.1	
		Week 52	Tezepelumab	76	67 (88.2)	1.58 (0.53)	0.7	1.15	1.47	1.81	3.3	
			Placebo	53	45 (84.9)	1.48 (0.49)	0.7	1.14	1.48	1.62	2.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Change from baseline	Week 2	Tezepelumab	76	74 (97.4)	0.09 (0.18)	-0.4	-0.01	0.07	0.21	0.7	0.16 [-0.20, 0.52]
			Placebo	53	50 (94.3)	0.05 (0.24)	-0.6	-0.07	0.03	0.13	0.7	
		Week 4	Tezepelumab	76	74 (97.4)	0.11 (0.21)	-0.3	-0.04	0.08	0.23	0.8	0.04 [-0.32, 0.40]
			Placebo	53	50 (94.3)	0.10 (0.29)	-0.9	-0.03	0.06	0.23	0.9	
		Week 8	Tezepelumab	76	74 (97.4)	0.14 (0.28)	-0.6	-0.04	0.08	0.27	1.0	0.18 [-0.18, 0.54]
			Placebo	53	50 (94.3)	0.09 (0.28)	-0.9	-0.06	0.09	0.24	0.7	
		Week 12	Tezepelumab	76	73 (96.1)	0.17 (0.28)	-0.7	0.01	0.19	0.31	1.2	0.41 [0.04, 0.77]
			Placebo	53	50 (94.3)	0.05 (0.28)	-1.1	-0.10	0.02	0.22	0.7	
		Week 16	Tezepelumab	76	73 (96.1)	0.16 (0.27)	-0.4	0.00	0.11	0.33	1.2	0.38 [0.01, 0.74]
			Placebo	53	49 (92.5)	0.06 (0.27)	-1.0	-0.08	0.04	0.25	0.6	
		Week 24	Tezepelumab	76	70 (92.1)	0.14 (0.26)	-0.4	-0.04	0.14	0.30	1.0	0.35 [-0.02, 0.72]
			Placebo	53	48 (90.6)	0.05 (0.29)	-1.1	-0.09	0.06	0.18	0.7	
		Week 36	Tezepelumab	76	68 (89.5)	0.14 (0.26)	-0.6	-0.03	0.08	0.32	1.0	0.39 [0.02, 0.77]
			Placebo	53	48 (90.6)	0.04 (0.27)	-0.6	-0.16	0.01	0.17	0.6	
		Week 52	Tezepelumab	76	67 (88.2)	0.13 (0.25)	-0.5	-0.03	0.08	0.26	0.9	0.44 [0.06, 0.82]
			Placebo	53	45 (84.9)	0.01 (0.34)	-1.0	-0.17	0.03	0.17	0.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Absolute values	Baseline	Tezepelumab	211	211 (100.0)	1.80 (0.67)	0.4	1.29	1.72	2.20	4.1	
			Placebo	226	226 (100.0)	1.90 (0.72)	0.6	1.36	1.80	2.29	4.9	
		Week 2	Tezepelumab	211	208 (98.6)	1.98 (0.71)	0.6	1.44	1.89	2.48	4.3	
			Placebo	226	217 (96.0)	1.98 (0.73)	0.7	1.42	1.90	2.40	4.7	
		Week 4	Tezepelumab	211	208 (98.6)	2.00 (0.72)	0.6	1.46	1.94	2.50	4.3	
			Placebo	226	217 (96.0)	1.96 (0.70)	0.5	1.45	1.90	2.35	4.8	
		Week 8	Tezepelumab	211	207 (98.1)	2.01 (0.75)	0.6	1.43	1.99	2.43	4.7	
			Placebo	226	219 (96.9)	1.99 (0.76)	0.6	1.41	1.91	2.40	4.9	
		Week 12	Tezepelumab	211	205 (97.2)	2.00 (0.74)	0.6	1.50	1.92	2.45	4.7	
			Placebo	226	220 (97.3)	1.99 (0.77)	0.5	1.41	1.92	2.45	5.0	
		Week 16	Tezepelumab	211	204 (96.7)	2.04 (0.75)	0.6	1.51	1.97	2.51	4.9	
			Placebo	226	216 (95.6)	2.00 (0.79)	0.5	1.40	1.85	2.47	5.2	
		Week 24	Tezepelumab	211	196 (92.9)	2.02 (0.73)	0.6	1.51	1.92	2.52	4.4	
			Placebo	226	206 (91.2)	1.97 (0.76)	0.8	1.40	1.90	2.31	5.1	
		Week 36	Tezepelumab	211	193 (91.5)	2.02 (0.76)	0.6	1.44	1.97	2.49	4.5	
			Placebo	226	204 (90.3)	2.00 (0.79)	0.6	1.45	1.86	2.39	5.3	
		Week 52	Tezepelumab	211	188 (89.1)	2.02 (0.75)	0.7	1.49	1.97	2.50	4.2	
			Placebo	226	191 (84.5)	1.96 (0.80)	0.6	1.36	1.79	2.41	5.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Change from baseline	Week 2	Tezepelumab	211	208 (98.6)	0.18 (0.35)	-0.7	-0.01	0.14	0.34	1.5	0.37 [0.18, 0.56]
			Placebo	226	217 (96.0)	0.06 (0.33)	-0.7	-0.12	0.00	0.13	1.3	
		Week 4	Tezepelumab	211	208 (98.6)	0.21 (0.39)	-0.9	-0.04	0.14	0.34	1.8	0.34 [0.15, 0.53]
			Placebo	226	217 (96.0)	0.08 (0.37)	-1.0	-0.12	0.04	0.22	1.6	
		Week 8	Tezepelumab	211	207 (98.1)	0.23 (0.45)	-0.8	-0.06	0.15	0.45	1.8	0.37 [0.18, 0.57]
			Placebo	226	219 (96.9)	0.08 (0.35)	-0.8	-0.12	0.05	0.23	1.6	
		Week 12	Tezepelumab	211	205 (97.2)	0.22 (0.45)	-1.5	-0.04	0.17	0.43	1.9	0.32 [0.13, 0.52]
			Placebo	226	220 (97.3)	0.08 (0.40)	-1.5	-0.10	0.04	0.22	1.7	
		Week 16	Tezepelumab	211	204 (96.7)	0.26 (0.43)	-0.6	-0.01	0.16	0.43	2.0	0.43 [0.24, 0.62]
			Placebo	226	216 (95.6)	0.08 (0.39)	-1.2	-0.13	0.03	0.25	1.8	
		Week 24	Tezepelumab	211	196 (92.9)	0.23 (0.43)	-1.0	-0.05	0.20	0.43	1.8	0.39 [0.19, 0.58]
			Placebo	226	206 (91.2)	0.07 (0.42)	-1.1	-0.16	0.03	0.23	1.7	
		Week 36	Tezepelumab	211	193 (91.5)	0.24 (0.44)	-1.0	-0.05	0.16	0.50	1.7	0.34 [0.14, 0.54]
			Placebo	226	204 (90.3)	0.10 (0.43)	-1.7	-0.17	0.04	0.27	1.7	
		Week 52	Tezepelumab	211	188 (89.1)	0.23 (0.43)	-1.0	-0.03	0.15	0.44	1.7	0.39 [0.18, 0.59]
			Placebo	226	191 (84.5)	0.07 (0.37)	-1.0	-0.14	0.04	0.25	1.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Absolute values	Baseline	Tezepelumab	184	184 (100.0)	1.74 (0.72)	0.5	1.24	1.59	2.10	4.0	
			Placebo	165	165 (100.0)	1.74 (0.70)	0.4	1.33	1.65	2.10	4.5	
		Week 2	Tezepelumab	184	176 (95.7)	1.92 (0.72)	0.7	1.37	1.80	2.38	4.1	
			Placebo	165	156 (94.5)	1.81 (0.70)	0.4	1.36	1.72	2.26	4.0	
		Week 4	Tezepelumab	184	183 (99.5)	1.93 (0.74)	0.7	1.36	1.74	2.47	4.2	
			Placebo	165	165 (100.0)	1.83 (0.68)	0.4	1.41	1.71	2.16	4.2	
		Week 8	Tezepelumab	184	181 (98.4)	1.95 (0.72)	0.7	1.36	1.82	2.46	4.2	
			Placebo	165	161 (97.6)	1.85 (0.70)	0.4	1.37	1.75	2.22	4.3	
		Week 12	Tezepelumab	184	177 (96.2)	1.98 (0.74)	0.7	1.46	1.83	2.41	4.3	
			Placebo	165	157 (95.2)	1.86 (0.70)	0.6	1.40	1.74	2.24	4.3	
		Week 16	Tezepelumab	184	176 (95.7)	1.98 (0.75)	0.6	1.44	1.86	2.37	4.3	
			Placebo	165	154 (93.3)	1.83 (0.66)	0.7	1.35	1.73	2.18	4.3	
		Week 24	Tezepelumab	184	173 (94.0)	1.94 (0.70)	0.6	1.48	1.79	2.32	4.0	
			Placebo	165	151 (91.5)	1.86 (0.70)	0.6	1.41	1.72	2.21	4.8	
		Week 36	Tezepelumab	184	163 (88.6)	1.97 (0.75)	0.5	1.43	1.81	2.37	4.4	
			Placebo	165	142 (86.1)	1.90 (0.72)	0.7	1.41	1.79	2.25	4.6	
		Week 52	Tezepelumab	184	161 (87.5)	1.99 (0.77)	0.6	1.43	1.85	2.39	4.3	
			Placebo	165	135 (81.8)	1.87 (0.75)	0.7	1.32	1.76	2.28	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Change from baseline	Week 2	Tezepelumab	184	176 (95.7)	0.18 (0.32)	-0.6	0.00	0.12	0.30	1.4	0.37 [0.15, 0.59]
			Placebo	165	156 (94.5)	0.05 (0.42)	-1.8	-0.10	0.03	0.22	1.7	
		Week 4	Tezepelumab	184	183 (99.5)	0.20 (0.33)	-0.7	0.01	0.13	0.36	1.6	0.32 [0.11, 0.53]
			Placebo	165	165 (100.0)	0.08 (0.42)	-1.8	-0.10	0.04	0.28	1.7	
		Week 8	Tezepelumab	184	181 (98.4)	0.23 (0.37)	-1.1	-0.01	0.16	0.44	1.4	0.36 [0.14, 0.57]
			Placebo	165	161 (97.6)	0.10 (0.39)	-1.7	-0.10	0.06	0.32	2.0	
		Week 12	Tezepelumab	184	177 (96.2)	0.25 (0.38)	-0.8	0.02	0.18	0.43	2.0	0.36 [0.14, 0.58]
			Placebo	165	157 (95.2)	0.11 (0.40)	-1.2	-0.10	0.07	0.32	1.5	
		Week 16	Tezepelumab	184	176 (95.7)	0.25 (0.38)	-0.8	0.01	0.18	0.39	1.7	0.44 [0.22, 0.66]
			Placebo	165	154 (93.3)	0.08 (0.38)	-1.6	-0.09	0.02	0.26	1.6	
		Week 24	Tezepelumab	184	173 (94.0)	0.24 (0.40)	-1.0	-0.04	0.16	0.43	1.7	0.40 [0.18, 0.63]
			Placebo	165	151 (91.5)	0.08 (0.36)	-1.4	-0.12	0.05	0.29	1.1	
		Week 36	Tezepelumab	184	163 (88.6)	0.23 (0.39)	-0.5	-0.03	0.17	0.40	1.6	0.33 [0.10, 0.55]
			Placebo	165	142 (86.1)	0.10 (0.41)	-1.2	-0.15	0.07	0.34	2.2	
		Week 52	Tezepelumab	184	161 (87.5)	0.26 (0.40)	-0.8	-0.01	0.23	0.52	1.6	0.50 [0.27, 0.73]
			Placebo	165	135 (81.8)	0.07 (0.38)	-1.4	-0.15	0.07	0.23	1.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Absolute values	Baseline	Tezepelumab	251	251 (100.0)	1.82 (0.69)	0.6	1.30	1.69	2.14	3.8	
			Placebo	252	252 (100.0)	1.89 (0.78)	0.6	1.33	1.72	2.27	4.9	
		Week 2	Tezepelumab	251	246 (98.0)	2.00 (0.72)	0.7	1.44	1.88	2.52	4.0	
			Placebo	252	239 (94.8)	1.95 (0.78)	0.6	1.37	1.86	2.40	4.7	
		Week 4	Tezepelumab	251	249 (99.2)	2.02 (0.75)	0.7	1.42	1.90	2.53	4.3	
			Placebo	252	243 (96.4)	1.95 (0.76)	0.5	1.42	1.85	2.43	4.8	
		Week 8	Tezepelumab	251	248 (98.8)	2.02 (0.77)	0.7	1.40	1.92	2.53	4.7	
			Placebo	252	242 (96.0)	2.01 (0.79)	0.6	1.43	1.94	2.49	4.9	
		Week 12	Tezepelumab	251	242 (96.4)	2.03 (0.76)	0.8	1.47	1.90	2.46	4.7	
			Placebo	252	240 (95.2)	1.99 (0.81)	0.5	1.39	1.88	2.49	5.0	
		Week 16	Tezepelumab	251	242 (96.4)	2.06 (0.77)	0.8	1.46	1.95	2.56	4.9	
			Placebo	252	236 (93.7)	1.98 (0.81)	0.5	1.33	1.85	2.48	5.2	
		Week 24	Tezepelumab	251	235 (93.6)	2.01 (0.75)	0.7	1.41	1.93	2.50	4.4	
			Placebo	252	227 (90.1)	1.99 (0.81)	0.6	1.40	1.89	2.41	5.1	
		Week 36	Tezepelumab	251	224 (89.2)	2.05 (0.77)	0.7	1.42	1.97	2.50	4.5	
			Placebo	252	218 (86.5)	2.05 (0.83)	0.6	1.43	1.89	2.50	5.3	
		Week 52	Tezepelumab	251	218 (86.9)	2.04 (0.79)	0.6	1.47	1.99	2.47	4.3	
			Placebo	252	201 (79.8)	2.03 (0.87)	0.6	1.34	1.90	2.51	5.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Change from baseline	Week 2	Tezepelumab	251	246 (98.0)	0.18 (0.32)	-0.6	0.00	0.14	0.31	1.5	0.40 [0.22, 0.58]
			Placebo	252	239 (94.8)	0.04 (0.39)	-1.8	-0.13	-0.01	0.17	1.7	
		Week 4	Tezepelumab	251	249 (99.2)	0.20 (0.36)	-0.7	-0.04	0.13	0.33	1.7	0.29 [0.11, 0.46]
			Placebo	252	243 (96.4)	0.09 (0.41)	-1.8	-0.11	0.05	0.26	1.7	
		Week 8	Tezepelumab	251	248 (98.8)	0.22 (0.42)	-1.1	-0.04	0.13	0.42	1.8	0.27 [0.09, 0.45]
			Placebo	252	242 (96.0)	0.11 (0.39)	-1.7	-0.10	0.06	0.28	2.0	
		Week 12	Tezepelumab	251	242 (96.4)	0.21 (0.41)	-1.5	-0.05	0.16	0.41	1.9	0.27 [0.09, 0.44]
			Placebo	252	240 (95.2)	0.10 (0.42)	-1.5	-0.11	0.05	0.30	1.6	
		Week 16	Tezepelumab	251	242 (96.4)	0.24 (0.41)	-0.8	0.00	0.16	0.39	2.0	0.38 [0.20, 0.56]
			Placebo	252	236 (93.7)	0.09 (0.40)	-1.6	-0.12	0.04	0.26	1.6	
		Week 24	Tezepelumab	251	235 (93.6)	0.22 (0.41)	-1.0	-0.06	0.16	0.43	1.8	0.34 [0.15, 0.52]
			Placebo	252	227 (90.1)	0.08 (0.40)	-1.4	-0.12	0.03	0.27	1.6	
		Week 36	Tezepelumab	251	224 (89.2)	0.23 (0.40)	-0.8	-0.05	0.16	0.46	1.7	0.25 [0.06, 0.44]
			Placebo	252	218 (86.5)	0.13 (0.43)	-1.2	-0.14	0.06	0.33	2.2	
		Week 52	Tezepelumab	251	218 (86.9)	0.23 (0.41)	-0.8	-0.03	0.16	0.44	1.7	0.31 [0.11, 0.50]
			Placebo	252	201 (79.8)	0.11 (0.38)	-1.4	-0.10	0.08	0.27	1.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Absolute values	Baseline	Tezepelumab	21	21 (100.0)	1.73 (0.87)	0.8	1.07	1.37	2.37	4.0	
			Placebo	21	21 (100.0)	1.76 (0.69)	0.9	1.22	1.77	2.10	3.2	
		Week 2	Tezepelumab	21	17 (81.0)	1.89 (0.84)	0.9	1.34	1.72	2.17	4.1	
			Placebo	21	21 (100.0)	1.92 (0.64)	0.9	1.47	1.90	2.28	3.1	
		Week 4	Tezepelumab	21	20 (95.2)	1.85 (0.78)	1.0	1.34	1.69	2.10	4.2	
			Placebo	21	21 (100.0)	1.86 (0.56)	1.0	1.39	1.95	2.21	3.1	
		Week 8	Tezepelumab	21	20 (95.2)	1.92 (0.73)	1.0	1.43	1.83	2.17	4.1	
			Placebo	21	21 (100.0)	1.75 (0.63)	0.8	1.38	1.55	2.16	3.4	
		Week 12	Tezepelumab	21	20 (95.2)	1.93 (0.82)	0.9	1.50	1.73	2.47	4.2	
			Placebo	21	21 (100.0)	1.85 (0.60)	1.0	1.43	1.74	2.10	3.3	
		Week 16	Tezepelumab	21	19 (90.5)	1.78 (0.71)	1.0	1.37	1.65	2.13	4.2	
			Placebo	21	20 (95.2)	1.87 (0.60)	0.8	1.46	1.86	2.18	3.1	
		Week 24	Tezepelumab	21	17 (81.0)	1.82 (0.72)	0.9	1.44	1.63	2.11	4.0	
			Placebo	21	19 (90.5)	1.75 (0.62)	0.9	1.30	1.69	1.99	3.3	
		Week 36	Tezepelumab	21	17 (81.0)	1.77 (0.81)	0.9	1.35	1.61	1.91	4.4	
			Placebo	21	20 (95.2)	1.80 (0.62)	1.0	1.33	1.80	2.15	3.3	
		Week 52	Tezepelumab	21	17 (81.0)	1.84 (0.76)	0.8	1.38	1.76	2.10	4.2	
			Placebo	21	18 (85.7)	1.75 (0.71)	0.7	1.06	1.74	2.33	3.1	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Change from baseline	Week 2	Tezepelumab	21	17 (81.0)	0.25 (0.46)	-0.7	0.03	0.21	0.53	1.4	0.23 [-0.41, 0.87]
			Placebo	21	21 (100.0)	0.16 (0.32)	-0.3	-0.06	0.01	0.31	1.0	
		Week 4	Tezepelumab	21	20 (95.2)	0.19 (0.35)	-0.5	0.06	0.18	0.35	1.1	0.23 [-0.38, 0.85]
			Placebo	21	21 (100.0)	0.10 (0.42)	-0.6	-0.13	-0.01	0.34	1.1	
		Week 8	Tezepelumab	21	20 (95.2)	0.26 (0.43)	-0.5	-0.06	0.28	0.49	1.1	0.66 [0.04, 1.29]
			Placebo	21	21 (100.0)	-0.01 (0.37)	-0.8	-0.19	0.06	0.29	0.5	
		Week 12	Tezepelumab	21	20 (95.2)	0.28 (0.42)	-0.4	0.03	0.18	0.48	1.5	0.42 [-0.20, 1.04]
			Placebo	21	21 (100.0)	0.09 (0.45)	-1.2	-0.08	0.13	0.40	1.0	
		Week 16	Tezepelumab	21	19 (90.5)	0.19 (0.41)	-0.5	-0.08	0.13	0.32	1.4	0.16 [-0.47, 0.79]
			Placebo	21	20 (95.2)	0.12 (0.43)	-0.7	-0.05	0.10	0.34	1.0	
		Week 24	Tezepelumab	21	17 (81.0)	0.25 (0.32)	-0.2	-0.05	0.23	0.39	1.1	0.58 [-0.09, 1.25]
			Placebo	21	19 (90.5)	0.01 (0.48)	-1.1	-0.21	0.02	0.28	1.1	
		Week 36	Tezepelumab	21	17 (81.0)	0.17 (0.30)	-0.2	-0.02	0.05	0.45	0.7	0.32 [-0.33, 0.97]
			Placebo	21	20 (95.2)	0.04 (0.48)	-1.7	-0.01	0.06	0.16	1.0	
		Week 52	Tezepelumab	21	17 (81.0)	0.26 (0.40)	-0.3	-0.03	0.14	0.55	1.1	0.80 [0.11, 1.49]
			Placebo	21	18 (85.7)	-0.05 (0.38)	-0.6	-0.23	-0.10	0.11	1.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Absolute values	Baseline	Tezepelumab	108	108 (100.0)	1.67 (0.67)	0.4	1.21	1.61	2.05	4.1	
			Placebo	104	104 (100.0)	1.75 (0.55)	0.4	1.38	1.71	2.10	3.1	
		Week 2	Tezepelumab	108	107 (99.1)	1.85 (0.68)	0.6	1.30	1.76	2.29	4.3	
			Placebo	104	101 (97.1)	1.82 (0.61)	0.4	1.46	1.73	2.20	3.9	
		Week 4	Tezepelumab	108	108 (100.0)	1.90 (0.68)	0.7	1.44	1.78	2.38	3.7	
			Placebo	104	104 (100.0)	1.80 (0.57)	0.4	1.44	1.72	2.13	3.7	
		Week 8	Tezepelumab	108	106 (98.1)	1.93 (0.68)	0.6	1.45	1.84	2.36	4.7	
			Placebo	104	104 (100.0)	1.79 (0.62)	0.4	1.40	1.75	2.20	4.3	
		Week 12	Tezepelumab	108	106 (98.1)	1.95 (0.68)	0.6	1.50	1.93	2.32	3.8	
			Placebo	104	102 (98.1)	1.84 (0.62)	0.7	1.44	1.78	2.23	4.3	
		Week 16	Tezepelumab	108	106 (98.1)	1.97 (0.73)	0.6	1.49	1.88	2.44	4.7	
			Placebo	104	101 (97.1)	1.83 (0.60)	0.7	1.47	1.72	2.14	4.4	
		Week 24	Tezepelumab	108	105 (97.2)	1.95 (0.65)	0.6	1.56	1.82	2.32	4.0	
			Placebo	104	99 (95.2)	1.83 (0.58)	0.7	1.45	1.71	2.14	4.3	
		Week 36	Tezepelumab	108	102 (94.4)	1.95 (0.72)	0.5	1.51	1.81	2.38	4.4	
			Placebo	104	95 (91.3)	1.81 (0.62)	0.7	1.41	1.69	2.19	4.3	
		Week 52	Tezepelumab	108	101 (93.5)	1.96 (0.70)	0.8	1.49	1.82	2.44	4.2	
			Placebo	104	95 (91.3)	1.76 (0.58)	0.7	1.38	1.62	2.16	3.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Change from baseline	Week 2	Tezepelumab	108	107 (99.1)	0.18 (0.36)	-0.6	-0.01	0.10	0.30	1.3	0.35 [0.07, 0.62]
			Placebo	104	101 (97.1)	0.06 (0.32)	-0.7	-0.09	0.04	0.17	1.2	
		Week 4	Tezepelumab	108	108 (100.0)	0.22 (0.39)	-0.9	0.02	0.15	0.37	1.8	0.47 [0.20, 0.75]
			Placebo	104	104 (100.0)	0.05 (0.35)	-0.9	-0.13	0.00	0.20	1.1	
		Week 8	Tezepelumab	108	106 (98.1)	0.27 (0.43)	-0.8	0.03	0.18	0.50	1.7	0.58 [0.31, 0.86]
			Placebo	104	104 (100.0)	0.05 (0.34)	-0.9	-0.16	0.01	0.21	1.6	
		Week 12	Tezepelumab	108	106 (98.1)	0.29 (0.45)	-0.7	0.04	0.20	0.52	2.0	0.53 [0.25, 0.81]
			Placebo	104	102 (98.1)	0.08 (0.36)	-1.1	-0.07	0.04	0.19	1.7	
		Week 16	Tezepelumab	108	106 (98.1)	0.30 (0.43)	-0.6	0.02	0.23	0.52	1.7	0.60 [0.32, 0.88]
			Placebo	104	101 (97.1)	0.06 (0.36)	-1.0	-0.11	0.00	0.22	1.8	
		Week 24	Tezepelumab	108	105 (97.2)	0.27 (0.44)	-1.0	-0.01	0.23	0.54	1.6	0.51 [0.23, 0.79]
			Placebo	104	99 (95.2)	0.06 (0.38)	-1.1	-0.14	0.07	0.22	1.7	
		Week 36	Tezepelumab	108	102 (94.4)	0.28 (0.46)	-1.0	0.01	0.24	0.55	1.5	0.57 [0.28, 0.85]
			Placebo	104	95 (91.3)	0.03 (0.39)	-1.0	-0.22	0.01	0.27	1.7	
		Week 52	Tezepelumab	108	101 (93.5)	0.28 (0.45)	-1.0	0.00	0.27	0.53	1.6	0.65 [0.37, 0.94]
			Placebo	104	95 (91.3)	0.01 (0.35)	-1.0	-0.22	0.02	0.23	0.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Absolute values	Baseline	Tezepelumab	15	15 (100.0)	1.71 (0.70)	0.7	1.26	1.66	2.14	3.2	
			Placebo	14	14 (100.0)	1.68 (0.52)	1.1	1.27	1.59	2.17	2.6	
		Week 2	Tezepelumab	15	14 (93.3)	1.93 (0.78)	0.6	1.48	2.00	2.25	3.7	
			Placebo	14	12 (85.7)	1.81 (0.51)	1.2	1.30	1.82	2.18	2.7	
		Week 4	Tezepelumab	15	14 (93.3)	1.81 (0.65)	0.6	1.37	1.75	2.56	2.6	
			Placebo	14	14 (100.0)	1.81 (0.41)	1.1	1.46	1.87	2.00	2.6	
		Week 8	Tezepelumab	15	14 (93.3)	1.79 (0.64)	0.6	1.36	1.85	2.45	2.6	
			Placebo	14	13 (92.9)	1.81 (0.57)	1.1	1.34	1.68	1.99	2.9	
		Week 12	Tezepelumab	15	14 (93.3)	1.76 (0.65)	0.6	1.31	1.83	2.30	2.7	
			Placebo	14	14 (100.0)	1.81 (0.49)	1.0	1.42	1.86	2.25	2.6	
		Week 16	Tezepelumab	15	13 (86.7)	1.88 (0.62)	0.6	1.70	1.85	2.50	2.6	
			Placebo	14	13 (92.9)	1.73 (0.52)	1.0	1.35	1.69	2.09	2.7	
		Week 24	Tezepelumab	15	12 (80.0)	1.83 (0.71)	0.6	1.28	1.87	2.42	2.7	
			Placebo	14	12 (85.7)	1.67 (0.43)	0.9	1.44	1.77	2.08	2.2	
		Week 36	Tezepelumab	15	13 (86.7)	1.83 (0.66)	0.7	1.45	1.83	2.27	2.7	
			Placebo	14	13 (92.9)	1.84 (0.54)	1.0	1.62	1.72	2.27	2.8	
		Week 52	Tezepelumab	15	13 (86.7)	1.85 (0.63)	0.7	1.60	1.89	2.29	2.8	
			Placebo	14	12 (85.7)	1.75 (0.44)	1.0	1.58	1.75	2.03	2.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Change from baseline	Week 2	Tezepelumab	15	14 (93.3)	0.16 (0.26)	-0.3	-0.03	0.11	0.36	0.6	0.21 [-0.56, 0.98]
			Placebo	14	12 (85.7)	0.11 (0.16)	-0.1	0.02	0.11	0.22	0.3	
		Week 4	Tezepelumab	15	14 (93.3)	0.20 (0.32)	-0.2	0.02	0.11	0.29	1.1	0.23 [-0.51, 0.97]
			Placebo	14	14 (100.0)	0.13 (0.30)	-0.3	0.02	0.08	0.20	0.9	
		Week 8	Tezepelumab	15	14 (93.3)	0.18 (0.34)	-0.3	-0.05	0.14	0.27	1.2	0.04 [-0.71, 0.80]
			Placebo	14	13 (92.9)	0.17 (0.18)	-0.2	0.07	0.15	0.26	0.5	
		Week 12	Tezepelumab	15	14 (93.3)	0.16 (0.32)	-0.2	0.04	0.08	0.17	1.1	0.11 [-0.63, 0.85]
			Placebo	14	14 (100.0)	0.13 (0.24)	-0.2	0.04	0.09	0.22	0.8	
		Week 16	Tezepelumab	15	13 (86.7)	0.21 (0.28)	-0.1	0.08	0.14	0.28	1.1	0.62 [-0.17, 1.41]
			Placebo	14	13 (92.9)	0.05 (0.22)	-0.4	-0.06	0.03	0.23	0.4	
		Week 24	Tezepelumab	15	12 (80.0)	0.16 (0.38)	-0.4	-0.02	0.14	0.22	1.2	0.19 [-0.61, 0.99]
			Placebo	14	12 (85.7)	0.08 (0.37)	-0.7	-0.17	0.07	0.32	0.8	
		Week 36	Tezepelumab	15	13 (86.7)	0.16 (0.39)	-0.2	-0.04	0.03	0.14	1.3	-0.05 [-0.81, 0.72]
			Placebo	14	13 (92.9)	0.17 (0.28)	-0.2	-0.12	0.19	0.37	0.6	
		Week 52	Tezepelumab	15	13 (86.7)	0.19 (0.27)	-0.2	0.05	0.08	0.23	0.8	0.45 [-0.35, 1.24]
			Placebo	14	12 (85.7)	0.05 (0.32)	-0.5	-0.13	0.04	0.23	0.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Absolute values	Baseline	Tezepelumab	65	65 (100.0)	1.86 (0.66)	0.8	1.41	1.75	2.27	3.6	
			Placebo	61	61 (100.0)	1.95 (0.81)	0.7	1.37	1.83	2.43	4.2	
		Week 2	Tezepelumab	65	65 (100.0)	2.04 (0.72)	0.7	1.49	1.96	2.44	3.9	
			Placebo	61	58 (95.1)	2.03 (0.82)	0.6	1.37	2.02	2.69	4.0	
		Week 4	Tezepelumab	65	65 (100.0)	2.07 (0.74)	0.7	1.59	2.03	2.48	4.3	
			Placebo	61	60 (98.4)	1.99 (0.84)	0.7	1.36	1.93	2.57	4.2	
		Week 8	Tezepelumab	65	65 (100.0)	2.07 (0.76)	0.8	1.56	2.08	2.44	4.7	
			Placebo	61	57 (93.4)	2.07 (0.83)	0.7	1.40	2.09	2.65	4.3	
		Week 12	Tezepelumab	65	63 (96.9)	2.05 (0.79)	0.8	1.52	1.98	2.37	4.7	
			Placebo	61	57 (93.4)	1.99 (0.88)	0.6	1.31	1.87	2.56	4.3	
		Week 16	Tezepelumab	65	62 (95.4)	2.13 (0.76)	0.9	1.65	2.04	2.43	4.9	
			Placebo	61	57 (93.4)	1.97 (0.80)	0.8	1.33	1.84	2.48	4.1	
		Week 24	Tezepelumab	65	62 (95.4)	2.04 (0.69)	0.7	1.65	1.99	2.42	4.4	
			Placebo	61	53 (86.9)	1.98 (0.87)	0.6	1.27	2.03	2.28	4.8	
		Week 36	Tezepelumab	65	60 (92.3)	2.07 (0.73)	0.8	1.55	2.03	2.50	4.5	
			Placebo	61	51 (83.6)	2.08 (0.83)	0.8	1.43	1.99	2.58	4.6	
		Week 52	Tezepelumab	65	57 (87.7)	2.06 (0.74)	0.8	1.58	2.04	2.42	4.1	
			Placebo	61	50 (82.0)	2.13 (0.88)	0.7	1.34	2.07	2.66	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Change from baseline	Week 2	Tezepelumab	65	65 (100.0)	0.18 (0.28)	-0.6	0.02	0.15	0.35	1.1	0.44 [0.08, 0.80]
			Placebo	61	58 (95.1)	0.05 (0.32)	-0.8	-0.12	0.04	0.20	1.0	
		Week 4	Tezepelumab	65	65 (100.0)	0.21 (0.35)	-0.7	0.01	0.17	0.32	1.4	0.47 [0.12, 0.83]
			Placebo	61	60 (98.4)	0.04 (0.34)	-0.7	-0.11	0.03	0.24	1.4	
		Week 8	Tezepelumab	65	65 (100.0)	0.21 (0.42)	-0.6	-0.07	0.14	0.44	1.8	0.33 [-0.02, 0.69]
			Placebo	61	57 (93.4)	0.08 (0.39)	-0.8	-0.12	0.04	0.29	1.3	
		Week 12	Tezepelumab	65	63 (96.9)	0.19 (0.44)	-0.8	-0.09	0.14	0.38	1.9	0.37 [0.01, 0.73]
			Placebo	61	57 (93.4)	0.05 (0.32)	-0.7	-0.11	0.02	0.22	1.2	
		Week 16	Tezepelumab	65	62 (95.4)	0.27 (0.42)	-0.8	0.03	0.21	0.42	2.0	0.66 [0.29, 1.03]
			Placebo	61	57 (93.4)	0.01 (0.37)	-1.2	-0.16	0.02	0.18	1.0	
		Week 24	Tezepelumab	65	62 (95.4)	0.21 (0.35)	-0.2	-0.06	0.17	0.40	1.5	0.57 [0.20, 0.95]
			Placebo	61	53 (86.9)	-0.00 (0.38)	-0.9	-0.17	-0.04	0.14	1.6	
		Week 36	Tezepelumab	65	60 (92.3)	0.22 (0.38)	-0.5	-0.05	0.14	0.47	1.7	0.38 [0.00, 0.75]
			Placebo	61	51 (83.6)	0.08 (0.37)	-1.1	-0.14	0.12	0.31	1.1	
		Week 52	Tezepelumab	65	57 (87.7)	0.21 (0.36)	-0.6	-0.01	0.22	0.35	1.2	0.30 [-0.08, 0.68]
			Placebo	61	50 (82.0)	0.10 (0.33)	-0.8	-0.05	0.09	0.21	1.1	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Absolute values	Baseline	Tezepelumab	151	151 (100.0)	1.85 (0.70)	0.7	1.35	1.65	2.14	4.0	
			Placebo	152	152 (100.0)	1.98 (0.81)	0.6	1.35	1.89	2.42	4.9	
		Week 2	Tezepelumab	151	145 (96.0)	2.04 (0.74)	0.8	1.46	1.86	2.58	4.1	
			Placebo	152	146 (96.1)	2.07 (0.77)	0.6	1.45	1.98	2.54	4.7	
		Week 4	Tezepelumab	151	147 (97.4)	2.02 (0.75)	0.7	1.46	1.90	2.58	4.2	
			Placebo	152	146 (96.1)	2.05 (0.74)	0.5	1.50	2.02	2.51	4.8	
		Week 8	Tezepelumab	151	147 (97.4)	2.03 (0.77)	0.7	1.36	1.88	2.52	4.2	
			Placebo	152	147 (96.7)	2.09 (0.82)	0.6	1.53	1.94	2.61	4.9	
		Week 12	Tezepelumab	151	143 (94.7)	2.04 (0.76)	0.8	1.55	1.88	2.57	4.3	
			Placebo	152	149 (98.0)	2.09 (0.80)	0.5	1.51	1.97	2.54	5.0	
		Week 16	Tezepelumab	151	143 (94.7)	2.04 (0.76)	0.8	1.49	1.87	2.56	4.3	
			Placebo	152	146 (96.1)	2.10 (0.84)	0.5	1.54	1.99	2.53	5.2	
		Week 24	Tezepelumab	151	136 (90.1)	2.03 (0.76)	0.7	1.43	1.85	2.60	4.0	
			Placebo	152	141 (92.8)	2.09 (0.82)	0.6	1.57	1.95	2.60	5.1	
		Week 36	Tezepelumab	151	132 (87.4)	2.06 (0.80)	0.7	1.43	1.99	2.46	4.4	
			Placebo	152	144 (94.7)	2.14 (0.86)	0.6	1.51	2.06	2.67	5.3	
		Week 52	Tezepelumab	151	128 (84.8)	2.07 (0.81)	0.6	1.49	1.99	2.50	4.3	
			Placebo	152	128 (84.2)	2.12 (0.89)	0.6	1.46	2.03	2.66	5.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Change from baseline	Week 2	Tezepelumab	151	145 (96.0)	0.20 (0.36)	-0.7	0.00	0.14	0.33	1.5	0.29 [0.06, 0.52]
			Placebo	152	146 (96.1)	0.08 (0.44)	-1.8	-0.10	0.00	0.22	1.7	
		Week 4	Tezepelumab	151	147 (97.4)	0.19 (0.36)	-0.5	-0.06	0.11	0.35	1.3	0.23 [-0.00, 0.46]
			Placebo	152	146 (96.1)	0.10 (0.44)	-1.8	-0.10	0.06	0.25	1.7	
		Week 8	Tezepelumab	151	147 (97.4)	0.21 (0.45)	-1.1	-0.05	0.11	0.39	1.6	0.24 [0.01, 0.46]
			Placebo	152	147 (96.7)	0.11 (0.40)	-1.7	-0.11	0.09	0.29	2.0	
		Week 12	Tezepelumab	151	143 (94.7)	0.20 (0.41)	-1.5	-0.04	0.14	0.40	1.6	0.21 [-0.02, 0.44]
			Placebo	152	149 (98.0)	0.11 (0.49)	-1.5	-0.12	0.06	0.33	1.6	
		Week 16	Tezepelumab	151	143 (94.7)	0.22 (0.39)	-0.5	-0.02	0.14	0.35	1.9	0.25 [0.02, 0.48]
			Placebo	152	146 (96.1)	0.12 (0.44)	-1.6	-0.12	0.04	0.27	1.6	
		Week 24	Tezepelumab	151	136 (90.1)	0.22 (0.43)	-0.8	-0.07	0.15	0.42	1.8	0.28 [0.05, 0.52]
			Placebo	152	141 (92.8)	0.10 (0.43)	-1.4	-0.11	0.05	0.28	1.6	
		Week 36	Tezepelumab	151	132 (87.4)	0.23 (0.41)	-0.8	-0.05	0.15	0.42	1.7	0.18 [-0.05, 0.42]
			Placebo	152	144 (94.7)	0.15 (0.48)	-1.7	-0.13	0.06	0.31	2.2	
		Week 52	Tezepelumab	151	128 (84.8)	0.25 (0.44)	-0.8	-0.03	0.15	0.52	1.7	0.31 [0.06, 0.55]
			Placebo	152	128 (84.2)	0.11 (0.44)	-1.4	-0.15	0.04	0.31	1.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Absolute values	Baseline	Tezepelumab	105	105 (100.0)	1.74 (0.68)	0.4	1.26	1.71	2.16	4.1	
			Placebo	105	105 (100.0)	1.72 (0.55)	0.4	1.37	1.69	2.06	3.1	
		Week 2	Tezepelumab	105	104 (99.0)	1.91 (0.68)	0.6	1.31	1.80	2.32	4.3	
			Placebo	105	101 (96.2)	1.77 (0.62)	0.4	1.44	1.67	2.10	3.9	
		Week 4	Tezepelumab	105	105 (100.0)	1.96 (0.68)	0.7	1.45	1.91	2.42	3.7	
			Placebo	105	104 (99.0)	1.77 (0.56)	0.4	1.44	1.69	2.04	3.7	
		Week 8	Tezepelumab	105	103 (98.1)	2.00 (0.70)	0.6	1.47	1.95	2.43	4.7	
			Placebo	105	104 (99.0)	1.79 (0.63)	0.4	1.39	1.73	2.22	4.3	
		Week 12	Tezepelumab	105	102 (97.1)	2.01 (0.69)	0.6	1.52	1.94	2.41	3.8	
			Placebo	105	102 (97.1)	1.82 (0.63)	0.7	1.44	1.73	2.22	4.3	
		Week 16	Tezepelumab	105	104 (99.0)	2.04 (0.75)	0.6	1.52	1.99	2.48	4.7	
			Placebo	105	100 (95.2)	1.81 (0.60)	0.7	1.44	1.71	2.13	4.4	
		Week 24	Tezepelumab	105	102 (97.1)	2.00 (0.65)	0.8	1.57	1.82	2.35	4.0	
			Placebo	105	97 (92.4)	1.81 (0.58)	0.7	1.42	1.71	2.11	4.3	
		Week 36	Tezepelumab	105	97 (92.4)	2.00 (0.71)	0.6	1.52	1.81	2.46	4.4	
			Placebo	105	92 (87.6)	1.81 (0.62)	0.7	1.42	1.70	2.18	4.3	
		Week 52	Tezepelumab	105	98 (93.3)	2.02 (0.69)	0.8	1.53	1.85	2.48	4.2	
			Placebo	105	91 (86.7)	1.75 (0.57)	0.7	1.37	1.61	2.12	3.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Change from baseline	Week 2	Tezepelumab	105	104 (99.0)	0.18 (0.35)	-0.6	-0.00	0.10	0.30	1.3	0.42 [0.14, 0.70]
			Placebo	105	101 (96.2)	0.04 (0.32)	-0.7	-0.11	0.03	0.17	1.2	
		Week 4	Tezepelumab	105	105 (100.0)	0.22 (0.38)	-0.9	0.02	0.15	0.37	1.8	0.49 [0.22, 0.77]
			Placebo	105	104 (99.0)	0.05 (0.33)	-0.7	-0.14	0.00	0.20	1.1	
		Week 8	Tezepelumab	105	103 (98.1)	0.28 (0.43)	-0.8	0.03	0.18	0.51	1.7	0.54 [0.26, 0.81]
			Placebo	105	104 (99.0)	0.07 (0.34)	-0.7	-0.14	0.03	0.23	1.6	
		Week 12	Tezepelumab	105	102 (97.1)	0.30 (0.45)	-0.7	0.05	0.21	0.52	2.0	0.55 [0.27, 0.83]
			Placebo	105	102 (97.1)	0.08 (0.35)	-0.9	-0.07	0.04	0.19	1.7	
		Week 16	Tezepelumab	105	104 (99.0)	0.31 (0.43)	-0.6	0.04	0.23	0.53	1.7	0.60 [0.32, 0.88]
			Placebo	105	100 (95.2)	0.07 (0.35)	-0.8	-0.12	0.01	0.25	1.8	
		Week 24	Tezepelumab	105	102 (97.1)	0.27 (0.43)	-1.0	0.00	0.22	0.53	1.6	0.51 [0.23, 0.80]
			Placebo	105	97 (92.4)	0.06 (0.37)	-0.9	-0.14	0.04	0.22	1.7	
		Week 36	Tezepelumab	105	97 (92.4)	0.28 (0.46)	-1.0	0.02	0.23	0.54	1.5	0.54 [0.25, 0.83]
			Placebo	105	92 (87.6)	0.04 (0.40)	-1.0	-0.22	0.01	0.27	1.7	
		Week 52	Tezepelumab	105	98 (93.3)	0.28 (0.45)	-1.0	0.01	0.26	0.53	1.6	0.64 [0.35, 0.94]
			Placebo	105	91 (86.7)	0.02 (0.34)	-1.0	-0.20	0.01	0.23	0.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Absolute values	Baseline	Tezepelumab	74	74 (100.0)	1.58 (0.70)	0.6	1.04	1.39	1.99	3.5	
			Placebo	73	73 (100.0)	1.61 (0.51)	0.8	1.26	1.50	1.88	3.0	
		Week 2	Tezepelumab	74	70 (94.6)	1.74 (0.68)	0.6	1.24	1.56	2.22	3.8	
			Placebo	73	68 (93.2)	1.65 (0.55)	0.7	1.24	1.62	2.04	2.7	
		Week 4	Tezepelumab	74	74 (100.0)	1.78 (0.73)	0.6	1.25	1.68	2.16	3.8	
			Placebo	73	72 (98.6)	1.72 (0.56)	0.7	1.32	1.65	2.05	3.4	
		Week 8	Tezepelumab	74	73 (98.6)	1.79 (0.69)	0.6	1.27	1.64	2.28	3.8	
			Placebo	73	72 (98.6)	1.68 (0.52)	0.7	1.33	1.63	2.00	3.0	
		Week 12	Tezepelumab	74	74 (100.0)	1.82 (0.71)	0.6	1.35	1.69	2.23	3.8	
			Placebo	73	69 (94.5)	1.73 (0.53)	0.8	1.31	1.61	2.14	3.1	
		Week 16	Tezepelumab	74	71 (95.9)	1.83 (0.71)	0.6	1.33	1.68	2.18	3.8	
			Placebo	73	67 (91.8)	1.69 (0.53)	0.8	1.28	1.68	2.11	3.1	
		Week 24	Tezepelumab	74	69 (93.2)	1.81 (0.74)	0.6	1.23	1.71	2.30	4.0	
			Placebo	73	66 (90.4)	1.68 (0.53)	0.8	1.32	1.63	2.11	3.1	
		Week 36	Tezepelumab	74	67 (90.5)	1.82 (0.73)	0.5	1.27	1.69	2.27	3.8	
			Placebo	73	59 (80.8)	1.65 (0.48)	0.8	1.26	1.60	2.03	2.8	
		Week 52	Tezepelumab	74	66 (89.2)	1.80 (0.72)	0.7	1.23	1.67	2.16	3.7	
			Placebo	73	57 (78.1)	1.60 (0.47)	0.8	1.24	1.55	1.88	2.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Change from baseline	Week 2	Tezepelumab	74	70 (94.6)	0.16 (0.31)	-0.5	-0.06	0.09	0.29	1.4	0.46 [0.12, 0.80]
			Placebo	73	68 (93.2)	0.02 (0.28)	-0.7	-0.13	0.01	0.11	1.0	
		Week 4	Tezepelumab	74	74 (100.0)	0.20 (0.36)	-0.5	-0.03	0.12	0.36	1.7	0.23 [-0.10, 0.56]
			Placebo	73	72 (98.6)	0.11 (0.42)	-1.0	-0.13	0.05	0.36	1.2	
		Week 8	Tezepelumab	74	73 (98.6)	0.23 (0.32)	-0.4	0.02	0.19	0.44	1.2	0.48 [0.15, 0.81]
			Placebo	73	72 (98.6)	0.07 (0.34)	-0.9	-0.11	0.04	0.21	1.2	
		Week 12	Tezepelumab	74	74 (100.0)	0.24 (0.36)	-0.4	-0.02	0.17	0.44	1.5	0.34 [0.01, 0.67]
			Placebo	73	69 (94.5)	0.12 (0.33)	-1.1	-0.03	0.05	0.22	1.0	
		Week 16	Tezepelumab	74	71 (95.9)	0.23 (0.40)	-0.6	-0.03	0.14	0.42	1.6	0.40 [0.06, 0.74]
			Placebo	73	67 (91.8)	0.08 (0.33)	-1.0	-0.06	0.04	0.24	1.2	
		Week 24	Tezepelumab	74	69 (93.2)	0.23 (0.42)	-1.0	-0.03	0.17	0.44	1.7	0.34 [0.00, 0.68]
			Placebo	73	66 (90.4)	0.09 (0.35)	-1.1	-0.10	0.04	0.28	0.9	
		Week 36	Tezepelumab	74	67 (90.5)	0.22 (0.39)	-0.4	-0.07	0.09	0.49	1.6	0.40 [0.04, 0.75]
			Placebo	73	59 (80.8)	0.08 (0.32)	-0.9	-0.10	0.06	0.27	0.9	
		Week 52	Tezepelumab	74	66 (89.2)	0.22 (0.39)	-0.5	-0.03	0.13	0.38	1.4	0.57 [0.21, 0.93]
			Placebo	73	57 (78.1)	0.03 (0.27)	-1.0	-0.14	0.06	0.18	0.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
< 18.5 kg/m**2	Absolute values	Baseline	Tezepelumab	5	5 (100.0)	2.20 (0.76)	1.3	1.43	2.69	2.73	2.8	
			Placebo	7	7 (100.0)	2.74 (0.75)	1.7	2.24	2.70	3.17	4.0	
		Week 2	Tezepelumab	5	5 (100.0)	2.22 (0.65)	1.4	1.69	2.36	2.74	2.9	
			Placebo	7	7 (100.0)	2.45 (0.68)	1.1	2.27	2.62	2.76	3.4	
		Week 4	Tezepelumab	5	5 (100.0)	2.04 (0.80)	1.3	1.28	1.98	2.61	3.1	
			Placebo	7	7 (100.0)	2.53 (0.73)	1.2	2.17	2.59	3.18	3.2	
		Week 8	Tezepelumab	5	5 (100.0)	2.13 (0.89)	1.0	1.61	2.00	2.71	3.3	
			Placebo	7	7 (100.0)	2.49 (0.54)	1.6	2.35	2.43	2.79	3.4	
		Week 12	Tezepelumab	5	5 (100.0)	2.02 (1.03)	0.8	1.22	2.10	2.74	3.3	
			Placebo	7	7 (100.0)	2.51 (0.83)	1.0	2.00	2.59	3.07	3.6	
		Week 16	Tezepelumab	5	5 (100.0)	2.22 (0.75)	1.4	1.54	2.26	2.73	3.2	
			Placebo	7	7 (100.0)	2.44 (0.68)	1.1	2.38	2.46	3.01	3.2	
		Week 24	Tezepelumab	5	5 (100.0)	2.30 (0.79)	1.4	1.70	2.24	2.90	3.3	
			Placebo	7	6 (85.7)	2.72 (0.49)	1.9	2.48	2.83	3.14	3.1	
		Week 36	Tezepelumab	5	5 (100.0)	2.23 (0.92)	1.3	1.43	2.12	3.08	3.3	
			Placebo	7	6 (85.7)	2.66 (0.75)	1.3	2.45	2.86	2.96	3.5	
		Week 52	Tezepelumab	5	5 (100.0)	2.18 (0.87)	1.1	1.80	1.85	3.08	3.1	
			Placebo	7	5 (71.4)	2.73 (0.47)	2.0	2.67	2.88	2.93	3.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
< 18.5 kg/m**2	Change from baseline	Week 2	Tezepelumab	5	5 (100.0)	0.02 (0.28)	-0.5	0.05	0.10	0.16	0.3	0.74 [-0.45, 1.93]
			Placebo	7	7 (100.0)	-0.29 (0.49)	-1.3	-0.55	-0.08	0.03	0.2	
		Week 4	Tezepelumab	5	5 (100.0)	-0.15 (0.44)	-0.9	-0.15	-0.08	-0.04	0.4	0.14 [-1.01, 1.29]
			Placebo	7	7 (100.0)	-0.21 (0.40)	-1.0	-0.48	-0.11	0.06	0.2	
		Week 8	Tezepelumab	5	5 (100.0)	-0.07 (0.56)	-0.8	-0.40	0.02	0.30	0.6	0.29 [-0.86, 1.45]
			Placebo	7	7 (100.0)	-0.25 (0.67)	-1.7	-0.45	0.02	0.17	0.2	
		Week 12	Tezepelumab	5	5 (100.0)	-0.18 (0.52)	-0.7	-0.64	-0.09	0.05	0.5	0.12 [-1.03, 1.27]
			Placebo	7	7 (100.0)	-0.24 (0.48)	-1.0	-0.69	-0.24	0.20	0.4	
		Week 16	Tezepelumab	5	5 (100.0)	0.03 (0.37)	-0.6	0.04	0.11	0.12	0.4	0.61 [-0.57, 1.79]
			Placebo	7	7 (100.0)	-0.30 (0.63)	-1.6	-0.59	-0.03	0.06	0.2	
		Week 24	Tezepelumab	5	5 (100.0)	0.11 (0.42)	-0.6	0.09	0.21	0.27	0.5	0.37 [-0.83, 1.57]
			Placebo	7	6 (85.7)	-0.11 (0.66)	-1.4	-0.03	0.12	0.23	0.3	
		Week 36	Tezepelumab	5	5 (100.0)	0.03 (0.49)	-0.7	-0.06	0.00	0.39	0.5	0.35 [-0.85, 1.54]
			Placebo	7	6 (85.7)	-0.16 (0.61)	-1.2	-0.35	-0.08	0.20	0.6	
		Week 52	Tezepelumab	5	5 (100.0)	-0.01 (0.62)	-1.0	-0.20	0.35	0.39	0.4	0.24 [-1.00, 1.49]
			Placebo	7	5 (71.4)	-0.17 (0.70)	-1.4	-0.29	0.23	0.25	0.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Absolute values	Baseline	Tezepelumab	117	117 (100.0)	1.72 (0.68)	0.4	1.23	1.61	2.01	3.7	
			Placebo	119	119 (100.0)	1.93 (0.76)	0.4	1.41	1.81	2.28	4.9	
		Week 2	Tezepelumab	117	114 (97.4)	1.93 (0.71)	0.6	1.35	1.82	2.41	4.0	
			Placebo	119	115 (96.6)	2.05 (0.75)	0.4	1.54	1.94	2.46	4.7	
		Week 4	Tezepelumab	117	117 (100.0)	1.95 (0.69)	0.7	1.47	1.82	2.48	3.8	
			Placebo	119	116 (97.5)	1.99 (0.68)	0.4	1.51	1.96	2.43	4.0	
		Week 8	Tezepelumab	117	116 (99.1)	2.00 (0.74)	0.6	1.44	1.83	2.47	3.7	
			Placebo	119	117 (98.3)	2.03 (0.78)	0.4	1.45	1.96	2.44	4.9	
		Week 12	Tezepelumab	117	117 (100.0)	2.01 (0.71)	0.6	1.55	1.82	2.53	3.9	
			Placebo	119	115 (96.6)	2.09 (0.79)	0.7	1.50	2.00	2.52	5.0	
		Week 16	Tezepelumab	117	110 (94.0)	2.06 (0.74)	0.6	1.54	1.96	2.53	4.2	
			Placebo	119	112 (94.1)	2.04 (0.79)	0.7	1.53	1.93	2.49	5.2	
		Week 24	Tezepelumab	117	112 (95.7)	1.98 (0.71)	0.7	1.53	1.82	2.46	3.8	
			Placebo	119	107 (89.9)	2.07 (0.78)	0.7	1.51	1.95	2.48	5.1	
		Week 36	Tezepelumab	117	107 (91.5)	2.04 (0.74)	0.6	1.52	1.90	2.54	4.0	
			Placebo	119	102 (85.7)	2.09 (0.84)	0.7	1.50	2.00	2.43	5.3	
		Week 52	Tezepelumab	117	101 (86.3)	2.02 (0.76)	0.8	1.54	1.77	2.53	4.2	
			Placebo	119	102 (85.7)	2.05 (0.87)	0.7	1.49	1.87	2.42	5.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Change from baseline	Week 2	Tezepelumab	117	114 (97.4)	0.22 (0.38)	-0.5	-0.01	0.13	0.34	1.4	0.34 [0.08, 0.60]
			Placebo	119	115 (96.6)	0.09 (0.38)	-1.1	-0.07	0.04	0.20	1.7	
		Week 4	Tezepelumab	117	117 (100.0)	0.23 (0.39)	-0.5	0.00	0.16	0.38	1.8	0.31 [0.05, 0.57]
			Placebo	119	116 (97.5)	0.10 (0.44)	-1.8	-0.11	0.05	0.32	1.7	
		Week 8	Tezepelumab	117	116 (99.1)	0.28 (0.49)	-1.1	-0.02	0.18	0.53	1.7	0.39 [0.13, 0.65]
			Placebo	119	117 (98.3)	0.11 (0.41)	-0.9	-0.13	0.03	0.30	2.0	
		Week 12	Tezepelumab	117	117 (100.0)	0.29 (0.49)	-1.5	0.01	0.21	0.53	2.0	0.30 [0.04, 0.55]
			Placebo	119	115 (96.6)	0.16 (0.42)	-1.1	-0.07	0.06	0.40	1.6	
		Week 16	Tezepelumab	117	110 (94.0)	0.36 (0.45)	-0.6	0.03	0.25	0.60	1.7	0.56 [0.29, 0.83]
			Placebo	119	112 (94.1)	0.11 (0.44)	-1.2	-0.12	0.05	0.34	1.6	
		Week 24	Tezepelumab	117	112 (95.7)	0.27 (0.48)	-1.0	-0.04	0.21	0.52	1.8	0.37 [0.10, 0.64]
			Placebo	119	107 (89.9)	0.10 (0.45)	-1.1	-0.13	0.06	0.38	1.6	
		Week 36	Tezepelumab	117	107 (91.5)	0.33 (0.46)	-1.0	0.00	0.28	0.54	1.7	0.40 [0.13, 0.67]
			Placebo	119	102 (85.7)	0.14 (0.50)	-1.1	-0.15	0.15	0.33	2.2	
		Week 52	Tezepelumab	117	101 (86.3)	0.32 (0.43)	-0.7	0.01	0.26	0.56	1.6	0.47 [0.20, 0.75]
			Placebo	119	102 (85.7)	0.11 (0.44)	-1.0	-0.13	0.08	0.31	1.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	130	130 (100.0)	1.80 (0.73)	0.6	1.31	1.68	2.19	4.1	
			Placebo	130	130 (100.0)	1.81 (0.67)	0.6	1.33	1.69	2.26	4.1	
		Week 2	Tezepelumab	130	128 (98.5)	1.98 (0.78)	0.7	1.43	1.80	2.44	4.3	
			Placebo	130	122 (93.8)	1.88 (0.70)	0.6	1.38	1.73	2.43	4.1	
		Week 4	Tezepelumab	130	128 (98.5)	2.01 (0.80)	0.7	1.42	1.90	2.58	4.3	
			Placebo	130	126 (96.9)	1.91 (0.71)	0.5	1.38	1.78	2.32	4.8	
		Week 8	Tezepelumab	130	127 (97.7)	2.03 (0.81)	0.7	1.40	1.88	2.45	4.7	
			Placebo	130	127 (97.7)	1.92 (0.75)	0.6	1.36	1.78	2.34	4.6	
		Week 12	Tezepelumab	130	125 (96.2)	2.05 (0.81)	0.7	1.46	1.95	2.45	4.7	
			Placebo	130	124 (95.4)	1.94 (0.73)	0.5	1.40	1.84	2.38	4.6	
		Week 16	Tezepelumab	130	126 (96.9)	2.06 (0.84)	0.6	1.40	1.92	2.54	4.9	
			Placebo	130	123 (94.6)	1.91 (0.75)	0.5	1.33	1.83	2.29	4.7	
		Week 24	Tezepelumab	130	119 (91.5)	2.01 (0.74)	0.6	1.48	1.94	2.48	4.4	
			Placebo	130	119 (91.5)	1.89 (0.72)	0.8	1.37	1.80	2.25	4.8	
		Week 36	Tezepelumab	130	115 (88.5)	2.01 (0.83)	0.5	1.37	1.92	2.41	4.5	
			Placebo	130	117 (90.0)	1.95 (0.74)	0.6	1.37	1.82	2.43	4.3	
		Week 52	Tezepelumab	130	116 (89.2)	2.05 (0.81)	0.7	1.48	1.97	2.47	4.3	
			Placebo	130	105 (80.8)	1.88 (0.72)	0.6	1.28	1.79	2.39	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Change from baseline	Week 2	Tezepelumab	130	128 (98.5)	0.19 (0.33)	-0.5	-0.01	0.14	0.30	1.5	0.41 [0.16, 0.66]
			Placebo	130	122 (93.8)	0.05 (0.35)	-0.7	-0.16	0.01	0.19	1.2	
		Week 4	Tezepelumab	130	128 (98.5)	0.23 (0.38)	-0.4	0.00	0.15	0.34	1.7	0.33 [0.08, 0.58]
			Placebo	130	126 (96.9)	0.10 (0.39)	-0.7	-0.11	0.03	0.23	1.6	
		Week 8	Tezepelumab	130	127 (97.7)	0.26 (0.39)	-0.8	0.04	0.18	0.44	1.8	0.44 [0.19, 0.69]
			Placebo	130	127 (97.7)	0.10 (0.33)	-0.5	-0.10	0.07	0.24	1.6	
		Week 12	Tezepelumab	130	125 (96.2)	0.26 (0.39)	-0.4	0.01	0.18	0.43	1.9	0.38 [0.13, 0.63]
			Placebo	130	124 (95.4)	0.12 (0.37)	-0.7	-0.11	0.02	0.27	1.7	
		Week 16	Tezepelumab	130	126 (96.9)	0.28 (0.41)	-0.3	0.00	0.18	0.43	2.0	0.50 [0.24, 0.75]
			Placebo	130	123 (94.6)	0.08 (0.38)	-1.0	-0.14	0.00	0.23	1.8	
		Week 24	Tezepelumab	130	119 (91.5)	0.25 (0.38)	-0.7	-0.01	0.23	0.43	1.5	0.46 [0.20, 0.72]
			Placebo	130	119 (91.5)	0.08 (0.38)	-0.5	-0.16	0.02	0.24	1.7	
		Week 36	Tezepelumab	130	115 (88.5)	0.25 (0.42)	-0.8	-0.02	0.16	0.50	1.7	0.36 [0.10, 0.62]
			Placebo	130	117 (90.0)	0.11 (0.39)	-0.7	-0.15	0.04	0.29	1.7	
		Week 52	Tezepelumab	130	116 (89.2)	0.28 (0.41)	-0.8	0.00	0.23	0.55	1.7	0.60 [0.33, 0.87]
			Placebo	130	105 (80.8)	0.05 (0.36)	-0.9	-0.18	-0.01	0.20	1.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	143	143 (100.0)	1.77 (0.66)	0.6	1.27	1.65	2.13	4.0	
			Placebo	135	135 (100.0)	1.73 (0.67)	0.7	1.21	1.59	2.13	4.2	
		Week 2	Tezepelumab	143	137 (95.8)	1.93 (0.66)	0.6	1.40	1.86	2.42	4.1	
			Placebo	135	129 (95.6)	1.77 (0.69)	0.6	1.29	1.66	2.13	4.0	
		Week 4	Tezepelumab	143	141 (98.6)	1.94 (0.69)	0.6	1.41	1.88	2.41	4.2	
			Placebo	135	133 (98.5)	1.79 (0.66)	0.7	1.33	1.71	2.07	4.2	
		Week 8	Tezepelumab	143	140 (97.9)	1.93 (0.66)	0.6	1.38	1.87	2.39	4.1	
			Placebo	135	129 (95.6)	1.82 (0.68)	0.7	1.34	1.69	2.13	4.3	
		Week 12	Tezepelumab	143	135 (94.4)	1.93 (0.68)	0.6	1.45	1.83	2.35	4.6	
			Placebo	135	131 (97.0)	1.77 (0.66)	0.6	1.31	1.65	2.09	4.3	
		Week 16	Tezepelumab	143	139 (97.2)	1.93 (0.66)	0.6	1.40	1.86	2.34	4.2	
			Placebo	135	128 (94.8)	1.81 (0.68)	0.6	1.33	1.74	2.11	4.1	
		Week 24	Tezepelumab	143	133 (93.0)	1.94 (0.71)	0.6	1.41	1.79	2.41	4.0	
			Placebo	135	125 (92.6)	1.78 (0.69)	0.6	1.34	1.74	2.13	4.8	
		Week 36	Tezepelumab	143	129 (90.2)	1.94 (0.70)	0.7	1.42	1.85	2.38	4.4	
			Placebo	135	121 (89.6)	1.83 (0.69)	0.7	1.43	1.70	2.20	4.6	
		Week 52	Tezepelumab	143	127 (88.8)	1.94 (0.71)	0.6	1.37	1.87	2.37	4.2	
			Placebo	135	114 (84.4)	1.82 (0.73)	0.6	1.30	1.71	2.25	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Change from baseline	Week 2	Tezepelumab	143	137 (95.8)	0.16 (0.29)	-0.7	0.00	0.12	0.32	1.1	0.34 [0.10, 0.59]
			Placebo	135	129 (95.6)	0.04 (0.36)	-1.8	-0.09	-0.01	0.17	1.1	
		Week 4	Tezepelumab	143	141 (98.6)	0.18 (0.31)	-0.7	-0.04	0.12	0.32	1.1	0.36 [0.13, 0.60]
			Placebo	135	133 (98.5)	0.06 (0.35)	-1.0	-0.12	0.05	0.24	1.1	
		Week 8	Tezepelumab	143	140 (97.9)	0.18 (0.36)	-0.6	-0.06	0.11	0.36	1.4	0.29 [0.05, 0.53]
			Placebo	135	129 (95.6)	0.07 (0.34)	-0.8	-0.12	0.06	0.28	1.2	
		Week 12	Tezepelumab	143	135 (94.4)	0.17 (0.35)	-0.8	-0.05	0.12	0.38	1.3	0.37 [0.13, 0.61]
			Placebo	135	131 (97.0)	0.04 (0.40)	-1.5	-0.11	0.05	0.21	1.2	
		Week 16	Tezepelumab	143	139 (97.2)	0.16 (0.35)	-0.8	-0.04	0.13	0.33	1.4	0.25 [0.00, 0.49]
			Placebo	135	128 (94.8)	0.08 (0.32)	-0.8	-0.07	0.04	0.24	1.0	
		Week 24	Tezepelumab	143	133 (93.0)	0.19 (0.39)	-1.0	-0.07	0.11	0.39	1.7	0.37 [0.12, 0.61]
			Placebo	135	125 (92.6)	0.05 (0.35)	-1.1	-0.11	0.05	0.25	1.2	
		Week 36	Tezepelumab	143	129 (90.2)	0.16 (0.36)	-0.5	-0.09	0.08	0.37	1.6	0.26 [0.01, 0.51]
			Placebo	135	121 (89.6)	0.07 (0.37)	-1.7	-0.15	0.05	0.28	1.1	
		Week 52	Tezepelumab	143	127 (88.8)	0.17 (0.39)	-1.0	-0.07	0.11	0.35	1.4	0.27 [0.02, 0.53]
			Placebo	135	114 (84.4)	0.07 (0.29)	-0.8	-0.11	0.07	0.23	1.1	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Absolute values	Baseline	Tezepelumab	96	96 (100.0)	1.90 (0.70)	0.4	1.32	1.87	2.45	4.0	
			Placebo	89	89 (100.0)	1.83 (0.68)	0.8	1.39	1.79	2.17	4.9	
		Week 2	Tezepelumab	96	94 (97.9)	1.98 (0.73)	0.6	1.40	1.93	2.44	4.1	
			Placebo	89	84 (94.4)	1.85 (0.72)	0.8	1.37	1.66	2.18	4.7	
		Week 4	Tezepelumab	96	95 (99.0)	1.98 (0.78)	0.7	1.32	1.98	2.56	4.2	
			Placebo	89	87 (97.8)	1.82 (0.64)	0.7	1.34	1.78	2.20	3.6	
		Week 8	Tezepelumab	96	93 (96.9)	1.97 (0.74)	0.6	1.43	1.87	2.51	4.1	
			Placebo	89	86 (96.6)	1.87 (0.74)	0.7	1.38	1.81	2.34	4.9	
		Week 12	Tezepelumab	96	92 (95.8)	1.98 (0.75)	0.6	1.45	1.91	2.45	4.2	
			Placebo	89	84 (94.4)	1.84 (0.75)	0.7	1.33	1.67	2.20	5.0	
		Week 16	Tezepelumab	96	93 (96.9)	2.02 (0.80)	0.6	1.43	1.87	2.54	4.3	
			Placebo	89	84 (94.4)	1.81 (0.74)	0.6	1.30	1.69	2.19	5.2	
		Week 24	Tezepelumab	96	86 (89.6)	1.95 (0.71)	0.6	1.40	1.88	2.42	4.0	
			Placebo	89	81 (91.0)	1.86 (0.71)	0.8	1.34	1.73	2.20	5.1	
		Week 36	Tezepelumab	96	87 (90.6)	1.95 (0.78)	0.5	1.33	1.90	2.47	4.4	
			Placebo	89	78 (87.6)	1.89 (0.74)	0.8	1.36	1.82	2.25	5.3	
		Week 52	Tezepelumab	96	86 (89.6)	1.98 (0.76)	0.7	1.41	1.86	2.59	4.2	
			Placebo	89	77 (86.5)	1.83 (0.77)	0.7	1.28	1.65	2.28	5.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Change from baseline	Week 2	Tezepelumab	96	94 (97.9)	0.07 (0.30)	-0.6	-0.08	0.08	0.19	1.5	0.21 [-0.08, 0.51]
			Placebo	89	84 (94.4)	0.00 (0.34)	-1.8	-0.14	-0.01	0.13	1.1	
		Week 4	Tezepelumab	96	95 (99.0)	0.09 (0.36)	-0.9	-0.08	0.03	0.27	1.7	0.20 [-0.09, 0.49]
			Placebo	89	87 (97.8)	0.02 (0.34)	-1.0	-0.08	0.03	0.15	0.9	
		Week 8	Tezepelumab	96	93 (96.9)	0.10 (0.36)	-0.8	-0.09	0.02	0.29	1.4	0.15 [-0.14, 0.44]
			Placebo	89	86 (96.6)	0.05 (0.30)	-0.9	-0.10	0.05	0.22	0.9	
		Week 12	Tezepelumab	96	92 (95.8)	0.09 (0.34)	-0.8	-0.09	0.07	0.22	1.4	0.20 [-0.09, 0.50]
			Placebo	89	84 (94.4)	0.02 (0.34)	-1.2	-0.09	0.02	0.19	1.0	
		Week 16	Tezepelumab	96	93 (96.9)	0.12 (0.41)	-0.8	-0.13	0.06	0.24	1.9	0.35 [0.05, 0.65]
			Placebo	89	84 (94.4)	-0.01 (0.34)	-1.0	-0.16	0.01	0.16	1.5	
		Week 24	Tezepelumab	96	86 (89.6)	0.09 (0.30)	-0.6	-0.07	0.03	0.22	1.1	0.23 [-0.08, 0.53]
			Placebo	89	81 (91.0)	0.02 (0.33)	-1.1	-0.12	0.02	0.14	1.4	
		Week 36	Tezepelumab	96	87 (90.6)	0.07 (0.35)	-0.7	-0.12	0.00	0.22	1.5	0.09 [-0.21, 0.40]
			Placebo	89	78 (87.6)	0.04 (0.30)	-0.7	-0.15	0.03	0.20	1.3	
		Week 52	Tezepelumab	96	86 (89.6)	0.10 (0.38)	-1.0	-0.08	0.05	0.25	1.3	0.29 [-0.02, 0.60]
			Placebo	89	77 (86.5)	-0.01 (0.35)	-1.0	-0.17	0.01	0.13	1.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Absolute values	Baseline	Tezepelumab	299	299 (100.0)	1.73 (0.69)	0.5	1.23	1.60	2.10	4.1	
			Placebo	302	302 (100.0)	1.84 (0.72)	0.4	1.33	1.70	2.26	4.5	
		Week 2	Tezepelumab	299	290 (97.0)	1.94 (0.71)	0.6	1.40	1.80	2.42	4.3	
			Placebo	302	289 (95.7)	1.92 (0.72)	0.4	1.39	1.83	2.36	4.1	
		Week 4	Tezepelumab	299	296 (99.0)	1.97 (0.71)	0.6	1.45	1.85	2.43	4.3	
			Placebo	302	295 (97.7)	1.92 (0.71)	0.4	1.44	1.84	2.32	4.8	
		Week 8	Tezepelumab	299	295 (98.7)	1.99 (0.74)	0.6	1.40	1.85	2.44	4.7	
			Placebo	302	294 (97.4)	1.95 (0.74)	0.4	1.41	1.85	2.35	4.6	
		Week 12	Tezepelumab	299	290 (97.0)	2.00 (0.74)	0.6	1.50	1.89	2.42	4.7	
			Placebo	302	293 (97.0)	1.96 (0.74)	0.5	1.44	1.87	2.40	4.6	
		Week 16	Tezepelumab	299	287 (96.0)	2.01 (0.73)	0.6	1.49	1.91	2.40	4.9	
			Placebo	302	286 (94.7)	1.96 (0.74)	0.5	1.41	1.84	2.35	4.7	
		Week 24	Tezepelumab	299	283 (94.6)	1.99 (0.72)	0.6	1.51	1.83	2.43	4.4	
			Placebo	302	276 (91.4)	1.94 (0.74)	0.6	1.43	1.83	2.28	4.8	
		Week 36	Tezepelumab	299	269 (90.0)	2.01 (0.75)	0.7	1.44	1.89	2.42	4.5	
			Placebo	302	268 (88.7)	1.98 (0.77)	0.6	1.44	1.83	2.37	4.6	
		Week 52	Tezepelumab	299	263 (88.0)	2.01 (0.76)	0.6	1.49	1.88	2.42	4.3	
			Placebo	302	249 (82.5)	1.95 (0.78)	0.6	1.38	1.81	2.33	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Change from baseline	Week 2	Tezepelumab	299	290 (97.0)	0.22 (0.34)	-0.7	0.01	0.16	0.36	1.4	0.43 [0.26, 0.59]
			Placebo	302	289 (95.7)	0.07 (0.37)	-1.3	-0.10	0.02	0.20	1.7	
		Week 4	Tezepelumab	299	296 (99.0)	0.24 (0.36)	-0.5	0.01	0.17	0.38	1.8	0.38 [0.22, 0.54]
			Placebo	302	295 (97.7)	0.10 (0.41)	-1.8	-0.11	0.05	0.28	1.7	
		Week 8	Tezepelumab	299	295 (98.7)	0.27 (0.43)	-1.1	0.03	0.19	0.50	1.8	0.43 [0.27, 0.60]
			Placebo	302	294 (97.4)	0.10 (0.39)	-1.7	-0.12	0.06	0.28	2.0	
		Week 12	Tezepelumab	299	290 (97.0)	0.28 (0.43)	-1.5	0.02	0.20	0.48	2.0	0.39 [0.23, 0.55]
			Placebo	302	293 (97.0)	0.12 (0.42)	-1.5	-0.10	0.06	0.29	1.7	
		Week 16	Tezepelumab	299	287 (96.0)	0.30 (0.40)	-0.6	0.04	0.23	0.49	2.0	0.47 [0.31, 0.64]
			Placebo	302	286 (94.7)	0.11 (0.40)	-1.6	-0.09	0.04	0.30	1.8	
		Week 24	Tezepelumab	299	283 (94.6)	0.28 (0.43)	-1.0	-0.02	0.24	0.48	1.8	0.44 [0.27, 0.61]
			Placebo	302	276 (91.4)	0.09 (0.41)	-1.4	-0.13	0.06	0.29	1.7	
		Week 36	Tezepelumab	299	269 (90.0)	0.30 (0.42)	-1.0	-0.01	0.24	0.53	1.7	0.41 [0.24, 0.58]
			Placebo	302	268 (88.7)	0.12 (0.45)	-1.7	-0.16	0.07	0.36	2.2	
		Week 52	Tezepelumab	299	263 (88.0)	0.29 (0.42)	-0.8	0.00	0.24	0.55	1.7	0.49 [0.32, 0.67]
			Placebo	302	249 (82.5)	0.10 (0.38)	-1.4	-0.14	0.07	0.30	1.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Absolute values	Baseline	Tezepelumab	225	225 (100.0)	1.83 (0.68)	0.4	1.31	1.74	2.30	4.0	
			Placebo	211	211 (100.0)	1.86 (0.70)	0.7	1.36	1.71	2.22	4.9	
		Week 2	Tezepelumab	225	220 (97.8)	1.95 (0.71)	0.6	1.41	1.86	2.44	4.1	
			Placebo	211	202 (95.7)	1.89 (0.75)	0.6	1.38	1.73	2.31	4.7	
		Week 4	Tezepelumab	225	223 (99.1)	1.95 (0.72)	0.6	1.36	1.92	2.50	4.2	
			Placebo	211	205 (97.2)	1.86 (0.69)	0.7	1.39	1.76	2.23	4.8	
		Week 8	Tezepelumab	225	221 (98.2)	1.95 (0.71)	0.6	1.36	1.88	2.44	4.1	
			Placebo	211	203 (96.2)	1.94 (0.76)	0.7	1.40	1.81	2.35	4.9	
		Week 12	Tezepelumab	225	217 (96.4)	1.94 (0.72)	0.6	1.40	1.85	2.41	4.2	
			Placebo	211	201 (95.3)	1.89 (0.77)	0.6	1.34	1.74	2.28	5.0	
		Week 16	Tezepelumab	225	219 (97.3)	1.97 (0.72)	0.6	1.39	1.86	2.47	4.3	
			Placebo	211	199 (94.3)	1.90 (0.79)	0.6	1.32	1.75	2.28	5.2	
		Week 24	Tezepelumab	225	211 (93.8)	1.92 (0.70)	0.6	1.38	1.79	2.42	4.0	
			Placebo	211	192 (91.0)	1.87 (0.76)	0.6	1.34	1.72	2.20	5.1	
		Week 36	Tezepelumab	225	205 (91.1)	1.93 (0.73)	0.5	1.31	1.85	2.46	4.4	
			Placebo	211	186 (88.2)	1.91 (0.77)	0.7	1.38	1.73	2.27	5.3	
		Week 52	Tezepelumab	225	206 (91.6)	1.95 (0.74)	0.7	1.41	1.84	2.51	4.2	
			Placebo	211	176 (83.4)	1.89 (0.80)	0.7	1.32	1.69	2.29	5.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Change from baseline	Week 2	Tezepelumab	225	220 (97.8)	0.12 (0.29)	-0.7	-0.04	0.08	0.25	1.5	0.32 [0.13, 0.51]
			Placebo	211	202 (95.7)	0.02 (0.32)	-1.8	-0.12	0.00	0.13	1.1	
		Week 4	Tezepelumab	225	223 (99.1)	0.13 (0.34)	-0.9	-0.05	0.09	0.25	1.7	0.29 [0.10, 0.48]
			Placebo	211	205 (97.2)	0.03 (0.34)	-1.0	-0.12	0.04	0.19	1.6	
		Week 8	Tezepelumab	225	221 (98.2)	0.14 (0.36)	-0.8	-0.06	0.10	0.29	1.4	0.21 [0.02, 0.40]
			Placebo	211	203 (96.2)	0.07 (0.30)	-0.9	-0.10	0.05	0.24	1.4	
		Week 12	Tezepelumab	225	217 (96.4)	0.13 (0.36)	-0.8	-0.06	0.09	0.25	2.0	0.23 [0.04, 0.42]
			Placebo	211	201 (95.3)	0.04 (0.35)	-1.5	-0.09	0.03	0.19	1.4	
		Week 16	Tezepelumab	225	219 (97.3)	0.15 (0.37)	-0.8	-0.06	0.10	0.28	1.9	0.29 [0.10, 0.49]
			Placebo	211	199 (94.3)	0.04 (0.35)	-1.2	-0.12	0.02	0.20	1.5	
		Week 24	Tezepelumab	225	211 (93.8)	0.11 (0.35)	-1.0	-0.08	0.06	0.29	1.3	0.27 [0.08, 0.47]
			Placebo	211	192 (91.0)	0.02 (0.33)	-1.1	-0.14	0.00	0.19	1.6	
		Week 36	Tezepelumab	225	205 (91.1)	0.11 (0.36)	-1.0	-0.09	0.04	0.26	1.5	0.20 [0.00, 0.40]
			Placebo	211	186 (88.2)	0.04 (0.36)	-1.1	-0.19	0.03	0.22	1.3	
		Week 52	Tezepelumab	225	206 (91.6)	0.13 (0.38)	-1.0	-0.07	0.06	0.28	1.5	0.27 [0.07, 0.48]
			Placebo	211	176 (83.4)	0.04 (0.33)	-1.0	-0.15	0.04	0.19	1.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Absolute values	Baseline	Tezepelumab	170	170 (100.0)	1.70 (0.71)	0.5	1.21	1.55	1.98	4.1	
			Placebo	180	180 (100.0)	1.81 (0.72)	0.4	1.31	1.70	2.23	4.5	
		Week 2	Tezepelumab	170	164 (96.5)	1.95 (0.73)	0.8	1.40	1.80	2.37	4.3	
			Placebo	180	171 (95.0)	1.92 (0.69)	0.4	1.41	1.90	2.37	4.0	
		Week 4	Tezepelumab	170	168 (98.8)	2.00 (0.74)	0.7	1.49	1.85	2.48	4.3	
			Placebo	180	177 (98.3)	1.94 (0.70)	0.4	1.44	1.90	2.33	4.2	
		Week 8	Tezepelumab	170	167 (98.2)	2.03 (0.77)	0.9	1.43	1.85	2.41	4.7	
			Placebo	180	177 (98.3)	1.92 (0.72)	0.4	1.40	1.89	2.33	4.3	
		Week 12	Tezepelumab	170	165 (97.1)	2.06 (0.76)	0.7	1.57	1.93	2.45	4.7	
			Placebo	180	176 (97.8)	1.98 (0.71)	0.5	1.48	1.97	2.44	4.3	
		Week 16	Tezepelumab	170	161 (94.7)	2.08 (0.78)	0.8	1.53	1.95	2.48	4.9	
			Placebo	180	171 (95.0)	1.96 (0.68)	0.5	1.48	1.88	2.34	4.4	
		Week 24	Tezepelumab	170	158 (92.9)	2.06 (0.74)	0.9	1.59	1.94	2.46	4.4	
			Placebo	180	165 (91.7)	1.98 (0.71)	0.7	1.48	1.90	2.32	4.8	
		Week 36	Tezepelumab	170	151 (88.8)	2.09 (0.78)	0.7	1.50	1.97	2.39	4.5	
			Placebo	180	160 (88.9)	2.01 (0.76)	0.6	1.49	1.93	2.38	4.6	
		Week 52	Tezepelumab	170	143 (84.1)	2.08 (0.78)	0.6	1.56	1.89	2.42	4.3	
			Placebo	180	150 (83.3)	1.96 (0.75)	0.6	1.37	1.90	2.39	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Change from baseline	Week 2	Tezepelumab	170	164 (96.5)	0.27 (0.36)	-0.5	0.06	0.21	0.42	1.4	0.46 [0.24, 0.67]
			Placebo	180	171 (95.0)	0.09 (0.41)	-1.3	-0.10	0.03	0.27	1.7	
		Week 4	Tezepelumab	170	168 (98.8)	0.30 (0.37)	-0.4	0.06	0.25	0.47	1.8	0.41 [0.20, 0.63]
			Placebo	180	177 (98.3)	0.14 (0.44)	-1.8	-0.11	0.05	0.36	1.7	
		Week 8	Tezepelumab	170	167 (98.2)	0.35 (0.46)	-1.1	0.06	0.29	0.62	1.8	0.56 [0.34, 0.77]
			Placebo	180	177 (98.3)	0.10 (0.44)	-1.7	-0.15	0.06	0.28	2.0	
		Week 12	Tezepelumab	170	165 (97.1)	0.38 (0.45)	-1.5	0.09	0.34	0.60	1.9	0.51 [0.29, 0.72]
			Placebo	180	176 (97.8)	0.15 (0.45)	-1.4	-0.11	0.08	0.38	1.7	
		Week 16	Tezepelumab	170	161 (94.7)	0.40 (0.42)	-0.5	0.12	0.34	0.60	2.0	0.65 [0.43, 0.87]
			Placebo	180	171 (95.0)	0.13 (0.43)	-1.6	-0.11	0.04	0.36	1.8	
		Week 24	Tezepelumab	170	158 (92.9)	0.39 (0.44)	-0.8	0.11	0.35	0.62	1.8	0.58 [0.36, 0.80]
			Placebo	180	165 (91.7)	0.13 (0.45)	-1.4	-0.13	0.08	0.36	1.7	
		Week 36	Tezepelumab	170	151 (88.8)	0.41 (0.42)	-0.3	0.10	0.37	0.63	1.7	0.54 [0.32, 0.77]
			Placebo	180	160 (88.9)	0.17 (0.48)	-1.7	-0.10	0.13	0.41	2.2	
		Week 52	Tezepelumab	170	143 (84.1)	0.41 (0.42)	-0.8	0.10	0.39	0.65	1.7	0.70 [0.46, 0.93]
			Placebo	180	150 (83.3)	0.11 (0.42)	-1.4	-0.13	0.06	0.33	1.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Absolute values	Baseline	Tezepelumab	158	158 (100.0)	1.71 (0.68)	0.4	1.23	1.56	2.13	4.0	
			Placebo	151	151 (100.0)	1.86 (0.74)	0.4	1.35	1.73	2.31	3.9	
		Week 2	Tezepelumab	158	153 (96.8)	1.86 (0.67)	0.6	1.35	1.72	2.36	4.1	
			Placebo	151	141 (93.4)	1.92 (0.73)	0.4	1.38	1.85	2.38	4.1	
		Week 4	Tezepelumab	158	155 (98.1)	1.85 (0.69)	0.6	1.28	1.73	2.37	4.2	
			Placebo	151	149 (98.7)	1.92 (0.74)	0.4	1.43	1.83	2.34	4.8	
		Week 8	Tezepelumab	158	155 (98.1)	1.86 (0.69)	0.6	1.32	1.68	2.36	4.1	
			Placebo	151	147 (97.4)	1.93 (0.74)	0.4	1.40	1.83	2.36	4.6	
		Week 12	Tezepelumab	158	152 (96.2)	1.85 (0.67)	0.6	1.38	1.74	2.26	4.2	
			Placebo	151	144 (95.4)	1.94 (0.76)	0.5	1.40	1.75	2.46	4.6	
		Week 16	Tezepelumab	158	151 (95.6)	1.89 (0.69)	0.6	1.37	1.79	2.39	4.2	
			Placebo	151	144 (95.4)	1.89 (0.75)	0.5	1.32	1.79	2.35	4.7	
		Week 24	Tezepelumab	158	149 (94.3)	1.84 (0.67)	0.6	1.30	1.74	2.30	4.0	
			Placebo	151	140 (92.7)	1.91 (0.75)	0.6	1.40	1.82	2.25	4.8	
		Week 36	Tezepelumab	158	140 (88.6)	1.83 (0.67)	0.5	1.28	1.76	2.31	4.4	
			Placebo	151	135 (89.4)	1.95 (0.76)	0.6	1.41	1.82	2.38	4.3	
		Week 52	Tezepelumab	158	142 (89.9)	1.84 (0.67)	0.7	1.36	1.74	2.24	4.2	
			Placebo	151	130 (86.1)	1.91 (0.79)	0.6	1.32	1.74	2.43	4.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Change from baseline	Week 2	Tezepelumab	158	153 (96.8)	0.14 (0.31)	-0.7	-0.01	0.09	0.25	1.4	0.39 [0.16, 0.62]
			Placebo	151	141 (93.4)	0.03 (0.27)	-0.8	-0.11	0.00	0.12	0.9	
		Week 4	Tezepelumab	158	155 (98.1)	0.15 (0.34)	-0.9	-0.04	0.09	0.29	1.7	0.27 [0.05, 0.50]
			Placebo	151	149 (98.7)	0.07 (0.31)	-0.9	-0.09	0.03	0.19	1.6	
		Week 8	Tezepelumab	158	155 (98.1)	0.17 (0.37)	-0.8	-0.05	0.11	0.27	1.6	0.32 [0.10, 0.55]
			Placebo	151	147 (97.4)	0.06 (0.31)	-0.9	-0.10	0.04	0.20	1.4	
		Week 12	Tezepelumab	158	152 (96.2)	0.15 (0.34)	-0.7	-0.04	0.10	0.28	1.5	0.28 [0.05, 0.51]
			Placebo	151	144 (95.4)	0.06 (0.33)	-1.5	-0.06	0.03	0.20	1.4	
		Week 16	Tezepelumab	158	151 (95.6)	0.16 (0.35)	-0.6	-0.04	0.11	0.29	1.6	0.43 [0.20, 0.66]
			Placebo	151	144 (95.4)	0.02 (0.32)	-1.0	-0.14	0.01	0.15	1.4	
		Week 24	Tezepelumab	158	149 (94.3)	0.15 (0.36)	-1.0	-0.07	0.09	0.32	1.5	0.39 [0.16, 0.62]
			Placebo	151	140 (92.7)	0.01 (0.33)	-1.1	-0.14	0.03	0.15	1.6	
		Week 36	Tezepelumab	158	140 (88.6)	0.12 (0.36)	-1.0	-0.11	0.07	0.32	1.4	0.15 [-0.09, 0.38]
			Placebo	151	135 (89.4)	0.07 (0.30)	-0.8	-0.10	0.06	0.21	1.1	
		Week 52	Tezepelumab	158	142 (89.9)	0.14 (0.37)	-1.0	-0.04	0.09	0.34	1.3	0.27 [0.03, 0.51]
			Placebo	151	130 (86.1)	0.05 (0.31)	-1.0	-0.14	0.05	0.21	1.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Absolute values	Baseline	Tezepelumab	234	234 (100.0)	1.82 (0.70)	0.5	1.33	1.70	2.15	4.1	
			Placebo	236	236 (100.0)	1.82 (0.70)	0.6	1.33	1.70	2.17	4.9	
		Week 2	Tezepelumab	234	228 (97.4)	2.03 (0.74)	0.7	1.48	1.89	2.45	4.3	
			Placebo	236	228 (96.6)	1.90 (0.72)	0.6	1.39	1.79	2.31	4.7	
		Week 4	Tezepelumab	234	233 (99.6)	2.05 (0.75)	0.7	1.48	1.93	2.58	4.3	
			Placebo	236	229 (97.0)	1.89 (0.66)	0.7	1.42	1.81	2.25	4.2	
		Week 8	Tezepelumab	234	230 (98.3)	2.08 (0.76)	0.8	1.47	2.01	2.48	4.7	
			Placebo	236	229 (97.0)	1.93 (0.74)	0.7	1.41	1.84	2.30	4.9	
		Week 12	Tezepelumab	234	227 (97.0)	2.09 (0.77)	0.7	1.55	1.94	2.59	4.7	
			Placebo	236	230 (97.5)	1.94 (0.73)	0.6	1.42	1.87	2.32	5.0	
		Week 16	Tezepelumab	234	226 (96.6)	2.11 (0.78)	0.8	1.59	2.00	2.51	4.9	
			Placebo	236	223 (94.5)	1.95 (0.74)	0.6	1.44	1.80	2.26	5.2	
		Week 24	Tezepelumab	234	217 (92.7)	2.08 (0.73)	0.7	1.60	1.98	2.53	4.4	
			Placebo	236	214 (90.7)	1.93 (0.74)	0.6	1.41	1.80	2.24	5.1	
		Week 36	Tezepelumab	234	213 (91.0)	2.12 (0.79)	0.6	1.53	2.00	2.54	4.5	
			Placebo	236	208 (88.1)	1.97 (0.77)	0.7	1.44	1.83	2.31	5.3	
		Week 52	Tezepelumab	234	204 (87.2)	2.12 (0.80)	0.6	1.57	2.04	2.58	4.3	
			Placebo	236	193 (81.8)	1.93 (0.78)	0.7	1.37	1.81	2.28	5.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Change from baseline	Week 2	Tezepelumab	234	228 (97.4)	0.22 (0.35)	-0.6	0.00	0.18	0.37	1.5	0.39 [0.20, 0.58]
			Placebo	236	228 (96.6)	0.07 (0.41)	-1.8	-0.11	0.02	0.23	1.7	
		Week 4	Tezepelumab	234	233 (99.6)	0.24 (0.38)	-0.7	0.01	0.17	0.38	1.8	0.38 [0.19, 0.56]
			Placebo	236	229 (97.0)	0.09 (0.44)	-1.8	-0.13	0.05	0.30	1.7	
		Week 8	Tezepelumab	234	230 (98.3)	0.28 (0.44)	-1.1	0.01	0.23	0.51	1.8	0.41 [0.22, 0.59]
			Placebo	236	229 (97.0)	0.11 (0.40)	-1.7	-0.12	0.07	0.30	2.0	
		Week 12	Tezepelumab	234	227 (97.0)	0.29 (0.46)	-1.5	0.01	0.23	0.52	2.0	0.39 [0.20, 0.57]
			Placebo	236	230 (97.5)	0.12 (0.44)	-1.4	-0.12	0.07	0.36	1.7	
		Week 16	Tezepelumab	234	226 (96.6)	0.32 (0.44)	-0.8	0.04	0.25	0.51	2.0	0.46 [0.27, 0.64]
			Placebo	236	223 (94.5)	0.12 (0.42)	-1.6	-0.10	0.04	0.35	1.8	
		Week 24	Tezepelumab	234	217 (92.7)	0.29 (0.44)	-1.0	-0.01	0.26	0.48	1.8	0.41 [0.22, 0.60]
			Placebo	236	214 (90.7)	0.12 (0.43)	-1.4	-0.12	0.06	0.33	1.7	
		Week 36	Tezepelumab	234	213 (91.0)	0.32 (0.44)	-0.6	-0.01	0.24	0.54	1.7	0.44 [0.25, 0.64]
			Placebo	236	208 (88.1)	0.12 (0.49)	-1.7	-0.18	0.06	0.40	2.2	
		Week 52	Tezepelumab	234	204 (87.2)	0.32 (0.43)	-0.8	0.01	0.26	0.57	1.7	0.55 [0.35, 0.75]
			Placebo	236	193 (81.8)	0.09 (0.42)	-1.4	-0.15	0.06	0.31	1.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	140	140 (100.0)	1.63 (0.62)	0.4	1.17	1.50	2.02	3.3	
			Placebo	131	131 (100.0)	1.70 (0.63)	0.6	1.28	1.64	2.05	4.2	
		Week 2	Tezepelumab	140	138 (98.6)	1.80 (0.63)	0.6	1.32	1.74	2.22	3.8	
			Placebo	131	125 (95.4)	1.74 (0.63)	0.6	1.36	1.63	2.09	4.0	
		Week 4	Tezepelumab	140	139 (99.3)	1.86 (0.67)	0.7	1.28	1.82	2.39	3.8	
			Placebo	131	128 (97.7)	1.79 (0.63)	0.7	1.36	1.72	2.20	4.2	
		Week 8	Tezepelumab	140	138 (98.6)	1.86 (0.65)	0.6	1.31	1.77	2.40	3.8	
			Placebo	131	126 (96.2)	1.79 (0.65)	0.7	1.35	1.66	2.08	4.3	
		Week 12	Tezepelumab	140	138 (98.6)	1.89 (0.69)	0.6	1.39	1.78	2.38	4.6	
			Placebo	131	127 (96.9)	1.79 (0.67)	0.6	1.31	1.69	2.16	4.3	
		Week 16	Tezepelumab	140	137 (97.9)	1.90 (0.68)	0.6	1.35	1.83	2.40	3.8	
			Placebo	131	123 (93.9)	1.78 (0.64)	0.7	1.31	1.68	2.16	4.1	
		Week 24	Tezepelumab	140	133 (95.0)	1.88 (0.66)	0.6	1.36	1.76	2.38	4.0	
			Placebo	131	114 (87.0)	1.78 (0.64)	0.8	1.38	1.67	2.12	4.8	
		Week 36	Tezepelumab	140	129 (92.1)	1.88 (0.68)	0.5	1.28	1.81	2.34	3.8	
			Placebo	131	113 (86.3)	1.79 (0.65)	0.8	1.36	1.69	2.21	4.6	
		Week 52	Tezepelumab	140	128 (91.4)	1.92 (0.68)	0.7	1.38	1.89	2.38	3.7	
			Placebo	131	106 (80.9)	1.70 (0.64)	0.6	1.27	1.60	2.07	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Change from baseline	Week 2	Tezepelumab	140	138 (98.6)	0.18 (0.29)	-0.4	0.02	0.12	0.30	1.1	0.49 [0.25, 0.74]
			Placebo	131	125 (95.4)	0.04 (0.29)	-0.7	-0.09	-0.01	0.16	1.0	
		Week 4	Tezepelumab	140	139 (99.3)	0.24 (0.33)	-0.5	0.01	0.17	0.38	1.7	0.43 [0.19, 0.67]
			Placebo	131	128 (97.7)	0.09 (0.33)	-1.0	-0.08	0.05	0.23	1.2	
		Week 8	Tezepelumab	140	138 (98.6)	0.25 (0.36)	-0.6	0.00	0.17	0.45	1.4	0.48 [0.24, 0.73]
			Placebo	131	126 (96.2)	0.09 (0.30)	-0.6	-0.12	0.05	0.21	1.2	
		Week 12	Tezepelumab	140	138 (98.6)	0.26 (0.38)	-0.7	0.01	0.21	0.45	1.4	0.42 [0.18, 0.67]
			Placebo	131	127 (96.9)	0.10 (0.35)	-0.7	-0.10	0.03	0.29	1.2	
		Week 16	Tezepelumab	140	137 (97.9)	0.28 (0.36)	-0.6	0.04	0.24	0.43	1.6	0.60 [0.35, 0.85]
			Placebo	131	123 (93.9)	0.08 (0.31)	-0.7	-0.10	0.02	0.26	1.2	
		Week 24	Tezepelumab	140	133 (95.0)	0.26 (0.37)	-0.4	-0.01	0.21	0.43	1.7	0.53 [0.28, 0.79]
			Placebo	131	114 (87.0)	0.07 (0.34)	-0.8	-0.12	0.04	0.25	1.2	
		Week 36	Tezepelumab	140	129 (92.1)	0.25 (0.39)	-0.5	-0.02	0.16	0.44	1.6	0.47 [0.21, 0.72]
			Placebo	131	113 (86.3)	0.08 (0.35)	-0.9	-0.16	0.04	0.25	1.3	
		Week 52	Tezepelumab	140	128 (91.4)	0.27 (0.39)	-0.4	-0.02	0.22	0.52	1.4	0.82 [0.55, 1.09]
			Placebo	131	106 (80.9)	-0.01 (0.27)	-0.7	-0.18	0.04	0.15	0.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	253	253 (100.0)	1.85 (0.72)	0.5	1.36	1.66	2.20	4.1	
			Placebo	253	253 (100.0)	1.91 (0.75)	0.4	1.37	1.80	2.29	4.9	
		Week 2	Tezepelumab	253	245 (96.8)	2.03 (0.75)	0.6	1.46	1.92	2.53	4.3	
			Placebo	253	243 (96.0)	2.00 (0.76)	0.4	1.42	1.93	2.46	4.7	
		Week 4	Tezepelumab	253	251 (99.2)	2.03 (0.76)	0.6	1.46	1.90	2.54	4.3	
			Placebo	253	248 (98.0)	1.97 (0.72)	0.4	1.46	1.89	2.41	4.8	
		Week 8	Tezepelumab	253	249 (98.4)	2.05 (0.78)	0.6	1.45	1.96	2.48	4.7	
			Placebo	253	247 (97.6)	2.01 (0.78)	0.4	1.41	1.95	2.42	4.9	
		Week 12	Tezepelumab	253	243 (96.0)	2.05 (0.76)	0.6	1.56	1.93	2.46	4.7	
			Placebo	253	244 (96.4)	2.01 (0.77)	0.5	1.47	1.92	2.44	5.0	
		Week 16	Tezepelumab	253	242 (95.7)	2.08 (0.78)	0.6	1.53	1.95	2.50	4.9	
			Placebo	253	240 (94.9)	2.01 (0.78)	0.5	1.44	1.89	2.46	5.2	
		Week 24	Tezepelumab	253	235 (92.9)	2.03 (0.74)	0.6	1.54	1.92	2.53	4.4	
			Placebo	253	236 (93.3)	2.00 (0.78)	0.6	1.43	1.90	2.42	5.1	
		Week 36	Tezepelumab	253	226 (89.3)	2.06 (0.79)	0.6	1.48	1.95	2.50	4.5	
			Placebo	253	227 (89.7)	2.05 (0.81)	0.6	1.48	1.91	2.48	5.3	
		Week 52	Tezepelumab	253	220 (87.0)	2.05 (0.80)	0.6	1.51	1.85	2.47	4.3	
			Placebo	253	216 (85.4)	2.04 (0.82)	0.6	1.42	1.91	2.50	5.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Change from baseline	Week 2	Tezepelumab	253	245 (96.8)	0.18 (0.36)	-0.7	-0.02	0.13	0.33	1.5	0.32 [0.14, 0.50]
			Placebo	253	243 (96.0)	0.06 (0.40)	-1.8	-0.12	0.03	0.20	1.7	
		Week 4	Tezepelumab	253	251 (99.2)	0.19 (0.38)	-0.9	-0.03	0.11	0.33	1.8	0.28 [0.10, 0.45]
			Placebo	253	248 (98.0)	0.08 (0.42)	-1.8	-0.12	0.03	0.27	1.7	
		Week 8	Tezepelumab	253	249 (98.4)	0.22 (0.45)	-1.1	-0.04	0.15	0.44	1.8	0.32 [0.14, 0.50]
			Placebo	253	247 (97.6)	0.09 (0.40)	-1.7	-0.12	0.05	0.30	2.0	
		Week 12	Tezepelumab	253	243 (96.0)	0.22 (0.44)	-1.5	-0.04	0.16	0.40	2.0	0.31 [0.13, 0.49]
			Placebo	253	244 (96.4)	0.09 (0.43)	-1.5	-0.10	0.05	0.26	1.7	
		Week 16	Tezepelumab	253	242 (95.7)	0.24 (0.44)	-0.8	-0.04	0.15	0.42	2.0	0.36 [0.18, 0.54]
			Placebo	253	240 (94.9)	0.09 (0.42)	-1.6	-0.13	0.03	0.26	1.8	
		Week 24	Tezepelumab	253	235 (92.9)	0.22 (0.44)	-1.0	-0.06	0.16	0.42	1.8	0.33 [0.15, 0.51]
			Placebo	253	236 (93.3)	0.08 (0.43)	-1.4	-0.14	0.03	0.27	1.7	
		Week 36	Tezepelumab	253	226 (89.3)	0.23 (0.43)	-1.0	-0.04	0.17	0.46	1.7	0.27 [0.08, 0.45]
			Placebo	253	227 (89.7)	0.11 (0.46)	-1.7	-0.15	0.07	0.31	2.2	
		Week 52	Tezepelumab	253	220 (87.0)	0.23 (0.44)	-1.0	-0.02	0.16	0.47	1.7	0.28 [0.09, 0.47]
			Placebo	253	216 (85.4)	0.11 (0.41)	-1.4	-0.12	0.07	0.32	1.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Absolute values	Baseline	Tezepelumab	116	116 (100.0)	1.69 (0.65)	0.4	1.20	1.59	2.05	3.3	
			Placebo	125	125 (100.0)	1.68 (0.59)	0.7	1.30	1.55	2.03	4.2	
		Week 2	Tezepelumab	116	113 (97.4)	1.81 (0.63)	0.6	1.38	1.69	2.22	3.8	
			Placebo	125	117 (93.6)	1.72 (0.61)	0.6	1.35	1.65	1.99	4.0	
		Week 4	Tezepelumab	116	116 (100.0)	1.85 (0.68)	0.7	1.30	1.67	2.42	3.8	
			Placebo	125	122 (97.6)	1.75 (0.60)	0.7	1.36	1.69	2.09	4.2	
		Week 8	Tezepelumab	116	113 (97.4)	1.83 (0.64)	0.6	1.33	1.68	2.30	3.7	
			Placebo	125	120 (96.0)	1.78 (0.63)	0.7	1.33	1.67	2.09	4.3	
		Week 12	Tezepelumab	116	112 (96.6)	1.86 (0.70)	0.6	1.39	1.73	2.30	4.6	
			Placebo	125	120 (96.0)	1.75 (0.65)	0.6	1.31	1.68	2.12	4.3	
		Week 16	Tezepelumab	116	114 (98.3)	1.88 (0.70)	0.6	1.36	1.78	2.31	3.7	
			Placebo	125	116 (92.8)	1.76 (0.63)	0.6	1.32	1.68	2.16	4.1	
		Week 24	Tezepelumab	116	112 (96.6)	1.82 (0.63)	0.6	1.26	1.77	2.30	3.7	
			Placebo	125	111 (88.8)	1.73 (0.63)	0.8	1.28	1.67	2.07	4.8	
		Week 36	Tezepelumab	116	107 (92.2)	1.82 (0.66)	0.5	1.28	1.71	2.20	3.7	
			Placebo	125	105 (84.0)	1.80 (0.64)	0.7	1.36	1.74	2.14	4.6	
		Week 52	Tezepelumab	116	107 (92.2)	1.84 (0.67)	0.7	1.37	1.74	2.29	3.6	
			Placebo	125	105 (84.0)	1.72 (0.63)	0.7	1.27	1.64	2.10	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Change from baseline	Week 2	Tezepelumab	116	113 (97.4)	0.13 (0.29)	-0.7	0.00	0.10	0.27	1.1	0.36 [0.10, 0.62]
			Placebo	125	117 (93.6)	0.03 (0.27)	-0.6	-0.09	-0.01	0.11	1.0	
		Week 4	Tezepelumab	116	116 (100.0)	0.16 (0.40)	-0.9	-0.06	0.10	0.32	1.7	0.22 [-0.03, 0.48]
			Placebo	125	122 (97.6)	0.08 (0.29)	-0.7	-0.07	0.05	0.20	1.1	
		Week 8	Tezepelumab	116	113 (97.4)	0.17 (0.37)	-0.8	-0.05	0.12	0.31	1.4	0.26 [0.01, 0.52]
			Placebo	125	120 (96.0)	0.08 (0.28)	-0.8	-0.08	0.04	0.19	1.2	
		Week 12	Tezepelumab	116	112 (96.6)	0.18 (0.40)	-0.8	-0.03	0.11	0.35	2.0	0.28 [0.02, 0.54]
			Placebo	125	120 (96.0)	0.08 (0.34)	-0.7	-0.11	0.03	0.22	1.2	
		Week 16	Tezepelumab	116	114 (98.3)	0.19 (0.38)	-0.8	0.00	0.15	0.34	1.7	0.36 [0.10, 0.62]
			Placebo	125	116 (92.8)	0.07 (0.31)	-0.7	-0.09	0.02	0.22	1.0	
		Week 24	Tezepelumab	116	112 (96.6)	0.17 (0.33)	-0.6	-0.06	0.13	0.35	1.2	0.35 [0.08, 0.61]
			Placebo	125	111 (88.8)	0.05 (0.32)	-0.8	-0.11	0.01	0.19	1.2	
		Week 36	Tezepelumab	116	107 (92.2)	0.14 (0.35)	-0.7	-0.08	0.07	0.32	1.3	0.11 [-0.16, 0.38]
			Placebo	125	105 (84.0)	0.10 (0.33)	-1.1	-0.10	0.06	0.28	1.1	
		Week 52	Tezepelumab	116	107 (92.2)	0.15 (0.38)	-1.0	-0.07	0.10	0.35	1.5	0.37 [0.10, 0.64]
			Placebo	125	105 (84.0)	0.02 (0.31)	-0.7	-0.17	0.01	0.15	1.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Absolute values	Baseline	Tezepelumab	247	247 (100.0)	1.79 (0.72)	0.6	1.29	1.63	2.20	4.1	
			Placebo	220	220 (100.0)	1.91 (0.77)	0.4	1.35	1.76	2.33	4.9	
		Week 2	Tezepelumab	247	240 (97.2)	1.99 (0.75)	0.6	1.40	1.86	2.46	4.3	
			Placebo	220	212 (96.4)	1.94 (0.74)	0.4	1.41	1.90	2.38	4.7	
		Week 4	Tezepelumab	247	243 (98.4)	2.00 (0.75)	0.6	1.41	1.90	2.48	4.2	
			Placebo	220	214 (97.3)	1.94 (0.69)	0.4	1.45	1.85	2.34	4.0	
		Week 8	Tezepelumab	247	243 (98.4)	2.02 (0.76)	0.6	1.40	1.93	2.46	4.7	
			Placebo	220	214 (97.3)	1.98 (0.75)	0.4	1.41	1.91	2.37	4.9	
		Week 12	Tezepelumab	247	239 (96.8)	2.02 (0.74)	0.6	1.52	1.92	2.46	4.3	
			Placebo	220	212 (96.4)	1.99 (0.75)	0.7	1.46	1.87	2.41	5.0	
		Week 16	Tezepelumab	247	235 (95.1)	2.05 (0.76)	0.6	1.52	1.95	2.51	4.7	
			Placebo	220	210 (95.5)	1.97 (0.76)	0.7	1.40	1.85	2.36	5.2	
		Week 24	Tezepelumab	247	227 (91.9)	2.02 (0.73)	0.6	1.52	1.86	2.52	4.0	
			Placebo	220	203 (92.3)	1.99 (0.74)	0.6	1.47	1.90	2.31	5.1	
		Week 36	Tezepelumab	247	221 (89.5)	2.05 (0.77)	0.6	1.44	1.98	2.48	4.4	
			Placebo	220	196 (89.1)	2.01 (0.78)	0.8	1.45	1.86	2.40	5.3	
		Week 52	Tezepelumab	247	214 (86.6)	2.06 (0.79)	0.6	1.49	1.96	2.50	4.3	
			Placebo	220	183 (83.2)	2.00 (0.81)	0.6	1.42	1.86	2.43	5.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Change from baseline	Week 2	Tezepelumab	247	240 (97.2)	0.19 (0.34)	-0.5	-0.02	0.14	0.34	1.5	0.50 [0.31, 0.68]
			Placebo	220	212 (96.4)	0.02 (0.38)	-1.8	-0.14	0.01	0.17	1.2	
		Week 4	Tezepelumab	247	243 (98.4)	0.21 (0.32)	-0.5	0.00	0.16	0.34	1.8	0.45 [0.27, 0.64]
			Placebo	220	214 (97.3)	0.05 (0.40)	-1.8	-0.12	0.03	0.24	1.4	
		Week 8	Tezepelumab	247	243 (98.4)	0.24 (0.41)	-1.1	-0.02	0.17	0.46	1.7	0.45 [0.27, 0.64]
			Placebo	220	214 (97.3)	0.07 (0.37)	-1.7	-0.13	0.06	0.25	1.6	
		Week 12	Tezepelumab	247	239 (96.8)	0.25 (0.41)	-1.5	-0.03	0.18	0.46	1.6	0.44 [0.26, 0.63]
			Placebo	220	212 (96.4)	0.07 (0.40)	-1.5	-0.11	0.05	0.24	1.7	
		Week 16	Tezepelumab	247	235 (95.1)	0.27 (0.40)	-0.6	0.00	0.20	0.50	1.9	0.56 [0.37, 0.75]
			Placebo	220	210 (95.5)	0.05 (0.39)	-1.6	-0.16	0.02	0.24	1.8	
		Week 24	Tezepelumab	247	227 (91.9)	0.25 (0.43)	-1.0	-0.03	0.21	0.47	1.7	0.46 [0.27, 0.65]
			Placebo	220	203 (92.3)	0.06 (0.40)	-1.4	-0.15	0.04	0.26	1.7	
		Week 36	Tezepelumab	247	221 (89.5)	0.27 (0.42)	-1.0	-0.03	0.22	0.53	1.6	0.51 [0.32, 0.71]
			Placebo	220	196 (89.1)	0.06 (0.40)	-1.2	-0.19	0.04	0.27	1.7	
		Week 52	Tezepelumab	247	214 (86.6)	0.29 (0.43)	-1.0	0.00	0.23	0.55	1.7	0.57 [0.37, 0.77]
			Placebo	220	183 (83.2)	0.06 (0.36)	-1.4	-0.15	0.06	0.26	1.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Absolute values	Baseline	Tezepelumab	32	32 (100.0)	1.90 (0.58)	0.8	1.56	1.91	2.13	3.8	
			Placebo	46	46 (100.0)	1.89 (0.63)	0.6	1.37	1.95	2.26	3.2	
		Week 2	Tezepelumab	32	31 (96.9)	2.19 (0.68)	1.0	1.64	2.13	2.56	3.8	
			Placebo	46	44 (95.7)	2.22 (0.79)	0.8	1.64	2.31	2.67	4.1	
		Week 4	Tezepelumab	32	32 (100.0)	2.21 (0.72)	0.9	1.61	2.20	2.60	4.3	
			Placebo	46	46 (100.0)	2.11 (0.86)	0.5	1.45	2.11	2.64	4.8	
		Week 8	Tezepelumab	32	32 (100.0)	2.27 (0.81)	1.0	1.66	2.17	2.63	4.7	
			Placebo	46	46 (100.0)	2.10 (0.86)	0.6	1.51	2.01	2.87	4.6	
		Week 12	Tezepelumab	32	31 (96.9)	2.25 (0.78)	1.2	1.64	2.20	2.53	4.7	
			Placebo	46	45 (97.8)	2.18 (0.82)	0.5	1.57	2.23	2.57	4.6	
		Week 16	Tezepelumab	32	31 (96.9)	2.24 (0.80)	1.0	1.67	2.12	2.39	4.9	
			Placebo	46	44 (95.7)	2.14 (0.86)	0.5	1.53	2.09	2.59	4.7	
		Week 24	Tezepelumab	32	30 (93.8)	2.27 (0.81)	0.9	1.68	2.18	2.57	4.4	
			Placebo	46	43 (93.5)	2.11 (0.86)	0.7	1.43	1.99	2.64	4.8	
		Week 36	Tezepelumab	32	28 (87.5)	2.25 (0.81)	0.9	1.67	2.07	2.53	4.5	
			Placebo	46	45 (97.8)	2.13 (0.91)	0.6	1.52	1.88	2.55	4.3	
		Week 52	Tezepelumab	32	28 (87.5)	2.19 (0.74)	0.9	1.64	2.12	2.59	4.0	
			Placebo	46	38 (82.6)	2.14 (0.90)	0.6	1.40	2.16	2.68	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Change from baseline	Week 2	Tezepelumab	32	31 (96.9)	0.29 (0.42)	-0.4	0.01	0.15	0.52	1.4	-0.00 [-0.46, 0.46]
			Placebo	46	44 (95.7)	0.29 (0.45)	-0.5	-0.04	0.21	0.52	1.7	
		Week 4	Tezepelumab	32	32 (100.0)	0.31 (0.46)	-0.4	0.05	0.21	0.48	1.4	0.19 [-0.26, 0.64]
			Placebo	46	46 (100.0)	0.21 (0.56)	-0.8	-0.13	0.06	0.52	1.7	
		Week 8	Tezepelumab	32	32 (100.0)	0.37 (0.55)	-0.4	0.04	0.18	0.59	1.8	0.31 [-0.14, 0.77]
			Placebo	46	46 (100.0)	0.20 (0.53)	-0.8	-0.12	0.09	0.49	2.0	
		Week 12	Tezepelumab	32	31 (96.9)	0.35 (0.52)	-0.3	0.05	0.19	0.54	1.9	0.15 [-0.31, 0.61]
			Placebo	46	45 (97.8)	0.28 (0.51)	-1.2	0.00	0.17	0.42	1.6	
		Week 16	Tezepelumab	32	31 (96.9)	0.33 (0.55)	-0.5	0.01	0.15	0.43	2.0	0.13 [-0.33, 0.59]
			Placebo	46	44 (95.7)	0.26 (0.50)	-0.7	-0.04	0.07	0.47	1.6	
		Week 24	Tezepelumab	32	30 (93.8)	0.37 (0.55)	-0.4	-0.06	0.26	0.52	1.8	0.32 [-0.15, 0.79]
			Placebo	46	43 (93.5)	0.20 (0.53)	-1.1	-0.10	0.09	0.54	1.6	
		Week 36	Tezepelumab	32	28 (87.5)	0.35 (0.54)	-0.8	-0.02	0.22	0.56	1.7	0.18 [-0.29, 0.66]
			Placebo	46	45 (97.8)	0.24 (0.62)	-1.7	-0.11	0.15	0.57	2.2	
		Week 52	Tezepelumab	32	28 (87.5)	0.30 (0.45)	-0.8	0.04	0.20	0.50	1.3	0.07 [-0.42, 0.56]
			Placebo	46	38 (82.6)	0.26 (0.53)	-0.7	-0.06	0.19	0.53	1.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Absolute values	Baseline	Tezepelumab	47	47 (100.0)	1.80 (0.73)	0.4	1.31	1.72	2.13	3.6	
			Placebo	42	42 (100.0)	1.85 (0.66)	0.8	1.43	1.77	2.22	3.7	
		Week 2	Tezepelumab	47	46 (97.9)	2.04 (0.74)	0.6	1.54	1.95	2.39	3.9	
			Placebo	42	40 (95.2)	1.84 (0.65)	0.8	1.34	1.78	2.29	3.7	
		Week 4	Tezepelumab	47	47 (100.0)	2.07 (0.77)	0.7	1.49	2.03	2.59	3.8	
			Placebo	42	41 (97.6)	1.86 (0.62)	0.7	1.56	1.76	2.09	4.0	
		Week 8	Tezepelumab	47	46 (97.9)	2.03 (0.73)	0.6	1.50	1.95	2.48	3.7	
			Placebo	42	42 (100.0)	1.90 (0.75)	0.7	1.51	1.78	2.28	3.9	
		Week 12	Tezepelumab	47	44 (93.6)	2.03 (0.80)	0.6	1.52	1.93	2.42	4.6	
			Placebo	42	39 (92.9)	1.89 (0.67)	0.7	1.48	1.73	2.16	3.6	
		Week 16	Tezepelumab	47	45 (95.7)	2.04 (0.77)	0.6	1.54	1.97	2.48	4.2	
			Placebo	42	35 (83.3)	1.85 (0.68)	0.9	1.36	1.76	2.14	3.6	
		Week 24	Tezepelumab	47	42 (89.4)	2.01 (0.68)	0.9	1.61	1.92	2.50	3.7	
			Placebo	42	31 (73.8)	1.84 (0.70)	0.9	1.29	1.76	2.19	4.2	
		Week 36	Tezepelumab	47	39 (83.0)	2.00 (0.71)	0.9	1.53	1.89	2.39	4.0	
			Placebo	42	32 (76.2)	1.87 (0.64)	0.8	1.42	1.82	2.10	3.6	
		Week 52	Tezepelumab	47	37 (78.7)	2.08 (0.72)	0.8	1.72	2.05	2.37	4.1	
			Placebo	42	28 (66.7)	1.88 (0.75)	0.9	1.26	1.72	2.25	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	47	46 (97.9)	0.23 (0.33)	-0.6	0.01	0.19	0.38	1.1	0.72 [0.28, 1.16]
			Placebo	42	40 (95.2)	-0.05 (0.43)	-1.8	-0.13	-0.03	0.12	1.0	
		Week 4	Tezepelumab	47	47 (100.0)	0.27 (0.34)	-0.7	0.05	0.27	0.41	1.1	0.66 [0.23, 1.09]
			Placebo	42	41 (97.6)	0.01 (0.46)	-1.0	-0.21	-0.01	0.22	1.4	
		Week 8	Tezepelumab	47	46 (97.9)	0.23 (0.36)	-0.4	0.00	0.21	0.39	1.2	0.48 [0.05, 0.90]
			Placebo	42	42 (100.0)	0.04 (0.40)	-0.6	-0.17	-0.01	0.20	1.3	
		Week 12	Tezepelumab	47	44 (93.6)	0.29 (0.44)	-0.8	0.11	0.22	0.49	1.3	0.56 [0.12, 1.00]
			Placebo	42	39 (92.9)	0.04 (0.46)	-1.2	-0.15	-0.04	0.25	1.2	
		Week 16	Tezepelumab	47	45 (95.7)	0.29 (0.36)	-0.8	0.07	0.28	0.45	1.2	0.90 [0.44, 1.37]
			Placebo	42	35 (83.3)	-0.03 (0.35)	-0.8	-0.22	-0.06	0.13	1.0	
		Week 24	Tezepelumab	47	42 (89.4)	0.33 (0.37)	-0.2	0.04	0.28	0.52	1.3	0.96 [0.47, 1.45]
			Placebo	42	31 (73.8)	-0.06 (0.45)	-0.9	-0.41	-0.04	0.14	1.6	
		Week 36	Tezepelumab	47	39 (83.0)	0.27 (0.38)	-0.8	-0.02	0.26	0.44	1.3	0.96 [0.47, 1.46]
			Placebo	42	32 (76.2)	-0.08 (0.33)	-0.7	-0.29	-0.09	0.08	1.1	
		Week 52	Tezepelumab	47	37 (78.7)	0.28 (0.40)	-0.8	0.00	0.34	0.52	1.0	0.82 [0.31, 1.33]
			Placebo	42	28 (66.7)	-0.04 (0.37)	-0.8	-0.26	-0.01	0.12	1.1	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Absolute values	Baseline	Tezepelumab	348	348 (100.0)	1.77 (0.69)	0.5	1.27	1.64	2.14	4.1	
			Placebo	349	349 (100.0)	1.83 (0.72)	0.4	1.34	1.70	2.23	4.9	
		Week 2	Tezepelumab	348	338 (97.1)	1.94 (0.71)	0.6	1.39	1.80	2.44	4.3	
			Placebo	349	333 (95.4)	1.91 (0.73)	0.4	1.39	1.80	2.33	4.7	
		Week 4	Tezepelumab	348	344 (98.9)	1.95 (0.72)	0.6	1.41	1.85	2.47	4.3	
			Placebo	349	341 (97.7)	1.90 (0.70)	0.4	1.42	1.83	2.32	4.8	
		Week 8	Tezepelumab	348	342 (98.3)	1.98 (0.74)	0.6	1.40	1.85	2.43	4.7	
			Placebo	349	338 (96.8)	1.93 (0.74)	0.4	1.40	1.85	2.35	4.9	
		Week 12	Tezepelumab	348	338 (97.1)	1.99 (0.73)	0.6	1.48	1.88	2.44	4.7	
			Placebo	349	338 (96.8)	1.94 (0.75)	0.5	1.40	1.83	2.40	5.0	
		Week 16	Tezepelumab	348	335 (96.3)	2.01 (0.75)	0.6	1.48	1.88	2.47	4.9	
			Placebo	349	335 (96.0)	1.93 (0.75)	0.5	1.36	1.80	2.33	5.2	
		Week 24	Tezepelumab	348	327 (94.0)	1.98 (0.72)	0.6	1.48	1.83	2.42	4.4	
			Placebo	349	326 (93.4)	1.93 (0.74)	0.6	1.42	1.81	2.25	5.1	
		Week 36	Tezepelumab	348	317 (91.1)	2.00 (0.76)	0.5	1.43	1.90	2.45	4.5	
			Placebo	349	314 (90.0)	1.97 (0.78)	0.6	1.42	1.84	2.34	5.3	
		Week 52	Tezepelumab	348	312 (89.7)	1.99 (0.76)	0.6	1.44	1.85	2.47	4.3	
			Placebo	349	298 (85.4)	1.93 (0.78)	0.6	1.36	1.79	2.33	5.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Change from baseline	Week 2	Tezepelumab	348	338 (97.1)	0.18 (0.34)	-0.7	-0.01	0.13	0.31	1.5	0.32 [0.17, 0.48]
			Placebo	349	333 (95.4)	0.07 (0.36)	-1.3	-0.11	0.01	0.19	1.7	
		Week 4	Tezepelumab	348	344 (98.9)	0.20 (0.36)	-0.9	-0.02	0.13	0.33	1.8	0.29 [0.14, 0.44]
			Placebo	349	341 (97.7)	0.09 (0.39)	-1.8	-0.11	0.05	0.25	1.7	
		Week 8	Tezepelumab	348	342 (98.3)	0.23 (0.42)	-1.1	-0.04	0.15	0.44	1.8	0.35 [0.20, 0.51]
			Placebo	349	338 (96.8)	0.09 (0.37)	-1.7	-0.11	0.06	0.28	2.0	
		Week 12	Tezepelumab	348	338 (97.1)	0.23 (0.41)	-1.5	-0.03	0.17	0.41	2.0	0.31 [0.16, 0.46]
			Placebo	349	338 (96.8)	0.10 (0.40)	-1.5	-0.09	0.05	0.26	1.7	
		Week 16	Tezepelumab	348	335 (96.3)	0.25 (0.42)	-0.6	0.00	0.16	0.40	2.0	0.39 [0.24, 0.54]
			Placebo	349	335 (96.0)	0.09 (0.39)	-1.6	-0.10	0.04	0.26	1.8	
		Week 24	Tezepelumab	348	327 (94.0)	0.22 (0.42)	-1.0	-0.05	0.17	0.42	1.8	0.33 [0.18, 0.49]
			Placebo	349	326 (93.4)	0.09 (0.39)	-1.4	-0.12	0.05	0.27	1.7	
		Week 36	Tezepelumab	348	317 (91.1)	0.24 (0.42)	-1.0	-0.04	0.15	0.46	1.7	0.28 [0.13, 0.44]
			Placebo	349	314 (90.0)	0.12 (0.43)	-1.7	-0.13	0.07	0.31	2.2	
		Week 52	Tezepelumab	348	312 (89.7)	0.24 (0.42)	-1.0	-0.02	0.17	0.47	1.7	0.40 [0.24, 0.56]
			Placebo	349	298 (85.4)	0.08 (0.37)	-1.4	-0.14	0.06	0.26	1.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	115	115 (100.0)	1.79 (0.71)	0.6	1.29	1.71	2.10	4.1	
			Placebo	110	110 (100.0)	1.84 (0.69)	0.4	1.41	1.75	2.17	4.2	
		Week 2	Tezepelumab	115	114 (99.1)	1.99 (0.73)	0.7	1.42	1.87	2.39	4.3	
			Placebo	110	107 (97.3)	1.87 (0.70)	0.4	1.36	1.83	2.31	4.0	
		Week 4	Tezepelumab	115	115 (100.0)	1.98 (0.74)	0.7	1.44	1.90	2.41	4.3	
			Placebo	110	109 (99.1)	1.89 (0.71)	0.4	1.44	1.75	2.28	4.2	
		Week 8	Tezepelumab	115	114 (99.1)	2.02 (0.77)	0.7	1.44	1.96	2.38	4.7	
			Placebo	110	105 (95.5)	1.91 (0.72)	0.4	1.51	1.79	2.33	4.3	
		Week 12	Tezepelumab	115	111 (96.5)	2.04 (0.79)	0.7	1.52	1.94	2.41	4.7	
			Placebo	110	105 (95.5)	1.85 (0.69)	0.6	1.40	1.72	2.25	4.3	
		Week 16	Tezepelumab	115	110 (95.7)	2.06 (0.81)	0.6	1.53	1.96	2.40	4.9	
			Placebo	110	102 (92.7)	1.89 (0.68)	0.7	1.41	1.74	2.24	4.1	
		Week 24	Tezepelumab	115	108 (93.9)	2.02 (0.75)	0.6	1.54	1.92	2.38	4.4	
			Placebo	110	99 (90.0)	1.90 (0.72)	0.6	1.41	1.77	2.25	4.8	
		Week 36	Tezepelumab	115	102 (88.7)	2.05 (0.81)	0.5	1.44	1.96	2.45	4.5	
			Placebo	110	96 (87.3)	1.96 (0.74)	0.7	1.44	1.81	2.31	4.6	
		Week 52	Tezepelumab	115	97 (84.3)	2.09 (0.81)	0.6	1.54	2.05	2.43	4.2	
			Placebo	110	92 (83.6)	1.91 (0.77)	0.7	1.31	1.77	2.30	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	115	114 (99.1)	0.19 (0.31)	-0.6	0.00	0.15	0.37	1.1	0.49 [0.22, 0.75]
			Placebo	110	107 (97.3)	0.03 (0.34)	-1.3	-0.14	0.03	0.17	1.0	
		Week 4	Tezepelumab	115	115 (100.0)	0.19 (0.34)	-0.7	0.01	0.16	0.31	1.6	0.41 [0.14, 0.67]
			Placebo	110	109 (99.1)	0.05 (0.36)	-1.0	-0.11	0.03	0.22	1.4	
		Week 8	Tezepelumab	115	114 (99.1)	0.23 (0.42)	-1.1	-0.02	0.20	0.46	1.8	0.46 [0.19, 0.72]
			Placebo	110	105 (95.5)	0.05 (0.38)	-1.7	-0.13	0.06	0.29	1.3	
		Week 12	Tezepelumab	115	111 (96.5)	0.26 (0.46)	-0.8	-0.05	0.18	0.48	2.0	0.60 [0.33, 0.87]
			Placebo	110	105 (95.5)	0.01 (0.37)	-1.5	-0.16	0.00	0.22	0.9	
		Week 16	Tezepelumab	115	110 (95.7)	0.28 (0.40)	-0.8	0.04	0.23	0.44	2.0	0.64 [0.36, 0.92]
			Placebo	110	102 (92.7)	0.03 (0.37)	-1.6	-0.12	0.02	0.22	0.7	
		Week 24	Tezepelumab	115	108 (93.9)	0.24 (0.39)	-0.7	-0.06	0.21	0.43	1.6	0.54 [0.26, 0.81]
			Placebo	110	99 (90.0)	0.04 (0.38)	-1.4	-0.14	0.05	0.23	1.6	
		Week 36	Tezepelumab	115	102 (88.7)	0.27 (0.37)	-0.5	0.00	0.23	0.46	1.7	0.48 [0.20, 0.77]
			Placebo	110	96 (87.3)	0.09 (0.35)	-1.2	-0.13	0.06	0.34	1.1	
		Week 52	Tezepelumab	115	97 (84.3)	0.28 (0.41)	-0.8	0.00	0.24	0.55	1.5	0.59 [0.30, 0.88]
			Placebo	110	92 (83.6)	0.05 (0.39)	-1.4	-0.12	0.07	0.22	1.1	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Absolute values	Baseline	Tezepelumab	280	280 (100.0)	1.76 (0.69)	0.4	1.27	1.63	2.15	3.8	
			Placebo	281	281 (100.0)	1.83 (0.72)	0.6	1.32	1.70	2.25	4.9	
		Week 2	Tezepelumab	280	270 (96.4)	1.94 (0.71)	0.6	1.38	1.80	2.45	4.0	
			Placebo	281	266 (94.7)	1.92 (0.73)	0.6	1.39	1.80	2.36	4.7	
		Week 4	Tezepelumab	280	276 (98.6)	1.96 (0.73)	0.6	1.41	1.86	2.54	4.2	
			Placebo	281	273 (97.2)	1.90 (0.69)	0.5	1.42	1.84	2.28	4.8	
		Week 8	Tezepelumab	280	274 (97.9)	1.97 (0.72)	0.6	1.40	1.85	2.46	4.2	
			Placebo	281	275 (97.9)	1.94 (0.75)	0.6	1.38	1.90	2.36	4.9	
		Week 12	Tezepelumab	280	271 (96.8)	1.97 (0.72)	0.6	1.46	1.85	2.45	4.3	
			Placebo	281	272 (96.8)	1.97 (0.76)	0.5	1.42	1.89	2.41	5.0	
		Week 16	Tezepelumab	280	270 (96.4)	2.00 (0.72)	0.6	1.44	1.87	2.50	4.3	
			Placebo	281	268 (95.4)	1.94 (0.76)	0.5	1.35	1.83	2.33	5.2	
		Week 24	Tezepelumab	280	261 (93.2)	1.96 (0.71)	0.6	1.45	1.82	2.47	4.0	
			Placebo	281	258 (91.8)	1.93 (0.74)	0.6	1.41	1.84	2.24	5.1	
		Week 36	Tezepelumab	280	254 (90.7)	1.98 (0.73)	0.6	1.43	1.88	2.44	4.2	
			Placebo	281	250 (89.0)	1.96 (0.77)	0.6	1.41	1.84	2.34	5.3	
		Week 52	Tezepelumab	280	252 (90.0)	1.97 (0.73)	0.7	1.44	1.85	2.46	4.3	
			Placebo	281	234 (83.3)	1.93 (0.78)	0.6	1.36	1.77	2.33	5.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Change from baseline	Week 2	Tezepelumab	280	270 (96.4)	0.18 (0.34)	-0.7	-0.01	0.13	0.30	1.5	0.33 [0.16, 0.50]
			Placebo	281	266 (94.7)	0.06 (0.37)	-1.8	-0.10	0.01	0.18	1.7	
		Week 4	Tezepelumab	280	276 (98.6)	0.21 (0.37)	-0.9	-0.02	0.13	0.37	1.8	0.30 [0.14, 0.47]
			Placebo	281	273 (97.2)	0.09 (0.40)	-1.8	-0.11	0.05	0.27	1.7	
		Week 8	Tezepelumab	280	274 (97.9)	0.23 (0.42)	-0.8	-0.04	0.14	0.44	1.7	0.33 [0.17, 0.50]
			Placebo	281	275 (97.9)	0.10 (0.36)	-0.9	-0.11	0.05	0.25	2.0	
		Week 12	Tezepelumab	280	271 (96.8)	0.23 (0.40)	-1.5	-0.02	0.17	0.39	1.6	0.24 [0.07, 0.41]
			Placebo	281	272 (96.8)	0.13 (0.41)	-1.4	-0.08	0.06	0.27	1.7	
		Week 16	Tezepelumab	280	270 (96.4)	0.24 (0.42)	-0.6	-0.02	0.15	0.41	1.9	0.36 [0.19, 0.53]
			Placebo	281	268 (95.4)	0.10 (0.39)	-1.2	-0.11	0.04	0.26	1.8	
		Week 24	Tezepelumab	280	261 (93.2)	0.23 (0.43)	-1.0	-0.04	0.18	0.43	1.8	0.34 [0.17, 0.52]
			Placebo	281	258 (91.8)	0.09 (0.40)	-1.1	-0.13	0.04	0.27	1.7	
		Week 36	Tezepelumab	280	254 (90.7)	0.23 (0.43)	-1.0	-0.06	0.13	0.46	1.7	0.29 [0.11, 0.47]
			Placebo	281	250 (89.0)	0.10 (0.45)	-1.7	-0.16	0.05	0.29	2.2	
		Week 52	Tezepelumab	280	252 (90.0)	0.23 (0.42)	-1.0	-0.04	0.15	0.46	1.7	0.38 [0.20, 0.56]
			Placebo	281	234 (83.3)	0.08 (0.37)	-1.0	-0.15	0.04	0.26	1.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	106	106 (100.0)	1.81 (0.71)	0.8	1.31	1.73	2.10	4.1	
			Placebo	106	106 (100.0)	1.84 (0.70)	0.4	1.41	1.74	2.17	4.2	
		Week 2	Tezepelumab	106	105 (99.1)	2.00 (0.74)	0.8	1.45	1.87	2.39	4.3	
			Placebo	106	103 (97.2)	1.88 (0.72)	0.4	1.36	1.89	2.32	4.0	
		Week 4	Tezepelumab	106	106 (100.0)	2.00 (0.74)	0.7	1.46	1.87	2.41	4.3	
			Placebo	106	105 (99.1)	1.90 (0.73)	0.4	1.44	1.75	2.35	4.2	
		Week 8	Tezepelumab	106	105 (99.1)	2.04 (0.78)	0.8	1.45	1.95	2.36	4.7	
			Placebo	106	101 (95.3)	1.92 (0.72)	0.4	1.51	1.81	2.33	4.3	
		Week 12	Tezepelumab	106	102 (96.2)	2.06 (0.79)	0.9	1.53	1.93	2.41	4.7	
			Placebo	106	101 (95.3)	1.86 (0.70)	0.6	1.40	1.73	2.25	4.3	
		Week 16	Tezepelumab	106	102 (96.2)	2.09 (0.80)	0.8	1.53	1.98	2.40	4.9	
			Placebo	106	99 (93.4)	1.88 (0.69)	0.7	1.41	1.72	2.24	4.1	
		Week 24	Tezepelumab	106	100 (94.3)	2.04 (0.74)	0.8	1.57	1.92	2.41	4.4	
			Placebo	106	96 (90.6)	1.90 (0.73)	0.6	1.40	1.77	2.25	4.8	
		Week 36	Tezepelumab	106	94 (88.7)	2.08 (0.81)	0.8	1.49	1.96	2.46	4.5	
			Placebo	106	93 (87.7)	1.96 (0.75)	0.7	1.43	1.81	2.31	4.6	
		Week 52	Tezepelumab	106	89 (84.0)	2.12 (0.81)	0.6	1.56	2.05	2.46	4.2	
			Placebo	106	90 (84.9)	1.91 (0.78)	0.7	1.30	1.77	2.31	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	106	105 (99.1)	0.19 (0.32)	-0.6	0.00	0.16	0.38	1.1	0.46 [0.18, 0.73]
			Placebo	106	103 (97.2)	0.04 (0.35)	-1.3	-0.13	0.04	0.19	1.0	
		Week 4	Tezepelumab	106	106 (100.0)	0.19 (0.35)	-0.7	-0.01	0.16	0.30	1.6	0.37 [0.10, 0.65]
			Placebo	106	105 (99.1)	0.06 (0.37)	-1.0	-0.11	0.03	0.23	1.4	
		Week 8	Tezepelumab	106	105 (99.1)	0.23 (0.43)	-1.1	-0.04	0.21	0.46	1.8	0.44 [0.16, 0.71]
			Placebo	106	101 (95.3)	0.06 (0.37)	-1.7	-0.13	0.06	0.29	1.3	
		Week 12	Tezepelumab	106	102 (96.2)	0.26 (0.48)	-0.8	-0.08	0.18	0.48	2.0	0.58 [0.30, 0.86]
			Placebo	106	101 (95.3)	0.01 (0.37)	-1.5	-0.14	0.01	0.22	0.9	
		Week 16	Tezepelumab	106	102 (96.2)	0.29 (0.41)	-0.8	0.04	0.23	0.45	2.0	0.66 [0.38, 0.94]
			Placebo	106	99 (93.4)	0.03 (0.37)	-1.6	-0.12	0.02	0.22	0.7	
		Week 24	Tezepelumab	106	100 (94.3)	0.24 (0.40)	-0.7	-0.06	0.21	0.43	1.6	0.52 [0.24, 0.81]
			Placebo	106	96 (90.6)	0.04 (0.39)	-1.4	-0.14	0.05	0.24	1.6	
		Week 36	Tezepelumab	106	94 (88.7)	0.27 (0.38)	-0.5	0.02	0.23	0.46	1.7	0.49 [0.20, 0.78]
			Placebo	106	93 (87.7)	0.09 (0.35)	-1.2	-0.12	0.06	0.33	1.1	
		Week 52	Tezepelumab	106	89 (84.0)	0.28 (0.42)	-0.8	0.00	0.24	0.55	1.5	0.59 [0.29, 0.89]
			Placebo	106	90 (84.9)	0.04 (0.39)	-1.4	-0.13	0.07	0.21	1.1	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Absolute values	Baseline	Tezepelumab	289	289 (100.0)	1.76 (0.69)	0.4	1.26	1.63	2.14	3.8	
			Placebo	285	285 (100.0)	1.83 (0.72)	0.6	1.33	1.70	2.23	4.9	
		Week 2	Tezepelumab	289	279 (96.5)	1.93 (0.71)	0.6	1.37	1.80	2.45	4.0	
			Placebo	285	270 (94.7)	1.91 (0.72)	0.6	1.39	1.80	2.33	4.7	
		Week 4	Tezepelumab	289	285 (98.6)	1.96 (0.73)	0.6	1.41	1.86	2.53	4.2	
			Placebo	285	277 (97.2)	1.90 (0.68)	0.5	1.42	1.84	2.27	4.8	
		Week 8	Tezepelumab	289	283 (97.9)	1.96 (0.72)	0.6	1.39	1.85	2.46	4.2	
			Placebo	285	279 (97.9)	1.94 (0.75)	0.6	1.38	1.87	2.36	4.9	
		Week 12	Tezepelumab	289	280 (96.9)	1.97 (0.72)	0.6	1.46	1.86	2.45	4.3	
			Placebo	285	276 (96.8)	1.96 (0.76)	0.5	1.42	1.88	2.41	5.0	
		Week 16	Tezepelumab	289	278 (96.2)	1.99 (0.73)	0.6	1.43	1.87	2.50	4.3	
			Placebo	285	271 (95.1)	1.94 (0.76)	0.5	1.35	1.83	2.33	5.2	
		Week 24	Tezepelumab	289	269 (93.1)	1.96 (0.71)	0.6	1.44	1.82	2.45	4.0	
			Placebo	285	261 (91.6)	1.93 (0.74)	0.6	1.42	1.83	2.24	5.1	
		Week 36	Tezepelumab	289	262 (90.7)	1.97 (0.74)	0.5	1.43	1.88	2.42	4.2	
			Placebo	285	253 (88.8)	1.96 (0.77)	0.6	1.41	1.84	2.34	5.3	
		Week 52	Tezepelumab	289	260 (90.0)	1.96 (0.73)	0.7	1.43	1.85	2.45	4.3	
			Placebo	285	236 (82.8)	1.93 (0.78)	0.6	1.37	1.77	2.33	5.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Change from baseline	Week 2	Tezepelumab	289	279 (96.5)	0.18 (0.34)	-0.7	-0.01	0.13	0.30	1.5	0.34 [0.17, 0.51]
			Placebo	285	270 (94.7)	0.06 (0.37)	-1.8	-0.11	0.00	0.18	1.7	
		Week 4	Tezepelumab	289	285 (98.6)	0.21 (0.37)	-0.9	-0.01	0.13	0.37	1.8	0.32 [0.15, 0.48]
			Placebo	285	277 (97.2)	0.09 (0.40)	-1.8	-0.12	0.05	0.25	1.7	
		Week 8	Tezepelumab	289	283 (97.9)	0.23 (0.41)	-0.8	-0.04	0.14	0.44	1.7	0.34 [0.17, 0.51]
			Placebo	285	279 (97.9)	0.10 (0.37)	-0.9	-0.11	0.05	0.25	2.0	
		Week 12	Tezepelumab	289	280 (96.9)	0.23 (0.40)	-1.5	-0.01	0.17	0.40	1.6	0.25 [0.08, 0.42]
			Placebo	285	276 (96.8)	0.13 (0.41)	-1.4	-0.08	0.06	0.27	1.7	
		Week 16	Tezepelumab	289	278 (96.2)	0.24 (0.41)	-0.6	-0.02	0.15	0.40	1.9	0.35 [0.19, 0.52]
			Placebo	285	271 (95.1)	0.10 (0.39)	-1.2	-0.11	0.03	0.26	1.8	
		Week 24	Tezepelumab	289	269 (93.1)	0.23 (0.42)	-1.0	-0.04	0.18	0.43	1.8	0.35 [0.18, 0.52]
			Placebo	285	261 (91.6)	0.09 (0.40)	-1.1	-0.13	0.03	0.27	1.7	
		Week 36	Tezepelumab	289	262 (90.7)	0.23 (0.43)	-1.0	-0.05	0.14	0.46	1.7	0.29 [0.12, 0.47]
			Placebo	285	253 (88.8)	0.10 (0.44)	-1.7	-0.16	0.04	0.29	2.2	
		Week 52	Tezepelumab	289	260 (90.0)	0.23 (0.42)	-1.0	-0.03	0.16	0.46	1.7	0.38 [0.20, 0.56]
			Placebo	285	236 (82.8)	0.08 (0.37)	-1.0	-0.15	0.04	0.26	1.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	168	168 (100.0)	1.71 (0.68)	0.5	1.24	1.60	2.06	4.0	
			Placebo	149	149 (100.0)	1.86 (0.68)	0.6	1.37	1.74	2.21	4.1	
		Week 2	Tezepelumab	168	163 (97.0)	1.91 (0.70)	0.6	1.37	1.79	2.38	4.1	
			Placebo	149	143 (96.0)	1.91 (0.68)	0.7	1.46	1.80	2.38	3.9	
		Week 4	Tezepelumab	168	167 (99.4)	1.94 (0.73)	0.6	1.42	1.78	2.41	4.3	
			Placebo	149	146 (98.0)	1.95 (0.66)	0.7	1.48	1.84	2.32	4.0	
		Week 8	Tezepelumab	168	166 (98.8)	1.96 (0.74)	0.6	1.39	1.85	2.44	4.7	
			Placebo	149	146 (98.0)	1.94 (0.72)	0.7	1.47	1.83	2.35	4.3	
		Week 12	Tezepelumab	168	161 (95.8)	1.98 (0.75)	0.6	1.50	1.87	2.41	4.7	
			Placebo	149	148 (99.3)	1.92 (0.68)	0.7	1.47	1.79	2.32	4.3	
		Week 16	Tezepelumab	168	162 (96.4)	1.98 (0.76)	0.6	1.44	1.86	2.41	4.9	
			Placebo	149	144 (96.6)	1.93 (0.68)	0.7	1.47	1.82	2.28	4.4	
		Week 24	Tezepelumab	168	157 (93.5)	1.92 (0.68)	0.6	1.48	1.79	2.32	4.4	
			Placebo	149	140 (94.0)	1.91 (0.68)	0.6	1.42	1.82	2.23	4.3	
		Week 36	Tezepelumab	168	152 (90.5)	1.99 (0.76)	0.6	1.44	1.82	2.40	4.5	
			Placebo	149	138 (92.6)	1.92 (0.70)	0.7	1.42	1.79	2.33	4.3	
		Week 52	Tezepelumab	168	150 (89.3)	2.00 (0.77)	0.6	1.48	1.88	2.47	4.3	
			Placebo	149	125 (83.9)	1.89 (0.73)	0.7	1.34	1.73	2.30	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	168	163 (97.0)	0.20 (0.32)	-0.5	0.00	0.14	0.32	1.3	0.43 [0.21, 0.66]
			Placebo	149	143 (96.0)	0.05 (0.39)	-1.8	-0.10	0.03	0.20	1.2	
		Week 4	Tezepelumab	168	167 (99.4)	0.24 (0.37)	-0.9	0.01	0.14	0.36	1.7	0.40 [0.17, 0.62]
			Placebo	149	146 (98.0)	0.08 (0.41)	-1.0	-0.14	0.05	0.28	1.4	
		Week 8	Tezepelumab	168	166 (98.8)	0.26 (0.43)	-0.8	-0.04	0.21	0.46	1.8	0.45 [0.22, 0.67]
			Placebo	149	146 (98.0)	0.08 (0.39)	-1.7	-0.17	0.07	0.25	1.6	
		Week 12	Tezepelumab	168	161 (95.8)	0.29 (0.44)	-0.7	0.03	0.20	0.48	2.0	0.54 [0.32, 0.77]
			Placebo	149	148 (99.3)	0.06 (0.43)	-1.5	-0.14	0.04	0.25	1.7	
		Week 16	Tezepelumab	168	162 (96.4)	0.27 (0.43)	-0.6	0.00	0.18	0.43	2.0	0.50 [0.28, 0.73]
			Placebo	149	144 (96.6)	0.07 (0.39)	-1.6	-0.13	0.06	0.24	1.8	
		Week 24	Tezepelumab	168	157 (93.5)	0.26 (0.43)	-1.0	-0.05	0.23	0.49	1.5	0.45 [0.22, 0.68]
			Placebo	149	140 (94.0)	0.07 (0.39)	-1.4	-0.13	0.04	0.26	1.7	
		Week 36	Tezepelumab	168	152 (90.5)	0.29 (0.43)	-1.0	0.02	0.22	0.53	1.7	0.55 [0.31, 0.78]
			Placebo	149	138 (92.6)	0.06 (0.41)	-1.2	-0.18	0.02	0.27	1.7	
		Week 52	Tezepelumab	168	150 (89.3)	0.29 (0.44)	-1.0	-0.01	0.25	0.56	1.6	0.62 [0.37, 0.86]
			Placebo	149	125 (83.9)	0.04 (0.37)	-1.4	-0.16	0.04	0.23	1.1	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Absolute values	Baseline	Tezepelumab	227	227 (100.0)	1.82 (0.70)	0.4	1.28	1.69	2.26	4.1	
			Placebo	242	242 (100.0)	1.82 (0.73)	0.4	1.31	1.69	2.23	4.9	
		Week 2	Tezepelumab	227	221 (97.4)	1.98 (0.73)	0.6	1.44	1.85	2.45	4.3	
			Placebo	242	230 (95.0)	1.90 (0.75)	0.4	1.37	1.83	2.31	4.7	
		Week 4	Tezepelumab	227	224 (98.7)	1.99 (0.73)	0.7	1.43	1.91	2.53	3.8	
			Placebo	242	236 (97.5)	1.87 (0.71)	0.4	1.35	1.81	2.27	4.8	
		Week 8	Tezepelumab	227	222 (97.8)	2.00 (0.74)	0.6	1.41	1.89	2.44	4.7	
			Placebo	242	234 (96.7)	1.92 (0.75)	0.4	1.37	1.84	2.33	4.9	
		Week 12	Tezepelumab	227	221 (97.4)	2.00 (0.73)	0.6	1.47	1.89	2.46	4.6	
			Placebo	242	229 (94.6)	1.95 (0.78)	0.5	1.37	1.83	2.40	5.0	
		Week 16	Tezepelumab	227	218 (96.0)	2.04 (0.74)	0.6	1.52	1.91	2.54	4.7	
			Placebo	242	226 (93.4)	1.92 (0.78)	0.5	1.32	1.79	2.33	5.2	
		Week 24	Tezepelumab	227	212 (93.4)	2.02 (0.74)	0.6	1.51	1.94	2.51	4.0	
			Placebo	242	217 (89.7)	1.93 (0.78)	0.8	1.40	1.80	2.25	5.1	
		Week 36	Tezepelumab	227	204 (89.9)	2.00 (0.75)	0.5	1.43	1.91	2.46	4.4	
			Placebo	242	208 (86.0)	1.98 (0.80)	0.6	1.42	1.84	2.34	5.3	
		Week 52	Tezepelumab	227	199 (87.7)	2.00 (0.75)	0.8	1.44	1.87	2.43	4.2	
			Placebo	242	201 (83.1)	1.95 (0.81)	0.6	1.34	1.81	2.32	5.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Change from baseline	Week 2	Tezepelumab	227	221 (97.4)	0.17 (0.34)	-0.7	-0.01	0.12	0.32	1.5	0.32 [0.14, 0.51]
			Placebo	242	230 (95.0)	0.06 (0.35)	-1.1	-0.12	0.00	0.16	1.7	
		Week 4	Tezepelumab	227	224 (98.7)	0.18 (0.35)	-0.7	-0.04	0.14	0.33	1.8	0.28 [0.10, 0.46]
			Placebo	242	236 (97.5)	0.08 (0.38)	-1.8	-0.11	0.04	0.23	1.7	
		Week 8	Tezepelumab	227	222 (97.8)	0.21 (0.40)	-1.1	-0.04	0.14	0.40	1.7	0.30 [0.12, 0.49]
			Placebo	242	234 (96.7)	0.09 (0.35)	-0.9	-0.10	0.05	0.26	2.0	
		Week 12	Tezepelumab	227	221 (97.4)	0.19 (0.39)	-1.5	-0.04	0.12	0.38	1.6	0.19 [0.00, 0.37]
			Placebo	242	229 (94.6)	0.12 (0.38)	-1.2	-0.08	0.05	0.26	1.6	
		Week 16	Tezepelumab	227	218 (96.0)	0.24 (0.40)	-0.8	0.00	0.16	0.40	1.9	0.38 [0.19, 0.57]
			Placebo	242	226 (93.4)	0.09 (0.38)	-1.2	-0.10	0.01	0.26	1.6	
		Week 24	Tezepelumab	227	212 (93.4)	0.22 (0.40)	-0.8	-0.04	0.14	0.41	1.8	0.35 [0.16, 0.54]
			Placebo	242	217 (89.7)	0.08 (0.40)	-1.1	-0.13	0.04	0.26	1.6	
		Week 36	Tezepelumab	227	204 (89.9)	0.20 (0.41)	-0.8	-0.08	0.11	0.39	1.7	0.19 [-0.00, 0.38]
			Placebo	242	208 (86.0)	0.13 (0.43)	-1.7	-0.13	0.07	0.33	2.2	
		Week 52	Tezepelumab	227	199 (87.7)	0.21 (0.40)	-1.0	-0.02	0.15	0.37	1.7	0.31 [0.11, 0.50]
			Placebo	242	201 (83.1)	0.09 (0.38)	-1.0	-0.13	0.06	0.24	1.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Sex									0.038 i
Male	Week 2	Tezepelumab	143	140 (97.9)	0.21 (0.03)	(0.15, 0.27)	0.17 (0.05)	(0.08, 0.26)	<0.001 *
		Placebo	147	143 (97.3)	0.04 (0.03)	(-0.02, 0.10)			
	Week 4	Tezepelumab	143	141 (98.6)	0.26 (0.04)	(0.19, 0.33)	0.21 (0.05)	(0.11, 0.31)	<0.001 *
		Placebo	147	143 (97.3)	0.05 (0.04)	(-0.02, 0.13)			
	Week 8	Tezepelumab	143	137 (95.8)	0.27 (0.04)	(0.20, 0.35)	0.19 (0.05)	(0.08, 0.29)	<0.001 *
		Placebo	147	147 (100.0)	0.09 (0.04)	(0.01, 0.16)			
	Week 12	Tezepelumab	143	136 (95.1)	0.26 (0.04)	(0.19, 0.34)	0.15 (0.05)	(0.04, 0.26)	0.006 *
		Placebo	147	145 (98.6)	0.11 (0.04)	(0.04, 0.19)			
	Week 16	Tezepelumab	143	136 (95.1)	0.31 (0.04)	(0.23, 0.39)	0.24 (0.06)	(0.13, 0.35)	<0.001 *
		Placebo	147	144 (98.0)	0.07 (0.04)	(-0.00, 0.15)			
	Week 24	Tezepelumab	143	127 (88.8)	0.28 (0.04)	(0.20, 0.36)	0.19 (0.05)	(0.09, 0.30)	<0.001 *
		Placebo	147	133 (90.5)	0.09 (0.04)	(0.01, 0.16)			
	Week 36	Tezepelumab	143	127 (88.8)	0.29 (0.04)	(0.21, 0.37)	0.20 (0.06)	(0.09, 0.32)	<0.001 *
		Placebo	147	132 (89.8)	0.09 (0.04)	(0.01, 0.17)			
	Week 52	Tezepelumab	143	125 (87.4)	0.32 (0.04)	(0.24, 0.40)	0.26 (0.06)	(0.15, 0.37)	<0.001 *
		Placebo	147	122 (83.0)	0.06 (0.04)	(-0.02, 0.14)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Female	Week 2	Tezepelumab	252	244 (96.8)	0.16 (0.02)	(0.12, 0.20)	0.10 (0.03)	(0.04, 0.15)	<0.001 *
		Placebo	244	230 (94.3)	0.06 (0.02)	(0.02, 0.10)			
	Week 4	Tezepelumab	252	250 (99.2)	0.17 (0.02)	(0.13, 0.21)	0.07 (0.03)	(0.01, 0.12)	0.016 *
		Placebo	244	239 (98.0)	0.10 (0.02)	(0.06, 0.14)			
	Week 8	Tezepelumab	252	251 (99.6)	0.20 (0.02)	(0.16, 0.25)	0.11 (0.03)	(0.05, 0.17)	<0.001 *
		Placebo	244	233 (95.5)	0.09 (0.02)	(0.05, 0.13)			
	Week 12	Tezepelumab	252	246 (97.6)	0.21 (0.02)	(0.17, 0.26)	0.13 (0.03)	(0.06, 0.19)	<0.001 *
		Placebo	244	232 (95.1)	0.09 (0.02)	(0.04, 0.13)			
	Week 16	Tezepelumab	252	244 (96.8)	0.22 (0.02)	(0.18, 0.26)	0.13 (0.03)	(0.07, 0.19)	<0.001 *
		Placebo	244	226 (92.6)	0.09 (0.02)	(0.05, 0.14)			
	Week 24	Tezepelumab	252	242 (96.0)	0.20 (0.02)	(0.15, 0.24)	0.12 (0.03)	(0.05, 0.18)	<0.001 *
		Placebo	244	224 (91.8)	0.08 (0.02)	(0.04, 0.13)			
	Week 36	Tezepelumab	252	229 (90.9)	0.21 (0.02)	(0.17, 0.26)	0.10 (0.03)	(0.04, 0.17)	0.002 *
		Placebo	244	214 (87.7)	0.11 (0.02)	(0.07, 0.16)			
	Week 52	Tezepelumab	252	224 (88.9)	0.21 (0.02)	(0.17, 0.26)	0.12 (0.03)	(0.05, 0.18)	<0.001 *
		Placebo	244	204 (83.6)	0.09 (0.02)	(0.04, 0.14)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Age									0.064
< 65 years	Week 2	Tezepelumab	319	310 (97.2)	0.20 (0.02)	(0.16, 0.24)	0.15 (0.03)	(0.09, 0.20)	<0.001 *
		Placebo	338	323 (95.6)	0.05 (0.02)	(0.01, 0.09)			
	Week 4	Tezepelumab	319	317 (99.4)	0.22 (0.02)	(0.18, 0.27)	0.15 (0.03)	(0.09, 0.20)	<0.001 *
		Placebo	338	332 (98.2)	0.08 (0.02)	(0.04, 0.12)			
	Week 8	Tezepelumab	319	314 (98.4)	0.25 (0.02)	(0.21, 0.30)	0.16 (0.03)	(0.10, 0.22)	<0.001 *
		Placebo	338	330 (97.6)	0.09 (0.02)	(0.05, 0.13)			
	Week 12	Tezepelumab	319	309 (96.9)	0.25 (0.02)	(0.20, 0.30)	0.15 (0.03)	(0.08, 0.21)	<0.001 *
		Placebo	338	327 (96.7)	0.10 (0.02)	(0.06, 0.15)			
	Week 16	Tezepelumab	319	307 (96.2)	0.27 (0.02)	(0.23, 0.32)	0.19 (0.03)	(0.12, 0.25)	<0.001 *
		Placebo	338	321 (95.0)	0.09 (0.02)	(0.04, 0.13)			
	Week 24	Tezepelumab	319	299 (93.7)	0.25 (0.02)	(0.20, 0.29)	0.16 (0.03)	(0.10, 0.23)	<0.001 *
		Placebo	338	309 (91.4)	0.09 (0.02)	(0.04, 0.13)			
	Week 36	Tezepelumab	319	288 (90.3)	0.27 (0.02)	(0.22, 0.31)	0.16 (0.03)	(0.09, 0.22)	<0.001 *
		Placebo	338	298 (88.2)	0.11 (0.02)	(0.06, 0.16)			
	Week 52	Tezepelumab	319	282 (88.4)	0.27 (0.02)	(0.23, 0.32)	0.19 (0.03)	(0.12, 0.25)	<0.001 *
		Placebo	338	281 (83.1)	0.09 (0.02)	(0.04, 0.13)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 65 years	Week 2	Tezepelumab	76	74 (97.4)	0.09 (0.02)	(0.04, 0.14)	0.03 (0.04)	(-0.05, 0.10)	0.447
		Placebo	53	50 (94.3)	0.06 (0.03)	(0.00, 0.12)			
	Week 4	Tezepelumab	76	74 (97.4)	0.11 (0.03)	(0.05, 0.16)	0.01 (0.04)	(-0.08, 0.10)	0.802
		Placebo	53	50 (94.3)	0.10 (0.03)	(0.03, 0.16)			
	Week 8	Tezepelumab	76	74 (97.4)	0.14 (0.03)	(0.08, 0.20)	0.05 (0.05)	(-0.05, 0.15)	0.331
		Placebo	53	50 (94.3)	0.09 (0.04)	(0.02, 0.17)			
	Week 12	Tezepelumab	76	73 (96.1)	0.16 (0.03)	(0.10, 0.22)	0.11 (0.05)	(0.01, 0.21)	0.032 *
		Placebo	53	50 (94.3)	0.05 (0.04)	(-0.02, 0.13)			
	Week 16	Tezepelumab	76	73 (96.1)	0.16 (0.03)	(0.10, 0.22)	0.09 (0.05)	(-0.00, 0.19)	0.061
		Placebo	53	49 (92.5)	0.07 (0.04)	(-0.01, 0.14)			
	Week 24	Tezepelumab	76	70 (92.1)	0.14 (0.03)	(0.08, 0.20)	0.08 (0.05)	(-0.02, 0.18)	0.105
		Placebo	53	48 (90.6)	0.06 (0.04)	(-0.02, 0.13)			
	Week 36	Tezepelumab	76	68 (89.5)	0.14 (0.03)	(0.08, 0.20)	0.10 (0.05)	(0.00, 0.19)	0.045 *
		Placebo	53	48 (90.6)	0.04 (0.04)	(-0.03, 0.12)			
	Week 52	Tezepelumab	76	67 (88.2)	0.15 (0.03)	(0.08, 0.22)	0.12 (0.05)	(0.02, 0.23)	0.024 *
		Placebo	53	45 (84.9)	0.03 (0.04)	(-0.06, 0.11)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Exacerbations in the year before study									0.756
<= 2	Week 2	Tezepelumab	211	208 (98.6)	0.18 (0.02)	(0.13, 0.22)	0.12 (0.03)	(0.05, 0.18)	<0.001 *
		Placebo	226	217 (96.0)	0.06 (0.02)	(0.02, 0.11)			
	Week 4	Tezepelumab	211	208 (98.6)	0.20 (0.03)	(0.15, 0.25)	0.12 (0.04)	(0.05, 0.19)	<0.001 *
		Placebo	226	217 (96.0)	0.08 (0.03)	(0.03, 0.13)			
	Week 8	Tezepelumab	211	207 (98.1)	0.23 (0.03)	(0.17, 0.28)	0.14 (0.04)	(0.07, 0.22)	<0.001 *
		Placebo	226	219 (96.9)	0.08 (0.03)	(0.03, 0.14)			
	Week 12	Tezepelumab	211	205 (97.2)	0.22 (0.03)	(0.16, 0.27)	0.12 (0.04)	(0.04, 0.20)	0.002 *
		Placebo	226	220 (97.3)	0.09 (0.03)	(0.04, 0.15)			
	Week 16	Tezepelumab	211	204 (96.7)	0.26 (0.03)	(0.20, 0.31)	0.17 (0.04)	(0.09, 0.25)	<0.001 *
		Placebo	226	216 (95.6)	0.09 (0.03)	(0.04, 0.14)			
	Week 24	Tezepelumab	211	196 (92.9)	0.22 (0.03)	(0.17, 0.28)	0.15 (0.04)	(0.07, 0.23)	<0.001 *
		Placebo	226	206 (91.2)	0.07 (0.03)	(0.02, 0.13)			
	Week 36	Tezepelumab	211	193 (91.5)	0.25 (0.03)	(0.19, 0.31)	0.15 (0.04)	(0.07, 0.23)	<0.001 *
		Placebo	226	204 (90.3)	0.10 (0.03)	(0.04, 0.15)			
	Week 52	Tezepelumab	211	188 (89.1)	0.24 (0.03)	(0.18, 0.30)	0.16 (0.04)	(0.08, 0.24)	<0.001 *
		Placebo	226	191 (84.5)	0.08 (0.03)	(0.03, 0.14)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
> 2	Week 2	Tezepelumab	184	176 (95.7)	0.18 (0.03)	(0.13, 0.23)	0.14 (0.04)	(0.07, 0.22)	<0.001 *
		Placebo	165	156 (94.5)	0.04 (0.03)	(-0.01, 0.10)			
	Week 4	Tezepelumab	184	183 (99.5)	0.20 (0.03)	(0.15, 0.25)	0.12 (0.04)	(0.04, 0.20)	0.002 *
		Placebo	165	165 (100.0)	0.08 (0.03)	(0.03, 0.14)			
	Week 8	Tezepelumab	184	181 (98.4)	0.23 (0.03)	(0.18, 0.28)	0.13 (0.04)	(0.05, 0.21)	<0.001 *
		Placebo	165	161 (97.6)	0.10 (0.03)	(0.04, 0.16)			
	Week 12	Tezepelumab	184	177 (96.2)	0.25 (0.03)	(0.20, 0.31)	0.15 (0.04)	(0.07, 0.23)	<0.001 *
		Placebo	165	157 (95.2)	0.10 (0.03)	(0.05, 0.16)			
	Week 16	Tezepelumab	184	176 (95.7)	0.25 (0.03)	(0.19, 0.30)	0.17 (0.04)	(0.09, 0.25)	<0.001 *
		Placebo	165	154 (93.3)	0.07 (0.03)	(0.02, 0.13)			
	Week 24	Tezepelumab	184	173 (94.0)	0.23 (0.03)	(0.17, 0.29)	0.13 (0.04)	(0.05, 0.21)	0.001 *
		Placebo	165	151 (91.5)	0.10 (0.03)	(0.04, 0.16)			
	Week 36	Tezepelumab	184	163 (88.6)	0.24 (0.03)	(0.18, 0.29)	0.13 (0.04)	(0.04, 0.21)	0.003 *
		Placebo	165	142 (86.1)	0.11 (0.03)	(0.05, 0.17)			
	Week 52	Tezepelumab	184	161 (87.5)	0.26 (0.03)	(0.20, 0.32)	0.18 (0.04)	(0.10, 0.27)	<0.001 *
		Placebo	165	135 (81.8)	0.08 (0.03)	(0.01, 0.14)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Race									0.889
White	Week 2	Tezepelumab	251	246 (98.0)	0.18 (0.02)	(0.14, 0.22)	0.14 (0.03)	(0.08, 0.20)	<0.001 *
		Placebo	252	239 (94.8)	0.04 (0.02)	(-0.01, 0.08)			
	Week 4	Tezepelumab	251	249 (99.2)	0.19 (0.02)	(0.15, 0.24)	0.10 (0.03)	(0.04, 0.17)	0.002 *
		Placebo	252	243 (96.4)	0.09 (0.02)	(0.04, 0.14)			
	Week 8	Tezepelumab	251	248 (98.8)	0.21 (0.03)	(0.16, 0.26)	0.10 (0.04)	(0.03, 0.17)	0.005 *
		Placebo	252	242 (96.0)	0.11 (0.03)	(0.06, 0.16)			
	Week 12	Tezepelumab	251	242 (96.4)	0.21 (0.03)	(0.16, 0.26)	0.10 (0.04)	(0.03, 0.18)	0.005 *
		Placebo	252	240 (95.2)	0.10 (0.03)	(0.05, 0.15)			
	Week 16	Tezepelumab	251	242 (96.4)	0.24 (0.03)	(0.19, 0.29)	0.15 (0.04)	(0.08, 0.22)	<0.001 *
		Placebo	252	236 (93.7)	0.09 (0.03)	(0.04, 0.14)			
	Week 24	Tezepelumab	251	235 (93.6)	0.21 (0.03)	(0.16, 0.26)	0.12 (0.04)	(0.05, 0.19)	0.001 *
		Placebo	252	227 (90.1)	0.10 (0.03)	(0.04, 0.15)			
	Week 36	Tezepelumab	251	224 (89.2)	0.23 (0.03)	(0.18, 0.28)	0.10 (0.04)	(0.03, 0.18)	0.007 *
		Placebo	252	218 (86.5)	0.13 (0.03)	(0.08, 0.18)			
	Week 52	Tezepelumab	251	218 (86.9)	0.24 (0.03)	(0.18, 0.29)	0.12 (0.04)	(0.05, 0.19)	0.001 *
		Placebo	252	201 (79.8)	0.11 (0.03)	(0.06, 0.17)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Black or African American	Week 2	Tezepelumab	21	17 (81.0)	0.21 (0.08)	(0.05, 0.38)	0.04 (0.11)	(-0.19, 0.28)	0.702
		Placebo	21	21 (100.0)	0.17 (0.08)	(0.01, 0.33)			
	Week 4	Tezepelumab	21	20 (95.2)	0.18 (0.08)	(0.02, 0.34)	0.07 (0.11)	(-0.15, 0.29)	0.532
		Placebo	21	21 (100.0)	0.11 (0.08)	(-0.04, 0.27)			
	Week 8	Tezepelumab	21	20 (95.2)	0.25 (0.08)	(0.09, 0.41)	0.25 (0.11)	(0.02, 0.48)	0.037 *
		Placebo	21	21 (100.0)	0.00 (0.08)	(-0.16, 0.17)			
	Week 12	Tezepelumab	21	20 (95.2)	0.27 (0.09)	(0.08, 0.45)	0.16 (0.13)	(-0.09, 0.42)	0.209
		Placebo	21	21 (100.0)	0.11 (0.09)	(-0.07, 0.29)			
	Week 16	Tezepelumab	21	19 (90.5)	0.19 (0.09)	(0.02, 0.37)	0.06 (0.12)	(-0.18, 0.30)	0.629
		Placebo	21	20 (95.2)	0.14 (0.08)	(-0.03, 0.31)			
	Week 24	Tezepelumab	21	17 (81.0)	0.22 (0.08)	(0.06, 0.38)	0.20 (0.11)	(-0.03, 0.43)	0.081
		Placebo	21	19 (90.5)	0.02 (0.08)	(-0.14, 0.18)			
	Week 36	Tezepelumab	21	17 (81.0)	0.19 (0.09)	(0.01, 0.38)	0.14 (0.13)	(-0.12, 0.40)	0.270
		Placebo	21	20 (95.2)	0.05 (0.09)	(-0.13, 0.23)			
	Week 52	Tezepelumab	21	17 (81.0)	0.27 (0.08)	(0.10, 0.44)	0.26 (0.12)	(0.02, 0.50)	0.032 *
		Placebo	21	18 (85.7)	0.01 (0.08)	(-0.16, 0.17)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Asian	Week 2	Tezepelumab	108	107 (99.1)	0.17 (0.03)	(0.11, 0.24)	0.11 (0.05)	(0.02, 0.20)	0.020 *
		Placebo	104	101 (97.1)	0.06 (0.03)	(-0.00, 0.13)			
	Week 4	Tezepelumab	108	108 (100.0)	0.22 (0.03)	(0.15, 0.29)	0.16 (0.05)	(0.07, 0.26)	<0.001 *
		Placebo	104	104 (100.0)	0.05 (0.04)	(-0.02, 0.12)			
	Week 8	Tezepelumab	108	106 (98.1)	0.26 (0.04)	(0.19, 0.34)	0.21 (0.05)	(0.11, 0.32)	<0.001 *
		Placebo	104	104 (100.0)	0.05 (0.04)	(-0.02, 0.12)			
	Week 12	Tezepelumab	108	106 (98.1)	0.29 (0.04)	(0.21, 0.37)	0.21 (0.05)	(0.10, 0.32)	<0.001 *
		Placebo	104	102 (98.1)	0.08 (0.04)	(0.00, 0.16)			
	Week 16	Tezepelumab	108	106 (98.1)	0.29 (0.04)	(0.22, 0.37)	0.22 (0.05)	(0.12, 0.33)	<0.001 *
		Placebo	104	101 (97.1)	0.07 (0.04)	(-0.01, 0.15)			
	Week 24	Tezepelumab	108	105 (97.2)	0.27 (0.04)	(0.19, 0.34)	0.20 (0.05)	(0.09, 0.31)	<0.001 *
		Placebo	104	99 (95.2)	0.07 (0.04)	(-0.01, 0.14)			
	Week 36	Tezepelumab	108	102 (94.4)	0.28 (0.04)	(0.20, 0.36)	0.24 (0.06)	(0.12, 0.35)	<0.001 *
		Placebo	104	95 (91.3)	0.04 (0.04)	(-0.04, 0.12)			
	Week 52	Tezepelumab	108	101 (93.5)	0.29 (0.04)	(0.21, 0.36)	0.25 (0.06)	(0.14, 0.37)	<0.001 *
		Placebo	104	95 (91.3)	0.03 (0.04)	(-0.05, 0.11)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Other	Week 2	Tezepelumab	15	14 (93.3)	0.16 (0.06)	(0.04, 0.28)	0.05 (0.08)	(-0.12, 0.22)	0.567
		Placebo	14	12 (85.7)	0.11 (0.06)	(-0.02, 0.24)			
	Week 4	Tezepelumab	15	14 (93.3)	0.22 (0.08)	(0.05, 0.40)	0.09 (0.12)	(-0.15, 0.34)	0.445
		Placebo	14	14 (100.0)	0.13 (0.09)	(-0.05, 0.31)			
	Week 8	Tezepelumab	15	14 (93.3)	0.20 (0.08)	(0.04, 0.36)	0.07 (0.11)	(-0.16, 0.30)	0.550
		Placebo	14	13 (92.9)	0.13 (0.08)	(-0.04, 0.29)			
	Week 12	Tezepelumab	15	14 (93.3)	0.18 (0.08)	(0.02, 0.34)	0.05 (0.11)	(-0.18, 0.28)	0.656
		Placebo	14	14 (100.0)	0.13 (0.08)	(-0.03, 0.29)			
	Week 16	Tezepelumab	15	13 (86.7)	0.23 (0.07)	(0.09, 0.37)	0.18 (0.10)	(-0.02, 0.38)	0.070
		Placebo	14	13 (92.9)	0.05 (0.07)	(-0.09, 0.19)			
	Week 24	Tezepelumab	15	12 (80.0)	0.18 (0.10)	(-0.02, 0.38)	0.12 (0.14)	(-0.17, 0.41)	0.395
		Placebo	14	12 (85.7)	0.06 (0.10)	(-0.15, 0.26)			
	Week 36	Tezepelumab	15	13 (86.7)	0.19 (0.09)	(0.01, 0.38)	0.04 (0.13)	(-0.22, 0.31)	0.746
		Placebo	14	13 (92.9)	0.15 (0.09)	(-0.04, 0.34)			
	Week 52	Tezepelumab	15	13 (86.7)	0.21 (0.08)	(0.05, 0.38)	0.16 (0.11)	(-0.08, 0.39)	0.182
		Placebo	14	12 (85.7)	0.06 (0.08)	(-0.11, 0.23)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Region									0.611
Europe	Week 2	Tezepelumab	65	65 (100.0)	0.18 (0.04)	(0.11, 0.25)	0.13 (0.05)	(0.03, 0.24)	0.014 *
		Placebo	61	58 (95.1)	0.05 (0.04)	(-0.03, 0.12)			
	Week 4	Tezepelumab	65	65 (100.0)	0.21 (0.04)	(0.12, 0.29)	0.16 (0.06)	(0.04, 0.28)	0.010 *
		Placebo	61	60 (98.4)	0.05 (0.04)	(-0.04, 0.13)			
	Week 8	Tezepelumab	65	65 (100.0)	0.21 (0.05)	(0.11, 0.31)	0.14 (0.07)	(-0.00, 0.28)	0.056
		Placebo	61	57 (93.4)	0.07 (0.05)	(-0.03, 0.17)			
	Week 12	Tezepelumab	65	63 (96.9)	0.18 (0.05)	(0.08, 0.28)	0.13 (0.07)	(-0.01, 0.26)	0.076
		Placebo	61	57 (93.4)	0.06 (0.05)	(-0.04, 0.15)			
	Week 16	Tezepelumab	65	62 (95.4)	0.26 (0.05)	(0.16, 0.36)	0.25 (0.07)	(0.11, 0.39)	<0.001 *
		Placebo	61	57 (93.4)	0.01 (0.05)	(-0.09, 0.11)			
	Week 24	Tezepelumab	65	62 (95.4)	0.20 (0.05)	(0.11, 0.29)	0.19 (0.07)	(0.06, 0.32)	0.005 *
		Placebo	61	53 (86.9)	0.01 (0.05)	(-0.09, 0.10)			
	Week 36	Tezepelumab	65	60 (92.3)	0.21 (0.05)	(0.12, 0.30)	0.11 (0.07)	(-0.02, 0.25)	0.100
		Placebo	61	51 (83.6)	0.10 (0.05)	(-0.00, 0.19)			
	Week 52	Tezepelumab	65	57 (87.7)	0.20 (0.04)	(0.12, 0.29)	0.10 (0.06)	(-0.03, 0.22)	0.128
		Placebo	61	50 (82.0)	0.11 (0.05)	(0.01, 0.20)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
America	Week 2	Tezepelumab	151	145 (96.0)	0.19 (0.03)	(0.13, 0.25)	0.11 (0.04)	(0.02, 0.20)	0.016 *
		Placebo	152	146 (96.1)	0.08 (0.03)	(0.02, 0.14)			
	Week 4	Tezepelumab	151	147 (97.4)	0.19 (0.03)	(0.12, 0.25)	0.08 (0.04)	(-0.01, 0.17)	0.084
		Placebo	152	146 (96.1)	0.11 (0.03)	(0.05, 0.17)			
	Week 8	Tezepelumab	151	147 (97.4)	0.20 (0.03)	(0.13, 0.27)	0.08 (0.05)	(-0.01, 0.18)	0.087
		Placebo	152	147 (96.7)	0.12 (0.03)	(0.05, 0.19)			
	Week 12	Tezepelumab	151	143 (94.7)	0.20 (0.04)	(0.13, 0.27)	0.09 (0.05)	(-0.01, 0.19)	0.091
		Placebo	152	149 (98.0)	0.12 (0.04)	(0.05, 0.19)			
	Week 16	Tezepelumab	151	143 (94.7)	0.22 (0.03)	(0.15, 0.28)	0.09 (0.05)	(-0.00, 0.19)	0.056
		Placebo	152	146 (96.1)	0.12 (0.03)	(0.06, 0.19)			
	Week 24	Tezepelumab	151	136 (90.1)	0.21 (0.04)	(0.14, 0.28)	0.10 (0.05)	(-0.00, 0.19)	0.057
		Placebo	152	141 (92.8)	0.11 (0.04)	(0.04, 0.18)			
	Week 36	Tezepelumab	151	132 (87.4)	0.23 (0.04)	(0.16, 0.31)	0.08 (0.05)	(-0.02, 0.18)	0.132
		Placebo	152	144 (94.7)	0.15 (0.04)	(0.08, 0.23)			
	Week 52	Tezepelumab	151	128 (84.8)	0.25 (0.04)	(0.17, 0.32)	0.12 (0.05)	(0.01, 0.22)	0.025 *
		Placebo	152	128 (84.2)	0.13 (0.04)	(0.05, 0.20)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Asia/Pacific	Week 2	Tezepelumab	105	104 (99.0)	0.18 (0.03)	(0.12, 0.25)	0.14 (0.05)	(0.05, 0.23)	0.002 *
		Placebo	105	101 (96.2)	0.04 (0.03)	(-0.02, 0.11)			
	Week 4	Tezepelumab	105	105 (100.0)	0.22 (0.03)	(0.16, 0.29)	0.18 (0.05)	(0.08, 0.27)	<0.001 *
		Placebo	105	104 (99.0)	0.04 (0.03)	(-0.02, 0.11)			
	Week 8	Tezepelumab	105	103 (98.1)	0.28 (0.04)	(0.21, 0.35)	0.21 (0.05)	(0.11, 0.31)	<0.001 *
		Placebo	105	104 (99.0)	0.07 (0.04)	(-0.00, 0.14)			
	Week 12	Tezepelumab	105	102 (97.1)	0.30 (0.04)	(0.23, 0.38)	0.22 (0.05)	(0.12, 0.33)	<0.001 *
		Placebo	105	102 (97.1)	0.08 (0.04)	(0.00, 0.15)			
	Week 16	Tezepelumab	105	104 (99.0)	0.31 (0.04)	(0.24, 0.39)	0.24 (0.05)	(0.13, 0.35)	<0.001 *
		Placebo	105	100 (95.2)	0.07 (0.04)	(-0.00, 0.15)			
	Week 24	Tezepelumab	105	102 (97.1)	0.27 (0.04)	(0.19, 0.34)	0.20 (0.05)	(0.10, 0.31)	<0.001 *
		Placebo	105	97 (92.4)	0.07 (0.04)	(-0.01, 0.14)			
	Week 36	Tezepelumab	105	97 (92.4)	0.28 (0.04)	(0.20, 0.36)	0.24 (0.06)	(0.13, 0.36)	<0.001 *
		Placebo	105	92 (87.6)	0.04 (0.04)	(-0.04, 0.12)			
	Week 52	Tezepelumab	105	98 (93.3)	0.30 (0.04)	(0.22, 0.38)	0.26 (0.06)	(0.15, 0.37)	<0.001 *
		Placebo	105	91 (86.7)	0.04 (0.04)	(-0.04, 0.12)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Rest of the world	Week 2	Tezepelumab	74	70 (94.6)	0.16 (0.03)	(0.09, 0.23)	0.13 (0.05)	(0.04, 0.23)	0.006 *
		Placebo	73	68 (93.2)	0.03 (0.03)	(-0.04, 0.09)			
	Week 4	Tezepelumab	74	74 (100.0)	0.20 (0.04)	(0.11, 0.29)	0.09 (0.06)	(-0.04, 0.21)	0.179
		Placebo	73	72 (98.6)	0.11 (0.05)	(0.02, 0.20)			
	Week 8	Tezepelumab	74	73 (98.6)	0.23 (0.04)	(0.15, 0.30)	0.15 (0.05)	(0.04, 0.26)	0.006 *
		Placebo	73	72 (98.6)	0.08 (0.04)	(0.00, 0.15)			
	Week 12	Tezepelumab	74	74 (100.0)	0.24 (0.04)	(0.16, 0.31)	0.12 (0.06)	(0.01, 0.23)	0.037 *
		Placebo	73	69 (94.5)	0.12 (0.04)	(0.04, 0.20)			
	Week 16	Tezepelumab	74	71 (95.9)	0.23 (0.04)	(0.14, 0.31)	0.15 (0.06)	(0.03, 0.26)	0.014 *
		Placebo	73	67 (91.8)	0.08 (0.04)	(-0.00, 0.16)			
	Week 24	Tezepelumab	74	69 (93.2)	0.23 (0.04)	(0.14, 0.31)	0.13 (0.06)	(0.01, 0.25)	0.039 *
		Placebo	73	66 (90.4)	0.10 (0.04)	(0.01, 0.19)			
	Week 36	Tezepelumab	74	67 (90.5)	0.23 (0.04)	(0.15, 0.32)	0.15 (0.06)	(0.03, 0.27)	0.016 *
		Placebo	73	59 (80.8)	0.08 (0.04)	(-0.00, 0.17)			
	Week 52	Tezepelumab	74	66 (89.2)	0.23 (0.04)	(0.15, 0.31)	0.20 (0.06)	(0.08, 0.31)	<0.001 *
		Placebo	73	57 (78.1)	0.04 (0.04)	(-0.05, 0.12)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
BMI									0.882
< 18.5 kg/m**2	Week 2	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 4	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 8	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 12	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 16	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 24	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	7	6 (85.7)					
	Week 36	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	7	6 (85.7)					
	Week 52	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	7	5 (71.4)					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
18.5 - < 25.0 kg/m**2	Week 2	Tezepelumab	117	114 (97.4)	0.20 (0.03)	(0.13, 0.27)	0.10 (0.05)	(0.00, 0.19)	0.043 *
		Placebo	119	115 (96.6)	0.10 (0.03)	(0.04, 0.17)			
	Week 4	Tezepelumab	117	117 (100.0)	0.22 (0.04)	(0.15, 0.29)	0.10 (0.05)	(-0.00, 0.21)	0.052
		Placebo	119	116 (97.5)	0.12 (0.04)	(0.04, 0.19)			
	Week 8	Tezepelumab	117	116 (99.1)	0.27 (0.04)	(0.19, 0.35)	0.14 (0.06)	(0.03, 0.26)	0.013 *
		Placebo	119	117 (98.3)	0.12 (0.04)	(0.04, 0.20)			
	Week 12	Tezepelumab	117	117 (100.0)	0.28 (0.04)	(0.20, 0.36)	0.11 (0.06)	(-0.01, 0.22)	0.063
		Placebo	119	115 (96.6)	0.17 (0.04)	(0.09, 0.25)			
	Week 16	Tezepelumab	117	110 (94.0)	0.34 (0.04)	(0.26, 0.42)	0.23 (0.06)	(0.12, 0.34)	<0.001 *
		Placebo	119	112 (94.1)	0.11 (0.04)	(0.03, 0.19)			
	Week 24	Tezepelumab	117	112 (95.7)	0.26 (0.04)	(0.18, 0.34)	0.13 (0.06)	(0.01, 0.25)	0.032 *
		Placebo	119	107 (89.9)	0.13 (0.04)	(0.05, 0.21)			
	Week 36	Tezepelumab	117	107 (91.5)	0.33 (0.04)	(0.24, 0.41)	0.19 (0.06)	(0.06, 0.31)	0.003 *
		Placebo	119	102 (85.7)	0.14 (0.04)	(0.05, 0.23)			
	Week 52	Tezepelumab	117	101 (86.3)	0.32 (0.04)	(0.24, 0.41)	0.20 (0.06)	(0.08, 0.32)	<0.001 *
		Placebo	119	102 (85.7)	0.12 (0.04)	(0.04, 0.21)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
25.0 - < 30.0 kg/m**2	Week 2	Tezepelumab	130	128 (98.5)	0.19 (0.03)	(0.13, 0.25)	0.15 (0.04)	(0.06, 0.23)	<0.001 *
		Placebo	130	122 (93.8)	0.04 (0.03)	(-0.02, 0.10)			
	Week 4	Tezepelumab	130	128 (98.5)	0.23 (0.03)	(0.16, 0.29)	0.13 (0.05)	(0.03, 0.22)	0.007 *
		Placebo	130	126 (96.9)	0.10 (0.03)	(0.03, 0.17)			
	Week 8	Tezepelumab	130	127 (97.7)	0.26 (0.03)	(0.20, 0.32)	0.16 (0.05)	(0.07, 0.25)	<0.001 *
		Placebo	130	127 (97.7)	0.10 (0.03)	(0.04, 0.16)			
	Week 12	Tezepelumab	130	125 (96.2)	0.26 (0.03)	(0.20, 0.33)	0.14 (0.05)	(0.05, 0.23)	0.003 *
		Placebo	130	124 (95.4)	0.12 (0.03)	(0.05, 0.19)			
	Week 16	Tezepelumab	130	126 (96.9)	0.28 (0.03)	(0.21, 0.35)	0.19 (0.05)	(0.10, 0.29)	<0.001 *
		Placebo	130	123 (94.6)	0.09 (0.04)	(0.02, 0.16)			
	Week 24	Tezepelumab	130	119 (91.5)	0.25 (0.03)	(0.19, 0.31)	0.17 (0.05)	(0.08, 0.26)	<0.001 *
		Placebo	130	119 (91.5)	0.08 (0.03)	(0.02, 0.15)			
	Week 36	Tezepelumab	130	115 (88.5)	0.26 (0.04)	(0.19, 0.33)	0.15 (0.05)	(0.05, 0.25)	0.003 *
		Placebo	130	117 (90.0)	0.11 (0.04)	(0.04, 0.18)			
	Week 52	Tezepelumab	130	116 (89.2)	0.28 (0.04)	(0.21, 0.35)	0.23 (0.05)	(0.13, 0.33)	<0.001 *
		Placebo	130	105 (80.8)	0.05 (0.04)	(-0.02, 0.12)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 30.0 kg/m**2	Week 2	Tezepelumab	143	137 (95.8)	0.16 (0.03)	(0.10, 0.21)	0.12 (0.04)	(0.04, 0.19)	0.003 *
		Placebo	135	129 (95.6)	0.04 (0.03)	(-0.02, 0.09)			
	Week 4	Tezepelumab	143	141 (98.6)	0.18 (0.03)	(0.12, 0.23)	0.12 (0.04)	(0.05, 0.20)	0.002 *
		Placebo	135	133 (98.5)	0.05 (0.03)	(-0.00, 0.11)			
	Week 8	Tezepelumab	143	140 (97.9)	0.18 (0.03)	(0.12, 0.24)	0.11 (0.04)	(0.03, 0.19)	0.010 *
		Placebo	135	129 (95.6)	0.07 (0.03)	(0.01, 0.13)			
	Week 12	Tezepelumab	143	135 (94.4)	0.18 (0.03)	(0.12, 0.24)	0.15 (0.04)	(0.06, 0.24)	<0.001 *
		Placebo	135	131 (97.0)	0.03 (0.03)	(-0.03, 0.09)			
	Week 16	Tezepelumab	143	139 (97.2)	0.16 (0.03)	(0.10, 0.21)	0.08 (0.04)	(0.01, 0.16)	0.036 *
		Placebo	135	128 (94.8)	0.07 (0.03)	(0.02, 0.13)			
	Week 24	Tezepelumab	143	133 (93.0)	0.18 (0.03)	(0.12, 0.24)	0.13 (0.04)	(0.04, 0.21)	0.004 *
		Placebo	135	125 (92.6)	0.05 (0.03)	(-0.01, 0.12)			
	Week 36	Tezepelumab	143	129 (90.2)	0.16 (0.03)	(0.10, 0.22)	0.08 (0.04)	(-0.00, 0.17)	0.064
		Placebo	135	121 (89.6)	0.08 (0.03)	(0.02, 0.14)			
	Week 52	Tezepelumab	143	127 (88.8)	0.17 (0.03)	(0.11, 0.23)	0.09 (0.04)	(-0.00, 0.17)	0.050
		Placebo	135	114 (84.4)	0.08 (0.03)	(0.02, 0.15)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline eosinophils - Low									0.180
< 150 cells/uL	Week 2	Tezepelumab	96	94 (97.9)	0.08 (0.03)	(0.01, 0.14)	0.07 (0.05)	(-0.02, 0.16)	0.122
		Placebo	89	84 (94.4)	0.00 (0.03)	(-0.06, 0.07)			
	Week 4	Tezepelumab	96	95 (99.0)	0.09 (0.04)	(0.02, 0.16)	0.07 (0.05)	(-0.03, 0.17)	0.168
		Placebo	89	87 (97.8)	0.02 (0.04)	(-0.05, 0.09)			
	Week 8	Tezepelumab	96	93 (96.9)	0.10 (0.03)	(0.03, 0.17)	0.05 (0.05)	(-0.04, 0.15)	0.266
		Placebo	89	86 (96.6)	0.05 (0.04)	(-0.02, 0.12)			
	Week 12	Tezepelumab	96	92 (95.8)	0.09 (0.03)	(0.02, 0.15)	0.06 (0.05)	(-0.04, 0.16)	0.214
		Placebo	89	84 (94.4)	0.02 (0.04)	(-0.05, 0.09)			
	Week 16	Tezepelumab	96	93 (96.9)	0.13 (0.04)	(0.05, 0.21)	0.14 (0.06)	(0.03, 0.25)	0.012 *
		Placebo	89	84 (94.4)	-0.01 (0.04)	(-0.09, 0.07)			
	Week 24	Tezepelumab	96	86 (89.6)	0.09 (0.03)	(0.02, 0.15)	0.06 (0.05)	(-0.03, 0.15)	0.207
		Placebo	89	81 (91.0)	0.03 (0.03)	(-0.04, 0.09)			
	Week 36	Tezepelumab	96	87 (90.6)	0.07 (0.03)	(0.00, 0.14)	0.03 (0.05)	(-0.07, 0.12)	0.575
		Placebo	89	78 (87.6)	0.04 (0.04)	(-0.03, 0.11)			
	Week 52	Tezepelumab	96	86 (89.6)	0.11 (0.04)	(0.03, 0.18)	0.12 (0.05)	(0.01, 0.22)	0.033 *
		Placebo	89	77 (86.5)	-0.01 (0.04)	(-0.09, 0.07)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 150 cells/uL	Week 2	Tezepelumab	299	290 (97.0)	0.21 (0.02)	(0.17, 0.25)	0.14 (0.03)	(0.08, 0.20)	<0.001 *
		Placebo	302	289 (95.7)	0.07 (0.02)	(0.03, 0.11)			
	Week 4	Tezepelumab	299	296 (99.0)	0.24 (0.02)	(0.19, 0.28)	0.13 (0.03)	(0.07, 0.19)	<0.001 *
		Placebo	302	295 (97.7)	0.10 (0.02)	(0.06, 0.15)			
	Week 8	Tezepelumab	299	295 (98.7)	0.27 (0.02)	(0.22, 0.31)	0.16 (0.03)	(0.10, 0.23)	<0.001 *
		Placebo	302	294 (97.4)	0.10 (0.02)	(0.06, 0.15)			
	Week 12	Tezepelumab	299	290 (97.0)	0.28 (0.02)	(0.23, 0.32)	0.16 (0.03)	(0.09, 0.22)	<0.001 *
		Placebo	302	293 (97.0)	0.12 (0.02)	(0.07, 0.17)			
	Week 16	Tezepelumab	299	287 (96.0)	0.29 (0.02)	(0.24, 0.33)	0.18 (0.03)	(0.11, 0.24)	<0.001 *
		Placebo	302	286 (94.7)	0.11 (0.02)	(0.07, 0.16)			
	Week 24	Tezepelumab	299	283 (94.6)	0.27 (0.02)	(0.22, 0.32)	0.17 (0.03)	(0.10, 0.24)	<0.001 *
		Placebo	302	276 (91.4)	0.10 (0.02)	(0.05, 0.15)			
	Week 36	Tezepelumab	299	269 (90.0)	0.30 (0.03)	(0.25, 0.35)	0.18 (0.04)	(0.11, 0.25)	<0.001 *
		Placebo	302	268 (88.7)	0.12 (0.03)	(0.07, 0.17)			
	Week 52	Tezepelumab	299	263 (88.0)	0.30 (0.02)	(0.25, 0.34)	0.19 (0.03)	(0.12, 0.25)	<0.001 *
		Placebo	302	249 (82.5)	0.11 (0.02)	(0.06, 0.16)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline eosinophils - High									0.030 i
< 300 cells/uL	Week 2	Tezepelumab	225	220 (97.8)	0.12 (0.02)	(0.08, 0.16)	0.10 (0.03)	(0.04, 0.16)	<0.001 *
		Placebo	211	202 (95.7)	0.02 (0.02)	(-0.02, 0.06)			
	Week 4	Tezepelumab	225	223 (99.1)	0.13 (0.02)	(0.09, 0.18)	0.10 (0.03)	(0.03, 0.16)	0.003 *
		Placebo	211	205 (97.2)	0.03 (0.02)	(-0.01, 0.08)			
	Week 8	Tezepelumab	225	221 (98.2)	0.14 (0.02)	(0.10, 0.18)	0.07 (0.03)	(0.01, 0.13)	0.030 *
		Placebo	211	203 (96.2)	0.07 (0.02)	(0.03, 0.12)			
	Week 12	Tezepelumab	225	217 (96.4)	0.12 (0.02)	(0.08, 0.17)	0.08 (0.03)	(0.01, 0.14)	0.024 *
		Placebo	211	201 (95.3)	0.05 (0.02)	(-0.00, 0.09)			
	Week 16	Tezepelumab	225	219 (97.3)	0.15 (0.02)	(0.10, 0.20)	0.11 (0.03)	(0.04, 0.18)	0.002 *
		Placebo	211	199 (94.3)	0.04 (0.02)	(-0.01, 0.09)			
	Week 24	Tezepelumab	225	211 (93.8)	0.11 (0.02)	(0.07, 0.16)	0.09 (0.03)	(0.02, 0.15)	0.008 *
		Placebo	211	192 (91.0)	0.02 (0.02)	(-0.02, 0.07)			
	Week 36	Tezepelumab	225	205 (91.1)	0.12 (0.02)	(0.07, 0.16)	0.08 (0.03)	(0.01, 0.15)	0.029 *
		Placebo	211	186 (88.2)	0.04 (0.03)	(-0.01, 0.09)			
	Week 52	Tezepelumab	225	206 (91.6)	0.14 (0.02)	(0.09, 0.19)	0.11 (0.04)	(0.04, 0.18)	0.002 *
		Placebo	211	176 (83.4)	0.03 (0.03)	(-0.02, 0.08)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 300 cells/uL	Week 2	Tezepelumab	170	164 (96.5)	0.26 (0.03)	(0.20, 0.31)	0.16 (0.04)	(0.08, 0.24)	<0.001 *
		Placebo	180	171 (95.0)	0.10 (0.03)	(0.04, 0.15)			
	Week 4	Tezepelumab	170	168 (98.8)	0.29 (0.03)	(0.23, 0.35)	0.15 (0.04)	(0.07, 0.23)	<0.001 *
		Placebo	180	177 (98.3)	0.14 (0.03)	(0.08, 0.20)			
	Week 8	Tezepelumab	170	167 (98.2)	0.34 (0.03)	(0.28, 0.41)	0.23 (0.05)	(0.14, 0.32)	<0.001 *
		Placebo	180	177 (98.3)	0.12 (0.03)	(0.05, 0.18)			
	Week 12	Tezepelumab	170	165 (97.1)	0.37 (0.03)	(0.31, 0.44)	0.21 (0.05)	(0.12, 0.30)	<0.001 *
		Placebo	180	176 (97.8)	0.16 (0.03)	(0.10, 0.22)			
	Week 16	Tezepelumab	170	161 (94.7)	0.38 (0.03)	(0.32, 0.45)	0.25 (0.04)	(0.16, 0.33)	<0.001 *
		Placebo	180	171 (95.0)	0.14 (0.03)	(0.08, 0.20)			
	Week 24	Tezepelumab	170	158 (92.9)	0.38 (0.03)	(0.31, 0.44)	0.22 (0.05)	(0.13, 0.31)	<0.001 *
		Placebo	180	165 (91.7)	0.15 (0.03)	(0.09, 0.22)			
	Week 36	Tezepelumab	170	151 (88.8)	0.41 (0.03)	(0.34, 0.47)	0.23 (0.05)	(0.13, 0.32)	<0.001 *
		Placebo	180	160 (88.9)	0.18 (0.03)	(0.11, 0.24)			
	Week 52	Tezepelumab	170	143 (84.1)	0.39 (0.03)	(0.32, 0.46)	0.25 (0.05)	(0.16, 0.34)	<0.001 *
		Placebo	180	150 (83.3)	0.14 (0.03)	(0.08, 0.21)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline FENO									0.123
< 25 ppb	Week 2	Tezepelumab	158	153 (96.8)	0.13 (0.02)	(0.09, 0.18)	0.10 (0.03)	(0.04, 0.17)	0.002 *
		Placebo	151	141 (93.4)	0.03 (0.02)	(-0.02, 0.08)			
	Week 4	Tezepelumab	158	155 (98.1)	0.15 (0.03)	(0.10, 0.20)	0.07 (0.04)	(0.00, 0.15)	0.044 *
		Placebo	151	149 (98.7)	0.07 (0.03)	(0.02, 0.12)			
	Week 8	Tezepelumab	158	155 (98.1)	0.16 (0.03)	(0.10, 0.21)	0.09 (0.04)	(0.02, 0.17)	0.015 *
		Placebo	151	147 (97.4)	0.06 (0.03)	(0.01, 0.12)			
	Week 12	Tezepelumab	158	152 (96.2)	0.15 (0.03)	(0.10, 0.20)	0.08 (0.04)	(0.01, 0.16)	0.027 *
		Placebo	151	144 (95.4)	0.06 (0.03)	(0.01, 0.12)			
	Week 16	Tezepelumab	158	151 (95.6)	0.16 (0.03)	(0.11, 0.21)	0.13 (0.04)	(0.05, 0.20)	<0.001 *
		Placebo	151	144 (95.4)	0.03 (0.03)	(-0.02, 0.08)			
	Week 24	Tezepelumab	158	149 (94.3)	0.13 (0.03)	(0.08, 0.19)	0.10 (0.04)	(0.02, 0.18)	0.011 *
		Placebo	151	140 (92.7)	0.03 (0.03)	(-0.02, 0.09)			
	Week 36	Tezepelumab	158	140 (88.6)	0.13 (0.03)	(0.07, 0.18)	0.05 (0.04)	(-0.03, 0.12)	0.236
		Placebo	151	135 (89.4)	0.08 (0.03)	(0.03, 0.14)			
	Week 52	Tezepelumab	158	142 (89.9)	0.14 (0.03)	(0.08, 0.19)	0.08 (0.04)	(0.00, 0.16)	0.037 *
		Placebo	151	130 (86.1)	0.05 (0.03)	(-0.00, 0.11)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 25 ppb	Week 2	Tezepelumab	234	228 (97.4)	0.22 (0.02)	(0.17, 0.26)	0.15 (0.03)	(0.08, 0.22)	<0.001 *
		Placebo	236	228 (96.6)	0.07 (0.02)	(0.02, 0.12)			
	Week 4	Tezepelumab	234	233 (99.6)	0.24 (0.03)	(0.19, 0.29)	0.16 (0.04)	(0.08, 0.23)	<0.001 *
		Placebo	236	229 (97.0)	0.09 (0.03)	(0.04, 0.14)			
	Week 8	Tezepelumab	234	230 (98.3)	0.28 (0.03)	(0.23, 0.34)	0.17 (0.04)	(0.10, 0.25)	<0.001 *
		Placebo	236	229 (97.0)	0.11 (0.03)	(0.06, 0.16)			
	Week 12	Tezepelumab	234	227 (97.0)	0.29 (0.03)	(0.24, 0.35)	0.17 (0.04)	(0.09, 0.25)	<0.001 *
		Placebo	236	230 (97.5)	0.12 (0.03)	(0.06, 0.18)			
	Week 16	Tezepelumab	234	226 (96.6)	0.32 (0.03)	(0.26, 0.37)	0.20 (0.04)	(0.12, 0.27)	<0.001 *
		Placebo	236	223 (94.5)	0.12 (0.03)	(0.07, 0.18)			
	Week 24	Tezepelumab	234	217 (92.7)	0.29 (0.03)	(0.24, 0.35)	0.17 (0.04)	(0.10, 0.25)	<0.001 *
		Placebo	236	214 (90.7)	0.12 (0.03)	(0.06, 0.17)			
	Week 36	Tezepelumab	234	213 (91.0)	0.32 (0.03)	(0.26, 0.38)	0.20 (0.04)	(0.12, 0.29)	<0.001 *
		Placebo	236	208 (88.1)	0.12 (0.03)	(0.06, 0.17)			
	Week 52	Tezepelumab	234	204 (87.2)	0.33 (0.03)	(0.27, 0.38)	0.23 (0.04)	(0.15, 0.31)	<0.001 *
		Placebo	236	193 (81.8)	0.10 (0.03)	(0.04, 0.15)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline specific perennial FEIA status									0.377
All negative	Week 2	Tezepelumab	140	138 (98.6)	0.18 (0.02)	(0.13, 0.22)	0.14 (0.03)	(0.07, 0.20)	<0.001 *
		Placebo	131	125 (95.4)	0.04 (0.02)	(-0.01, 0.09)			
	Week 4	Tezepelumab	140	139 (99.3)	0.23 (0.03)	(0.18, 0.29)	0.14 (0.04)	(0.06, 0.22)	<0.001 *
		Placebo	131	128 (97.7)	0.10 (0.03)	(0.04, 0.15)			
	Week 8	Tezepelumab	140	138 (98.6)	0.24 (0.03)	(0.19, 0.30)	0.16 (0.04)	(0.08, 0.23)	<0.001 *
		Placebo	131	126 (96.2)	0.09 (0.03)	(0.03, 0.14)			
	Week 12	Tezepelumab	140	138 (98.6)	0.26 (0.03)	(0.20, 0.32)	0.15 (0.04)	(0.06, 0.23)	0.001 *
		Placebo	131	127 (96.9)	0.11 (0.03)	(0.05, 0.17)			
	Week 16	Tezepelumab	140	137 (97.9)	0.27 (0.03)	(0.21, 0.33)	0.20 (0.04)	(0.12, 0.28)	<0.001 *
		Placebo	131	123 (93.9)	0.07 (0.03)	(0.02, 0.13)			
	Week 24	Tezepelumab	140	133 (95.0)	0.25 (0.03)	(0.19, 0.31)	0.17 (0.04)	(0.08, 0.25)	<0.001 *
		Placebo	131	114 (87.0)	0.08 (0.03)	(0.02, 0.15)			
	Week 36	Tezepelumab	140	129 (92.1)	0.25 (0.03)	(0.19, 0.31)	0.16 (0.05)	(0.07, 0.25)	<0.001 *
		Placebo	131	113 (86.3)	0.09 (0.03)	(0.03, 0.15)			
	Week 52	Tezepelumab	140	128 (91.4)	0.28 (0.03)	(0.22, 0.33)	0.25 (0.04)	(0.17, 0.34)	<0.001 *
		Placebo	131	106 (80.9)	0.02 (0.03)	(-0.04, 0.08)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Any positive	Week 2	Tezepelumab	253	245 (96.8)	0.18 (0.02)	(0.13, 0.23)	0.12 (0.03)	(0.05, 0.18)	<0.001 *
		Placebo	253	243 (96.0)	0.06 (0.02)	(0.02, 0.11)			
	Week 4	Tezepelumab	253	251 (99.2)	0.18 (0.02)	(0.14, 0.23)	0.10 (0.03)	(0.04, 0.17)	0.003 *
		Placebo	253	248 (98.0)	0.08 (0.02)	(0.03, 0.13)			
	Week 8	Tezepelumab	253	249 (98.4)	0.22 (0.03)	(0.17, 0.27)	0.13 (0.04)	(0.05, 0.20)	<0.001 *
		Placebo	253	247 (97.6)	0.09 (0.03)	(0.04, 0.14)			
	Week 12	Tezepelumab	253	243 (96.0)	0.22 (0.03)	(0.16, 0.27)	0.13 (0.04)	(0.05, 0.20)	<0.001 *
		Placebo	253	244 (96.4)	0.09 (0.03)	(0.04, 0.14)			
	Week 16	Tezepelumab	253	242 (95.7)	0.24 (0.03)	(0.19, 0.29)	0.15 (0.04)	(0.07, 0.22)	<0.001 *
		Placebo	253	240 (94.9)	0.09 (0.03)	(0.04, 0.14)			
	Week 24	Tezepelumab	253	235 (92.9)	0.21 (0.03)	(0.16, 0.26)	0.13 (0.04)	(0.05, 0.20)	0.001 *
		Placebo	253	236 (93.3)	0.09 (0.03)	(0.03, 0.14)			
	Week 36	Tezepelumab	253	226 (89.3)	0.24 (0.03)	(0.18, 0.29)	0.13 (0.04)	(0.05, 0.20)	0.002 *
		Placebo	253	227 (89.7)	0.11 (0.03)	(0.06, 0.17)			
	Week 52	Tezepelumab	253	220 (87.0)	0.23 (0.03)	(0.18, 0.29)	0.12 (0.04)	(0.05, 0.20)	0.002 *
		Placebo	253	216 (85.4)	0.11 (0.03)	(0.06, 0.17)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Total serum IgE									0.248
Low	Week 2	Tezepelumab	116	113 (97.4)	0.13 (0.03)	(0.08, 0.18)	0.11 (0.04)	(0.04, 0.18)	0.003 *
		Placebo	125	117 (93.6)	0.03 (0.02)	(-0.02, 0.07)			
	Week 4	Tezepelumab	116	116 (100.0)	0.16 (0.03)	(0.10, 0.22)	0.08 (0.04)	(-0.01, 0.16)	0.071
		Placebo	125	122 (97.6)	0.08 (0.03)	(0.02, 0.14)			
	Week 8	Tezepelumab	116	113 (97.4)	0.16 (0.03)	(0.10, 0.22)	0.08 (0.04)	(-0.00, 0.16)	0.053
		Placebo	125	120 (96.0)	0.08 (0.03)	(0.03, 0.14)			
	Week 12	Tezepelumab	116	112 (96.6)	0.18 (0.03)	(0.11, 0.25)	0.10 (0.05)	(0.01, 0.19)	0.033 *
		Placebo	125	120 (96.0)	0.08 (0.03)	(0.01, 0.14)			
	Week 16	Tezepelumab	116	114 (98.3)	0.19 (0.03)	(0.13, 0.25)	0.13 (0.04)	(0.04, 0.21)	0.004 *
		Placebo	125	116 (92.8)	0.06 (0.03)	(0.00, 0.13)			
	Week 24	Tezepelumab	116	112 (96.6)	0.16 (0.03)	(0.10, 0.22)	0.10 (0.04)	(0.02, 0.18)	0.017 *
		Placebo	125	111 (88.8)	0.06 (0.03)	(0.00, 0.12)			
	Week 36	Tezepelumab	116	107 (92.2)	0.14 (0.03)	(0.08, 0.21)	0.03 (0.04)	(-0.05, 0.12)	0.442
		Placebo	125	105 (84.0)	0.11 (0.03)	(0.05, 0.17)			
	Week 52	Tezepelumab	116	107 (92.2)	0.16 (0.03)	(0.09, 0.22)	0.12 (0.05)	(0.03, 0.21)	0.007 *
		Placebo	125	105 (84.0)	0.03 (0.03)	(-0.03, 0.10)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Normal	Week 2	Tezepelumab	247	240 (97.2)	0.19 (0.02)	(0.14, 0.23)	0.16 (0.03)	(0.10, 0.22)	<0.001 *
		Placebo	220	212 (96.4)	0.03 (0.02)	(-0.02, 0.07)			
	Week 4	Tezepelumab	247	243 (98.4)	0.21 (0.02)	(0.16, 0.25)	0.15 (0.03)	(0.08, 0.21)	<0.001 *
		Placebo	220	214 (97.3)	0.06 (0.02)	(0.01, 0.11)			
	Week 8	Tezepelumab	247	243 (98.4)	0.24 (0.02)	(0.19, 0.29)	0.16 (0.04)	(0.09, 0.23)	<0.001 *
		Placebo	220	214 (97.3)	0.07 (0.03)	(0.02, 0.12)			
	Week 12	Tezepelumab	247	239 (96.8)	0.24 (0.03)	(0.19, 0.29)	0.16 (0.04)	(0.09, 0.24)	<0.001 *
		Placebo	220	212 (96.4)	0.07 (0.03)	(0.02, 0.13)			
	Week 16	Tezepelumab	247	235 (95.1)	0.27 (0.02)	(0.22, 0.32)	0.21 (0.04)	(0.14, 0.28)	<0.001 *
		Placebo	220	210 (95.5)	0.06 (0.03)	(0.01, 0.11)			
	Week 24	Tezepelumab	247	227 (91.9)	0.23 (0.03)	(0.18, 0.28)	0.17 (0.04)	(0.10, 0.24)	<0.001 *
		Placebo	220	203 (92.3)	0.07 (0.03)	(0.01, 0.12)			
	Week 36	Tezepelumab	247	221 (89.5)	0.27 (0.03)	(0.22, 0.32)	0.20 (0.04)	(0.12, 0.27)	<0.001 *
		Placebo	220	196 (89.1)	0.07 (0.03)	(0.02, 0.13)			
	Week 52	Tezepelumab	247	214 (86.6)	0.28 (0.03)	(0.23, 0.33)	0.20 (0.04)	(0.12, 0.28)	<0.001 *
		Placebo	220	183 (83.2)	0.08 (0.03)	(0.03, 0.14)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
High	Week 2	Tezepelumab	32	31 (96.9)	0.28 (0.08)	(0.13, 0.44)	0.00 (0.10)	(-0.20, 0.21)	0.972
		Placebo	46	44 (95.7)	0.28 (0.07)	(0.15, 0.41)			
	Week 4	Tezepelumab	32	32 (100.0)	0.31 (0.09)	(0.13, 0.49)	0.10 (0.12)	(-0.14, 0.34)	0.415
		Placebo	46	46 (100.0)	0.21 (0.08)	(0.06, 0.37)			
	Week 8	Tezepelumab	32	32 (100.0)	0.37 (0.10)	(0.18, 0.56)	0.17 (0.12)	(-0.08, 0.42)	0.180
		Placebo	46	46 (100.0)	0.20 (0.08)	(0.04, 0.36)			
	Week 12	Tezepelumab	32	31 (96.9)	0.36 (0.09)	(0.18, 0.54)	0.09 (0.12)	(-0.15, 0.33)	0.448
		Placebo	46	45 (97.8)	0.27 (0.08)	(0.12, 0.42)			
	Week 16	Tezepelumab	32	31 (96.9)	0.35 (0.09)	(0.16, 0.53)	0.09 (0.12)	(-0.15, 0.33)	0.448
		Placebo	46	44 (95.7)	0.26 (0.08)	(0.10, 0.41)			
	Week 24	Tezepelumab	32	30 (93.8)	0.38 (0.10)	(0.18, 0.58)	0.15 (0.13)	(-0.11, 0.41)	0.245
		Placebo	46	43 (93.5)	0.23 (0.08)	(0.06, 0.39)			
	Week 36	Tezepelumab	32	28 (87.5)	0.40 (0.11)	(0.18, 0.62)	0.15 (0.14)	(-0.13, 0.43)	0.286
		Placebo	46	45 (97.8)	0.25 (0.09)	(0.07, 0.43)			
	Week 52	Tezepelumab	32	28 (87.5)	0.33 (0.09)	(0.15, 0.50)	0.10 (0.12)	(-0.13, 0.34)	0.382
		Placebo	46	38 (82.6)	0.22 (0.08)	(0.07, 0.37)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
OCS at baseline									0.030 i
Yes	Week 2	Tezepelumab	47	46 (97.9)	0.22 (0.05)	(0.12, 0.33)	0.26 (0.08)	(0.11, 0.42)	0.001 *
		Placebo	42	40 (95.2)	-0.04 (0.06)	(-0.15, 0.07)			
	Week 4	Tezepelumab	47	47 (100.0)	0.27 (0.06)	(0.16, 0.38)	0.25 (0.08)	(0.09, 0.42)	0.003 *
		Placebo	42	41 (97.6)	0.01 (0.06)	(-0.10, 0.13)			
	Week 8	Tezepelumab	47	46 (97.9)	0.22 (0.05)	(0.11, 0.33)	0.18 (0.08)	(0.02, 0.33)	0.031 *
		Placebo	42	42 (100.0)	0.05 (0.06)	(-0.07, 0.16)			
	Week 12	Tezepelumab	47	44 (93.6)	0.27 (0.06)	(0.14, 0.40)	0.23 (0.09)	(0.05, 0.42)	0.015 *
		Placebo	42	39 (92.9)	0.04 (0.07)	(-0.10, 0.18)			
	Week 16	Tezepelumab	47	45 (95.7)	0.29 (0.05)	(0.19, 0.39)	0.32 (0.08)	(0.17, 0.47)	<0.001 *
		Placebo	42	35 (83.3)	-0.03 (0.06)	(-0.14, 0.09)			
	Week 24	Tezepelumab	47	42 (89.4)	0.32 (0.06)	(0.20, 0.44)	0.36 (0.09)	(0.18, 0.53)	<0.001 *
		Placebo	42	31 (73.8)	-0.04 (0.07)	(-0.17, 0.09)			
	Week 36	Tezepelumab	47	39 (83.0)	0.24 (0.05)	(0.14, 0.35)	0.28 (0.08)	(0.13, 0.43)	<0.001 *
		Placebo	42	32 (76.2)	-0.04 (0.06)	(-0.15, 0.07)			
	Week 52	Tezepelumab	47	37 (78.7)	0.28 (0.06)	(0.17, 0.40)	0.31 (0.09)	(0.13, 0.48)	<0.001 *
		Placebo	42	28 (66.7)	-0.03 (0.07)	(-0.16, 0.10)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 2	Tezepelumab	348	338 (97.1)	0.17 (0.02)	(0.14, 0.21)	0.11 (0.03)	(0.06, 0.16)	<0.001 *
		Placebo	349	333 (95.4)	0.07 (0.02)	(0.03, 0.10)			
	Week 4	Tezepelumab	348	344 (98.9)	0.19 (0.02)	(0.15, 0.23)	0.10 (0.03)	(0.05, 0.16)	<0.001 *
		Placebo	349	341 (97.7)	0.09 (0.02)	(0.05, 0.13)			
	Week 8	Tezepelumab	348	342 (98.3)	0.23 (0.02)	(0.19, 0.27)	0.13 (0.03)	(0.08, 0.19)	<0.001 *
		Placebo	349	338 (96.8)	0.10 (0.02)	(0.05, 0.14)			
	Week 12	Tezepelumab	348	338 (97.1)	0.23 (0.02)	(0.18, 0.27)	0.12 (0.03)	(0.06, 0.18)	<0.001 *
		Placebo	349	338 (96.8)	0.10 (0.02)	(0.06, 0.15)			
	Week 16	Tezepelumab	348	335 (96.3)	0.25 (0.02)	(0.20, 0.29)	0.15 (0.03)	(0.09, 0.21)	<0.001 *
		Placebo	349	335 (96.0)	0.10 (0.02)	(0.05, 0.14)			
	Week 24	Tezepelumab	348	327 (94.0)	0.21 (0.02)	(0.17, 0.26)	0.12 (0.03)	(0.06, 0.18)	<0.001 *
		Placebo	349	326 (93.4)	0.10 (0.02)	(0.05, 0.14)			
	Week 36	Tezepelumab	348	317 (91.1)	0.24 (0.02)	(0.20, 0.29)	0.12 (0.03)	(0.06, 0.19)	<0.001 *
		Placebo	349	314 (90.0)	0.12 (0.02)	(0.07, 0.16)			
	Week 52	Tezepelumab	348	312 (89.7)	0.24 (0.02)	(0.20, 0.29)	0.15 (0.03)	(0.09, 0.21)	<0.001 *
		Placebo	349	298 (85.4)	0.09 (0.02)	(0.05, 0.14)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
LAMA use at baseline									0.302
Yes	Week 2	Tezepelumab	115	114 (99.1)	0.19 (0.03)	(0.13, 0.25)	0.16 (0.04)	(0.07, 0.24)	<0.001 *
		Placebo	110	107 (97.3)	0.03 (0.03)	(-0.03, 0.09)			
	Week 4	Tezepelumab	115	115 (100.0)	0.19 (0.03)	(0.13, 0.26)	0.14 (0.05)	(0.05, 0.23)	0.003 *
		Placebo	110	109 (99.1)	0.05 (0.03)	(-0.02, 0.12)			
	Week 8	Tezepelumab	115	114 (99.1)	0.23 (0.04)	(0.16, 0.30)	0.18 (0.05)	(0.07, 0.28)	<0.001 *
		Placebo	110	105 (95.5)	0.05 (0.04)	(-0.02, 0.13)			
	Week 12	Tezepelumab	115	111 (96.5)	0.25 (0.04)	(0.17, 0.32)	0.24 (0.06)	(0.13, 0.35)	<0.001 *
		Placebo	110	105 (95.5)	0.00 (0.04)	(-0.07, 0.08)			
	Week 16	Tezepelumab	115	110 (95.7)	0.27 (0.04)	(0.20, 0.34)	0.24 (0.05)	(0.14, 0.34)	<0.001 *
		Placebo	110	102 (92.7)	0.03 (0.04)	(-0.04, 0.10)			
	Week 24	Tezepelumab	115	108 (93.9)	0.23 (0.04)	(0.16, 0.30)	0.19 (0.05)	(0.09, 0.29)	<0.001 *
		Placebo	110	99 (90.0)	0.04 (0.04)	(-0.03, 0.11)			
	Week 36	Tezepelumab	115	102 (88.7)	0.25 (0.03)	(0.19, 0.32)	0.16 (0.05)	(0.07, 0.26)	0.001 *
		Placebo	110	96 (87.3)	0.09 (0.04)	(0.02, 0.16)			
	Week 52	Tezepelumab	115	97 (84.3)	0.27 (0.04)	(0.19, 0.34)	0.23 (0.05)	(0.12, 0.34)	<0.001 *
		Placebo	110	92 (83.6)	0.04 (0.04)	(-0.04, 0.12)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 2	Tezepelumab	280	270 (96.4)	0.17 (0.02)	(0.13, 0.22)	0.11 (0.03)	(0.05, 0.17)	<0.001 *
		Placebo	281	266 (94.7)	0.06 (0.02)	(0.02, 0.10)			
	Week 4	Tezepelumab	280	276 (98.6)	0.21 (0.02)	(0.16, 0.25)	0.11 (0.03)	(0.05, 0.17)	<0.001 *
		Placebo	281	273 (97.2)	0.10 (0.02)	(0.05, 0.14)			
	Week 8	Tezepelumab	280	274 (97.9)	0.23 (0.02)	(0.18, 0.27)	0.12 (0.03)	(0.06, 0.19)	<0.001 *
		Placebo	281	275 (97.9)	0.11 (0.02)	(0.06, 0.15)			
	Week 12	Tezepelumab	280	271 (96.8)	0.23 (0.02)	(0.18, 0.27)	0.09 (0.03)	(0.03, 0.16)	0.007 *
		Placebo	281	272 (96.8)	0.13 (0.02)	(0.09, 0.18)			
	Week 16	Tezepelumab	280	270 (96.4)	0.24 (0.02)	(0.20, 0.29)	0.14 (0.03)	(0.07, 0.20)	<0.001 *
		Placebo	281	268 (95.4)	0.11 (0.02)	(0.06, 0.15)			
	Week 24	Tezepelumab	280	261 (93.2)	0.22 (0.02)	(0.18, 0.27)	0.13 (0.03)	(0.06, 0.19)	<0.001 *
		Placebo	281	258 (91.8)	0.10 (0.02)	(0.05, 0.15)			
	Week 36	Tezepelumab	280	254 (90.7)	0.24 (0.03)	(0.19, 0.29)	0.13 (0.04)	(0.06, 0.20)	<0.001 *
		Placebo	281	250 (89.0)	0.11 (0.03)	(0.06, 0.16)			
	Week 52	Tezepelumab	280	252 (90.0)	0.24 (0.02)	(0.19, 0.29)	0.15 (0.03)	(0.08, 0.21)	<0.001 *
		Placebo	281	234 (83.3)	0.10 (0.02)	(0.05, 0.14)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Tiotropium use at baseline									0.362
Yes	Week 2	Tezepelumab	106	105 (99.1)	0.19 (0.03)	(0.13, 0.26)	0.15 (0.05)	(0.06, 0.24)	<0.001 *
		Placebo	106	103 (97.2)	0.04 (0.03)	(-0.03, 0.10)			
	Week 4	Tezepelumab	106	106 (100.0)	0.19 (0.03)	(0.12, 0.26)	0.13 (0.05)	(0.04, 0.23)	0.007 *
		Placebo	106	105 (99.1)	0.06 (0.03)	(-0.01, 0.13)			
	Week 8	Tezepelumab	106	105 (99.1)	0.23 (0.04)	(0.15, 0.30)	0.17 (0.05)	(0.07, 0.28)	0.002 *
		Placebo	106	101 (95.3)	0.05 (0.04)	(-0.02, 0.13)			
	Week 12	Tezepelumab	106	102 (96.2)	0.24 (0.04)	(0.16, 0.33)	0.24 (0.06)	(0.13, 0.35)	<0.001 *
		Placebo	106	101 (95.3)	0.01 (0.04)	(-0.08, 0.09)			
	Week 16	Tezepelumab	106	102 (96.2)	0.28 (0.04)	(0.21, 0.35)	0.25 (0.05)	(0.15, 0.36)	<0.001 *
		Placebo	106	99 (93.4)	0.03 (0.04)	(-0.05, 0.10)			
	Week 24	Tezepelumab	106	100 (94.3)	0.23 (0.04)	(0.16, 0.30)	0.19 (0.05)	(0.08, 0.29)	<0.001 *
		Placebo	106	96 (90.6)	0.04 (0.04)	(-0.03, 0.12)			
	Week 36	Tezepelumab	106	94 (88.7)	0.26 (0.04)	(0.19, 0.33)	0.17 (0.05)	(0.06, 0.27)	0.001 *
		Placebo	106	93 (87.7)	0.09 (0.04)	(0.02, 0.16)			
	Week 52	Tezepelumab	106	89 (84.0)	0.27 (0.04)	(0.19, 0.35)	0.24 (0.06)	(0.12, 0.35)	<0.001 *
		Placebo	106	90 (84.9)	0.03 (0.04)	(-0.05, 0.11)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 2	Tezepelumab	289	279 (96.5)	0.17 (0.02)	(0.13, 0.21)	0.11 (0.03)	(0.06, 0.17)	<0.001 *
		Placebo	285	270 (94.7)	0.06 (0.02)	(0.02, 0.10)			
	Week 4	Tezepelumab	289	285 (98.6)	0.21 (0.02)	(0.16, 0.25)	0.11 (0.03)	(0.05, 0.18)	<0.001 *
		Placebo	285	277 (97.2)	0.09 (0.02)	(0.05, 0.14)			
	Week 8	Tezepelumab	289	283 (97.9)	0.23 (0.02)	(0.18, 0.27)	0.12 (0.03)	(0.06, 0.19)	<0.001 *
		Placebo	285	279 (97.9)	0.10 (0.02)	(0.06, 0.15)			
	Week 12	Tezepelumab	289	280 (96.9)	0.23 (0.02)	(0.18, 0.27)	0.10 (0.03)	(0.03, 0.16)	0.004 *
		Placebo	285	276 (96.8)	0.13 (0.02)	(0.09, 0.18)			
	Week 16	Tezepelumab	289	278 (96.2)	0.24 (0.02)	(0.20, 0.29)	0.14 (0.03)	(0.07, 0.20)	<0.001 *
		Placebo	285	271 (95.1)	0.11 (0.02)	(0.06, 0.15)			
	Week 24	Tezepelumab	289	269 (93.1)	0.23 (0.02)	(0.18, 0.27)	0.13 (0.03)	(0.06, 0.19)	<0.001 *
		Placebo	285	261 (91.6)	0.10 (0.02)	(0.05, 0.15)			
	Week 36	Tezepelumab	289	262 (90.7)	0.24 (0.03)	(0.19, 0.29)	0.13 (0.04)	(0.06, 0.20)	<0.001 *
		Placebo	285	253 (88.8)	0.11 (0.03)	(0.06, 0.16)			
	Week 52	Tezepelumab	289	260 (90.0)	0.24 (0.02)	(0.20, 0.29)	0.15 (0.03)	(0.08, 0.21)	<0.001 *
		Placebo	285	236 (82.8)	0.10 (0.02)	(0.05, 0.15)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Montelukast/ Cromoglicic acid use at baseline									0.425
Yes	Week 2	Tezepelumab	168	163 (97.0)	0.19 (0.03)	(0.14, 0.24)	0.14 (0.04)	(0.06, 0.22)	<0.001 *
		Placebo	149	143 (96.0)	0.05 (0.03)	(-0.00, 0.11)			
	Week 4	Tezepelumab	168	167 (99.4)	0.23 (0.03)	(0.17, 0.29)	0.14 (0.04)	(0.05, 0.22)	0.002 *
		Placebo	149	146 (98.0)	0.09 (0.03)	(0.03, 0.15)			
	Week 8	Tezepelumab	168	166 (98.8)	0.25 (0.03)	(0.19, 0.31)	0.17 (0.05)	(0.07, 0.26)	<0.001 *
		Placebo	149	146 (98.0)	0.09 (0.03)	(0.02, 0.15)			
	Week 12	Tezepelumab	168	161 (95.8)	0.28 (0.03)	(0.21, 0.35)	0.21 (0.05)	(0.12, 0.31)	<0.001 *
		Placebo	149	148 (99.3)	0.07 (0.04)	(-0.00, 0.14)			
	Week 16	Tezepelumab	168	162 (96.4)	0.26 (0.03)	(0.20, 0.32)	0.18 (0.05)	(0.09, 0.27)	<0.001 *
		Placebo	149	144 (96.6)	0.08 (0.03)	(0.01, 0.15)			
	Week 24	Tezepelumab	168	157 (93.5)	0.23 (0.03)	(0.17, 0.29)	0.16 (0.04)	(0.07, 0.25)	<0.001 *
		Placebo	149	140 (94.0)	0.08 (0.03)	(0.01, 0.14)			
	Week 36	Tezepelumab	168	152 (90.5)	0.27 (0.03)	(0.21, 0.33)	0.20 (0.05)	(0.11, 0.29)	<0.001 *
		Placebo	149	138 (92.6)	0.07 (0.03)	(0.00, 0.13)			
	Week 52	Tezepelumab	168	150 (89.3)	0.28 (0.03)	(0.21, 0.34)	0.21 (0.05)	(0.12, 0.31)	<0.001 *
		Placebo	149	125 (83.9)	0.07 (0.04)	(-0.00, 0.14)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 2	Tezepelumab	227	221 (97.4)	0.17 (0.02)	(0.13, 0.21)	0.11 (0.03)	(0.05, 0.17)	<0.001 *
		Placebo	242	230 (95.0)	0.06 (0.02)	(0.01, 0.10)			
	Week 4	Tezepelumab	227	224 (98.7)	0.18 (0.02)	(0.13, 0.23)	0.10 (0.03)	(0.04, 0.17)	0.002 *
		Placebo	242	236 (97.5)	0.08 (0.02)	(0.03, 0.12)			
	Week 8	Tezepelumab	227	222 (97.8)	0.21 (0.02)	(0.16, 0.26)	0.12 (0.03)	(0.05, 0.18)	<0.001 *
		Placebo	242	234 (96.7)	0.09 (0.02)	(0.05, 0.14)			
	Week 12	Tezepelumab	227	221 (97.4)	0.20 (0.03)	(0.15, 0.25)	0.08 (0.04)	(0.01, 0.15)	0.030 *
		Placebo	242	229 (94.6)	0.12 (0.02)	(0.07, 0.17)			
	Week 16	Tezepelumab	227	218 (96.0)	0.24 (0.03)	(0.19, 0.29)	0.16 (0.04)	(0.08, 0.23)	<0.001 *
		Placebo	242	226 (93.4)	0.09 (0.03)	(0.04, 0.14)			
	Week 24	Tezepelumab	227	212 (93.4)	0.22 (0.03)	(0.17, 0.27)	0.13 (0.04)	(0.06, 0.20)	<0.001 *
		Placebo	242	217 (89.7)	0.09 (0.03)	(0.04, 0.14)			
	Week 36	Tezepelumab	227	204 (89.9)	0.22 (0.03)	(0.17, 0.28)	0.09 (0.04)	(0.02, 0.17)	0.017 *
		Placebo	242	208 (86.0)	0.13 (0.03)	(0.07, 0.18)			
	Week 52	Tezepelumab	227	199 (87.7)	0.23 (0.03)	(0.17, 0.28)	0.13 (0.04)	(0.06, 0.21)	<0.001 *
		Placebo	242	201 (83.1)	0.09 (0.03)	(0.04, 0.14)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age (cat. N)												
< 18 years	Absolute values	Baseline	Tezepelumab	15	15 (100.0)	2.59 (0.68)	1.4	2.12	2.69	3.18	3.7	
			Placebo	20	20 (100.0)	2.53 (0.93)	1.0	2.07	2.34	3.00	4.9	
		Week 2	Tezepelumab	15	14 (93.3)	2.80 (0.70)	1.7	2.41	2.67	3.36	4.0	
			Placebo	20	20 (100.0)	2.67 (0.68)	1.3	2.31	2.66	2.98	4.7	
		Week 4	Tezepelumab	15	14 (93.3)	2.68 (0.68)	1.3	2.47	2.64	3.18	3.8	
			Placebo	20	19 (95.0)	2.62 (0.50)	1.4	2.39	2.59	2.86	3.7	
		Week 8	Tezepelumab	15	14 (93.3)	2.58 (0.95)	1.0	2.15	2.65	3.43	3.7	
			Placebo	20	19 (95.0)	2.67 (0.75)	1.4	2.30	2.69	2.99	4.9	
		Week 12	Tezepelumab	15	13 (86.7)	2.58 (0.89)	0.8	2.07	2.64	3.37	3.6	
			Placebo	20	20 (100.0)	2.71 (0.77)	1.4	2.39	2.55	3.02	5.0	
		Week 16	Tezepelumab	15	13 (86.7)	2.68 (0.64)	1.5	2.22	2.50	3.31	3.8	
			Placebo	20	20 (100.0)	2.69 (0.75)	1.5	2.39	2.51	2.98	5.2	
		Week 24	Tezepelumab	15	13 (86.7)	2.65 (0.71)	1.6	2.20	2.88	3.16	3.7	
			Placebo	20	18 (90.0)	2.79 (0.77)	1.5	2.52	2.69	3.11	5.1	
		Week 36	Tezepelumab	15	13 (86.7)	2.88 (0.67)	1.4	2.56	2.93	3.30	4.0	
			Placebo	20	18 (90.0)	2.83 (0.96)	1.4	2.34	2.92	3.33	5.3	
		Week 52	Tezepelumab	15	12 (80.0)	2.94 (0.68)	1.9	2.45	2.94	3.38	4.2	
			Placebo	20	18 (90.0)	2.77 (0.95)	1.2	2.14	2.64	3.22	5.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age (cat. N)												
< 18 years	Change from baseline	Week 2	Tezepelumab	15	14 (93.3)	0.23 (0.49)	-0.5	-0.04	0.23	0.47	1.4	0.15 [-0.54, 0.83]
			Placebo	20	20 (100.0)	0.15 (0.59)	-1.3	-0.08	0.01	0.25	1.7	
		Week 4	Tezepelumab	15	14 (93.3)	0.13 (0.48)	-0.3	-0.18	-0.11	0.39	1.2	-0.14 [-0.83, 0.55]
			Placebo	20	19 (95.0)	0.21 (0.64)	-1.0	-0.11	0.02	0.40	1.7	
		Week 8	Tezepelumab	15	14 (93.3)	0.03 (0.66)	-1.1	-0.40	0.03	0.42	1.6	-0.13 [-0.82, 0.56]
			Placebo	20	19 (95.0)	0.13 (0.79)	-1.7	-0.22	0.05	0.49	2.0	
		Week 12	Tezepelumab	15	13 (86.7)	-0.00 (0.73)	-1.5	-0.30	-0.09	0.30	1.5	-0.26 [-0.96, 0.44]
			Placebo	20	20 (100.0)	0.18 (0.70)	-1.2	-0.19	0.07	0.40	1.6	
		Week 16	Tezepelumab	15	13 (86.7)	0.19 (0.47)	-0.5	0.00	0.10	0.36	1.4	0.05 [-0.65, 0.74]
			Placebo	20	20 (100.0)	0.16 (0.72)	-1.6	-0.18	0.08	0.35	1.6	
		Week 24	Tezepelumab	15	13 (86.7)	0.15 (0.62)	-0.8	-0.16	0.18	0.27	1.8	-0.01 [-0.72, 0.70]
			Placebo	20	18 (90.0)	0.16 (0.68)	-1.4	-0.06	0.20	0.54	1.5	
		Week 36	Tezepelumab	15	13 (86.7)	0.38 (0.50)	-0.1	-0.01	0.32	0.57	1.7	0.16 [-0.55, 0.88]
			Placebo	20	18 (90.0)	0.26 (0.87)	-1.7	0.03	0.22	0.47	2.2	
		Week 52	Tezepelumab	15	12 (80.0)	0.42 (0.49)	-0.6	0.20	0.47	0.70	1.3	0.31 [-0.42, 1.05]
			Placebo	20	18 (90.0)	0.22 (0.72)	-1.4	-0.02	0.24	0.53	1.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age (cat. N)												
18 - < 65 years	Absolute values	Baseline	Tezepelumab	304	304 (100.0)	1.81 (0.69)	0.4	1.31	1.72	2.20	4.1	
			Placebo	318	318 (100.0)	1.86 (0.69)	0.4	1.37	1.75	2.23	4.5	
		Week 2	Tezepelumab	304	296 (97.4)	2.02 (0.71)	0.6	1.49	1.96	2.48	4.3	
			Placebo	318	303 (95.3)	1.92 (0.71)	0.4	1.41	1.85	2.34	4.1	
		Week 4	Tezepelumab	304	303 (99.7)	2.04 (0.73)	0.7	1.51	1.99	2.54	4.3	
			Placebo	318	313 (98.4)	1.92 (0.69)	0.4	1.44	1.84	2.27	4.8	
		Week 8	Tezepelumab	304	300 (98.7)	2.06 (0.74)	0.6	1.50	2.01	2.48	4.7	
			Placebo	318	311 (97.8)	1.95 (0.73)	0.4	1.42	1.87	2.35	4.6	
		Week 12	Tezepelumab	304	296 (97.4)	2.07 (0.74)	0.6	1.57	1.97	2.49	4.7	
			Placebo	318	307 (96.5)	1.96 (0.73)	0.5	1.43	1.87	2.40	4.6	
		Week 16	Tezepelumab	304	294 (96.7)	2.09 (0.76)	0.6	1.56	2.02	2.54	4.9	
			Placebo	318	301 (94.7)	1.94 (0.73)	0.5	1.41	1.83	2.32	4.7	
		Week 24	Tezepelumab	304	286 (94.1)	2.06 (0.72)	0.6	1.59	1.98	2.51	4.4	
			Placebo	318	291 (91.5)	1.94 (0.72)	0.6	1.42	1.84	2.24	4.8	
		Week 36	Tezepelumab	304	275 (90.5)	2.06 (0.75)	0.5	1.49	1.99	2.49	4.5	
			Placebo	318	280 (88.1)	1.98 (0.74)	0.6	1.48	1.87	2.34	4.6	
		Week 52	Tezepelumab	304	270 (88.8)	2.07 (0.75)	0.6	1.57	2.01	2.51	4.3	
			Placebo	318	263 (82.7)	1.94 (0.76)	0.6	1.37	1.81	2.33	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age (cat. N)												
18 - < 65 years	Change from baseline	Week 2	Tezepelumab	304	296 (97.4)	0.20 (0.35)	-0.7	0.00	0.14	0.37	1.5	0.44 [0.28, 0.60]
			Placebo	318	303 (95.3)	0.05 (0.36)	-1.8	-0.12	0.01	0.18	1.2	
		Week 4	Tezepelumab	304	303 (99.7)	0.23 (0.38)	-0.9	0.01	0.16	0.38	1.8	0.42 [0.26, 0.58]
			Placebo	318	313 (98.4)	0.07 (0.39)	-1.8	-0.12	0.04	0.24	1.6	
		Week 8	Tezepelumab	304	300 (98.7)	0.26 (0.43)	-0.8	-0.03	0.18	0.50	1.8	0.47 [0.31, 0.63]
			Placebo	318	311 (97.8)	0.08 (0.34)	-0.8	-0.12	0.05	0.26	1.6	
		Week 12	Tezepelumab	304	296 (97.4)	0.26 (0.42)	-0.8	-0.03	0.17	0.46	2.0	0.41 [0.25, 0.57]
			Placebo	318	307 (96.5)	0.10 (0.39)	-1.5	-0.10	0.05	0.27	1.7	
		Week 16	Tezepelumab	304	294 (96.7)	0.28 (0.43)	-0.8	0.01	0.20	0.47	2.0	0.50 [0.33, 0.66]
			Placebo	318	301 (94.7)	0.08 (0.37)	-1.2	-0.12	0.02	0.24	1.8	
		Week 24	Tezepelumab	304	286 (94.1)	0.26 (0.43)	-1.0	-0.04	0.22	0.48	1.7	0.46 [0.29, 0.62]
			Placebo	318	291 (91.5)	0.07 (0.39)	-0.9	-0.15	0.03	0.27	1.7	
		Week 36	Tezepelumab	304	275 (90.5)	0.26 (0.44)	-1.0	-0.05	0.20	0.52	1.7	0.38 [0.21, 0.55]
			Placebo	318	280 (88.1)	0.10 (0.40)	-1.1	-0.16	0.06	0.29	1.7	
		Week 52	Tezepelumab	304	270 (88.8)	0.27 (0.44)	-1.0	-0.01	0.21	0.52	1.7	0.49 [0.31, 0.66]
			Placebo	318	263 (82.7)	0.07 (0.35)	-1.0	-0.15	0.05	0.23	1.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age (cat. N)												
>= 65 years	Absolute values	Baseline	Tezepelumab	76	76 (100.0)	1.45 (0.50)	0.7	1.16	1.40	1.58	3.2	
			Placebo	53	53 (100.0)	1.45 (0.48)	0.7	1.08	1.38	1.70	2.6	
		Week 2	Tezepelumab	76	74 (97.4)	1.52 (0.48)	0.6	1.23	1.44	1.70	3.1	
			Placebo	53	50 (94.3)	1.52 (0.50)	0.7	1.11	1.45	1.68	3.1	
		Week 4	Tezepelumab	76	74 (97.4)	1.54 (0.49)	0.6	1.20	1.49	1.76	3.1	
			Placebo	53	50 (94.3)	1.53 (0.50)	0.7	1.18	1.46	1.79	3.1	
		Week 8	Tezepelumab	76	74 (97.4)	1.55 (0.47)	0.6	1.23	1.50	1.82	2.9	
			Placebo	53	50 (94.3)	1.53 (0.50)	0.7	1.23	1.53	1.76	3.2	
		Week 12	Tezepelumab	76	73 (96.1)	1.57 (0.45)	0.6	1.24	1.52	1.80	2.7	
			Placebo	53	50 (94.3)	1.49 (0.49)	0.7	1.18	1.48	1.69	3.1	
		Week 16	Tezepelumab	76	73 (96.1)	1.59 (0.51)	0.6	1.26	1.52	1.84	3.4	
			Placebo	53	49 (92.5)	1.50 (0.46)	0.8	1.19	1.44	1.68	3.0	
		Week 24	Tezepelumab	76	70 (92.1)	1.54 (0.48)	0.6	1.19	1.53	1.78	2.8	
			Placebo	53	48 (90.6)	1.49 (0.46)	0.6	1.18	1.45	1.74	3.0	
		Week 36	Tezepelumab	76	68 (89.5)	1.57 (0.52)	0.6	1.16	1.52	1.86	3.2	
			Placebo	53	48 (90.6)	1.50 (0.47)	0.7	1.17	1.41	1.77	3.1	
		Week 52	Tezepelumab	76	67 (88.2)	1.58 (0.53)	0.7	1.15	1.47	1.81	3.3	
			Placebo	53	45 (84.9)	1.48 (0.49)	0.7	1.14	1.48	1.62	2.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age (cat. N)												
>= 65 years	Change from baseline	Week 2	Tezepelumab	76	74 (97.4)	0.09 (0.18)	-0.4	-0.01	0.07	0.21	0.7	0.16 [-0.20, 0.52]
			Placebo	53	50 (94.3)	0.05 (0.24)	-0.6	-0.07	0.03	0.13	0.7	
		Week 4	Tezepelumab	76	74 (97.4)	0.11 (0.21)	-0.3	-0.04	0.08	0.23	0.8	0.04 [-0.32, 0.40]
			Placebo	53	50 (94.3)	0.10 (0.29)	-0.9	-0.03	0.06	0.23	0.9	
		Week 8	Tezepelumab	76	74 (97.4)	0.14 (0.28)	-0.6	-0.04	0.08	0.27	1.0	0.18 [-0.18, 0.54]
			Placebo	53	50 (94.3)	0.09 (0.28)	-0.9	-0.06	0.09	0.24	0.7	
		Week 12	Tezepelumab	76	73 (96.1)	0.17 (0.28)	-0.7	0.01	0.19	0.31	1.2	0.41 [0.04, 0.77]
			Placebo	53	50 (94.3)	0.05 (0.28)	-1.1	-0.10	0.02	0.22	0.7	
		Week 16	Tezepelumab	76	73 (96.1)	0.16 (0.27)	-0.4	0.00	0.11	0.33	1.2	0.38 [0.01, 0.74]
			Placebo	53	49 (92.5)	0.06 (0.27)	-1.0	-0.08	0.04	0.25	0.6	
		Week 24	Tezepelumab	76	70 (92.1)	0.14 (0.26)	-0.4	-0.04	0.14	0.30	1.0	0.35 [-0.02, 0.72]
			Placebo	53	48 (90.6)	0.05 (0.29)	-1.1	-0.09	0.06	0.18	0.7	
		Week 36	Tezepelumab	76	68 (89.5)	0.14 (0.26)	-0.6	-0.03	0.08	0.32	1.0	0.39 [0.02, 0.77]
			Placebo	53	48 (90.6)	0.04 (0.27)	-0.6	-0.16	0.01	0.17	0.6	
		Week 52	Tezepelumab	76	67 (88.2)	0.13 (0.25)	-0.5	-0.03	0.08	0.26	0.9	0.44 [0.06, 0.82]
			Placebo	53	45 (84.9)	0.01 (0.34)	-1.0	-0.17	0.03	0.17	0.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Western Europe	Absolute values	Baseline	Tezepelumab	72	72 (100.0)	1.89 (0.67)	0.8	1.39	1.77	2.35	3.6	
			Placebo	72	72 (100.0)	1.90 (0.77)	0.7	1.36	1.78	2.29	4.2	
		Week 2	Tezepelumab	72	71 (98.6)	2.06 (0.72)	0.7	1.42	1.96	2.47	3.9	
			Placebo	72	67 (93.1)	1.97 (0.79)	0.6	1.37	1.85	2.37	4.0	
		Week 4	Tezepelumab	72	72 (100.0)	2.09 (0.74)	0.7	1.57	2.06	2.55	4.3	
			Placebo	72	70 (97.2)	1.93 (0.79)	0.7	1.39	1.77	2.42	4.2	
		Week 8	Tezepelumab	72	72 (100.0)	2.11 (0.77)	0.8	1.54	2.11	2.54	4.7	
			Placebo	72	67 (93.1)	2.03 (0.80)	0.7	1.35	2.02	2.52	4.3	
		Week 12	Tezepelumab	72	69 (95.8)	2.07 (0.79)	0.8	1.52	2.02	2.39	4.7	
			Placebo	72	66 (91.7)	1.95 (0.85)	0.6	1.31	1.73	2.52	4.3	
		Week 16	Tezepelumab	72	69 (95.8)	2.17 (0.78)	0.9	1.65	2.06	2.45	4.9	
			Placebo	72	66 (91.7)	1.92 (0.77)	0.8	1.32	1.78	2.32	4.1	
		Week 24	Tezepelumab	72	68 (94.4)	2.05 (0.70)	0.7	1.63	2.00	2.43	4.4	
			Placebo	72	61 (84.7)	1.94 (0.83)	0.6	1.27	1.96	2.25	4.8	
		Week 36	Tezepelumab	72	65 (90.3)	2.07 (0.74)	0.8	1.53	2.05	2.50	4.5	
			Placebo	72	57 (79.2)	2.06 (0.79)	0.8	1.49	1.97	2.55	4.6	
		Week 52	Tezepelumab	72	63 (87.5)	2.07 (0.74)	0.8	1.56	2.06	2.45	4.1	
			Placebo	72	55 (76.4)	2.09 (0.85)	0.7	1.37	1.98	2.64	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Western Europe	Change from baseline	Week 2	Tezepelumab	72	71 (98.6)	0.18 (0.28)	-0.6	0.01	0.14	0.36	1.1	0.50 [0.16, 0.84]
			Placebo	72	67 (93.1)	0.03 (0.31)	-0.8	-0.15	0.01	0.20	1.0	
		Week 4	Tezepelumab	72	72 (100.0)	0.20 (0.34)	-0.7	0.01	0.17	0.32	1.4	0.52 [0.18, 0.85]
			Placebo	72	70 (97.2)	0.03 (0.33)	-0.7	-0.11	0.03	0.24	1.4	
		Week 8	Tezepelumab	72	72 (100.0)	0.22 (0.41)	-0.6	-0.07	0.15	0.45	1.8	0.35 [0.01, 0.68]
			Placebo	72	67 (93.1)	0.08 (0.37)	-0.8	-0.12	0.05	0.32	1.3	
		Week 12	Tezepelumab	72	69 (95.8)	0.21 (0.43)	-0.8	-0.05	0.16	0.39	1.9	0.41 [0.07, 0.75]
			Placebo	72	66 (91.7)	0.05 (0.32)	-0.7	-0.11	0.02	0.24	1.2	
		Week 16	Tezepelumab	72	69 (95.8)	0.28 (0.41)	-0.8	0.04	0.23	0.42	2.0	0.69 [0.35, 1.04]
			Placebo	72	66 (91.7)	0.01 (0.37)	-1.2	-0.16	0.02	0.19	1.0	
		Week 24	Tezepelumab	72	68 (94.4)	0.21 (0.34)	-0.2	-0.04	0.17	0.41	1.5	0.63 [0.28, 0.99]
			Placebo	72	61 (84.7)	-0.01 (0.37)	-0.9	-0.17	-0.04	0.14	1.6	
		Week 36	Tezepelumab	72	65 (90.3)	0.22 (0.37)	-0.5	-0.05	0.15	0.46	1.7	0.40 [0.04, 0.75]
			Placebo	72	57 (79.2)	0.07 (0.37)	-1.1	-0.15	0.08	0.31	1.1	
		Week 52	Tezepelumab	72	63 (87.5)	0.21 (0.34)	-0.6	-0.01	0.22	0.35	1.2	0.33 [-0.04, 0.69]
			Placebo	72	55 (76.4)	0.10 (0.32)	-0.8	-0.07	0.08	0.21	1.1	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
North America	Absolute values	Baseline	Tezepelumab	77	77 (100.0)	1.78 (0.68)	0.7	1.28	1.58	2.12	4.0	
			Placebo	77	77 (100.0)	1.89 (0.65)	0.9	1.34	1.74	2.24	4.0	
		Week 2	Tezepelumab	77	71 (92.2)	2.05 (0.73)	0.8	1.47	1.95	2.59	4.1	
			Placebo	77	73 (94.8)	1.96 (0.61)	1.0	1.45	1.93	2.38	3.4	
		Week 4	Tezepelumab	77	74 (96.1)	2.02 (0.71)	0.7	1.51	1.92	2.54	4.2	
			Placebo	77	76 (98.7)	1.98 (0.55)	1.0	1.57	1.94	2.32	3.2	
		Week 8	Tezepelumab	77	74 (96.1)	2.03 (0.71)	0.8	1.44	1.97	2.47	4.1	
			Placebo	77	75 (97.4)	1.95 (0.62)	0.8	1.53	1.87	2.30	3.7	
		Week 12	Tezepelumab	77	72 (93.5)	2.05 (0.72)	0.9	1.54	2.00	2.50	4.2	
			Placebo	77	75 (97.4)	1.95 (0.63)	0.9	1.49	1.82	2.44	3.6	
		Week 16	Tezepelumab	77	72 (93.5)	2.02 (0.74)	0.9	1.49	1.86	2.59	4.3	
			Placebo	77	74 (96.1)	1.97 (0.56)	1.0	1.60	1.93	2.34	3.2	
		Week 24	Tezepelumab	77	66 (85.7)	2.01 (0.75)	0.8	1.45	1.94	2.61	4.0	
			Placebo	77	71 (92.2)	1.94 (0.57)	0.8	1.57	1.93	2.28	3.3	
		Week 36	Tezepelumab	77	62 (80.5)	2.05 (0.77)	0.9	1.44	1.99	2.42	4.4	
			Placebo	77	71 (92.2)	1.99 (0.62)	1.0	1.53	1.92	2.40	3.4	
		Week 52	Tezepelumab	77	59 (76.6)	2.06 (0.78)	0.7	1.57	2.06	2.56	4.2	
			Placebo	77	57 (74.0)	1.95 (0.67)	0.6	1.40	1.85	2.44	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
North America	Change from baseline	Week 2	Tezepelumab	77	71 (92.2)	0.29 (0.34)	-0.3	0.07	0.21	0.47	1.5	0.56 [0.23, 0.89]
			Placebo	77	73 (94.8)	0.07 (0.43)	-1.8	-0.08	0.01	0.27	1.1	
		Week 4	Tezepelumab	77	74 (96.1)	0.27 (0.35)	-0.3	0.03	0.18	0.42	1.3	0.50 [0.18, 0.83]
			Placebo	77	76 (98.7)	0.09 (0.37)	-1.0	-0.10	0.05	0.23	1.0	
		Week 8	Tezepelumab	77	74 (96.1)	0.30 (0.44)	-0.8	0.02	0.22	0.50	1.4	0.59 [0.27, 0.92]
			Placebo	77	75 (97.4)	0.06 (0.35)	-1.7	-0.12	0.09	0.25	0.9	
		Week 12	Tezepelumab	77	72 (93.5)	0.30 (0.36)	-0.3	0.04	0.27	0.50	1.3	0.53 [0.20, 0.86]
			Placebo	77	75 (97.4)	0.07 (0.48)	-1.5	-0.13	0.05	0.34	1.3	
		Week 16	Tezepelumab	77	72 (93.5)	0.29 (0.40)	-0.4	0.02	0.18	0.42	1.9	0.53 [0.20, 0.86]
			Placebo	77	74 (96.1)	0.09 (0.36)	-1.6	-0.08	0.06	0.28	1.0	
		Week 24	Tezepelumab	77	66 (85.7)	0.30 (0.42)	-0.7	0.02	0.27	0.49	1.6	0.56 [0.22, 0.91]
			Placebo	77	71 (92.2)	0.07 (0.39)	-1.4	-0.11	0.10	0.27	0.9	
		Week 36	Tezepelumab	77	62 (80.5)	0.32 (0.42)	-0.3	-0.01	0.22	0.54	1.5	0.50 [0.16, 0.85]
			Placebo	77	71 (92.2)	0.12 (0.38)	-1.2	-0.09	0.06	0.29	1.3	
		Week 52	Tezepelumab	77	59 (76.6)	0.33 (0.45)	-0.3	-0.01	0.18	0.70	1.3	0.66 [0.28, 1.03]
			Placebo	77	57 (74.0)	0.06 (0.36)	-1.4	-0.15	0.01	0.23	1.1	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
South America	Absolute values	Baseline	Tezepelumab	74	74 (100.0)	1.92 (0.72)	0.8	1.41	1.72	2.37	3.8	
			Placebo	75	75 (100.0)	2.07 (0.93)	0.6	1.35	2.03	2.68	4.9	
		Week 2	Tezepelumab	74	74 (100.0)	2.02 (0.75)	0.9	1.44	1.84	2.53	4.0	
			Placebo	75	73 (97.3)	2.18 (0.90)	0.6	1.45	2.09	2.79	4.7	
		Week 4	Tezepelumab	74	73 (98.6)	2.03 (0.79)	0.8	1.44	1.90	2.65	4.2	
			Placebo	75	70 (93.3)	2.12 (0.89)	0.5	1.44	2.08	2.68	4.8	
		Week 8	Tezepelumab	74	73 (98.6)	2.02 (0.83)	0.7	1.29	1.84	2.56	4.2	
			Placebo	75	72 (96.0)	2.24 (0.97)	0.6	1.54	2.10	2.94	4.9	
		Week 12	Tezepelumab	74	71 (95.9)	2.03 (0.80)	0.8	1.55	1.78	2.64	4.3	
			Placebo	75	74 (98.7)	2.23 (0.93)	0.5	1.51	2.13	2.73	5.0	
		Week 16	Tezepelumab	74	71 (95.9)	2.06 (0.79)	0.8	1.50	1.91	2.56	4.3	
			Placebo	75	72 (96.0)	2.23 (1.04)	0.5	1.37	2.18	2.91	5.2	
		Week 24	Tezepelumab	74	70 (94.6)	2.04 (0.78)	0.7	1.41	1.81	2.59	3.7	
			Placebo	75	70 (93.3)	2.24 (1.00)	0.6	1.48	2.09	2.92	5.1	
		Week 36	Tezepelumab	74	70 (94.6)	2.06 (0.83)	0.7	1.35	1.99	2.52	4.2	
			Placebo	75	73 (97.3)	2.28 (1.02)	0.6	1.49	2.21	2.97	5.3	
		Week 52	Tezepelumab	74	69 (93.2)	2.08 (0.85)	0.6	1.47	1.89	2.46	4.3	
			Placebo	75	71 (94.7)	2.25 (1.03)	0.6	1.53	2.19	2.82	5.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
South America	Change from baseline	Week 2	Tezepelumab	74	74 (100.0)	0.11 (0.35)	-0.7	-0.10	0.11	0.26	1.4	0.05 [-0.27, 0.38]
			Placebo	75	73 (97.3)	0.09 (0.46)	-1.1	-0.14	-0.01	0.18	1.7	
		Week 4	Tezepelumab	74	73 (98.6)	0.12 (0.35)	-0.5	-0.11	0.07	0.19	1.3	-0.01 [-0.33, 0.32]
			Placebo	75	70 (93.3)	0.12 (0.50)	-1.8	-0.09	0.06	0.28	1.7	
		Week 8	Tezepelumab	74	73 (98.6)	0.12 (0.45)	-1.1	-0.11	0.06	0.29	1.6	-0.09 [-0.41, 0.24]
			Placebo	75	72 (96.0)	0.16 (0.44)	-0.8	-0.10	0.08	0.30	2.0	
		Week 12	Tezepelumab	74	71 (95.9)	0.10 (0.44)	-1.5	-0.10	0.07	0.21	1.6	-0.08 [-0.41, 0.24]
			Placebo	75	74 (98.7)	0.14 (0.49)	-1.2	-0.12	0.07	0.29	1.6	
		Week 16	Tezepelumab	74	71 (95.9)	0.15 (0.37)	-0.5	-0.07	0.10	0.27	1.5	0.01 [-0.31, 0.34]
			Placebo	75	72 (96.0)	0.14 (0.51)	-0.7	-0.15	0.01	0.27	1.6	
		Week 24	Tezepelumab	74	70 (94.6)	0.15 (0.43)	-0.8	-0.09	0.12	0.31	1.8	0.05 [-0.28, 0.38]
			Placebo	75	70 (93.3)	0.13 (0.48)	-1.1	-0.12	0.03	0.31	1.6	
		Week 36	Tezepelumab	74	70 (94.6)	0.16 (0.40)	-0.8	-0.09	0.04	0.35	1.7	-0.05 [-0.38, 0.28]
			Placebo	75	73 (97.3)	0.18 (0.57)	-1.7	-0.17	0.07	0.33	2.2	
		Week 52	Tezepelumab	74	69 (93.2)	0.18 (0.41)	-0.8	-0.06	0.09	0.37	1.7	0.05 [-0.28, 0.38]
			Placebo	75	71 (94.7)	0.16 (0.50)	-0.9	-0.15	0.11	0.37	1.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Central/Eastern Europe	Absolute values	Baseline	Tezepelumab	20	20 (100.0)	1.69 (0.69)	0.9	1.23	1.45	1.93	3.5	
			Placebo	18	18 (100.0)	1.35 (0.48)	0.8	1.07	1.25	1.49	2.6	
		Week 2	Tezepelumab	20	19 (95.0)	1.78 (0.68)	1.1	1.41	1.58	2.07	3.8	
			Placebo	18	16 (88.9)	1.40 (0.52)	0.7	1.05	1.29	1.78	2.4	
		Week 4	Tezepelumab	20	20 (100.0)	1.92 (0.77)	0.9	1.35	1.71	2.25	3.7	
			Placebo	18	18 (100.0)	1.45 (0.49)	0.7	1.08	1.39	1.91	2.3	
		Week 8	Tezepelumab	20	20 (100.0)	1.91 (0.77)	1.0	1.41	1.66	2.37	3.7	
			Placebo	18	18 (100.0)	1.47 (0.49)	0.7	1.09	1.41	1.89	2.4	
		Week 12	Tezepelumab	20	20 (100.0)	1.94 (0.74)	1.1	1.43	1.70	2.30	3.6	
			Placebo	18	17 (94.4)	1.54 (0.58)	0.8	1.12	1.37	1.91	2.9	
		Week 16	Tezepelumab	20	20 (100.0)	1.95 (0.71)	1.0	1.50	1.76	2.17	3.4	
			Placebo	18	18 (100.0)	1.47 (0.51)	0.9	1.06	1.30	1.75	2.4	
		Week 24	Tezepelumab	20	19 (95.0)	1.87 (0.73)	0.9	1.40	1.74	2.17	3.8	
			Placebo	18	18 (100.0)	1.53 (0.52)	0.8	1.07	1.55	1.89	2.4	
		Week 36	Tezepelumab	20	20 (100.0)	1.93 (0.75)	1.0	1.36	1.79	2.39	3.6	
			Placebo	18	17 (94.4)	1.49 (0.49)	0.8	1.08	1.45	1.78	2.3	
		Week 52	Tezepelumab	20	20 (100.0)	1.91 (0.79)	1.0	1.34	1.68	2.44	3.6	
			Placebo	18	18 (100.0)	1.48 (0.52)	0.8	1.05	1.42	1.63	2.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Central/Eastern Europe	Change from baseline	Week 2	Tezepelumab	20	19 (95.0)	0.15 (0.25)	-0.2	-0.06	0.08	0.30	0.8	0.56 [-0.12, 1.24]
			Placebo	18	16 (88.9)	0.01 (0.23)	-0.4	-0.11	-0.01	0.09	0.7	
		Week 4	Tezepelumab	20	20 (100.0)	0.23 (0.43)	-0.3	0.01	0.17	0.33	1.7	0.33 [-0.31, 0.98]
			Placebo	18	18 (100.0)	0.10 (0.33)	-0.3	-0.11	0.07	0.31	1.0	
		Week 8	Tezepelumab	20	20 (100.0)	0.22 (0.35)	-0.2	-0.06	0.18	0.40	1.2	0.30 [-0.34, 0.94]
			Placebo	18	18 (100.0)	0.12 (0.32)	-0.4	-0.05	0.03	0.24	0.9	
		Week 12	Tezepelumab	20	20 (100.0)	0.25 (0.37)	-0.3	-0.04	0.25	0.42	1.4	0.22 [-0.42, 0.87]
			Placebo	18	17 (94.4)	0.18 (0.28)	-0.2	0.03	0.09	0.33	1.0	
		Week 16	Tezepelumab	20	20 (100.0)	0.26 (0.46)	-0.6	0.05	0.20	0.58	1.6	0.39 [-0.25, 1.03]
			Placebo	18	18 (100.0)	0.12 (0.25)	-0.2	-0.06	0.05	0.20	0.7	
		Week 24	Tezepelumab	20	19 (95.0)	0.16 (0.44)	-1.0	-0.13	0.09	0.38	1.0	-0.05 [-0.69, 0.60]
			Placebo	18	18 (100.0)	0.18 (0.33)	-0.4	-0.02	0.12	0.46	0.8	
		Week 36	Tezepelumab	20	20 (100.0)	0.24 (0.40)	-0.3	-0.07	0.12	0.51	1.1	0.34 [-0.31, 0.99]
			Placebo	18	17 (94.4)	0.12 (0.25)	-0.3	-0.04	0.06	0.29	0.6	
		Week 52	Tezepelumab	20	20 (100.0)	0.22 (0.38)	-0.4	-0.02	0.16	0.47	1.0	0.29 [-0.35, 0.93]
			Placebo	18	18 (100.0)	0.13 (0.22)	-0.3	-0.05	0.11	0.23	0.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Asia Pacific	Absolute values	Baseline	Tezepelumab	98	98 (100.0)	1.71 (0.66)	0.4	1.26	1.65	2.13	4.1	
			Placebo	94	94 (100.0)	1.73 (0.56)	0.4	1.37	1.69	2.06	3.1	
		Week 2	Tezepelumab	98	98 (100.0)	1.89 (0.67)	0.6	1.31	1.79	2.30	4.3	
			Placebo	94	92 (97.9)	1.79 (0.63)	0.4	1.45	1.68	2.17	3.9	
		Week 4	Tezepelumab	98	98 (100.0)	1.94 (0.68)	0.7	1.45	1.80	2.41	3.7	
			Placebo	94	94 (100.0)	1.79 (0.58)	0.4	1.43	1.72	2.13	3.7	
		Week 8	Tezepelumab	98	96 (98.0)	1.97 (0.68)	0.6	1.48	1.90	2.38	4.7	
			Placebo	94	94 (100.0)	1.79 (0.64)	0.4	1.39	1.73	2.23	4.3	
		Week 12	Tezepelumab	98	96 (98.0)	2.00 (0.67)	0.6	1.53	1.94	2.39	3.8	
			Placebo	94	93 (98.9)	1.83 (0.64)	0.7	1.44	1.74	2.22	4.3	
		Week 16	Tezepelumab	98	97 (99.0)	2.01 (0.73)	0.6	1.52	1.89	2.48	4.7	
			Placebo	94	91 (96.8)	1.83 (0.62)	0.7	1.46	1.71	2.14	4.4	
		Week 24	Tezepelumab	98	96 (98.0)	1.98 (0.64)	0.8	1.58	1.82	2.33	4.0	
			Placebo	94	89 (94.7)	1.82 (0.60)	0.7	1.42	1.71	2.11	4.3	
		Week 36	Tezepelumab	98	92 (93.9)	1.99 (0.71)	0.6	1.53	1.81	2.42	4.4	
			Placebo	94	86 (91.5)	1.81 (0.64)	0.7	1.41	1.70	2.18	4.3	
		Week 52	Tezepelumab	98	92 (93.9)	2.01 (0.69)	0.8	1.54	1.84	2.47	4.2	
			Placebo	94	86 (91.5)	1.75 (0.59)	0.7	1.34	1.61	2.13	3.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Asia Pacific	Change from baseline	Week 2	Tezepelumab	98	98 (100.0)	0.18 (0.36)	-0.6	0.00	0.10	0.29	1.3	0.38 [0.09, 0.67]
			Placebo	94	92 (97.9)	0.05 (0.33)	-0.7	-0.09	0.03	0.18	1.2	
		Week 4	Tezepelumab	98	98 (100.0)	0.23 (0.39)	-0.9	0.02	0.15	0.37	1.8	0.46 [0.18, 0.75]
			Placebo	94	94 (100.0)	0.06 (0.34)	-0.7	-0.13	0.01	0.20	1.1	
		Week 8	Tezepelumab	98	96 (98.0)	0.28 (0.44)	-0.8	0.02	0.17	0.50	1.7	0.54 [0.25, 0.83]
			Placebo	94	94 (100.0)	0.06 (0.34)	-0.7	-0.15	0.02	0.23	1.6	
		Week 12	Tezepelumab	98	96 (98.0)	0.30 (0.46)	-0.7	0.05	0.20	0.52	2.0	0.53 [0.24, 0.82]
			Placebo	94	93 (98.9)	0.08 (0.35)	-0.9	-0.07	0.04	0.19	1.7	
		Week 16	Tezepelumab	98	97 (99.0)	0.31 (0.44)	-0.6	0.02	0.22	0.51	1.7	0.57 [0.28, 0.86]
			Placebo	94	91 (96.8)	0.08 (0.35)	-0.8	-0.11	0.01	0.24	1.8	
		Week 24	Tezepelumab	98	96 (98.0)	0.27 (0.44)	-1.0	0.00	0.23	0.53	1.6	0.47 [0.18, 0.77]
			Placebo	94	89 (94.7)	0.08 (0.38)	-0.9	-0.14	0.07	0.22	1.7	
		Week 36	Tezepelumab	98	92 (93.9)	0.28 (0.47)	-1.0	0.02	0.24	0.55	1.5	0.53 [0.24, 0.83]
			Placebo	94	86 (91.5)	0.05 (0.40)	-1.0	-0.21	0.02	0.27	1.7	
		Week 52	Tezepelumab	98	92 (93.9)	0.29 (0.46)	-1.0	0.00	0.27	0.54	1.6	0.64 [0.34, 0.95]
			Placebo	94	86 (91.5)	0.02 (0.34)	-1.0	-0.22	0.02	0.23	0.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Rest of the world	Absolute values	Baseline	Tezepelumab	54	54 (100.0)	1.54 (0.70)	0.6	1.02	1.33	2.02	3.3	
			Placebo	55	55 (100.0)	1.70 (0.49)	0.9	1.35	1.59	2.02	3.0	
		Week 2	Tezepelumab	54	51 (94.4)	1.73 (0.68)	0.6	1.23	1.53	2.26	3.5	
			Placebo	55	52 (94.5)	1.73 (0.53)	0.8	1.31	1.73	2.14	2.7	
		Week 4	Tezepelumab	54	54 (100.0)	1.73 (0.71)	0.6	1.20	1.66	2.16	3.8	
			Placebo	55	54 (98.2)	1.81 (0.56)	0.9	1.36	1.79	2.12	3.4	
		Week 8	Tezepelumab	54	53 (98.1)	1.74 (0.66)	0.6	1.19	1.64	2.28	3.8	
			Placebo	55	54 (98.2)	1.75 (0.51)	0.7	1.34	1.67	2.14	3.0	
		Week 12	Tezepelumab	54	54 (100.0)	1.77 (0.70)	0.6	1.31	1.66	2.23	3.8	
			Placebo	55	52 (94.5)	1.79 (0.50)	1.0	1.38	1.75	2.24	3.1	
		Week 16	Tezepelumab	54	51 (94.4)	1.78 (0.71)	0.6	1.28	1.65	2.33	3.8	
			Placebo	55	49 (89.1)	1.77 (0.51)	0.8	1.33	1.76	2.17	3.1	
		Week 24	Tezepelumab	54	50 (92.6)	1.79 (0.75)	0.6	1.16	1.68	2.32	4.0	
			Placebo	55	48 (87.3)	1.73 (0.52)	0.9	1.37	1.65	2.12	3.1	
		Week 36	Tezepelumab	54	47 (87.0)	1.77 (0.73)	0.5	1.23	1.66	2.27	3.8	
			Placebo	55	42 (76.4)	1.71 (0.47)	0.9	1.36	1.67	2.11	2.8	
		Week 52	Tezepelumab	54	46 (85.2)	1.75 (0.70)	0.7	1.23	1.67	2.16	3.7	
			Placebo	55	39 (70.9)	1.65 (0.44)	1.0	1.27	1.66	1.88	2.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Rest of the world	Change from baseline	Week 2	Tezepelumab	54	51 (94.4)	0.16 (0.33)	-0.5	-0.06	0.12	0.29	1.4	0.44 [0.05, 0.83]
			Placebo	55	52 (94.5)	0.02 (0.29)	-0.7	-0.14	0.03	0.13	1.0	
		Week 4	Tezepelumab	54	54 (100.0)	0.19 (0.34)	-0.5	-0.04	0.12	0.36	1.1	0.19 [-0.19, 0.57]
			Placebo	55	54 (98.2)	0.11 (0.45)	-1.0	-0.13	0.05	0.36	1.2	
		Week 8	Tezepelumab	54	53 (98.1)	0.24 (0.32)	-0.4	0.06	0.19	0.44	1.1	0.54 [0.15, 0.92]
			Placebo	55	54 (98.2)	0.06 (0.35)	-0.9	-0.13	0.04	0.20	1.2	
		Week 12	Tezepelumab	54	54 (100.0)	0.23 (0.36)	-0.4	-0.01	0.16	0.44	1.5	0.37 [-0.01, 0.76]
			Placebo	55	52 (94.5)	0.10 (0.34)	-1.1	-0.08	0.05	0.22	0.9	
		Week 16	Tezepelumab	54	51 (94.4)	0.22 (0.38)	-0.6	-0.04	0.13	0.40	1.4	0.40 [0.00, 0.79]
			Placebo	55	49 (89.1)	0.07 (0.35)	-1.0	-0.06	0.03	0.24	1.2	
		Week 24	Tezepelumab	54	50 (92.6)	0.25 (0.41)	-0.4	-0.03	0.17	0.45	1.7	0.49 [0.09, 0.89]
			Placebo	55	48 (87.3)	0.06 (0.35)	-1.1	-0.13	-0.02	0.27	0.9	
		Week 36	Tezepelumab	54	47 (87.0)	0.21 (0.39)	-0.4	-0.07	0.09	0.45	1.6	0.42 [-0.00, 0.84]
			Placebo	55	42 (76.4)	0.06 (0.35)	-0.9	-0.12	0.04	0.27	0.9	
		Week 52	Tezepelumab	54	46 (85.2)	0.22 (0.40)	-0.5	-0.03	0.13	0.34	1.4	0.69 [0.25, 1.13]
			Placebo	55	39 (70.9)	-0.02 (0.28)	-1.0	-0.18	-0.03	0.13	0.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
< 150 cells/uL	Absolute values	Baseline	Tezepelumab	96	96 (100.0)	1.90 (0.70)	0.4	1.32	1.87	2.45	4.0	
			Placebo	89	89 (100.0)	1.83 (0.68)	0.8	1.39	1.79	2.17	4.9	
		Week 2	Tezepelumab	96	94 (97.9)	1.98 (0.73)	0.6	1.40	1.93	2.44	4.1	
			Placebo	89	84 (94.4)	1.85 (0.72)	0.8	1.37	1.66	2.18	4.7	
		Week 4	Tezepelumab	96	95 (99.0)	1.98 (0.78)	0.7	1.32	1.98	2.56	4.2	
			Placebo	89	87 (97.8)	1.82 (0.64)	0.7	1.34	1.78	2.20	3.6	
		Week 8	Tezepelumab	96	93 (96.9)	1.97 (0.74)	0.6	1.43	1.87	2.51	4.1	
			Placebo	89	86 (96.6)	1.87 (0.74)	0.7	1.38	1.81	2.34	4.9	
		Week 12	Tezepelumab	96	92 (95.8)	1.98 (0.75)	0.6	1.45	1.91	2.45	4.2	
			Placebo	89	84 (94.4)	1.84 (0.75)	0.7	1.33	1.67	2.20	5.0	
		Week 16	Tezepelumab	96	93 (96.9)	2.02 (0.80)	0.6	1.43	1.87	2.54	4.3	
			Placebo	89	84 (94.4)	1.81 (0.74)	0.6	1.30	1.69	2.19	5.2	
		Week 24	Tezepelumab	96	86 (89.6)	1.95 (0.71)	0.6	1.40	1.88	2.42	4.0	
			Placebo	89	81 (91.0)	1.86 (0.71)	0.8	1.34	1.73	2.20	5.1	
		Week 36	Tezepelumab	96	87 (90.6)	1.95 (0.78)	0.5	1.33	1.90	2.47	4.4	
			Placebo	89	78 (87.6)	1.89 (0.74)	0.8	1.36	1.82	2.25	5.3	
		Week 52	Tezepelumab	96	86 (89.6)	1.98 (0.76)	0.7	1.41	1.86	2.59	4.2	
			Placebo	89	77 (86.5)	1.83 (0.77)	0.7	1.28	1.65	2.28	5.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
< 150 cells/uL	Change from baseline	Week 2	Tezepelumab	96	94 (97.9)	0.07 (0.30)	-0.6	-0.08	0.08	0.19	1.5	0.21 [-0.08, 0.51]
			Placebo	89	84 (94.4)	0.00 (0.34)	-1.8	-0.14	-0.01	0.13	1.1	
		Week 4	Tezepelumab	96	95 (99.0)	0.09 (0.36)	-0.9	-0.08	0.03	0.27	1.7	0.20 [-0.09, 0.49]
			Placebo	89	87 (97.8)	0.02 (0.34)	-1.0	-0.08	0.03	0.15	0.9	
		Week 8	Tezepelumab	96	93 (96.9)	0.10 (0.36)	-0.8	-0.09	0.02	0.29	1.4	0.15 [-0.14, 0.44]
			Placebo	89	86 (96.6)	0.05 (0.30)	-0.9	-0.10	0.05	0.22	0.9	
		Week 12	Tezepelumab	96	92 (95.8)	0.09 (0.34)	-0.8	-0.09	0.07	0.22	1.4	0.20 [-0.09, 0.50]
			Placebo	89	84 (94.4)	0.02 (0.34)	-1.2	-0.09	0.02	0.19	1.0	
		Week 16	Tezepelumab	96	93 (96.9)	0.12 (0.41)	-0.8	-0.13	0.06	0.24	1.9	0.35 [0.05, 0.65]
			Placebo	89	84 (94.4)	-0.01 (0.34)	-1.0	-0.16	0.01	0.16	1.5	
		Week 24	Tezepelumab	96	86 (89.6)	0.09 (0.30)	-0.6	-0.07	0.03	0.22	1.1	0.23 [-0.08, 0.53]
			Placebo	89	81 (91.0)	0.02 (0.33)	-1.1	-0.12	0.02	0.14	1.4	
		Week 36	Tezepelumab	96	87 (90.6)	0.07 (0.35)	-0.7	-0.12	0.00	0.22	1.5	0.09 [-0.21, 0.40]
			Placebo	89	78 (87.6)	0.04 (0.30)	-0.7	-0.15	0.03	0.20	1.3	
		Week 52	Tezepelumab	96	86 (89.6)	0.10 (0.38)	-1.0	-0.08	0.05	0.25	1.3	0.29 [-0.02, 0.60]
			Placebo	89	77 (86.5)	-0.01 (0.35)	-1.0	-0.17	0.01	0.13	1.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
150 - < 300 cells/uL	Absolute values	Baseline	Tezepelumab	129	129 (100.0)	1.78 (0.66)	0.6	1.27	1.65	2.20	3.7	
			Placebo	122	122 (100.0)	1.87 (0.72)	0.7	1.36	1.70	2.29	4.1	
		Week 2	Tezepelumab	129	126 (97.7)	1.94 (0.69)	0.6	1.42	1.84	2.44	4.0	
			Placebo	122	118 (96.7)	1.92 (0.77)	0.6	1.38	1.74	2.36	4.1	
		Week 4	Tezepelumab	129	128 (99.2)	1.93 (0.68)	0.6	1.38	1.90	2.42	3.8	
			Placebo	122	118 (96.7)	1.90 (0.72)	0.7	1.43	1.75	2.27	4.8	
		Week 8	Tezepelumab	129	128 (99.2)	1.93 (0.69)	0.6	1.34	1.91	2.44	3.7	
			Placebo	122	117 (95.9)	1.99 (0.77)	0.7	1.42	1.81	2.35	4.6	
		Week 12	Tezepelumab	129	125 (96.9)	1.91 (0.69)	0.6	1.35	1.82	2.38	3.6	
			Placebo	122	117 (95.9)	1.93 (0.78)	0.6	1.37	1.75	2.39	4.6	
		Week 16	Tezepelumab	129	126 (97.7)	1.93 (0.66)	0.6	1.39	1.86	2.39	3.8	
			Placebo	122	115 (94.3)	1.96 (0.82)	0.7	1.33	1.77	2.39	4.7	
		Week 24	Tezepelumab	129	125 (96.9)	1.90 (0.69)	0.6	1.34	1.77	2.42	3.8	
			Placebo	122	111 (91.0)	1.88 (0.79)	0.6	1.34	1.69	2.19	4.8	
		Week 36	Tezepelumab	129	118 (91.5)	1.91 (0.70)	0.7	1.29	1.81	2.46	4.0	
			Placebo	122	108 (88.5)	1.93 (0.79)	0.7	1.41	1.68	2.28	4.3	
		Week 52	Tezepelumab	129	120 (93.0)	1.93 (0.72)	0.7	1.42	1.83	2.43	4.2	
			Placebo	122	99 (81.1)	1.94 (0.82)	0.7	1.39	1.70	2.29	4.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
150 - < 300 cells/uL	Change from baseline	Week 2	Tezepelumab	129	126 (97.7)	0.15 (0.29)	-0.7	-0.03	0.09	0.28	1.1	0.40 [0.15, 0.66]
			Placebo	122	118 (96.7)	0.03 (0.32)	-1.0	-0.11	0.01	0.13	1.1	
		Week 4	Tezepelumab	129	128 (99.2)	0.16 (0.32)	-0.5	-0.01	0.10	0.25	1.6	0.36 [0.11, 0.61]
			Placebo	122	118 (96.7)	0.04 (0.35)	-1.0	-0.12	0.04	0.20	1.6	
		Week 8	Tezepelumab	129	128 (99.2)	0.17 (0.35)	-0.8	-0.02	0.12	0.28	1.4	0.25 [-0.00, 0.50]
			Placebo	122	117 (95.9)	0.09 (0.29)	-0.7	-0.08	0.05	0.28	1.4	
		Week 12	Tezepelumab	129	125 (96.9)	0.15 (0.37)	-0.7	-0.04	0.10	0.28	2.0	0.25 [-0.00, 0.50]
			Placebo	122	117 (95.9)	0.06 (0.36)	-1.5	-0.08	0.05	0.19	1.4	
		Week 16	Tezepelumab	129	126 (97.7)	0.17 (0.34)	-0.6	0.00	0.13	0.30	1.7	0.25 [-0.00, 0.50]
			Placebo	122	115 (94.3)	0.08 (0.35)	-1.2	-0.06	0.02	0.26	1.4	
		Week 24	Tezepelumab	129	125 (96.9)	0.13 (0.38)	-1.0	-0.11	0.12	0.31	1.3	0.30 [0.04, 0.56]
			Placebo	122	111 (91.0)	0.02 (0.34)	-0.9	-0.15	-0.01	0.22	1.6	
		Week 36	Tezepelumab	129	118 (91.5)	0.14 (0.37)	-1.0	-0.08	0.07	0.32	1.3	0.27 [0.01, 0.54]
			Placebo	122	108 (88.5)	0.04 (0.40)	-1.1	-0.19	0.03	0.28	1.1	
		Week 52	Tezepelumab	129	120 (93.0)	0.16 (0.38)	-0.8	-0.06	0.10	0.29	1.5	0.25 [-0.01, 0.52]
			Placebo	122	99 (81.1)	0.07 (0.30)	-1.0	-0.14	0.08	0.23	1.1	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
300 - < 450 cells/uL	Absolute values	Baseline	Tezepelumab	70	70 (100.0)	1.72 (0.76)	0.5	1.19	1.64	2.00	4.1	
			Placebo	75	75 (100.0)	1.85 (0.77)	0.4	1.26	1.71	2.29	4.5	
		Week 2	Tezepelumab	70	67 (95.7)	1.91 (0.77)	0.9	1.35	1.70	2.43	4.3	
			Placebo	75	70 (93.3)	1.93 (0.69)	0.4	1.44	1.93	2.34	3.4	
		Week 4	Tezepelumab	70	68 (97.1)	1.94 (0.78)	0.9	1.32	1.75	2.34	4.3	
			Placebo	75	74 (98.7)	1.93 (0.66)	0.4	1.45	1.92	2.35	3.5	
		Week 8	Tezepelumab	70	69 (98.6)	2.01 (0.85)	0.9	1.38	1.78	2.30	4.7	
			Placebo	75	74 (98.7)	1.96 (0.69)	0.4	1.45	1.94	2.36	3.9	
		Week 12	Tezepelumab	70	66 (94.3)	2.04 (0.81)	0.7	1.55	1.88	2.46	4.7	
			Placebo	75	71 (94.7)	1.96 (0.68)	0.8	1.47	1.99	2.40	4.0	
		Week 16	Tezepelumab	70	66 (94.3)	2.02 (0.87)	1.0	1.37	1.75	2.40	4.9	
			Placebo	75	70 (93.3)	1.95 (0.69)	0.8	1.43	1.89	2.45	4.3	
		Week 24	Tezepelumab	70	66 (94.3)	2.03 (0.78)	0.9	1.41	1.94	2.32	4.4	
			Placebo	75	69 (92.0)	1.98 (0.69)	0.8	1.48	1.89	2.31	4.3	
		Week 36	Tezepelumab	70	60 (85.7)	2.05 (0.87)	0.7	1.37	1.84	2.37	4.5	
			Placebo	75	66 (88.0)	1.96 (0.74)	0.8	1.38	1.85	2.38	4.2	
		Week 52	Tezepelumab	70	60 (85.7)	2.01 (0.85)	0.6	1.39	1.80	2.33	4.2	
			Placebo	75	66 (88.0)	1.95 (0.75)	0.7	1.37	1.85	2.29	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
300 - < 450 cells/uL	Change from baseline	Week 2	Tezepelumab	70	67 (95.7)	0.22 (0.36)	-0.5	0.03	0.14	0.41	1.4	0.43 [0.09, 0.77]
			Placebo	75	70 (93.3)	0.06 (0.40)	-1.1	-0.12	0.04	0.22	1.7	
		Week 4	Tezepelumab	70	68 (97.1)	0.23 (0.36)	-0.4	0.00	0.15	0.36	1.4	0.37 [0.04, 0.70]
			Placebo	75	74 (98.7)	0.08 (0.44)	-1.8	-0.11	0.02	0.25	1.7	
		Week 8	Tezepelumab	70	69 (98.6)	0.31 (0.45)	-0.6	0.04	0.24	0.52	1.8	0.53 [0.19, 0.86]
			Placebo	75	74 (98.7)	0.09 (0.39)	-0.6	-0.12	0.04	0.21	2.0	
		Week 12	Tezepelumab	70	66 (94.3)	0.32 (0.43)	-0.3	0.00	0.25	0.48	1.9	0.63 [0.29, 0.97]
			Placebo	75	71 (94.7)	0.06 (0.42)	-1.4	-0.15	0.00	0.29	1.5	
		Week 16	Tezepelumab	70	66 (94.3)	0.32 (0.42)	-0.4	0.04	0.26	0.50	2.0	0.61 [0.27, 0.96]
			Placebo	75	70 (93.3)	0.07 (0.38)	-1.0	-0.12	0.03	0.18	1.6	
		Week 24	Tezepelumab	70	66 (94.3)	0.33 (0.38)	-0.3	0.03	0.30	0.51	1.5	0.68 [0.34, 1.03]
			Placebo	75	69 (92.0)	0.07 (0.35)	-0.9	-0.12	0.05	0.27	1.1	
		Week 36	Tezepelumab	70	60 (85.7)	0.34 (0.42)	-0.3	0.01	0.34	0.54	1.7	0.64 [0.28, 1.00]
			Placebo	75	66 (88.0)	0.07 (0.42)	-0.8	-0.13	0.02	0.19	2.2	
		Week 52	Tezepelumab	70	60 (85.7)	0.32 (0.42)	-0.8	0.02	0.35	0.54	1.7	0.63 [0.27, 0.99]
			Placebo	75	66 (88.0)	0.07 (0.39)	-0.6	-0.19	0.00	0.23	1.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
>= 450 cells/uL	Absolute values	Baseline	Tezepelumab	100	100 (100.0)	1.68 (0.67)	0.6	1.22	1.54	1.93	3.7	
			Placebo	105	105 (100.0)	1.78 (0.68)	0.6	1.32	1.69	2.18	4.2	
		Week 2	Tezepelumab	100	97 (97.0)	1.98 (0.70)	0.8	1.47	1.84	2.33	4.0	
			Placebo	105	101 (96.2)	1.92 (0.69)	0.8	1.38	1.86	2.38	4.0	
		Week 4	Tezepelumab	100	100 (100.0)	2.04 (0.71)	0.7	1.57	1.90	2.49	4.2	
			Placebo	105	103 (98.1)	1.95 (0.72)	0.5	1.43	1.88	2.32	4.2	
		Week 8	Tezepelumab	100	98 (98.0)	2.04 (0.71)	1.0	1.52	1.89	2.46	4.2	
			Placebo	105	103 (98.1)	1.90 (0.74)	0.6	1.33	1.78	2.33	4.3	
		Week 12	Tezepelumab	100	99 (99.0)	2.08 (0.73)	0.9	1.61	1.95	2.45	4.6	
			Placebo	105	105 (100.0)	2.00 (0.72)	0.5	1.50	1.95	2.44	4.3	
		Week 16	Tezepelumab	100	95 (95.0)	2.11 (0.72)	0.8	1.61	2.02	2.50	4.3	
			Placebo	105	101 (96.2)	1.96 (0.68)	0.5	1.53	1.85	2.24	4.4	
		Week 24	Tezepelumab	100	92 (92.0)	2.08 (0.70)	0.9	1.61	1.91	2.49	3.8	
			Placebo	105	96 (91.4)	1.99 (0.73)	0.7	1.49	1.91	2.34	4.8	
		Week 36	Tezepelumab	100	91 (91.0)	2.12 (0.72)	0.8	1.57	2.00	2.46	4.2	
			Placebo	105	94 (89.5)	2.05 (0.77)	0.6	1.53	1.98	2.38	4.6	
		Week 52	Tezepelumab	100	83 (83.0)	2.12 (0.73)	0.9	1.64	1.95	2.43	4.3	
			Placebo	105	84 (80.0)	1.97 (0.76)	0.6	1.38	1.97	2.41	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
>= 450 cells/uL	Change from baseline	Week 2	Tezepelumab	100	97 (97.0)	0.30 (0.37)	-0.5	0.10	0.24	0.43	1.4	0.48 [0.20, 0.76]
			Placebo	105	101 (96.2)	0.12 (0.41)	-1.3	-0.10	0.03	0.33	1.3	
		Week 4	Tezepelumab	100	100 (100.0)	0.35 (0.38)	-0.4	0.08	0.33	0.51	1.8	0.45 [0.17, 0.72]
			Placebo	105	103 (98.1)	0.17 (0.44)	-1.0	-0.12	0.06	0.45	1.4	
		Week 8	Tezepelumab	100	98 (98.0)	0.39 (0.47)	-1.1	0.10	0.32	0.67	1.7	0.57 [0.29, 0.86]
			Placebo	105	103 (98.1)	0.11 (0.47)	-1.7	-0.19	0.09	0.34	1.6	
		Week 12	Tezepelumab	100	99 (99.0)	0.41 (0.46)	-1.5	0.14	0.37	0.62	1.5	0.43 [0.16, 0.71]
			Placebo	105	105 (100.0)	0.22 (0.46)	-1.2	-0.06	0.14	0.42	1.7	
		Week 16	Tezepelumab	100	95 (95.0)	0.45 (0.41)	-0.5	0.16	0.39	0.67	1.6	0.68 [0.39, 0.96]
			Placebo	105	101 (96.2)	0.16 (0.45)	-1.6	-0.10	0.08	0.43	1.8	
		Week 24	Tezepelumab	100	92 (92.0)	0.44 (0.47)	-0.8	0.17	0.38	0.64	1.8	0.53 [0.24, 0.83]
			Placebo	105	96 (91.4)	0.18 (0.51)	-1.4	-0.15	0.13	0.41	1.7	
		Week 36	Tezepelumab	100	91 (91.0)	0.46 (0.42)	-0.3	0.17	0.40	0.69	1.7	0.49 [0.19, 0.78]
			Placebo	105	94 (89.5)	0.24 (0.50)	-1.7	-0.04	0.20	0.51	1.7	
		Week 52	Tezepelumab	100	83 (83.0)	0.46 (0.41)	-0.6	0.22	0.49	0.75	1.6	0.75 [0.43, 1.06]
			Placebo	105	84 (80.0)	0.15 (0.44)	-1.4	-0.10	0.11	0.35	1.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q1: < 140 cells/uL	Absolute values	Baseline	Tezepelumab	89	89 (100.0)	1.90 (0.70)	0.4	1.35	1.87	2.43	4.0	
			Placebo	81	81 (100.0)	1.79 (0.69)	0.8	1.34	1.69	2.13	4.9	
		Week 2	Tezepelumab	89	87 (97.8)	2.00 (0.73)	0.6	1.40	1.96	2.47	4.1	
			Placebo	81	76 (93.8)	1.81 (0.72)	0.8	1.35	1.64	2.11	4.7	
		Week 4	Tezepelumab	89	88 (98.9)	1.99 (0.78)	0.7	1.38	1.99	2.58	4.2	
			Placebo	81	79 (97.5)	1.78 (0.65)	0.7	1.31	1.69	2.18	3.6	
		Week 8	Tezepelumab	89	87 (97.8)	2.00 (0.75)	0.6	1.45	1.95	2.52	4.1	
			Placebo	81	78 (96.3)	1.81 (0.72)	0.7	1.33	1.72	2.26	4.9	
		Week 12	Tezepelumab	89	85 (95.5)	1.99 (0.74)	0.6	1.47	1.94	2.45	4.2	
			Placebo	81	77 (95.1)	1.81 (0.76)	0.7	1.30	1.61	2.18	5.0	
		Week 16	Tezepelumab	89	86 (96.6)	2.05 (0.80)	0.6	1.46	1.95	2.55	4.3	
			Placebo	81	76 (93.8)	1.76 (0.75)	0.6	1.27	1.62	2.08	5.2	
		Week 24	Tezepelumab	89	80 (89.9)	1.98 (0.72)	0.6	1.43	1.97	2.44	4.0	
			Placebo	81	74 (91.4)	1.83 (0.73)	0.8	1.28	1.72	2.15	5.1	
		Week 36	Tezepelumab	89	81 (91.0)	1.99 (0.78)	0.5	1.44	1.91	2.47	4.4	
			Placebo	81	71 (87.7)	1.86 (0.76)	0.8	1.26	1.79	2.23	5.3	
		Week 52	Tezepelumab	89	80 (89.9)	2.02 (0.76)	0.7	1.43	1.98	2.61	4.2	
			Placebo	81	70 (86.4)	1.78 (0.77)	0.7	1.24	1.61	2.19	5.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q1: < 140 cells/uL	Change from baseline	Week 2	Tezepelumab	89	87 (97.8)	0.08 (0.30)	-0.6	-0.07	0.09	0.20	1.5	0.23 [-0.07, 0.54]
			Placebo	81	76 (93.8)	0.01 (0.28)	-0.7	-0.14	-0.02	0.12	1.1	
		Week 4	Tezepelumab	89	88 (98.9)	0.10 (0.37)	-0.9	-0.08	0.04	0.27	1.7	0.19 [-0.11, 0.50]
			Placebo	81	79 (97.5)	0.03 (0.32)	-0.9	-0.07	0.04	0.15	0.9	
		Week 8	Tezepelumab	89	87 (97.8)	0.11 (0.37)	-0.8	-0.09	0.02	0.32	1.4	0.20 [-0.11, 0.50]
			Placebo	81	78 (96.3)	0.04 (0.29)	-0.9	-0.12	0.05	0.20	0.7	
		Week 12	Tezepelumab	89	85 (95.5)	0.10 (0.35)	-0.8	-0.09	0.08	0.25	1.4	0.20 [-0.11, 0.51]
			Placebo	81	77 (95.1)	0.03 (0.31)	-1.1	-0.09	0.02	0.19	1.0	
		Week 16	Tezepelumab	89	86 (96.6)	0.14 (0.42)	-0.8	-0.09	0.07	0.26	1.9	0.39 [0.08, 0.70]
			Placebo	81	76 (93.8)	-0.01 (0.35)	-1.0	-0.16	0.02	0.14	1.5	
		Week 24	Tezepelumab	89	80 (89.9)	0.10 (0.31)	-0.6	-0.07	0.03	0.26	1.1	0.21 [-0.11, 0.53]
			Placebo	81	74 (91.4)	0.04 (0.31)	-1.1	-0.11	0.03	0.16	1.4	
		Week 36	Tezepelumab	89	81 (91.0)	0.08 (0.36)	-0.7	-0.11	0.02	0.22	1.5	0.08 [-0.24, 0.40]
			Placebo	81	71 (87.7)	0.05 (0.28)	-0.7	-0.12	0.04	0.20	1.3	
		Week 52	Tezepelumab	89	80 (89.9)	0.11 (0.38)	-1.0	-0.06	0.06	0.27	1.3	0.34 [0.02, 0.66]
			Placebo	81	70 (86.4)	-0.01 (0.35)	-1.0	-0.17	0.01	0.13	1.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q2: 140 - < 250 cells/uL	Absolute values	Baseline	Tezepelumab	99	99 (100.0)	1.80 (0.63)	0.8	1.31	1.65	2.20	3.5	
			Placebo	94	94 (100.0)	1.96 (0.70)	0.7	1.42	1.77	2.53	4.1	
		Week 2	Tezepelumab	99	96 (97.0)	1.93 (0.66)	0.8	1.42	1.73	2.43	3.8	
			Placebo	94	91 (96.8)	1.96 (0.74)	0.8	1.38	1.75	2.49	4.0	
		Week 4	Tezepelumab	99	99 (100.0)	1.92 (0.66)	0.8	1.37	1.76	2.42	3.7	
			Placebo	94	90 (95.7)	1.95 (0.65)	0.8	1.46	1.86	2.29	3.7	
		Week 8	Tezepelumab	99	98 (99.0)	1.92 (0.67)	0.8	1.35	1.76	2.43	3.7	
			Placebo	94	93 (98.9)	2.03 (0.74)	0.7	1.51	1.91	2.39	4.1	
		Week 12	Tezepelumab	99	97 (98.0)	1.89 (0.68)	0.8	1.33	1.77	2.37	3.6	
			Placebo	94	90 (95.7)	1.97 (0.75)	0.8	1.49	1.75	2.52	4.1	
		Week 16	Tezepelumab	99	97 (98.0)	1.93 (0.64)	0.8	1.43	1.86	2.40	3.5	
			Placebo	94	90 (95.7)	2.02 (0.79)	0.7	1.41	1.81	2.54	4.1	
		Week 24	Tezepelumab	99	96 (97.0)	1.89 (0.68)	0.7	1.34	1.76	2.40	3.8	
			Placebo	94	86 (91.5)	1.96 (0.74)	0.6	1.40	1.78	2.41	4.0	
		Week 36	Tezepelumab	99	92 (92.9)	1.87 (0.68)	0.7	1.26	1.74	2.42	3.5	
			Placebo	94	83 (88.3)	1.97 (0.76)	0.8	1.44	1.72	2.47	4.1	
		Week 52	Tezepelumab	99	93 (93.9)	1.89 (0.71)	0.7	1.38	1.79	2.37	3.5	
			Placebo	94	77 (81.9)	1.99 (0.79)	0.7	1.45	1.75	2.43	4.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q2: 140 - < 250 cells/uL	Change from baseline	Week 2	Tezepelumab	99	96 (97.0)	0.13 (0.29)	-0.7	-0.03	0.08	0.25	1.1	0.45 [0.16, 0.74]
			Placebo	94	91 (96.8)	-0.02 (0.34)	-1.8	-0.12	0.00	0.13	1.1	
		Week 4	Tezepelumab	99	99 (100.0)	0.12 (0.27)	-0.5	-0.05	0.10	0.23	1.2	0.37 [0.08, 0.66]
			Placebo	94	90 (95.7)	0.01 (0.36)	-1.0	-0.14	0.04	0.19	1.1	
		Week 8	Tezepelumab	99	98 (99.0)	0.13 (0.33)	-0.8	-0.05	0.11	0.23	1.4	0.20 [-0.09, 0.48]
			Placebo	94	93 (98.9)	0.07 (0.27)	-0.7	-0.10	0.05	0.22	0.9	
		Week 12	Tezepelumab	99	97 (98.0)	0.10 (0.32)	-0.7	-0.06	0.08	0.20	1.4	0.25 [-0.04, 0.54]
			Placebo	94	90 (95.7)	0.02 (0.38)	-1.5	-0.10	0.02	0.18	1.2	
		Week 16	Tezepelumab	99	97 (98.0)	0.14 (0.30)	-0.6	-0.04	0.11	0.27	1.3	0.26 [-0.03, 0.55]
			Placebo	94	90 (95.7)	0.06 (0.31)	-0.8	-0.11	0.01	0.21	1.0	
		Week 24	Tezepelumab	99	96 (97.0)	0.10 (0.36)	-1.0	-0.12	0.09	0.26	1.3	0.30 [0.00, 0.59]
			Placebo	94	86 (91.5)	-0.00 (0.33)	-0.9	-0.16	-0.02	0.20	0.9	
		Week 36	Tezepelumab	99	92 (92.9)	0.08 (0.32)	-0.8	-0.09	0.03	0.22	1.3	0.23 [-0.07, 0.52]
			Placebo	94	83 (88.3)	0.00 (0.39)	-1.1	-0.23	-0.02	0.21	1.1	
		Week 52	Tezepelumab	99	93 (93.9)	0.10 (0.36)	-0.8	-0.11	0.03	0.22	1.3	0.11 [-0.19, 0.41]
			Placebo	94	77 (81.9)	0.06 (0.31)	-1.0	-0.15	0.06	0.22	1.1	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q3: 250 - < 430 cells/uL	Absolute values	Baseline	Tezepelumab	103	103 (100.0)	1.74 (0.77)	0.5	1.12	1.64	2.05	4.1	
			Placebo	103	103 (100.0)	1.77 (0.67)	0.4	1.27	1.69	2.17	3.7	
		Week 2	Tezepelumab	103	101 (98.1)	1.92 (0.77)	0.6	1.35	1.81	2.43	4.3	
			Placebo	103	98 (95.1)	1.88 (0.70)	0.4	1.43	1.88	2.31	4.1	
		Week 4	Tezepelumab	103	100 (97.1)	1.94 (0.78)	0.6	1.29	1.83	2.52	4.3	
			Placebo	103	102 (99.0)	1.86 (0.70)	0.4	1.44	1.81	2.31	4.8	
		Week 8	Tezepelumab	103	101 (98.1)	1.99 (0.82)	0.6	1.34	1.84	2.44	4.7	
			Placebo	103	98 (95.1)	1.93 (0.70)	0.4	1.45	1.91	2.29	4.6	
		Week 12	Tezepelumab	103	97 (94.2)	2.02 (0.79)	0.6	1.52	1.91	2.46	4.7	
			Placebo	103	97 (94.2)	1.91 (0.69)	0.6	1.43	1.88	2.32	4.6	
		Week 16	Tezepelumab	103	98 (95.1)	1.99 (0.83)	0.6	1.36	1.82	2.39	4.9	
			Placebo	103	95 (92.2)	1.90 (0.67)	0.7	1.36	1.85	2.26	4.7	
		Week 24	Tezepelumab	103	97 (94.2)	1.99 (0.77)	0.6	1.41	1.92	2.42	4.4	
			Placebo	103	93 (90.3)	1.85 (0.70)	0.6	1.41	1.75	2.23	4.8	
		Week 36	Tezepelumab	103	88 (85.4)	2.02 (0.84)	0.7	1.39	1.85	2.53	4.5	
			Placebo	103	90 (87.4)	1.90 (0.70)	0.7	1.37	1.79	2.26	4.3	
		Week 52	Tezepelumab	103	89 (86.4)	2.01 (0.84)	0.6	1.38	1.83	2.46	4.2	
			Placebo	103	87 (84.5)	1.89 (0.71)	0.7	1.34	1.73	2.27	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q3: 250 - < 430 cells/uL	Change from baseline	Week 2	Tezepelumab	103	101 (98.1)	0.21 (0.33)	-0.5	-0.01	0.15	0.41	1.4	0.31 [0.03, 0.59]
			Placebo	103	98 (95.1)	0.10 (0.38)	-0.8	-0.09	0.04	0.25	1.7	
		Week 4	Tezepelumab	103	100 (97.1)	0.23 (0.38)	-0.5	0.00	0.14	0.36	1.6	0.37 [0.09, 0.64]
			Placebo	103	102 (99.0)	0.10 (0.36)	-0.8	-0.09	0.03	0.25	1.7	
		Week 8	Tezepelumab	103	101 (98.1)	0.29 (0.43)	-0.6	0.02	0.22	0.51	1.8	0.41 [0.13, 0.69]
			Placebo	103	98 (95.1)	0.12 (0.38)	-0.6	-0.07	0.06	0.28	2.0	
		Week 12	Tezepelumab	103	97 (94.2)	0.30 (0.44)	-0.6	0.00	0.23	0.48	2.0	0.48 [0.19, 0.76]
			Placebo	103	97 (94.2)	0.11 (0.38)	-0.7	-0.10	0.04	0.27	1.5	
		Week 16	Tezepelumab	103	98 (95.1)	0.28 (0.43)	-0.6	0.00	0.20	0.45	2.0	0.42 [0.13, 0.71]
			Placebo	103	95 (92.2)	0.11 (0.40)	-1.2	-0.07	0.04	0.26	1.6	
		Week 24	Tezepelumab	103	97 (94.2)	0.28 (0.41)	-1.0	-0.01	0.26	0.49	1.5	0.55 [0.26, 0.84]
			Placebo	103	93 (90.3)	0.07 (0.35)	-0.9	-0.12	0.03	0.24	1.6	
		Week 36	Tezepelumab	103	88 (85.4)	0.32 (0.43)	-1.0	0.02	0.32	0.54	1.7	0.53 [0.23, 0.83]
			Placebo	103	90 (87.4)	0.09 (0.43)	-0.8	-0.15	0.04	0.26	2.2	
		Week 52	Tezepelumab	103	89 (86.4)	0.31 (0.43)	-0.8	0.02	0.26	0.53	1.7	0.57 [0.27, 0.87]
			Placebo	103	87 (84.5)	0.08 (0.37)	-0.6	-0.18	0.03	0.23	1.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q4: >= 430 cells/uL	Absolute values	Baseline	Tezepelumab	104	104 (100.0)	1.67 (0.66)	0.6	1.22	1.54	1.89	3.7	
			Placebo	113	113 (100.0)	1.82 (0.77)	0.6	1.31	1.69	2.22	4.5	
		Week 2	Tezepelumab	104	100 (96.2)	1.96 (0.70)	0.8	1.46	1.82	2.32	4.0	
			Placebo	113	108 (95.6)	1.95 (0.73)	0.8	1.38	1.86	2.47	4.0	
		Week 4	Tezepelumab	104	104 (100.0)	2.02 (0.70)	0.7	1.56	1.89	2.48	4.2	
			Placebo	113	111 (98.2)	1.98 (0.74)	0.5	1.43	1.93	2.43	4.2	
		Week 8	Tezepelumab	104	102 (98.1)	2.03 (0.71)	1.0	1.49	1.87	2.44	4.2	
			Placebo	113	111 (98.2)	1.93 (0.78)	0.6	1.33	1.78	2.35	4.3	
		Week 12	Tezepelumab	104	103 (99.0)	2.06 (0.72)	0.9	1.58	1.94	2.44	4.6	
			Placebo	113	113 (100.0)	2.01 (0.76)	0.5	1.50	1.95	2.45	4.3	
		Week 16	Tezepelumab	104	99 (95.2)	2.09 (0.72)	0.8	1.59	1.99	2.48	4.3	
			Placebo	113	109 (96.5)	1.98 (0.74)	0.5	1.52	1.89	2.33	4.4	
		Week 24	Tezepelumab	104	96 (92.3)	2.06 (0.70)	0.9	1.61	1.87	2.47	3.8	
			Placebo	113	104 (92.0)	2.02 (0.77)	0.7	1.49	1.92	2.38	4.8	
		Week 36	Tezepelumab	104	95 (91.3)	2.10 (0.71)	0.8	1.57	2.00	2.41	4.2	
			Placebo	113	102 (90.3)	2.07 (0.81)	0.6	1.52	1.98	2.43	4.6	
		Week 52	Tezepelumab	104	87 (83.7)	2.11 (0.72)	0.9	1.64	1.90	2.42	4.3	
			Placebo	113	92 (81.4)	2.01 (0.83)	0.6	1.37	1.97	2.45	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q4: >= 430 cells/uL	Change from baseline	Week 2	Tezepelumab	104	100 (96.2)	0.30 (0.36)	-0.5	0.08	0.23	0.42	1.4	0.51 [0.23, 0.78]
			Placebo	113	108 (95.6)	0.10 (0.42)	-1.3	-0.11	0.01	0.31	1.3	
		Week 4	Tezepelumab	104	104 (100.0)	0.35 (0.37)	-0.4	0.07	0.32	0.49	1.8	0.44 [0.17, 0.71]
			Placebo	113	111 (98.2)	0.16 (0.48)	-1.8	-0.13	0.05	0.45	1.4	
		Week 8	Tezepelumab	104	102 (98.1)	0.38 (0.46)	-1.1	0.10	0.31	0.66	1.7	0.59 [0.32, 0.87]
			Placebo	113	111 (98.2)	0.10 (0.47)	-1.7	-0.20	0.08	0.33	1.6	
		Week 12	Tezepelumab	104	103 (99.0)	0.41 (0.45)	-1.5	0.14	0.35	0.62	1.5	0.47 [0.20, 0.74]
			Placebo	113	113 (100.0)	0.19 (0.47)	-1.4	-0.09	0.12	0.42	1.7	
		Week 16	Tezepelumab	104	99 (95.2)	0.44 (0.41)	-0.5	0.15	0.36	0.66	1.6	0.70 [0.42, 0.98]
			Placebo	113	109 (96.5)	0.14 (0.45)	-1.6	-0.13	0.05	0.43	1.8	
		Week 24	Tezepelumab	104	96 (92.3)	0.43 (0.46)	-0.8	0.17	0.38	0.64	1.8	0.54 [0.26, 0.83]
			Placebo	113	104 (92.0)	0.17 (0.51)	-1.4	-0.15	0.10	0.41	1.7	
		Week 36	Tezepelumab	104	95 (91.3)	0.46 (0.42)	-0.3	0.17	0.40	0.69	1.7	0.52 [0.24, 0.81]
			Placebo	113	102 (90.3)	0.22 (0.49)	-1.7	-0.07	0.16	0.50	1.7	
		Week 52	Tezepelumab	104	87 (83.7)	0.46 (0.40)	-0.6	0.22	0.47	0.74	1.6	0.77 [0.47, 1.08]
			Placebo	113	92 (81.4)	0.14 (0.43)	-1.4	-0.10	0.11	0.34	1.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
< 25 ppb	Absolute values	Baseline	Tezepelumab	158	158 (100.0)	1.71 (0.68)	0.4	1.23	1.56	2.13	4.0	
			Placebo	151	151 (100.0)	1.86 (0.74)	0.4	1.35	1.73	2.31	3.9	
		Week 2	Tezepelumab	158	153 (96.8)	1.86 (0.67)	0.6	1.35	1.72	2.36	4.1	
			Placebo	151	141 (93.4)	1.92 (0.73)	0.4	1.38	1.85	2.38	4.1	
		Week 4	Tezepelumab	158	155 (98.1)	1.85 (0.69)	0.6	1.28	1.73	2.37	4.2	
			Placebo	151	149 (98.7)	1.92 (0.74)	0.4	1.43	1.83	2.34	4.8	
		Week 8	Tezepelumab	158	155 (98.1)	1.86 (0.69)	0.6	1.32	1.68	2.36	4.1	
			Placebo	151	147 (97.4)	1.93 (0.74)	0.4	1.40	1.83	2.36	4.6	
		Week 12	Tezepelumab	158	152 (96.2)	1.85 (0.67)	0.6	1.38	1.74	2.26	4.2	
			Placebo	151	144 (95.4)	1.94 (0.76)	0.5	1.40	1.75	2.46	4.6	
		Week 16	Tezepelumab	158	151 (95.6)	1.89 (0.69)	0.6	1.37	1.79	2.39	4.2	
			Placebo	151	144 (95.4)	1.89 (0.75)	0.5	1.32	1.79	2.35	4.7	
		Week 24	Tezepelumab	158	149 (94.3)	1.84 (0.67)	0.6	1.30	1.74	2.30	4.0	
			Placebo	151	140 (92.7)	1.91 (0.75)	0.6	1.40	1.82	2.25	4.8	
		Week 36	Tezepelumab	158	140 (88.6)	1.83 (0.67)	0.5	1.28	1.76	2.31	4.4	
			Placebo	151	135 (89.4)	1.95 (0.76)	0.6	1.41	1.82	2.38	4.3	
		Week 52	Tezepelumab	158	142 (89.9)	1.84 (0.67)	0.7	1.36	1.74	2.24	4.2	
			Placebo	151	130 (86.1)	1.91 (0.79)	0.6	1.32	1.74	2.43	4.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
< 25 ppb	Change from baseline	Week 2	Tezepelumab	158	153 (96.8)	0.14 (0.31)	-0.7	-0.01	0.09	0.25	1.4	0.39 [0.16, 0.62]
			Placebo	151	141 (93.4)	0.03 (0.27)	-0.8	-0.11	0.00	0.12	0.9	
		Week 4	Tezepelumab	158	155 (98.1)	0.15 (0.34)	-0.9	-0.04	0.09	0.29	1.7	0.27 [0.05, 0.50]
			Placebo	151	149 (98.7)	0.07 (0.31)	-0.9	-0.09	0.03	0.19	1.6	
		Week 8	Tezepelumab	158	155 (98.1)	0.17 (0.37)	-0.8	-0.05	0.11	0.27	1.6	0.32 [0.10, 0.55]
			Placebo	151	147 (97.4)	0.06 (0.31)	-0.9	-0.10	0.04	0.20	1.4	
		Week 12	Tezepelumab	158	152 (96.2)	0.15 (0.34)	-0.7	-0.04	0.10	0.28	1.5	0.28 [0.05, 0.51]
			Placebo	151	144 (95.4)	0.06 (0.33)	-1.5	-0.06	0.03	0.20	1.4	
		Week 16	Tezepelumab	158	151 (95.6)	0.16 (0.35)	-0.6	-0.04	0.11	0.29	1.6	0.43 [0.20, 0.66]
			Placebo	151	144 (95.4)	0.02 (0.32)	-1.0	-0.14	0.01	0.15	1.4	
		Week 24	Tezepelumab	158	149 (94.3)	0.15 (0.36)	-1.0	-0.07	0.09	0.32	1.5	0.39 [0.16, 0.62]
			Placebo	151	140 (92.7)	0.01 (0.33)	-1.1	-0.14	0.03	0.15	1.6	
		Week 36	Tezepelumab	158	140 (88.6)	0.12 (0.36)	-1.0	-0.11	0.07	0.32	1.4	0.15 [-0.09, 0.38]
			Placebo	151	135 (89.4)	0.07 (0.30)	-0.8	-0.10	0.06	0.21	1.1	
		Week 52	Tezepelumab	158	142 (89.9)	0.14 (0.37)	-1.0	-0.04	0.09	0.34	1.3	0.27 [0.03, 0.51]
			Placebo	151	130 (86.1)	0.05 (0.31)	-1.0	-0.14	0.05	0.21	1.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
25 - < 50 ppb	Absolute values	Baseline	Tezepelumab	114	114 (100.0)	1.70 (0.68)	0.5	1.20	1.58	2.06	3.7	
			Placebo	116	116 (100.0)	1.84 (0.78)	0.7	1.28	1.69	2.17	4.9	
		Week 2	Tezepelumab	114	113 (99.1)	1.88 (0.66)	0.7	1.38	1.78	2.41	4.0	
			Placebo	116	114 (98.3)	1.87 (0.77)	0.6	1.33	1.67	2.20	4.7	
		Week 4	Tezepelumab	114	114 (100.0)	1.92 (0.73)	0.7	1.34	1.77	2.51	4.2	
			Placebo	116	112 (96.6)	1.87 (0.68)	0.7	1.40	1.74	2.14	4.2	
		Week 8	Tezepelumab	114	113 (99.1)	1.90 (0.68)	0.8	1.35	1.78	2.38	4.2	
			Placebo	116	112 (96.6)	1.94 (0.79)	0.7	1.33	1.85	2.28	4.9	
		Week 12	Tezepelumab	114	111 (97.4)	1.93 (0.69)	0.7	1.47	1.79	2.34	4.3	
			Placebo	116	112 (96.6)	1.91 (0.79)	0.7	1.36	1.84	2.26	5.0	
		Week 16	Tezepelumab	114	113 (99.1)	1.91 (0.68)	0.8	1.49	1.77	2.30	4.3	
			Placebo	116	110 (94.8)	1.92 (0.80)	0.6	1.41	1.74	2.24	5.2	
		Week 24	Tezepelumab	114	107 (93.9)	1.90 (0.67)	0.7	1.44	1.77	2.39	3.8	
			Placebo	116	103 (88.8)	1.93 (0.79)	0.6	1.41	1.80	2.17	5.1	
		Week 36	Tezepelumab	114	106 (93.0)	1.92 (0.74)	0.6	1.35	1.80	2.39	4.2	
			Placebo	116	105 (90.5)	1.94 (0.81)	0.7	1.41	1.74	2.21	5.3	
		Week 52	Tezepelumab	114	103 (90.4)	1.93 (0.75)	0.6	1.39	1.81	2.39	4.3	
			Placebo	116	95 (81.9)	1.91 (0.84)	0.7	1.37	1.70	2.26	5.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
25 - < 50 ppb	Change from baseline	Week 2	Tezepelumab	114	113 (99.1)	0.18 (0.31)	-0.5	-0.01	0.14	0.32	1.3	0.44 [0.18, 0.70]
			Placebo	116	114 (98.3)	0.02 (0.42)	-1.8	-0.16	-0.01	0.18	1.7	
		Week 4	Tezepelumab	114	114 (100.0)	0.22 (0.32)	-0.5	0.03	0.15	0.36	1.3	0.46 [0.19, 0.72]
			Placebo	116	112 (96.6)	0.05 (0.43)	-1.8	-0.13	0.02	0.26	1.7	
		Week 8	Tezepelumab	114	113 (99.1)	0.22 (0.38)	-0.8	-0.02	0.17	0.41	1.5	0.31 [0.05, 0.58]
			Placebo	116	112 (96.6)	0.10 (0.36)	-0.8	-0.08	0.06	0.26	2.0	
		Week 12	Tezepelumab	114	111 (97.4)	0.25 (0.39)	-1.5	0.02	0.20	0.41	1.6	0.42 [0.16, 0.69]
			Placebo	116	112 (96.6)	0.08 (0.42)	-1.2	-0.13	0.03	0.31	1.5	
		Week 16	Tezepelumab	114	113 (99.1)	0.23 (0.38)	-0.6	0.00	0.20	0.40	1.5	0.42 [0.15, 0.69]
			Placebo	116	110 (94.8)	0.07 (0.39)	-1.2	-0.13	0.01	0.22	1.6	
		Week 24	Tezepelumab	114	107 (93.9)	0.24 (0.44)	-1.0	-0.05	0.22	0.45	1.6	0.36 [0.09, 0.64]
			Placebo	116	103 (88.8)	0.09 (0.39)	-1.1	-0.11	0.03	0.29	1.4	
		Week 36	Tezepelumab	114	106 (93.0)	0.26 (0.41)	-0.6	-0.02	0.12	0.46	1.6	0.38 [0.11, 0.65]
			Placebo	116	105 (90.5)	0.08 (0.50)	-1.7	-0.21	0.02	0.29	2.2	
		Week 52	Tezepelumab	114	103 (90.4)	0.27 (0.42)	-0.8	-0.04	0.21	0.55	1.7	0.55 [0.26, 0.83]
			Placebo	116	95 (81.9)	0.05 (0.40)	-1.0	-0.18	-0.03	0.24	1.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
>= 50 ppb	Absolute values	Baseline	Tezepelumab	120	120 (100.0)	1.93 (0.71)	0.7	1.48	1.76	2.30	4.1	
			Placebo	120	120 (100.0)	1.79 (0.62)	0.6	1.37	1.72	2.20	4.0	
		Week 2	Tezepelumab	120	115 (95.8)	2.17 (0.78)	0.8	1.60	2.07	2.59	4.3	
			Placebo	120	114 (95.0)	1.93 (0.66)	0.6	1.47	1.86	2.43	3.9	
		Week 4	Tezepelumab	120	119 (99.2)	2.18 (0.75)	0.7	1.63	2.03	2.72	4.3	
			Placebo	120	117 (97.5)	1.91 (0.65)	0.7	1.44	1.86	2.27	4.0	
		Week 8	Tezepelumab	120	117 (97.5)	2.25 (0.79)	1.0	1.66	2.20	2.62	4.7	
			Placebo	120	117 (97.5)	1.93 (0.70)	0.7	1.48	1.82	2.33	4.3	
		Week 12	Tezepelumab	120	116 (96.7)	2.25 (0.81)	0.8	1.68	2.12	2.73	4.7	
			Placebo	120	118 (98.3)	1.96 (0.67)	0.6	1.50	1.87	2.34	4.3	
		Week 16	Tezepelumab	120	113 (94.2)	2.31 (0.81)	0.8	1.80	2.18	2.75	4.9	
			Placebo	120	113 (94.2)	1.98 (0.68)	0.8	1.51	1.89	2.35	4.4	
		Week 24	Tezepelumab	120	110 (91.7)	2.26 (0.75)	0.9	1.76	2.08	2.72	4.4	
			Placebo	120	111 (92.5)	1.94 (0.68)	0.8	1.41	1.80	2.35	4.3	
		Week 36	Tezepelumab	120	107 (89.2)	2.31 (0.80)	0.9	1.79	2.24	2.82	4.5	
			Placebo	120	103 (85.8)	1.99 (0.73)	0.8	1.46	1.95	2.32	4.3	
		Week 52	Tezepelumab	120	101 (84.2)	2.32 (0.80)	0.9	1.76	2.13	2.88	4.2	
			Placebo	120	98 (81.7)	1.95 (0.71)	0.7	1.32	1.92	2.37	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
>= 50 ppb	Change from baseline	Week 2	Tezepelumab	120	115 (95.8)	0.25 (0.38)	-0.6	0.03	0.21	0.44	1.5	0.35 [0.09, 0.61]
			Placebo	120	114 (95.0)	0.12 (0.41)	-1.3	-0.07	0.07	0.28	1.3	
		Week 4	Tezepelumab	120	119 (99.2)	0.26 (0.43)	-0.7	0.00	0.20	0.41	1.8	0.31 [0.06, 0.57]
			Placebo	120	117 (97.5)	0.12 (0.46)	-1.0	-0.14	0.06	0.40	1.4	
		Week 8	Tezepelumab	120	117 (97.5)	0.34 (0.49)	-1.1	0.05	0.31	0.60	1.8	0.49 [0.23, 0.75]
			Placebo	120	117 (97.5)	0.11 (0.44)	-1.7	-0.15	0.09	0.32	1.6	
		Week 12	Tezepelumab	120	116 (96.7)	0.34 (0.51)	-0.8	-0.03	0.28	0.57	2.0	0.37 [0.11, 0.63]
			Placebo	120	118 (98.3)	0.16 (0.46)	-1.4	-0.10	0.11	0.40	1.7	
		Week 16	Tezepelumab	120	113 (94.2)	0.41 (0.48)	-0.8	0.10	0.34	0.62	2.0	0.50 [0.24, 0.77]
			Placebo	120	113 (94.2)	0.17 (0.45)	-1.6	-0.06	0.11	0.42	1.8	
		Week 24	Tezepelumab	120	110 (91.7)	0.34 (0.44)	-0.5	0.06	0.29	0.55	1.8	0.46 [0.19, 0.73]
			Placebo	120	111 (92.5)	0.14 (0.47)	-1.4	-0.14	0.07	0.38	1.7	
		Week 36	Tezepelumab	120	107 (89.2)	0.39 (0.45)	-0.5	0.03	0.35	0.63	1.7	0.51 [0.23, 0.78]
			Placebo	120	103 (85.8)	0.16 (0.48)	-1.2	-0.17	0.15	0.45	1.7	
		Week 52	Tezepelumab	120	101 (84.2)	0.37 (0.44)	-0.6	0.08	0.34	0.65	1.6	0.57 [0.28, 0.85]
			Placebo	120	98 (81.7)	0.12 (0.43)	-1.4	-0.14	0.11	0.33	1.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q1: < 16 ppb	Absolute values	Baseline	Tezepelumab	94	94 (100.0)	1.71 (0.68)	0.7	1.18	1.59	2.13	4.0	
			Placebo	85	85 (100.0)	1.79 (0.71)	0.4	1.26	1.67	2.29	3.5	
		Week 2	Tezepelumab	94	90 (95.7)	1.87 (0.68)	0.6	1.31	1.83	2.42	4.1	
			Placebo	85	77 (90.6)	1.85 (0.74)	0.4	1.34	1.71	2.32	4.1	
		Week 4	Tezepelumab	94	92 (97.9)	1.87 (0.68)	0.6	1.30	1.85	2.39	4.2	
			Placebo	85	84 (98.8)	1.84 (0.75)	0.4	1.29	1.79	2.33	4.8	
		Week 8	Tezepelumab	94	92 (97.9)	1.85 (0.67)	0.6	1.33	1.68	2.37	4.1	
			Placebo	85	82 (96.5)	1.84 (0.72)	0.4	1.34	1.78	2.30	4.6	
		Week 12	Tezepelumab	94	90 (95.7)	1.84 (0.66)	0.6	1.38	1.76	2.21	4.2	
			Placebo	85	81 (95.3)	1.89 (0.76)	0.5	1.33	1.74	2.44	4.6	
		Week 16	Tezepelumab	94	89 (94.7)	1.90 (0.69)	0.6	1.38	1.84	2.40	4.2	
			Placebo	85	80 (94.1)	1.82 (0.75)	0.5	1.24	1.78	2.31	4.7	
		Week 24	Tezepelumab	94	89 (94.7)	1.84 (0.65)	0.6	1.38	1.75	2.30	4.0	
			Placebo	85	78 (91.8)	1.85 (0.76)	0.6	1.24	1.82	2.23	4.8	
		Week 36	Tezepelumab	94	84 (89.4)	1.85 (0.69)	0.7	1.29	1.78	2.41	4.4	
			Placebo	85	77 (90.6)	1.88 (0.76)	0.6	1.36	1.82	2.28	4.3	
		Week 52	Tezepelumab	94	83 (88.3)	1.87 (0.67)	0.7	1.43	1.76	2.37	4.2	
			Placebo	85	71 (83.5)	1.84 (0.81)	0.6	1.16	1.66	2.42	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q1: < 16 ppb	Change from baseline	Week 2	Tezepelumab	94	90 (95.7)	0.16 (0.33)	-0.6	-0.02	0.10	0.24	1.4	0.40 [0.09, 0.71]
			Placebo	85	77 (90.6)	0.03 (0.27)	-0.8	-0.07	0.00	0.13	0.9	
		Week 4	Tezepelumab	94	92 (97.9)	0.18 (0.36)	-0.6	-0.02	0.11	0.29	1.7	0.36 [0.07, 0.66]
			Placebo	85	84 (98.8)	0.06 (0.34)	-0.9	-0.08	0.02	0.14	1.6	
		Week 8	Tezepelumab	94	92 (97.9)	0.16 (0.36)	-0.8	-0.05	0.08	0.28	1.3	0.40 [0.10, 0.70]
			Placebo	85	82 (96.5)	0.03 (0.29)	-0.9	-0.10	0.01	0.13	1.4	
		Week 12	Tezepelumab	94	90 (95.7)	0.16 (0.36)	-0.6	-0.04	0.10	0.26	1.5	0.21 [-0.09, 0.52]
			Placebo	85	81 (95.3)	0.09 (0.31)	-1.1	-0.04	0.05	0.22	1.4	
		Week 16	Tezepelumab	94	89 (94.7)	0.18 (0.35)	-0.6	-0.04	0.13	0.28	1.6	0.45 [0.14, 0.76]
			Placebo	85	80 (94.1)	0.02 (0.33)	-1.0	-0.11	0.02	0.16	1.4	
		Week 24	Tezepelumab	94	89 (94.7)	0.14 (0.37)	-1.0	-0.07	0.03	0.29	1.3	0.28 [-0.02, 0.59]
			Placebo	85	78 (91.8)	0.03 (0.36)	-1.1	-0.12	0.04	0.17	1.6	
		Week 36	Tezepelumab	94	84 (89.4)	0.14 (0.38)	-1.0	-0.08	0.10	0.35	1.4	0.15 [-0.16, 0.46]
			Placebo	85	77 (90.6)	0.08 (0.29)	-0.8	-0.08	0.06	0.26	1.1	
		Week 52	Tezepelumab	94	83 (88.3)	0.15 (0.39)	-1.0	-0.03	0.10	0.34	1.3	0.22 [-0.10, 0.54]
			Placebo	85	71 (83.5)	0.07 (0.34)	-1.0	-0.09	0.07	0.21	1.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)											
Q2: 16 - < 30 ppb Absolute values	Baseline	Tezepelumab	88	88 (100.0)	1.69 (0.68)	0.4	1.23	1.50	2.09	3.5	
		Placebo	99	99 (100.0)	1.91 (0.81)	0.7	1.28	1.76	2.29	4.5	
	Week 2	Tezepelumab	88	87 (98.9)	1.79 (0.64)	0.6	1.30	1.69	2.13	3.8	
		Placebo	99	97 (98.0)	1.93 (0.75)	0.6	1.38	1.83	2.31	3.9	
	Week 4	Tezepelumab	88	87 (98.9)	1.80 (0.67)	0.7	1.28	1.65	2.20	3.7	
		Placebo	99	97 (98.0)	1.95 (0.73)	0.7	1.44	1.83	2.32	3.6	
	Week 8	Tezepelumab	88	87 (98.9)	1.81 (0.69)	0.6	1.32	1.68	2.22	3.7	
		Placebo	99	97 (98.0)	1.99 (0.78)	0.7	1.47	1.84	2.36	4.1	
	Week 12	Tezepelumab	88	84 (95.5)	1.83 (0.66)	0.6	1.35	1.69	2.23	3.6	
		Placebo	99	96 (97.0)	1.95 (0.79)	0.8	1.36	1.74	2.45	4.1	
	Week 16	Tezepelumab	88	86 (97.7)	1.84 (0.69)	0.6	1.35	1.65	2.27	3.5	
		Placebo	99	97 (98.0)	1.94 (0.79)	0.7	1.35	1.78	2.33	4.3	
	Week 24	Tezepelumab	88	82 (93.2)	1.81 (0.68)	0.6	1.30	1.71	2.29	3.8	
		Placebo	99	94 (94.9)	1.97 (0.77)	0.6	1.42	1.82	2.35	4.3	
	Week 36	Tezepelumab	88	80 (90.9)	1.78 (0.64)	0.5	1.28	1.69	2.13	3.5	
		Placebo	99	89 (89.9)	2.00 (0.77)	0.9	1.46	1.84	2.48	4.2	
	Week 52	Tezepelumab	88	82 (93.2)	1.78 (0.66)	0.7	1.32	1.65	2.19	3.5	
		Placebo	99	87 (87.9)	1.95 (0.80)	0.7	1.37	1.74	2.47	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q2: 16 - < 30 ppb	Change from baseline	Week 2	Tezepelumab	88	87 (98.9)	0.10 (0.25)	-0.7	-0.03	0.07	0.22	0.8	0.29 [-0.00, 0.58]
			Placebo	99	97 (98.0)	0.01 (0.31)	-1.1	-0.14	0.00	0.13	0.9	
		Week 4	Tezepelumab	88	87 (98.9)	0.11 (0.27)	-0.9	-0.06	0.08	0.25	1.1	0.17 [-0.12, 0.46]
			Placebo	99	97 (98.0)	0.06 (0.36)	-1.8	-0.11	0.07	0.28	1.0	
		Week 8	Tezepelumab	88	87 (98.9)	0.14 (0.36)	-0.8	-0.06	0.10	0.24	1.6	0.16 [-0.13, 0.45]
			Placebo	99	97 (98.0)	0.09 (0.34)	-0.8	-0.13	0.07	0.33	1.2	
		Week 12	Tezepelumab	88	84 (95.5)	0.14 (0.29)	-0.7	-0.05	0.11	0.28	1.2	0.34 [0.04, 0.63]
			Placebo	99	96 (97.0)	0.03 (0.35)	-1.5	-0.11	0.03	0.19	1.2	
		Week 16	Tezepelumab	88	86 (97.7)	0.14 (0.33)	-0.6	-0.02	0.10	0.30	1.4	0.35 [0.05, 0.64]
			Placebo	99	97 (98.0)	0.03 (0.32)	-0.8	-0.15	0.03	0.16	1.0	
		Week 24	Tezepelumab	88	82 (93.2)	0.15 (0.34)	-0.6	-0.07	0.12	0.32	1.5	0.40 [0.10, 0.70]
			Placebo	99	94 (94.9)	0.02 (0.29)	-0.9	-0.14	0.03	0.21	0.8	
		Week 36	Tezepelumab	88	80 (90.9)	0.09 (0.32)	-0.7	-0.11	0.02	0.22	1.0	0.12 [-0.18, 0.42]
			Placebo	99	89 (89.9)	0.05 (0.37)	-1.0	-0.20	0.02	0.21	1.3	
		Week 52	Tezepelumab	88	82 (93.2)	0.12 (0.32)	-1.0	-0.06	0.09	0.31	1.1	0.39 [0.08, 0.69]
			Placebo	99	87 (87.9)	0.00 (0.31)	-1.0	-0.20	-0.01	0.19	0.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)											
Q3: 30 - < 56 ppb Absolute values	Baseline	Tezepelumab	106	106 (100.0)	1.74 (0.68)	0.5	1.28	1.63	2.13	3.7	
		Placebo	96	96 (100.0)	1.85 (0.70)	0.8	1.37	1.70	2.17	4.9	
	Week 2	Tezepelumab	106	105 (99.1)	1.95 (0.68)	0.7	1.47	1.86	2.41	4.0	
		Placebo	96	93 (96.9)	1.91 (0.75)	0.8	1.39	1.71	2.28	4.7	
	Week 4	Tezepelumab	106	106 (100.0)	1.99 (0.74)	0.7	1.44	1.97	2.51	4.2	
		Placebo	96	92 (95.8)	1.89 (0.64)	0.7	1.44	1.81	2.16	4.2	
	Week 8	Tezepelumab	106	105 (99.1)	1.99 (0.70)	0.8	1.39	1.95	2.43	4.2	
		Placebo	96	93 (96.9)	1.97 (0.75)	0.8	1.41	1.93	2.28	4.9	
	Week 12	Tezepelumab	106	105 (99.1)	2.00 (0.70)	0.8	1.52	1.89	2.41	4.3	
		Placebo	96	92 (95.8)	1.94 (0.76)	0.7	1.39	1.88	2.31	5.0	
	Week 16	Tezepelumab	106	105 (99.1)	1.99 (0.69)	0.8	1.53	1.91	2.31	4.3	
		Placebo	96	89 (92.7)	1.92 (0.75)	0.6	1.48	1.75	2.29	5.2	
	Week 24	Tezepelumab	106	101 (95.3)	1.97 (0.67)	0.7	1.53	1.93	2.41	3.8	
		Placebo	96	83 (86.5)	1.94 (0.75)	0.9	1.44	1.80	2.20	5.1	
	Week 36	Tezepelumab	106	96 (90.6)	2.02 (0.74)	0.7	1.43	2.00	2.42	4.2	
		Placebo	96	87 (90.6)	1.94 (0.78)	0.7	1.44	1.69	2.34	5.3	
	Week 52	Tezepelumab	106	94 (88.7)	2.03 (0.77)	0.6	1.49	2.02	2.41	4.3	
		Placebo	96	79 (82.3)	1.93 (0.79)	0.7	1.38	1.79	2.27	5.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q3: 30 - < 56 ppb	Change from baseline	Week 2	Tezepelumab	106	105 (99.1)	0.21 (0.31)	-0.4	0.02	0.17	0.33	1.3	0.43 [0.15, 0.72]
			Placebo	96	93 (96.9)	0.05 (0.42)	-1.8	-0.11	0.00	0.20	1.7	
		Week 4	Tezepelumab	106	106 (100.0)	0.25 (0.33)	-0.5	0.04	0.18	0.39	1.3	0.46 [0.18, 0.74]
			Placebo	96	92 (95.8)	0.08 (0.39)	-1.0	-0.11	0.03	0.21	1.7	
		Week 8	Tezepelumab	106	105 (99.1)	0.26 (0.39)	-0.8	0.00	0.23	0.48	1.5	0.35 [0.07, 0.64]
			Placebo	96	93 (96.9)	0.12 (0.35)	-0.8	-0.06	0.07	0.21	2.0	
		Week 12	Tezepelumab	106	105 (99.1)	0.26 (0.42)	-1.5	0.02	0.20	0.44	1.6	0.39 [0.11, 0.67]
			Placebo	96	92 (95.8)	0.09 (0.42)	-1.2	-0.12	0.03	0.30	1.5	
		Week 16	Tezepelumab	106	105 (99.1)	0.27 (0.41)	-0.6	0.00	0.22	0.45	1.5	0.50 [0.22, 0.79]
			Placebo	96	89 (92.7)	0.06 (0.39)	-1.2	-0.14	-0.01	0.21	1.6	
		Week 24	Tezepelumab	106	101 (95.3)	0.28 (0.46)	-1.0	-0.05	0.27	0.47	1.6	0.39 [0.09, 0.68]
			Placebo	96	83 (86.5)	0.11 (0.41)	-1.1	-0.12	0.03	0.31	1.4	
		Week 36	Tezepelumab	106	96 (90.6)	0.31 (0.42)	-0.5	-0.02	0.23	0.54	1.6	0.49 [0.19, 0.78]
			Placebo	96	87 (90.6)	0.09 (0.48)	-1.7	-0.18	0.02	0.27	2.2	
		Week 52	Tezepelumab	106	94 (88.7)	0.31 (0.44)	-0.8	-0.04	0.25	0.58	1.7	0.53 [0.22, 0.83]
			Placebo	96	79 (82.3)	0.09 (0.39)	-0.7	-0.17	-0.02	0.31	1.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q4: >= 56 ppb	Absolute values	Baseline	Tezepelumab	104	104 (100.0)	1.94 (0.72)	0.8	1.46	1.76	2.32	4.1	
			Placebo	107	107 (100.0)	1.79 (0.63)	0.6	1.36	1.73	2.22	4.0	
		Week 2	Tezepelumab	104	99 (95.2)	2.19 (0.79)	0.8	1.60	2.07	2.73	4.3	
			Placebo	107	102 (95.3)	1.91 (0.67)	0.6	1.47	1.85	2.40	3.9	
		Week 4	Tezepelumab	104	103 (99.0)	2.19 (0.76)	0.8	1.63	2.03	2.77	4.3	
			Placebo	107	105 (98.1)	1.90 (0.67)	0.7	1.44	1.86	2.26	4.0	
		Week 8	Tezepelumab	104	101 (97.1)	2.27 (0.81)	1.0	1.66	2.22	2.66	4.7	
			Placebo	107	104 (97.2)	1.91 (0.71)	0.7	1.42	1.82	2.34	4.3	
		Week 12	Tezepelumab	104	100 (96.2)	2.27 (0.82)	0.8	1.69	2.12	2.79	4.7	
			Placebo	107	105 (98.1)	1.95 (0.67)	0.6	1.50	1.87	2.34	4.3	
		Week 16	Tezepelumab	104	97 (93.3)	2.32 (0.83)	0.8	1.80	2.18	2.77	4.9	
			Placebo	107	101 (94.4)	1.99 (0.69)	0.8	1.55	1.89	2.26	4.4	
		Week 24	Tezepelumab	104	94 (90.4)	2.29 (0.77)	0.9	1.74	2.13	2.75	4.4	
			Placebo	107	99 (92.5)	1.93 (0.69)	0.8	1.41	1.80	2.28	4.3	
		Week 36	Tezepelumab	104	93 (89.4)	2.31 (0.82)	0.9	1.74	2.25	2.88	4.5	
			Placebo	107	90 (84.1)	2.01 (0.75)	0.8	1.46	1.96	2.32	4.3	
		Week 52	Tezepelumab	104	87 (83.7)	2.33 (0.81)	0.9	1.72	2.16	2.95	4.2	
			Placebo	107	86 (80.4)	1.96 (0.72)	0.7	1.44	1.92	2.30	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q4: >= 56 ppb	Change from baseline	Week 2	Tezepelumab	104	99 (95.2)	0.27 (0.39)	-0.6	0.03	0.23	0.47	1.5	0.40 [0.12, 0.68]
			Placebo	107	102 (95.3)	0.11 (0.42)	-1.3	-0.09	0.06	0.27	1.3	
		Week 4	Tezepelumab	104	103 (99.0)	0.27 (0.44)	-0.7	-0.01	0.19	0.43	1.8	0.33 [0.06, 0.60]
			Placebo	107	105 (98.1)	0.12 (0.47)	-1.0	-0.17	0.06	0.41	1.4	
		Week 8	Tezepelumab	104	101 (97.1)	0.36 (0.51)	-1.1	0.07	0.33	0.65	1.8	0.54 [0.26, 0.81]
			Placebo	107	104 (97.2)	0.10 (0.46)	-1.7	-0.17	0.05	0.33	1.6	
		Week 12	Tezepelumab	104	100 (96.2)	0.36 (0.52)	-0.8	0.02	0.33	0.58	2.0	0.40 [0.13, 0.68]
			Placebo	107	105 (98.1)	0.16 (0.48)	-1.4	-0.09	0.11	0.42	1.7	
		Week 16	Tezepelumab	104	97 (93.3)	0.42 (0.48)	-0.8	0.10	0.34	0.62	2.0	0.49 [0.20, 0.77]
			Placebo	107	101 (94.4)	0.19 (0.47)	-1.6	-0.04	0.14	0.45	1.8	
		Week 24	Tezepelumab	104	94 (90.4)	0.36 (0.44)	-0.5	0.06	0.29	0.63	1.8	0.50 [0.21, 0.79]
			Placebo	107	99 (92.5)	0.13 (0.48)	-1.4	-0.15	0.07	0.38	1.7	
		Week 36	Tezepelumab	104	93 (89.4)	0.40 (0.45)	-0.3	0.03	0.35	0.63	1.7	0.47 [0.18, 0.77]
			Placebo	107	90 (84.1)	0.18 (0.50)	-1.2	-0.17	0.16	0.49	1.7	
		Week 52	Tezepelumab	104	87 (83.7)	0.39 (0.44)	-0.6	0.08	0.34	0.69	1.6	0.58 [0.28, 0.89]
			Placebo	107	86 (80.4)	0.13 (0.44)	-1.4	-0.11	0.11	0.34	1.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q1: < 53.1 IU/ml	Absolute values	Baseline	Tezepelumab	94	94 (100.0)	1.66 (0.65)	0.4	1.18	1.56	2.04	3.3	
			Placebo	99	99 (100.0)	1.69 (0.59)	0.7	1.35	1.59	2.04	4.2	
		Week 2	Tezepelumab	94	91 (96.8)	1.78 (0.60)	0.6	1.36	1.69	2.21	3.3	
			Placebo	99	93 (93.9)	1.72 (0.61)	0.6	1.35	1.63	2.07	4.0	
		Week 4	Tezepelumab	94	94 (100.0)	1.80 (0.66)	0.7	1.28	1.66	2.39	3.3	
			Placebo	99	96 (97.0)	1.76 (0.60)	0.7	1.35	1.69	2.10	4.2	
		Week 8	Tezepelumab	94	92 (97.9)	1.80 (0.61)	0.6	1.35	1.68	2.24	3.3	
			Placebo	99	96 (97.0)	1.77 (0.61)	0.7	1.34	1.66	2.09	4.3	
		Week 12	Tezepelumab	94	91 (96.8)	1.80 (0.65)	0.6	1.37	1.70	2.23	3.6	
			Placebo	99	95 (96.0)	1.74 (0.62)	0.6	1.31	1.69	2.09	4.3	
		Week 16	Tezepelumab	94	92 (97.9)	1.85 (0.66)	0.6	1.38	1.71	2.29	3.5	
			Placebo	99	93 (93.9)	1.74 (0.61)	0.6	1.31	1.66	2.10	4.1	
		Week 24	Tezepelumab	94	90 (95.7)	1.76 (0.59)	0.6	1.24	1.71	2.28	3.3	
			Placebo	99	87 (87.9)	1.69 (0.62)	0.8	1.28	1.63	2.02	4.8	
		Week 36	Tezepelumab	94	86 (91.5)	1.77 (0.63)	0.5	1.25	1.65	2.16	3.3	
			Placebo	99	83 (83.8)	1.79 (0.63)	0.8	1.36	1.69	2.11	4.6	
		Week 52	Tezepelumab	94	87 (92.6)	1.80 (0.65)	0.7	1.35	1.69	2.27	3.3	
			Placebo	99	81 (81.8)	1.71 (0.61)	0.7	1.27	1.64	2.03	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q1: < 53.1 IU/ml	Change from baseline	Week 2	Tezepelumab	94	91 (96.8)	0.12 (0.28)	-0.7	-0.01	0.10	0.27	1.1	0.34 [0.05, 0.63]
			Placebo	99	93 (93.9)	0.03 (0.28)	-0.6	-0.09	-0.01	0.11	1.0	
		Week 4	Tezepelumab	94	94 (100.0)	0.14 (0.37)	-0.9	-0.06	0.10	0.30	1.6	0.19 [-0.09, 0.48]
			Placebo	99	96 (97.0)	0.08 (0.27)	-0.7	-0.07	0.06	0.21	1.1	
		Week 8	Tezepelumab	94	92 (97.9)	0.16 (0.37)	-0.8	-0.06	0.11	0.32	1.4	0.27 [-0.02, 0.56]
			Placebo	99	96 (97.0)	0.07 (0.28)	-0.8	-0.08	0.04	0.19	1.2	
		Week 12	Tezepelumab	94	91 (96.8)	0.15 (0.36)	-0.7	-0.05	0.11	0.31	2.0	0.26 [-0.03, 0.55]
			Placebo	99	95 (96.0)	0.07 (0.33)	-0.7	-0.10	0.01	0.19	1.2	
		Week 16	Tezepelumab	94	92 (97.9)	0.19 (0.34)	-0.6	0.01	0.15	0.32	1.7	0.44 [0.15, 0.74]
			Placebo	99	93 (93.9)	0.05 (0.29)	-0.6	-0.09	0.01	0.17	1.0	
		Week 24	Tezepelumab	94	90 (95.7)	0.15 (0.31)	-0.6	-0.06	0.13	0.34	1.2	0.43 [0.14, 0.73]
			Placebo	99	87 (87.9)	0.02 (0.29)	-0.8	-0.16	-0.01	0.13	1.1	
		Week 36	Tezepelumab	94	86 (91.5)	0.12 (0.34)	-0.7	-0.07	0.06	0.29	1.3	0.10 [-0.20, 0.40]
			Placebo	99	83 (83.8)	0.09 (0.30)	-0.4	-0.14	0.06	0.26	1.1	
		Week 52	Tezepelumab	94	87 (92.6)	0.14 (0.37)	-1.0	-0.07	0.09	0.35	1.5	0.39 [0.08, 0.69]
			Placebo	99	81 (81.8)	0.01 (0.31)	-0.7	-0.18	0.00	0.14	1.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q2: 53.1 - < 195.6 IU/ml	Absolute values	Baseline	Tezepelumab	101	101 (100.0)	1.74 (0.69)	0.8	1.24	1.54	2.10	4.0	
			Placebo	101	101 (100.0)	1.79 (0.63)	0.7	1.35	1.69	2.12	3.7	
		Week 2	Tezepelumab	101	101 (100.0)	1.90 (0.72)	0.9	1.31	1.78	2.41	4.1	
			Placebo	101	97 (96.0)	1.84 (0.65)	0.7	1.40	1.73	2.23	3.7	
		Week 4	Tezepelumab	101	99 (98.0)	1.96 (0.74)	0.9	1.39	1.81	2.51	4.2	
			Placebo	101	101 (100.0)	1.86 (0.58)	0.7	1.47	1.82	2.19	3.7	
		Week 8	Tezepelumab	101	99 (98.0)	1.95 (0.74)	0.8	1.32	1.76	2.56	4.1	
			Placebo	101	99 (98.0)	1.88 (0.64)	0.7	1.41	1.87	2.28	3.5	
		Week 12	Tezepelumab	101	98 (97.0)	2.01 (0.75)	1.0	1.46	1.84	2.50	4.6	
			Placebo	101	99 (98.0)	1.88 (0.64)	0.7	1.35	1.81	2.34	3.6	
		Week 16	Tezepelumab	101	96 (95.0)	2.01 (0.77)	0.8	1.33	1.87	2.54	4.2	
			Placebo	101	95 (94.1)	1.89 (0.64)	0.7	1.38	1.80	2.23	3.6	
		Week 24	Tezepelumab	101	95 (94.1)	2.02 (0.75)	0.8	1.44	1.96	2.52	4.0	
			Placebo	101	94 (93.1)	1.87 (0.58)	0.9	1.44	1.85	2.22	3.4	
		Week 36	Tezepelumab	101	93 (92.1)	2.05 (0.76)	1.0	1.42	1.90	2.53	4.4	
			Placebo	101	92 (91.1)	1.91 (0.66)	0.7	1.42	1.86	2.29	3.7	
		Week 52	Tezepelumab	101	87 (86.1)	2.05 (0.75)	0.8	1.43	1.91	2.67	4.2	
			Placebo	101	86 (85.1)	1.90 (0.67)	0.7	1.47	1.79	2.28	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q2: 53.1 - < 195.6 IU/ml	Change from baseline	Week 2	Tezepelumab	101	101 (100.0)	0.16 (0.32)	-0.6	0.01	0.12	0.26	1.4	0.46 [0.18, 0.74]
			Placebo	101	97 (96.0)	0.03 (0.27)	-1.0	-0.12	0.00	0.16	1.0	
		Week 4	Tezepelumab	101	99 (98.0)	0.22 (0.35)	-0.7	0.01	0.16	0.35	1.7	0.46 [0.18, 0.74]
			Placebo	101	101 (100.0)	0.06 (0.35)	-0.6	-0.11	0.02	0.20	1.2	
		Week 8	Tezepelumab	101	99 (98.0)	0.23 (0.36)	-0.4	0.02	0.13	0.39	1.2	0.47 [0.18, 0.75]
			Placebo	101	99 (98.0)	0.08 (0.29)	-0.5	-0.11	0.05	0.22	1.2	
		Week 12	Tezepelumab	101	98 (97.0)	0.27 (0.37)	-0.8	0.04	0.19	0.43	1.5	0.49 [0.21, 0.77]
			Placebo	101	99 (98.0)	0.08 (0.40)	-1.5	-0.14	0.07	0.33	1.3	
		Week 16	Tezepelumab	101	96 (95.0)	0.28 (0.41)	-0.8	0.02	0.23	0.47	1.6	0.51 [0.22, 0.80]
			Placebo	101	95 (94.1)	0.09 (0.36)	-1.2	-0.14	0.04	0.29	1.2	
		Week 24	Tezepelumab	101	95 (94.1)	0.29 (0.39)	-0.3	-0.01	0.23	0.48	1.7	0.56 [0.27, 0.85]
			Placebo	101	94 (93.1)	0.08 (0.35)	-0.8	-0.14	0.01	0.27	1.2	
		Week 36	Tezepelumab	101	93 (92.1)	0.29 (0.38)	-0.3	-0.02	0.30	0.52	1.6	0.49 [0.20, 0.78]
			Placebo	101	92 (91.1)	0.10 (0.39)	-1.1	-0.18	0.02	0.39	1.3	
		Week 52	Tezepelumab	101	87 (86.1)	0.29 (0.40)	-0.6	0.00	0.22	0.55	1.4	0.54 [0.23, 0.84]
			Placebo	101	86 (85.1)	0.10 (0.30)	-0.9	-0.09	0.07	0.27	0.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q3: 195.6 - < 572.4 IU/ml	Absolute values	Baseline	Tezepelumab	108	108 (100.0)	1.77 (0.69)	0.6	1.35	1.63	2.14	3.7	
			Placebo	87	87 (100.0)	1.93 (0.81)	0.6	1.30	1.74	2.43	4.5	
		Week 2	Tezepelumab	108	104 (96.3)	1.99 (0.73)	0.6	1.47	1.88	2.43	4.0	
			Placebo	87	81 (93.1)	1.91 (0.75)	0.7	1.35	1.75	2.38	3.9	
		Week 4	Tezepelumab	108	107 (99.1)	1.95 (0.72)	0.6	1.41	1.89	2.47	4.2	
			Placebo	87	82 (94.3)	1.92 (0.70)	0.7	1.41	1.84	2.33	3.6	
		Week 8	Tezepelumab	108	106 (98.1)	1.99 (0.71)	0.6	1.42	2.01	2.41	4.2	
			Placebo	87	85 (97.7)	1.97 (0.75)	0.7	1.41	1.94	2.37	4.1	
		Week 12	Tezepelumab	108	104 (96.3)	2.00 (0.73)	0.6	1.52	1.93	2.45	4.3	
			Placebo	87	83 (95.4)	1.99 (0.78)	0.7	1.45	1.79	2.44	4.1	
		Week 16	Tezepelumab	108	104 (96.3)	2.02 (0.71)	0.6	1.54	1.97	2.46	4.3	
			Placebo	87	85 (97.7)	1.94 (0.76)	0.8	1.35	1.75	2.39	4.3	
		Week 24	Tezepelumab	108	98 (90.7)	1.97 (0.65)	0.6	1.58	1.90	2.34	3.8	
			Placebo	87	80 (92.0)	1.99 (0.78)	0.6	1.46	1.89	2.44	4.3	
		Week 36	Tezepelumab	108	93 (86.1)	1.99 (0.71)	0.7	1.51	1.98	2.35	4.2	
			Placebo	87	75 (86.2)	2.01 (0.78)	0.8	1.48	1.83	2.47	4.2	
		Week 52	Tezepelumab	108	95 (88.0)	2.00 (0.72)	0.6	1.54	1.90	2.44	4.3	
			Placebo	87	72 (82.8)	2.01 (0.85)	0.7	1.40	1.84	2.45	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q3: 195.6 - < 572.4 IU/ml	Change from baseline	Week 2	Tezepelumab	108	104 (96.3)	0.23 (0.36)	-0.5	-0.03	0.19	0.36	1.5	0.70 [0.40, 1.00]
			Placebo	87	81 (93.1)	-0.05 (0.43)	-1.8	-0.17	-0.02	0.12	1.1	
		Week 4	Tezepelumab	108	107 (99.1)	0.19 (0.32)	-0.5	-0.02	0.15	0.34	1.3	0.51 [0.22, 0.80]
			Placebo	87	82 (94.3)	0.00 (0.44)	-1.8	-0.18	0.03	0.20	1.0	
		Week 8	Tezepelumab	108	106 (98.1)	0.25 (0.41)	-0.8	-0.04	0.21	0.50	1.4	0.58 [0.29, 0.87]
			Placebo	87	85 (97.7)	0.02 (0.34)	-0.9	-0.20	0.03	0.23	0.9	
		Week 12	Tezepelumab	108	104 (96.3)	0.26 (0.45)	-1.5	-0.04	0.19	0.56	1.4	0.49 [0.19, 0.78]
			Placebo	87	83 (95.4)	0.05 (0.38)	-1.2	-0.10	0.04	0.22	1.0	
		Week 16	Tezepelumab	108	104 (96.3)	0.26 (0.42)	-0.6	-0.04	0.17	0.49	1.9	0.63 [0.33, 0.92]
			Placebo	87	85 (97.7)	0.01 (0.35)	-1.0	-0.21	0.01	0.18	1.5	
		Week 24	Tezepelumab	108	98 (90.7)	0.22 (0.43)	-1.0	-0.04	0.22	0.43	1.3	0.43 [0.13, 0.72]
			Placebo	87	80 (92.0)	0.05 (0.39)	-1.1	-0.16	0.03	0.28	1.4	
		Week 36	Tezepelumab	108	93 (86.1)	0.25 (0.44)	-1.0	-0.03	0.15	0.54	1.5	0.51 [0.20, 0.82]
			Placebo	87	75 (86.2)	0.05 (0.35)	-0.9	-0.18	0.04	0.26	1.3	
		Week 52	Tezepelumab	108	95 (88.0)	0.28 (0.45)	-1.0	0.02	0.23	0.65	1.6	0.52 [0.21, 0.83]
			Placebo	87	72 (82.8)	0.06 (0.35)	-1.0	-0.13	0.04	0.23	1.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q4: >= 572.4 IU/ml	Absolute values	Baseline	Tezepelumab	92	92 (100.0)	1.92 (0.73)	0.8	1.43	1.80	2.23	4.1	
			Placebo	104	104 (100.0)	1.93 (0.78)	0.4	1.37	1.96	2.36	4.9	
		Week 2	Tezepelumab	92	88 (95.7)	2.14 (0.76)	0.9	1.55	1.99	2.58	4.3	
			Placebo	104	102 (98.1)	2.13 (0.80)	0.4	1.52	2.17	2.60	4.7	
		Week 4	Tezepelumab	92	91 (98.9)	2.17 (0.77)	0.9	1.58	2.09	2.69	4.3	
			Placebo	104	103 (99.0)	2.06 (0.83)	0.4	1.44	2.01	2.57	4.8	
		Week 8	Tezepelumab	92	91 (98.9)	2.19 (0.84)	0.8	1.52	2.08	2.66	4.7	
			Placebo	104	100 (96.2)	2.10 (0.89)	0.4	1.44	1.98	2.69	4.9	
		Week 12	Tezepelumab	92	89 (96.7)	2.16 (0.79)	0.8	1.62	2.01	2.46	4.7	
			Placebo	104	100 (96.2)	2.13 (0.85)	0.5	1.50	2.06	2.54	5.0	
		Week 16	Tezepelumab	92	88 (95.7)	2.19 (0.82)	0.9	1.66	2.07	2.56	4.9	
			Placebo	104	97 (93.3)	2.13 (0.87)	0.5	1.55	2.06	2.52	5.2	
		Week 24	Tezepelumab	92	86 (93.5)	2.17 (0.82)	0.9	1.66	2.01	2.62	4.4	
			Placebo	104	96 (92.3)	2.13 (0.88)	0.6	1.54	1.96	2.61	5.1	
		Week 36	Tezepelumab	92	84 (91.3)	2.19 (0.86)	0.6	1.57	2.10	2.58	4.5	
			Placebo	104	96 (92.3)	2.11 (0.91)	0.6	1.49	1.90	2.56	5.3	
		Week 52	Tezepelumab	92	80 (87.0)	2.17 (0.87)	0.8	1.62	2.06	2.54	4.2	
			Placebo	104	87 (83.7)	2.08 (0.91)	0.6	1.37	1.88	2.67	5.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q4: >= 572.4 IU/ml	Change from baseline	Week 2	Tezepelumab	92	88 (95.7)	0.22 (0.36)	-0.5	0.00	0.13	0.36	1.4	0.09 [-0.20, 0.37]
			Placebo	104	102 (98.1)	0.18 (0.42)	-1.3	-0.07	0.11	0.44	1.7	
		Week 4	Tezepelumab	92	91 (98.9)	0.26 (0.41)	-0.4	0.02	0.15	0.39	1.8	0.24 [-0.04, 0.52]
			Placebo	104	103 (99.0)	0.15 (0.48)	-1.0	-0.12	0.05	0.43	1.7	
		Week 8	Tezepelumab	92	91 (98.9)	0.29 (0.52)	-1.1	-0.04	0.16	0.50	1.8	0.25 [-0.04, 0.53]
			Placebo	104	100 (96.2)	0.16 (0.51)	-1.7	-0.12	0.09	0.41	2.0	
		Week 12	Tezepelumab	92	89 (96.7)	0.25 (0.48)	-0.6	-0.06	0.19	0.45	1.9	0.18 [-0.11, 0.46]
			Placebo	104	100 (96.2)	0.17 (0.47)	-1.2	-0.06	0.10	0.36	1.7	
		Week 16	Tezepelumab	92	88 (95.7)	0.29 (0.46)	-0.5	0.00	0.16	0.49	2.0	0.25 [-0.04, 0.54]
			Placebo	104	97 (93.3)	0.17 (0.49)	-1.6	-0.07	0.08	0.40	1.8	
		Week 24	Tezepelumab	92	86 (93.5)	0.28 (0.50)	-0.7	-0.07	0.19	0.52	1.8	0.27 [-0.02, 0.57]
			Placebo	104	96 (92.3)	0.14 (0.51)	-1.4	-0.11	0.09	0.34	1.7	
		Week 36	Tezepelumab	92	84 (91.3)	0.29 (0.48)	-0.8	-0.02	0.21	0.53	1.7	0.28 [-0.02, 0.57]
			Placebo	104	96 (92.3)	0.15 (0.57)	-1.7	-0.16	0.12	0.39	2.2	
		Week 52	Tezepelumab	92	80 (87.0)	0.28 (0.43)	-0.8	-0.01	0.20	0.48	1.7	0.35 [0.05, 0.66]
			Placebo	104	87 (83.7)	0.11 (0.50)	-1.4	-0.15	0.11	0.35	1.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Nasal polyps last 2 years												
Yes	Absolute values	Baseline	Tezepelumab	33	33 (100.0)	2.00 (0.79)	0.8	1.44	1.71	2.51	3.7	
			Placebo	31	31 (100.0)	1.89 (0.68)	0.6	1.44	1.68	2.27	3.4	
		Week 2	Tezepelumab	33	32 (97.0)	2.22 (0.81)	0.9	1.60	2.15	2.66	4.0	
			Placebo	31	31 (100.0)	1.97 (0.76)	0.9	1.36	1.96	2.54	4.1	
		Week 4	Tezepelumab	33	33 (100.0)	2.27 (0.84)	0.9	1.64	2.00	2.86	4.2	
			Placebo	31	31 (100.0)	2.03 (0.81)	0.9	1.42	2.00	2.55	4.8	
		Week 8	Tezepelumab	33	33 (100.0)	2.34 (0.82)	1.0	1.67	2.40	3.01	4.2	
			Placebo	31	31 (100.0)	2.05 (0.84)	0.7	1.51	1.89	2.75	4.6	
		Week 12	Tezepelumab	33	32 (97.0)	2.32 (0.92)	0.9	1.64	2.10	3.05	4.6	
			Placebo	31	31 (100.0)	2.06 (0.77)	1.0	1.44	1.99	2.52	4.6	
		Week 16	Tezepelumab	33	32 (97.0)	2.33 (0.87)	0.9	1.67	2.19	2.95	4.3	
			Placebo	31	30 (96.8)	2.04 (0.84)	0.7	1.55	1.84	2.53	4.7	
		Week 24	Tezepelumab	33	31 (93.9)	2.19 (0.73)	0.9	1.71	1.94	2.77	3.7	
			Placebo	31	30 (96.8)	2.03 (0.76)	0.9	1.60	1.94	2.48	4.8	
		Week 36	Tezepelumab	33	31 (93.9)	2.35 (0.86)	0.9	1.54	2.39	3.05	4.2	
			Placebo	31	28 (90.3)	2.03 (0.73)	0.8	1.54	1.86	2.35	4.3	
		Week 52	Tezepelumab	33	30 (90.9)	2.32 (0.92)	0.6	1.60	2.34	2.80	4.3	
			Placebo	31	28 (90.3)	1.92 (0.70)	0.9	1.35	1.89	2.35	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Nasal polyps last 2 years												
Yes	Change from baseline	Week 2	Tezepelumab	33	32 (97.0)	0.24 (0.33)	-0.3	0.07	0.17	0.42	1.0	0.47 [-0.03, 0.97]
			Placebo	31	31 (100.0)	0.08 (0.38)	-0.5	-0.15	-0.04	0.26	1.0	
		Week 4	Tezepelumab	33	33 (100.0)	0.27 (0.38)	-0.5	0.07	0.19	0.38	1.8	0.30 [-0.19, 0.80]
			Placebo	31	31 (100.0)	0.14 (0.48)	-0.7	-0.11	0.00	0.24	1.6	
		Week 8	Tezepelumab	33	33 (100.0)	0.35 (0.40)	-0.3	0.10	0.25	0.52	1.7	0.44 [-0.06, 0.94]
			Placebo	31	31 (100.0)	0.16 (0.45)	-0.5	-0.13	0.08	0.51	1.4	
		Week 12	Tezepelumab	33	32 (97.0)	0.30 (0.41)	-0.2	0.04	0.18	0.50	1.5	0.30 [-0.20, 0.80]
			Placebo	31	31 (100.0)	0.17 (0.42)	-0.5	-0.11	0.03	0.41	1.4	
		Week 16	Tezepelumab	33	32 (97.0)	0.32 (0.41)	-0.6	0.03	0.28	0.61	1.3	0.39 [-0.12, 0.89]
			Placebo	31	30 (96.8)	0.16 (0.45)	-0.6	-0.14	0.03	0.43	1.4	
		Week 24	Tezepelumab	33	31 (93.9)	0.24 (0.42)	-1.0	-0.05	0.29	0.43	1.3	0.14 [-0.36, 0.65]
			Placebo	31	30 (96.8)	0.18 (0.48)	-0.5	-0.17	0.09	0.53	1.6	
		Week 36	Tezepelumab	33	31 (93.9)	0.34 (0.41)	-0.3	0.02	0.37	0.56	1.4	0.30 [-0.21, 0.82]
			Placebo	31	28 (90.3)	0.22 (0.37)	-0.4	-0.02	0.15	0.51	1.1	
		Week 52	Tezepelumab	33	30 (90.9)	0.33 (0.41)	-0.8	0.02	0.39	0.58	1.1	0.71 [0.18, 1.24]
			Placebo	31	28 (90.3)	0.04 (0.42)	-0.7	-0.21	-0.06	0.26	1.1	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Nasal polyps last 2 years												
No	Absolute values	Baseline	Tezepelumab	362	362 (100.0)	1.75 (0.68)	0.4	1.26	1.63	2.13	4.1	
			Placebo	360	360 (100.0)	1.83 (0.71)	0.4	1.34	1.72	2.22	4.9	
		Week 2	Tezepelumab	362	352 (97.2)	1.93 (0.70)	0.6	1.39	1.80	2.42	4.3	
			Placebo	360	342 (95.0)	1.90 (0.72)	0.4	1.39	1.80	2.31	4.7	
		Week 4	Tezepelumab	362	358 (98.9)	1.94 (0.71)	0.6	1.39	1.84	2.45	4.3	
			Placebo	360	351 (97.5)	1.89 (0.68)	0.4	1.43	1.82	2.28	4.2	
		Week 8	Tezepelumab	362	355 (98.1)	1.95 (0.72)	0.6	1.38	1.84	2.41	4.7	
			Placebo	360	349 (96.9)	1.92 (0.73)	0.4	1.40	1.83	2.33	4.9	
		Week 12	Tezepelumab	362	350 (96.7)	1.96 (0.71)	0.6	1.47	1.88	2.41	4.7	
			Placebo	360	346 (96.1)	1.92 (0.74)	0.5	1.40	1.80	2.36	5.0	
		Week 16	Tezepelumab	362	348 (96.1)	1.99 (0.73)	0.6	1.46	1.87	2.43	4.9	
			Placebo	360	340 (94.4)	1.92 (0.73)	0.5	1.36	1.80	2.29	5.2	
		Week 24	Tezepelumab	362	338 (93.4)	1.96 (0.71)	0.6	1.45	1.83	2.41	4.4	
			Placebo	360	327 (90.8)	1.91 (0.74)	0.6	1.41	1.80	2.24	5.1	
		Week 36	Tezepelumab	362	325 (89.8)	1.96 (0.74)	0.5	1.42	1.86	2.39	4.5	
			Placebo	360	318 (88.3)	1.95 (0.77)	0.6	1.41	1.82	2.33	5.3	
		Week 52	Tezepelumab	362	319 (88.1)	1.97 (0.73)	0.7	1.46	1.85	2.40	4.2	
			Placebo	360	298 (82.8)	1.92 (0.79)	0.6	1.34	1.77	2.32	5.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Nasal polyps last 2 years												
No	Change from baseline	Week 2	Tezepelumab	362	352 (97.2)	0.18 (0.33)	-0.7	-0.01	0.13	0.32	1.5	0.36 [0.21, 0.51]
			Placebo	360	342 (95.0)	0.05 (0.36)	-1.8	-0.10	0.01	0.18	1.7	
		Week 4	Tezepelumab	362	358 (98.9)	0.20 (0.36)	-0.9	-0.02	0.13	0.33	1.7	0.33 [0.19, 0.48]
			Placebo	360	351 (97.5)	0.08 (0.39)	-1.8	-0.11	0.04	0.25	1.7	
		Week 8	Tezepelumab	362	355 (98.1)	0.22 (0.42)	-1.1	-0.04	0.15	0.42	1.8	0.36 [0.21, 0.51]
			Placebo	360	349 (96.9)	0.08 (0.36)	-1.7	-0.11	0.05	0.25	2.0	
		Week 12	Tezepelumab	362	350 (96.7)	0.23 (0.42)	-1.5	-0.03	0.17	0.43	2.0	0.35 [0.20, 0.50]
			Placebo	360	346 (96.1)	0.09 (0.40)	-1.5	-0.10	0.05	0.26	1.7	
		Week 16	Tezepelumab	362	348 (96.1)	0.25 (0.41)	-0.8	0.00	0.16	0.40	2.0	0.44 [0.29, 0.59]
			Placebo	360	340 (94.4)	0.07 (0.38)	-1.6	-0.11	0.03	0.23	1.8	
		Week 24	Tezepelumab	362	338 (93.4)	0.23 (0.41)	-1.0	-0.05	0.18	0.43	1.8	0.42 [0.27, 0.58]
			Placebo	360	327 (90.8)	0.06 (0.39)	-1.4	-0.13	0.03	0.24	1.7	
		Week 36	Tezepelumab	362	325 (89.8)	0.23 (0.42)	-1.0	-0.05	0.16	0.44	1.7	0.34 [0.18, 0.49]
			Placebo	360	318 (88.3)	0.09 (0.42)	-1.7	-0.16	0.04	0.29	2.2	
		Week 52	Tezepelumab	362	319 (88.1)	0.24 (0.42)	-1.0	-0.03	0.17	0.47	1.7	0.41 [0.25, 0.57]
			Placebo	360	298 (82.8)	0.07 (0.37)	-1.4	-0.14	0.06	0.23	1.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Age (cat. N)									0.097
< 18 years	Week 2	Tezepelumab	15	14 (93.3)	0.26 (0.12)	(0.02, 0.50)	0.12 (0.15)	(-0.20, 0.43)	0.446
		Placebo	20	20 (100.0)	0.14 (0.10)	(-0.06, 0.35)			
	Week 4	Tezepelumab	15	14 (93.3)	0.16 (0.12)	(-0.09, 0.41)	-0.02 (0.16)	(-0.35, 0.31)	0.895
		Placebo	20	19 (95.0)	0.18 (0.11)	(-0.03, 0.40)			
	Week 8	Tezepelumab	15	14 (93.3)	0.08 (0.17)	(-0.27, 0.43)	-0.03 (0.23)	(-0.50, 0.43)	0.880
		Placebo	20	19 (95.0)	0.11 (0.15)	(-0.19, 0.41)			
	Week 12	Tezepelumab	15	13 (86.7)	0.08 (0.17)	(-0.27, 0.42)	-0.10 (0.22)	(-0.55, 0.34)	0.636
		Placebo	20	20 (100.0)	0.18 (0.14)	(-0.11, 0.47)			
	Week 16	Tezepelumab	15	13 (86.7)	0.23 (0.14)	(-0.05, 0.51)	0.07 (0.18)	(-0.30, 0.44)	0.692
		Placebo	20	20 (100.0)	0.16 (0.12)	(-0.08, 0.40)			
	Week 24	Tezepelumab	15	13 (86.7)	0.21 (0.15)	(-0.11, 0.52)	-0.03 (0.20)	(-0.45, 0.38)	0.871
		Placebo	20	18 (90.0)	0.24 (0.13)	(-0.03, 0.51)			
	Week 36	Tezepelumab	15	13 (86.7)	0.44 (0.17)	(0.08, 0.79)	0.17 (0.23)	(-0.29, 0.63)	0.464
		Placebo	20	18 (90.0)	0.27 (0.15)	(-0.03, 0.57)			
	Week 52	Tezepelumab	15	12 (80.0)	0.41 (0.16)	(0.09, 0.73)	0.20 (0.21)	(-0.22, 0.62)	0.339
		Placebo	20	18 (90.0)	0.21 (0.13)	(-0.06, 0.48)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
18 - < 65 years	Week 2	Tezepelumab	304	296 (97.4)	0.20 (0.02)	(0.16, 0.24)	0.15 (0.03)	(0.10, 0.21)	<0.001 *
		Placebo	318	303 (95.3)	0.05 (0.02)	(0.01, 0.08)			
	Week 4	Tezepelumab	304	303 (99.7)	0.23 (0.02)	(0.19, 0.27)	0.16 (0.03)	(0.10, 0.22)	<0.001 *
		Placebo	318	313 (98.4)	0.07 (0.02)	(0.03, 0.11)			
	Week 8	Tezepelumab	304	300 (98.7)	0.26 (0.02)	(0.22, 0.30)	0.18 (0.03)	(0.11, 0.24)	<0.001 *
		Placebo	318	311 (97.8)	0.09 (0.02)	(0.04, 0.13)			
	Week 12	Tezepelumab	304	296 (97.4)	0.26 (0.02)	(0.21, 0.30)	0.16 (0.03)	(0.10, 0.22)	<0.001 *
		Placebo	318	307 (96.5)	0.10 (0.02)	(0.05, 0.14)			
	Week 16	Tezepelumab	304	294 (96.7)	0.28 (0.02)	(0.23, 0.32)	0.20 (0.03)	(0.13, 0.26)	<0.001 *
		Placebo	318	301 (94.7)	0.08 (0.02)	(0.04, 0.13)			
	Week 24	Tezepelumab	304	286 (94.1)	0.25 (0.02)	(0.21, 0.30)	0.18 (0.03)	(0.11, 0.24)	<0.001 *
		Placebo	318	291 (91.5)	0.07 (0.02)	(0.03, 0.12)			
	Week 36	Tezepelumab	304	275 (90.5)	0.26 (0.02)	(0.21, 0.31)	0.16 (0.03)	(0.09, 0.23)	<0.001 *
		Placebo	318	280 (88.1)	0.10 (0.02)	(0.05, 0.15)			
	Week 52	Tezepelumab	304	270 (88.8)	0.27 (0.02)	(0.22, 0.31)	0.19 (0.03)	(0.12, 0.25)	<0.001 *
		Placebo	318	263 (82.7)	0.08 (0.02)	(0.03, 0.12)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 65 years	Week 2	Tezepelumab	76	74 (97.4)	0.09 (0.02)	(0.04, 0.14)	0.03 (0.04)	(-0.05, 0.10)	0.447
		Placebo	53	50 (94.3)	0.06 (0.03)	(0.00, 0.12)			
	Week 4	Tezepelumab	76	74 (97.4)	0.11 (0.03)	(0.05, 0.16)	0.01 (0.04)	(-0.08, 0.10)	0.802
		Placebo	53	50 (94.3)	0.10 (0.03)	(0.03, 0.16)			
	Week 8	Tezepelumab	76	74 (97.4)	0.14 (0.03)	(0.08, 0.20)	0.05 (0.05)	(-0.05, 0.15)	0.331
		Placebo	53	50 (94.3)	0.09 (0.04)	(0.02, 0.17)			
	Week 12	Tezepelumab	76	73 (96.1)	0.16 (0.03)	(0.10, 0.22)	0.11 (0.05)	(0.01, 0.21)	0.032 *
		Placebo	53	50 (94.3)	0.05 (0.04)	(-0.02, 0.13)			
	Week 16	Tezepelumab	76	73 (96.1)	0.16 (0.03)	(0.10, 0.22)	0.09 (0.05)	(-0.00, 0.19)	0.061
		Placebo	53	49 (92.5)	0.07 (0.04)	(-0.01, 0.14)			
	Week 24	Tezepelumab	76	70 (92.1)	0.14 (0.03)	(0.08, 0.20)	0.08 (0.05)	(-0.02, 0.18)	0.105
		Placebo	53	48 (90.6)	0.06 (0.04)	(-0.02, 0.13)			
	Week 36	Tezepelumab	76	68 (89.5)	0.14 (0.03)	(0.08, 0.20)	0.10 (0.05)	(0.00, 0.19)	0.045 *
		Placebo	53	48 (90.6)	0.04 (0.04)	(-0.03, 0.12)			
	Week 52	Tezepelumab	76	67 (88.2)	0.15 (0.03)	(0.08, 0.22)	0.12 (0.05)	(0.02, 0.23)	0.024 *
		Placebo	53	45 (84.9)	0.03 (0.04)	(-0.06, 0.11)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Region (cat. N)									0.087
Western Europe	Week 2	Tezepelumab	72	71 (98.6)	0.18 (0.03)	(0.11, 0.25)	0.15 (0.05)	(0.06, 0.25)	0.002 *
		Placebo	72	67 (93.1)	0.03 (0.04)	(-0.04, 0.10)			
	Week 4	Tezepelumab	72	72 (100.0)	0.20 (0.04)	(0.12, 0.28)	0.17 (0.06)	(0.06, 0.28)	0.002 *
		Placebo	72	70 (97.2)	0.03 (0.04)	(-0.05, 0.11)			
	Week 8	Tezepelumab	72	72 (100.0)	0.22 (0.05)	(0.13, 0.31)	0.14 (0.07)	(0.01, 0.27)	0.032 *
		Placebo	72	67 (93.1)	0.08 (0.05)	(-0.01, 0.17)			
	Week 12	Tezepelumab	72	69 (95.8)	0.19 (0.05)	(0.10, 0.28)	0.14 (0.06)	(0.01, 0.27)	0.029 *
		Placebo	72	66 (91.7)	0.05 (0.05)	(-0.04, 0.14)			
	Week 16	Tezepelumab	72	69 (95.8)	0.27 (0.05)	(0.18, 0.36)	0.27 (0.07)	(0.14, 0.39)	<0.001 *
		Placebo	72	66 (91.7)	0.00 (0.05)	(-0.09, 0.10)			
	Week 24	Tezepelumab	72	68 (94.4)	0.20 (0.04)	(0.12, 0.28)	0.20 (0.06)	(0.08, 0.32)	<0.001 *
		Placebo	72	61 (84.7)	-0.00 (0.04)	(-0.09, 0.08)			
	Week 36	Tezepelumab	72	65 (90.3)	0.21 (0.04)	(0.13, 0.30)	0.13 (0.06)	(0.00, 0.25)	0.045 *
		Placebo	72	57 (79.2)	0.09 (0.05)	(-0.00, 0.18)			
	Week 52	Tezepelumab	72	63 (87.5)	0.21 (0.04)	(0.13, 0.29)	0.12 (0.06)	(0.00, 0.23)	0.048 *
		Placebo	72	55 (76.4)	0.09 (0.04)	(0.01, 0.18)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
North America	Week 2	Tezepelumab	77	71 (92.2)	0.28 (0.04)	(0.19, 0.36)	0.20 (0.06)	(0.08, 0.32)	0.001 *
		Placebo	77	73 (94.8)	0.07 (0.04)	(-0.01, 0.16)			
	Week 4	Tezepelumab	77	74 (96.1)	0.26 (0.04)	(0.18, 0.34)	0.16 (0.06)	(0.05, 0.27)	0.004 *
		Placebo	77	76 (98.7)	0.10 (0.04)	(0.02, 0.17)			
	Week 8	Tezepelumab	77	74 (96.1)	0.29 (0.04)	(0.20, 0.38)	0.21 (0.06)	(0.09, 0.34)	<0.001 *
		Placebo	77	75 (97.4)	0.08 (0.04)	(-0.01, 0.17)			
	Week 12	Tezepelumab	77	72 (93.5)	0.30 (0.05)	(0.20, 0.39)	0.22 (0.07)	(0.08, 0.35)	0.002 *
		Placebo	77	75 (97.4)	0.08 (0.05)	(-0.01, 0.17)			
	Week 16	Tezepelumab	77	72 (93.5)	0.29 (0.04)	(0.21, 0.37)	0.19 (0.06)	(0.07, 0.31)	0.002 *
		Placebo	77	74 (96.1)	0.10 (0.04)	(0.02, 0.18)			
	Week 24	Tezepelumab	77	66 (85.7)	0.27 (0.04)	(0.19, 0.36)	0.20 (0.06)	(0.08, 0.33)	0.002 *
		Placebo	77	71 (92.2)	0.07 (0.04)	(-0.01, 0.16)			
	Week 36	Tezepelumab	77	62 (80.5)	0.31 (0.05)	(0.22, 0.40)	0.19 (0.06)	(0.06, 0.32)	0.004 *
		Placebo	77	71 (92.2)	0.12 (0.04)	(0.03, 0.21)			
	Week 52	Tezepelumab	77	59 (76.6)	0.31 (0.05)	(0.21, 0.41)	0.21 (0.07)	(0.07, 0.35)	0.003 *
		Placebo	77	57 (74.0)	0.10 (0.05)	(0.00, 0.20)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
South America	Week 2	Tezepelumab	74	74 (100.0)	0.10 (0.05)	(0.01, 0.19)	0.01 (0.06)	(-0.12, 0.14)	0.840
		Placebo	75	73 (97.3)	0.09 (0.05)	(-0.00, 0.18)			
	Week 4	Tezepelumab	74	73 (98.6)	0.11 (0.05)	(0.01, 0.21)	-0.01 (0.07)	(-0.15, 0.13)	0.858
		Placebo	75	70 (93.3)	0.12 (0.05)	(0.03, 0.22)			
	Week 8	Tezepelumab	74	73 (98.6)	0.11 (0.05)	(0.01, 0.21)	-0.05 (0.07)	(-0.20, 0.09)	0.463
		Placebo	75	72 (96.0)	0.16 (0.05)	(0.06, 0.26)			
	Week 12	Tezepelumab	74	71 (95.9)	0.10 (0.05)	(-0.00, 0.21)	-0.05 (0.08)	(-0.20, 0.10)	0.480
		Placebo	75	74 (98.7)	0.16 (0.05)	(0.05, 0.26)			
	Week 16	Tezepelumab	74	71 (95.9)	0.14 (0.05)	(0.04, 0.24)	-0.01 (0.07)	(-0.16, 0.13)	0.847
		Placebo	75	72 (96.0)	0.16 (0.05)	(0.05, 0.26)			
	Week 24	Tezepelumab	74	70 (94.6)	0.14 (0.05)	(0.03, 0.25)	-0.02 (0.08)	(-0.17, 0.14)	0.836
		Placebo	75	70 (93.3)	0.16 (0.05)	(0.05, 0.26)			
	Week 36	Tezepelumab	74	70 (94.6)	0.16 (0.06)	(0.04, 0.27)	-0.03 (0.08)	(-0.19, 0.13)	0.707
		Placebo	75	73 (97.3)	0.19 (0.06)	(0.07, 0.30)			
	Week 52	Tezepelumab	74	69 (93.2)	0.18 (0.05)	(0.07, 0.29)	0.02 (0.08)	(-0.14, 0.17)	0.846
		Placebo	75	71 (94.7)	0.16 (0.05)	(0.05, 0.27)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Central/Eastern Europe	Week 2	Tezepelumab	20	19 (95.0)	0.15 (0.06)	(0.02, 0.28)	0.11 (0.09)	(-0.08, 0.30)	0.254
		Placebo	18	16 (88.9)	0.04 (0.07)	(-0.09, 0.18)			
	Week 4	Tezepelumab	20	20 (100.0)	0.24 (0.09)	(0.07, 0.42)	0.15 (0.13)	(-0.11, 0.40)	0.260
		Placebo	18	18 (100.0)	0.09 (0.09)	(-0.09, 0.28)			
	Week 8	Tezepelumab	20	20 (100.0)	0.23 (0.08)	(0.08, 0.38)	0.12 (0.11)	(-0.11, 0.35)	0.299
		Placebo	18	18 (100.0)	0.11 (0.08)	(-0.05, 0.28)			
	Week 12	Tezepelumab	20	20 (100.0)	0.26 (0.08)	(0.11, 0.41)	0.10 (0.11)	(-0.13, 0.33)	0.380
		Placebo	18	17 (94.4)	0.16 (0.08)	(-0.00, 0.33)			
	Week 16	Tezepelumab	20	20 (100.0)	0.27 (0.08)	(0.10, 0.44)	0.16 (0.12)	(-0.09, 0.41)	0.195
		Placebo	18	18 (100.0)	0.11 (0.09)	(-0.07, 0.29)			
	Week 24	Tezepelumab	20	19 (95.0)	0.16 (0.09)	(-0.01, 0.34)	-0.00 (0.13)	(-0.26, 0.25)	0.976
		Placebo	18	18 (100.0)	0.17 (0.09)	(-0.02, 0.35)			
	Week 36	Tezepelumab	20	20 (100.0)	0.24 (0.08)	(0.09, 0.40)	0.14 (0.11)	(-0.09, 0.37)	0.222
		Placebo	18	17 (94.4)	0.10 (0.08)	(-0.06, 0.27)			
	Week 52	Tezepelumab	20	20 (100.0)	0.23 (0.07)	(0.08, 0.37)	0.11 (0.11)	(-0.11, 0.32)	0.316
		Placebo	18	18 (100.0)	0.12 (0.08)	(-0.03, 0.27)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Asia Pacific	Week 2	Tezepelumab	98	98 (100.0)	0.18 (0.03)	(0.11, 0.25)	0.12 (0.05)	(0.03, 0.22)	0.011 *
		Placebo	94	92 (97.9)	0.05 (0.04)	(-0.01, 0.12)			
	Week 4	Tezepelumab	98	98 (100.0)	0.23 (0.04)	(0.15, 0.30)	0.17 (0.05)	(0.07, 0.27)	0.001 *
		Placebo	94	94 (100.0)	0.06 (0.04)	(-0.01, 0.13)			
	Week 8	Tezepelumab	98	96 (98.0)	0.27 (0.04)	(0.20, 0.35)	0.21 (0.06)	(0.10, 0.32)	<0.001 *
		Placebo	94	94 (100.0)	0.07 (0.04)	(-0.01, 0.14)			
	Week 12	Tezepelumab	98	96 (98.0)	0.30 (0.04)	(0.22, 0.38)	0.21 (0.06)	(0.10, 0.33)	<0.001 *
		Placebo	94	93 (98.9)	0.08 (0.04)	(0.00, 0.17)			
	Week 16	Tezepelumab	98	97 (99.0)	0.31 (0.04)	(0.23, 0.39)	0.23 (0.06)	(0.11, 0.34)	<0.001 *
		Placebo	94	91 (96.8)	0.08 (0.04)	(0.00, 0.16)			
	Week 24	Tezepelumab	98	96 (98.0)	0.27 (0.04)	(0.19, 0.35)	0.19 (0.06)	(0.08, 0.31)	<0.001 *
		Placebo	94	89 (94.7)	0.08 (0.04)	(-0.00, 0.16)			
	Week 36	Tezepelumab	98	92 (93.9)	0.28 (0.04)	(0.20, 0.37)	0.23 (0.06)	(0.11, 0.36)	<0.001 *
		Placebo	94	86 (91.5)	0.05 (0.04)	(-0.04, 0.13)			
	Week 52	Tezepelumab	98	92 (93.9)	0.30 (0.04)	(0.21, 0.38)	0.26 (0.06)	(0.14, 0.38)	<0.001 *
		Placebo	94	86 (91.5)	0.04 (0.04)	(-0.05, 0.12)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Rest of the world	Week 2	Tezepelumab	54	51 (94.4)	0.15 (0.04)	(0.07, 0.23)	0.12 (0.06)	(0.00, 0.24)	0.043 *
		Placebo	55	52 (94.5)	0.03 (0.04)	(-0.05, 0.11)			
	Week 4	Tezepelumab	54	54 (100.0)	0.18 (0.05)	(0.07, 0.28)	0.05 (0.07)	(-0.09, 0.20)	0.474
		Placebo	55	54 (98.2)	0.13 (0.05)	(0.02, 0.23)			
	Week 8	Tezepelumab	54	53 (98.1)	0.22 (0.04)	(0.13, 0.31)	0.15 (0.06)	(0.03, 0.27)	0.018 *
		Placebo	55	54 (98.2)	0.07 (0.04)	(-0.01, 0.16)			
	Week 12	Tezepelumab	54	54 (100.0)	0.22 (0.05)	(0.13, 0.31)	0.11 (0.07)	(-0.02, 0.24)	0.097
		Placebo	55	52 (94.5)	0.11 (0.05)	(0.02, 0.21)			
	Week 16	Tezepelumab	54	51 (94.4)	0.20 (0.05)	(0.11, 0.30)	0.13 (0.07)	(-0.01, 0.26)	0.065
		Placebo	55	49 (89.1)	0.08 (0.05)	(-0.02, 0.17)			
	Week 24	Tezepelumab	54	50 (92.6)	0.24 (0.05)	(0.14, 0.35)	0.17 (0.07)	(0.03, 0.31)	0.022 *
		Placebo	55	48 (87.3)	0.07 (0.05)	(-0.03, 0.18)			
	Week 36	Tezepelumab	54	47 (87.0)	0.22 (0.05)	(0.12, 0.33)	0.14 (0.07)	(-0.01, 0.29)	0.063
		Placebo	55	42 (76.4)	0.08 (0.05)	(-0.02, 0.19)			
	Week 52	Tezepelumab	54	46 (85.2)	0.23 (0.05)	(0.14, 0.33)	0.22 (0.07)	(0.08, 0.36)	0.002 *
		Placebo	55	39 (70.9)	0.01 (0.05)	(-0.09, 0.11)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline eosinophils (cat. N)									0.164
< 150 cells/uL	Week 2	Tezepelumab	96	94 (97.9)	0.08 (0.03)	(0.01, 0.14)	0.07 (0.05)	(-0.02, 0.16)	0.122
		Placebo	89	84 (94.4)	0.00 (0.03)	(-0.06, 0.07)			
	Week 4	Tezepelumab	96	95 (99.0)	0.09 (0.04)	(0.02, 0.16)	0.07 (0.05)	(-0.03, 0.17)	0.168
		Placebo	89	87 (97.8)	0.02 (0.04)	(-0.05, 0.09)			
	Week 8	Tezepelumab	96	93 (96.9)	0.10 (0.03)	(0.03, 0.17)	0.05 (0.05)	(-0.04, 0.15)	0.266
		Placebo	89	86 (96.6)	0.05 (0.04)	(-0.02, 0.12)			
	Week 12	Tezepelumab	96	92 (95.8)	0.09 (0.03)	(0.02, 0.15)	0.06 (0.05)	(-0.04, 0.16)	0.214
		Placebo	89	84 (94.4)	0.02 (0.04)	(-0.05, 0.09)			
	Week 16	Tezepelumab	96	93 (96.9)	0.13 (0.04)	(0.05, 0.21)	0.14 (0.06)	(0.03, 0.25)	0.012 *
		Placebo	89	84 (94.4)	-0.01 (0.04)	(-0.09, 0.07)			
	Week 24	Tezepelumab	96	86 (89.6)	0.09 (0.03)	(0.02, 0.15)	0.06 (0.05)	(-0.03, 0.15)	0.207
		Placebo	89	81 (91.0)	0.03 (0.03)	(-0.04, 0.09)			
	Week 36	Tezepelumab	96	87 (90.6)	0.07 (0.03)	(0.00, 0.14)	0.03 (0.05)	(-0.07, 0.12)	0.575
		Placebo	89	78 (87.6)	0.04 (0.04)	(-0.03, 0.11)			
	Week 52	Tezepelumab	96	86 (89.6)	0.11 (0.04)	(0.03, 0.18)	0.12 (0.05)	(0.01, 0.22)	0.033 *
		Placebo	89	77 (86.5)	-0.01 (0.04)	(-0.09, 0.07)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
150 - < 300 cells/uL	Week 2	Tezepelumab	129	126 (97.7)	0.15 (0.03)	(0.10, 0.20)	0.12 (0.04)	(0.05, 0.20)	0.002 *
		Placebo	122	118 (96.7)	0.03 (0.03)	(-0.02, 0.08)			
	Week 4	Tezepelumab	129	128 (99.2)	0.16 (0.03)	(0.11, 0.22)	0.12 (0.04)	(0.04, 0.20)	0.005 *
		Placebo	122	118 (96.7)	0.04 (0.03)	(-0.02, 0.10)			
	Week 8	Tezepelumab	129	128 (99.2)	0.17 (0.03)	(0.11, 0.23)	0.08 (0.04)	(0.00, 0.16)	0.048 *
		Placebo	122	117 (95.9)	0.09 (0.03)	(0.03, 0.15)			
	Week 12	Tezepelumab	129	125 (96.9)	0.15 (0.03)	(0.09, 0.22)	0.09 (0.05)	(-0.00, 0.18)	0.053
		Placebo	122	117 (95.9)	0.06 (0.03)	(-0.00, 0.13)			
	Week 16	Tezepelumab	129	126 (97.7)	0.17 (0.03)	(0.11, 0.23)	0.09 (0.04)	(0.00, 0.17)	0.048 *
		Placebo	122	115 (94.3)	0.08 (0.03)	(0.02, 0.14)			
	Week 24	Tezepelumab	129	125 (96.9)	0.13 (0.03)	(0.07, 0.20)	0.11 (0.05)	(0.02, 0.20)	0.015 *
		Placebo	122	111 (91.0)	0.02 (0.03)	(-0.04, 0.09)			
	Week 36	Tezepelumab	129	118 (91.5)	0.15 (0.03)	(0.08, 0.22)	0.11 (0.05)	(0.02, 0.21)	0.021 *
		Placebo	122	108 (88.5)	0.04 (0.04)	(-0.03, 0.11)			
	Week 52	Tezepelumab	129	120 (93.0)	0.17 (0.03)	(0.11, 0.23)	0.11 (0.05)	(0.02, 0.20)	0.022 *
		Placebo	122	99 (81.1)	0.06 (0.03)	(-0.00, 0.13)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
300 - < 450 cells/uL	Week 2	Tezepelumab	70	67 (95.7)	0.21 (0.04)	(0.12, 0.29)	0.14 (0.06)	(0.02, 0.26)	0.019 *
		Placebo	75	70 (93.3)	0.07 (0.04)	(-0.02, 0.15)			
	Week 4	Tezepelumab	70	68 (97.1)	0.21 (0.05)	(0.12, 0.30)	0.12 (0.06)	(-0.00, 0.25)	0.054
		Placebo	75	74 (98.7)	0.09 (0.04)	(0.01, 0.18)			
	Week 8	Tezepelumab	70	69 (98.6)	0.29 (0.05)	(0.20, 0.39)	0.19 (0.07)	(0.05, 0.32)	0.006 *
		Placebo	75	74 (98.7)	0.10 (0.05)	(0.01, 0.20)			
	Week 12	Tezepelumab	70	66 (94.3)	0.32 (0.05)	(0.22, 0.42)	0.25 (0.07)	(0.12, 0.39)	<0.001 *
		Placebo	75	71 (94.7)	0.07 (0.05)	(-0.03, 0.16)			
	Week 16	Tezepelumab	70	66 (94.3)	0.29 (0.05)	(0.20, 0.39)	0.21 (0.07)	(0.08, 0.34)	0.002 *
		Placebo	75	70 (93.3)	0.08 (0.05)	(-0.01, 0.18)			
	Week 24	Tezepelumab	70	66 (94.3)	0.30 (0.05)	(0.21, 0.39)	0.20 (0.06)	(0.07, 0.32)	0.002 *
		Placebo	75	69 (92.0)	0.11 (0.04)	(0.02, 0.19)			
	Week 36	Tezepelumab	70	60 (85.7)	0.34 (0.05)	(0.23, 0.44)	0.25 (0.07)	(0.11, 0.39)	<0.001 *
		Placebo	75	66 (88.0)	0.09 (0.05)	(-0.01, 0.19)			
	Week 52	Tezepelumab	70	60 (85.7)	0.29 (0.05)	(0.20, 0.39)	0.22 (0.07)	(0.08, 0.35)	0.002 *
		Placebo	75	66 (88.0)	0.08 (0.05)	(-0.02, 0.17)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 450 cells/uL	Week 2	Tezepelumab	100	97 (97.0)	0.29 (0.04)	(0.22, 0.37)	0.17 (0.05)	(0.06, 0.27)	0.002 *
		Placebo	105	101 (96.2)	0.12 (0.04)	(0.05, 0.20)			
	Week 4	Tezepelumab	100	100 (100.0)	0.35 (0.04)	(0.27, 0.43)	0.17 (0.06)	(0.06, 0.28)	0.003 *
		Placebo	105	103 (98.1)	0.18 (0.04)	(0.10, 0.26)			
	Week 8	Tezepelumab	100	98 (98.0)	0.38 (0.05)	(0.29, 0.47)	0.26 (0.06)	(0.13, 0.38)	<0.001 *
		Placebo	105	103 (98.1)	0.12 (0.04)	(0.04, 0.21)			
	Week 12	Tezepelumab	100	99 (99.0)	0.41 (0.04)	(0.32, 0.50)	0.19 (0.06)	(0.06, 0.31)	0.003 *
		Placebo	105	105 (100.0)	0.22 (0.04)	(0.14, 0.31)			
	Week 16	Tezepelumab	100	95 (95.0)	0.44 (0.04)	(0.36, 0.53)	0.27 (0.06)	(0.16, 0.39)	<0.001 *
		Placebo	105	101 (96.2)	0.17 (0.04)	(0.09, 0.25)			
	Week 24	Tezepelumab	100	92 (92.0)	0.43 (0.05)	(0.33, 0.52)	0.24 (0.07)	(0.11, 0.37)	<0.001 *
		Placebo	105	96 (91.4)	0.19 (0.05)	(0.09, 0.28)			
	Week 36	Tezepelumab	100	91 (91.0)	0.46 (0.05)	(0.36, 0.55)	0.21 (0.06)	(0.09, 0.34)	0.001 *
		Placebo	105	94 (89.5)	0.24 (0.05)	(0.15, 0.33)			
	Week 52	Tezepelumab	100	83 (83.0)	0.46 (0.05)	(0.37, 0.55)	0.27 (0.06)	(0.15, 0.40)	<0.001 *
		Placebo	105	84 (80.0)	0.19 (0.05)	(0.10, 0.28)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline eosinophils (cat. Q)									0.183
Q1: < 140 cells/uL	Week 2	Tezepelumab	89	87 (97.8)	0.09 (0.03)	(0.03, 0.15)	0.08 (0.04)	(-0.01, 0.16)	0.087
		Placebo	81	76 (93.8)	0.01 (0.03)	(-0.05, 0.08)			
	Week 4	Tezepelumab	89	88 (98.9)	0.10 (0.04)	(0.03, 0.17)	0.07 (0.05)	(-0.03, 0.18)	0.187
		Placebo	81	79 (97.5)	0.03 (0.04)	(-0.04, 0.11)			
	Week 8	Tezepelumab	89	87 (97.8)	0.11 (0.04)	(0.04, 0.18)	0.07 (0.05)	(-0.03, 0.18)	0.146
		Placebo	81	78 (96.3)	0.03 (0.04)	(-0.04, 0.11)			
	Week 12	Tezepelumab	89	85 (95.5)	0.10 (0.04)	(0.03, 0.16)	0.06 (0.05)	(-0.04, 0.17)	0.206
		Placebo	81	77 (95.1)	0.03 (0.04)	(-0.04, 0.10)			
	Week 16	Tezepelumab	89	86 (96.6)	0.15 (0.04)	(0.07, 0.23)	0.17 (0.06)	(0.05, 0.28)	0.006 *
		Placebo	81	76 (93.8)	-0.02 (0.04)	(-0.10, 0.07)			
	Week 24	Tezepelumab	89	80 (89.9)	0.09 (0.03)	(0.03, 0.16)	0.06 (0.05)	(-0.04, 0.15)	0.229
		Placebo	81	74 (91.4)	0.04 (0.03)	(-0.03, 0.11)			
	Week 36	Tezepelumab	89	81 (91.0)	0.09 (0.04)	(0.02, 0.16)	0.03 (0.05)	(-0.07, 0.13)	0.537
		Placebo	81	71 (87.7)	0.05 (0.04)	(-0.02, 0.13)			
	Week 52	Tezepelumab	89	80 (89.9)	0.12 (0.04)	(0.04, 0.20)	0.14 (0.06)	(0.03, 0.25)	0.015 *
		Placebo	81	70 (86.4)	-0.02 (0.04)	(-0.10, 0.06)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q2: 140 - < 250 cells/uL	Week 2	Tezepelumab	99	96 (97.0)	0.12 (0.03)	(0.06, 0.19)	0.14 (0.05)	(0.05, 0.23)	0.003 *
		Placebo	94	91 (96.8)	-0.02 (0.03)	(-0.08, 0.05)			
	Week 4	Tezepelumab	99	99 (100.0)	0.12 (0.03)	(0.06, 0.18)	0.11 (0.05)	(0.02, 0.20)	0.018 *
		Placebo	94	90 (95.7)	0.01 (0.03)	(-0.05, 0.08)			
	Week 8	Tezepelumab	99	98 (99.0)	0.13 (0.03)	(0.07, 0.19)	0.05 (0.04)	(-0.04, 0.14)	0.256
		Placebo	94	93 (98.9)	0.08 (0.03)	(0.01, 0.14)			
	Week 12	Tezepelumab	99	97 (98.0)	0.10 (0.04)	(0.03, 0.17)	0.08 (0.05)	(-0.02, 0.18)	0.131
		Placebo	94	90 (95.7)	0.02 (0.04)	(-0.05, 0.09)			
	Week 16	Tezepelumab	99	97 (98.0)	0.13 (0.03)	(0.07, 0.19)	0.07 (0.04)	(-0.01, 0.16)	0.094
		Placebo	94	90 (95.7)	0.06 (0.03)	(-0.00, 0.12)			
	Week 24	Tezepelumab	99	96 (97.0)	0.09 (0.03)	(0.03, 0.16)	0.09 (0.05)	(-0.00, 0.19)	0.060
		Placebo	94	86 (91.5)	-0.00 (0.04)	(-0.07, 0.07)			
	Week 36	Tezepelumab	99	92 (92.9)	0.08 (0.04)	(0.01, 0.16)	0.08 (0.05)	(-0.03, 0.18)	0.153
		Placebo	94	83 (88.3)	0.01 (0.04)	(-0.07, 0.08)			
	Week 52	Tezepelumab	99	93 (93.9)	0.10 (0.03)	(0.03, 0.17)	0.03 (0.05)	(-0.07, 0.13)	0.501
		Placebo	94	77 (81.9)	0.06 (0.04)	(-0.01, 0.14)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q3: 250 - < 430 cells/uL	Week 2	Tezepelumab	103	101 (98.1)	0.21 (0.03)	(0.14, 0.28)	0.12 (0.05)	(0.02, 0.21)	0.019 *
		Placebo	103	98 (95.1)	0.09 (0.03)	(0.02, 0.16)			
	Week 4	Tezepelumab	103	100 (97.1)	0.23 (0.04)	(0.16, 0.30)	0.13 (0.05)	(0.03, 0.23)	0.010 *
		Placebo	103	102 (99.0)	0.10 (0.04)	(0.03, 0.17)			
	Week 8	Tezepelumab	103	101 (98.1)	0.29 (0.04)	(0.21, 0.37)	0.17 (0.06)	(0.06, 0.28)	0.003 *
		Placebo	103	98 (95.1)	0.12 (0.04)	(0.04, 0.20)			
	Week 12	Tezepelumab	103	97 (94.2)	0.31 (0.04)	(0.24, 0.39)	0.21 (0.06)	(0.10, 0.32)	<0.001 *
		Placebo	103	97 (94.2)	0.11 (0.04)	(0.03, 0.19)			
	Week 16	Tezepelumab	103	98 (95.1)	0.27 (0.04)	(0.19, 0.35)	0.17 (0.06)	(0.05, 0.28)	0.004 *
		Placebo	103	95 (92.2)	0.11 (0.04)	(0.03, 0.19)			
	Week 24	Tezepelumab	103	97 (94.2)	0.27 (0.04)	(0.20, 0.35)	0.19 (0.06)	(0.08, 0.30)	<0.001 *
		Placebo	103	93 (90.3)	0.08 (0.04)	(0.00, 0.16)			
	Week 36	Tezepelumab	103	88 (85.4)	0.33 (0.04)	(0.24, 0.41)	0.23 (0.06)	(0.11, 0.35)	<0.001 *
		Placebo	103	90 (87.4)	0.09 (0.04)	(0.01, 0.18)			
	Week 52	Tezepelumab	103	89 (86.4)	0.30 (0.04)	(0.22, 0.38)	0.23 (0.06)	(0.12, 0.34)	<0.001 *
		Placebo	103	87 (84.5)	0.07 (0.04)	(-0.01, 0.15)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q4: >= 430 cells/uL	Week 2	Tezepelumab	104	100 (96.2)	0.28 (0.04)	(0.21, 0.35)	0.17 (0.05)	(0.07, 0.27)	0.001 *
		Placebo	113	108 (95.6)	0.11 (0.04)	(0.04, 0.18)			
	Week 4	Tezepelumab	104	104 (100.0)	0.34 (0.04)	(0.26, 0.42)	0.17 (0.06)	(0.06, 0.28)	0.003 *
		Placebo	113	111 (98.2)	0.17 (0.04)	(0.09, 0.24)			
	Week 8	Tezepelumab	104	102 (98.1)	0.37 (0.04)	(0.28, 0.46)	0.25 (0.06)	(0.13, 0.37)	<0.001 *
		Placebo	113	111 (98.2)	0.12 (0.04)	(0.03, 0.20)			
	Week 12	Tezepelumab	104	103 (99.0)	0.39 (0.04)	(0.31, 0.48)	0.19 (0.06)	(0.07, 0.32)	0.002 *
		Placebo	113	113 (100.0)	0.20 (0.04)	(0.12, 0.28)			
	Week 16	Tezepelumab	104	99 (95.2)	0.43 (0.04)	(0.35, 0.51)	0.27 (0.06)	(0.16, 0.38)	<0.001 *
		Placebo	113	109 (96.5)	0.16 (0.04)	(0.08, 0.24)			
	Week 24	Tezepelumab	104	96 (92.3)	0.42 (0.05)	(0.32, 0.51)	0.23 (0.06)	(0.10, 0.36)	<0.001 *
		Placebo	113	104 (92.0)	0.18 (0.04)	(0.10, 0.27)			
	Week 36	Tezepelumab	104	95 (91.3)	0.44 (0.04)	(0.36, 0.53)	0.22 (0.06)	(0.09, 0.34)	<0.001 *
		Placebo	113	102 (90.3)	0.23 (0.04)	(0.14, 0.31)			
	Week 52	Tezepelumab	104	87 (83.7)	0.45 (0.04)	(0.36, 0.54)	0.27 (0.06)	(0.15, 0.39)	<0.001 *
		Placebo	113	92 (81.4)	0.18 (0.04)	(0.10, 0.27)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline FENO (cat. N)									0.245
< 25 ppb	Week 2	Tezepelumab	158	153 (96.8)	0.13 (0.02)	(0.09, 0.18)	0.10 (0.03)	(0.04, 0.17)	0.002 *
		Placebo	151	141 (93.4)	0.03 (0.02)	(-0.02, 0.08)			
	Week 4	Tezepelumab	158	155 (98.1)	0.15 (0.03)	(0.10, 0.20)	0.07 (0.04)	(0.00, 0.15)	0.044 *
		Placebo	151	149 (98.7)	0.07 (0.03)	(0.02, 0.12)			
	Week 8	Tezepelumab	158	155 (98.1)	0.16 (0.03)	(0.10, 0.21)	0.09 (0.04)	(0.02, 0.17)	0.015 *
		Placebo	151	147 (97.4)	0.06 (0.03)	(0.01, 0.12)			
	Week 12	Tezepelumab	158	152 (96.2)	0.15 (0.03)	(0.10, 0.20)	0.08 (0.04)	(0.01, 0.16)	0.027 *
		Placebo	151	144 (95.4)	0.06 (0.03)	(0.01, 0.12)			
	Week 16	Tezepelumab	158	151 (95.6)	0.16 (0.03)	(0.11, 0.21)	0.13 (0.04)	(0.05, 0.20)	<0.001 *
		Placebo	151	144 (95.4)	0.03 (0.03)	(-0.02, 0.08)			
	Week 24	Tezepelumab	158	149 (94.3)	0.13 (0.03)	(0.08, 0.19)	0.10 (0.04)	(0.02, 0.18)	0.011 *
		Placebo	151	140 (92.7)	0.03 (0.03)	(-0.02, 0.09)			
	Week 36	Tezepelumab	158	140 (88.6)	0.13 (0.03)	(0.07, 0.18)	0.05 (0.04)	(-0.03, 0.12)	0.236
		Placebo	151	135 (89.4)	0.08 (0.03)	(0.03, 0.14)			
	Week 52	Tezepelumab	158	142 (89.9)	0.14 (0.03)	(0.08, 0.19)	0.08 (0.04)	(0.00, 0.16)	0.037 *
		Placebo	151	130 (86.1)	0.05 (0.03)	(-0.00, 0.11)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
25 - < 50 ppb	Week 2	Tezepelumab	114	113 (99.1)	0.18 (0.03)	(0.11, 0.24)	0.15 (0.05)	(0.05, 0.24)	0.002 *
		Placebo	116	114 (98.3)	0.03 (0.03)	(-0.03, 0.10)			
	Week 4	Tezepelumab	114	114 (100.0)	0.22 (0.03)	(0.15, 0.28)	0.15 (0.05)	(0.06, 0.25)	0.002 *
		Placebo	116	112 (96.6)	0.06 (0.03)	(-0.00, 0.13)			
	Week 8	Tezepelumab	114	113 (99.1)	0.21 (0.03)	(0.15, 0.28)	0.10 (0.05)	(0.01, 0.20)	0.034 *
		Placebo	116	112 (96.6)	0.11 (0.03)	(0.05, 0.18)			
	Week 12	Tezepelumab	114	111 (97.4)	0.23 (0.04)	(0.16, 0.31)	0.15 (0.05)	(0.05, 0.25)	0.004 *
		Placebo	116	112 (96.6)	0.09 (0.04)	(0.01, 0.16)			
	Week 16	Tezepelumab	114	113 (99.1)	0.22 (0.04)	(0.15, 0.29)	0.14 (0.05)	(0.04, 0.24)	0.004 *
		Placebo	116	110 (94.8)	0.08 (0.04)	(0.01, 0.15)			
	Week 24	Tezepelumab	114	107 (93.9)	0.24 (0.04)	(0.16, 0.32)	0.12 (0.06)	(0.02, 0.23)	0.026 *
		Placebo	116	103 (88.8)	0.11 (0.04)	(0.04, 0.19)			
	Week 36	Tezepelumab	114	106 (93.0)	0.24 (0.04)	(0.16, 0.33)	0.15 (0.06)	(0.03, 0.27)	0.011 *
		Placebo	116	105 (90.5)	0.09 (0.04)	(0.01, 0.18)			
	Week 52	Tezepelumab	114	103 (90.4)	0.26 (0.04)	(0.19, 0.34)	0.19 (0.06)	(0.08, 0.30)	<0.001 *
		Placebo	116	95 (81.9)	0.07 (0.04)	(-0.01, 0.15)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 50 ppb	Week 2	Tezepelumab	120	115 (95.8)	0.26 (0.04)	(0.19, 0.33)	0.15 (0.05)	(0.05, 0.25)	0.003 *
		Placebo	120	114 (95.0)	0.10 (0.04)	(0.03, 0.17)			
	Week 4	Tezepelumab	120	119 (99.2)	0.27 (0.04)	(0.19, 0.35)	0.16 (0.06)	(0.05, 0.27)	0.006 *
		Placebo	120	117 (97.5)	0.11 (0.04)	(0.04, 0.19)			
	Week 8	Tezepelumab	120	117 (97.5)	0.35 (0.04)	(0.27, 0.43)	0.24 (0.06)	(0.12, 0.36)	<0.001 *
		Placebo	120	117 (97.5)	0.11 (0.04)	(0.02, 0.19)			
	Week 12	Tezepelumab	120	116 (96.7)	0.35 (0.04)	(0.26, 0.43)	0.19 (0.06)	(0.07, 0.32)	0.002 *
		Placebo	120	118 (98.3)	0.15 (0.04)	(0.07, 0.24)			
	Week 16	Tezepelumab	120	113 (94.2)	0.41 (0.04)	(0.33, 0.50)	0.25 (0.06)	(0.13, 0.37)	<0.001 *
		Placebo	120	113 (94.2)	0.16 (0.04)	(0.08, 0.25)			
	Week 24	Tezepelumab	120	110 (91.7)	0.34 (0.04)	(0.26, 0.42)	0.22 (0.06)	(0.11, 0.33)	<0.001 *
		Placebo	120	111 (92.5)	0.12 (0.04)	(0.04, 0.20)			
	Week 36	Tezepelumab	120	107 (89.2)	0.39 (0.04)	(0.31, 0.48)	0.25 (0.06)	(0.14, 0.37)	<0.001 *
		Placebo	120	103 (85.8)	0.14 (0.04)	(0.06, 0.22)			
	Week 52	Tezepelumab	120	101 (84.2)	0.39 (0.04)	(0.30, 0.47)	0.26 (0.06)	(0.15, 0.38)	<0.001 *
		Placebo	120	98 (81.7)	0.12 (0.04)	(0.04, 0.21)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline FENO (cat. Q)									0.131
Q1: < 16 ppb	Week 2	Tezepelumab	94	90 (95.7)	0.15 (0.03)	(0.09, 0.22)	0.12 (0.05)	(0.03, 0.21)	0.009 *
		Placebo	85	77 (90.6)	0.03 (0.03)	(-0.03, 0.10)			
	Week 4	Tezepelumab	94	92 (97.9)	0.18 (0.04)	(0.11, 0.25)	0.12 (0.05)	(0.02, 0.22)	0.021 *
		Placebo	85	84 (98.8)	0.06 (0.04)	(-0.02, 0.13)			
	Week 8	Tezepelumab	94	92 (97.9)	0.16 (0.03)	(0.09, 0.22)	0.12 (0.05)	(0.03, 0.22)	0.012 *
		Placebo	85	82 (96.5)	0.04 (0.03)	(-0.03, 0.10)			
	Week 12	Tezepelumab	94	90 (95.7)	0.15 (0.03)	(0.08, 0.22)	0.06 (0.05)	(-0.04, 0.16)	0.212
		Placebo	85	81 (95.3)	0.09 (0.04)	(0.01, 0.16)			
	Week 16	Tezepelumab	94	89 (94.7)	0.17 (0.03)	(0.10, 0.24)	0.14 (0.05)	(0.05, 0.24)	0.004 *
		Placebo	85	80 (94.1)	0.02 (0.04)	(-0.05, 0.10)			
	Week 24	Tezepelumab	94	89 (94.7)	0.13 (0.04)	(0.05, 0.20)	0.09 (0.05)	(-0.02, 0.19)	0.109
		Placebo	85	78 (91.8)	0.04 (0.04)	(-0.04, 0.12)			
	Week 36	Tezepelumab	94	84 (89.4)	0.13 (0.04)	(0.06, 0.20)	0.05 (0.05)	(-0.05, 0.15)	0.328
		Placebo	85	77 (90.6)	0.08 (0.04)	(0.01, 0.16)			
	Week 52	Tezepelumab	94	83 (88.3)	0.14 (0.04)	(0.07, 0.21)	0.08 (0.06)	(-0.03, 0.19)	0.144
		Placebo	85	71 (83.5)	0.06 (0.04)	(-0.02, 0.14)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q2: 16 - < 30 ppb	Week 2	Tezepelumab	88	87 (98.9)	0.08 (0.03)	(0.03, 0.14)	0.06 (0.04)	(-0.02, 0.14)	0.142
		Placebo	99	97 (98.0)	0.02 (0.03)	(-0.03, 0.08)			
	Week 4	Tezepelumab	88	87 (98.9)	0.10 (0.03)	(0.03, 0.16)	0.03 (0.04)	(-0.06, 0.11)	0.553
		Placebo	99	97 (98.0)	0.07 (0.03)	(0.01, 0.13)			
	Week 8	Tezepelumab	88	87 (98.9)	0.12 (0.04)	(0.05, 0.20)	0.03 (0.05)	(-0.07, 0.12)	0.593
		Placebo	99	97 (98.0)	0.10 (0.03)	(0.03, 0.17)			
	Week 12	Tezepelumab	88	84 (95.5)	0.14 (0.03)	(0.07, 0.21)	0.09 (0.05)	(-0.00, 0.18)	0.054
		Placebo	99	96 (97.0)	0.05 (0.03)	(-0.02, 0.11)			
	Week 16	Tezepelumab	88	86 (97.7)	0.13 (0.03)	(0.07, 0.20)	0.09 (0.05)	(-0.01, 0.18)	0.064
		Placebo	99	97 (98.0)	0.05 (0.03)	(-0.02, 0.11)			
	Week 24	Tezepelumab	88	82 (93.2)	0.13 (0.03)	(0.06, 0.19)	0.07 (0.05)	(-0.02, 0.16)	0.127
		Placebo	99	94 (94.9)	0.05 (0.03)	(-0.01, 0.12)			
	Week 36	Tezepelumab	88	80 (90.9)	0.11 (0.04)	(0.03, 0.18)	0.03 (0.05)	(-0.07, 0.14)	0.510
		Placebo	99	89 (89.9)	0.07 (0.04)	(0.00, 0.15)			
	Week 52	Tezepelumab	88	82 (93.2)	0.13 (0.04)	(0.06, 0.20)	0.10 (0.05)	(0.00, 0.20)	0.045 *
		Placebo	99	87 (87.9)	0.03 (0.03)	(-0.04, 0.09)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q3: 30 - < 56 ppb	Week 2	Tezepelumab	106	105 (99.1)	0.21 (0.04)	(0.14, 0.28)	0.15 (0.05)	(0.05, 0.25)	0.003 *
		Placebo	96	93 (96.9)	0.05 (0.04)	(-0.02, 0.13)			
	Week 4	Tezepelumab	106	106 (100.0)	0.25 (0.03)	(0.18, 0.31)	0.16 (0.05)	(0.06, 0.26)	0.002 *
		Placebo	96	92 (95.8)	0.09 (0.04)	(0.02, 0.16)			
	Week 8	Tezepelumab	106	105 (99.1)	0.25 (0.04)	(0.18, 0.32)	0.13 (0.05)	(0.03, 0.23)	0.015 *
		Placebo	96	93 (96.9)	0.13 (0.04)	(0.05, 0.20)			
	Week 12	Tezepelumab	106	105 (99.1)	0.26 (0.04)	(0.18, 0.34)	0.16 (0.06)	(0.05, 0.28)	0.006 *
		Placebo	96	92 (95.8)	0.09 (0.04)	(0.01, 0.18)			
	Week 16	Tezepelumab	106	105 (99.1)	0.26 (0.04)	(0.19, 0.34)	0.19 (0.06)	(0.08, 0.30)	<0.001 *
		Placebo	96	89 (92.7)	0.07 (0.04)	(-0.01, 0.15)			
	Week 24	Tezepelumab	106	101 (95.3)	0.28 (0.04)	(0.19, 0.36)	0.16 (0.06)	(0.03, 0.28)	0.014 *
		Placebo	96	83 (86.5)	0.12 (0.05)	(0.03, 0.21)			
	Week 36	Tezepelumab	106	96 (90.6)	0.30 (0.04)	(0.21, 0.38)	0.21 (0.06)	(0.08, 0.33)	0.001 *
		Placebo	96	87 (90.6)	0.09 (0.05)	(-0.00, 0.18)			
	Week 52	Tezepelumab	106	94 (88.7)	0.30 (0.04)	(0.22, 0.38)	0.20 (0.06)	(0.09, 0.32)	<0.001 *
		Placebo	96	79 (82.3)	0.10 (0.04)	(0.01, 0.18)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q4: >= 56 ppb	Week 2	Tezepelumab	104	99 (95.2)	0.27 (0.04)	(0.19, 0.35)	0.18 (0.06)	(0.07, 0.29)	0.002 *
		Placebo	107	102 (95.3)	0.09 (0.04)	(0.02, 0.17)			
	Week 4	Tezepelumab	104	103 (99.0)	0.28 (0.04)	(0.19, 0.36)	0.17 (0.06)	(0.05, 0.29)	0.006 *
		Placebo	107	105 (98.1)	0.11 (0.04)	(0.02, 0.19)			
	Week 8	Tezepelumab	104	101 (97.1)	0.37 (0.05)	(0.28, 0.46)	0.27 (0.07)	(0.14, 0.40)	<0.001 *
		Placebo	107	104 (97.2)	0.09 (0.05)	(0.00, 0.19)			
	Week 12	Tezepelumab	104	100 (96.2)	0.37 (0.05)	(0.28, 0.47)	0.22 (0.07)	(0.08, 0.35)	0.001 *
		Placebo	107	105 (98.1)	0.15 (0.05)	(0.06, 0.25)			
	Week 16	Tezepelumab	104	97 (93.3)	0.43 (0.05)	(0.34, 0.52)	0.25 (0.07)	(0.12, 0.38)	<0.001 *
		Placebo	107	101 (94.4)	0.18 (0.05)	(0.09, 0.27)			
	Week 24	Tezepelumab	104	94 (90.4)	0.36 (0.04)	(0.27, 0.45)	0.24 (0.06)	(0.12, 0.37)	<0.001 *
		Placebo	107	99 (92.5)	0.12 (0.04)	(0.03, 0.20)			
	Week 36	Tezepelumab	104	93 (89.4)	0.41 (0.05)	(0.32, 0.50)	0.25 (0.07)	(0.12, 0.38)	<0.001 *
		Placebo	107	90 (84.1)	0.16 (0.05)	(0.07, 0.25)			
	Week 52	Tezepelumab	104	87 (83.7)	0.41 (0.05)	(0.32, 0.50)	0.28 (0.07)	(0.15, 0.40)	<0.001 *
		Placebo	107	86 (80.4)	0.13 (0.05)	(0.04, 0.22)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Total serum IgE (cat. N)									0.152
Q1: < 53.1 IU/ml	Week 2	Tezepelumab	94	91 (96.8)	0.12 (0.03)	(0.07, 0.18)	0.10 (0.04)	(0.03, 0.18)	0.010 *
		Placebo	99	93 (93.9)	0.02 (0.03)	(-0.03, 0.08)			
	Week 4	Tezepelumab	94	94 (100.0)	0.14 (0.03)	(0.08, 0.21)	0.06 (0.04)	(-0.03, 0.15)	0.185
		Placebo	99	96 (97.0)	0.08 (0.03)	(0.02, 0.15)			
	Week 8	Tezepelumab	94	92 (97.9)	0.16 (0.03)	(0.09, 0.22)	0.08 (0.05)	(-0.01, 0.17)	0.085
		Placebo	99	96 (97.0)	0.08 (0.03)	(0.01, 0.14)			
	Week 12	Tezepelumab	94	91 (96.8)	0.16 (0.03)	(0.09, 0.23)	0.09 (0.05)	(-0.01, 0.18)	0.082
		Placebo	99	95 (96.0)	0.07 (0.03)	(0.00, 0.14)			
	Week 16	Tezepelumab	94	92 (97.9)	0.19 (0.03)	(0.12, 0.25)	0.14 (0.05)	(0.05, 0.23)	0.003 *
		Placebo	99	93 (93.9)	0.05 (0.03)	(-0.01, 0.11)			
	Week 24	Tezepelumab	94	90 (95.7)	0.14 (0.03)	(0.08, 0.20)	0.11 (0.04)	(0.03, 0.19)	0.010 *
		Placebo	99	87 (87.9)	0.03 (0.03)	(-0.03, 0.09)			
	Week 36	Tezepelumab	94	86 (91.5)	0.12 (0.03)	(0.06, 0.19)	0.03 (0.05)	(-0.06, 0.12)	0.571
		Placebo	99	83 (83.8)	0.10 (0.03)	(0.03, 0.16)			
	Week 52	Tezepelumab	94	87 (92.6)	0.14 (0.04)	(0.07, 0.21)	0.12 (0.05)	(0.02, 0.22)	0.022 *
		Placebo	99	81 (81.8)	0.03 (0.04)	(-0.04, 0.10)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q2: 53.1 - < 195.6 IU/ml	Week 2	Tezepelumab	101	101 (100.0)	0.16 (0.03)	(0.10, 0.22)	0.13 (0.04)	(0.05, 0.21)	0.002 *
		Placebo	101	97 (96.0)	0.03 (0.03)	(-0.03, 0.09)			
	Week 4	Tezepelumab	101	99 (98.0)	0.22 (0.03)	(0.15, 0.28)	0.15 (0.05)	(0.06, 0.25)	0.002 *
		Placebo	101	101 (100.0)	0.07 (0.03)	(0.00, 0.13)			
	Week 8	Tezepelumab	101	99 (98.0)	0.23 (0.03)	(0.17, 0.29)	0.15 (0.05)	(0.06, 0.24)	0.001 *
		Placebo	101	99 (98.0)	0.08 (0.03)	(0.02, 0.15)			
	Week 12	Tezepelumab	101	98 (97.0)	0.26 (0.04)	(0.19, 0.34)	0.18 (0.05)	(0.08, 0.29)	<0.001 *
		Placebo	101	99 (98.0)	0.08 (0.04)	(0.01, 0.16)			
	Week 16	Tezepelumab	101	96 (95.0)	0.28 (0.04)	(0.20, 0.35)	0.19 (0.05)	(0.08, 0.30)	<0.001 *
		Placebo	101	95 (94.1)	0.09 (0.04)	(0.01, 0.16)			
	Week 24	Tezepelumab	101	95 (94.1)	0.27 (0.04)	(0.20, 0.35)	0.20 (0.05)	(0.10, 0.30)	<0.001 *
		Placebo	101	94 (93.1)	0.08 (0.04)	(0.00, 0.15)			
	Week 36	Tezepelumab	101	93 (92.1)	0.28 (0.04)	(0.21, 0.36)	0.18 (0.05)	(0.08, 0.29)	<0.001 *
		Placebo	101	92 (91.1)	0.10 (0.04)	(0.02, 0.17)			
	Week 52	Tezepelumab	101	87 (86.1)	0.28 (0.04)	(0.21, 0.35)	0.18 (0.05)	(0.07, 0.28)	<0.001 *
		Placebo	101	86 (85.1)	0.10 (0.04)	(0.03, 0.17)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q3: 195.6 - < 572.4 IU/ml	Week 2	Tezepelumab	108	104 (96.3)	0.21 (0.04)	(0.14, 0.29)	0.25 (0.05)	(0.14, 0.35)	<0.001 *
		Placebo	87	81 (93.1)	-0.03 (0.04)	(-0.11, 0.05)			
	Week 4	Tezepelumab	108	107 (99.1)	0.19 (0.03)	(0.12, 0.25)	0.16 (0.05)	(0.06, 0.27)	0.002 *
		Placebo	87	82 (94.3)	0.02 (0.04)	(-0.06, 0.10)			
	Week 8	Tezepelumab	108	106 (98.1)	0.24 (0.04)	(0.17, 0.31)	0.20 (0.05)	(0.10, 0.31)	<0.001 *
		Placebo	87	85 (97.7)	0.04 (0.04)	(-0.04, 0.12)			
	Week 12	Tezepelumab	108	104 (96.3)	0.24 (0.04)	(0.16, 0.32)	0.17 (0.06)	(0.06, 0.29)	0.004 *
		Placebo	87	83 (95.4)	0.07 (0.04)	(-0.02, 0.15)			
	Week 16	Tezepelumab	108	104 (96.3)	0.25 (0.04)	(0.17, 0.32)	0.22 (0.06)	(0.11, 0.33)	<0.001 *
		Placebo	87	85 (97.7)	0.03 (0.04)	(-0.05, 0.11)			
	Week 24	Tezepelumab	108	98 (90.7)	0.21 (0.04)	(0.13, 0.28)	0.14 (0.06)	(0.03, 0.25)	0.015 *
		Placebo	87	80 (92.0)	0.07 (0.04)	(-0.02, 0.15)			
	Week 36	Tezepelumab	108	93 (86.1)	0.25 (0.04)	(0.17, 0.32)	0.19 (0.06)	(0.07, 0.30)	0.001 *
		Placebo	87	75 (86.2)	0.06 (0.04)	(-0.02, 0.15)			
	Week 52	Tezepelumab	108	95 (88.0)	0.27 (0.04)	(0.19, 0.35)	0.20 (0.06)	(0.08, 0.32)	0.002 *
		Placebo	87	72 (82.8)	0.08 (0.05)	(-0.01, 0.17)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q4: >= 572.4 IU/ml	Week 2	Tezepelumab	92	88 (95.7)	0.21 (0.04)	(0.13, 0.29)	0.04 (0.06)	(-0.08, 0.15)	0.531
		Placebo	104	102 (98.1)	0.18 (0.04)	(0.10, 0.25)			
	Week 4	Tezepelumab	92	91 (98.9)	0.26 (0.05)	(0.17, 0.35)	0.11 (0.06)	(-0.02, 0.23)	0.094
		Placebo	104	103 (99.0)	0.15 (0.04)	(0.07, 0.24)			
	Week 8	Tezepelumab	92	91 (98.9)	0.28 (0.05)	(0.18, 0.39)	0.13 (0.07)	(-0.02, 0.27)	0.080
		Placebo	104	100 (96.2)	0.16 (0.05)	(0.06, 0.25)			
	Week 12	Tezepelumab	92	89 (96.7)	0.26 (0.05)	(0.16, 0.36)	0.10 (0.07)	(-0.04, 0.23)	0.162
		Placebo	104	100 (96.2)	0.17 (0.05)	(0.07, 0.26)			
	Week 16	Tezepelumab	92	88 (95.7)	0.29 (0.05)	(0.19, 0.39)	0.12 (0.07)	(-0.01, 0.26)	0.073
		Placebo	104	97 (93.3)	0.17 (0.05)	(0.08, 0.26)			
	Week 24	Tezepelumab	92	86 (93.5)	0.28 (0.05)	(0.17, 0.38)	0.12 (0.07)	(-0.02, 0.27)	0.098
		Placebo	104	96 (92.3)	0.16 (0.05)	(0.06, 0.26)			
	Week 36	Tezepelumab	92	84 (91.3)	0.31 (0.06)	(0.20, 0.42)	0.16 (0.08)	(0.01, 0.31)	0.040 *
		Placebo	104	96 (92.3)	0.15 (0.05)	(0.05, 0.25)			
	Week 52	Tezepelumab	92	80 (87.0)	0.30 (0.05)	(0.20, 0.40)	0.18 (0.07)	(0.04, 0.32)	0.012 *
		Placebo	104	87 (83.7)	0.12 (0.05)	(0.02, 0.21)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Nasal polyps last 2 years									0.548
Yes	Week 2	Tezepelumab	33	32 (97.0)	0.24 (0.06)	(0.12, 0.37)	0.17 (0.09)	(-0.01, 0.35)	0.060
		Placebo	31	31 (100.0)	0.08 (0.06)	(-0.05, 0.20)			
	Week 4	Tezepelumab	33	33 (100.0)	0.27 (0.08)	(0.12, 0.42)	0.13 (0.11)	(-0.08, 0.35)	0.220
		Placebo	31	31 (100.0)	0.13 (0.08)	(-0.02, 0.29)			
	Week 8	Tezepelumab	33	33 (100.0)	0.35 (0.07)	(0.20, 0.49)	0.19 (0.11)	(-0.02, 0.40)	0.079
		Placebo	31	31 (100.0)	0.16 (0.08)	(0.01, 0.31)			
	Week 12	Tezepelumab	33	32 (97.0)	0.30 (0.07)	(0.15, 0.44)	0.13 (0.10)	(-0.08, 0.34)	0.228
		Placebo	31	31 (100.0)	0.17 (0.07)	(0.02, 0.32)			
	Week 16	Tezepelumab	33	32 (97.0)	0.32 (0.08)	(0.17, 0.47)	0.16 (0.11)	(-0.05, 0.38)	0.139
		Placebo	31	30 (96.8)	0.15 (0.08)	(-0.00, 0.31)			
	Week 24	Tezepelumab	33	31 (93.9)	0.24 (0.08)	(0.09, 0.40)	0.07 (0.11)	(-0.15, 0.30)	0.506
		Placebo	31	30 (96.8)	0.17 (0.08)	(0.01, 0.33)			
	Week 36	Tezepelumab	33	31 (93.9)	0.34 (0.07)	(0.21, 0.48)	0.13 (0.10)	(-0.06, 0.32)	0.188
		Placebo	31	28 (90.3)	0.21 (0.07)	(0.07, 0.35)			
	Week 52	Tezepelumab	33	30 (90.9)	0.35 (0.08)	(0.20, 0.51)	0.29 (0.11)	(0.06, 0.51)	0.014 *
		Placebo	31	28 (90.3)	0.07 (0.08)	(-0.09, 0.23)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ILSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 2	Tezepelumab	362	352 (97.2)	0.17 (0.02)	(0.14, 0.21)	0.12 (0.03)	(0.07, 0.17)	<0.001 *
		Placebo	360	342 (95.0)	0.05 (0.02)	(0.02, 0.09)			
	Week 4	Tezepelumab	362	358 (98.9)	0.20 (0.02)	(0.16, 0.23)	0.12 (0.03)	(0.06, 0.17)	<0.001 *
		Placebo	360	351 (97.5)	0.08 (0.02)	(0.04, 0.12)			
	Week 8	Tezepelumab	362	355 (98.1)	0.22 (0.02)	(0.18, 0.26)	0.13 (0.03)	(0.08, 0.19)	<0.001 *
		Placebo	360	349 (96.9)	0.09 (0.02)	(0.05, 0.12)			
	Week 12	Tezepelumab	362	350 (96.7)	0.23 (0.02)	(0.18, 0.27)	0.13 (0.03)	(0.07, 0.19)	<0.001 *
		Placebo	360	346 (96.1)	0.09 (0.02)	(0.05, 0.13)			
	Week 16	Tezepelumab	362	348 (96.1)	0.24 (0.02)	(0.20, 0.29)	0.17 (0.03)	(0.11, 0.22)	<0.001 *
		Placebo	360	340 (94.4)	0.08 (0.02)	(0.04, 0.12)			
	Week 24	Tezepelumab	362	338 (93.4)	0.22 (0.02)	(0.18, 0.26)	0.15 (0.03)	(0.09, 0.21)	<0.001 *
		Placebo	360	327 (90.8)	0.08 (0.02)	(0.04, 0.12)			
	Week 36	Tezepelumab	362	325 (89.8)	0.23 (0.02)	(0.19, 0.28)	0.14 (0.03)	(0.08, 0.20)	<0.001 *
		Placebo	360	318 (88.3)	0.09 (0.02)	(0.05, 0.14)			
	Week 52	Tezepelumab	362	319 (88.1)	0.24 (0.02)	(0.20, 0.28)	0.16 (0.03)	(0.10, 0.22)	<0.001 *
		Placebo	360	298 (82.8)	0.08 (0.02)	(0.04, 0.13)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Figure NF2FAC_ILSHK01: Course of FEV1 Pre-BD by sex
DITTL

Sex: Male



Note: DITTL = Dossier Label Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source tables: NT2FAC_ILSHK

Figure NF2FAC_ILSHK01: Course of FEV1 Pre-BD by sex
DITTL

Sex: Female



Note: DITTL = Dossier Label Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source tables: NT2FAC_ILSHK

Figure NF2FAC_ILSHK14: Course of FEV1 Pre-BD by baseline eosinophils - High
DITTL

Baseline eosinophils - High: < 300 cells/uL



Note: DITTL = Dossier Label Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source tables: NT2FAC_ILSHK

Figure NF2FAC_ILSHK14: Course of FEV1 Pre-BD by baseline eosinophils - High
DITTL

Baseline eosinophils - High: >= 300 cells/uL



Note: DITTL = Dossier Label Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source tables: NT2FAC_ILSHK

Figure NF2FAC_ILSHK36: Course of FEV1 Pre-BD by OCS at baseline
DITTL

OCS at baseline: Yes



Note: DITTL = Dossier Label Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source tables: NT2FAC_ILSHK

Figure NF2FAC_ILSHK36: Course of FEV1 Pre-BD by OCS at baseline
DITTL

OCS at baseline: No



Note: DITTL = Dossier Label Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source tables: NT2FAC_ILSHK

Table NT2FAC_KLMH0: Course of FEV1 Pre-BD
DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
FEV1 Pre-BD	Baseline	Tezepelumab	15	15 (100.0)	2.59 (0.68)	1.4	2.12	2.69	3.18	3.7	
		Placebo	20	20 (100.0)	2.53 (0.93)	1.0	2.07	2.34	3.00	4.9	
	Week 2	Tezepelumab	15	14 (93.3)	2.80 (0.70)	1.7	2.41	2.67	3.36	4.0	
		Placebo	20	20 (100.0)	2.67 (0.68)	1.3	2.31	2.66	2.98	4.7	
	Week 4	Tezepelumab	15	14 (93.3)	2.68 (0.68)	1.3	2.47	2.64	3.18	3.8	
		Placebo	20	19 (95.0)	2.62 (0.50)	1.4	2.39	2.59	2.86	3.7	
	Week 8	Tezepelumab	15	14 (93.3)	2.58 (0.95)	1.0	2.15	2.65	3.43	3.7	
		Placebo	20	19 (95.0)	2.67 (0.75)	1.4	2.30	2.69	2.99	4.9	
	Week 12	Tezepelumab	15	13 (86.7)	2.58 (0.89)	0.8	2.07	2.64	3.37	3.6	
		Placebo	20	20 (100.0)	2.71 (0.77)	1.4	2.39	2.55	3.02	5.0	
	Week 16	Tezepelumab	15	13 (86.7)	2.68 (0.64)	1.5	2.22	2.50	3.31	3.8	
		Placebo	20	20 (100.0)	2.69 (0.75)	1.5	2.39	2.51	2.98	5.2	
	Week 24	Tezepelumab	15	13 (86.7)	2.65 (0.71)	1.6	2.20	2.88	3.16	3.7	
		Placebo	20	18 (90.0)	2.79 (0.77)	1.5	2.52	2.69	3.11	5.1	
	Week 36	Tezepelumab	15	13 (86.7)	2.88 (0.67)	1.4	2.56	2.93	3.30	4.0	
		Placebo	20	18 (90.0)	2.83 (0.96)	1.4	2.34	2.92	3.33	5.3	
	Week 52	Tezepelumab	15	12 (80.0)	2.94 (0.68)	1.9	2.45	2.94	3.38	4.2	
		Placebo	20	18 (90.0)	2.77 (0.95)	1.2	2.14	2.64	3.22	5.3	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLMH0: Course of FEV1 Pre-BD
DITTL - adolescents

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in FEV1 Pre-BD	Week 2	Tezepelumab	15	14 (93.3)	0.23 (0.49)	-0.5	-0.04	0.23	0.47	1.4	0.15 [-0.54, 0.83]
		Placebo	20	20 (100.0)	0.15 (0.59)	-1.3	-0.08	0.01	0.25	1.7	
	Week 4	Tezepelumab	15	14 (93.3)	0.13 (0.48)	-0.3	-0.18	-0.11	0.39	1.2	-0.14 [-0.83, 0.55]
		Placebo	20	19 (95.0)	0.21 (0.64)	-1.0	-0.11	0.02	0.40	1.7	
	Week 8	Tezepelumab	15	14 (93.3)	0.03 (0.66)	-1.1	-0.40	0.03	0.42	1.6	-0.13 [-0.82, 0.56]
		Placebo	20	19 (95.0)	0.13 (0.79)	-1.7	-0.22	0.05	0.49	2.0	
	Week 12	Tezepelumab	15	13 (86.7)	-0.00 (0.73)	-1.5	-0.30	-0.09	0.30	1.5	-0.26 [-0.96, 0.44]
		Placebo	20	20 (100.0)	0.18 (0.70)	-1.2	-0.19	0.07	0.40	1.6	
	Week 16	Tezepelumab	15	13 (86.7)	0.19 (0.47)	-0.5	0.00	0.10	0.36	1.4	0.05 [-0.65, 0.74]
		Placebo	20	20 (100.0)	0.16 (0.72)	-1.6	-0.18	0.08	0.35	1.6	
	Week 24	Tezepelumab	15	13 (86.7)	0.15 (0.62)	-0.8	-0.16	0.18	0.27	1.8	-0.01 [-0.72, 0.70]
		Placebo	20	18 (90.0)	0.16 (0.68)	-1.4	-0.06	0.20	0.54	1.5	
	Week 36	Tezepelumab	15	13 (86.7)	0.38 (0.50)	-0.1	-0.01	0.32	0.57	1.7	0.16 [-0.55, 0.88]
		Placebo	20	18 (90.0)	0.26 (0.87)	-1.7	0.03	0.22	0.47	2.2	
	Week 52	Tezepelumab	15	12 (80.0)	0.42 (0.49)	-0.6	0.20	0.47	0.70	1.3	0.31 [-0.42, 1.05]
		Placebo	20	18 (90.0)	0.22 (0.72)	-1.4	-0.02	0.24	0.53	1.9	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLMC0: Change from baseline in FEV1 Pre-BD - MMRM results
DITTL - adolescents

Change from baseline in FEV1 Pre-BD				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Tezepelumab	15	14 (93.3)	0.26 (0.12)	(0.02, 0.50)	0.12 (0.15)	(-0.20, 0.43)	0.446
	Placebo	20	20 (100.0)	0.14 (0.10)	(-0.06, 0.35)			
Week 4	Tezepelumab	15	14 (93.3)	0.16 (0.12)	(-0.09, 0.41)	-0.02 (0.16)	(-0.35, 0.31)	0.895
	Placebo	20	19 (95.0)	0.18 (0.11)	(-0.03, 0.40)			
Week 8	Tezepelumab	15	14 (93.3)	0.08 (0.17)	(-0.27, 0.43)	-0.03 (0.23)	(-0.50, 0.43)	0.880
	Placebo	20	19 (95.0)	0.11 (0.15)	(-0.19, 0.41)			
Week 12	Tezepelumab	15	13 (86.7)	0.08 (0.17)	(-0.27, 0.42)	-0.10 (0.22)	(-0.55, 0.34)	0.636
	Placebo	20	20 (100.0)	0.18 (0.14)	(-0.11, 0.47)			
Week 16	Tezepelumab	15	13 (86.7)	0.23 (0.14)	(-0.05, 0.51)	0.07 (0.18)	(-0.30, 0.44)	0.692
	Placebo	20	20 (100.0)	0.16 (0.12)	(-0.08, 0.40)			
Week 24	Tezepelumab	15	13 (86.7)	0.21 (0.15)	(-0.11, 0.52)	-0.03 (0.20)	(-0.45, 0.38)	0.871
	Placebo	20	18 (90.0)	0.24 (0.13)	(-0.03, 0.51)			
Week 36	Tezepelumab	15	13 (86.7)	0.44 (0.17)	(0.08, 0.79)	0.17 (0.23)	(-0.29, 0.63)	0.464
	Placebo	20	18 (90.0)	0.27 (0.15)	(-0.03, 0.57)			
Week 52	Tezepelumab	15	12 (80.0)	0.41 (0.16)	(0.09, 0.73)	0.20 (0.21)	(-0.22, 0.62)	0.339
	Placebo	20	18 (90.0)	0.21 (0.13)	(-0.06, 0.48)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Figure NF2FAC_KLMG0: Course of FEV1 Pre-BD
DITTL - adolescents



Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source table: NT2FAC_KLMH0
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Absolute values	Baseline	Tezepelumab	8	8 (100.0)	2.64 (0.73)	1.4	2.09	2.74	3.20	3.7	
			Placebo	11	11 (100.0)	2.60 (1.13)	1.0	1.89	2.43	3.02	4.9	
		Week 2	Tezepelumab	8	7 (87.5)	2.91 (0.92)	1.7	1.69	3.26	3.70	4.0	
			Placebo	11	11 (100.0)	2.75 (0.80)	1.3	2.40	2.70	2.94	4.7	
		Week 4	Tezepelumab	8	7 (87.5)	2.68 (0.89)	1.3	1.90	2.61	3.51	3.8	
			Placebo	11	10 (90.9)	2.61 (0.56)	1.4	2.39	2.60	3.04	3.5	
		Week 8	Tezepelumab	8	7 (87.5)	2.70 (1.17)	1.0	1.07	3.43	3.53	3.7	
			Placebo	11	11 (100.0)	2.80 (0.84)	1.5	2.35	2.69	3.09	4.9	
		Week 12	Tezepelumab	8	7 (87.5)	2.73 (1.09)	0.8	1.68	3.37	3.51	3.6	
			Placebo	11	11 (100.0)	2.88 (0.91)	1.4	2.44	2.86	3.38	5.0	
		Week 16	Tezepelumab	8	6 (75.0)	2.83 (0.84)	1.5	2.20	3.04	3.39	3.8	
			Placebo	11	11 (100.0)	2.86 (0.93)	1.5	2.46	2.52	3.17	5.2	
		Week 24	Tezepelumab	8	6 (75.0)	2.80 (0.90)	1.7	1.70	3.03	3.59	3.7	
			Placebo	11	9 (81.8)	3.03 (0.95)	1.5	2.66	3.05	3.14	5.1	
		Week 36	Tezepelumab	8	6 (75.0)	3.01 (0.95)	1.4	2.39	3.32	3.64	4.0	
			Placebo	11	10 (90.9)	3.19 (0.97)	1.4	2.81	3.16	3.51	5.3	
		Week 52	Tezepelumab	8	5 (62.5)	3.21 (0.88)	1.9	3.08	3.29	3.57	4.2	
			Placebo	11	9 (81.8)	3.11 (1.07)	1.5	2.65	2.93	3.65	5.3	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Change from baseline	Week 2	Tezepelumab	8	7 (87.5)	0.29 (0.57)	-0.5	0.05	0.26	0.48	1.4	0.19 [-0.76, 1.14]
			Placebo	11	11 (100.0)	0.16 (0.80)	-1.3	-0.19	-0.07	0.74	1.7	
		Week 4	Tezepelumab	8	7 (87.5)	0.12 (0.53)	-0.3	-0.30	-0.08	0.33	1.2	-0.17 [-1.14, 0.79]
			Placebo	11	10 (90.9)	0.24 (0.81)	-1.0	-0.11	-0.01	0.77	1.7	
		Week 8	Tezepelumab	8	7 (87.5)	0.14 (0.84)	-1.1	-0.40	0.04	0.65	1.6	-0.07 [-1.02, 0.88]
			Placebo	11	11 (100.0)	0.20 (0.98)	-1.7	-0.33	0.09	1.03	2.0	
		Week 12	Tezepelumab	8	7 (87.5)	0.17 (0.74)	-0.6	-0.52	0.05	0.59	1.5	-0.13 [-1.08, 0.82]
			Placebo	11	11 (100.0)	0.28 (0.84)	-1.0	-0.24	0.03	1.32	1.6	
		Week 16	Tezepelumab	8	6 (75.0)	0.37 (0.54)	0.0	0.04	0.11	0.61	1.4	0.14 [-0.86, 1.13]
			Placebo	11	11 (100.0)	0.26 (0.93)	-1.6	-0.21	0.09	1.11	1.6	
		Week 24	Tezepelumab	8	6 (75.0)	0.34 (0.76)	-0.5	-0.06	0.24	0.38	1.8	0.16 [-0.87, 1.20]
			Placebo	11	9 (81.8)	0.21 (0.81)	-1.4	0.07	0.23	0.35	1.5	
		Week 36	Tezepelumab	8	6 (75.0)	0.56 (0.60)	0.0	0.19	0.36	0.77	1.7	0.00 [-1.01, 1.02]
			Placebo	11	10 (90.9)	0.55 (0.93)	-1.2	0.20	0.37	1.16	2.2	
		Week 52	Tezepelumab	8	5 (62.5)	0.70 (0.38)	0.4	0.42	0.59	0.79	1.3	0.32 [-0.78, 1.42]
			Placebo	11	9 (81.8)	0.45 (0.90)	-1.4	0.23	0.38	0.63	1.9	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Absolute values	Baseline	Tezepelumab	7	7 (100.0)	2.53 (0.68)	1.4	2.12	2.69	2.98	3.4	
			Placebo	9	9 (100.0)	2.44 (0.67)	1.3	2.10	2.16	2.94	3.5	
		Week 2	Tezepelumab	7	7 (100.0)	2.69 (0.41)	2.2	2.41	2.59	3.13	3.4	
			Placebo	9	9 (100.0)	2.57 (0.54)	1.7	2.30	2.37	3.01	3.5	
		Week 4	Tezepelumab	7	7 (100.0)	2.68 (0.47)	1.8	2.51	2.67	3.08	3.3	
			Placebo	9	9 (100.0)	2.62 (0.45)	2.1	2.44	2.50	2.66	3.7	
		Week 8	Tezepelumab	7	7 (100.0)	2.45 (0.76)	1.0	2.15	2.56	3.08	3.3	
			Placebo	9	8 (88.9)	2.50 (0.60)	1.4	2.16	2.68	2.88	3.2	
		Week 12	Tezepelumab	7	6 (85.7)	2.39 (0.63)	1.4	2.07	2.43	2.64	3.3	
			Placebo	9	9 (100.0)	2.50 (0.53)	1.7	2.34	2.52	2.56	3.5	
		Week 16	Tezepelumab	7	7 (100.0)	2.56 (0.43)	2.0	2.22	2.50	2.94	3.3	
			Placebo	9	9 (100.0)	2.47 (0.41)	1.9	2.26	2.41	2.63	3.2	
		Week 24	Tezepelumab	7	7 (100.0)	2.52 (0.53)	1.6	2.20	2.53	2.91	3.2	
			Placebo	9	9 (100.0)	2.54 (0.47)	2.0	2.15	2.60	2.71	3.4	
		Week 36	Tezepelumab	7	7 (100.0)	2.77 (0.33)	2.3	2.56	2.71	2.95	3.3	
			Placebo	9	8 (88.9)	2.39 (0.81)	1.4	1.63	2.45	2.95	3.7	
		Week 52	Tezepelumab	7	7 (100.0)	2.75 (0.47)	2.2	2.37	2.64	3.31	3.5	
			Placebo	9	9 (100.0)	2.43 (0.72)	1.2	2.09	2.47	2.63	3.7	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Change from baseline	Week 2	Tezepelumab	7	7 (100.0)	0.16 (0.43)	-0.4	-0.28	0.19	0.47	0.8	0.09 [-0.90, 1.08]
			Placebo	9	9 (100.0)	0.13 (0.18)	-0.1	0.00	0.07	0.23	0.5	
		Week 4	Tezepelumab	7	7 (100.0)	0.15 (0.46)	-0.3	-0.18	-0.13	0.43	1.0	-0.07 [-1.06, 0.91]
			Placebo	9	9 (100.0)	0.18 (0.43)	-0.5	-0.08	0.22	0.36	1.0	
		Week 8	Tezepelumab	7	7 (100.0)	-0.08 (0.46)	-0.8	-0.46	-0.13	0.42	0.4	-0.23 [-1.25, 0.79]
			Placebo	9	8 (88.9)	0.03 (0.44)	-0.8	-0.14	0.02	0.29	0.7	
		Week 12	Tezepelumab	7	6 (85.7)	-0.21 (0.73)	-1.5	-0.30	-0.11	0.16	0.6	-0.45 [-1.50, 0.60]
			Placebo	9	9 (100.0)	0.06 (0.51)	-1.2	0.02	0.26	0.39	0.4	
		Week 16	Tezepelumab	7	7 (100.0)	0.03 (0.37)	-0.5	-0.26	0.00	0.36	0.6	-0.01 [-1.00, 0.98]
			Placebo	9	9 (100.0)	0.03 (0.38)	-0.7	-0.15	0.00	0.26	0.6	
		Week 24	Tezepelumab	7	7 (100.0)	-0.01 (0.47)	-0.8	-0.24	-0.03	0.18	0.8	-0.22 [-1.21, 0.77]
			Placebo	9	9 (100.0)	0.10 (0.57)	-1.1	-0.06	-0.01	0.54	0.7	
		Week 36	Tezepelumab	7	7 (100.0)	0.23 (0.37)	-0.1	-0.03	-0.01	0.57	0.8	0.59 [-0.45, 1.63]
			Placebo	9	8 (88.9)	-0.10 (0.68)	-1.7	-0.13	0.14	0.22	0.5	
		Week 52	Tezepelumab	7	7 (100.0)	0.22 (0.49)	-0.6	-0.16	0.37	0.65	0.7	0.53 [-0.48, 1.54]
			Placebo	9	9 (100.0)	-0.01 (0.40)	-0.7	-0.11	0.03	0.28	0.5	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Absolute values	Baseline	Tezepelumab	7	7 (100.0)	2.58 (0.74)	1.4	1.98	2.94	3.18	3.4	
			Placebo	12	12 (100.0)	2.75 (0.88)	1.4	2.20	2.74	3.03	4.9	
		Week 2	Tezepelumab	7	7 (100.0)	2.92 (0.47)	2.2	2.50	3.13	3.36	3.4	
			Placebo	12	12 (100.0)	2.80 (0.82)	1.3	2.34	2.72	3.10	4.7	
		Week 4	Tezepelumab	7	7 (100.0)	2.84 (0.56)	1.8	2.57	2.81	3.29	3.5	
			Placebo	12	11 (91.7)	2.61 (0.56)	1.4	2.39	2.59	2.86	3.7	
		Week 8	Tezepelumab	7	7 (100.0)	2.72 (0.92)	1.0	2.15	3.08	3.43	3.5	
			Placebo	12	11 (91.7)	2.82 (0.85)	1.5	2.30	2.76	3.24	4.9	
		Week 12	Tezepelumab	7	7 (100.0)	2.68 (0.80)	1.4	2.07	2.64	3.48	3.5	
			Placebo	12	12 (100.0)	2.78 (0.92)	1.4	2.22	2.58	3.24	5.0	
		Week 16	Tezepelumab	7	6 (85.7)	2.77 (0.52)	2.0	2.50	2.72	3.31	3.4	
			Placebo	12	12 (100.0)	2.83 (0.92)	1.5	2.44	2.58	3.11	5.2	
		Week 24	Tezepelumab	7	6 (85.7)	2.66 (0.77)	1.6	2.20	2.62	3.19	3.7	
			Placebo	12	11 (91.7)	2.89 (0.95)	1.5	2.15	2.93	3.39	5.1	
		Week 36	Tezepelumab	7	6 (85.7)	2.96 (0.48)	2.3	2.71	2.94	3.30	3.6	
			Placebo	12	11 (91.7)	2.93 (1.13)	1.4	1.86	2.93	3.54	5.3	
		Week 52	Tezepelumab	7	6 (85.7)	2.90 (0.54)	2.2	2.37	3.04	3.31	3.5	
			Placebo	12	10 (83.3)	3.06 (1.05)	1.5	2.47	2.99	3.74	5.3	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Change from baseline	Week 2	Tezepelumab	7	7 (100.0)	0.34 (0.59)	-0.4	-0.04	0.19	0.81	1.4	0.60 [-0.36, 1.55]
			Placebo	12	12 (100.0)	0.06 (0.40)	-0.3	-0.08	-0.03	0.04	1.3	
		Week 4	Tezepelumab	7	7 (100.0)	0.25 (0.51)	-0.3	-0.14	0.33	0.43	1.2	0.48 [-0.48, 1.44]
			Placebo	12	11 (91.7)	0.06 (0.33)	-0.5	-0.11	-0.04	0.22	0.8	
		Week 8	Tezepelumab	7	7 (100.0)	0.14 (0.76)	-0.8	-0.46	0.14	0.44	1.6	0.18 [-0.77, 1.13]
			Placebo	12	11 (91.7)	0.02 (0.53)	-0.8	-0.22	0.03	0.13	1.4	
		Week 12	Tezepelumab	7	7 (100.0)	0.10 (0.94)	-1.5	-0.30	0.16	0.64	1.5	0.09 [-0.85, 1.02]
			Placebo	12	12 (100.0)	0.04 (0.63)	-1.2	-0.23	0.03	0.14	1.6	
		Week 16	Tezepelumab	7	6 (85.7)	0.29 (0.65)	-0.5	-0.12	0.18	0.60	1.4	0.34 [-0.64, 1.33]
			Placebo	12	12 (100.0)	0.09 (0.55)	-0.7	-0.18	0.02	0.15	1.6	
		Week 24	Tezepelumab	7	6 (85.7)	0.18 (0.85)	-0.8	-0.24	0.07	0.18	1.8	0.11 [-0.89, 1.11]
			Placebo	12	11 (91.7)	0.10 (0.60)	-1.1	-0.06	0.07	0.23	1.5	
		Week 36	Tezepelumab	7	6 (85.7)	0.48 (0.69)	-0.1	-0.03	0.28	0.82	1.7	0.46 [-0.55, 1.47]
			Placebo	12	11 (91.7)	0.14 (0.78)	-1.7	-0.03	0.20	0.42	1.6	
		Week 52	Tezepelumab	7	6 (85.7)	0.41 (0.66)	-0.6	0.02	0.51	0.74	1.3	0.26 [-0.75, 1.28]
			Placebo	12	10 (83.3)	0.23 (0.71)	-0.7	0.08	0.24	0.31	1.9	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Absolute values	Baseline	Tezepelumab	8	8 (100.0)	2.60 (0.69)	1.4	2.16	2.69	3.00	3.7	
			Placebo	8	8 (100.0)	2.20 (0.97)	1.0	1.66	2.09	2.57	4.0	
		Week 2	Tezepelumab	8	7 (87.5)	2.68 (0.89)	1.7	1.69	2.59	3.70	4.0	
			Placebo	8	8 (100.0)	2.48 (0.38)	1.7	2.31	2.49	2.78	2.9	
		Week 4	Tezepelumab	8	7 (87.5)	2.52 (0.80)	1.3	1.90	2.51	3.08	3.8	
			Placebo	8	8 (100.0)	2.63 (0.44)	2.1	2.36	2.55	2.82	3.5	
		Week 8	Tezepelumab	8	7 (87.5)	2.43 (1.04)	1.0	1.07	2.56	3.43	3.7	
			Placebo	8	8 (100.0)	2.47 (0.56)	1.4	2.19	2.64	2.85	3.1	
		Week 12	Tezepelumab	8	6 (75.0)	2.45 (1.05)	0.8	1.68	2.66	3.37	3.6	
			Placebo	8	8 (100.0)	2.60 (0.51)	1.7	2.42	2.51	2.97	3.4	
		Week 16	Tezepelumab	8	7 (87.5)	2.61 (0.75)	1.5	2.20	2.43	3.39	3.8	
			Placebo	8	8 (100.0)	2.47 (0.36)	1.9	2.31	2.46	2.56	3.2	
		Week 24	Tezepelumab	8	7 (87.5)	2.64 (0.72)	1.7	1.70	2.88	3.16	3.6	
			Placebo	8	7 (87.5)	2.63 (0.35)	2.0	2.60	2.64	2.76	3.1	
		Week 36	Tezepelumab	8	7 (87.5)	2.81 (0.83)	1.4	2.39	2.67	3.55	4.0	
			Placebo	8	7 (87.5)	2.68 (0.67)	1.4	2.34	2.81	3.22	3.3	
		Week 52	Tezepelumab	8	6 (75.0)	2.99 (0.84)	1.9	2.53	2.86	3.57	4.2	
			Placebo	8	8 (100.0)	2.40 (0.71)	1.2	2.10	2.45	2.66	3.7	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Change from baseline	Week 2	Tezepelumab	8	7 (87.5)	0.11 (0.38)	-0.5	-0.28	0.26	0.47	0.5	-0.25 [-1.27, 0.77]
			Placebo	8	8 (100.0)	0.28 (0.82)	-1.3	0.06	0.25	0.61	1.7	
		Week 4	Tezepelumab	8	7 (87.5)	0.01 (0.44)	-0.3	-0.30	-0.15	0.13	1.0	-0.57 [-1.60, 0.47]
			Placebo	8	8 (100.0)	0.42 (0.91)	-1.0	-0.23	0.38	1.21	1.7	
		Week 8	Tezepelumab	8	7 (87.5)	-0.08 (0.58)	-1.1	-0.40	0.02	0.42	0.7	-0.40 [-1.42, 0.63]
			Placebo	8	8 (100.0)	0.27 (1.07)	-1.7	-0.20	0.29	0.84	2.0	
		Week 12	Tezepelumab	8	6 (75.0)	-0.12 (0.44)	-0.6	-0.52	-0.11	0.05	0.6	-0.79 [-1.90, 0.31]
			Placebo	8	8 (100.0)	0.40 (0.79)	-1.0	0.05	0.40	0.87	1.5	
		Week 16	Tezepelumab	8	7 (87.5)	0.10 (0.26)	-0.3	0.00	0.10	0.11	0.6	-0.23 [-1.24, 0.79]
			Placebo	8	8 (100.0)	0.26 (0.96)	-1.6	-0.12	0.32	0.87	1.6	
		Week 24	Tezepelumab	8	7 (87.5)	0.13 (0.41)	-0.5	-0.16	0.21	0.38	0.8	-0.18 [-1.23, 0.87]
			Placebo	8	7 (87.5)	0.25 (0.83)	-1.4	-0.26	0.54	0.69	1.1	
		Week 36	Tezepelumab	8	7 (87.5)	0.30 (0.27)	-0.0	0.00	0.32	0.44	0.8	-0.22 [-1.27, 0.84]
			Placebo	8	7 (87.5)	0.46 (1.03)	-1.2	0.12	0.31	1.16	2.2	
		Week 52	Tezepelumab	8	6 (75.0)	0.43 (0.32)	-0.2	0.39	0.47	0.59	0.8	0.35 [-0.71, 1.42]
			Placebo	8	8 (100.0)	0.20 (0.78)	-1.4	-0.07	0.28	0.61	1.3	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Absolute values	Baseline	Tezepelumab	12	12 (100.0)	2.67 (0.64)	1.4	2.16	2.74	3.08	3.7	
			Placebo	17	17 (100.0)	2.64 (0.90)	1.0	2.10	2.43	2.97	4.9	
		Week 2	Tezepelumab	12	11 (91.7)	2.80 (0.71)	1.7	2.41	2.74	3.36	4.0	
			Placebo	17	17 (100.0)	2.79 (0.61)	2.2	2.37	2.70	2.94	4.7	
		Week 4	Tezepelumab	12	12 (100.0)	2.76 (0.69)	1.3	2.49	2.74	3.24	3.8	
			Placebo	17	16 (94.1)	2.71 (0.44)	2.1	2.47	2.60	2.95	3.7	
		Week 8	Tezepelumab	12	12 (100.0)	2.71 (0.91)	1.0	2.35	2.90	3.43	3.7	
			Placebo	17	16 (94.1)	2.85 (0.65)	2.0	2.47	2.76	3.04	4.9	
		Week 12	Tezepelumab	12	11 (91.7)	2.65 (0.95)	0.8	1.68	2.74	3.48	3.6	
			Placebo	17	17 (100.0)	2.89 (0.68)	2.0	2.49	2.59	3.07	5.0	
		Week 16	Tezepelumab	12	11 (91.7)	2.76 (0.66)	1.5	2.22	2.73	3.35	3.8	
			Placebo	17	17 (100.0)	2.82 (0.72)	2.1	2.46	2.52	3.01	5.2	
		Week 24	Tezepelumab	12	11 (91.7)	2.77 (0.68)	1.7	2.20	2.90	3.19	3.7	
			Placebo	17	15 (88.2)	2.99 (0.68)	2.2	2.61	2.76	3.14	5.1	
		Week 36	Tezepelumab	12	11 (91.7)	2.95 (0.70)	1.4	2.56	2.95	3.55	4.0	
			Placebo	17	15 (88.2)	3.12 (0.77)	1.9	2.76	2.97	3.51	5.3	
		Week 52	Tezepelumab	12	10 (83.3)	3.03 (0.69)	1.9	2.53	3.19	3.45	4.2	
			Placebo	17	15 (88.2)	2.98 (0.86)	2.1	2.27	2.67	3.65	5.3	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Change from baseline	Week 2	Tezepelumab	12	11 (91.7)	0.14 (0.51)	-0.5	-0.28	0.08	0.32	1.4	-0.02 [-0.78, 0.74]
			Placebo	17	17 (100.0)	0.15 (0.64)	-1.3	-0.08	0.03	0.23	1.7	
		Week 4	Tezepelumab	12	12 (100.0)	0.08 (0.50)	-0.3	-0.24	-0.14	0.23	1.2	-0.23 [-0.98, 0.52]
			Placebo	17	16 (94.1)	0.22 (0.64)	-1.0	-0.10	0.09	0.38	1.7	
		Week 8	Tezepelumab	12	12 (100.0)	0.04 (0.69)	-1.1	-0.27	0.03	0.34	1.6	-0.19 [-0.94, 0.56]
			Placebo	17	16 (94.1)	0.19 (0.83)	-1.7	-0.18	0.04	0.57	2.0	
		Week 12	Tezepelumab	12	11 (91.7)	-0.08 (0.77)	-1.5	-0.52	-0.10	0.30	1.5	-0.46 [-1.23, 0.30]
			Placebo	17	17 (100.0)	0.26 (0.68)	-1.0	-0.16	0.09	0.39	1.6	
		Week 16	Tezepelumab	12	11 (91.7)	0.13 (0.49)	-0.5	-0.12	0.04	0.11	1.4	-0.08 [-0.83, 0.68]
			Placebo	17	17 (100.0)	0.18 (0.75)	-1.6	-0.15	0.09	0.33	1.6	
		Week 24	Tezepelumab	12	11 (91.7)	0.15 (0.68)	-0.8	-0.24	-0.03	0.38	1.8	-0.10 [-0.88, 0.68]
			Placebo	17	15 (88.2)	0.21 (0.66)	-1.4	-0.06	0.23	0.54	1.5	
		Week 36	Tezepelumab	12	11 (91.7)	0.33 (0.52)	-0.1	-0.02	0.19	0.44	1.7	-0.14 [-0.92, 0.64]
			Placebo	17	15 (88.2)	0.42 (0.78)	-1.2	0.15	0.31	0.57	2.2	
		Week 52	Tezepelumab	12	10 (83.3)	0.36 (0.53)	-0.6	0.02	0.41	0.59	1.3	0.09 [-0.71, 0.89]
			Placebo	17	15 (88.2)	0.30 (0.75)	-1.4	0.03	0.28	0.59	1.9	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Absolute values	Baseline	Placebo	2	2 (100.0)	2.17 (1.29)	1.3	1.26	2.17	3.08	3.1	
		Week 2	Placebo	2	2 (100.0)	2.38 (0.90)	1.7	1.74	2.38	3.01	3.0	
		Week 4	Placebo	2	2 (100.0)	2.43 (0.21)	2.3	2.28	2.43	2.57	2.6	
		Week 8	Placebo	2	2 (100.0)	1.83 (0.67)	1.4	1.35	1.83	2.30	2.3	
		Week 12	Placebo	2	2 (100.0)	1.81 (0.18)	1.7	1.68	1.81	1.93	1.9	
		Week 16	Placebo	2	2 (100.0)	2.15 (0.37)	1.9	1.89	2.15	2.41	2.4	
		Week 24	Placebo	2	2 (100.0)	1.97 (0.03)	2.0	1.95	1.97	1.99	2.0	
		Week 36	Placebo	2	2 (100.0)	1.39 (0.01)	1.4	1.38	1.39	1.40	1.4	
		Week 52	Placebo	2	2 (100.0)	1.83 (0.96)	1.2	1.15	1.83	2.51	2.5	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Change from baseline	Week 2	Placebo	2	2 (100.0)	0.20 (0.39)	-0.1	-0.07	0.20	0.48	0.5	
		Week 4	Placebo	2	2 (100.0)	0.25 (1.08)	-0.5	-0.51	0.25	1.02	1.0	
		Week 8	Placebo	2	2 (100.0)	-0.35 (0.62)	-0.8	-0.78	-0.35	0.09	0.1	
		Week 12	Placebo	2	2 (100.0)	-0.37 (1.11)	-1.2	-1.15	-0.37	0.42	0.4	
		Week 16	Placebo	2	2 (100.0)	-0.02 (0.92)	-0.7	-0.67	-0.02	0.63	0.6	
		Week 24	Placebo	2	2 (100.0)	-0.20 (1.26)	-1.1	-1.09	-0.20	0.69	0.7	
		Week 36	Placebo	2	2 (100.0)	-0.78 (1.27)	-1.7	-1.68	-0.78	0.12	0.1	
		Week 52	Placebo	2	2 (100.0)	-0.34 (0.33)	-0.6	-0.57	-0.34	-0.11	-0.1	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	1.43	1.4	1.43	1.43	1.43	1.4	
			Placebo	1	1 (100.0)	1.41	1.4	1.41	1.41	1.41	1.4	
		Week 2	Tezepelumab	1	1 (100.0)	2.24	2.2	2.24	2.24	2.24	2.2	
			Placebo	1	1 (100.0)	1.34	1.3	1.34	1.34	1.34	1.3	
		Week 4	Tezepelumab	1	1 (100.0)	1.82	1.8	1.82	1.82	1.82	1.8	
			Placebo	1	1 (100.0)	1.43	1.4	1.43	1.43	1.43	1.4	
		Week 8	Tezepelumab	1	1 (100.0)	0.97	1.0	0.97	0.97	0.97	1.0	
			Placebo	1	1 (100.0)	1.54	1.5	1.54	1.54	1.54	1.5	
		Week 12	Tezepelumab	1	1 (100.0)	2.07	2.1	2.07	2.07	2.07	2.1	
			Placebo	1	1 (100.0)	1.44	1.4	1.44	1.44	1.44	1.4	
		Week 16	Tezepelumab	1	1 (100.0)	2.03	2.0	2.03	2.03	2.03	2.0	
			Placebo	1	1 (100.0)	1.49	1.5	1.49	1.49	1.49	1.5	
		Week 24	Tezepelumab	1	1 (100.0)	1.61	1.6	1.61	1.61	1.61	1.6	
			Placebo	1	1 (100.0)	1.48	1.5	1.48	1.48	1.48	1.5	
		Week 36	Tezepelumab	1	1 (100.0)	2.25	2.3	2.25	2.25	2.25	2.3	
			Placebo	1	1 (100.0)	1.38	1.4	1.38	1.38	1.38	1.4	
		Week 52	Tezepelumab	1	1 (100.0)	2.17	2.2	2.17	2.17	2.17	2.2	
			Placebo	1	1 (100.0)	1.49	1.5	1.49	1.49	1.49	1.5	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Change from baseline	Week 2	Tezepelumab	1	1 (100.0)	0.81	0.8	0.81	0.81	0.81	0.8	NE
			Placebo	1	1 (100.0)	-0.07	-0.1	-0.07	-0.07	-0.07	-0.1	
		Week 4	Tezepelumab	1	1 (100.0)	0.39	0.4	0.39	0.39	0.39	0.4	NE
			Placebo	1	1 (100.0)	0.02	0.0	0.02	0.02	0.02	0.0	
		Week 8	Tezepelumab	1	1 (100.0)	-0.46	-0.5	-0.46	-0.46	-0.46	-0.5	NE
			Placebo	1	1 (100.0)	0.13	0.1	0.13	0.13	0.13	0.1	
		Week 12	Tezepelumab	1	1 (100.0)	0.64	0.6	0.64	0.64	0.64	0.6	NE
			Placebo	1	1 (100.0)	0.03	0.0	0.03	0.03	0.03	0.0	
		Week 16	Tezepelumab	1	1 (100.0)	0.60	0.6	0.60	0.60	0.60	0.6	NE
			Placebo	1	1 (100.0)	0.08	0.1	0.08	0.08	0.08	0.1	
		Week 24	Tezepelumab	1	1 (100.0)	0.18	0.2	0.18	0.18	0.18	0.2	NE
			Placebo	1	1 (100.0)	0.07	0.1	0.07	0.07	0.07	0.1	
		Week 36	Tezepelumab	1	1 (100.0)	0.82	0.8	0.82	0.82	0.82	0.8	NE
			Placebo	1	1 (100.0)	-0.03	-0.0	-0.03	-0.03	-0.03	-0.0	
		Week 52	Tezepelumab	1	1 (100.0)	0.74	0.7	0.74	0.74	0.74	0.7	NE
			Placebo	1	1 (100.0)	0.08	0.1	0.08	0.08	0.08	0.1	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Absolute values	Baseline	Tezepelumab	2	2 (100.0)	2.68 (0.76)	2.1	2.14	2.68	3.22	3.2	
		Week 2	Tezepelumab	2	2 (100.0)	3.10 (0.85)	2.5	2.50	3.10	3.70	3.7	
		Week 4	Tezepelumab	2	1 (50.0)	2.57	2.6	2.57	2.57	2.57	2.6	
		Week 8	Tezepelumab	2	1 (50.0)	2.58	2.6	2.58	2.58	2.58	2.6	
		Week 12	Tezepelumab	2	1 (50.0)	2.30	2.3	2.30	2.30	2.30	2.3	
		Week 16	Tezepelumab	2	1 (50.0)	2.50	2.5	2.50	2.50	2.50	2.5	
		Week 24	Tezepelumab	2	1 (50.0)	2.32	2.3	2.32	2.32	2.32	2.3	
		Week 36	Tezepelumab	2	1 (50.0)	2.71	2.7	2.71	2.71	2.71	2.7	
		Week 52	Tezepelumab	2	1 (50.0)	2.79	2.8	2.79	2.79	2.79	2.8	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Change from baseline	Week 2	Tezepelumab	2	2 (100.0)	0.42 (0.08)	0.4	0.36	0.42	0.48	0.5	NE
		Week 4	Tezepelumab	2	1 (50.0)	0.43	0.4	0.43	0.43	0.43	0.4	NE
		Week 8	Tezepelumab	2	1 (50.0)	0.44	0.4	0.44	0.44	0.44	0.4	NE
		Week 12	Tezepelumab	2	1 (50.0)	0.16	0.2	0.16	0.16	0.16	0.2	NE
		Week 16	Tezepelumab	2	1 (50.0)	0.36	0.4	0.36	0.36	0.36	0.4	NE
		Week 24	Tezepelumab	2	1 (50.0)	0.18	0.2	0.18	0.18	0.18	0.2	NE
		Week 36	Tezepelumab	2	1 (50.0)	0.57	0.6	0.57	0.57	0.57	0.6	NE
		Week 52	Tezepelumab	2	1 (50.0)	0.65	0.7	0.65	0.65	0.65	0.7	NE

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	3.18	3.2	3.18	3.18	3.18	3.2	
			Placebo	1	1 (100.0)	2.11	2.1	2.11	2.11	2.11	2.1	
		Week 2	Tezepelumab	1	1 (100.0)	3.26	3.3	3.26	3.26	3.26	3.3	
			Placebo	1	1 (100.0)	2.37	2.4	2.37	2.37	2.37	2.4	
		Week 4	Tezepelumab	1	1 (100.0)	3.51	3.5	3.51	3.51	3.51	3.5	
			Placebo	1	1 (100.0)	2.09	2.1	2.09	2.09	2.09	2.1	
		Week 8	Tezepelumab	1	1 (100.0)	3.43	3.4	3.43	3.43	3.43	3.4	
			Placebo	1	1 (100.0)	2.76	2.8	2.76	2.76	2.76	2.8	
		Week 12	Tezepelumab	1	1 (100.0)	3.48	3.5	3.48	3.48	3.48	3.5	
			Placebo	1	1 (100.0)	2.52	2.5	2.52	2.52	2.52	2.5	
		Week 16	Placebo	1	1 (100.0)	2.48	2.5	2.48	2.48	2.48	2.5	
		Week 24	Placebo	1	1 (100.0)	2.71	2.7	2.71	2.71	2.71	2.7	
		Week 52	Placebo	1	1 (100.0)	2.14	2.1	2.14	2.14	2.14	2.1	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Change from baseline	Week 2	Tezepelumab	1	1 (100.0)	0.08	0.1	0.08	0.08	0.08	0.1	NE
			Placebo	1	1 (100.0)	0.26	0.3	0.26	0.26	0.26	0.3	
		Week 4	Tezepelumab	1	1 (100.0)	0.33	0.3	0.33	0.33	0.33	0.3	NE
			Placebo	1	1 (100.0)	-0.02	-0.0	-0.02	-0.02	-0.02	-0.0	
		Week 8	Tezepelumab	1	1 (100.0)	0.25	0.3	0.25	0.25	0.25	0.3	NE
			Placebo	1	1 (100.0)	0.65	0.7	0.65	0.65	0.65	0.7	
		Week 12	Tezepelumab	1	1 (100.0)	0.30	0.3	0.30	0.30	0.30	0.3	NE
			Placebo	1	1 (100.0)	0.41	0.4	0.41	0.41	0.41	0.4	
		Week 16	Placebo	1	1 (100.0)	0.37	0.4	0.37	0.37	0.37	0.4	
		Week 24	Placebo	1	1 (100.0)	0.60	0.6	0.60	0.60	0.60	0.6	
		Week 52	Placebo	1	1 (100.0)	0.03	0.0	0.03	0.03	0.03	0.0	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Absolute values	Baseline	Tezepelumab	11	11 (100.0)	2.67 (0.67)	1.4	2.12	2.69	3.22	3.7	
			Placebo	18	18 (100.0)	2.61 (0.94)	1.0	2.08	2.57	3.02	4.9	
		Week 2	Tezepelumab	11	11 (100.0)	2.84 (0.75)	1.7	2.41	2.74	3.39	4.0	
			Placebo	18	18 (100.0)	2.76 (0.64)	1.7	2.31	2.72	3.01	4.7	
		Week 4	Tezepelumab	11	10 (90.9)	2.71 (0.72)	1.3	2.51	2.74	3.18	3.8	
			Placebo	18	17 (94.4)	2.72 (0.41)	2.2	2.50	2.59	2.86	3.7	
		Week 8	Tezepelumab	11	10 (90.9)	2.57 (0.93)	1.0	2.15	2.64	3.30	3.7	
			Placebo	18	17 (94.4)	2.74 (0.74)	1.4	2.35	2.69	2.99	4.9	
		Week 12	Tezepelumab	11	9 (81.8)	2.47 (0.98)	0.8	1.68	2.64	3.34	3.6	
			Placebo	18	18 (100.0)	2.79 (0.75)	1.7	2.44	2.58	3.07	5.0	
		Week 16	Tezepelumab	11	10 (90.9)	2.70 (0.66)	1.5	2.22	2.62	3.31	3.8	
			Placebo	18	18 (100.0)	2.76 (0.74)	1.9	2.41	2.52	3.01	5.2	
		Week 24	Tezepelumab	11	10 (90.9)	2.73 (0.71)	1.7	2.20	2.89	3.19	3.7	
			Placebo	18	16 (88.9)	2.88 (0.74)	2.0	2.56	2.71	3.13	5.1	
		Week 36	Tezepelumab	11	10 (90.9)	2.89 (0.71)	1.4	2.56	2.94	3.30	4.0	
			Placebo	18	17 (94.4)	2.92 (0.92)	1.4	2.55	2.93	3.33	5.3	
		Week 52	Tezepelumab	11	9 (81.8)	2.97 (0.71)	1.9	2.53	3.08	3.31	4.2	
			Placebo	18	16 (88.9)	2.89 (0.94)	1.2	2.37	2.66	3.44	5.3	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Change from baseline	Week 2	Tezepelumab	11	11 (100.0)	0.17 (0.52)	-0.5	-0.28	0.19	0.47	1.4	0.04 [-0.71, 0.79]
			Placebo	18	18 (100.0)	0.15 (0.62)	-1.3	-0.08	0.01	0.23	1.7	
		Week 4	Tezepelumab	11	10 (90.9)	0.10 (0.53)	-0.3	-0.18	-0.14	0.13	1.2	-0.22 [-1.00, 0.57]
			Placebo	18	17 (94.4)	0.24 (0.68)	-1.0	-0.11	0.21	0.40	1.7	
		Week 8	Tezepelumab	11	10 (90.9)	-0.05 (0.73)	-1.1	-0.40	-0.05	0.14	1.6	-0.18 [-0.96, 0.60]
			Placebo	18	17 (94.4)	0.10 (0.82)	-1.7	-0.22	0.03	0.17	2.0	
		Week 12	Tezepelumab	11	9 (81.8)	-0.19 (0.81)	-1.5	-0.52	-0.12	-0.09	1.5	-0.49 [-1.30, 0.32]
			Placebo	18	18 (100.0)	0.18 (0.74)	-1.2	-0.22	0.07	0.39	1.6	
		Week 16	Tezepelumab	11	10 (90.9)	0.09 (0.49)	-0.5	-0.12	0.02	0.10	1.4	-0.09 [-0.87, 0.68]
			Placebo	18	18 (100.0)	0.15 (0.76)	-1.6	-0.21	0.06	0.33	1.6	
		Week 24	Tezepelumab	11	10 (90.9)	0.12 (0.71)	-0.8	-0.24	-0.04	0.27	1.8	-0.02 [-0.81, 0.77]
			Placebo	18	16 (88.9)	0.14 (0.72)	-1.4	-0.16	0.20	0.53	1.5	
		Week 36	Tezepelumab	11	10 (90.9)	0.28 (0.52)	-0.1	-0.02	0.09	0.39	1.7	0.00 [-0.78, 0.78]
			Placebo	18	17 (94.4)	0.28 (0.89)	-1.7	0.12	0.24	0.47	2.2	
		Week 52	Tezepelumab	11	9 (81.8)	0.32 (0.54)	-0.6	0.02	0.39	0.52	1.3	0.11 [-0.70, 0.93]
			Placebo	18	16 (88.9)	0.24 (0.76)	-1.4	-0.07	0.27	0.56	1.9	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	1.43	1.4	1.43	1.43	1.43	1.4	
			Placebo	1	1 (100.0)	1.41	1.4	1.41	1.41	1.41	1.4	
		Week 2	Tezepelumab	1	1 (100.0)	2.24	2.2	2.24	2.24	2.24	2.2	
			Placebo	1	1 (100.0)	1.34	1.3	1.34	1.34	1.34	1.3	
		Week 4	Tezepelumab	1	1 (100.0)	1.82	1.8	1.82	1.82	1.82	1.8	
			Placebo	1	1 (100.0)	1.43	1.4	1.43	1.43	1.43	1.4	
		Week 8	Tezepelumab	1	1 (100.0)	0.97	1.0	0.97	0.97	0.97	1.0	
			Placebo	1	1 (100.0)	1.54	1.5	1.54	1.54	1.54	1.5	
		Week 12	Tezepelumab	1	1 (100.0)	2.07	2.1	2.07	2.07	2.07	2.1	
			Placebo	1	1 (100.0)	1.44	1.4	1.44	1.44	1.44	1.4	
		Week 16	Tezepelumab	1	1 (100.0)	2.03	2.0	2.03	2.03	2.03	2.0	
			Placebo	1	1 (100.0)	1.49	1.5	1.49	1.49	1.49	1.5	
		Week 24	Tezepelumab	1	1 (100.0)	1.61	1.6	1.61	1.61	1.61	1.6	
			Placebo	1	1 (100.0)	1.48	1.5	1.48	1.48	1.48	1.5	
		Week 36	Tezepelumab	1	1 (100.0)	2.25	2.3	2.25	2.25	2.25	2.3	
			Placebo	1	1 (100.0)	1.38	1.4	1.38	1.38	1.38	1.4	
		Week 52	Tezepelumab	1	1 (100.0)	2.17	2.2	2.17	2.17	2.17	2.2	
			Placebo	1	1 (100.0)	1.49	1.5	1.49	1.49	1.49	1.5	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Change from baseline	Week 2	Tezepelumab	1	1 (100.0)	0.81	0.8	0.81	0.81	0.81	0.8	NE
			Placebo	1	1 (100.0)	-0.07	-0.1	-0.07	-0.07	-0.07	-0.1	
		Week 4	Tezepelumab	1	1 (100.0)	0.39	0.4	0.39	0.39	0.39	0.4	NE
			Placebo	1	1 (100.0)	0.02	0.0	0.02	0.02	0.02	0.0	
		Week 8	Tezepelumab	1	1 (100.0)	-0.46	-0.5	-0.46	-0.46	-0.46	-0.5	NE
			Placebo	1	1 (100.0)	0.13	0.1	0.13	0.13	0.13	0.1	
		Week 12	Tezepelumab	1	1 (100.0)	0.64	0.6	0.64	0.64	0.64	0.6	NE
			Placebo	1	1 (100.0)	0.03	0.0	0.03	0.03	0.03	0.0	
		Week 16	Tezepelumab	1	1 (100.0)	0.60	0.6	0.60	0.60	0.60	0.6	NE
			Placebo	1	1 (100.0)	0.08	0.1	0.08	0.08	0.08	0.1	
		Week 24	Tezepelumab	1	1 (100.0)	0.18	0.2	0.18	0.18	0.18	0.2	NE
			Placebo	1	1 (100.0)	0.07	0.1	0.07	0.07	0.07	0.1	
		Week 36	Tezepelumab	1	1 (100.0)	0.82	0.8	0.82	0.82	0.82	0.8	NE
			Placebo	1	1 (100.0)	-0.03	-0.0	-0.03	-0.03	-0.03	-0.0	
		Week 52	Tezepelumab	1	1 (100.0)	0.74	0.7	0.74	0.74	0.74	0.7	NE
			Placebo	1	1 (100.0)	0.08	0.1	0.08	0.08	0.08	0.1	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Absolute values	Baseline	Tezepelumab	2	2 (100.0)	2.46 (0.45)	2.1	2.14	2.46	2.78	2.8	
		Week 2	Tezepelumab	2	1 (50.0)	2.50	2.5	2.50	2.50	2.50	2.5	
		Week 4	Tezepelumab	2	2 (100.0)	2.52 (0.07)	2.5	2.47	2.52	2.57	2.6	
		Week 8	Tezepelumab	2	2 (100.0)	3.01 (0.60)	2.6	2.58	3.01	3.43	3.4	
		Week 12	Tezepelumab	2	2 (100.0)	2.84 (0.76)	2.3	2.30	2.84	3.37	3.4	
		Week 16	Tezepelumab	2	2 (100.0)	2.95 (0.63)	2.5	2.50	2.95	3.39	3.4	
		Week 24	Tezepelumab	2	2 (100.0)	2.74 (0.59)	2.3	2.32	2.74	3.16	3.2	
		Week 36	Tezepelumab	2	2 (100.0)	3.13 (0.59)	2.7	2.71	3.13	3.55	3.6	
		Week 52	Tezepelumab	2	2 (100.0)	3.18 (0.55)	2.8	2.79	3.18	3.57	3.6	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Change from baseline	Week 2	Tezepelumab	2	1 (50.0)	0.36	0.4	0.36	0.36	0.36	0.4	NE
		Week 4	Tezepelumab	2	2 (100.0)	0.06 (0.52)	-0.3	-0.31	0.06	0.43	0.4	NE
		Week 8	Tezepelumab	2	2 (100.0)	0.55 (0.15)	0.4	0.44	0.55	0.65	0.7	NE
		Week 12	Tezepelumab	2	2 (100.0)	0.38 (0.30)	0.2	0.16	0.38	0.59	0.6	NE
		Week 16	Tezepelumab	2	2 (100.0)	0.49 (0.18)	0.4	0.36	0.49	0.61	0.6	NE
		Week 24	Tezepelumab	2	2 (100.0)	0.28 (0.14)	0.2	0.18	0.28	0.38	0.4	NE
		Week 36	Tezepelumab	2	2 (100.0)	0.67 (0.14)	0.6	0.57	0.67	0.77	0.8	NE
		Week 52	Tezepelumab	2	2 (100.0)	0.72 (0.10)	0.7	0.65	0.72	0.79	0.8	NE

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
< 18.5 kg/m**2	Absolute values	Baseline	Tezepelumab	2	2 (100.0)	2.06 (0.89)	1.4	1.43	2.06	2.69	2.7	
			Placebo	4	4 (100.0)	2.99 (0.76)	2.2	2.47	2.84	3.50	4.0	
		Week 2	Tezepelumab	2	2 (100.0)	2.22 (0.74)	1.7	1.69	2.22	2.74	2.7	
			Placebo	4	4 (100.0)	2.59 (0.22)	2.3	2.45	2.66	2.73	2.8	
		Week 4	Tezepelumab	2	2 (100.0)	1.95 (0.94)	1.3	1.28	1.95	2.61	2.6	
			Placebo	4	4 (100.0)	2.75 (0.46)	2.2	2.38	2.82	3.11	3.2	
		Week 8	Tezepelumab	2	2 (100.0)	1.87 (1.19)	1.0	1.03	1.87	2.71	2.7	
			Placebo	4	4 (100.0)	2.52 (0.19)	2.4	2.38	2.47	2.66	2.8	
		Week 12	Tezepelumab	2	2 (100.0)	1.77 (1.38)	0.8	0.79	1.77	2.74	2.7	
			Placebo	4	4 (100.0)	2.64 (0.47)	2.0	2.30	2.75	2.99	3.1	
		Week 16	Tezepelumab	2	2 (100.0)	2.14 (0.84)	1.5	1.54	2.14	2.73	2.7	
			Placebo	4	4 (100.0)	2.60 (0.27)	2.4	2.45	2.48	2.75	3.0	
		Week 24	Tezepelumab	2	2 (100.0)	2.30 (0.85)	1.7	1.70	2.30	2.90	2.9	
			Placebo	4	3 (75.0)	2.93 (0.28)	2.6	2.61	3.05	3.14	3.1	
		Week 36	Tezepelumab	2	2 (100.0)	2.26 (1.17)	1.4	1.43	2.26	3.08	3.1	
			Placebo	4	3 (75.0)	3.08 (0.40)	2.8	2.81	2.90	3.54	3.5	
		Week 52	Tezepelumab	2	2 (100.0)	2.47 (0.87)	1.9	1.85	2.47	3.08	3.1	
			Placebo	4	3 (75.0)	2.94 (0.28)	2.7	2.67	2.93	3.22	3.2	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
< 18.5 kg/m**2	Change from baseline	Week 2	Tezepelumab	2	2 (100.0)	0.16 (0.15)	0.1	0.05	0.16	0.26	0.3	1.06 [-0.79, 2.91]
			Placebo	4	4 (100.0)	-0.40 (0.59)	-1.3	-0.77	-0.18	-0.03	0.0	
		Week 4	Tezepelumab	2	2 (100.0)	-0.12 (0.05)	-0.1	-0.15	-0.12	-0.08	-0.1	0.28 [-1.43, 1.99]
			Placebo	4	4 (100.0)	-0.24 (0.52)	-1.0	-0.55	-0.09	0.07	0.2	
		Week 8	Tezepelumab	2	2 (100.0)	-0.19 (0.30)	-0.4	-0.40	-0.19	0.02	0.0	0.37 [-1.35, 2.08]
			Placebo	4	4 (100.0)	-0.47 (0.85)	-1.7	-1.07	-0.18	0.13	0.2	
		Week 12	Tezepelumab	2	2 (100.0)	-0.29 (0.49)	-0.6	-0.64	-0.29	0.05	0.1	0.10 [-1.59, 1.80]
			Placebo	4	4 (100.0)	-0.35 (0.48)	-1.0	-0.67	-0.31	-0.02	0.2	
		Week 16	Tezepelumab	2	2 (100.0)	0.08 (0.05)	0.0	0.04	0.08	0.11	0.1	0.65 [-1.11, 2.40]
			Placebo	4	4 (100.0)	-0.39 (0.82)	-1.6	-0.90	-0.09	0.13	0.2	
		Week 24	Tezepelumab	2	2 (100.0)	0.24 (0.04)	0.2	0.21	0.24	0.27	0.3	0.68 [-1.19, 2.55]
			Placebo	4	3 (75.0)	-0.30 (0.97)	-1.4	-1.42	0.17	0.35	0.3	
		Week 36	Tezepelumab	2	2 (100.0)	0.20 (0.28)	0.0	0.00	0.20	0.39	0.4	0.44 [-1.39, 2.26]
			Placebo	4	3 (75.0)	-0.15 (0.94)	-1.2	-1.22	0.20	0.57	0.6	
		Week 52	Tezepelumab	2	2 (100.0)	0.41 (0.02)	0.4	0.39	0.41	0.42	0.4	0.93 [-1.01, 2.86]
			Placebo	4	3 (75.0)	-0.29 (0.92)	-1.4	-1.36	0.23	0.25	0.3	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Absolute values	Baseline	Tezepelumab	8	8 (100.0)	2.63 (0.72)	1.4	2.09	2.82	3.08	3.7	
			Placebo	11	11 (100.0)	2.41 (1.06)	1.0	1.89	2.11	3.02	4.9	
		Week 2	Tezepelumab	8	8 (100.0)	2.83 (0.73)	1.7	2.33	2.86	3.31	4.0	
			Placebo	11	11 (100.0)	2.71 (0.87)	1.3	2.30	2.40	3.18	4.7	
		Week 4	Tezepelumab	8	8 (100.0)	2.77 (0.70)	1.8	2.21	2.74	3.35	3.8	
			Placebo	11	10 (90.9)	2.49 (0.55)	1.4	2.39	2.50	2.60	3.7	
		Week 8	Tezepelumab	8	8 (100.0)	2.56 (1.08)	1.0	1.61	2.82	3.48	3.7	
			Placebo	11	10 (90.9)	2.83 (0.91)	1.5	2.30	2.73	3.24	4.9	
		Week 12	Tezepelumab	8	8 (100.0)	2.62 (0.84)	1.4	1.88	2.61	3.50	3.6	
			Placebo	11	11 (100.0)	2.83 (0.91)	1.4	2.44	2.52	3.52	5.0	
		Week 16	Tezepelumab	8	7 (87.5)	2.74 (0.63)	2.0	2.20	2.50	3.35	3.8	
			Placebo	11	11 (100.0)	2.75 (0.97)	1.5	2.26	2.52	3.21	5.2	
		Week 24	Tezepelumab	8	7 (87.5)	2.61 (0.85)	1.6	1.69	2.53	3.59	3.7	
			Placebo	11	10 (90.9)	2.89 (0.96)	1.5	2.60	2.69	3.39	5.1	
		Week 36	Tezepelumab	8	7 (87.5)	2.97 (0.63)	2.3	2.39	2.93	3.64	4.0	
			Placebo	11	10 (90.9)	2.98 (1.09)	1.4	2.34	2.93	3.51	5.3	
		Week 52	Tezepelumab	8	6 (75.0)	2.99 (0.78)	2.2	2.37	2.91	3.31	4.2	
			Placebo	11	10 (90.9)	2.95 (1.14)	1.5	2.14	2.55	3.74	5.3	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Change from baseline	Week 2	Tezepelumab	8	8 (100.0)	0.20 (0.64)	-0.5	-0.34	0.13	0.57	1.4	-0.17 [-1.08, 0.75]
			Placebo	11	11 (100.0)	0.30 (0.60)	-0.2	-0.07	0.06	0.26	1.7	
		Week 4	Tezepelumab	8	8 (100.0)	0.14 (0.51)	-0.3	-0.24	0.00	0.36	1.2	-0.34 [-1.28, 0.59]
			Placebo	11	10 (90.9)	0.33 (0.57)	-0.4	-0.02	0.28	0.40	1.7	
		Week 8	Tezepelumab	8	8 (100.0)	-0.07 (0.81)	-1.1	-0.65	-0.04	0.20	1.6	-0.59 [-1.55, 0.36]
			Placebo	11	10 (90.9)	0.39 (0.76)	-0.3	-0.13	0.08	0.65	2.0	
		Week 12	Tezepelumab	8	8 (100.0)	-0.01 (0.89)	-1.5	-0.41	-0.11	0.47	1.5	-0.59 [-1.52, 0.34]
			Placebo	11	11 (100.0)	0.42 (0.60)	-0.2	0.03	0.26	0.41	1.6	
		Week 16	Tezepelumab	8	7 (87.5)	0.19 (0.62)	-0.5	-0.26	0.00	0.60	1.4	-0.24 [-1.19, 0.71]
			Placebo	11	11 (100.0)	0.34 (0.67)	-0.4	-0.07	0.18	0.37	1.6	
		Week 24	Tezepelumab	8	7 (87.5)	0.06 (0.82)	-0.8	-0.51	-0.06	0.18	1.8	-0.43 [-1.41, 0.55]
			Placebo	11	10 (90.9)	0.34 (0.50)	-0.3	-0.01	0.23	0.54	1.5	
		Week 36	Tezepelumab	8	7 (87.5)	0.42 (0.62)	-0.0	-0.02	0.19	0.82	1.7	-0.17 [-1.14, 0.79]
			Placebo	11	10 (90.9)	0.54 (0.75)	-0.3	0.20	0.32	0.47	2.2	
		Week 52	Tezepelumab	8	6 (75.0)	0.37 (0.68)	-0.6	-0.16	0.48	0.74	1.3	-0.27 [-1.29, 0.75]
			Placebo	11	10 (90.9)	0.55 (0.62)	-0.0	0.08	0.35	0.63	1.9	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	2.71 (0.54)	2.1	2.14	2.78	3.22	3.2	
			Placebo	4	4 (100.0)	2.26 (0.77)	1.3	1.66	2.42	2.86	2.9	
		Week 2	Tezepelumab	3	2 (66.7)	3.10 (0.85)	2.5	2.50	3.10	3.70	3.7	
			Placebo	4	4 (100.0)	2.57 (0.57)	1.7	2.24	2.77	2.91	3.0	
		Week 4	Tezepelumab	3	2 (66.7)	2.52 (0.07)	2.5	2.47	2.52	2.57	2.6	
			Placebo	4	4 (100.0)	2.82 (0.49)	2.3	2.47	2.76	3.16	3.5	
		Week 8	Tezepelumab	3	2 (66.7)	3.01 (0.60)	2.6	2.58	3.01	3.43	3.4	
			Placebo	4	4 (100.0)	2.55 (0.81)	1.4	2.06	2.88	3.04	3.1	
		Week 12	Tezepelumab	3	2 (66.7)	2.84 (0.76)	2.3	2.30	2.84	3.37	3.4	
			Placebo	4	4 (100.0)	2.65 (0.73)	1.7	2.12	2.76	3.17	3.4	
		Week 16	Tezepelumab	3	2 (66.7)	2.95 (0.63)	2.5	2.50	2.95	3.39	3.4	
			Placebo	4	4 (100.0)	2.66 (0.56)	1.9	2.26	2.79	3.06	3.2	
		Week 24	Tezepelumab	3	2 (66.7)	2.74 (0.59)	2.3	2.32	2.74	3.16	3.2	
			Placebo	4	4 (100.0)	2.63 (0.51)	2.0	2.24	2.73	3.02	3.1	
		Week 36	Tezepelumab	3	2 (66.7)	3.13 (0.59)	2.7	2.71	3.13	3.55	3.6	
			Placebo	4	4 (100.0)	2.63 (0.84)	1.4	2.16	2.95	3.10	3.2	
		Week 52	Tezepelumab	3	2 (66.7)	3.18 (0.55)	2.8	2.79	3.18	3.57	3.6	
			Placebo	4	4 (100.0)	2.24 (0.82)	1.2	1.62	2.37	2.85	3.1	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Change from baseline	Week 2	Tezepelumab	3	2 (66.7)	0.42 (0.08)	0.4	0.36	0.42	0.48	0.5	0.34 [-1.37, 2.05]
			Placebo	4	4 (100.0)	0.31 (0.36)	-0.0	0.02	0.27	0.61	0.7	
		Week 4	Tezepelumab	3	2 (66.7)	0.06 (0.52)	-0.3	-0.31	0.06	0.43	0.4	-0.69 [-2.45, 1.07]
			Placebo	4	4 (100.0)	0.56 (0.77)	-0.1	-0.10	0.47	1.21	1.4	
		Week 8	Tezepelumab	3	2 (66.7)	0.55 (0.15)	0.4	0.44	0.55	0.65	0.7	0.59 [-1.16, 2.34]
			Placebo	4	4 (100.0)	0.29 (0.50)	-0.0	0.02	0.07	0.56	1.0	
		Week 12	Tezepelumab	3	2 (66.7)	0.38 (0.30)	0.2	0.16	0.38	0.59	0.6	-0.02 [-1.71, 1.68]
			Placebo	4	4 (100.0)	0.39 (0.68)	-0.2	-0.10	0.22	0.87	1.3	
		Week 16	Tezepelumab	3	2 (66.7)	0.49 (0.18)	0.4	0.36	0.49	0.61	0.6	0.17 [-1.53, 1.87]
			Placebo	4	4 (100.0)	0.40 (0.58)	-0.1	-0.07	0.32	0.87	1.1	
		Week 24	Tezepelumab	3	2 (66.7)	0.28 (0.14)	0.2	0.18	0.28	0.38	0.4	-0.16 [-1.87, 1.54]
			Placebo	4	4 (100.0)	0.37 (0.61)	-0.3	-0.13	0.34	0.87	1.1	
		Week 36	Tezepelumab	3	2 (66.7)	0.67 (0.14)	0.6	0.57	0.67	0.77	0.8	0.65 [-1.10, 2.41]
			Placebo	4	4 (100.0)	0.37 (0.53)	0.0	0.08	0.14	0.66	1.2	
		Week 52	Tezepelumab	3	2 (66.7)	0.72 (0.10)	0.7	0.65	0.72	0.79	0.8	1.61 [-0.42, 3.64]
			Placebo	4	4 (100.0)	-0.03 (0.53)	-0.7	-0.40	-0.00	0.35	0.6	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	2	2 (100.0)	2.78 (0.93)	2.1	2.12	2.78	3.43	3.4	
			Placebo	1	1 (100.0)	3.08	3.1	3.08	3.08	3.08	3.1	
		Week 2	Tezepelumab	2	2 (100.0)	2.99 (0.57)	2.6	2.59	2.99	3.39	3.4	
			Placebo	1	1 (100.0)	3.01	3.0	3.01	3.01	3.01	3.0	
		Week 4	Tezepelumab	2	2 (100.0)	3.19 (0.15)	3.1	3.08	3.19	3.29	3.3	
			Placebo	1	1 (100.0)	2.57	2.6	2.57	2.57	2.57	2.6	
		Week 8	Tezepelumab	2	2 (100.0)	2.92 (0.54)	2.5	2.54	2.92	3.30	3.3	
			Placebo	1	1 (100.0)	2.30	2.3	2.30	2.30	2.30	2.3	
		Week 12	Tezepelumab	2	1 (50.0)	3.34	3.3	3.34	3.34	3.34	3.3	
			Placebo	1	1 (100.0)	1.93	1.9	1.93	1.93	1.93	1.9	
		Week 16	Tezepelumab	2	2 (100.0)	2.77 (0.77)	2.2	2.22	2.77	3.31	3.3	
			Placebo	1	1 (100.0)	2.41	2.4	2.41	2.41	2.41	2.4	
		Week 24	Tezepelumab	2	2 (100.0)	3.04 (0.22)	2.9	2.88	3.04	3.19	3.2	
			Placebo	1	1 (100.0)	1.99	2.0	1.99	1.99	1.99	2.0	
		Week 36	Tezepelumab	2	2 (100.0)	2.93 (0.52)	2.6	2.56	2.93	3.30	3.3	
			Placebo	1	1 (100.0)	1.40	1.4	1.40	1.40	1.40	1.4	
		Week 52	Tezepelumab	2	2 (100.0)	3.05 (0.57)	2.6	2.64	3.05	3.45	3.5	
			Placebo	1	1 (100.0)	2.51	2.5	2.51	2.51	2.51	2.5	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Change from baseline	Week 2	Tezepelumab	2	2 (100.0)	0.21 (0.36)	-0.0	-0.04	0.21	0.47	0.5	NE
			Placebo	1	1 (100.0)	-0.07	-0.1	-0.07	-0.07	-0.07	-0.1	
		Week 4	Tezepelumab	2	2 (100.0)	0.41 (0.78)	-0.1	-0.14	0.41	0.96	1.0	NE
			Placebo	1	1 (100.0)	-0.51	-0.5	-0.51	-0.51	-0.51	-0.5	
		Week 8	Tezepelumab	2	2 (100.0)	0.14 (0.39)	-0.1	-0.13	0.14	0.42	0.4	NE
			Placebo	1	1 (100.0)	-0.78	-0.8	-0.78	-0.78	-0.78	-0.8	
		Week 12	Tezepelumab	2	1 (50.0)	-0.09	-0.1	-0.09	-0.09	-0.09	-0.1	NE
			Placebo	1	1 (100.0)	-1.15	-1.2	-1.15	-1.15	-1.15	-1.2	
		Week 16	Tezepelumab	2	2 (100.0)	-0.01 (0.16)	-0.1	-0.12	-0.01	0.10	0.1	NE
			Placebo	1	1 (100.0)	-0.67	-0.7	-0.67	-0.67	-0.67	-0.7	
		Week 24	Tezepelumab	2	2 (100.0)	0.26 (0.71)	-0.2	-0.24	0.26	0.76	0.8	NE
			Placebo	1	1 (100.0)	-1.09	-1.1	-1.09	-1.09	-1.09	-1.1	
		Week 36	Tezepelumab	2	2 (100.0)	0.15 (0.40)	-0.1	-0.13	0.15	0.44	0.4	NE
			Placebo	1	1 (100.0)	-1.68	-1.7	-1.68	-1.68	-1.68	-1.7	
		Week 52	Tezepelumab	2	2 (100.0)	0.27 (0.35)	0.0	0.02	0.27	0.52	0.5	NE
			Placebo	1	1 (100.0)	-0.57	-0.6	-0.57	-0.57	-0.57	-0.6	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	2.69	2.7	2.69	2.69	2.69	2.7	
			Placebo	2	2 (100.0)	3.15 (2.45)	1.4	1.41	3.15	4.88	4.9	
		Week 2	Tezepelumab	1	1 (100.0)	2.41	2.4	2.41	2.41	2.41	2.4	
			Placebo	2	2 (100.0)	3.02 (2.37)	1.3	1.34	3.02	4.69	4.7	
		Week 4	Tezepelumab	1	1 (100.0)	2.51	2.5	2.51	2.51	2.51	2.5	
			Placebo	2	1 (50.0)	1.43	1.4	1.43	1.43	1.43	1.4	
		Week 8	Tezepelumab	1	1 (100.0)	2.56	2.6	2.56	2.56	2.56	2.6	
			Placebo	2	2 (100.0)	3.23 (2.38)	1.5	1.54	3.23	4.91	4.9	
		Week 12	Tezepelumab	1	1 (100.0)	2.57	2.6	2.57	2.57	2.57	2.6	
			Placebo	2	2 (100.0)	3.21 (2.50)	1.4	1.44	3.21	4.97	5.0	
		Week 16	Tezepelumab	1	1 (100.0)	2.43	2.4	2.43	2.43	2.43	2.4	
			Placebo	2	2 (100.0)	3.35 (2.63)	1.5	1.49	3.35	5.21	5.2	
		Week 24	Tezepelumab	1	1 (100.0)	2.53	2.5	2.53	2.53	2.53	2.5	
			Placebo	2	2 (100.0)	3.30 (2.57)	1.5	1.48	3.30	5.11	5.1	
		Week 36	Tezepelumab	1	1 (100.0)	2.67	2.7	2.67	2.67	2.67	2.7	
			Placebo	2	2 (100.0)	3.34 (2.77)	1.4	1.38	3.34	5.30	5.3	
		Week 52	Tezepelumab	1	1 (100.0)	2.53	2.5	2.53	2.53	2.53	2.5	
			Placebo	2	2 (100.0)	3.38 (2.67)	1.5	1.49	3.38	5.26	5.3	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Change from baseline	Week 2	Tezepelumab	1	1 (100.0)	-0.28	-0.3	-0.28	-0.28	-0.28	-0.3	NE
			Placebo	2	2 (100.0)	-0.13 (0.08)	-0.2	-0.19	-0.13	-0.07	-0.1	
		Week 4	Tezepelumab	1	1 (100.0)	-0.18	-0.2	-0.18	-0.18	-0.18	-0.2	NE
			Placebo	2	1 (50.0)	0.02	0.0	0.02	0.02	0.02	0.0	
		Week 8	Tezepelumab	1	1 (100.0)	-0.13	-0.1	-0.13	-0.13	-0.13	-0.1	NE
			Placebo	2	2 (100.0)	0.08 (0.07)	0.0	0.03	0.08	0.13	0.1	
		Week 12	Tezepelumab	1	1 (100.0)	-0.12	-0.1	-0.12	-0.12	-0.12	-0.1	NE
			Placebo	2	2 (100.0)	0.06 (0.04)	0.0	0.03	0.06	0.09	0.1	
		Week 16	Tezepelumab	1	1 (100.0)	-0.26	-0.3	-0.26	-0.26	-0.26	-0.3	NE
			Placebo	2	2 (100.0)	0.21 (0.18)	0.1	0.08	0.21	0.33	0.3	
		Week 24	Tezepelumab	1	1 (100.0)	-0.16	-0.2	-0.16	-0.16	-0.16	-0.2	NE
			Placebo	2	2 (100.0)	0.15 (0.11)	0.1	0.07	0.15	0.23	0.2	
		Week 36	Tezepelumab	1	1 (100.0)	-0.02	-0.0	-0.02	-0.02	-0.02	-0.0	NE
			Placebo	2	2 (100.0)	0.19 (0.32)	-0.0	-0.03	0.19	0.42	0.4	
		Week 52	Tezepelumab	1	1 (100.0)	-0.16	-0.2	-0.16	-0.16	-0.16	-0.2	NE
			Placebo	2	2 (100.0)	0.23 (0.21)	0.1	0.08	0.23	0.38	0.4	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Absolute values	Baseline	Tezepelumab	14	14 (100.0)	2.58 (0.71)	1.4	2.12	2.74	3.18	3.7	
			Placebo	18	18 (100.0)	2.46 (0.75)	1.0	2.08	2.34	2.97	4.0	
		Week 2	Tezepelumab	14	13 (92.9)	2.83 (0.71)	1.7	2.50	2.74	3.36	4.0	
			Placebo	18	18 (100.0)	2.64 (0.42)	1.7	2.31	2.66	2.94	3.5	
		Week 4	Tezepelumab	14	13 (92.9)	2.69 (0.71)	1.3	2.47	2.67	3.18	3.8	
			Placebo	18	18 (100.0)	2.68 (0.42)	2.1	2.44	2.59	2.86	3.7	
		Week 8	Tezepelumab	14	13 (92.9)	2.58 (0.99)	1.0	2.15	2.71	3.43	3.7	
			Placebo	18	17 (94.4)	2.61 (0.48)	1.4	2.35	2.69	2.93	3.3	
		Week 12	Tezepelumab	14	12 (85.7)	2.58 (0.93)	0.8	1.88	2.69	3.43	3.6	
			Placebo	18	18 (100.0)	2.66 (0.52)	1.7	2.44	2.55	2.96	3.5	
		Week 16	Tezepelumab	14	12 (85.7)	2.71 (0.66)	1.5	2.21	2.62	3.33	3.8	
			Placebo	18	18 (100.0)	2.61 (0.41)	1.9	2.41	2.51	2.94	3.5	
		Week 24	Tezepelumab	14	12 (85.7)	2.66 (0.74)	1.6	1.95	2.89	3.18	3.7	
			Placebo	18	16 (88.9)	2.73 (0.44)	2.0	2.56	2.69	3.08	3.4	
		Week 36	Tezepelumab	14	12 (85.7)	2.90 (0.69)	1.4	2.48	2.94	3.43	4.0	
			Placebo	18	16 (88.9)	2.77 (0.71)	1.4	2.45	2.92	3.28	3.7	
		Week 52	Tezepelumab	14	11 (78.6)	2.98 (0.69)	1.9	2.37	3.08	3.45	4.2	
			Placebo	18	16 (88.9)	2.69 (0.71)	1.2	2.21	2.64	3.14	3.8	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Change from baseline	Week 2	Tezepelumab	14	13 (92.9)	0.27 (0.49)	-0.5	0.05	0.26	0.47	1.4	0.16 [-0.56, 0.87]
			Placebo	18	18 (100.0)	0.18 (0.62)	-1.3	-0.07	0.04	0.26	1.7	
		Week 4	Tezepelumab	14	13 (92.9)	0.16 (0.49)	-0.3	-0.15	-0.08	0.39	1.2	-0.11 [-0.83, 0.60]
			Placebo	18	18 (100.0)	0.22 (0.66)	-1.0	-0.11	0.09	0.40	1.7	
		Week 8	Tezepelumab	14	13 (92.9)	0.04 (0.68)	-1.1	-0.40	0.04	0.42	1.6	-0.12 [-0.84, 0.61]
			Placebo	18	17 (94.4)	0.13 (0.83)	-1.7	-0.22	0.05	0.49	2.0	
		Week 12	Tezepelumab	14	12 (85.7)	0.01 (0.76)	-1.5	-0.41	-0.02	0.45	1.5	-0.25 [-0.99, 0.48]
			Placebo	18	18 (100.0)	0.20 (0.74)	-1.2	-0.22	0.13	0.41	1.6	
		Week 16	Tezepelumab	14	12 (85.7)	0.22 (0.47)	-0.5	0.00	0.10	0.48	1.4	0.11 [-0.62, 0.84]
			Placebo	18	18 (100.0)	0.15 (0.76)	-1.6	-0.21	0.06	0.37	1.6	
		Week 24	Tezepelumab	14	12 (85.7)	0.18 (0.64)	-0.8	-0.15	0.18	0.33	1.8	0.03 [-0.72, 0.77]
			Placebo	18	16 (88.9)	0.16 (0.73)	-1.4	-0.16	0.20	0.57	1.5	
		Week 36	Tezepelumab	14	12 (85.7)	0.42 (0.50)	-0.1	-0.00	0.36	0.67	1.7	0.19 [-0.56, 0.94]
			Placebo	18	16 (88.9)	0.27 (0.92)	-1.7	0.08	0.22	0.52	2.2	
		Week 52	Tezepelumab	14	11 (78.6)	0.47 (0.48)	-0.6	0.37	0.52	0.74	1.3	0.38 [-0.39, 1.16]
			Placebo	18	16 (88.9)	0.22 (0.76)	-1.4	-0.07	0.24	0.56	1.9	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	2.70 (0.71)	1.4	2.14	2.69	3.22	3.7	
			Placebo	4	4 (100.0)	2.92 (1.46)	1.4	1.92	2.69	3.91	4.9	
		Week 2	Tezepelumab	9	9 (100.0)	2.90 (0.71)	1.7	2.50	2.74	3.39	4.0	
			Placebo	4	4 (100.0)	2.86 (1.40)	1.3	1.87	2.71	3.85	4.7	
		Week 4	Tezepelumab	9	8 (88.9)	2.74 (0.73)	1.3	2.54	2.71	3.19	3.8	
			Placebo	4	3 (75.0)	2.23 (0.73)	1.4	1.43	2.39	2.86	2.9	
		Week 8	Tezepelumab	9	8 (88.9)	2.69 (0.79)	1.0	2.55	2.65	3.19	3.7	
			Placebo	4	4 (100.0)	2.94 (1.44)	1.5	1.92	2.65	3.95	4.9	
		Week 12	Tezepelumab	9	7 (77.8)	2.56 (0.90)	0.8	2.30	2.64	3.34	3.6	
			Placebo	4	4 (100.0)	2.95 (1.49)	1.4	1.94	2.70	3.97	5.0	
		Week 16	Tezepelumab	9	8 (88.9)	2.68 (0.68)	1.5	2.33	2.62	3.13	3.8	
			Placebo	4	4 (100.0)	3.04 (1.57)	1.5	2.01	2.73	4.08	5.2	
		Week 24	Tezepelumab	9	8 (88.9)	2.75 (0.57)	1.7	2.43	2.89	3.05	3.6	
			Placebo	4	4 (100.0)	3.05 (1.51)	1.5	2.07	2.80	4.02	5.1	
		Week 36	Tezepelumab	9	8 (88.9)	2.83 (0.72)	1.4	2.62	2.82	3.19	4.0	
			Placebo	4	4 (100.0)	3.10 (1.63)	1.4	2.07	2.87	4.14	5.3	
		Week 52	Tezepelumab	9	8 (88.9)	2.99 (0.71)	1.9	2.59	2.94	3.38	4.2	
			Placebo	4	3 (75.0)	3.27 (1.89)	1.5	1.49	3.05	5.26	5.3	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Change from baseline	Week 2	Tezepelumab	9	9 (100.0)	0.20 (0.25)	-0.3	0.05	0.26	0.36	0.5	1.16 [-0.12, 2.43]
			Placebo	4	4 (100.0)	-0.05 (0.11)	-0.2	-0.13	-0.05	0.02	0.1	
		Week 4	Tezepelumab	9	8 (88.9)	0.10 (0.40)	-0.2	-0.15	-0.11	0.28	1.0	0.39 [-0.95, 1.73]
			Placebo	4	3 (75.0)	-0.03 (0.05)	-0.1	-0.08	-0.04	0.02	0.0	
		Week 8	Tezepelumab	9	8 (88.9)	0.05 (0.28)	-0.4	-0.13	0.03	0.28	0.4	0.12 [-1.08, 1.32]
			Placebo	4	4 (100.0)	0.02 (0.11)	-0.1	-0.05	0.04	0.09	0.1	
		Week 12	Tezepelumab	9	7 (77.8)	-0.15 (0.26)	-0.6	-0.30	-0.10	0.05	0.2	-0.87 [-2.17, 0.42]
			Placebo	4	4 (100.0)	0.04 (0.04)	0.0	0.01	0.03	0.06	0.1	
		Week 16	Tezepelumab	9	8 (88.9)	0.04 (0.18)	-0.3	-0.06	0.07	0.11	0.4	-0.49 [-1.71, 0.73]
			Placebo	4	4 (100.0)	0.13 (0.14)	0.0	0.04	0.08	0.21	0.3	
		Week 24	Tezepelumab	9	8 (88.9)	0.12 (0.32)	-0.2	-0.11	0.07	0.24	0.8	-0.05 [-1.25, 1.15]
			Placebo	4	4 (100.0)	0.13 (0.12)	-0.0	0.03	0.15	0.23	0.2	
		Week 36	Tezepelumab	9	8 (88.9)	0.20 (0.26)	-0.1	-0.01	0.16	0.42	0.6	0.03 [-1.17, 1.23]
			Placebo	4	4 (100.0)	0.19 (0.22)	-0.0	0.00	0.18	0.37	0.4	
		Week 52	Tezepelumab	9	8 (88.9)	0.35 (0.28)	-0.2	0.20	0.41	0.56	0.7	0.62 [-0.74, 1.97]
			Placebo	4	3 (75.0)	0.19 (0.17)	0.1	0.08	0.11	0.38	0.4	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Absolute values	Baseline	Tezepelumab	6	6 (100.0)	2.43 (0.67)	1.4	1.98	2.49	2.98	3.2	
			Placebo	16	16 (100.0)	2.43 (0.79)	1.0	2.07	2.20	3.00	4.0	
		Week 2	Tezepelumab	6	5 (83.3)	2.63 (0.70)	1.7	2.24	2.59	3.26	3.4	
			Placebo	16	16 (100.0)	2.63 (0.43)	1.7	2.31	2.66	2.87	3.5	
		Week 4	Tezepelumab	6	6 (100.0)	2.59 (0.68)	1.8	1.90	2.57	3.18	3.5	
			Placebo	16	16 (100.0)	2.69 (0.44)	2.1	2.47	2.59	2.85	3.7	
		Week 8	Tezepelumab	6	6 (100.0)	2.43 (1.21)	1.0	1.07	2.79	3.43	3.5	
			Placebo	16	15 (93.8)	2.61 (0.49)	1.4	2.35	2.69	2.93	3.3	
		Week 12	Tezepelumab	6	6 (100.0)	2.59 (0.97)	1.4	1.68	2.72	3.48	3.5	
			Placebo	16	16 (100.0)	2.65 (0.54)	1.7	2.42	2.55	2.99	3.5	
		Week 16	Tezepelumab	6	5 (83.3)	2.69 (0.64)	2.0	2.20	2.50	3.35	3.4	
			Placebo	16	16 (100.0)	2.60 (0.43)	1.9	2.39	2.49	2.82	3.5	
		Week 24	Tezepelumab	6	5 (83.3)	2.48 (0.94)	1.6	1.69	2.20	3.16	3.7	
			Placebo	16	14 (87.5)	2.72 (0.47)	2.0	2.52	2.68	3.11	3.4	
		Week 36	Tezepelumab	6	5 (83.3)	2.96 (0.64)	2.3	2.39	2.95	3.55	3.6	
			Placebo	16	14 (87.5)	2.75 (0.76)	1.4	2.34	2.92	3.33	3.7	
		Week 52	Tezepelumab	6	4 (66.7)	2.85 (0.68)	2.2	2.27	2.83	3.43	3.6	
			Placebo	16	15 (93.8)	2.67 (0.72)	1.2	2.14	2.63	3.22	3.8	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Change from baseline	Week 2	Tezepelumab	6	5 (83.3)	0.27 (0.81)	-0.5	-0.39	0.08	0.81	1.4	0.11 [-0.89, 1.12]
			Placebo	16	16 (100.0)	0.20 (0.65)	-1.3	-0.08	0.04	0.37	1.7	
		Week 4	Tezepelumab	6	6 (100.0)	0.17 (0.60)	-0.3	-0.31	0.01	0.39	1.2	-0.14 [-1.07, 0.80]
			Placebo	16	16 (100.0)	0.26 (0.69)	-1.0	-0.12	0.22	0.59	1.7	
		Week 8	Tezepelumab	6	6 (100.0)	0.01 (1.01)	-1.1	-0.83	-0.11	0.65	1.6	-0.16 [-1.11, 0.78]
			Placebo	16	15 (93.8)	0.16 (0.89)	-1.7	-0.33	0.09	0.65	2.0	
		Week 12	Tezepelumab	6	6 (100.0)	0.17 (1.06)	-1.5	-0.52	0.45	0.64	1.5	-0.06 [-1.00, 0.88]
			Placebo	16	16 (100.0)	0.22 (0.79)	-1.2	-0.23	0.23	0.42	1.6	
		Week 16	Tezepelumab	6	5 (83.3)	0.42 (0.70)	-0.5	0.00	0.60	0.61	1.4	0.32 [-0.69, 1.33]
			Placebo	16	16 (100.0)	0.17 (0.81)	-1.6	-0.23	0.11	0.50	1.6	
		Week 24	Tezepelumab	6	5 (83.3)	0.21 (0.99)	-0.8	-0.51	0.18	0.38	1.8	0.05 [-0.97, 1.07]
			Placebo	16	14 (87.5)	0.17 (0.78)	-1.4	-0.26	0.26	0.60	1.5	
		Week 36	Tezepelumab	6	5 (83.3)	0.68 (0.66)	-0.0	0.19	0.77	0.82	1.7	0.43 [-0.60, 1.46]
			Placebo	16	14 (87.5)	0.29 (0.99)	-1.7	0.12	0.22	0.57	2.2	
		Week 52	Tezepelumab	6	4 (66.7)	0.56 (0.82)	-0.6	0.07	0.77	1.05	1.3	0.42 [-0.69, 1.53]
			Placebo	16	15 (93.8)	0.22 (0.79)	-1.4	-0.11	0.25	0.59	1.9	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	2.59 (0.41)	2.1	2.14	2.69	2.94	2.9	
			Placebo	6	6 (100.0)	2.66 (0.70)	1.4	2.43	2.82	3.02	3.5	
		Week 2	Tezepelumab	3	3 (100.0)	2.79 (0.32)	2.5	2.50	2.74	3.13	3.1	
			Placebo	6	6 (100.0)	2.64 (0.74)	1.3	2.40	2.78	3.01	3.5	
		Week 4	Tezepelumab	3	3 (100.0)	2.66 (0.13)	2.6	2.57	2.61	2.81	2.8	
			Placebo	6	6 (100.0)	2.59 (0.73)	1.4	2.39	2.59	2.86	3.7	
		Week 8	Tezepelumab	3	3 (100.0)	2.79 (0.26)	2.6	2.58	2.71	3.08	3.1	
			Placebo	6	6 (100.0)	2.59 (0.60)	1.5	2.30	2.74	2.99	3.2	
		Week 12	Tezepelumab	3	3 (100.0)	2.56 (0.23)	2.3	2.30	2.64	2.74	2.7	
			Placebo	6	6 (100.0)	2.69 (0.70)	1.4	2.44	2.88	2.96	3.5	
		Week 16	Tezepelumab	3	3 (100.0)	2.72 (0.22)	2.5	2.50	2.73	2.94	2.9	
			Placebo	6	6 (100.0)	2.54 (0.59)	1.5	2.49	2.56	2.94	3.2	
		Week 24	Tezepelumab	3	3 (100.0)	2.71 (0.34)	2.3	2.32	2.90	2.91	2.9	
			Placebo	6	6 (100.0)	2.71 (0.66)	1.5	2.66	2.85	3.05	3.4	
		Week 36	Tezepelumab	3	3 (100.0)	2.91 (0.19)	2.7	2.71	2.93	3.08	3.1	
			Placebo	6	6 (100.0)	2.83 (0.78)	1.4	2.76	2.94	3.33	3.7	
		Week 52	Tezepelumab	3	3 (100.0)	3.06 (0.26)	2.8	2.79	3.08	3.31	3.3	
			Placebo	6	5 (83.3)	2.97 (0.90)	1.5	2.93	3.05	3.65	3.7	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Change from baseline	Week 2	Tezepelumab	3	3 (100.0)	0.20 (0.16)	0.1	0.05	0.19	0.36	0.4	2.18 [0.38, 3.97]
			Placebo	6	6 (100.0)	-0.02 (0.07)	-0.1	-0.08	-0.05	0.06	0.1	
		Week 4	Tezepelumab	3	3 (100.0)	0.07 (0.31)	-0.1	-0.13	-0.08	0.43	0.4	0.59 [-0.83, 2.01]
			Placebo	6	6 (100.0)	-0.07 (0.21)	-0.4	-0.11	-0.06	0.02	0.2	
		Week 8	Tezepelumab	3	3 (100.0)	0.20 (0.22)	0.0	0.02	0.14	0.44	0.4	1.37 [-0.19, 2.93]
			Placebo	6	6 (100.0)	-0.07 (0.19)	-0.3	-0.22	-0.04	0.09	0.1	
		Week 12	Tezepelumab	3	3 (100.0)	-0.03 (0.24)	-0.3	-0.30	0.05	0.16	0.2	-0.35 [-1.75, 1.05]
			Placebo	6	6 (100.0)	0.03 (0.12)	-0.2	0.01	0.03	0.06	0.2	
		Week 16	Tezepelumab	3	3 (100.0)	0.13 (0.20)	0.0	0.00	0.04	0.36	0.4	1.23 [-0.30, 2.76]
			Placebo	6	6 (100.0)	-0.12 (0.21)	-0.4	-0.25	-0.11	0.08	0.1	
		Week 24	Tezepelumab	3	3 (100.0)	0.12 (0.13)	-0.0	-0.03	0.18	0.21	0.2	0.34 [-1.06, 1.74]
			Placebo	6	6 (100.0)	0.05 (0.22)	-0.3	-0.06	0.03	0.23	0.3	
		Week 36	Tezepelumab	3	3 (100.0)	0.32 (0.30)	-0.0	-0.01	0.39	0.57	0.6	0.71 [-0.72, 2.15]
			Placebo	6	6 (100.0)	0.17 (0.15)	-0.0	0.03	0.20	0.31	0.3	
		Week 52	Tezepelumab	3	3 (100.0)	0.47 (0.16)	0.4	0.37	0.39	0.65	0.7	1.02 [-0.53, 2.56]
			Placebo	6	5 (83.3)	0.27 (0.22)	0.1	0.11	0.23	0.28	0.6	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Absolute values	Baseline	Tezepelumab	12	12 (100.0)	2.59 (0.75)	1.4	2.05	2.74	3.20	3.7	
			Placebo	14	14 (100.0)	2.47 (1.03)	1.0	2.06	2.14	2.97	4.9	
		Week 2	Tezepelumab	12	11 (91.7)	2.81 (0.78)	1.7	2.24	2.59	3.39	4.0	
			Placebo	14	14 (100.0)	2.69 (0.69)	1.7	2.30	2.65	2.80	4.7	
		Week 4	Tezepelumab	12	11 (91.7)	2.68 (0.78)	1.3	1.90	2.67	3.29	3.8	
			Placebo	14	13 (92.9)	2.63 (0.39)	2.1	2.44	2.57	2.66	3.5	
		Week 8	Tezepelumab	12	11 (91.7)	2.52 (1.07)	1.0	1.07	2.56	3.43	3.7	
			Placebo	14	13 (92.9)	2.71 (0.82)	1.4	2.35	2.59	2.93	4.9	
		Week 12	Tezepelumab	12	10 (83.3)	2.58 (1.02)	0.8	1.68	2.96	3.48	3.6	
			Placebo	14	14 (100.0)	2.72 (0.83)	1.7	2.34	2.53	3.07	5.0	
		Week 16	Tezepelumab	12	10 (83.3)	2.67 (0.73)	1.5	2.20	2.47	3.35	3.8	
			Placebo	14	14 (100.0)	2.75 (0.83)	1.9	2.36	2.47	3.01	5.2	
		Week 24	Tezepelumab	12	10 (83.3)	2.63 (0.80)	1.6	1.70	2.71	3.19	3.7	
			Placebo	14	12 (85.7)	2.83 (0.85)	2.0	2.34	2.63	3.13	5.1	
		Week 36	Tezepelumab	12	10 (83.3)	2.87 (0.77)	1.4	2.39	2.81	3.55	4.0	
			Placebo	14	12 (85.7)	2.83 (1.07)	1.4	2.10	2.87	3.37	5.3	
		Week 52	Tezepelumab	12	9 (75.0)	2.90 (0.78)	1.9	2.37	2.64	3.45	4.2	
			Placebo	14	13 (92.9)	2.69 (0.99)	1.2	2.14	2.51	2.67	5.3	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Change from baseline	Week 2	Tezepelumab	12	11 (91.7)	0.23 (0.56)	-0.5	-0.28	0.26	0.48	1.4	0.03 [-0.76, 0.82]
			Placebo	14	14 (100.0)	0.22 (0.70)	-1.3	-0.07	0.11	0.48	1.7	
		Week 4	Tezepelumab	12	11 (91.7)	0.15 (0.53)	-0.3	-0.30	-0.14	0.39	1.2	-0.30 [-1.11, 0.51]
			Placebo	14	13 (92.9)	0.34 (0.74)	-1.0	-0.07	0.34	0.77	1.7	
		Week 8	Tezepelumab	12	11 (91.7)	-0.02 (0.74)	-1.1	-0.46	-0.13	0.42	1.6	-0.27 [-1.08, 0.53]
			Placebo	14	13 (92.9)	0.22 (0.94)	-1.7	-0.06	0.09	0.65	2.0	
		Week 12	Tezepelumab	12	10 (83.3)	0.00 (0.83)	-1.5	-0.52	-0.10	0.59	1.5	-0.29 [-1.11, 0.52]
			Placebo	14	14 (100.0)	0.25 (0.84)	-1.2	-0.24	0.32	0.42	1.6	
		Week 16	Tezepelumab	12	10 (83.3)	0.20 (0.53)	-0.5	-0.12	0.10	0.60	1.4	-0.10 [-0.91, 0.71]
			Placebo	14	14 (100.0)	0.28 (0.84)	-1.6	-0.07	0.24	0.63	1.6	
		Week 24	Tezepelumab	12	10 (83.3)	0.16 (0.72)	-0.8	-0.24	0.06	0.38	1.8	-0.06 [-0.90, 0.78]
			Placebo	14	12 (85.7)	0.21 (0.83)	-1.4	-0.14	0.38	0.65	1.5	
		Week 36	Tezepelumab	12	10 (83.3)	0.40 (0.55)	-0.1	-0.02	0.26	0.77	1.7	0.11 [-0.73, 0.95]
			Placebo	14	12 (85.7)	0.31 (1.07)	-1.7	-0.09	0.33	0.87	2.2	
		Week 52	Tezepelumab	12	9 (75.0)	0.40 (0.57)	-0.6	0.02	0.52	0.74	1.3	0.27 [-0.58, 1.12]
			Placebo	14	13 (92.9)	0.20 (0.85)	-1.4	-0.11	0.25	0.53	1.9	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	2.27 (0.73)	1.4	1.43	2.69	2.69	2.7	
			Placebo	2	2 (100.0)	2.10 (0.97)	1.4	1.41	2.10	2.78	2.8	
		Week 2	Tezepelumab	3	3 (100.0)	2.46 (0.25)	2.2	2.24	2.41	2.74	2.7	
			Placebo	2	2 (100.0)	2.04 (0.99)	1.3	1.34	2.04	2.74	2.7	
		Week 4	Tezepelumab	3	3 (100.0)	2.31 (0.43)	1.8	1.82	2.51	2.61	2.6	
			Placebo	2	2 (100.0)	2.05 (0.87)	1.4	1.43	2.05	2.66	2.7	
		Week 8	Tezepelumab	3	3 (100.0)	2.08 (0.96)	1.0	0.97	2.56	2.71	2.7	
			Placebo	2	2 (100.0)	2.15 (0.86)	1.5	1.54	2.15	2.76	2.8	
		Week 12	Tezepelumab	3	3 (100.0)	2.46 (0.35)	2.1	2.07	2.57	2.74	2.7	
			Placebo	2	2 (100.0)	2.00 (0.79)	1.4	1.44	2.00	2.56	2.6	
		Week 16	Tezepelumab	3	3 (100.0)	2.40 (0.35)	2.0	2.03	2.43	2.73	2.7	
			Placebo	2	2 (100.0)	2.06 (0.81)	1.5	1.49	2.06	2.63	2.6	
		Week 24	Tezepelumab	3	3 (100.0)	2.35 (0.66)	1.6	1.61	2.53	2.90	2.9	
			Placebo	2	2 (100.0)	2.00 (0.74)	1.5	1.48	2.00	2.52	2.5	
		Week 36	Tezepelumab	3	3 (100.0)	2.67 (0.42)	2.3	2.25	2.67	3.08	3.1	
			Placebo	2	2 (100.0)	2.16 (1.10)	1.4	1.38	2.16	2.93	2.9	
		Week 52	Tezepelumab	3	3 (100.0)	2.59 (0.46)	2.2	2.17	2.53	3.08	3.1	
			Placebo	2	2 (100.0)	1.79 (0.42)	1.5	1.49	1.79	2.09	2.1	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Change from baseline	Week 2	Tezepelumab	3	3 (100.0)	0.19 (0.56)	-0.3	-0.28	0.05	0.81	0.8	0.54 [-1.30, 2.39]
			Placebo	2	2 (100.0)	-0.05 (0.02)	-0.1	-0.07	-0.05	-0.04	-0.0	
		Week 4	Tezepelumab	3	3 (100.0)	0.04 (0.30)	-0.2	-0.18	-0.08	0.39	0.4	0.37 [-1.45, 2.18]
			Placebo	2	2 (100.0)	-0.05 (0.10)	-0.1	-0.12	-0.05	0.02	0.0	
		Week 8	Tezepelumab	3	3 (100.0)	-0.19 (0.25)	-0.5	-0.46	-0.13	0.02	0.0	-1.17 [-3.19, 0.85]
			Placebo	2	2 (100.0)	0.06 (0.11)	-0.0	-0.02	0.06	0.13	0.1	
		Week 12	Tezepelumab	3	3 (100.0)	0.19 (0.40)	-0.1	-0.12	0.05	0.64	0.6	0.84 [-1.07, 2.74]
			Placebo	2	2 (100.0)	-0.09 (0.18)	-0.2	-0.22	-0.09	0.03	0.0	
		Week 16	Tezepelumab	3	3 (100.0)	0.13 (0.44)	-0.3	-0.26	0.04	0.60	0.6	0.44 [-1.38, 2.26]
			Placebo	2	2 (100.0)	-0.03 (0.16)	-0.1	-0.15	-0.03	0.08	0.1	
		Week 24	Tezepelumab	3	3 (100.0)	0.08 (0.21)	-0.2	-0.16	0.18	0.21	0.2	0.80 [-1.10, 2.70]
			Placebo	2	2 (100.0)	-0.09 (0.23)	-0.3	-0.26	-0.09	0.07	0.1	
		Week 36	Tezepelumab	3	3 (100.0)	0.40 (0.42)	-0.0	-0.02	0.39	0.82	0.8	0.96 [-0.99, 2.91]
			Placebo	2	2 (100.0)	0.06 (0.13)	-0.0	-0.03	0.06	0.15	0.2	
		Week 52	Tezepelumab	3	3 (100.0)	0.32 (0.45)	-0.2	-0.16	0.39	0.74	0.7	1.29 [-0.77, 3.36]
			Placebo	2	2 (100.0)	-0.30 (0.54)	-0.7	-0.69	-0.30	0.08	0.1	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	12	12 (100.0)	2.67 (0.68)	1.4	2.13	2.86	3.20	3.7	
			Placebo	18	18 (100.0)	2.58 (0.94)	1.0	2.08	2.34	3.02	4.9	
		Week 2	Tezepelumab	12	11 (91.7)	2.90 (0.76)	1.7	2.50	3.13	3.39	4.0	
			Placebo	18	18 (100.0)	2.74 (0.64)	1.7	2.31	2.66	3.01	4.7	
		Week 4	Tezepelumab	12	11 (91.7)	2.78 (0.72)	1.3	2.47	2.81	3.29	3.8	
			Placebo	18	17 (94.4)	2.68 (0.44)	2.1	2.44	2.59	2.86	3.7	
		Week 8	Tezepelumab	12	11 (91.7)	2.71 (0.95)	1.0	2.15	3.08	3.43	3.7	
			Placebo	18	17 (94.4)	2.74 (0.74)	1.4	2.35	2.69	2.99	4.9	
		Week 12	Tezepelumab	12	10 (83.3)	2.61 (1.01)	0.8	1.68	2.99	3.48	3.6	
			Placebo	18	18 (100.0)	2.79 (0.75)	1.7	2.44	2.57	3.07	5.0	
		Week 16	Tezepelumab	12	10 (83.3)	2.77 (0.69)	1.5	2.22	2.72	3.35	3.8	
			Placebo	18	18 (100.0)	2.76 (0.74)	1.9	2.41	2.51	3.01	5.2	
		Week 24	Tezepelumab	12	10 (83.3)	2.74 (0.73)	1.7	2.20	2.90	3.19	3.7	
			Placebo	18	16 (88.9)	2.89 (0.74)	2.0	2.61	2.74	3.13	5.1	
		Week 36	Tezepelumab	12	10 (83.3)	2.94 (0.73)	1.4	2.56	2.94	3.55	4.0	
			Placebo	18	16 (88.9)	2.91 (0.95)	1.4	2.45	2.94	3.42	5.3	
		Week 52	Tezepelumab	12	9 (75.0)	3.06 (0.72)	1.9	2.64	3.29	3.45	4.2	
			Placebo	18	16 (88.9)	2.89 (0.93)	1.2	2.37	2.66	3.44	5.3	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Change from baseline	Week 2	Tezepelumab	12	11 (91.7)	0.24 (0.50)	-0.5	-0.04	0.26	0.47	1.4	0.12 [-0.63, 0.87]
			Placebo	18	18 (100.0)	0.17 (0.62)	-1.3	-0.08	0.04	0.26	1.7	
		Week 4	Tezepelumab	12	11 (91.7)	0.16 (0.52)	-0.3	-0.30	-0.13	0.43	1.2	-0.14 [-0.90, 0.62]
			Placebo	18	17 (94.4)	0.24 (0.67)	-1.0	-0.08	0.21	0.40	1.7	
		Week 8	Tezepelumab	12	11 (91.7)	0.09 (0.73)	-1.1	-0.40	0.14	0.44	1.6	-0.06 [-0.82, 0.70]
			Placebo	18	17 (94.4)	0.14 (0.83)	-1.7	-0.22	0.05	0.49	2.0	
		Week 12	Tezepelumab	12	10 (83.3)	-0.06 (0.81)	-1.5	-0.52	-0.10	0.30	1.5	-0.36 [-1.14, 0.42]
			Placebo	18	18 (100.0)	0.21 (0.74)	-1.2	-0.16	0.14	0.41	1.6	
		Week 16	Tezepelumab	12	10 (83.3)	0.21 (0.50)	-0.5	0.00	0.10	0.36	1.4	0.04 [-0.74, 0.81]
			Placebo	18	18 (100.0)	0.18 (0.76)	-1.6	-0.21	0.13	0.37	1.6	
		Week 24	Tezepelumab	12	10 (83.3)	0.17 (0.71)	-0.8	-0.24	0.07	0.38	1.8	-0.02 [-0.81, 0.77]
			Placebo	18	16 (88.9)	0.19 (0.72)	-1.4	-0.04	0.23	0.57	1.5	
		Week 36	Tezepelumab	12	10 (83.3)	0.38 (0.54)	-0.1	-0.01	0.26	0.57	1.7	0.11 [-0.68, 0.90]
			Placebo	18	16 (88.9)	0.29 (0.92)	-1.7	0.08	0.27	0.52	2.2	
		Week 52	Tezepelumab	12	9 (75.0)	0.45 (0.53)	-0.6	0.37	0.52	0.65	1.3	0.25 [-0.57, 1.07]
			Placebo	18	16 (88.9)	0.28 (0.72)	-1.4	0.01	0.27	0.56	1.9	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	2.69	2.7	2.69	2.69	2.69	2.7	
			Placebo	4	4 (100.0)	2.14 (0.56)	1.4	1.76	2.18	2.51	2.8	
		Week 2	Tezepelumab	1	1 (100.0)	2.74	2.7	2.74	2.74	2.74	2.7	
			Placebo	4	4 (100.0)	2.18 (0.60)	1.3	1.81	2.32	2.56	2.7	
		Week 4	Tezepelumab	1	1 (100.0)	2.61	2.6	2.61	2.61	2.61	2.6	
			Placebo	4	4 (100.0)	2.09 (0.51)	1.4	1.76	2.13	2.42	2.7	
		Week 8	Tezepelumab	1	1 (100.0)	2.71	2.7	2.71	2.71	2.71	2.7	
			Placebo	4	4 (100.0)	2.37 (0.58)	1.5	1.98	2.59	2.76	2.8	
		Week 12	Tezepelumab	1	1 (100.0)	2.74	2.7	2.74	2.74	2.74	2.7	
			Placebo	4	4 (100.0)	2.13 (0.53)	1.4	1.72	2.26	2.54	2.6	
		Week 16	Tezepelumab	1	1 (100.0)	2.73	2.7	2.73	2.73	2.73	2.7	
			Placebo	4	4 (100.0)	2.27 (0.52)	1.5	1.98	2.47	2.56	2.6	
		Week 24	Tezepelumab	1	1 (100.0)	2.90	2.9	2.90	2.90	2.90	2.9	
			Placebo	4	3 (75.0)	2.24 (0.66)	1.5	1.48	2.52	2.71	2.7	
		Week 36	Tezepelumab	1	1 (100.0)	3.08	3.1	3.08	3.08	3.08	3.1	
			Placebo	4	2 (50.0)	2.16 (1.10)	1.4	1.38	2.16	2.93	2.9	
		Week 52	Tezepelumab	1	1 (100.0)	3.08	3.1	3.08	3.08	3.08	3.1	
			Placebo	4	3 (75.0)	1.91 (0.36)	1.5	1.49	2.09	2.14	2.1	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Change from baseline	Week 2	Tezepelumab	1	1 (100.0)	0.05	0.1	0.05	0.05	0.05	0.1	NE
			Placebo	4	4 (100.0)	0.05 (0.15)	-0.1	-0.05	-0.00	0.15	0.3	
		Week 4	Tezepelumab	1	1 (100.0)	-0.08	-0.1	-0.08	-0.08	-0.08	-0.1	NE
			Placebo	4	4 (100.0)	-0.05 (0.06)	-0.1	-0.09	-0.05	0.00	0.0	
		Week 8	Tezepelumab	1	1 (100.0)	0.02	0.0	0.02	0.02	0.02	0.0	NE
			Placebo	4	4 (100.0)	0.23 (0.29)	-0.0	0.06	0.15	0.41	0.7	
		Week 12	Tezepelumab	1	1 (100.0)	0.05	0.1	0.05	0.05	0.05	0.1	NE
			Placebo	4	4 (100.0)	-0.00 (0.30)	-0.2	-0.23	-0.09	0.22	0.4	
		Week 16	Tezepelumab	1	1 (100.0)	0.04	0.0	0.04	0.04	0.04	0.0	NE
			Placebo	4	4 (100.0)	0.13 (0.22)	-0.1	-0.03	0.15	0.29	0.4	
		Week 24	Tezepelumab	1	1 (100.0)	0.21	0.2	0.21	0.21	0.21	0.2	NE
			Placebo	4	3 (75.0)	0.14 (0.43)	-0.3	-0.26	0.07	0.60	0.6	
		Week 36	Tezepelumab	1	1 (100.0)	0.39	0.4	0.39	0.39	0.39	0.4	NE
			Placebo	4	2 (50.0)	0.06 (0.13)	-0.0	-0.03	0.06	0.15	0.2	
		Week 52	Tezepelumab	1	1 (100.0)	0.39	0.4	0.39	0.39	0.39	0.4	NE
			Placebo	4	3 (75.0)	-0.19 (0.43)	-0.7	-0.69	0.03	0.08	0.1	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Absolute values	Baseline	Tezepelumab	12	12 (100.0)	2.67 (0.73)	1.4	2.17	2.86	3.20	3.7	
			Placebo	8	8 (100.0)	3.20 (0.89)	2.2	2.57	2.98	3.75	4.9	
		Week 2	Tezepelumab	12	11 (91.7)	2.78 (0.77)	1.7	2.24	2.59	3.39	4.0	
			Placebo	8	8 (100.0)	3.01 (0.79)	2.2	2.51	2.85	3.27	4.7	
		Week 4	Tezepelumab	12	11 (91.7)	2.60 (0.75)	1.3	1.90	2.57	3.29	3.8	
			Placebo	8	7 (87.5)	2.81 (0.44)	2.4	2.50	2.59	3.04	3.7	
		Week 8	Tezepelumab	12	11 (91.7)	2.48 (1.04)	1.0	1.07	2.58	3.43	3.7	
			Placebo	8	7 (87.5)	3.04 (0.89)	2.3	2.35	2.79	3.24	4.9	
		Week 12	Tezepelumab	12	11 (91.7)	2.48 (0.92)	0.8	1.68	2.57	3.37	3.6	
			Placebo	8	8 (100.0)	3.16 (0.80)	2.4	2.70	2.93	3.30	5.0	
		Week 16	Tezepelumab	12	10 (83.3)	2.66 (0.68)	1.5	2.20	2.50	3.31	3.8	
			Placebo	8	8 (100.0)	2.94 (0.98)	2.1	2.47	2.56	3.08	5.2	
		Week 24	Tezepelumab	12	10 (83.3)	2.49 (0.71)	1.6	1.70	2.43	3.16	3.6	
			Placebo	8	8 (100.0)	3.08 (0.90)	2.2	2.64	2.85	3.23	5.1	
		Week 36	Tezepelumab	12	10 (83.3)	2.82 (0.71)	1.4	2.39	2.82	3.30	4.0	
			Placebo	8	8 (100.0)	3.20 (0.99)	1.9	2.79	2.94	3.50	5.3	
		Week 52	Tezepelumab	12	9 (75.0)	2.92 (0.77)	1.9	2.37	2.79	3.45	4.2	
			Placebo	8	7 (87.5)	3.40 (0.95)	2.5	2.67	3.05	3.74	5.3	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Change from baseline	Week 2	Tezepelumab	12	11 (91.7)	0.12 (0.40)	-0.5	-0.28	0.19	0.36	0.8	0.73 [-0.21, 1.67]
			Placebo	8	8 (100.0)	-0.19 (0.44)	-1.3	-0.13	-0.06	0.03	0.1	
		Week 4	Tezepelumab	12	11 (91.7)	-0.02 (0.29)	-0.3	-0.30	-0.14	0.33	0.4	0.38 [-0.58, 1.33]
			Placebo	8	7 (87.5)	-0.16 (0.44)	-1.0	-0.43	-0.08	0.22	0.3	
		Week 8	Tezepelumab	12	11 (91.7)	-0.14 (0.53)	-1.1	-0.46	-0.13	0.25	0.7	0.30 [-0.65, 1.25]
			Placebo	8	7 (87.5)	-0.31 (0.62)	-1.7	-0.33	-0.13	0.05	0.1	
		Week 12	Tezepelumab	12	11 (91.7)	-0.15 (0.62)	-1.5	-0.52	-0.10	0.30	0.6	-0.19 [-1.10, 0.72]
			Placebo	8	8 (100.0)	-0.05 (0.40)	-1.0	-0.08	0.04	0.14	0.4	
		Week 16	Tezepelumab	12	10 (83.3)	0.09 (0.35)	-0.5	-0.12	0.05	0.36	0.6	0.77 [-0.20, 1.73]
			Placebo	8	8 (100.0)	-0.27 (0.58)	-1.6	-0.34	-0.14	0.04	0.3	
		Week 24	Tezepelumab	12	10 (83.3)	-0.08 (0.36)	-0.8	-0.24	-0.04	0.18	0.4	0.09 [-0.84, 1.02]
			Placebo	8	8 (100.0)	-0.12 (0.56)	-1.4	-0.16	-0.01	0.23	0.3	
		Week 36	Tezepelumab	12	10 (83.3)	0.25 (0.35)	-0.1	-0.02	0.09	0.57	0.8	0.57 [-0.38, 1.52]
			Placebo	8	8 (100.0)	-0.00 (0.54)	-1.2	-0.13	0.20	0.32	0.4	
		Week 52	Tezepelumab	12	9 (75.0)	0.31 (0.47)	-0.6	0.02	0.42	0.65	0.8	0.41 [-0.59, 1.41]
			Placebo	8	7 (87.5)	0.08 (0.66)	-1.4	0.11	0.28	0.38	0.6	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Absolute values	Baseline	Tezepelumab	2	2 (100.0)	2.05 (0.10)	2.0	1.98	2.05	2.12	2.1	
			Placebo	8	8 (100.0)	2.05 (0.73)	1.0	1.58	2.07	2.54	3.1	
		Week 2	Tezepelumab	2	2 (100.0)	2.98 (0.54)	2.6	2.59	2.98	3.36	3.4	
			Placebo	8	8 (100.0)	2.58 (0.46)	1.7	2.31	2.65	2.91	3.2	
		Week 4	Tezepelumab	2	2 (100.0)	3.13 (0.07)	3.1	3.08	3.13	3.18	3.2	
			Placebo	8	8 (100.0)	2.71 (0.40)	2.3	2.47	2.59	2.92	3.5	
		Week 8	Tezepelumab	2	2 (100.0)	3.04 (0.70)	2.5	2.54	3.04	3.53	3.5	
			Placebo	8	8 (100.0)	2.51 (0.63)	1.4	2.16	2.56	3.01	3.3	
		Week 12	Tezepelumab	2	1 (50.0)	3.51	3.5	3.51	3.51	3.51	3.5	
			Placebo	8	8 (100.0)	2.55 (0.64)	1.7	2.14	2.49	2.99	3.5	
		Week 16	Tezepelumab	2	2 (100.0)	2.79 (0.80)	2.2	2.22	2.79	3.35	3.4	
			Placebo	8	8 (100.0)	2.64 (0.54)	1.9	2.31	2.47	3.09	3.5	
		Week 24	Tezepelumab	2	2 (100.0)	3.31 (0.61)	2.9	2.88	3.31	3.74	3.7	
			Placebo	8	7 (87.5)	2.69 (0.57)	2.0	1.99	2.64	3.14	3.4	
		Week 36	Tezepelumab	2	2 (100.0)	3.10 (0.76)	2.6	2.56	3.10	3.64	3.6	
			Placebo	8	8 (100.0)	2.63 (0.87)	1.4	1.87	2.83	3.37	3.5	
		Week 52	Tezepelumab	2	2 (100.0)	2.97 (0.46)	2.6	2.64	2.97	3.29	3.3	
			Placebo	8	8 (100.0)	2.54 (0.79)	1.2	2.17	2.57	2.94	3.8	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Change from baseline	Week 2	Tezepelumab	2	2 (100.0)	0.93 (0.64)	0.5	0.47	0.93	1.38	1.4	0.60 [-0.98, 2.17]
			Placebo	8	8 (100.0)	0.53 (0.66)	-0.3	0.06	0.36	1.02	1.7	
		Week 4	Tezepelumab	2	2 (100.0)	1.08 (0.17)	1.0	0.96	1.08	1.20	1.2	0.64 [-0.94, 2.22]
			Placebo	8	8 (100.0)	0.66 (0.70)	-0.5	0.28	0.59	1.21	1.7	
		Week 8	Tezepelumab	2	2 (100.0)	0.99 (0.80)	0.4	0.42	0.99	1.55	1.6	0.56 [-1.01, 2.14]
			Placebo	8	8 (100.0)	0.46 (0.95)	-0.8	-0.26	0.29	1.21	2.0	
		Week 12	Tezepelumab	2	1 (50.0)	1.53	1.5	1.53	1.53	1.53	1.5	NE
			Placebo	8	8 (100.0)	0.50 (0.97)	-1.2	-0.06	0.41	1.43	1.6	
		Week 16	Tezepelumab	2	2 (100.0)	0.74 (0.90)	0.1	0.10	0.74	1.37	1.4	0.17 [-1.38, 1.72]
			Placebo	8	8 (100.0)	0.59 (0.80)	-0.7	0.11	0.44	1.34	1.6	
		Week 24	Tezepelumab	2	2 (100.0)	1.26 (0.71)	0.8	0.76	1.26	1.76	1.8	0.97 [-0.68, 2.62]
			Placebo	8	7 (87.5)	0.48 (0.81)	-1.1	0.17	0.54	1.05	1.5	
		Week 36	Tezepelumab	2	2 (100.0)	1.05 (0.86)	0.4	0.44	1.05	1.66	1.7	0.42 [-1.15, 1.98]
			Placebo	8	8 (100.0)	0.58 (1.15)	-1.7	0.18	0.52	1.39	2.2	
		Week 52	Tezepelumab	2	2 (100.0)	0.92 (0.56)	0.5	0.52	0.92	1.31	1.3	0.54 [-1.03, 2.11]
			Placebo	8	8 (100.0)	0.49 (0.81)	-0.6	-0.07	0.39	0.96	1.9	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	3.18	3.2	3.18	3.18	3.18	3.2	
		Week 2	Tezepelumab	1	1 (100.0)	3.26	3.3	3.26	3.26	3.26	3.3	
		Week 4	Tezepelumab	1	1 (100.0)	3.51	3.5	3.51	3.51	3.51	3.5	
		Week 8	Tezepelumab	1	1 (100.0)	3.43	3.4	3.43	3.43	3.43	3.4	
		Week 12	Tezepelumab	1	1 (100.0)	3.48	3.5	3.48	3.48	3.48	3.5	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	1	1 (100.0)	0.08	0.1	0.08	0.08	0.08	0.1	NE
		Week 4	Tezepelumab	1	1 (100.0)	0.33	0.3	0.33	0.33	0.33	0.3	NE
		Week 8	Tezepelumab	1	1 (100.0)	0.25	0.3	0.25	0.25	0.25	0.3	NE
		Week 12	Tezepelumab	1	1 (100.0)	0.30	0.3	0.30	0.30	0.30	0.3	NE

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Absolute values	Baseline	Tezepelumab	14	14 (100.0)	2.55 (0.69)	1.4	2.12	2.69	2.98	3.7	
			Placebo	20	20 (100.0)	2.53 (0.93)	1.0	2.07	2.34	3.00	4.9	
		Week 2	Tezepelumab	14	13 (92.9)	2.77 (0.71)	1.7	2.41	2.59	3.36	4.0	
			Placebo	20	20 (100.0)	2.67 (0.68)	1.3	2.31	2.66	2.98	4.7	
		Week 4	Tezepelumab	14	13 (92.9)	2.61 (0.67)	1.3	2.47	2.61	3.08	3.8	
			Placebo	20	19 (95.0)	2.62 (0.50)	1.4	2.39	2.59	2.86	3.7	
		Week 8	Tezepelumab	14	13 (92.9)	2.51 (0.96)	1.0	2.15	2.58	3.30	3.7	
			Placebo	20	19 (95.0)	2.67 (0.75)	1.4	2.30	2.69	2.99	4.9	
		Week 12	Tezepelumab	14	12 (85.7)	2.50 (0.88)	0.8	1.88	2.61	3.36	3.6	
			Placebo	20	20 (100.0)	2.71 (0.77)	1.4	2.39	2.55	3.02	5.0	
		Week 16	Tezepelumab	14	13 (92.9)	2.68 (0.64)	1.5	2.22	2.50	3.31	3.8	
			Placebo	20	20 (100.0)	2.69 (0.75)	1.5	2.39	2.51	2.98	5.2	
		Week 24	Tezepelumab	14	13 (92.9)	2.65 (0.71)	1.6	2.20	2.88	3.16	3.7	
			Placebo	20	18 (90.0)	2.79 (0.77)	1.5	2.52	2.69	3.11	5.1	
		Week 36	Tezepelumab	14	13 (92.9)	2.88 (0.67)	1.4	2.56	2.93	3.30	4.0	
			Placebo	20	18 (90.0)	2.83 (0.96)	1.4	2.34	2.92	3.33	5.3	
		Week 52	Tezepelumab	14	12 (85.7)	2.94 (0.68)	1.9	2.45	2.94	3.38	4.2	
			Placebo	20	18 (90.0)	2.77 (0.95)	1.2	2.14	2.64	3.22	5.3	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Change from baseline	Week 2	Tezepelumab	14	13 (92.9)	0.24 (0.51)	-0.5	-0.04	0.26	0.47	1.4	0.16 [-0.54, 0.86]
			Placebo	20	20 (100.0)	0.15 (0.59)	-1.3	-0.08	0.01	0.25	1.7	
		Week 4	Tezepelumab	14	13 (92.9)	0.12 (0.49)	-0.3	-0.18	-0.13	0.39	1.2	-0.16 [-0.87, 0.54]
			Placebo	20	19 (95.0)	0.21 (0.64)	-1.0	-0.11	0.02	0.40	1.7	
		Week 8	Tezepelumab	14	13 (92.9)	0.01 (0.68)	-1.1	-0.40	0.02	0.42	1.6	-0.15 [-0.86, 0.55]
			Placebo	20	19 (95.0)	0.13 (0.79)	-1.7	-0.22	0.05	0.49	2.0	
		Week 12	Tezepelumab	14	12 (85.7)	-0.03 (0.76)	-1.5	-0.41	-0.10	0.38	1.5	-0.29 [-1.01, 0.43]
			Placebo	20	20 (100.0)	0.18 (0.70)	-1.2	-0.19	0.07	0.40	1.6	
		Week 16	Tezepelumab	14	13 (92.9)	0.19 (0.47)	-0.5	0.00	0.10	0.36	1.4	0.05 [-0.65, 0.74]
			Placebo	20	20 (100.0)	0.16 (0.72)	-1.6	-0.18	0.08	0.35	1.6	
		Week 24	Tezepelumab	14	13 (92.9)	0.15 (0.62)	-0.8	-0.16	0.18	0.27	1.8	-0.01 [-0.72, 0.70]
			Placebo	20	18 (90.0)	0.16 (0.68)	-1.4	-0.06	0.20	0.54	1.5	
		Week 36	Tezepelumab	14	13 (92.9)	0.38 (0.50)	-0.1	-0.01	0.32	0.57	1.7	0.16 [-0.55, 0.88]
			Placebo	20	18 (90.0)	0.26 (0.87)	-1.7	0.03	0.22	0.47	2.2	
		Week 52	Tezepelumab	14	12 (85.7)	0.42 (0.49)	-0.6	0.20	0.47	0.70	1.3	0.31 [-0.42, 1.05]
			Placebo	20	18 (90.0)	0.22 (0.72)	-1.4	-0.02	0.24	0.53	1.9	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	2.85 (0.74)	2.2	2.20	2.69	3.65	3.7	
			Placebo	6	6 (100.0)	2.49 (1.06)	1.3	1.41	2.61	3.02	4.0	
		Week 2	Tezepelumab	3	3 (100.0)	2.69 (1.17)	1.7	1.68	2.41	3.97	4.0	
			Placebo	6	6 (100.0)	2.29 (0.64)	1.3	1.74	2.49	2.76	2.9	
		Week 4	Tezepelumab	3	3 (100.0)	2.73 (0.96)	1.9	1.90	2.51	3.78	3.8	
			Placebo	6	6 (100.0)	2.45 (0.64)	1.4	2.17	2.43	3.04	3.2	
		Week 8	Tezepelumab	3	3 (100.0)	2.44 (1.31)	1.1	1.07	2.56	3.69	3.7	
			Placebo	6	6 (100.0)	2.14 (0.56)	1.4	1.54	2.38	2.52	2.7	
		Week 12	Tezepelumab	3	3 (100.0)	2.60 (0.94)	1.7	1.68	2.57	3.55	3.6	
			Placebo	6	6 (100.0)	2.27 (0.66)	1.4	1.68	2.30	2.86	3.1	
		Week 16	Tezepelumab	3	3 (100.0)	2.79 (0.84)	2.2	2.20	2.43	3.75	3.8	
			Placebo	6	6 (100.0)	2.32 (0.54)	1.5	1.89	2.45	2.60	3.0	
		Week 24	Tezepelumab	3	3 (100.0)	2.60 (0.95)	1.7	1.69	2.53	3.59	3.6	
			Placebo	6	5 (83.3)	2.39 (0.67)	1.5	1.95	2.61	2.76	3.1	
		Week 36	Tezepelumab	3	3 (100.0)	3.01 (0.84)	2.4	2.39	2.67	3.97	4.0	
			Placebo	6	5 (83.3)	2.49 (1.05)	1.4	1.38	2.81	3.33	3.5	
		Week 52	Tezepelumab	3	2 (66.7)	3.39 (1.21)	2.5	2.53	3.39	4.24	4.2	
			Placebo	6	5 (83.3)	2.44 (1.08)	1.2	1.49	2.67	3.22	3.7	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	3	3 (100.0)	-0.16 (0.43)	-0.5	-0.52	-0.28	0.32	0.3	0.07 [-1.32, 1.45]
			Placebo	6	6 (100.0)	-0.20 (0.58)	-1.3	-0.27	-0.07	0.03	0.5	
		Week 4	Tezepelumab	3	3 (100.0)	-0.12 (0.22)	-0.3	-0.30	-0.18	0.13	0.1	-0.13 [-1.52, 1.26]
			Placebo	6	6 (100.0)	-0.04 (0.67)	-1.0	-0.43	-0.03	0.21	1.0	
		Week 8	Tezepelumab	3	3 (100.0)	-0.41 (0.63)	-1.1	-1.13	-0.13	0.04	0.0	-0.09 [-1.48, 1.30]
			Placebo	6	6 (100.0)	-0.35 (0.70)	-1.7	-0.45	-0.12	0.13	0.2	
		Week 12	Tezepelumab	3	3 (100.0)	-0.25 (0.24)	-0.5	-0.52	-0.12	-0.10	-0.1	-0.08 [-1.46, 1.31]
			Placebo	6	6 (100.0)	-0.22 (0.46)	-1.0	-0.38	-0.20	0.03	0.4	
		Week 16	Tezepelumab	3	3 (100.0)	-0.05 (0.19)	-0.3	-0.26	0.00	0.10	0.1	0.18 [-1.21, 1.57]
			Placebo	6	6 (100.0)	-0.17 (0.77)	-1.6	-0.42	0.06	0.22	0.6	
		Week 24	Tezepelumab	3	3 (100.0)	-0.24 (0.24)	-0.5	-0.51	-0.16	-0.06	-0.1	-0.14 [-1.58, 1.29]
			Placebo	6	5 (83.3)	-0.15 (0.79)	-1.4	-0.26	0.07	0.17	0.7	
		Week 36	Tezepelumab	3	3 (100.0)	0.16 (0.17)	-0.0	-0.02	0.19	0.32	0.3	0.37 [-1.07, 1.82]
			Placebo	6	5 (83.3)	-0.05 (0.69)	-1.2	-0.03	0.12	0.31	0.6	
		Week 52	Tezepelumab	3	2 (66.7)	0.22 (0.53)	-0.2	-0.16	0.22	0.59	0.6	0.44 [-1.22, 2.11]
			Placebo	6	5 (83.3)	-0.10 (0.75)	-1.4	-0.11	0.08	0.25	0.6	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Absolute values	Baseline	Tezepelumab	12	12 (100.0)	2.53 (0.69)	1.4	2.05	2.74	3.08	3.4	
			Placebo	14	14 (100.0)	2.54 (0.91)	1.0	2.08	2.30	2.94	4.9	
		Week 2	Tezepelumab	12	11 (91.7)	2.84 (0.59)	1.7	2.50	2.74	3.36	3.7	
			Placebo	14	14 (100.0)	2.84 (0.66)	2.2	2.37	2.68	3.01	4.7	
		Week 4	Tezepelumab	12	11 (91.7)	2.66 (0.65)	1.3	2.47	2.67	3.18	3.5	
			Placebo	14	13 (92.9)	2.69 (0.43)	2.1	2.50	2.59	2.66	3.7	
		Week 8	Tezepelumab	12	11 (91.7)	2.61 (0.91)	1.0	2.15	2.71	3.43	3.5	
			Placebo	14	13 (92.9)	2.92 (0.71)	2.0	2.59	2.79	3.09	4.9	
		Week 12	Tezepelumab	12	10 (83.3)	2.57 (0.93)	0.8	2.07	2.69	3.37	3.5	
			Placebo	14	14 (100.0)	2.90 (0.76)	1.9	2.49	2.55	3.38	5.0	
		Week 16	Tezepelumab	12	10 (83.3)	2.65 (0.62)	1.5	2.22	2.62	3.31	3.4	
			Placebo	14	14 (100.0)	2.84 (0.79)	2.1	2.41	2.52	3.17	5.2	
		Week 24	Tezepelumab	12	10 (83.3)	2.66 (0.68)	1.6	2.20	2.89	3.16	3.7	
			Placebo	14	13 (92.9)	2.94 (0.77)	2.0	2.60	2.71	3.11	5.1	
		Week 36	Tezepelumab	12	10 (83.3)	2.84 (0.66)	1.4	2.56	2.94	3.30	3.6	
			Placebo	14	13 (92.9)	2.96 (0.94)	1.4	2.55	2.93	3.22	5.3	
		Week 52	Tezepelumab	12	10 (83.3)	2.85 (0.58)	1.9	2.37	2.94	3.31	3.6	
			Placebo	14	13 (92.9)	2.89 (0.91)	2.1	2.27	2.63	3.05	5.3	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Change from baseline	Week 2	Tezepelumab	12	11 (91.7)	0.33 (0.47)	-0.4	0.05	0.26	0.48	1.4	0.08 [-0.71, 0.87]
			Placebo	14	14 (100.0)	0.29 (0.55)	-0.2	-0.04	0.06	0.26	1.7	
		Week 4	Tezepelumab	12	11 (91.7)	0.20 (0.51)	-0.3	-0.15	-0.08	0.43	1.2	-0.22 [-1.03, 0.58]
			Placebo	14	13 (92.9)	0.33 (0.62)	-0.5	-0.08	0.22	0.40	1.7	
		Week 8	Tezepelumab	12	11 (91.7)	0.15 (0.64)	-0.8	-0.40	0.14	0.44	1.6	-0.28 [-1.09, 0.53]
			Placebo	14	13 (92.9)	0.35 (0.75)	-0.8	-0.06	0.05	0.65	2.0	
		Week 12	Tezepelumab	12	10 (83.3)	0.07 (0.82)	-1.5	-0.30	0.11	0.59	1.5	-0.37 [-1.19, 0.45]
			Placebo	14	14 (100.0)	0.35 (0.73)	-1.2	0.02	0.23	0.41	1.6	
		Week 16	Tezepelumab	12	10 (83.3)	0.26 (0.51)	-0.5	0.00	0.11	0.60	1.4	-0.07 [-0.88, 0.75]
			Placebo	14	14 (100.0)	0.30 (0.68)	-0.7	-0.15	0.13	0.37	1.6	
		Week 24	Tezepelumab	12	10 (83.3)	0.27 (0.66)	-0.8	-0.03	0.20	0.38	1.8	-0.01 [-0.84, 0.81]
			Placebo	14	13 (92.9)	0.28 (0.63)	-1.1	-0.01	0.23	0.54	1.5	
		Week 36	Tezepelumab	12	10 (83.3)	0.45 (0.55)	-0.1	-0.01	0.42	0.77	1.7	0.08 [-0.74, 0.91]
			Placebo	14	13 (92.9)	0.38 (0.92)	-1.7	0.15	0.24	0.47	2.2	
		Week 52	Tezepelumab	12	10 (83.3)	0.46 (0.51)	-0.6	0.37	0.47	0.74	1.3	0.19 [-0.64, 1.02]
			Placebo	14	13 (92.9)	0.34 (0.70)	-0.7	0.03	0.28	0.53	1.9	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	2.85 (0.74)	2.2	2.20	2.69	3.65	3.7	
			Placebo	6	6 (100.0)	2.49 (1.06)	1.3	1.41	2.61	3.02	4.0	
		Week 2	Tezepelumab	3	3 (100.0)	2.69 (1.17)	1.7	1.68	2.41	3.97	4.0	
			Placebo	6	6 (100.0)	2.29 (0.64)	1.3	1.74	2.49	2.76	2.9	
		Week 4	Tezepelumab	3	3 (100.0)	2.73 (0.96)	1.9	1.90	2.51	3.78	3.8	
			Placebo	6	6 (100.0)	2.45 (0.64)	1.4	2.17	2.43	3.04	3.2	
		Week 8	Tezepelumab	3	3 (100.0)	2.44 (1.31)	1.1	1.07	2.56	3.69	3.7	
			Placebo	6	6 (100.0)	2.14 (0.56)	1.4	1.54	2.38	2.52	2.7	
		Week 12	Tezepelumab	3	3 (100.0)	2.60 (0.94)	1.7	1.68	2.57	3.55	3.6	
			Placebo	6	6 (100.0)	2.27 (0.66)	1.4	1.68	2.30	2.86	3.1	
		Week 16	Tezepelumab	3	3 (100.0)	2.79 (0.84)	2.2	2.20	2.43	3.75	3.8	
			Placebo	6	6 (100.0)	2.32 (0.54)	1.5	1.89	2.45	2.60	3.0	
		Week 24	Tezepelumab	3	3 (100.0)	2.60 (0.95)	1.7	1.69	2.53	3.59	3.6	
			Placebo	6	5 (83.3)	2.39 (0.67)	1.5	1.95	2.61	2.76	3.1	
		Week 36	Tezepelumab	3	3 (100.0)	3.01 (0.84)	2.4	2.39	2.67	3.97	4.0	
			Placebo	6	5 (83.3)	2.49 (1.05)	1.4	1.38	2.81	3.33	3.5	
		Week 52	Tezepelumab	3	2 (66.7)	3.39 (1.21)	2.5	2.53	3.39	4.24	4.2	
			Placebo	6	5 (83.3)	2.44 (1.08)	1.2	1.49	2.67	3.22	3.7	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	3	3 (100.0)	-0.16 (0.43)	-0.5	-0.52	-0.28	0.32	0.3	0.07 [-1.32, 1.45]
			Placebo	6	6 (100.0)	-0.20 (0.58)	-1.3	-0.27	-0.07	0.03	0.5	
		Week 4	Tezepelumab	3	3 (100.0)	-0.12 (0.22)	-0.3	-0.30	-0.18	0.13	0.1	-0.13 [-1.52, 1.26]
			Placebo	6	6 (100.0)	-0.04 (0.67)	-1.0	-0.43	-0.03	0.21	1.0	
		Week 8	Tezepelumab	3	3 (100.0)	-0.41 (0.63)	-1.1	-1.13	-0.13	0.04	0.0	-0.09 [-1.48, 1.30]
			Placebo	6	6 (100.0)	-0.35 (0.70)	-1.7	-0.45	-0.12	0.13	0.2	
		Week 12	Tezepelumab	3	3 (100.0)	-0.25 (0.24)	-0.5	-0.52	-0.12	-0.10	-0.1	-0.08 [-1.46, 1.31]
			Placebo	6	6 (100.0)	-0.22 (0.46)	-1.0	-0.38	-0.20	0.03	0.4	
		Week 16	Tezepelumab	3	3 (100.0)	-0.05 (0.19)	-0.3	-0.26	0.00	0.10	0.1	0.18 [-1.21, 1.57]
			Placebo	6	6 (100.0)	-0.17 (0.77)	-1.6	-0.42	0.06	0.22	0.6	
		Week 24	Tezepelumab	3	3 (100.0)	-0.24 (0.24)	-0.5	-0.51	-0.16	-0.06	-0.1	-0.14 [-1.58, 1.29]
			Placebo	6	5 (83.3)	-0.15 (0.79)	-1.4	-0.26	0.07	0.17	0.7	
		Week 36	Tezepelumab	3	3 (100.0)	0.16 (0.17)	-0.0	-0.02	0.19	0.32	0.3	0.37 [-1.07, 1.82]
			Placebo	6	5 (83.3)	-0.05 (0.69)	-1.2	-0.03	0.12	0.31	0.6	
		Week 52	Tezepelumab	3	2 (66.7)	0.22 (0.53)	-0.2	-0.16	0.22	0.59	0.6	0.44 [-1.22, 2.11]
			Placebo	6	5 (83.3)	-0.10 (0.75)	-1.4	-0.11	0.08	0.25	0.6	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Absolute values	Baseline	Tezepelumab	12	12 (100.0)	2.53 (0.69)	1.4	2.05	2.74	3.08	3.4	
			Placebo	14	14 (100.0)	2.54 (0.91)	1.0	2.08	2.30	2.94	4.9	
		Week 2	Tezepelumab	12	11 (91.7)	2.84 (0.59)	1.7	2.50	2.74	3.36	3.7	
			Placebo	14	14 (100.0)	2.84 (0.66)	2.2	2.37	2.68	3.01	4.7	
		Week 4	Tezepelumab	12	11 (91.7)	2.66 (0.65)	1.3	2.47	2.67	3.18	3.5	
			Placebo	14	13 (92.9)	2.69 (0.43)	2.1	2.50	2.59	2.66	3.7	
		Week 8	Tezepelumab	12	11 (91.7)	2.61 (0.91)	1.0	2.15	2.71	3.43	3.5	
			Placebo	14	13 (92.9)	2.92 (0.71)	2.0	2.59	2.79	3.09	4.9	
		Week 12	Tezepelumab	12	10 (83.3)	2.57 (0.93)	0.8	2.07	2.69	3.37	3.5	
			Placebo	14	14 (100.0)	2.90 (0.76)	1.9	2.49	2.55	3.38	5.0	
		Week 16	Tezepelumab	12	10 (83.3)	2.65 (0.62)	1.5	2.22	2.62	3.31	3.4	
			Placebo	14	14 (100.0)	2.84 (0.79)	2.1	2.41	2.52	3.17	5.2	
		Week 24	Tezepelumab	12	10 (83.3)	2.66 (0.68)	1.6	2.20	2.89	3.16	3.7	
			Placebo	14	13 (92.9)	2.94 (0.77)	2.0	2.60	2.71	3.11	5.1	
		Week 36	Tezepelumab	12	10 (83.3)	2.84 (0.66)	1.4	2.56	2.94	3.30	3.6	
			Placebo	14	13 (92.9)	2.96 (0.94)	1.4	2.55	2.93	3.22	5.3	
		Week 52	Tezepelumab	12	10 (83.3)	2.85 (0.58)	1.9	2.37	2.94	3.31	3.6	
			Placebo	14	13 (92.9)	2.89 (0.91)	2.1	2.27	2.63	3.05	5.3	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Change from baseline	Week 2	Tezepelumab	12	11 (91.7)	0.33 (0.47)	-0.4	0.05	0.26	0.48	1.4	0.08 [-0.71, 0.87]
			Placebo	14	14 (100.0)	0.29 (0.55)	-0.2	-0.04	0.06	0.26	1.7	
		Week 4	Tezepelumab	12	11 (91.7)	0.20 (0.51)	-0.3	-0.15	-0.08	0.43	1.2	-0.22 [-1.03, 0.58]
			Placebo	14	13 (92.9)	0.33 (0.62)	-0.5	-0.08	0.22	0.40	1.7	
		Week 8	Tezepelumab	12	11 (91.7)	0.15 (0.64)	-0.8	-0.40	0.14	0.44	1.6	-0.28 [-1.09, 0.53]
			Placebo	14	13 (92.9)	0.35 (0.75)	-0.8	-0.06	0.05	0.65	2.0	
		Week 12	Tezepelumab	12	10 (83.3)	0.07 (0.82)	-1.5	-0.30	0.11	0.59	1.5	-0.37 [-1.19, 0.45]
			Placebo	14	14 (100.0)	0.35 (0.73)	-1.2	0.02	0.23	0.41	1.6	
		Week 16	Tezepelumab	12	10 (83.3)	0.26 (0.51)	-0.5	0.00	0.11	0.60	1.4	-0.07 [-0.88, 0.75]
			Placebo	14	14 (100.0)	0.30 (0.68)	-0.7	-0.15	0.13	0.37	1.6	
		Week 24	Tezepelumab	12	10 (83.3)	0.27 (0.66)	-0.8	-0.03	0.20	0.38	1.8	-0.01 [-0.84, 0.81]
			Placebo	14	13 (92.9)	0.28 (0.63)	-1.1	-0.01	0.23	0.54	1.5	
		Week 36	Tezepelumab	12	10 (83.3)	0.45 (0.55)	-0.1	-0.01	0.42	0.77	1.7	0.08 [-0.74, 0.91]
			Placebo	14	13 (92.9)	0.38 (0.92)	-1.7	0.15	0.24	0.47	2.2	
		Week 52	Tezepelumab	12	10 (83.3)	0.46 (0.51)	-0.6	0.37	0.47	0.74	1.3	0.19 [-0.64, 1.02]
			Placebo	14	13 (92.9)	0.34 (0.70)	-0.7	0.03	0.28	0.53	1.9	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	5	5 (100.0)	2.21 (0.52)	1.4	2.12	2.14	2.69	2.7	
			Placebo	8	8 (100.0)	2.39 (0.89)	1.3	1.76	2.30	2.86	4.0	
		Week 2	Tezepelumab	5	5 (100.0)	2.50 (0.19)	2.2	2.41	2.50	2.59	2.7	
			Placebo	8	8 (100.0)	2.29 (0.53)	1.3	1.95	2.39	2.69	2.9	
		Week 4	Tezepelumab	5	5 (100.0)	2.52 (0.45)	1.8	2.51	2.57	2.61	3.1	
			Placebo	8	8 (100.0)	2.36 (0.47)	1.4	2.18	2.45	2.59	3.0	
		Week 8	Tezepelumab	5	5 (100.0)	2.27 (0.73)	1.0	2.54	2.56	2.58	2.7	
			Placebo	8	7 (87.5)	2.25 (0.59)	1.4	1.54	2.35	2.76	2.8	
		Week 12	Tezepelumab	5	4 (80.0)	2.42 (0.30)	2.1	2.18	2.43	2.66	2.7	
			Placebo	8	8 (100.0)	2.43 (0.58)	1.4	2.06	2.53	2.88	3.1	
		Week 16	Tezepelumab	5	5 (100.0)	2.38 (0.27)	2.0	2.22	2.43	2.50	2.7	
			Placebo	8	8 (100.0)	2.25 (0.39)	1.5	1.99	2.46	2.51	2.6	
		Week 24	Tezepelumab	5	5 (100.0)	2.45 (0.53)	1.6	2.32	2.53	2.88	2.9	
			Placebo	8	8 (100.0)	2.42 (0.52)	1.5	2.05	2.64	2.74	3.1	
		Week 36	Tezepelumab	5	5 (100.0)	2.65 (0.30)	2.3	2.56	2.67	2.71	3.1	
			Placebo	8	7 (87.5)	2.35 (0.79)	1.4	1.38	2.76	2.90	3.3	
		Week 52	Tezepelumab	5	5 (100.0)	2.64 (0.34)	2.2	2.53	2.64	2.79	3.1	
			Placebo	8	7 (87.5)	2.36 (0.85)	1.2	1.49	2.47	2.93	3.7	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	5	5 (100.0)	0.28 (0.42)	-0.3	0.05	0.36	0.47	0.8	0.79 [-0.37, 1.96]
			Placebo	8	8 (100.0)	-0.10 (0.51)	-1.3	-0.08	-0.05	0.13	0.5	
		Week 4	Tezepelumab	5	5 (100.0)	0.30 (0.46)	-0.2	-0.08	0.39	0.43	1.0	0.62 [-0.53, 1.76]
			Placebo	8	8 (100.0)	-0.03 (0.58)	-1.0	-0.27	-0.03	0.18	1.0	
		Week 8	Tezepelumab	5	5 (100.0)	0.06 (0.38)	-0.5	-0.13	0.02	0.42	0.4	0.37 [-0.79, 1.53]
			Placebo	8	7 (87.5)	-0.17 (0.73)	-1.7	-0.33	0.09	0.13	0.7	
		Week 12	Tezepelumab	5	4 (80.0)	0.18 (0.33)	-0.1	-0.03	0.11	0.40	0.6	0.33 [-0.87, 1.54]
			Placebo	8	8 (100.0)	0.04 (0.46)	-1.0	-0.08	0.11	0.40	0.4	
		Week 16	Tezepelumab	5	5 (100.0)	0.17 (0.33)	-0.3	0.04	0.10	0.36	0.6	0.54 [-0.60, 1.68]
			Placebo	8	8 (100.0)	-0.14 (0.67)	-1.6	-0.32	0.00	0.23	0.6	
		Week 24	Tezepelumab	5	5 (100.0)	0.23 (0.33)	-0.2	0.18	0.18	0.21	0.8	0.36 [-0.77, 1.49]
			Placebo	8	8 (100.0)	0.03 (0.66)	-1.4	-0.14	0.15	0.47	0.7	
		Week 36	Tezepelumab	5	5 (100.0)	0.44 (0.31)	-0.0	0.39	0.44	0.57	0.8	1.13 [-0.12, 2.38]
			Placebo	8	7 (87.5)	-0.08 (0.55)	-1.2	-0.30	0.12	0.31	0.3	
		Week 52	Tezepelumab	5	5 (100.0)	0.43 (0.35)	-0.2	0.39	0.52	0.65	0.7	0.84 [-0.36, 2.05]
			Placebo	8	7 (87.5)	-0.03 (0.63)	-1.4	-0.11	0.08	0.31	0.6	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Absolute values	Baseline	Tezepelumab	10	10 (100.0)	2.78 (0.70)	1.4	2.20	2.96	3.22	3.7	
			Placebo	12	12 (100.0)	2.62 (0.98)	1.0	2.07	2.51	3.03	4.9	
		Week 2	Tezepelumab	10	9 (90.0)	2.97 (0.82)	1.7	2.59	3.26	3.39	4.0	
			Placebo	12	12 (100.0)	2.93 (0.67)	2.3	2.46	2.77	3.10	4.7	
		Week 4	Tezepelumab	10	9 (90.0)	2.77 (0.80)	1.3	2.47	2.81	3.29	3.8	
			Placebo	12	11 (91.7)	2.80 (0.46)	2.2	2.50	2.66	3.18	3.7	
		Week 8	Tezepelumab	10	9 (90.0)	2.75 (1.06)	1.0	2.15	3.30	3.43	3.7	
			Placebo	12	12 (100.0)	2.92 (0.74)	2.0	2.47	2.85	3.17	4.9	
		Week 12	Tezepelumab	10	9 (90.0)	2.64 (1.07)	0.8	1.68	3.34	3.48	3.6	
			Placebo	12	12 (100.0)	2.90 (0.85)	1.9	2.42	2.58	3.45	5.0	
		Week 16	Tezepelumab	10	8 (80.0)	2.87 (0.74)	1.5	2.35	3.13	3.37	3.8	
			Placebo	12	12 (100.0)	2.98 (0.81)	2.3	2.44	2.79	3.19	5.2	
		Week 24	Tezepelumab	10	8 (80.0)	2.77 (0.81)	1.7	1.95	3.04	3.39	3.7	
			Placebo	12	10 (83.3)	3.08 (0.83)	2.0	2.60	3.02	3.39	5.1	
		Week 36	Tezepelumab	10	8 (80.0)	3.02 (0.81)	1.4	2.66	3.13	3.60	4.0	
			Placebo	12	11 (91.7)	3.14 (0.97)	1.4	2.55	3.10	3.54	5.3	
		Week 52	Tezepelumab	10	7 (70.0)	3.15 (0.80)	1.9	2.37	3.31	3.57	4.2	
			Placebo	12	11 (91.7)	3.03 (0.96)	2.1	2.27	2.65	3.74	5.3	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Change from baseline	Week 2	Tezepelumab	10	9 (90.0)	0.20 (0.55)	-0.5	-0.04	0.19	0.32	1.4	-0.19 [-1.06, 0.67]
			Placebo	12	12 (100.0)	0.31 (0.60)	-0.3	-0.05	0.06	0.48	1.7	
		Week 4	Tezepelumab	10	9 (90.0)	0.04 (0.49)	-0.3	-0.30	-0.14	0.13	1.2	-0.59 [-1.50, 0.31]
			Placebo	12	11 (91.7)	0.38 (0.66)	-0.5	-0.08	0.22	0.77	1.7	
		Week 8	Tezepelumab	10	9 (90.0)	0.02 (0.79)	-1.1	-0.40	0.04	0.25	1.6	-0.36 [-1.23, 0.51]
			Placebo	12	12 (100.0)	0.30 (0.80)	-0.8	-0.14	0.04	0.76	2.0	
		Week 12	Tezepelumab	10	9 (90.0)	-0.09 (0.86)	-1.5	-0.52	-0.10	0.30	1.5	-0.43 [-1.30, 0.45]
			Placebo	12	12 (100.0)	0.28 (0.83)	-1.2	-0.23	0.07	0.86	1.6	
		Week 16	Tezepelumab	10	8 (80.0)	0.20 (0.56)	-0.5	-0.06	0.05	0.36	1.4	-0.24 [-1.14, 0.66]
			Placebo	12	12 (100.0)	0.36 (0.72)	-0.7	-0.07	0.20	0.72	1.6	
		Week 24	Tezepelumab	10	8 (80.0)	0.10 (0.77)	-0.8	-0.38	-0.04	0.33	1.8	-0.22 [-1.15, 0.72]
			Placebo	12	10 (83.3)	0.26 (0.71)	-1.1	-0.06	0.20	0.54	1.5	
		Week 36	Tezepelumab	10	8 (80.0)	0.35 (0.60)	-0.1	-0.02	0.09	0.55	1.7	-0.16 [-1.08, 0.75]
			Placebo	12	11 (91.7)	0.48 (0.98)	-1.7	0.15	0.42	1.16	2.2	
		Week 52	Tezepelumab	10	7 (70.0)	0.41 (0.60)	-0.6	0.02	0.42	0.79	1.3	0.05 [-0.89, 1.00]
			Placebo	12	11 (91.7)	0.37 (0.75)	-0.7	-0.02	0.28	0.59	1.9	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Sex									0.929
Male	Week 2	Tezepelumab	8	7 (87.5)	0.28 (0.22)	(-0.17, 0.74)	0.12 (0.28)	(-0.48, 0.72)	0.671
		Placebo	11	11 (100.0)	0.16 (0.18)	(-0.22, 0.55)			
	Week 4	Tezepelumab	8	7 (87.5)	0.16 (0.21)	(-0.30, 0.61)	-0.05 (0.28)	(-0.65, 0.54)	0.856
		Placebo	11	10 (90.9)	0.21 (0.18)	(-0.17, 0.59)			
	Week 8	Tezepelumab	8	7 (87.5)	0.20 (0.29)	(-0.42, 0.83)	-0.01 (0.39)	(-0.82, 0.81)	0.989
		Placebo	11	11 (100.0)	0.21 (0.25)	(-0.32, 0.74)			
	Week 12	Tezepelumab	8	7 (87.5)	0.23 (0.26)	(-0.33, 0.78)	-0.06 (0.34)	(-0.78, 0.66)	0.860
		Placebo	11	11 (100.0)	0.29 (0.22)	(-0.18, 0.75)			
	Week 16	Tezepelumab	8	6 (75.0)	0.43 (0.25)	(-0.10, 0.96)	0.16 (0.33)	(-0.53, 0.85)	0.623
		Placebo	11	11 (100.0)	0.27 (0.21)	(-0.17, 0.71)			
	Week 24	Tezepelumab	8	6 (75.0)	0.41 (0.29)	(-0.21, 1.03)	-0.06 (0.37)	(-0.87, 0.76)	0.877
		Placebo	11	9 (81.8)	0.47 (0.24)	(-0.06, 0.99)			
	Week 36	Tezepelumab	8	6 (75.0)	0.61 (0.25)	(0.08, 1.14)	0.07 (0.33)	(-0.62, 0.76)	0.835
		Placebo	11	10 (90.9)	0.54 (0.21)	(0.10, 0.99)			
	Week 52	Tezepelumab	8	5 (62.5)	0.62 (0.23)	(0.13, 1.10)	0.17 (0.30)	(-0.46, 0.80)	0.579
		Placebo	11	9 (81.8)	0.45 (0.19)	(0.05, 0.84)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Female	Week 2	Tezepelumab	7	7 (100.0)	0.18 (0.08)	(0.00, 0.35)	0.06 (0.11)	(-0.17, 0.29)	0.576
		Placebo	9	9 (100.0)	0.11 (0.07)	(-0.04, 0.27)			
	Week 4	Tezepelumab	7	7 (100.0)	0.16 (0.12)	(-0.10, 0.42)	0.00 (0.16)	(-0.34, 0.34)	0.996
		Placebo	9	9 (100.0)	0.16 (0.10)	(-0.07, 0.39)			
	Week 8	Tezepelumab	7	7 (100.0)	-0.06 (0.16)	(-0.41, 0.28)	-0.07 (0.22)	(-0.54, 0.40)	0.757
		Placebo	9	8 (88.9)	0.01 (0.15)	(-0.31, 0.33)			
	Week 12	Tezepelumab	7	6 (85.7)	-0.14 (0.19)	(-0.55, 0.27)	-0.19 (0.25)	(-0.73, 0.35)	0.465
		Placebo	9	9 (100.0)	0.05 (0.16)	(-0.30, 0.39)			
	Week 16	Tezepelumab	7	7 (100.0)	0.04 (0.08)	(-0.14, 0.23)	0.03 (0.11)	(-0.22, 0.28)	0.800
		Placebo	9	9 (100.0)	0.02 (0.07)	(-0.15, 0.18)			
	Week 24	Tezepelumab	7	7 (100.0)	0.00 (0.15)	(-0.33, 0.33)	-0.08 (0.20)	(-0.52, 0.36)	0.696
		Placebo	9	9 (100.0)	0.08 (0.13)	(-0.21, 0.37)			
	Week 36	Tezepelumab	7	7 (100.0)	0.25 (0.19)	(-0.16, 0.66)	0.29 (0.26)	(-0.27, 0.84)	0.284
		Placebo	9	8 (88.9)	-0.04 (0.17)	(-0.41, 0.34)			
	Week 52	Tezepelumab	7	7 (100.0)	0.23 (0.15)	(-0.09, 0.56)	0.27 (0.20)	(-0.17, 0.70)	0.211
		Placebo	9	9 (100.0)	-0.03 (0.13)	(-0.32, 0.26)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Exacerbations in the year before study									0.480
<= 2	Week 2	Tezepelumab	7	7 (100.0)	0.32 (0.16)	(-0.01, 0.66)	0.25 (0.20)	(-0.17, 0.68)	0.229
		Placebo	12	12 (100.0)	0.07 (0.12)	(-0.19, 0.33)			
	Week 4	Tezepelumab	7	7 (100.0)	0.24 (0.14)	(-0.05, 0.52)	0.18 (0.17)	(-0.18, 0.55)	0.299
		Placebo	12	11 (91.7)	0.05 (0.11)	(-0.17, 0.27)			
	Week 8	Tezepelumab	7	7 (100.0)	0.12 (0.22)	(-0.35, 0.59)	0.08 (0.28)	(-0.52, 0.67)	0.790
		Placebo	12	11 (91.7)	0.04 (0.17)	(-0.32, 0.41)			
	Week 12	Tezepelumab	7	7 (100.0)	0.08 (0.27)	(-0.49, 0.65)	0.03 (0.34)	(-0.68, 0.75)	0.925
		Placebo	12	12 (100.0)	0.05 (0.21)	(-0.38, 0.48)			
	Week 16	Tezepelumab	7	6 (85.7)	0.26 (0.21)	(-0.17, 0.69)	0.16 (0.26)	(-0.38, 0.70)	0.542
		Placebo	12	12 (100.0)	0.10 (0.15)	(-0.22, 0.43)			
	Week 24	Tezepelumab	7	6 (85.7)	0.19 (0.24)	(-0.32, 0.70)	0.08 (0.30)	(-0.56, 0.72)	0.805
		Placebo	12	11 (91.7)	0.12 (0.18)	(-0.27, 0.50)			
	Week 36	Tezepelumab	7	6 (85.7)	0.51 (0.27)	(-0.07, 1.08)	0.35 (0.34)	(-0.37, 1.07)	0.323
		Placebo	12	11 (91.7)	0.16 (0.20)	(-0.27, 0.59)			
	Week 52	Tezepelumab	7	6 (85.7)	0.40 (0.23)	(-0.09, 0.89)	0.15 (0.30)	(-0.47, 0.77)	0.613
		Placebo	12	10 (83.3)	0.25 (0.18)	(-0.13, 0.63)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
> 2	Week 2	Tezepelumab	8	7 (87.5)	0.16 (0.20)	(-0.28, 0.61)	-0.08 (0.28)	(-0.71, 0.55)	0.782
		Placebo	8	8 (100.0)	0.24 (0.19)	(-0.20, 0.68)			
	Week 4	Tezepelumab	8	7 (87.5)	0.11 (0.23)	(-0.41, 0.62)	-0.28 (0.32)	(-1.01, 0.44)	0.401
		Placebo	8	8 (100.0)	0.39 (0.22)	(-0.12, 0.90)			
	Week 8	Tezepelumab	8	7 (87.5)	0.05 (0.29)	(-0.58, 0.67)	-0.19 (0.41)	(-1.08, 0.69)	0.647
		Placebo	8	8 (100.0)	0.24 (0.28)	(-0.38, 0.85)			
	Week 12	Tezepelumab	8	6 (75.0)	-0.02 (0.21)	(-0.48, 0.45)	-0.39 (0.30)	(-1.03, 0.26)	0.220
		Placebo	8	8 (100.0)	0.37 (0.20)	(-0.08, 0.81)			
	Week 16	Tezepelumab	8	7 (87.5)	0.20 (0.22)	(-0.31, 0.71)	-0.03 (0.32)	(-0.76, 0.69)	0.923
		Placebo	8	8 (100.0)	0.23 (0.22)	(-0.27, 0.74)			
	Week 24	Tezepelumab	8	7 (87.5)	0.25 (0.26)	(-0.35, 0.84)	-0.24 (0.37)	(-1.08, 0.61)	0.535
		Placebo	8	7 (87.5)	0.48 (0.26)	(-0.11, 1.08)			
	Week 36	Tezepelumab	8	7 (87.5)	0.40 (0.24)	(-0.12, 0.92)	0.03 (0.34)	(-0.71, 0.78)	0.921
		Placebo	8	7 (87.5)	0.37 (0.24)	(-0.15, 0.88)			
	Week 52	Tezepelumab	8	6 (75.0)	0.50 (0.21)	(0.04, 0.95)	0.33 (0.29)	(-0.30, 0.96)	0.275
		Placebo	8	8 (100.0)	0.17 (0.19)	(-0.26, 0.59)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Race				N<10 any level					NE

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Region				N<10 any level					NE

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
BMI				N<10 any level					NE

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline eosinophils - Low				N<10 any level					NE

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline eosinophils - High									0.702
< 300 cells/uL	Week 2	Tezepelumab	9	9 (100.0)	0.20 (0.07)	(0.04, 0.36)	0.25 (0.13)	(-0.04, 0.54)	0.086
		Placebo	4	4 (100.0)	-0.05 (0.11)	(-0.29, 0.19)			
	Week 4	Tezepelumab	9	8 (88.9)	0.14 (0.12)	(-0.12, 0.41)	0.21 (0.22)	(-0.28, 0.71)	0.355
		Placebo	4	3 (75.0)	-0.07 (0.19)	(-0.49, 0.35)			
	Week 8	Tezepelumab	9	8 (88.9)	0.07 (0.09)	(-0.13, 0.27)	0.04 (0.15)	(-0.30, 0.39)	0.789
		Placebo	4	4 (100.0)	0.03 (0.13)	(-0.26, 0.31)			
	Week 12	Tezepelumab	9	7 (77.8)	-0.18 (0.09)	(-0.43, 0.06)	-0.23 (0.14)	(-0.63, 0.18)	0.196
		Placebo	4	4 (100.0)	0.04 (0.11)	(-0.28, 0.36)			
	Week 16	Tezepelumab	9	8 (88.9)	0.06 (0.06)	(-0.09, 0.20)	-0.07 (0.11)	(-0.33, 0.18)	0.523
		Placebo	4	4 (100.0)	0.13 (0.09)	(-0.08, 0.34)			
	Week 24	Tezepelumab	9	8 (88.9)	0.14 (0.09)	(-0.07, 0.35)	0.00 (0.17)	(-0.37, 0.38)	0.982
		Placebo	4	4 (100.0)	0.14 (0.14)	(-0.17, 0.44)			
	Week 36	Tezepelumab	9	8 (88.9)	0.21 (0.09)	(0.00, 0.42)	0.02 (0.16)	(-0.35, 0.39)	0.907
		Placebo	4	4 (100.0)	0.19 (0.13)	(-0.11, 0.49)			
	Week 52	Tezepelumab	9	8 (88.9)	0.38 (0.09)	(0.18, 0.58)	0.17 (0.16)	(-0.19, 0.53)	0.313
		Placebo	4	3 (75.0)	0.21 (0.13)	(-0.09, 0.51)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 300 cells/uL	Week 2	Tezepelumab	6	5 (83.3)	0.33 (0.19)	(-0.07, 0.73)	0.13 (0.22)	(-0.34, 0.60)	0.567
		Placebo	16	16 (100.0)	0.20 (0.12)	(-0.04, 0.44)			
	Week 4	Tezepelumab	6	6 (100.0)	0.17 (0.19)	(-0.22, 0.55)	-0.10 (0.22)	(-0.55, 0.36)	0.667
		Placebo	16	16 (100.0)	0.26 (0.11)	(0.02, 0.50)			
	Week 8	Tezepelumab	6	6 (100.0)	0.00 (0.30)	(-0.62, 0.63)	-0.11 (0.35)	(-0.85, 0.62)	0.753
		Placebo	16	15 (93.8)	0.12 (0.19)	(-0.27, 0.50)			
	Week 12	Tezepelumab	6	6 (100.0)	0.17 (0.27)	(-0.39, 0.72)	-0.06 (0.31)	(-0.71, 0.59)	0.858
		Placebo	16	16 (100.0)	0.22 (0.16)	(-0.12, 0.56)			
	Week 16	Tezepelumab	6	5 (83.3)	0.42 (0.20)	(-0.01, 0.84)	0.25 (0.24)	(-0.25, 0.74)	0.311
		Placebo	16	16 (100.0)	0.17 (0.12)	(-0.09, 0.42)			
	Week 24	Tezepelumab	6	5 (83.3)	0.25 (0.25)	(-0.27, 0.78)	-0.02 (0.29)	(-0.64, 0.59)	0.946
		Placebo	16	14 (87.5)	0.27 (0.15)	(-0.05, 0.59)			
	Week 36	Tezepelumab	6	5 (83.3)	0.73 (0.30)	(0.11, 1.36)	0.44 (0.35)	(-0.29, 1.17)	0.226
		Placebo	16	14 (87.5)	0.29 (0.18)	(-0.08, 0.67)			
	Week 52	Tezepelumab	6	4 (66.7)	0.28 (0.31)	(-0.37, 0.93)	0.07 (0.36)	(-0.68, 0.82)	0.851
		Placebo	16	15 (93.8)	0.21 (0.17)	(-0.16, 0.58)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline FENO				N<10 any level					NE

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline specific perennial FEIA status				N<10 any level					NE

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Total serum IgE				N<10 any level					NE

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
OCS at baseline				N<10 any level					NE

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
LAMA use at baseline				N<10 any level					NE

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Tiotropium use at baseline				N<10 any level					NE

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Montelukast/ Cromoglicic acid use at baseline									0.248
Yes	Week 2	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	8	8 (100.0)					
	Week 4	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	8	8 (100.0)					
	Week 8	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	8	7 (87.5)					
	Week 12	Tezepelumab	5	4 (80.0)	NE		NE		
		Placebo	8	8 (100.0)					
	Week 16	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	8	8 (100.0)					
	Week 24	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	8	8 (100.0)					
	Week 36	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	8	7 (87.5)					
	Week 52	Tezepelumab	5	5 (100.0)	NE		NE		
		Placebo	8	7 (87.5)					

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 2	Tezepelumab	10	9 (90.0)	0.26 (0.15)	(-0.06, 0.58)	-0.04 (0.21)	(-0.47, 0.40)	0.864
		Placebo	12	12 (100.0)	0.29 (0.14)	(0.00, 0.58)			
	Week 4	Tezepelumab	10	9 (90.0)	0.09 (0.16)	(-0.24, 0.43)	-0.23 (0.22)	(-0.68, 0.23)	0.311
		Placebo	12	11 (91.7)	0.32 (0.15)	(0.01, 0.63)			
	Week 8	Tezepelumab	10	9 (90.0)	0.10 (0.23)	(-0.38, 0.58)	-0.19 (0.31)	(-0.83, 0.46)	0.554
		Placebo	12	12 (100.0)	0.29 (0.21)	(-0.15, 0.72)			
	Week 12	Tezepelumab	10	9 (90.0)	-0.00 (0.25)	(-0.52, 0.52)	-0.26 (0.34)	(-0.96, 0.44)	0.442
		Placebo	12	12 (100.0)	0.26 (0.22)	(-0.21, 0.73)			
	Week 16	Tezepelumab	10	8 (80.0)	0.29 (0.18)	(-0.09, 0.67)	-0.05 (0.24)	(-0.56, 0.45)	0.826
		Placebo	12	12 (100.0)	0.34 (0.16)	(0.01, 0.68)			
	Week 24	Tezepelumab	10	8 (80.0)	0.21 (0.22)	(-0.25, 0.67)	-0.15 (0.29)	(-0.77, 0.46)	0.605
		Placebo	12	10 (83.3)	0.36 (0.20)	(-0.05, 0.77)			
	Week 36	Tezepelumab	10	8 (80.0)	0.48 (0.25)	(-0.04, 0.99)	0.02 (0.33)	(-0.66, 0.71)	0.944
		Placebo	12	11 (91.7)	0.46 (0.22)	(0.00, 0.91)			
	Week 52	Tezepelumab	10	7 (70.0)	0.47 (0.21)	(0.04, 0.91)	0.14 (0.28)	(-0.44, 0.71)	0.624
		Placebo	12	11 (91.7)	0.33 (0.18)	(-0.04, 0.71)			

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Western Europe	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	3.18	3.2	3.18	3.18	3.18	3.2	
			Placebo	1	1 (100.0)	2.11	2.1	2.11	2.11	2.11	2.1	
		Week 2	Tezepelumab	1	1 (100.0)	3.26	3.3	3.26	3.26	3.26	3.3	
			Placebo	1	1 (100.0)	2.37	2.4	2.37	2.37	2.37	2.4	
		Week 4	Tezepelumab	1	1 (100.0)	3.51	3.5	3.51	3.51	3.51	3.5	
			Placebo	1	1 (100.0)	2.09	2.1	2.09	2.09	2.09	2.1	
		Week 8	Tezepelumab	1	1 (100.0)	3.43	3.4	3.43	3.43	3.43	3.4	
			Placebo	1	1 (100.0)	2.76	2.8	2.76	2.76	2.76	2.8	
		Week 12	Tezepelumab	1	1 (100.0)	3.48	3.5	3.48	3.48	3.48	3.5	
			Placebo	1	1 (100.0)	2.52	2.5	2.52	2.52	2.52	2.5	
		Week 16	Placebo	1	1 (100.0)	2.48	2.5	2.48	2.48	2.48	2.5	
		Week 24	Placebo	1	1 (100.0)	2.71	2.7	2.71	2.71	2.71	2.7	
		Week 52	Placebo	1	1 (100.0)	2.14	2.1	2.14	2.14	2.14	2.1	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Western Europe	Change from baseline	Week 2	Tezepelumab	1	1 (100.0)	0.08	0.1	0.08	0.08	0.08	0.1	NE
			Placebo	1	1 (100.0)	0.26	0.3	0.26	0.26	0.26	0.3	
		Week 4	Tezepelumab	1	1 (100.0)	0.33	0.3	0.33	0.33	0.33	0.3	NE
			Placebo	1	1 (100.0)	-0.02	-0.0	-0.02	-0.02	-0.02	-0.0	
		Week 8	Tezepelumab	1	1 (100.0)	0.25	0.3	0.25	0.25	0.25	0.3	NE
			Placebo	1	1 (100.0)	0.65	0.7	0.65	0.65	0.65	0.7	
		Week 12	Tezepelumab	1	1 (100.0)	0.30	0.3	0.30	0.30	0.30	0.3	NE
			Placebo	1	1 (100.0)	0.41	0.4	0.41	0.41	0.41	0.4	
		Week 16	Placebo	1	1 (100.0)	0.37	0.4	0.37	0.37	0.37	0.4	
		Week 24	Placebo	1	1 (100.0)	0.60	0.6	0.60	0.60	0.60	0.6	
		Week 52	Placebo	1	1 (100.0)	0.03	0.0	0.03	0.03	0.03	0.0	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
North America	Absolute values	Baseline	Tezepelumab	2	2 (100.0)	2.96 (0.37)	2.7	2.69	2.96	3.22	3.2	
			Placebo	6	6 (100.0)	2.61 (0.91)	1.3	2.24	2.57	3.02	4.0	
		Week 2	Tezepelumab	2	2 (100.0)	3.22 (0.68)	2.7	2.74	3.22	3.70	3.7	
			Placebo	6	6 (100.0)	2.46 (0.43)	1.7	2.27	2.51	2.76	2.9	
		Week 4	Tezepelumab	2	1 (50.0)	2.61	2.6	2.61	2.61	2.61	2.6	
			Placebo	6	6 (100.0)	2.51 (0.31)	2.2	2.28	2.49	2.59	3.0	
		Week 8	Tezepelumab	2	1 (50.0)	2.71	2.7	2.71	2.71	2.71	2.7	
			Placebo	6	6 (100.0)	2.32 (0.51)	1.4	2.30	2.38	2.69	2.8	
		Week 12	Tezepelumab	2	1 (50.0)	2.74	2.7	2.74	2.74	2.74	2.7	
			Placebo	6	6 (100.0)	2.49 (0.55)	1.7	2.00	2.65	2.90	3.1	
		Week 16	Tezepelumab	2	1 (50.0)	2.73	2.7	2.73	2.73	2.73	2.7	
			Placebo	6	6 (100.0)	2.40 (0.26)	1.9	2.44	2.48	2.52	2.6	
		Week 24	Tezepelumab	2	1 (50.0)	2.90	2.9	2.90	2.90	2.90	2.9	
			Placebo	6	5 (83.3)	2.61 (0.40)	2.0	2.61	2.66	2.76	3.1	
		Week 36	Tezepelumab	2	1 (50.0)	3.08	3.1	3.08	3.08	3.08	3.1	
			Placebo	6	5 (83.3)	2.64 (0.74)	1.4	2.76	2.81	2.90	3.3	
		Week 52	Tezepelumab	2	1 (50.0)	3.08	3.1	3.08	3.08	3.08	3.1	
			Placebo	6	4 (66.7)	2.60 (1.05)	1.2	1.91	2.80	3.29	3.7	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
North America	Change from baseline	Week 2	Tezepelumab	2	2 (100.0)	0.27 (0.30)	0.1	0.05	0.27	0.48	0.5	0.77 [-0.89, 2.43]
			Placebo	6	6 (100.0)	-0.16 (0.58)	-1.3	-0.08	-0.06	0.03	0.5	
		Week 4	Tezepelumab	2	1 (50.0)	-0.08	-0.1	-0.08	-0.08	-0.08	-0.1	NE
			Placebo	6	6 (100.0)	-0.10 (0.66)	-1.0	-0.43	-0.09	-0.04	1.0	
		Week 8	Tezepelumab	2	1 (50.0)	0.02	0.0	0.02	0.02	0.02	0.0	NE
			Placebo	6	6 (100.0)	-0.30 (0.70)	-1.7	-0.33	-0.02	0.09	0.2	
		Week 12	Tezepelumab	2	1 (50.0)	0.05	0.1	0.05	0.05	0.05	0.1	NE
			Placebo	6	6 (100.0)	-0.12 (0.48)	-1.0	-0.24	-0.08	0.20	0.4	
		Week 16	Tezepelumab	2	1 (50.0)	0.04	0.0	0.04	0.04	0.04	0.0	NE
			Placebo	6	6 (100.0)	-0.21 (0.77)	-1.6	-0.42	-0.06	0.22	0.6	
		Week 24	Tezepelumab	2	1 (50.0)	0.21	0.2	0.21	0.21	0.21	0.2	NE
			Placebo	6	5 (83.3)	-0.08 (0.82)	-1.4	-0.26	0.23	0.35	0.7	
		Week 36	Tezepelumab	2	1 (50.0)	0.39	0.4	0.39	0.39	0.39	0.4	NE
			Placebo	6	5 (83.3)	-0.05 (0.66)	-1.2	0.12	0.20	0.31	0.3	
		Week 52	Tezepelumab	2	1 (50.0)	0.39	0.4	0.39	0.39	0.39	0.4	NE
			Placebo	6	4 (66.7)	-0.15 (0.86)	-1.4	-0.74	0.06	0.43	0.6	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
South America	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	2.60 (0.72)	1.4	2.12	2.69	2.98	3.7	
			Placebo	12	12 (100.0)	2.61 (0.99)	1.0	2.07	2.47	3.03	4.9	
		Week 2	Tezepelumab	9	9 (100.0)	2.76 (0.78)	1.7	2.41	2.59	3.36	4.0	
			Placebo	12	12 (100.0)	2.92 (0.68)	2.2	2.46	2.77	3.10	4.7	
		Week 4	Tezepelumab	9	9 (100.0)	2.72 (0.76)	1.3	2.51	2.81	3.18	3.8	
			Placebo	12	11 (91.7)	2.83 (0.42)	2.4	2.50	2.66	3.18	3.7	
		Week 8	Tezepelumab	9	9 (100.0)	2.55 (0.99)	1.0	2.15	2.56	3.30	3.7	
			Placebo	12	11 (91.7)	2.97 (0.75)	2.0	2.52	2.93	3.24	4.9	
		Week 12	Tezepelumab	9	8 (88.9)	2.44 (1.04)	0.8	1.56	2.61	3.43	3.6	
			Placebo	12	12 (100.0)	2.94 (0.81)	1.9	2.49	2.58	3.45	5.0	
		Week 16	Tezepelumab	9	9 (100.0)	2.69 (0.70)	1.5	2.22	2.50	3.31	3.8	
			Placebo	12	12 (100.0)	2.94 (0.84)	2.1	2.39	2.79	3.19	5.2	
		Week 24	Tezepelumab	9	9 (100.0)	2.71 (0.75)	1.7	2.20	2.88	3.19	3.7	
			Placebo	12	11 (91.7)	3.00 (0.84)	2.0	2.52	2.93	3.39	5.1	
		Week 36	Tezepelumab	9	9 (100.0)	2.87 (0.74)	1.4	2.56	2.93	3.30	4.0	
			Placebo	12	12 (100.0)	3.03 (0.99)	1.4	2.45	3.04	3.53	5.3	
		Week 52	Tezepelumab	9	8 (88.9)	2.96 (0.75)	1.9	2.45	2.97	3.38	4.2	
			Placebo	12	12 (100.0)	2.98 (0.93)	2.1	2.37	2.64	3.48	5.3	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
South America	Change from baseline	Week 2	Tezepelumab	9	9 (100.0)	0.15 (0.57)	-0.5	-0.28	0.19	0.32	1.4	-0.26 [-1.12, 0.61]
			Placebo	12	12 (100.0)	0.31 (0.61)	-0.3	-0.05	0.06	0.48	1.7	
		Week 4	Tezepelumab	9	9 (100.0)	0.12 (0.56)	-0.3	-0.18	-0.14	0.13	1.2	-0.50 [-1.39, 0.40]
			Placebo	12	11 (91.7)	0.42 (0.64)	-0.5	-0.08	0.34	0.77	1.7	
		Week 8	Tezepelumab	9	9 (100.0)	-0.05 (0.77)	-1.1	-0.40	-0.13	0.14	1.6	-0.45 [-1.35, 0.44]
			Placebo	12	11 (91.7)	0.31 (0.83)	-0.8	-0.22	0.03	1.03	2.0	
		Week 12	Tezepelumab	9	8 (88.9)	-0.22 (0.86)	-1.5	-0.58	-0.21	-0.10	1.5	-0.66 [-1.58, 0.26]
			Placebo	12	12 (100.0)	0.33 (0.82)	-1.2	-0.10	0.17	0.86	1.6	
		Week 16	Tezepelumab	9	9 (100.0)	0.09 (0.52)	-0.5	-0.12	0.00	0.10	1.4	-0.37 [-1.25, 0.50]
			Placebo	12	12 (100.0)	0.33 (0.73)	-0.7	-0.11	0.11	0.72	1.6	
		Week 24	Tezepelumab	9	9 (100.0)	0.11 (0.76)	-0.8	-0.24	-0.06	0.27	1.8	-0.17 [-1.05, 0.71]
			Placebo	12	11 (91.7)	0.23 (0.68)	-1.1	-0.06	0.17	0.54	1.5	
		Week 36	Tezepelumab	9	9 (100.0)	0.27 (0.55)	-0.1	-0.02	0.00	0.32	1.7	-0.18 [-1.05, 0.68]
			Placebo	12	12 (100.0)	0.42 (0.96)	-1.7	0.09	0.33	0.87	2.2	
		Week 52	Tezepelumab	9	8 (88.9)	0.31 (0.57)	-0.6	-0.07	0.40	0.56	1.3	-0.09 [-0.99, 0.80]
			Placebo	12	12 (100.0)	0.37 (0.72)	-0.7	0.04	0.30	0.56	1.9	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Central/Eastern Europe	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	2.78	2.8	2.78	2.78	2.78	2.8	
		Week 4	Tezepelumab	1	1 (100.0)	2.47	2.5	2.47	2.47	2.47	2.5	
		Week 8	Tezepelumab	1	1 (100.0)	3.43	3.4	3.43	3.43	3.43	3.4	
		Week 12	Tezepelumab	1	1 (100.0)	3.37	3.4	3.37	3.37	3.37	3.4	
		Week 16	Tezepelumab	1	1 (100.0)	3.39	3.4	3.39	3.39	3.39	3.4	
		Week 24	Tezepelumab	1	1 (100.0)	3.16	3.2	3.16	3.16	3.16	3.2	
		Week 36	Tezepelumab	1	1 (100.0)	3.55	3.6	3.55	3.55	3.55	3.6	
		Week 52	Tezepelumab	1	1 (100.0)	3.57	3.6	3.57	3.57	3.57	3.6	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Central/Eastern Europe	Change from baseline	Week 4	Tezepelumab	1	1 (100.0)	-0.31	-0.3	-0.31	-0.31	-0.31	-0.3	NE
		Week 8	Tezepelumab	1	1 (100.0)	0.65	0.7	0.65	0.65	0.65	0.7	NE
		Week 12	Tezepelumab	1	1 (100.0)	0.59	0.6	0.59	0.59	0.59	0.6	NE
		Week 16	Tezepelumab	1	1 (100.0)	0.61	0.6	0.61	0.61	0.61	0.6	NE
		Week 24	Tezepelumab	1	1 (100.0)	0.38	0.4	0.38	0.38	0.38	0.4	NE
		Week 36	Tezepelumab	1	1 (100.0)	0.77	0.8	0.77	0.77	0.77	0.8	NE
		Week 52	Tezepelumab	1	1 (100.0)	0.79	0.8	0.79	0.79	0.79	0.8	NE

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Asia Pacific	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	1.43	1.4	1.43	1.43	1.43	1.4	
			Placebo	1	1 (100.0)	1.41	1.4	1.41	1.41	1.41	1.4	
		Week 2	Tezepelumab	1	1 (100.0)	2.24	2.2	2.24	2.24	2.24	2.2	
			Placebo	1	1 (100.0)	1.34	1.3	1.34	1.34	1.34	1.3	
		Week 4	Tezepelumab	1	1 (100.0)	1.82	1.8	1.82	1.82	1.82	1.8	
			Placebo	1	1 (100.0)	1.43	1.4	1.43	1.43	1.43	1.4	
		Week 8	Tezepelumab	1	1 (100.0)	0.97	1.0	0.97	0.97	0.97	1.0	
			Placebo	1	1 (100.0)	1.54	1.5	1.54	1.54	1.54	1.5	
		Week 12	Tezepelumab	1	1 (100.0)	2.07	2.1	2.07	2.07	2.07	2.1	
			Placebo	1	1 (100.0)	1.44	1.4	1.44	1.44	1.44	1.4	
		Week 16	Tezepelumab	1	1 (100.0)	2.03	2.0	2.03	2.03	2.03	2.0	
			Placebo	1	1 (100.0)	1.49	1.5	1.49	1.49	1.49	1.5	
		Week 24	Tezepelumab	1	1 (100.0)	1.61	1.6	1.61	1.61	1.61	1.6	
			Placebo	1	1 (100.0)	1.48	1.5	1.48	1.48	1.48	1.5	
		Week 36	Tezepelumab	1	1 (100.0)	2.25	2.3	2.25	2.25	2.25	2.3	
			Placebo	1	1 (100.0)	1.38	1.4	1.38	1.38	1.38	1.4	
		Week 52	Tezepelumab	1	1 (100.0)	2.17	2.2	2.17	2.17	2.17	2.2	
			Placebo	1	1 (100.0)	1.49	1.5	1.49	1.49	1.49	1.5	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Asia Pacific	Change from baseline	Week 2	Tezepelumab	1	1 (100.0)	0.81	0.8	0.81	0.81	0.81	0.8	NE
			Placebo	1	1 (100.0)	-0.07	-0.1	-0.07	-0.07	-0.07	-0.1	
		Week 4	Tezepelumab	1	1 (100.0)	0.39	0.4	0.39	0.39	0.39	0.4	NE
			Placebo	1	1 (100.0)	0.02	0.0	0.02	0.02	0.02	0.0	
		Week 8	Tezepelumab	1	1 (100.0)	-0.46	-0.5	-0.46	-0.46	-0.46	-0.5	NE
			Placebo	1	1 (100.0)	0.13	0.1	0.13	0.13	0.13	0.1	
		Week 12	Tezepelumab	1	1 (100.0)	0.64	0.6	0.64	0.64	0.64	0.6	NE
			Placebo	1	1 (100.0)	0.03	0.0	0.03	0.03	0.03	0.0	
		Week 16	Tezepelumab	1	1 (100.0)	0.60	0.6	0.60	0.60	0.60	0.6	NE
			Placebo	1	1 (100.0)	0.08	0.1	0.08	0.08	0.08	0.1	
		Week 24	Tezepelumab	1	1 (100.0)	0.18	0.2	0.18	0.18	0.18	0.2	NE
			Placebo	1	1 (100.0)	0.07	0.1	0.07	0.07	0.07	0.1	
		Week 36	Tezepelumab	1	1 (100.0)	0.82	0.8	0.82	0.82	0.82	0.8	NE
			Placebo	1	1 (100.0)	-0.03	-0.0	-0.03	-0.03	-0.03	-0.0	
		Week 52	Tezepelumab	1	1 (100.0)	0.74	0.7	0.74	0.74	0.74	0.7	NE
			Placebo	1	1 (100.0)	0.08	0.1	0.08	0.08	0.08	0.1	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Rest of the world	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	2.14	2.1	2.14	2.14	2.14	2.1	
		Week 2	Tezepelumab	1	1 (100.0)	2.50	2.5	2.50	2.50	2.50	2.5	
		Week 4	Tezepelumab	1	1 (100.0)	2.57	2.6	2.57	2.57	2.57	2.6	
		Week 8	Tezepelumab	1	1 (100.0)	2.58	2.6	2.58	2.58	2.58	2.6	
		Week 12	Tezepelumab	1	1 (100.0)	2.30	2.3	2.30	2.30	2.30	2.3	
		Week 16	Tezepelumab	1	1 (100.0)	2.50	2.5	2.50	2.50	2.50	2.5	
		Week 24	Tezepelumab	1	1 (100.0)	2.32	2.3	2.32	2.32	2.32	2.3	
		Week 36	Tezepelumab	1	1 (100.0)	2.71	2.7	2.71	2.71	2.71	2.7	
		Week 52	Tezepelumab	1	1 (100.0)	2.79	2.8	2.79	2.79	2.79	2.8	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Rest of the world	Change from baseline	Week 2	Tezepelumab	1	1 (100.0)	0.36	0.4	0.36	0.36	0.36	0.4	NE
		Week 4	Tezepelumab	1	1 (100.0)	0.43	0.4	0.43	0.43	0.43	0.4	NE
		Week 8	Tezepelumab	1	1 (100.0)	0.44	0.4	0.44	0.44	0.44	0.4	NE
		Week 12	Tezepelumab	1	1 (100.0)	0.16	0.2	0.16	0.16	0.16	0.2	NE
		Week 16	Tezepelumab	1	1 (100.0)	0.36	0.4	0.36	0.36	0.36	0.4	NE
		Week 24	Tezepelumab	1	1 (100.0)	0.18	0.2	0.18	0.18	0.18	0.2	NE
		Week 36	Tezepelumab	1	1 (100.0)	0.57	0.6	0.57	0.57	0.57	0.6	NE
		Week 52	Tezepelumab	1	1 (100.0)	0.65	0.7	0.65	0.65	0.65	0.7	NE

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
< 150 cells/uL	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	2.69	2.7	2.69	2.69	2.69	2.7	
			Placebo	2	2 (100.0)	3.15 (2.45)	1.4	1.41	3.15	4.88	4.9	
		Week 2	Tezepelumab	1	1 (100.0)	2.41	2.4	2.41	2.41	2.41	2.4	
			Placebo	2	2 (100.0)	3.02 (2.37)	1.3	1.34	3.02	4.69	4.7	
		Week 4	Tezepelumab	1	1 (100.0)	2.51	2.5	2.51	2.51	2.51	2.5	
			Placebo	2	1 (50.0)	1.43	1.4	1.43	1.43	1.43	1.4	
		Week 8	Tezepelumab	1	1 (100.0)	2.56	2.6	2.56	2.56	2.56	2.6	
			Placebo	2	2 (100.0)	3.23 (2.38)	1.5	1.54	3.23	4.91	4.9	
		Week 12	Tezepelumab	1	1 (100.0)	2.57	2.6	2.57	2.57	2.57	2.6	
			Placebo	2	2 (100.0)	3.21 (2.50)	1.4	1.44	3.21	4.97	5.0	
		Week 16	Tezepelumab	1	1 (100.0)	2.43	2.4	2.43	2.43	2.43	2.4	
			Placebo	2	2 (100.0)	3.35 (2.63)	1.5	1.49	3.35	5.21	5.2	
		Week 24	Tezepelumab	1	1 (100.0)	2.53	2.5	2.53	2.53	2.53	2.5	
			Placebo	2	2 (100.0)	3.30 (2.57)	1.5	1.48	3.30	5.11	5.1	
		Week 36	Tezepelumab	1	1 (100.0)	2.67	2.7	2.67	2.67	2.67	2.7	
			Placebo	2	2 (100.0)	3.34 (2.77)	1.4	1.38	3.34	5.30	5.3	
		Week 52	Tezepelumab	1	1 (100.0)	2.53	2.5	2.53	2.53	2.53	2.5	
			Placebo	2	2 (100.0)	3.38 (2.67)	1.5	1.49	3.38	5.26	5.3	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
< 150 cells/uL	Change from baseline	Week 2	Tezepelumab	1	1 (100.0)	-0.28	-0.3	-0.28	-0.28	-0.28	-0.3	NE
			Placebo	2	2 (100.0)	-0.13 (0.08)	-0.2	-0.19	-0.13	-0.07	-0.1	
		Week 4	Tezepelumab	1	1 (100.0)	-0.18	-0.2	-0.18	-0.18	-0.18	-0.2	NE
			Placebo	2	1 (50.0)	0.02	0.0	0.02	0.02	0.02	0.0	
		Week 8	Tezepelumab	1	1 (100.0)	-0.13	-0.1	-0.13	-0.13	-0.13	-0.1	NE
			Placebo	2	2 (100.0)	0.08 (0.07)	0.0	0.03	0.08	0.13	0.1	
		Week 12	Tezepelumab	1	1 (100.0)	-0.12	-0.1	-0.12	-0.12	-0.12	-0.1	NE
			Placebo	2	2 (100.0)	0.06 (0.04)	0.0	0.03	0.06	0.09	0.1	
		Week 16	Tezepelumab	1	1 (100.0)	-0.26	-0.3	-0.26	-0.26	-0.26	-0.3	NE
			Placebo	2	2 (100.0)	0.21 (0.18)	0.1	0.08	0.21	0.33	0.3	
		Week 24	Tezepelumab	1	1 (100.0)	-0.16	-0.2	-0.16	-0.16	-0.16	-0.2	NE
			Placebo	2	2 (100.0)	0.15 (0.11)	0.1	0.07	0.15	0.23	0.2	
		Week 36	Tezepelumab	1	1 (100.0)	-0.02	-0.0	-0.02	-0.02	-0.02	-0.0	NE
			Placebo	2	2 (100.0)	0.19 (0.32)	-0.0	-0.03	0.19	0.42	0.4	
		Week 52	Tezepelumab	1	1 (100.0)	-0.16	-0.2	-0.16	-0.16	-0.16	-0.2	NE
			Placebo	2	2 (100.0)	0.23 (0.21)	0.1	0.08	0.23	0.38	0.4	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
150 - < 300 cells/uL	Absolute values	Baseline	Tezepelumab	8	8 (100.0)	2.70 (0.76)	1.4	2.13	2.82	3.33	3.7	
			Placebo	2	2 (100.0)	2.69 (0.36)	2.4	2.43	2.69	2.94	2.9	
		Week 2	Tezepelumab	8	8 (100.0)	2.96 (0.74)	1.7	2.55	2.94	3.55	4.0	
			Placebo	2	2 (100.0)	2.71 (0.43)	2.4	2.40	2.71	3.01	3.0	
		Week 4	Tezepelumab	8	7 (87.5)	2.77 (0.78)	1.3	2.57	2.81	3.29	3.8	
			Placebo	2	2 (100.0)	2.63 (0.33)	2.4	2.39	2.63	2.86	2.9	
		Week 8	Tezepelumab	8	7 (87.5)	2.70 (0.85)	1.0	2.54	2.71	3.30	3.7	
			Placebo	2	2 (100.0)	2.65 (0.49)	2.3	2.30	2.65	2.99	3.0	
		Week 12	Tezepelumab	8	6 (75.0)	2.56 (0.98)	0.8	2.30	2.69	3.34	3.6	
			Placebo	2	2 (100.0)	2.70 (0.37)	2.4	2.44	2.70	2.96	3.0	
		Week 16	Tezepelumab	8	7 (87.5)	2.71 (0.72)	1.5	2.22	2.73	3.31	3.8	
			Placebo	2	2 (100.0)	2.73 (0.30)	2.5	2.52	2.73	2.94	2.9	
		Week 24	Tezepelumab	8	7 (87.5)	2.78 (0.61)	1.7	2.32	2.90	3.19	3.6	
			Placebo	2	2 (100.0)	2.80 (0.19)	2.7	2.66	2.80	2.93	2.9	
		Week 36	Tezepelumab	8	7 (87.5)	2.85 (0.78)	1.4	2.56	2.93	3.30	4.0	
			Placebo	2	2 (100.0)	2.87 (0.15)	2.8	2.76	2.87	2.97	3.0	
		Week 52	Tezepelumab	8	7 (87.5)	3.05 (0.74)	1.9	2.64	3.08	3.45	4.2	
			Placebo	2	1 (50.0)	3.05	3.1	3.05	3.05	3.05	3.1	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
150 - < 300 cells/uL	Change from baseline	Week 2	Tezepelumab	8	8 (100.0)	0.26 (0.19)	-0.0	0.12	0.29	0.41	0.5	1.36 [-0.32, 3.05]
			Placebo	2	2 (100.0)	0.02 (0.07)	-0.0	-0.03	0.02	0.07	0.1	
		Week 4	Tezepelumab	8	7 (87.5)	0.15 (0.42)	-0.1	-0.14	-0.08	0.43	1.0	0.53 [-1.06, 2.13]
			Placebo	2	2 (100.0)	-0.06 (0.03)	-0.1	-0.08	-0.06	-0.04	-0.0	
		Week 8	Tezepelumab	8	7 (87.5)	0.08 (0.30)	-0.4	-0.13	0.04	0.42	0.4	0.41 [-1.17, 2.00]
			Placebo	2	2 (100.0)	-0.04 (0.13)	-0.1	-0.13	-0.04	0.05	0.1	
		Week 12	Tezepelumab	8	6 (75.0)	-0.15 (0.28)	-0.6	-0.30	-0.10	0.05	0.2	-0.65 [-2.29, 0.99]
			Placebo	2	2 (100.0)	0.01 (0.01)	0.0	0.01	0.01	0.02	0.0	
		Week 16	Tezepelumab	8	7 (87.5)	0.08 (0.15)	-0.1	0.00	0.10	0.11	0.4	0.29 [-1.29, 1.86]
			Placebo	2	2 (100.0)	0.04 (0.06)	0.0	0.00	0.04	0.09	0.1	
		Week 24	Tezepelumab	8	7 (87.5)	0.16 (0.32)	-0.2	-0.06	0.18	0.27	0.8	0.15 [-1.42, 1.72]
			Placebo	2	2 (100.0)	0.11 (0.17)	-0.0	-0.01	0.11	0.23	0.2	
		Week 36	Tezepelumab	8	7 (87.5)	0.23 (0.27)	-0.1	-0.01	0.32	0.44	0.6	0.17 [-1.40, 1.75]
			Placebo	2	2 (100.0)	0.18 (0.21)	0.0	0.03	0.18	0.33	0.3	
		Week 52	Tezepelumab	8	7 (87.5)	0.42 (0.21)	0.0	0.37	0.42	0.59	0.7	NE
			Placebo	2	1 (50.0)	0.11	0.1	0.11	0.11	0.11	0.1	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
300 - < 450 cells/uL	Absolute values	Baseline	Placebo	6	6 (100.0)	1.87 (0.64)	1.0	1.26	2.09	2.11	2.7	
		Week 2	Placebo	6	6 (100.0)	2.32 (0.32)	1.7	2.30	2.34	2.60	2.6	
		Week 4	Placebo	6	6 (100.0)	2.42 (0.20)	2.1	2.28	2.47	2.59	2.6	
		Week 8	Placebo	6	6 (100.0)	2.41 (0.61)	1.4	2.02	2.68	2.79	2.9	
		Week 12	Placebo	6	6 (100.0)	2.40 (0.40)	1.7	2.34	2.49	2.52	2.9	
		Week 16	Placebo	6	6 (100.0)	2.33 (0.24)	1.9	2.26	2.42	2.49	2.5	
		Week 24	Placebo	6	5 (83.3)	2.59 (0.40)	2.0	2.60	2.64	2.71	3.1	
		Week 36	Placebo	6	5 (83.3)	2.45 (0.67)	1.4	2.34	2.55	2.90	3.1	
		Week 52	Placebo	6	6 (100.0)	2.20 (0.61)	1.2	2.06	2.21	2.63	2.9	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
300 - < 450 cells/uL	Change from baseline	Week 2	Placebo	6	6 (100.0)	0.46 (0.61)	-0.1	0.20	0.25	0.48	1.7	
		Week 4	Placebo	6	6 (100.0)	0.55 (0.67)	-0.1	-0.02	0.38	1.02	1.7	
		Week 8	Placebo	6	6 (100.0)	0.54 (0.76)	-0.1	0.09	0.29	0.65	2.0	
		Week 12	Placebo	6	6 (100.0)	0.54 (0.50)	0.2	0.26	0.40	0.42	1.5	
		Week 16	Placebo	6	6 (100.0)	0.47 (0.61)	-0.2	0.18	0.32	0.63	1.6	
		Week 24	Placebo	6	5 (83.3)	0.54 (0.13)	0.3	0.52	0.54	0.60	0.7	
		Week 36	Placebo	6	5 (83.3)	0.64 (0.86)	0.1	0.20	0.24	0.47	2.2	
		Week 52	Placebo	6	6 (100.0)	0.33 (0.54)	-0.1	-0.02	0.13	0.53	1.3	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
>= 450 cells/uL	Absolute values	Baseline	Tezepelumab	6	6 (100.0)	2.43 (0.67)	1.4	1.98	2.49	2.98	3.2	
			Placebo	10	10 (100.0)	2.77 (0.68)	1.9	2.16	2.88	3.08	4.0	
		Week 2	Tezepelumab	6	5 (83.3)	2.63 (0.70)	1.7	2.24	2.59	3.26	3.4	
			Placebo	10	10 (100.0)	2.81 (0.40)	2.2	2.70	2.78	3.01	3.5	
		Week 4	Tezepelumab	6	6 (100.0)	2.59 (0.68)	1.8	1.90	2.57	3.18	3.5	
			Placebo	10	10 (100.0)	2.85 (0.47)	2.2	2.57	2.66	3.18	3.7	
		Week 8	Tezepelumab	6	6 (100.0)	2.43 (1.21)	1.0	1.07	2.79	3.43	3.5	
			Placebo	10	9 (90.0)	2.74 (0.38)	2.3	2.41	2.69	3.09	3.3	
		Week 12	Tezepelumab	6	6 (100.0)	2.59 (0.97)	1.4	1.68	2.72	3.48	3.5	
			Placebo	10	10 (100.0)	2.80 (0.58)	1.9	2.54	2.73	3.38	3.5	
		Week 16	Tezepelumab	6	5 (83.3)	2.69 (0.64)	2.0	2.20	2.50	3.35	3.4	
			Placebo	10	10 (100.0)	2.76 (0.45)	2.1	2.44	2.62	3.17	3.5	
		Week 24	Tezepelumab	6	5 (83.3)	2.48 (0.94)	1.6	1.69	2.20	3.16	3.7	
			Placebo	10	9 (90.0)	2.79 (0.51)	2.0	2.52	2.76	3.14	3.4	
		Week 36	Tezepelumab	6	5 (83.3)	2.96 (0.64)	2.3	2.39	2.95	3.55	3.6	
			Placebo	10	9 (90.0)	2.92 (0.79)	1.4	2.81	3.22	3.51	3.7	
		Week 52	Tezepelumab	6	4 (66.7)	2.85 (0.68)	2.2	2.27	2.83	3.43	3.6	
			Placebo	10	9 (90.0)	2.98 (0.64)	2.1	2.51	2.67	3.65	3.8	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
>= 450 cells/uL	Change from baseline	Week 2	Tezepelumab	6	5 (83.3)	0.27 (0.81)	-0.5	-0.39	0.08	0.81	1.4	0.33 [-0.75, 1.41]
			Placebo	10	10 (100.0)	0.04 (0.66)	-1.3	-0.08	-0.02	0.06	1.3	
		Week 4	Tezepelumab	6	6 (100.0)	0.17 (0.60)	-0.3	-0.31	0.01	0.39	1.2	0.13 [-0.88, 1.14]
			Placebo	10	10 (100.0)	0.08 (0.68)	-1.0	-0.43	0.07	0.34	1.4	
		Week 8	Tezepelumab	6	6 (100.0)	0.01 (1.01)	-1.1	-0.83	-0.11	0.65	1.6	0.11 [-0.92, 1.14]
			Placebo	10	9 (90.0)	-0.10 (0.92)	-1.7	-0.45	-0.22	0.17	1.4	
		Week 12	Tezepelumab	6	6 (100.0)	0.17 (1.06)	-1.5	-0.52	0.45	0.64	1.5	0.15 [-0.87, 1.16]
			Placebo	10	10 (100.0)	0.03 (0.89)	-1.2	-0.38	-0.19	0.38	1.6	
		Week 16	Tezepelumab	6	5 (83.3)	0.42 (0.70)	-0.5	0.00	0.60	0.61	1.4	0.52 [-0.58, 1.61]
			Placebo	10	10 (100.0)	-0.01 (0.90)	-1.6	-0.42	-0.11	0.22	1.6	
		Week 24	Tezepelumab	6	5 (83.3)	0.21 (0.99)	-0.8	-0.51	0.18	0.38	1.8	0.26 [-0.83, 1.36]
			Placebo	10	9 (90.0)	-0.04 (0.92)	-1.4	-0.26	-0.06	0.17	1.5	
		Week 36	Tezepelumab	6	5 (83.3)	0.68 (0.66)	-0.0	0.19	0.77	0.82	1.7	0.63 [-0.49, 1.75]
			Placebo	10	9 (90.0)	0.09 (1.05)	-1.7	-0.30	0.20	0.57	1.6	
		Week 52	Tezepelumab	6	4 (66.7)	0.56 (0.82)	-0.6	0.07	0.77	1.05	1.3	0.44 [-0.75, 1.63]
			Placebo	10	9 (90.0)	0.15 (0.95)	-1.4	-0.57	0.28	0.59	1.9	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q1: < 140 cells/uL	Absolute values	Baseline	Placebo	2	2 (100.0)	3.15 (2.45)	1.4	1.41	3.15	4.88	4.9	
		Week 2	Placebo	2	2 (100.0)	3.02 (2.37)	1.3	1.34	3.02	4.69	4.7	
		Week 4	Placebo	2	1 (50.0)	1.43	1.4	1.43	1.43	1.43	1.4	
		Week 8	Placebo	2	2 (100.0)	3.23 (2.38)	1.5	1.54	3.23	4.91	4.9	
		Week 12	Placebo	2	2 (100.0)	3.21 (2.50)	1.4	1.44	3.21	4.97	5.0	
		Week 16	Placebo	2	2 (100.0)	3.35 (2.63)	1.5	1.49	3.35	5.21	5.2	
		Week 24	Placebo	2	2 (100.0)	3.30 (2.57)	1.5	1.48	3.30	5.11	5.1	
		Week 36	Placebo	2	2 (100.0)	3.34 (2.77)	1.4	1.38	3.34	5.30	5.3	
		Week 52	Placebo	2	2 (100.0)	3.38 (2.67)	1.5	1.49	3.38	5.26	5.3	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q1: < 140 cells/uL	Change from baseline	Week 2	Placebo	2	2 (100.0)	-0.13 (0.08)	-0.2	-0.19	-0.13	-0.07	-0.1	
		Week 4	Placebo	2	1 (50.0)	0.02	0.0	0.02	0.02	0.02	0.0	
		Week 8	Placebo	2	2 (100.0)	0.08 (0.07)	0.0	0.03	0.08	0.13	0.1	
		Week 12	Placebo	2	2 (100.0)	0.06 (0.04)	0.0	0.03	0.06	0.09	0.1	
		Week 16	Placebo	2	2 (100.0)	0.21 (0.18)	0.1	0.08	0.21	0.33	0.3	
		Week 24	Placebo	2	2 (100.0)	0.15 (0.11)	0.1	0.07	0.15	0.23	0.2	
		Week 36	Placebo	2	2 (100.0)	0.19 (0.32)	-0.0	-0.03	0.19	0.42	0.4	
		Week 52	Placebo	2	2 (100.0)	0.23 (0.21)	0.1	0.08	0.23	0.38	0.4	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q2: 140 - < 250 cells/uL	Absolute values	Baseline	Tezepelumab	6	6 (100.0)	2.55 (0.69)	1.4	2.14	2.69	2.94	3.4	
			Placebo	2	2 (100.0)	2.69 (0.36)	2.4	2.43	2.69	2.94	2.9	
		Week 2	Tezepelumab	6	6 (100.0)	2.64 (0.60)	1.7	2.41	2.62	3.13	3.4	
			Placebo	2	2 (100.0)	2.71 (0.43)	2.4	2.40	2.71	3.01	3.0	
		Week 4	Tezepelumab	6	6 (100.0)	2.51 (0.67)	1.3	2.51	2.59	2.81	3.3	
			Placebo	2	2 (100.0)	2.63 (0.33)	2.4	2.39	2.63	2.86	2.9	
		Week 8	Tezepelumab	6	6 (100.0)	2.54 (0.80)	1.0	2.56	2.65	3.08	3.3	
			Placebo	2	2 (100.0)	2.65 (0.49)	2.3	2.30	2.65	2.99	3.0	
		Week 12	Tezepelumab	6	6 (100.0)	2.40 (0.86)	0.8	2.30	2.61	2.74	3.3	
			Placebo	2	2 (100.0)	2.70 (0.37)	2.4	2.44	2.70	2.96	3.0	
		Week 16	Tezepelumab	6	6 (100.0)	2.58 (0.60)	1.5	2.43	2.62	2.94	3.3	
			Placebo	2	2 (100.0)	2.73 (0.30)	2.5	2.52	2.73	2.94	2.9	
		Week 24	Tezepelumab	6	6 (100.0)	2.59 (0.53)	1.7	2.32	2.72	2.91	3.2	
			Placebo	2	2 (100.0)	2.80 (0.19)	2.7	2.66	2.80	2.93	2.9	
		Week 36	Tezepelumab	6	6 (100.0)	2.69 (0.66)	1.4	2.67	2.82	3.08	3.3	
			Placebo	2	2 (100.0)	2.87 (0.15)	2.8	2.76	2.87	2.97	3.0	
		Week 52	Tezepelumab	6	6 (100.0)	2.84 (0.59)	1.9	2.53	2.94	3.31	3.5	
			Placebo	2	1 (50.0)	3.05	3.1	3.05	3.05	3.05	3.1	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q2: 140 - < 250 cells/uL	Change from baseline	Week 2	Tezepelumab	6	6 (100.0)	0.09 (0.23)	-0.3	-0.04	0.12	0.26	0.4	0.33 [-1.28, 1.94]
			Placebo	2	2 (100.0)	0.02 (0.07)	-0.0	-0.03	0.02	0.07	0.1	
		Week 4	Tezepelumab	6	6 (100.0)	-0.04 (0.23)	-0.2	-0.15	-0.14	-0.08	0.4	0.09 [-1.52, 1.69]
			Placebo	2	2 (100.0)	-0.06 (0.03)	-0.1	-0.08	-0.06	-0.04	-0.0	
		Week 8	Tezepelumab	6	6 (100.0)	-0.01 (0.29)	-0.4	-0.13	-0.05	0.14	0.4	0.11 [-1.49, 1.71]
			Placebo	2	2 (100.0)	-0.04 (0.13)	-0.1	-0.13	-0.04	0.05	0.1	
		Week 12	Tezepelumab	6	6 (100.0)	-0.16 (0.28)	-0.6	-0.30	-0.11	0.05	0.2	-0.66 [-2.31, 0.98]
			Placebo	2	2 (100.0)	0.01 (0.01)	0.0	0.01	0.01	0.02	0.0	
		Week 16	Tezepelumab	6	6 (100.0)	0.02 (0.21)	-0.3	-0.12	0.02	0.11	0.4	-0.12 [-1.72, 1.48]
			Placebo	2	2 (100.0)	0.04 (0.06)	0.0	0.00	0.04	0.09	0.1	
		Week 24	Tezepelumab	6	6 (100.0)	0.04 (0.21)	-0.2	-0.16	0.07	0.21	0.3	-0.35 [-1.96, 1.26]
			Placebo	2	2 (100.0)	0.11 (0.17)	-0.0	-0.01	0.11	0.23	0.2	
		Week 36	Tezepelumab	6	6 (100.0)	0.13 (0.28)	-0.1	-0.02	-0.00	0.39	0.6	-0.17 [-1.78, 1.43]
			Placebo	2	2 (100.0)	0.18 (0.21)	0.0	0.03	0.18	0.33	0.3	
		Week 52	Tezepelumab	6	6 (100.0)	0.28 (0.30)	-0.2	0.02	0.38	0.42	0.7	NE
			Placebo	2	1 (50.0)	0.11	0.1	0.11	0.11	0.11	0.1	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q3: 250 - < 430 cells/uL	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	3.00 (0.79)	2.1	2.12	3.22	3.65	3.7	
			Placebo	5	5 (100.0)	1.99 (0.64)	1.0	2.08	2.10	2.11	2.7	
		Week 2	Tezepelumab	3	3 (100.0)	3.42 (0.73)	2.6	2.59	3.70	3.97	4.0	
			Placebo	5	5 (100.0)	2.44 (0.16)	2.3	2.31	2.37	2.60	2.6	
		Week 4	Tezepelumab	3	2 (66.7)	3.43 (0.49)	3.1	3.08	3.43	3.78	3.8	
			Placebo	5	5 (100.0)	2.44 (0.21)	2.1	2.44	2.50	2.59	2.6	
		Week 8	Tezepelumab	3	2 (66.7)	3.12 (0.81)	2.5	2.54	3.12	3.69	3.7	
			Placebo	5	5 (100.0)	2.62 (0.36)	2.0	2.59	2.76	2.79	2.9	
		Week 12	Tezepelumab	3	1 (33.3)	3.55	3.6	3.55	3.55	3.55	3.6	
			Placebo	5	5 (100.0)	2.55 (0.21)	2.3	2.49	2.49	2.52	2.9	
		Week 16	Tezepelumab	3	2 (66.7)	2.99 (1.08)	2.2	2.22	2.99	3.75	3.8	
			Placebo	5	5 (100.0)	2.42 (0.11)	2.3	2.36	2.48	2.49	2.5	
		Week 24	Tezepelumab	3	2 (66.7)	3.24 (0.50)	2.9	2.88	3.24	3.59	3.6	
			Placebo	5	4 (80.0)	2.75 (0.21)	2.6	2.62	2.68	2.88	3.1	
		Week 36	Tezepelumab	3	2 (66.7)	3.27 (1.00)	2.6	2.56	3.27	3.97	4.0	
			Placebo	5	4 (80.0)	2.72 (0.34)	2.3	2.45	2.73	3.00	3.1	
		Week 52	Tezepelumab	3	2 (66.7)	3.44 (1.13)	2.6	2.64	3.44	4.24	4.2	
			Placebo	5	5 (100.0)	2.41 (0.37)	2.1	2.14	2.27	2.63	2.9	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q3: 250 - < 430 cells/uL	Change from baseline	Week 2	Tezepelumab	3	3 (100.0)	0.42 (0.09)	0.3	0.32	0.47	0.48	0.5	-0.05 [-1.48, 1.38]
			Placebo	5	5 (100.0)	0.45 (0.68)	-0.1	0.20	0.23	0.26	1.7	
		Week 4	Tezepelumab	3	2 (66.7)	0.55 (0.59)	0.1	0.13	0.55	0.96	1.0	0.13 [-1.51, 1.77]
			Placebo	5	5 (100.0)	0.46 (0.70)	-0.1	-0.02	0.36	0.40	1.7	
		Week 8	Tezepelumab	3	2 (66.7)	0.23 (0.27)	0.0	0.04	0.23	0.42	0.4	-0.55 [-2.22, 1.13]
			Placebo	5	5 (100.0)	0.63 (0.81)	-0.1	0.09	0.49	0.65	2.0	
		Week 12	Tezepelumab	3	1 (33.3)	-0.10	-0.1	-0.10	-0.10	-0.10	-0.1	NE
			Placebo	5	5 (100.0)	0.56 (0.55)	0.2	0.26	0.39	0.41	1.5	
		Week 16	Tezepelumab	3	2 (66.7)	0.10 (0.00)	0.1	0.10	0.10	0.10	0.1	-0.56 [-2.23, 1.12]
			Placebo	5	5 (100.0)	0.43 (0.67)	-0.2	0.18	0.26	0.37	1.6	
		Week 24	Tezepelumab	3	2 (66.7)	0.35 (0.58)	-0.1	-0.06	0.35	0.76	0.8	-0.50 [-2.23, 1.23]
			Placebo	5	4 (80.0)	0.50 (0.11)	0.3	0.43	0.53	0.57	0.6	
		Week 36	Tezepelumab	3	2 (66.7)	0.38 (0.08)	0.3	0.32	0.38	0.44	0.4	-0.48 [-2.21, 1.25]
			Placebo	5	4 (80.0)	0.77 (0.93)	0.2	0.22	0.35	1.31	2.2	
		Week 52	Tezepelumab	3	2 (66.7)	0.56 (0.05)	0.5	0.52	0.56	0.59	0.6	0.28 [-1.37, 1.93]
			Placebo	5	5 (100.0)	0.42 (0.55)	-0.0	0.03	0.23	0.53	1.3	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q4: >= 430 cells/uL	Absolute values	Baseline	Tezepelumab	6	6 (100.0)	2.43 (0.67)	1.4	1.98	2.49	2.98	3.2	
			Placebo	11	11 (100.0)	2.63 (0.79)	1.3	2.06	2.78	3.08	4.0	
		Week 2	Tezepelumab	6	5 (83.3)	2.63 (0.70)	1.7	2.24	2.59	3.26	3.4	
			Placebo	11	11 (100.0)	2.71 (0.50)	1.7	2.27	2.76	3.01	3.5	
		Week 4	Tezepelumab	6	6 (100.0)	2.59 (0.68)	1.8	1.90	2.57	3.18	3.5	
			Placebo	11	11 (100.0)	2.80 (0.48)	2.2	2.50	2.66	3.18	3.7	
		Week 8	Tezepelumab	6	6 (100.0)	2.43 (1.21)	1.0	1.07	2.79	3.43	3.5	
			Placebo	11	10 (90.9)	2.60 (0.57)	1.4	2.35	2.61	3.09	3.3	
		Week 12	Tezepelumab	6	6 (100.0)	2.59 (0.97)	1.4	1.68	2.72	3.48	3.5	
			Placebo	11	11 (100.0)	2.70 (0.64)	1.7	2.00	2.59	3.38	3.5	
		Week 16	Tezepelumab	6	5 (83.3)	2.69 (0.64)	2.0	2.20	2.50	3.35	3.4	
			Placebo	11	11 (100.0)	2.68 (0.50)	1.9	2.41	2.60	3.17	3.5	
		Week 24	Tezepelumab	6	5 (83.3)	2.48 (0.94)	1.6	1.69	2.20	3.16	3.7	
			Placebo	11	10 (90.9)	2.70 (0.55)	2.0	2.15	2.69	3.14	3.4	
		Week 36	Tezepelumab	6	5 (83.3)	2.96 (0.64)	2.3	2.39	2.95	3.55	3.6	
			Placebo	11	10 (90.9)	2.76 (0.89)	1.4	1.86	3.08	3.51	3.7	
		Week 52	Tezepelumab	6	4 (66.7)	2.85 (0.68)	2.2	2.27	2.83	3.43	3.6	
			Placebo	11	10 (90.9)	2.80 (0.84)	1.2	2.47	2.66	3.65	3.8	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q4: >= 430 cells/uL	Change from baseline	Week 2	Tezepelumab	6	5 (83.3)	0.27 (0.81)	-0.5	-0.39	0.08	0.81	1.4	0.28 [-0.78, 1.34]
			Placebo	11	11 (100.0)	0.08 (0.64)	-1.3	-0.08	0.00	0.48	1.3	
		Week 4	Tezepelumab	6	6 (100.0)	0.17 (0.60)	-0.3	-0.31	0.01	0.39	1.2	-0.00 [-1.00, 0.99]
			Placebo	11	11 (100.0)	0.17 (0.70)	-1.0	-0.43	0.21	0.77	1.4	
		Week 8	Tezepelumab	6	6 (100.0)	0.01 (1.01)	-1.1	-0.83	-0.11	0.65	1.6	0.09 [-0.92, 1.11]
			Placebo	11	10 (90.9)	-0.08 (0.87)	-1.7	-0.45	-0.12	0.17	1.4	
		Week 12	Tezepelumab	6	6 (100.0)	0.17 (1.06)	-1.5	-0.52	0.45	0.64	1.5	0.11 [-0.88, 1.11]
			Placebo	11	11 (100.0)	0.06 (0.85)	-1.2	-0.38	-0.16	0.42	1.6	
		Week 16	Tezepelumab	6	5 (83.3)	0.42 (0.70)	-0.5	0.00	0.60	0.61	1.4	0.45 [-0.62, 1.53]
			Placebo	11	11 (100.0)	0.04 (0.87)	-1.6	-0.42	-0.07	0.63	1.6	
		Week 24	Tezepelumab	6	5 (83.3)	0.21 (0.99)	-0.8	-0.51	0.18	0.38	1.8	0.19 [-0.89, 1.27]
			Placebo	11	10 (90.9)	0.03 (0.89)	-1.4	-0.26	-0.04	0.69	1.5	
		Week 36	Tezepelumab	6	5 (83.3)	0.68 (0.66)	-0.0	0.19	0.77	0.82	1.7	0.65 [-0.45, 1.76]
			Placebo	11	10 (90.9)	0.09 (0.99)	-1.7	-0.30	0.18	0.57	1.6	
		Week 52	Tezepelumab	6	4 (66.7)	0.56 (0.82)	-0.6	0.07	0.77	1.05	1.3	0.49 [-0.69, 1.67]
			Placebo	11	10 (90.9)	0.13 (0.90)	-1.4	-0.57	0.27	0.59	1.9	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
< 25 ppb	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	2.59 (0.41)	2.1	2.14	2.69	2.94	2.9	
			Placebo	6	6 (100.0)	2.66 (0.70)	1.4	2.43	2.82	3.02	3.5	
		Week 2	Tezepelumab	3	3 (100.0)	2.79 (0.32)	2.5	2.50	2.74	3.13	3.1	
			Placebo	6	6 (100.0)	2.64 (0.74)	1.3	2.40	2.78	3.01	3.5	
		Week 4	Tezepelumab	3	3 (100.0)	2.66 (0.13)	2.6	2.57	2.61	2.81	2.8	
			Placebo	6	6 (100.0)	2.59 (0.73)	1.4	2.39	2.59	2.86	3.7	
		Week 8	Tezepelumab	3	3 (100.0)	2.79 (0.26)	2.6	2.58	2.71	3.08	3.1	
			Placebo	6	6 (100.0)	2.59 (0.60)	1.5	2.30	2.74	2.99	3.2	
		Week 12	Tezepelumab	3	3 (100.0)	2.56 (0.23)	2.3	2.30	2.64	2.74	2.7	
			Placebo	6	6 (100.0)	2.69 (0.70)	1.4	2.44	2.88	2.96	3.5	
		Week 16	Tezepelumab	3	3 (100.0)	2.72 (0.22)	2.5	2.50	2.73	2.94	2.9	
			Placebo	6	6 (100.0)	2.54 (0.59)	1.5	2.49	2.56	2.94	3.2	
		Week 24	Tezepelumab	3	3 (100.0)	2.71 (0.34)	2.3	2.32	2.90	2.91	2.9	
			Placebo	6	6 (100.0)	2.71 (0.66)	1.5	2.66	2.85	3.05	3.4	
		Week 36	Tezepelumab	3	3 (100.0)	2.91 (0.19)	2.7	2.71	2.93	3.08	3.1	
			Placebo	6	6 (100.0)	2.83 (0.78)	1.4	2.76	2.94	3.33	3.7	
		Week 52	Tezepelumab	3	3 (100.0)	3.06 (0.26)	2.8	2.79	3.08	3.31	3.3	
			Placebo	6	5 (83.3)	2.97 (0.90)	1.5	2.93	3.05	3.65	3.7	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
< 25 ppb	Change from baseline	Week 2	Tezepelumab	3	3 (100.0)	0.20 (0.16)	0.1	0.05	0.19	0.36	0.4	2.18 [0.38, 3.97]
			Placebo	6	6 (100.0)	-0.02 (0.07)	-0.1	-0.08	-0.05	0.06	0.1	
		Week 4	Tezepelumab	3	3 (100.0)	0.07 (0.31)	-0.1	-0.13	-0.08	0.43	0.4	0.59 [-0.83, 2.01]
			Placebo	6	6 (100.0)	-0.07 (0.21)	-0.4	-0.11	-0.06	0.02	0.2	
		Week 8	Tezepelumab	3	3 (100.0)	0.20 (0.22)	0.0	0.02	0.14	0.44	0.4	1.37 [-0.19, 2.93]
			Placebo	6	6 (100.0)	-0.07 (0.19)	-0.3	-0.22	-0.04	0.09	0.1	
		Week 12	Tezepelumab	3	3 (100.0)	-0.03 (0.24)	-0.3	-0.30	0.05	0.16	0.2	-0.35 [-1.75, 1.05]
			Placebo	6	6 (100.0)	0.03 (0.12)	-0.2	0.01	0.03	0.06	0.2	
		Week 16	Tezepelumab	3	3 (100.0)	0.13 (0.20)	0.0	0.00	0.04	0.36	0.4	1.23 [-0.30, 2.76]
			Placebo	6	6 (100.0)	-0.12 (0.21)	-0.4	-0.25	-0.11	0.08	0.1	
		Week 24	Tezepelumab	3	3 (100.0)	0.12 (0.13)	-0.0	-0.03	0.18	0.21	0.2	0.34 [-1.06, 1.74]
			Placebo	6	6 (100.0)	0.05 (0.22)	-0.3	-0.06	0.03	0.23	0.3	
		Week 36	Tezepelumab	3	3 (100.0)	0.32 (0.30)	-0.0	-0.01	0.39	0.57	0.6	0.71 [-0.72, 2.15]
			Placebo	6	6 (100.0)	0.17 (0.15)	-0.0	0.03	0.20	0.31	0.3	
		Week 52	Tezepelumab	3	3 (100.0)	0.47 (0.16)	0.4	0.37	0.39	0.65	0.7	1.02 [-0.53, 2.56]
			Placebo	6	5 (83.3)	0.27 (0.22)	0.1	0.11	0.23	0.28	0.6	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
25 - < 50 ppb	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	2.95 (0.25)	2.7	2.69	2.98	3.18	3.2	
			Placebo	7	7 (100.0)	2.60 (1.21)	1.0	2.11	2.24	3.08	4.9	
		Week 2	Tezepelumab	3	3 (100.0)	2.75 (0.45)	2.4	2.41	2.59	3.26	3.3	
			Placebo	7	7 (100.0)	2.83 (0.87)	2.2	2.27	2.60	3.01	4.7	
		Week 4	Tezepelumab	3	3 (100.0)	2.90 (0.54)	2.5	2.51	2.67	3.51	3.5	
			Placebo	7	6 (85.7)	2.43 (0.24)	2.1	2.17	2.54	2.60	2.7	
		Week 8	Tezepelumab	3	3 (100.0)	2.71 (0.65)	2.2	2.15	2.56	3.43	3.4	
			Placebo	7	6 (85.7)	3.01 (0.96)	2.3	2.41	2.76	2.93	4.9	
		Week 12	Tezepelumab	3	3 (100.0)	2.50 (1.02)	1.4	1.44	2.57	3.48	3.5	
			Placebo	7	7 (100.0)	2.72 (1.03)	1.9	2.00	2.52	2.56	5.0	
		Week 16	Tezepelumab	3	2 (66.7)	2.47 (0.05)	2.4	2.43	2.47	2.50	2.5	
			Placebo	7	7 (100.0)	2.83 (1.06)	2.1	2.41	2.48	2.63	5.2	
		Week 24	Tezepelumab	3	2 (66.7)	2.37 (0.23)	2.2	2.20	2.37	2.53	2.5	
			Placebo	7	5 (71.4)	2.90 (1.27)	2.0	2.15	2.52	2.71	5.1	
		Week 36	Tezepelumab	3	2 (66.7)	2.81 (0.20)	2.7	2.67	2.81	2.95	3.0	
			Placebo	7	5 (71.4)	2.92 (1.51)	1.4	1.86	2.93	3.10	5.3	
		Week 52	Tezepelumab	3	2 (66.7)	2.45 (0.11)	2.4	2.37	2.45	2.53	2.5	
			Placebo	7	6 (85.7)	2.79 (1.22)	2.1	2.14	2.37	2.51	5.3	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
25 - < 50 ppb	Change from baseline	Week 2	Tezepelumab	3	3 (100.0)	-0.20 (0.25)	-0.4	-0.39	-0.28	0.08	0.1	-0.76 [-2.16, 0.64]
			Placebo	7	7 (100.0)	0.23 (0.64)	-0.2	-0.07	0.00	0.26	1.7	
		Week 4	Tezepelumab	3	3 (100.0)	-0.05 (0.34)	-0.3	-0.31	-0.18	0.33	0.3	-0.40 [-1.80, 1.00]
			Placebo	7	6 (85.7)	0.21 (0.75)	-0.5	-0.12	-0.05	0.34	1.7	
		Week 8	Tezepelumab	3	3 (100.0)	-0.24 (0.55)	-0.8	-0.83	-0.13	0.25	0.3	-0.69 [-2.12, 0.74]
			Placebo	7	6 (85.7)	0.34 (0.93)	-0.8	-0.02	0.10	0.65	2.0	
		Week 12	Tezepelumab	3	3 (100.0)	-0.45 (0.96)	-1.5	-1.54	-0.12	0.30	0.3	-0.66 [-2.05, 0.73]
			Placebo	7	7 (100.0)	0.12 (0.82)	-1.2	-0.24	0.09	0.41	1.5	
		Week 16	Tezepelumab	3	2 (66.7)	-0.37 (0.16)	-0.5	-0.48	-0.37	-0.26	-0.3	-0.93 [-2.58, 0.71]
			Placebo	7	7 (100.0)	0.23 (0.69)	-0.7	-0.15	0.22	0.37	1.6	
		Week 24	Tezepelumab	3	2 (66.7)	-0.47 (0.44)	-0.8	-0.78	-0.47	-0.16	-0.2	-0.61 [-2.29, 1.08]
			Placebo	7	5 (71.4)	-0.11 (0.63)	-1.1	-0.26	-0.01	0.23	0.6	
		Week 36	Tezepelumab	3	2 (66.7)	-0.02 (0.01)	-0.0	-0.03	-0.02	-0.02	-0.0	-0.14 [-1.78, 1.50]
			Placebo	7	5 (71.4)	0.15 (1.38)	-1.7	-0.30	0.15	0.42	2.2	
		Week 52	Tezepelumab	3	2 (66.7)	-0.39 (0.32)	-0.6	-0.61	-0.39	-0.16	-0.2	-0.76 [-2.41, 0.90]
			Placebo	7	6 (85.7)	0.13 (0.73)	-0.7	-0.57	0.17	0.38	1.3	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
>= 50 ppb	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	2.47 (0.83)	1.4	1.98	2.20	3.22	3.7	
			Placebo	7	7 (100.0)	2.34 (0.90)	1.3	1.89	2.08	2.97	4.0	
		Week 2	Tezepelumab	9	8 (88.9)	2.83 (0.90)	1.7	1.97	2.98	3.55	4.0	
			Placebo	7	7 (100.0)	2.54 (0.47)	1.7	2.30	2.70	2.80	3.2	
		Week 4	Tezepelumab	9	8 (88.9)	2.60 (0.87)	1.3	1.86	2.78	3.24	3.8	
			Placebo	7	7 (100.0)	2.79 (0.44)	2.3	2.44	2.66	3.18	3.5	
		Week 8	Tezepelumab	9	8 (88.9)	2.45 (1.23)	1.0	1.05	2.92	3.48	3.7	
			Placebo	7	7 (100.0)	2.46 (0.65)	1.4	2.02	2.52	3.09	3.3	
		Week 12	Tezepelumab	9	7 (77.8)	2.62 (1.10)	0.8	1.68	3.34	3.51	3.6	
			Placebo	7	7 (100.0)	2.72 (0.64)	1.7	2.34	2.59	3.38	3.5	
		Week 16	Tezepelumab	9	8 (88.9)	2.72 (0.81)	1.5	2.12	2.77	3.37	3.8	
			Placebo	7	7 (100.0)	2.67 (0.58)	1.9	2.26	2.44	3.17	3.5	
		Week 24	Tezepelumab	9	8 (88.9)	2.70 (0.89)	1.6	1.70	3.02	3.39	3.7	
			Placebo	7	7 (100.0)	2.78 (0.48)	2.0	2.60	2.64	3.14	3.4	
		Week 36	Tezepelumab	9	8 (88.9)	2.89 (0.86)	1.4	2.32	2.93	3.60	4.0	
			Placebo	7	7 (100.0)	2.76 (0.76)	1.4	2.34	2.81	3.51	3.5	
		Week 52	Tezepelumab	9	7 (77.8)	3.03 (0.84)	1.9	2.17	3.29	3.57	4.2	
			Placebo	7	7 (100.0)	2.60 (0.85)	1.2	2.06	2.65	3.22	3.8	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
>= 50 ppb	Change from baseline	Week 2	Tezepelumab	9	8 (88.9)	0.40 (0.56)	-0.5	0.11	0.40	0.65	1.4	0.28 [-0.74, 1.30]
			Placebo	7	7 (100.0)	0.20 (0.81)	-1.3	-0.27	0.23	0.74	1.3	
		Week 4	Tezepelumab	9	8 (88.9)	0.22 (0.58)	-0.3	-0.23	-0.01	0.68	1.2	-0.34 [-1.37, 0.68]
			Placebo	7	7 (100.0)	0.45 (0.76)	-1.0	0.21	0.40	1.02	1.4	
		Week 8	Tezepelumab	9	8 (88.9)	0.07 (0.81)	-1.1	-0.43	-0.05	0.54	1.6	-0.05 [-1.07, 0.96]
			Placebo	7	7 (100.0)	0.12 (1.01)	-1.7	-0.45	0.09	1.03	1.4	
		Week 12	Tezepelumab	9	7 (77.8)	0.20 (0.77)	-0.6	-0.52	-0.09	0.64	1.5	-0.22 [-1.27, 0.83]
			Placebo	7	7 (100.0)	0.38 (0.90)	-1.0	-0.38	0.39	1.32	1.6	
		Week 16	Tezepelumab	9	8 (88.9)	0.35 (0.49)	-0.1	0.05	0.11	0.61	1.4	0.03 [-0.99, 1.04]
			Placebo	7	7 (100.0)	0.32 (1.02)	-1.6	0.04	0.26	1.11	1.6	
		Week 24	Tezepelumab	9	8 (88.9)	0.32 (0.70)	-0.5	-0.15	0.23	0.57	1.8	-0.15 [-1.16, 0.87]
			Placebo	7	7 (100.0)	0.44 (0.92)	-1.4	0.17	0.54	1.05	1.5	
		Week 36	Tezepelumab	9	8 (88.9)	0.51 (0.57)	-0.1	0.09	0.38	0.80	1.7	0.12 [-0.90, 1.13]
			Placebo	7	7 (100.0)	0.42 (0.90)	-1.2	0.12	0.47	1.16	1.6	
		Week 52	Tezepelumab	9	7 (77.8)	0.63 (0.39)	0.0	0.42	0.59	0.79	1.3	0.49 [-0.58, 1.55]
			Placebo	7	7 (100.0)	0.26 (0.99)	-1.4	-0.11	0.25	0.59	1.9	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q1: < 16 ppb	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	2.69	2.7	2.69	2.69	2.69	2.7	
			Placebo	4	4 (100.0)	2.90 (0.44)	2.4	2.57	2.86	3.24	3.5	
		Week 2	Tezepelumab	1	1 (100.0)	2.74	2.7	2.74	2.74	2.74	2.7	
			Placebo	4	4 (100.0)	2.87 (0.49)	2.4	2.51	2.78	3.23	3.5	
		Week 4	Tezepelumab	1	1 (100.0)	2.61	2.6	2.61	2.61	2.61	2.6	
			Placebo	4	4 (100.0)	2.81 (0.59)	2.4	2.49	2.59	3.14	3.7	
		Week 8	Tezepelumab	1	1 (100.0)	2.71	2.7	2.71	2.71	2.71	2.7	
			Placebo	4	4 (100.0)	2.76 (0.39)	2.3	2.50	2.74	3.02	3.2	
		Week 12	Tezepelumab	1	1 (100.0)	2.74	2.7	2.74	2.74	2.74	2.7	
			Placebo	4	4 (100.0)	2.93 (0.44)	2.4	2.65	2.88	3.21	3.5	
		Week 16	Tezepelumab	1	1 (100.0)	2.73	2.7	2.73	2.73	2.73	2.7	
			Placebo	4	4 (100.0)	2.71 (0.34)	2.5	2.51	2.56	2.91	3.2	
		Week 24	Tezepelumab	1	1 (100.0)	2.90	2.9	2.90	2.90	2.90	2.9	
			Placebo	4	4 (100.0)	2.97 (0.33)	2.7	2.71	2.91	3.23	3.4	
		Week 36	Tezepelumab	1	1 (100.0)	3.08	3.1	3.08	3.08	3.08	3.1	
			Placebo	4	4 (100.0)	3.16 (0.41)	2.8	2.83	3.12	3.50	3.7	
		Week 52	Tezepelumab	1	1 (100.0)	3.08	3.1	3.08	3.08	3.08	3.1	
			Placebo	4	3 (75.0)	3.44 (0.44)	2.9	2.93	3.65	3.74	3.7	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q1: < 16 ppb	Change from baseline	Week 2	Tezepelumab	1	1 (100.0)	0.05	0.1	0.05	0.05	0.05	0.1	NE
			Placebo	4	4 (100.0)	-0.03 (0.07)	-0.1	-0.08	-0.06	0.01	0.1	
		Week 4	Tezepelumab	1	1 (100.0)	-0.08	-0.1	-0.08	-0.08	-0.08	-0.1	NE
			Placebo	4	4 (100.0)	-0.09 (0.27)	-0.4	-0.27	-0.08	0.09	0.2	
		Week 8	Tezepelumab	1	1 (100.0)	0.02	0.0	0.02	0.02	0.02	0.0	NE
			Placebo	4	4 (100.0)	-0.15 (0.18)	-0.3	-0.27	-0.18	-0.02	0.1	
		Week 12	Tezepelumab	1	1 (100.0)	0.05	0.1	0.05	0.05	0.05	0.1	NE
			Placebo	4	4 (100.0)	0.03 (0.15)	-0.2	-0.08	0.03	0.13	0.2	
		Week 16	Tezepelumab	1	1 (100.0)	0.04	0.0	0.04	0.04	0.04	0.0	NE
			Placebo	4	4 (100.0)	-0.20 (0.21)	-0.4	-0.34	-0.23	-0.06	0.1	
		Week 24	Tezepelumab	1	1 (100.0)	0.21	0.2	0.21	0.21	0.21	0.2	NE
			Placebo	4	4 (100.0)	0.06 (0.28)	-0.3	-0.16	0.08	0.29	0.3	
		Week 36	Tezepelumab	1	1 (100.0)	0.39	0.4	0.39	0.39	0.39	0.4	NE
			Placebo	4	4 (100.0)	0.26 (0.07)	0.2	0.20	0.26	0.32	0.3	
		Week 52	Tezepelumab	1	1 (100.0)	0.39	0.4	0.39	0.39	0.39	0.4	NE
			Placebo	4	3 (75.0)	0.38 (0.22)	0.2	0.23	0.28	0.63	0.6	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)											
Q2: 16 - < 30 ppb Absolute values	Baseline	Tezepelumab	2	2 (100.0)	2.54 (0.57)	2.1	2.14	2.54	2.94	2.9	
		Placebo	3	3 (100.0)	2.17 (0.77)	1.4	1.41	2.16	2.94	2.9	
	Week 2	Tezepelumab	2	2 (100.0)	2.82 (0.45)	2.5	2.50	2.82	3.13	3.1	
		Placebo	3	3 (100.0)	2.17 (0.84)	1.3	1.34	2.16	3.01	3.0	
	Week 4	Tezepelumab	2	2 (100.0)	2.69 (0.17)	2.6	2.57	2.69	2.81	2.8	
		Placebo	3	3 (100.0)	2.26 (0.74)	1.4	1.43	2.50	2.86	2.9	
	Week 8	Tezepelumab	2	2 (100.0)	2.83 (0.35)	2.6	2.58	2.83	3.08	3.1	
		Placebo	3	2 (66.7)	2.27 (1.03)	1.5	1.54	2.27	2.99	3.0	
	Week 12	Tezepelumab	2	2 (100.0)	2.47 (0.24)	2.3	2.30	2.47	2.64	2.6	
		Placebo	3	3 (100.0)	2.31 (0.78)	1.4	1.44	2.54	2.96	3.0	
	Week 16	Tezepelumab	2	2 (100.0)	2.72 (0.31)	2.5	2.50	2.72	2.94	2.9	
		Placebo	3	3 (100.0)	2.17 (0.73)	1.5	1.49	2.09	2.94	2.9	
	Week 24	Tezepelumab	2	2 (100.0)	2.62 (0.42)	2.3	2.32	2.62	2.91	2.9	
		Placebo	3	3 (100.0)	2.19 (0.73)	1.5	1.48	2.15	2.93	2.9	
	Week 36	Tezepelumab	2	2 (100.0)	2.82 (0.16)	2.7	2.71	2.82	2.93	2.9	
		Placebo	3	3 (100.0)	2.07 (0.82)	1.4	1.38	1.86	2.97	3.0	
	Week 52	Tezepelumab	2	2 (100.0)	3.05 (0.37)	2.8	2.79	3.05	3.31	3.3	
		Placebo	3	3 (100.0)	2.34 (0.79)	1.5	1.49	2.47	3.05	3.1	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q2: 16 - < 30 ppb	Change from baseline	Week 2	Tezepelumab	2	2 (100.0)	0.27 (0.12)	0.2	0.19	0.27	0.36	0.4	3.06 [0.03, 6.09]
			Placebo	3	3 (100.0)	0.00 (0.07)	-0.1	-0.07	0.00	0.07	0.1	
		Week 4	Tezepelumab	2	2 (100.0)	0.15 (0.40)	-0.1	-0.13	0.15	0.43	0.4	0.20 [-1.60, 1.99]
			Placebo	3	3 (100.0)	0.09 (0.22)	-0.1	-0.08	0.02	0.34	0.3	
		Week 8	Tezepelumab	2	2 (100.0)	0.29 (0.21)	0.1	0.14	0.29	0.44	0.4	1.29 [-1.04, 3.62]
			Placebo	3	2 (66.7)	0.09 (0.06)	0.1	0.05	0.09	0.13	0.1	
		Week 12	Tezepelumab	2	2 (100.0)	-0.07 (0.33)	-0.3	-0.30	-0.07	0.16	0.2	-0.85 [-2.76, 1.07]
			Placebo	3	3 (100.0)	0.14 (0.21)	0.0	0.02	0.03	0.38	0.4	
		Week 16	Tezepelumab	2	2 (100.0)	0.18 (0.25)	0.0	0.00	0.18	0.36	0.4	1.11 [-0.89, 3.11]
			Placebo	3	3 (100.0)	0.00 (0.08)	-0.1	-0.07	0.00	0.08	0.1	
		Week 24	Tezepelumab	2	2 (100.0)	0.07 (0.15)	-0.0	-0.03	0.07	0.18	0.2	0.62 [-1.23, 2.48]
			Placebo	3	3 (100.0)	0.02 (0.05)	-0.0	-0.01	-0.01	0.07	0.1	
		Week 36	Tezepelumab	2	2 (100.0)	0.28 (0.41)	-0.0	-0.01	0.28	0.57	0.6	1.37 [-0.73, 3.47]
			Placebo	3	3 (100.0)	-0.10 (0.18)	-0.3	-0.30	-0.03	0.03	0.0	
		Week 52	Tezepelumab	2	2 (100.0)	0.51 (0.20)	0.4	0.37	0.51	0.65	0.7	2.24 [-0.29, 4.77]
			Placebo	3	3 (100.0)	0.17 (0.13)	0.1	0.08	0.11	0.31	0.3	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)											
Q3: 30 - < 56 ppb Absolute values	Baseline	Tezepelumab	4	4 (100.0)	3.13 (0.40)	2.7	2.84	3.08	3.42	3.7	
		Placebo	7	7 (100.0)	2.59 (1.21)	1.0	2.10	2.24	3.08	4.9	
	Week 2	Tezepelumab	4	4 (100.0)	3.06 (0.71)	2.4	2.50	2.93	3.62	4.0	
		Placebo	7	7 (100.0)	2.85 (0.85)	2.3	2.30	2.60	3.01	4.7	
	Week 4	Tezepelumab	4	4 (100.0)	3.12 (0.62)	2.5	2.59	3.09	3.65	3.8	
		Placebo	7	6 (85.7)	2.43 (0.24)	2.1	2.17	2.54	2.60	2.7	
	Week 8	Tezepelumab	4	4 (100.0)	2.96 (0.72)	2.2	2.36	3.00	3.56	3.7	
		Placebo	7	7 (100.0)	2.95 (0.89)	2.3	2.41	2.76	2.93	4.9	
	Week 12	Tezepelumab	4	4 (100.0)	2.76 (0.99)	1.4	2.01	3.03	3.52	3.6	
		Placebo	7	7 (100.0)	2.71 (1.03)	1.9	2.00	2.49	2.56	5.0	
	Week 16	Tezepelumab	4	3 (75.0)	2.89 (0.74)	2.4	2.43	2.50	3.75	3.8	
		Placebo	7	7 (100.0)	2.87 (1.04)	2.4	2.41	2.48	2.63	5.2	
	Week 24	Tezepelumab	4	3 (75.0)	2.77 (0.73)	2.2	2.20	2.53	3.59	3.6	
		Placebo	7	5 (71.4)	2.99 (1.22)	2.0	2.52	2.64	2.71	5.1	
	Week 36	Tezepelumab	4	3 (75.0)	3.20 (0.68)	2.7	2.67	2.95	3.97	4.0	
		Placebo	7	5 (71.4)	3.01 (1.44)	1.4	2.34	2.93	3.10	5.3	
	Week 52	Tezepelumab	4	3 (75.0)	3.05 (1.04)	2.4	2.37	2.53	4.24	4.2	
		Placebo	7	6 (85.7)	2.82 (1.22)	2.1	2.14	2.39	2.63	5.3	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q3: 30 - < 56 ppb	Change from baseline	Week 2	Tezepelumab	4	4 (100.0)	-0.07 (0.33)	-0.4	-0.34	-0.10	0.20	0.3	-0.60 [-1.86, 0.66]
			Placebo	7	7 (100.0)	0.26 (0.63)	-0.2	-0.07	0.03	0.26	1.7	
		Week 4	Tezepelumab	4	4 (100.0)	-0.01 (0.29)	-0.3	-0.25	-0.03	0.23	0.3	-0.37 [-1.64, 0.91]
			Placebo	7	6 (85.7)	0.22 (0.76)	-0.5	-0.12	-0.05	0.40	1.7	
		Week 8	Tezepelumab	4	4 (100.0)	-0.17 (0.47)	-0.8	-0.48	-0.04	0.15	0.3	-0.71 [-1.98, 0.56]
			Placebo	7	7 (100.0)	0.36 (0.85)	-0.8	-0.02	0.17	0.65	2.0	
		Week 12	Tezepelumab	4	4 (100.0)	-0.37 (0.81)	-1.5	-0.83	-0.11	0.10	0.3	-0.59 [-1.85, 0.67]
			Placebo	7	7 (100.0)	0.12 (0.82)	-1.2	-0.24	0.09	0.41	1.5	
		Week 16	Tezepelumab	4	3 (75.0)	-0.21 (0.29)	-0.5	-0.48	-0.26	0.10	0.1	-0.81 [-2.22, 0.60]
			Placebo	7	7 (100.0)	0.28 (0.68)	-0.7	-0.15	0.26	0.37	1.6	
		Week 24	Tezepelumab	4	3 (75.0)	-0.33 (0.39)	-0.8	-0.78	-0.16	-0.06	-0.1	-0.55 [-2.01, 0.92]
			Placebo	7	5 (71.4)	0.00 (0.70)	-1.1	-0.26	0.23	0.54	0.6	
		Week 36	Tezepelumab	4	3 (75.0)	0.09 (0.20)	-0.0	-0.03	-0.02	0.32	0.3	-0.15 [-1.58, 1.28]
			Placebo	7	5 (71.4)	0.26 (1.36)	-1.7	0.15	0.24	0.42	2.2	
		Week 52	Tezepelumab	4	3 (75.0)	-0.06 (0.61)	-0.6	-0.61	-0.16	0.59	0.6	-0.32 [-1.71, 1.08]
			Placebo	7	6 (85.7)	0.17 (0.75)	-0.7	-0.57	0.21	0.53	1.3	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q4: >= 56 ppb	Absolute values	Baseline	Tezepelumab	8	8 (100.0)	2.32 (0.76)	1.4	1.71	2.16	3.00	3.4	
			Placebo	6	6 (100.0)	2.38 (0.98)	1.3	1.89	2.07	2.97	4.0	
		Week 2	Tezepelumab	8	7 (87.5)	2.66 (0.84)	1.7	1.69	2.59	3.39	3.7	
			Placebo	6	6 (100.0)	2.58 (0.50)	1.7	2.31	2.73	2.80	3.2	
		Week 4	Tezepelumab	8	7 (87.5)	2.43 (0.79)	1.3	1.82	2.47	3.18	3.3	
			Placebo	6	6 (100.0)	2.84 (0.46)	2.3	2.44	2.85	3.18	3.5	
		Week 8	Tezepelumab	8	7 (87.5)	2.27 (1.21)	1.0	1.03	2.54	3.43	3.5	
			Placebo	6	6 (100.0)	2.43 (0.71)	1.4	2.02	2.44	3.09	3.3	
		Week 12	Tezepelumab	8	6 (75.0)	2.46 (1.12)	0.8	1.68	2.71	3.37	3.5	
			Placebo	6	6 (100.0)	2.76 (0.70)	1.7	2.34	2.83	3.38	3.5	
		Week 16	Tezepelumab	8	7 (87.5)	2.58 (0.76)	1.5	2.03	2.22	3.35	3.4	
			Placebo	6	6 (100.0)	2.72 (0.62)	1.9	2.26	2.73	3.17	3.5	
		Week 24	Tezepelumab	8	7 (87.5)	2.57 (0.88)	1.6	1.69	2.88	3.19	3.7	
			Placebo	6	6 (100.0)	2.80 (0.52)	2.0	2.60	2.86	3.14	3.4	
		Week 36	Tezepelumab	8	7 (87.5)	2.73 (0.81)	1.4	2.25	2.56	3.55	3.6	
			Placebo	6	6 (100.0)	2.84 (0.81)	1.4	2.55	3.02	3.51	3.5	
		Week 52	Tezepelumab	8	6 (75.0)	2.83 (0.72)	1.9	2.17	2.97	3.45	3.6	
			Placebo	6	6 (100.0)	2.60 (0.93)	1.2	2.06	2.66	3.22	3.8	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q4: >= 56 ppb	Change from baseline	Week 2	Tezepelumab	8	7 (87.5)	0.41 (0.61)	-0.5	-0.04	0.47	0.81	1.4	0.28 [-0.82, 1.37]
			Placebo	6	6 (100.0)	0.20 (0.89)	-1.3	-0.27	0.36	0.74	1.3	
		Week 4	Tezepelumab	8	7 (87.5)	0.24 (0.63)	-0.3	-0.30	-0.14	0.96	1.2	-0.31 [-1.41, 0.79]
			Placebo	6	6 (100.0)	0.46 (0.83)	-1.0	0.21	0.57	1.02	1.4	
		Week 8	Tezepelumab	8	7 (87.5)	0.07 (0.88)	-1.1	-0.46	-0.13	0.65	1.6	0.02 [-1.07, 1.11]
			Placebo	6	6 (100.0)	0.05 (1.10)	-1.7	-0.45	0.02	1.03	1.4	
		Week 12	Tezepelumab	8	6 (75.0)	0.25 (0.83)	-0.6	-0.52	0.25	0.64	1.5	-0.14 [-1.28, 0.99]
			Placebo	6	6 (100.0)	0.38 (0.98)	-1.0	-0.38	0.34	1.32	1.6	
		Week 16	Tezepelumab	8	7 (87.5)	0.38 (0.52)	-0.1	0.00	0.11	0.61	1.4	0.06 [-1.04, 1.15]
			Placebo	6	6 (100.0)	0.33 (1.11)	-1.6	0.04	0.40	1.11	1.6	
		Week 24	Tezepelumab	8	7 (87.5)	0.37 (0.74)	-0.5	-0.24	0.27	0.76	1.8	-0.05 [-1.14, 1.04]
			Placebo	6	6 (100.0)	0.42 (1.01)	-1.4	0.17	0.61	1.05	1.5	
		Week 36	Tezepelumab	8	7 (87.5)	0.54 (0.61)	-0.1	0.00	0.44	0.82	1.7	0.10 [-0.99, 1.19]
			Placebo	6	6 (100.0)	0.45 (0.98)	-1.2	0.12	0.52	1.16	1.6	
		Week 52	Tezepelumab	8	6 (75.0)	0.63 (0.43)	0.0	0.42	0.63	0.79	1.3	0.51 [-0.64, 1.67]
			Placebo	6	6 (100.0)	0.22 (1.07)	-1.4	-0.11	0.12	0.59	1.9	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q1: < 53.1 IU/ml	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	2.69	2.7	2.69	2.69	2.69	2.7	
			Placebo	3	3 (100.0)	2.14 (0.69)	1.4	1.41	2.24	2.78	2.8	
		Week 2	Tezepelumab	1	1 (100.0)	2.74	2.7	2.74	2.74	2.74	2.7	
			Placebo	3	3 (100.0)	2.12 (0.71)	1.3	1.34	2.27	2.74	2.7	
		Week 4	Tezepelumab	1	1 (100.0)	2.61	2.6	2.61	2.61	2.61	2.6	
			Placebo	3	3 (100.0)	2.09 (0.62)	1.4	1.43	2.17	2.66	2.7	
		Week 8	Tezepelumab	1	1 (100.0)	2.71	2.7	2.71	2.71	2.71	2.7	
			Placebo	3	3 (100.0)	2.24 (0.63)	1.5	1.54	2.41	2.76	2.8	
		Week 12	Tezepelumab	1	1 (100.0)	2.74	2.7	2.74	2.74	2.74	2.7	
			Placebo	3	3 (100.0)	2.00 (0.56)	1.4	1.44	2.00	2.56	2.6	
		Week 16	Tezepelumab	1	1 (100.0)	2.73	2.7	2.73	2.73	2.73	2.7	
			Placebo	3	3 (100.0)	2.19 (0.62)	1.5	1.49	2.46	2.63	2.6	
		Week 24	Tezepelumab	1	1 (100.0)	2.90	2.9	2.90	2.90	2.90	2.9	
			Placebo	3	2 (66.7)	2.00 (0.74)	1.5	1.48	2.00	2.52	2.5	
		Week 36	Tezepelumab	1	1 (100.0)	3.08	3.1	3.08	3.08	3.08	3.1	
			Placebo	3	2 (66.7)	2.16 (1.10)	1.4	1.38	2.16	2.93	2.9	
		Week 52	Tezepelumab	1	1 (100.0)	3.08	3.1	3.08	3.08	3.08	3.1	
			Placebo	3	2 (66.7)	1.79 (0.42)	1.5	1.49	1.79	2.09	2.1	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q1: < 53.1 IU/ml	Change from baseline	Week 2	Tezepelumab	1	1 (100.0)	0.05	0.1	0.05	0.05	0.05	0.1	NE
			Placebo	3	3 (100.0)	-0.03 (0.05)	-0.1	-0.07	-0.04	0.03	0.0	
		Week 4	Tezepelumab	1	1 (100.0)	-0.08	-0.1	-0.08	-0.08	-0.08	-0.1	NE
			Placebo	3	3 (100.0)	-0.06 (0.07)	-0.1	-0.12	-0.07	0.02	0.0	
		Week 8	Tezepelumab	1	1 (100.0)	0.02	0.0	0.02	0.02	0.02	0.0	NE
			Placebo	3	3 (100.0)	0.09 (0.10)	-0.0	-0.02	0.13	0.17	0.2	
		Week 12	Tezepelumab	1	1 (100.0)	0.05	0.1	0.05	0.05	0.05	0.1	NE
			Placebo	3	3 (100.0)	-0.14 (0.15)	-0.2	-0.24	-0.22	0.03	0.0	
		Week 16	Tezepelumab	1	1 (100.0)	0.04	0.0	0.04	0.04	0.04	0.0	NE
			Placebo	3	3 (100.0)	0.05 (0.19)	-0.1	-0.15	0.08	0.22	0.2	
		Week 24	Tezepelumab	1	1 (100.0)	0.21	0.2	0.21	0.21	0.21	0.2	NE
			Placebo	3	2 (66.7)	-0.09 (0.23)	-0.3	-0.26	-0.09	0.07	0.1	
		Week 36	Tezepelumab	1	1 (100.0)	0.39	0.4	0.39	0.39	0.39	0.4	NE
			Placebo	3	2 (66.7)	0.06 (0.13)	-0.0	-0.03	0.06	0.15	0.2	
		Week 52	Tezepelumab	1	1 (100.0)	0.39	0.4	0.39	0.39	0.39	0.4	NE
			Placebo	3	2 (66.7)	-0.30 (0.54)	-0.7	-0.69	-0.30	0.08	0.1	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q2: 53.1 - < 195.6 IU/ml	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	2.69	2.7	2.69	2.69	2.69	2.7	
			Placebo	2	2 (100.0)	2.79 (0.95)	2.1	2.11	2.79	3.46	3.5	
		Week 2	Tezepelumab	1	1 (100.0)	2.41	2.4	2.41	2.41	2.41	2.4	
			Placebo	2	2 (100.0)	2.95 (0.81)	2.4	2.37	2.95	3.52	3.5	
		Week 4	Tezepelumab	1	1 (100.0)	2.51	2.5	2.51	2.51	2.51	2.5	
			Placebo	2	2 (100.0)	2.89 (1.12)	2.1	2.09	2.89	3.68	3.7	
		Week 8	Tezepelumab	1	1 (100.0)	2.56	2.6	2.56	2.56	2.56	2.6	
			Placebo	2	2 (100.0)	3.00 (0.34)	2.8	2.76	3.00	3.24	3.2	
		Week 12	Tezepelumab	1	1 (100.0)	2.57	2.6	2.57	2.57	2.57	2.6	
			Placebo	2	2 (100.0)	3.02 (0.71)	2.5	2.52	3.02	3.52	3.5	
		Week 16	Tezepelumab	1	1 (100.0)	2.43	2.4	2.43	2.43	2.43	2.4	
			Placebo	2	2 (100.0)	2.85 (0.52)	2.5	2.48	2.85	3.21	3.2	
		Week 24	Tezepelumab	1	1 (100.0)	2.53	2.5	2.53	2.53	2.53	2.5	
			Placebo	2	2 (100.0)	3.06 (0.49)	2.7	2.71	3.06	3.40	3.4	
		Week 36	Tezepelumab	1	1 (100.0)	2.67	2.7	2.67	2.67	2.67	2.7	
			Placebo	2	1 (50.0)	3.66	3.7	3.66	3.66	3.66	3.7	
		Week 52	Tezepelumab	1	1 (100.0)	2.53	2.5	2.53	2.53	2.53	2.5	
			Placebo	2	2 (100.0)	2.94 (1.13)	2.1	2.14	2.94	3.74	3.7	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q2: 53.1 - < 195.6 IU/ml	Change from baseline	Week 2	Tezepelumab	1	1 (100.0)	-0.28	-0.3	-0.28	-0.28	-0.28	-0.3	NE
			Placebo	2	2 (100.0)	0.16 (0.14)	0.1	0.06	0.16	0.26	0.3	
		Week 4	Tezepelumab	1	1 (100.0)	-0.18	-0.2	-0.18	-0.18	-0.18	-0.2	NE
			Placebo	2	2 (100.0)	0.10 (0.17)	-0.0	-0.02	0.10	0.22	0.2	
		Week 8	Tezepelumab	1	1 (100.0)	-0.13	-0.1	-0.13	-0.13	-0.13	-0.1	NE
			Placebo	2	2 (100.0)	0.22 (0.62)	-0.2	-0.22	0.22	0.65	0.7	
		Week 12	Tezepelumab	1	1 (100.0)	-0.12	-0.1	-0.12	-0.12	-0.12	-0.1	NE
			Placebo	2	2 (100.0)	0.24 (0.25)	0.1	0.06	0.24	0.41	0.4	
		Week 16	Tezepelumab	1	1 (100.0)	-0.26	-0.3	-0.26	-0.26	-0.26	-0.3	NE
			Placebo	2	2 (100.0)	0.06 (0.44)	-0.3	-0.25	0.06	0.37	0.4	
		Week 24	Tezepelumab	1	1 (100.0)	-0.16	-0.2	-0.16	-0.16	-0.16	-0.2	NE
			Placebo	2	2 (100.0)	0.27 (0.47)	-0.1	-0.06	0.27	0.60	0.6	
		Week 36	Tezepelumab	1	1 (100.0)	-0.02	-0.0	-0.02	-0.02	-0.02	-0.0	NE
			Placebo	2	1 (50.0)	0.20	0.2	0.20	0.20	0.20	0.2	
		Week 52	Tezepelumab	1	1 (100.0)	-0.16	-0.2	-0.16	-0.16	-0.16	-0.2	NE
			Placebo	2	2 (100.0)	0.16 (0.18)	0.0	0.03	0.16	0.28	0.3	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q3: 195.6 - < 572.4 IU/ml	Absolute values	Baseline	Tezepelumab	5	5 (100.0)	2.51 (0.72)	1.4	2.14	2.78	2.98	3.2	
			Placebo	2	2 (100.0)	2.73 (0.42)	2.4	2.43	2.73	3.02	3.0	
		Week 2	Tezepelumab	5	4 (80.0)	2.76 (0.65)	2.2	2.37	2.55	3.15	3.7	
			Placebo	2	2 (100.0)	2.67 (0.38)	2.4	2.40	2.67	2.94	2.9	
		Week 4	Tezepelumab	5	4 (80.0)	2.38 (0.38)	1.8	2.15	2.52	2.62	2.7	
			Placebo	2	2 (100.0)	2.49 (0.14)	2.4	2.39	2.49	2.59	2.6	
		Week 8	Tezepelumab	5	4 (80.0)	2.28 (1.02)	1.0	1.56	2.37	3.01	3.4	
			Placebo	2	2 (100.0)	2.50 (0.28)	2.3	2.30	2.50	2.69	2.7	
		Week 12	Tezepelumab	5	4 (80.0)	2.30 (0.80)	1.4	1.76	2.18	2.84	3.4	
			Placebo	2	2 (100.0)	2.65 (0.30)	2.4	2.44	2.65	2.86	2.9	
		Week 16	Tezepelumab	5	4 (80.0)	2.61 (0.57)	2.0	2.27	2.50	2.95	3.4	
			Placebo	2	2 (100.0)	2.56 (0.06)	2.5	2.52	2.56	2.60	2.6	
		Week 24	Tezepelumab	5	4 (80.0)	2.32 (0.64)	1.6	1.91	2.26	2.74	3.2	
			Placebo	2	2 (100.0)	2.71 (0.07)	2.7	2.66	2.71	2.76	2.8	
		Week 36	Tezepelumab	5	4 (80.0)	2.87 (0.54)	2.3	2.48	2.83	3.25	3.6	
			Placebo	2	2 (100.0)	3.05 (0.40)	2.8	2.76	3.05	3.33	3.3	
		Week 52	Tezepelumab	5	4 (80.0)	2.73 (0.62)	2.2	2.27	2.58	3.18	3.6	
			Placebo	2	1 (50.0)	3.65	3.7	3.65	3.65	3.65	3.7	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q3: 195.6 - < 572.4 IU/ml	Change from baseline	Week 2	Tezepelumab	5	4 (80.0)	0.32 (0.51)	-0.4	-0.02	0.42	0.65	0.8	0.84 [-0.95, 2.64]
			Placebo	2	2 (100.0)	-0.06 (0.04)	-0.1	-0.08	-0.06	-0.03	-0.0	
		Week 4	Tezepelumab	5	4 (80.0)	0.05 (0.42)	-0.3	-0.31	0.04	0.41	0.4	0.74 [-1.03, 2.51]
			Placebo	2	2 (100.0)	-0.24 (0.28)	-0.4	-0.43	-0.24	-0.04	-0.0	
		Week 8	Tezepelumab	5	4 (80.0)	-0.05 (0.71)	-0.8	-0.65	-0.01	0.55	0.7	0.29 [-1.42, 2.00]
			Placebo	2	2 (100.0)	-0.23 (0.14)	-0.3	-0.33	-0.23	-0.13	-0.1	
		Week 12	Tezepelumab	5	4 (80.0)	-0.04 (1.02)	-1.5	-0.69	0.38	0.62	0.6	0.04 [-1.66, 1.74]
			Placebo	2	2 (100.0)	-0.08 (0.12)	-0.2	-0.16	-0.08	0.01	0.0	
		Week 16	Tezepelumab	5	4 (80.0)	0.27 (0.51)	-0.5	-0.06	0.48	0.61	0.6	0.91 [-0.90, 2.72]
			Placebo	2	2 (100.0)	-0.17 (0.36)	-0.4	-0.42	-0.17	0.09	0.1	
		Week 24	Tezepelumab	5	4 (80.0)	-0.01 (0.52)	-0.8	-0.30	0.18	0.28	0.4	0.01 [-1.69, 1.71]
			Placebo	2	2 (100.0)	-0.02 (0.35)	-0.3	-0.26	-0.02	0.23	0.2	
		Week 36	Tezepelumab	5	4 (80.0)	0.53 (0.39)	-0.0	0.27	0.67	0.80	0.8	0.63 [-1.12, 2.38]
			Placebo	2	2 (100.0)	0.32 (0.01)	0.3	0.31	0.32	0.33	0.3	
		Week 52	Tezepelumab	5	4 (80.0)	0.39 (0.67)	-0.6	0.02	0.70	0.77	0.8	NE
			Placebo	2	1 (50.0)	0.63	0.6	0.63	0.63	0.63	0.6	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q4: >= 572.4 IU/ml	Absolute values	Baseline	Tezepelumab	8	8 (100.0)	2.62 (0.79)	1.4	2.05	2.57	3.31	3.7	
			Placebo	13	13 (100.0)	2.55 (1.07)	1.0	2.06	2.16	2.97	4.9	
		Week 2	Tezepelumab	8	8 (100.0)	2.88 (0.83)	1.7	2.14	3.20	3.38	4.0	
			Placebo	13	13 (100.0)	2.76 (0.70)	1.7	2.31	2.70	3.01	4.7	
		Week 4	Tezepelumab	8	8 (100.0)	2.85 (0.85)	1.3	2.36	3.13	3.40	3.8	
			Placebo	13	12 (92.3)	2.72 (0.34)	2.3	2.50	2.60	2.95	3.5	
		Week 8	Tezepelumab	8	8 (100.0)	2.71 (1.08)	1.0	1.81	3.19	3.48	3.7	
			Placebo	13	12 (92.3)	2.76 (0.86)	1.4	2.33	2.69	3.04	4.9	
		Week 12	Tezepelumab	8	7 (87.5)	2.71 (1.09)	0.8	1.68	3.34	3.51	3.6	
			Placebo	13	13 (100.0)	2.84 (0.83)	1.7	2.49	2.59	3.07	5.0	
		Week 16	Tezepelumab	8	7 (87.5)	2.76 (0.79)	1.5	2.20	2.94	3.35	3.8	
			Placebo	13	13 (100.0)	2.79 (0.86)	1.9	2.36	2.49	3.01	5.2	
		Week 24	Tezepelumab	8	7 (87.5)	2.81 (0.83)	1.7	1.70	2.91	3.59	3.7	
			Placebo	13	12 (92.3)	2.89 (0.84)	2.0	2.38	2.79	3.13	5.1	
		Week 36	Tezepelumab	8	7 (87.5)	2.89 (0.86)	1.4	2.39	2.93	3.64	4.0	
			Placebo	13	13 (100.0)	2.84 (1.03)	1.4	2.34	2.90	3.22	5.3	
		Week 52	Tezepelumab	8	6 (75.0)	3.13 (0.81)	1.9	2.64	3.30	3.45	4.2	
			Placebo	13	13 (100.0)	2.82 (0.96)	1.2	2.47	2.65	3.05	5.3	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q4: >= 572.4 IU/ml	Change from baseline	Week 2	Tezepelumab	8	8 (100.0)	0.27 (0.54)	-0.5	0.02	0.23	0.40	1.4	0.08 [-0.80, 0.96]
			Placebo	13	13 (100.0)	0.21 (0.73)	-1.3	-0.08	0.07	0.48	1.7	
		Week 4	Tezepelumab	8	8 (100.0)	0.24 (0.56)	-0.3	-0.15	0.00	0.64	1.2	-0.19 [-1.09, 0.70]
			Placebo	13	12 (92.3)	0.37 (0.76)	-1.0	-0.10	0.35	0.90	1.7	
		Week 8	Tezepelumab	8	8 (100.0)	0.09 (0.76)	-1.1	-0.27	0.09	0.34	1.6	-0.10 [-0.99, 0.80]
			Placebo	13	12 (92.3)	0.18 (0.97)	-1.7	-0.26	0.07	0.76	2.0	
		Week 12	Tezepelumab	8	7 (87.5)	0.03 (0.73)	-0.6	-0.52	-0.10	0.30	1.5	-0.32 [-1.25, 0.60]
			Placebo	13	13 (100.0)	0.29 (0.85)	-1.2	0.02	0.26	0.42	1.6	
		Week 16	Tezepelumab	8	7 (87.5)	0.22 (0.51)	-0.1	0.00	0.10	0.11	1.4	-0.03 [-0.95, 0.89]
			Placebo	13	13 (100.0)	0.25 (0.88)	-1.6	-0.07	0.18	0.63	1.6	
		Week 24	Tezepelumab	8	7 (87.5)	0.28 (0.77)	-0.5	-0.24	-0.03	0.76	1.8	0.09 [-0.85, 1.02]
			Placebo	13	12 (92.3)	0.21 (0.81)	-1.4	-0.01	0.29	0.62	1.5	
		Week 36	Tezepelumab	8	7 (87.5)	0.35 (0.61)	-0.1	-0.01	0.19	0.44	1.7	0.07 [-0.85, 0.99]
			Placebo	13	13 (100.0)	0.29 (1.03)	-1.7	0.03	0.24	0.57	2.2	
		Week 52	Tezepelumab	8	6 (75.0)	0.54 (0.43)	0.0	0.37	0.47	0.59	1.3	0.37 [-0.61, 1.34]
			Placebo	13	13 (100.0)	0.28 (0.80)	-1.4	-0.02	0.25	0.53	1.9	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Nasal polyps last 2 years												
Yes	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	2.78	2.8	2.78	2.78	2.78	2.8	
			Placebo	2	2 (100.0)	2.45 (0.47)	2.1	2.11	2.45	2.78	2.8	
		Week 2	Placebo	2	2 (100.0)	2.56 (0.26)	2.4	2.37	2.56	2.74	2.7	
		Week 4	Tezepelumab	1	1 (100.0)	2.47	2.5	2.47	2.47	2.47	2.5	
			Placebo	2	2 (100.0)	2.38 (0.40)	2.1	2.09	2.38	2.66	2.7	
		Week 8	Tezepelumab	1	1 (100.0)	3.43	3.4	3.43	3.43	3.43	3.4	
			Placebo	2	2 (100.0)	2.76 (0.00)	2.8	2.76	2.76	2.76	2.8	
		Week 12	Tezepelumab	1	1 (100.0)	3.37	3.4	3.37	3.37	3.37	3.4	
			Placebo	2	2 (100.0)	2.54 (0.03)	2.5	2.52	2.54	2.56	2.6	
		Week 16	Tezepelumab	1	1 (100.0)	3.39	3.4	3.39	3.39	3.39	3.4	
			Placebo	2	2 (100.0)	2.56 (0.11)	2.5	2.48	2.56	2.63	2.6	
		Week 24	Tezepelumab	1	1 (100.0)	3.16	3.2	3.16	3.16	3.16	3.2	
			Placebo	2	2 (100.0)	2.62 (0.13)	2.5	2.52	2.62	2.71	2.7	
		Week 36	Tezepelumab	1	1 (100.0)	3.55	3.6	3.55	3.55	3.55	3.6	
			Placebo	2	1 (50.0)	2.93	2.9	2.93	2.93	2.93	2.9	
		Week 52	Tezepelumab	1	1 (100.0)	3.57	3.6	3.57	3.57	3.57	3.6	
			Placebo	2	2 (100.0)	2.12 (0.04)	2.1	2.09	2.12	2.14	2.1	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Nasal polyps last 2 years												
Yes	Change from baseline	Week 2	Placebo	2	2 (100.0)	0.11 (0.21)	-0.0	-0.04	0.11	0.26	0.3	
		Week 4	Tezepelumab	1	1 (100.0)	-0.31	-0.3	-0.31	-0.31	-0.31	-0.3	NE
			Placebo	2	2 (100.0)	-0.07 (0.07)	-0.1	-0.12	-0.07	-0.02	-0.0	
		Week 8	Tezepelumab	1	1 (100.0)	0.65	0.7	0.65	0.65	0.65	0.7	NE
			Placebo	2	2 (100.0)	0.32 (0.47)	-0.0	-0.02	0.32	0.65	0.7	
		Week 12	Tezepelumab	1	1 (100.0)	0.59	0.6	0.59	0.59	0.59	0.6	NE
			Placebo	2	2 (100.0)	0.10 (0.45)	-0.2	-0.22	0.10	0.41	0.4	
		Week 16	Tezepelumab	1	1 (100.0)	0.61	0.6	0.61	0.61	0.61	0.6	NE
			Placebo	2	2 (100.0)	0.11 (0.37)	-0.1	-0.15	0.11	0.37	0.4	
		Week 24	Tezepelumab	1	1 (100.0)	0.38	0.4	0.38	0.38	0.38	0.4	NE
			Placebo	2	2 (100.0)	0.17 (0.61)	-0.3	-0.26	0.17	0.60	0.6	
		Week 36	Tezepelumab	1	1 (100.0)	0.77	0.8	0.77	0.77	0.77	0.8	NE
			Placebo	2	1 (50.0)	0.15	0.2	0.15	0.15	0.15	0.2	
		Week 52	Tezepelumab	1	1 (100.0)	0.79	0.8	0.79	0.79	0.79	0.8	NE
			Placebo	2	2 (100.0)	-0.33 (0.51)	-0.7	-0.69	-0.33	0.03	0.0	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Nasal polyps last 2 years												
No	Absolute values	Baseline	Tezepelumab	14	14 (100.0)	2.58 (0.71)	1.4	2.12	2.69	3.18	3.7	
			Placebo	18	18 (100.0)	2.54 (0.98)	1.0	2.06	2.34	3.02	4.9	
		Week 2	Tezepelumab	14	14 (100.0)	2.80 (0.70)	1.7	2.41	2.67	3.36	4.0	
			Placebo	18	18 (100.0)	2.69 (0.72)	1.3	2.30	2.66	3.01	4.7	
		Week 4	Tezepelumab	14	13 (92.9)	2.69 (0.71)	1.3	2.51	2.67	3.18	3.8	
			Placebo	18	17 (94.4)	2.64 (0.51)	1.4	2.44	2.59	2.86	3.7	
		Week 8	Tezepelumab	14	13 (92.9)	2.51 (0.96)	1.0	2.15	2.58	3.30	3.7	
			Placebo	18	17 (94.4)	2.66 (0.79)	1.4	2.30	2.59	2.99	4.9	
		Week 12	Tezepelumab	14	12 (85.7)	2.51 (0.90)	0.8	1.88	2.61	3.41	3.6	
			Placebo	18	18 (100.0)	2.73 (0.81)	1.4	2.34	2.57	3.07	5.0	
		Week 16	Tezepelumab	14	12 (85.7)	2.63 (0.63)	1.5	2.21	2.50	3.13	3.8	
			Placebo	18	18 (100.0)	2.70 (0.80)	1.5	2.36	2.51	3.01	5.2	
		Week 24	Tezepelumab	14	12 (85.7)	2.61 (0.72)	1.6	1.95	2.71	3.05	3.7	
			Placebo	18	16 (88.9)	2.81 (0.82)	1.5	2.38	2.71	3.13	5.1	
		Week 36	Tezepelumab	14	12 (85.7)	2.82 (0.67)	1.4	2.48	2.82	3.19	4.0	
			Placebo	18	17 (94.4)	2.82 (0.99)	1.4	2.34	2.90	3.33	5.3	
		Week 52	Tezepelumab	14	11 (78.6)	2.88 (0.68)	1.9	2.37	2.79	3.31	4.2	
			Placebo	18	16 (88.9)	2.85 (0.98)	1.2	2.37	2.66	3.44	5.3	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adolescents

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Nasal polyps last 2 years												
No	Change from baseline	Week 2	Tezepelumab	14	14 (100.0)	0.23 (0.49)	-0.5	-0.04	0.23	0.47	1.4	0.14 [-0.56, 0.83]
			Placebo	18	18 (100.0)	0.15 (0.62)	-1.3	-0.08	0.01	0.23	1.7	
		Week 4	Tezepelumab	14	13 (92.9)	0.17 (0.48)	-0.3	-0.15	-0.08	0.39	1.2	-0.13 [-0.86, 0.59]
			Placebo	18	17 (94.4)	0.24 (0.67)	-1.0	-0.08	0.21	0.40	1.7	
		Week 8	Tezepelumab	14	13 (92.9)	-0.02 (0.66)	-1.1	-0.40	0.02	0.25	1.6	-0.16 [-0.89, 0.56]
			Placebo	18	17 (94.4)	0.11 (0.82)	-1.7	-0.22	0.05	0.17	2.0	
		Week 12	Tezepelumab	14	12 (85.7)	-0.05 (0.74)	-1.5	-0.41	-0.10	0.23	1.5	-0.33 [-1.07, 0.40]
			Placebo	18	18 (100.0)	0.19 (0.73)	-1.2	-0.16	0.07	0.39	1.6	
		Week 16	Tezepelumab	14	12 (85.7)	0.15 (0.47)	-0.5	-0.06	0.07	0.24	1.4	-0.02 [-0.75, 0.71]
			Placebo	18	18 (100.0)	0.16 (0.76)	-1.6	-0.21	0.08	0.33	1.6	
		Week 24	Tezepelumab	14	12 (85.7)	0.13 (0.65)	-0.8	-0.20	0.07	0.24	1.8	-0.04 [-0.78, 0.71]
			Placebo	18	16 (88.9)	0.16 (0.71)	-1.4	-0.04	0.20	0.53	1.5	
		Week 36	Tezepelumab	14	12 (85.7)	0.35 (0.50)	-0.1	-0.01	0.26	0.51	1.7	0.11 [-0.63, 0.84]
			Placebo	18	17 (94.4)	0.27 (0.90)	-1.7	0.03	0.24	0.47	2.2	
		Week 52	Tezepelumab	14	11 (78.6)	0.39 (0.50)	-0.6	0.02	0.42	0.65	1.3	0.15 [-0.62, 0.92]
			Placebo	18	16 (88.9)	0.29 (0.72)	-1.4	0.03	0.27	0.56	1.9	

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Region (cat. N)				N<10 any level					NE

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline eosinophils (cat. N)				N<10 any level					NE

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline eosinophils (cat. Q)				N<10 any level					NE

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline FENO (cat. N)				N<10 any level					NE

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline FENO (cat. Q)				N<10 any level					NE

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Total serum IgE (cat. N)				N<10 any level					NE

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_KLSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL - adolescents

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Nasal polyps last 2 years				N<10 any level					NE

Note: DITTL - adolescents = Dossier Label Intent-to-Treat - adolescents.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALMH0: Course of FEV1 Pre-BD
DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
FEV1 Pre-BD	Baseline	Tezepelumab	380	380 (100.0)	1.74 (0.67)	0.4	1.26	1.62	2.12	4.1	
		Placebo	371	371 (100.0)	1.80 (0.68)	0.4	1.33	1.69	2.18	4.5	
	Week 2	Tezepelumab	380	370 (97.4)	1.92 (0.70)	0.6	1.39	1.80	2.39	4.3	
		Placebo	371	353 (95.1)	1.86 (0.70)	0.4	1.38	1.75	2.28	4.1	
	Week 4	Tezepelumab	380	377 (99.2)	1.94 (0.72)	0.6	1.41	1.84	2.42	4.3	
		Placebo	371	363 (97.8)	1.86 (0.68)	0.4	1.40	1.79	2.22	4.8	
	Week 8	Tezepelumab	380	374 (98.4)	1.96 (0.72)	0.6	1.41	1.85	2.41	4.7	
		Placebo	371	361 (97.3)	1.89 (0.72)	0.4	1.39	1.79	2.27	4.6	
	Week 12	Tezepelumab	380	369 (97.1)	1.97 (0.72)	0.6	1.48	1.87	2.41	4.7	
		Placebo	371	357 (96.2)	1.89 (0.72)	0.5	1.38	1.76	2.29	4.6	
	Week 16	Tezepelumab	380	367 (96.6)	1.99 (0.74)	0.6	1.45	1.87	2.42	4.9	
		Placebo	371	350 (94.3)	1.88 (0.72)	0.5	1.35	1.77	2.23	4.7	
	Week 24	Tezepelumab	380	356 (93.7)	1.96 (0.71)	0.6	1.46	1.82	2.40	4.4	
		Placebo	371	339 (91.4)	1.88 (0.71)	0.6	1.39	1.76	2.22	4.8	
	Week 36	Tezepelumab	380	343 (90.3)	1.96 (0.74)	0.5	1.42	1.86	2.39	4.5	
		Placebo	371	328 (88.4)	1.91 (0.72)	0.6	1.41	1.80	2.28	4.6	
	Week 52	Tezepelumab	380	337 (88.7)	1.97 (0.74)	0.6	1.44	1.84	2.40	4.3	
		Placebo	371	308 (83.0)	1.87 (0.74)	0.6	1.32	1.73	2.29	4.5	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALMH0: Course of FEV1 Pre-BD
DITTL - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in FEV1 Pre-BD	Week 2	Tezepelumab	380	370 (97.4)	0.18 (0.33)	-0.7	0.00	0.13	0.31	1.5	0.39 [0.25, 0.54]
		Placebo	371	353 (95.1)	0.05 (0.35)	-1.8	-0.12	0.01	0.18	1.2	
	Week 4	Tezepelumab	380	377 (99.2)	0.21 (0.36)	-0.9	0.00	0.14	0.34	1.8	0.37 [0.22, 0.51]
		Placebo	371	363 (97.8)	0.07 (0.38)	-1.8	-0.11	0.04	0.24	1.6	
	Week 8	Tezepelumab	380	374 (98.4)	0.24 (0.40)	-0.8	-0.04	0.16	0.44	1.8	0.42 [0.27, 0.56]
		Placebo	371	361 (97.3)	0.08 (0.34)	-0.9	-0.11	0.05	0.25	1.6	
	Week 12	Tezepelumab	380	369 (97.1)	0.24 (0.40)	-0.8	-0.01	0.18	0.43	2.0	0.39 [0.25, 0.54]
		Placebo	371	357 (96.2)	0.09 (0.38)	-1.5	-0.10	0.05	0.26	1.7	
	Week 16	Tezepelumab	380	367 (96.6)	0.26 (0.41)	-0.8	0.00	0.17	0.42	2.0	0.47 [0.32, 0.62]
		Placebo	371	350 (94.3)	0.08 (0.36)	-1.2	-0.11	0.02	0.24	1.8	
	Week 24	Tezepelumab	380	356 (93.7)	0.24 (0.41)	-1.0	-0.04	0.19	0.43	1.7	0.43 [0.28, 0.58]
		Placebo	371	339 (91.4)	0.07 (0.38)	-1.1	-0.14	0.03	0.25	1.7	
	Week 36	Tezepelumab	380	343 (90.3)	0.23 (0.41)	-1.0	-0.04	0.16	0.46	1.7	0.36 [0.21, 0.52]
		Placebo	371	328 (88.4)	0.09 (0.38)	-1.1	-0.16	0.04	0.29	1.7	
	Week 52	Tezepelumab	380	337 (88.7)	0.24 (0.41)	-1.0	-0.02	0.17	0.47	1.7	0.46 [0.30, 0.62]
		Placebo	371	308 (83.0)	0.06 (0.34)	-1.0	-0.15	0.05	0.23	1.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALMC0: Change from baseline in FEV1 Pre-BD - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Tezepelumab	380	370 (97.4)	0.18 (0.02)	(0.14, 0.21)	0.13 (0.02)	(0.08, 0.18)	<0.001 *
	Placebo	371	353 (95.1)	0.05 (0.02)	(0.01, 0.08)			
Week 4	Tezepelumab	380	377 (99.2)	0.20 (0.02)	(0.17, 0.24)	0.13 (0.03)	(0.08, 0.18)	<0.001 *
	Placebo	371	363 (97.8)	0.08 (0.02)	(0.04, 0.11)			
Week 8	Tezepelumab	380	374 (98.4)	0.24 (0.02)	(0.20, 0.27)	0.15 (0.03)	(0.10, 0.20)	<0.001 *
	Placebo	371	361 (97.3)	0.09 (0.02)	(0.05, 0.13)			
Week 12	Tezepelumab	380	369 (97.1)	0.24 (0.02)	(0.20, 0.28)	0.15 (0.03)	(0.09, 0.20)	<0.001 *
	Placebo	371	357 (96.2)	0.09 (0.02)	(0.05, 0.13)			
Week 16	Tezepelumab	380	367 (96.6)	0.25 (0.02)	(0.21, 0.29)	0.17 (0.03)	(0.12, 0.23)	<0.001 *
	Placebo	371	350 (94.3)	0.08 (0.02)	(0.04, 0.12)			
Week 24	Tezepelumab	380	356 (93.7)	0.23 (0.02)	(0.19, 0.27)	0.15 (0.03)	(0.10, 0.21)	<0.001 *
	Placebo	371	339 (91.4)	0.07 (0.02)	(0.03, 0.11)			
Week 36	Tezepelumab	380	343 (90.3)	0.24 (0.02)	(0.20, 0.28)	0.14 (0.03)	(0.09, 0.20)	<0.001 *
	Placebo	371	328 (88.4)	0.09 (0.02)	(0.05, 0.13)			
Week 52	Tezepelumab	380	337 (88.7)	0.24 (0.02)	(0.20, 0.28)	0.17 (0.03)	(0.11, 0.23)	<0.001 *
	Placebo	371	308 (83.0)	0.07 (0.02)	(0.03, 0.11)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Figure NF2FAC_ALMG0: Course of FEV1 Pre-BD
DITTL - adult



Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source table: NT2FAC_ALMH0
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Absolute values	Baseline	Tezepelumab	135	135 (100.0)	2.09 (0.76)	0.6	1.54	2.02	2.62	4.1	
			Placebo	136	136 (100.0)	2.12 (0.76)	0.8	1.54	2.07	2.61	4.5	
		Week 2	Tezepelumab	135	133 (98.5)	2.29 (0.77)	0.7	1.72	2.31	2.83	4.3	
			Placebo	136	132 (97.1)	2.17 (0.75)	0.8	1.58	2.17	2.69	4.1	
		Week 4	Tezepelumab	135	134 (99.3)	2.36 (0.79)	0.7	1.77	2.39	2.90	4.3	
			Placebo	136	133 (97.8)	2.15 (0.74)	0.9	1.65	2.02	2.66	4.8	
		Week 8	Tezepelumab	135	130 (96.3)	2.34 (0.81)	0.7	1.68	2.37	2.83	4.7	
			Placebo	136	136 (100.0)	2.19 (0.78)	0.7	1.69	2.08	2.65	4.6	
		Week 12	Tezepelumab	135	129 (95.6)	2.34 (0.84)	0.7	1.70	2.31	2.83	4.7	
			Placebo	136	134 (98.5)	2.21 (0.77)	0.9	1.64	2.16	2.73	4.6	
		Week 16	Tezepelumab	135	130 (96.3)	2.40 (0.86)	0.6	1.72	2.39	2.96	4.9	
			Placebo	136	133 (97.8)	2.17 (0.80)	0.7	1.59	2.08	2.69	4.7	
		Week 24	Tezepelumab	135	121 (89.6)	2.35 (0.80)	0.6	1.74	2.38	2.78	4.4	
			Placebo	136	124 (91.2)	2.21 (0.78)	0.9	1.66	2.09	2.74	4.8	
		Week 36	Tezepelumab	135	121 (89.6)	2.36 (0.86)	0.5	1.75	2.34	2.93	4.5	
			Placebo	136	122 (89.7)	2.20 (0.79)	0.9	1.61	2.10	2.74	4.6	
		Week 52	Tezepelumab	135	120 (88.9)	2.38 (0.82)	0.8	1.76	2.37	2.96	4.3	
			Placebo	136	113 (83.1)	2.19 (0.84)	0.7	1.50	2.10	2.75	4.5	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Change from baseline	Week 2	Tezepelumab	135	133 (98.5)	0.21 (0.39)	-0.7	-0.02	0.16	0.36	1.5	0.50 [0.25, 0.74]
			Placebo	136	132 (97.1)	0.03 (0.35)	-1.1	-0.17	-0.01	0.19	1.1	
		Week 4	Tezepelumab	135	134 (99.3)	0.27 (0.44)	-0.7	-0.03	0.18	0.44	1.8	0.53 [0.29, 0.77]
			Placebo	136	133 (97.8)	0.04 (0.44)	-1.8	-0.20	0.00	0.20	1.6	
		Week 8	Tezepelumab	135	130 (96.3)	0.28 (0.48)	-0.6	-0.05	0.15	0.52	1.8	0.49 [0.24, 0.73]
			Placebo	136	136 (100.0)	0.08 (0.37)	-0.9	-0.16	0.05	0.28	1.4	
		Week 12	Tezepelumab	135	129 (95.6)	0.27 (0.49)	-0.8	-0.06	0.17	0.50	2.0	0.40 [0.15, 0.64]
			Placebo	136	134 (98.5)	0.10 (0.39)	-1.4	-0.10	0.05	0.29	1.4	
		Week 16	Tezepelumab	135	130 (96.3)	0.31 (0.51)	-0.8	-0.02	0.17	0.50	2.0	0.57 [0.33, 0.82]
			Placebo	136	133 (97.8)	0.05 (0.37)	-1.2	-0.15	-0.01	0.23	1.5	
		Week 24	Tezepelumab	135	121 (89.6)	0.29 (0.45)	-0.5	-0.05	0.20	0.47	1.7	0.52 [0.27, 0.78]
			Placebo	136	124 (91.2)	0.06 (0.42)	-1.1	-0.21	0.06	0.31	1.6	
		Week 36	Tezepelumab	135	121 (89.6)	0.27 (0.49)	-0.8	-0.06	0.16	0.46	1.7	0.48 [0.23, 0.74]
			Placebo	136	122 (89.7)	0.05 (0.42)	-1.1	-0.21	0.04	0.29	1.3	
		Week 52	Tezepelumab	135	120 (88.9)	0.29 (0.49)	-1.0	-0.03	0.23	0.52	1.7	0.58 [0.32, 0.85]
			Placebo	136	113 (83.1)	0.03 (0.38)	-1.0	-0.18	-0.01	0.21	1.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Absolute values	Baseline	Tezepelumab	245	245 (100.0)	1.54 (0.53)	0.4	1.19	1.47	1.87	3.2	
			Placebo	235	235 (100.0)	1.61 (0.55)	0.4	1.25	1.55	1.95	3.6	
		Week 2	Tezepelumab	245	237 (96.7)	1.71 (0.55)	0.6	1.30	1.60	2.07	3.4	
			Placebo	235	221 (94.0)	1.68 (0.60)	0.4	1.29	1.60	1.99	4.0	
		Week 4	Tezepelumab	245	243 (99.2)	1.71 (0.56)	0.6	1.28	1.65	2.09	3.2	
			Placebo	235	230 (97.9)	1.70 (0.59)	0.4	1.31	1.65	2.04	3.7	
		Week 8	Tezepelumab	245	244 (99.6)	1.76 (0.57)	0.6	1.31	1.69	2.15	3.4	
			Placebo	235	225 (95.7)	1.71 (0.62)	0.4	1.31	1.61	2.05	4.3	
		Week 12	Tezepelumab	245	240 (98.0)	1.77 (0.56)	0.6	1.38	1.69	2.11	3.5	
			Placebo	235	223 (94.9)	1.70 (0.61)	0.5	1.31	1.63	2.06	4.3	
		Week 16	Tezepelumab	245	237 (96.7)	1.77 (0.55)	0.6	1.36	1.68	2.11	3.5	
			Placebo	235	217 (92.3)	1.70 (0.60)	0.5	1.31	1.65	2.04	4.4	
		Week 24	Tezepelumab	245	235 (95.9)	1.75 (0.55)	0.6	1.32	1.71	2.10	3.4	
			Placebo	235	215 (91.5)	1.68 (0.58)	0.6	1.28	1.64	2.04	4.3	
		Week 36	Tezepelumab	245	222 (90.6)	1.75 (0.56)	0.6	1.30	1.69	2.13	3.3	
			Placebo	235	206 (87.7)	1.74 (0.62)	0.6	1.28	1.66	2.20	4.3	
		Week 52	Tezepelumab	245	217 (88.6)	1.75 (0.58)	0.6	1.36	1.69	2.11	3.4	
			Placebo	235	195 (83.0)	1.69 (0.60)	0.6	1.27	1.61	2.07	3.9	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Change from baseline	Week 2	Tezepelumab	245	237 (96.7)	0.17 (0.29)	-0.6	0.01	0.12	0.28	1.3	0.33 [0.14, 0.51]
			Placebo	235	221 (94.0)	0.06 (0.35)	-1.8	-0.08	0.03	0.17	1.2	
		Week 4	Tezepelumab	245	243 (99.2)	0.17 (0.30)	-0.9	0.00	0.13	0.30	1.2	0.25 [0.07, 0.43]
			Placebo	235	230 (97.9)	0.09 (0.33)	-1.0	-0.08	0.06	0.24	1.2	
		Week 8	Tezepelumab	245	244 (99.6)	0.22 (0.36)	-0.8	-0.01	0.16	0.40	1.4	0.37 [0.19, 0.55]
			Placebo	235	225 (95.7)	0.09 (0.31)	-0.8	-0.10	0.06	0.24	1.6	
		Week 12	Tezepelumab	245	240 (98.0)	0.23 (0.35)	-0.7	0.00	0.18	0.40	1.4	0.39 [0.21, 0.58]
			Placebo	235	223 (94.9)	0.09 (0.37)	-1.5	-0.09	0.05	0.24	1.7	
		Week 16	Tezepelumab	245	237 (96.7)	0.23 (0.34)	-0.6	0.00	0.18	0.38	1.4	0.40 [0.21, 0.58]
			Placebo	235	217 (92.3)	0.09 (0.35)	-1.0	-0.07	0.04	0.24	1.8	
		Week 24	Tezepelumab	245	235 (95.9)	0.21 (0.38)	-1.0	-0.02	0.17	0.41	1.6	0.37 [0.19, 0.56]
			Placebo	235	215 (91.5)	0.07 (0.35)	-0.9	-0.11	0.03	0.22	1.7	
		Week 36	Tezepelumab	245	222 (90.6)	0.22 (0.37)	-1.0	-0.02	0.16	0.46	1.4	0.28 [0.09, 0.47]
			Placebo	235	206 (87.7)	0.12 (0.36)	-0.8	-0.12	0.06	0.28	1.7	
		Week 52	Tezepelumab	245	217 (88.6)	0.21 (0.37)	-1.0	-0.01	0.16	0.44	1.3	0.38 [0.18, 0.57]
			Placebo	235	195 (83.0)	0.08 (0.32)	-0.8	-0.11	0.07	0.23	1.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Absolute values	Baseline	Tezepelumab	304	304 (100.0)	1.81 (0.69)	0.4	1.31	1.72	2.20	4.1	
			Placebo	318	318 (100.0)	1.86 (0.69)	0.4	1.37	1.75	2.23	4.5	
		Week 2	Tezepelumab	304	296 (97.4)	2.02 (0.71)	0.6	1.49	1.96	2.48	4.3	
			Placebo	318	303 (95.3)	1.92 (0.71)	0.4	1.41	1.85	2.34	4.1	
		Week 4	Tezepelumab	304	303 (99.7)	2.04 (0.73)	0.7	1.51	1.99	2.54	4.3	
			Placebo	318	313 (98.4)	1.92 (0.69)	0.4	1.44	1.84	2.27	4.8	
		Week 8	Tezepelumab	304	300 (98.7)	2.06 (0.74)	0.6	1.50	2.01	2.48	4.7	
			Placebo	318	311 (97.8)	1.95 (0.73)	0.4	1.42	1.87	2.35	4.6	
		Week 12	Tezepelumab	304	296 (97.4)	2.07 (0.74)	0.6	1.57	1.97	2.49	4.7	
			Placebo	318	307 (96.5)	1.96 (0.73)	0.5	1.43	1.87	2.40	4.6	
		Week 16	Tezepelumab	304	294 (96.7)	2.09 (0.76)	0.6	1.56	2.02	2.54	4.9	
			Placebo	318	301 (94.7)	1.94 (0.73)	0.5	1.41	1.83	2.32	4.7	
		Week 24	Tezepelumab	304	286 (94.1)	2.06 (0.72)	0.6	1.59	1.98	2.51	4.4	
			Placebo	318	291 (91.5)	1.94 (0.72)	0.6	1.42	1.84	2.24	4.8	
		Week 36	Tezepelumab	304	275 (90.5)	2.06 (0.75)	0.5	1.49	1.99	2.49	4.5	
			Placebo	318	280 (88.1)	1.98 (0.74)	0.6	1.48	1.87	2.34	4.6	
		Week 52	Tezepelumab	304	270 (88.8)	2.07 (0.75)	0.6	1.57	2.01	2.51	4.3	
			Placebo	318	263 (82.7)	1.94 (0.76)	0.6	1.37	1.81	2.33	4.5	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Change from baseline	Week 2	Tezepelumab	304	296 (97.4)	0.20 (0.35)	-0.7	0.00	0.14	0.37	1.5	0.44 [0.28, 0.60]
			Placebo	318	303 (95.3)	0.05 (0.36)	-1.8	-0.12	0.01	0.18	1.2	
		Week 4	Tezepelumab	304	303 (99.7)	0.23 (0.38)	-0.9	0.01	0.16	0.38	1.8	0.42 [0.26, 0.58]
			Placebo	318	313 (98.4)	0.07 (0.39)	-1.8	-0.12	0.04	0.24	1.6	
		Week 8	Tezepelumab	304	300 (98.7)	0.26 (0.43)	-0.8	-0.03	0.18	0.50	1.8	0.47 [0.31, 0.63]
			Placebo	318	311 (97.8)	0.08 (0.34)	-0.8	-0.12	0.05	0.26	1.6	
		Week 12	Tezepelumab	304	296 (97.4)	0.26 (0.42)	-0.8	-0.03	0.17	0.46	2.0	0.41 [0.25, 0.57]
			Placebo	318	307 (96.5)	0.10 (0.39)	-1.5	-0.10	0.05	0.27	1.7	
		Week 16	Tezepelumab	304	294 (96.7)	0.28 (0.43)	-0.8	0.01	0.20	0.47	2.0	0.50 [0.33, 0.66]
			Placebo	318	301 (94.7)	0.08 (0.37)	-1.2	-0.12	0.02	0.24	1.8	
		Week 24	Tezepelumab	304	286 (94.1)	0.26 (0.43)	-1.0	-0.04	0.22	0.48	1.7	0.46 [0.29, 0.62]
			Placebo	318	291 (91.5)	0.07 (0.39)	-0.9	-0.15	0.03	0.27	1.7	
		Week 36	Tezepelumab	304	275 (90.5)	0.26 (0.44)	-1.0	-0.05	0.20	0.52	1.7	0.38 [0.21, 0.55]
			Placebo	318	280 (88.1)	0.10 (0.40)	-1.1	-0.16	0.06	0.29	1.7	
		Week 52	Tezepelumab	304	270 (88.8)	0.27 (0.44)	-1.0	-0.01	0.21	0.52	1.7	0.49 [0.31, 0.66]
			Placebo	318	263 (82.7)	0.07 (0.35)	-1.0	-0.15	0.05	0.23	1.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Absolute values	Baseline	Tezepelumab	76	76 (100.0)	1.45 (0.50)	0.7	1.16	1.40	1.58	3.2	
			Placebo	53	53 (100.0)	1.45 (0.48)	0.7	1.08	1.38	1.70	2.6	
		Week 2	Tezepelumab	76	74 (97.4)	1.52 (0.48)	0.6	1.23	1.44	1.70	3.1	
			Placebo	53	50 (94.3)	1.52 (0.50)	0.7	1.11	1.45	1.68	3.1	
		Week 4	Tezepelumab	76	74 (97.4)	1.54 (0.49)	0.6	1.20	1.49	1.76	3.1	
			Placebo	53	50 (94.3)	1.53 (0.50)	0.7	1.18	1.46	1.79	3.1	
		Week 8	Tezepelumab	76	74 (97.4)	1.55 (0.47)	0.6	1.23	1.50	1.82	2.9	
			Placebo	53	50 (94.3)	1.53 (0.50)	0.7	1.23	1.53	1.76	3.2	
		Week 12	Tezepelumab	76	73 (96.1)	1.57 (0.45)	0.6	1.24	1.52	1.80	2.7	
			Placebo	53	50 (94.3)	1.49 (0.49)	0.7	1.18	1.48	1.69	3.1	
		Week 16	Tezepelumab	76	73 (96.1)	1.59 (0.51)	0.6	1.26	1.52	1.84	3.4	
			Placebo	53	49 (92.5)	1.50 (0.46)	0.8	1.19	1.44	1.68	3.0	
		Week 24	Tezepelumab	76	70 (92.1)	1.54 (0.48)	0.6	1.19	1.53	1.78	2.8	
			Placebo	53	48 (90.6)	1.49 (0.46)	0.6	1.18	1.45	1.74	3.0	
		Week 36	Tezepelumab	76	68 (89.5)	1.57 (0.52)	0.6	1.16	1.52	1.86	3.2	
			Placebo	53	48 (90.6)	1.50 (0.47)	0.7	1.17	1.41	1.77	3.1	
		Week 52	Tezepelumab	76	67 (88.2)	1.58 (0.53)	0.7	1.15	1.47	1.81	3.3	
			Placebo	53	45 (84.9)	1.48 (0.49)	0.7	1.14	1.48	1.62	2.8	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Change from baseline	Week 2	Tezepelumab	76	74 (97.4)	0.09 (0.18)	-0.4	-0.01	0.07	0.21	0.7	0.16 [-0.20, 0.52]
			Placebo	53	50 (94.3)	0.05 (0.24)	-0.6	-0.07	0.03	0.13	0.7	
		Week 4	Tezepelumab	76	74 (97.4)	0.11 (0.21)	-0.3	-0.04	0.08	0.23	0.8	0.04 [-0.32, 0.40]
			Placebo	53	50 (94.3)	0.10 (0.29)	-0.9	-0.03	0.06	0.23	0.9	
		Week 8	Tezepelumab	76	74 (97.4)	0.14 (0.28)	-0.6	-0.04	0.08	0.27	1.0	0.18 [-0.18, 0.54]
			Placebo	53	50 (94.3)	0.09 (0.28)	-0.9	-0.06	0.09	0.24	0.7	
		Week 12	Tezepelumab	76	73 (96.1)	0.17 (0.28)	-0.7	0.01	0.19	0.31	1.2	0.41 [0.04, 0.77]
			Placebo	53	50 (94.3)	0.05 (0.28)	-1.1	-0.10	0.02	0.22	0.7	
		Week 16	Tezepelumab	76	73 (96.1)	0.16 (0.27)	-0.4	0.00	0.11	0.33	1.2	0.38 [0.01, 0.74]
			Placebo	53	49 (92.5)	0.06 (0.27)	-1.0	-0.08	0.04	0.25	0.6	
		Week 24	Tezepelumab	76	70 (92.1)	0.14 (0.26)	-0.4	-0.04	0.14	0.30	1.0	0.35 [-0.02, 0.72]
			Placebo	53	48 (90.6)	0.05 (0.29)	-1.1	-0.09	0.06	0.18	0.7	
		Week 36	Tezepelumab	76	68 (89.5)	0.14 (0.26)	-0.6	-0.03	0.08	0.32	1.0	0.39 [0.02, 0.77]
			Placebo	53	48 (90.6)	0.04 (0.27)	-0.6	-0.16	0.01	0.17	0.6	
		Week 52	Tezepelumab	76	67 (88.2)	0.13 (0.25)	-0.5	-0.03	0.08	0.26	0.9	0.44 [0.06, 0.82]
			Placebo	53	45 (84.9)	0.01 (0.34)	-1.0	-0.17	0.03	0.17	0.7	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Absolute values	Baseline	Tezepelumab	204	204 (100.0)	1.78 (0.65)	0.4	1.29	1.70	2.15	4.1	
			Placebo	214	214 (100.0)	1.86 (0.68)	0.6	1.33	1.77	2.26	4.1	
		Week 2	Tezepelumab	204	201 (98.5)	1.94 (0.70)	0.6	1.43	1.84	2.42	4.3	
			Placebo	214	205 (95.8)	1.93 (0.70)	0.7	1.42	1.83	2.33	4.1	
		Week 4	Tezepelumab	204	201 (98.5)	1.97 (0.71)	0.6	1.45	1.91	2.45	4.3	
			Placebo	214	206 (96.3)	1.92 (0.69)	0.5	1.42	1.87	2.29	4.8	
		Week 8	Tezepelumab	204	200 (98.0)	1.99 (0.74)	0.6	1.43	1.96	2.41	4.7	
			Placebo	214	208 (97.2)	1.94 (0.73)	0.6	1.40	1.87	2.36	4.6	
		Week 12	Tezepelumab	204	198 (97.1)	1.98 (0.73)	0.6	1.50	1.91	2.42	4.7	
			Placebo	214	208 (97.2)	1.95 (0.74)	0.5	1.40	1.87	2.41	4.6	
		Week 16	Tezepelumab	204	198 (97.1)	2.02 (0.74)	0.6	1.49	1.92	2.48	4.9	
			Placebo	214	204 (95.3)	1.95 (0.75)	0.5	1.36	1.84	2.35	4.7	
		Week 24	Tezepelumab	204	190 (93.1)	1.99 (0.72)	0.6	1.48	1.90	2.50	4.4	
			Placebo	214	195 (91.1)	1.91 (0.72)	0.8	1.39	1.86	2.24	4.8	
		Week 36	Tezepelumab	204	187 (91.7)	1.99 (0.74)	0.6	1.42	1.92	2.47	4.5	
			Placebo	214	193 (90.2)	1.95 (0.74)	0.6	1.43	1.84	2.35	4.3	
		Week 52	Tezepelumab	204	182 (89.2)	1.99 (0.74)	0.7	1.48	1.89	2.47	4.2	
			Placebo	214	181 (84.6)	1.90 (0.74)	0.6	1.34	1.74	2.30	4.3	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Change from baseline	Week 2	Tezepelumab	204	201 (98.5)	0.18 (0.34)	-0.7	-0.01	0.13	0.33	1.5	0.36 [0.16, 0.56]
			Placebo	214	205 (95.8)	0.06 (0.32)	-0.7	-0.12	0.01	0.16	1.2	
		Week 4	Tezepelumab	204	201 (98.5)	0.21 (0.39)	-0.9	-0.03	0.14	0.33	1.8	0.33 [0.14, 0.53]
			Placebo	214	206 (96.3)	0.08 (0.38)	-1.0	-0.12	0.05	0.23	1.6	
		Week 8	Tezepelumab	204	200 (98.0)	0.23 (0.44)	-0.8	-0.06	0.15	0.45	1.8	0.39 [0.19, 0.58]
			Placebo	214	208 (97.2)	0.08 (0.34)	-0.8	-0.12	0.05	0.24	1.6	
		Week 12	Tezepelumab	204	198 (97.1)	0.23 (0.42)	-0.7	-0.04	0.17	0.43	1.9	0.34 [0.15, 0.54]
			Placebo	214	208 (97.2)	0.09 (0.39)	-1.5	-0.10	0.04	0.22	1.7	
		Week 16	Tezepelumab	204	198 (97.1)	0.26 (0.43)	-0.6	0.00	0.16	0.43	2.0	0.44 [0.24, 0.64]
			Placebo	214	204 (95.3)	0.08 (0.39)	-1.2	-0.12	0.03	0.26	1.8	
		Week 24	Tezepelumab	204	190 (93.1)	0.23 (0.41)	-1.0	-0.05	0.22	0.43	1.5	0.41 [0.21, 0.61]
			Placebo	214	195 (91.1)	0.07 (0.41)	-0.9	-0.16	0.03	0.24	1.7	
		Week 36	Tezepelumab	204	187 (91.7)	0.24 (0.43)	-1.0	-0.05	0.16	0.49	1.7	0.34 [0.14, 0.55]
			Placebo	214	193 (90.2)	0.09 (0.41)	-1.1	-0.17	0.04	0.27	1.7	
		Week 52	Tezepelumab	204	182 (89.2)	0.22 (0.43)	-1.0	-0.03	0.15	0.44	1.7	0.41 [0.20, 0.62]
			Placebo	214	181 (84.6)	0.06 (0.34)	-1.0	-0.14	0.02	0.23	1.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Absolute values	Baseline	Tezepelumab	176	176 (100.0)	1.70 (0.70)	0.5	1.22	1.55	2.02	4.0	
			Placebo	157	157 (100.0)	1.72 (0.68)	0.4	1.33	1.62	2.07	4.5	
		Week 2	Tezepelumab	176	169 (96.0)	1.89 (0.70)	0.7	1.35	1.78	2.32	4.1	
			Placebo	157	148 (94.3)	1.77 (0.69)	0.4	1.34	1.66	2.15	4.0	
		Week 4	Tezepelumab	176	176 (100.0)	1.91 (0.73)	0.7	1.35	1.73	2.39	4.2	
			Placebo	157	157 (100.0)	1.78 (0.66)	0.4	1.39	1.68	2.09	4.2	
		Week 8	Tezepelumab	176	174 (98.9)	1.93 (0.71)	0.7	1.36	1.80	2.43	4.2	
			Placebo	157	153 (97.5)	1.82 (0.70)	0.4	1.36	1.72	2.16	4.3	
		Week 12	Tezepelumab	176	171 (97.2)	1.96 (0.72)	0.7	1.46	1.82	2.37	4.3	
			Placebo	157	149 (94.9)	1.82 (0.68)	0.6	1.36	1.72	2.15	4.3	
		Week 16	Tezepelumab	176	169 (96.0)	1.96 (0.74)	0.6	1.43	1.83	2.34	4.3	
			Placebo	157	146 (93.0)	1.79 (0.66)	0.7	1.33	1.70	2.14	4.3	
		Week 24	Tezepelumab	176	166 (94.3)	1.91 (0.69)	0.6	1.44	1.78	2.30	4.0	
			Placebo	157	144 (91.7)	1.82 (0.69)	0.6	1.41	1.69	2.16	4.8	
		Week 36	Tezepelumab	176	156 (88.6)	1.93 (0.73)	0.5	1.39	1.80	2.33	4.4	
			Placebo	157	135 (86.0)	1.86 (0.70)	0.7	1.40	1.75	2.22	4.6	
		Week 52	Tezepelumab	176	155 (88.1)	1.95 (0.74)	0.6	1.39	1.82	2.37	4.3	
			Placebo	157	127 (80.9)	1.84 (0.74)	0.7	1.30	1.66	2.27	4.5	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Change from baseline	Week 2	Tezepelumab	176	169 (96.0)	0.19 (0.32)	-0.6	0.00	0.12	0.29	1.4	0.43 [0.21, 0.66]
			Placebo	157	148 (94.3)	0.03 (0.38)	-1.8	-0.10	0.02	0.20	1.0	
		Week 4	Tezepelumab	176	176 (100.0)	0.21 (0.32)	-0.7	0.02	0.15	0.36	1.6	0.41 [0.20, 0.63]
			Placebo	157	157 (100.0)	0.07 (0.38)	-1.8	-0.10	0.04	0.26	1.1	
		Week 8	Tezepelumab	176	174 (98.9)	0.25 (0.36)	-0.6	0.00	0.17	0.44	1.4	0.46 [0.24, 0.68]
			Placebo	157	153 (97.5)	0.09 (0.32)	-0.9	-0.10	0.06	0.28	1.2	
		Week 12	Tezepelumab	176	171 (97.2)	0.26 (0.38)	-0.8	0.02	0.19	0.44	2.0	0.46 [0.23, 0.68]
			Placebo	157	149 (94.9)	0.09 (0.37)	-1.2	-0.10	0.06	0.29	1.2	
		Week 16	Tezepelumab	176	169 (96.0)	0.25 (0.39)	-0.8	0.01	0.20	0.39	1.7	0.51 [0.29, 0.74]
			Placebo	157	146 (93.0)	0.07 (0.32)	-1.0	-0.09	0.02	0.21	1.0	
		Week 24	Tezepelumab	176	166 (94.3)	0.24 (0.40)	-1.0	-0.03	0.16	0.43	1.7	0.46 [0.23, 0.68]
			Placebo	157	144 (91.7)	0.07 (0.32)	-1.1	-0.12	0.05	0.27	0.9	
		Week 36	Tezepelumab	176	156 (88.6)	0.23 (0.39)	-0.5	-0.04	0.16	0.40	1.6	0.39 [0.16, 0.63]
			Placebo	157	135 (86.0)	0.08 (0.34)	-0.8	-0.15	0.06	0.33	1.0	
		Week 52	Tezepelumab	176	155 (88.1)	0.26 (0.40)	-0.8	-0.01	0.21	0.52	1.6	0.52 [0.28, 0.76]
			Placebo	157	127 (80.9)	0.06 (0.35)	-1.0	-0.15	0.07	0.21	1.1	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Absolute values	Baseline	Tezepelumab	239	239 (100.0)	1.78 (0.66)	0.6	1.29	1.64	2.11	3.8	
			Placebo	235	235 (100.0)	1.83 (0.74)	0.6	1.30	1.68	2.23	4.5	
		Week 2	Tezepelumab	239	235 (98.3)	1.96 (0.70)	0.7	1.42	1.86	2.46	4.0	
			Placebo	235	222 (94.5)	1.88 (0.75)	0.6	1.36	1.74	2.31	4.1	
		Week 4	Tezepelumab	239	237 (99.2)	1.98 (0.73)	0.7	1.41	1.89	2.50	4.3	
			Placebo	235	227 (96.6)	1.90 (0.75)	0.5	1.36	1.79	2.28	4.8	
		Week 8	Tezepelumab	239	236 (98.7)	1.99 (0.75)	0.7	1.39	1.86	2.46	4.7	
			Placebo	235	226 (96.2)	1.95 (0.77)	0.6	1.37	1.88	2.35	4.6	
		Week 12	Tezepelumab	239	231 (96.7)	2.00 (0.74)	0.8	1.46	1.88	2.42	4.7	
			Placebo	235	223 (94.9)	1.92 (0.78)	0.5	1.35	1.75	2.40	4.6	
		Week 16	Tezepelumab	239	231 (96.7)	2.03 (0.76)	0.8	1.43	1.91	2.51	4.9	
			Placebo	235	219 (93.2)	1.92 (0.78)	0.5	1.31	1.77	2.33	4.7	
		Week 24	Tezepelumab	239	224 (93.7)	1.97 (0.73)	0.7	1.40	1.87	2.42	4.4	
			Placebo	235	212 (90.2)	1.92 (0.77)	0.6	1.37	1.84	2.25	4.8	
		Week 36	Tezepelumab	239	213 (89.1)	2.00 (0.74)	0.7	1.38	1.92	2.42	4.5	
			Placebo	235	203 (86.4)	1.97 (0.78)	0.6	1.41	1.83	2.37	4.6	
		Week 52	Tezepelumab	239	208 (87.0)	2.00 (0.76)	0.6	1.43	1.88	2.43	4.3	
			Placebo	235	186 (79.1)	1.95 (0.82)	0.6	1.31	1.79	2.41	4.5	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Change from baseline	Week 2	Tezepelumab	239	235 (98.3)	0.19 (0.31)	-0.6	0.00	0.14	0.31	1.5	0.46 [0.27, 0.64]
			Placebo	235	222 (94.5)	0.03 (0.37)	-1.8	-0.13	-0.01	0.16	1.1	
		Week 4	Tezepelumab	239	237 (99.2)	0.21 (0.35)	-0.7	-0.02	0.14	0.33	1.7	0.34 [0.15, 0.52]
			Placebo	235	227 (96.6)	0.08 (0.39)	-1.8	-0.11	0.05	0.25	1.6	
		Week 8	Tezepelumab	239	236 (98.7)	0.23 (0.40)	-0.8	-0.04	0.14	0.43	1.8	0.33 [0.15, 0.51]
			Placebo	235	226 (96.2)	0.10 (0.34)	-0.8	-0.10	0.06	0.28	1.4	
		Week 12	Tezepelumab	239	231 (96.7)	0.22 (0.38)	-0.8	-0.04	0.17	0.42	1.9	0.35 [0.16, 0.53]
			Placebo	235	223 (94.9)	0.09 (0.40)	-1.5	-0.11	0.04	0.29	1.4	
		Week 16	Tezepelumab	239	231 (96.7)	0.25 (0.40)	-0.8	0.00	0.17	0.40	2.0	0.43 [0.25, 0.62]
			Placebo	235	219 (93.2)	0.08 (0.36)	-1.2	-0.12	0.04	0.25	1.5	
		Week 24	Tezepelumab	239	224 (93.7)	0.22 (0.40)	-1.0	-0.06	0.16	0.43	1.7	0.39 [0.20, 0.57]
			Placebo	235	212 (90.2)	0.07 (0.37)	-0.9	-0.12	0.03	0.26	1.6	
		Week 36	Tezepelumab	239	213 (89.1)	0.23 (0.40)	-0.8	-0.06	0.16	0.46	1.7	0.31 [0.11, 0.50]
			Placebo	235	203 (86.4)	0.11 (0.39)	-1.1	-0.15	0.04	0.30	1.3	
		Week 52	Tezepelumab	239	208 (87.0)	0.23 (0.41)	-0.8	-0.04	0.16	0.44	1.7	0.35 [0.15, 0.55]
			Placebo	235	186 (79.1)	0.09 (0.34)	-0.9	-0.12	0.06	0.23	1.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Absolute values	Baseline	Tezepelumab	21	21 (100.0)	1.73 (0.87)	0.8	1.07	1.37	2.37	4.0	
			Placebo	19	19 (100.0)	1.72 (0.65)	0.9	1.12	1.77	2.10	3.2	
		Week 2	Tezepelumab	21	17 (81.0)	1.89 (0.84)	0.9	1.34	1.72	2.17	4.1	
			Placebo	19	19 (100.0)	1.87 (0.62)	0.9	1.40	1.90	2.28	3.1	
		Week 4	Tezepelumab	21	20 (95.2)	1.85 (0.78)	1.0	1.34	1.69	2.10	4.2	
			Placebo	19	19 (100.0)	1.80 (0.56)	1.0	1.31	1.87	2.09	3.1	
		Week 8	Tezepelumab	21	20 (95.2)	1.92 (0.73)	1.0	1.43	1.83	2.17	4.1	
			Placebo	19	19 (100.0)	1.74 (0.65)	0.8	1.38	1.55	2.16	3.4	
		Week 12	Tezepelumab	21	20 (95.2)	1.93 (0.82)	0.9	1.50	1.73	2.47	4.2	
			Placebo	19	19 (100.0)	1.86 (0.63)	1.0	1.35	1.74	2.44	3.3	
		Week 16	Tezepelumab	21	19 (90.5)	1.78 (0.71)	1.0	1.37	1.65	2.13	4.2	
			Placebo	19	18 (94.7)	1.83 (0.62)	0.8	1.38	1.81	2.16	3.1	
		Week 24	Tezepelumab	21	17 (81.0)	1.82 (0.72)	0.9	1.44	1.63	2.11	4.0	
			Placebo	19	17 (89.5)	1.72 (0.65)	0.9	1.30	1.68	1.96	3.3	
		Week 36	Tezepelumab	21	17 (81.0)	1.77 (0.81)	0.9	1.35	1.61	1.91	4.4	
			Placebo	19	18 (94.7)	1.84 (0.64)	1.0	1.28	2.02	2.17	3.3	
		Week 52	Tezepelumab	21	17 (81.0)	1.84 (0.76)	0.8	1.38	1.76	2.10	4.2	
			Placebo	19	16 (84.2)	1.74 (0.71)	0.7	1.06	1.74	2.31	3.1	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Change from baseline	Week 2	Tezepelumab	21	17 (81.0)	0.25 (0.46)	-0.7	0.03	0.21	0.53	1.4	0.24 [-0.42, 0.89]
			Placebo	19	19 (100.0)	0.15 (0.33)	-0.3	-0.06	0.01	0.31	1.0	
		Week 4	Tezepelumab	21	20 (95.2)	0.19 (0.35)	-0.5	0.06	0.18	0.35	1.1	0.30 [-0.33, 0.93]
			Placebo	19	19 (100.0)	0.08 (0.36)	-0.6	-0.13	-0.01	0.34	1.1	
		Week 8	Tezepelumab	21	20 (95.2)	0.26 (0.43)	-0.5	-0.06	0.28	0.49	1.1	0.59 [-0.05, 1.23]
			Placebo	19	19 (100.0)	0.03 (0.34)	-0.8	-0.19	0.06	0.32	0.5	
		Week 12	Tezepelumab	21	20 (95.2)	0.28 (0.42)	-0.4	0.03	0.18	0.48	1.5	0.34 [-0.29, 0.98]
			Placebo	19	19 (100.0)	0.14 (0.36)	-0.4	-0.08	0.13	0.40	1.0	
		Week 16	Tezepelumab	21	19 (90.5)	0.19 (0.41)	-0.5	-0.08	0.13	0.32	1.4	0.12 [-0.52, 0.77]
			Placebo	19	18 (94.7)	0.14 (0.40)	-0.6	-0.03	0.10	0.33	1.0	
		Week 24	Tezepelumab	21	17 (81.0)	0.25 (0.32)	-0.2	-0.05	0.23	0.39	1.1	0.60 [-0.09, 1.28]
			Placebo	19	17 (89.5)	0.03 (0.39)	-0.5	-0.19	0.02	0.24	1.1	
		Week 36	Tezepelumab	21	17 (81.0)	0.17 (0.30)	-0.2	-0.02	0.05	0.45	0.7	0.13 [-0.53, 0.80]
			Placebo	19	18 (94.7)	0.13 (0.27)	-0.2	0.02	0.06	0.16	1.0	
		Week 52	Tezepelumab	21	17 (81.0)	0.26 (0.40)	-0.3	-0.03	0.14	0.55	1.1	0.70 [-0.00, 1.41]
			Placebo	19	16 (84.2)	-0.01 (0.37)	-0.5	-0.21	-0.09	0.12	1.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Absolute values	Baseline	Tezepelumab	107	107 (100.0)	1.67 (0.67)	0.4	1.20	1.62	2.09	4.1	
			Placebo	103	103 (100.0)	1.75 (0.55)	0.4	1.37	1.71	2.11	3.1	
		Week 2	Tezepelumab	107	106 (99.1)	1.84 (0.68)	0.6	1.30	1.76	2.29	4.3	
			Placebo	103	100 (97.1)	1.82 (0.61)	0.4	1.46	1.74	2.21	3.9	
		Week 4	Tezepelumab	107	107 (100.0)	1.90 (0.68)	0.7	1.44	1.77	2.38	3.7	
			Placebo	103	103 (100.0)	1.80 (0.57)	0.4	1.44	1.72	2.13	3.7	
		Week 8	Tezepelumab	107	105 (98.1)	1.94 (0.68)	0.6	1.47	1.84	2.36	4.7	
			Placebo	103	103 (100.0)	1.80 (0.62)	0.4	1.39	1.76	2.20	4.3	
		Week 12	Tezepelumab	107	105 (98.1)	1.95 (0.68)	0.6	1.50	1.92	2.32	3.8	
			Placebo	103	101 (98.1)	1.84 (0.62)	0.7	1.46	1.79	2.23	4.3	
		Week 16	Tezepelumab	107	105 (98.1)	1.97 (0.73)	0.6	1.49	1.87	2.44	4.7	
			Placebo	103	100 (97.1)	1.84 (0.60)	0.7	1.47	1.73	2.15	4.4	
		Week 24	Tezepelumab	107	104 (97.2)	1.95 (0.65)	0.6	1.56	1.82	2.32	4.0	
			Placebo	103	98 (95.1)	1.83 (0.58)	0.7	1.45	1.72	2.14	4.3	
		Week 36	Tezepelumab	107	101 (94.4)	1.95 (0.72)	0.5	1.51	1.80	2.38	4.4	
			Placebo	103	94 (91.3)	1.81 (0.62)	0.7	1.42	1.70	2.19	4.3	
		Week 52	Tezepelumab	107	100 (93.5)	1.96 (0.70)	0.8	1.49	1.81	2.45	4.2	
			Placebo	103	94 (91.3)	1.77 (0.58)	0.7	1.38	1.66	2.16	3.4	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Change from baseline	Week 2	Tezepelumab	107	106 (99.1)	0.17 (0.35)	-0.6	-0.01	0.10	0.29	1.3	0.33 [0.05, 0.60]
			Placebo	103	100 (97.1)	0.06 (0.32)	-0.7	-0.09	0.04	0.18	1.2	
		Week 4	Tezepelumab	107	107 (100.0)	0.22 (0.39)	-0.9	0.02	0.14	0.37	1.8	0.47 [0.19, 0.74]
			Placebo	103	103 (100.0)	0.05 (0.35)	-0.9	-0.14	0.00	0.20	1.1	
		Week 8	Tezepelumab	107	105 (98.1)	0.28 (0.42)	-0.8	0.03	0.18	0.50	1.7	0.60 [0.33, 0.88]
			Placebo	103	103 (100.0)	0.05 (0.34)	-0.9	-0.16	0.01	0.22	1.6	
		Week 12	Tezepelumab	107	105 (98.1)	0.29 (0.45)	-0.7	0.04	0.20	0.51	2.0	0.52 [0.24, 0.80]
			Placebo	103	101 (98.1)	0.08 (0.36)	-1.1	-0.07	0.04	0.19	1.7	
		Week 16	Tezepelumab	107	105 (98.1)	0.30 (0.43)	-0.6	0.02	0.22	0.51	1.7	0.59 [0.31, 0.87]
			Placebo	103	100 (97.1)	0.06 (0.36)	-1.0	-0.12	0.00	0.23	1.8	
		Week 24	Tezepelumab	107	104 (97.2)	0.27 (0.44)	-1.0	-0.02	0.24	0.55	1.6	0.51 [0.23, 0.79]
			Placebo	103	98 (95.1)	0.06 (0.38)	-1.1	-0.14	0.06	0.22	1.7	
		Week 36	Tezepelumab	107	101 (94.4)	0.27 (0.46)	-1.0	0.01	0.23	0.54	1.5	0.55 [0.27, 0.84]
			Placebo	103	94 (91.3)	0.04 (0.40)	-1.0	-0.22	0.02	0.27	1.7	
		Week 52	Tezepelumab	107	100 (93.5)	0.28 (0.45)	-1.0	-0.01	0.27	0.53	1.6	0.64 [0.35, 0.93]
			Placebo	103	94 (91.3)	0.01 (0.35)	-1.0	-0.22	0.02	0.23	0.8	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Absolute values	Baseline	Tezepelumab	13	13 (100.0)	1.56 (0.58)	0.7	1.26	1.62	1.81	2.6	
			Placebo	14	14 (100.0)	1.68 (0.52)	1.1	1.27	1.59	2.17	2.6	
		Week 2	Tezepelumab	13	12 (92.3)	1.74 (0.60)	0.6	1.36	1.82	2.18	2.7	
			Placebo	14	12 (85.7)	1.81 (0.51)	1.2	1.30	1.82	2.18	2.7	
		Week 4	Tezepelumab	13	13 (100.0)	1.75 (0.63)	0.6	1.37	1.66	2.18	2.6	
			Placebo	14	14 (100.0)	1.81 (0.41)	1.1	1.46	1.87	2.00	2.6	
		Week 8	Tezepelumab	13	13 (100.0)	1.72 (0.62)	0.6	1.36	1.85	2.17	2.6	
			Placebo	14	13 (92.9)	1.81 (0.57)	1.1	1.34	1.68	1.99	2.9	
		Week 12	Tezepelumab	13	13 (100.0)	1.72 (0.66)	0.6	1.31	1.83	2.16	2.7	
			Placebo	14	14 (100.0)	1.81 (0.49)	1.0	1.42	1.86	2.25	2.6	
		Week 16	Tezepelumab	13	12 (92.3)	1.82 (0.62)	0.6	1.52	1.83	2.36	2.6	
			Placebo	14	13 (92.9)	1.73 (0.52)	1.0	1.35	1.69	2.09	2.7	
		Week 24	Tezepelumab	13	11 (84.6)	1.78 (0.73)	0.6	0.88	1.81	2.52	2.7	
			Placebo	14	12 (85.7)	1.67 (0.43)	0.9	1.44	1.77	2.08	2.2	
		Week 36	Tezepelumab	13	12 (92.3)	1.75 (0.64)	0.7	1.37	1.74	2.20	2.7	
			Placebo	14	13 (92.9)	1.84 (0.54)	1.0	1.62	1.72	2.27	2.8	
		Week 52	Tezepelumab	13	12 (92.3)	1.78 (0.59)	0.7	1.46	1.78	2.26	2.6	
			Placebo	14	12 (85.7)	1.75 (0.44)	1.0	1.58	1.75	2.03	2.5	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Change from baseline	Week 2	Tezepelumab	13	12 (92.3)	0.11 (0.26)	-0.3	-0.04	0.09	0.19	0.6	0.01 [-0.79, 0.81]
			Placebo	14	12 (85.7)	0.11 (0.16)	-0.1	0.02	0.11	0.22	0.3	
		Week 4	Tezepelumab	13	13 (100.0)	0.18 (0.33)	-0.2	0.02	0.11	0.25	1.1	0.17 [-0.58, 0.93]
			Placebo	14	14 (100.0)	0.13 (0.30)	-0.3	0.02	0.08	0.20	0.9	
		Week 8	Tezepelumab	13	13 (100.0)	0.16 (0.34)	-0.3	-0.05	0.13	0.21	1.2	-0.03 [-0.80, 0.74]
			Placebo	14	13 (92.9)	0.17 (0.18)	-0.2	0.07	0.15	0.26	0.5	
		Week 12	Tezepelumab	13	13 (100.0)	0.16 (0.34)	-0.2	0.04	0.07	0.17	1.1	0.11 [-0.65, 0.87]
			Placebo	14	14 (100.0)	0.13 (0.24)	-0.2	0.04	0.09	0.22	0.8	
		Week 16	Tezepelumab	13	12 (92.3)	0.19 (0.29)	-0.1	0.07	0.12	0.23	1.1	0.56 [-0.24, 1.36]
			Placebo	14	13 (92.9)	0.05 (0.22)	-0.4	-0.06	0.03	0.23	0.4	
		Week 24	Tezepelumab	13	11 (84.6)	0.15 (0.40)	-0.4	-0.05	0.13	0.23	1.2	0.18 [-0.64, 1.00]
			Placebo	14	12 (85.7)	0.08 (0.37)	-0.7	-0.17	0.07	0.32	0.8	
		Week 36	Tezepelumab	13	12 (92.3)	0.12 (0.38)	-0.2	-0.04	0.02	0.12	1.3	-0.15 [-0.94, 0.64]
			Placebo	14	13 (92.9)	0.17 (0.28)	-0.2	-0.12	0.19	0.37	0.6	
		Week 52	Tezepelumab	13	12 (92.3)	0.15 (0.25)	-0.2	0.04	0.07	0.21	0.8	0.33 [-0.48, 1.14]
			Placebo	14	12 (85.7)	0.05 (0.32)	-0.5	-0.13	0.04	0.23	0.6	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Absolute values	Baseline	Tezepelumab	64	64 (100.0)	1.84 (0.64)	0.8	1.39	1.75	2.23	3.6	
			Placebo	60	60 (100.0)	1.95 (0.82)	0.7	1.32	1.80	2.46	4.2	
		Week 2	Tezepelumab	64	64 (100.0)	2.02 (0.70)	0.7	1.46	1.95	2.44	3.9	
			Placebo	60	57 (95.0)	2.02 (0.83)	0.6	1.37	1.97	2.69	4.0	
		Week 4	Tezepelumab	64	64 (100.0)	2.05 (0.72)	0.7	1.57	2.02	2.48	4.3	
			Placebo	60	59 (98.3)	1.99 (0.85)	0.7	1.33	1.89	2.57	4.2	
		Week 8	Tezepelumab	64	64 (100.0)	2.05 (0.75)	0.8	1.54	2.08	2.44	4.7	
			Placebo	60	56 (93.3)	2.06 (0.83)	0.7	1.38	2.08	2.58	4.3	
		Week 12	Tezepelumab	64	62 (96.9)	2.02 (0.77)	0.8	1.52	1.97	2.34	4.7	
			Placebo	60	56 (93.3)	1.98 (0.89)	0.6	1.30	1.81	2.59	4.3	
		Week 16	Tezepelumab	64	62 (96.9)	2.13 (0.76)	0.9	1.65	2.04	2.43	4.9	
			Placebo	60	56 (93.3)	1.96 (0.81)	0.8	1.33	1.81	2.49	4.1	
		Week 24	Tezepelumab	64	62 (96.9)	2.04 (0.69)	0.7	1.65	1.99	2.42	4.4	
			Placebo	60	52 (86.7)	1.96 (0.87)	0.6	1.26	2.03	2.28	4.8	
		Week 36	Tezepelumab	64	60 (93.8)	2.07 (0.73)	0.8	1.55	2.03	2.50	4.5	
			Placebo	60	51 (85.0)	2.08 (0.83)	0.8	1.43	1.99	2.58	4.6	
		Week 52	Tezepelumab	64	57 (89.1)	2.06 (0.74)	0.8	1.58	2.04	2.42	4.1	
			Placebo	60	49 (81.7)	2.13 (0.88)	0.7	1.34	1.99	2.66	4.4	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Change from baseline	Week 2	Tezepelumab	64	64 (100.0)	0.18 (0.28)	-0.6	0.02	0.15	0.36	1.1	0.46 [0.10, 0.82]
			Placebo	60	57 (95.0)	0.04 (0.32)	-0.8	-0.12	0.03	0.18	1.0	
		Week 4	Tezepelumab	64	64 (100.0)	0.21 (0.35)	-0.7	0.01	0.17	0.32	1.4	0.46 [0.10, 0.82]
			Placebo	60	59 (98.3)	0.05 (0.34)	-0.7	-0.11	0.03	0.24	1.4	
		Week 8	Tezepelumab	64	64 (100.0)	0.21 (0.42)	-0.6	-0.07	0.13	0.44	1.8	0.36 [-0.00, 0.72]
			Placebo	60	56 (93.3)	0.06 (0.38)	-0.8	-0.12	0.04	0.28	1.3	
		Week 12	Tezepelumab	64	62 (96.9)	0.19 (0.44)	-0.8	-0.09	0.13	0.38	1.9	0.38 [0.01, 0.74]
			Placebo	60	56 (93.3)	0.04 (0.32)	-0.7	-0.11	0.02	0.21	1.2	
		Week 16	Tezepelumab	64	62 (96.9)	0.27 (0.42)	-0.8	0.03	0.21	0.42	2.0	0.68 [0.31, 1.05]
			Placebo	60	56 (93.3)	-0.00 (0.37)	-1.2	-0.16	0.02	0.17	1.0	
		Week 24	Tezepelumab	64	62 (96.9)	0.21 (0.35)	-0.2	-0.06	0.17	0.40	1.5	0.61 [0.23, 0.99]
			Placebo	60	52 (86.7)	-0.01 (0.38)	-0.9	-0.18	-0.04	0.13	1.6	
		Week 36	Tezepelumab	64	60 (93.8)	0.22 (0.38)	-0.5	-0.05	0.14	0.47	1.7	0.38 [0.00, 0.75]
			Placebo	60	51 (85.0)	0.08 (0.37)	-1.1	-0.14	0.12	0.31	1.1	
		Week 52	Tezepelumab	64	57 (89.1)	0.21 (0.36)	-0.6	-0.01	0.22	0.35	1.2	0.30 [-0.09, 0.68]
			Placebo	60	49 (81.7)	0.10 (0.34)	-0.8	-0.05	0.09	0.21	1.1	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Absolute values	Baseline	Tezepelumab	140	140 (100.0)	1.79 (0.67)	0.7	1.33	1.62	2.12	4.0	
			Placebo	134	134 (100.0)	1.89 (0.75)	0.6	1.33	1.79	2.26	4.5	
		Week 2	Tezepelumab	140	134 (95.7)	1.97 (0.70)	0.8	1.44	1.81	2.50	4.1	
			Placebo	134	128 (95.5)	1.97 (0.74)	0.6	1.41	1.90	2.38	4.1	
		Week 4	Tezepelumab	140	137 (97.9)	1.97 (0.73)	0.7	1.45	1.89	2.50	4.2	
			Placebo	134	129 (96.3)	1.96 (0.73)	0.5	1.45	1.93	2.27	4.8	
		Week 8	Tezepelumab	140	137 (97.9)	1.99 (0.74)	0.7	1.36	1.85	2.45	4.2	
			Placebo	134	130 (97.0)	2.01 (0.79)	0.6	1.50	1.89	2.36	4.6	
		Week 12	Tezepelumab	140	134 (95.7)	2.01 (0.74)	0.8	1.55	1.86	2.46	4.3	
			Placebo	134	131 (97.8)	2.00 (0.77)	0.5	1.47	1.90	2.45	4.6	
		Week 16	Tezepelumab	140	133 (95.0)	1.99 (0.74)	0.8	1.48	1.84	2.51	4.3	
			Placebo	134	128 (95.5)	2.00 (0.82)	0.5	1.38	1.88	2.47	4.7	
		Week 24	Tezepelumab	140	126 (90.0)	1.97 (0.74)	0.7	1.41	1.79	2.55	4.0	
			Placebo	134	125 (93.3)	1.99 (0.78)	0.6	1.46	1.90	2.28	4.8	
		Week 36	Tezepelumab	140	122 (87.1)	1.99 (0.77)	0.7	1.37	1.91	2.36	4.4	
			Placebo	134	127 (94.8)	2.03 (0.79)	0.6	1.49	1.93	2.40	4.3	
		Week 52	Tezepelumab	140	119 (85.0)	2.00 (0.78)	0.6	1.42	1.89	2.43	4.3	
			Placebo	134	112 (83.6)	2.01 (0.84)	0.6	1.39	1.91	2.46	4.5	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Change from baseline	Week 2	Tezepelumab	140	134 (95.7)	0.20 (0.34)	-0.7	0.00	0.14	0.33	1.5	0.34 [0.10, 0.59]
			Placebo	134	128 (95.5)	0.07 (0.41)	-1.8	-0.11	-0.00	0.22	1.1	
		Week 4	Tezepelumab	140	137 (97.9)	0.20 (0.34)	-0.5	-0.01	0.13	0.35	1.3	0.31 [0.07, 0.55]
			Placebo	134	129 (96.3)	0.09 (0.39)	-1.8	-0.09	0.06	0.23	1.6	
		Week 8	Tezepelumab	140	137 (97.9)	0.23 (0.42)	-0.8	-0.04	0.12	0.39	1.6	0.32 [0.07, 0.56]
			Placebo	134	130 (97.0)	0.11 (0.31)	-0.8	-0.10	0.09	0.29	1.4	
		Week 12	Tezepelumab	140	134 (95.7)	0.23 (0.36)	-0.4	0.00	0.17	0.41	1.6	0.32 [0.08, 0.57]
			Placebo	134	131 (97.8)	0.10 (0.44)	-1.5	-0.11	0.06	0.32	1.4	
		Week 16	Tezepelumab	140	133 (95.0)	0.23 (0.39)	-0.5	0.00	0.15	0.36	1.9	0.31 [0.07, 0.56]
			Placebo	134	128 (95.5)	0.11 (0.37)	-0.7	-0.10	0.04	0.27	1.5	
		Week 24	Tezepelumab	140	126 (90.0)	0.23 (0.40)	-0.7	-0.06	0.17	0.43	1.6	0.34 [0.09, 0.59]
			Placebo	134	125 (93.3)	0.09 (0.39)	-0.9	-0.11	0.05	0.27	1.6	
		Week 36	Tezepelumab	140	122 (87.1)	0.23 (0.41)	-0.8	-0.06	0.15	0.46	1.6	0.24 [-0.01, 0.49]
			Placebo	134	127 (94.8)	0.13 (0.40)	-0.8	-0.16	0.03	0.29	1.3	
		Week 52	Tezepelumab	140	119 (85.0)	0.24 (0.43)	-0.8	-0.03	0.14	0.52	1.7	0.37 [0.11, 0.63]
			Placebo	134	112 (83.6)	0.10 (0.38)	-0.9	-0.15	0.02	0.28	1.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Absolute values	Baseline	Tezepelumab	104	104 (100.0)	1.74 (0.68)	0.4	1.25	1.71	2.18	4.1	
			Placebo	104	104 (100.0)	1.72 (0.56)	0.4	1.37	1.69	2.06	3.1	
		Week 2	Tezepelumab	104	103 (99.0)	1.91 (0.69)	0.6	1.31	1.79	2.32	4.3	
			Placebo	104	100 (96.2)	1.78 (0.62)	0.4	1.45	1.68	2.14	3.9	
		Week 4	Tezepelumab	104	104 (100.0)	1.96 (0.69)	0.7	1.45	1.92	2.43	3.7	
			Placebo	104	103 (99.0)	1.77 (0.57)	0.4	1.44	1.69	2.06	3.7	
		Week 8	Tezepelumab	104	102 (98.1)	2.01 (0.69)	0.6	1.48	1.96	2.43	4.7	
			Placebo	104	103 (99.0)	1.80 (0.63)	0.4	1.39	1.74	2.23	4.3	
		Week 12	Tezepelumab	104	101 (97.1)	2.01 (0.69)	0.6	1.52	1.94	2.41	3.8	
			Placebo	104	101 (97.1)	1.82 (0.63)	0.7	1.44	1.73	2.22	4.3	
		Week 16	Tezepelumab	104	103 (99.0)	2.04 (0.75)	0.6	1.52	1.97	2.48	4.7	
			Placebo	104	99 (95.2)	1.82 (0.61)	0.7	1.43	1.71	2.14	4.4	
		Week 24	Tezepelumab	104	101 (97.1)	2.00 (0.65)	0.8	1.57	1.82	2.35	4.0	
			Placebo	104	96 (92.3)	1.82 (0.59)	0.7	1.42	1.72	2.12	4.3	
		Week 36	Tezepelumab	104	96 (92.3)	2.00 (0.72)	0.6	1.52	1.81	2.47	4.4	
			Placebo	104	91 (87.5)	1.81 (0.63)	0.7	1.42	1.70	2.18	4.3	
		Week 52	Tezepelumab	104	97 (93.3)	2.02 (0.70)	0.8	1.53	1.84	2.48	4.2	
			Placebo	104	90 (86.5)	1.75 (0.58)	0.7	1.37	1.61	2.12	3.4	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Change from baseline	Week 2	Tezepelumab	104	103 (99.0)	0.18 (0.35)	-0.6	-0.01	0.10	0.29	1.3	0.40 [0.12, 0.68]
			Placebo	104	100 (96.2)	0.04 (0.33)	-0.7	-0.12	0.03	0.18	1.2	
		Week 4	Tezepelumab	104	104 (100.0)	0.22 (0.38)	-0.9	0.02	0.15	0.36	1.8	0.48 [0.21, 0.76]
			Placebo	104	103 (99.0)	0.05 (0.34)	-0.7	-0.14	0.00	0.20	1.1	
		Week 8	Tezepelumab	104	102 (98.1)	0.29 (0.43)	-0.8	0.03	0.19	0.51	1.7	0.56 [0.28, 0.84]
			Placebo	104	103 (99.0)	0.07 (0.34)	-0.7	-0.15	0.03	0.24	1.6	
		Week 12	Tezepelumab	104	101 (97.1)	0.30 (0.45)	-0.7	0.05	0.20	0.51	2.0	0.54 [0.26, 0.82]
			Placebo	104	101 (97.1)	0.08 (0.35)	-0.9	-0.07	0.04	0.19	1.7	
		Week 16	Tezepelumab	104	103 (99.0)	0.31 (0.43)	-0.6	0.04	0.22	0.51	1.7	0.59 [0.31, 0.88]
			Placebo	104	99 (95.2)	0.07 (0.35)	-0.8	-0.12	0.00	0.26	1.8	
		Week 24	Tezepelumab	104	101 (97.1)	0.27 (0.44)	-1.0	0.00	0.23	0.53	1.6	0.51 [0.23, 0.80]
			Placebo	104	96 (92.3)	0.06 (0.37)	-0.9	-0.15	0.04	0.22	1.7	
		Week 36	Tezepelumab	104	96 (92.3)	0.27 (0.46)	-1.0	0.02	0.23	0.54	1.5	0.52 [0.23, 0.81]
			Placebo	104	91 (87.5)	0.05 (0.40)	-1.0	-0.22	0.01	0.27	1.7	
		Week 52	Tezepelumab	104	97 (93.3)	0.28 (0.45)	-1.0	0.01	0.26	0.52	1.6	0.63 [0.34, 0.93]
			Placebo	104	90 (86.5)	0.02 (0.34)	-1.0	-0.20	0.01	0.23	0.8	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Absolute values	Baseline	Tezepelumab	72	72 (100.0)	1.55 (0.69)	0.6	1.04	1.35	1.90	3.5	
			Placebo	73	73 (100.0)	1.61 (0.51)	0.8	1.26	1.50	1.88	3.0	
		Week 2	Tezepelumab	72	69 (95.8)	1.73 (0.67)	0.6	1.24	1.53	2.22	3.8	
			Placebo	73	68 (93.2)	1.65 (0.55)	0.7	1.24	1.62	2.04	2.7	
		Week 4	Tezepelumab	72	72 (100.0)	1.76 (0.72)	0.6	1.24	1.67	2.10	3.8	
			Placebo	73	72 (98.6)	1.72 (0.56)	0.7	1.32	1.65	2.05	3.4	
		Week 8	Tezepelumab	72	71 (98.6)	1.76 (0.67)	0.6	1.19	1.64	2.22	3.8	
			Placebo	73	72 (98.6)	1.68 (0.52)	0.7	1.33	1.63	2.00	3.0	
		Week 12	Tezepelumab	72	72 (100.0)	1.79 (0.69)	0.6	1.33	1.67	2.18	3.8	
			Placebo	73	69 (94.5)	1.73 (0.53)	0.8	1.31	1.61	2.14	3.1	
		Week 16	Tezepelumab	72	69 (95.8)	1.80 (0.69)	0.6	1.33	1.67	2.16	3.8	
			Placebo	73	67 (91.8)	1.69 (0.53)	0.8	1.28	1.68	2.11	3.1	
		Week 24	Tezepelumab	72	67 (93.1)	1.79 (0.73)	0.6	1.22	1.69	2.28	4.0	
			Placebo	73	66 (90.4)	1.68 (0.53)	0.8	1.32	1.63	2.11	3.1	
		Week 36	Tezepelumab	72	65 (90.3)	1.78 (0.70)	0.5	1.27	1.66	2.25	3.8	
			Placebo	73	59 (80.8)	1.65 (0.48)	0.8	1.26	1.60	2.03	2.8	
		Week 52	Tezepelumab	72	64 (88.9)	1.75 (0.69)	0.7	1.19	1.64	2.12	3.7	
			Placebo	73	57 (78.1)	1.60 (0.47)	0.8	1.24	1.55	1.88	2.7	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Change from baseline	Week 2	Tezepelumab	72	69 (95.8)	0.15 (0.31)	-0.5	-0.06	0.09	0.28	1.4	0.45 [0.11, 0.79]
			Placebo	73	68 (93.2)	0.02 (0.28)	-0.7	-0.13	0.01	0.11	1.0	
		Week 4	Tezepelumab	72	72 (100.0)	0.20 (0.36)	-0.5	-0.03	0.12	0.35	1.7	0.24 [-0.09, 0.57]
			Placebo	73	72 (98.6)	0.11 (0.42)	-1.0	-0.13	0.05	0.36	1.2	
		Week 8	Tezepelumab	72	71 (98.6)	0.22 (0.32)	-0.4	0.01	0.18	0.34	1.2	0.45 [0.12, 0.78]
			Placebo	73	72 (98.6)	0.07 (0.34)	-0.9	-0.11	0.04	0.21	1.2	
		Week 12	Tezepelumab	72	72 (100.0)	0.24 (0.36)	-0.4	-0.03	0.17	0.42	1.5	0.33 [-0.00, 0.66]
			Placebo	73	69 (94.5)	0.12 (0.33)	-1.1	-0.03	0.05	0.22	1.0	
		Week 16	Tezepelumab	72	69 (95.8)	0.22 (0.40)	-0.6	-0.03	0.14	0.40	1.6	0.38 [0.04, 0.72]
			Placebo	73	67 (91.8)	0.08 (0.33)	-1.0	-0.06	0.04	0.24	1.2	
		Week 24	Tezepelumab	72	67 (93.1)	0.22 (0.42)	-1.0	-0.05	0.14	0.45	1.7	0.34 [-0.01, 0.68]
			Placebo	73	66 (90.4)	0.09 (0.35)	-1.1	-0.10	0.04	0.28	0.9	
		Week 36	Tezepelumab	72	65 (90.3)	0.21 (0.39)	-0.4	-0.07	0.09	0.38	1.6	0.36 [0.01, 0.72]
			Placebo	73	59 (80.8)	0.08 (0.32)	-0.9	-0.10	0.06	0.27	0.9	
		Week 52	Tezepelumab	72	64 (88.9)	0.20 (0.38)	-0.5	-0.04	0.12	0.34	1.4	0.53 [0.16, 0.89]
			Placebo	73	57 (78.1)	0.03 (0.27)	-1.0	-0.14	0.06	0.18	0.6	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
< 18.5 kg/m**2	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	2.29 (0.85)	1.3	1.31	2.73	2.83	2.8	
			Placebo	3	3 (100.0)	2.42 (0.75)	1.7	1.67	2.41	3.17	3.2	
		Week 2	Tezepelumab	3	3 (100.0)	2.22 (0.75)	1.4	1.41	2.36	2.89	2.9	
			Placebo	3	3 (100.0)	2.27 (1.12)	1.1	1.12	2.33	3.35	3.4	
		Week 4	Tezepelumab	3	3 (100.0)	2.11 (0.91)	1.3	1.27	1.98	3.08	3.1	
			Placebo	3	3 (100.0)	2.24 (1.02)	1.2	1.19	2.30	3.23	3.2	
		Week 8	Tezepelumab	3	3 (100.0)	2.30 (0.88)	1.6	1.61	2.00	3.30	3.3	
			Placebo	3	3 (100.0)	2.46 (0.91)	1.6	1.56	2.43	3.38	3.4	
		Week 12	Tezepelumab	3	3 (100.0)	2.19 (1.02)	1.2	1.22	2.10	3.26	3.3	
			Placebo	3	3 (100.0)	2.33 (1.29)	1.0	0.98	2.44	3.56	3.6	
		Week 16	Tezepelumab	3	3 (100.0)	2.28 (0.87)	1.4	1.43	2.26	3.16	3.2	
			Placebo	3	3 (100.0)	2.23 (1.08)	1.1	1.08	2.38	3.23	3.2	
		Week 24	Tezepelumab	3	3 (100.0)	2.31 (0.94)	1.4	1.40	2.24	3.28	3.3	
			Placebo	3	3 (100.0)	2.51 (0.62)	1.9	1.90	2.48	3.14	3.1	
		Week 36	Tezepelumab	3	3 (100.0)	2.21 (1.01)	1.3	1.25	2.12	3.27	3.3	
			Placebo	3	3 (100.0)	2.24 (0.84)	1.3	1.32	2.45	2.96	3.0	
		Week 52	Tezepelumab	3	3 (100.0)	2.00 (1.00)	1.1	1.11	1.80	3.08	3.1	
			Placebo	3	2 (66.7)	2.43 (0.64)	2.0	1.97	2.43	2.88	2.9	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
< 18.5 kg/m**2	Change from baseline	Week 2	Tezepelumab	3	3 (100.0)	-0.07 (0.35)	-0.5	-0.47	0.10	0.16	0.2	0.22 [-1.38, 1.83]
			Placebo	3	3 (100.0)	-0.15 (0.37)	-0.5	-0.55	-0.08	0.18	0.2	
		Week 4	Tezepelumab	3	3 (100.0)	-0.18 (0.61)	-0.9	-0.85	-0.04	0.35	0.4	-0.01 [-1.61, 1.59]
			Placebo	3	3 (100.0)	-0.18 (0.28)	-0.5	-0.48	-0.11	0.06	0.1	
		Week 8	Tezepelumab	3	3 (100.0)	0.01 (0.74)	-0.8	-0.83	0.30	0.57	0.6	-0.05 [-1.65, 1.55]
			Placebo	3	3 (100.0)	0.04 (0.16)	-0.1	-0.11	0.02	0.21	0.2	
		Week 12	Tezepelumab	3	3 (100.0)	-0.10 (0.63)	-0.7	-0.73	-0.09	0.53	0.5	-0.01 [-1.61, 1.59]
			Placebo	3	3 (100.0)	-0.09 (0.55)	-0.7	-0.69	0.03	0.39	0.4	
		Week 16	Tezepelumab	3	3 (100.0)	-0.01 (0.51)	-0.6	-0.57	0.12	0.43	0.4	0.41 [-1.22, 2.03]
			Placebo	3	3 (100.0)	-0.19 (0.35)	-0.6	-0.59	-0.03	0.06	0.1	
		Week 24	Tezepelumab	3	3 (100.0)	0.02 (0.57)	-0.6	-0.59	0.09	0.55	0.5	-0.18 [-1.78, 1.43]
			Placebo	3	3 (100.0)	0.09 (0.13)	-0.0	-0.03	0.07	0.23	0.2	
		Week 36	Tezepelumab	3	3 (100.0)	-0.08 (0.63)	-0.7	-0.71	-0.06	0.54	0.5	0.21 [-1.40, 1.82]
			Placebo	3	3 (100.0)	-0.17 (0.20)	-0.3	-0.35	-0.21	0.04	0.0	
		Week 52	Tezepelumab	3	3 (100.0)	-0.29 (0.69)	-1.0	-1.03	-0.20	0.35	0.4	-0.48 [-2.31, 1.35]
			Placebo	3	2 (66.7)	0.01 (0.42)	-0.3	-0.29	0.01	0.30	0.3	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Absolute values	Baseline	Tezepelumab	109	109 (100.0)	1.65 (0.63)	0.4	1.22	1.56	1.96	3.6	
			Placebo	108	108 (100.0)	1.88 (0.70)	0.4	1.39	1.78	2.24	4.5	
		Week 2	Tezepelumab	109	106 (97.2)	1.86 (0.66)	0.6	1.33	1.77	2.30	3.9	
			Placebo	108	104 (96.3)	1.98 (0.70)	0.4	1.53	1.90	2.42	3.9	
		Week 4	Tezepelumab	109	109 (100.0)	1.89 (0.66)	0.7	1.46	1.76	2.29	3.7	
			Placebo	108	106 (98.1)	1.94 (0.67)	0.4	1.48	1.92	2.26	4.0	
		Week 8	Tezepelumab	109	108 (99.1)	1.96 (0.70)	0.6	1.44	1.80	2.42	3.7	
			Placebo	108	107 (99.1)	1.96 (0.73)	0.4	1.41	1.86	2.37	4.1	
		Week 12	Tezepelumab	109	109 (100.0)	1.96 (0.68)	0.6	1.54	1.80	2.41	3.9	
			Placebo	108	104 (96.3)	2.01 (0.74)	0.7	1.46	1.87	2.47	4.1	
		Week 16	Tezepelumab	109	103 (94.5)	2.02 (0.73)	0.6	1.52	1.89	2.51	4.2	
			Placebo	108	101 (93.5)	1.96 (0.73)	0.7	1.47	1.82	2.32	4.3	
		Week 24	Tezepelumab	109	105 (96.3)	1.94 (0.68)	0.7	1.52	1.77	2.39	3.8	
			Placebo	108	97 (89.8)	1.98 (0.71)	0.7	1.45	1.87	2.31	4.3	
		Week 36	Tezepelumab	109	100 (91.7)	1.98 (0.71)	0.6	1.51	1.86	2.48	4.0	
			Placebo	108	92 (85.2)	1.99 (0.75)	0.7	1.49	1.92	2.33	4.2	
		Week 52	Tezepelumab	109	95 (87.2)	1.96 (0.72)	0.8	1.50	1.76	2.44	4.1	
			Placebo	108	92 (85.2)	1.95 (0.78)	0.7	1.45	1.82	2.31	4.5	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Change from baseline	Week 2	Tezepelumab	109	106 (97.2)	0.22 (0.35)	-0.4	0.00	0.13	0.34	1.4	0.43 [0.16, 0.70]
			Placebo	108	104 (96.3)	0.07 (0.35)	-1.1	-0.07	0.04	0.18	1.1	
		Week 4	Tezepelumab	109	109 (100.0)	0.24 (0.39)	-0.5	0.01	0.16	0.38	1.8	0.39 [0.12, 0.66]
			Placebo	108	106 (98.1)	0.08 (0.42)	-1.8	-0.11	0.04	0.29	1.4	
		Week 8	Tezepelumab	109	108 (99.1)	0.31 (0.45)	-0.6	0.01	0.19	0.53	1.7	0.56 [0.29, 0.83]
			Placebo	108	107 (99.1)	0.08 (0.36)	-0.9	-0.13	0.03	0.30	1.3	
		Week 12	Tezepelumab	109	109 (100.0)	0.31 (0.44)	-0.6	0.02	0.21	0.53	2.0	0.44 [0.17, 0.71]
			Placebo	108	104 (96.3)	0.13 (0.39)	-1.1	-0.09	0.06	0.38	1.2	
		Week 16	Tezepelumab	109	103 (94.5)	0.37 (0.44)	-0.6	0.06	0.25	0.61	1.7	0.68 [0.39, 0.96]
			Placebo	108	101 (93.5)	0.08 (0.40)	-1.2	-0.12	0.04	0.33	1.5	
		Week 24	Tezepelumab	109	105 (96.3)	0.29 (0.45)	-1.0	-0.03	0.23	0.52	1.6	0.47 [0.19, 0.75]
			Placebo	108	97 (89.8)	0.08 (0.44)	-1.1	-0.14	0.03	0.32	1.6	
		Week 36	Tezepelumab	109	100 (91.7)	0.32 (0.45)	-1.0	0.01	0.28	0.54	1.5	0.51 [0.22, 0.80]
			Placebo	108	92 (85.2)	0.10 (0.45)	-1.1	-0.17	0.11	0.27	1.3	
		Week 52	Tezepelumab	109	95 (87.2)	0.31 (0.41)	-0.7	0.01	0.26	0.55	1.6	0.62 [0.33, 0.91]
			Placebo	108	92 (85.2)	0.06 (0.39)	-1.0	-0.14	0.06	0.24	1.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	127	127 (100.0)	1.78 (0.73)	0.6	1.30	1.64	2.15	4.1	
			Placebo	126	126 (100.0)	1.80 (0.66)	0.6	1.33	1.69	2.25	4.1	
		Week 2	Tezepelumab	127	126 (99.2)	1.97 (0.77)	0.7	1.42	1.79	2.43	4.3	
			Placebo	126	118 (93.7)	1.86 (0.69)	0.6	1.38	1.71	2.36	4.1	
		Week 4	Tezepelumab	127	126 (99.2)	2.00 (0.81)	0.7	1.42	1.90	2.59	4.3	
			Placebo	126	122 (96.8)	1.88 (0.70)	0.5	1.36	1.74	2.31	4.8	
		Week 8	Tezepelumab	127	125 (98.4)	2.01 (0.81)	0.7	1.40	1.87	2.43	4.7	
			Placebo	126	123 (97.6)	1.90 (0.74)	0.6	1.36	1.78	2.29	4.6	
		Week 12	Tezepelumab	127	123 (96.9)	2.03 (0.81)	0.7	1.45	1.94	2.45	4.7	
			Placebo	126	120 (95.2)	1.91 (0.72)	0.5	1.40	1.80	2.35	4.6	
		Week 16	Tezepelumab	127	124 (97.6)	2.05 (0.83)	0.6	1.39	1.90	2.54	4.9	
			Placebo	126	119 (94.4)	1.88 (0.74)	0.5	1.33	1.77	2.26	4.7	
		Week 24	Tezepelumab	127	117 (92.1)	2.00 (0.74)	0.6	1.48	1.93	2.32	4.4	
			Placebo	126	115 (91.3)	1.87 (0.72)	0.8	1.37	1.72	2.24	4.8	
		Week 36	Tezepelumab	127	113 (89.0)	1.99 (0.82)	0.5	1.37	1.91	2.36	4.5	
			Placebo	126	113 (89.7)	1.92 (0.73)	0.6	1.37	1.81	2.40	4.3	
		Week 52	Tezepelumab	127	114 (89.8)	2.03 (0.80)	0.7	1.47	1.96	2.46	4.3	
			Placebo	126	101 (80.2)	1.87 (0.71)	0.6	1.28	1.75	2.33	4.0	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Change from baseline	Week 2	Tezepelumab	127	126 (99.2)	0.18 (0.34)	-0.5	-0.01	0.13	0.29	1.5	0.42 [0.17, 0.68]
			Placebo	126	118 (93.7)	0.04 (0.34)	-0.7	-0.16	0.01	0.17	1.2	
		Week 4	Tezepelumab	127	126 (99.2)	0.23 (0.38)	-0.4	0.00	0.15	0.33	1.7	0.39 [0.14, 0.64]
			Placebo	126	122 (96.8)	0.09 (0.37)	-0.7	-0.11	0.03	0.20	1.6	
		Week 8	Tezepelumab	127	125 (98.4)	0.25 (0.39)	-0.8	0.04	0.17	0.42	1.8	0.45 [0.20, 0.70]
			Placebo	126	123 (97.6)	0.09 (0.32)	-0.5	-0.10	0.07	0.24	1.6	
		Week 12	Tezepelumab	127	123 (96.9)	0.26 (0.40)	-0.4	0.00	0.18	0.43	1.9	0.40 [0.15, 0.66]
			Placebo	126	120 (95.2)	0.11 (0.36)	-0.7	-0.11	0.02	0.25	1.7	
		Week 16	Tezepelumab	127	124 (97.6)	0.28 (0.42)	-0.3	0.00	0.17	0.42	2.0	0.52 [0.26, 0.77]
			Placebo	126	119 (94.4)	0.07 (0.37)	-1.0	-0.14	-0.01	0.21	1.8	
		Week 24	Tezepelumab	127	117 (92.1)	0.25 (0.38)	-0.7	-0.01	0.23	0.43	1.5	0.49 [0.23, 0.75]
			Placebo	126	115 (91.3)	0.07 (0.37)	-0.5	-0.16	0.02	0.22	1.7	
		Week 36	Tezepelumab	127	113 (89.0)	0.24 (0.42)	-0.8	-0.02	0.15	0.46	1.7	0.36 [0.10, 0.63]
			Placebo	126	113 (89.7)	0.10 (0.39)	-0.7	-0.16	0.04	0.29	1.7	
		Week 52	Tezepelumab	127	114 (89.8)	0.27 (0.41)	-0.8	0.00	0.23	0.53	1.7	0.58 [0.30, 0.85]
			Placebo	126	101 (80.2)	0.05 (0.36)	-0.9	-0.18	-0.01	0.20	1.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	141	141 (100.0)	1.76 (0.65)	0.6	1.27	1.64	2.13	4.0	
			Placebo	134	134 (100.0)	1.72 (0.66)	0.7	1.21	1.57	2.08	4.2	
		Week 2	Tezepelumab	141	135 (95.7)	1.92 (0.65)	0.6	1.39	1.86	2.41	4.1	
			Placebo	134	128 (95.5)	1.76 (0.69)	0.6	1.28	1.66	2.12	4.0	
		Week 4	Tezepelumab	141	139 (98.6)	1.92 (0.68)	0.6	1.38	1.85	2.40	4.2	
			Placebo	134	132 (98.5)	1.78 (0.66)	0.7	1.32	1.71	2.07	4.2	
		Week 8	Tezepelumab	141	138 (97.9)	1.91 (0.66)	0.6	1.36	1.85	2.37	4.1	
			Placebo	134	128 (95.5)	1.82 (0.68)	0.7	1.33	1.69	2.13	4.3	
		Week 12	Tezepelumab	141	134 (95.0)	1.92 (0.67)	0.6	1.45	1.82	2.34	4.6	
			Placebo	134	130 (97.0)	1.77 (0.67)	0.6	1.31	1.65	2.09	4.3	
		Week 16	Tezepelumab	141	137 (97.2)	1.92 (0.66)	0.6	1.40	1.86	2.31	4.2	
			Placebo	134	127 (94.8)	1.81 (0.68)	0.6	1.32	1.73	2.11	4.1	
		Week 24	Tezepelumab	141	131 (92.9)	1.93 (0.70)	0.6	1.40	1.79	2.40	4.0	
			Placebo	134	124 (92.5)	1.78 (0.69)	0.6	1.34	1.73	2.13	4.8	
		Week 36	Tezepelumab	141	127 (90.1)	1.92 (0.69)	0.7	1.42	1.79	2.38	4.4	
			Placebo	134	120 (89.6)	1.83 (0.69)	0.7	1.43	1.71	2.21	4.6	
		Week 52	Tezepelumab	141	125 (88.7)	1.92 (0.70)	0.6	1.37	1.87	2.30	4.2	
			Placebo	134	113 (84.3)	1.81 (0.73)	0.6	1.30	1.70	2.23	4.4	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Change from baseline	Week 2	Tezepelumab	141	135 (95.7)	0.15 (0.29)	-0.7	0.00	0.12	0.32	1.1	0.34 [0.09, 0.58]
			Placebo	134	128 (95.5)	0.04 (0.36)	-1.8	-0.10	-0.01	0.17	1.1	
		Week 4	Tezepelumab	141	139 (98.6)	0.17 (0.30)	-0.7	-0.04	0.12	0.32	1.1	0.35 [0.11, 0.59]
			Placebo	134	132 (98.5)	0.06 (0.35)	-1.0	-0.11	0.05	0.25	1.1	
		Week 8	Tezepelumab	141	138 (97.9)	0.18 (0.36)	-0.6	-0.06	0.11	0.36	1.4	0.27 [0.03, 0.52]
			Placebo	134	128 (95.5)	0.08 (0.33)	-0.8	-0.11	0.06	0.28	1.2	
		Week 12	Tezepelumab	141	134 (95.0)	0.18 (0.35)	-0.8	-0.05	0.13	0.38	1.3	0.36 [0.11, 0.60]
			Placebo	134	130 (97.0)	0.04 (0.38)	-1.5	-0.10	0.05	0.21	1.2	
		Week 16	Tezepelumab	141	137 (97.2)	0.16 (0.35)	-0.8	-0.04	0.13	0.33	1.4	0.24 [-0.01, 0.48]
			Placebo	134	127 (94.8)	0.08 (0.31)	-0.8	-0.07	0.04	0.24	1.0	
		Week 24	Tezepelumab	141	131 (92.9)	0.19 (0.38)	-1.0	-0.07	0.11	0.39	1.7	0.35 [0.10, 0.59]
			Placebo	134	124 (92.5)	0.06 (0.33)	-0.9	-0.11	0.05	0.26	1.2	
		Week 36	Tezepelumab	141	127 (90.1)	0.16 (0.36)	-0.5	-0.09	0.08	0.37	1.6	0.23 [-0.02, 0.48]
			Placebo	134	120 (89.6)	0.08 (0.33)	-0.9	-0.14	0.05	0.29	1.1	
		Week 52	Tezepelumab	141	125 (88.7)	0.17 (0.39)	-1.0	-0.07	0.11	0.35	1.4	0.25 [-0.00, 0.51]
			Placebo	134	113 (84.3)	0.08 (0.29)	-0.8	-0.10	0.08	0.23	1.1	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Absolute values	Baseline	Tezepelumab	95	95 (100.0)	1.89 (0.70)	0.4	1.31	1.87	2.43	4.0	
			Placebo	87	87 (100.0)	1.80 (0.61)	0.8	1.37	1.79	2.17	3.4	
		Week 2	Tezepelumab	95	93 (97.9)	1.97 (0.73)	0.6	1.40	1.92	2.44	4.1	
			Placebo	87	82 (94.3)	1.82 (0.65)	0.8	1.38	1.66	2.17	3.5	
		Week 4	Tezepelumab	95	94 (98.9)	1.97 (0.78)	0.7	1.32	1.98	2.56	4.2	
			Placebo	87	86 (98.9)	1.82 (0.65)	0.7	1.34	1.78	2.20	3.6	
		Week 8	Tezepelumab	95	92 (96.8)	1.96 (0.74)	0.6	1.43	1.87	2.47	4.1	
			Placebo	87	84 (96.6)	1.84 (0.67)	0.7	1.38	1.81	2.31	3.7	
		Week 12	Tezepelumab	95	91 (95.8)	1.97 (0.75)	0.6	1.44	1.89	2.45	4.2	
			Placebo	87	82 (94.3)	1.81 (0.68)	0.7	1.31	1.67	2.18	3.6	
		Week 16	Tezepelumab	95	92 (96.8)	2.02 (0.80)	0.6	1.41	1.86	2.55	4.3	
			Placebo	87	82 (94.3)	1.78 (0.65)	0.6	1.29	1.69	2.16	3.6	
		Week 24	Tezepelumab	95	85 (89.5)	1.94 (0.71)	0.6	1.40	1.87	2.41	4.0	
			Placebo	87	79 (90.8)	1.82 (0.62)	0.8	1.30	1.73	2.20	3.6	
		Week 36	Tezepelumab	95	86 (90.5)	1.94 (0.78)	0.5	1.33	1.90	2.44	4.4	
			Placebo	87	76 (87.4)	1.85 (0.64)	0.8	1.32	1.82	2.25	3.4	
		Week 52	Tezepelumab	95	85 (89.5)	1.97 (0.76)	0.7	1.41	1.84	2.59	4.2	
			Placebo	87	75 (86.2)	1.79 (0.67)	0.7	1.25	1.65	2.28	3.5	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Change from baseline	Week 2	Tezepelumab	95	93 (97.9)	0.07 (0.29)	-0.6	-0.07	0.08	0.19	1.5	0.22 [-0.08, 0.51]
			Placebo	87	82 (94.3)	0.01 (0.34)	-1.8	-0.13	-0.01	0.13	1.1	
		Week 4	Tezepelumab	95	94 (98.9)	0.09 (0.36)	-0.9	-0.07	0.04	0.27	1.7	0.21 [-0.09, 0.50]
			Placebo	87	86 (98.9)	0.02 (0.34)	-1.0	-0.08	0.04	0.15	0.9	
		Week 8	Tezepelumab	95	92 (96.8)	0.10 (0.36)	-0.8	-0.09	0.02	0.30	1.4	0.16 [-0.14, 0.45]
			Placebo	87	84 (96.6)	0.05 (0.31)	-0.9	-0.11	0.05	0.23	0.9	
		Week 12	Tezepelumab	95	91 (95.8)	0.09 (0.34)	-0.8	-0.09	0.07	0.23	1.4	0.21 [-0.09, 0.51]
			Placebo	87	82 (94.3)	0.02 (0.35)	-1.2	-0.09	0.01	0.19	1.0	
		Week 16	Tezepelumab	95	92 (96.8)	0.13 (0.41)	-0.8	-0.11	0.06	0.24	1.9	0.38 [0.08, 0.68]
			Placebo	87	82 (94.3)	-0.02 (0.34)	-1.0	-0.16	0.01	0.15	1.5	
		Week 24	Tezepelumab	95	85 (89.5)	0.09 (0.30)	-0.6	-0.07	0.03	0.22	1.1	0.25 [-0.06, 0.56]
			Placebo	87	79 (90.8)	0.02 (0.33)	-1.1	-0.14	0.01	0.14	1.4	
		Week 36	Tezepelumab	95	86 (90.5)	0.07 (0.36)	-0.7	-0.12	0.01	0.22	1.5	0.11 [-0.20, 0.42]
			Placebo	87	76 (87.4)	0.03 (0.30)	-0.7	-0.17	0.03	0.19	1.3	
		Week 52	Tezepelumab	95	85 (89.5)	0.10 (0.38)	-1.0	-0.07	0.06	0.25	1.3	0.32 [0.00, 0.63]
			Placebo	87	75 (86.2)	-0.01 (0.35)	-1.0	-0.18	0.00	0.13	1.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Absolute values	Baseline	Tezepelumab	285	285 (100.0)	1.69 (0.66)	0.5	1.21	1.56	2.04	4.1	
			Placebo	284	284 (100.0)	1.80 (0.70)	0.4	1.31	1.69	2.22	4.5	
		Week 2	Tezepelumab	285	277 (97.2)	1.90 (0.68)	0.6	1.39	1.74	2.35	4.3	
			Placebo	284	271 (95.4)	1.87 (0.71)	0.4	1.37	1.77	2.31	4.1	
		Week 4	Tezepelumab	285	283 (99.3)	1.93 (0.70)	0.6	1.44	1.82	2.38	4.3	
			Placebo	284	277 (97.5)	1.87 (0.69)	0.4	1.42	1.79	2.25	4.8	
		Week 8	Tezepelumab	285	282 (98.9)	1.96 (0.72)	0.6	1.40	1.84	2.40	4.7	
			Placebo	284	277 (97.5)	1.91 (0.73)	0.4	1.40	1.78	2.26	4.6	
		Week 12	Tezepelumab	285	278 (97.5)	1.97 (0.72)	0.6	1.50	1.86	2.38	4.7	
			Placebo	284	275 (96.8)	1.92 (0.73)	0.5	1.41	1.76	2.33	4.6	
		Week 16	Tezepelumab	285	275 (96.5)	1.98 (0.72)	0.6	1.46	1.88	2.36	4.9	
			Placebo	284	268 (94.4)	1.91 (0.74)	0.5	1.37	1.78	2.23	4.7	
		Week 24	Tezepelumab	285	271 (95.1)	1.96 (0.71)	0.6	1.48	1.81	2.39	4.4	
			Placebo	284	260 (91.5)	1.89 (0.73)	0.6	1.41	1.78	2.22	4.8	
		Week 36	Tezepelumab	285	257 (90.2)	1.97 (0.73)	0.7	1.43	1.85	2.38	4.5	
			Placebo	284	252 (88.7)	1.93 (0.75)	0.6	1.43	1.79	2.30	4.6	
		Week 52	Tezepelumab	285	252 (88.4)	1.97 (0.73)	0.6	1.48	1.85	2.37	4.3	
			Placebo	284	233 (82.0)	1.90 (0.76)	0.6	1.37	1.74	2.29	4.5	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Change from baseline	Week 2	Tezepelumab	285	277 (97.2)	0.22 (0.33)	-0.7	0.01	0.15	0.35	1.4	0.46 [0.29, 0.63]
			Placebo	284	271 (95.4)	0.06 (0.35)	-1.1	-0.11	0.01	0.20	1.2	
		Week 4	Tezepelumab	285	283 (99.3)	0.25 (0.35)	-0.5	0.02	0.17	0.37	1.8	0.43 [0.26, 0.59]
			Placebo	284	277 (97.5)	0.09 (0.39)	-1.8	-0.11	0.05	0.27	1.6	
		Week 8	Tezepelumab	285	282 (98.9)	0.28 (0.41)	-0.8	0.03	0.19	0.50	1.8	0.50 [0.33, 0.67]
			Placebo	284	277 (97.5)	0.10 (0.34)	-0.8	-0.11	0.06	0.28	1.6	
		Week 12	Tezepelumab	285	278 (97.5)	0.29 (0.41)	-0.7	0.02	0.20	0.48	2.0	0.46 [0.29, 0.63]
			Placebo	284	275 (96.8)	0.11 (0.39)	-1.5	-0.10	0.06	0.28	1.7	
		Week 16	Tezepelumab	285	275 (96.5)	0.30 (0.40)	-0.6	0.04	0.23	0.49	2.0	0.51 [0.34, 0.68]
			Placebo	284	268 (94.4)	0.11 (0.36)	-1.2	-0.09	0.04	0.30	1.8	
		Week 24	Tezepelumab	285	271 (95.1)	0.28 (0.42)	-1.0	-0.02	0.25	0.48	1.7	0.48 [0.31, 0.66]
			Placebo	284	260 (91.5)	0.09 (0.39)	-0.9	-0.13	0.05	0.27	1.7	
		Week 36	Tezepelumab	285	257 (90.2)	0.29 (0.42)	-1.0	-0.01	0.23	0.53	1.7	0.45 [0.27, 0.62]
			Placebo	284	252 (88.7)	0.11 (0.40)	-1.1	-0.16	0.05	0.34	1.7	
		Week 52	Tezepelumab	285	252 (88.4)	0.29 (0.42)	-0.8	0.00	0.23	0.53	1.7	0.52 [0.34, 0.70]
			Placebo	284	233 (82.0)	0.09 (0.34)	-1.0	-0.14	0.06	0.26	1.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Absolute values	Baseline	Tezepelumab	216	216 (100.0)	1.79 (0.65)	0.4	1.29	1.72	2.23	4.0	
			Placebo	207	207 (100.0)	1.84 (0.67)	0.7	1.36	1.71	2.19	4.1	
		Week 2	Tezepelumab	216	211 (97.7)	1.91 (0.68)	0.6	1.39	1.81	2.42	4.1	
			Placebo	207	198 (95.7)	1.87 (0.72)	0.6	1.38	1.72	2.29	4.1	
		Week 4	Tezepelumab	216	215 (99.5)	1.92 (0.71)	0.6	1.36	1.85	2.44	4.2	
			Placebo	207	202 (97.6)	1.86 (0.69)	0.7	1.38	1.76	2.20	4.8	
		Week 8	Tezepelumab	216	213 (98.6)	1.92 (0.70)	0.6	1.36	1.85	2.41	4.1	
			Placebo	207	199 (96.1)	1.92 (0.73)	0.7	1.40	1.81	2.34	4.6	
		Week 12	Tezepelumab	216	210 (97.2)	1.92 (0.70)	0.6	1.38	1.83	2.38	4.2	
			Placebo	207	197 (95.2)	1.87 (0.74)	0.6	1.34	1.74	2.25	4.6	
		Week 16	Tezepelumab	216	211 (97.7)	1.94 (0.71)	0.6	1.37	1.85	2.43	4.3	
			Placebo	207	195 (94.2)	1.88 (0.76)	0.6	1.32	1.73	2.26	4.7	
		Week 24	Tezepelumab	216	203 (94.0)	1.89 (0.68)	0.6	1.34	1.78	2.40	4.0	
			Placebo	207	188 (90.8)	1.84 (0.72)	0.6	1.33	1.72	2.18	4.8	
		Week 36	Tezepelumab	216	197 (91.2)	1.89 (0.71)	0.5	1.29	1.81	2.41	4.4	
			Placebo	207	182 (87.9)	1.89 (0.73)	0.7	1.38	1.71	2.25	4.3	
		Week 52	Tezepelumab	216	198 (91.7)	1.91 (0.71)	0.7	1.39	1.81	2.39	4.2	
			Placebo	207	173 (83.6)	1.87 (0.76)	0.7	1.32	1.68	2.28	4.3	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Change from baseline	Week 2	Tezepelumab	216	211 (97.7)	0.11 (0.30)	-0.7	-0.04	0.08	0.25	1.5	0.30 [0.10, 0.50]
			Placebo	207	198 (95.7)	0.02 (0.33)	-1.8	-0.12	0.00	0.13	1.1	
		Week 4	Tezepelumab	216	215 (99.5)	0.13 (0.33)	-0.9	-0.05	0.09	0.25	1.7	0.29 [0.10, 0.48]
			Placebo	207	202 (97.6)	0.03 (0.35)	-1.0	-0.12	0.04	0.20	1.6	
		Week 8	Tezepelumab	216	213 (98.6)	0.14 (0.36)	-0.8	-0.06	0.10	0.29	1.4	0.21 [0.02, 0.41]
			Placebo	207	199 (96.1)	0.07 (0.30)	-0.9	-0.10	0.05	0.24	1.4	
		Week 12	Tezepelumab	216	210 (97.2)	0.14 (0.36)	-0.8	-0.06	0.10	0.26	2.0	0.26 [0.06, 0.45]
			Placebo	207	197 (95.2)	0.04 (0.36)	-1.5	-0.09	0.03	0.19	1.4	
		Week 16	Tezepelumab	216	211 (97.7)	0.15 (0.38)	-0.8	-0.06	0.11	0.28	1.9	0.31 [0.11, 0.50]
			Placebo	207	195 (94.2)	0.04 (0.35)	-1.2	-0.12	0.02	0.20	1.5	
		Week 24	Tezepelumab	216	203 (94.0)	0.11 (0.35)	-1.0	-0.08	0.06	0.29	1.3	0.28 [0.08, 0.48]
			Placebo	207	188 (90.8)	0.02 (0.33)	-1.1	-0.14	-0.00	0.17	1.6	
		Week 36	Tezepelumab	216	197 (91.2)	0.11 (0.37)	-1.0	-0.09	0.04	0.24	1.5	0.20 [-0.00, 0.40]
			Placebo	207	182 (87.9)	0.03 (0.36)	-1.1	-0.19	0.03	0.22	1.3	
		Week 52	Tezepelumab	216	198 (91.7)	0.13 (0.38)	-1.0	-0.07	0.06	0.26	1.5	0.26 [0.05, 0.46]
			Placebo	207	173 (83.6)	0.03 (0.33)	-1.0	-0.15	0.04	0.19	1.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Absolute values	Baseline	Tezepelumab	164	164 (100.0)	1.67 (0.70)	0.5	1.20	1.53	1.95	4.1	
			Placebo	164	164 (100.0)	1.75 (0.69)	0.4	1.28	1.68	2.18	4.5	
		Week 2	Tezepelumab	164	159 (97.0)	1.93 (0.72)	0.8	1.39	1.74	2.31	4.3	
			Placebo	164	155 (94.5)	1.85 (0.67)	0.4	1.37	1.83	2.28	4.0	
		Week 4	Tezepelumab	164	162 (98.8)	1.97 (0.73)	0.7	1.46	1.84	2.38	4.3	
			Placebo	164	161 (98.2)	1.87 (0.67)	0.4	1.42	1.83	2.22	4.2	
		Week 8	Tezepelumab	164	161 (98.2)	2.01 (0.75)	0.9	1.43	1.84	2.37	4.7	
			Placebo	164	162 (98.8)	1.86 (0.71)	0.4	1.33	1.78	2.19	4.3	
		Week 12	Tezepelumab	164	159 (97.0)	2.04 (0.75)	0.7	1.56	1.92	2.45	4.7	
			Placebo	164	160 (97.6)	1.92 (0.69)	0.5	1.45	1.90	2.33	4.3	
		Week 16	Tezepelumab	164	156 (95.1)	2.06 (0.78)	0.8	1.52	1.93	2.39	4.9	
			Placebo	164	155 (94.5)	1.89 (0.67)	0.5	1.41	1.80	2.20	4.4	
		Week 24	Tezepelumab	164	153 (93.3)	2.04 (0.73)	0.9	1.57	1.93	2.39	4.4	
			Placebo	164	151 (92.1)	1.92 (0.69)	0.7	1.45	1.84	2.23	4.8	
		Week 36	Tezepelumab	164	146 (89.0)	2.06 (0.77)	0.7	1.49	1.92	2.37	4.5	
			Placebo	164	146 (89.0)	1.94 (0.72)	0.6	1.48	1.87	2.31	4.6	
		Week 52	Tezepelumab	164	139 (84.8)	2.05 (0.78)	0.6	1.54	1.88	2.41	4.3	
			Placebo	164	135 (82.3)	1.88 (0.72)	0.6	1.34	1.82	2.29	4.5	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Change from baseline	Week 2	Tezepelumab	164	159 (97.0)	0.27 (0.35)	-0.5	0.07	0.21	0.41	1.4	0.52 [0.29, 0.74]
			Placebo	164	155 (94.5)	0.08 (0.37)	-1.1	-0.12	0.03	0.27	1.2	
		Week 4	Tezepelumab	164	162 (98.8)	0.31 (0.36)	-0.4	0.06	0.25	0.47	1.8	0.48 [0.26, 0.71]
			Placebo	164	161 (98.2)	0.12 (0.41)	-1.8	-0.11	0.05	0.31	1.4	
		Week 8	Tezepelumab	164	161 (98.2)	0.37 (0.43)	-0.6	0.07	0.30	0.61	1.8	0.66 [0.44, 0.89]
			Placebo	164	162 (98.8)	0.10 (0.38)	-0.8	-0.13	0.06	0.26	1.6	
		Week 12	Tezepelumab	164	159 (97.0)	0.39 (0.41)	-0.3	0.09	0.34	0.60	1.9	0.59 [0.37, 0.82]
			Placebo	164	160 (97.6)	0.15 (0.40)	-1.4	-0.11	0.07	0.36	1.7	
		Week 16	Tezepelumab	164	156 (95.1)	0.40 (0.41)	-0.4	0.12	0.34	0.59	2.0	0.71 [0.48, 0.94]
			Placebo	164	155 (94.5)	0.12 (0.37)	-1.0	-0.09	0.04	0.36	1.8	
		Week 24	Tezepelumab	164	153 (93.3)	0.40 (0.41)	-0.3	0.13	0.35	0.62	1.7	0.65 [0.41, 0.88]
			Placebo	164	151 (92.1)	0.13 (0.41)	-0.9	-0.13	0.07	0.34	1.7	
		Week 36	Tezepelumab	164	146 (89.0)	0.40 (0.41)	-0.3	0.10	0.37	0.58	1.7	0.61 [0.37, 0.84]
			Placebo	164	146 (89.0)	0.16 (0.40)	-0.8	-0.10	0.11	0.40	1.7	
		Week 52	Tezepelumab	164	139 (84.8)	0.40 (0.41)	-0.8	0.10	0.38	0.65	1.7	0.78 [0.54, 1.03]
			Placebo	164	135 (82.3)	0.10 (0.36)	-0.9	-0.15	0.06	0.32	1.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Absolute values	Baseline	Tezepelumab	155	155 (100.0)	1.69 (0.67)	0.4	1.22	1.55	2.12	4.0	
			Placebo	145	145 (100.0)	1.83 (0.72)	0.4	1.34	1.71	2.23	3.9	
		Week 2	Tezepelumab	155	150 (96.8)	1.84 (0.66)	0.6	1.35	1.72	2.31	4.1	
			Placebo	145	135 (93.1)	1.88 (0.72)	0.4	1.37	1.80	2.31	4.1	
		Week 4	Tezepelumab	155	152 (98.1)	1.84 (0.68)	0.6	1.28	1.69	2.31	4.2	
			Placebo	145	143 (98.6)	1.89 (0.73)	0.4	1.42	1.82	2.32	4.8	
		Week 8	Tezepelumab	155	152 (98.1)	1.84 (0.68)	0.6	1.32	1.68	2.35	4.1	
			Placebo	145	141 (97.2)	1.90 (0.73)	0.4	1.39	1.81	2.35	4.6	
		Week 12	Tezepelumab	155	149 (96.1)	1.84 (0.67)	0.6	1.37	1.70	2.21	4.2	
			Placebo	145	138 (95.2)	1.91 (0.75)	0.5	1.37	1.74	2.44	4.6	
		Week 16	Tezepelumab	155	148 (95.5)	1.87 (0.69)	0.6	1.37	1.74	2.34	4.2	
			Placebo	145	138 (95.2)	1.86 (0.74)	0.5	1.29	1.78	2.28	4.7	
		Week 24	Tezepelumab	155	146 (94.2)	1.82 (0.66)	0.6	1.29	1.73	2.29	4.0	
			Placebo	145	134 (92.4)	1.87 (0.73)	0.6	1.37	1.80	2.23	4.8	
		Week 36	Tezepelumab	155	137 (88.4)	1.81 (0.65)	0.5	1.28	1.74	2.25	4.4	
			Placebo	145	129 (89.0)	1.91 (0.73)	0.6	1.41	1.81	2.33	4.3	
		Week 52	Tezepelumab	155	139 (89.7)	1.82 (0.65)	0.7	1.36	1.72	2.23	4.2	
			Placebo	145	125 (86.2)	1.87 (0.76)	0.6	1.27	1.73	2.33	4.3	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Change from baseline	Week 2	Tezepelumab	155	150 (96.8)	0.14 (0.31)	-0.7	-0.01	0.09	0.25	1.4	0.37 [0.14, 0.60]
			Placebo	145	135 (93.1)	0.03 (0.28)	-0.8	-0.12	0.00	0.13	0.9	
		Week 4	Tezepelumab	155	152 (98.1)	0.16 (0.34)	-0.9	-0.04	0.09	0.29	1.7	0.26 [0.03, 0.49]
			Placebo	145	143 (98.6)	0.07 (0.31)	-0.9	-0.09	0.04	0.20	1.6	
		Week 8	Tezepelumab	155	152 (98.1)	0.16 (0.37)	-0.8	-0.05	0.11	0.27	1.6	0.30 [0.07, 0.53]
			Placebo	145	141 (97.2)	0.06 (0.31)	-0.9	-0.10	0.04	0.20	1.4	
		Week 12	Tezepelumab	155	149 (96.1)	0.16 (0.34)	-0.7	-0.04	0.10	0.28	1.5	0.28 [0.05, 0.52]
			Placebo	145	138 (95.2)	0.06 (0.33)	-1.5	-0.07	0.04	0.20	1.4	
		Week 16	Tezepelumab	155	148 (95.5)	0.17 (0.35)	-0.6	-0.05	0.11	0.29	1.6	0.41 [0.18, 0.64]
			Placebo	145	138 (95.2)	0.03 (0.32)	-1.0	-0.12	0.02	0.16	1.4	
		Week 24	Tezepelumab	155	146 (94.2)	0.15 (0.37)	-1.0	-0.07	0.09	0.32	1.5	0.39 [0.15, 0.63]
			Placebo	145	134 (92.4)	0.01 (0.33)	-1.1	-0.14	0.03	0.15	1.6	
		Week 36	Tezepelumab	155	137 (88.4)	0.11 (0.36)	-1.0	-0.11	0.06	0.30	1.4	0.15 [-0.10, 0.39]
			Placebo	145	129 (89.0)	0.06 (0.30)	-0.8	-0.11	0.04	0.20	1.1	
		Week 52	Tezepelumab	155	139 (89.7)	0.13 (0.37)	-1.0	-0.05	0.08	0.31	1.3	0.27 [0.03, 0.51]
			Placebo	145	125 (86.2)	0.04 (0.31)	-1.0	-0.14	0.04	0.20	1.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Absolute values	Baseline	Tezepelumab	222	222 (100.0)	1.77 (0.68)	0.5	1.31	1.66	2.12	4.1	
			Placebo	222	222 (100.0)	1.77 (0.65)	0.6	1.32	1.68	2.13	4.5	
		Week 2	Tezepelumab	222	217 (97.7)	1.99 (0.71)	0.7	1.46	1.86	2.42	4.3	
			Placebo	222	214 (96.4)	1.85 (0.69)	0.6	1.38	1.73	2.24	4.0	
		Week 4	Tezepelumab	222	222 (100.0)	2.02 (0.74)	0.7	1.47	1.92	2.54	4.3	
			Placebo	222	216 (97.3)	1.84 (0.65)	0.7	1.40	1.75	2.15	4.2	
		Week 8	Tezepelumab	222	219 (98.6)	2.06 (0.74)	0.8	1.47	2.00	2.46	4.7	
			Placebo	222	216 (97.3)	1.88 (0.71)	0.7	1.37	1.75	2.22	4.3	
		Week 12	Tezepelumab	222	217 (97.7)	2.07 (0.75)	0.7	1.55	1.94	2.48	4.7	
			Placebo	222	216 (97.3)	1.88 (0.70)	0.6	1.40	1.79	2.24	4.3	
		Week 16	Tezepelumab	222	216 (97.3)	2.08 (0.77)	0.8	1.58	1.97	2.48	4.9	
			Placebo	222	209 (94.1)	1.89 (0.71)	0.6	1.41	1.75	2.20	4.4	
		Week 24	Tezepelumab	222	207 (93.2)	2.06 (0.72)	0.7	1.58	1.97	2.50	4.4	
			Placebo	222	202 (91.0)	1.88 (0.70)	0.6	1.40	1.74	2.19	4.8	
		Week 36	Tezepelumab	222	203 (91.4)	2.08 (0.78)	0.6	1.52	1.98	2.49	4.5	
			Placebo	222	196 (88.3)	1.91 (0.72)	0.7	1.43	1.79	2.25	4.6	
		Week 52	Tezepelumab	222	195 (87.8)	2.09 (0.78)	0.6	1.56	2.01	2.52	4.3	
			Placebo	222	180 (81.1)	1.88 (0.73)	0.7	1.32	1.74	2.26	4.5	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Change from baseline	Week 2	Tezepelumab	222	217 (97.7)	0.22 (0.33)	-0.6	0.01	0.18	0.37	1.5	0.44 [0.24, 0.63]
			Placebo	222	214 (96.4)	0.06 (0.39)	-1.8	-0.11	0.01	0.22	1.2	
		Week 4	Tezepelumab	222	222 (100.0)	0.25 (0.37)	-0.7	0.02	0.17	0.38	1.8	0.44 [0.25, 0.63]
			Placebo	222	216 (97.3)	0.07 (0.42)	-1.8	-0.14	0.05	0.28	1.4	
		Week 8	Tezepelumab	222	219 (98.6)	0.30 (0.42)	-0.6	0.03	0.24	0.51	1.8	0.50 [0.31, 0.69]
			Placebo	222	216 (97.3)	0.10 (0.35)	-0.7	-0.12	0.07	0.29	1.6	
		Week 12	Tezepelumab	222	217 (97.7)	0.31 (0.43)	-0.8	0.02	0.23	0.52	2.0	0.47 [0.28, 0.66]
			Placebo	222	216 (97.3)	0.11 (0.41)	-1.4	-0.11	0.07	0.33	1.7	
		Week 16	Tezepelumab	222	216 (97.3)	0.32 (0.43)	-0.8	0.04	0.25	0.51	2.0	0.52 [0.33, 0.71]
			Placebo	222	209 (94.1)	0.11 (0.38)	-1.2	-0.10	0.04	0.33	1.8	
		Week 24	Tezepelumab	222	207 (93.2)	0.30 (0.42)	-1.0	0.00	0.26	0.49	1.7	0.47 [0.27, 0.66]
			Placebo	222	202 (91.0)	0.11 (0.40)	-0.9	-0.12	0.06	0.31	1.7	
		Week 36	Tezepelumab	222	203 (91.4)	0.32 (0.43)	-0.6	-0.01	0.24	0.54	1.7	0.49 [0.29, 0.69]
			Placebo	222	196 (88.3)	0.11 (0.43)	-1.1	-0.18	0.05	0.38	1.7	
		Week 52	Tezepelumab	222	195 (87.8)	0.32 (0.43)	-0.8	0.01	0.25	0.56	1.7	0.60 [0.39, 0.80]
			Placebo	222	180 (81.1)	0.08 (0.37)	-1.0	-0.16	0.06	0.28	1.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	137	137 (100.0)	1.61 (0.61)	0.4	1.16	1.49	2.01	3.3	
			Placebo	129	129 (100.0)	1.69 (0.63)	0.6	1.28	1.64	2.03	4.2	
		Week 2	Tezepelumab	137	135 (98.5)	1.79 (0.62)	0.6	1.31	1.73	2.21	3.8	
			Placebo	129	123 (95.3)	1.74 (0.62)	0.6	1.36	1.63	2.09	4.0	
		Week 4	Tezepelumab	137	136 (99.3)	1.85 (0.67)	0.7	1.28	1.77	2.35	3.8	
			Placebo	129	126 (97.7)	1.79 (0.63)	0.7	1.36	1.72	2.19	4.2	
		Week 8	Tezepelumab	137	135 (98.5)	1.85 (0.65)	0.6	1.31	1.76	2.38	3.8	
			Placebo	129	124 (96.1)	1.78 (0.65)	0.7	1.34	1.66	2.07	4.3	
		Week 12	Tezepelumab	137	135 (98.5)	1.88 (0.69)	0.6	1.38	1.76	2.37	4.6	
			Placebo	129	125 (96.9)	1.79 (0.67)	0.6	1.31	1.69	2.15	4.3	
		Week 16	Tezepelumab	137	134 (97.8)	1.89 (0.68)	0.6	1.33	1.83	2.40	3.8	
			Placebo	129	121 (93.8)	1.77 (0.64)	0.7	1.31	1.68	2.16	4.1	
		Week 24	Tezepelumab	137	130 (94.9)	1.87 (0.66)	0.6	1.34	1.76	2.35	4.0	
			Placebo	129	112 (86.8)	1.78 (0.64)	0.8	1.38	1.67	2.12	4.8	
		Week 36	Tezepelumab	137	126 (92.0)	1.86 (0.67)	0.5	1.27	1.77	2.34	3.8	
			Placebo	129	111 (86.0)	1.78 (0.64)	0.8	1.34	1.69	2.21	4.6	
		Week 52	Tezepelumab	137	125 (91.2)	1.90 (0.68)	0.7	1.38	1.87	2.35	3.7	
			Placebo	129	104 (80.6)	1.69 (0.64)	0.6	1.27	1.60	2.05	4.4	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Change from baseline	Week 2	Tezepelumab	137	135 (98.5)	0.18 (0.28)	-0.4	0.02	0.12	0.30	1.1	0.49 [0.24, 0.74]
			Placebo	129	123 (95.3)	0.04 (0.29)	-0.7	-0.10	-0.01	0.16	1.0	
		Week 4	Tezepelumab	137	136 (99.3)	0.24 (0.34)	-0.5	0.02	0.18	0.37	1.7	0.43 [0.19, 0.68]
			Placebo	129	126 (97.7)	0.10 (0.34)	-1.0	-0.08	0.05	0.23	1.2	
		Week 8	Tezepelumab	137	135 (98.5)	0.26 (0.35)	-0.6	0.00	0.18	0.45	1.4	0.51 [0.26, 0.76]
			Placebo	129	124 (96.1)	0.09 (0.31)	-0.6	-0.12	0.05	0.21	1.2	
		Week 12	Tezepelumab	137	135 (98.5)	0.26 (0.38)	-0.7	0.01	0.21	0.45	1.4	0.42 [0.17, 0.66]
			Placebo	129	125 (96.9)	0.11 (0.36)	-0.7	-0.10	0.03	0.29	1.2	
		Week 16	Tezepelumab	137	134 (97.8)	0.28 (0.36)	-0.6	0.04	0.24	0.43	1.6	0.60 [0.35, 0.85]
			Placebo	129	121 (93.8)	0.08 (0.31)	-0.7	-0.09	0.02	0.26	1.2	
		Week 24	Tezepelumab	137	130 (94.9)	0.27 (0.37)	-0.4	-0.01	0.21	0.44	1.7	0.53 [0.27, 0.79]
			Placebo	129	112 (86.8)	0.08 (0.34)	-0.8	-0.12	0.04	0.26	1.2	
		Week 36	Tezepelumab	137	126 (92.0)	0.25 (0.39)	-0.5	-0.02	0.16	0.44	1.6	0.46 [0.20, 0.71]
			Placebo	129	111 (86.0)	0.08 (0.35)	-0.9	-0.17	0.04	0.26	1.3	
		Week 52	Tezepelumab	137	125 (91.2)	0.27 (0.39)	-0.4	-0.02	0.22	0.51	1.4	0.80 [0.53, 1.07]
			Placebo	129	104 (80.6)	-0.00 (0.27)	-0.6	-0.18	0.04	0.15	0.7	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	241	241 (100.0)	1.81 (0.69)	0.5	1.34	1.64	2.13	4.1	
			Placebo	235	235 (100.0)	1.86 (0.70)	0.4	1.35	1.75	2.27	4.5	
		Week 2	Tezepelumab	241	234 (97.1)	1.99 (0.73)	0.6	1.45	1.86	2.45	4.3	
			Placebo	235	225 (95.7)	1.94 (0.73)	0.4	1.40	1.89	2.40	4.1	
		Week 4	Tezepelumab	241	240 (99.6)	1.99 (0.74)	0.6	1.45	1.86	2.48	4.3	
			Placebo	235	231 (98.3)	1.91 (0.71)	0.4	1.44	1.83	2.27	4.8	
		Week 8	Tezepelumab	241	238 (98.8)	2.02 (0.76)	0.6	1.44	1.93	2.43	4.7	
			Placebo	235	230 (97.9)	1.96 (0.76)	0.4	1.40	1.91	2.36	4.6	
		Week 12	Tezepelumab	241	233 (96.7)	2.03 (0.74)	0.6	1.56	1.92	2.44	4.7	
			Placebo	235	226 (96.2)	1.95 (0.74)	0.5	1.41	1.85	2.37	4.6	
		Week 16	Tezepelumab	241	232 (96.3)	2.05 (0.77)	0.6	1.52	1.92	2.46	4.9	
			Placebo	235	222 (94.5)	1.95 (0.76)	0.5	1.41	1.84	2.33	4.7	
		Week 24	Tezepelumab	241	225 (93.4)	2.00 (0.73)	0.6	1.53	1.88	2.48	4.4	
			Placebo	235	220 (93.6)	1.93 (0.74)	0.6	1.41	1.83	2.26	4.8	
		Week 36	Tezepelumab	241	216 (89.6)	2.02 (0.77)	0.6	1.47	1.91	2.46	4.5	
			Placebo	235	211 (89.8)	1.98 (0.76)	0.6	1.46	1.86	2.36	4.3	
		Week 52	Tezepelumab	241	211 (87.6)	2.01 (0.77)	0.6	1.49	1.83	2.44	4.3	
			Placebo	235	200 (85.1)	1.97 (0.78)	0.6	1.40	1.83	2.41	4.5	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Change from baseline	Week 2	Tezepelumab	241	234 (97.1)	0.18 (0.35)	-0.7	-0.02	0.13	0.32	1.5	0.35 [0.16, 0.53]
			Placebo	235	225 (95.7)	0.05 (0.38)	-1.8	-0.12	0.03	0.20	1.2	
		Week 4	Tezepelumab	241	240 (99.6)	0.19 (0.37)	-0.9	-0.01	0.12	0.32	1.8	0.32 [0.14, 0.51]
			Placebo	235	231 (98.3)	0.07 (0.40)	-1.8	-0.12	0.03	0.25	1.6	
		Week 8	Tezepelumab	241	238 (98.8)	0.23 (0.43)	-0.8	-0.04	0.15	0.44	1.8	0.37 [0.18, 0.55]
			Placebo	235	230 (97.9)	0.08 (0.35)	-0.9	-0.11	0.05	0.29	1.6	
		Week 12	Tezepelumab	241	233 (96.7)	0.23 (0.41)	-0.8	-0.03	0.16	0.40	2.0	0.38 [0.20, 0.57]
			Placebo	235	226 (96.2)	0.08 (0.39)	-1.5	-0.10	0.05	0.24	1.7	
		Week 16	Tezepelumab	241	232 (96.3)	0.24 (0.43)	-0.8	-0.04	0.16	0.42	2.0	0.39 [0.21, 0.58]
			Placebo	235	222 (94.5)	0.08 (0.38)	-1.2	-0.12	0.03	0.24	1.8	
		Week 24	Tezepelumab	241	225 (93.4)	0.22 (0.42)	-1.0	-0.05	0.16	0.42	1.6	0.37 [0.18, 0.56]
			Placebo	235	220 (93.6)	0.07 (0.40)	-1.1	-0.14	0.03	0.25	1.7	
		Week 36	Tezepelumab	241	216 (89.6)	0.23 (0.43)	-1.0	-0.05	0.17	0.46	1.7	0.30 [0.11, 0.49]
			Placebo	235	211 (89.8)	0.10 (0.40)	-1.1	-0.15	0.05	0.30	1.7	
		Week 52	Tezepelumab	241	211 (87.6)	0.22 (0.43)	-1.0	-0.02	0.16	0.43	1.7	0.30 [0.11, 0.50]
			Placebo	235	200 (85.1)	0.10 (0.38)	-1.0	-0.13	0.06	0.31	1.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Absolute values	Baseline	Tezepelumab	115	115 (100.0)	1.68 (0.65)	0.4	1.19	1.58	2.04	3.3	
			Placebo	121	121 (100.0)	1.67 (0.59)	0.7	1.30	1.55	1.98	4.2	
		Week 2	Tezepelumab	115	112 (97.4)	1.81 (0.62)	0.6	1.38	1.69	2.22	3.8	
			Placebo	121	113 (93.4)	1.70 (0.61)	0.6	1.35	1.63	1.97	4.0	
		Week 4	Tezepelumab	115	115 (100.0)	1.84 (0.68)	0.7	1.30	1.66	2.40	3.8	
			Placebo	121	118 (97.5)	1.74 (0.60)	0.7	1.33	1.68	2.05	4.2	
		Week 8	Tezepelumab	115	112 (97.4)	1.82 (0.63)	0.6	1.32	1.68	2.28	3.7	
			Placebo	121	116 (95.9)	1.76 (0.63)	0.7	1.33	1.66	2.07	4.3	
		Week 12	Tezepelumab	115	111 (96.5)	1.85 (0.70)	0.6	1.38	1.72	2.28	4.6	
			Placebo	121	116 (95.9)	1.74 (0.65)	0.6	1.31	1.66	2.10	4.3	
		Week 16	Tezepelumab	115	113 (98.3)	1.87 (0.70)	0.6	1.36	1.74	2.30	3.7	
			Placebo	121	112 (92.6)	1.74 (0.63)	0.6	1.31	1.67	2.10	4.1	
		Week 24	Tezepelumab	115	111 (96.5)	1.81 (0.62)	0.6	1.26	1.76	2.29	3.7	
			Placebo	121	108 (89.3)	1.71 (0.63)	0.8	1.28	1.66	2.05	4.8	
		Week 36	Tezepelumab	115	106 (92.2)	1.80 (0.66)	0.5	1.28	1.70	2.20	3.7	
			Placebo	121	103 (85.1)	1.79 (0.63)	0.7	1.34	1.74	2.14	4.6	
		Week 52	Tezepelumab	115	106 (92.2)	1.82 (0.67)	0.7	1.37	1.73	2.27	3.6	
			Placebo	121	102 (84.3)	1.72 (0.63)	0.7	1.27	1.63	2.10	4.4	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Change from baseline	Week 2	Tezepelumab	115	112 (97.4)	0.13 (0.29)	-0.7	-0.00	0.10	0.27	1.1	0.36 [0.10, 0.62]
			Placebo	121	113 (93.4)	0.03 (0.27)	-0.6	-0.09	-0.01	0.11	1.0	
		Week 4	Tezepelumab	115	115 (100.0)	0.16 (0.40)	-0.9	-0.06	0.10	0.32	1.7	0.21 [-0.05, 0.47]
			Placebo	121	118 (97.5)	0.09 (0.29)	-0.7	-0.07	0.06	0.20	1.1	
		Week 8	Tezepelumab	115	112 (97.4)	0.17 (0.38)	-0.8	-0.06	0.12	0.32	1.4	0.28 [0.02, 0.54]
			Placebo	121	116 (95.9)	0.08 (0.28)	-0.8	-0.09	0.04	0.19	1.2	
		Week 12	Tezepelumab	115	111 (96.5)	0.18 (0.40)	-0.8	-0.03	0.12	0.36	2.0	0.27 [0.01, 0.53]
			Placebo	121	116 (95.9)	0.08 (0.34)	-0.7	-0.10	0.03	0.22	1.2	
		Week 16	Tezepelumab	115	113 (98.3)	0.19 (0.38)	-0.8	0.00	0.15	0.34	1.7	0.37 [0.11, 0.63]
			Placebo	121	112 (92.6)	0.07 (0.31)	-0.7	-0.09	0.02	0.21	1.0	
		Week 24	Tezepelumab	115	111 (96.5)	0.17 (0.33)	-0.6	-0.06	0.12	0.35	1.2	0.35 [0.09, 0.62]
			Placebo	121	108 (89.3)	0.05 (0.31)	-0.8	-0.11	0.01	0.18	1.2	
		Week 36	Tezepelumab	115	106 (92.2)	0.14 (0.35)	-0.7	-0.08	0.06	0.31	1.3	0.10 [-0.18, 0.37]
			Placebo	121	103 (85.1)	0.11 (0.34)	-1.1	-0.11	0.06	0.29	1.1	
		Week 52	Tezepelumab	115	106 (92.2)	0.15 (0.38)	-1.0	-0.07	0.10	0.34	1.5	0.35 [0.07, 0.62]
			Placebo	121	102 (84.3)	0.03 (0.30)	-0.6	-0.17	0.01	0.15	1.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Absolute values	Baseline	Tezepelumab	235	235 (100.0)	1.75 (0.69)	0.6	1.26	1.60	2.12	4.1	
			Placebo	212	212 (100.0)	1.86 (0.73)	0.4	1.34	1.74	2.29	4.5	
		Week 2	Tezepelumab	235	229 (97.4)	1.95 (0.73)	0.6	1.38	1.83	2.42	4.3	
			Placebo	212	204 (96.2)	1.90 (0.70)	0.4	1.40	1.83	2.30	3.9	
		Week 4	Tezepelumab	235	232 (98.7)	1.97 (0.73)	0.6	1.41	1.87	2.42	4.2	
			Placebo	212	207 (97.6)	1.91 (0.68)	0.4	1.44	1.83	2.31	4.0	
		Week 8	Tezepelumab	235	232 (98.7)	1.99 (0.74)	0.6	1.41	1.89	2.44	4.7	
			Placebo	212	207 (97.6)	1.95 (0.72)	0.4	1.41	1.90	2.36	4.3	
		Week 12	Tezepelumab	235	228 (97.0)	2.00 (0.73)	0.6	1.51	1.91	2.45	4.3	
			Placebo	212	204 (96.2)	1.94 (0.72)	0.7	1.43	1.79	2.38	4.3	
		Week 16	Tezepelumab	235	225 (95.7)	2.02 (0.75)	0.6	1.50	1.89	2.48	4.7	
			Placebo	212	202 (95.3)	1.93 (0.72)	0.7	1.37	1.84	2.32	4.4	
		Week 24	Tezepelumab	235	217 (92.3)	2.00 (0.73)	0.6	1.51	1.84	2.50	4.0	
			Placebo	212	195 (92.0)	1.95 (0.70)	0.6	1.46	1.87	2.24	4.3	
		Week 36	Tezepelumab	235	211 (89.8)	2.02 (0.76)	0.6	1.43	1.92	2.45	4.4	
			Placebo	212	188 (88.7)	1.95 (0.73)	0.8	1.43	1.84	2.32	4.3	
		Week 52	Tezepelumab	235	205 (87.2)	2.02 (0.77)	0.6	1.47	1.90	2.46	4.3	
			Placebo	212	176 (83.0)	1.94 (0.75)	0.6	1.40	1.82	2.40	4.5	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Change from baseline	Week 2	Tezepelumab	235	229 (97.4)	0.20 (0.34)	-0.5	-0.01	0.14	0.33	1.5	0.49 [0.30, 0.68]
			Placebo	212	204 (96.2)	0.02 (0.37)	-1.8	-0.14	0.01	0.17	1.2	
		Week 4	Tezepelumab	235	232 (98.7)	0.23 (0.32)	-0.5	0.01	0.16	0.35	1.8	0.47 [0.28, 0.66]
			Placebo	212	207 (97.6)	0.06 (0.40)	-1.8	-0.12	0.03	0.24	1.4	
		Week 8	Tezepelumab	235	232 (98.7)	0.26 (0.40)	-0.8	0.00	0.18	0.47	1.7	0.49 [0.30, 0.68]
			Placebo	212	207 (97.6)	0.08 (0.35)	-0.9	-0.13	0.07	0.28	1.6	
		Week 12	Tezepelumab	235	228 (97.0)	0.26 (0.39)	-0.7	-0.01	0.20	0.47	1.6	0.49 [0.30, 0.68]
			Placebo	212	204 (96.2)	0.07 (0.40)	-1.5	-0.11	0.05	0.25	1.7	
		Week 16	Tezepelumab	235	225 (95.7)	0.28 (0.40)	-0.6	0.00	0.20	0.50	1.9	0.56 [0.37, 0.75]
			Placebo	212	202 (95.3)	0.06 (0.38)	-1.2	-0.15	0.03	0.24	1.8	
		Week 24	Tezepelumab	235	217 (92.3)	0.26 (0.42)	-1.0	-0.02	0.23	0.48	1.7	0.49 [0.29, 0.68]
			Placebo	212	195 (92.0)	0.06 (0.39)	-1.1	-0.15	0.05	0.27	1.7	
		Week 36	Tezepelumab	235	211 (89.8)	0.27 (0.42)	-1.0	-0.03	0.22	0.53	1.6	0.51 [0.31, 0.71]
			Placebo	212	188 (88.7)	0.07 (0.40)	-1.0	-0.19	0.04	0.27	1.7	
		Week 52	Tezepelumab	235	205 (87.2)	0.28 (0.43)	-1.0	0.00	0.22	0.55	1.7	0.58 [0.37, 0.78]
			Placebo	212	176 (83.0)	0.06 (0.35)	-1.0	-0.15	0.06	0.24	1.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Absolute values	Baseline	Tezepelumab	30	30 (100.0)	1.89 (0.60)	0.8	1.55	1.80	2.13	3.8	
			Placebo	38	38 (100.0)	1.86 (0.62)	0.6	1.37	1.80	2.26	3.2	
		Week 2	Tezepelumab	30	29 (96.7)	2.13 (0.66)	1.0	1.64	2.12	2.53	3.8	
			Placebo	38	36 (94.7)	2.14 (0.82)	0.8	1.48	2.24	2.60	4.1	
		Week 4	Tezepelumab	30	30 (100.0)	2.15 (0.70)	0.9	1.58	2.12	2.52	4.3	
			Placebo	38	38 (100.0)	1.98 (0.88)	0.5	1.42	1.98	2.30	4.8	
		Week 8	Tezepelumab	30	30 (100.0)	2.22 (0.80)	1.0	1.60	2.11	2.59	4.7	
			Placebo	38	38 (100.0)	2.01 (0.89)	0.6	1.46	1.90	2.43	4.6	
		Week 12	Tezepelumab	30	30 (100.0)	2.21 (0.76)	1.2	1.64	2.19	2.44	4.7	
			Placebo	38	37 (97.4)	2.09 (0.84)	0.5	1.49	2.08	2.47	4.6	
		Week 16	Tezepelumab	30	29 (96.7)	2.20 (0.80)	1.0	1.67	2.10	2.37	4.9	
			Placebo	38	36 (94.7)	2.03 (0.88)	0.5	1.42	1.94	2.49	4.7	
		Week 24	Tezepelumab	30	28 (93.3)	2.20 (0.78)	0.9	1.67	2.11	2.55	4.4	
			Placebo	38	36 (94.7)	1.99 (0.87)	0.7	1.42	1.79	2.42	4.8	
		Week 36	Tezepelumab	30	26 (86.7)	2.18 (0.79)	0.9	1.59	1.93	2.50	4.5	
			Placebo	38	37 (97.4)	2.03 (0.89)	0.6	1.52	1.84	2.32	4.3	
		Week 52	Tezepelumab	30	26 (86.7)	2.13 (0.72)	0.9	1.63	1.94	2.47	4.0	
			Placebo	38	30 (78.9)	2.03 (0.91)	0.6	1.40	1.95	2.68	4.0	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Change from baseline	Week 2	Tezepelumab	30	29 (96.7)	0.25 (0.38)	-0.4	0.01	0.13	0.43	1.3	0.02 [-0.47, 0.51]
			Placebo	38	36 (94.7)	0.24 (0.38)	-0.5	-0.04	0.18	0.51	1.1	
		Week 4	Tezepelumab	30	30 (100.0)	0.26 (0.42)	-0.4	0.05	0.18	0.39	1.4	0.31 [-0.17, 0.79]
			Placebo	38	38 (100.0)	0.12 (0.48)	-0.8	-0.18	-0.02	0.49	1.6	
		Week 8	Tezepelumab	30	30 (100.0)	0.33 (0.53)	-0.4	0.04	0.16	0.53	1.8	0.40 [-0.08, 0.88]
			Placebo	38	38 (100.0)	0.15 (0.39)	-0.6	-0.12	0.07	0.39	1.4	
		Week 12	Tezepelumab	30	30 (100.0)	0.31 (0.47)	-0.3	0.05	0.19	0.44	1.9	0.21 [-0.27, 0.69]
			Placebo	38	37 (97.4)	0.23 (0.35)	-0.2	0.00	0.12	0.36	1.4	
		Week 16	Tezepelumab	30	29 (96.7)	0.30 (0.53)	-0.5	0.01	0.15	0.30	2.0	0.26 [-0.23, 0.75]
			Placebo	38	36 (94.7)	0.18 (0.39)	-0.4	-0.04	0.04	0.41	1.4	
		Week 24	Tezepelumab	30	28 (93.3)	0.30 (0.49)	-0.4	-0.07	0.24	0.48	1.5	0.35 [-0.15, 0.85]
			Placebo	38	36 (94.7)	0.14 (0.45)	-0.8	-0.10	0.04	0.39	1.6	
		Week 36	Tezepelumab	30	26 (86.7)	0.30 (0.50)	-0.8	-0.02	0.16	0.54	1.7	0.28 [-0.22, 0.78]
			Placebo	38	37 (97.4)	0.17 (0.43)	-0.6	-0.16	0.05	0.37	1.1	
		Week 52	Tezepelumab	30	26 (86.7)	0.25 (0.41)	-0.8	0.03	0.19	0.44	1.2	0.12 [-0.41, 0.65]
			Placebo	38	30 (78.9)	0.20 (0.43)	-0.7	-0.06	0.17	0.45	1.1	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Absolute values	Baseline	Tezepelumab	46	46 (100.0)	1.77 (0.71)	0.4	1.31	1.72	2.11	3.6	
			Placebo	42	42 (100.0)	1.85 (0.66)	0.8	1.43	1.77	2.22	3.7	
		Week 2	Tezepelumab	46	45 (97.8)	2.01 (0.72)	0.6	1.54	1.93	2.32	3.9	
			Placebo	42	40 (95.2)	1.84 (0.65)	0.8	1.34	1.78	2.29	3.7	
		Week 4	Tezepelumab	46	46 (100.0)	2.04 (0.74)	0.7	1.49	2.00	2.59	3.8	
			Placebo	42	41 (97.6)	1.86 (0.62)	0.7	1.56	1.76	2.09	4.0	
		Week 8	Tezepelumab	46	45 (97.8)	2.00 (0.71)	0.6	1.50	1.95	2.46	3.7	
			Placebo	42	42 (100.0)	1.90 (0.75)	0.7	1.51	1.78	2.28	3.9	
		Week 12	Tezepelumab	46	43 (93.5)	2.00 (0.78)	0.6	1.50	1.92	2.38	4.6	
			Placebo	42	39 (92.9)	1.89 (0.67)	0.7	1.48	1.73	2.16	3.6	
		Week 16	Tezepelumab	46	45 (97.8)	2.04 (0.77)	0.6	1.54	1.97	2.48	4.2	
			Placebo	42	35 (83.3)	1.85 (0.68)	0.9	1.36	1.76	2.14	3.6	
		Week 24	Tezepelumab	46	42 (91.3)	2.01 (0.68)	0.9	1.61	1.92	2.50	3.7	
			Placebo	42	31 (73.8)	1.84 (0.70)	0.9	1.29	1.76	2.19	4.2	
		Week 36	Tezepelumab	46	39 (84.8)	2.00 (0.71)	0.9	1.53	1.89	2.39	4.0	
			Placebo	42	32 (76.2)	1.87 (0.64)	0.8	1.42	1.82	2.10	3.6	
		Week 52	Tezepelumab	46	37 (80.4)	2.08 (0.72)	0.8	1.72	2.05	2.37	4.1	
			Placebo	42	28 (66.7)	1.88 (0.75)	0.9	1.26	1.72	2.25	3.7	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	46	45 (97.8)	0.23 (0.33)	-0.6	0.01	0.19	0.38	1.1	0.73 [0.29, 1.17]
			Placebo	42	40 (95.2)	-0.05 (0.43)	-1.8	-0.13	-0.03	0.12	1.0	
		Week 4	Tezepelumab	46	46 (100.0)	0.27 (0.35)	-0.7	0.05	0.26	0.41	1.1	0.65 [0.22, 1.08]
			Placebo	42	41 (97.6)	0.01 (0.46)	-1.0	-0.21	-0.01	0.22	1.4	
		Week 8	Tezepelumab	46	45 (97.8)	0.23 (0.36)	-0.4	0.00	0.20	0.39	1.2	0.48 [0.05, 0.90]
			Placebo	42	42 (100.0)	0.04 (0.40)	-0.6	-0.17	-0.01	0.20	1.3	
		Week 12	Tezepelumab	46	43 (93.5)	0.29 (0.45)	-0.8	0.10	0.21	0.50	1.3	0.56 [0.12, 1.00]
			Placebo	42	39 (92.9)	0.04 (0.46)	-1.2	-0.15	-0.04	0.25	1.2	
		Week 16	Tezepelumab	46	45 (97.8)	0.29 (0.36)	-0.8	0.07	0.28	0.45	1.2	0.90 [0.44, 1.37]
			Placebo	42	35 (83.3)	-0.03 (0.35)	-0.8	-0.22	-0.06	0.13	1.0	
		Week 24	Tezepelumab	46	42 (91.3)	0.33 (0.37)	-0.2	0.04	0.28	0.52	1.3	0.96 [0.47, 1.45]
			Placebo	42	31 (73.8)	-0.06 (0.45)	-0.9	-0.41	-0.04	0.14	1.6	
		Week 36	Tezepelumab	46	39 (84.8)	0.27 (0.38)	-0.8	-0.02	0.26	0.44	1.3	0.96 [0.47, 1.46]
			Placebo	42	32 (76.2)	-0.08 (0.33)	-0.7	-0.29	-0.09	0.08	1.1	
		Week 52	Tezepelumab	46	37 (80.4)	0.28 (0.40)	-0.8	0.00	0.34	0.52	1.0	0.82 [0.31, 1.33]
			Placebo	42	28 (66.7)	-0.04 (0.37)	-0.8	-0.26	-0.01	0.12	1.1	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Absolute values	Baseline	Tezepelumab	334	334 (100.0)	1.73 (0.67)	0.5	1.26	1.61	2.12	4.1	
			Placebo	329	329 (100.0)	1.79 (0.68)	0.4	1.33	1.69	2.18	4.5	
		Week 2	Tezepelumab	334	325 (97.3)	1.91 (0.69)	0.6	1.38	1.78	2.41	4.3	
			Placebo	329	313 (95.1)	1.86 (0.71)	0.4	1.38	1.75	2.28	4.1	
		Week 4	Tezepelumab	334	331 (99.1)	1.93 (0.71)	0.6	1.41	1.83	2.41	4.3	
			Placebo	329	322 (97.9)	1.86 (0.69)	0.4	1.38	1.79	2.25	4.8	
		Week 8	Tezepelumab	334	329 (98.5)	1.96 (0.72)	0.6	1.40	1.83	2.40	4.7	
			Placebo	329	319 (97.0)	1.89 (0.72)	0.4	1.38	1.79	2.27	4.6	
		Week 12	Tezepelumab	334	326 (97.6)	1.97 (0.72)	0.6	1.47	1.85	2.41	4.7	
			Placebo	329	318 (96.7)	1.89 (0.72)	0.5	1.37	1.76	2.29	4.6	
		Week 16	Tezepelumab	334	322 (96.4)	1.99 (0.74)	0.6	1.45	1.86	2.40	4.9	
			Placebo	329	315 (95.7)	1.89 (0.72)	0.5	1.33	1.77	2.23	4.7	
		Week 24	Tezepelumab	334	314 (94.0)	1.95 (0.71)	0.6	1.44	1.82	2.38	4.4	
			Placebo	329	308 (93.6)	1.88 (0.71)	0.6	1.40	1.77	2.22	4.8	
		Week 36	Tezepelumab	334	304 (91.0)	1.96 (0.74)	0.5	1.41	1.86	2.40	4.5	
			Placebo	329	296 (90.0)	1.92 (0.73)	0.6	1.41	1.79	2.29	4.6	
		Week 52	Tezepelumab	334	300 (89.8)	1.96 (0.74)	0.6	1.43	1.82	2.43	4.3	
			Placebo	329	280 (85.1)	1.87 (0.74)	0.6	1.32	1.74	2.29	4.5	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Change from baseline	Week 2	Tezepelumab	334	325 (97.3)	0.17 (0.33)	-0.7	-0.01	0.12	0.30	1.5	0.34 [0.19, 0.50]
			Placebo	329	313 (95.1)	0.06 (0.34)	-1.1	-0.12	0.01	0.19	1.2	
		Week 4	Tezepelumab	334	331 (99.1)	0.20 (0.36)	-0.9	-0.01	0.13	0.33	1.8	0.33 [0.17, 0.48]
			Placebo	329	322 (97.9)	0.08 (0.36)	-1.8	-0.11	0.05	0.24	1.6	
		Week 8	Tezepelumab	334	329 (98.5)	0.24 (0.41)	-0.8	-0.04	0.15	0.45	1.8	0.41 [0.25, 0.56]
			Placebo	329	319 (97.0)	0.09 (0.33)	-0.9	-0.11	0.06	0.28	1.6	
		Week 12	Tezepelumab	334	326 (97.6)	0.24 (0.40)	-0.7	-0.02	0.17	0.41	2.0	0.37 [0.21, 0.52]
			Placebo	329	318 (96.7)	0.10 (0.37)	-1.5	-0.09	0.05	0.26	1.7	
		Week 16	Tezepelumab	334	322 (96.4)	0.25 (0.42)	-0.6	0.00	0.16	0.40	2.0	0.42 [0.26, 0.58]
			Placebo	329	315 (95.7)	0.09 (0.36)	-1.2	-0.09	0.04	0.26	1.8	
		Week 24	Tezepelumab	334	314 (94.0)	0.22 (0.41)	-1.0	-0.05	0.17	0.42	1.7	0.37 [0.21, 0.52]
			Placebo	329	308 (93.6)	0.08 (0.36)	-1.1	-0.13	0.04	0.27	1.7	
		Week 36	Tezepelumab	334	304 (91.0)	0.23 (0.42)	-1.0	-0.04	0.15	0.46	1.7	0.30 [0.14, 0.47]
			Placebo	329	296 (90.0)	0.11 (0.38)	-1.1	-0.14	0.06	0.30	1.7	
		Week 52	Tezepelumab	334	300 (89.8)	0.23 (0.42)	-1.0	-0.02	0.16	0.46	1.7	0.42 [0.26, 0.59]
			Placebo	329	280 (85.1)	0.07 (0.34)	-1.0	-0.15	0.06	0.23	1.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	112	112 (100.0)	1.76 (0.69)	0.6	1.29	1.70	2.05	4.1	
			Placebo	104	104 (100.0)	1.80 (0.65)	0.4	1.42	1.74	2.15	4.2	
		Week 2	Tezepelumab	112	111 (99.1)	1.97 (0.72)	0.7	1.42	1.86	2.38	4.3	
			Placebo	104	101 (97.1)	1.85 (0.70)	0.4	1.36	1.82	2.26	4.0	
		Week 4	Tezepelumab	112	112 (100.0)	1.96 (0.73)	0.7	1.44	1.83	2.39	4.3	
			Placebo	104	103 (99.0)	1.86 (0.71)	0.4	1.42	1.73	2.20	4.2	
		Week 8	Tezepelumab	112	111 (99.1)	2.01 (0.76)	0.7	1.44	1.95	2.36	4.7	
			Placebo	104	99 (95.2)	1.89 (0.73)	0.4	1.50	1.76	2.28	4.3	
		Week 12	Tezepelumab	112	108 (96.4)	2.03 (0.79)	0.7	1.52	1.93	2.37	4.7	
			Placebo	104	99 (95.2)	1.83 (0.69)	0.6	1.37	1.72	2.24	4.3	
		Week 16	Tezepelumab	112	107 (95.5)	2.04 (0.80)	0.6	1.52	1.93	2.39	4.9	
			Placebo	104	96 (92.3)	1.86 (0.68)	0.7	1.39	1.71	2.19	4.1	
		Week 24	Tezepelumab	112	105 (93.8)	2.00 (0.74)	0.6	1.52	1.91	2.32	4.4	
			Placebo	104	94 (90.4)	1.87 (0.72)	0.6	1.38	1.74	2.22	4.8	
		Week 36	Tezepelumab	112	99 (88.4)	2.02 (0.79)	0.5	1.42	1.92	2.42	4.5	
			Placebo	104	91 (87.5)	1.93 (0.72)	0.7	1.44	1.80	2.29	4.6	
		Week 52	Tezepelumab	112	95 (84.8)	2.07 (0.78)	0.6	1.51	2.02	2.42	4.2	
			Placebo	104	87 (83.7)	1.88 (0.75)	0.7	1.30	1.75	2.23	4.4	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	112	111 (99.1)	0.20 (0.31)	-0.6	0.01	0.15	0.38	1.1	0.49 [0.22, 0.77]
			Placebo	104	101 (97.1)	0.05 (0.32)	-1.0	-0.13	0.04	0.17	1.0	
		Week 4	Tezepelumab	112	112 (100.0)	0.20 (0.34)	-0.7	0.02	0.17	0.31	1.6	0.43 [0.16, 0.70]
			Placebo	104	103 (99.0)	0.05 (0.34)	-0.7	-0.11	0.03	0.23	1.4	
		Week 8	Tezepelumab	112	111 (99.1)	0.25 (0.40)	-0.6	0.00	0.22	0.46	1.8	0.47 [0.19, 0.74]
			Placebo	104	99 (95.2)	0.08 (0.34)	-0.8	-0.13	0.06	0.31	1.3	
		Week 12	Tezepelumab	112	108 (96.4)	0.27 (0.46)	-0.8	-0.02	0.19	0.49	2.0	0.61 [0.33, 0.89]
			Placebo	104	99 (95.2)	0.02 (0.37)	-1.5	-0.13	0.01	0.26	0.9	
		Week 16	Tezepelumab	112	107 (95.5)	0.29 (0.40)	-0.8	0.04	0.24	0.45	2.0	0.66 [0.37, 0.94]
			Placebo	104	96 (92.3)	0.05 (0.33)	-1.0	-0.11	0.02	0.24	0.7	
		Week 24	Tezepelumab	112	105 (93.8)	0.26 (0.38)	-0.7	-0.03	0.23	0.43	1.6	0.57 [0.29, 0.85]
			Placebo	104	94 (90.4)	0.05 (0.35)	-0.9	-0.14	0.04	0.23	1.6	
		Week 36	Tezepelumab	112	99 (88.4)	0.27 (0.38)	-0.5	0.00	0.23	0.48	1.7	0.48 [0.19, 0.77]
			Placebo	104	91 (87.5)	0.10 (0.33)	-1.0	-0.14	0.06	0.35	1.1	
		Week 52	Tezepelumab	112	95 (84.8)	0.28 (0.41)	-0.8	0.00	0.24	0.55	1.5	0.59 [0.29, 0.88]
			Placebo	104	87 (83.7)	0.06 (0.36)	-1.0	-0.13	0.06	0.21	1.1	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Absolute values	Baseline	Tezepelumab	268	268 (100.0)	1.73 (0.67)	0.4	1.25	1.61	2.13	3.8	
			Placebo	267	267 (100.0)	1.80 (0.69)	0.6	1.30	1.69	2.22	4.5	
		Week 2	Tezepelumab	268	259 (96.6)	1.90 (0.69)	0.6	1.37	1.74	2.42	4.0	
			Placebo	267	252 (94.4)	1.87 (0.70)	0.6	1.38	1.73	2.29	4.1	
		Week 4	Tezepelumab	268	265 (98.9)	1.93 (0.72)	0.6	1.41	1.84	2.48	4.2	
			Placebo	267	260 (97.4)	1.87 (0.67)	0.5	1.38	1.82	2.24	4.8	
		Week 8	Tezepelumab	268	263 (98.1)	1.94 (0.71)	0.6	1.39	1.82	2.43	4.2	
			Placebo	267	262 (98.1)	1.89 (0.72)	0.6	1.34	1.81	2.27	4.6	
		Week 12	Tezepelumab	268	261 (97.4)	1.95 (0.70)	0.6	1.46	1.83	2.41	4.3	
			Placebo	267	258 (96.6)	1.92 (0.73)	0.5	1.39	1.81	2.32	4.6	
		Week 16	Tezepelumab	268	260 (97.0)	1.97 (0.72)	0.6	1.43	1.86	2.48	4.3	
			Placebo	267	254 (95.1)	1.89 (0.73)	0.5	1.33	1.78	2.23	4.7	
		Week 24	Tezepelumab	268	251 (93.7)	1.94 (0.69)	0.6	1.41	1.80	2.42	4.0	
			Placebo	267	245 (91.8)	1.88 (0.70)	0.6	1.40	1.78	2.21	4.8	
		Week 36	Tezepelumab	268	244 (91.0)	1.94 (0.72)	0.6	1.42	1.85	2.39	4.2	
			Placebo	267	237 (88.8)	1.91 (0.73)	0.6	1.40	1.79	2.27	4.3	
		Week 52	Tezepelumab	268	242 (90.3)	1.93 (0.72)	0.7	1.43	1.82	2.39	4.3	
			Placebo	267	221 (82.8)	1.87 (0.74)	0.6	1.32	1.73	2.29	4.5	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Change from baseline	Week 2	Tezepelumab	268	259 (96.6)	0.17 (0.34)	-0.7	-0.01	0.12	0.29	1.5	0.35 [0.18, 0.53]
			Placebo	267	252 (94.4)	0.05 (0.36)	-1.8	-0.11	0.01	0.18	1.2	
		Week 4	Tezepelumab	268	265 (98.9)	0.21 (0.36)	-0.9	-0.01	0.13	0.36	1.8	0.35 [0.17, 0.52]
			Placebo	267	260 (97.4)	0.08 (0.39)	-1.8	-0.12	0.05	0.25	1.6	
		Week 8	Tezepelumab	268	263 (98.1)	0.23 (0.41)	-0.8	-0.04	0.14	0.44	1.7	0.39 [0.22, 0.57]
			Placebo	267	262 (98.1)	0.09 (0.33)	-0.9	-0.11	0.05	0.24	1.6	
		Week 12	Tezepelumab	268	261 (97.4)	0.23 (0.38)	-0.7	-0.01	0.17	0.39	1.6	0.30 [0.13, 0.48]
			Placebo	267	258 (96.6)	0.12 (0.38)	-1.4	-0.08	0.06	0.26	1.7	
		Week 16	Tezepelumab	268	260 (97.0)	0.24 (0.41)	-0.6	-0.02	0.15	0.41	1.9	0.40 [0.22, 0.57]
			Placebo	267	254 (95.1)	0.09 (0.37)	-1.2	-0.11	0.03	0.24	1.8	
		Week 24	Tezepelumab	268	251 (93.7)	0.23 (0.42)	-1.0	-0.05	0.17	0.43	1.7	0.38 [0.20, 0.55]
			Placebo	267	245 (91.8)	0.08 (0.38)	-1.1	-0.13	0.03	0.26	1.7	
		Week 36	Tezepelumab	268	244 (91.0)	0.22 (0.43)	-1.0	-0.06	0.12	0.45	1.6	0.32 [0.14, 0.50]
			Placebo	267	237 (88.8)	0.09 (0.40)	-1.1	-0.16	0.04	0.27	1.7	
		Week 52	Tezepelumab	268	242 (90.3)	0.22 (0.42)	-1.0	-0.04	0.13	0.44	1.7	0.41 [0.23, 0.60]
			Placebo	267	221 (82.8)	0.07 (0.34)	-1.0	-0.15	0.04	0.23	1.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	103	103 (100.0)	1.78 (0.69)	0.8	1.29	1.71	2.07	4.1	
			Placebo	100	100 (100.0)	1.80 (0.66)	0.4	1.40	1.72	2.17	4.2	
		Week 2	Tezepelumab	103	102 (99.0)	1.98 (0.72)	0.8	1.42	1.87	2.38	4.3	
			Placebo	100	97 (97.0)	1.86 (0.72)	0.4	1.36	1.85	2.31	4.0	
		Week 4	Tezepelumab	103	103 (100.0)	1.98 (0.73)	0.7	1.44	1.82	2.40	4.3	
			Placebo	100	99 (99.0)	1.86 (0.72)	0.4	1.42	1.73	2.22	4.2	
		Week 8	Tezepelumab	103	102 (99.0)	2.02 (0.76)	0.8	1.45	1.95	2.36	4.7	
			Placebo	100	95 (95.0)	1.90 (0.73)	0.4	1.51	1.79	2.28	4.3	
		Week 12	Tezepelumab	103	99 (96.1)	2.04 (0.79)	0.9	1.52	1.92	2.39	4.7	
			Placebo	100	95 (95.0)	1.83 (0.70)	0.6	1.37	1.72	2.24	4.3	
		Week 16	Tezepelumab	103	99 (96.1)	2.07 (0.80)	0.8	1.53	1.95	2.39	4.9	
			Placebo	100	93 (93.0)	1.86 (0.69)	0.7	1.36	1.71	2.18	4.1	
		Week 24	Tezepelumab	103	97 (94.2)	2.03 (0.73)	0.8	1.56	1.91	2.35	4.4	
			Placebo	100	91 (91.0)	1.88 (0.73)	0.6	1.38	1.75	2.24	4.8	
		Week 36	Tezepelumab	103	91 (88.3)	2.05 (0.79)	0.8	1.44	1.92	2.45	4.5	
			Placebo	100	88 (88.0)	1.93 (0.73)	0.7	1.45	1.81	2.29	4.6	
		Week 52	Tezepelumab	103	87 (84.5)	2.09 (0.79)	0.6	1.54	2.02	2.43	4.2	
			Placebo	100	85 (85.0)	1.88 (0.76)	0.7	1.30	1.75	2.21	4.4	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	103	102 (99.0)	0.21 (0.32)	-0.6	0.00	0.16	0.40	1.1	0.46 [0.18, 0.74]
			Placebo	100	97 (97.0)	0.06 (0.33)	-1.0	-0.12	0.06	0.19	1.0	
		Week 4	Tezepelumab	103	103 (100.0)	0.20 (0.35)	-0.7	0.01	0.17	0.31	1.6	0.39 [0.12, 0.67]
			Placebo	100	99 (99.0)	0.06 (0.35)	-0.7	-0.11	0.04	0.24	1.4	
		Week 8	Tezepelumab	103	102 (99.0)	0.25 (0.42)	-0.6	-0.02	0.23	0.50	1.8	0.45 [0.17, 0.73]
			Placebo	100	95 (95.0)	0.08 (0.33)	-0.7	-0.12	0.06	0.31	1.3	
		Week 12	Tezepelumab	103	99 (96.1)	0.27 (0.47)	-0.8	-0.05	0.19	0.50	2.0	0.59 [0.30, 0.88]
			Placebo	100	95 (95.0)	0.02 (0.36)	-1.5	-0.13	0.02	0.26	0.9	
		Week 16	Tezepelumab	103	99 (96.1)	0.30 (0.41)	-0.8	0.04	0.24	0.47	2.0	0.68 [0.39, 0.97]
			Placebo	100	93 (93.0)	0.04 (0.33)	-1.0	-0.10	0.02	0.21	0.7	
		Week 24	Tezepelumab	103	97 (94.2)	0.26 (0.39)	-0.7	-0.04	0.23	0.43	1.6	0.56 [0.27, 0.85]
			Placebo	100	91 (91.0)	0.05 (0.36)	-0.9	-0.14	0.05	0.25	1.6	
		Week 36	Tezepelumab	103	91 (88.3)	0.28 (0.39)	-0.5	0.02	0.23	0.48	1.7	0.49 [0.19, 0.78]
			Placebo	100	88 (88.0)	0.10 (0.33)	-1.0	-0.13	0.06	0.34	1.1	
		Week 52	Tezepelumab	103	87 (84.5)	0.29 (0.42)	-0.8	0.00	0.24	0.55	1.5	0.59 [0.28, 0.89]
			Placebo	100	85 (85.0)	0.05 (0.36)	-1.0	-0.13	0.06	0.19	1.1	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Absolute values	Baseline	Tezepelumab	277	277 (100.0)	1.73 (0.67)	0.4	1.24	1.61	2.13	3.8	
			Placebo	271	271 (100.0)	1.80 (0.69)	0.6	1.31	1.69	2.22	4.5	
		Week 2	Tezepelumab	277	268 (96.8)	1.90 (0.69)	0.6	1.37	1.77	2.42	4.0	
			Placebo	271	256 (94.5)	1.86 (0.69)	0.6	1.38	1.73	2.28	4.1	
		Week 4	Tezepelumab	277	274 (98.9)	1.93 (0.72)	0.6	1.39	1.85	2.48	4.2	
			Placebo	271	264 (97.4)	1.86 (0.67)	0.5	1.38	1.82	2.22	4.8	
		Week 8	Tezepelumab	277	272 (98.2)	1.94 (0.71)	0.6	1.39	1.83	2.44	4.2	
			Placebo	271	266 (98.2)	1.89 (0.72)	0.6	1.34	1.80	2.27	4.6	
		Week 12	Tezepelumab	277	270 (97.5)	1.95 (0.70)	0.6	1.46	1.83	2.41	4.3	
			Placebo	271	262 (96.7)	1.91 (0.72)	0.5	1.39	1.80	2.32	4.6	
		Week 16	Tezepelumab	277	268 (96.8)	1.96 (0.72)	0.6	1.42	1.85	2.48	4.3	
			Placebo	271	257 (94.8)	1.89 (0.73)	0.5	1.33	1.78	2.23	4.7	
		Week 24	Tezepelumab	277	259 (93.5)	1.93 (0.70)	0.6	1.41	1.80	2.41	4.0	
			Placebo	271	248 (91.5)	1.88 (0.70)	0.6	1.40	1.77	2.21	4.8	
		Week 36	Tezepelumab	277	252 (91.0)	1.94 (0.72)	0.5	1.41	1.85	2.38	4.2	
			Placebo	271	240 (88.6)	1.90 (0.72)	0.6	1.41	1.79	2.28	4.3	
		Week 52	Tezepelumab	277	250 (90.3)	1.93 (0.72)	0.7	1.43	1.82	2.39	4.3	
			Placebo	271	223 (82.3)	1.87 (0.74)	0.6	1.32	1.73	2.29	4.5	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Change from baseline	Week 2	Tezepelumab	277	268 (96.8)	0.17 (0.33)	-0.7	-0.01	0.12	0.29	1.5	0.37 [0.20, 0.54]
			Placebo	271	256 (94.5)	0.05 (0.36)	-1.8	-0.11	0.00	0.18	1.2	
		Week 4	Tezepelumab	277	274 (98.9)	0.21 (0.36)	-0.9	-0.01	0.14	0.36	1.8	0.36 [0.19, 0.53]
			Placebo	271	264 (97.4)	0.08 (0.39)	-1.8	-0.12	0.05	0.24	1.6	
		Week 8	Tezepelumab	277	272 (98.2)	0.24 (0.40)	-0.8	-0.04	0.14	0.44	1.7	0.40 [0.23, 0.57]
			Placebo	271	266 (98.2)	0.09 (0.34)	-0.9	-0.11	0.05	0.24	1.6	
		Week 12	Tezepelumab	277	270 (97.5)	0.23 (0.37)	-0.7	-0.01	0.17	0.40	1.6	0.32 [0.14, 0.49]
			Placebo	271	262 (96.7)	0.11 (0.38)	-1.4	-0.09	0.05	0.26	1.7	
		Week 16	Tezepelumab	277	268 (96.8)	0.24 (0.41)	-0.6	-0.02	0.15	0.40	1.9	0.39 [0.22, 0.56]
			Placebo	271	257 (94.8)	0.09 (0.37)	-1.2	-0.11	0.03	0.24	1.8	
		Week 24	Tezepelumab	277	259 (93.5)	0.23 (0.41)	-1.0	-0.04	0.17	0.43	1.7	0.38 [0.21, 0.56]
			Placebo	271	248 (91.5)	0.08 (0.38)	-1.1	-0.14	0.03	0.25	1.7	
		Week 36	Tezepelumab	277	252 (91.0)	0.22 (0.42)	-1.0	-0.06	0.13	0.45	1.6	0.32 [0.15, 0.50]
			Placebo	271	240 (88.6)	0.09 (0.40)	-1.1	-0.17	0.04	0.27	1.7	
		Week 52	Tezepelumab	277	250 (90.3)	0.22 (0.41)	-1.0	-0.03	0.14	0.44	1.7	0.41 [0.23, 0.60]
			Placebo	271	223 (82.3)	0.07 (0.34)	-1.0	-0.15	0.04	0.23	1.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	163	163 (100.0)	1.69 (0.68)	0.5	1.22	1.59	2.02	4.0	
			Placebo	141	141 (100.0)	1.83 (0.66)	0.6	1.37	1.73	2.13	4.1	
		Week 2	Tezepelumab	163	158 (96.9)	1.89 (0.70)	0.6	1.35	1.75	2.33	4.1	
			Placebo	141	135 (95.7)	1.89 (0.68)	0.7	1.45	1.80	2.32	3.9	
		Week 4	Tezepelumab	163	162 (99.4)	1.92 (0.74)	0.6	1.41	1.76	2.38	4.3	
			Placebo	141	138 (97.9)	1.92 (0.66)	0.7	1.48	1.82	2.26	4.0	
		Week 8	Tezepelumab	163	161 (98.8)	1.95 (0.74)	0.6	1.39	1.84	2.41	4.7	
			Placebo	141	139 (98.6)	1.93 (0.73)	0.7	1.42	1.81	2.34	4.3	
		Week 12	Tezepelumab	163	157 (96.3)	1.97 (0.76)	0.6	1.50	1.83	2.37	4.7	
			Placebo	141	140 (99.3)	1.89 (0.67)	0.7	1.45	1.76	2.25	4.3	
		Week 16	Tezepelumab	163	157 (96.3)	1.97 (0.77)	0.6	1.40	1.83	2.34	4.9	
			Placebo	141	136 (96.5)	1.91 (0.69)	0.7	1.45	1.78	2.22	4.4	
		Week 24	Tezepelumab	163	152 (93.3)	1.91 (0.68)	0.6	1.45	1.79	2.30	4.4	
			Placebo	141	132 (93.6)	1.88 (0.68)	0.6	1.40	1.79	2.22	4.3	
		Week 36	Tezepelumab	163	147 (90.2)	1.97 (0.76)	0.6	1.42	1.81	2.37	4.5	
			Placebo	141	131 (92.9)	1.90 (0.69)	0.7	1.42	1.79	2.29	4.3	
		Week 52	Tezepelumab	163	145 (89.0)	1.98 (0.77)	0.6	1.47	1.84	2.43	4.3	
			Placebo	141	118 (83.7)	1.86 (0.72)	0.7	1.32	1.73	2.26	4.0	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	163	158 (96.9)	0.20 (0.32)	-0.5	0.00	0.14	0.31	1.3	0.41 [0.18, 0.64]
			Placebo	141	135 (95.7)	0.05 (0.38)	-1.8	-0.11	0.04	0.20	1.2	
		Week 4	Tezepelumab	163	162 (99.4)	0.23 (0.37)	-0.9	0.01	0.13	0.35	1.7	0.38 [0.15, 0.61]
			Placebo	141	138 (97.9)	0.09 (0.40)	-1.0	-0.14	0.06	0.28	1.4	
		Week 8	Tezepelumab	163	161 (98.8)	0.27 (0.43)	-0.8	-0.04	0.21	0.48	1.8	0.45 [0.22, 0.67]
			Placebo	141	139 (98.6)	0.09 (0.37)	-0.7	-0.17	0.07	0.25	1.6	
		Week 12	Tezepelumab	163	157 (96.3)	0.30 (0.44)	-0.7	0.03	0.21	0.48	2.0	0.54 [0.31, 0.78]
			Placebo	141	140 (99.3)	0.06 (0.44)	-1.5	-0.14	0.04	0.24	1.7	
		Week 16	Tezepelumab	163	157 (96.3)	0.28 (0.43)	-0.6	0.00	0.18	0.43	2.0	0.49 [0.26, 0.73]
			Placebo	141	136 (96.5)	0.08 (0.37)	-1.0	-0.12	0.06	0.24	1.8	
		Week 24	Tezepelumab	163	152 (93.3)	0.26 (0.43)	-1.0	-0.05	0.24	0.49	1.5	0.46 [0.22, 0.69]
			Placebo	141	132 (93.6)	0.07 (0.37)	-0.9	-0.13	0.03	0.25	1.7	
		Week 36	Tezepelumab	163	147 (90.2)	0.28 (0.43)	-1.0	0.01	0.21	0.52	1.7	0.52 [0.28, 0.76]
			Placebo	141	131 (92.9)	0.06 (0.40)	-1.1	-0.18	0.02	0.27	1.7	
		Week 52	Tezepelumab	163	145 (89.0)	0.29 (0.44)	-1.0	-0.01	0.24	0.55	1.6	0.60 [0.35, 0.85]
			Placebo	141	118 (83.7)	0.05 (0.35)	-1.0	-0.17	0.03	0.23	1.1	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Absolute values	Baseline	Tezepelumab	217	217 (100.0)	1.77 (0.67)	0.4	1.28	1.64	2.14	4.1	
			Placebo	230	230 (100.0)	1.78 (0.69)	0.4	1.28	1.69	2.19	4.5	
		Week 2	Tezepelumab	217	212 (97.7)	1.94 (0.69)	0.6	1.42	1.83	2.43	4.3	
			Placebo	230	218 (94.8)	1.85 (0.71)	0.4	1.36	1.73	2.28	4.1	
		Week 4	Tezepelumab	217	215 (99.1)	1.96 (0.71)	0.7	1.41	1.90	2.50	3.8	
			Placebo	230	225 (97.8)	1.83 (0.69)	0.4	1.32	1.76	2.19	4.8	
		Week 8	Tezepelumab	217	213 (98.2)	1.97 (0.71)	0.6	1.41	1.87	2.41	4.7	
			Placebo	230	222 (96.5)	1.87 (0.71)	0.4	1.34	1.78	2.26	4.6	
		Week 12	Tezepelumab	217	212 (97.7)	1.97 (0.70)	0.6	1.47	1.89	2.45	4.6	
			Placebo	230	217 (94.3)	1.89 (0.74)	0.5	1.35	1.76	2.32	4.6	
		Week 16	Tezepelumab	217	210 (96.8)	2.01 (0.73)	0.6	1.49	1.89	2.51	4.7	
			Placebo	230	214 (93.0)	1.86 (0.74)	0.5	1.31	1.76	2.23	4.7	
		Week 24	Tezepelumab	217	204 (94.0)	1.99 (0.72)	0.6	1.48	1.92	2.47	4.0	
			Placebo	230	207 (90.0)	1.87 (0.73)	0.8	1.39	1.76	2.22	4.8	
		Week 36	Tezepelumab	217	196 (90.3)	1.96 (0.72)	0.5	1.40	1.90	2.41	4.4	
			Placebo	230	197 (85.7)	1.92 (0.74)	0.6	1.41	1.81	2.27	4.6	
		Week 52	Tezepelumab	217	192 (88.5)	1.96 (0.72)	0.8	1.43	1.85	2.40	4.2	
			Placebo	230	190 (82.6)	1.88 (0.76)	0.6	1.32	1.76	2.29	4.5	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Change from baseline	Week 2	Tezepelumab	217	212 (97.7)	0.17 (0.33)	-0.7	-0.01	0.12	0.32	1.5	0.38 [0.19, 0.57]
			Placebo	230	218 (94.8)	0.04 (0.33)	-1.1	-0.12	0.00	0.16	1.1	
		Week 4	Tezepelumab	217	215 (99.1)	0.19 (0.35)	-0.7	-0.02	0.14	0.34	1.8	0.35 [0.16, 0.54]
			Placebo	230	225 (97.8)	0.06 (0.36)	-1.8	-0.11	0.03	0.20	1.6	
		Week 8	Tezepelumab	217	213 (98.2)	0.22 (0.38)	-0.6	-0.01	0.14	0.40	1.7	0.39 [0.20, 0.58]
			Placebo	230	222 (96.5)	0.08 (0.31)	-0.9	-0.10	0.05	0.26	1.4	
		Week 12	Tezepelumab	217	212 (97.7)	0.20 (0.36)	-0.8	-0.04	0.12	0.39	1.6	0.27 [0.07, 0.46]
			Placebo	230	217 (94.3)	0.11 (0.34)	-1.1	-0.08	0.05	0.26	1.4	
		Week 16	Tezepelumab	217	210 (96.8)	0.24 (0.39)	-0.8	0.00	0.17	0.40	1.9	0.44 [0.25, 0.64]
			Placebo	230	214 (93.0)	0.08 (0.35)	-1.2	-0.10	0.01	0.25	1.5	
		Week 24	Tezepelumab	217	204 (94.0)	0.22 (0.39)	-0.7	-0.04	0.15	0.42	1.7	0.40 [0.21, 0.60]
			Placebo	230	207 (90.0)	0.07 (0.38)	-1.1	-0.14	0.03	0.26	1.6	
		Week 36	Tezepelumab	217	196 (90.3)	0.20 (0.40)	-0.8	-0.08	0.11	0.39	1.6	0.24 [0.04, 0.44]
			Placebo	230	197 (85.7)	0.11 (0.37)	-0.9	-0.14	0.06	0.30	1.3	
		Week 52	Tezepelumab	217	192 (88.5)	0.20 (0.39)	-1.0	-0.03	0.14	0.36	1.7	0.35 [0.15, 0.55]
			Placebo	230	190 (82.6)	0.07 (0.34)	-1.0	-0.14	0.05	0.23	1.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Sex									0.029 i
Male	Week 2	Tezepelumab	135	133 (98.5)	0.21 (0.03)	(0.14, 0.27)	0.17 (0.04)	(0.09, 0.26)	<0.001 *
		Placebo	136	132 (97.1)	0.03 (0.03)	(-0.03, 0.09)			
	Week 4	Tezepelumab	135	134 (99.3)	0.27 (0.04)	(0.20, 0.34)	0.23 (0.05)	(0.13, 0.33)	<0.001 *
		Placebo	136	133 (97.8)	0.04 (0.04)	(-0.03, 0.11)			
	Week 8	Tezepelumab	135	130 (96.3)	0.28 (0.04)	(0.21, 0.35)	0.20 (0.05)	(0.10, 0.30)	<0.001 *
		Placebo	136	136 (100.0)	0.08 (0.04)	(0.01, 0.15)			
	Week 12	Tezepelumab	135	129 (95.6)	0.27 (0.04)	(0.19, 0.34)	0.17 (0.05)	(0.06, 0.27)	0.002 *
		Placebo	136	134 (98.5)	0.10 (0.04)	(0.02, 0.17)			
	Week 16	Tezepelumab	135	130 (96.3)	0.31 (0.04)	(0.23, 0.38)	0.25 (0.05)	(0.14, 0.36)	<0.001 *
		Placebo	136	133 (97.8)	0.05 (0.04)	(-0.02, 0.13)			
	Week 24	Tezepelumab	135	121 (89.6)	0.28 (0.04)	(0.20, 0.35)	0.21 (0.05)	(0.11, 0.31)	<0.001 *
		Placebo	136	124 (91.2)	0.07 (0.04)	(-0.01, 0.14)			
	Week 36	Tezepelumab	135	121 (89.6)	0.28 (0.04)	(0.20, 0.36)	0.23 (0.06)	(0.12, 0.34)	<0.001 *
		Placebo	136	122 (89.7)	0.05 (0.04)	(-0.03, 0.13)			
	Week 52	Tezepelumab	135	120 (88.9)	0.31 (0.04)	(0.23, 0.38)	0.27 (0.06)	(0.17, 0.38)	<0.001 *
		Placebo	136	113 (83.1)	0.03 (0.04)	(-0.04, 0.11)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Female	Week 2	Tezepelumab	245	237 (96.7)	0.16 (0.02)	(0.12, 0.20)	0.10 (0.03)	(0.05, 0.16)	<0.001 *
		Placebo	235	221 (94.0)	0.06 (0.02)	(0.02, 0.10)			
	Week 4	Tezepelumab	245	243 (99.2)	0.17 (0.02)	(0.13, 0.21)	0.07 (0.03)	(0.02, 0.13)	0.011 *
		Placebo	235	230 (97.9)	0.10 (0.02)	(0.06, 0.14)			
	Week 8	Tezepelumab	245	244 (99.6)	0.21 (0.02)	(0.17, 0.25)	0.12 (0.03)	(0.06, 0.18)	<0.001 *
		Placebo	235	225 (95.7)	0.09 (0.02)	(0.05, 0.14)			
	Week 12	Tezepelumab	245	240 (98.0)	0.22 (0.02)	(0.18, 0.27)	0.14 (0.03)	(0.07, 0.20)	<0.001 *
		Placebo	235	223 (94.9)	0.09 (0.02)	(0.04, 0.13)			
	Week 16	Tezepelumab	245	237 (96.7)	0.22 (0.02)	(0.18, 0.27)	0.13 (0.03)	(0.07, 0.19)	<0.001 *
		Placebo	235	217 (92.3)	0.09 (0.02)	(0.05, 0.14)			
	Week 24	Tezepelumab	245	235 (95.9)	0.20 (0.02)	(0.16, 0.25)	0.12 (0.03)	(0.06, 0.19)	<0.001 *
		Placebo	235	215 (91.5)	0.08 (0.02)	(0.03, 0.13)			
	Week 36	Tezepelumab	245	222 (90.6)	0.21 (0.02)	(0.17, 0.26)	0.09 (0.03)	(0.03, 0.16)	0.005 *
		Placebo	235	206 (87.7)	0.12 (0.02)	(0.07, 0.17)			
	Week 52	Tezepelumab	245	217 (88.6)	0.21 (0.02)	(0.16, 0.26)	0.11 (0.03)	(0.05, 0.18)	<0.001 *
		Placebo	235	195 (83.0)	0.10 (0.02)	(0.05, 0.14)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Age									0.041 i
< 65 years	Week 2	Tezepelumab	304	296 (97.4)	0.20 (0.02)	(0.16, 0.24)	0.15 (0.03)	(0.10, 0.21)	<0.001 *
		Placebo	318	303 (95.3)	0.05 (0.02)	(0.01, 0.08)			
	Week 4	Tezepelumab	304	303 (99.7)	0.23 (0.02)	(0.19, 0.27)	0.16 (0.03)	(0.10, 0.22)	<0.001 *
		Placebo	318	313 (98.4)	0.07 (0.02)	(0.03, 0.11)			
	Week 8	Tezepelumab	304	300 (98.7)	0.26 (0.02)	(0.22, 0.30)	0.18 (0.03)	(0.11, 0.24)	<0.001 *
		Placebo	318	311 (97.8)	0.09 (0.02)	(0.04, 0.13)			
	Week 12	Tezepelumab	304	296 (97.4)	0.26 (0.02)	(0.21, 0.30)	0.16 (0.03)	(0.10, 0.22)	<0.001 *
		Placebo	318	307 (96.5)	0.10 (0.02)	(0.05, 0.14)			
	Week 16	Tezepelumab	304	294 (96.7)	0.28 (0.02)	(0.23, 0.32)	0.20 (0.03)	(0.13, 0.26)	<0.001 *
		Placebo	318	301 (94.7)	0.08 (0.02)	(0.04, 0.13)			
	Week 24	Tezepelumab	304	286 (94.1)	0.25 (0.02)	(0.21, 0.30)	0.18 (0.03)	(0.11, 0.24)	<0.001 *
		Placebo	318	291 (91.5)	0.07 (0.02)	(0.03, 0.12)			
	Week 36	Tezepelumab	304	275 (90.5)	0.26 (0.02)	(0.21, 0.31)	0.16 (0.03)	(0.09, 0.23)	<0.001 *
		Placebo	318	280 (88.1)	0.10 (0.02)	(0.05, 0.15)			
	Week 52	Tezepelumab	304	270 (88.8)	0.27 (0.02)	(0.22, 0.31)	0.19 (0.03)	(0.12, 0.25)	<0.001 *
		Placebo	318	263 (82.7)	0.08 (0.02)	(0.03, 0.12)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 65 years	Week 2	Tezepelumab	76	74 (97.4)	0.09 (0.02)	(0.04, 0.14)	0.03 (0.04)	(-0.05, 0.10)	0.447
		Placebo	53	50 (94.3)	0.06 (0.03)	(0.00, 0.12)			
	Week 4	Tezepelumab	76	74 (97.4)	0.11 (0.03)	(0.05, 0.16)	0.01 (0.04)	(-0.08, 0.10)	0.802
		Placebo	53	50 (94.3)	0.10 (0.03)	(0.03, 0.16)			
	Week 8	Tezepelumab	76	74 (97.4)	0.14 (0.03)	(0.08, 0.20)	0.05 (0.05)	(-0.05, 0.15)	0.331
		Placebo	53	50 (94.3)	0.09 (0.04)	(0.02, 0.17)			
	Week 12	Tezepelumab	76	73 (96.1)	0.16 (0.03)	(0.10, 0.22)	0.11 (0.05)	(0.01, 0.21)	0.032 *
		Placebo	53	50 (94.3)	0.05 (0.04)	(-0.02, 0.13)			
	Week 16	Tezepelumab	76	73 (96.1)	0.16 (0.03)	(0.10, 0.22)	0.09 (0.05)	(-0.00, 0.19)	0.061
		Placebo	53	49 (92.5)	0.07 (0.04)	(-0.01, 0.14)			
	Week 24	Tezepelumab	76	70 (92.1)	0.14 (0.03)	(0.08, 0.20)	0.08 (0.05)	(-0.02, 0.18)	0.105
		Placebo	53	48 (90.6)	0.06 (0.04)	(-0.02, 0.13)			
	Week 36	Tezepelumab	76	68 (89.5)	0.14 (0.03)	(0.08, 0.20)	0.10 (0.05)	(0.00, 0.19)	0.045 *
		Placebo	53	48 (90.6)	0.04 (0.04)	(-0.03, 0.12)			
	Week 52	Tezepelumab	76	67 (88.2)	0.15 (0.03)	(0.08, 0.22)	0.12 (0.05)	(0.02, 0.23)	0.024 *
		Placebo	53	45 (84.9)	0.03 (0.04)	(-0.06, 0.11)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Exacerbations in the year before study									0.550
<= 2	Week 2	Tezepelumab	204	201 (98.5)	0.17 (0.02)	(0.13, 0.22)	0.11 (0.03)	(0.05, 0.17)	<0.001 *
		Placebo	214	205 (95.8)	0.06 (0.02)	(0.02, 0.11)			
	Week 4	Tezepelumab	204	201 (98.5)	0.20 (0.03)	(0.15, 0.25)	0.12 (0.04)	(0.05, 0.19)	0.001 *
		Placebo	214	206 (96.3)	0.08 (0.03)	(0.03, 0.13)			
	Week 8	Tezepelumab	204	200 (98.0)	0.23 (0.03)	(0.18, 0.28)	0.15 (0.04)	(0.07, 0.22)	<0.001 *
		Placebo	214	208 (97.2)	0.08 (0.03)	(0.03, 0.14)			
	Week 12	Tezepelumab	204	198 (97.1)	0.22 (0.03)	(0.17, 0.28)	0.13 (0.04)	(0.05, 0.21)	0.001 *
		Placebo	214	208 (97.2)	0.09 (0.03)	(0.04, 0.15)			
	Week 16	Tezepelumab	204	198 (97.1)	0.26 (0.03)	(0.20, 0.31)	0.17 (0.04)	(0.09, 0.25)	<0.001 *
		Placebo	214	204 (95.3)	0.09 (0.03)	(0.03, 0.14)			
	Week 24	Tezepelumab	204	190 (93.1)	0.23 (0.03)	(0.17, 0.28)	0.16 (0.04)	(0.08, 0.24)	<0.001 *
		Placebo	214	195 (91.1)	0.07 (0.03)	(0.01, 0.12)			
	Week 36	Tezepelumab	204	187 (91.7)	0.24 (0.03)	(0.18, 0.30)	0.15 (0.04)	(0.07, 0.23)	<0.001 *
		Placebo	214	193 (90.2)	0.09 (0.03)	(0.04, 0.15)			
	Week 52	Tezepelumab	204	182 (89.2)	0.24 (0.03)	(0.18, 0.29)	0.17 (0.04)	(0.09, 0.24)	<0.001 *
		Placebo	214	181 (84.6)	0.07 (0.03)	(0.02, 0.13)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
> 2	Week 2	Tezepelumab	176	169 (96.0)	0.18 (0.03)	(0.13, 0.24)	0.15 (0.04)	(0.08, 0.23)	<0.001 *
		Placebo	157	148 (94.3)	0.03 (0.03)	(-0.02, 0.08)			
	Week 4	Tezepelumab	176	176 (100.0)	0.21 (0.03)	(0.16, 0.26)	0.14 (0.04)	(0.07, 0.22)	<0.001 *
		Placebo	157	157 (100.0)	0.07 (0.03)	(0.01, 0.12)			
	Week 8	Tezepelumab	176	174 (98.9)	0.24 (0.03)	(0.19, 0.29)	0.15 (0.04)	(0.08, 0.22)	<0.001 *
		Placebo	157	153 (97.5)	0.09 (0.03)	(0.04, 0.14)			
	Week 12	Tezepelumab	176	171 (97.2)	0.26 (0.03)	(0.21, 0.31)	0.17 (0.04)	(0.09, 0.25)	<0.001 *
		Placebo	157	149 (94.9)	0.09 (0.03)	(0.03, 0.15)			
	Week 16	Tezepelumab	176	169 (96.0)	0.25 (0.03)	(0.20, 0.30)	0.18 (0.04)	(0.11, 0.26)	<0.001 *
		Placebo	157	146 (93.0)	0.07 (0.03)	(0.01, 0.12)			
	Week 24	Tezepelumab	176	166 (94.3)	0.23 (0.03)	(0.18, 0.29)	0.15 (0.04)	(0.07, 0.23)	<0.001 *
		Placebo	157	144 (91.7)	0.08 (0.03)	(0.02, 0.14)			
	Week 36	Tezepelumab	176	156 (88.6)	0.23 (0.03)	(0.18, 0.29)	0.14 (0.04)	(0.06, 0.22)	<0.001 *
		Placebo	157	135 (86.0)	0.09 (0.03)	(0.03, 0.15)			
	Week 52	Tezepelumab	176	155 (88.1)	0.25 (0.03)	(0.19, 0.31)	0.18 (0.04)	(0.09, 0.26)	<0.001 *
		Placebo	157	127 (80.9)	0.07 (0.03)	(0.01, 0.14)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Race									0.766
White	Week 2	Tezepelumab	239	235 (98.3)	0.18 (0.02)	(0.14, 0.22)	0.15 (0.03)	(0.09, 0.21)	<0.001 *
		Placebo	235	222 (94.5)	0.03 (0.02)	(-0.01, 0.07)			
	Week 4	Tezepelumab	239	237 (99.2)	0.20 (0.02)	(0.16, 0.25)	0.12 (0.03)	(0.05, 0.19)	<0.001 *
		Placebo	235	227 (96.6)	0.08 (0.02)	(0.03, 0.13)			
	Week 8	Tezepelumab	239	236 (98.7)	0.22 (0.02)	(0.18, 0.27)	0.12 (0.03)	(0.05, 0.18)	<0.001 *
		Placebo	235	226 (96.2)	0.11 (0.02)	(0.06, 0.15)			
	Week 12	Tezepelumab	239	231 (96.7)	0.22 (0.02)	(0.17, 0.27)	0.13 (0.04)	(0.06, 0.20)	<0.001 *
		Placebo	235	223 (94.9)	0.09 (0.03)	(0.04, 0.14)			
	Week 16	Tezepelumab	239	231 (96.7)	0.24 (0.02)	(0.19, 0.29)	0.16 (0.04)	(0.09, 0.23)	<0.001 *
		Placebo	235	219 (93.2)	0.08 (0.03)	(0.03, 0.13)			
	Week 24	Tezepelumab	239	224 (93.7)	0.22 (0.02)	(0.17, 0.27)	0.14 (0.04)	(0.07, 0.21)	<0.001 *
		Placebo	235	212 (90.2)	0.08 (0.03)	(0.03, 0.13)			
	Week 36	Tezepelumab	239	213 (89.1)	0.23 (0.03)	(0.18, 0.28)	0.12 (0.04)	(0.05, 0.19)	0.001 *
		Placebo	235	203 (86.4)	0.11 (0.03)	(0.06, 0.16)			
	Week 52	Tezepelumab	239	208 (87.0)	0.23 (0.03)	(0.18, 0.28)	0.13 (0.04)	(0.06, 0.20)	<0.001 *
		Placebo	235	186 (79.1)	0.10 (0.03)	(0.05, 0.15)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Black or African American	Week 2	Tezepelumab	21	17 (81.0)	0.21 (0.08)	(0.04, 0.38)	0.05 (0.12)	(-0.19, 0.30)	0.659
		Placebo	19	19 (100.0)	0.16 (0.08)	(-0.01, 0.33)			
	Week 4	Tezepelumab	21	20 (95.2)	0.19 (0.07)	(0.04, 0.34)	0.10 (0.10)	(-0.12, 0.31)	0.360
		Placebo	19	19 (100.0)	0.09 (0.07)	(-0.06, 0.24)			
	Week 8	Tezepelumab	21	20 (95.2)	0.26 (0.08)	(0.09, 0.42)	0.22 (0.12)	(-0.01, 0.46)	0.065
		Placebo	19	19 (100.0)	0.03 (0.08)	(-0.14, 0.20)			
	Week 12	Tezepelumab	21	20 (95.2)	0.27 (0.09)	(0.10, 0.45)	0.13 (0.12)	(-0.12, 0.37)	0.307
		Placebo	19	19 (100.0)	0.15 (0.09)	(-0.03, 0.33)			
	Week 16	Tezepelumab	21	19 (90.5)	0.20 (0.08)	(0.03, 0.37)	0.05 (0.12)	(-0.19, 0.30)	0.656
		Placebo	19	18 (94.7)	0.15 (0.09)	(-0.03, 0.32)			
	Week 24	Tezepelumab	21	17 (81.0)	0.22 (0.07)	(0.08, 0.37)	0.19 (0.10)	(-0.02, 0.40)	0.076
		Placebo	19	17 (89.5)	0.03 (0.07)	(-0.12, 0.18)			
	Week 36	Tezepelumab	21	17 (81.0)	0.20 (0.07)	(0.06, 0.35)	0.07 (0.10)	(-0.13, 0.27)	0.485
		Placebo	19	18 (94.7)	0.13 (0.07)	(-0.01, 0.28)			
	Week 52	Tezepelumab	21	17 (81.0)	0.28 (0.08)	(0.11, 0.45)	0.26 (0.12)	(0.02, 0.50)	0.033 *
		Placebo	19	16 (84.2)	0.02 (0.08)	(-0.16, 0.19)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Asian	Week 2	Tezepelumab	107	106 (99.1)	0.17 (0.03)	(0.10, 0.23)	0.10 (0.05)	(0.01, 0.19)	0.031 *
		Placebo	103	100 (97.1)	0.07 (0.03)	(0.00, 0.13)			
	Week 4	Tezepelumab	107	107 (100.0)	0.22 (0.03)	(0.15, 0.29)	0.16 (0.05)	(0.06, 0.26)	0.001 *
		Placebo	103	103 (100.0)	0.05 (0.04)	(-0.02, 0.12)			
	Week 8	Tezepelumab	107	105 (98.1)	0.27 (0.04)	(0.20, 0.34)	0.22 (0.05)	(0.12, 0.32)	<0.001 *
		Placebo	103	103 (100.0)	0.05 (0.04)	(-0.02, 0.12)			
	Week 12	Tezepelumab	107	105 (98.1)	0.29 (0.04)	(0.21, 0.36)	0.21 (0.06)	(0.10, 0.32)	<0.001 *
		Placebo	103	101 (98.1)	0.08 (0.04)	(0.00, 0.16)			
	Week 16	Tezepelumab	107	105 (98.1)	0.29 (0.04)	(0.22, 0.37)	0.22 (0.05)	(0.11, 0.33)	<0.001 *
		Placebo	103	100 (97.1)	0.07 (0.04)	(-0.01, 0.15)			
	Week 24	Tezepelumab	107	104 (97.2)	0.27 (0.04)	(0.19, 0.34)	0.20 (0.05)	(0.09, 0.31)	<0.001 *
		Placebo	103	98 (95.1)	0.07 (0.04)	(-0.01, 0.15)			
	Week 36	Tezepelumab	107	101 (94.4)	0.27 (0.04)	(0.19, 0.35)	0.23 (0.06)	(0.12, 0.35)	<0.001 *
		Placebo	103	94 (91.3)	0.04 (0.04)	(-0.04, 0.12)			
	Week 52	Tezepelumab	107	100 (93.5)	0.28 (0.04)	(0.20, 0.36)	0.25 (0.06)	(0.14, 0.37)	<0.001 *
		Placebo	103	94 (91.3)	0.03 (0.04)	(-0.05, 0.11)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Other	Week 2	Tezepelumab	13	12 (92.3)	0.11 (0.06)	(-0.01, 0.24)	-0.00 (0.08)	(-0.18, 0.17)	0.962
		Placebo	14	12 (85.7)	0.12 (0.06)	(-0.00, 0.24)			
	Week 4	Tezepelumab	13	13 (100.0)	0.18 (0.08)	(0.01, 0.36)	0.05 (0.12)	(-0.20, 0.29)	0.695
		Placebo	14	14 (100.0)	0.13 (0.08)	(-0.03, 0.30)			
	Week 8	Tezepelumab	13	13 (100.0)	0.16 (0.08)	(-0.01, 0.32)	0.02 (0.11)	(-0.21, 0.26)	0.838
		Placebo	14	13 (92.9)	0.13 (0.08)	(-0.03, 0.30)			
	Week 12	Tezepelumab	13	13 (100.0)	0.16 (0.08)	(-0.01, 0.32)	0.02 (0.11)	(-0.21, 0.26)	0.826
		Placebo	14	14 (100.0)	0.13 (0.08)	(-0.03, 0.29)			
	Week 16	Tezepelumab	13	12 (92.3)	0.20 (0.07)	(0.06, 0.34)	0.15 (0.10)	(-0.05, 0.35)	0.137
		Placebo	14	13 (92.9)	0.05 (0.07)	(-0.09, 0.19)			
	Week 24	Tezepelumab	13	11 (84.6)	0.15 (0.10)	(-0.06, 0.36)	0.09 (0.14)	(-0.20, 0.38)	0.533
		Placebo	14	12 (85.7)	0.06 (0.10)	(-0.14, 0.26)			
	Week 36	Tezepelumab	13	12 (92.3)	0.14 (0.09)	(-0.05, 0.33)	-0.02 (0.13)	(-0.28, 0.24)	0.872
		Placebo	14	13 (92.9)	0.16 (0.09)	(-0.02, 0.34)			
	Week 52	Tezepelumab	13	12 (92.3)	0.15 (0.08)	(-0.01, 0.31)	0.08 (0.11)	(-0.14, 0.30)	0.447
		Placebo	14	12 (85.7)	0.07 (0.07)	(-0.09, 0.22)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Region									0.779
Europe	Week 2	Tezepelumab	64	64 (100.0)	0.18 (0.04)	(0.11, 0.25)	0.14 (0.05)	(0.03, 0.24)	0.012 *
		Placebo	60	57 (95.0)	0.04 (0.04)	(-0.04, 0.12)			
	Week 4	Tezepelumab	64	64 (100.0)	0.20 (0.04)	(0.12, 0.29)	0.16 (0.06)	(0.03, 0.28)	0.014 *
		Placebo	60	59 (98.3)	0.05 (0.04)	(-0.04, 0.14)			
	Week 8	Tezepelumab	64	64 (100.0)	0.21 (0.05)	(0.11, 0.30)	0.15 (0.07)	(0.00, 0.29)	0.044 *
		Placebo	60	56 (93.3)	0.06 (0.05)	(-0.04, 0.16)			
	Week 12	Tezepelumab	64	62 (96.9)	0.18 (0.05)	(0.08, 0.27)	0.13 (0.07)	(-0.01, 0.27)	0.072
		Placebo	60	56 (93.3)	0.05 (0.05)	(-0.05, 0.15)			
	Week 16	Tezepelumab	64	62 (96.9)	0.26 (0.05)	(0.16, 0.36)	0.26 (0.07)	(0.12, 0.40)	<0.001 *
		Placebo	60	56 (93.3)	0.00 (0.05)	(-0.10, 0.10)			
	Week 24	Tezepelumab	64	62 (96.9)	0.20 (0.05)	(0.11, 0.29)	0.20 (0.07)	(0.07, 0.33)	0.003 *
		Placebo	60	52 (86.7)	-0.01 (0.05)	(-0.10, 0.09)			
	Week 36	Tezepelumab	64	60 (93.8)	0.21 (0.05)	(0.11, 0.30)	0.12 (0.07)	(-0.02, 0.25)	0.089
		Placebo	60	51 (85.0)	0.09 (0.05)	(-0.01, 0.19)			
	Week 52	Tezepelumab	64	57 (89.1)	0.20 (0.04)	(0.11, 0.29)	0.09 (0.06)	(-0.03, 0.22)	0.148
		Placebo	60	49 (81.7)	0.11 (0.05)	(0.02, 0.20)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
America	Week 2	Tezepelumab	140	134 (95.7)	0.19 (0.03)	(0.13, 0.25)	0.13 (0.04)	(0.04, 0.22)	0.005 *
		Placebo	134	128 (95.5)	0.07 (0.03)	(0.00, 0.13)			
	Week 4	Tezepelumab	140	137 (97.9)	0.19 (0.03)	(0.13, 0.26)	0.11 (0.04)	(0.02, 0.19)	0.018 *
		Placebo	134	129 (96.3)	0.09 (0.03)	(0.03, 0.15)			
	Week 8	Tezepelumab	140	137 (97.9)	0.22 (0.03)	(0.16, 0.28)	0.10 (0.05)	(0.02, 0.19)	0.021 *
		Placebo	134	130 (97.0)	0.12 (0.03)	(0.05, 0.18)			
	Week 12	Tezepelumab	140	134 (95.7)	0.23 (0.03)	(0.16, 0.29)	0.12 (0.05)	(0.03, 0.22)	0.011 *
		Placebo	134	131 (97.8)	0.10 (0.03)	(0.03, 0.17)			
	Week 16	Tezepelumab	140	133 (95.0)	0.23 (0.03)	(0.16, 0.29)	0.11 (0.05)	(0.02, 0.20)	0.019 *
		Placebo	134	128 (95.5)	0.12 (0.03)	(0.05, 0.18)			
	Week 24	Tezepelumab	140	126 (90.0)	0.22 (0.03)	(0.15, 0.28)	0.12 (0.05)	(0.03, 0.22)	0.012 *
		Placebo	134	125 (93.3)	0.09 (0.03)	(0.03, 0.16)			
	Week 36	Tezepelumab	140	122 (87.1)	0.23 (0.04)	(0.16, 0.30)	0.10 (0.05)	(-0.00, 0.20)	0.055
		Placebo	134	127 (94.8)	0.13 (0.04)	(0.06, 0.20)			
	Week 52	Tezepelumab	140	119 (85.0)	0.24 (0.04)	(0.17, 0.31)	0.13 (0.05)	(0.03, 0.24)	0.010 *
		Placebo	134	112 (83.6)	0.11 (0.04)	(0.04, 0.18)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Asia/Pacific	Week 2	Tezepelumab	104	103 (99.0)	0.18 (0.03)	(0.11, 0.24)	0.14 (0.05)	(0.04, 0.23)	0.004 *
		Placebo	104	100 (96.2)	0.04 (0.03)	(-0.02, 0.11)			
	Week 4	Tezepelumab	104	104 (100.0)	0.22 (0.03)	(0.15, 0.29)	0.18 (0.05)	(0.08, 0.27)	<0.001 *
		Placebo	104	103 (99.0)	0.05 (0.03)	(-0.02, 0.11)			
	Week 8	Tezepelumab	104	102 (98.1)	0.29 (0.04)	(0.21, 0.36)	0.22 (0.05)	(0.11, 0.32)	<0.001 *
		Placebo	104	103 (99.0)	0.07 (0.04)	(-0.00, 0.14)			
	Week 12	Tezepelumab	104	101 (97.1)	0.30 (0.04)	(0.22, 0.38)	0.22 (0.05)	(0.11, 0.33)	<0.001 *
		Placebo	104	101 (97.1)	0.08 (0.04)	(0.00, 0.16)			
	Week 16	Tezepelumab	104	103 (99.0)	0.31 (0.04)	(0.23, 0.38)	0.24 (0.05)	(0.13, 0.35)	<0.001 *
		Placebo	104	99 (95.2)	0.07 (0.04)	(-0.01, 0.15)			
	Week 24	Tezepelumab	104	101 (97.1)	0.27 (0.04)	(0.20, 0.35)	0.20 (0.05)	(0.10, 0.31)	<0.001 *
		Placebo	104	96 (92.3)	0.07 (0.04)	(-0.01, 0.14)			
	Week 36	Tezepelumab	104	96 (92.3)	0.28 (0.04)	(0.20, 0.36)	0.23 (0.06)	(0.12, 0.35)	<0.001 *
		Placebo	104	91 (87.5)	0.04 (0.04)	(-0.04, 0.12)			
	Week 52	Tezepelumab	104	97 (93.3)	0.29 (0.04)	(0.21, 0.37)	0.26 (0.06)	(0.14, 0.37)	<0.001 *
		Placebo	104	90 (86.5)	0.04 (0.04)	(-0.05, 0.12)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Rest of the world	Week 2	Tezepelumab	72	69 (95.8)	0.15 (0.03)	(0.09, 0.22)	0.12 (0.05)	(0.03, 0.22)	0.010 *
		Placebo	73	68 (93.2)	0.03 (0.03)	(-0.04, 0.10)			
	Week 4	Tezepelumab	72	72 (100.0)	0.20 (0.05)	(0.11, 0.29)	0.09 (0.06)	(-0.04, 0.21)	0.181
		Placebo	73	72 (98.6)	0.12 (0.05)	(0.03, 0.20)			
	Week 8	Tezepelumab	72	71 (98.6)	0.22 (0.04)	(0.14, 0.29)	0.14 (0.05)	(0.03, 0.24)	0.011 *
		Placebo	73	72 (98.6)	0.08 (0.04)	(0.01, 0.15)			
	Week 12	Tezepelumab	72	72 (100.0)	0.23 (0.04)	(0.15, 0.31)	0.11 (0.06)	(-0.00, 0.22)	0.052
		Placebo	73	69 (94.5)	0.12 (0.04)	(0.04, 0.20)			
	Week 16	Tezepelumab	72	69 (95.8)	0.22 (0.04)	(0.14, 0.30)	0.13 (0.06)	(0.02, 0.25)	0.024 *
		Placebo	73	67 (91.8)	0.08 (0.04)	(0.00, 0.16)			
	Week 24	Tezepelumab	72	67 (93.1)	0.22 (0.04)	(0.14, 0.31)	0.13 (0.06)	(0.00, 0.25)	0.049 *
		Placebo	73	66 (90.4)	0.10 (0.04)	(0.01, 0.19)			
	Week 36	Tezepelumab	72	65 (90.3)	0.22 (0.04)	(0.13, 0.30)	0.13 (0.06)	(0.01, 0.25)	0.031 *
		Placebo	73	59 (80.8)	0.09 (0.04)	(0.00, 0.17)			
	Week 52	Tezepelumab	72	64 (88.9)	0.22 (0.04)	(0.14, 0.30)	0.18 (0.06)	(0.07, 0.29)	0.002 *
		Placebo	73	57 (78.1)	0.04 (0.04)	(-0.04, 0.12)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
BMI				N<10 any level					NE

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline eosinophils - Low									0.120
< 150 cells/uL	Week 2	Tezepelumab	95	93 (97.9)	0.08 (0.03)	(0.02, 0.14)	0.07 (0.05)	(-0.02, 0.17)	0.116
		Placebo	87	82 (94.3)	0.01 (0.03)	(-0.06, 0.07)			
	Week 4	Tezepelumab	95	94 (98.9)	0.09 (0.04)	(0.02, 0.16)	0.08 (0.05)	(-0.02, 0.18)	0.138
		Placebo	87	86 (98.9)	0.02 (0.04)	(-0.06, 0.09)			
	Week 8	Tezepelumab	95	92 (96.8)	0.10 (0.03)	(0.04, 0.17)	0.06 (0.05)	(-0.04, 0.16)	0.230
		Placebo	87	84 (96.6)	0.04 (0.04)	(-0.03, 0.12)			
	Week 12	Tezepelumab	95	91 (95.8)	0.09 (0.04)	(0.02, 0.16)	0.07 (0.05)	(-0.03, 0.17)	0.187
		Placebo	87	82 (94.3)	0.02 (0.04)	(-0.05, 0.09)			
	Week 16	Tezepelumab	95	92 (96.8)	0.13 (0.04)	(0.06, 0.21)	0.15 (0.06)	(0.04, 0.27)	0.007 *
		Placebo	87	82 (94.3)	-0.02 (0.04)	(-0.10, 0.06)			
	Week 24	Tezepelumab	95	85 (89.5)	0.09 (0.03)	(0.03, 0.15)	0.07 (0.05)	(-0.03, 0.16)	0.158
		Placebo	87	79 (90.8)	0.02 (0.03)	(-0.04, 0.09)			
	Week 36	Tezepelumab	95	86 (90.5)	0.07 (0.03)	(0.01, 0.14)	0.03 (0.05)	(-0.06, 0.13)	0.492
		Placebo	87	76 (87.4)	0.04 (0.04)	(-0.03, 0.11)			
	Week 52	Tezepelumab	95	85 (89.5)	0.11 (0.04)	(0.04, 0.19)	0.13 (0.05)	(0.02, 0.23)	0.021 *
		Placebo	87	75 (86.2)	-0.02 (0.04)	(-0.09, 0.06)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 150 cells/uL	Week 2	Tezepelumab	285	277 (97.2)	0.21 (0.02)	(0.17, 0.25)	0.15 (0.03)	(0.09, 0.20)	<0.001 *
		Placebo	284	271 (95.4)	0.06 (0.02)	(0.02, 0.10)			
	Week 4	Tezepelumab	285	283 (99.3)	0.24 (0.02)	(0.20, 0.28)	0.15 (0.03)	(0.09, 0.21)	<0.001 *
		Placebo	284	277 (97.5)	0.09 (0.02)	(0.05, 0.14)			
	Week 8	Tezepelumab	285	282 (98.9)	0.28 (0.02)	(0.24, 0.32)	0.18 (0.03)	(0.12, 0.24)	<0.001 *
		Placebo	284	277 (97.5)	0.10 (0.02)	(0.06, 0.15)			
	Week 12	Tezepelumab	285	278 (97.5)	0.29 (0.02)	(0.24, 0.33)	0.17 (0.03)	(0.11, 0.24)	<0.001 *
		Placebo	284	275 (96.8)	0.11 (0.02)	(0.07, 0.16)			
	Week 16	Tezepelumab	285	275 (96.5)	0.29 (0.02)	(0.25, 0.34)	0.18 (0.03)	(0.12, 0.24)	<0.001 *
		Placebo	284	268 (94.4)	0.11 (0.02)	(0.07, 0.15)			
	Week 24	Tezepelumab	285	271 (95.1)	0.27 (0.02)	(0.23, 0.32)	0.18 (0.03)	(0.12, 0.25)	<0.001 *
		Placebo	284	260 (91.5)	0.09 (0.02)	(0.04, 0.14)			
	Week 36	Tezepelumab	285	257 (90.2)	0.29 (0.02)	(0.24, 0.34)	0.18 (0.03)	(0.11, 0.25)	<0.001 *
		Placebo	284	252 (88.7)	0.11 (0.02)	(0.06, 0.16)			
	Week 52	Tezepelumab	285	252 (88.4)	0.29 (0.02)	(0.24, 0.34)	0.19 (0.03)	(0.12, 0.26)	<0.001 *
		Placebo	284	233 (82.0)	0.10 (0.02)	(0.05, 0.15)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline eosinophils - High									0.005 i
< 300 cells/uL	Week 2	Tezepelumab	216	211 (97.7)	0.11 (0.02)	(0.07, 0.16)	0.09 (0.03)	(0.03, 0.15)	0.002 *
		Placebo	207	198 (95.7)	0.02 (0.02)	(-0.02, 0.06)			
	Week 4	Tezepelumab	216	215 (99.5)	0.13 (0.02)	(0.09, 0.18)	0.10 (0.03)	(0.03, 0.16)	0.004 *
		Placebo	207	202 (97.6)	0.04 (0.02)	(-0.01, 0.08)			
	Week 8	Tezepelumab	216	213 (98.6)	0.14 (0.02)	(0.10, 0.18)	0.07 (0.03)	(0.01, 0.13)	0.033 *
		Placebo	207	199 (96.1)	0.07 (0.02)	(0.03, 0.12)			
	Week 12	Tezepelumab	216	210 (97.2)	0.13 (0.02)	(0.08, 0.18)	0.08 (0.03)	(0.01, 0.15)	0.018 *
		Placebo	207	197 (95.2)	0.05 (0.02)	(-0.00, 0.10)			
	Week 16	Tezepelumab	216	211 (97.7)	0.15 (0.02)	(0.10, 0.20)	0.11 (0.04)	(0.04, 0.18)	0.002 *
		Placebo	207	195 (94.2)	0.04 (0.03)	(-0.01, 0.09)			
	Week 24	Tezepelumab	216	203 (94.0)	0.11 (0.02)	(0.06, 0.16)	0.09 (0.03)	(0.02, 0.15)	0.009 *
		Placebo	207	188 (90.8)	0.02 (0.02)	(-0.02, 0.07)			
	Week 36	Tezepelumab	216	197 (91.2)	0.11 (0.02)	(0.06, 0.16)	0.07 (0.04)	(0.00, 0.14)	0.038 *
		Placebo	207	182 (87.9)	0.04 (0.03)	(-0.01, 0.09)			
	Week 52	Tezepelumab	216	198 (91.7)	0.13 (0.02)	(0.08, 0.18)	0.10 (0.04)	(0.03, 0.17)	0.005 *
		Placebo	207	173 (83.6)	0.03 (0.03)	(-0.02, 0.08)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 300 cells/uL	Week 2	Tezepelumab	164	159 (97.0)	0.26 (0.03)	(0.21, 0.32)	0.18 (0.04)	(0.10, 0.25)	<0.001 *
		Placebo	164	155 (94.5)	0.08 (0.03)	(0.03, 0.14)			
	Week 4	Tezepelumab	164	162 (98.8)	0.30 (0.03)	(0.24, 0.36)	0.17 (0.04)	(0.09, 0.26)	<0.001 *
		Placebo	164	161 (98.2)	0.13 (0.03)	(0.07, 0.18)			
	Week 8	Tezepelumab	164	161 (98.2)	0.36 (0.03)	(0.30, 0.42)	0.25 (0.04)	(0.17, 0.34)	<0.001 *
		Placebo	164	162 (98.8)	0.11 (0.03)	(0.05, 0.17)			
	Week 12	Tezepelumab	164	159 (97.0)	0.38 (0.03)	(0.32, 0.45)	0.23 (0.04)	(0.15, 0.32)	<0.001 *
		Placebo	164	160 (97.6)	0.15 (0.03)	(0.09, 0.21)			
	Week 16	Tezepelumab	164	156 (95.1)	0.39 (0.03)	(0.33, 0.45)	0.26 (0.04)	(0.17, 0.34)	<0.001 *
		Placebo	164	155 (94.5)	0.13 (0.03)	(0.07, 0.19)			
	Week 24	Tezepelumab	164	153 (93.3)	0.39 (0.03)	(0.32, 0.45)	0.25 (0.05)	(0.16, 0.34)	<0.001 *
		Placebo	164	151 (92.1)	0.14 (0.03)	(0.08, 0.20)			
	Week 36	Tezepelumab	164	146 (89.0)	0.40 (0.03)	(0.34, 0.46)	0.24 (0.05)	(0.15, 0.33)	<0.001 *
		Placebo	164	146 (89.0)	0.16 (0.03)	(0.10, 0.23)			
	Week 52	Tezepelumab	164	139 (84.8)	0.40 (0.03)	(0.33, 0.46)	0.27 (0.05)	(0.18, 0.36)	<0.001 *
		Placebo	164	135 (82.3)	0.13 (0.03)	(0.06, 0.19)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline FENO									0.063
< 25 ppb	Week 2	Tezepelumab	155	150 (96.8)	0.13 (0.02)	(0.09, 0.18)	0.10 (0.03)	(0.03, 0.17)	0.003 *
		Placebo	145	135 (93.1)	0.03 (0.02)	(-0.02, 0.08)			
	Week 4	Tezepelumab	155	152 (98.1)	0.15 (0.03)	(0.10, 0.20)	0.07 (0.04)	(-0.00, 0.14)	0.060
		Placebo	145	143 (98.6)	0.08 (0.03)	(0.02, 0.13)			
	Week 8	Tezepelumab	155	152 (98.1)	0.16 (0.03)	(0.10, 0.21)	0.09 (0.04)	(0.01, 0.17)	0.024 *
		Placebo	145	141 (97.2)	0.07 (0.03)	(0.01, 0.12)			
	Week 12	Tezepelumab	155	149 (96.1)	0.15 (0.03)	(0.10, 0.21)	0.09 (0.04)	(0.01, 0.16)	0.025 *
		Placebo	145	138 (95.2)	0.07 (0.03)	(0.01, 0.12)			
	Week 16	Tezepelumab	155	148 (95.5)	0.16 (0.03)	(0.11, 0.21)	0.12 (0.04)	(0.05, 0.20)	0.001 *
		Placebo	145	138 (95.2)	0.03 (0.03)	(-0.02, 0.09)			
	Week 24	Tezepelumab	155	146 (94.2)	0.13 (0.03)	(0.08, 0.19)	0.10 (0.04)	(0.02, 0.18)	0.011 *
		Placebo	145	134 (92.4)	0.03 (0.03)	(-0.03, 0.09)			
	Week 36	Tezepelumab	155	137 (88.4)	0.12 (0.03)	(0.07, 0.18)	0.05 (0.04)	(-0.03, 0.13)	0.229
		Placebo	145	129 (89.0)	0.08 (0.03)	(0.02, 0.13)			
	Week 52	Tezepelumab	155	139 (89.7)	0.13 (0.03)	(0.08, 0.19)	0.09 (0.04)	(0.01, 0.17)	0.030 *
		Placebo	145	125 (86.2)	0.04 (0.03)	(-0.01, 0.10)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 25 ppb	Week 2	Tezepelumab	222	217 (97.7)	0.22 (0.02)	(0.17, 0.26)	0.16 (0.03)	(0.09, 0.22)	<0.001 *
		Placebo	222	214 (96.4)	0.06 (0.02)	(0.01, 0.11)			
	Week 4	Tezepelumab	222	222 (100.0)	0.25 (0.03)	(0.20, 0.30)	0.17 (0.04)	(0.10, 0.25)	<0.001 *
		Placebo	222	216 (97.3)	0.07 (0.03)	(0.02, 0.12)			
	Week 8	Tezepelumab	222	219 (98.6)	0.30 (0.03)	(0.25, 0.35)	0.19 (0.04)	(0.12, 0.27)	<0.001 *
		Placebo	222	216 (97.3)	0.10 (0.03)	(0.05, 0.15)			
	Week 12	Tezepelumab	222	217 (97.7)	0.30 (0.03)	(0.25, 0.36)	0.19 (0.04)	(0.12, 0.27)	<0.001 *
		Placebo	222	216 (97.3)	0.11 (0.03)	(0.06, 0.17)			
	Week 16	Tezepelumab	222	216 (97.3)	0.32 (0.03)	(0.27, 0.38)	0.21 (0.04)	(0.14, 0.29)	<0.001 *
		Placebo	222	209 (94.1)	0.11 (0.03)	(0.06, 0.17)			
	Week 24	Tezepelumab	222	207 (93.2)	0.30 (0.03)	(0.24, 0.35)	0.19 (0.04)	(0.12, 0.27)	<0.001 *
		Placebo	222	202 (91.0)	0.11 (0.03)	(0.05, 0.16)			
	Week 36	Tezepelumab	222	203 (91.4)	0.32 (0.03)	(0.26, 0.37)	0.21 (0.04)	(0.13, 0.29)	<0.001 *
		Placebo	222	196 (88.3)	0.10 (0.03)	(0.05, 0.16)			
	Week 52	Tezepelumab	222	195 (87.8)	0.32 (0.03)	(0.27, 0.38)	0.23 (0.04)	(0.15, 0.31)	<0.001 *
		Placebo	222	180 (81.1)	0.09 (0.03)	(0.03, 0.15)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline specific perennial FEIA status									0.516
All negative	Week 2	Tezepelumab	137	135 (98.5)	0.18 (0.02)	(0.13, 0.22)	0.14 (0.03)	(0.07, 0.20)	<0.001 *
		Placebo	129	123 (95.3)	0.04 (0.02)	(-0.01, 0.09)			
	Week 4	Tezepelumab	137	136 (99.3)	0.24 (0.03)	(0.18, 0.29)	0.14 (0.04)	(0.06, 0.22)	<0.001 *
		Placebo	129	126 (97.7)	0.10 (0.03)	(0.04, 0.16)			
	Week 8	Tezepelumab	137	135 (98.5)	0.25 (0.03)	(0.20, 0.31)	0.16 (0.04)	(0.08, 0.24)	<0.001 *
		Placebo	129	124 (96.1)	0.09 (0.03)	(0.03, 0.15)			
	Week 12	Tezepelumab	137	135 (98.5)	0.26 (0.03)	(0.20, 0.32)	0.14 (0.05)	(0.06, 0.23)	0.001 *
		Placebo	129	125 (96.9)	0.11 (0.03)	(0.05, 0.18)			
	Week 16	Tezepelumab	137	134 (97.8)	0.27 (0.03)	(0.22, 0.33)	0.20 (0.04)	(0.12, 0.28)	<0.001 *
		Placebo	129	121 (93.8)	0.08 (0.03)	(0.02, 0.13)			
	Week 24	Tezepelumab	137	130 (94.9)	0.26 (0.03)	(0.20, 0.31)	0.17 (0.04)	(0.08, 0.25)	<0.001 *
		Placebo	129	112 (86.8)	0.09 (0.03)	(0.02, 0.15)			
	Week 36	Tezepelumab	137	126 (92.0)	0.25 (0.03)	(0.18, 0.31)	0.15 (0.05)	(0.06, 0.24)	<0.001 *
		Placebo	129	111 (86.0)	0.09 (0.03)	(0.03, 0.16)			
	Week 52	Tezepelumab	137	125 (91.2)	0.27 (0.03)	(0.22, 0.33)	0.25 (0.04)	(0.16, 0.33)	<0.001 *
		Placebo	129	104 (80.6)	0.03 (0.03)	(-0.04, 0.09)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Any positive	Week 2	Tezepelumab	241	234 (97.1)	0.18 (0.02)	(0.13, 0.22)	0.12 (0.03)	(0.06, 0.19)	<0.001 *
		Placebo	235	225 (95.7)	0.05 (0.02)	(0.01, 0.10)			
	Week 4	Tezepelumab	241	240 (99.6)	0.19 (0.02)	(0.14, 0.23)	0.12 (0.03)	(0.05, 0.19)	<0.001 *
		Placebo	235	231 (98.3)	0.07 (0.02)	(0.02, 0.12)			
	Week 8	Tezepelumab	241	238 (98.8)	0.23 (0.03)	(0.18, 0.28)	0.14 (0.04)	(0.07, 0.21)	<0.001 *
		Placebo	235	230 (97.9)	0.09 (0.03)	(0.04, 0.14)			
	Week 12	Tezepelumab	241	233 (96.7)	0.23 (0.03)	(0.18, 0.28)	0.15 (0.04)	(0.08, 0.22)	<0.001 *
		Placebo	235	226 (96.2)	0.08 (0.03)	(0.03, 0.13)			
	Week 16	Tezepelumab	241	232 (96.3)	0.24 (0.03)	(0.19, 0.29)	0.16 (0.04)	(0.08, 0.23)	<0.001 *
		Placebo	235	222 (94.5)	0.08 (0.03)	(0.03, 0.14)			
	Week 24	Tezepelumab	241	225 (93.4)	0.21 (0.03)	(0.16, 0.26)	0.14 (0.04)	(0.07, 0.22)	<0.001 *
		Placebo	235	220 (93.6)	0.07 (0.03)	(0.02, 0.12)			
	Week 36	Tezepelumab	241	216 (89.6)	0.23 (0.03)	(0.18, 0.28)	0.13 (0.04)	(0.06, 0.21)	<0.001 *
		Placebo	235	211 (89.8)	0.10 (0.03)	(0.04, 0.15)			
	Week 52	Tezepelumab	241	211 (87.6)	0.23 (0.03)	(0.17, 0.28)	0.13 (0.04)	(0.05, 0.20)	<0.001 *
		Placebo	235	200 (85.1)	0.10 (0.03)	(0.04, 0.15)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Total serum IgE									0.310
Low	Week 2	Tezepelumab	115	112 (97.4)	0.13 (0.03)	(0.08, 0.18)	0.11 (0.04)	(0.04, 0.18)	0.003 *
		Placebo	121	113 (93.4)	0.02 (0.03)	(-0.03, 0.07)			
	Week 4	Tezepelumab	115	115 (100.0)	0.16 (0.03)	(0.10, 0.22)	0.08 (0.04)	(-0.01, 0.17)	0.083
		Placebo	121	118 (97.5)	0.08 (0.03)	(0.02, 0.15)			
	Week 8	Tezepelumab	115	112 (97.4)	0.17 (0.03)	(0.11, 0.23)	0.09 (0.04)	(0.01, 0.17)	0.038 *
		Placebo	121	116 (95.9)	0.08 (0.03)	(0.02, 0.14)			
	Week 12	Tezepelumab	115	111 (96.5)	0.18 (0.03)	(0.11, 0.25)	0.10 (0.05)	(0.01, 0.19)	0.038 *
		Placebo	121	116 (95.9)	0.08 (0.03)	(0.02, 0.15)			
	Week 16	Tezepelumab	115	113 (98.3)	0.19 (0.03)	(0.13, 0.26)	0.13 (0.04)	(0.04, 0.22)	0.004 *
		Placebo	121	112 (92.6)	0.06 (0.03)	(0.00, 0.12)			
	Week 24	Tezepelumab	115	111 (96.5)	0.16 (0.03)	(0.10, 0.22)	0.10 (0.04)	(0.02, 0.19)	0.015 *
		Placebo	121	108 (89.3)	0.06 (0.03)	(0.00, 0.12)			
	Week 36	Tezepelumab	115	106 (92.2)	0.14 (0.03)	(0.08, 0.21)	0.03 (0.04)	(-0.05, 0.12)	0.457
		Placebo	121	103 (85.1)	0.11 (0.03)	(0.05, 0.17)			
	Week 52	Tezepelumab	115	106 (92.2)	0.15 (0.03)	(0.09, 0.22)	0.11 (0.05)	(0.02, 0.20)	0.013 *
		Placebo	121	102 (84.3)	0.04 (0.03)	(-0.02, 0.10)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Normal	Week 2	Tezepelumab	235	229 (97.4)	0.19 (0.02)	(0.15, 0.23)	0.16 (0.03)	(0.09, 0.22)	<0.001 *
		Placebo	212	204 (96.2)	0.03 (0.02)	(-0.01, 0.08)			
	Week 4	Tezepelumab	235	232 (98.7)	0.22 (0.02)	(0.17, 0.26)	0.15 (0.03)	(0.09, 0.22)	<0.001 *
		Placebo	212	207 (97.6)	0.06 (0.02)	(0.02, 0.11)			
	Week 8	Tezepelumab	235	232 (98.7)	0.26 (0.02)	(0.21, 0.30)	0.17 (0.04)	(0.10, 0.24)	<0.001 *
		Placebo	212	207 (97.6)	0.08 (0.03)	(0.03, 0.14)			
	Week 12	Tezepelumab	235	228 (97.0)	0.26 (0.03)	(0.21, 0.31)	0.18 (0.04)	(0.11, 0.25)	<0.001 *
		Placebo	212	204 (96.2)	0.08 (0.03)	(0.02, 0.13)			
	Week 16	Tezepelumab	235	225 (95.7)	0.27 (0.03)	(0.22, 0.32)	0.20 (0.04)	(0.13, 0.27)	<0.001 *
		Placebo	212	202 (95.3)	0.07 (0.03)	(0.02, 0.12)			
	Week 24	Tezepelumab	235	217 (92.3)	0.25 (0.03)	(0.20, 0.30)	0.18 (0.04)	(0.10, 0.25)	<0.001 *
		Placebo	212	195 (92.0)	0.07 (0.03)	(0.02, 0.13)			
	Week 36	Tezepelumab	235	211 (89.8)	0.27 (0.03)	(0.21, 0.32)	0.19 (0.04)	(0.12, 0.27)	<0.001 *
		Placebo	212	188 (88.7)	0.07 (0.03)	(0.02, 0.13)			
	Week 52	Tezepelumab	235	205 (87.2)	0.28 (0.03)	(0.23, 0.33)	0.20 (0.04)	(0.13, 0.28)	<0.001 *
		Placebo	212	176 (83.0)	0.08 (0.03)	(0.02, 0.13)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
High	Week 2	Tezepelumab	30	29 (96.7)	0.24 (0.07)	(0.10, 0.38)	0.01 (0.09)	(-0.17, 0.20)	0.883
		Placebo	38	36 (94.7)	0.23 (0.06)	(0.10, 0.35)			
	Week 4	Tezepelumab	30	30 (100.0)	0.26 (0.08)	(0.09, 0.42)	0.14 (0.11)	(-0.08, 0.36)	0.217
		Placebo	38	38 (100.0)	0.12 (0.07)	(-0.03, 0.27)			
	Week 8	Tezepelumab	30	30 (100.0)	0.33 (0.08)	(0.16, 0.49)	0.18 (0.11)	(-0.04, 0.40)	0.105
		Placebo	38	38 (100.0)	0.15 (0.07)	(0.00, 0.29)			
	Week 12	Tezepelumab	30	30 (100.0)	0.31 (0.07)	(0.16, 0.46)	0.09 (0.10)	(-0.11, 0.29)	0.357
		Placebo	38	37 (97.4)	0.22 (0.07)	(0.09, 0.35)			
	Week 16	Tezepelumab	30	29 (96.7)	0.32 (0.08)	(0.16, 0.49)	0.14 (0.11)	(-0.08, 0.36)	0.216
		Placebo	38	36 (94.7)	0.18 (0.07)	(0.04, 0.33)			
	Week 24	Tezepelumab	30	28 (93.3)	0.32 (0.09)	(0.14, 0.49)	0.17 (0.12)	(-0.06, 0.40)	0.136
		Placebo	38	36 (94.7)	0.14 (0.08)	(-0.01, 0.29)			
	Week 36	Tezepelumab	30	26 (86.7)	0.35 (0.09)	(0.18, 0.53)	0.18 (0.12)	(-0.06, 0.41)	0.141
		Placebo	38	37 (97.4)	0.18 (0.08)	(0.02, 0.33)			
	Week 52	Tezepelumab	30	26 (86.7)	0.29 (0.08)	(0.13, 0.45)	0.13 (0.11)	(-0.08, 0.34)	0.230
		Placebo	38	30 (78.9)	0.16 (0.07)	(0.02, 0.30)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
OCS at baseline									0.036 i
Yes	Week 2	Tezepelumab	46	45 (97.8)	0.22 (0.05)	(0.12, 0.33)	0.26 (0.08)	(0.11, 0.42)	0.001 *
		Placebo	42	40 (95.2)	-0.04 (0.06)	(-0.15, 0.08)			
	Week 4	Tezepelumab	46	46 (100.0)	0.26 (0.06)	(0.15, 0.38)	0.25 (0.08)	(0.08, 0.41)	0.003 *
		Placebo	42	41 (97.6)	0.02 (0.06)	(-0.10, 0.13)			
	Week 8	Tezepelumab	46	45 (97.8)	0.22 (0.06)	(0.11, 0.33)	0.17 (0.08)	(0.01, 0.33)	0.038 *
		Placebo	42	42 (100.0)	0.05 (0.06)	(-0.07, 0.17)			
	Week 12	Tezepelumab	46	43 (93.5)	0.27 (0.07)	(0.14, 0.40)	0.23 (0.09)	(0.04, 0.42)	0.018 *
		Placebo	42	39 (92.9)	0.04 (0.07)	(-0.09, 0.18)			
	Week 16	Tezepelumab	46	45 (97.8)	0.29 (0.05)	(0.18, 0.39)	0.31 (0.08)	(0.16, 0.47)	<0.001 *
		Placebo	42	35 (83.3)	-0.02 (0.06)	(-0.14, 0.09)			
	Week 24	Tezepelumab	46	42 (91.3)	0.31 (0.06)	(0.20, 0.43)	0.35 (0.09)	(0.17, 0.53)	<0.001 *
		Placebo	42	31 (73.8)	-0.04 (0.07)	(-0.17, 0.09)			
	Week 36	Tezepelumab	46	39 (84.8)	0.24 (0.05)	(0.14, 0.35)	0.28 (0.08)	(0.13, 0.43)	<0.001 *
		Placebo	42	32 (76.2)	-0.04 (0.06)	(-0.15, 0.08)			
	Week 52	Tezepelumab	46	37 (80.4)	0.28 (0.06)	(0.16, 0.40)	0.30 (0.09)	(0.13, 0.48)	<0.001 *
		Placebo	42	28 (66.7)	-0.02 (0.07)	(-0.15, 0.11)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 2	Tezepelumab	334	325 (97.3)	0.17 (0.02)	(0.14, 0.21)	0.11 (0.03)	(0.06, 0.16)	<0.001 *
		Placebo	329	313 (95.1)	0.06 (0.02)	(0.02, 0.10)			
	Week 4	Tezepelumab	334	331 (99.1)	0.20 (0.02)	(0.16, 0.23)	0.11 (0.03)	(0.06, 0.17)	<0.001 *
		Placebo	329	322 (97.9)	0.08 (0.02)	(0.05, 0.12)			
	Week 8	Tezepelumab	334	329 (98.5)	0.24 (0.02)	(0.20, 0.28)	0.15 (0.03)	(0.09, 0.20)	<0.001 *
		Placebo	329	319 (97.0)	0.09 (0.02)	(0.05, 0.13)			
	Week 12	Tezepelumab	334	326 (97.6)	0.23 (0.02)	(0.19, 0.28)	0.14 (0.03)	(0.08, 0.19)	<0.001 *
		Placebo	329	318 (96.7)	0.10 (0.02)	(0.06, 0.14)			
	Week 16	Tezepelumab	334	322 (96.4)	0.25 (0.02)	(0.21, 0.29)	0.16 (0.03)	(0.10, 0.22)	<0.001 *
		Placebo	329	315 (95.7)	0.09 (0.02)	(0.05, 0.13)			
	Week 24	Tezepelumab	334	314 (94.0)	0.22 (0.02)	(0.18, 0.26)	0.13 (0.03)	(0.07, 0.19)	<0.001 *
		Placebo	329	308 (93.6)	0.09 (0.02)	(0.05, 0.13)			
	Week 36	Tezepelumab	334	304 (91.0)	0.23 (0.02)	(0.19, 0.28)	0.13 (0.03)	(0.06, 0.19)	<0.001 *
		Placebo	329	296 (90.0)	0.11 (0.02)	(0.06, 0.15)			
	Week 52	Tezepelumab	334	300 (89.8)	0.24 (0.02)	(0.20, 0.28)	0.15 (0.03)	(0.09, 0.21)	<0.001 *
		Placebo	329	280 (85.1)	0.08 (0.02)	(0.04, 0.13)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
LAMA use at baseline									0.393
Yes	Week 2	Tezepelumab	112	111 (99.1)	0.20 (0.03)	(0.14, 0.26)	0.16 (0.04)	(0.07, 0.24)	<0.001 *
		Placebo	104	101 (97.1)	0.05 (0.03)	(-0.02, 0.11)			
	Week 4	Tezepelumab	112	112 (100.0)	0.20 (0.03)	(0.14, 0.26)	0.15 (0.05)	(0.05, 0.24)	0.002 *
		Placebo	104	103 (99.0)	0.05 (0.03)	(-0.01, 0.12)			
	Week 8	Tezepelumab	112	111 (99.1)	0.25 (0.04)	(0.18, 0.32)	0.18 (0.05)	(0.07, 0.28)	<0.001 *
		Placebo	104	99 (95.2)	0.07 (0.04)	(0.00, 0.15)			
	Week 12	Tezepelumab	112	108 (96.4)	0.26 (0.04)	(0.19, 0.34)	0.25 (0.06)	(0.13, 0.36)	<0.001 *
		Placebo	104	99 (95.2)	0.02 (0.04)	(-0.06, 0.10)			
	Week 16	Tezepelumab	112	107 (95.5)	0.28 (0.04)	(0.21, 0.35)	0.24 (0.05)	(0.14, 0.34)	<0.001 *
		Placebo	104	96 (92.3)	0.04 (0.04)	(-0.03, 0.11)			
	Week 24	Tezepelumab	112	105 (93.8)	0.24 (0.03)	(0.18, 0.31)	0.20 (0.05)	(0.10, 0.30)	<0.001 *
		Placebo	104	94 (90.4)	0.05 (0.04)	(-0.02, 0.12)			
	Week 36	Tezepelumab	112	99 (88.4)	0.26 (0.03)	(0.19, 0.32)	0.16 (0.05)	(0.06, 0.26)	0.001 *
		Placebo	104	91 (87.5)	0.09 (0.04)	(0.02, 0.16)			
	Week 52	Tezepelumab	112	95 (84.8)	0.27 (0.04)	(0.20, 0.35)	0.23 (0.05)	(0.12, 0.33)	<0.001 *
		Placebo	104	87 (83.7)	0.05 (0.04)	(-0.03, 0.12)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 2	Tezepelumab	268	259 (96.6)	0.17 (0.02)	(0.13, 0.21)	0.12 (0.03)	(0.06, 0.17)	<0.001 *
		Placebo	267	252 (94.4)	0.05 (0.02)	(0.01, 0.09)			
	Week 4	Tezepelumab	268	265 (98.9)	0.21 (0.02)	(0.16, 0.25)	0.12 (0.03)	(0.06, 0.18)	<0.001 *
		Placebo	267	260 (97.4)	0.08 (0.02)	(0.04, 0.13)			
	Week 8	Tezepelumab	268	263 (98.1)	0.23 (0.02)	(0.19, 0.27)	0.14 (0.03)	(0.07, 0.20)	<0.001 *
		Placebo	267	262 (98.1)	0.09 (0.02)	(0.05, 0.14)			
	Week 12	Tezepelumab	268	261 (97.4)	0.23 (0.02)	(0.18, 0.27)	0.11 (0.03)	(0.04, 0.17)	<0.001 *
		Placebo	267	258 (96.6)	0.12 (0.02)	(0.08, 0.17)			
	Week 16	Tezepelumab	268	260 (97.0)	0.24 (0.02)	(0.20, 0.29)	0.15 (0.03)	(0.08, 0.21)	<0.001 *
		Placebo	267	254 (95.1)	0.10 (0.02)	(0.05, 0.14)			
	Week 24	Tezepelumab	268	251 (93.7)	0.22 (0.02)	(0.18, 0.27)	0.14 (0.03)	(0.07, 0.21)	<0.001 *
		Placebo	267	245 (91.8)	0.08 (0.02)	(0.04, 0.13)			
	Week 36	Tezepelumab	268	244 (91.0)	0.23 (0.03)	(0.18, 0.28)	0.14 (0.04)	(0.06, 0.21)	<0.001 *
		Placebo	267	237 (88.8)	0.09 (0.03)	(0.04, 0.14)			
	Week 52	Tezepelumab	268	242 (90.3)	0.23 (0.02)	(0.18, 0.28)	0.15 (0.03)	(0.08, 0.22)	<0.001 *
		Placebo	267	221 (82.8)	0.08 (0.02)	(0.03, 0.13)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Tiotropium use at baseline									0.467
Yes	Week 2	Tezepelumab	103	102 (99.0)	0.20 (0.03)	(0.14, 0.27)	0.15 (0.05)	(0.06, 0.24)	<0.001 *
		Placebo	100	97 (97.0)	0.05 (0.03)	(-0.01, 0.12)			
	Week 4	Tezepelumab	103	103 (100.0)	0.20 (0.03)	(0.13, 0.27)	0.14 (0.05)	(0.04, 0.23)	0.006 *
		Placebo	100	99 (99.0)	0.06 (0.03)	(-0.01, 0.13)			
	Week 8	Tezepelumab	103	102 (99.0)	0.25 (0.04)	(0.18, 0.32)	0.17 (0.05)	(0.07, 0.27)	0.002 *
		Placebo	100	95 (95.0)	0.08 (0.04)	(0.00, 0.15)			
	Week 12	Tezepelumab	103	99 (96.1)	0.26 (0.04)	(0.18, 0.34)	0.24 (0.06)	(0.13, 0.36)	<0.001 *
		Placebo	100	95 (95.0)	0.02 (0.04)	(-0.07, 0.10)			
	Week 16	Tezepelumab	103	99 (96.1)	0.29 (0.04)	(0.22, 0.36)	0.25 (0.05)	(0.15, 0.36)	<0.001 *
		Placebo	100	93 (93.0)	0.04 (0.04)	(-0.04, 0.11)			
	Week 24	Tezepelumab	103	97 (94.2)	0.25 (0.04)	(0.17, 0.32)	0.19 (0.05)	(0.09, 0.30)	<0.001 *
		Placebo	100	91 (91.0)	0.05 (0.04)	(-0.02, 0.13)			
	Week 36	Tezepelumab	103	91 (88.3)	0.26 (0.04)	(0.19, 0.33)	0.16 (0.05)	(0.06, 0.27)	0.002 *
		Placebo	100	88 (88.0)	0.10 (0.04)	(0.02, 0.17)			
	Week 52	Tezepelumab	103	87 (84.5)	0.27 (0.04)	(0.19, 0.35)	0.23 (0.06)	(0.12, 0.35)	<0.001 *
		Placebo	100	85 (85.0)	0.04 (0.04)	(-0.04, 0.12)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 2	Tezepelumab	277	268 (96.8)	0.17 (0.02)	(0.13, 0.21)	0.12 (0.03)	(0.06, 0.18)	<0.001 *
		Placebo	271	256 (94.5)	0.05 (0.02)	(0.01, 0.09)			
	Week 4	Tezepelumab	277	274 (98.9)	0.21 (0.02)	(0.16, 0.25)	0.13 (0.03)	(0.06, 0.19)	<0.001 *
		Placebo	271	264 (97.4)	0.08 (0.02)	(0.04, 0.12)			
	Week 8	Tezepelumab	277	272 (98.2)	0.23 (0.02)	(0.19, 0.27)	0.14 (0.03)	(0.08, 0.20)	<0.001 *
		Placebo	271	266 (98.2)	0.09 (0.02)	(0.05, 0.14)			
	Week 12	Tezepelumab	277	270 (97.5)	0.23 (0.02)	(0.19, 0.28)	0.11 (0.03)	(0.05, 0.17)	<0.001 *
		Placebo	271	262 (96.7)	0.12 (0.02)	(0.07, 0.16)			
	Week 16	Tezepelumab	277	268 (96.8)	0.24 (0.02)	(0.19, 0.29)	0.14 (0.03)	(0.08, 0.21)	<0.001 *
		Placebo	271	257 (94.8)	0.10 (0.02)	(0.05, 0.14)			
	Week 24	Tezepelumab	277	259 (93.5)	0.22 (0.02)	(0.18, 0.27)	0.14 (0.03)	(0.08, 0.21)	<0.001 *
		Placebo	271	248 (91.5)	0.08 (0.02)	(0.04, 0.13)			
	Week 36	Tezepelumab	277	252 (91.0)	0.23 (0.02)	(0.18, 0.28)	0.14 (0.04)	(0.07, 0.20)	<0.001 *
		Placebo	271	240 (88.6)	0.09 (0.03)	(0.04, 0.14)			
	Week 52	Tezepelumab	277	250 (90.3)	0.23 (0.02)	(0.19, 0.28)	0.15 (0.03)	(0.08, 0.22)	<0.001 *
		Placebo	271	223 (82.3)	0.08 (0.02)	(0.04, 0.13)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Montelukast/ Cromoglicic acid use at baseline									0.672
Yes	Week 2	Tezepelumab	163	158 (96.9)	0.19 (0.03)	(0.14, 0.24)	0.13 (0.04)	(0.05, 0.21)	<0.001 *
		Placebo	141	135 (95.7)	0.06 (0.03)	(0.00, 0.11)			
	Week 4	Tezepelumab	163	162 (99.4)	0.23 (0.03)	(0.17, 0.29)	0.13 (0.04)	(0.05, 0.22)	0.003 *
		Placebo	141	138 (97.9)	0.10 (0.03)	(0.03, 0.16)			
	Week 8	Tezepelumab	163	161 (98.8)	0.26 (0.03)	(0.20, 0.32)	0.17 (0.05)	(0.07, 0.26)	<0.001 *
		Placebo	141	139 (98.6)	0.10 (0.03)	(0.03, 0.16)			
	Week 12	Tezepelumab	163	157 (96.3)	0.28 (0.03)	(0.22, 0.35)	0.22 (0.05)	(0.12, 0.32)	<0.001 *
		Placebo	141	140 (99.3)	0.07 (0.04)	(-0.01, 0.14)			
	Week 16	Tezepelumab	163	157 (96.3)	0.27 (0.03)	(0.20, 0.33)	0.18 (0.05)	(0.08, 0.27)	<0.001 *
		Placebo	141	136 (96.5)	0.09 (0.03)	(0.02, 0.16)			
	Week 24	Tezepelumab	163	152 (93.3)	0.24 (0.03)	(0.18, 0.30)	0.16 (0.05)	(0.07, 0.25)	<0.001 *
		Placebo	141	132 (93.6)	0.08 (0.03)	(0.01, 0.14)			
	Week 36	Tezepelumab	163	147 (90.2)	0.27 (0.03)	(0.20, 0.33)	0.20 (0.05)	(0.10, 0.29)	<0.001 *
		Placebo	141	131 (92.9)	0.07 (0.03)	(0.00, 0.14)			
	Week 52	Tezepelumab	163	145 (89.0)	0.28 (0.03)	(0.21, 0.34)	0.21 (0.05)	(0.11, 0.30)	<0.001 *
		Placebo	141	118 (83.7)	0.07 (0.04)	(-0.00, 0.14)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 2	Tezepelumab	217	212 (97.7)	0.17 (0.02)	(0.12, 0.21)	0.12 (0.03)	(0.06, 0.18)	<0.001 *
		Placebo	230	218 (94.8)	0.04 (0.02)	(0.00, 0.09)			
	Week 4	Tezepelumab	217	215 (99.1)	0.19 (0.02)	(0.14, 0.23)	0.12 (0.03)	(0.06, 0.19)	<0.001 *
		Placebo	230	225 (97.8)	0.06 (0.02)	(0.02, 0.11)			
	Week 8	Tezepelumab	217	213 (98.2)	0.22 (0.02)	(0.17, 0.26)	0.13 (0.03)	(0.07, 0.20)	<0.001 *
		Placebo	230	222 (96.5)	0.08 (0.02)	(0.04, 0.13)			
	Week 12	Tezepelumab	217	212 (97.7)	0.21 (0.02)	(0.16, 0.25)	0.10 (0.03)	(0.03, 0.16)	0.004 *
		Placebo	230	217 (94.3)	0.11 (0.02)	(0.06, 0.16)			
	Week 16	Tezepelumab	217	210 (96.8)	0.24 (0.03)	(0.19, 0.29)	0.17 (0.04)	(0.10, 0.24)	<0.001 *
		Placebo	230	214 (93.0)	0.07 (0.02)	(0.03, 0.12)			
	Week 24	Tezepelumab	217	204 (94.0)	0.22 (0.03)	(0.17, 0.27)	0.15 (0.04)	(0.08, 0.22)	<0.001 *
		Placebo	230	207 (90.0)	0.07 (0.03)	(0.02, 0.12)			
	Week 36	Tezepelumab	217	196 (90.3)	0.21 (0.03)	(0.16, 0.27)	0.10 (0.04)	(0.03, 0.18)	0.005 *
		Placebo	230	197 (85.7)	0.11 (0.03)	(0.06, 0.16)			
	Week 52	Tezepelumab	217	192 (88.5)	0.22 (0.03)	(0.17, 0.27)	0.14 (0.04)	(0.07, 0.21)	<0.001 *
		Placebo	230	190 (82.6)	0.08 (0.03)	(0.03, 0.13)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Western Europe	Absolute values	Baseline	Tezepelumab	71	71 (100.0)	1.87 (0.65)	0.8	1.36	1.77	2.30	3.6	
			Placebo	71	71 (100.0)	1.90 (0.78)	0.7	1.35	1.77	2.34	4.2	
		Week 2	Tezepelumab	71	70 (98.6)	2.04 (0.71)	0.7	1.42	1.96	2.45	3.9	
			Placebo	71	66 (93.0)	1.96 (0.80)	0.6	1.37	1.84	2.37	4.0	
		Week 4	Tezepelumab	71	71 (100.0)	2.07 (0.72)	0.7	1.54	2.05	2.53	4.3	
			Placebo	71	69 (97.2)	1.93 (0.80)	0.7	1.39	1.76	2.42	4.2	
		Week 8	Tezepelumab	71	71 (100.0)	2.09 (0.76)	0.8	1.52	2.11	2.53	4.7	
			Placebo	71	66 (93.0)	2.02 (0.80)	0.7	1.35	2.01	2.51	4.3	
		Week 12	Tezepelumab	71	68 (95.8)	2.05 (0.78)	0.8	1.52	2.00	2.39	4.7	
			Placebo	71	65 (91.5)	1.94 (0.85)	0.6	1.31	1.70	2.52	4.3	
		Week 16	Tezepelumab	71	69 (97.2)	2.17 (0.78)	0.9	1.65	2.06	2.45	4.9	
			Placebo	71	65 (91.5)	1.92 (0.77)	0.8	1.32	1.77	2.28	4.1	
		Week 24	Tezepelumab	71	68 (95.8)	2.05 (0.70)	0.7	1.63	2.00	2.43	4.4	
			Placebo	71	60 (84.5)	1.92 (0.83)	0.6	1.26	1.90	2.25	4.8	
		Week 36	Tezepelumab	71	65 (91.5)	2.07 (0.74)	0.8	1.53	2.05	2.50	4.5	
			Placebo	71	57 (80.3)	2.06 (0.79)	0.8	1.49	1.97	2.55	4.6	
		Week 52	Tezepelumab	71	63 (88.7)	2.07 (0.74)	0.8	1.56	2.06	2.45	4.1	
			Placebo	71	54 (76.1)	2.09 (0.85)	0.7	1.37	1.98	2.64	4.4	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Western Europe	Change from baseline	Week 2	Tezepelumab	71	70 (98.6)	0.18 (0.28)	-0.6	0.01	0.14	0.36	1.1	0.52 [0.18, 0.86]
			Placebo	71	66 (93.0)	0.03 (0.32)	-0.8	-0.15	0.00	0.18	1.0	
		Week 4	Tezepelumab	71	71 (100.0)	0.20 (0.34)	-0.7	0.01	0.17	0.32	1.4	0.51 [0.17, 0.84]
			Placebo	71	69 (97.2)	0.03 (0.34)	-0.7	-0.11	0.03	0.24	1.4	
		Week 8	Tezepelumab	71	71 (100.0)	0.22 (0.41)	-0.6	-0.07	0.15	0.46	1.8	0.37 [0.03, 0.71]
			Placebo	71	66 (93.0)	0.08 (0.37)	-0.8	-0.12	0.05	0.29	1.3	
		Week 12	Tezepelumab	71	68 (95.8)	0.21 (0.43)	-0.8	-0.06	0.15	0.42	1.9	0.42 [0.08, 0.77]
			Placebo	71	65 (91.5)	0.05 (0.32)	-0.7	-0.11	0.02	0.22	1.2	
		Week 16	Tezepelumab	71	69 (97.2)	0.28 (0.41)	-0.8	0.04	0.23	0.42	2.0	0.71 [0.36, 1.06]
			Placebo	71	65 (91.5)	-0.00 (0.37)	-1.2	-0.16	0.02	0.18	1.0	
		Week 24	Tezepelumab	71	68 (95.8)	0.21 (0.34)	-0.2	-0.04	0.17	0.41	1.5	0.67 [0.31, 1.02]
			Placebo	71	60 (84.5)	-0.02 (0.36)	-0.9	-0.18	-0.04	0.13	1.6	
		Week 36	Tezepelumab	71	65 (91.5)	0.22 (0.37)	-0.5	-0.05	0.15	0.46	1.7	0.40 [0.04, 0.75]
			Placebo	71	57 (80.3)	0.07 (0.37)	-1.1	-0.15	0.08	0.31	1.1	
		Week 52	Tezepelumab	71	63 (88.7)	0.21 (0.34)	-0.6	-0.01	0.22	0.35	1.2	0.32 [-0.04, 0.69]
			Placebo	71	54 (76.1)	0.10 (0.33)	-0.8	-0.07	0.09	0.21	1.1	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
North America	Absolute values	Baseline	Tezepelumab	75	75 (100.0)	1.75 (0.66)	0.7	1.28	1.56	2.08	4.0	
			Placebo	71	71 (100.0)	1.83 (0.59)	0.9	1.33	1.69	2.18	3.3	
		Week 2	Tezepelumab	75	69 (92.0)	2.02 (0.71)	0.8	1.47	1.85	2.58	4.1	
			Placebo	71	67 (94.4)	1.91 (0.60)	1.0	1.43	1.90	2.27	3.4	
		Week 4	Tezepelumab	75	73 (97.3)	2.01 (0.72)	0.7	1.51	1.91	2.52	4.2	
			Placebo	71	70 (98.6)	1.93 (0.55)	1.0	1.56	1.89	2.25	3.2	
		Week 8	Tezepelumab	75	73 (97.3)	2.02 (0.71)	0.8	1.44	1.95	2.45	4.1	
			Placebo	71	69 (97.2)	1.92 (0.62)	0.8	1.53	1.85	2.13	3.7	
		Week 12	Tezepelumab	75	71 (94.7)	2.04 (0.72)	0.9	1.52	1.99	2.46	4.2	
			Placebo	71	69 (97.2)	1.91 (0.62)	0.9	1.47	1.75	2.30	3.6	
		Week 16	Tezepelumab	75	71 (94.7)	2.01 (0.74)	0.9	1.49	1.86	2.56	4.3	
			Placebo	71	68 (95.8)	1.93 (0.57)	1.0	1.49	1.90	2.27	3.2	
		Week 24	Tezepelumab	75	65 (86.7)	2.00 (0.74)	0.8	1.45	1.94	2.57	4.0	
			Placebo	71	66 (93.0)	1.89 (0.55)	0.8	1.51	1.90	2.22	3.3	
		Week 36	Tezepelumab	75	61 (81.3)	2.03 (0.76)	0.9	1.44	1.91	2.39	4.4	
			Placebo	71	66 (93.0)	1.94 (0.58)	1.0	1.53	1.89	2.29	3.4	
		Week 52	Tezepelumab	75	58 (77.3)	2.04 (0.77)	0.7	1.57	2.02	2.53	4.2	
			Placebo	71	53 (74.6)	1.90 (0.62)	0.6	1.40	1.83	2.40	3.6	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
North America	Change from baseline	Week 2	Tezepelumab	75	69 (92.0)	0.29 (0.35)	-0.3	0.07	0.21	0.46	1.5	0.52 [0.18, 0.86]
			Placebo	71	67 (94.4)	0.09 (0.41)	-1.8	-0.08	0.01	0.31	1.1	
		Week 4	Tezepelumab	75	73 (97.3)	0.27 (0.35)	-0.3	0.03	0.19	0.42	1.3	0.49 [0.16, 0.83]
			Placebo	71	70 (98.6)	0.10 (0.33)	-1.0	-0.06	0.06	0.24	1.0	
		Week 8	Tezepelumab	75	73 (97.3)	0.30 (0.44)	-0.8	0.03	0.25	0.50	1.4	0.55 [0.22, 0.89]
			Placebo	71	69 (97.2)	0.09 (0.29)	-0.5	-0.10	0.10	0.28	0.9	
		Week 12	Tezepelumab	75	71 (94.7)	0.30 (0.36)	-0.3	0.04	0.28	0.50	1.3	0.50 [0.16, 0.84]
			Placebo	71	69 (97.2)	0.09 (0.48)	-1.5	-0.10	0.06	0.34	1.3	
		Week 16	Tezepelumab	75	71 (94.7)	0.30 (0.40)	-0.4	0.01	0.19	0.43	1.9	0.50 [0.16, 0.84]
			Placebo	71	68 (95.8)	0.12 (0.29)	-0.4	-0.07	0.06	0.28	1.0	
		Week 24	Tezepelumab	75	65 (86.7)	0.30 (0.42)	-0.7	0.02	0.27	0.49	1.6	0.56 [0.21, 0.91]
			Placebo	71	66 (93.0)	0.08 (0.34)	-0.9	-0.11	0.10	0.27	0.9	
		Week 36	Tezepelumab	75	61 (81.3)	0.32 (0.42)	-0.3	-0.01	0.22	0.54	1.5	0.48 [0.12, 0.83]
			Placebo	71	66 (93.0)	0.13 (0.35)	-0.4	-0.09	0.04	0.27	1.3	
		Week 52	Tezepelumab	75	58 (77.3)	0.33 (0.45)	-0.3	-0.01	0.17	0.70	1.3	0.65 [0.26, 1.03]
			Placebo	71	53 (74.6)	0.08 (0.31)	-0.5	-0.15	0.01	0.23	1.1	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
South America	Absolute values	Baseline	Tezepelumab	65	65 (100.0)	1.82 (0.67)	0.8	1.36	1.65	2.13	3.8	
			Placebo	63	63 (100.0)	1.96 (0.90)	0.6	1.14	1.92	2.56	4.5	
		Week 2	Tezepelumab	65	65 (100.0)	1.92 (0.69)	0.9	1.44	1.80	2.39	4.0	
			Placebo	63	61 (96.8)	2.03 (0.87)	0.6	1.38	1.90	2.54	4.1	
		Week 4	Tezepelumab	65	64 (98.5)	1.93 (0.75)	0.8	1.37	1.79	2.40	4.2	
			Placebo	63	59 (93.7)	1.99 (0.89)	0.5	1.27	1.97	2.51	4.8	
		Week 8	Tezepelumab	65	64 (98.5)	1.95 (0.79)	0.7	1.29	1.82	2.44	4.2	
			Placebo	63	61 (96.8)	2.11 (0.95)	0.6	1.41	1.94	2.84	4.6	
		Week 12	Tezepelumab	65	63 (96.9)	1.98 (0.76)	0.8	1.55	1.77	2.49	4.3	
			Placebo	63	62 (98.4)	2.09 (0.90)	0.5	1.48	2.05	2.58	4.6	
		Week 16	Tezepelumab	65	62 (95.4)	1.97 (0.76)	0.8	1.43	1.80	2.36	4.3	
			Placebo	63	60 (95.2)	2.08 (1.03)	0.5	1.28	1.85	2.68	4.7	
		Week 24	Tezepelumab	65	61 (93.8)	1.94 (0.74)	0.7	1.33	1.74	2.46	3.7	
			Placebo	63	59 (93.7)	2.10 (0.96)	0.6	1.44	1.90	2.79	4.8	
		Week 36	Tezepelumab	65	61 (93.8)	1.94 (0.78)	0.7	1.32	1.86	2.31	4.2	
			Placebo	63	61 (96.8)	2.14 (0.97)	0.6	1.41	2.10	2.78	4.3	
		Week 52	Tezepelumab	65	61 (93.8)	1.97 (0.80)	0.6	1.42	1.81	2.33	4.3	
			Placebo	63	59 (93.7)	2.10 (0.99)	0.6	1.27	2.07	2.76	4.5	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
South America	Change from baseline	Week 2	Tezepelumab	65	65 (100.0)	0.10 (0.31)	-0.7	-0.09	0.10	0.24	1.3	0.16 [-0.19, 0.51]
			Placebo	63	61 (96.8)	0.04 (0.41)	-1.1	-0.14	-0.01	0.16	1.1	
		Week 4	Tezepelumab	65	64 (98.5)	0.12 (0.31)	-0.5	-0.08	0.08	0.21	1.3	0.14 [-0.22, 0.49]
			Placebo	63	59 (93.7)	0.07 (0.46)	-1.8	-0.10	0.03	0.23	1.6	
		Week 8	Tezepelumab	65	64 (98.5)	0.14 (0.38)	-0.6	-0.08	0.08	0.30	1.6	0.04 [-0.31, 0.39]
			Placebo	63	61 (96.8)	0.13 (0.34)	-0.8	-0.10	0.09	0.29	1.4	
		Week 12	Tezepelumab	65	63 (96.9)	0.15 (0.34)	-0.4	-0.07	0.08	0.24	1.6	0.10 [-0.25, 0.45]
			Placebo	63	62 (98.4)	0.11 (0.40)	-0.7	-0.12	0.07	0.26	1.4	
		Week 16	Tezepelumab	65	62 (95.4)	0.16 (0.35)	-0.5	-0.05	0.14	0.28	1.5	0.13 [-0.23, 0.48]
			Placebo	63	60 (95.2)	0.10 (0.45)	-0.7	-0.16	0.00	0.26	1.5	
		Week 24	Tezepelumab	65	61 (93.8)	0.15 (0.36)	-0.7	-0.08	0.12	0.31	1.5	0.12 [-0.24, 0.47]
			Placebo	63	59 (93.7)	0.11 (0.44)	-0.8	-0.13	0.03	0.29	1.6	
		Week 36	Tezepelumab	65	61 (93.8)	0.14 (0.37)	-0.8	-0.09	0.05	0.35	1.6	0.01 [-0.34, 0.37]
			Placebo	63	61 (96.8)	0.13 (0.45)	-0.8	-0.17	0.03	0.29	1.3	
		Week 52	Tezepelumab	65	61 (93.8)	0.16 (0.39)	-0.8	-0.06	0.08	0.36	1.7	0.12 [-0.24, 0.48]
			Placebo	63	59 (93.7)	0.11 (0.44)	-0.9	-0.16	0.03	0.35	1.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Central/Eastern Europe	Absolute values	Baseline	Tezepelumab	19	19 (100.0)	1.63 (0.66)	0.9	1.23	1.43	1.87	3.5	
			Placebo	18	18 (100.0)	1.35 (0.48)	0.8	1.07	1.25	1.49	2.6	
		Week 2	Tezepelumab	19	19 (100.0)	1.78 (0.68)	1.1	1.41	1.58	2.07	3.8	
			Placebo	18	16 (88.9)	1.40 (0.52)	0.7	1.05	1.29	1.78	2.4	
		Week 4	Tezepelumab	19	19 (100.0)	1.89 (0.78)	0.9	1.28	1.69	2.02	3.7	
			Placebo	18	18 (100.0)	1.45 (0.49)	0.7	1.08	1.39	1.91	2.3	
		Week 8	Tezepelumab	19	19 (100.0)	1.83 (0.70)	1.0	1.40	1.64	2.11	3.7	
			Placebo	18	18 (100.0)	1.47 (0.49)	0.7	1.09	1.41	1.89	2.4	
		Week 12	Tezepelumab	19	19 (100.0)	1.87 (0.68)	1.1	1.38	1.69	2.14	3.6	
			Placebo	18	17 (94.4)	1.54 (0.58)	0.8	1.12	1.37	1.91	2.9	
		Week 16	Tezepelumab	19	19 (100.0)	1.88 (0.65)	1.0	1.43	1.68	2.16	3.3	
			Placebo	18	18 (100.0)	1.47 (0.51)	0.9	1.06	1.30	1.75	2.4	
		Week 24	Tezepelumab	19	18 (94.7)	1.80 (0.68)	0.9	1.40	1.73	2.05	3.8	
			Placebo	18	18 (100.0)	1.53 (0.52)	0.8	1.07	1.55	1.89	2.4	
		Week 36	Tezepelumab	19	19 (100.0)	1.84 (0.67)	1.0	1.28	1.69	2.24	3.5	
			Placebo	18	17 (94.4)	1.49 (0.49)	0.8	1.08	1.45	1.78	2.3	
		Week 52	Tezepelumab	19	19 (100.0)	1.82 (0.71)	1.0	1.15	1.60	2.13	3.5	
			Placebo	18	18 (100.0)	1.48 (0.52)	0.8	1.05	1.42	1.63	2.4	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Central/Eastern Europe	Change from baseline	Week 2	Tezepelumab	19	19 (100.0)	0.15 (0.25)	-0.2	-0.06	0.08	0.30	0.8	0.56 [-0.12, 1.24]
			Placebo	18	16 (88.9)	0.01 (0.23)	-0.4	-0.11	-0.01	0.09	0.7	
		Week 4	Tezepelumab	19	19 (100.0)	0.26 (0.42)	-0.3	0.03	0.19	0.33	1.7	0.41 [-0.24, 1.07]
			Placebo	18	18 (100.0)	0.10 (0.33)	-0.3	-0.11	0.07	0.31	1.0	
		Week 8	Tezepelumab	19	19 (100.0)	0.20 (0.34)	-0.2	-0.08	0.16	0.30	1.2	0.24 [-0.41, 0.88]
			Placebo	18	18 (100.0)	0.12 (0.32)	-0.4	-0.05	0.03	0.24	0.9	
		Week 12	Tezepelumab	19	19 (100.0)	0.24 (0.38)	-0.3	-0.05	0.24	0.40	1.4	0.17 [-0.48, 0.83]
			Placebo	18	17 (94.4)	0.18 (0.28)	-0.2	0.03	0.09	0.33	1.0	
		Week 16	Tezepelumab	19	19 (100.0)	0.25 (0.46)	-0.6	0.03	0.17	0.54	1.6	0.34 [-0.31, 0.99]
			Placebo	18	18 (100.0)	0.12 (0.25)	-0.2	-0.06	0.05	0.20	0.7	
		Week 24	Tezepelumab	19	18 (94.7)	0.15 (0.44)	-1.0	-0.13	0.08	0.35	1.0	-0.08 [-0.73, 0.58]
			Placebo	18	18 (100.0)	0.18 (0.33)	-0.4	-0.02	0.12	0.46	0.8	
		Week 36	Tezepelumab	19	19 (100.0)	0.21 (0.39)	-0.3	-0.09	0.02	0.49	1.1	0.26 [-0.40, 0.92]
			Placebo	18	17 (94.4)	0.12 (0.25)	-0.3	-0.04	0.06	0.29	0.6	
		Week 52	Tezepelumab	19	19 (100.0)	0.19 (0.36)	-0.4	-0.04	0.10	0.44	1.0	0.20 [-0.44, 0.85]
			Placebo	18	18 (100.0)	0.13 (0.22)	-0.3	-0.05	0.11	0.23	0.5	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Asia Pacific	Absolute values	Baseline	Tezepelumab	97	97 (100.0)	1.72 (0.67)	0.4	1.26	1.66	2.13	4.1	
			Placebo	93	93 (100.0)	1.73 (0.57)	0.4	1.37	1.69	2.06	3.1	
		Week 2	Tezepelumab	97	97 (100.0)	1.89 (0.67)	0.6	1.31	1.78	2.30	4.3	
			Placebo	93	91 (97.8)	1.80 (0.63)	0.4	1.45	1.69	2.17	3.9	
		Week 4	Tezepelumab	97	97 (100.0)	1.94 (0.68)	0.7	1.45	1.78	2.41	3.7	
			Placebo	93	93 (100.0)	1.79 (0.59)	0.4	1.44	1.72	2.13	3.7	
		Week 8	Tezepelumab	97	95 (97.9)	1.98 (0.67)	0.6	1.48	1.93	2.38	4.7	
			Placebo	93	93 (100.0)	1.80 (0.64)	0.4	1.39	1.74	2.23	4.3	
		Week 12	Tezepelumab	97	95 (97.9)	1.99 (0.68)	0.6	1.52	1.93	2.41	3.8	
			Placebo	93	92 (98.9)	1.83 (0.64)	0.7	1.43	1.75	2.23	4.3	
		Week 16	Tezepelumab	97	96 (99.0)	2.01 (0.73)	0.6	1.52	1.89	2.48	4.7	
			Placebo	93	90 (96.8)	1.83 (0.62)	0.7	1.46	1.71	2.14	4.4	
		Week 24	Tezepelumab	97	95 (97.9)	1.99 (0.64)	0.8	1.57	1.82	2.34	4.0	
			Placebo	93	88 (94.6)	1.83 (0.60)	0.7	1.42	1.72	2.12	4.3	
		Week 36	Tezepelumab	97	91 (93.8)	1.99 (0.71)	0.6	1.52	1.81	2.44	4.4	
			Placebo	93	85 (91.4)	1.81 (0.64)	0.7	1.42	1.70	2.18	4.3	
		Week 52	Tezepelumab	97	91 (93.8)	2.01 (0.69)	0.8	1.53	1.83	2.48	4.2	
			Placebo	93	85 (91.4)	1.75 (0.59)	0.7	1.34	1.61	2.13	3.4	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Asia Pacific	Change from baseline	Week 2	Tezepelumab	97	97 (100.0)	0.18 (0.35)	-0.6	0.00	0.10	0.26	1.3	0.36 [0.07, 0.65]
			Placebo	93	91 (97.8)	0.05 (0.33)	-0.7	-0.09	0.04	0.19	1.2	
		Week 4	Tezepelumab	97	97 (100.0)	0.23 (0.39)	-0.9	0.02	0.14	0.35	1.8	0.45 [0.17, 0.74]
			Placebo	93	93 (100.0)	0.06 (0.34)	-0.7	-0.13	0.01	0.20	1.1	
		Week 8	Tezepelumab	97	95 (97.9)	0.28 (0.43)	-0.8	0.03	0.17	0.50	1.7	0.56 [0.27, 0.85]
			Placebo	93	93 (100.0)	0.06 (0.34)	-0.7	-0.15	0.02	0.23	1.6	
		Week 12	Tezepelumab	97	95 (97.9)	0.30 (0.46)	-0.7	0.04	0.20	0.51	2.0	0.51 [0.22, 0.80]
			Placebo	93	92 (98.9)	0.09 (0.35)	-0.9	-0.07	0.04	0.19	1.7	
		Week 16	Tezepelumab	97	96 (99.0)	0.30 (0.44)	-0.6	0.02	0.22	0.51	1.7	0.56 [0.27, 0.86]
			Placebo	93	90 (96.8)	0.08 (0.35)	-0.8	-0.11	0.01	0.24	1.8	
		Week 24	Tezepelumab	97	95 (97.9)	0.27 (0.45)	-1.0	0.00	0.23	0.54	1.6	0.47 [0.18, 0.77]
			Placebo	93	88 (94.6)	0.08 (0.38)	-0.9	-0.14	0.06	0.22	1.7	
		Week 36	Tezepelumab	97	91 (93.8)	0.27 (0.47)	-1.0	0.01	0.23	0.54	1.5	0.52 [0.22, 0.82]
			Placebo	93	85 (91.4)	0.05 (0.40)	-1.0	-0.21	0.02	0.27	1.7	
		Week 52	Tezepelumab	97	91 (93.8)	0.28 (0.46)	-1.0	0.00	0.26	0.53	1.6	0.63 [0.33, 0.93]
			Placebo	93	85 (91.4)	0.02 (0.35)	-1.0	-0.22	0.01	0.23	0.8	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Rest of the world	Absolute values	Baseline	Tezepelumab	53	53 (100.0)	1.53 (0.70)	0.6	1.02	1.31	1.92	3.3	
			Placebo	55	55 (100.0)	1.70 (0.49)	0.9	1.35	1.59	2.02	3.0	
		Week 2	Tezepelumab	53	50 (94.3)	1.71 (0.68)	0.6	1.23	1.53	2.22	3.5	
			Placebo	55	52 (94.5)	1.73 (0.53)	0.8	1.31	1.73	2.14	2.7	
		Week 4	Tezepelumab	53	53 (100.0)	1.71 (0.71)	0.6	1.20	1.65	2.13	3.8	
			Placebo	55	54 (98.2)	1.81 (0.56)	0.9	1.36	1.79	2.12	3.4	
		Week 8	Tezepelumab	53	52 (98.1)	1.73 (0.66)	0.6	1.19	1.63	2.25	3.8	
			Placebo	55	54 (98.2)	1.75 (0.51)	0.7	1.34	1.67	2.14	3.0	
		Week 12	Tezepelumab	53	53 (100.0)	1.76 (0.70)	0.6	1.31	1.66	2.20	3.8	
			Placebo	55	52 (94.5)	1.79 (0.50)	1.0	1.38	1.75	2.24	3.1	
		Week 16	Tezepelumab	53	50 (94.3)	1.77 (0.71)	0.6	1.28	1.63	2.18	3.8	
			Placebo	55	49 (89.1)	1.77 (0.51)	0.8	1.33	1.76	2.17	3.1	
		Week 24	Tezepelumab	53	49 (92.5)	1.78 (0.76)	0.6	1.16	1.67	2.30	4.0	
			Placebo	55	48 (87.3)	1.73 (0.52)	0.9	1.37	1.65	2.12	3.1	
		Week 36	Tezepelumab	53	46 (86.8)	1.75 (0.72)	0.5	1.23	1.66	2.27	3.8	
			Placebo	55	42 (76.4)	1.71 (0.47)	0.9	1.36	1.67	2.11	2.8	
		Week 52	Tezepelumab	53	45 (84.9)	1.73 (0.69)	0.7	1.23	1.66	2.10	3.7	
			Placebo	55	39 (70.9)	1.65 (0.44)	1.0	1.27	1.66	1.88	2.7	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Rest of the world	Change from baseline	Week 2	Tezepelumab	53	50 (94.3)	0.16 (0.33)	-0.5	-0.06	0.11	0.28	1.4	0.42 [0.03, 0.82]
			Placebo	55	52 (94.5)	0.02 (0.29)	-0.7	-0.14	0.03	0.13	1.0	
		Week 4	Tezepelumab	53	53 (100.0)	0.18 (0.34)	-0.5	-0.04	0.11	0.36	1.1	0.18 [-0.20, 0.56]
			Placebo	55	54 (98.2)	0.11 (0.45)	-1.0	-0.13	0.05	0.36	1.2	
		Week 8	Tezepelumab	53	52 (98.1)	0.23 (0.32)	-0.4	0.05	0.19	0.40	1.1	0.52 [0.14, 0.91]
			Placebo	55	54 (98.2)	0.06 (0.35)	-0.9	-0.13	0.04	0.20	1.2	
		Week 12	Tezepelumab	53	53 (100.0)	0.23 (0.36)	-0.4	-0.01	0.17	0.44	1.5	0.37 [-0.01, 0.76]
			Placebo	55	52 (94.5)	0.10 (0.34)	-1.1	-0.08	0.05	0.22	0.9	
		Week 16	Tezepelumab	53	50 (94.3)	0.21 (0.38)	-0.6	-0.04	0.12	0.40	1.4	0.39 [-0.01, 0.79]
			Placebo	55	49 (89.1)	0.07 (0.35)	-1.0	-0.06	0.03	0.24	1.2	
		Week 24	Tezepelumab	53	49 (92.5)	0.25 (0.42)	-0.4	-0.03	0.17	0.45	1.7	0.49 [0.09, 0.90]
			Placebo	55	48 (87.3)	0.06 (0.35)	-1.1	-0.13	-0.02	0.27	0.9	
		Week 36	Tezepelumab	53	46 (86.8)	0.21 (0.39)	-0.4	-0.07	0.09	0.38	1.6	0.40 [-0.03, 0.82]
			Placebo	55	42 (76.4)	0.06 (0.35)	-0.9	-0.12	0.04	0.27	0.9	
		Week 52	Tezepelumab	53	45 (84.9)	0.21 (0.40)	-0.5	-0.03	0.13	0.34	1.4	0.66 [0.22, 1.10]
			Placebo	55	39 (70.9)	-0.02 (0.28)	-1.0	-0.18	-0.03	0.13	0.6	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
< 150 cells/uL	Absolute values	Baseline	Tezepelumab	95	95 (100.0)	1.89 (0.70)	0.4	1.31	1.87	2.43	4.0	
			Placebo	87	87 (100.0)	1.80 (0.61)	0.8	1.37	1.79	2.17	3.4	
		Week 2	Tezepelumab	95	93 (97.9)	1.97 (0.73)	0.6	1.40	1.92	2.44	4.1	
			Placebo	87	82 (94.3)	1.82 (0.65)	0.8	1.38	1.66	2.17	3.5	
		Week 4	Tezepelumab	95	94 (98.9)	1.97 (0.78)	0.7	1.32	1.98	2.56	4.2	
			Placebo	87	86 (98.9)	1.82 (0.65)	0.7	1.34	1.78	2.20	3.6	
		Week 8	Tezepelumab	95	92 (96.8)	1.96 (0.74)	0.6	1.43	1.87	2.47	4.1	
			Placebo	87	84 (96.6)	1.84 (0.67)	0.7	1.38	1.81	2.31	3.7	
		Week 12	Tezepelumab	95	91 (95.8)	1.97 (0.75)	0.6	1.44	1.89	2.45	4.2	
			Placebo	87	82 (94.3)	1.81 (0.68)	0.7	1.31	1.67	2.18	3.6	
		Week 16	Tezepelumab	95	92 (96.8)	2.02 (0.80)	0.6	1.41	1.86	2.55	4.3	
			Placebo	87	82 (94.3)	1.78 (0.65)	0.6	1.29	1.69	2.16	3.6	
		Week 24	Tezepelumab	95	85 (89.5)	1.94 (0.71)	0.6	1.40	1.87	2.41	4.0	
			Placebo	87	79 (90.8)	1.82 (0.62)	0.8	1.30	1.73	2.20	3.6	
		Week 36	Tezepelumab	95	86 (90.5)	1.94 (0.78)	0.5	1.33	1.90	2.44	4.4	
			Placebo	87	76 (87.4)	1.85 (0.64)	0.8	1.32	1.82	2.25	3.4	
		Week 52	Tezepelumab	95	85 (89.5)	1.97 (0.76)	0.7	1.41	1.84	2.59	4.2	
			Placebo	87	75 (86.2)	1.79 (0.67)	0.7	1.25	1.65	2.28	3.5	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
< 150 cells/uL	Change from baseline	Week 2	Tezepelumab	95	93 (97.9)	0.07 (0.29)	-0.6	-0.07	0.08	0.19	1.5	0.22 [-0.08, 0.51]
			Placebo	87	82 (94.3)	0.01 (0.34)	-1.8	-0.13	-0.01	0.13	1.1	
		Week 4	Tezepelumab	95	94 (98.9)	0.09 (0.36)	-0.9	-0.07	0.04	0.27	1.7	0.21 [-0.09, 0.50]
			Placebo	87	86 (98.9)	0.02 (0.34)	-1.0	-0.08	0.04	0.15	0.9	
		Week 8	Tezepelumab	95	92 (96.8)	0.10 (0.36)	-0.8	-0.09	0.02	0.30	1.4	0.16 [-0.14, 0.45]
			Placebo	87	84 (96.6)	0.05 (0.31)	-0.9	-0.11	0.05	0.23	0.9	
		Week 12	Tezepelumab	95	91 (95.8)	0.09 (0.34)	-0.8	-0.09	0.07	0.23	1.4	0.21 [-0.09, 0.51]
			Placebo	87	82 (94.3)	0.02 (0.35)	-1.2	-0.09	0.01	0.19	1.0	
		Week 16	Tezepelumab	95	92 (96.8)	0.13 (0.41)	-0.8	-0.11	0.06	0.24	1.9	0.38 [0.08, 0.68]
			Placebo	87	82 (94.3)	-0.02 (0.34)	-1.0	-0.16	0.01	0.15	1.5	
		Week 24	Tezepelumab	95	85 (89.5)	0.09 (0.30)	-0.6	-0.07	0.03	0.22	1.1	0.25 [-0.06, 0.56]
			Placebo	87	79 (90.8)	0.02 (0.33)	-1.1	-0.14	0.01	0.14	1.4	
		Week 36	Tezepelumab	95	86 (90.5)	0.07 (0.36)	-0.7	-0.12	0.01	0.22	1.5	0.11 [-0.20, 0.42]
			Placebo	87	76 (87.4)	0.03 (0.30)	-0.7	-0.17	0.03	0.19	1.3	
		Week 52	Tezepelumab	95	85 (89.5)	0.10 (0.38)	-1.0	-0.07	0.06	0.25	1.3	0.32 [0.00, 0.63]
			Placebo	87	75 (86.2)	-0.01 (0.35)	-1.0	-0.18	0.00	0.13	1.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
150 - < 300 cells/uL	Absolute values	Baseline	Tezepelumab	121	121 (100.0)	1.72 (0.61)	0.6	1.24	1.61	2.13	3.5	
			Placebo	120	120 (100.0)	1.86 (0.72)	0.7	1.36	1.70	2.27	4.1	
		Week 2	Tezepelumab	121	118 (97.5)	1.87 (0.64)	0.6	1.39	1.76	2.39	3.8	
			Placebo	120	116 (96.7)	1.91 (0.77)	0.6	1.38	1.74	2.31	4.1	
		Week 4	Tezepelumab	121	121 (100.0)	1.88 (0.65)	0.6	1.37	1.78	2.38	3.7	
			Placebo	120	116 (96.7)	1.88 (0.72)	0.7	1.41	1.74	2.25	4.8	
		Week 8	Tezepelumab	121	121 (100.0)	1.89 (0.66)	0.6	1.33	1.83	2.40	3.7	
			Placebo	120	115 (95.8)	1.97 (0.77)	0.7	1.41	1.81	2.35	4.6	
		Week 12	Tezepelumab	121	119 (98.3)	1.88 (0.66)	0.6	1.34	1.79	2.35	3.6	
			Placebo	120	115 (95.8)	1.92 (0.78)	0.6	1.35	1.74	2.34	4.6	
		Week 16	Tezepelumab	121	119 (98.3)	1.89 (0.63)	0.6	1.37	1.85	2.34	3.5	
			Placebo	120	113 (94.2)	1.95 (0.82)	0.7	1.33	1.76	2.28	4.7	
		Week 24	Tezepelumab	121	118 (97.5)	1.85 (0.66)	0.6	1.32	1.74	2.39	3.8	
			Placebo	120	109 (90.8)	1.86 (0.79)	0.6	1.34	1.69	2.17	4.8	
		Week 36	Tezepelumab	121	111 (91.7)	1.85 (0.65)	0.7	1.28	1.77	2.38	3.5	
			Placebo	120	106 (88.3)	1.91 (0.79)	0.7	1.41	1.67	2.26	4.3	
		Week 52	Tezepelumab	121	113 (93.4)	1.86 (0.66)	0.7	1.38	1.79	2.33	3.5	
			Placebo	120	98 (81.7)	1.93 (0.82)	0.7	1.39	1.70	2.29	4.3	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
150 - < 300 cells/uL	Change from baseline	Week 2	Tezepelumab	121	118 (97.5)	0.15 (0.29)	-0.7	-0.03	0.08	0.28	1.1	0.37 [0.11, 0.63]
			Placebo	120	116 (96.7)	0.03 (0.32)	-1.0	-0.11	0.01	0.14	1.1	
		Week 4	Tezepelumab	121	121 (100.0)	0.16 (0.31)	-0.5	0.00	0.10	0.24	1.6	0.36 [0.10, 0.61]
			Placebo	120	116 (96.7)	0.04 (0.35)	-1.0	-0.12	0.05	0.20	1.6	
		Week 8	Tezepelumab	121	121 (100.0)	0.17 (0.36)	-0.8	-0.01	0.12	0.27	1.4	0.26 [0.00, 0.51]
			Placebo	120	115 (95.8)	0.09 (0.29)	-0.7	-0.08	0.06	0.29	1.4	
		Week 12	Tezepelumab	121	119 (98.3)	0.17 (0.37)	-0.7	-0.03	0.11	0.29	2.0	0.29 [0.03, 0.55]
			Placebo	120	115 (95.8)	0.06 (0.36)	-1.5	-0.09	0.06	0.20	1.4	
		Week 16	Tezepelumab	121	119 (98.3)	0.17 (0.35)	-0.6	0.00	0.13	0.31	1.7	0.26 [0.00, 0.52]
			Placebo	120	113 (94.2)	0.08 (0.35)	-1.2	-0.06	0.02	0.26	1.4	
		Week 24	Tezepelumab	121	118 (97.5)	0.13 (0.39)	-1.0	-0.12	0.12	0.31	1.3	0.30 [0.04, 0.56]
			Placebo	120	109 (90.8)	0.02 (0.34)	-0.9	-0.15	-0.02	0.20	1.6	
		Week 36	Tezepelumab	121	111 (91.7)	0.14 (0.38)	-1.0	-0.08	0.07	0.29	1.3	0.26 [-0.00, 0.53]
			Placebo	120	106 (88.3)	0.04 (0.40)	-1.1	-0.19	0.03	0.27	1.1	
		Week 52	Tezepelumab	121	113 (93.4)	0.14 (0.39)	-0.8	-0.06	0.08	0.26	1.5	0.21 [-0.06, 0.48]
			Placebo	120	98 (81.7)	0.07 (0.31)	-1.0	-0.14	0.07	0.23	1.1	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
300 - < 450 cells/uL	Absolute values	Baseline	Tezepelumab	70	70 (100.0)	1.72 (0.76)	0.5	1.19	1.64	2.00	4.1	
			Placebo	69	69 (100.0)	1.85 (0.78)	0.4	1.27	1.69	2.29	4.5	
		Week 2	Tezepelumab	70	67 (95.7)	1.91 (0.77)	0.9	1.35	1.70	2.43	4.3	
			Placebo	69	64 (92.8)	1.89 (0.70)	0.4	1.43	1.91	2.31	3.4	
		Week 4	Tezepelumab	70	68 (97.1)	1.94 (0.78)	0.9	1.32	1.75	2.34	4.3	
			Placebo	69	68 (98.6)	1.88 (0.67)	0.4	1.44	1.85	2.32	3.5	
		Week 8	Tezepelumab	70	69 (98.6)	2.01 (0.85)	0.9	1.38	1.78	2.30	4.7	
			Placebo	69	68 (98.6)	1.92 (0.68)	0.4	1.44	1.91	2.23	3.9	
		Week 12	Tezepelumab	70	66 (94.3)	2.04 (0.81)	0.7	1.55	1.88	2.46	4.7	
			Placebo	69	65 (94.2)	1.92 (0.69)	0.8	1.46	1.91	2.32	4.0	
		Week 16	Tezepelumab	70	66 (94.3)	2.02 (0.87)	1.0	1.37	1.75	2.40	4.9	
			Placebo	69	64 (92.8)	1.92 (0.71)	0.8	1.36	1.84	2.36	4.3	
		Week 24	Tezepelumab	70	66 (94.3)	2.03 (0.78)	0.9	1.41	1.94	2.32	4.4	
			Placebo	69	64 (92.8)	1.93 (0.69)	0.8	1.47	1.79	2.25	4.3	
		Week 36	Tezepelumab	70	60 (85.7)	2.05 (0.87)	0.7	1.37	1.84	2.37	4.5	
			Placebo	69	61 (88.4)	1.92 (0.73)	0.8	1.37	1.79	2.31	4.2	
		Week 52	Tezepelumab	70	60 (85.7)	2.01 (0.85)	0.6	1.39	1.80	2.33	4.2	
			Placebo	69	60 (87.0)	1.93 (0.76)	0.7	1.36	1.78	2.29	4.5	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
300 - < 450 cells/uL	Change from baseline	Week 2	Tezepelumab	70	67 (95.7)	0.22 (0.36)	-0.5	0.03	0.14	0.41	1.4	0.56 [0.21, 0.91]
			Placebo	69	64 (92.8)	0.02 (0.36)	-1.1	-0.13	0.01	0.17	0.9	
		Week 4	Tezepelumab	70	68 (97.1)	0.23 (0.36)	-0.4	0.00	0.15	0.36	1.4	0.50 [0.16, 0.84]
			Placebo	69	68 (98.6)	0.04 (0.39)	-1.8	-0.11	0.01	0.23	1.1	
		Week 8	Tezepelumab	70	69 (98.6)	0.31 (0.45)	-0.6	0.04	0.24	0.52	1.8	0.67 [0.33, 1.01]
			Placebo	69	68 (98.6)	0.05 (0.32)	-0.6	-0.13	0.03	0.20	1.1	
		Week 12	Tezepelumab	70	66 (94.3)	0.32 (0.43)	-0.3	0.00	0.25	0.48	1.9	0.76 [0.41, 1.12]
			Placebo	69	65 (94.2)	0.02 (0.39)	-1.4	-0.18	-0.01	0.13	1.0	
		Week 16	Tezepelumab	70	66 (94.3)	0.32 (0.42)	-0.4	0.04	0.26	0.50	2.0	0.74 [0.38, 1.09]
			Placebo	69	64 (92.8)	0.04 (0.34)	-1.0	-0.12	0.02	0.15	1.0	
		Week 24	Tezepelumab	70	66 (94.3)	0.33 (0.38)	-0.3	0.03	0.30	0.51	1.5	0.79 [0.44, 1.15]
			Placebo	69	64 (92.8)	0.04 (0.34)	-0.9	-0.13	0.01	0.19	1.1	
		Week 36	Tezepelumab	70	60 (85.7)	0.34 (0.42)	-0.3	0.01	0.34	0.54	1.7	0.83 [0.46, 1.20]
			Placebo	69	61 (88.4)	0.02 (0.34)	-0.8	-0.15	0.00	0.18	1.1	
		Week 52	Tezepelumab	70	60 (85.7)	0.32 (0.42)	-0.8	0.02	0.35	0.54	1.7	0.71 [0.34, 1.08]
			Placebo	69	60 (87.0)	0.04 (0.37)	-0.6	-0.20	-0.02	0.23	1.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
>= 450 cells/uL	Absolute values	Baseline	Tezepelumab	94	94 (100.0)	1.63 (0.64)	0.6	1.20	1.52	1.80	3.7	
			Placebo	95	95 (100.0)	1.68 (0.60)	0.6	1.28	1.59	2.06	4.2	
		Week 2	Tezepelumab	94	92 (97.9)	1.94 (0.68)	0.8	1.46	1.82	2.31	4.0	
			Placebo	95	91 (95.8)	1.82 (0.65)	0.8	1.35	1.73	2.24	4.0	
		Week 4	Tezepelumab	94	94 (100.0)	2.00 (0.70)	0.7	1.53	1.87	2.38	4.2	
			Placebo	95	93 (97.9)	1.86 (0.68)	0.5	1.42	1.79	2.13	4.2	
		Week 8	Tezepelumab	94	92 (97.9)	2.02 (0.67)	1.0	1.53	1.87	2.43	4.2	
			Placebo	95	94 (98.9)	1.82 (0.72)	0.6	1.31	1.66	2.13	4.3	
		Week 12	Tezepelumab	94	93 (98.9)	2.05 (0.71)	0.9	1.61	1.94	2.34	4.6	
			Placebo	95	95 (100.0)	1.91 (0.68)	0.5	1.40	1.87	2.34	4.3	
		Week 16	Tezepelumab	94	90 (95.7)	2.08 (0.71)	0.8	1.59	1.97	2.37	4.3	
			Placebo	95	91 (95.8)	1.87 (0.64)	0.5	1.44	1.78	2.17	4.4	
		Week 24	Tezepelumab	94	87 (92.6)	2.05 (0.69)	0.9	1.59	1.88	2.48	3.8	
			Placebo	95	87 (91.6)	1.91 (0.70)	0.7	1.45	1.87	2.22	4.8	
		Week 36	Tezepelumab	94	86 (91.5)	2.07 (0.69)	0.8	1.57	1.98	2.39	4.2	
			Placebo	95	85 (89.5)	1.96 (0.71)	0.6	1.52	1.94	2.31	4.6	
		Week 52	Tezepelumab	94	79 (84.0)	2.09 (0.72)	0.9	1.61	1.89	2.42	4.3	
			Placebo	95	75 (78.9)	1.85 (0.68)	0.6	1.32	1.82	2.30	4.4	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
>= 450 cells/uL	Change from baseline	Week 2	Tezepelumab	94	92 (97.9)	0.31 (0.34)	-0.3	0.10	0.25	0.42	1.3	0.50 [0.21, 0.80]
			Placebo	95	91 (95.8)	0.13 (0.38)	-0.6	-0.10	0.04	0.35	1.2	
		Week 4	Tezepelumab	94	94 (100.0)	0.37 (0.36)	-0.4	0.11	0.33	0.51	1.8	0.48 [0.19, 0.77]
			Placebo	95	93 (97.9)	0.18 (0.41)	-0.5	-0.11	0.06	0.45	1.4	
		Week 8	Tezepelumab	94	92 (97.9)	0.41 (0.41)	-0.4	0.11	0.33	0.69	1.7	0.67 [0.37, 0.96]
			Placebo	95	94 (98.9)	0.14 (0.41)	-0.8	-0.15	0.09	0.34	1.6	
		Week 12	Tezepelumab	94	93 (98.9)	0.43 (0.40)	-0.3	0.14	0.37	0.62	1.5	0.50 [0.20, 0.79]
			Placebo	95	95 (100.0)	0.24 (0.39)	-0.5	-0.03	0.16	0.42	1.7	
		Week 16	Tezepelumab	94	90 (95.7)	0.46 (0.39)	-0.3	0.17	0.38	0.67	1.6	0.71 [0.41, 1.01]
			Placebo	95	91 (95.8)	0.18 (0.38)	-0.5	-0.09	0.08	0.43	1.8	
		Week 24	Tezepelumab	94	87 (92.6)	0.45 (0.43)	-0.2	0.21	0.39	0.64	1.7	0.58 [0.27, 0.88]
			Placebo	95	87 (91.6)	0.20 (0.45)	-0.8	-0.14	0.14	0.41	1.7	
		Week 36	Tezepelumab	94	86 (91.5)	0.45 (0.40)	-0.3	0.17	0.40	0.65	1.6	0.48 [0.18, 0.79]
			Placebo	95	85 (89.5)	0.26 (0.41)	-0.5	-0.03	0.20	0.51	1.7	
		Week 52	Tezepelumab	94	79 (84.0)	0.46 (0.38)	-0.4	0.22	0.49	0.74	1.6	0.85 [0.52, 1.18]
			Placebo	95	75 (78.9)	0.15 (0.35)	-0.9	-0.09	0.10	0.35	1.1	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q1: < 140 cells/uL	Absolute values	Baseline	Tezepelumab	89	89 (100.0)	1.90 (0.70)	0.4	1.35	1.87	2.43	4.0	
			Placebo	79	79 (100.0)	1.75 (0.60)	0.8	1.34	1.69	2.13	3.4	
		Week 2	Tezepelumab	89	87 (97.8)	2.00 (0.73)	0.6	1.40	1.96	2.47	4.1	
			Placebo	79	74 (93.7)	1.78 (0.64)	0.8	1.36	1.64	2.11	3.5	
		Week 4	Tezepelumab	89	88 (98.9)	1.99 (0.78)	0.7	1.38	1.99	2.58	4.2	
			Placebo	79	78 (98.7)	1.79 (0.65)	0.7	1.31	1.72	2.18	3.6	
		Week 8	Tezepelumab	89	87 (97.8)	2.00 (0.75)	0.6	1.45	1.95	2.52	4.1	
			Placebo	79	76 (96.2)	1.78 (0.64)	0.7	1.32	1.72	2.25	3.5	
		Week 12	Tezepelumab	89	85 (95.5)	1.99 (0.74)	0.6	1.47	1.94	2.45	4.2	
			Placebo	79	75 (94.9)	1.77 (0.67)	0.7	1.23	1.61	2.18	3.6	
		Week 16	Tezepelumab	89	86 (96.6)	2.05 (0.80)	0.6	1.46	1.95	2.55	4.3	
			Placebo	79	74 (93.7)	1.72 (0.64)	0.6	1.25	1.62	2.07	3.6	
		Week 24	Tezepelumab	89	80 (89.9)	1.98 (0.72)	0.6	1.43	1.97	2.44	4.0	
			Placebo	79	72 (91.1)	1.79 (0.63)	0.8	1.27	1.72	2.15	3.6	
		Week 36	Tezepelumab	89	81 (91.0)	1.99 (0.78)	0.5	1.44	1.91	2.47	4.4	
			Placebo	79	69 (87.3)	1.81 (0.65)	0.8	1.26	1.79	2.22	3.4	
		Week 52	Tezepelumab	89	80 (89.9)	2.02 (0.76)	0.7	1.43	1.98	2.61	4.2	
			Placebo	79	68 (86.1)	1.73 (0.66)	0.7	1.23	1.61	2.19	3.5	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q1: < 140 cells/uL	Change from baseline	Week 2	Tezepelumab	89	87 (97.8)	0.08 (0.30)	-0.6	-0.07	0.09	0.20	1.5	0.22 [-0.09, 0.53]
			Placebo	79	74 (93.7)	0.02 (0.28)	-0.7	-0.13	-0.01	0.13	1.1	
		Week 4	Tezepelumab	89	88 (98.9)	0.10 (0.37)	-0.9	-0.08	0.04	0.27	1.7	0.19 [-0.11, 0.50]
			Placebo	79	78 (98.7)	0.03 (0.32)	-0.9	-0.07	0.04	0.15	0.9	
		Week 8	Tezepelumab	89	87 (97.8)	0.11 (0.37)	-0.8	-0.09	0.02	0.32	1.4	0.20 [-0.11, 0.51]
			Placebo	79	76 (96.2)	0.04 (0.30)	-0.9	-0.12	0.05	0.21	0.7	
		Week 12	Tezepelumab	89	85 (95.5)	0.10 (0.35)	-0.8	-0.09	0.08	0.25	1.4	0.20 [-0.11, 0.51]
			Placebo	79	75 (94.9)	0.03 (0.31)	-1.1	-0.09	0.02	0.19	1.0	
		Week 16	Tezepelumab	89	86 (96.6)	0.14 (0.42)	-0.8	-0.09	0.07	0.26	1.9	0.41 [0.09, 0.72]
			Placebo	79	74 (93.7)	-0.02 (0.35)	-1.0	-0.16	0.01	0.14	1.5	
		Week 24	Tezepelumab	89	80 (89.9)	0.10 (0.31)	-0.6	-0.07	0.03	0.26	1.1	0.22 [-0.10, 0.54]
			Placebo	79	72 (91.1)	0.03 (0.31)	-1.1	-0.12	0.02	0.15	1.4	
		Week 36	Tezepelumab	89	81 (91.0)	0.08 (0.36)	-0.7	-0.11	0.02	0.22	1.5	0.10 [-0.23, 0.42]
			Placebo	79	69 (87.3)	0.05 (0.28)	-0.7	-0.12	0.04	0.20	1.3	
		Week 52	Tezepelumab	89	80 (89.9)	0.11 (0.38)	-1.0	-0.06	0.06	0.27	1.3	0.36 [0.03, 0.69]
			Placebo	79	68 (86.1)	-0.02 (0.35)	-1.0	-0.18	-0.01	0.13	1.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q2: 140 - < 250 cells/uL	Absolute values	Baseline	Tezepelumab	93	93 (100.0)	1.75 (0.59)	0.8	1.28	1.61	2.14	3.5	
			Placebo	92	92 (100.0)	1.95 (0.69)	0.7	1.42	1.77	2.50	4.1	
		Week 2	Tezepelumab	93	90 (96.8)	1.89 (0.64)	0.8	1.39	1.70	2.39	3.8	
			Placebo	92	89 (96.7)	1.94 (0.74)	0.8	1.38	1.75	2.44	4.0	
		Week 4	Tezepelumab	93	93 (100.0)	1.88 (0.65)	0.8	1.37	1.74	2.38	3.7	
			Placebo	92	88 (95.7)	1.93 (0.65)	0.8	1.46	1.84	2.28	3.7	
		Week 8	Tezepelumab	93	92 (98.9)	1.87 (0.65)	0.8	1.35	1.71	2.37	3.7	
			Placebo	92	91 (98.9)	2.02 (0.74)	0.7	1.48	1.87	2.39	4.1	
		Week 12	Tezepelumab	93	91 (97.8)	1.86 (0.66)	0.8	1.32	1.68	2.34	3.6	
			Placebo	92	88 (95.7)	1.95 (0.75)	0.8	1.46	1.75	2.46	4.1	
		Week 16	Tezepelumab	93	91 (97.8)	1.89 (0.62)	0.8	1.39	1.84	2.36	3.5	
			Placebo	92	88 (95.7)	2.00 (0.79)	0.7	1.41	1.78	2.54	4.1	
		Week 24	Tezepelumab	93	90 (96.8)	1.84 (0.66)	0.7	1.32	1.71	2.28	3.8	
			Placebo	92	84 (91.3)	1.94 (0.73)	0.6	1.40	1.76	2.33	4.0	
		Week 36	Tezepelumab	93	86 (92.5)	1.82 (0.65)	0.7	1.25	1.72	2.34	3.5	
			Placebo	92	81 (88.0)	1.95 (0.76)	0.8	1.44	1.69	2.37	4.1	
		Week 52	Tezepelumab	93	87 (93.5)	1.83 (0.67)	0.7	1.34	1.73	2.30	3.5	
			Placebo	92	76 (82.6)	1.98 (0.79)	0.7	1.45	1.74	2.42	4.3	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q2: 140 - < 250 cells/uL	Change from baseline	Week 2	Tezepelumab	93	90 (96.8)	0.13 (0.30)	-0.7	-0.03	0.08	0.24	1.1	0.45 [0.16, 0.75]
			Placebo	92	89 (96.7)	-0.02 (0.34)	-1.8	-0.12	0.00	0.13	1.1	
		Week 4	Tezepelumab	93	93 (100.0)	0.14 (0.27)	-0.5	-0.01	0.11	0.23	1.2	0.39 [0.10, 0.69]
			Placebo	92	88 (95.7)	0.01 (0.36)	-1.0	-0.14	0.05	0.19	1.1	
		Week 8	Tezepelumab	93	92 (98.9)	0.14 (0.33)	-0.8	-0.04	0.11	0.24	1.4	0.22 [-0.07, 0.51]
			Placebo	92	91 (98.9)	0.07 (0.27)	-0.7	-0.10	0.05	0.26	0.9	
		Week 12	Tezepelumab	93	91 (97.8)	0.12 (0.32)	-0.7	-0.05	0.10	0.20	1.4	0.30 [0.00, 0.59]
			Placebo	92	88 (95.7)	0.02 (0.38)	-1.5	-0.12	0.03	0.18	1.2	
		Week 16	Tezepelumab	93	91 (97.8)	0.14 (0.30)	-0.6	-0.04	0.12	0.28	1.3	0.28 [-0.01, 0.58]
			Placebo	92	88 (95.7)	0.06 (0.31)	-0.8	-0.12	0.01	0.22	1.0	
		Week 24	Tezepelumab	93	90 (96.8)	0.10 (0.37)	-1.0	-0.12	0.09	0.27	1.3	0.31 [0.01, 0.61]
			Placebo	92	84 (91.3)	-0.01 (0.33)	-0.9	-0.17	-0.02	0.19	0.9	
		Week 36	Tezepelumab	93	86 (92.5)	0.08 (0.32)	-0.8	-0.10	0.04	0.22	1.3	0.23 [-0.08, 0.53]
			Placebo	92	81 (88.0)	-0.00 (0.40)	-1.1	-0.23	-0.03	0.21	1.1	
		Week 52	Tezepelumab	93	87 (93.5)	0.09 (0.36)	-0.8	-0.11	0.03	0.19	1.3	0.08 [-0.23, 0.38]
			Placebo	92	76 (82.6)	0.06 (0.31)	-1.0	-0.16	0.06	0.23	1.1	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q3: 250 - < 430 cells/uL	Absolute values	Baseline	Tezepelumab	100	100 (100.0)	1.70 (0.74)	0.5	1.12	1.60	2.05	4.1	
			Placebo	98	98 (100.0)	1.76 (0.67)	0.4	1.27	1.69	2.17	3.7	
		Week 2	Tezepelumab	100	98 (98.0)	1.88 (0.73)	0.6	1.35	1.77	2.30	4.3	
			Placebo	98	93 (94.9)	1.84 (0.70)	0.4	1.42	1.82	2.28	4.1	
		Week 4	Tezepelumab	100	98 (98.0)	1.91 (0.76)	0.6	1.28	1.79	2.38	4.3	
			Placebo	98	97 (99.0)	1.83 (0.70)	0.4	1.43	1.78	2.21	4.8	
		Week 8	Tezepelumab	100	99 (99.0)	1.97 (0.81)	0.6	1.31	1.84	2.40	4.7	
			Placebo	98	93 (94.9)	1.89 (0.70)	0.4	1.42	1.87	2.22	4.6	
		Week 12	Tezepelumab	100	96 (96.0)	2.00 (0.78)	0.6	1.50	1.91	2.46	4.7	
			Placebo	98	92 (93.9)	1.88 (0.69)	0.6	1.42	1.83	2.25	4.6	
		Week 16	Tezepelumab	100	96 (96.0)	1.97 (0.82)	0.6	1.36	1.82	2.38	4.9	
			Placebo	98	90 (91.8)	1.87 (0.68)	0.7	1.35	1.84	2.18	4.7	
		Week 24	Tezepelumab	100	95 (95.0)	1.97 (0.76)	0.6	1.38	1.86	2.41	4.4	
			Placebo	98	89 (90.8)	1.81 (0.69)	0.6	1.41	1.74	2.18	4.8	
		Week 36	Tezepelumab	100	86 (86.0)	2.00 (0.82)	0.7	1.36	1.83	2.39	4.5	
			Placebo	98	86 (87.8)	1.86 (0.69)	0.7	1.37	1.73	2.25	4.3	
		Week 52	Tezepelumab	100	87 (87.0)	1.97 (0.81)	0.6	1.38	1.82	2.39	4.2	
			Placebo	98	82 (83.7)	1.86 (0.72)	0.7	1.31	1.71	2.25	4.0	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q3: 250 - < 430 cells/uL	Change from baseline	Week 2	Tezepelumab	100	98 (98.0)	0.20 (0.34)	-0.5	-0.04	0.14	0.38	1.4	0.36 [0.07, 0.64]
			Placebo	98	93 (94.9)	0.08 (0.35)	-0.8	-0.10	0.04	0.22	1.0	
		Week 4	Tezepelumab	100	98 (98.0)	0.23 (0.38)	-0.5	-0.01	0.14	0.36	1.6	0.42 [0.13, 0.70]
			Placebo	98	97 (99.0)	0.08 (0.33)	-0.8	-0.09	0.02	0.23	1.6	
		Week 8	Tezepelumab	100	99 (99.0)	0.29 (0.44)	-0.6	0.00	0.22	0.52	1.8	0.51 [0.22, 0.80]
			Placebo	98	93 (94.9)	0.09 (0.33)	-0.6	-0.07	0.05	0.24	1.4	
		Week 12	Tezepelumab	100	96 (96.0)	0.31 (0.44)	-0.6	0.01	0.23	0.48	2.0	0.56 [0.27, 0.85]
			Placebo	98	92 (93.9)	0.08 (0.35)	-0.7	-0.12	0.02	0.24	1.4	
		Week 16	Tezepelumab	100	96 (96.0)	0.29 (0.43)	-0.6	0.00	0.22	0.45	2.0	0.48 [0.19, 0.77]
			Placebo	98	90 (91.8)	0.09 (0.38)	-1.2	-0.07	0.04	0.26	1.4	
		Week 24	Tezepelumab	100	95 (95.0)	0.28 (0.41)	-1.0	-0.01	0.26	0.49	1.5	0.61 [0.31, 0.90]
			Placebo	98	89 (90.8)	0.05 (0.35)	-0.9	-0.13	0.02	0.18	1.6	
		Week 36	Tezepelumab	100	86 (86.0)	0.31 (0.44)	-1.0	0.02	0.32	0.54	1.7	0.63 [0.33, 0.94]
			Placebo	98	86 (87.8)	0.06 (0.37)	-0.8	-0.16	0.03	0.26	1.1	
		Week 52	Tezepelumab	100	87 (87.0)	0.30 (0.43)	-0.8	0.01	0.26	0.53	1.7	0.62 [0.31, 0.93]
			Placebo	98	82 (83.7)	0.06 (0.35)	-0.6	-0.19	0.03	0.23	1.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q4: >= 430 cells/uL	Absolute values	Baseline	Tezepelumab	98	98 (100.0)	1.62 (0.64)	0.6	1.20	1.52	1.77	3.7	
			Placebo	102	102 (100.0)	1.74 (0.72)	0.6	1.26	1.59	2.13	4.5	
		Week 2	Tezepelumab	98	95 (96.9)	1.92 (0.68)	0.8	1.43	1.79	2.31	4.0	
			Placebo	102	97 (95.1)	1.86 (0.70)	0.8	1.35	1.80	2.32	4.0	
		Week 4	Tezepelumab	98	98 (100.0)	1.98 (0.69)	0.7	1.53	1.85	2.37	4.2	
			Placebo	102	100 (98.0)	1.89 (0.71)	0.5	1.42	1.81	2.19	4.2	
		Week 8	Tezepelumab	98	96 (98.0)	2.00 (0.67)	1.0	1.51	1.85	2.39	4.2	
			Placebo	102	101 (99.0)	1.86 (0.77)	0.6	1.31	1.69	2.16	4.3	
		Week 12	Tezepelumab	98	97 (99.0)	2.03 (0.70)	0.9	1.58	1.93	2.21	4.6	
			Placebo	102	102 (100.0)	1.94 (0.74)	0.5	1.40	1.89	2.37	4.3	
		Week 16	Tezepelumab	98	94 (95.9)	2.06 (0.71)	0.8	1.59	1.96	2.31	4.3	
			Placebo	102	98 (96.1)	1.91 (0.73)	0.5	1.41	1.79	2.20	4.4	
		Week 24	Tezepelumab	98	91 (92.9)	2.04 (0.68)	0.9	1.59	1.85	2.46	3.8	
			Placebo	102	94 (92.2)	1.95 (0.76)	0.7	1.45	1.89	2.24	4.8	
		Week 36	Tezepelumab	98	90 (91.8)	2.06 (0.69)	0.8	1.56	1.96	2.36	4.2	
			Placebo	102	92 (90.2)	2.00 (0.77)	0.6	1.51	1.95	2.33	4.6	
		Week 52	Tezepelumab	98	83 (84.7)	2.07 (0.71)	0.9	1.61	1.89	2.41	4.3	
			Placebo	102	82 (80.4)	1.91 (0.78)	0.6	1.32	1.83	2.33	4.5	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q4: >= 430 cells/uL	Change from baseline	Week 2	Tezepelumab	98	95 (96.9)	0.30 (0.33)	-0.3	0.10	0.23	0.41	1.3	0.55 [0.26, 0.83]
			Placebo	102	97 (95.1)	0.10 (0.39)	-1.1	-0.11	0.02	0.28	1.2	
		Week 4	Tezepelumab	98	98 (100.0)	0.36 (0.36)	-0.4	0.09	0.33	0.50	1.8	0.50 [0.21, 0.78]
			Placebo	102	100 (98.0)	0.16 (0.45)	-1.8	-0.13	0.05	0.43	1.4	
		Week 8	Tezepelumab	98	96 (98.0)	0.40 (0.40)	-0.4	0.11	0.32	0.67	1.7	0.69 [0.40, 0.98]
			Placebo	102	101 (99.0)	0.12 (0.41)	-0.8	-0.17	0.09	0.33	1.6	
		Week 12	Tezepelumab	98	97 (99.0)	0.42 (0.39)	-0.3	0.14	0.35	0.62	1.5	0.54 [0.25, 0.82]
			Placebo	102	102 (100.0)	0.20 (0.42)	-1.4	-0.06	0.14	0.42	1.7	
		Week 16	Tezepelumab	98	94 (95.9)	0.45 (0.39)	-0.3	0.16	0.36	0.66	1.6	0.75 [0.46, 1.05]
			Placebo	102	98 (96.1)	0.16 (0.38)	-0.5	-0.11	0.07	0.43	1.8	
		Week 24	Tezepelumab	98	91 (92.9)	0.45 (0.42)	-0.2	0.19	0.39	0.64	1.7	0.60 [0.30, 0.89]
			Placebo	102	94 (92.2)	0.19 (0.45)	-0.8	-0.14	0.13	0.40	1.7	
		Week 36	Tezepelumab	98	90 (91.8)	0.44 (0.40)	-0.3	0.17	0.40	0.65	1.6	0.53 [0.23, 0.82]
			Placebo	102	92 (90.2)	0.23 (0.41)	-0.5	-0.06	0.16	0.50	1.7	
		Week 52	Tezepelumab	98	83 (84.7)	0.45 (0.38)	-0.4	0.22	0.47	0.73	1.6	0.87 [0.55, 1.19]
			Placebo	102	82 (80.4)	0.14 (0.35)	-0.9	-0.09	0.11	0.34	1.1	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
< 25 ppb	Absolute values	Baseline	Tezepelumab	155	155 (100.0)	1.69 (0.67)	0.4	1.22	1.55	2.12	4.0	
			Placebo	145	145 (100.0)	1.83 (0.72)	0.4	1.34	1.71	2.23	3.9	
		Week 2	Tezepelumab	155	150 (96.8)	1.84 (0.66)	0.6	1.35	1.72	2.31	4.1	
			Placebo	145	135 (93.1)	1.88 (0.72)	0.4	1.37	1.80	2.31	4.1	
		Week 4	Tezepelumab	155	152 (98.1)	1.84 (0.68)	0.6	1.28	1.69	2.31	4.2	
			Placebo	145	143 (98.6)	1.89 (0.73)	0.4	1.42	1.82	2.32	4.8	
		Week 8	Tezepelumab	155	152 (98.1)	1.84 (0.68)	0.6	1.32	1.68	2.35	4.1	
			Placebo	145	141 (97.2)	1.90 (0.73)	0.4	1.39	1.81	2.35	4.6	
		Week 12	Tezepelumab	155	149 (96.1)	1.84 (0.67)	0.6	1.37	1.70	2.21	4.2	
			Placebo	145	138 (95.2)	1.91 (0.75)	0.5	1.37	1.74	2.44	4.6	
		Week 16	Tezepelumab	155	148 (95.5)	1.87 (0.69)	0.6	1.37	1.74	2.34	4.2	
			Placebo	145	138 (95.2)	1.86 (0.74)	0.5	1.29	1.78	2.28	4.7	
		Week 24	Tezepelumab	155	146 (94.2)	1.82 (0.66)	0.6	1.29	1.73	2.29	4.0	
			Placebo	145	134 (92.4)	1.87 (0.73)	0.6	1.37	1.80	2.23	4.8	
		Week 36	Tezepelumab	155	137 (88.4)	1.81 (0.65)	0.5	1.28	1.74	2.25	4.4	
			Placebo	145	129 (89.0)	1.91 (0.73)	0.6	1.41	1.81	2.33	4.3	
		Week 52	Tezepelumab	155	139 (89.7)	1.82 (0.65)	0.7	1.36	1.72	2.23	4.2	
			Placebo	145	125 (86.2)	1.87 (0.76)	0.6	1.27	1.73	2.33	4.3	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
< 25 ppb	Change from baseline	Week 2	Tezepelumab	155	150 (96.8)	0.14 (0.31)	-0.7	-0.01	0.09	0.25	1.4	0.37 [0.14, 0.60]
			Placebo	145	135 (93.1)	0.03 (0.28)	-0.8	-0.12	0.00	0.13	0.9	
		Week 4	Tezepelumab	155	152 (98.1)	0.16 (0.34)	-0.9	-0.04	0.09	0.29	1.7	0.26 [0.03, 0.49]
			Placebo	145	143 (98.6)	0.07 (0.31)	-0.9	-0.09	0.04	0.20	1.6	
		Week 8	Tezepelumab	155	152 (98.1)	0.16 (0.37)	-0.8	-0.05	0.11	0.27	1.6	0.30 [0.07, 0.53]
			Placebo	145	141 (97.2)	0.06 (0.31)	-0.9	-0.10	0.04	0.20	1.4	
		Week 12	Tezepelumab	155	149 (96.1)	0.16 (0.34)	-0.7	-0.04	0.10	0.28	1.5	0.28 [0.05, 0.52]
			Placebo	145	138 (95.2)	0.06 (0.33)	-1.5	-0.07	0.04	0.20	1.4	
		Week 16	Tezepelumab	155	148 (95.5)	0.17 (0.35)	-0.6	-0.05	0.11	0.29	1.6	0.41 [0.18, 0.64]
			Placebo	145	138 (95.2)	0.03 (0.32)	-1.0	-0.12	0.02	0.16	1.4	
		Week 24	Tezepelumab	155	146 (94.2)	0.15 (0.37)	-1.0	-0.07	0.09	0.32	1.5	0.39 [0.15, 0.63]
			Placebo	145	134 (92.4)	0.01 (0.33)	-1.1	-0.14	0.03	0.15	1.6	
		Week 36	Tezepelumab	155	137 (88.4)	0.11 (0.36)	-1.0	-0.11	0.06	0.30	1.4	0.15 [-0.10, 0.39]
			Placebo	145	129 (89.0)	0.06 (0.30)	-0.8	-0.11	0.04	0.20	1.1	
		Week 52	Tezepelumab	155	139 (89.7)	0.13 (0.37)	-1.0	-0.05	0.08	0.31	1.3	0.27 [0.03, 0.51]
			Placebo	145	125 (86.2)	0.04 (0.31)	-1.0	-0.14	0.04	0.20	1.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
25 - < 50 ppb	Absolute values	Baseline	Tezepelumab	111	111 (100.0)	1.66 (0.65)	0.5	1.20	1.52	2.02	3.7	
			Placebo	109	109 (100.0)	1.79 (0.72)	0.7	1.27	1.68	2.10	4.5	
		Week 2	Tezepelumab	111	110 (99.1)	1.86 (0.65)	0.7	1.34	1.74	2.38	4.0	
			Placebo	109	107 (98.2)	1.80 (0.72)	0.6	1.30	1.63	2.14	4.0	
		Week 4	Tezepelumab	111	111 (100.0)	1.89 (0.71)	0.7	1.33	1.76	2.41	4.2	
			Placebo	109	106 (97.2)	1.83 (0.68)	0.7	1.36	1.72	2.11	4.2	
		Week 8	Tezepelumab	111	110 (99.1)	1.88 (0.67)	0.8	1.35	1.77	2.36	4.2	
			Placebo	109	106 (97.2)	1.88 (0.74)	0.7	1.33	1.73	2.22	4.3	
		Week 12	Tezepelumab	111	108 (97.3)	1.92 (0.68)	0.7	1.48	1.79	2.30	4.3	
			Placebo	109	105 (96.3)	1.86 (0.75)	0.7	1.34	1.75	2.19	4.3	
		Week 16	Tezepelumab	111	111 (100.0)	1.90 (0.69)	0.8	1.45	1.75	2.20	4.3	
			Placebo	109	103 (94.5)	1.85 (0.75)	0.6	1.35	1.69	2.12	4.3	
		Week 24	Tezepelumab	111	105 (94.6)	1.89 (0.67)	0.7	1.44	1.73	2.34	3.8	
			Placebo	109	98 (89.9)	1.88 (0.74)	0.6	1.41	1.75	2.12	4.8	
		Week 36	Tezepelumab	111	104 (93.7)	1.91 (0.74)	0.6	1.35	1.77	2.38	4.2	
			Placebo	109	100 (91.7)	1.89 (0.74)	0.7	1.41	1.71	2.19	4.6	
		Week 52	Tezepelumab	111	101 (91.0)	1.92 (0.75)	0.6	1.39	1.77	2.39	4.3	
			Placebo	109	89 (81.7)	1.85 (0.78)	0.7	1.37	1.63	2.12	4.5	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
25 - < 50 ppb	Change from baseline	Week 2	Tezepelumab	111	110 (99.1)	0.19 (0.30)	-0.5	0.00	0.15	0.33	1.3	0.52 [0.25, 0.79]
			Placebo	109	107 (98.2)	0.01 (0.40)	-1.8	-0.16	-0.01	0.18	1.1	
		Week 4	Tezepelumab	111	111 (100.0)	0.23 (0.31)	-0.5	0.04	0.15	0.37	1.3	0.52 [0.25, 0.79]
			Placebo	109	106 (97.2)	0.04 (0.40)	-1.8	-0.13	0.03	0.25	1.0	
		Week 8	Tezepelumab	111	110 (99.1)	0.23 (0.37)	-0.6	-0.01	0.17	0.44	1.5	0.42 [0.15, 0.69]
			Placebo	109	106 (97.2)	0.09 (0.30)	-0.7	-0.09	0.06	0.24	0.9	
		Week 12	Tezepelumab	111	108 (97.3)	0.27 (0.35)	-0.4	0.03	0.20	0.43	1.6	0.52 [0.25, 0.80]
			Placebo	109	105 (96.3)	0.08 (0.38)	-1.2	-0.13	0.03	0.28	1.2	
		Week 16	Tezepelumab	111	111 (100.0)	0.24 (0.37)	-0.6	0.02	0.20	0.40	1.5	0.50 [0.22, 0.77]
			Placebo	109	103 (94.5)	0.06 (0.36)	-1.2	-0.13	0.00	0.19	1.5	
		Week 24	Tezepelumab	111	105 (94.6)	0.26 (0.43)	-1.0	-0.04	0.23	0.45	1.6	0.38 [0.10, 0.66]
			Placebo	109	98 (89.9)	0.10 (0.38)	-0.9	-0.11	0.03	0.29	1.4	
		Week 36	Tezepelumab	111	104 (93.7)	0.26 (0.41)	-0.6	-0.02	0.12	0.47	1.6	0.43 [0.15, 0.71]
			Placebo	109	100 (91.7)	0.08 (0.43)	-1.0	-0.21	0.02	0.29	1.3	
		Week 52	Tezepelumab	111	101 (91.0)	0.29 (0.41)	-0.8	-0.02	0.22	0.55	1.7	0.61 [0.32, 0.90]
			Placebo	109	89 (81.7)	0.04 (0.38)	-1.0	-0.17	-0.03	0.21	1.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
>= 50 ppb	Absolute values	Baseline	Tezepelumab	111	111 (100.0)	1.89 (0.69)	0.7	1.47	1.74	2.26	4.1	
			Placebo	113	113 (100.0)	1.76 (0.58)	0.6	1.37	1.69	2.18	3.3	
		Week 2	Tezepelumab	111	107 (96.4)	2.12 (0.75)	0.8	1.57	2.02	2.45	4.3	
			Placebo	113	107 (94.7)	1.89 (0.65)	0.6	1.42	1.82	2.38	3.9	
		Week 4	Tezepelumab	111	111 (100.0)	2.15 (0.74)	0.7	1.62	2.02	2.64	4.3	
			Placebo	113	110 (97.3)	1.85 (0.63)	0.7	1.41	1.80	2.25	4.0	
		Week 8	Tezepelumab	111	109 (98.2)	2.23 (0.76)	1.0	1.68	2.19	2.55	4.7	
			Placebo	113	110 (97.3)	1.89 (0.69)	0.7	1.43	1.78	2.22	4.3	
		Week 12	Tezepelumab	111	109 (98.2)	2.22 (0.78)	0.9	1.68	2.12	2.69	4.7	
			Placebo	113	111 (98.2)	1.91 (0.65)	0.6	1.47	1.83	2.29	4.3	
		Week 16	Tezepelumab	111	105 (94.6)	2.27 (0.81)	0.8	1.74	2.17	2.67	4.9	
			Placebo	113	106 (93.8)	1.93 (0.66)	0.8	1.45	1.81	2.23	4.4	
		Week 24	Tezepelumab	111	102 (91.9)	2.23 (0.73)	0.9	1.76	2.06	2.59	4.4	
			Placebo	113	104 (92.0)	1.88 (0.66)	0.8	1.40	1.73	2.22	4.3	
		Week 36	Tezepelumab	111	99 (89.2)	2.26 (0.78)	0.9	1.74	2.13	2.70	4.5	
			Placebo	113	96 (85.0)	1.94 (0.70)	0.8	1.45	1.87	2.27	4.3	
		Week 52	Tezepelumab	111	94 (84.7)	2.27 (0.77)	0.9	1.72	2.10	2.72	4.2	
			Placebo	113	91 (80.5)	1.90 (0.68)	0.7	1.31	1.88	2.30	3.7	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
>= 50 ppb	Change from baseline	Week 2	Tezepelumab	111	107 (96.4)	0.24 (0.36)	-0.6	0.03	0.19	0.40	1.5	0.36 [0.09, 0.63]
			Placebo	113	107 (94.7)	0.11 (0.37)	-0.7	-0.07	0.06	0.27	1.2	
		Week 4	Tezepelumab	111	111 (100.0)	0.26 (0.42)	-0.7	0.01	0.21	0.41	1.8	0.38 [0.12, 0.65]
			Placebo	113	110 (97.3)	0.10 (0.43)	-0.8	-0.15	0.06	0.30	1.4	
		Week 8	Tezepelumab	111	109 (98.2)	0.36 (0.46)	-0.6	0.07	0.33	0.60	1.8	0.59 [0.31, 0.86]
			Placebo	113	110 (97.3)	0.11 (0.39)	-0.6	-0.15	0.09	0.31	1.6	
		Week 12	Tezepelumab	111	109 (98.2)	0.35 (0.50)	-0.8	0.01	0.29	0.54	2.0	0.44 [0.17, 0.71]
			Placebo	113	111 (98.2)	0.14 (0.43)	-1.4	-0.10	0.10	0.37	1.7	
		Week 16	Tezepelumab	111	105 (94.6)	0.41 (0.48)	-0.8	0.10	0.34	0.66	2.0	0.57 [0.29, 0.84]
			Placebo	113	106 (93.8)	0.16 (0.39)	-1.0	-0.07	0.11	0.39	1.8	
		Week 24	Tezepelumab	111	102 (91.9)	0.35 (0.41)	-0.5	0.06	0.29	0.55	1.7	0.55 [0.27, 0.83]
			Placebo	113	104 (92.0)	0.12 (0.42)	-0.8	-0.15	0.06	0.34	1.7	
		Week 36	Tezepelumab	111	99 (89.2)	0.38 (0.44)	-0.5	0.03	0.35	0.62	1.7	0.56 [0.27, 0.85]
			Placebo	113	96 (85.0)	0.14 (0.43)	-1.1	-0.17	0.13	0.41	1.7	
		Week 52	Tezepelumab	111	94 (84.7)	0.35 (0.44)	-0.6	0.05	0.28	0.63	1.6	0.59 [0.29, 0.88]
			Placebo	113	91 (80.5)	0.11 (0.36)	-0.9	-0.15	0.11	0.31	1.1	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q1: < 16 ppb	Absolute values	Baseline	Tezepelumab	93	93 (100.0)	1.70 (0.68)	0.7	1.18	1.58	2.12	4.0	
			Placebo	81	81 (100.0)	1.73 (0.67)	0.4	1.23	1.61	2.21	3.3	
		Week 2	Tezepelumab	93	89 (95.7)	1.86 (0.68)	0.6	1.31	1.79	2.38	4.1	
			Placebo	81	73 (90.1)	1.80 (0.71)	0.4	1.31	1.65	2.29	4.1	
		Week 4	Tezepelumab	93	91 (97.8)	1.86 (0.68)	0.6	1.28	1.84	2.37	4.2	
			Placebo	81	80 (98.8)	1.80 (0.73)	0.4	1.26	1.74	2.21	4.8	
		Week 8	Tezepelumab	93	91 (97.8)	1.85 (0.67)	0.6	1.32	1.67	2.36	4.1	
			Placebo	81	78 (96.3)	1.79 (0.71)	0.4	1.33	1.72	2.20	4.6	
		Week 12	Tezepelumab	93	89 (95.7)	1.83 (0.66)	0.6	1.38	1.75	2.20	4.2	
			Placebo	81	77 (95.1)	1.84 (0.73)	0.5	1.31	1.69	2.30	4.6	
		Week 16	Tezepelumab	93	88 (94.6)	1.89 (0.69)	0.6	1.37	1.84	2.40	4.2	
			Placebo	81	76 (93.8)	1.78 (0.74)	0.5	1.21	1.70	2.17	4.7	
		Week 24	Tezepelumab	93	88 (94.6)	1.83 (0.65)	0.6	1.34	1.75	2.29	4.0	
			Placebo	81	74 (91.4)	1.79 (0.73)	0.6	1.22	1.77	2.21	4.8	
		Week 36	Tezepelumab	93	83 (89.2)	1.84 (0.68)	0.7	1.28	1.77	2.40	4.4	
			Placebo	81	73 (90.1)	1.81 (0.71)	0.6	1.27	1.78	2.26	4.3	
		Week 52	Tezepelumab	93	82 (88.2)	1.85 (0.66)	0.7	1.43	1.76	2.25	4.2	
			Placebo	81	68 (84.0)	1.77 (0.75)	0.6	1.16	1.61	2.31	4.0	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q1: < 16 ppb	Change from baseline	Week 2	Tezepelumab	93	89 (95.7)	0.16 (0.34)	-0.6	-0.02	0.10	0.24	1.4	0.39 [0.07, 0.70]
			Placebo	81	73 (90.1)	0.04 (0.28)	-0.8	-0.06	0.01	0.13	0.9	
		Week 4	Tezepelumab	93	91 (97.8)	0.19 (0.36)	-0.6	-0.02	0.12	0.29	1.7	0.35 [0.05, 0.65]
			Placebo	81	80 (98.8)	0.06 (0.35)	-0.9	-0.07	0.02	0.14	1.6	
		Week 8	Tezepelumab	93	91 (97.8)	0.16 (0.36)	-0.8	-0.05	0.09	0.29	1.3	0.37 [0.06, 0.67]
			Placebo	81	78 (96.3)	0.04 (0.29)	-0.9	-0.10	0.01	0.14	1.4	
		Week 12	Tezepelumab	93	89 (95.7)	0.16 (0.36)	-0.6	-0.04	0.10	0.26	1.5	0.21 [-0.10, 0.51]
			Placebo	81	77 (95.1)	0.09 (0.31)	-1.1	-0.04	0.05	0.22	1.4	
		Week 16	Tezepelumab	93	88 (94.6)	0.18 (0.35)	-0.6	-0.04	0.13	0.29	1.6	0.42 [0.11, 0.73]
			Placebo	81	76 (93.8)	0.04 (0.33)	-1.0	-0.09	0.02	0.17	1.4	
		Week 24	Tezepelumab	93	88 (94.6)	0.14 (0.37)	-1.0	-0.07	0.03	0.30	1.3	0.28 [-0.03, 0.59]
			Placebo	81	74 (91.4)	0.03 (0.37)	-1.1	-0.12	0.04	0.15	1.6	
		Week 36	Tezepelumab	93	83 (89.2)	0.13 (0.38)	-1.0	-0.09	0.10	0.34	1.4	0.17 [-0.14, 0.49]
			Placebo	81	73 (90.1)	0.07 (0.30)	-0.8	-0.09	0.06	0.26	1.1	
		Week 52	Tezepelumab	93	82 (88.2)	0.15 (0.39)	-1.0	-0.03	0.08	0.34	1.3	0.25 [-0.08, 0.57]
			Placebo	81	68 (84.0)	0.06 (0.34)	-1.0	-0.10	0.06	0.21	1.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)											
Q2: 16 - < 30 ppb Absolute values	Baseline	Tezepelumab	86	86 (100.0)	1.67 (0.67)	0.4	1.23	1.49	2.05	3.5	
		Placebo	96	96 (100.0)	1.90 (0.82)	0.7	1.28	1.76	2.29	4.5	
	Week 2	Tezepelumab	86	85 (98.8)	1.77 (0.63)	0.6	1.30	1.68	2.10	3.8	
		Placebo	96	94 (97.9)	1.93 (0.75)	0.6	1.38	1.83	2.31	3.9	
	Week 4	Tezepelumab	86	85 (98.8)	1.78 (0.67)	0.7	1.28	1.64	2.12	3.7	
		Placebo	96	94 (97.9)	1.94 (0.73)	0.7	1.44	1.83	2.32	3.6	
	Week 8	Tezepelumab	86	85 (98.8)	1.79 (0.68)	0.6	1.32	1.67	2.15	3.7	
		Placebo	96	95 (99.0)	1.99 (0.78)	0.7	1.47	1.84	2.36	4.1	
	Week 12	Tezepelumab	86	82 (95.3)	1.81 (0.66)	0.6	1.32	1.68	2.21	3.6	
		Placebo	96	93 (96.9)	1.94 (0.79)	0.8	1.35	1.74	2.40	4.1	
	Week 16	Tezepelumab	86	84 (97.7)	1.82 (0.68)	0.6	1.34	1.63	2.24	3.5	
		Placebo	96	94 (97.9)	1.93 (0.79)	0.7	1.33	1.78	2.33	4.3	
	Week 24	Tezepelumab	86	80 (93.0)	1.79 (0.67)	0.6	1.28	1.71	2.20	3.8	
		Placebo	96	91 (94.8)	1.96 (0.78)	0.6	1.41	1.81	2.35	4.3	
	Week 36	Tezepelumab	86	78 (90.7)	1.75 (0.63)	0.5	1.27	1.66	2.10	3.5	
		Placebo	96	86 (89.6)	2.00 (0.78)	0.9	1.46	1.83	2.48	4.2	
	Week 52	Tezepelumab	86	80 (93.0)	1.74 (0.63)	0.7	1.31	1.64	2.14	3.5	
		Placebo	96	84 (87.5)	1.94 (0.81)	0.7	1.37	1.74	2.33	4.5	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q2: 16 - < 30 ppb	Change from baseline	Week 2	Tezepelumab	86	85 (98.8)	0.09 (0.25)	-0.7	-0.03	0.07	0.21	0.8	0.27 [-0.02, 0.56]
			Placebo	96	94 (97.9)	0.02 (0.31)	-1.1	-0.15	-0.01	0.13	0.9	
		Week 4	Tezepelumab	86	85 (98.8)	0.11 (0.27)	-0.9	-0.05	0.08	0.24	1.1	0.17 [-0.12, 0.47]
			Placebo	96	94 (97.9)	0.05 (0.36)	-1.8	-0.11	0.07	0.28	1.0	
		Week 8	Tezepelumab	86	85 (98.8)	0.14 (0.36)	-0.8	-0.06	0.10	0.20	1.6	0.15 [-0.14, 0.44]
			Placebo	96	95 (99.0)	0.09 (0.34)	-0.8	-0.13	0.07	0.33	1.2	
		Week 12	Tezepelumab	86	82 (95.3)	0.15 (0.29)	-0.7	-0.04	0.11	0.28	1.2	0.36 [0.07, 0.66]
			Placebo	96	93 (96.9)	0.03 (0.36)	-1.5	-0.12	0.03	0.18	1.2	
		Week 16	Tezepelumab	86	84 (97.7)	0.14 (0.33)	-0.6	-0.04	0.10	0.29	1.4	0.34 [0.04, 0.63]
			Placebo	96	94 (97.9)	0.03 (0.32)	-0.8	-0.15	0.04	0.16	1.0	
		Week 24	Tezepelumab	86	80 (93.0)	0.15 (0.34)	-0.6	-0.08	0.12	0.32	1.5	0.40 [0.09, 0.70]
			Placebo	96	91 (94.8)	0.02 (0.30)	-0.9	-0.15	0.03	0.21	0.8	
		Week 36	Tezepelumab	86	78 (90.7)	0.08 (0.32)	-0.7	-0.12	0.02	0.21	1.0	0.09 [-0.22, 0.40]
			Placebo	96	86 (89.6)	0.05 (0.37)	-1.0	-0.20	0.02	0.22	1.3	
		Week 52	Tezepelumab	86	80 (93.0)	0.11 (0.32)	-1.0	-0.06	0.08	0.29	1.1	0.37 [0.06, 0.68]
			Placebo	96	84 (87.5)	-0.01 (0.31)	-1.0	-0.21	-0.02	0.18	0.7	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)											
Q3: 30 - < 56 ppb Absolute values	Baseline	Tezepelumab	102	102 (100.0)	1.69 (0.63)	0.5	1.27	1.60	2.06	3.7	
		Placebo	89	89 (100.0)	1.79 (0.62)	0.8	1.37	1.68	2.10	4.2	
	Week 2	Tezepelumab	102	101 (99.0)	1.91 (0.64)	0.7	1.46	1.85	2.38	4.0	
		Placebo	89	86 (96.6)	1.83 (0.69)	0.8	1.37	1.63	2.17	4.0	
	Week 4	Tezepelumab	102	102 (100.0)	1.94 (0.71)	0.7	1.41	1.91	2.42	4.2	
		Placebo	89	86 (96.6)	1.86 (0.64)	0.7	1.42	1.72	2.12	4.2	
	Week 8	Tezepelumab	102	101 (99.0)	1.95 (0.67)	0.8	1.38	1.94	2.41	4.2	
		Placebo	89	86 (96.6)	1.89 (0.68)	0.8	1.34	1.82	2.22	4.3	
	Week 12	Tezepelumab	102	101 (99.0)	1.97 (0.68)	0.8	1.52	1.89	2.35	4.3	
		Placebo	89	85 (95.5)	1.88 (0.70)	0.7	1.37	1.79	2.25	4.3	
	Week 16	Tezepelumab	102	102 (100.0)	1.97 (0.67)	0.8	1.53	1.90	2.30	4.3	
		Placebo	89	82 (92.1)	1.84 (0.67)	0.6	1.44	1.71	2.12	4.1	
	Week 24	Tezepelumab	102	98 (96.1)	1.95 (0.66)	0.7	1.51	1.86	2.40	3.8	
		Placebo	89	78 (87.6)	1.88 (0.66)	0.9	1.42	1.75	2.17	4.8	
	Week 36	Tezepelumab	102	93 (91.2)	1.98 (0.72)	0.7	1.42	1.97	2.38	4.2	
		Placebo	89	82 (92.1)	1.87 (0.69)	0.7	1.44	1.69	2.19	4.6	
	Week 52	Tezepelumab	102	91 (89.2)	2.00 (0.74)	0.6	1.48	1.99	2.40	4.3	
		Placebo	89	73 (82.0)	1.86 (0.71)	0.7	1.37	1.65	2.26	4.4	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q3: 30 - < 56 ppb	Change from baseline	Week 2	Tezepelumab	102	101 (99.0)	0.22 (0.31)	-0.4	0.02	0.19	0.34	1.3	0.53 [0.24, 0.82]
			Placebo	89	86 (96.6)	0.03 (0.40)	-1.8	-0.14	0.00	0.18	1.1	
		Week 4	Tezepelumab	102	102 (100.0)	0.26 (0.33)	-0.5	0.04	0.20	0.40	1.3	0.54 [0.25, 0.83]
			Placebo	89	86 (96.6)	0.07 (0.35)	-1.0	-0.11	0.04	0.20	1.1	
		Week 8	Tezepelumab	102	101 (99.0)	0.27 (0.38)	-0.6	0.00	0.23	0.50	1.5	0.50 [0.21, 0.79]
			Placebo	89	86 (96.6)	0.10 (0.28)	-0.6	-0.06	0.07	0.19	0.9	
		Week 12	Tezepelumab	102	101 (99.0)	0.28 (0.38)	-0.7	0.04	0.20	0.45	1.6	0.50 [0.21, 0.79]
			Placebo	89	85 (95.5)	0.09 (0.38)	-1.2	-0.11	0.03	0.26	1.2	
		Week 16	Tezepelumab	102	102 (100.0)	0.28 (0.40)	-0.6	0.01	0.23	0.45	1.5	0.61 [0.31, 0.91]
			Placebo	89	82 (92.1)	0.05 (0.35)	-1.2	-0.14	-0.02	0.17	1.5	
		Week 24	Tezepelumab	102	98 (96.1)	0.29 (0.45)	-1.0	-0.01	0.27	0.49	1.6	0.43 [0.13, 0.73]
			Placebo	89	78 (87.6)	0.11 (0.39)	-0.9	-0.11	0.03	0.31	1.4	
		Week 36	Tezepelumab	102	93 (91.2)	0.31 (0.42)	-0.5	-0.02	0.24	0.54	1.6	0.58 [0.28, 0.88]
			Placebo	89	82 (92.1)	0.08 (0.39)	-0.6	-0.18	0.01	0.25	1.3	
		Week 52	Tezepelumab	102	91 (89.2)	0.32 (0.44)	-0.8	-0.04	0.25	0.58	1.7	0.60 [0.28, 0.91]
			Placebo	89	73 (82.0)	0.08 (0.36)	-0.7	-0.17	-0.03	0.23	1.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q4: >= 56 ppb	Absolute values	Baseline	Tezepelumab	96	96 (100.0)	1.90 (0.71)	0.8	1.46	1.75	2.30	4.1	
			Placebo	101	101 (100.0)	1.75 (0.59)	0.6	1.36	1.69	2.18	3.3	
		Week 2	Tezepelumab	96	92 (95.8)	2.15 (0.78)	0.8	1.59	2.05	2.62	4.3	
			Placebo	101	96 (95.0)	1.87 (0.66)	0.6	1.42	1.80	2.36	3.9	
		Week 4	Tezepelumab	96	96 (100.0)	2.17 (0.76)	0.8	1.62	2.03	2.74	4.3	
			Placebo	101	99 (98.0)	1.84 (0.63)	0.7	1.40	1.79	2.25	4.0	
		Week 8	Tezepelumab	96	94 (97.9)	2.27 (0.78)	1.0	1.71	2.21	2.64	4.7	
			Placebo	101	98 (97.0)	1.88 (0.70)	0.7	1.41	1.75	2.22	4.3	
		Week 12	Tezepelumab	96	94 (97.9)	2.26 (0.81)	0.9	1.69	2.12	2.74	4.7	
			Placebo	101	99 (98.0)	1.91 (0.64)	0.6	1.50	1.83	2.24	4.3	
		Week 16	Tezepelumab	96	90 (93.8)	2.30 (0.84)	0.8	1.74	2.17	2.75	4.9	
			Placebo	101	95 (94.1)	1.95 (0.67)	0.8	1.52	1.83	2.23	4.4	
		Week 24	Tezepelumab	96	87 (90.6)	2.26 (0.76)	0.9	1.76	2.12	2.72	4.4	
			Placebo	101	93 (92.1)	1.87 (0.67)	0.8	1.39	1.73	2.22	4.3	
		Week 36	Tezepelumab	96	86 (89.6)	2.28 (0.81)	0.9	1.72	2.19	2.82	4.5	
			Placebo	101	84 (83.2)	1.95 (0.71)	0.8	1.45	1.91	2.28	4.3	
		Week 52	Tezepelumab	96	81 (84.4)	2.30 (0.81)	0.9	1.69	2.13	2.88	4.2	
			Placebo	101	80 (79.2)	1.91 (0.69)	0.7	1.38	1.89	2.28	3.7	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q4: >= 56 ppb	Change from baseline	Week 2	Tezepelumab	96	92 (95.8)	0.26 (0.37)	-0.6	0.05	0.22	0.42	1.5	0.41 [0.12, 0.70]
			Placebo	101	96 (95.0)	0.10 (0.38)	-0.7	-0.08	0.05	0.26	1.2	
		Week 4	Tezepelumab	96	96 (100.0)	0.27 (0.43)	-0.7	0.00	0.20	0.42	1.8	0.40 [0.12, 0.68]
			Placebo	101	99 (98.0)	0.10 (0.43)	-0.8	-0.18	0.05	0.31	1.4	
		Week 8	Tezepelumab	96	94 (97.9)	0.38 (0.47)	-0.6	0.10	0.33	0.65	1.8	0.64 [0.35, 0.93]
			Placebo	101	98 (97.0)	0.10 (0.40)	-0.6	-0.17	0.05	0.32	1.6	
		Week 12	Tezepelumab	96	94 (97.9)	0.37 (0.50)	-0.8	0.02	0.33	0.57	2.0	0.47 [0.19, 0.76]
			Placebo	101	99 (98.0)	0.15 (0.44)	-1.4	-0.09	0.10	0.40	1.7	
		Week 16	Tezepelumab	96	90 (93.8)	0.43 (0.48)	-0.8	0.14	0.34	0.66	2.0	0.55 [0.25, 0.84]
			Placebo	101	95 (94.1)	0.18 (0.40)	-1.0	-0.05	0.12	0.44	1.8	
		Week 24	Tezepelumab	96	87 (90.6)	0.36 (0.41)	-0.3	0.06	0.29	0.63	1.7	0.59 [0.29, 0.89]
			Placebo	101	93 (92.1)	0.11 (0.43)	-0.8	-0.15	0.06	0.34	1.7	
		Week 36	Tezepelumab	96	86 (89.6)	0.39 (0.44)	-0.3	0.03	0.35	0.62	1.7	0.52 [0.22, 0.83]
			Placebo	101	84 (83.2)	0.16 (0.45)	-1.1	-0.17	0.15	0.47	1.7	
		Week 52	Tezepelumab	96	81 (84.4)	0.37 (0.44)	-0.6	0.08	0.29	0.63	1.6	0.61 [0.29, 0.92]
			Placebo	101	80 (79.2)	0.13 (0.37)	-0.9	-0.13	0.11	0.34	1.1	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q1: < 53.1 IU/ml	Absolute values	Baseline	Tezepelumab	93	93 (100.0)	1.65 (0.64)	0.4	1.18	1.53	2.02	3.3	
			Placebo	96	96 (100.0)	1.67 (0.59)	0.7	1.33	1.57	1.98	4.2	
		Week 2	Tezepelumab	93	90 (96.8)	1.77 (0.59)	0.6	1.36	1.69	2.18	3.3	
			Placebo	96	90 (93.8)	1.70 (0.60)	0.6	1.35	1.62	1.99	4.0	
		Week 4	Tezepelumab	93	93 (100.0)	1.80 (0.65)	0.7	1.28	1.66	2.30	3.3	
			Placebo	96	93 (96.9)	1.74 (0.60)	0.7	1.33	1.68	2.05	4.2	
		Week 8	Tezepelumab	93	91 (97.8)	1.79 (0.61)	0.6	1.31	1.68	2.22	3.3	
			Placebo	96	93 (96.9)	1.75 (0.61)	0.7	1.33	1.66	2.07	4.3	
		Week 12	Tezepelumab	93	90 (96.8)	1.79 (0.64)	0.6	1.37	1.68	2.20	3.6	
			Placebo	96	92 (95.8)	1.73 (0.63)	0.6	1.31	1.68	2.09	4.3	
		Week 16	Tezepelumab	93	91 (97.8)	1.84 (0.66)	0.6	1.37	1.70	2.28	3.5	
			Placebo	96	90 (93.8)	1.72 (0.61)	0.6	1.31	1.66	2.09	4.1	
		Week 24	Tezepelumab	93	89 (95.7)	1.75 (0.58)	0.6	1.24	1.70	2.24	3.3	
			Placebo	96	85 (88.5)	1.68 (0.62)	0.8	1.28	1.63	1.98	4.8	
		Week 36	Tezepelumab	93	85 (91.4)	1.75 (0.62)	0.5	1.25	1.65	2.16	3.3	
			Placebo	96	81 (84.4)	1.78 (0.62)	0.8	1.36	1.69	2.10	4.6	
		Week 52	Tezepelumab	93	86 (92.5)	1.79 (0.64)	0.7	1.35	1.68	2.23	3.3	
			Placebo	96	79 (82.3)	1.71 (0.62)	0.7	1.27	1.64	2.03	4.4	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q1: < 53.1 IU/ml	Change from baseline	Week 2	Tezepelumab	93	90 (96.8)	0.13 (0.29)	-0.7	-0.01	0.10	0.27	1.1	0.33 [0.04, 0.62]
			Placebo	96	90 (93.8)	0.03 (0.29)	-0.6	-0.10	-0.01	0.11	1.0	
		Week 4	Tezepelumab	93	93 (100.0)	0.15 (0.37)	-0.9	-0.06	0.10	0.30	1.6	0.18 [-0.10, 0.47]
			Placebo	96	93 (96.9)	0.09 (0.27)	-0.7	-0.06	0.06	0.21	1.1	
		Week 8	Tezepelumab	93	91 (97.8)	0.16 (0.37)	-0.8	-0.06	0.11	0.33	1.4	0.27 [-0.02, 0.56]
			Placebo	96	93 (96.9)	0.07 (0.28)	-0.8	-0.08	0.04	0.20	1.2	
		Week 12	Tezepelumab	93	90 (96.8)	0.16 (0.37)	-0.7	-0.05	0.12	0.31	2.0	0.24 [-0.05, 0.53]
			Placebo	96	92 (95.8)	0.07 (0.33)	-0.7	-0.10	0.02	0.20	1.2	
		Week 16	Tezepelumab	93	91 (97.8)	0.19 (0.35)	-0.6	0.00	0.15	0.33	1.7	0.45 [0.15, 0.74]
			Placebo	96	90 (93.8)	0.05 (0.30)	-0.6	-0.09	0.01	0.17	1.0	
		Week 24	Tezepelumab	93	89 (95.7)	0.15 (0.31)	-0.6	-0.06	0.12	0.34	1.2	0.42 [0.12, 0.72]
			Placebo	96	85 (88.5)	0.02 (0.29)	-0.8	-0.14	-0.01	0.13	1.1	
		Week 36	Tezepelumab	93	85 (91.4)	0.12 (0.34)	-0.7	-0.07	0.05	0.29	1.3	0.09 [-0.22, 0.39]
			Placebo	96	81 (84.4)	0.09 (0.30)	-0.4	-0.14	0.06	0.26	1.1	
		Week 52	Tezepelumab	93	86 (92.5)	0.14 (0.37)	-1.0	-0.07	0.09	0.34	1.5	0.36 [0.05, 0.67]
			Placebo	96	79 (82.3)	0.02 (0.30)	-0.6	-0.18	0.00	0.15	1.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q2: 53.1 - < 195.6 IU/ml	Absolute values	Baseline	Tezepelumab	100	100 (100.0)	1.73 (0.69)	0.8	1.24	1.53	2.10	4.0	
			Placebo	99	99 (100.0)	1.77 (0.61)	0.7	1.34	1.69	2.12	3.7	
		Week 2	Tezepelumab	100	100 (100.0)	1.90 (0.72)	0.9	1.31	1.76	2.42	4.1	
			Placebo	99	95 (96.0)	1.82 (0.63)	0.7	1.38	1.73	2.16	3.7	
		Week 4	Tezepelumab	100	98 (98.0)	1.96 (0.74)	0.9	1.39	1.79	2.44	4.2	
			Placebo	99	99 (100.0)	1.84 (0.55)	0.7	1.46	1.82	2.19	3.1	
		Week 8	Tezepelumab	100	98 (98.0)	1.95 (0.74)	0.8	1.32	1.75	2.44	4.1	
			Placebo	99	97 (98.0)	1.86 (0.62)	0.7	1.41	1.82	2.22	3.5	
		Week 12	Tezepelumab	100	97 (97.0)	2.00 (0.75)	1.0	1.46	1.83	2.48	4.6	
			Placebo	99	97 (98.0)	1.85 (0.62)	0.7	1.35	1.75	2.30	3.6	
		Week 16	Tezepelumab	100	95 (95.0)	2.01 (0.77)	0.8	1.32	1.86	2.54	4.2	
			Placebo	99	93 (93.9)	1.87 (0.63)	0.7	1.38	1.79	2.20	3.6	
		Week 24	Tezepelumab	100	94 (94.0)	2.02 (0.75)	0.8	1.44	1.94	2.52	4.0	
			Placebo	99	92 (92.9)	1.84 (0.55)	0.9	1.43	1.81	2.22	3.3	
		Week 36	Tezepelumab	100	92 (92.0)	2.04 (0.76)	1.0	1.40	1.88	2.53	4.4	
			Placebo	99	91 (91.9)	1.89 (0.64)	0.7	1.41	1.85	2.28	3.4	
		Week 52	Tezepelumab	100	86 (86.0)	2.04 (0.75)	0.8	1.43	1.90	2.67	4.2	
			Placebo	99	84 (84.8)	1.87 (0.64)	0.7	1.47	1.76	2.28	3.6	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q2: 53.1 - < 195.6 IU/ml	Change from baseline	Week 2	Tezepelumab	100	100 (100.0)	0.17 (0.32)	-0.6	0.01	0.13	0.27	1.4	0.48 [0.20, 0.77]
			Placebo	99	95 (96.0)	0.02 (0.27)	-1.0	-0.13	-0.01	0.16	1.0	
		Week 4	Tezepelumab	100	98 (98.0)	0.23 (0.35)	-0.7	0.01	0.16	0.35	1.7	0.47 [0.19, 0.75]
			Placebo	99	99 (100.0)	0.06 (0.35)	-0.6	-0.12	0.02	0.20	1.2	
		Week 8	Tezepelumab	100	98 (98.0)	0.24 (0.36)	-0.4	0.02	0.13	0.39	1.2	0.49 [0.20, 0.77]
			Placebo	99	97 (98.0)	0.08 (0.28)	-0.5	-0.11	0.05	0.22	1.2	
		Week 12	Tezepelumab	100	97 (97.0)	0.28 (0.37)	-0.8	0.05	0.19	0.43	1.5	0.51 [0.22, 0.79]
			Placebo	99	97 (98.0)	0.08 (0.40)	-1.5	-0.14	0.07	0.31	1.3	
		Week 16	Tezepelumab	100	95 (95.0)	0.29 (0.41)	-0.8	0.02	0.23	0.49	1.6	0.52 [0.23, 0.81]
			Placebo	99	93 (93.9)	0.09 (0.36)	-1.2	-0.13	0.04	0.28	1.2	
		Week 24	Tezepelumab	100	94 (94.0)	0.29 (0.39)	-0.3	-0.01	0.23	0.48	1.7	0.58 [0.29, 0.88]
			Placebo	99	92 (92.9)	0.08 (0.35)	-0.8	-0.14	0.01	0.25	1.2	
		Week 36	Tezepelumab	100	92 (92.0)	0.29 (0.38)	-0.3	-0.02	0.30	0.53	1.6	0.50 [0.21, 0.79]
			Placebo	99	91 (91.9)	0.10 (0.39)	-1.1	-0.18	0.01	0.39	1.3	
		Week 52	Tezepelumab	100	86 (86.0)	0.29 (0.40)	-0.6	0.00	0.23	0.55	1.4	0.56 [0.25, 0.86]
			Placebo	99	84 (84.8)	0.10 (0.30)	-0.9	-0.10	0.07	0.27	0.9	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q3: 195.6 - < 572.4 IU/ml	Absolute values	Baseline	Tezepelumab	103	103 (100.0)	1.73 (0.67)	0.6	1.34	1.62	2.08	3.7	
			Placebo	85	85 (100.0)	1.91 (0.81)	0.6	1.30	1.73	2.38	4.5	
		Week 2	Tezepelumab	103	100 (97.1)	1.96 (0.72)	0.6	1.46	1.84	2.40	4.0	
			Placebo	85	79 (92.9)	1.90 (0.75)	0.7	1.34	1.69	2.36	3.9	
		Week 4	Tezepelumab	103	103 (100.0)	1.93 (0.73)	0.6	1.41	1.86	2.42	4.2	
			Placebo	85	80 (94.1)	1.90 (0.70)	0.7	1.40	1.82	2.31	3.6	
		Week 8	Tezepelumab	103	102 (99.0)	1.98 (0.70)	0.6	1.42	1.98	2.41	4.2	
			Placebo	85	83 (97.6)	1.96 (0.75)	0.7	1.39	1.90	2.37	4.1	
		Week 12	Tezepelumab	103	100 (97.1)	1.99 (0.73)	0.6	1.52	1.90	2.45	4.3	
			Placebo	85	81 (95.3)	1.97 (0.78)	0.7	1.45	1.77	2.39	4.1	
		Week 16	Tezepelumab	103	100 (97.1)	1.99 (0.71)	0.6	1.54	1.94	2.43	4.3	
			Placebo	85	83 (97.6)	1.93 (0.77)	0.8	1.35	1.73	2.38	4.3	
		Week 24	Tezepelumab	103	94 (91.3)	1.95 (0.65)	0.6	1.54	1.86	2.34	3.8	
			Placebo	85	78 (91.8)	1.97 (0.78)	0.6	1.45	1.88	2.41	4.3	
		Week 36	Tezepelumab	103	89 (86.4)	1.95 (0.69)	0.7	1.49	1.94	2.31	4.2	
			Placebo	85	73 (85.9)	1.99 (0.77)	0.8	1.48	1.79	2.35	4.2	
		Week 52	Tezepelumab	103	91 (88.3)	1.97 (0.71)	0.6	1.50	1.89	2.43	4.3	
			Placebo	85	71 (83.5)	1.99 (0.84)	0.7	1.37	1.79	2.43	4.5	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q3: 195.6 - < 572.4 IU/ml	Change from baseline	Week 2	Tezepelumab	103	100 (97.1)	0.22 (0.36)	-0.5	-0.03	0.18	0.35	1.5	0.69 [0.39, 1.00]
			Placebo	85	79 (92.9)	-0.05 (0.43)	-1.8	-0.18	-0.01	0.13	1.1	
		Week 4	Tezepelumab	103	103 (100.0)	0.20 (0.31)	-0.5	-0.02	0.15	0.33	1.3	0.51 [0.21, 0.80]
			Placebo	85	80 (94.1)	0.01 (0.45)	-1.8	-0.17	0.04	0.24	1.0	
		Week 8	Tezepelumab	103	102 (99.0)	0.26 (0.39)	-0.6	-0.04	0.21	0.50	1.4	0.61 [0.31, 0.91]
			Placebo	85	83 (97.6)	0.03 (0.34)	-0.9	-0.20	0.03	0.24	0.9	
		Week 12	Tezepelumab	103	100 (97.1)	0.27 (0.42)	-0.7	-0.04	0.19	0.53	1.4	0.53 [0.23, 0.83]
			Placebo	85	81 (95.3)	0.06 (0.38)	-1.2	-0.09	0.05	0.22	1.0	
		Week 16	Tezepelumab	103	100 (97.1)	0.26 (0.42)	-0.6	-0.04	0.17	0.45	1.9	0.62 [0.32, 0.91]
			Placebo	85	83 (97.6)	0.01 (0.36)	-1.0	-0.21	0.01	0.18	1.5	
		Week 24	Tezepelumab	103	94 (91.3)	0.23 (0.43)	-1.0	-0.04	0.23	0.44	1.3	0.45 [0.14, 0.75]
			Placebo	85	78 (91.8)	0.05 (0.39)	-1.1	-0.15	0.03	0.30	1.4	
		Week 36	Tezepelumab	103	89 (86.4)	0.24 (0.44)	-1.0	-0.04	0.11	0.50	1.5	0.50 [0.19, 0.82]
			Placebo	85	73 (85.9)	0.04 (0.35)	-0.9	-0.18	0.04	0.21	1.3	
		Week 52	Tezepelumab	103	91 (88.3)	0.27 (0.45)	-1.0	0.02	0.22	0.58	1.6	0.54 [0.22, 0.85]
			Placebo	85	71 (83.5)	0.05 (0.35)	-1.0	-0.14	0.03	0.22	1.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q4: >= 572.4 IU/ml	Absolute values	Baseline	Tezepelumab	84	84 (100.0)	1.86 (0.69)	0.8	1.40	1.76	2.17	4.1	
			Placebo	91	91 (100.0)	1.85 (0.69)	0.4	1.36	1.85	2.29	3.6	
		Week 2	Tezepelumab	84	80 (95.2)	2.06 (0.72)	0.9	1.52	1.98	2.52	4.3	
			Placebo	91	89 (97.8)	2.04 (0.78)	0.4	1.47	1.99	2.43	4.1	
		Week 4	Tezepelumab	84	83 (98.8)	2.10 (0.73)	0.9	1.57	2.05	2.54	4.3	
			Placebo	91	91 (100.0)	1.97 (0.84)	0.4	1.40	1.93	2.31	4.8	
		Week 8	Tezepelumab	84	83 (98.8)	2.14 (0.80)	0.8	1.52	1.95	2.52	4.7	
			Placebo	91	88 (96.7)	2.01 (0.86)	0.4	1.40	1.88	2.43	4.6	
		Week 12	Tezepelumab	84	82 (97.6)	2.11 (0.74)	0.8	1.61	1.99	2.39	4.7	
			Placebo	91	87 (95.6)	2.03 (0.81)	0.5	1.46	2.00	2.41	4.6	
		Week 16	Tezepelumab	84	81 (96.4)	2.15 (0.81)	0.9	1.65	2.02	2.37	4.9	
			Placebo	91	84 (92.3)	2.02 (0.83)	0.5	1.39	1.96	2.42	4.7	
		Week 24	Tezepelumab	84	79 (94.0)	2.12 (0.80)	0.9	1.61	1.97	2.57	4.4	
			Placebo	91	84 (92.3)	2.02 (0.83)	0.6	1.44	1.85	2.35	4.8	
		Week 36	Tezepelumab	84	77 (91.7)	2.12 (0.84)	0.6	1.57	1.97	2.50	4.5	
			Placebo	91	83 (91.2)	2.00 (0.85)	0.6	1.43	1.84	2.32	4.3	
		Week 52	Tezepelumab	84	74 (88.1)	2.09 (0.83)	0.8	1.53	1.98	2.46	4.2	
			Placebo	91	74 (81.3)	1.95 (0.84)	0.6	1.32	1.82	2.33	4.0	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q4: >= 572.4 IU/ml	Change from baseline	Week 2	Tezepelumab	84	80 (95.2)	0.21 (0.34)	-0.4	0.00	0.13	0.36	1.3	0.09 [-0.21, 0.40]
			Placebo	91	89 (97.8)	0.18 (0.36)	-0.5	-0.07	0.12	0.44	1.2	
		Week 4	Tezepelumab	84	83 (98.8)	0.26 (0.40)	-0.4	0.05	0.16	0.39	1.8	0.34 [0.04, 0.64]
			Placebo	91	91 (100.0)	0.13 (0.42)	-0.8	-0.13	0.03	0.36	1.6	
		Week 8	Tezepelumab	84	83 (98.8)	0.31 (0.49)	-0.8	0.02	0.17	0.51	1.8	0.33 [0.03, 0.63]
			Placebo	91	88 (96.7)	0.16 (0.42)	-0.7	-0.12	0.09	0.37	1.6	
		Week 12	Tezepelumab	84	82 (97.6)	0.27 (0.45)	-0.4	-0.03	0.19	0.46	1.9	0.29 [-0.02, 0.59]
			Placebo	91	87 (95.6)	0.15 (0.39)	-0.9	-0.06	0.07	0.31	1.7	
		Week 16	Tezepelumab	84	81 (96.4)	0.29 (0.45)	-0.5	0.01	0.17	0.51	2.0	0.32 [0.01, 0.62]
			Placebo	91	84 (92.3)	0.16 (0.41)	-0.8	-0.06	0.07	0.40	1.8	
		Week 24	Tezepelumab	84	79 (94.0)	0.28 (0.47)	-0.7	-0.07	0.20	0.52	1.6	0.32 [0.01, 0.63]
			Placebo	91	84 (92.3)	0.13 (0.46)	-0.9	-0.11	0.07	0.31	1.7	
		Week 36	Tezepelumab	84	77 (91.7)	0.29 (0.47)	-0.8	-0.02	0.23	0.53	1.7	0.35 [0.04, 0.66]
			Placebo	91	83 (91.2)	0.13 (0.47)	-1.0	-0.17	0.06	0.35	1.7	
		Week 52	Tezepelumab	84	74 (88.1)	0.26 (0.43)	-0.8	-0.03	0.19	0.47	1.7	0.40 [0.08, 0.73]
			Placebo	91	74 (81.3)	0.08 (0.42)	-1.0	-0.16	0.06	0.33	1.1	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Nasal polyps last 2 years												
Yes	Absolute values	Baseline	Tezepelumab	32	32 (100.0)	1.97 (0.79)	0.8	1.44	1.69	2.50	3.7	
			Placebo	29	29 (100.0)	1.85 (0.68)	0.6	1.44	1.67	2.26	3.4	
		Week 2	Tezepelumab	32	32 (100.0)	2.22 (0.81)	0.9	1.60	2.15	2.66	4.0	
			Placebo	29	29 (100.0)	1.93 (0.77)	0.9	1.36	1.71	2.48	4.1	
		Week 4	Tezepelumab	32	32 (100.0)	2.26 (0.85)	0.9	1.64	1.98	2.88	4.2	
			Placebo	29	29 (100.0)	2.00 (0.83)	0.9	1.42	1.99	2.34	4.8	
		Week 8	Tezepelumab	32	32 (100.0)	2.31 (0.81)	1.0	1.66	2.25	2.87	4.2	
			Placebo	29	29 (100.0)	2.00 (0.85)	0.7	1.51	1.74	2.46	4.6	
		Week 12	Tezepelumab	32	31 (96.9)	2.28 (0.92)	0.9	1.55	2.07	2.97	4.6	
			Placebo	29	29 (100.0)	2.03 (0.78)	1.0	1.44	1.95	2.37	4.6	
		Week 16	Tezepelumab	32	31 (96.9)	2.30 (0.86)	0.9	1.54	2.16	2.92	4.3	
			Placebo	29	28 (96.6)	2.00 (0.86)	0.7	1.42	1.77	2.43	4.7	
		Week 24	Tezepelumab	32	30 (93.8)	2.16 (0.72)	0.9	1.71	1.91	2.53	3.7	
			Placebo	29	28 (96.6)	1.99 (0.77)	0.9	1.50	1.92	2.23	4.8	
		Week 36	Tezepelumab	32	30 (93.8)	2.31 (0.84)	0.9	1.54	2.29	3.04	4.2	
			Placebo	29	27 (93.1)	2.00 (0.72)	0.8	1.48	1.84	2.31	4.3	
		Week 52	Tezepelumab	32	29 (90.6)	2.27 (0.91)	0.6	1.60	2.29	2.78	4.3	
			Placebo	29	26 (89.7)	1.90 (0.72)	0.9	1.32	1.74	2.39	4.0	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Nasal polyps last 2 years												
Yes	Change from baseline	Week 2	Tezepelumab	32	32 (100.0)	0.24 (0.33)	-0.3	0.07	0.17	0.42	1.0	0.47 [-0.04, 0.98]
			Placebo	29	29 (100.0)	0.07 (0.39)	-0.5	-0.15	-0.05	0.19	1.0	
		Week 4	Tezepelumab	32	32 (100.0)	0.29 (0.37)	-0.5	0.08	0.24	0.41	1.8	0.31 [-0.19, 0.82]
			Placebo	29	29 (100.0)	0.15 (0.49)	-0.7	-0.10	0.05	0.24	1.6	
		Week 8	Tezepelumab	32	32 (100.0)	0.34 (0.40)	-0.3	0.10	0.25	0.50	1.7	0.44 [-0.07, 0.95]
			Placebo	29	29 (100.0)	0.15 (0.45)	-0.5	-0.13	0.08	0.31	1.4	
		Week 12	Tezepelumab	32	31 (96.9)	0.29 (0.41)	-0.2	0.02	0.17	0.46	1.5	0.26 [-0.25, 0.77]
			Placebo	29	29 (100.0)	0.18 (0.43)	-0.5	-0.11	0.03	0.37	1.4	
		Week 16	Tezepelumab	32	31 (96.9)	0.31 (0.42)	-0.6	0.02	0.26	0.60	1.3	0.35 [-0.16, 0.87]
			Placebo	29	28 (96.6)	0.16 (0.46)	-0.6	-0.14	0.03	0.44	1.4	
		Week 24	Tezepelumab	32	30 (93.8)	0.24 (0.43)	-1.0	-0.05	0.25	0.43	1.3	0.13 [-0.38, 0.65]
			Placebo	29	28 (96.6)	0.18 (0.48)	-0.5	-0.17	0.09	0.52	1.6	
		Week 36	Tezepelumab	32	30 (93.8)	0.33 (0.41)	-0.3	0.02	0.32	0.54	1.4	0.26 [-0.26, 0.78]
			Placebo	29	27 (93.1)	0.23 (0.38)	-0.4	-0.03	0.15	0.51	1.1	
		Week 52	Tezepelumab	32	29 (90.6)	0.32 (0.41)	-0.8	0.02	0.34	0.56	1.1	0.61 [0.07, 1.15]
			Placebo	29	26 (89.7)	0.07 (0.41)	-0.6	-0.18	-0.06	0.33	1.1	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Nasal polyps last 2 years												
No	Absolute values	Baseline	Tezepelumab	348	348 (100.0)	1.72 (0.66)	0.4	1.24	1.61	2.10	4.1	
			Placebo	342	342 (100.0)	1.79 (0.68)	0.4	1.32	1.69	2.18	4.5	
		Week 2	Tezepelumab	348	338 (97.1)	1.89 (0.68)	0.6	1.38	1.79	2.38	4.3	
			Placebo	342	324 (94.7)	1.86 (0.69)	0.4	1.38	1.75	2.28	4.0	
		Week 4	Tezepelumab	348	345 (99.1)	1.91 (0.70)	0.6	1.37	1.81	2.40	4.3	
			Placebo	342	334 (97.7)	1.85 (0.67)	0.4	1.40	1.79	2.20	4.2	
		Week 8	Tezepelumab	348	342 (98.3)	1.93 (0.71)	0.6	1.38	1.83	2.37	4.7	
			Placebo	342	332 (97.1)	1.88 (0.71)	0.4	1.38	1.80	2.26	4.3	
		Week 12	Tezepelumab	348	338 (97.1)	1.94 (0.70)	0.6	1.47	1.84	2.37	4.7	
			Placebo	342	328 (95.9)	1.88 (0.71)	0.5	1.38	1.75	2.29	4.3	
		Week 16	Tezepelumab	348	336 (96.6)	1.96 (0.73)	0.6	1.44	1.86	2.40	4.9	
			Placebo	342	322 (94.2)	1.87 (0.70)	0.5	1.35	1.76	2.21	4.4	
		Week 24	Tezepelumab	348	326 (93.7)	1.94 (0.70)	0.6	1.44	1.82	2.34	4.4	
			Placebo	342	311 (90.9)	1.87 (0.70)	0.6	1.39	1.75	2.21	4.8	
		Week 36	Tezepelumab	348	313 (89.9)	1.93 (0.72)	0.5	1.37	1.85	2.36	4.5	
			Placebo	342	301 (88.0)	1.90 (0.72)	0.6	1.40	1.79	2.28	4.6	
		Week 52	Tezepelumab	348	308 (88.5)	1.94 (0.72)	0.7	1.43	1.82	2.37	4.2	
			Placebo	342	282 (82.5)	1.87 (0.74)	0.6	1.32	1.73	2.28	4.5	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Nasal polyps last 2 years												
No	Change from baseline	Week 2	Tezepelumab	348	338 (97.1)	0.18 (0.33)	-0.7	-0.01	0.13	0.31	1.5	0.39 [0.23, 0.54]
			Placebo	342	324 (94.7)	0.05 (0.35)	-1.8	-0.11	0.01	0.18	1.2	
		Week 4	Tezepelumab	348	345 (99.1)	0.20 (0.36)	-0.9	-0.01	0.13	0.33	1.7	0.37 [0.22, 0.53]
			Placebo	342	334 (97.7)	0.07 (0.36)	-1.8	-0.11	0.04	0.24	1.4	
		Week 8	Tezepelumab	348	342 (98.3)	0.23 (0.40)	-0.8	-0.04	0.15	0.44	1.8	0.41 [0.26, 0.56]
			Placebo	342	332 (97.1)	0.08 (0.32)	-0.9	-0.11	0.05	0.25	1.6	
		Week 12	Tezepelumab	348	338 (97.1)	0.24 (0.40)	-0.8	-0.02	0.18	0.43	2.0	0.41 [0.25, 0.56]
			Placebo	342	328 (95.9)	0.08 (0.37)	-1.5	-0.10	0.05	0.25	1.7	
		Week 16	Tezepelumab	348	336 (96.6)	0.25 (0.41)	-0.8	0.00	0.17	0.40	2.0	0.48 [0.32, 0.63]
			Placebo	342	322 (94.2)	0.07 (0.35)	-1.2	-0.10	0.02	0.23	1.8	
		Week 24	Tezepelumab	348	326 (93.7)	0.24 (0.40)	-1.0	-0.04	0.18	0.43	1.7	0.46 [0.30, 0.62]
			Placebo	342	311 (90.9)	0.06 (0.36)	-1.1	-0.13	0.03	0.24	1.7	
		Week 36	Tezepelumab	348	313 (89.9)	0.23 (0.41)	-1.0	-0.05	0.16	0.43	1.7	0.37 [0.21, 0.53]
			Placebo	342	301 (88.0)	0.08 (0.38)	-1.1	-0.16	0.04	0.27	1.7	
		Week 52	Tezepelumab	348	308 (88.5)	0.23 (0.42)	-1.0	-0.03	0.16	0.44	1.7	0.45 [0.28, 0.61]
			Placebo	342	282 (82.5)	0.06 (0.34)	-1.0	-0.14	0.05	0.23	1.2	

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Region (cat. N)									0.394
Western Europe	Week 2	Tezepelumab	71	70 (98.6)	0.18 (0.04)	(0.11, 0.25)	0.16 (0.05)	(0.06, 0.26)	0.002 *
		Placebo	71	66 (93.0)	0.02 (0.04)	(-0.05, 0.10)			
	Week 4	Tezepelumab	71	71 (100.0)	0.20 (0.04)	(0.12, 0.28)	0.17 (0.06)	(0.06, 0.28)	0.003 *
		Placebo	71	69 (97.2)	0.03 (0.04)	(-0.05, 0.11)			
	Week 8	Tezepelumab	71	71 (100.0)	0.22 (0.05)	(0.13, 0.31)	0.15 (0.07)	(0.02, 0.28)	0.025 *
		Placebo	71	66 (93.0)	0.07 (0.05)	(-0.02, 0.16)			
	Week 12	Tezepelumab	71	68 (95.8)	0.19 (0.05)	(0.10, 0.28)	0.14 (0.06)	(0.02, 0.27)	0.027 *
		Placebo	71	65 (91.5)	0.05 (0.05)	(-0.04, 0.14)			
	Week 16	Tezepelumab	71	69 (97.2)	0.27 (0.05)	(0.18, 0.36)	0.27 (0.07)	(0.14, 0.40)	<0.001 *
		Placebo	71	65 (91.5)	-0.00 (0.05)	(-0.09, 0.09)			
	Week 24	Tezepelumab	71	68 (95.8)	0.20 (0.04)	(0.12, 0.28)	0.21 (0.06)	(0.09, 0.33)	<0.001 *
		Placebo	71	60 (84.5)	-0.01 (0.04)	(-0.10, 0.07)			
	Week 36	Tezepelumab	71	65 (91.5)	0.21 (0.04)	(0.13, 0.30)	0.13 (0.06)	(0.01, 0.26)	0.039 *
		Placebo	71	57 (80.3)	0.08 (0.05)	(-0.01, 0.17)			
	Week 52	Tezepelumab	71	63 (88.7)	0.21 (0.04)	(0.13, 0.29)	0.11 (0.06)	(-0.00, 0.23)	0.057
		Placebo	71	54 (76.1)	0.10 (0.04)	(0.01, 0.18)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
North America	Week 2	Tezepelumab	75	69 (92.0)	0.28 (0.04)	(0.19, 0.37)	0.19 (0.06)	(0.07, 0.32)	0.002 *
		Placebo	71	67 (94.4)	0.09 (0.04)	(-0.00, 0.17)			
	Week 4	Tezepelumab	75	73 (97.3)	0.27 (0.04)	(0.19, 0.35)	0.16 (0.06)	(0.05, 0.27)	0.005 *
		Placebo	71	70 (98.6)	0.11 (0.04)	(0.03, 0.19)			
	Week 8	Tezepelumab	75	73 (97.3)	0.30 (0.04)	(0.21, 0.38)	0.19 (0.06)	(0.07, 0.32)	0.002 *
		Placebo	71	69 (97.2)	0.10 (0.04)	(0.02, 0.19)			
	Week 12	Tezepelumab	75	71 (94.7)	0.30 (0.05)	(0.21, 0.40)	0.21 (0.07)	(0.07, 0.35)	0.003 *
		Placebo	71	69 (97.2)	0.09 (0.05)	(-0.01, 0.19)			
	Week 16	Tezepelumab	75	71 (94.7)	0.30 (0.04)	(0.21, 0.38)	0.18 (0.06)	(0.06, 0.29)	0.004 *
		Placebo	71	68 (95.8)	0.12 (0.04)	(0.04, 0.20)			
	Week 24	Tezepelumab	75	65 (86.7)	0.28 (0.04)	(0.19, 0.36)	0.20 (0.06)	(0.07, 0.32)	0.002 *
		Placebo	71	66 (93.0)	0.08 (0.04)	(-0.01, 0.17)			
	Week 36	Tezepelumab	75	61 (81.3)	0.31 (0.05)	(0.22, 0.40)	0.18 (0.06)	(0.05, 0.31)	0.006 *
		Placebo	71	66 (93.0)	0.13 (0.05)	(0.04, 0.22)			
	Week 52	Tezepelumab	75	58 (77.3)	0.31 (0.05)	(0.22, 0.41)	0.21 (0.07)	(0.07, 0.35)	0.003 *
		Placebo	71	53 (74.6)	0.10 (0.05)	(0.01, 0.20)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
South America	Week 2	Tezepelumab	65	65 (100.0)	0.10 (0.04)	(0.01, 0.19)	0.06 (0.06)	(-0.07, 0.18)	0.381
		Placebo	63	61 (96.8)	0.04 (0.05)	(-0.05, 0.13)			
	Week 4	Tezepelumab	65	64 (98.5)	0.11 (0.05)	(0.02, 0.21)	0.04 (0.07)	(-0.09, 0.18)	0.541
		Placebo	63	59 (93.7)	0.07 (0.05)	(-0.03, 0.17)			
	Week 8	Tezepelumab	65	64 (98.5)	0.14 (0.05)	(0.05, 0.23)	0.00 (0.07)	(-0.13, 0.13)	0.960
		Placebo	63	61 (96.8)	0.13 (0.05)	(0.04, 0.22)			
	Week 12	Tezepelumab	65	63 (96.9)	0.14 (0.05)	(0.05, 0.23)	0.02 (0.07)	(-0.11, 0.15)	0.742
		Placebo	63	62 (98.4)	0.12 (0.05)	(0.03, 0.21)			
	Week 16	Tezepelumab	65	62 (95.4)	0.15 (0.05)	(0.05, 0.25)	0.03 (0.07)	(-0.11, 0.18)	0.653
		Placebo	63	60 (95.2)	0.12 (0.05)	(0.02, 0.22)			
	Week 24	Tezepelumab	65	61 (93.8)	0.15 (0.05)	(0.05, 0.25)	0.04 (0.07)	(-0.11, 0.18)	0.622
		Placebo	63	59 (93.7)	0.11 (0.05)	(0.01, 0.21)			
	Week 36	Tezepelumab	65	61 (93.8)	0.14 (0.05)	(0.04, 0.25)	0.00 (0.08)	(-0.15, 0.15)	0.978
		Placebo	63	61 (96.8)	0.14 (0.05)	(0.03, 0.25)			
	Week 52	Tezepelumab	65	61 (93.8)	0.17 (0.05)	(0.06, 0.27)	0.05 (0.08)	(-0.10, 0.20)	0.523
		Placebo	63	59 (93.7)	0.12 (0.05)	(0.01, 0.22)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Central/Eastern Europe	Week 2	Tezepelumab	19	19 (100.0)	0.16 (0.06)	(0.03, 0.29)	0.12 (0.09)	(-0.08, 0.31)	0.222
		Placebo	18	16 (88.9)	0.04 (0.07)	(-0.10, 0.18)			
	Week 4	Tezepelumab	19	19 (100.0)	0.27 (0.09)	(0.09, 0.45)	0.18 (0.13)	(-0.08, 0.44)	0.164
		Placebo	18	18 (100.0)	0.09 (0.09)	(-0.09, 0.27)			
	Week 8	Tezepelumab	19	19 (100.0)	0.21 (0.08)	(0.06, 0.36)	0.10 (0.11)	(-0.12, 0.32)	0.365
		Placebo	18	18 (100.0)	0.11 (0.08)	(-0.05, 0.27)			
	Week 12	Tezepelumab	19	19 (100.0)	0.25 (0.08)	(0.09, 0.40)	0.09 (0.11)	(-0.14, 0.31)	0.445
		Placebo	18	17 (94.4)	0.16 (0.08)	(-0.00, 0.32)			
	Week 16	Tezepelumab	19	19 (100.0)	0.26 (0.08)	(0.08, 0.43)	0.15 (0.12)	(-0.10, 0.40)	0.228
		Placebo	18	18 (100.0)	0.11 (0.09)	(-0.07, 0.28)			
	Week 24	Tezepelumab	19	18 (94.7)	0.15 (0.09)	(-0.03, 0.33)	-0.01 (0.13)	(-0.27, 0.25)	0.934
		Placebo	18	18 (100.0)	0.17 (0.09)	(-0.02, 0.35)			
	Week 36	Tezepelumab	19	19 (100.0)	0.22 (0.07)	(0.07, 0.37)	0.12 (0.11)	(-0.10, 0.34)	0.287
		Placebo	18	17 (94.4)	0.10 (0.08)	(-0.06, 0.26)			
	Week 52	Tezepelumab	19	19 (100.0)	0.20 (0.07)	(0.06, 0.34)	0.08 (0.10)	(-0.12, 0.29)	0.418
		Placebo	18	18 (100.0)	0.12 (0.07)	(-0.03, 0.26)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Asia Pacific	Week 2	Tezepelumab	97	97 (100.0)	0.17 (0.03)	(0.11, 0.24)	0.12 (0.05)	(0.02, 0.21)	0.018 *
		Placebo	93	91 (97.8)	0.06 (0.04)	(-0.01, 0.13)			
	Week 4	Tezepelumab	97	97 (100.0)	0.22 (0.04)	(0.15, 0.29)	0.16 (0.05)	(0.06, 0.27)	0.002 *
		Placebo	93	93 (100.0)	0.06 (0.04)	(-0.01, 0.13)			
	Week 8	Tezepelumab	97	95 (97.9)	0.28 (0.04)	(0.20, 0.36)	0.22 (0.06)	(0.11, 0.33)	<0.001 *
		Placebo	93	93 (100.0)	0.06 (0.04)	(-0.01, 0.14)			
	Week 12	Tezepelumab	97	95 (97.9)	0.30 (0.04)	(0.22, 0.38)	0.21 (0.06)	(0.10, 0.33)	<0.001 *
		Placebo	93	92 (98.9)	0.09 (0.04)	(0.00, 0.17)			
	Week 16	Tezepelumab	97	96 (99.0)	0.30 (0.04)	(0.22, 0.38)	0.22 (0.06)	(0.11, 0.34)	<0.001 *
		Placebo	93	90 (96.8)	0.08 (0.04)	(-0.00, 0.16)			
	Week 24	Tezepelumab	97	95 (97.9)	0.27 (0.04)	(0.19, 0.35)	0.19 (0.06)	(0.08, 0.31)	<0.001 *
		Placebo	93	88 (94.6)	0.08 (0.04)	(-0.01, 0.16)			
	Week 36	Tezepelumab	97	91 (93.8)	0.28 (0.04)	(0.19, 0.36)	0.23 (0.06)	(0.11, 0.35)	<0.001 *
		Placebo	93	85 (91.4)	0.05 (0.04)	(-0.04, 0.14)			
	Week 52	Tezepelumab	97	91 (93.8)	0.29 (0.04)	(0.21, 0.38)	0.25 (0.06)	(0.13, 0.38)	<0.001 *
		Placebo	93	85 (91.4)	0.04 (0.04)	(-0.05, 0.12)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Rest of the world	Week 2	Tezepelumab	53	50 (94.3)	0.15 (0.04)	(0.06, 0.23)	0.11 (0.06)	(-0.00, 0.23)	0.057
		Placebo	55	52 (94.5)	0.03 (0.04)	(-0.05, 0.12)			
	Week 4	Tezepelumab	53	53 (100.0)	0.17 (0.05)	(0.07, 0.28)	0.05 (0.08)	(-0.10, 0.20)	0.536
		Placebo	55	54 (98.2)	0.13 (0.05)	(0.02, 0.23)			
	Week 8	Tezepelumab	53	52 (98.1)	0.22 (0.04)	(0.13, 0.30)	0.14 (0.06)	(0.02, 0.27)	0.024 *
		Placebo	55	54 (98.2)	0.07 (0.04)	(-0.01, 0.16)			
	Week 12	Tezepelumab	53	53 (100.0)	0.22 (0.05)	(0.13, 0.32)	0.11 (0.07)	(-0.02, 0.24)	0.104
		Placebo	55	52 (94.5)	0.11 (0.05)	(0.02, 0.21)			
	Week 16	Tezepelumab	53	50 (94.3)	0.20 (0.05)	(0.10, 0.30)	0.12 (0.07)	(-0.01, 0.26)	0.080
		Placebo	55	49 (89.1)	0.08 (0.05)	(-0.02, 0.17)			
	Week 24	Tezepelumab	53	49 (92.5)	0.24 (0.05)	(0.14, 0.35)	0.17 (0.07)	(0.02, 0.32)	0.024 *
		Placebo	55	48 (87.3)	0.08 (0.05)	(-0.03, 0.18)			
	Week 36	Tezepelumab	53	46 (86.8)	0.22 (0.05)	(0.11, 0.32)	0.13 (0.08)	(-0.02, 0.28)	0.083
		Placebo	55	42 (76.4)	0.08 (0.05)	(-0.02, 0.19)			
	Week 52	Tezepelumab	53	45 (84.9)	0.22 (0.05)	(0.13, 0.32)	0.21 (0.07)	(0.07, 0.35)	0.003 *
		Placebo	55	39 (70.9)	0.01 (0.05)	(-0.09, 0.11)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline eosinophils (cat. N)									0.045 i
< 150 cells/uL	Week 2	Tezepelumab	95	93 (97.9)	0.08 (0.03)	(0.02, 0.14)	0.07 (0.05)	(-0.02, 0.17)	0.116
		Placebo	87	82 (94.3)	0.01 (0.03)	(-0.06, 0.07)			
	Week 4	Tezepelumab	95	94 (98.9)	0.09 (0.04)	(0.02, 0.16)	0.08 (0.05)	(-0.02, 0.18)	0.138
		Placebo	87	86 (98.9)	0.02 (0.04)	(-0.06, 0.09)			
	Week 8	Tezepelumab	95	92 (96.8)	0.10 (0.03)	(0.04, 0.17)	0.06 (0.05)	(-0.04, 0.16)	0.230
		Placebo	87	84 (96.6)	0.04 (0.04)	(-0.03, 0.12)			
	Week 12	Tezepelumab	95	91 (95.8)	0.09 (0.04)	(0.02, 0.16)	0.07 (0.05)	(-0.03, 0.17)	0.187
		Placebo	87	82 (94.3)	0.02 (0.04)	(-0.05, 0.09)			
	Week 16	Tezepelumab	95	92 (96.8)	0.13 (0.04)	(0.06, 0.21)	0.15 (0.06)	(0.04, 0.27)	0.007 *
		Placebo	87	82 (94.3)	-0.02 (0.04)	(-0.10, 0.06)			
	Week 24	Tezepelumab	95	85 (89.5)	0.09 (0.03)	(0.03, 0.15)	0.07 (0.05)	(-0.03, 0.16)	0.158
		Placebo	87	79 (90.8)	0.02 (0.03)	(-0.04, 0.09)			
	Week 36	Tezepelumab	95	86 (90.5)	0.07 (0.03)	(0.01, 0.14)	0.03 (0.05)	(-0.06, 0.13)	0.492
		Placebo	87	76 (87.4)	0.04 (0.04)	(-0.03, 0.11)			
	Week 52	Tezepelumab	95	85 (89.5)	0.11 (0.04)	(0.04, 0.19)	0.13 (0.05)	(0.02, 0.23)	0.021 *
		Placebo	87	75 (86.2)	-0.02 (0.04)	(-0.09, 0.06)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
150 - < 300 cells/uL	Week 2	Tezepelumab	121	118 (97.5)	0.14 (0.03)	(0.09, 0.20)	0.11 (0.04)	(0.03, 0.19)	0.006 *
		Placebo	120	116 (96.7)	0.03 (0.03)	(-0.02, 0.09)			
	Week 4	Tezepelumab	121	121 (100.0)	0.16 (0.03)	(0.10, 0.22)	0.11 (0.04)	(0.03, 0.20)	0.009 *
		Placebo	120	116 (96.7)	0.05 (0.03)	(-0.01, 0.11)			
	Week 8	Tezepelumab	121	121 (100.0)	0.17 (0.03)	(0.11, 0.23)	0.08 (0.04)	(-0.00, 0.16)	0.057
		Placebo	120	115 (95.8)	0.09 (0.03)	(0.03, 0.15)			
	Week 12	Tezepelumab	121	119 (98.3)	0.16 (0.03)	(0.10, 0.23)	0.10 (0.05)	(0.00, 0.19)	0.040 *
		Placebo	120	115 (95.8)	0.06 (0.03)	(-0.00, 0.13)			
	Week 16	Tezepelumab	121	119 (98.3)	0.17 (0.03)	(0.11, 0.23)	0.09 (0.05)	(-0.00, 0.18)	0.057
		Placebo	120	113 (94.2)	0.08 (0.03)	(0.02, 0.15)			
	Week 24	Tezepelumab	121	118 (97.5)	0.13 (0.03)	(0.07, 0.20)	0.11 (0.05)	(0.02, 0.20)	0.022 *
		Placebo	120	109 (90.8)	0.02 (0.03)	(-0.05, 0.09)			
	Week 36	Tezepelumab	121	111 (91.7)	0.14 (0.04)	(0.07, 0.21)	0.11 (0.05)	(0.01, 0.21)	0.034 *
		Placebo	120	106 (88.3)	0.04 (0.04)	(-0.04, 0.11)			
	Week 52	Tezepelumab	121	113 (93.4)	0.15 (0.03)	(0.09, 0.21)	0.09 (0.05)	(-0.00, 0.18)	0.060
		Placebo	120	98 (81.7)	0.06 (0.03)	(-0.01, 0.13)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
300 - < 450 cells/uL	Week 2	Tezepelumab	70	67 (95.7)	0.21 (0.04)	(0.13, 0.29)	0.18 (0.06)	(0.06, 0.29)	0.003 *
		Placebo	69	64 (92.8)	0.03 (0.04)	(-0.05, 0.11)			
	Week 4	Tezepelumab	70	68 (97.1)	0.22 (0.04)	(0.13, 0.30)	0.17 (0.06)	(0.05, 0.29)	0.007 *
		Placebo	69	68 (98.6)	0.05 (0.04)	(-0.03, 0.13)			
	Week 8	Tezepelumab	70	69 (98.6)	0.30 (0.05)	(0.20, 0.39)	0.23 (0.07)	(0.10, 0.36)	<0.001 *
		Placebo	69	68 (98.6)	0.07 (0.05)	(-0.03, 0.16)			
	Week 12	Tezepelumab	70	66 (94.3)	0.32 (0.05)	(0.23, 0.42)	0.30 (0.07)	(0.16, 0.43)	<0.001 *
		Placebo	69	65 (94.2)	0.03 (0.05)	(-0.07, 0.12)			
	Week 16	Tezepelumab	70	66 (94.3)	0.29 (0.05)	(0.20, 0.39)	0.24 (0.07)	(0.11, 0.37)	<0.001 *
		Placebo	69	64 (92.8)	0.05 (0.05)	(-0.04, 0.14)			
	Week 24	Tezepelumab	70	66 (94.3)	0.30 (0.04)	(0.22, 0.39)	0.25 (0.06)	(0.14, 0.37)	<0.001 *
		Placebo	69	64 (92.8)	0.05 (0.04)	(-0.03, 0.13)			
	Week 36	Tezepelumab	70	60 (85.7)	0.34 (0.05)	(0.24, 0.43)	0.29 (0.07)	(0.16, 0.43)	<0.001 *
		Placebo	69	61 (88.4)	0.04 (0.05)	(-0.05, 0.14)			
	Week 52	Tezepelumab	70	60 (85.7)	0.30 (0.05)	(0.20, 0.39)	0.24 (0.07)	(0.11, 0.38)	<0.001 *
		Placebo	69	60 (87.0)	0.05 (0.05)	(-0.04, 0.15)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 450 cells/uL	Week 2	Tezepelumab	94	92 (97.9)	0.30 (0.04)	(0.23, 0.37)	0.17 (0.05)	(0.07, 0.27)	0.001 *
		Placebo	95	91 (95.8)	0.13 (0.04)	(0.06, 0.20)			
	Week 4	Tezepelumab	94	94 (100.0)	0.36 (0.04)	(0.29, 0.44)	0.18 (0.06)	(0.07, 0.29)	0.001 *
		Placebo	95	93 (97.9)	0.18 (0.04)	(0.11, 0.26)			
	Week 8	Tezepelumab	94	92 (97.9)	0.41 (0.04)	(0.33, 0.49)	0.27 (0.06)	(0.15, 0.39)	<0.001 *
		Placebo	95	94 (98.9)	0.14 (0.04)	(0.06, 0.22)			
	Week 12	Tezepelumab	94	93 (98.9)	0.43 (0.04)	(0.35, 0.51)	0.19 (0.06)	(0.08, 0.30)	<0.001 *
		Placebo	95	95 (100.0)	0.24 (0.04)	(0.16, 0.32)			
	Week 16	Tezepelumab	94	90 (95.7)	0.45 (0.04)	(0.37, 0.53)	0.27 (0.06)	(0.16, 0.38)	<0.001 *
		Placebo	95	91 (95.8)	0.18 (0.04)	(0.11, 0.26)			
	Week 24	Tezepelumab	94	87 (92.6)	0.44 (0.05)	(0.36, 0.53)	0.24 (0.06)	(0.11, 0.37)	<0.001 *
		Placebo	95	87 (91.6)	0.20 (0.05)	(0.11, 0.29)			
	Week 36	Tezepelumab	94	86 (91.5)	0.45 (0.04)	(0.36, 0.53)	0.19 (0.06)	(0.07, 0.31)	0.002 *
		Placebo	95	85 (89.5)	0.25 (0.04)	(0.17, 0.34)			
	Week 52	Tezepelumab	94	79 (84.0)	0.47 (0.04)	(0.39, 0.56)	0.29 (0.06)	(0.17, 0.41)	<0.001 *
		Placebo	95	75 (78.9)	0.18 (0.04)	(0.10, 0.27)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline eosinophils (cat. Q)									0.104
Q1: < 140 cells/uL	Week 2	Tezepelumab	89	87 (97.8)	0.09 (0.03)	(0.03, 0.15)	0.08 (0.05)	(-0.01, 0.16)	0.096
		Placebo	79	74 (93.7)	0.01 (0.03)	(-0.05, 0.08)			
	Week 4	Tezepelumab	89	88 (98.9)	0.10 (0.04)	(0.03, 0.18)	0.07 (0.05)	(-0.03, 0.18)	0.166
		Placebo	79	78 (98.7)	0.03 (0.04)	(-0.05, 0.11)			
	Week 8	Tezepelumab	89	87 (97.8)	0.11 (0.04)	(0.04, 0.18)	0.08 (0.05)	(-0.02, 0.18)	0.130
		Placebo	79	76 (96.2)	0.03 (0.04)	(-0.04, 0.11)			
	Week 12	Tezepelumab	89	85 (95.5)	0.10 (0.04)	(0.03, 0.17)	0.07 (0.05)	(-0.03, 0.17)	0.188
		Placebo	79	75 (94.9)	0.03 (0.04)	(-0.05, 0.10)			
	Week 16	Tezepelumab	89	86 (96.6)	0.15 (0.04)	(0.07, 0.23)	0.17 (0.06)	(0.05, 0.29)	0.004 *
		Placebo	79	74 (93.7)	-0.03 (0.04)	(-0.11, 0.06)			
	Week 24	Tezepelumab	89	80 (89.9)	0.10 (0.03)	(0.03, 0.16)	0.06 (0.05)	(-0.03, 0.16)	0.188
		Placebo	79	72 (91.1)	0.03 (0.03)	(-0.03, 0.10)			
	Week 36	Tezepelumab	89	81 (91.0)	0.09 (0.04)	(0.02, 0.16)	0.04 (0.05)	(-0.06, 0.14)	0.457
		Placebo	79	69 (87.3)	0.05 (0.04)	(-0.02, 0.12)			
	Week 52	Tezepelumab	89	80 (89.9)	0.12 (0.04)	(0.05, 0.20)	0.15 (0.06)	(0.04, 0.26)	0.010 *
		Placebo	79	68 (86.1)	-0.03 (0.04)	(-0.11, 0.06)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q2: 140 - < 250 cells/uL	Week 2	Tezepelumab	93	90 (96.8)	0.12 (0.03)	(0.06, 0.19)	0.14 (0.05)	(0.05, 0.23)	0.003 *
		Placebo	92	89 (96.7)	-0.02 (0.03)	(-0.08, 0.05)			
	Week 4	Tezepelumab	93	93 (100.0)	0.13 (0.03)	(0.07, 0.20)	0.12 (0.05)	(0.02, 0.21)	0.014 *
		Placebo	92	88 (95.7)	0.02 (0.03)	(-0.05, 0.08)			
	Week 8	Tezepelumab	93	92 (98.9)	0.14 (0.03)	(0.07, 0.20)	0.06 (0.05)	(-0.03, 0.15)	0.217
		Placebo	92	91 (98.9)	0.08 (0.03)	(0.02, 0.14)			
	Week 12	Tezepelumab	93	91 (97.8)	0.11 (0.04)	(0.04, 0.19)	0.09 (0.05)	(-0.01, 0.20)	0.074
		Placebo	92	88 (95.7)	0.02 (0.04)	(-0.05, 0.09)			
	Week 16	Tezepelumab	93	91 (97.8)	0.14 (0.03)	(0.08, 0.20)	0.08 (0.05)	(-0.01, 0.17)	0.079
		Placebo	92	88 (95.7)	0.06 (0.03)	(-0.00, 0.12)			
	Week 24	Tezepelumab	93	90 (96.8)	0.10 (0.04)	(0.03, 0.17)	0.10 (0.05)	(-0.00, 0.20)	0.055
		Placebo	92	84 (91.3)	-0.00 (0.04)	(-0.08, 0.07)			
	Week 36	Tezepelumab	93	86 (92.5)	0.08 (0.04)	(0.00, 0.15)	0.08 (0.05)	(-0.03, 0.18)	0.168
		Placebo	92	81 (88.0)	0.00 (0.04)	(-0.07, 0.08)			
	Week 52	Tezepelumab	93	87 (93.5)	0.09 (0.04)	(0.02, 0.16)	0.02 (0.05)	(-0.08, 0.13)	0.638
		Placebo	92	76 (82.6)	0.06 (0.04)	(-0.01, 0.14)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q3: 250 - < 430 cells/uL	Week 2	Tezepelumab	100	98 (98.0)	0.20 (0.03)	(0.13, 0.27)	0.13 (0.05)	(0.03, 0.22)	0.010 *
		Placebo	98	93 (94.9)	0.08 (0.03)	(0.01, 0.14)			
	Week 4	Tezepelumab	100	98 (98.0)	0.22 (0.04)	(0.15, 0.29)	0.14 (0.05)	(0.04, 0.24)	0.005 *
		Placebo	98	97 (99.0)	0.08 (0.04)	(0.01, 0.15)			
	Week 8	Tezepelumab	100	99 (99.0)	0.28 (0.04)	(0.21, 0.36)	0.19 (0.06)	(0.08, 0.30)	<0.001 *
		Placebo	98	93 (94.9)	0.09 (0.04)	(0.02, 0.17)			
	Week 12	Tezepelumab	100	96 (96.0)	0.31 (0.04)	(0.23, 0.39)	0.23 (0.06)	(0.12, 0.34)	<0.001 *
		Placebo	98	92 (93.9)	0.09 (0.04)	(0.01, 0.16)			
	Week 16	Tezepelumab	100	96 (96.0)	0.27 (0.04)	(0.20, 0.35)	0.18 (0.06)	(0.07, 0.30)	0.002 *
		Placebo	98	90 (91.8)	0.09 (0.04)	(0.01, 0.17)			
	Week 24	Tezepelumab	100	95 (95.0)	0.27 (0.04)	(0.20, 0.34)	0.22 (0.05)	(0.12, 0.33)	<0.001 *
		Placebo	98	89 (90.8)	0.05 (0.04)	(-0.03, 0.12)			
	Week 36	Tezepelumab	100	86 (86.0)	0.32 (0.04)	(0.24, 0.40)	0.26 (0.06)	(0.14, 0.37)	<0.001 *
		Placebo	98	86 (87.8)	0.06 (0.04)	(-0.02, 0.14)			
	Week 52	Tezepelumab	100	87 (87.0)	0.29 (0.04)	(0.21, 0.37)	0.24 (0.06)	(0.13, 0.35)	<0.001 *
		Placebo	98	82 (83.7)	0.05 (0.04)	(-0.03, 0.13)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q4: >= 430 cells/uL	Week 2	Tezepelumab	98	95 (96.9)	0.29 (0.04)	(0.22, 0.36)	0.18 (0.05)	(0.08, 0.28)	<0.001 *
		Placebo	102	97 (95.1)	0.11 (0.04)	(0.04, 0.18)			
	Week 4	Tezepelumab	98	98 (100.0)	0.35 (0.04)	(0.27, 0.43)	0.19 (0.06)	(0.08, 0.30)	<0.001 *
		Placebo	102	100 (98.0)	0.16 (0.04)	(0.08, 0.24)			
	Week 8	Tezepelumab	98	96 (98.0)	0.40 (0.04)	(0.32, 0.48)	0.27 (0.06)	(0.15, 0.38)	<0.001 *
		Placebo	102	101 (99.0)	0.13 (0.04)	(0.05, 0.21)			
	Week 12	Tezepelumab	98	97 (99.0)	0.41 (0.04)	(0.33, 0.49)	0.21 (0.06)	(0.09, 0.32)	<0.001 *
		Placebo	102	102 (100.0)	0.21 (0.04)	(0.13, 0.29)			
	Week 16	Tezepelumab	98	94 (95.9)	0.44 (0.04)	(0.36, 0.51)	0.27 (0.05)	(0.17, 0.38)	<0.001 *
		Placebo	102	98 (96.1)	0.16 (0.04)	(0.09, 0.24)			
	Week 24	Tezepelumab	98	91 (92.9)	0.43 (0.04)	(0.35, 0.52)	0.24 (0.06)	(0.12, 0.36)	<0.001 *
		Placebo	102	94 (92.2)	0.19 (0.04)	(0.11, 0.28)			
	Week 36	Tezepelumab	98	90 (91.8)	0.44 (0.04)	(0.35, 0.52)	0.20 (0.06)	(0.09, 0.32)	<0.001 *
		Placebo	102	92 (90.2)	0.23 (0.04)	(0.15, 0.31)			
	Week 52	Tezepelumab	98	83 (84.7)	0.46 (0.04)	(0.38, 0.54)	0.28 (0.06)	(0.17, 0.40)	<0.001 *
		Placebo	102	82 (80.4)	0.18 (0.04)	(0.10, 0.26)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline FENO (cat. N)									0.154
< 25 ppb	Week 2	Tezepelumab	155	150 (96.8)	0.13 (0.02)	(0.09, 0.18)	0.10 (0.03)	(0.03, 0.17)	0.003 *
		Placebo	145	135 (93.1)	0.03 (0.02)	(-0.02, 0.08)			
	Week 4	Tezepelumab	155	152 (98.1)	0.15 (0.03)	(0.10, 0.20)	0.07 (0.04)	(-0.00, 0.14)	0.060
		Placebo	145	143 (98.6)	0.08 (0.03)	(0.02, 0.13)			
	Week 8	Tezepelumab	155	152 (98.1)	0.16 (0.03)	(0.10, 0.21)	0.09 (0.04)	(0.01, 0.17)	0.024 *
		Placebo	145	141 (97.2)	0.07 (0.03)	(0.01, 0.12)			
	Week 12	Tezepelumab	155	149 (96.1)	0.15 (0.03)	(0.10, 0.21)	0.09 (0.04)	(0.01, 0.16)	0.025 *
		Placebo	145	138 (95.2)	0.07 (0.03)	(0.01, 0.12)			
	Week 16	Tezepelumab	155	148 (95.5)	0.16 (0.03)	(0.11, 0.21)	0.12 (0.04)	(0.05, 0.20)	0.001 *
		Placebo	145	138 (95.2)	0.03 (0.03)	(-0.02, 0.09)			
	Week 24	Tezepelumab	155	146 (94.2)	0.13 (0.03)	(0.08, 0.19)	0.10 (0.04)	(0.02, 0.18)	0.011 *
		Placebo	145	134 (92.4)	0.03 (0.03)	(-0.03, 0.09)			
	Week 36	Tezepelumab	155	137 (88.4)	0.12 (0.03)	(0.07, 0.18)	0.05 (0.04)	(-0.03, 0.13)	0.229
		Placebo	145	129 (89.0)	0.08 (0.03)	(0.02, 0.13)			
	Week 52	Tezepelumab	155	139 (89.7)	0.13 (0.03)	(0.08, 0.19)	0.09 (0.04)	(0.01, 0.17)	0.030 *
		Placebo	145	125 (86.2)	0.04 (0.03)	(-0.01, 0.10)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
25 - < 50 ppb	Week 2	Tezepelumab	111	110 (99.1)	0.19 (0.03)	(0.12, 0.25)	0.17 (0.05)	(0.08, 0.26)	<0.001 *
		Placebo	109	107 (98.2)	0.02 (0.03)	(-0.05, 0.08)			
	Week 4	Tezepelumab	111	111 (100.0)	0.22 (0.03)	(0.16, 0.29)	0.17 (0.05)	(0.08, 0.27)	<0.001 *
		Placebo	109	106 (97.2)	0.05 (0.03)	(-0.01, 0.12)			
	Week 8	Tezepelumab	111	110 (99.1)	0.23 (0.03)	(0.16, 0.29)	0.13 (0.05)	(0.04, 0.22)	0.004 *
		Placebo	109	106 (97.2)	0.10 (0.03)	(0.03, 0.16)			
	Week 12	Tezepelumab	111	108 (97.3)	0.26 (0.03)	(0.19, 0.32)	0.17 (0.05)	(0.08, 0.27)	<0.001 *
		Placebo	109	105 (96.3)	0.08 (0.03)	(0.01, 0.15)			
	Week 16	Tezepelumab	111	111 (100.0)	0.24 (0.03)	(0.17, 0.30)	0.17 (0.05)	(0.07, 0.26)	<0.001 *
		Placebo	109	103 (94.5)	0.07 (0.04)	(-0.00, 0.14)			
	Week 24	Tezepelumab	111	105 (94.6)	0.25 (0.04)	(0.18, 0.33)	0.15 (0.05)	(0.04, 0.25)	0.007 *
		Placebo	109	98 (89.9)	0.11 (0.04)	(0.03, 0.18)			
	Week 36	Tezepelumab	111	104 (93.7)	0.25 (0.04)	(0.17, 0.33)	0.16 (0.06)	(0.05, 0.27)	0.004 *
		Placebo	109	100 (91.7)	0.09 (0.04)	(0.01, 0.16)			
	Week 52	Tezepelumab	111	101 (91.0)	0.27 (0.04)	(0.20, 0.35)	0.21 (0.06)	(0.10, 0.32)	<0.001 *
		Placebo	109	89 (81.7)	0.07 (0.04)	(-0.01, 0.15)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 50 ppb	Week 2	Tezepelumab	111	107 (96.4)	0.24 (0.03)	(0.17, 0.31)	0.14 (0.05)	(0.04, 0.24)	0.005 *
		Placebo	113	107 (94.7)	0.10 (0.03)	(0.03, 0.17)			
	Week 4	Tezepelumab	111	111 (100.0)	0.27 (0.04)	(0.19, 0.35)	0.17 (0.06)	(0.07, 0.28)	0.002 *
		Placebo	113	110 (97.3)	0.10 (0.04)	(0.02, 0.17)			
	Week 8	Tezepelumab	111	109 (98.2)	0.37 (0.04)	(0.29, 0.45)	0.26 (0.06)	(0.14, 0.37)	<0.001 *
		Placebo	113	110 (97.3)	0.11 (0.04)	(0.03, 0.19)			
	Week 12	Tezepelumab	111	109 (98.2)	0.35 (0.04)	(0.27, 0.44)	0.21 (0.06)	(0.09, 0.33)	<0.001 *
		Placebo	113	111 (98.2)	0.14 (0.04)	(0.05, 0.22)			
	Week 16	Tezepelumab	111	105 (94.6)	0.41 (0.04)	(0.33, 0.50)	0.26 (0.06)	(0.14, 0.37)	<0.001 *
		Placebo	113	106 (93.8)	0.16 (0.04)	(0.07, 0.24)			
	Week 24	Tezepelumab	111	102 (91.9)	0.34 (0.04)	(0.26, 0.42)	0.24 (0.06)	(0.13, 0.35)	<0.001 *
		Placebo	113	104 (92.0)	0.11 (0.04)	(0.03, 0.18)			
	Week 36	Tezepelumab	111	99 (89.2)	0.38 (0.04)	(0.30, 0.46)	0.26 (0.06)	(0.14, 0.37)	<0.001 *
		Placebo	113	96 (85.0)	0.12 (0.04)	(0.04, 0.21)			
	Week 52	Tezepelumab	111	94 (84.7)	0.37 (0.04)	(0.29, 0.45)	0.25 (0.06)	(0.14, 0.37)	<0.001 *
		Placebo	113	91 (80.5)	0.12 (0.04)	(0.04, 0.20)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline FENO (cat. Q)									0.058
Q1: < 16 ppb	Week 2	Tezepelumab	93	89 (95.7)	0.16 (0.03)	(0.09, 0.22)	0.12 (0.05)	(0.03, 0.22)	0.010 *
		Placebo	81	73 (90.1)	0.03 (0.03)	(-0.03, 0.10)			
	Week 4	Tezepelumab	93	91 (97.8)	0.18 (0.04)	(0.11, 0.25)	0.12 (0.05)	(0.02, 0.23)	0.025 *
		Placebo	81	80 (98.8)	0.06 (0.04)	(-0.01, 0.14)			
	Week 8	Tezepelumab	93	91 (97.8)	0.16 (0.03)	(0.09, 0.23)	0.12 (0.05)	(0.02, 0.21)	0.018 *
		Placebo	81	78 (96.3)	0.04 (0.04)	(-0.03, 0.11)			
	Week 12	Tezepelumab	93	89 (95.7)	0.15 (0.04)	(0.08, 0.22)	0.06 (0.05)	(-0.04, 0.17)	0.211
		Placebo	81	77 (95.1)	0.09 (0.04)	(0.01, 0.16)			
	Week 16	Tezepelumab	93	88 (94.6)	0.17 (0.04)	(0.10, 0.24)	0.14 (0.05)	(0.04, 0.24)	0.008 *
		Placebo	81	76 (93.8)	0.03 (0.04)	(-0.04, 0.11)			
	Week 24	Tezepelumab	93	88 (94.6)	0.13 (0.04)	(0.05, 0.20)	0.09 (0.05)	(-0.02, 0.20)	0.100
		Placebo	81	74 (91.4)	0.03 (0.04)	(-0.04, 0.11)			
	Week 36	Tezepelumab	93	83 (89.2)	0.13 (0.04)	(0.06, 0.20)	0.06 (0.05)	(-0.04, 0.17)	0.244
		Placebo	81	73 (90.1)	0.07 (0.04)	(-0.01, 0.15)			
	Week 52	Tezepelumab	93	82 (88.2)	0.14 (0.04)	(0.07, 0.21)	0.10 (0.06)	(-0.01, 0.21)	0.074
		Placebo	81	68 (84.0)	0.04 (0.04)	(-0.04, 0.12)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q2: 16 - < 30 ppb	Week 2	Tezepelumab	86	85 (98.8)	0.08 (0.03)	(0.02, 0.13)	0.05 (0.04)	(-0.03, 0.13)	0.206
		Placebo	96	94 (97.9)	0.03 (0.03)	(-0.03, 0.08)			
	Week 4	Tezepelumab	86	85 (98.8)	0.09 (0.03)	(0.03, 0.16)	0.02 (0.05)	(-0.07, 0.11)	0.599
		Placebo	96	94 (97.9)	0.07 (0.03)	(0.01, 0.13)			
	Week 8	Tezepelumab	86	85 (98.8)	0.12 (0.04)	(0.05, 0.19)	0.02 (0.05)	(-0.08, 0.12)	0.679
		Placebo	96	95 (99.0)	0.10 (0.03)	(0.03, 0.17)			
	Week 12	Tezepelumab	86	82 (95.3)	0.14 (0.03)	(0.07, 0.21)	0.10 (0.05)	(0.00, 0.19)	0.043 *
		Placebo	96	93 (96.9)	0.05 (0.03)	(-0.02, 0.11)			
	Week 16	Tezepelumab	86	84 (97.7)	0.13 (0.03)	(0.06, 0.20)	0.08 (0.05)	(-0.01, 0.17)	0.087
		Placebo	96	94 (97.9)	0.05 (0.03)	(-0.02, 0.11)			
	Week 24	Tezepelumab	86	80 (93.0)	0.13 (0.03)	(0.06, 0.19)	0.07 (0.05)	(-0.02, 0.16)	0.149
		Placebo	96	91 (94.8)	0.06 (0.03)	(-0.01, 0.12)			
	Week 36	Tezepelumab	86	78 (90.7)	0.10 (0.04)	(0.03, 0.18)	0.02 (0.05)	(-0.08, 0.13)	0.679
		Placebo	96	86 (89.6)	0.08 (0.04)	(0.01, 0.15)			
	Week 52	Tezepelumab	86	80 (93.0)	0.11 (0.04)	(0.04, 0.19)	0.09 (0.05)	(-0.01, 0.19)	0.063
		Placebo	96	84 (87.5)	0.02 (0.03)	(-0.05, 0.09)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q3: 30 - < 56 ppb	Week 2	Tezepelumab	102	101 (99.0)	0.22 (0.03)	(0.15, 0.29)	0.18 (0.05)	(0.08, 0.29)	<0.001 *
		Placebo	89	86 (96.6)	0.03 (0.04)	(-0.04, 0.11)			
	Week 4	Tezepelumab	102	102 (100.0)	0.26 (0.03)	(0.19, 0.32)	0.18 (0.05)	(0.08, 0.28)	<0.001 *
		Placebo	89	86 (96.6)	0.08 (0.04)	(0.01, 0.15)			
	Week 8	Tezepelumab	102	101 (99.0)	0.27 (0.03)	(0.21, 0.34)	0.17 (0.05)	(0.07, 0.26)	<0.001 *
		Placebo	89	86 (96.6)	0.11 (0.04)	(0.03, 0.18)			
	Week 12	Tezepelumab	102	101 (99.0)	0.28 (0.04)	(0.21, 0.36)	0.19 (0.06)	(0.08, 0.30)	<0.001 *
		Placebo	89	85 (95.5)	0.09 (0.04)	(0.01, 0.17)			
	Week 16	Tezepelumab	102	102 (100.0)	0.28 (0.04)	(0.20, 0.35)	0.23 (0.06)	(0.12, 0.34)	<0.001 *
		Placebo	89	82 (92.1)	0.05 (0.04)	(-0.03, 0.13)			
	Week 24	Tezepelumab	102	98 (96.1)	0.29 (0.04)	(0.21, 0.38)	0.19 (0.06)	(0.07, 0.31)	0.002 *
		Placebo	89	78 (87.6)	0.10 (0.04)	(0.02, 0.19)			
	Week 36	Tezepelumab	102	93 (91.2)	0.30 (0.04)	(0.22, 0.38)	0.23 (0.06)	(0.11, 0.34)	<0.001 *
		Placebo	89	82 (92.1)	0.07 (0.04)	(-0.01, 0.16)			
	Week 52	Tezepelumab	102	91 (89.2)	0.31 (0.04)	(0.23, 0.39)	0.22 (0.06)	(0.10, 0.34)	<0.001 *
		Placebo	89	73 (82.0)	0.10 (0.04)	(0.01, 0.18)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q4: >= 56 ppb	Week 2	Tezepelumab	96	92 (95.8)	0.26 (0.04)	(0.18, 0.33)	0.17 (0.05)	(0.06, 0.27)	0.002 *
		Placebo	101	96 (95.0)	0.09 (0.04)	(0.02, 0.16)			
	Week 4	Tezepelumab	96	96 (100.0)	0.28 (0.04)	(0.19, 0.36)	0.19 (0.06)	(0.07, 0.31)	0.002 *
		Placebo	101	99 (98.0)	0.09 (0.04)	(0.00, 0.17)			
	Week 8	Tezepelumab	96	94 (97.9)	0.39 (0.04)	(0.30, 0.47)	0.29 (0.06)	(0.16, 0.41)	<0.001 *
		Placebo	101	98 (97.0)	0.10 (0.04)	(0.01, 0.19)			
	Week 12	Tezepelumab	96	94 (97.9)	0.37 (0.05)	(0.28, 0.47)	0.23 (0.07)	(0.10, 0.36)	<0.001 *
		Placebo	101	99 (98.0)	0.14 (0.05)	(0.05, 0.23)			
	Week 16	Tezepelumab	96	90 (93.8)	0.43 (0.05)	(0.34, 0.52)	0.25 (0.06)	(0.13, 0.38)	<0.001 *
		Placebo	101	95 (94.1)	0.18 (0.04)	(0.09, 0.26)			
	Week 24	Tezepelumab	96	87 (90.6)	0.35 (0.04)	(0.27, 0.44)	0.25 (0.06)	(0.13, 0.37)	<0.001 *
		Placebo	101	93 (92.1)	0.10 (0.04)	(0.02, 0.18)			
	Week 36	Tezepelumab	96	86 (89.6)	0.39 (0.05)	(0.30, 0.48)	0.25 (0.06)	(0.12, 0.38)	<0.001 *
		Placebo	101	84 (83.2)	0.14 (0.05)	(0.05, 0.23)			
	Week 52	Tezepelumab	96	81 (84.4)	0.40 (0.05)	(0.31, 0.48)	0.26 (0.06)	(0.14, 0.39)	<0.001 *
		Placebo	101	80 (79.2)	0.13 (0.04)	(0.04, 0.22)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Total serum IgE (cat. N)									0.185
Q1: < 53.1 IU/ml	Week 2	Tezepelumab	93	90 (96.8)	0.13 (0.03)	(0.07, 0.18)	0.10 (0.04)	(0.02, 0.18)	0.011 *
		Placebo	96	90 (93.8)	0.02 (0.03)	(-0.03, 0.08)			
	Week 4	Tezepelumab	93	93 (100.0)	0.15 (0.03)	(0.08, 0.21)	0.06 (0.05)	(-0.03, 0.15)	0.207
		Placebo	96	93 (96.9)	0.09 (0.03)	(0.02, 0.15)			
	Week 8	Tezepelumab	93	91 (97.8)	0.16 (0.03)	(0.09, 0.22)	0.08 (0.05)	(-0.01, 0.17)	0.081
		Placebo	96	93 (96.9)	0.08 (0.03)	(0.01, 0.14)			
	Week 12	Tezepelumab	93	90 (96.8)	0.16 (0.04)	(0.09, 0.23)	0.08 (0.05)	(-0.02, 0.18)	0.109
		Placebo	96	92 (95.8)	0.08 (0.04)	(0.01, 0.15)			
	Week 16	Tezepelumab	93	91 (97.8)	0.19 (0.03)	(0.12, 0.25)	0.14 (0.05)	(0.05, 0.23)	0.003 *
		Placebo	96	90 (93.8)	0.05 (0.03)	(-0.01, 0.11)			
	Week 24	Tezepelumab	93	89 (95.7)	0.14 (0.03)	(0.08, 0.20)	0.11 (0.04)	(0.02, 0.19)	0.014 *
		Placebo	96	85 (88.5)	0.03 (0.03)	(-0.03, 0.09)			
	Week 36	Tezepelumab	93	85 (91.4)	0.12 (0.03)	(0.06, 0.19)	0.02 (0.05)	(-0.07, 0.11)	0.629
		Placebo	96	81 (84.4)	0.10 (0.03)	(0.03, 0.16)			
	Week 52	Tezepelumab	93	86 (92.5)	0.14 (0.04)	(0.07, 0.21)	0.11 (0.05)	(0.01, 0.21)	0.040 *
		Placebo	96	79 (82.3)	0.04 (0.04)	(-0.04, 0.11)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q2: 53.1 - < 195.6 IU/ml	Week 2	Tezepelumab	100	100 (100.0)	0.16 (0.03)	(0.11, 0.22)	0.14 (0.04)	(0.06, 0.22)	0.001 *
		Placebo	99	95 (96.0)	0.03 (0.03)	(-0.03, 0.09)			
	Week 4	Tezepelumab	100	98 (98.0)	0.22 (0.03)	(0.16, 0.29)	0.16 (0.05)	(0.06, 0.25)	0.001 *
		Placebo	99	99 (100.0)	0.07 (0.03)	(-0.00, 0.13)			
	Week 8	Tezepelumab	100	98 (98.0)	0.23 (0.03)	(0.17, 0.30)	0.15 (0.05)	(0.06, 0.24)	<0.001 *
		Placebo	99	97 (98.0)	0.08 (0.03)	(0.01, 0.14)			
	Week 12	Tezepelumab	100	97 (97.0)	0.27 (0.04)	(0.19, 0.34)	0.19 (0.05)	(0.08, 0.30)	<0.001 *
		Placebo	99	97 (98.0)	0.08 (0.04)	(0.00, 0.15)			
	Week 16	Tezepelumab	100	95 (95.0)	0.28 (0.04)	(0.21, 0.36)	0.20 (0.05)	(0.09, 0.30)	<0.001 *
		Placebo	99	93 (93.9)	0.09 (0.04)	(0.01, 0.16)			
	Week 24	Tezepelumab	100	94 (94.0)	0.28 (0.04)	(0.21, 0.35)	0.21 (0.05)	(0.11, 0.31)	<0.001 *
		Placebo	99	92 (92.9)	0.07 (0.04)	(-0.00, 0.14)			
	Week 36	Tezepelumab	100	92 (92.0)	0.29 (0.04)	(0.21, 0.36)	0.19 (0.05)	(0.08, 0.30)	<0.001 *
		Placebo	99	91 (91.9)	0.10 (0.04)	(0.02, 0.17)			
	Week 52	Tezepelumab	100	86 (86.0)	0.28 (0.04)	(0.21, 0.36)	0.18 (0.05)	(0.08, 0.29)	<0.001 *
		Placebo	99	84 (84.8)	0.10 (0.04)	(0.03, 0.17)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q3: 195.6 - < 572.4 IU/ml	Week 2	Tezepelumab	103	100 (97.1)	0.21 (0.04)	(0.14, 0.28)	0.24 (0.06)	(0.13, 0.35)	<0.001 *
		Placebo	85	79 (92.9)	-0.03 (0.04)	(-0.11, 0.05)			
	Week 4	Tezepelumab	103	103 (100.0)	0.19 (0.04)	(0.12, 0.26)	0.16 (0.05)	(0.06, 0.27)	0.003 *
		Placebo	85	80 (94.1)	0.03 (0.04)	(-0.05, 0.11)			
	Week 8	Tezepelumab	103	102 (99.0)	0.25 (0.04)	(0.18, 0.32)	0.20 (0.05)	(0.10, 0.31)	<0.001 *
		Placebo	85	83 (97.6)	0.05 (0.04)	(-0.03, 0.12)			
	Week 12	Tezepelumab	103	100 (97.1)	0.25 (0.04)	(0.17, 0.33)	0.18 (0.06)	(0.07, 0.29)	0.002 *
		Placebo	85	81 (95.3)	0.07 (0.04)	(-0.01, 0.16)			
	Week 16	Tezepelumab	103	100 (97.1)	0.24 (0.04)	(0.17, 0.32)	0.21 (0.06)	(0.10, 0.32)	<0.001 *
		Placebo	85	83 (97.6)	0.03 (0.04)	(-0.05, 0.11)			
	Week 24	Tezepelumab	103	94 (91.3)	0.21 (0.04)	(0.14, 0.29)	0.15 (0.06)	(0.03, 0.26)	0.013 *
		Placebo	85	78 (91.8)	0.07 (0.04)	(-0.02, 0.15)			
	Week 36	Tezepelumab	103	89 (86.4)	0.23 (0.04)	(0.15, 0.31)	0.18 (0.06)	(0.06, 0.29)	0.002 *
		Placebo	85	73 (85.9)	0.05 (0.04)	(-0.03, 0.14)			
	Week 52	Tezepelumab	103	91 (88.3)	0.26 (0.04)	(0.18, 0.34)	0.20 (0.06)	(0.08, 0.32)	0.001 *
		Placebo	85	71 (83.5)	0.07 (0.05)	(-0.02, 0.16)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q4: >= 572.4 IU/ml	Week 2	Tezepelumab	84	80 (95.2)	0.21 (0.04)	(0.13, 0.29)	0.04 (0.05)	(-0.07, 0.14)	0.483
		Placebo	91	89 (97.8)	0.17 (0.04)	(0.10, 0.25)			
	Week 4	Tezepelumab	84	83 (98.8)	0.26 (0.05)	(0.17, 0.35)	0.14 (0.06)	(0.01, 0.26)	0.029 *
		Placebo	91	91 (100.0)	0.13 (0.04)	(0.04, 0.21)			
	Week 8	Tezepelumab	84	83 (98.8)	0.30 (0.05)	(0.21, 0.40)	0.15 (0.07)	(0.02, 0.29)	0.030 *
		Placebo	91	88 (96.7)	0.15 (0.05)	(0.06, 0.25)			
	Week 12	Tezepelumab	84	82 (97.6)	0.28 (0.05)	(0.19, 0.37)	0.13 (0.06)	(0.01, 0.26)	0.041 *
		Placebo	91	87 (95.6)	0.15 (0.04)	(0.06, 0.24)			
	Week 16	Tezepelumab	84	81 (96.4)	0.30 (0.05)	(0.20, 0.39)	0.14 (0.07)	(0.01, 0.27)	0.033 *
		Placebo	91	84 (92.3)	0.16 (0.05)	(0.06, 0.25)			
	Week 24	Tezepelumab	84	79 (94.0)	0.28 (0.05)	(0.18, 0.38)	0.15 (0.07)	(0.01, 0.29)	0.037 *
		Placebo	91	84 (92.3)	0.13 (0.05)	(0.03, 0.23)			
	Week 36	Tezepelumab	84	77 (91.7)	0.31 (0.05)	(0.20, 0.41)	0.18 (0.07)	(0.04, 0.32)	0.015 *
		Placebo	91	83 (91.2)	0.13 (0.05)	(0.03, 0.23)			
	Week 52	Tezepelumab	84	74 (88.1)	0.28 (0.05)	(0.18, 0.38)	0.19 (0.07)	(0.05, 0.33)	0.007 *
		Placebo	91	74 (81.3)	0.09 (0.05)	(-0.00, 0.19)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Nasal polyps last 2 years									0.661
Yes	Week 2	Tezepelumab	32	32 (100.0)	0.24 (0.06)	(0.12, 0.37)	0.17 (0.09)	(-0.01, 0.36)	0.069
		Placebo	29	29 (100.0)	0.07 (0.07)	(-0.06, 0.21)			
	Week 4	Tezepelumab	32	32 (100.0)	0.29 (0.08)	(0.13, 0.44)	0.14 (0.11)	(-0.08, 0.36)	0.219
		Placebo	29	29 (100.0)	0.15 (0.08)	(-0.01, 0.31)			
	Week 8	Tezepelumab	32	32 (100.0)	0.34 (0.08)	(0.19, 0.49)	0.19 (0.11)	(-0.03, 0.41)	0.086
		Placebo	29	29 (100.0)	0.15 (0.08)	(-0.01, 0.31)			
	Week 12	Tezepelumab	32	31 (96.9)	0.29 (0.08)	(0.14, 0.44)	0.12 (0.11)	(-0.10, 0.33)	0.290
		Placebo	29	29 (100.0)	0.17 (0.08)	(0.02, 0.33)			
	Week 16	Tezepelumab	32	31 (96.9)	0.31 (0.08)	(0.15, 0.46)	0.15 (0.11)	(-0.07, 0.38)	0.186
		Placebo	29	28 (96.6)	0.16 (0.08)	(-0.01, 0.32)			
	Week 24	Tezepelumab	32	30 (93.8)	0.24 (0.08)	(0.08, 0.40)	0.07 (0.12)	(-0.16, 0.30)	0.536
		Placebo	29	28 (96.6)	0.17 (0.08)	(-0.00, 0.33)			
	Week 36	Tezepelumab	32	30 (93.8)	0.33 (0.07)	(0.19, 0.47)	0.12 (0.10)	(-0.08, 0.32)	0.231
		Placebo	29	27 (93.1)	0.21 (0.07)	(0.06, 0.35)			
	Week 52	Tezepelumab	32	29 (90.6)	0.34 (0.08)	(0.18, 0.50)	0.24 (0.11)	(0.01, 0.47)	0.041 *
		Placebo	29	26 (89.7)	0.10 (0.08)	(-0.07, 0.27)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ALSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 2	Tezepelumab	348	338 (97.1)	0.17 (0.02)	(0.14, 0.21)	0.12 (0.03)	(0.07, 0.17)	<0.001 *
		Placebo	342	324 (94.7)	0.05 (0.02)	(0.01, 0.08)			
	Week 4	Tezepelumab	348	345 (99.1)	0.20 (0.02)	(0.16, 0.23)	0.13 (0.03)	(0.07, 0.18)	<0.001 *
		Placebo	342	334 (97.7)	0.07 (0.02)	(0.03, 0.11)			
	Week 8	Tezepelumab	348	342 (98.3)	0.23 (0.02)	(0.19, 0.26)	0.14 (0.03)	(0.09, 0.20)	<0.001 *
		Placebo	342	332 (97.1)	0.08 (0.02)	(0.04, 0.12)			
	Week 12	Tezepelumab	348	338 (97.1)	0.23 (0.02)	(0.19, 0.27)	0.15 (0.03)	(0.09, 0.21)	<0.001 *
		Placebo	342	328 (95.9)	0.09 (0.02)	(0.05, 0.13)			
	Week 16	Tezepelumab	348	336 (96.6)	0.25 (0.02)	(0.21, 0.29)	0.17 (0.03)	(0.12, 0.23)	<0.001 *
		Placebo	342	322 (94.2)	0.07 (0.02)	(0.03, 0.11)			
	Week 24	Tezepelumab	348	326 (93.7)	0.23 (0.02)	(0.19, 0.27)	0.16 (0.03)	(0.10, 0.22)	<0.001 *
		Placebo	342	311 (90.9)	0.07 (0.02)	(0.03, 0.11)			
	Week 36	Tezepelumab	348	313 (89.9)	0.23 (0.02)	(0.18, 0.27)	0.14 (0.03)	(0.08, 0.20)	<0.001 *
		Placebo	342	301 (88.0)	0.08 (0.02)	(0.04, 0.13)			
	Week 52	Tezepelumab	348	308 (88.5)	0.24 (0.02)	(0.19, 0.28)	0.16 (0.03)	(0.10, 0.22)	<0.001 *
		Placebo	342	282 (82.5)	0.07 (0.02)	(0.03, 0.11)			

Note: DITTL - adult = Dossier Label Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Figure NF2FAC_ALSHK01: Course of FEV1 Pre-BD by sex
DITTL - adult

Sex: Male



Note: DITTL - adult = Dossier Label Intent-to-Treat Set - adults.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source tables: NT2FAC_ALSHK

Figure NF2FAC_ALSHK01: Course of FEV1 Pre-BD by sex
DITTL - adult

Sex: Female



Note: DITTL - adult = Dossier Label Intent-to-Treat Set - adults.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source tables: NT2FAC_ALSHK

Figure NF2FAC_ALSHK03: Course of FEV1 Pre-BD by age
DITTL - adult

Age: < 65 years



Note: DITTL - adult = Dossier Label Intent-to-Treat Set - adults.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source tables: NT2FAC_ALSHK

Figure NF2FAC_ALSHK03: Course of FEV1 Pre-BD by age
DITTL - adult

Age: >= 65 years



Note: DITTL - adult = Dossier Label Intent-to-Treat Set - adults.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source tables: NT2FAC_ALSHK

Figure NF2FAC_ALSHK14: Course of FEV1 Pre-BD by baseline eosinophils - High
DITTL - adult

Baseline eosinophils - High: < 300 cells/uL



Note: DITTL - adult = Dossier Label Intent-to-Treat Set - adults.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source tables: NT2FAC_ALSHK

Figure NF2FAC_ALSHK14: Course of FEV1 Pre-BD by baseline eosinophils - High
DITTL - adult

Baseline eosinophils - High: >= 300 cells/uL



Note: DITTL - adult = Dossier Label Intent-to-Treat Set - adults.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source tables: NT2FAC_ALSHK

Figure NF2FAC_ALSHK36: Course of FEV1 Pre-BD by OCS at baseline
DITTL - adult

OCS at baseline: Yes



Note: DITTL - adult = Dossier Label Intent-to-Treat Set - adults.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source tables: NT2FAC_ALSHK

Figure NF2FAC_ALSHK36: Course of FEV1 Pre-BD by OCS at baseline
DITTL - adult

OCS at baseline: No



Note: DITTL - adult = Dossier Label Intent-to-Treat Set - adults.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source tables: NT2FAC_ALSHK

Figure NF2FAC_ALSHN15: Course of FEV1 Pre-BD by baseline eosinophils (cat. N)
DITTL - adult

Baseline eosinophils (cat. N): < 150 cells/uL



Note: DITTL - adult = Dossier Label Intent-to-Treat Set - adults.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source tables: NT2FAC_ALSHN

Figure NF2FAC_ALSHN15: Course of FEV1 Pre-BD by baseline eosinophils (cat. N)
DITTL - adult

Baseline eosinophils (cat. N): 150 - < 300 cells/uL



Note: DITTL - adult = Dossier Label Intent-to-Treat Set - adults.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source tables: NT2FAC_ALSHN

Figure NF2FAC_ALSHN15: Course of FEV1 Pre-BD by baseline eosinophils (cat. N)
DITTL - adult

Baseline eosinophils (cat. N): 300 - < 450 cells/uL



Note: DITTL - adult = Dossier Label Intent-to-Treat Set - adults.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source tables: NT2FAC_ALSHN

Figure NF2FAC_ALSHN15: Course of FEV1 Pre-BD by baseline eosinophils (cat. N)
DITTL - adult

Baseline eosinophils (cat. N): >= 450 cells/uL



Note: DITTL - adult = Dossier Label Intent-to-Treat Set - adults.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source tables: NT2FAC_ALSHN

Table NT2FAC_IBMH0: Course of FEV1 Pre-BD
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
FEV1 Pre-BD	Baseline	Tezepelumab	55	55 (100.0)	1.80 (0.64)	0.4	1.28	1.79	2.20	3.3	
		Placebo	40	40 (100.0)	1.73 (0.53)	0.8	1.40	1.70	2.07	3.2	
	Week 2	Tezepelumab	55	53 (96.4)	1.86 (0.62)	0.6	1.42	1.80	2.36	3.4	
		Placebo	40	35 (87.5)	1.74 (0.66)	0.8	1.34	1.71	1.97	4.1	
	Week 4	Tezepelumab	55	55 (100.0)	1.85 (0.66)	0.7	1.44	1.75	2.40	3.4	
		Placebo	40	39 (97.5)	1.80 (0.72)	0.9	1.38	1.69	2.02	4.8	
	Week 8	Tezepelumab	55	53 (96.4)	1.85 (0.62)	0.6	1.55	1.79	2.38	3.3	
		Placebo	40	39 (97.5)	1.81 (0.70)	0.8	1.41	1.74	2.03	4.6	
	Week 12	Tezepelumab	55	54 (98.2)	1.86 (0.67)	0.6	1.44	1.76	2.32	3.6	
		Placebo	40	39 (97.5)	1.80 (0.71)	0.8	1.41	1.62	2.14	4.6	
	Week 16	Tezepelumab	55	54 (98.2)	1.91 (0.68)	0.6	1.46	1.84	2.34	3.5	
		Placebo	40	39 (97.5)	1.77 (0.71)	0.8	1.33	1.68	2.04	4.7	
	Week 24	Tezepelumab	55	54 (98.2)	1.84 (0.61)	0.6	1.52	1.83	2.29	3.5	
		Placebo	40	36 (90.0)	1.76 (0.73)	0.8	1.38	1.63	2.09	4.8	
	Week 36	Tezepelumab	55	53 (96.4)	1.83 (0.65)	0.5	1.33	1.83	2.30	3.5	
		Placebo	40	35 (87.5)	1.81 (0.68)	0.9	1.41	1.69	1.94	4.3	
	Week 52	Tezepelumab	55	51 (92.7)	1.83 (0.63)	0.7	1.43	1.79	2.26	3.4	
		Placebo	40	35 (87.5)	1.76 (0.67)	0.9	1.24	1.66	2.15	4.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBMH0: Course of FEV1 Pre-BD
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in FEV1 Pre-BD	Week 2	Tezepelumab	55	53 (96.4)	0.05 (0.24)	-0.7	-0.01	0.05	0.15	0.8	0.14 [-0.29, 0.57]
		Placebo	40	35 (87.5)	0.01 (0.24)	-0.4	-0.09	-0.01	0.08	0.9	
	Week 4	Tezepelumab	55	55 (100.0)	0.05 (0.35)	-0.9	-0.09	0.04	0.17	1.7	-0.07 [-0.48, 0.34]
		Placebo	40	39 (97.5)	0.08 (0.31)	-0.3	-0.05	0.04	0.12	1.6	
	Week 8	Tezepelumab	55	53 (96.4)	0.08 (0.30)	-0.8	-0.07	0.04	0.19	1.2	0.06 [-0.36, 0.47]
		Placebo	40	39 (97.5)	0.07 (0.32)	-0.8	-0.07	0.04	0.18	1.4	
	Week 12	Tezepelumab	55	54 (98.2)	0.06 (0.29)	-0.7	-0.09	0.05	0.17	1.4	-0.03 [-0.44, 0.38]
		Placebo	40	39 (97.5)	0.07 (0.29)	-0.4	-0.06	0.02	0.20	1.4	
	Week 16	Tezepelumab	55	54 (98.2)	0.10 (0.33)	-0.6	-0.05	0.10	0.22	1.6	0.19 [-0.22, 0.60]
		Placebo	40	39 (97.5)	0.03 (0.33)	-0.6	-0.10	0.01	0.18	1.4	
	Week 24	Tezepelumab	55	54 (98.2)	0.07 (0.27)	-0.6	-0.11	0.00	0.22	1.0	0.14 [-0.29, 0.56]
		Placebo	40	36 (90.0)	0.02 (0.35)	-0.5	-0.11	0.03	0.09	1.6	
	Week 36	Tezepelumab	55	53 (96.4)	0.05 (0.34)	-0.8	-0.12	0.04	0.21	1.1	-0.12 [-0.55, 0.30]
		Placebo	40	35 (87.5)	0.09 (0.27)	-0.3	-0.09	0.06	0.29	1.1	
	Week 52	Tezepelumab	55	51 (92.7)	0.04 (0.35)	-1.0	-0.07	0.01	0.23	1.0	-0.03 [-0.46, 0.40]
		Placebo	40	35 (87.5)	0.05 (0.26)	-0.5	-0.08	0.06	0.15	0.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBMC0: Change from baseline in FEV1 Pre-BD - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Tezepelumab	55	53 (96.4)	0.05 (0.03)	(-0.01, 0.12)	0.06 (0.05)	(-0.04, 0.16)	0.260
	Placebo	40	35 (87.5)	-0.01 (0.04)	(-0.08, 0.07)			
Week 4	Tezepelumab	55	55 (100.0)	0.06 (0.05)	(-0.03, 0.15)	-0.01 (0.07)	(-0.15, 0.13)	0.857
	Placebo	40	39 (97.5)	0.07 (0.05)	(-0.04, 0.17)			
Week 8	Tezepelumab	55	53 (96.4)	0.08 (0.04)	(-0.01, 0.16)	0.01 (0.06)	(-0.12, 0.14)	0.880
	Placebo	40	39 (97.5)	0.07 (0.05)	(-0.03, 0.16)			
Week 12	Tezepelumab	55	54 (98.2)	0.06 (0.04)	(-0.01, 0.14)	-0.00 (0.06)	(-0.12, 0.12)	0.963
	Placebo	40	39 (97.5)	0.07 (0.05)	(-0.02, 0.16)			
Week 16	Tezepelumab	55	54 (98.2)	0.10 (0.04)	(0.01, 0.19)	0.07 (0.07)	(-0.06, 0.21)	0.297
	Placebo	40	39 (97.5)	0.03 (0.05)	(-0.07, 0.13)			
Week 24	Tezepelumab	55	54 (98.2)	0.07 (0.04)	(-0.01, 0.15)	0.04 (0.06)	(-0.08, 0.17)	0.516
	Placebo	40	36 (90.0)	0.03 (0.05)	(-0.07, 0.12)			
Week 36	Tezepelumab	55	53 (96.4)	0.05 (0.04)	(-0.03, 0.14)	-0.03 (0.06)	(-0.16, 0.10)	0.614
	Placebo	40	35 (87.5)	0.09 (0.05)	(-0.01, 0.19)			
Week 52	Tezepelumab	55	51 (92.7)	0.04 (0.04)	(-0.04, 0.13)	-0.00 (0.07)	(-0.13, 0.13)	0.972
	Placebo	40	35 (87.5)	0.05 (0.05)	(-0.05, 0.14)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Figure NF2FAC_IBMG0: Course of FEV1 Pre-BD
DITTB



Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source table: NT2FAC_IBMH0
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Absolute values	Baseline	Tezepelumab	19	19 (100.0)	2.06 (0.75)	0.6	1.47	2.12	2.62	3.3	
			Placebo	8	8 (100.0)	2.19 (0.55)	1.4	1.88	2.11	2.46	3.2	
		Week 2	Tezepelumab	19	19 (100.0)	2.10 (0.74)	0.7	1.55	2.13	2.74	3.4	
			Placebo	8	8 (100.0)	2.21 (0.86)	1.3	1.75	1.83	2.53	4.1	
		Week 4	Tezepelumab	19	19 (100.0)	2.15 (0.79)	0.7	1.61	2.17	2.69	3.4	
			Placebo	8	8 (100.0)	2.35 (1.11)	1.4	1.67	1.91	2.69	4.8	
		Week 8	Tezepelumab	19	18 (94.7)	2.10 (0.73)	0.7	1.63	2.18	2.71	3.3	
			Placebo	8	8 (100.0)	2.36 (1.08)	1.1	1.65	2.27	2.69	4.6	
		Week 12	Tezepelumab	19	19 (100.0)	2.20 (0.80)	0.7	1.62	2.21	2.74	3.6	
			Placebo	8	8 (100.0)	2.39 (1.02)	1.4	1.69	2.12	2.77	4.6	
		Week 16	Tezepelumab	19	19 (100.0)	2.14 (0.83)	0.6	1.54	2.27	2.73	3.5	
			Placebo	8	8 (100.0)	2.37 (1.04)	1.5	1.72	1.94	2.74	4.7	
		Week 24	Tezepelumab	19	18 (94.7)	2.14 (0.76)	0.6	1.61	2.34	2.64	3.5	
			Placebo	8	8 (100.0)	2.36 (1.09)	1.5	1.65	1.96	2.70	4.8	
		Week 36	Tezepelumab	19	18 (94.7)	2.05 (0.80)	0.5	1.51	2.04	2.78	3.5	
			Placebo	8	8 (100.0)	2.32 (0.97)	1.4	1.66	1.93	2.83	4.3	
		Week 52	Tezepelumab	19	18 (94.7)	2.07 (0.71)	0.9	1.60	2.22	2.47	3.4	
			Placebo	8	7 (87.5)	2.38 (0.89)	1.5	1.62	2.23	2.79	4.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Change from baseline	Week 2	Tezepelumab	19	19 (100.0)	0.04 (0.28)	-0.7	-0.02	0.05	0.12	0.8	0.08 [-0.74, 0.91]
			Placebo	8	8 (100.0)	0.01 (0.39)	-0.3	-0.22	-0.13	0.13	0.9	
		Week 4	Tezepelumab	19	19 (100.0)	0.09 (0.44)	-0.3	-0.13	0.03	0.08	1.7	-0.13 [-0.96, 0.69]
			Placebo	8	8 (100.0)	0.16 (0.63)	-0.3	-0.29	0.05	0.24	1.6	
		Week 8	Tezepelumab	19	18 (94.7)	0.10 (0.34)	-0.5	-0.08	0.06	0.19	1.2	-0.15 [-0.99, 0.68]
			Placebo	8	8 (100.0)	0.17 (0.61)	-0.8	-0.12	0.11	0.39	1.4	
		Week 12	Tezepelumab	19	19 (100.0)	0.14 (0.39)	-0.2	-0.17	0.08	0.19	1.4	-0.15 [-0.98, 0.68]
			Placebo	8	8 (100.0)	0.20 (0.52)	-0.4	0.00	0.03	0.31	1.4	
		Week 16	Tezepelumab	19	19 (100.0)	0.08 (0.42)	-0.5	-0.07	0.02	0.15	1.6	-0.21 [-1.04, 0.61]
			Placebo	8	8 (100.0)	0.18 (0.56)	-0.5	-0.11	0.05	0.28	1.4	
		Week 24	Tezepelumab	19	18 (94.7)	0.14 (0.33)	-0.4	-0.10	0.12	0.29	1.0	-0.07 [-0.90, 0.76]
			Placebo	8	8 (100.0)	0.17 (0.61)	-0.3	-0.23	0.01	0.25	1.6	
		Week 36	Tezepelumab	19	18 (94.7)	0.05 (0.42)	-0.8	-0.13	-0.04	0.25	1.1	-0.17 [-1.01, 0.66]
			Placebo	8	8 (100.0)	0.13 (0.47)	-0.3	-0.19	-0.10	0.37	1.1	
		Week 52	Tezepelumab	19	18 (94.7)	0.07 (0.40)	-0.8	-0.15	0.07	0.27	1.0	-0.25 [-1.12, 0.63]
			Placebo	8	7 (87.5)	0.17 (0.43)	-0.5	-0.20	0.15	0.48	0.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Absolute values	Baseline	Tezepelumab	36	36 (100.0)	1.66 (0.53)	0.4	1.28	1.67	2.04	2.8	
			Placebo	32	32 (100.0)	1.61 (0.46)	0.8	1.36	1.57	1.88	2.8	
		Week 2	Tezepelumab	36	34 (94.4)	1.72 (0.51)	0.6	1.32	1.75	2.06	2.5	
			Placebo	32	27 (84.4)	1.60 (0.53)	0.8	1.15	1.59	1.93	2.8	
		Week 4	Tezepelumab	36	36 (100.0)	1.70 (0.54)	0.7	1.37	1.68	2.04	2.6	
			Placebo	32	31 (96.9)	1.66 (0.52)	0.9	1.31	1.57	1.90	3.0	
		Week 8	Tezepelumab	36	35 (97.2)	1.72 (0.51)	0.6	1.30	1.68	2.11	2.7	
			Placebo	32	31 (96.9)	1.67 (0.51)	0.8	1.40	1.69	1.94	2.8	
		Week 12	Tezepelumab	36	35 (97.2)	1.67 (0.51)	0.6	1.32	1.63	2.08	2.5	
			Placebo	32	31 (96.9)	1.65 (0.52)	0.8	1.31	1.60	1.82	3.0	
		Week 16	Tezepelumab	36	35 (97.2)	1.78 (0.55)	0.6	1.39	1.67	2.22	3.0	
			Placebo	32	31 (96.9)	1.61 (0.51)	0.8	1.31	1.64	1.78	3.0	
		Week 24	Tezepelumab	36	36 (100.0)	1.69 (0.46)	0.8	1.18	1.71	2.05	2.4	
			Placebo	32	28 (87.5)	1.59 (0.49)	0.8	1.25	1.50	2.05	2.7	
		Week 36	Tezepelumab	36	35 (97.2)	1.72 (0.53)	0.8	1.25	1.65	2.14	2.8	
			Placebo	32	27 (84.4)	1.65 (0.50)	0.9	1.38	1.57	1.81	3.0	
		Week 52	Tezepelumab	36	33 (91.7)	1.71 (0.54)	0.7	1.37	1.64	2.11	2.9	
			Placebo	32	28 (87.5)	1.61 (0.51)	0.9	1.15	1.61	1.82	2.9	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Change from baseline	Week 2	Tezepelumab	36	34 (94.4)	0.05 (0.22)	-0.6	0.00	0.05	0.15	0.5	0.18 [-0.33, 0.69]
			Placebo	32	27 (84.4)	0.01 (0.19)	-0.4	-0.07	0.00	0.08	0.5	
		Week 4	Tezepelumab	36	36 (100.0)	0.04 (0.29)	-0.9	-0.08	0.05	0.25	0.6	-0.08 [-0.56, 0.40]
			Placebo	32	31 (96.9)	0.06 (0.17)	-0.3	-0.04	0.04	0.12	0.5	
		Week 8	Tezepelumab	36	35 (97.2)	0.07 (0.28)	-0.8	-0.07	0.04	0.20	0.7	0.14 [-0.34, 0.62]
			Placebo	32	31 (96.9)	0.04 (0.20)	-0.5	-0.06	0.04	0.13	0.5	
		Week 12	Tezepelumab	36	35 (97.2)	0.02 (0.23)	-0.7	-0.05	0.04	0.17	0.5	-0.07 [-0.55, 0.41]
			Placebo	32	31 (96.9)	0.04 (0.19)	-0.4	-0.06	0.00	0.19	0.4	
		Week 16	Tezepelumab	36	35 (97.2)	0.11 (0.27)	-0.6	-0.02	0.14	0.28	0.7	0.43 [-0.06, 0.92]
			Placebo	32	31 (96.9)	-0.00 (0.24)	-0.6	-0.10	0.01	0.14	0.5	
		Week 24	Tezepelumab	36	36 (100.0)	0.03 (0.23)	-0.6	-0.12	0.00	0.18	0.7	0.20 [-0.30, 0.70]
			Placebo	32	28 (87.5)	-0.02 (0.22)	-0.5	-0.09	0.03	0.09	0.4	
		Week 36	Tezepelumab	36	35 (97.2)	0.05 (0.29)	-0.7	-0.12	0.04	0.21	0.6	-0.11 [-0.61, 0.39]
			Placebo	32	27 (84.4)	0.08 (0.19)	-0.3	-0.07	0.07	0.22	0.4	
		Week 52	Tezepelumab	36	33 (91.7)	0.03 (0.32)	-1.0	-0.06	0.01	0.11	0.7	0.02 [-0.48, 0.52]
			Placebo	32	28 (87.5)	0.02 (0.20)	-0.4	-0.08	0.04	0.13	0.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Absolute values	Baseline	Tezepelumab	46	46 (100.0)	1.85 (0.67)	0.4	1.41	1.91	2.27	3.3	
			Placebo	33	33 (100.0)	1.74 (0.56)	0.8	1.41	1.69	2.10	3.2	
		Week 2	Tezepelumab	46	45 (97.8)	1.90 (0.65)	0.6	1.53	1.94	2.42	3.4	
			Placebo	33	29 (87.9)	1.75 (0.70)	0.8	1.34	1.71	1.97	4.1	
		Week 4	Tezepelumab	46	46 (100.0)	1.92 (0.69)	0.7	1.61	1.99	2.46	3.4	
			Placebo	33	33 (100.0)	1.82 (0.76)	0.9	1.38	1.69	2.02	4.8	
		Week 8	Tezepelumab	46	44 (95.7)	1.89 (0.65)	0.6	1.49	1.91	2.41	3.3	
			Placebo	33	33 (100.0)	1.79 (0.75)	0.8	1.40	1.74	1.98	4.6	
		Week 12	Tezepelumab	46	45 (97.8)	1.92 (0.70)	0.6	1.46	2.06	2.37	3.6	
			Placebo	33	32 (97.0)	1.82 (0.77)	0.8	1.40	1.61	2.20	4.6	
		Week 16	Tezepelumab	46	46 (100.0)	1.97 (0.70)	0.6	1.52	1.97	2.41	3.5	
			Placebo	33	32 (97.0)	1.78 (0.77)	0.8	1.32	1.71	2.07	4.7	
		Week 24	Tezepelumab	46	45 (97.8)	1.89 (0.63)	0.6	1.59	1.91	2.32	3.5	
			Placebo	33	29 (87.9)	1.78 (0.79)	0.8	1.36	1.63	2.11	4.8	
		Week 36	Tezepelumab	46	45 (97.8)	1.87 (0.67)	0.5	1.33	1.90	2.32	3.5	
			Placebo	33	28 (84.8)	1.85 (0.74)	0.9	1.44	1.70	2.15	4.3	
		Week 52	Tezepelumab	46	43 (93.5)	1.89 (0.65)	0.7	1.54	1.97	2.27	3.4	
			Placebo	33	29 (87.9)	1.78 (0.72)	0.9	1.24	1.68	2.15	4.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Change from baseline	Week 2	Tezepelumab	46	45 (97.8)	0.05 (0.26)	-0.7	-0.02	0.05	0.17	0.8	0.20 [-0.27, 0.67]
			Placebo	33	29 (87.9)	0.00 (0.25)	-0.4	-0.09	-0.06	0.06	0.9	
		Week 4	Tezepelumab	46	46 (100.0)	0.07 (0.37)	-0.9	-0.08	0.05	0.22	1.7	-0.03 [-0.47, 0.42]
			Placebo	33	33 (100.0)	0.08 (0.33)	-0.3	-0.05	0.04	0.12	1.6	
		Week 8	Tezepelumab	46	44 (95.7)	0.08 (0.31)	-0.8	-0.08	0.03	0.18	1.2	0.09 [-0.36, 0.55]
			Placebo	33	33 (100.0)	0.05 (0.33)	-0.8	-0.07	0.04	0.13	1.4	
		Week 12	Tezepelumab	46	45 (97.8)	0.08 (0.31)	-0.7	-0.03	0.07	0.18	1.4	0.05 [-0.40, 0.51]
			Placebo	33	32 (97.0)	0.07 (0.31)	-0.4	-0.06	0.00	0.20	1.4	
		Week 16	Tezepelumab	46	46 (100.0)	0.12 (0.34)	-0.6	-0.02	0.14	0.28	1.6	0.26 [-0.19, 0.72]
			Placebo	33	32 (97.0)	0.03 (0.34)	-0.6	-0.08	0.01	0.14	1.4	
		Week 24	Tezepelumab	46	45 (97.8)	0.08 (0.28)	-0.6	-0.10	0.00	0.23	1.0	0.17 [-0.30, 0.64]
			Placebo	33	29 (87.9)	0.02 (0.37)	-0.5	-0.11	0.03	0.09	1.6	
		Week 36	Tezepelumab	46	45 (97.8)	0.06 (0.36)	-0.8	-0.15	0.04	0.24	1.1	-0.18 [-0.65, 0.29]
			Placebo	33	28 (84.8)	0.12 (0.28)	-0.3	-0.06	0.07	0.30	1.1	
		Week 52	Tezepelumab	46	43 (93.5)	0.06 (0.38)	-1.0	-0.06	0.08	0.27	1.0	-0.03 [-0.50, 0.44]
			Placebo	33	29 (87.9)	0.07 (0.25)	-0.4	-0.07	0.08	0.15	0.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	1.55 (0.40)	1.2	1.28	1.44	1.74	2.4	
			Placebo	7	7 (100.0)	1.66 (0.37)	1.1	1.35	1.85	1.89	2.1	
		Week 2	Tezepelumab	9	8 (88.9)	1.61 (0.37)	1.2	1.35	1.54	1.74	2.4	
			Placebo	7	6 (85.7)	1.69 (0.45)	1.0	1.39	1.75	1.93	2.3	
		Week 4	Tezepelumab	9	9 (100.0)	1.52 (0.42)	0.9	1.27	1.53	1.64	2.5	
			Placebo	7	6 (85.7)	1.68 (0.46)	1.1	1.43	1.63	1.99	2.4	
		Week 8	Tezepelumab	9	9 (100.0)	1.65 (0.35)	1.2	1.58	1.67	1.68	2.4	
			Placebo	7	6 (85.7)	1.92 (0.40)	1.5	1.54	1.81	2.30	2.5	
		Week 12	Tezepelumab	9	9 (100.0)	1.51 (0.31)	1.2	1.23	1.49	1.55	2.2	
			Placebo	7	7 (100.0)	1.75 (0.35)	1.3	1.41	1.73	2.13	2.3	
		Week 16	Tezepelumab	9	8 (88.9)	1.54 (0.39)	1.1	1.33	1.49	1.62	2.4	
			Placebo	7	7 (100.0)	1.70 (0.32)	1.3	1.42	1.66	1.90	2.3	
		Week 24	Tezepelumab	9	9 (100.0)	1.57 (0.35)	1.1	1.40	1.60	1.71	2.3	
			Placebo	7	7 (100.0)	1.70 (0.42)	1.1	1.42	1.51	2.07	2.3	
		Week 36	Tezepelumab	9	8 (88.9)	1.61 (0.42)	1.2	1.35	1.53	1.74	2.5	
			Placebo	7	7 (100.0)	1.64 (0.38)	1.1	1.38	1.59	1.92	2.3	
		Week 52	Tezepelumab	9	8 (88.9)	1.54 (0.42)	1.1	1.24	1.44	1.73	2.4	
			Placebo	7	6 (85.7)	1.67 (0.39)	1.1	1.57	1.62	1.83	2.3	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Change from baseline	Week 2	Tezepelumab	9	8 (88.9)	0.01 (0.10)	-0.2	-0.00	0.05	0.07	0.1	-0.30 [-1.36, 0.77]
			Placebo	7	6 (85.7)	0.07 (0.24)	-0.3	-0.05	0.04	0.16	0.5	
		Week 4	Tezepelumab	9	9 (100.0)	-0.03 (0.18)	-0.3	-0.13	-0.04	0.06	0.3	-0.40 [-1.45, 0.64]
			Placebo	7	6 (85.7)	0.06 (0.26)	-0.3	-0.03	0.04	0.10	0.5	
		Week 8	Tezepelumab	9	9 (100.0)	0.10 (0.21)	-0.2	-0.05	0.05	0.25	0.5	-0.26 [-1.30, 0.78]
			Placebo	7	6 (85.7)	0.16 (0.23)	-0.1	-0.03	0.12	0.40	0.4	
		Week 12	Tezepelumab	9	9 (100.0)	-0.04 (0.14)	-0.2	-0.17	-0.05	0.05	0.2	-0.81 [-1.84, 0.22]
			Placebo	7	7 (100.0)	0.09 (0.18)	-0.1	-0.07	0.06	0.22	0.4	
		Week 16	Tezepelumab	9	8 (88.9)	-0.05 (0.15)	-0.4	-0.13	-0.02	0.06	0.1	-0.40 [-1.42, 0.63]
			Placebo	7	7 (100.0)	0.04 (0.29)	-0.5	-0.20	0.07	0.26	0.4	
		Week 24	Tezepelumab	9	9 (100.0)	0.02 (0.22)	-0.4	-0.12	0.02	0.16	0.4	-0.09 [-1.08, 0.90]
			Placebo	7	7 (100.0)	0.04 (0.23)	-0.4	-0.04	0.06	0.13	0.4	
		Week 36	Tezepelumab	9	8 (88.9)	0.02 (0.10)	-0.1	-0.05	0.01	0.09	0.2	0.21 [-0.81, 1.22]
			Placebo	7	7 (100.0)	-0.02 (0.23)	-0.3	-0.19	-0.08	0.08	0.4	
		Week 52	Tezepelumab	9	8 (88.9)	-0.06 (0.09)	-0.2	-0.12	-0.05	0.00	0.1	-0.07 [-1.13, 0.99]
			Placebo	7	6 (85.7)	-0.04 (0.32)	-0.5	-0.26	-0.01	0.08	0.4	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Absolute values	Baseline	Tezepelumab	31	31 (100.0)	1.85 (0.65)	0.4	1.48	1.87	2.39	3.2	
			Placebo	27	27 (100.0)	1.75 (0.55)	0.8	1.41	1.77	2.10	3.2	
		Week 2	Tezepelumab	31	31 (100.0)	1.89 (0.64)	0.6	1.56	1.80	2.38	3.4	
			Placebo	27	24 (88.9)	1.74 (0.72)	0.8	1.32	1.71	1.89	4.1	
		Week 4	Tezepelumab	31	31 (100.0)	1.88 (0.68)	0.7	1.61	1.94	2.24	3.4	
			Placebo	27	26 (96.3)	1.85 (0.79)	0.9	1.43	1.76	2.02	4.8	
		Week 8	Tezepelumab	31	31 (100.0)	1.91 (0.67)	0.6	1.57	1.90	2.43	3.3	
			Placebo	27	26 (96.3)	1.87 (0.76)	0.8	1.53	1.76	2.03	4.6	
		Week 12	Tezepelumab	31	31 (100.0)	1.90 (0.71)	0.6	1.45	1.83	2.39	3.6	
			Placebo	27	27 (100.0)	1.84 (0.74)	0.8	1.43	1.69	2.14	4.6	
		Week 16	Tezepelumab	31	31 (100.0)	1.93 (0.71)	0.6	1.52	1.85	2.39	3.5	
			Placebo	27	27 (100.0)	1.81 (0.75)	0.8	1.42	1.71	2.04	4.7	
		Week 24	Tezepelumab	31	31 (100.0)	1.92 (0.63)	0.8	1.57	1.89	2.38	3.5	
			Placebo	27	24 (88.9)	1.78 (0.81)	0.8	1.35	1.63	2.09	4.8	
		Week 36	Tezepelumab	31	31 (100.0)	1.92 (0.69)	0.8	1.33	1.86	2.50	3.5	
			Placebo	27	25 (92.6)	1.83 (0.72)	0.9	1.43	1.69	1.94	4.3	
		Week 52	Tezepelumab	31	31 (100.0)	1.87 (0.68)	0.7	1.43	1.80	2.39	3.4	
			Placebo	27	23 (85.2)	1.77 (0.71)	0.9	1.15	1.68	2.15	4.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Change from baseline	Week 2	Tezepelumab	31	31 (100.0)	0.04 (0.29)	-0.7	-0.02	0.05	0.17	0.8	0.04 [-0.49, 0.58]
			Placebo	27	24 (88.9)	0.02 (0.27)	-0.3	-0.09	-0.03	0.05	0.9	
		Week 4	Tezepelumab	31	31 (100.0)	0.03 (0.41)	-0.9	-0.13	0.03	0.15	1.7	-0.19 [-0.71, 0.33]
			Placebo	27	26 (96.3)	0.11 (0.36)	-0.3	-0.01	0.08	0.12	1.6	
		Week 8	Tezepelumab	31	31 (100.0)	0.06 (0.35)	-0.8	-0.08	0.04	0.19	1.2	-0.07 [-0.59, 0.45]
			Placebo	27	26 (96.3)	0.09 (0.38)	-0.8	-0.07	0.05	0.20	1.4	
		Week 12	Tezepelumab	31	31 (100.0)	0.05 (0.36)	-0.7	-0.18	0.03	0.18	1.4	-0.12 [-0.64, 0.40]
			Placebo	27	27 (100.0)	0.09 (0.31)	-0.4	-0.04	0.02	0.20	1.4	
		Week 16	Tezepelumab	31	31 (100.0)	0.08 (0.37)	-0.6	-0.13	0.09	0.19	1.6	0.05 [-0.47, 0.57]
			Placebo	27	27 (100.0)	0.06 (0.36)	-0.6	-0.10	0.01	0.18	1.4	
		Week 24	Tezepelumab	31	31 (100.0)	0.07 (0.32)	-0.6	-0.12	0.02	0.29	1.0	0.14 [-0.39, 0.68]
			Placebo	27	24 (88.9)	0.02 (0.40)	-0.5	-0.23	-0.00	0.09	1.6	
		Week 36	Tezepelumab	31	31 (100.0)	0.07 (0.40)	-0.8	-0.13	0.03	0.29	1.1	-0.03 [-0.56, 0.50]
			Placebo	27	25 (92.6)	0.08 (0.29)	-0.3	-0.09	0.04	0.19	1.1	
		Week 52	Tezepelumab	31	31 (100.0)	0.02 (0.41)	-1.0	-0.09	0.00	0.18	1.0	-0.09 [-0.63, 0.45]
			Placebo	27	23 (85.2)	0.06 (0.29)	-0.5	-0.11	0.04	0.19	0.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Absolute values	Baseline	Tezepelumab	24	24 (100.0)	1.73 (0.63)	0.6	1.28	1.69	2.12	3.3	
			Placebo	13	13 (100.0)	1.68 (0.50)	0.9	1.39	1.59	2.04	2.6	
		Week 2	Tezepelumab	24	22 (91.7)	1.82 (0.61)	0.7	1.32	1.83	2.29	2.9	
			Placebo	13	11 (84.6)	1.75 (0.54)	1.0	1.35	1.65	2.26	2.6	
		Week 4	Tezepelumab	24	24 (100.0)	1.82 (0.66)	0.7	1.36	1.67	2.44	3.3	
			Placebo	13	13 (100.0)	1.70 (0.58)	1.0	1.32	1.57	1.85	2.7	
		Week 8	Tezepelumab	24	22 (91.7)	1.77 (0.53)	0.7	1.30	1.66	2.11	2.7	
			Placebo	13	13 (100.0)	1.71 (0.60)	0.8	1.41	1.59	1.94	2.7	
		Week 12	Tezepelumab	24	23 (95.8)	1.79 (0.62)	0.7	1.32	1.70	2.24	3.3	
			Placebo	13	12 (92.3)	1.71 (0.64)	0.9	1.34	1.57	2.14	2.8	
		Week 16	Tezepelumab	24	23 (95.8)	1.87 (0.64)	0.6	1.43	1.60	2.34	3.1	
			Placebo	13	12 (92.3)	1.66 (0.61)	0.9	1.32	1.52	1.95	2.9	
		Week 24	Tezepelumab	24	23 (95.8)	1.72 (0.57)	0.6	1.18	1.61	2.26	2.9	
			Placebo	13	12 (92.3)	1.72 (0.55)	1.0	1.38	1.63	1.96	2.7	
		Week 36	Tezepelumab	24	22 (91.7)	1.71 (0.57)	0.5	1.28	1.58	2.14	3.1	
			Placebo	13	10 (76.9)	1.76 (0.62)	1.0	1.41	1.64	1.81	2.9	
		Week 52	Tezepelumab	24	20 (83.3)	1.77 (0.55)	0.9	1.41	1.67	2.20	3.1	
			Placebo	13	12 (92.3)	1.74 (0.61)	1.0	1.36	1.58	2.14	2.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Change from baseline	Week 2	Tezepelumab	24	22 (91.7)	0.06 (0.15)	-0.3	0.01	0.06	0.12	0.4	0.46 [-0.27, 1.19]
			Placebo	13	11 (84.6)	-0.02 (0.19)	-0.4	-0.10	-0.01	0.10	0.3	
		Week 4	Tezepelumab	24	24 (100.0)	0.09 (0.24)	-0.4	-0.08	0.05	0.30	0.6	0.29 [-0.39, 0.97]
			Placebo	13	13 (100.0)	0.02 (0.20)	-0.3	-0.05	-0.02	0.07	0.4	
		Week 8	Tezepelumab	24	22 (91.7)	0.12 (0.20)	-0.1	-0.01	0.06	0.25	0.7	0.50 [-0.20, 1.19]
			Placebo	13	13 (100.0)	0.03 (0.15)	-0.3	-0.06	0.00	0.08	0.4	
		Week 12	Tezepelumab	24	23 (95.8)	0.08 (0.19)	-0.2	-0.05	0.05	0.15	0.7	0.26 [-0.44, 0.96]
			Placebo	13	12 (92.3)	0.02 (0.24)	-0.4	-0.13	0.01	0.17	0.4	
		Week 16	Tezepelumab	24	23 (95.8)	0.12 (0.27)	-0.6	0.01	0.10	0.28	0.7	0.56 [-0.15, 1.28]
			Placebo	13	12 (92.3)	-0.03 (0.24)	-0.6	-0.09	-0.03	0.08	0.3	
		Week 24	Tezepelumab	24	23 (95.8)	0.06 (0.20)	-0.2	-0.07	0.00	0.16	0.6	0.12 [-0.57, 0.82]
			Placebo	13	12 (92.3)	0.03 (0.21)	-0.5	-0.01	0.03	0.10	0.4	
		Week 36	Tezepelumab	24	22 (91.7)	0.03 (0.22)	-0.5	-0.11	0.05	0.20	0.4	-0.39 [-1.15, 0.36]
			Placebo	13	10 (76.9)	0.11 (0.22)	-0.2	-0.08	0.14	0.30	0.4	
		Week 52	Tezepelumab	24	20 (83.3)	0.08 (0.24)	-0.4	-0.04	0.09	0.25	0.5	0.11 [-0.61, 0.82]
			Placebo	13	12 (92.3)	0.05 (0.20)	-0.3	-0.08	0.10	0.14	0.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Absolute values	Baseline	Tezepelumab	34	34 (100.0)	1.92 (0.62)	0.8	1.41	1.92	2.39	3.3	
			Placebo	28	28 (100.0)	1.77 (0.60)	0.8	1.38	1.76	2.17	3.2	
		Week 2	Tezepelumab	34	33 (97.1)	2.02 (0.62)	0.9	1.56	1.97	2.52	3.4	
			Placebo	28	24 (85.7)	1.83 (0.75)	0.8	1.34	1.70	2.29	4.1	
		Week 4	Tezepelumab	34	34 (100.0)	2.00 (0.69)	0.7	1.61	2.01	2.50	3.4	
			Placebo	28	27 (96.4)	1.88 (0.84)	0.9	1.32	1.64	2.35	4.8	
		Week 8	Tezepelumab	34	33 (97.1)	1.99 (0.63)	0.7	1.58	1.99	2.53	3.3	
			Placebo	28	27 (96.4)	1.87 (0.80)	0.8	1.40	1.74	2.30	4.6	
		Week 12	Tezepelumab	34	34 (100.0)	1.98 (0.70)	0.8	1.44	2.07	2.39	3.6	
			Placebo	28	27 (96.4)	1.88 (0.81)	0.8	1.37	1.61	2.46	4.6	
		Week 16	Tezepelumab	34	33 (97.1)	2.09 (0.67)	0.9	1.54	2.16	2.57	3.5	
			Placebo	28	27 (96.4)	1.87 (0.81)	0.9	1.32	1.66	2.18	4.7	
		Week 24	Tezepelumab	34	33 (97.1)	1.93 (0.63)	0.8	1.52	1.94	2.32	3.5	
			Placebo	28	26 (92.9)	1.85 (0.81)	0.8	1.40	1.66	2.21	4.8	
		Week 36	Tezepelumab	34	32 (94.1)	1.96 (0.65)	0.8	1.46	1.92	2.38	3.5	
			Placebo	28	25 (89.3)	1.90 (0.78)	0.9	1.41	1.75	2.36	4.3	
		Week 52	Tezepelumab	34	30 (88.2)	1.94 (0.63)	0.7	1.54	1.93	2.27	3.4	
			Placebo	28	24 (85.7)	1.87 (0.77)	0.9	1.20	1.68	2.30	4.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Change from baseline	Week 2	Tezepelumab	34	33 (97.1)	0.09 (0.20)	-0.3	0.00	0.05	0.15	0.8	0.14 [-0.39, 0.67]
			Placebo	28	24 (85.7)	0.05 (0.27)	-0.4	-0.08	0.00	0.13	0.9	
		Week 4	Tezepelumab	34	34 (100.0)	0.08 (0.34)	-0.4	-0.08	0.02	0.15	1.7	-0.11 [-0.61, 0.40]
			Placebo	28	27 (96.4)	0.11 (0.36)	-0.3	-0.05	0.07	0.24	1.6	
		Week 8	Tezepelumab	34	33 (97.1)	0.12 (0.29)	-0.2	-0.08	0.02	0.18	1.2	0.12 [-0.39, 0.63]
			Placebo	28	27 (96.4)	0.08 (0.37)	-0.8	-0.07	0.04	0.19	1.4	
		Week 12	Tezepelumab	34	34 (100.0)	0.07 (0.30)	-0.3	-0.09	0.02	0.19	1.4	-0.12 [-0.63, 0.39]
			Placebo	28	27 (96.4)	0.10 (0.33)	-0.4	-0.05	0.05	0.22	1.4	
		Week 16	Tezepelumab	34	33 (97.1)	0.15 (0.36)	-0.6	0.01	0.14	0.25	1.6	0.16 [-0.35, 0.67]
			Placebo	28	27 (96.4)	0.09 (0.35)	-0.6	-0.06	0.02	0.19	1.4	
		Week 24	Tezepelumab	34	33 (97.1)	0.06 (0.27)	-0.4	-0.12	0.00	0.22	1.0	-0.01 [-0.52, 0.50]
			Placebo	28	26 (92.9)	0.06 (0.37)	-0.5	-0.10	0.03	0.10	1.6	
		Week 36	Tezepelumab	34	32 (94.1)	0.06 (0.35)	-0.8	-0.11	0.02	0.22	1.1	-0.22 [-0.74, 0.31]
			Placebo	28	25 (89.3)	0.13 (0.29)	-0.3	-0.07	0.08	0.30	1.1	
		Week 52	Tezepelumab	34	30 (88.2)	0.02 (0.32)	-0.8	-0.15	0.01	0.18	1.0	-0.33 [-0.87, 0.21]
			Placebo	28	24 (85.7)	0.12 (0.25)	-0.3	-0.02	0.09	0.20	0.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Absolute values	Baseline	Tezepelumab	4	4 (100.0)	1.93 (0.59)	1.3	1.43	1.98	2.43	2.5	
			Placebo	3	3 (100.0)	1.42 (0.37)	1.0	1.04	1.44	1.77	1.8	
		Week 2	Tezepelumab	4	3 (75.0)	1.90 (0.24)	1.7	1.72	1.80	2.17	2.2	
			Placebo	3	3 (100.0)	1.28 (0.39)	1.0	0.97	1.15	1.71	1.7	
		Week 4	Tezepelumab	4	4 (100.0)	1.91 (0.14)	1.8	1.79	1.92	2.03	2.1	
			Placebo	3	3 (100.0)	1.39 (0.44)	1.0	1.00	1.31	1.87	1.9	
		Week 8	Tezepelumab	4	4 (100.0)	1.93 (0.35)	1.6	1.70	1.89	2.16	2.4	
			Placebo	3	3 (100.0)	1.29 (0.51)	0.8	0.79	1.27	1.81	1.8	
		Week 12	Tezepelumab	4	4 (100.0)	2.10 (0.46)	1.6	1.70	2.13	2.50	2.5	
			Placebo	3	3 (100.0)	1.30 (0.39)	1.0	0.98	1.19	1.74	1.7	
		Week 16	Tezepelumab	4	4 (100.0)	1.82 (0.32)	1.5	1.57	1.78	2.07	2.2	
			Placebo	3	3 (100.0)	1.19 (0.52)	0.8	0.81	0.97	1.78	1.8	
		Week 24	Tezepelumab	4	4 (100.0)	2.10 (0.52)	1.6	1.66	2.07	2.54	2.6	
			Placebo	3	2 (66.7)	1.00 (0.10)	0.9	0.93	1.00	1.07	1.1	
		Week 36	Tezepelumab	4	4 (100.0)	2.01 (0.46)	1.4	1.67	2.05	2.36	2.5	
			Placebo	3	2 (66.7)	1.24 (0.33)	1.0	1.00	1.24	1.47	1.5	
		Week 52	Tezepelumab	4	4 (100.0)	2.11 (0.44)	1.6	1.77	2.14	2.44	2.6	
			Placebo	3	3 (100.0)	1.23 (0.38)	1.0	0.96	1.06	1.66	1.7	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Change from baseline	Week 2	Tezepelumab	4	3 (75.0)	-0.14 (0.61)	-0.7	-0.65	-0.31	0.53	0.5	-0.01 [-1.61, 1.59]
			Placebo	3	3 (100.0)	-0.14 (0.13)	-0.3	-0.29	-0.07	-0.06	-0.1	
		Week 4	Tezepelumab	4	4 (100.0)	-0.02 (0.47)	-0.5	-0.40	-0.07	0.37	0.6	0.02 [-1.47, 1.52]
			Placebo	3	3 (100.0)	-0.02 (0.12)	-0.1	-0.13	-0.04	0.10	0.1	
		Week 8	Tezepelumab	4	4 (100.0)	0.00 (0.43)	-0.5	-0.27	-0.06	0.28	0.6	0.38 [-1.13, 1.90]
			Placebo	3	3 (100.0)	-0.13 (0.15)	-0.3	-0.25	-0.17	0.04	0.0	
		Week 12	Tezepelumab	4	4 (100.0)	0.17 (0.22)	0.0	0.03	0.08	0.31	0.5	1.52 [-0.25, 3.29]
			Placebo	3	3 (100.0)	-0.11 (0.12)	-0.3	-0.25	-0.06	-0.03	-0.0	
		Week 16	Tezepelumab	4	4 (100.0)	-0.11 (0.36)	-0.5	-0.36	-0.17	0.14	0.4	0.35 [-1.17, 1.86]
			Placebo	3	3 (100.0)	-0.23 (0.35)	-0.6	-0.63	-0.07	0.01	0.0	
		Week 24	Tezepelumab	4	4 (100.0)	0.17 (0.22)	-0.0	-0.01	0.15	0.35	0.4	1.52 [-0.48, 3.52]
			Placebo	3	2 (66.7)	-0.24 (0.38)	-0.5	-0.51	-0.24	0.03	0.0	
		Week 36	Tezepelumab	4	4 (100.0)	0.09 (0.37)	-0.2	-0.16	-0.06	0.34	0.6	0.28 [-1.42, 1.99]
			Placebo	3	2 (66.7)	-0.01 (0.05)	-0.0	-0.04	-0.01	0.03	0.0	
		Week 52	Tezepelumab	4	4 (100.0)	0.18 (0.35)	-0.1	-0.04	0.05	0.40	0.7	1.26 [-0.43, 2.95]
			Placebo	3	3 (100.0)	-0.19 (0.17)	-0.4	-0.38	-0.11	-0.08	-0.1	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Absolute values	Baseline	Tezepelumab	15	15 (100.0)	1.57 (0.66)	0.4	1.03	1.50	2.13	2.8	
			Placebo	7	7 (100.0)	1.74 (0.23)	1.4	1.54	1.70	1.93	2.1	
		Week 2	Tezepelumab	15	15 (100.0)	1.54 (0.55)	0.6	1.23	1.55	2.03	2.4	
			Placebo	7	7 (100.0)	1.67 (0.21)	1.3	1.41	1.74	1.85	1.9	
		Week 4	Tezepelumab	15	15 (100.0)	1.58 (0.62)	0.7	0.92	1.61	2.13	2.5	
			Placebo	7	7 (100.0)	1.73 (0.19)	1.4	1.56	1.78	1.85	2.0	
		Week 8	Tezepelumab	15	14 (93.3)	1.56 (0.56)	0.6	1.23	1.61	2.00	2.4	
			Placebo	7	7 (100.0)	1.84 (0.31)	1.5	1.69	1.76	1.82	2.5	
		Week 12	Tezepelumab	15	14 (93.3)	1.55 (0.56)	0.6	1.19	1.55	2.06	2.4	
			Placebo	7	7 (100.0)	1.72 (0.24)	1.4	1.48	1.69	1.93	2.1	
		Week 16	Tezepelumab	15	15 (100.0)	1.60 (0.68)	0.6	1.05	1.55	2.26	2.6	
			Placebo	7	7 (100.0)	1.69 (0.10)	1.5	1.66	1.71	1.76	1.8	
		Week 24	Tezepelumab	15	15 (100.0)	1.62 (0.51)	0.6	1.12	1.71	1.89	2.4	
			Placebo	7	7 (100.0)	1.71 (0.30)	1.3	1.48	1.67	2.07	2.1	
		Week 36	Tezepelumab	15	15 (100.0)	1.58 (0.63)	0.5	1.16	1.51	2.12	2.8	
			Placebo	7	7 (100.0)	1.68 (0.20)	1.4	1.46	1.70	1.88	1.9	
		Week 52	Tezepelumab	15	15 (100.0)	1.60 (0.61)	0.8	1.09	1.54	2.11	2.9	
			Placebo	7	7 (100.0)	1.67 (0.11)	1.5	1.59	1.70	1.73	1.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Change from baseline	Week 2	Tezepelumab	15	15 (100.0)	-0.02 (0.23)	-0.6	-0.10	0.05	0.09	0.2	0.22 [-0.68, 1.12]
			Placebo	7	7 (100.0)	-0.07 (0.17)	-0.3	-0.26	-0.07	0.08	0.2	
		Week 4	Tezepelumab	15	15 (100.0)	0.01 (0.38)	-0.9	-0.18	0.08	0.27	0.6	0.06 [-0.84, 0.95]
			Placebo	7	7 (100.0)	-0.01 (0.16)	-0.3	-0.14	0.04	0.09	0.1	
		Week 8	Tezepelumab	15	14 (93.3)	0.02 (0.29)	-0.8	-0.05	0.11	0.20	0.3	-0.29 [-1.20, 0.62]
			Placebo	7	7 (100.0)	0.09 (0.18)	-0.2	-0.02	0.13	0.20	0.4	
		Week 12	Tezepelumab	15	14 (93.3)	0.02 (0.33)	-0.7	-0.11	0.08	0.15	0.7	0.14 [-0.77, 1.04]
			Placebo	7	7 (100.0)	-0.02 (0.04)	-0.1	-0.06	0.00	0.02	0.0	
		Week 16	Tezepelumab	15	15 (100.0)	0.03 (0.24)	-0.6	-0.13	0.02	0.22	0.4	0.37 [-0.54, 1.27]
			Placebo	7	7 (100.0)	-0.05 (0.21)	-0.5	-0.15	0.00	0.08	0.2	
		Week 24	Tezepelumab	15	15 (100.0)	0.05 (0.32)	-0.6	-0.10	0.00	0.16	0.7	0.27 [-0.63, 1.17]
			Placebo	7	7 (100.0)	-0.03 (0.27)	-0.4	-0.26	-0.04	0.09	0.4	
		Week 36	Tezepelumab	15	15 (100.0)	0.01 (0.34)	-0.7	-0.13	0.04	0.25	0.6	0.23 [-0.67, 1.13]
			Placebo	7	7 (100.0)	-0.06 (0.17)	-0.2	-0.19	-0.11	0.15	0.2	
		Week 52	Tezepelumab	15	15 (100.0)	0.03 (0.44)	-1.0	-0.07	0.00	0.35	0.7	0.28 [-0.62, 1.18]
			Placebo	7	7 (100.0)	-0.07 (0.24)	-0.5	-0.22	0.00	0.12	0.2	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Absolute values	Baseline	Tezepelumab	2	2 (100.0)	1.26 (0.61)	0.8	0.83	1.26	1.69	1.7	
			Placebo	2	2 (100.0)	1.62 (0.37)	1.4	1.35	1.62	1.88	1.9	
		Week 2	Tezepelumab	2	2 (100.0)	1.43 (0.72)	0.9	0.92	1.43	1.94	1.9	
			Placebo	2	1 (50.0)	1.35	1.4	1.35	1.35	1.35	1.4	
		Week 4	Tezepelumab	2	2 (100.0)	1.42 (0.74)	0.9	0.89	1.42	1.94	1.9	
			Placebo	2	2 (100.0)	1.64 (0.37)	1.4	1.38	1.64	1.90	1.9	
		Week 8	Tezepelumab	2	2 (100.0)	1.43 (0.66)	1.0	0.96	1.43	1.90	1.9	
			Placebo	2	2 (100.0)	1.73 (0.35)	1.5	1.48	1.73	1.98	2.0	
		Week 12	Tezepelumab	2	2 (100.0)	1.37 (0.66)	0.9	0.90	1.37	1.83	1.8	
			Placebo	2	2 (100.0)	1.84 (0.59)	1.4	1.42	1.84	2.25	2.3	
		Week 16	Tezepelumab	2	2 (100.0)	1.39 (0.66)	0.9	0.92	1.39	1.85	1.9	
			Placebo	2	2 (100.0)	1.56 (0.32)	1.3	1.33	1.56	1.78	1.8	
		Week 24	Tezepelumab	2	2 (100.0)	1.39 (0.75)	0.9	0.86	1.39	1.92	1.9	
			Placebo	2	1 (50.0)	1.40	1.4	1.40	1.40	1.40	1.4	
		Week 36	Tezepelumab	2	2 (100.0)	1.37 (0.65)	0.9	0.91	1.37	1.83	1.8	
			Placebo	2	1 (50.0)	1.57	1.6	1.57	1.57	1.57	1.6	
		Week 52	Tezepelumab	2	2 (100.0)	1.43 (0.76)	0.9	0.89	1.43	1.97	2.0	
			Placebo	2	1 (50.0)	1.47	1.5	1.47	1.47	1.47	1.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Change from baseline	Week 2	Tezepelumab	2	2 (100.0)	0.17 (0.11)	0.1	0.09	0.17	0.25	0.3	NE
			Placebo	2	1 (50.0)	0.00	0.0	0.00	0.00	0.00	0.0	
		Week 4	Tezepelumab	2	2 (100.0)	0.16 (0.13)	0.1	0.06	0.16	0.25	0.3	1.37 [-1.01, 3.74]
			Placebo	2	2 (100.0)	0.02 (0.01)	0.0	0.02	0.02	0.03	0.0	
		Week 8	Tezepelumab	2	2 (100.0)	0.17 (0.06)	0.1	0.13	0.17	0.21	0.2	1.29 [-1.04, 3.62]
			Placebo	2	2 (100.0)	0.12 (0.02)	0.1	0.10	0.12	0.13	0.1	
		Week 12	Tezepelumab	2	2 (100.0)	0.11 (0.05)	0.1	0.07	0.11	0.14	0.1	-0.75 [-2.84, 1.35]
			Placebo	2	2 (100.0)	0.22 (0.21)	0.1	0.07	0.22	0.37	0.4	
		Week 16	Tezepelumab	2	2 (100.0)	0.13 (0.05)	0.1	0.09	0.13	0.16	0.2	3.48 [-0.45, 7.41]
			Placebo	2	2 (100.0)	-0.06 (0.06)	-0.1	-0.10	-0.06	-0.02	-0.0	
		Week 24	Tezepelumab	2	2 (100.0)	0.13 (0.14)	0.0	0.03	0.13	0.23	0.2	NE
			Placebo	2	1 (50.0)	0.05	0.0	0.05	0.05	0.05	0.0	
		Week 36	Tezepelumab	2	2 (100.0)	0.11 (0.04)	0.1	0.08	0.11	0.14	0.1	NE
			Placebo	2	1 (50.0)	0.22	0.2	0.22	0.22	0.22	0.2	
		Week 52	Tezepelumab	2	2 (100.0)	0.17 (0.16)	0.1	0.06	0.17	0.28	0.3	NE
			Placebo	2	1 (50.0)	0.12	0.1	0.12	0.12	0.12	0.1	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Absolute values	Baseline	Tezepelumab	11	11 (100.0)	2.02 (0.40)	1.4	1.65	2.02	2.39	2.6	
			Placebo	10	10 (100.0)	1.73 (0.64)	0.9	1.06	1.84	2.17	2.8	
		Week 2	Tezepelumab	11	11 (100.0)	2.10 (0.44)	1.4	1.70	2.17	2.47	2.7	
			Placebo	10	9 (90.0)	1.93 (0.69)	0.9	1.46	2.11	2.31	2.8	
		Week 4	Tezepelumab	11	11 (100.0)	2.06 (0.42)	1.4	1.65	2.07	2.45	2.6	
			Placebo	10	10 (100.0)	1.89 (0.73)	1.0	1.08	1.88	2.47	3.0	
		Week 8	Tezepelumab	11	11 (100.0)	2.06 (0.51)	1.2	1.58	2.11	2.53	2.7	
			Placebo	10	9 (90.0)	1.84 (0.81)	0.8	1.07	2.23	2.35	2.8	
		Week 12	Tezepelumab	11	11 (100.0)	2.01 (0.44)	1.2	1.62	2.18	2.39	2.5	
			Placebo	10	10 (100.0)	1.84 (0.75)	0.8	1.28	1.81	2.52	3.0	
		Week 16	Tezepelumab	11	11 (100.0)	2.08 (0.49)	1.2	1.63	2.22	2.34	3.0	
			Placebo	10	10 (100.0)	1.88 (0.70)	0.9	1.32	1.97	2.28	3.0	
		Week 24	Tezepelumab	11	11 (100.0)	1.99 (0.42)	1.2	1.61	2.26	2.30	2.4	
			Placebo	10	10 (100.0)	1.74 (0.63)	0.8	1.12	1.85	2.25	2.7	
		Week 36	Tezepelumab	11	11 (100.0)	2.00 (0.50)	1.2	1.53	2.10	2.50	2.6	
			Placebo	10	9 (90.0)	1.89 (0.67)	1.1	1.19	1.75	2.36	3.0	
		Week 52	Tezepelumab	11	10 (90.9)	1.99 (0.45)	1.2	1.64	2.20	2.26	2.6	
			Placebo	10	10 (100.0)	1.94 (0.69)	1.0	1.10	2.19	2.31	2.9	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Change from baseline	Week 2	Tezepelumab	11	11 (100.0)	0.08 (0.22)	-0.3	-0.01	0.05	0.15	0.5	-0.12 [-1.00, 0.76]
			Placebo	10	9 (90.0)	0.11 (0.22)	-0.1	-0.05	0.03	0.10	0.5	
		Week 4	Tezepelumab	11	11 (100.0)	0.04 (0.23)	-0.5	-0.06	0.05	0.22	0.3	-0.55 [-1.42, 0.32]
			Placebo	10	10 (100.0)	0.16 (0.22)	-0.3	0.03	0.16	0.31	0.5	
		Week 8	Tezepelumab	11	11 (100.0)	0.04 (0.25)	-0.2	-0.09	-0.06	0.04	0.7	0.01 [-0.87, 0.89]
			Placebo	10	9 (90.0)	0.03 (0.37)	-0.8	-0.06	0.04	0.19	0.5	
		Week 12	Tezepelumab	11	11 (100.0)	-0.01 (0.18)	-0.2	-0.18	-0.03	0.10	0.4	-0.56 [-1.43, 0.32]
			Placebo	10	10 (100.0)	0.11 (0.25)	-0.4	-0.03	0.12	0.33	0.4	
		Week 16	Tezepelumab	11	11 (100.0)	0.06 (0.28)	-0.3	-0.22	0.03	0.18	0.7	-0.39 [-1.26, 0.47]
			Placebo	10	10 (100.0)	0.15 (0.19)	-0.1	0.01	0.10	0.26	0.5	
		Week 24	Tezepelumab	11	11 (100.0)	-0.03 (0.16)	-0.2	-0.18	-0.05	0.10	0.3	-0.28 [-1.14, 0.58]
			Placebo	10	10 (100.0)	0.02 (0.17)	-0.2	-0.10	-0.01	0.06	0.4	
		Week 36	Tezepelumab	11	11 (100.0)	-0.02 (0.28)	-0.5	-0.18	-0.05	0.11	0.6	-0.93 [-1.86, 0.01]
			Placebo	10	9 (90.0)	0.21 (0.20)	-0.3	0.17	0.30	0.31	0.4	
		Week 52	Tezepelumab	11	10 (90.9)	-0.01 (0.20)	-0.4	-0.05	-0.01	0.10	0.2	-1.21 [-2.17, -0.24]
			Placebo	10	10 (100.0)	0.21 (0.17)	-0.0	0.10	0.16	0.40	0.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Absolute values	Baseline	Tezepelumab	20	20 (100.0)	1.91 (0.68)	0.8	1.28	1.92	2.56	3.2	
			Placebo	11	11 (100.0)	1.88 (0.70)	1.0	1.35	1.88	2.47	3.2	
		Week 2	Tezepelumab	20	19 (95.0)	1.97 (0.69)	0.9	1.32	1.97	2.58	3.4	
			Placebo	11	9 (81.8)	1.93 (1.00)	1.0	1.29	1.61	2.43	4.1	
		Week 4	Tezepelumab	20	20 (100.0)	1.92 (0.69)	0.7	1.42	2.01	2.48	3.2	
			Placebo	11	10 (90.9)	2.12 (1.13)	1.0	1.43	1.86	2.68	4.8	
		Week 8	Tezepelumab	20	20 (100.0)	1.99 (0.66)	0.7	1.57	1.96	2.55	3.3	
			Placebo	11	11 (100.0)	2.04 (1.02)	0.8	1.53	1.76	2.68	4.6	
		Week 12	Tezepelumab	20	20 (100.0)	1.99 (0.74)	0.8	1.48	2.07	2.45	3.6	
			Placebo	11	11 (100.0)	2.09 (1.02)	1.0	1.41	1.73	2.70	4.6	
		Week 16	Tezepelumab	20	20 (100.0)	2.03 (0.67)	0.9	1.52	1.97	2.59	3.5	
			Placebo	11	11 (100.0)	2.03 (1.05)	1.0	1.26	1.68	2.60	4.7	
		Week 24	Tezepelumab	20	20 (100.0)	1.99 (0.72)	0.8	1.35	2.01	2.55	3.5	
			Placebo	11	10 (90.9)	2.11 (1.11)	1.1	1.42	1.77	2.66	4.8	
		Week 36	Tezepelumab	20	20 (100.0)	2.00 (0.71)	0.8	1.44	1.98	2.38	3.5	
			Placebo	11	11 (100.0)	2.01 (1.00)	1.0	1.38	1.59	2.74	4.3	
		Week 52	Tezepelumab	20	19 (95.0)	2.00 (0.69)	0.7	1.57	1.98	2.47	3.4	
			Placebo	11	9 (81.8)	1.96 (1.02)	1.0	1.15	1.62	2.76	4.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Change from baseline	Week 2	Tezepelumab	20	19 (95.0)	0.05 (0.23)	-0.7	0.00	0.04	0.18	0.5	-0.24 [-1.04, 0.55]
			Placebo	11	9 (81.8)	0.11 (0.32)	-0.2	-0.07	0.04	0.16	0.9	
		Week 4	Tezepelumab	20	20 (100.0)	0.01 (0.20)	-0.3	-0.11	0.02	0.11	0.6	-0.71 [-1.50, 0.07]
			Placebo	11	10 (90.9)	0.24 (0.50)	-0.2	-0.01	0.09	0.28	1.6	
		Week 8	Tezepelumab	20	20 (100.0)	0.09 (0.26)	-0.5	-0.07	0.05	0.16	0.7	-0.19 [-0.93, 0.55]
			Placebo	11	11 (100.0)	0.15 (0.48)	-0.5	-0.12	0.11	0.30	1.4	
		Week 12	Tezepelumab	20	20 (100.0)	0.09 (0.20)	-0.2	-0.04	0.05	0.18	0.5	-0.41 [-1.15, 0.34]
			Placebo	11	11 (100.0)	0.20 (0.41)	-0.1	-0.06	0.06	0.26	1.4	
		Week 16	Tezepelumab	20	20 (100.0)	0.12 (0.26)	-0.5	0.02	0.14	0.27	0.7	-0.09 [-0.83, 0.65]
			Placebo	11	11 (100.0)	0.15 (0.47)	-0.3	-0.10	0.07	0.26	1.4	
		Week 24	Tezepelumab	20	20 (100.0)	0.08 (0.23)	-0.4	-0.09	0.03	0.29	0.4	-0.28 [-1.05, 0.48]
			Placebo	11	10 (90.9)	0.19 (0.54)	-0.4	0.03	0.08	0.13	1.6	
		Week 36	Tezepelumab	20	20 (100.0)	0.09 (0.33)	-0.8	-0.13	0.09	0.26	0.8	-0.13 [-0.86, 0.61]
			Placebo	11	11 (100.0)	0.13 (0.37)	-0.3	-0.07	0.03	0.30	1.1	
		Week 52	Tezepelumab	20	19 (95.0)	0.03 (0.32)	-0.8	-0.07	0.08	0.18	0.7	-0.14 [-0.93, 0.66]
			Placebo	11	9 (81.8)	0.08 (0.35)	-0.3	-0.08	-0.02	0.15	0.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Absolute values	Baseline	Tezepelumab	13	13 (100.0)	1.69 (0.62)	0.4	1.44	1.74	2.13	2.8	
			Placebo	10	10 (100.0)	1.75 (0.22)	1.4	1.59	1.70	1.93	2.1	
		Week 2	Tezepelumab	13	13 (100.0)	1.66 (0.50)	0.6	1.29	1.59	2.03	2.4	
			Placebo	10	9 (90.0)	1.70 (0.21)	1.3	1.59	1.74	1.85	2.0	
		Week 4	Tezepelumab	13	13 (100.0)	1.71 (0.55)	0.7	1.44	1.64	2.13	2.5	
			Placebo	10	10 (100.0)	1.71 (0.17)	1.4	1.57	1.73	1.79	2.0	
		Week 8	Tezepelumab	13	12 (92.3)	1.69 (0.50)	0.6	1.43	1.65	2.08	2.4	
			Placebo	10	10 (100.0)	1.81 (0.27)	1.5	1.69	1.75	1.82	2.5	
		Week 12	Tezepelumab	13	12 (92.3)	1.67 (0.49)	0.6	1.47	1.59	2.08	2.4	
			Placebo	10	9 (90.0)	1.69 (0.22)	1.4	1.53	1.66	1.72	2.1	
		Week 16	Tezepelumab	13	13 (100.0)	1.73 (0.62)	0.6	1.37	1.67	2.26	2.6	
			Placebo	10	9 (90.0)	1.65 (0.12)	1.4	1.66	1.70	1.71	1.8	
		Week 24	Tezepelumab	13	13 (100.0)	1.76 (0.38)	1.1	1.61	1.76	1.89	2.4	
			Placebo	10	9 (90.0)	1.70 (0.26)	1.3	1.57	1.67	1.73	2.1	
		Week 36	Tezepelumab	13	13 (100.0)	1.71 (0.55)	0.9	1.33	1.54	2.12	2.8	
			Placebo	10	8 (80.0)	1.70 (0.19)	1.4	1.58	1.72	1.85	1.9	
		Week 52	Tezepelumab	13	13 (100.0)	1.71 (0.58)	0.8	1.43	1.60	2.11	2.9	
			Placebo	10	9 (90.0)	1.70 (0.14)	1.5	1.62	1.70	1.73	2.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Change from baseline	Week 2	Tezepelumab	13	13 (100.0)	-0.04 (0.24)	-0.6	-0.10	0.05	0.09	0.2	0.18 [-0.67, 1.03]
			Placebo	10	9 (90.0)	-0.07 (0.15)	-0.3	-0.17	-0.07	0.04	0.2	
		Week 4	Tezepelumab	13	13 (100.0)	0.02 (0.41)	-0.9	-0.13	0.12	0.27	0.6	0.18 [-0.64, 1.01]
			Placebo	10	10 (100.0)	-0.04 (0.16)	-0.3	-0.14	0.00	0.09	0.1	
		Week 8	Tezepelumab	13	12 (92.3)	0.02 (0.31)	-0.8	-0.06	0.15	0.23	0.3	-0.17 [-1.01, 0.67]
			Placebo	10	10 (100.0)	0.06 (0.16)	-0.2	-0.02	0.03	0.13	0.4	
		Week 12	Tezepelumab	13	12 (92.3)	0.02 (0.35)	-0.7	-0.09	0.08	0.16	0.7	0.36 [-0.51, 1.23]
			Placebo	10	9 (90.0)	-0.08 (0.15)	-0.4	-0.09	-0.04	0.00	0.0	
		Week 16	Tezepelumab	13	13 (100.0)	0.04 (0.26)	-0.6	-0.13	0.08	0.22	0.4	0.59 [-0.28, 1.46]
			Placebo	10	9 (90.0)	-0.12 (0.27)	-0.6	-0.15	-0.03	0.02	0.2	
		Week 24	Tezepelumab	13	13 (100.0)	0.07 (0.34)	-0.6	-0.07	0.02	0.16	0.7	0.45 [-0.41, 1.31]
			Placebo	10	9 (90.0)	-0.07 (0.28)	-0.5	-0.26	-0.04	0.07	0.4	
		Week 36	Tezepelumab	13	13 (100.0)	0.02 (0.37)	-0.7	-0.13	0.04	0.25	0.6	0.34 [-0.55, 1.23]
			Placebo	10	8 (80.0)	-0.08 (0.17)	-0.2	-0.21	-0.15	0.06	0.2	
		Week 52	Tezepelumab	13	13 (100.0)	0.02 (0.47)	-1.0	-0.07	0.00	0.35	0.7	0.22 [-0.63, 1.08]
			Placebo	10	9 (90.0)	-0.07 (0.21)	-0.5	-0.20	-0.01	0.08	0.2	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Absolute values	Baseline	Tezepelumab	11	11 (100.0)	1.51 (0.72)	0.6	0.92	1.31	1.72	3.3	
			Placebo	9	9 (100.0)	1.52 (0.37)	0.8	1.39	1.49	1.77	2.1	
		Week 2	Tezepelumab	11	10 (90.9)	1.64 (0.71)	0.7	0.92	1.56	1.94	2.9	
			Placebo	9	8 (88.9)	1.36 (0.35)	0.8	1.12	1.37	1.68	1.8	
		Week 4	Tezepelumab	11	11 (100.0)	1.71 (0.91)	0.7	0.89	1.66	1.94	3.4	
			Placebo	9	9 (100.0)	1.45 (0.35)	0.9	1.31	1.38	1.80	1.9	
		Week 8	Tezepelumab	11	10 (90.9)	1.54 (0.65)	0.7	0.96	1.61	1.90	2.9	
			Placebo	9	9 (100.0)	1.52 (0.39)	0.8	1.37	1.48	1.81	2.0	
		Week 12	Tezepelumab	11	11 (100.0)	1.64 (0.85)	0.7	0.90	1.44	1.83	3.3	
			Placebo	9	9 (100.0)	1.54 (0.44)	0.9	1.30	1.42	1.74	2.3	
		Week 16	Tezepelumab	11	10 (90.9)	1.70 (0.90)	0.6	0.94	1.51	1.85	3.3	
			Placebo	9	9 (100.0)	1.43 (0.42)	0.8	1.31	1.33	1.78	2.0	
		Week 24	Tezepelumab	11	10 (90.9)	1.46 (0.65)	0.6	0.86	1.49	1.92	2.7	
			Placebo	9	7 (77.8)	1.37 (0.37)	0.8	0.93	1.40	1.69	1.9	
		Week 36	Tezepelumab	11	9 (81.8)	1.43 (0.67)	0.5	0.91	1.48	1.65	2.8	
			Placebo	9	7 (77.8)	1.50 (0.33)	0.9	1.41	1.47	1.78	1.9	
		Week 52	Tezepelumab	11	9 (81.8)	1.50 (0.63)	0.9	0.90	1.54	1.87	2.8	
			Placebo	9	7 (77.8)	1.34 (0.30)	0.9	1.06	1.47	1.57	1.7	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Change from baseline	Week 2	Tezepelumab	11	10 (90.9)	0.11 (0.29)	-0.3	-0.08	0.09	0.25	0.8	0.87 [-0.11, 1.84]
			Placebo	9	8 (88.9)	-0.12 (0.19)	-0.4	-0.30	-0.04	-0.01	0.2	
		Week 4	Tezepelumab	11	11 (100.0)	0.20 (0.55)	-0.4	-0.04	0.06	0.30	1.7	0.64 [-0.26, 1.55]
			Placebo	9	9 (100.0)	-0.07 (0.14)	-0.3	-0.13	-0.03	0.03	0.1	
		Week 8	Tezepelumab	11	10 (90.9)	0.21 (0.38)	-0.1	-0.04	0.11	0.30	1.2	0.74 [-0.19, 1.67]
			Placebo	9	9 (100.0)	-0.00 (0.09)	-0.2	-0.07	-0.01	0.05	0.1	
		Week 12	Tezepelumab	11	11 (100.0)	0.14 (0.45)	-0.3	-0.11	0.07	0.21	1.4	0.34 [-0.54, 1.23]
			Placebo	9	9 (100.0)	0.01 (0.18)	-0.3	-0.03	0.00	0.07	0.4	
		Week 16	Tezepelumab	11	10 (90.9)	0.16 (0.55)	-0.6	-0.07	0.11	0.16	1.6	0.60 [-0.33, 1.52]
			Placebo	9	9 (100.0)	-0.09 (0.22)	-0.6	-0.10	-0.06	0.01	0.1	
		Week 24	Tezepelumab	11	10 (90.9)	0.13 (0.35)	-0.2	-0.10	0.02	0.23	1.0	0.65 [-0.34, 1.64]
			Placebo	9	7 (77.8)	-0.07 (0.24)	-0.5	-0.25	0.00	0.05	0.2	
		Week 36	Tezepelumab	11	9 (81.8)	0.09 (0.41)	-0.4	-0.09	-0.06	0.14	1.1	0.08 [-0.90, 1.07]
			Placebo	9	7 (77.8)	0.06 (0.16)	-0.2	-0.08	0.06	0.22	0.3	
		Week 52	Tezepelumab	11	9 (81.8)	0.16 (0.38)	-0.2	-0.10	0.06	0.27	1.0	0.67 [-0.35, 1.69]
			Placebo	9	7 (77.8)	-0.05 (0.20)	-0.4	-0.25	0.06	0.12	0.1	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
< 18.5 kg/m**2	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	2.28 (0.84)	1.3	1.31	2.69	2.83	2.8	
		Week 2	Tezepelumab	3	3 (100.0)	2.17 (0.69)	1.4	1.41	2.36	2.74	2.7	
		Week 4	Tezepelumab	3	3 (100.0)	1.95 (0.67)	1.3	1.27	1.98	2.61	2.6	
		Week 8	Tezepelumab	3	3 (100.0)	2.11 (0.56)	1.6	1.61	2.00	2.71	2.7	
		Week 12	Tezepelumab	3	3 (100.0)	2.02 (0.76)	1.2	1.22	2.10	2.74	2.7	
		Week 16	Tezepelumab	3	3 (100.0)	2.14 (0.66)	1.4	1.43	2.26	2.73	2.7	
		Week 24	Tezepelumab	3	3 (100.0)	2.18 (0.75)	1.4	1.40	2.24	2.90	2.9	
		Week 36	Tezepelumab	3	3 (100.0)	2.15 (0.92)	1.3	1.25	2.12	3.08	3.1	
		Week 52	Tezepelumab	3	3 (100.0)	2.00 (1.00)	1.1	1.11	1.80	3.08	3.1	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
< 18.5 kg/m**2	Change from baseline	Week 2	Tezepelumab	3	3 (100.0)	-0.11 (0.32)	-0.5	-0.47	0.05	0.10	0.1	NE
		Week 4	Tezepelumab	3	3 (100.0)	-0.32 (0.46)	-0.9	-0.85	-0.08	-0.04	-0.0	NE
		Week 8	Tezepelumab	3	3 (100.0)	-0.17 (0.59)	-0.8	-0.83	0.02	0.30	0.3	NE
		Week 12	Tezepelumab	3	3 (100.0)	-0.26 (0.42)	-0.7	-0.73	-0.09	0.05	0.1	NE
		Week 16	Tezepelumab	3	3 (100.0)	-0.14 (0.38)	-0.6	-0.57	0.04	0.12	0.1	NE
		Week 24	Tezepelumab	3	3 (100.0)	-0.10 (0.43)	-0.6	-0.59	0.09	0.21	0.2	NE
		Week 36	Tezepelumab	3	3 (100.0)	-0.13 (0.55)	-0.7	-0.71	-0.06	0.39	0.4	NE
		Week 52	Tezepelumab	3	3 (100.0)	-0.28 (0.71)	-1.0	-1.03	-0.20	0.39	0.4	NE

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Absolute values	Baseline	Tezepelumab	11	11 (100.0)	1.65 (0.79)	0.4	1.03	1.74	2.20	3.2	
			Placebo	8	8 (100.0)	1.85 (0.29)	1.4	1.62	1.85	2.14	2.2	
		Week 2	Tezepelumab	11	10 (90.9)	1.67 (0.79)	0.6	1.04	1.74	2.03	3.4	
			Placebo	8	8 (100.0)	1.81 (0.32)	1.3	1.56	1.87	2.02	2.3	
		Week 4	Tezepelumab	11	11 (100.0)	1.70 (0.74)	0.7	1.06	1.64	2.13	3.2	
			Placebo	8	8 (100.0)	1.90 (0.32)	1.4	1.74	1.82	2.10	2.5	
		Week 8	Tezepelumab	11	10 (90.9)	1.69 (0.79)	0.6	1.18	1.68	2.15	3.3	
			Placebo	8	8 (100.0)	1.98 (0.34)	1.5	1.77	1.84	2.29	2.5	
		Week 12	Tezepelumab	11	11 (100.0)	1.77 (0.84)	0.6	1.08	1.73	2.37	3.6	
			Placebo	8	8 (100.0)	1.87 (0.38)	1.4	1.59	1.77	2.14	2.6	
		Week 16	Tezepelumab	11	10 (90.9)	1.77 (0.87)	0.6	1.05	1.62	2.22	3.5	
			Placebo	8	8 (100.0)	1.81 (0.23)	1.5	1.69	1.74	2.00	2.2	
		Week 24	Tezepelumab	11	11 (100.0)	1.75 (0.72)	0.8	1.12	1.67	1.89	3.5	
			Placebo	8	8 (100.0)	1.91 (0.26)	1.5	1.68	2.05	2.09	2.2	
		Week 36	Tezepelumab	11	10 (90.9)	1.87 (0.89)	0.9	1.15	1.74	2.52	3.5	
			Placebo	8	7 (87.5)	1.82 (0.30)	1.4	1.69	1.80	1.92	2.4	
		Week 52	Tezepelumab	11	10 (90.9)	1.92 (0.88)	0.8	1.22	1.73	2.58	3.4	
			Placebo	8	8 (100.0)	1.82 (0.28)	1.5	1.61	1.77	1.99	2.3	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Change from baseline	Week 2	Tezepelumab	11	10 (90.9)	-0.03 (0.19)	-0.3	-0.17	-0.06	0.17	0.2	0.05 [-0.88, 0.98]
			Placebo	8	8 (100.0)	-0.04 (0.17)	-0.3	-0.16	-0.01	0.09	0.2	
		Week 4	Tezepelumab	11	11 (100.0)	0.05 (0.34)	-0.5	-0.18	-0.07	0.30	0.6	-0.02 [-0.93, 0.90]
			Placebo	8	8 (100.0)	0.05 (0.18)	-0.3	0.03	0.07	0.13	0.3	
		Week 8	Tezepelumab	11	10 (90.9)	0.06 (0.20)	-0.2	-0.07	0.00	0.20	0.5	-0.39 [-1.33, 0.55]
			Placebo	8	8 (100.0)	0.13 (0.14)	-0.0	0.02	0.13	0.19	0.4	
		Week 12	Tezepelumab	11	11 (100.0)	0.12 (0.27)	-0.2	-0.11	0.10	0.21	0.7	0.40 [-0.52, 1.32]
			Placebo	8	8 (100.0)	0.03 (0.16)	-0.1	-0.06	-0.01	0.03	0.4	
		Week 16	Tezepelumab	11	10 (90.9)	0.08 (0.25)	-0.4	-0.04	0.11	0.25	0.4	0.49 [-0.46, 1.43]
			Placebo	8	8 (100.0)	-0.03 (0.19)	-0.5	-0.08	0.02	0.05	0.2	
		Week 24	Tezepelumab	11	11 (100.0)	0.10 (0.36)	-0.4	-0.10	-0.02	0.38	0.7	0.12 [-0.80, 1.03]
			Placebo	8	8 (100.0)	0.06 (0.17)	-0.1	-0.06	0.05	0.11	0.4	
		Week 36	Tezepelumab	11	10 (90.9)	0.18 (0.25)	-0.1	-0.04	0.15	0.36	0.6	0.74 [-0.26, 1.74]
			Placebo	8	7 (87.5)	0.02 (0.16)	-0.2	-0.11	-0.03	0.19	0.2	
		Week 52	Tezepelumab	11	10 (90.9)	0.22 (0.28)	-0.1	-0.02	0.17	0.41	0.7	0.98 [-0.01, 1.97]
			Placebo	8	8 (100.0)	-0.03 (0.23)	-0.5	-0.14	0.03	0.14	0.2	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	20	20 (100.0)	1.71 (0.67)	0.6	1.30	1.71	2.11	3.3	
			Placebo	14	14 (100.0)	1.86 (0.71)	0.9	1.39	1.77	2.47	3.2	
		Week 2	Tezepelumab	20	20 (100.0)	1.83 (0.66)	0.7	1.33	1.93	2.40	2.9	
			Placebo	14	11 (78.6)	1.94 (0.92)	0.9	1.38	1.59	2.43	4.1	
		Week 4	Tezepelumab	20	20 (100.0)	1.86 (0.82)	0.7	1.17	1.98	2.43	3.4	
			Placebo	14	13 (92.9)	2.03 (1.05)	1.0	1.32	1.64	2.35	4.8	
		Week 8	Tezepelumab	20	19 (95.0)	1.82 (0.67)	0.7	1.23	1.88	2.43	2.9	
			Placebo	14	14 (100.0)	1.94 (0.98)	0.8	1.37	1.75	2.30	4.6	
		Week 12	Tezepelumab	20	20 (100.0)	1.82 (0.75)	0.7	1.20	1.95	2.21	3.3	
			Placebo	14	14 (100.0)	1.98 (1.00)	0.8	1.37	1.63	2.46	4.6	
		Week 16	Tezepelumab	20	20 (100.0)	1.89 (0.77)	0.6	1.28	1.94	2.34	3.3	
			Placebo	14	14 (100.0)	1.95 (1.03)	0.8	1.33	1.67	2.28	4.7	
		Week 24	Tezepelumab	20	19 (95.0)	1.77 (0.66)	0.6	1.10	1.92	2.29	2.7	
			Placebo	14	14 (100.0)	1.90 (1.03)	0.8	1.36	1.62	2.25	4.8	
		Week 36	Tezepelumab	20	19 (95.0)	1.73 (0.67)	0.5	1.16	1.83	2.30	2.9	
			Placebo	14	13 (92.9)	2.06 (0.91)	1.2	1.45	1.75	2.40	4.3	
		Week 52	Tezepelumab	20	17 (85.0)	1.71 (0.62)	0.7	1.17	1.79	2.20	2.8	
			Placebo	14	11 (78.6)	1.96 (0.94)	1.0	1.06	1.68	2.76	4.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Change from baseline	Week 2	Tezepelumab	20	20 (100.0)	0.12 (0.21)	-0.3	0.01	0.09	0.17	0.8	0.25 [-0.49, 0.99]
			Placebo	14	11 (78.6)	0.05 (0.34)	-0.3	-0.18	0.01	0.06	0.9	
		Week 4	Tezepelumab	20	20 (100.0)	0.15 (0.40)	-0.3	0.01	0.06	0.14	1.7	-0.06 [-0.75, 0.64]
			Placebo	14	13 (92.9)	0.17 (0.47)	-0.3	-0.07	0.08	0.20	1.6	
		Week 8	Tezepelumab	20	19 (95.0)	0.19 (0.31)	-0.2	0.04	0.13	0.25	1.2	0.31 [-0.38, 1.00]
			Placebo	14	14 (100.0)	0.08 (0.43)	-0.5	-0.08	-0.03	0.08	1.4	
		Week 12	Tezepelumab	20	20 (100.0)	0.11 (0.32)	-0.2	0.01	0.06	0.13	1.4	-0.02 [-0.70, 0.67]
			Placebo	14	14 (100.0)	0.12 (0.39)	-0.3	-0.05	0.01	0.19	1.4	
		Week 16	Tezepelumab	20	20 (100.0)	0.18 (0.41)	-0.2	-0.06	0.11	0.17	1.6	0.20 [-0.49, 0.88]
			Placebo	14	14 (100.0)	0.09 (0.47)	-0.6	-0.06	0.02	0.19	1.4	
		Week 24	Tezepelumab	20	19 (95.0)	0.14 (0.27)	-0.2	-0.06	0.14	0.23	1.0	0.24 [-0.45, 0.93]
			Placebo	14	14 (100.0)	0.05 (0.50)	-0.5	-0.25	-0.04	0.07	1.6	
		Week 36	Tezepelumab	20	19 (95.0)	0.10 (0.36)	-0.8	-0.02	0.06	0.20	1.1	-0.25 [-0.96, 0.46]
			Placebo	14	13 (92.9)	0.19 (0.34)	-0.3	0.03	0.17	0.30	1.1	
		Week 52	Tezepelumab	20	17 (85.0)	0.08 (0.36)	-0.8	-0.06	0.06	0.24	1.0	-0.17 [-0.93, 0.59]
			Placebo	14	11 (78.6)	0.13 (0.31)	-0.4	-0.01	0.13	0.23	0.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	21	21 (100.0)	1.89 (0.47)	1.3	1.49	1.87	2.20	2.6	
			Placebo	18	18 (100.0)	1.58 (0.42)	0.8	1.35	1.54	1.88	2.3	
		Week 2	Tezepelumab	21	20 (95.2)	1.94 (0.48)	1.3	1.57	1.80	2.41	2.7	
			Placebo	18	16 (88.9)	1.56 (0.55)	0.8	1.05	1.63	1.75	2.7	
		Week 4	Tezepelumab	21	21 (100.0)	1.92 (0.47)	1.1	1.66	1.75	2.25	2.8	
			Placebo	18	18 (100.0)	1.60 (0.50)	0.9	1.20	1.56	1.87	2.7	
		Week 8	Tezepelumab	21	21 (100.0)	1.92 (0.50)	1.2	1.57	1.85	2.38	2.8	
			Placebo	18	17 (94.4)	1.63 (0.53)	0.8	1.41	1.65	1.81	2.7	
		Week 12	Tezepelumab	21	20 (95.2)	1.91 (0.50)	1.2	1.50	1.74	2.36	3.0	
			Placebo	18	17 (94.4)	1.63 (0.49)	0.9	1.31	1.60	1.74	2.7	
		Week 16	Tezepelumab	21	21 (100.0)	1.95 (0.50)	1.3	1.56	1.83	2.34	3.0	
			Placebo	18	17 (94.4)	1.59 (0.48)	0.9	1.31	1.63	1.78	2.7	
		Week 24	Tezepelumab	21	21 (100.0)	1.90 (0.49)	1.1	1.61	1.87	2.32	2.9	
			Placebo	18	14 (77.8)	1.53 (0.49)	0.8	1.21	1.48	1.67	2.7	
		Week 36	Tezepelumab	21	21 (100.0)	1.86 (0.46)	1.1	1.48	1.77	2.20	2.8	
			Placebo	18	15 (83.3)	1.58 (0.52)	0.9	1.14	1.49	1.78	2.7	
		Week 52	Tezepelumab	21	21 (100.0)	1.87 (0.46)	1.0	1.57	1.87	2.20	2.8	
			Placebo	18	16 (88.9)	1.60 (0.57)	0.9	1.15	1.52	1.85	2.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Change from baseline	Week 2	Tezepelumab	21	20 (95.2)	0.03 (0.28)	-0.7	-0.00	0.05	0.11	0.5	0.10 [-0.55, 0.76]
			Placebo	18	16 (88.9)	0.01 (0.21)	-0.4	-0.08	-0.06	0.10	0.5	
		Week 4	Tezepelumab	21	21 (100.0)	0.03 (0.26)	-0.6	-0.13	0.00	0.17	0.6	0.02 [-0.61, 0.65]
			Placebo	18	18 (100.0)	0.02 (0.20)	-0.3	-0.04	0.02	0.10	0.4	
		Week 8	Tezepelumab	21	21 (100.0)	0.03 (0.25)	-0.5	-0.09	-0.03	0.15	0.7	0.02 [-0.61, 0.66]
			Placebo	18	17 (94.4)	0.03 (0.28)	-0.8	-0.08	0.04	0.13	0.5	
		Week 12	Tezepelumab	21	20 (95.2)	0.03 (0.25)	-0.4	-0.18	0.01	0.22	0.5	-0.09 [-0.74, 0.56]
			Placebo	18	17 (94.4)	0.05 (0.24)	-0.4	-0.04	0.06	0.22	0.4	
		Week 16	Tezepelumab	21	21 (100.0)	0.06 (0.26)	-0.6	-0.02	0.04	0.28	0.4	0.18 [-0.46, 0.82]
			Placebo	18	17 (94.4)	0.02 (0.24)	-0.6	-0.10	0.01	0.14	0.5	
		Week 24	Tezepelumab	21	21 (100.0)	0.01 (0.19)	-0.2	-0.13	0.00	0.10	0.4	0.13 [-0.55, 0.81]
			Placebo	18	14 (77.8)	-0.02 (0.24)	-0.5	-0.21	0.04	0.10	0.4	
		Week 36	Tezepelumab	21	21 (100.0)	-0.03 (0.31)	-0.5	-0.18	-0.10	0.16	0.6	-0.24 [-0.91, 0.42]
			Placebo	18	15 (83.3)	0.03 (0.22)	-0.3	-0.19	0.04	0.22	0.4	
		Week 52	Tezepelumab	21	21 (100.0)	-0.02 (0.28)	-0.7	-0.10	-0.01	0.11	0.7	-0.24 [-0.89, 0.42]
			Placebo	18	16 (88.9)	0.04 (0.24)	-0.3	-0.10	0.02	0.10	0.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Absolute values	Baseline	Tezepelumab	32	32 (100.0)	1.71 (0.71)	0.4	1.25	1.73	2.06	3.3	
			Placebo	22	22 (100.0)	1.76 (0.52)	0.8	1.49	1.75	2.11	2.8	
		Week 2	Tezepelumab	32	31 (96.9)	1.78 (0.68)	0.6	1.29	1.79	2.36	3.4	
			Placebo	22	18 (81.8)	1.74 (0.55)	0.8	1.38	1.73	1.97	2.8	
		Week 4	Tezepelumab	32	32 (100.0)	1.78 (0.77)	0.7	1.23	1.66	2.44	3.4	
			Placebo	22	22 (100.0)	1.76 (0.55)	0.9	1.43	1.73	1.99	3.0	
		Week 8	Tezepelumab	32	30 (93.8)	1.73 (0.65)	0.6	1.23	1.68	2.05	3.3	
			Placebo	22	22 (100.0)	1.76 (0.60)	0.8	1.41	1.77	1.98	2.8	
		Week 12	Tezepelumab	32	32 (100.0)	1.76 (0.73)	0.6	1.23	1.68	2.23	3.6	
			Placebo	22	21 (95.5)	1.76 (0.60)	0.9	1.43	1.61	2.14	3.0	
		Week 16	Tezepelumab	32	31 (96.9)	1.85 (0.77)	0.6	1.43	1.65	2.28	3.5	
			Placebo	22	21 (95.5)	1.75 (0.57)	0.9	1.41	1.71	1.90	3.0	
		Week 24	Tezepelumab	32	31 (96.9)	1.73 (0.64)	0.6	1.12	1.70	2.26	3.5	
			Placebo	22	20 (90.9)	1.77 (0.50)	0.8	1.49	1.71	2.09	2.7	
		Week 36	Tezepelumab	32	30 (93.8)	1.70 (0.66)	0.5	1.25	1.63	2.12	3.5	
			Placebo	22	19 (86.4)	1.82 (0.59)	0.9	1.41	1.78	2.36	3.0	
		Week 52	Tezepelumab	32	28 (87.5)	1.73 (0.65)	0.7	1.16	1.73	2.20	3.4	
			Placebo	22	19 (86.4)	1.77 (0.58)	0.9	1.49	1.68	2.15	2.9	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Change from baseline	Week 2	Tezepelumab	32	31 (96.9)	0.06 (0.25)	-0.6	-0.02	0.08	0.15	0.8	0.41 [-0.18, 0.99]
			Placebo	22	18 (81.8)	-0.03 (0.20)	-0.4	-0.10	-0.06	0.04	0.5	
		Week 4	Tezepelumab	32	32 (100.0)	0.08 (0.42)	-0.9	-0.11	0.04	0.28	1.7	0.24 [-0.31, 0.78]
			Placebo	22	22 (100.0)	-0.01 (0.18)	-0.3	-0.07	0.02	0.09	0.4	
		Week 8	Tezepelumab	32	30 (93.8)	0.08 (0.34)	-0.8	-0.08	0.03	0.16	1.2	0.28 [-0.27, 0.83]
			Placebo	22	22 (100.0)	-0.00 (0.26)	-0.8	-0.06	0.02	0.10	0.5	
		Week 12	Tezepelumab	32	32 (100.0)	0.06 (0.34)	-0.7	-0.10	0.02	0.19	1.4	0.22 [-0.33, 0.78]
			Placebo	22	21 (95.5)	-0.01 (0.20)	-0.4	-0.07	-0.01	0.05	0.4	
		Week 16	Tezepelumab	32	31 (96.9)	0.12 (0.40)	-0.6	-0.07	0.12	0.28	1.6	0.44 [-0.12, 1.00]
			Placebo	22	21 (95.5)	-0.03 (0.24)	-0.6	-0.10	0.01	0.08	0.5	
		Week 24	Tezepelumab	32	31 (96.9)	0.07 (0.30)	-0.6	-0.10	0.00	0.22	1.0	0.29 [-0.27, 0.86]
			Placebo	22	20 (90.9)	-0.00 (0.18)	-0.5	-0.09	0.03	0.08	0.4	
		Week 36	Tezepelumab	32	30 (93.8)	0.03 (0.35)	-0.7	-0.12	0.01	0.21	1.1	-0.07 [-0.64, 0.51]
			Placebo	22	19 (86.4)	0.05 (0.19)	-0.3	-0.09	0.06	0.19	0.4	
		Week 52	Tezepelumab	32	28 (87.5)	0.05 (0.38)	-1.0	-0.07	0.03	0.23	1.0	0.03 [-0.55, 0.62]
			Placebo	22	19 (86.4)	0.04 (0.22)	-0.5	-0.07	0.08	0.13	0.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Absolute values	Baseline	Tezepelumab	23	23 (100.0)	1.93 (0.52)	1.0	1.48	2.02	2.39	2.7	
			Placebo	18	18 (100.0)	1.69 (0.55)	0.9	1.35	1.58	1.93	3.2	
		Week 2	Tezepelumab	23	22 (95.7)	1.97 (0.52)	1.0	1.58	1.99	2.38	2.9	
			Placebo	18	17 (94.4)	1.74 (0.77)	0.9	1.29	1.61	1.80	4.1	
		Week 4	Tezepelumab	23	23 (100.0)	1.95 (0.47)	1.1	1.64	2.00	2.25	2.8	
			Placebo	18	17 (94.4)	1.86 (0.91)	1.0	1.38	1.56	2.02	4.8	
		Week 8	Tezepelumab	23	23 (100.0)	2.01 (0.54)	1.2	1.58	1.92	2.51	2.8	
			Placebo	18	17 (94.4)	1.88 (0.84)	0.8	1.48	1.69	2.03	4.6	
		Week 12	Tezepelumab	23	22 (95.7)	1.99 (0.55)	1.1	1.55	1.96	2.41	3.0	
			Placebo	18	18 (100.0)	1.85 (0.83)	0.8	1.41	1.64	2.10	4.6	
		Week 16	Tezepelumab	23	23 (100.0)	1.98 (0.54)	1.1	1.49	1.91	2.41	3.0	
			Placebo	18	18 (100.0)	1.79 (0.86)	0.8	1.32	1.66	2.04	4.7	
		Week 24	Tezepelumab	23	23 (100.0)	1.98 (0.53)	1.1	1.61	1.91	2.43	2.9	
			Placebo	18	16 (88.9)	1.76 (0.96)	0.8	1.25	1.44	2.02	4.8	
		Week 36	Tezepelumab	23	23 (100.0)	2.00 (0.60)	1.1	1.51	1.85	2.52	3.1	
			Placebo	18	16 (88.9)	1.79 (0.80)	1.1	1.41	1.53	1.85	4.3	
		Week 52	Tezepelumab	23	23 (100.0)	1.97 (0.58)	1.0	1.54	1.97	2.39	3.1	
			Placebo	18	16 (88.9)	1.76 (0.78)	1.1	1.15	1.64	2.01	4.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Change from baseline	Week 2	Tezepelumab	23	22 (95.7)	0.02 (0.23)	-0.7	-0.01	0.03	0.09	0.5	-0.15 [-0.78, 0.49]
			Placebo	18	17 (94.4)	0.06 (0.28)	-0.3	-0.07	0.01	0.10	0.9	
		Week 4	Tezepelumab	23	23 (100.0)	0.03 (0.22)	-0.5	-0.08	0.01	0.15	0.6	-0.50 [-1.14, 0.14]
			Placebo	18	17 (94.4)	0.18 (0.41)	-0.3	0.01	0.10	0.28	1.6	
		Week 8	Tezepelumab	23	23 (100.0)	0.08 (0.22)	-0.5	-0.05	0.04	0.21	0.7	-0.25 [-0.88, 0.38]
			Placebo	18	17 (94.4)	0.16 (0.37)	-0.2	-0.07	0.11	0.20	1.4	
		Week 12	Tezepelumab	23	22 (95.7)	0.07 (0.23)	-0.3	-0.06	0.05	0.14	0.7	-0.32 [-0.95, 0.31]
			Placebo	18	18 (100.0)	0.16 (0.35)	-0.3	-0.03	0.06	0.26	1.4	
		Week 16	Tezepelumab	23	23 (100.0)	0.06 (0.20)	-0.5	-0.05	0.04	0.19	0.4	-0.15 [-0.76, 0.47]
			Placebo	18	18 (100.0)	0.10 (0.40)	-0.6	-0.06	0.02	0.19	1.4	
		Week 24	Tezepelumab	23	23 (100.0)	0.05 (0.24)	-0.3	-0.12	0.00	0.23	0.6	-0.01 [-0.65, 0.63]
			Placebo	18	16 (88.9)	0.06 (0.48)	-0.5	-0.26	0.04	0.10	1.6	
		Week 36	Tezepelumab	23	23 (100.0)	0.07 (0.32)	-0.8	-0.15	0.04	0.25	0.8	-0.18 [-0.82, 0.46]
			Placebo	18	16 (88.9)	0.13 (0.34)	-0.3	-0.10	0.05	0.31	1.1	
		Week 52	Tezepelumab	23	23 (100.0)	0.04 (0.32)	-0.8	-0.07	0.00	0.18	0.7	-0.11 [-0.75, 0.53]
			Placebo	18	16 (88.9)	0.07 (0.31)	-0.4	-0.16	0.04	0.20	0.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	33	33 (100.0)	1.70 (0.63)	0.4	1.27	1.72	2.20	2.7	
			Placebo	25	25 (100.0)	1.67 (0.47)	0.8	1.41	1.54	1.89	2.8	
		Week 2	Tezepelumab	33	32 (97.0)	1.80 (0.62)	0.6	1.31	1.80	2.36	2.7	
			Placebo	25	22 (88.0)	1.62 (0.54)	0.8	1.34	1.54	1.85	2.8	
		Week 4	Tezepelumab	33	33 (100.0)	1.79 (0.68)	0.7	1.27	1.67	2.40	3.4	
			Placebo	25	24 (96.0)	1.73 (0.54)	0.9	1.35	1.71	2.01	3.0	
		Week 8	Tezepelumab	33	33 (100.0)	1.81 (0.64)	0.6	1.29	1.79	2.38	2.9	
			Placebo	25	24 (96.0)	1.76 (0.52)	0.8	1.45	1.75	1.96	2.8	
		Week 12	Tezepelumab	33	32 (97.0)	1.77 (0.67)	0.6	1.23	1.73	2.35	3.1	
			Placebo	25	25 (100.0)	1.73 (0.54)	0.8	1.41	1.61	2.13	3.0	
		Week 16	Tezepelumab	33	32 (97.0)	1.84 (0.74)	0.6	1.31	1.77	2.48	3.3	
			Placebo	25	25 (100.0)	1.68 (0.51)	0.8	1.33	1.66	1.78	3.0	
		Week 24	Tezepelumab	33	33 (100.0)	1.79 (0.60)	0.6	1.18	1.71	2.30	2.9	
			Placebo	25	22 (88.0)	1.66 (0.51)	0.8	1.40	1.57	2.11	2.7	
		Week 36	Tezepelumab	33	32 (97.0)	1.78 (0.67)	0.5	1.24	1.68	2.32	3.1	
			Placebo	25	22 (88.0)	1.71 (0.49)	0.9	1.41	1.64	1.88	3.0	
		Week 52	Tezepelumab	33	31 (93.9)	1.78 (0.68)	0.7	1.17	1.74	2.21	3.1	
			Placebo	25	22 (88.0)	1.65 (0.52)	0.9	1.24	1.62	1.81	2.9	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Change from baseline	Week 2	Tezepelumab	33	32 (97.0)	0.09 (0.19)	-0.3	0.01	0.06	0.12	0.8	0.40 [-0.15, 0.94]
			Placebo	25	22 (88.0)	0.01 (0.22)	-0.4	-0.07	0.01	0.10	0.5	
		Week 4	Tezepelumab	33	33 (100.0)	0.10 (0.37)	-0.5	-0.08	0.04	0.17	1.7	0.09 [-0.44, 0.61]
			Placebo	25	24 (96.0)	0.07 (0.19)	-0.3	-0.01	0.08	0.13	0.5	
		Week 8	Tezepelumab	33	33 (100.0)	0.11 (0.26)	-0.2	-0.06	0.04	0.20	1.2	0.21 [-0.32, 0.74]
			Placebo	25	24 (96.0)	0.06 (0.22)	-0.5	-0.07	0.05	0.18	0.5	
		Week 12	Tezepelumab	33	32 (97.0)	0.09 (0.32)	-0.3	-0.09	0.03	0.18	1.4	0.10 [-0.42, 0.63]
			Placebo	25	25 (100.0)	0.06 (0.17)	-0.3	-0.03	0.02	0.12	0.4	
		Week 16	Tezepelumab	33	32 (97.0)	0.13 (0.35)	-0.6	-0.02	0.11	0.27	1.6	0.39 [-0.13, 0.92]
			Placebo	25	25 (100.0)	0.01 (0.25)	-0.6	-0.10	0.02	0.18	0.5	
		Week 24	Tezepelumab	33	33 (100.0)	0.09 (0.29)	-0.3	-0.12	0.00	0.21	1.0	0.37 [-0.18, 0.91]
			Placebo	25	22 (88.0)	-0.00 (0.22)	-0.5	-0.05	0.03	0.07	0.4	
		Week 36	Tezepelumab	33	32 (97.0)	0.07 (0.32)	-0.5	-0.12	0.04	0.20	1.1	-0.04 [-0.59, 0.50]
			Placebo	25	22 (88.0)	0.08 (0.19)	-0.3	-0.07	0.07	0.22	0.4	
		Week 52	Tezepelumab	33	31 (93.9)	0.09 (0.32)	-0.4	-0.09	0.01	0.18	1.0	0.26 [-0.29, 0.81]
			Placebo	25	22 (88.0)	0.01 (0.25)	-0.5	-0.20	0.08	0.15	0.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	22	22 (100.0)	1.95 (0.64)	0.9	1.48	1.93	2.37	3.3	
			Placebo	14	14 (100.0)	1.87 (0.63)	0.9	1.59	1.82	2.17	3.2	
		Week 2	Tezepelumab	22	21 (95.5)	1.95 (0.63)	0.9	1.55	1.86	2.36	3.4	
			Placebo	14	12 (85.7)	2.00 (0.82)	1.0	1.67	1.85	2.27	4.1	
		Week 4	Tezepelumab	22	22 (100.0)	1.94 (0.65)	0.7	1.64	1.96	2.24	3.3	
			Placebo	14	14 (100.0)	1.95 (0.98)	1.0	1.55	1.70	2.20	4.8	
		Week 8	Tezepelumab	22	20 (90.9)	1.92 (0.58)	0.9	1.58	1.78	2.27	3.3	
			Placebo	14	14 (100.0)	1.92 (0.98)	0.8	1.22	1.77	2.23	4.6	
		Week 12	Tezepelumab	22	22 (100.0)	1.98 (0.66)	0.8	1.62	1.95	2.21	3.6	
			Placebo	14	13 (92.9)	1.96 (0.98)	0.9	1.43	1.66	2.14	4.6	
		Week 16	Tezepelumab	22	22 (100.0)	2.00 (0.58)	0.9	1.56	1.88	2.27	3.5	
			Placebo	14	13 (92.9)	1.98 (0.99)	0.9	1.41	1.71	2.10	4.7	
		Week 24	Tezepelumab	22	21 (95.5)	1.91 (0.62)	0.8	1.61	1.89	2.27	3.5	
			Placebo	14	13 (92.9)	1.95 (1.01)	1.0	1.29	1.72	2.07	4.8	
		Week 36	Tezepelumab	22	21 (95.5)	1.91 (0.61)	0.9	1.51	1.85	2.20	3.5	
			Placebo	14	12 (85.7)	2.01 (0.96)	1.0	1.32	1.76	2.55	4.3	
		Week 52	Tezepelumab	22	20 (90.9)	1.91 (0.55)	0.9	1.58	1.80	2.28	3.4	
			Placebo	14	12 (85.7)	2.00 (0.88)	1.0	1.37	1.84	2.50	4.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Change from baseline	Week 2	Tezepelumab	22	21 (95.5)	-0.02 (0.30)	-0.7	-0.10	0.01	0.20	0.5	-0.15 [-0.86, 0.56]
			Placebo	14	12 (85.7)	0.03 (0.30)	-0.3	-0.09	-0.07	0.06	0.9	
		Week 4	Tezepelumab	22	22 (100.0)	-0.01 (0.30)	-0.9	-0.18	0.04	0.17	0.5	-0.25 [-0.93, 0.42]
			Placebo	14	14 (100.0)	0.09 (0.47)	-0.3	-0.14	-0.02	0.07	1.6	
		Week 8	Tezepelumab	22	20 (90.9)	0.03 (0.35)	-0.8	-0.13	0.05	0.17	0.7	-0.05 [-0.74, 0.63]
			Placebo	14	14 (100.0)	0.06 (0.45)	-0.8	-0.07	-0.01	0.08	1.4	
		Week 12	Tezepelumab	22	22 (100.0)	0.02 (0.25)	-0.7	-0.03	0.07	0.15	0.4	-0.15 [-0.84, 0.53]
			Placebo	14	13 (92.9)	0.08 (0.45)	-0.4	-0.09	-0.03	0.20	1.4	
		Week 16	Tezepelumab	22	22 (100.0)	0.04 (0.28)	-0.6	-0.09	0.09	0.19	0.7	-0.13 [-0.82, 0.56]
			Placebo	14	13 (92.9)	0.09 (0.46)	-0.6	-0.07	0.00	0.10	1.4	
		Week 24	Tezepelumab	22	21 (95.5)	0.02 (0.24)	-0.6	-0.10	0.00	0.23	0.4	-0.11 [-0.81, 0.58]
			Placebo	14	13 (92.9)	0.06 (0.51)	-0.5	-0.21	0.03	0.10	1.6	
		Week 36	Tezepelumab	22	21 (95.5)	0.02 (0.37)	-0.8	-0.12	0.04	0.22	0.8	-0.22 [-0.93, 0.49]
			Placebo	14	12 (85.7)	0.11 (0.39)	-0.3	-0.20	-0.04	0.30	1.1	
		Week 52	Tezepelumab	22	20 (90.9)	-0.03 (0.38)	-1.0	-0.05	0.01	0.23	0.4	-0.46 [-1.18, 0.27]
			Placebo	14	12 (85.7)	0.13 (0.28)	-0.2	-0.05	0.02	0.27	0.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Absolute values	Baseline	Tezepelumab	50	50 (100.0)	1.76 (0.65)	0.4	1.28	1.71	2.20	3.3	
			Placebo	38	38 (100.0)	1.71 (0.47)	0.8	1.41	1.70	2.04	2.8	
		Week 2	Tezepelumab	50	48 (96.0)	1.80 (0.62)	0.6	1.37	1.76	2.24	3.4	
			Placebo	38	33 (86.8)	1.69 (0.52)	0.8	1.35	1.71	1.93	2.8	
		Week 4	Tezepelumab	50	50 (100.0)	1.81 (0.68)	0.7	1.42	1.68	2.25	3.4	
			Placebo	38	37 (97.4)	1.74 (0.52)	0.9	1.43	1.69	1.99	3.0	
		Week 8	Tezepelumab	50	48 (96.0)	1.79 (0.60)	0.6	1.37	1.68	2.13	3.3	
			Placebo	38	37 (97.4)	1.77 (0.52)	0.8	1.48	1.74	1.98	2.8	
		Week 12	Tezepelumab	50	49 (98.0)	1.81 (0.68)	0.6	1.38	1.70	2.28	3.6	
			Placebo	38	37 (97.4)	1.75 (0.54)	0.8	1.42	1.62	2.13	3.0	
		Week 16	Tezepelumab	50	49 (98.0)	1.86 (0.70)	0.6	1.43	1.67	2.28	3.5	
			Placebo	38	37 (97.4)	1.71 (0.52)	0.8	1.33	1.68	1.90	3.0	
		Week 24	Tezepelumab	50	49 (98.0)	1.79 (0.61)	0.6	1.40	1.71	2.24	3.5	
			Placebo	38	34 (89.5)	1.69 (0.51)	0.8	1.40	1.63	2.07	2.7	
		Week 36	Tezepelumab	50	48 (96.0)	1.78 (0.64)	0.5	1.27	1.68	2.20	3.5	
			Placebo	38	33 (86.8)	1.75 (0.52)	0.9	1.43	1.69	1.92	3.0	
		Week 52	Tezepelumab	50	46 (92.0)	1.79 (0.64)	0.7	1.37	1.73	2.20	3.4	
			Placebo	38	33 (86.8)	1.72 (0.54)	0.9	1.34	1.66	1.97	2.9	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Change from baseline	Week 2	Tezepelumab	50	48 (96.0)	0.03 (0.24)	-0.7	-0.01	0.05	0.14	0.8	0.21 [-0.24, 0.65]
			Placebo	38	33 (86.8)	-0.01 (0.20)	-0.4	-0.09	-0.01	0.06	0.5	
		Week 4	Tezepelumab	50	50 (100.0)	0.05 (0.36)	-0.9	-0.13	0.01	0.17	1.7	0.04 [-0.38, 0.47]
			Placebo	38	37 (97.4)	0.04 (0.20)	-0.3	-0.05	0.04	0.11	0.5	
		Week 8	Tezepelumab	50	48 (96.0)	0.07 (0.29)	-0.8	-0.08	0.03	0.18	1.2	0.11 [-0.32, 0.54]
			Placebo	38	37 (97.4)	0.04 (0.24)	-0.8	-0.06	0.04	0.13	0.5	
		Week 12	Tezepelumab	50	49 (98.0)	0.06 (0.30)	-0.7	-0.09	0.04	0.15	1.4	0.07 [-0.36, 0.50]
			Placebo	38	37 (97.4)	0.04 (0.20)	-0.4	-0.05	0.02	0.19	0.4	
		Week 16	Tezepelumab	50	49 (98.0)	0.09 (0.34)	-0.6	-0.07	0.09	0.22	1.6	0.32 [-0.11, 0.75]
			Placebo	38	37 (97.4)	-0.00 (0.24)	-0.6	-0.10	0.01	0.14	0.5	
		Week 24	Tezepelumab	50	49 (98.0)	0.06 (0.28)	-0.6	-0.10	0.00	0.21	1.0	0.33 [-0.11, 0.77]
			Placebo	38	34 (89.5)	-0.02 (0.23)	-0.5	-0.11	0.03	0.09	0.4	
		Week 36	Tezepelumab	50	48 (96.0)	0.04 (0.31)	-0.7	-0.12	0.04	0.21	1.1	-0.07 [-0.51, 0.37]
			Placebo	38	33 (86.8)	0.06 (0.21)	-0.3	-0.09	0.06	0.22	0.4	
		Week 52	Tezepelumab	50	46 (92.0)	0.05 (0.34)	-1.0	-0.07	0.01	0.18	1.0	0.05 [-0.40, 0.49]
			Placebo	38	33 (86.8)	0.04 (0.23)	-0.5	-0.07	0.06	0.15	0.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Absolute values	Baseline	Tezepelumab	5	5 (100.0)	2.23 (0.26)	2.0	2.02	2.12	2.39	2.6	
			Placebo	2	2 (100.0)	2.14 (1.55)	1.0	1.04	2.14	3.23	3.2	
		Week 2	Tezepelumab	5	5 (100.0)	2.38 (0.39)	1.9	2.13	2.38	2.54	2.9	
			Placebo	2	2 (100.0)	2.53 (2.21)	1.0	0.97	2.53	4.09	4.1	
		Week 4	Tezepelumab	5	5 (100.0)	2.32 (0.25)	2.1	2.17	2.24	2.45	2.7	
			Placebo	2	2 (100.0)	2.92 (2.71)	1.0	1.00	2.92	4.83	4.8	
		Week 8	Tezepelumab	5	5 (100.0)	2.47 (0.35)	1.9	2.43	2.59	2.68	2.8	
			Placebo	2	2 (100.0)	2.70 (2.70)	0.8	0.79	2.70	4.61	4.6	
		Week 12	Tezepelumab	5	5 (100.0)	2.34 (0.23)	2.2	2.20	2.21	2.39	2.7	
			Placebo	2	2 (100.0)	2.78 (2.55)	1.0	0.98	2.78	4.58	4.6	
		Week 16	Tezepelumab	5	5 (100.0)	2.35 (0.14)	2.2	2.27	2.31	2.39	2.6	
			Placebo	2	2 (100.0)	2.82 (2.62)	1.0	0.97	2.82	4.67	4.7	
		Week 24	Tezepelumab	5	5 (100.0)	2.31 (0.26)	1.9	2.27	2.29	2.55	2.6	
			Placebo	2	2 (100.0)	2.94 (2.64)	1.1	1.07	2.94	4.81	4.8	
		Week 36	Tezepelumab	5	5 (100.0)	2.36 (0.43)	1.9	1.97	2.50	2.59	2.9	
			Placebo	2	2 (100.0)	2.67 (2.35)	1.0	1.00	2.67	4.33	4.3	
		Week 52	Tezepelumab	5	5 (100.0)	2.22 (0.26)	1.8	2.20	2.26	2.39	2.5	
			Placebo	2	2 (100.0)	2.49 (2.16)	1.0	0.96	2.49	4.01	4.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Change from baseline	Week 2	Tezepelumab	5	5 (100.0)	0.15 (0.26)	-0.1	-0.01	0.01	0.31	0.5	-0.66 [-2.35, 1.03]
			Placebo	2	2 (100.0)	0.40 (0.66)	-0.1	-0.07	0.40	0.86	0.9	
		Week 4	Tezepelumab	5	5 (100.0)	0.09 (0.07)	0.0	0.05	0.06	0.07	0.2	-1.32 [-3.15, 0.51]
			Placebo	2	2 (100.0)	0.78 (1.16)	-0.0	-0.04	0.78	1.60	1.6	
		Week 8	Tezepelumab	5	5 (100.0)	0.23 (0.33)	-0.1	0.04	0.13	0.47	0.7	-0.56 [-2.24, 1.11]
			Placebo	2	2 (100.0)	0.57 (1.15)	-0.3	-0.25	0.57	1.38	1.4	
		Week 12	Tezepelumab	5	5 (100.0)	0.11 (0.21)	-0.2	0.08	0.10	0.19	0.4	-1.11 [-2.89, 0.67]
			Placebo	2	2 (100.0)	0.65 (1.00)	-0.1	-0.06	0.65	1.35	1.4	
		Week 16	Tezepelumab	5	5 (100.0)	0.11 (0.14)	-0.1	0.00	0.15	0.17	0.3	-1.16 [-2.95, 0.63]
			Placebo	2	2 (100.0)	0.69 (1.07)	-0.1	-0.07	0.69	1.44	1.4	
		Week 24	Tezepelumab	5	5 (100.0)	0.08 (0.25)	-0.1	-0.11	-0.07	0.27	0.4	-1.34 [-3.18, 0.50]
			Placebo	2	2 (100.0)	0.81 (1.10)	0.0	0.03	0.81	1.58	1.6	
		Week 36	Tezepelumab	5	5 (100.0)	0.12 (0.60)	-0.8	-0.05	0.11	0.57	0.8	-0.63 [-2.32, 1.05]
			Placebo	2	2 (100.0)	0.53 (0.81)	-0.0	-0.04	0.53	1.10	1.1	
		Week 52	Tezepelumab	5	5 (100.0)	-0.01 (0.47)	-0.8	0.00	0.18	0.24	0.4	-0.72 [-2.42, 0.98]
			Placebo	2	2 (100.0)	0.35 (0.61)	-0.1	-0.08	0.35	0.78	0.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Absolute values	Baseline	Tezepelumab	8	8 (100.0)	1.67 (0.69)	0.4	1.22	1.88	2.08	2.6	
			Placebo	7	7 (100.0)	1.72 (0.45)	0.9	1.54	1.70	2.11	2.2	
		Week 2	Tezepelumab	8	8 (100.0)	1.75 (0.68)	0.6	1.35	1.83	2.05	2.9	
			Placebo	7	5 (71.4)	1.91 (0.22)	1.7	1.74	1.85	1.97	2.3	
		Week 4	Tezepelumab	8	8 (100.0)	1.86 (0.65)	0.7	1.52	1.86	2.37	2.7	
			Placebo	7	7 (100.0)	1.70 (0.41)	1.1	1.56	1.69	1.79	2.5	
		Week 8	Tezepelumab	8	7 (87.5)	1.70 (0.73)	0.6	1.21	1.79	2.38	2.8	
			Placebo	7	7 (100.0)	1.81 (0.55)	0.8	1.59	1.74	2.35	2.5	
		Week 12	Tezepelumab	8	7 (87.5)	1.76 (0.68)	0.6	1.21	1.75	2.21	2.7	
			Placebo	7	6 (85.7)	1.73 (0.56)	0.9	1.48	1.63	2.13	2.6	
		Week 16	Tezepelumab	8	8 (100.0)	1.76 (0.71)	0.6	1.12	2.01	2.30	2.6	
			Placebo	7	6 (85.7)	1.60 (0.42)	0.9	1.41	1.68	1.76	2.2	
		Week 24	Tezepelumab	8	8 (100.0)	1.81 (0.51)	1.1	1.40	1.78	2.21	2.6	
			Placebo	7	6 (85.7)	1.63 (0.45)	1.0	1.29	1.60	2.07	2.2	
		Week 36	Tezepelumab	8	8 (100.0)	1.68 (0.51)	0.9	1.26	1.78	2.09	2.3	
			Placebo	7	5 (71.4)	1.61 (0.30)	1.2	1.46	1.69	1.81	1.9	
		Week 52	Tezepelumab	8	8 (100.0)	1.72 (0.55)	0.8	1.36	1.77	2.18	2.4	
			Placebo	7	6 (85.7)	1.72 (0.43)	1.0	1.62	1.72	1.97	2.3	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	8	8 (100.0)	0.07 (0.15)	-0.1	-0.04	0.03	0.21	0.3	0.49 [-0.64, 1.63]
			Placebo	7	5 (71.4)	-0.00 (0.17)	-0.3	-0.07	0.04	0.10	0.2	
		Week 4	Tezepelumab	8	8 (100.0)	0.18 (0.27)	-0.2	0.03	0.09	0.40	0.6	0.77 [-0.29, 1.83]
			Placebo	7	7 (100.0)	-0.01 (0.24)	-0.3	-0.28	-0.02	0.20	0.3	
		Week 8	Tezepelumab	8	7 (87.5)	0.07 (0.19)	-0.2	-0.14	0.13	0.25	0.3	-0.09 [-1.14, 0.96]
			Placebo	7	7 (100.0)	0.09 (0.18)	-0.1	-0.06	0.00	0.20	0.4	
		Week 12	Tezepelumab	8	7 (87.5)	0.15 (0.29)	-0.2	-0.09	0.10	0.21	0.7	0.57 [-0.55, 1.69]
			Placebo	7	6 (85.7)	-0.01 (0.27)	-0.4	-0.06	-0.01	0.04	0.4	
		Week 16	Tezepelumab	8	8 (100.0)	0.08 (0.17)	-0.2	-0.02	0.11	0.21	0.3	0.88 [-0.23, 2.00]
			Placebo	7	6 (85.7)	-0.14 (0.33)	-0.6	-0.45	0.01	0.02	0.2	
		Week 24	Tezepelumab	8	8 (100.0)	0.13 (0.36)	-0.2	-0.13	-0.04	0.46	0.7	0.74 [-0.36, 1.84]
			Placebo	7	6 (85.7)	-0.11 (0.26)	-0.5	-0.41	-0.01	0.09	0.1	
		Week 36	Tezepelumab	8	8 (100.0)	0.01 (0.38)	-0.8	-0.13	0.01	0.30	0.4	0.14 [-0.98, 1.26]
			Placebo	7	5 (71.4)	-0.04 (0.25)	-0.2	-0.23	-0.19	0.15	0.3	
		Week 52	Tezepelumab	8	8 (100.0)	0.05 (0.44)	-0.8	-0.15	0.11	0.38	0.5	0.16 [-0.90, 1.23]
			Placebo	7	6 (85.7)	-0.02 (0.25)	-0.5	-0.07	0.07	0.15	0.2	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Absolute values	Baseline	Tezepelumab	47	47 (100.0)	1.82 (0.63)	0.6	1.28	1.74	2.27	3.3	
			Placebo	33	33 (100.0)	1.73 (0.55)	0.8	1.39	1.69	1.93	3.2	
		Week 2	Tezepelumab	47	45 (95.7)	1.88 (0.61)	0.7	1.48	1.80	2.38	3.4	
			Placebo	33	30 (90.9)	1.71 (0.70)	0.8	1.29	1.60	1.93	4.1	
		Week 4	Tezepelumab	47	47 (100.0)	1.85 (0.68)	0.7	1.44	1.75	2.40	3.4	
			Placebo	33	32 (97.0)	1.82 (0.77)	0.9	1.35	1.69	2.11	4.8	
		Week 8	Tezepelumab	47	46 (97.9)	1.87 (0.60)	0.7	1.57	1.80	2.40	3.3	
			Placebo	33	32 (97.0)	1.81 (0.74)	0.8	1.41	1.75	2.01	4.6	
		Week 12	Tezepelumab	47	47 (100.0)	1.87 (0.67)	0.7	1.44	1.77	2.37	3.6	
			Placebo	33	33 (100.0)	1.82 (0.74)	0.8	1.41	1.62	2.14	4.6	
		Week 16	Tezepelumab	47	46 (97.9)	1.93 (0.68)	0.6	1.49	1.77	2.34	3.5	
			Placebo	33	33 (100.0)	1.80 (0.75)	0.8	1.33	1.68	2.04	4.7	
		Week 24	Tezepelumab	47	46 (97.9)	1.84 (0.63)	0.6	1.52	1.83	2.30	3.5	
			Placebo	33	30 (90.9)	1.79 (0.77)	0.8	1.40	1.65	2.11	4.8	
		Week 36	Tezepelumab	47	45 (95.7)	1.86 (0.67)	0.5	1.43	1.83	2.33	3.5	
			Placebo	33	30 (90.9)	1.84 (0.73)	0.9	1.41	1.65	2.26	4.3	
		Week 52	Tezepelumab	47	43 (91.5)	1.85 (0.64)	0.7	1.43	1.80	2.27	3.4	
			Placebo	33	29 (87.9)	1.77 (0.71)	0.9	1.24	1.62	2.15	4.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Change from baseline	Week 2	Tezepelumab	47	45 (95.7)	0.04 (0.26)	-0.7	-0.01	0.05	0.12	0.8	0.10 [-0.36, 0.57]
			Placebo	33	30 (90.9)	0.01 (0.26)	-0.4	-0.09	-0.03	0.06	0.9	
		Week 4	Tezepelumab	47	47 (100.0)	0.03 (0.36)	-0.9	-0.13	0.01	0.17	1.7	-0.18 [-0.63, 0.27]
			Placebo	33	32 (97.0)	0.10 (0.33)	-0.3	-0.04	0.04	0.11	1.6	
		Week 8	Tezepelumab	47	46 (97.9)	0.09 (0.31)	-0.8	-0.07	0.04	0.18	1.2	0.07 [-0.38, 0.53]
			Placebo	33	32 (97.0)	0.06 (0.34)	-0.8	-0.08	0.05	0.13	1.4	
		Week 12	Tezepelumab	47	47 (100.0)	0.05 (0.30)	-0.7	-0.09	0.04	0.15	1.4	-0.12 [-0.57, 0.32]
			Placebo	33	33 (100.0)	0.09 (0.29)	-0.4	-0.05	0.02	0.20	1.4	
		Week 16	Tezepelumab	47	46 (97.9)	0.10 (0.35)	-0.6	-0.07	0.10	0.25	1.6	0.10 [-0.35, 0.55]
			Placebo	33	33 (100.0)	0.06 (0.32)	-0.6	-0.07	0.01	0.18	1.4	
		Week 24	Tezepelumab	47	46 (97.9)	0.05 (0.26)	-0.6	-0.11	0.01	0.21	1.0	0.01 [-0.45, 0.47]
			Placebo	33	30 (90.9)	0.05 (0.36)	-0.5	-0.10	0.03	0.10	1.6	
		Week 36	Tezepelumab	47	45 (95.7)	0.06 (0.33)	-0.7	-0.12	0.04	0.20	1.1	-0.17 [-0.63, 0.29]
			Placebo	33	30 (90.9)	0.11 (0.27)	-0.3	-0.07	0.06	0.29	1.1	
		Week 52	Tezepelumab	47	43 (91.5)	0.04 (0.34)	-1.0	-0.07	0.01	0.18	1.0	-0.08 [-0.55, 0.39]
			Placebo	33	29 (87.9)	0.07 (0.26)	-0.4	-0.08	0.06	0.15	0.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	15	15 (100.0)	1.80 (0.61)	0.6	1.41	1.96	2.20	2.6	
			Placebo	16	16 (100.0)	1.80 (0.41)	0.9	1.52	1.84	2.10	2.6	
		Week 2	Tezepelumab	15	15 (100.0)	1.85 (0.61)	0.7	1.29	1.86	2.38	2.7	
			Placebo	16	15 (93.8)	1.85 (0.48)	0.9	1.41	1.89	2.26	2.7	
		Week 4	Tezepelumab	15	15 (100.0)	1.88 (0.67)	0.7	1.42	2.07	2.48	2.8	
			Placebo	16	16 (100.0)	1.90 (0.46)	1.0	1.56	1.82	2.28	2.7	
		Week 8	Tezepelumab	15	14 (93.3)	1.92 (0.63)	0.7	1.57	1.84	2.43	2.8	
			Placebo	16	16 (100.0)	1.86 (0.52)	0.8	1.62	1.81	2.27	2.7	
		Week 12	Tezepelumab	15	14 (93.3)	1.86 (0.65)	0.7	1.45	1.91	2.32	3.0	
			Placebo	16	15 (93.8)	1.86 (0.52)	0.8	1.51	1.72	2.25	2.8	
		Week 16	Tezepelumab	15	15 (100.0)	1.92 (0.65)	0.6	1.55	2.18	2.39	3.0	
			Placebo	16	15 (93.8)	1.85 (0.52)	0.9	1.49	1.78	2.18	2.9	
		Week 24	Tezepelumab	15	15 (100.0)	1.84 (0.62)	0.6	1.61	1.89	2.29	2.9	
			Placebo	16	14 (87.5)	1.85 (0.46)	0.8	1.57	1.88	2.19	2.7	
		Week 36	Tezepelumab	15	15 (100.0)	1.81 (0.64)	0.5	1.28	1.97	2.32	2.8	
			Placebo	16	14 (87.5)	1.86 (0.49)	1.2	1.49	1.77	2.26	2.9	
		Week 52	Tezepelumab	15	14 (93.3)	1.90 (0.55)	0.9	1.54	2.15	2.26	2.8	
			Placebo	16	15 (93.8)	1.89 (0.52)	1.1	1.49	1.83	2.29	2.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	15	15 (100.0)	0.04 (0.23)	-0.6	-0.01	0.05	0.12	0.5	0.08 [-0.64, 0.79]
			Placebo	16	15 (93.8)	0.03 (0.22)	-0.3	-0.09	-0.06	0.10	0.5	
		Week 4	Tezepelumab	15	15 (100.0)	0.08 (0.29)	-0.6	-0.06	0.08	0.22	0.6	-0.06 [-0.77, 0.64]
			Placebo	16	16 (100.0)	0.10 (0.21)	-0.3	0.03	0.09	0.20	0.5	
		Week 8	Tezepelumab	15	14 (93.3)	0.12 (0.29)	-0.3	-0.09	0.11	0.25	0.7	0.24 [-0.48, 0.96]
			Placebo	16	16 (100.0)	0.06 (0.29)	-0.8	-0.05	0.07	0.19	0.5	
		Week 12	Tezepelumab	15	14 (93.3)	0.07 (0.30)	-0.4	-0.18	0.11	0.19	0.7	0.12 [-0.61, 0.85]
			Placebo	16	15 (93.8)	0.04 (0.25)	-0.4	-0.07	0.00	0.26	0.4	
		Week 16	Tezepelumab	15	15 (100.0)	0.11 (0.26)	-0.3	-0.07	0.08	0.29	0.7	0.33 [-0.39, 1.05]
			Placebo	16	15 (93.8)	0.03 (0.26)	-0.6	-0.10	0.01	0.18	0.5	
		Week 24	Tezepelumab	15	15 (100.0)	0.03 (0.23)	-0.2	-0.12	-0.03	0.15	0.6	0.11 [-0.62, 0.84]
			Placebo	16	14 (87.5)	0.01 (0.24)	-0.5	-0.10	0.04	0.10	0.4	
		Week 36	Tezepelumab	15	15 (100.0)	0.01 (0.30)	-0.5	-0.18	0.04	0.22	0.6	-0.23 [-0.96, 0.50]
			Placebo	16	14 (87.5)	0.07 (0.23)	-0.3	-0.11	0.05	0.30	0.4	
		Week 52	Tezepelumab	15	14 (93.3)	0.04 (0.32)	-0.7	-0.05	0.07	0.24	0.5	-0.13 [-0.86, 0.60]
			Placebo	16	15 (93.8)	0.07 (0.24)	-0.3	-0.07	0.08	0.17	0.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Absolute values	Baseline	Tezepelumab	40	40 (100.0)	1.80 (0.66)	0.4	1.28	1.71	2.24	3.3	
			Placebo	24	24 (100.0)	1.68 (0.60)	0.8	1.35	1.52	1.99	3.2	
		Week 2	Tezepelumab	40	38 (95.0)	1.86 (0.63)	0.6	1.48	1.80	2.36	3.4	
			Placebo	24	20 (83.3)	1.66 (0.77)	0.8	1.12	1.53	1.77	4.1	
		Week 4	Tezepelumab	40	40 (100.0)	1.84 (0.67)	0.7	1.49	1.74	2.15	3.4	
			Placebo	24	23 (95.8)	1.73 (0.86)	0.9	1.20	1.56	1.87	4.8	
		Week 8	Tezepelumab	40	39 (97.5)	1.83 (0.62)	0.6	1.43	1.75	2.15	3.3	
			Placebo	24	23 (95.8)	1.78 (0.82)	0.8	1.37	1.69	1.98	4.6	
		Week 12	Tezepelumab	40	40 (100.0)	1.86 (0.69)	0.6	1.41	1.75	2.33	3.6	
			Placebo	24	24 (100.0)	1.77 (0.81)	0.9	1.31	1.51	2.12	4.6	
		Week 16	Tezepelumab	40	39 (97.5)	1.90 (0.70)	0.6	1.43	1.70	2.28	3.5	
			Placebo	24	24 (100.0)	1.72 (0.81)	0.8	1.32	1.65	1.78	4.7	
		Week 24	Tezepelumab	40	39 (97.5)	1.84 (0.61)	0.8	1.40	1.76	2.30	3.5	
			Placebo	24	22 (91.7)	1.70 (0.86)	0.8	1.21	1.46	1.85	4.8	
		Week 36	Tezepelumab	40	38 (95.0)	1.84 (0.66)	0.8	1.43	1.80	2.30	3.5	
			Placebo	24	21 (87.5)	1.77 (0.79)	0.9	1.38	1.57	1.92	4.3	
		Week 52	Tezepelumab	40	37 (92.5)	1.81 (0.66)	0.7	1.43	1.75	2.20	3.4	
			Placebo	24	20 (83.3)	1.67 (0.76)	0.9	1.13	1.60	1.69	4.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Change from baseline	Week 2	Tezepelumab	40	38 (95.0)	0.05 (0.25)	-0.7	-0.02	0.05	0.15	0.8	0.18 [-0.36, 0.72]
			Placebo	24	20 (83.3)	-0.00 (0.27)	-0.4	-0.09	-0.01	0.04	0.9	
		Week 4	Tezepelumab	40	40 (100.0)	0.05 (0.37)	-0.9	-0.11	0.01	0.17	1.7	-0.05 [-0.56, 0.46]
			Placebo	24	23 (95.8)	0.06 (0.38)	-0.3	-0.13	0.01	0.11	1.6	
		Week 8	Tezepelumab	40	39 (97.5)	0.07 (0.30)	-0.8	-0.07	0.02	0.18	1.2	-0.01 [-0.53, 0.50]
			Placebo	24	23 (95.8)	0.07 (0.34)	-0.5	-0.07	0.04	0.13	1.4	
		Week 12	Tezepelumab	40	40 (100.0)	0.06 (0.30)	-0.7	-0.05	0.04	0.16	1.4	-0.10 [-0.61, 0.40]
			Placebo	24	24 (100.0)	0.09 (0.31)	-0.3	-0.05	0.02	0.16	1.4	
		Week 16	Tezepelumab	40	39 (97.5)	0.09 (0.35)	-0.6	-0.05	0.10	0.19	1.6	0.15 [-0.36, 0.66]
			Placebo	24	24 (100.0)	0.04 (0.37)	-0.6	-0.08	0.01	0.16	1.4	
		Week 24	Tezepelumab	40	39 (97.5)	0.08 (0.29)	-0.6	-0.10	0.02	0.23	1.0	0.13 [-0.40, 0.65]
			Placebo	24	22 (91.7)	0.04 (0.41)	-0.5	-0.11	0.03	0.09	1.6	
		Week 36	Tezepelumab	40	38 (95.0)	0.07 (0.35)	-0.8	-0.12	0.04	0.21	1.1	-0.10 [-0.64, 0.43]
			Placebo	24	21 (87.5)	0.10 (0.30)	-0.3	-0.07	0.06	0.22	1.1	
		Week 52	Tezepelumab	40	37 (92.5)	0.05 (0.36)	-1.0	-0.07	0.01	0.18	1.0	0.02 [-0.52, 0.56]
			Placebo	24	20 (83.3)	0.04 (0.28)	-0.5	-0.10	0.05	0.13	0.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	13	13 (100.0)	1.83 (0.51)	0.9	1.47	1.96	2.13	2.6	
			Placebo	15	15 (100.0)	1.80 (0.43)	0.9	1.45	1.85	2.16	2.6	
		Week 2	Tezepelumab	13	13 (100.0)	1.87 (0.53)	1.1	1.42	1.86	2.29	2.7	
			Placebo	15	14 (93.3)	1.85 (0.49)	0.9	1.41	1.91	2.26	2.7	
		Week 4	Tezepelumab	13	13 (100.0)	1.91 (0.58)	0.7	1.59	2.07	2.45	2.6	
			Placebo	15	15 (100.0)	1.92 (0.47)	1.0	1.57	1.85	2.35	2.7	
		Week 8	Tezepelumab	13	12 (92.3)	1.94 (0.51)	1.2	1.58	1.84	2.41	2.7	
			Placebo	15	15 (100.0)	1.91 (0.49)	0.8	1.65	1.82	2.30	2.7	
		Week 12	Tezepelumab	13	12 (92.3)	1.85 (0.50)	0.9	1.54	1.91	2.27	2.4	
			Placebo	15	14 (93.3)	1.89 (0.53)	0.8	1.60	1.77	2.25	2.8	
		Week 16	Tezepelumab	13	13 (100.0)	1.94 (0.49)	1.1	1.60	2.18	2.34	2.5	
			Placebo	15	14 (93.3)	1.85 (0.54)	0.9	1.49	1.75	2.18	2.9	
		Week 24	Tezepelumab	13	13 (100.0)	1.85 (0.47)	0.8	1.61	1.89	2.27	2.4	
			Placebo	15	13 (86.7)	1.87 (0.47)	0.8	1.57	2.02	2.19	2.7	
		Week 36	Tezepelumab	13	13 (100.0)	1.84 (0.51)	1.1	1.33	1.97	2.20	2.6	
			Placebo	15	13 (86.7)	1.88 (0.50)	1.2	1.49	1.80	2.26	2.9	
		Week 52	Tezepelumab	13	12 (92.3)	1.92 (0.44)	1.2	1.57	2.15	2.24	2.4	
			Placebo	15	14 (93.3)	1.87 (0.53)	1.1	1.49	1.82	2.29	2.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	13	13 (100.0)	0.04 (0.25)	-0.6	-0.01	0.05	0.12	0.5	0.01 [-0.74, 0.77]
			Placebo	15	14 (93.3)	0.04 (0.22)	-0.3	-0.07	-0.01	0.10	0.5	
		Week 4	Tezepelumab	13	13 (100.0)	0.08 (0.31)	-0.6	-0.06	0.06	0.22	0.6	-0.18 [-0.93, 0.56]
			Placebo	15	15 (100.0)	0.12 (0.19)	-0.3	0.03	0.09	0.28	0.5	
		Week 8	Tezepelumab	13	12 (92.3)	0.12 (0.31)	-0.3	-0.12	0.09	0.26	0.7	0.05 [-0.71, 0.81]
			Placebo	15	15 (100.0)	0.11 (0.20)	-0.2	-0.03	0.08	0.20	0.5	
		Week 12	Tezepelumab	13	12 (92.3)	0.04 (0.30)	-0.4	-0.19	0.04	0.17	0.7	-0.11 [-0.88, 0.66]
			Placebo	15	14 (93.3)	0.07 (0.23)	-0.4	-0.05	0.02	0.26	0.4	
		Week 16	Tezepelumab	13	13 (100.0)	0.11 (0.27)	-0.3	0.00	0.08	0.28	0.7	0.30 [-0.46, 1.06]
			Placebo	15	14 (93.3)	0.03 (0.27)	-0.6	-0.10	0.02	0.18	0.5	
		Week 24	Tezepelumab	13	13 (100.0)	0.02 (0.24)	-0.2	-0.12	-0.06	0.14	0.6	-0.02 [-0.79, 0.75]
			Placebo	15	13 (86.7)	0.02 (0.24)	-0.5	-0.08	0.05	0.10	0.4	
		Week 36	Tezepelumab	13	13 (100.0)	0.01 (0.32)	-0.5	-0.18	0.04	0.22	0.6	-0.33 [-1.10, 0.45]
			Placebo	15	13 (86.7)	0.09 (0.22)	-0.2	-0.09	0.07	0.30	0.4	
		Week 52	Tezepelumab	13	12 (92.3)	0.01 (0.33)	-0.7	-0.15	0.00	0.21	0.5	-0.15 [-0.92, 0.62]
			Placebo	15	14 (93.3)	0.05 (0.23)	-0.3	-0.07	0.03	0.15	0.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Absolute values	Baseline	Tezepelumab	42	42 (100.0)	1.79 (0.68)	0.4	1.28	1.71	2.27	3.3	
			Placebo	25	25 (100.0)	1.69 (0.58)	0.8	1.35	1.54	1.88	3.2	
		Week 2	Tezepelumab	42	40 (95.2)	1.86 (0.65)	0.6	1.45	1.80	2.39	3.4	
			Placebo	25	21 (84.0)	1.66 (0.75)	0.8	1.15	1.59	1.74	4.1	
		Week 4	Tezepelumab	42	42 (100.0)	1.84 (0.69)	0.7	1.44	1.74	2.17	3.4	
			Placebo	25	24 (96.0)	1.73 (0.84)	0.9	1.26	1.56	1.84	4.8	
		Week 8	Tezepelumab	42	41 (97.6)	1.83 (0.65)	0.6	1.43	1.75	2.15	3.3	
			Placebo	25	24 (96.0)	1.75 (0.81)	0.8	1.32	1.62	1.96	4.6	
		Week 12	Tezepelumab	42	42 (100.0)	1.86 (0.72)	0.6	1.38	1.75	2.37	3.6	
			Placebo	25	25 (100.0)	1.76 (0.80)	0.9	1.31	1.48	2.10	4.6	
		Week 16	Tezepelumab	42	41 (97.6)	1.89 (0.73)	0.6	1.43	1.70	2.28	3.5	
			Placebo	25	25 (100.0)	1.72 (0.80)	0.8	1.32	1.66	1.78	4.7	
		Week 24	Tezepelumab	42	41 (97.6)	1.83 (0.65)	0.6	1.40	1.76	2.30	3.5	
			Placebo	25	23 (92.0)	1.70 (0.84)	0.8	1.21	1.49	1.85	4.8	
		Week 36	Tezepelumab	42	40 (95.2)	1.83 (0.69)	0.5	1.34	1.80	2.32	3.5	
			Placebo	25	22 (88.0)	1.76 (0.78)	0.9	1.38	1.58	1.92	4.3	
		Week 52	Tezepelumab	42	39 (92.9)	1.81 (0.68)	0.7	1.37	1.75	2.27	3.4	
			Placebo	25	21 (84.0)	1.69 (0.75)	0.9	1.15	1.62	1.70	4.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Change from baseline	Week 2	Tezepelumab	42	40 (95.2)	0.05 (0.24)	-0.7	-0.01	0.05	0.15	0.8	0.21 [-0.32, 0.74]
			Placebo	25	21 (84.0)	-0.01 (0.26)	-0.4	-0.09	-0.01	0.04	0.9	
		Week 4	Tezepelumab	42	42 (100.0)	0.05 (0.36)	-0.9	-0.09	0.02	0.17	1.7	-0.00 [-0.50, 0.50]
			Placebo	25	24 (96.0)	0.05 (0.37)	-0.3	-0.13	0.00	0.11	1.6	
		Week 8	Tezepelumab	42	41 (97.6)	0.07 (0.29)	-0.8	-0.07	0.04	0.18	1.2	0.10 [-0.40, 0.61]
			Placebo	25	24 (96.0)	0.04 (0.38)	-0.8	-0.08	0.02	0.12	1.4	
		Week 12	Tezepelumab	42	42 (100.0)	0.07 (0.30)	-0.7	-0.05	0.05	0.17	1.4	-0.00 [-0.50, 0.49]
			Placebo	25	25 (100.0)	0.07 (0.32)	-0.4	-0.06	0.02	0.12	1.4	
		Week 16	Tezepelumab	42	41 (97.6)	0.09 (0.35)	-0.6	-0.05	0.10	0.19	1.6	0.16 [-0.34, 0.66]
			Placebo	25	25 (100.0)	0.04 (0.36)	-0.6	-0.07	0.01	0.14	1.4	
		Week 24	Tezepelumab	42	41 (97.6)	0.08 (0.28)	-0.6	-0.10	0.02	0.23	1.0	0.17 [-0.34, 0.68]
			Placebo	25	23 (92.0)	0.03 (0.40)	-0.5	-0.21	0.03	0.09	1.6	
		Week 36	Tezepelumab	42	40 (95.2)	0.06 (0.34)	-0.8	-0.11	0.04	0.21	1.1	-0.06 [-0.58, 0.46]
			Placebo	25	22 (88.0)	0.09 (0.30)	-0.3	-0.08	0.05	0.22	1.1	
		Week 52	Tezepelumab	42	39 (92.9)	0.06 (0.36)	-1.0	-0.07	0.01	0.23	1.0	-0.01 [-0.54, 0.52]
			Placebo	25	21 (84.0)	0.06 (0.28)	-0.5	-0.08	0.06	0.13	0.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	20	20 (100.0)	1.91 (0.58)	0.8	1.49	1.92	2.40	2.8	
			Placebo	14	14 (100.0)	1.71 (0.46)	0.9	1.41	1.76	2.10	2.5	
		Week 2	Tezepelumab	20	19 (95.0)	2.00 (0.52)	0.9	1.59	1.97	2.49	2.7	
			Placebo	14	11 (78.6)	1.70 (0.41)	1.0	1.39	1.74	1.85	2.6	
		Week 4	Tezepelumab	20	20 (100.0)	2.05 (0.58)	0.8	1.63	2.04	2.47	3.4	
			Placebo	14	13 (92.9)	1.72 (0.46)	1.0	1.43	1.73	1.85	2.7	
		Week 8	Tezepelumab	20	19 (95.0)	1.99 (0.58)	0.7	1.67	1.99	2.51	2.9	
			Placebo	14	14 (100.0)	1.73 (0.51)	0.8	1.54	1.75	1.94	2.7	
		Week 12	Tezepelumab	20	19 (95.0)	2.02 (0.60)	0.8	1.55	2.06	2.41	3.1	
			Placebo	14	14 (100.0)	1.73 (0.51)	0.9	1.44	1.69	2.10	2.7	
		Week 16	Tezepelumab	20	19 (95.0)	2.07 (0.65)	0.9	1.55	2.18	2.56	3.3	
			Placebo	14	14 (100.0)	1.68 (0.43)	0.9	1.49	1.69	1.78	2.6	
		Week 24	Tezepelumab	20	20 (100.0)	2.02 (0.50)	1.1	1.69	2.00	2.34	2.9	
			Placebo	14	13 (92.9)	1.67 (0.47)	1.0	1.42	1.63	1.85	2.7	
		Week 36	Tezepelumab	20	19 (95.0)	2.03 (0.60)	0.8	1.54	2.10	2.34	3.1	
			Placebo	14	14 (100.0)	1.69 (0.46)	1.0	1.38	1.64	1.92	2.7	
		Week 52	Tezepelumab	20	19 (95.0)	2.04 (0.61)	0.7	1.60	2.06	2.37	3.1	
			Placebo	14	11 (78.6)	1.58 (0.49)	1.0	1.14	1.62	1.73	2.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	20	19 (95.0)	0.06 (0.23)	-0.5	-0.01	0.05	0.12	0.8	0.30 [-0.44, 1.05]
			Placebo	14	11 (78.6)	-0.01 (0.19)	-0.3	-0.17	0.04	0.16	0.3	
		Week 4	Tezepelumab	20	20 (100.0)	0.14 (0.47)	-0.9	-0.07	0.08	0.20	1.7	0.31 [-0.39, 1.01]
			Placebo	14	13 (92.9)	0.02 (0.21)	-0.3	-0.14	0.04	0.15	0.4	
		Week 8	Tezepelumab	20	19 (95.0)	0.08 (0.37)	-0.8	-0.08	0.06	0.25	1.2	0.20 [-0.49, 0.89]
			Placebo	14	14 (100.0)	0.02 (0.25)	-0.5	-0.12	-0.02	0.20	0.4	
		Week 12	Tezepelumab	20	19 (95.0)	0.12 (0.42)	-0.7	-0.18	0.10	0.19	1.4	0.33 [-0.37, 1.02]
			Placebo	14	14 (100.0)	0.01 (0.12)	-0.1	-0.06	0.00	0.04	0.4	
		Week 16	Tezepelumab	20	19 (95.0)	0.13 (0.42)	-0.6	-0.04	0.11	0.22	1.6	0.47 [-0.23, 1.17]
			Placebo	14	14 (100.0)	-0.03 (0.20)	-0.5	-0.15	-0.03	0.08	0.3	
		Week 24	Tezepelumab	20	20 (100.0)	0.12 (0.35)	-0.6	-0.14	0.18	0.28	1.0	0.58 [-0.13, 1.30]
			Placebo	14	13 (92.9)	-0.06 (0.24)	-0.4	-0.26	-0.04	0.07	0.4	
		Week 36	Tezepelumab	20	19 (95.0)	0.08 (0.39)	-0.7	-0.13	0.04	0.25	1.1	0.34 [-0.36, 1.03]
			Placebo	14	14 (100.0)	-0.03 (0.21)	-0.3	-0.19	-0.06	0.04	0.4	
		Week 52	Tezepelumab	20	19 (95.0)	0.10 (0.45)	-1.0	-0.07	0.11	0.39	1.0	0.40 [-0.35, 1.15]
			Placebo	14	11 (78.6)	-0.06 (0.27)	-0.5	-0.26	-0.08	0.13	0.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Absolute values	Baseline	Tezepelumab	35	35 (100.0)	1.74 (0.67)	0.4	1.27	1.70	2.20	3.3	
			Placebo	26	26 (100.0)	1.74 (0.57)	0.8	1.39	1.69	2.04	3.2	
		Week 2	Tezepelumab	35	34 (97.1)	1.78 (0.67)	0.6	1.29	1.70	2.29	3.4	
			Placebo	26	24 (92.3)	1.76 (0.75)	0.8	1.22	1.62	2.18	4.1	
		Week 4	Tezepelumab	35	35 (100.0)	1.74 (0.69)	0.7	1.19	1.67	2.24	3.3	
			Placebo	26	26 (100.0)	1.84 (0.82)	0.9	1.32	1.61	2.20	4.8	
		Week 8	Tezepelumab	35	34 (97.1)	1.78 (0.63)	0.6	1.30	1.64	2.35	3.3	
			Placebo	26	25 (96.2)	1.86 (0.80)	0.8	1.40	1.74	2.23	4.6	
		Week 12	Tezepelumab	35	35 (100.0)	1.77 (0.70)	0.6	1.23	1.66	2.28	3.6	
			Placebo	26	25 (96.2)	1.85 (0.80)	0.8	1.37	1.61	2.25	4.6	
		Week 16	Tezepelumab	35	35 (100.0)	1.82 (0.68)	0.6	1.43	1.65	2.28	3.5	
			Placebo	26	25 (96.2)	1.82 (0.83)	0.8	1.32	1.66	2.10	4.7	
		Week 24	Tezepelumab	35	34 (97.1)	1.73 (0.64)	0.6	1.16	1.63	2.27	3.5	
			Placebo	26	23 (88.5)	1.81 (0.84)	0.8	1.36	1.62	2.19	4.8	
		Week 36	Tezepelumab	35	34 (97.1)	1.72 (0.65)	0.5	1.25	1.63	2.20	3.5	
			Placebo	26	21 (80.8)	1.89 (0.80)	0.9	1.43	1.75	2.26	4.3	
		Week 52	Tezepelumab	35	32 (91.4)	1.71 (0.61)	0.8	1.22	1.62	2.20	3.4	
			Placebo	26	24 (92.3)	1.85 (0.73)	0.9	1.29	1.68	2.26	4.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Change from baseline	Week 2	Tezepelumab	35	34 (97.1)	0.04 (0.25)	-0.7	-0.02	0.05	0.17	0.5	0.07 [-0.45, 0.59]
			Placebo	26	24 (92.3)	0.02 (0.27)	-0.4	-0.09	-0.03	0.05	0.9	
		Week 4	Tezepelumab	35	35 (100.0)	0.00 (0.25)	-0.6	-0.18	0.00	0.17	0.6	-0.33 [-0.84, 0.18]
			Placebo	26	26 (100.0)	0.10 (0.36)	-0.3	-0.03	0.04	0.11	1.6	
		Week 8	Tezepelumab	35	34 (97.1)	0.08 (0.25)	-0.5	-0.06	0.04	0.15	0.7	-0.03 [-0.55, 0.48]
			Placebo	26	25 (96.2)	0.09 (0.35)	-0.8	-0.03	0.05	0.13	1.4	
		Week 12	Tezepelumab	35	35 (100.0)	0.03 (0.20)	-0.4	-0.09	0.03	0.12	0.5	-0.27 [-0.79, 0.25]
			Placebo	26	25 (96.2)	0.10 (0.35)	-0.4	-0.05	0.05	0.22	1.4	
		Week 16	Tezepelumab	35	35 (100.0)	0.08 (0.27)	-0.6	-0.07	0.09	0.25	0.7	0.02 [-0.49, 0.54]
			Placebo	26	25 (96.2)	0.07 (0.38)	-0.6	-0.06	0.01	0.18	1.4	
		Week 24	Tezepelumab	35	34 (97.1)	0.04 (0.21)	-0.4	-0.11	-0.01	0.15	0.7	-0.13 [-0.66, 0.40]
			Placebo	26	23 (88.5)	0.07 (0.39)	-0.5	-0.05	0.04	0.10	1.6	
		Week 36	Tezepelumab	35	34 (97.1)	0.03 (0.31)	-0.8	-0.12	-0.01	0.20	0.8	-0.45 [-1.00, 0.10]
			Placebo	26	21 (80.8)	0.17 (0.28)	-0.3	0.03	0.17	0.30	1.1	
		Week 52	Tezepelumab	35	32 (91.4)	0.01 (0.28)	-0.8	-0.08	0.00	0.15	0.7	-0.36 [-0.89, 0.18]
			Placebo	26	24 (92.3)	0.11 (0.24)	-0.4	-0.02	0.09	0.16	0.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Sex									0.725
Male	Week 2	Tezepelumab	19	19 (100.0)	0.04 (0.07)	(-0.11, 0.19)	0.02 (0.13)	(-0.26, 0.30)	0.871
		Placebo	8	8 (100.0)	0.02 (0.11)	(-0.22, 0.25)			
	Week 4	Tezepelumab	19	19 (100.0)	0.09 (0.12)	(-0.15, 0.33)	-0.07 (0.21)	(-0.51, 0.37)	0.741
		Placebo	8	8 (100.0)	0.16 (0.18)	(-0.21, 0.53)			
	Week 8	Tezepelumab	19	18 (94.7)	0.09 (0.10)	(-0.12, 0.30)	-0.08 (0.18)	(-0.46, 0.30)	0.651
		Placebo	8	8 (100.0)	0.17 (0.15)	(-0.14, 0.49)			
	Week 12	Tezepelumab	19	19 (100.0)	0.14 (0.10)	(-0.07, 0.34)	-0.07 (0.18)	(-0.44, 0.31)	0.713
		Placebo	8	8 (100.0)	0.20 (0.15)	(-0.11, 0.52)			
	Week 16	Tezepelumab	19	19 (100.0)	0.08 (0.11)	(-0.14, 0.30)	-0.10 (0.20)	(-0.51, 0.31)	0.607
		Placebo	8	8 (100.0)	0.18 (0.17)	(-0.16, 0.52)			
	Week 24	Tezepelumab	19	18 (94.7)	0.13 (0.10)	(-0.07, 0.34)	-0.04 (0.18)	(-0.42, 0.34)	0.818
		Placebo	8	8 (100.0)	0.17 (0.15)	(-0.14, 0.49)			
	Week 36	Tezepelumab	19	18 (94.7)	0.05 (0.10)	(-0.16, 0.26)	-0.08 (0.18)	(-0.46, 0.30)	0.658
		Placebo	8	8 (100.0)	0.13 (0.15)	(-0.19, 0.45)			
	Week 52	Tezepelumab	19	18 (94.7)	0.07 (0.09)	(-0.13, 0.26)	-0.06 (0.17)	(-0.41, 0.30)	0.753
		Placebo	8	7 (87.5)	0.12 (0.15)	(-0.18, 0.42)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Female	Week 2	Tezepelumab	36	34 (94.4)	0.06 (0.03)	(-0.01, 0.13)	0.07 (0.05)	(-0.03, 0.17)	0.188
		Placebo	32	27 (84.4)	-0.01 (0.04)	(-0.08, 0.07)			
	Week 4	Tezepelumab	36	36 (100.0)	0.04 (0.04)	(-0.04, 0.12)	-0.01 (0.06)	(-0.13, 0.11)	0.920
		Placebo	32	31 (96.9)	0.04 (0.04)	(-0.04, 0.13)			
	Week 8	Tezepelumab	36	35 (97.2)	0.07 (0.04)	(-0.01, 0.15)	0.03 (0.06)	(-0.08, 0.15)	0.595
		Placebo	32	31 (96.9)	0.04 (0.04)	(-0.04, 0.12)			
	Week 12	Tezepelumab	36	35 (97.2)	0.03 (0.04)	(-0.04, 0.10)	-0.01 (0.05)	(-0.11, 0.10)	0.893
		Placebo	32	31 (96.9)	0.03 (0.04)	(-0.04, 0.11)			
	Week 16	Tezepelumab	36	35 (97.2)	0.12 (0.04)	(0.03, 0.20)	0.12 (0.06)	(0.00, 0.25)	0.050 *
		Placebo	32	31 (96.9)	-0.01 (0.05)	(-0.10, 0.08)			
	Week 24	Tezepelumab	36	36 (100.0)	0.03 (0.04)	(-0.04, 0.10)	0.05 (0.05)	(-0.06, 0.15)	0.393
		Placebo	32	28 (87.5)	-0.01 (0.04)	(-0.09, 0.06)			
	Week 36	Tezepelumab	36	35 (97.2)	0.06 (0.04)	(-0.02, 0.14)	-0.02 (0.06)	(-0.14, 0.10)	0.728
		Placebo	32	27 (84.4)	0.08 (0.04)	(-0.01, 0.17)			
	Week 52	Tezepelumab	36	33 (91.7)	0.05 (0.04)	(-0.04, 0.14)	0.03 (0.07)	(-0.10, 0.16)	0.669
		Placebo	32	28 (87.5)	0.02 (0.05)	(-0.08, 0.12)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Age									0.594
< 65 years	Week 2	Tezepelumab	46	45 (97.8)	0.05 (0.04)	(-0.02, 0.13)	0.07 (0.06)	(-0.05, 0.19)	0.234
		Placebo	33	29 (87.9)	-0.02 (0.04)	(-0.11, 0.07)			
	Week 4	Tezepelumab	46	46 (100.0)	0.07 (0.05)	(-0.03, 0.18)	-0.01 (0.08)	(-0.17, 0.15)	0.937
		Placebo	33	33 (100.0)	0.08 (0.06)	(-0.04, 0.20)			
	Week 8	Tezepelumab	46	44 (95.7)	0.07 (0.05)	(-0.02, 0.17)	0.02 (0.07)	(-0.12, 0.17)	0.754
		Placebo	33	33 (100.0)	0.05 (0.06)	(-0.06, 0.16)			
	Week 12	Tezepelumab	46	45 (97.8)	0.09 (0.05)	(-0.01, 0.18)	0.02 (0.07)	(-0.12, 0.16)	0.758
		Placebo	33	32 (97.0)	0.06 (0.05)	(-0.04, 0.17)			
	Week 16	Tezepelumab	46	46 (100.0)	0.12 (0.05)	(0.02, 0.22)	0.09 (0.08)	(-0.06, 0.25)	0.233
		Placebo	33	32 (97.0)	0.03 (0.06)	(-0.09, 0.15)			
	Week 24	Tezepelumab	46	45 (97.8)	0.08 (0.05)	(-0.02, 0.17)	0.05 (0.07)	(-0.09, 0.20)	0.470
		Placebo	33	29 (87.9)	0.02 (0.06)	(-0.09, 0.14)			
	Week 36	Tezepelumab	46	45 (97.8)	0.06 (0.05)	(-0.04, 0.15)	-0.06 (0.08)	(-0.21, 0.09)	0.444
		Placebo	33	28 (84.8)	0.11 (0.06)	(-0.00, 0.23)			
	Week 52	Tezepelumab	46	43 (93.5)	0.06 (0.05)	(-0.04, 0.15)	-0.01 (0.08)	(-0.16, 0.14)	0.919
		Placebo	33	29 (87.9)	0.07 (0.06)	(-0.05, 0.18)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 65 years	Week 2	Tezepelumab	9	8 (88.9)	0.03 (0.07)	(-0.13, 0.18)	-0.02 (0.10)	(-0.25, 0.21)	0.840
		Placebo	7	6 (85.7)	0.05 (0.08)	(-0.12, 0.22)			
	Week 4	Tezepelumab	9	9 (100.0)	-0.05 (0.09)	(-0.24, 0.14)	-0.06 (0.13)	(-0.35, 0.23)	0.654
		Placebo	7	6 (85.7)	0.01 (0.10)	(-0.21, 0.23)			
	Week 8	Tezepelumab	9	9 (100.0)	0.08 (0.08)	(-0.09, 0.25)	-0.09 (0.12)	(-0.35, 0.17)	0.440
		Placebo	7	6 (85.7)	0.17 (0.09)	(-0.02, 0.37)			
	Week 12	Tezepelumab	9	9 (100.0)	-0.07 (0.05)	(-0.18, 0.05)	-0.17 (0.08)	(-0.34, 0.00)	0.055
		Placebo	7	7 (100.0)	0.10 (0.06)	(-0.03, 0.23)			
	Week 16	Tezepelumab	9	8 (88.9)	-0.05 (0.07)	(-0.20, 0.11)	-0.10 (0.11)	(-0.34, 0.14)	0.374
		Placebo	7	7 (100.0)	0.05 (0.08)	(-0.12, 0.23)			
	Week 24	Tezepelumab	9	9 (100.0)	-0.01 (0.08)	(-0.17, 0.16)	-0.06 (0.12)	(-0.31, 0.19)	0.616
		Placebo	7	7 (100.0)	0.05 (0.09)	(-0.13, 0.24)			
	Week 36	Tezepelumab	9	8 (88.9)	0.03 (0.07)	(-0.13, 0.18)	0.03 (0.10)	(-0.21, 0.26)	0.799
		Placebo	7	7 (100.0)	-0.00 (0.08)	(-0.18, 0.17)			
	Week 52	Tezepelumab	9	8 (88.9)	-0.05 (0.08)	(-0.22, 0.12)	-0.03 (0.11)	(-0.28, 0.22)	0.816
		Placebo	7	6 (85.7)	-0.02 (0.08)	(-0.21, 0.16)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Exacerbations in the year before study									0.605
<= 2	Week 2	Tezepelumab	31	31 (100.0)	0.04 (0.05)	(-0.07, 0.14)	0.04 (0.08)	(-0.11, 0.19)	0.592
		Placebo	27	24 (88.9)	-0.00 (0.06)	(-0.12, 0.11)			
	Week 4	Tezepelumab	31	31 (100.0)	0.03 (0.07)	(-0.11, 0.17)	-0.06 (0.10)	(-0.27, 0.15)	0.560
		Placebo	27	26 (96.3)	0.09 (0.08)	(-0.06, 0.24)			
	Week 8	Tezepelumab	31	31 (100.0)	0.06 (0.06)	(-0.07, 0.19)	-0.03 (0.10)	(-0.22, 0.16)	0.784
		Placebo	27	26 (96.3)	0.09 (0.07)	(-0.05, 0.23)			
	Week 12	Tezepelumab	31	31 (100.0)	0.05 (0.06)	(-0.07, 0.17)	-0.04 (0.09)	(-0.22, 0.14)	0.676
		Placebo	27	27 (100.0)	0.09 (0.07)	(-0.04, 0.22)			
	Week 16	Tezepelumab	31	31 (100.0)	0.08 (0.07)	(-0.05, 0.21)	0.02 (0.10)	(-0.17, 0.21)	0.829
		Placebo	27	27 (100.0)	0.06 (0.07)	(-0.08, 0.20)			
	Week 24	Tezepelumab	31	31 (100.0)	0.07 (0.06)	(-0.05, 0.20)	0.05 (0.09)	(-0.14, 0.24)	0.594
		Placebo	27	24 (88.9)	0.02 (0.07)	(-0.12, 0.16)			
	Week 36	Tezepelumab	31	31 (100.0)	0.07 (0.06)	(-0.06, 0.20)	-0.01 (0.09)	(-0.19, 0.18)	0.948
		Placebo	27	25 (92.6)	0.08 (0.07)	(-0.06, 0.21)			
	Week 52	Tezepelumab	31	31 (100.0)	0.02 (0.06)	(-0.10, 0.15)	-0.02 (0.09)	(-0.21, 0.17)	0.841
		Placebo	27	23 (85.2)	0.04 (0.07)	(-0.10, 0.18)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
> 2	Week 2	Tezepelumab	24	22 (91.7)	0.07 (0.03)	(0.00, 0.14)	0.09 (0.06)	(-0.03, 0.20)	0.138
		Placebo	13	11 (84.6)	-0.02 (0.05)	(-0.11, 0.08)			
	Week 4	Tezepelumab	24	24 (100.0)	0.09 (0.05)	(-0.01, 0.18)	0.07 (0.08)	(-0.09, 0.23)	0.396
		Placebo	13	13 (100.0)	0.02 (0.06)	(-0.11, 0.15)			
	Week 8	Tezepelumab	24	22 (91.7)	0.09 (0.04)	(0.01, 0.17)	0.07 (0.07)	(-0.07, 0.20)	0.339
		Placebo	13	13 (100.0)	0.03 (0.05)	(-0.09, 0.14)			
	Week 12	Tezepelumab	24	23 (95.8)	0.08 (0.04)	(-0.01, 0.16)	0.06 (0.07)	(-0.09, 0.20)	0.423
		Placebo	13	12 (92.3)	0.02 (0.06)	(-0.10, 0.14)			
	Week 16	Tezepelumab	24	23 (95.8)	0.13 (0.05)	(0.02, 0.24)	0.17 (0.09)	(-0.02, 0.35)	0.081
		Placebo	13	12 (92.3)	-0.03 (0.07)	(-0.19, 0.12)			
	Week 24	Tezepelumab	24	23 (95.8)	0.06 (0.04)	(-0.03, 0.14)	0.03 (0.07)	(-0.12, 0.17)	0.695
		Placebo	13	12 (92.3)	0.03 (0.06)	(-0.09, 0.14)			
	Week 36	Tezepelumab	24	22 (91.7)	0.03 (0.05)	(-0.06, 0.13)	-0.07 (0.08)	(-0.24, 0.09)	0.362
		Placebo	13	10 (76.9)	0.11 (0.07)	(-0.02, 0.24)			
	Week 52	Tezepelumab	24	20 (83.3)	0.07 (0.05)	(-0.03, 0.17)	0.02 (0.08)	(-0.14, 0.18)	0.791
		Placebo	13	12 (92.3)	0.05 (0.06)	(-0.08, 0.18)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Race				N<10 any level					NE

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Region									0.599
Europe	Week 2	Tezepelumab	11	11 (100.0)	0.08 (0.07)	(-0.06, 0.22)	-0.02 (0.10)	(-0.23, 0.19)	0.853
		Placebo	10	9 (90.0)	0.10 (0.07)	(-0.05, 0.25)			
	Week 4	Tezepelumab	11	11 (100.0)	0.04 (0.07)	(-0.11, 0.18)	-0.12 (0.10)	(-0.34, 0.09)	0.247
		Placebo	10	10 (100.0)	0.16 (0.07)	(0.01, 0.31)			
	Week 8	Tezepelumab	11	11 (100.0)	0.04 (0.09)	(-0.16, 0.23)	-0.02 (0.14)	(-0.30, 0.27)	0.905
		Placebo	10	9 (90.0)	0.06 (0.10)	(-0.15, 0.26)			
	Week 12	Tezepelumab	11	11 (100.0)	-0.01 (0.07)	(-0.15, 0.13)	-0.12 (0.10)	(-0.32, 0.09)	0.242
		Placebo	10	10 (100.0)	0.11 (0.07)	(-0.03, 0.26)			
	Week 16	Tezepelumab	11	11 (100.0)	0.06 (0.07)	(-0.10, 0.21)	-0.09 (0.11)	(-0.32, 0.13)	0.402
		Placebo	10	10 (100.0)	0.15 (0.08)	(-0.01, 0.31)			
	Week 24	Tezepelumab	11	11 (100.0)	-0.03 (0.05)	(-0.14, 0.08)	-0.05 (0.08)	(-0.21, 0.12)	0.565
		Placebo	10	10 (100.0)	0.02 (0.06)	(-0.10, 0.13)			
	Week 36	Tezepelumab	11	11 (100.0)	-0.02 (0.08)	(-0.18, 0.14)	-0.25 (0.11)	(-0.48, -0.01)	0.041 *
		Placebo	10	9 (90.0)	0.23 (0.08)	(0.06, 0.40)			
	Week 52	Tezepelumab	11	10 (90.9)	0.01 (0.06)	(-0.12, 0.13)	-0.20 (0.09)	(-0.39, -0.02)	0.032 *
		Placebo	10	10 (100.0)	0.21 (0.06)	(0.08, 0.34)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
America	Week 2	Tezepelumab	20	19 (95.0)	0.05 (0.06)	(-0.07, 0.18)	0.00 (0.10)	(-0.21, 0.21)	0.981
		Placebo	11	9 (81.8)	0.05 (0.08)	(-0.12, 0.22)			
	Week 4	Tezepelumab	20	20 (100.0)	0.01 (0.07)	(-0.14, 0.16)	-0.20 (0.12)	(-0.45, 0.05)	0.119
		Placebo	11	10 (90.9)	0.20 (0.10)	(0.00, 0.41)			
	Week 8	Tezepelumab	20	20 (100.0)	0.09 (0.08)	(-0.08, 0.25)	-0.07 (0.13)	(-0.34, 0.20)	0.608
		Placebo	11	11 (100.0)	0.16 (0.11)	(-0.06, 0.37)			
	Week 12	Tezepelumab	20	20 (100.0)	0.09 (0.06)	(-0.04, 0.21)	-0.12 (0.11)	(-0.34, 0.10)	0.262
		Placebo	11	11 (100.0)	0.21 (0.08)	(0.03, 0.38)			
	Week 16	Tezepelumab	20	20 (100.0)	0.12 (0.08)	(-0.03, 0.28)	-0.03 (0.13)	(-0.29, 0.23)	0.801
		Placebo	11	11 (100.0)	0.15 (0.10)	(-0.06, 0.36)			
	Week 24	Tezepelumab	20	20 (100.0)	0.08 (0.08)	(-0.07, 0.24)	-0.11 (0.13)	(-0.37, 0.16)	0.428
		Placebo	11	10 (90.9)	0.19 (0.11)	(-0.03, 0.40)			
	Week 36	Tezepelumab	20	20 (100.0)	0.09 (0.08)	(-0.07, 0.24)	-0.05 (0.13)	(-0.31, 0.22)	0.726
		Placebo	11	11 (100.0)	0.13 (0.10)	(-0.08, 0.34)			
	Week 52	Tezepelumab	20	19 (95.0)	0.02 (0.07)	(-0.12, 0.17)	-0.05 (0.12)	(-0.29, 0.20)	0.690
		Placebo	11	9 (81.8)	0.07 (0.10)	(-0.13, 0.27)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Asia/Pacific	Week 2	Tezepelumab	13	13 (100.0)	-0.04 (0.05)	(-0.14, 0.06)	0.02 (0.07)	(-0.14, 0.17)	0.822
		Placebo	10	9 (90.0)	-0.06 (0.06)	(-0.18, 0.06)			
	Week 4	Tezepelumab	13	13 (100.0)	0.01 (0.08)	(-0.15, 0.17)	0.04 (0.12)	(-0.21, 0.29)	0.735
		Placebo	10	10 (100.0)	-0.03 (0.09)	(-0.22, 0.15)			
	Week 8	Tezepelumab	13	12 (92.3)	-0.01 (0.06)	(-0.14, 0.11)	-0.09 (0.09)	(-0.28, 0.11)	0.363
		Placebo	10	10 (100.0)	0.07 (0.07)	(-0.07, 0.22)			
	Week 12	Tezepelumab	13	12 (92.3)	0.02 (0.07)	(-0.11, 0.16)	0.09 (0.10)	(-0.11, 0.30)	0.353
		Placebo	10	9 (90.0)	-0.07 (0.07)	(-0.23, 0.08)			
	Week 16	Tezepelumab	13	13 (100.0)	0.03 (0.07)	(-0.12, 0.18)	0.13 (0.11)	(-0.10, 0.37)	0.244
		Placebo	10	9 (90.0)	-0.10 (0.09)	(-0.28, 0.08)			
	Week 24	Tezepelumab	13	13 (100.0)	0.06 (0.06)	(-0.07, 0.19)	0.12 (0.10)	(-0.08, 0.33)	0.221
		Placebo	10	9 (90.0)	-0.06 (0.07)	(-0.22, 0.09)			
	Week 36	Tezepelumab	13	13 (100.0)	0.02 (0.07)	(-0.14, 0.17)	0.08 (0.11)	(-0.16, 0.31)	0.510
		Placebo	10	8 (80.0)	-0.06 (0.09)	(-0.24, 0.12)			
	Week 52	Tezepelumab	13	13 (100.0)	0.01 (0.09)	(-0.18, 0.20)	0.06 (0.14)	(-0.23, 0.36)	0.657
		Placebo	10	9 (90.0)	-0.05 (0.11)	(-0.28, 0.17)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Rest of the world	Week 2	Tezepelumab	11	10 (90.9)	NE		NE		
		Placebo	9	8 (88.9)					
	Week 4	Tezepelumab	11	11 (100.0)	NE		NE		
		Placebo	9	9 (100.0)					
	Week 8	Tezepelumab	11	10 (90.9)	NE		NE		
		Placebo	9	9 (100.0)					
	Week 12	Tezepelumab	11	11 (100.0)	NE		NE		
		Placebo	9	9 (100.0)					
	Week 16	Tezepelumab	11	10 (90.9)	NE		NE		
		Placebo	9	9 (100.0)					
	Week 24	Tezepelumab	11	10 (90.9)	NE		NE		
		Placebo	9	7 (77.8)					
	Week 36	Tezepelumab	11	9 (81.8)	NE		NE		
		Placebo	9	7 (77.8)					
	Week 52	Tezepelumab	11	9 (81.8)	NE		NE		
		Placebo	9	7 (77.8)					

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
BMI				N<10 any level					NE

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline eosinophils - Low									0.712
< 150 cells/uL	Week 2	Tezepelumab	32	31 (96.9)	0.06 (0.04)	(-0.02, 0.15)	0.10 (0.06)	(-0.03, 0.23)	0.121
		Placebo	22	18 (81.8)	-0.04 (0.05)	(-0.14, 0.06)			
	Week 4	Tezepelumab	32	32 (100.0)	0.07 (0.06)	(-0.05, 0.20)	0.07 (0.10)	(-0.12, 0.27)	0.438
		Placebo	22	22 (100.0)	-0.00 (0.07)	(-0.15, 0.15)			
	Week 8	Tezepelumab	32	30 (93.8)	0.07 (0.05)	(-0.04, 0.18)	0.07 (0.09)	(-0.11, 0.24)	0.443
		Placebo	22	22 (100.0)	0.00 (0.07)	(-0.13, 0.13)			
	Week 12	Tezepelumab	32	32 (100.0)	0.06 (0.05)	(-0.05, 0.16)	0.06 (0.08)	(-0.11, 0.22)	0.478
		Placebo	22	21 (95.5)	-0.00 (0.06)	(-0.13, 0.12)			
	Week 16	Tezepelumab	32	31 (96.9)	0.13 (0.06)	(0.01, 0.25)	0.15 (0.09)	(-0.04, 0.34)	0.116
		Placebo	22	21 (95.5)	-0.02 (0.07)	(-0.17, 0.13)			
	Week 24	Tezepelumab	32	31 (96.9)	0.07 (0.04)	(-0.02, 0.16)	0.06 (0.07)	(-0.08, 0.20)	0.391
		Placebo	22	20 (90.9)	0.01 (0.05)	(-0.10, 0.12)			
	Week 36	Tezepelumab	32	30 (93.8)	0.03 (0.05)	(-0.07, 0.14)	-0.03 (0.08)	(-0.19, 0.13)	0.711
		Placebo	22	19 (86.4)	0.07 (0.06)	(-0.06, 0.19)			
	Week 52	Tezepelumab	32	28 (87.5)	0.04 (0.06)	(-0.07, 0.15)	-0.01 (0.09)	(-0.18, 0.16)	0.913
		Placebo	22	19 (86.4)	0.05 (0.07)	(-0.08, 0.18)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 150 cells/uL	Week 2	Tezepelumab	23	22 (95.7)	0.02 (0.05)	(-0.09, 0.12)	-0.05 (0.08)	(-0.21, 0.12)	0.572
		Placebo	18	17 (94.4)	0.06 (0.06)	(-0.06, 0.18)			
	Week 4	Tezepelumab	23	23 (100.0)	0.02 (0.07)	(-0.11, 0.15)	-0.16 (0.10)	(-0.36, 0.04)	0.118
		Placebo	18	17 (94.4)	0.18 (0.07)	(0.03, 0.33)			
	Week 8	Tezepelumab	23	23 (100.0)	0.08 (0.06)	(-0.04, 0.19)	-0.10 (0.09)	(-0.28, 0.09)	0.295
		Placebo	18	17 (94.4)	0.17 (0.07)	(0.04, 0.31)			
	Week 12	Tezepelumab	23	22 (95.7)	0.06 (0.06)	(-0.05, 0.18)	-0.11 (0.09)	(-0.29, 0.07)	0.222
		Placebo	18	18 (100.0)	0.17 (0.07)	(0.04, 0.31)			
	Week 16	Tezepelumab	23	23 (100.0)	0.05 (0.06)	(-0.08, 0.17)	-0.07 (0.09)	(-0.26, 0.13)	0.491
		Placebo	18	18 (100.0)	0.11 (0.07)	(-0.03, 0.26)			
	Week 24	Tezepelumab	23	23 (100.0)	0.05 (0.07)	(-0.10, 0.19)	-0.01 (0.11)	(-0.24, 0.21)	0.914
		Placebo	18	16 (88.9)	0.06 (0.08)	(-0.11, 0.22)			
	Week 36	Tezepelumab	23	23 (100.0)	0.06 (0.07)	(-0.07, 0.20)	-0.08 (0.10)	(-0.28, 0.13)	0.466
		Placebo	18	16 (88.9)	0.14 (0.08)	(-0.02, 0.29)			
	Week 52	Tezepelumab	23	23 (100.0)	0.03 (0.06)	(-0.10, 0.16)	-0.03 (0.10)	(-0.23, 0.16)	0.728
		Placebo	18	16 (88.9)	0.06 (0.07)	(-0.09, 0.21)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline specific perennial FEIA status									0.201
All negative	Week 2	Tezepelumab	33	32 (97.0)	0.09 (0.04)	(0.02, 0.16)	0.11 (0.06)	(-0.00, 0.22)	0.057
		Placebo	25	22 (88.0)	-0.01 (0.04)	(-0.10, 0.07)			
	Week 4	Tezepelumab	33	33 (100.0)	0.10 (0.05)	(-0.01, 0.21)	0.04 (0.08)	(-0.13, 0.20)	0.632
		Placebo	25	24 (96.0)	0.06 (0.06)	(-0.07, 0.18)			
	Week 8	Tezepelumab	33	33 (100.0)	0.11 (0.04)	(0.03, 0.20)	0.05 (0.06)	(-0.08, 0.18)	0.462
		Placebo	25	24 (96.0)	0.07 (0.05)	(-0.03, 0.16)			
	Week 12	Tezepelumab	33	32 (97.0)	0.09 (0.05)	(-0.00, 0.18)	0.03 (0.07)	(-0.11, 0.17)	0.674
		Placebo	25	25 (100.0)	0.06 (0.05)	(-0.05, 0.17)			
	Week 16	Tezepelumab	33	32 (97.0)	0.14 (0.06)	(0.03, 0.25)	0.13 (0.08)	(-0.04, 0.30)	0.121
		Placebo	25	25 (100.0)	0.01 (0.06)	(-0.12, 0.13)			
	Week 24	Tezepelumab	33	33 (100.0)	0.09 (0.04)	(0.01, 0.18)	0.09 (0.07)	(-0.04, 0.23)	0.179
		Placebo	25	22 (88.0)	0.00 (0.05)	(-0.10, 0.11)			
	Week 36	Tezepelumab	33	32 (97.0)	0.07 (0.05)	(-0.02, 0.17)	-0.01 (0.07)	(-0.15, 0.13)	0.877
		Placebo	25	22 (88.0)	0.09 (0.05)	(-0.02, 0.19)			
	Week 52	Tezepelumab	33	31 (93.9)	0.09 (0.05)	(-0.01, 0.19)	0.07 (0.08)	(-0.08, 0.23)	0.337
		Placebo	25	22 (88.0)	0.02 (0.06)	(-0.10, 0.14)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Any positive	Week 2	Tezepelumab	22	21 (95.5)	-0.01 (0.06)	(-0.14, 0.11)	-0.03 (0.10)	(-0.24, 0.18)	0.773
		Placebo	14	12 (85.7)	0.02 (0.08)	(-0.15, 0.18)			
	Week 4	Tezepelumab	22	22 (100.0)	-0.01 (0.08)	(-0.17, 0.15)	-0.10 (0.13)	(-0.36, 0.16)	0.444
		Placebo	14	14 (100.0)	0.09 (0.10)	(-0.12, 0.29)			
	Week 8	Tezepelumab	22	20 (90.9)	0.01 (0.08)	(-0.16, 0.18)	-0.05 (0.13)	(-0.32, 0.23)	0.734
		Placebo	14	14 (100.0)	0.06 (0.10)	(-0.15, 0.27)			
	Week 12	Tezepelumab	22	22 (100.0)	0.02 (0.07)	(-0.12, 0.16)	-0.05 (0.11)	(-0.28, 0.18)	0.667
		Placebo	14	13 (92.9)	0.07 (0.09)	(-0.11, 0.25)			
	Week 16	Tezepelumab	22	22 (100.0)	0.04 (0.08)	(-0.11, 0.20)	-0.05 (0.12)	(-0.29, 0.20)	0.715
		Placebo	14	13 (92.9)	0.09 (0.10)	(-0.11, 0.28)			
	Week 24	Tezepelumab	22	21 (95.5)	0.03 (0.08)	(-0.13, 0.18)	-0.04 (0.12)	(-0.29, 0.22)	0.775
		Placebo	14	13 (92.9)	0.06 (0.10)	(-0.14, 0.26)			
	Week 36	Tezepelumab	22	21 (95.5)	0.02 (0.08)	(-0.14, 0.18)	-0.08 (0.13)	(-0.34, 0.18)	0.537
		Placebo	14	12 (85.7)	0.10 (0.10)	(-0.11, 0.30)			
	Week 52	Tezepelumab	22	20 (90.9)	-0.04 (0.08)	(-0.19, 0.12)	-0.14 (0.12)	(-0.39, 0.11)	0.263
		Placebo	14	12 (85.7)	0.10 (0.10)	(-0.10, 0.30)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Total serum IgE				N<10 any level					NE

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
OCS at baseline									0.757
Yes	Week 2	Tezepelumab	8	8 (100.0)	NE		NE		
		Placebo	7	5 (71.4)					
	Week 4	Tezepelumab	8	8 (100.0)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 8	Tezepelumab	8	7 (87.5)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 12	Tezepelumab	8	7 (87.5)	NE		NE		
		Placebo	7	6 (85.7)					
	Week 16	Tezepelumab	8	8 (100.0)	NE		NE		
		Placebo	7	6 (85.7)					
	Week 24	Tezepelumab	8	8 (100.0)	NE		NE		
		Placebo	7	6 (85.7)					
	Week 36	Tezepelumab	8	8 (100.0)	NE		NE		
		Placebo	7	5 (71.4)					
	Week 52	Tezepelumab	8	8 (100.0)	NE		NE		
		Placebo	7	6 (85.7)					

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 2	Tezepelumab	47	45 (95.7)	0.05 (0.04)	(-0.03, 0.12)	0.05 (0.06)	(-0.07, 0.17)	0.407
		Placebo	33	30 (90.9)	-0.00 (0.05)	(-0.09, 0.09)			
	Week 4	Tezepelumab	47	47 (100.0)	0.03 (0.05)	(-0.07, 0.13)	-0.05 (0.08)	(-0.21, 0.10)	0.494
		Placebo	33	32 (97.0)	0.09 (0.06)	(-0.03, 0.21)			
	Week 8	Tezepelumab	47	46 (97.9)	0.08 (0.05)	(-0.01, 0.17)	0.02 (0.07)	(-0.13, 0.16)	0.812
		Placebo	33	32 (97.0)	0.06 (0.06)	(-0.05, 0.18)			
	Week 12	Tezepelumab	47	47 (100.0)	0.05 (0.04)	(-0.04, 0.14)	-0.04 (0.07)	(-0.17, 0.10)	0.601
		Placebo	33	33 (100.0)	0.09 (0.05)	(-0.02, 0.19)			
	Week 16	Tezepelumab	47	46 (97.9)	0.10 (0.05)	(0.01, 0.20)	0.04 (0.08)	(-0.11, 0.19)	0.600
		Placebo	33	33 (100.0)	0.06 (0.06)	(-0.05, 0.18)			
	Week 24	Tezepelumab	47	46 (97.9)	0.06 (0.04)	(-0.03, 0.14)	0.00 (0.07)	(-0.14, 0.14)	1.000
		Placebo	33	30 (90.9)	0.05 (0.05)	(-0.05, 0.16)			
	Week 36	Tezepelumab	47	45 (95.7)	0.06 (0.04)	(-0.03, 0.15)	-0.05 (0.07)	(-0.19, 0.09)	0.496
		Placebo	33	30 (90.9)	0.11 (0.05)	(0.00, 0.22)			
	Week 52	Tezepelumab	47	43 (91.5)	0.04 (0.04)	(-0.05, 0.13)	-0.02 (0.07)	(-0.16, 0.12)	0.807
		Placebo	33	29 (87.9)	0.06 (0.05)	(-0.05, 0.17)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
LAMA use at baseline									0.488
Yes	Week 2	Tezepelumab	15	15 (100.0)	0.04 (0.06)	(-0.07, 0.16)	0.02 (0.08)	(-0.14, 0.19)	0.796
		Placebo	16	15 (93.8)	0.02 (0.06)	(-0.09, 0.14)			
	Week 4	Tezepelumab	15	15 (100.0)	0.08 (0.06)	(-0.05, 0.21)	-0.02 (0.09)	(-0.20, 0.17)	0.864
		Placebo	16	16 (100.0)	0.10 (0.06)	(-0.03, 0.23)			
	Week 8	Tezepelumab	15	14 (93.3)	0.10 (0.08)	(-0.05, 0.26)	0.05 (0.10)	(-0.17, 0.26)	0.650
		Placebo	16	16 (100.0)	0.06 (0.07)	(-0.09, 0.20)			
	Week 12	Tezepelumab	15	14 (93.3)	0.08 (0.07)	(-0.07, 0.22)	0.04 (0.10)	(-0.16, 0.24)	0.659
		Placebo	16	15 (93.8)	0.03 (0.07)	(-0.11, 0.17)			
	Week 16	Tezepelumab	15	15 (100.0)	0.11 (0.07)	(-0.02, 0.25)	0.09 (0.09)	(-0.11, 0.28)	0.359
		Placebo	16	15 (93.8)	0.03 (0.07)	(-0.11, 0.16)			
	Week 24	Tezepelumab	15	15 (100.0)	0.03 (0.06)	(-0.09, 0.15)	0.03 (0.08)	(-0.14, 0.21)	0.702
		Placebo	16	14 (87.5)	-0.00 (0.06)	(-0.12, 0.12)			
	Week 36	Tezepelumab	15	15 (100.0)	0.01 (0.07)	(-0.13, 0.15)	-0.07 (0.10)	(-0.26, 0.13)	0.499
		Placebo	16	14 (87.5)	0.07 (0.07)	(-0.07, 0.21)			
	Week 52	Tezepelumab	15	14 (93.3)	0.02 (0.07)	(-0.13, 0.17)	-0.05 (0.10)	(-0.25, 0.16)	0.647
		Placebo	16	15 (93.8)	0.07 (0.07)	(-0.08, 0.21)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 2	Tezepelumab	40	38 (95.0)	0.05 (0.04)	(-0.03, 0.13)	0.08 (0.07)	(-0.05, 0.21)	0.230
		Placebo	24	20 (83.3)	-0.03 (0.05)	(-0.13, 0.08)			
	Week 4	Tezepelumab	40	40 (100.0)	0.05 (0.06)	(-0.07, 0.16)	-0.00 (0.10)	(-0.20, 0.19)	0.980
		Placebo	24	23 (95.8)	0.05 (0.08)	(-0.10, 0.20)			
	Week 8	Tezepelumab	40	39 (97.5)	0.07 (0.05)	(-0.04, 0.17)	-0.01 (0.08)	(-0.17, 0.16)	0.914
		Placebo	24	23 (95.8)	0.07 (0.06)	(-0.06, 0.20)			
	Week 12	Tezepelumab	40	40 (100.0)	0.06 (0.05)	(-0.04, 0.16)	-0.03 (0.08)	(-0.19, 0.13)	0.727
		Placebo	24	24 (100.0)	0.09 (0.06)	(-0.04, 0.21)			
	Week 16	Tezepelumab	40	39 (97.5)	0.10 (0.06)	(-0.02, 0.21)	0.06 (0.09)	(-0.12, 0.25)	0.508
		Placebo	24	24 (100.0)	0.03 (0.07)	(-0.11, 0.18)			
	Week 24	Tezepelumab	40	39 (97.5)	0.08 (0.05)	(-0.03, 0.18)	0.04 (0.09)	(-0.13, 0.21)	0.641
		Placebo	24	22 (91.7)	0.04 (0.07)	(-0.10, 0.18)			
	Week 36	Tezepelumab	40	38 (95.0)	0.07 (0.05)	(-0.03, 0.18)	-0.03 (0.09)	(-0.20, 0.15)	0.761
		Placebo	24	21 (87.5)	0.10 (0.07)	(-0.04, 0.24)			
	Week 52	Tezepelumab	40	37 (92.5)	0.05 (0.05)	(-0.05, 0.16)	0.03 (0.09)	(-0.15, 0.20)	0.771
		Placebo	24	20 (83.3)	0.03 (0.07)	(-0.11, 0.16)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Tiotropium use at baseline									0.449
Yes	Week 2	Tezepelumab	13	13 (100.0)	0.04 (0.07)	(-0.10, 0.18)	0.01 (0.09)	(-0.17, 0.20)	0.876
		Placebo	15	14 (93.3)	0.03 (0.06)	(-0.10, 0.15)			
	Week 4	Tezepelumab	13	13 (100.0)	0.08 (0.07)	(-0.07, 0.22)	-0.04 (0.10)	(-0.24, 0.16)	0.661
		Placebo	15	15 (100.0)	0.12 (0.07)	(-0.02, 0.26)			
	Week 8	Tezepelumab	13	12 (92.3)	0.10 (0.07)	(-0.05, 0.25)	-0.01 (0.10)	(-0.21, 0.19)	0.927
		Placebo	15	15 (100.0)	0.11 (0.07)	(-0.03, 0.24)			
	Week 12	Tezepelumab	13	12 (92.3)	0.05 (0.07)	(-0.10, 0.20)	-0.01 (0.10)	(-0.22, 0.19)	0.914
		Placebo	15	14 (93.3)	0.06 (0.07)	(-0.08, 0.20)			
	Week 16	Tezepelumab	13	13 (100.0)	0.11 (0.07)	(-0.04, 0.26)	0.09 (0.10)	(-0.12, 0.30)	0.381
		Placebo	15	14 (93.3)	0.02 (0.07)	(-0.12, 0.16)			
	Week 24	Tezepelumab	13	13 (100.0)	0.02 (0.06)	(-0.11, 0.15)	0.01 (0.09)	(-0.18, 0.19)	0.924
		Placebo	15	13 (86.7)	0.01 (0.06)	(-0.12, 0.14)			
	Week 36	Tezepelumab	13	13 (100.0)	0.01 (0.07)	(-0.15, 0.16)	-0.09 (0.10)	(-0.29, 0.12)	0.412
		Placebo	15	13 (86.7)	0.09 (0.07)	(-0.05, 0.24)			
	Week 52	Tezepelumab	13	12 (92.3)	-0.01 (0.08)	(-0.17, 0.16)	-0.04 (0.11)	(-0.26, 0.18)	0.694
		Placebo	15	14 (93.3)	0.04 (0.07)	(-0.11, 0.19)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 2	Tezepelumab	42	40 (95.2)	0.05 (0.04)	(-0.02, 0.13)	0.08 (0.06)	(-0.04, 0.21)	0.200
		Placebo	25	21 (84.0)	-0.03 (0.05)	(-0.13, 0.07)			
	Week 4	Tezepelumab	42	42 (100.0)	0.05 (0.06)	(-0.06, 0.16)	0.01 (0.09)	(-0.17, 0.20)	0.885
		Placebo	25	24 (96.0)	0.04 (0.07)	(-0.11, 0.18)			
	Week 8	Tezepelumab	42	41 (97.6)	0.07 (0.05)	(-0.03, 0.17)	0.03 (0.08)	(-0.14, 0.19)	0.726
		Placebo	25	24 (96.0)	0.04 (0.07)	(-0.09, 0.17)			
	Week 12	Tezepelumab	42	42 (100.0)	0.07 (0.05)	(-0.03, 0.16)	0.00 (0.08)	(-0.15, 0.16)	0.988
		Placebo	25	25 (100.0)	0.07 (0.06)	(-0.06, 0.19)			
	Week 16	Tezepelumab	42	41 (97.6)	0.10 (0.05)	(-0.01, 0.21)	0.06 (0.09)	(-0.11, 0.24)	0.478
		Placebo	25	25 (100.0)	0.03 (0.07)	(-0.11, 0.18)			
	Week 24	Tezepelumab	42	41 (97.6)	0.08 (0.05)	(-0.02, 0.18)	0.05 (0.08)	(-0.11, 0.22)	0.532
		Placebo	25	23 (92.0)	0.03 (0.07)	(-0.10, 0.16)			
	Week 36	Tezepelumab	42	40 (95.2)	0.07 (0.05)	(-0.03, 0.17)	-0.01 (0.08)	(-0.18, 0.15)	0.867
		Placebo	25	22 (88.0)	0.09 (0.07)	(-0.05, 0.22)			
	Week 52	Tezepelumab	42	39 (92.9)	0.06 (0.05)	(-0.05, 0.16)	0.01 (0.08)	(-0.16, 0.18)	0.892
		Placebo	25	21 (84.0)	0.04 (0.07)	(-0.09, 0.18)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Montelukast/ Cromoglicic acid use at baseline									0.231
Yes	Week 2	Tezepelumab	20	19 (95.0)	0.08 (0.05)	(-0.02, 0.18)	0.13 (0.08)	(-0.03, 0.28)	0.108
		Placebo	14	11 (78.6)	-0.05 (0.06)	(-0.17, 0.07)			
	Week 4	Tezepelumab	20	20 (100.0)	0.15 (0.08)	(-0.03, 0.32)	0.15 (0.13)	(-0.12, 0.42)	0.268
		Placebo	14	13 (92.9)	-0.00 (0.10)	(-0.21, 0.21)			
	Week 8	Tezepelumab	20	19 (95.0)	0.07 (0.07)	(-0.08, 0.22)	0.06 (0.11)	(-0.18, 0.29)	0.626
		Placebo	14	14 (100.0)	0.01 (0.09)	(-0.17, 0.19)			
	Week 12	Tezepelumab	20	19 (95.0)	0.13 (0.07)	(-0.02, 0.27)	0.12 (0.11)	(-0.11, 0.35)	0.288
		Placebo	14	14 (100.0)	0.01 (0.09)	(-0.17, 0.18)			
	Week 16	Tezepelumab	20	19 (95.0)	0.14 (0.08)	(-0.01, 0.30)	0.18 (0.12)	(-0.06, 0.42)	0.135
		Placebo	14	14 (100.0)	-0.04 (0.09)	(-0.23, 0.14)			
	Week 24	Tezepelumab	20	20 (100.0)	0.12 (0.07)	(-0.01, 0.26)	0.18 (0.10)	(-0.03, 0.40)	0.094
		Placebo	14	13 (92.9)	-0.06 (0.08)	(-0.22, 0.11)			
	Week 36	Tezepelumab	20	19 (95.0)	0.09 (0.07)	(-0.05, 0.24)	0.13 (0.11)	(-0.10, 0.36)	0.268
		Placebo	14	14 (100.0)	-0.03 (0.09)	(-0.21, 0.14)			
	Week 52	Tezepelumab	20	19 (95.0)	0.10 (0.08)	(-0.07, 0.27)	0.17 (0.13)	(-0.10, 0.44)	0.212
		Placebo	14	11 (78.6)	-0.07 (0.10)	(-0.28, 0.14)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 2	Tezepelumab	35	34 (97.1)	0.04 (0.04)	(-0.05, 0.12)	0.03 (0.07)	(-0.11, 0.16)	0.688
		Placebo	26	24 (92.3)	0.01 (0.05)	(-0.09, 0.11)			
	Week 4	Tezepelumab	35	35 (100.0)	0.00 (0.05)	(-0.10, 0.11)	-0.10 (0.08)	(-0.25, 0.06)	0.203
		Placebo	26	26 (100.0)	0.10 (0.06)	(-0.01, 0.22)			
	Week 8	Tezepelumab	35	34 (97.1)	0.08 (0.05)	(-0.02, 0.18)	-0.02 (0.08)	(-0.17, 0.14)	0.824
		Placebo	26	25 (96.2)	0.09 (0.06)	(-0.02, 0.21)			
	Week 12	Tezepelumab	35	35 (100.0)	0.03 (0.05)	(-0.06, 0.12)	-0.07 (0.07)	(-0.21, 0.07)	0.327
		Placebo	26	25 (96.2)	0.10 (0.05)	(-0.01, 0.20)			
	Week 16	Tezepelumab	35	35 (100.0)	0.08 (0.05)	(-0.03, 0.19)	0.01 (0.08)	(-0.15, 0.18)	0.892
		Placebo	26	25 (96.2)	0.07 (0.06)	(-0.06, 0.19)			
	Week 24	Tezepelumab	35	34 (97.1)	0.04 (0.05)	(-0.06, 0.14)	-0.03 (0.08)	(-0.19, 0.12)	0.667
		Placebo	26	23 (88.5)	0.07 (0.06)	(-0.05, 0.19)			
	Week 36	Tezepelumab	35	34 (97.1)	0.03 (0.05)	(-0.07, 0.13)	-0.13 (0.08)	(-0.28, 0.03)	0.108
		Placebo	26	21 (80.8)	0.16 (0.06)	(0.04, 0.28)			
	Week 52	Tezepelumab	35	32 (91.4)	0.01 (0.04)	(-0.08, 0.10)	-0.10 (0.07)	(-0.24, 0.04)	0.152
		Placebo	26	24 (92.3)	0.11 (0.05)	(0.00, 0.21)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age (cat. N)												
< 18 years	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	2.69	2.7	2.69	2.69	2.69	2.7	
			Placebo	1	1 (100.0)	1.41	1.4	1.41	1.41	1.41	1.4	
		Week 2	Tezepelumab	1	1 (100.0)	2.74	2.7	2.74	2.74	2.74	2.7	
			Placebo	1	1 (100.0)	1.34	1.3	1.34	1.34	1.34	1.3	
		Week 4	Tezepelumab	1	1 (100.0)	2.61	2.6	2.61	2.61	2.61	2.6	
			Placebo	1	1 (100.0)	1.43	1.4	1.43	1.43	1.43	1.4	
		Week 8	Tezepelumab	1	1 (100.0)	2.71	2.7	2.71	2.71	2.71	2.7	
			Placebo	1	1 (100.0)	1.54	1.5	1.54	1.54	1.54	1.5	
		Week 12	Tezepelumab	1	1 (100.0)	2.74	2.7	2.74	2.74	2.74	2.7	
			Placebo	1	1 (100.0)	1.44	1.4	1.44	1.44	1.44	1.4	
		Week 16	Tezepelumab	1	1 (100.0)	2.73	2.7	2.73	2.73	2.73	2.7	
			Placebo	1	1 (100.0)	1.49	1.5	1.49	1.49	1.49	1.5	
		Week 24	Tezepelumab	1	1 (100.0)	2.90	2.9	2.90	2.90	2.90	2.9	
			Placebo	1	1 (100.0)	1.48	1.5	1.48	1.48	1.48	1.5	
		Week 36	Tezepelumab	1	1 (100.0)	3.08	3.1	3.08	3.08	3.08	3.1	
			Placebo	1	1 (100.0)	1.38	1.4	1.38	1.38	1.38	1.4	
		Week 52	Tezepelumab	1	1 (100.0)	3.08	3.1	3.08	3.08	3.08	3.1	
			Placebo	1	1 (100.0)	1.49	1.5	1.49	1.49	1.49	1.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age (cat. N)												
< 18 years	Change from baseline	Week 2	Tezepelumab	1	1 (100.0)	0.05	0.1	0.05	0.05	0.05	0.1	NE
			Placebo	1	1 (100.0)	-0.07	-0.1	-0.07	-0.07	-0.07	-0.1	
		Week 4	Tezepelumab	1	1 (100.0)	-0.08	-0.1	-0.08	-0.08	-0.08	-0.1	NE
			Placebo	1	1 (100.0)	0.02	0.0	0.02	0.02	0.02	0.0	
		Week 8	Tezepelumab	1	1 (100.0)	0.02	0.0	0.02	0.02	0.02	0.0	NE
			Placebo	1	1 (100.0)	0.13	0.1	0.13	0.13	0.13	0.1	
		Week 12	Tezepelumab	1	1 (100.0)	0.05	0.1	0.05	0.05	0.05	0.1	NE
			Placebo	1	1 (100.0)	0.03	0.0	0.03	0.03	0.03	0.0	
		Week 16	Tezepelumab	1	1 (100.0)	0.04	0.0	0.04	0.04	0.04	0.0	NE
			Placebo	1	1 (100.0)	0.08	0.1	0.08	0.08	0.08	0.1	
		Week 24	Tezepelumab	1	1 (100.0)	0.21	0.2	0.21	0.21	0.21	0.2	NE
			Placebo	1	1 (100.0)	0.07	0.1	0.07	0.07	0.07	0.1	
		Week 36	Tezepelumab	1	1 (100.0)	0.39	0.4	0.39	0.39	0.39	0.4	NE
			Placebo	1	1 (100.0)	-0.03	-0.0	-0.03	-0.03	-0.03	-0.0	
		Week 52	Tezepelumab	1	1 (100.0)	0.39	0.4	0.39	0.39	0.39	0.4	NE
			Placebo	1	1 (100.0)	0.08	0.1	0.08	0.08	0.08	0.1	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age (cat. N)												
18 - < 65 years	Absolute values	Baseline	Tezepelumab	45	45 (100.0)	1.83 (0.66)	0.4	1.41	1.87	2.20	3.3	
			Placebo	32	32 (100.0)	1.75 (0.56)	0.8	1.42	1.70	2.13	3.2	
		Week 2	Tezepelumab	45	44 (97.8)	1.89 (0.64)	0.6	1.48	1.93	2.39	3.4	
			Placebo	32	28 (87.5)	1.76 (0.71)	0.8	1.32	1.71	2.04	4.1	
		Week 4	Tezepelumab	45	45 (100.0)	1.90 (0.69)	0.7	1.61	1.98	2.40	3.4	
			Placebo	32	32 (100.0)	1.84 (0.77)	0.9	1.35	1.71	2.11	4.8	
		Week 8	Tezepelumab	45	43 (95.6)	1.87 (0.65)	0.6	1.43	1.90	2.40	3.3	
			Placebo	32	32 (100.0)	1.80 (0.76)	0.8	1.39	1.74	2.01	4.6	
		Week 12	Tezepelumab	45	44 (97.8)	1.91 (0.70)	0.6	1.46	1.95	2.37	3.6	
			Placebo	32	31 (96.9)	1.83 (0.78)	0.8	1.37	1.62	2.25	4.6	
		Week 16	Tezepelumab	45	45 (100.0)	1.95 (0.70)	0.6	1.52	1.91	2.34	3.5	
			Placebo	32	31 (96.9)	1.79 (0.78)	0.8	1.31	1.71	2.10	4.7	
		Week 24	Tezepelumab	45	44 (97.8)	1.87 (0.62)	0.6	1.58	1.90	2.31	3.5	
			Placebo	32	28 (87.5)	1.79 (0.80)	0.8	1.33	1.65	2.15	4.8	
		Week 36	Tezepelumab	45	44 (97.8)	1.84 (0.66)	0.5	1.31	1.88	2.31	3.5	
			Placebo	32	27 (84.4)	1.86 (0.75)	0.9	1.45	1.70	2.36	4.3	
		Week 52	Tezepelumab	45	42 (93.3)	1.86 (0.63)	0.7	1.54	1.92	2.26	3.4	
			Placebo	32	28 (87.5)	1.79 (0.73)	0.9	1.20	1.68	2.19	4.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age (cat. N)												
18 - < 65 years	Change from baseline	Week 2	Tezepelumab	45	44 (97.8)	0.05 (0.26)	-0.7	-0.05	0.06	0.18	0.8	0.19 [-0.29, 0.66]
			Placebo	32	28 (87.5)	0.00 (0.25)	-0.4	-0.09	-0.04	0.07	0.9	
		Week 4	Tezepelumab	45	45 (100.0)	0.08 (0.37)	-0.9	-0.07	0.05	0.22	1.7	-0.02 [-0.47, 0.43]
			Placebo	32	32 (100.0)	0.08 (0.33)	-0.3	-0.06	0.04	0.13	1.6	
		Week 8	Tezepelumab	45	43 (95.6)	0.08 (0.32)	-0.8	-0.08	0.04	0.19	1.2	0.11 [-0.35, 0.56]
			Placebo	32	32 (100.0)	0.05 (0.34)	-0.8	-0.08	0.02	0.13	1.4	
		Week 12	Tezepelumab	45	44 (97.8)	0.08 (0.32)	-0.7	-0.04	0.08	0.18	1.4	0.05 [-0.41, 0.51]
			Placebo	32	31 (96.9)	0.07 (0.31)	-0.4	-0.06	0.00	0.20	1.4	
		Week 16	Tezepelumab	45	45 (100.0)	0.12 (0.35)	-0.6	-0.02	0.14	0.28	1.6	0.27 [-0.19, 0.73]
			Placebo	32	31 (96.9)	0.03 (0.34)	-0.6	-0.10	0.01	0.18	1.4	
		Week 24	Tezepelumab	45	44 (97.8)	0.07 (0.28)	-0.6	-0.11	0.00	0.25	1.0	0.16 [-0.31, 0.64]
			Placebo	32	28 (87.5)	0.02 (0.38)	-0.5	-0.16	0.03	0.09	1.6	
		Week 36	Tezepelumab	45	44 (97.8)	0.05 (0.36)	-0.8	-0.15	0.04	0.23	1.1	-0.22 [-0.70, 0.26]
			Placebo	32	27 (84.4)	0.12 (0.28)	-0.3	-0.07	0.08	0.30	1.1	
		Week 52	Tezepelumab	45	42 (93.3)	0.05 (0.38)	-1.0	-0.06	0.07	0.24	1.0	-0.06 [-0.53, 0.42]
			Placebo	32	28 (87.5)	0.07 (0.25)	-0.4	-0.08	0.08	0.16	0.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age (cat. N)												
>= 65 years	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	1.55 (0.40)	1.2	1.28	1.44	1.74	2.4	
			Placebo	7	7 (100.0)	1.66 (0.37)	1.1	1.35	1.85	1.89	2.1	
		Week 2	Tezepelumab	9	8 (88.9)	1.61 (0.37)	1.2	1.35	1.54	1.74	2.4	
			Placebo	7	6 (85.7)	1.69 (0.45)	1.0	1.39	1.75	1.93	2.3	
		Week 4	Tezepelumab	9	9 (100.0)	1.52 (0.42)	0.9	1.27	1.53	1.64	2.5	
			Placebo	7	6 (85.7)	1.68 (0.46)	1.1	1.43	1.63	1.99	2.4	
		Week 8	Tezepelumab	9	9 (100.0)	1.65 (0.35)	1.2	1.58	1.67	1.68	2.4	
			Placebo	7	6 (85.7)	1.92 (0.40)	1.5	1.54	1.81	2.30	2.5	
		Week 12	Tezepelumab	9	9 (100.0)	1.51 (0.31)	1.2	1.23	1.49	1.55	2.2	
			Placebo	7	7 (100.0)	1.75 (0.35)	1.3	1.41	1.73	2.13	2.3	
		Week 16	Tezepelumab	9	8 (88.9)	1.54 (0.39)	1.1	1.33	1.49	1.62	2.4	
			Placebo	7	7 (100.0)	1.70 (0.32)	1.3	1.42	1.66	1.90	2.3	
		Week 24	Tezepelumab	9	9 (100.0)	1.57 (0.35)	1.1	1.40	1.60	1.71	2.3	
			Placebo	7	7 (100.0)	1.70 (0.42)	1.1	1.42	1.51	2.07	2.3	
		Week 36	Tezepelumab	9	8 (88.9)	1.61 (0.42)	1.2	1.35	1.53	1.74	2.5	
			Placebo	7	7 (100.0)	1.64 (0.38)	1.1	1.38	1.59	1.92	2.3	
		Week 52	Tezepelumab	9	8 (88.9)	1.54 (0.42)	1.1	1.24	1.44	1.73	2.4	
			Placebo	7	6 (85.7)	1.67 (0.39)	1.1	1.57	1.62	1.83	2.3	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age (cat. N)												
>= 65 years	Change from baseline	Week 2	Tezepelumab	9	8 (88.9)	0.01 (0.10)	-0.2	-0.00	0.05	0.07	0.1	-0.30 [-1.36, 0.77]
			Placebo	7	6 (85.7)	0.07 (0.24)	-0.3	-0.05	0.04	0.16	0.5	
		Week 4	Tezepelumab	9	9 (100.0)	-0.03 (0.18)	-0.3	-0.13	-0.04	0.06	0.3	-0.40 [-1.45, 0.64]
			Placebo	7	6 (85.7)	0.06 (0.26)	-0.3	-0.03	0.04	0.10	0.5	
		Week 8	Tezepelumab	9	9 (100.0)	0.10 (0.21)	-0.2	-0.05	0.05	0.25	0.5	-0.26 [-1.30, 0.78]
			Placebo	7	6 (85.7)	0.16 (0.23)	-0.1	-0.03	0.12	0.40	0.4	
		Week 12	Tezepelumab	9	9 (100.0)	-0.04 (0.14)	-0.2	-0.17	-0.05	0.05	0.2	-0.81 [-1.84, 0.22]
			Placebo	7	7 (100.0)	0.09 (0.18)	-0.1	-0.07	0.06	0.22	0.4	
		Week 16	Tezepelumab	9	8 (88.9)	-0.05 (0.15)	-0.4	-0.13	-0.02	0.06	0.1	-0.40 [-1.42, 0.63]
			Placebo	7	7 (100.0)	0.04 (0.29)	-0.5	-0.20	0.07	0.26	0.4	
		Week 24	Tezepelumab	9	9 (100.0)	0.02 (0.22)	-0.4	-0.12	0.02	0.16	0.4	-0.09 [-1.08, 0.90]
			Placebo	7	7 (100.0)	0.04 (0.23)	-0.4	-0.04	0.06	0.13	0.4	
		Week 36	Tezepelumab	9	8 (88.9)	0.02 (0.10)	-0.1	-0.05	0.01	0.09	0.2	0.21 [-0.81, 1.22]
			Placebo	7	7 (100.0)	-0.02 (0.23)	-0.3	-0.19	-0.08	0.08	0.4	
		Week 52	Tezepelumab	9	8 (88.9)	-0.06 (0.09)	-0.2	-0.12	-0.05	0.00	0.1	-0.07 [-1.13, 0.99]
			Placebo	7	6 (85.7)	-0.04 (0.32)	-0.5	-0.26	-0.01	0.08	0.4	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Western Europe	Absolute values	Baseline	Tezepelumab	11	11 (100.0)	2.02 (0.40)	1.4	1.65	2.02	2.39	2.6	
			Placebo	13	13 (100.0)	1.74 (0.57)	0.9	1.45	1.83	2.16	2.8	
		Week 2	Tezepelumab	11	11 (100.0)	2.10 (0.44)	1.4	1.70	2.17	2.47	2.7	
			Placebo	13	11 (84.6)	1.90 (0.62)	0.9	1.46	1.97	2.31	2.8	
		Week 4	Tezepelumab	11	11 (100.0)	2.06 (0.42)	1.4	1.65	2.07	2.45	2.6	
			Placebo	13	13 (100.0)	1.84 (0.64)	1.0	1.55	1.64	2.35	3.0	
		Week 8	Tezepelumab	11	11 (100.0)	2.06 (0.51)	1.2	1.58	2.11	2.53	2.7	
			Placebo	13	12 (92.3)	1.82 (0.70)	0.8	1.24	1.84	2.33	2.8	
		Week 12	Tezepelumab	11	11 (100.0)	2.01 (0.44)	1.2	1.62	2.18	2.39	2.5	
			Placebo	13	12 (92.3)	1.79 (0.69)	0.8	1.36	1.57	2.39	3.0	
		Week 16	Tezepelumab	11	11 (100.0)	2.08 (0.49)	1.2	1.63	2.22	2.34	3.0	
			Placebo	13	12 (92.3)	1.82 (0.65)	0.9	1.37	1.75	2.23	3.0	
		Week 24	Tezepelumab	11	11 (100.0)	1.99 (0.42)	1.2	1.61	2.26	2.30	2.4	
			Placebo	13	12 (92.3)	1.73 (0.57)	0.8	1.26	1.67	2.22	2.7	
		Week 36	Tezepelumab	11	11 (100.0)	2.00 (0.50)	1.2	1.53	2.10	2.50	2.6	
			Placebo	13	10 (76.9)	1.88 (0.64)	1.1	1.19	1.78	2.36	3.0	
		Week 52	Tezepelumab	11	10 (90.9)	1.99 (0.45)	1.2	1.64	2.20	2.26	2.6	
			Placebo	13	12 (92.3)	1.92 (0.63)	1.0	1.39	2.06	2.30	2.9	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Western Europe	Change from baseline	Week 2	Tezepelumab	11	11 (100.0)	0.08 (0.22)	-0.3	-0.01	0.05	0.15	0.5	0.04 [-0.80, 0.87]
			Placebo	13	11 (84.6)	0.07 (0.21)	-0.1	-0.07	0.01	0.10	0.5	
		Week 4	Tezepelumab	11	11 (100.0)	0.04 (0.23)	-0.5	-0.06	0.05	0.22	0.3	-0.26 [-1.06, 0.55]
			Placebo	13	13 (100.0)	0.10 (0.23)	-0.3	-0.02	0.11	0.24	0.5	
		Week 8	Tezepelumab	11	11 (100.0)	0.04 (0.25)	-0.2	-0.09	-0.06	0.04	0.7	0.06 [-0.76, 0.88]
			Placebo	13	12 (92.3)	0.02 (0.32)	-0.8	-0.07	0.02	0.13	0.5	
		Week 12	Tezepelumab	11	11 (100.0)	-0.01 (0.18)	-0.2	-0.18	-0.03	0.10	0.4	-0.21 [-1.03, 0.61]
			Placebo	13	12 (92.3)	0.04 (0.28)	-0.4	-0.11	0.03	0.28	0.4	
		Week 16	Tezepelumab	11	11 (100.0)	0.06 (0.28)	-0.3	-0.22	0.03	0.18	0.7	-0.05 [-0.87, 0.77]
			Placebo	13	12 (92.3)	0.07 (0.28)	-0.6	-0.01	0.02	0.23	0.5	
		Week 24	Tezepelumab	11	11 (100.0)	-0.03 (0.16)	-0.2	-0.18	-0.05	0.10	0.3	-0.04 [-0.86, 0.78]
			Placebo	13	12 (92.3)	-0.02 (0.21)	-0.5	-0.11	-0.01	0.06	0.4	
		Week 36	Tezepelumab	11	11 (100.0)	-0.02 (0.28)	-0.5	-0.18	-0.05	0.11	0.6	-0.71 [-1.60, 0.17]
			Placebo	13	10 (76.9)	0.16 (0.23)	-0.3	0.08	0.25	0.31	0.4	
		Week 52	Tezepelumab	11	10 (90.9)	-0.01 (0.20)	-0.4	-0.05	-0.01	0.10	0.2	-0.95 [-1.84, -0.06]
			Placebo	13	12 (92.3)	0.17 (0.18)	-0.1	0.02	0.14	0.32	0.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
North America	Absolute values	Baseline	Tezepelumab	15	15 (100.0)	1.94 (0.66)	0.9	1.28	1.90	2.59	3.2	
			Placebo	8	8 (100.0)	1.68 (0.54)	1.0	1.23	1.62	2.10	2.5	
		Week 2	Tezepelumab	15	14 (93.3)	2.06 (0.65)	1.1	1.68	1.99	2.58	3.4	
			Placebo	8	6 (75.0)	1.54 (0.64)	1.0	1.02	1.34	1.93	2.6	
		Week 4	Tezepelumab	15	15 (100.0)	1.97 (0.67)	0.7	1.64	1.99	2.50	3.2	
			Placebo	8	7 (87.5)	1.71 (0.64)	1.0	1.10	1.46	2.32	2.7	
		Week 8	Tezepelumab	15	15 (100.0)	2.05 (0.60)	1.2	1.58	1.99	2.51	3.3	
			Placebo	8	8 (100.0)	1.68 (0.55)	0.8	1.38	1.71	1.90	2.7	
		Week 12	Tezepelumab	15	15 (100.0)	2.04 (0.71)	0.9	1.63	2.06	2.41	3.6	
			Placebo	8	8 (100.0)	1.75 (0.58)	1.0	1.36	1.68	2.14	2.7	
		Week 16	Tezepelumab	15	15 (100.0)	2.10 (0.68)	1.3	1.54	2.03	2.73	3.5	
			Placebo	8	8 (100.0)	1.65 (0.55)	1.0	1.24	1.55	2.03	2.6	
		Week 24	Tezepelumab	15	15 (100.0)	1.99 (0.72)	0.8	1.52	1.94	2.38	3.5	
			Placebo	8	8 (100.0)	1.71 (0.57)	1.1	1.32	1.49	2.12	2.7	
		Week 36	Tezepelumab	15	15 (100.0)	2.07 (0.68)	1.1	1.44	2.06	2.42	3.5	
			Placebo	8	8 (100.0)	1.68 (0.61)	1.0	1.23	1.51	2.10	2.7	
		Week 52	Tezepelumab	15	14 (93.3)	2.10 (0.67)	1.0	1.59	2.02	2.53	3.4	
			Placebo	8	6 (75.0)	1.62 (0.66)	1.0	1.15	1.48	1.83	2.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
North America	Change from baseline	Week 2	Tezepelumab	15	14 (93.3)	0.09 (0.17)	-0.2	0.01	0.05	0.18	0.5	0.36 [-0.61, 1.32]
			Placebo	8	6 (75.0)	0.03 (0.15)	-0.1	-0.07	-0.02	0.04	0.3	
		Week 4	Tezepelumab	15	15 (100.0)	0.03 (0.21)	-0.3	-0.13	0.01	0.15	0.6	-0.21 [-1.11, 0.69]
			Placebo	8	7 (87.5)	0.07 (0.17)	-0.2	-0.04	0.08	0.10	0.4	
		Week 8	Tezepelumab	15	15 (100.0)	0.11 (0.24)	-0.2	-0.05	0.06	0.18	0.7	0.40 [-0.47, 1.26]
			Placebo	8	8 (100.0)	0.00 (0.30)	-0.5	-0.18	0.04	0.24	0.4	
		Week 12	Tezepelumab	15	15 (100.0)	0.10 (0.23)	-0.2	-0.05	0.05	0.30	0.5	0.10 [-0.76, 0.96]
			Placebo	8	8 (100.0)	0.08 (0.19)	-0.1	-0.06	0.02	0.23	0.4	
		Week 16	Tezepelumab	15	15 (100.0)	0.16 (0.24)	-0.4	0.02	0.16	0.34	0.7	0.82 [-0.08, 1.71]
			Placebo	8	8 (100.0)	-0.03 (0.19)	-0.3	-0.15	-0.03	0.08	0.3	
		Week 24	Tezepelumab	15	15 (100.0)	0.05 (0.23)	-0.4	-0.12	0.02	0.29	0.4	0.08 [-0.77, 0.94]
			Placebo	8	8 (100.0)	0.03 (0.25)	-0.4	-0.12	0.08	0.12	0.4	
		Week 36	Tezepelumab	15	15 (100.0)	0.13 (0.24)	-0.3	-0.10	0.16	0.29	0.6	0.55 [-0.32, 1.43]
			Placebo	8	8 (100.0)	0.00 (0.20)	-0.3	-0.08	-0.04	0.05	0.4	
		Week 52	Tezepelumab	15	14 (93.3)	0.09 (0.26)	-0.3	-0.01	0.10	0.18	0.7	0.26 [-0.70, 1.22]
			Placebo	8	6 (75.0)	0.02 (0.25)	-0.3	-0.08	-0.04	0.04	0.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
South America	Absolute values	Baseline	Tezepelumab	5	5 (100.0)	1.80 (0.81)	0.8	1.14	2.12	2.37	2.6	
			Placebo	3	3 (100.0)	2.43 (0.90)	1.5	1.45	2.61	3.23	3.2	
		Week 2	Tezepelumab	5	5 (100.0)	1.75 (0.83)	0.9	1.04	1.72	2.13	2.9	
			Placebo	3	3 (100.0)	2.71 (1.26)	1.6	1.61	2.43	4.09	4.1	
		Week 4	Tezepelumab	5	5 (100.0)	1.76 (0.80)	0.8	1.06	2.06	2.17	2.7	
			Placebo	3	3 (100.0)	3.08 (1.59)	1.7	1.73	2.68	4.83	4.8	
		Week 8	Tezepelumab	5	5 (100.0)	1.82 (0.89)	0.7	1.18	1.92	2.59	2.8	
			Placebo	3	3 (100.0)	2.98 (1.50)	1.7	1.65	2.69	4.61	4.6	
		Week 12	Tezepelumab	5	5 (100.0)	1.85 (0.88)	0.8	1.08	2.20	2.49	2.7	
			Placebo	3	3 (100.0)	2.97 (1.54)	1.5	1.51	2.83	4.58	4.6	
		Week 16	Tezepelumab	5	5 (100.0)	1.81 (0.67)	0.9	1.39	1.91	2.27	2.6	
			Placebo	3	3 (100.0)	3.06 (1.53)	1.6	1.63	2.87	4.67	4.7	
		Week 24	Tezepelumab	5	5 (100.0)	1.99 (0.81)	1.1	1.12	2.55	2.55	2.6	
			Placebo	3	2 (66.7)	3.74 (1.52)	2.7	2.66	3.74	4.81	4.8	
		Week 36	Tezepelumab	5	5 (100.0)	1.77 (0.83)	0.8	1.15	1.85	2.20	2.9	
			Placebo	3	3 (100.0)	2.91 (1.42)	1.5	1.49	2.91	4.33	4.3	
		Week 52	Tezepelumab	5	5 (100.0)	1.70 (0.74)	0.7	1.22	1.79	2.30	2.5	
			Placebo	3	3 (100.0)	2.64 (1.44)	1.1	1.14	2.76	4.01	4.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
South America	Change from baseline	Week 2	Tezepelumab	5	5 (100.0)	-0.06 (0.37)	-0.7	-0.10	0.01	0.15	0.3	-0.79 [-2.28, 0.71]
			Placebo	3	3 (100.0)	0.28 (0.53)	-0.2	-0.18	0.16	0.86	0.9	
		Week 4	Tezepelumab	5	5 (100.0)	-0.05 (0.16)	-0.3	-0.08	0.04	0.05	0.1	-1.40 [-3.04, 0.23]
			Placebo	3	3 (100.0)	0.65 (0.83)	0.1	0.07	0.28	1.60	1.6	
		Week 8	Tezepelumab	5	5 (100.0)	0.02 (0.33)	-0.5	-0.08	0.04	0.13	0.5	-1.07 [-2.62, 0.48]
			Placebo	3	3 (100.0)	0.55 (0.72)	0.1	0.08	0.20	1.38	1.4	
		Week 12	Tezepelumab	5	5 (100.0)	0.05 (0.08)	-0.1	0.00	0.08	0.10	0.1	-1.21 [-2.79, 0.38]
			Placebo	3	3 (100.0)	0.54 (0.70)	0.1	0.06	0.22	1.35	1.4	
		Week 16	Tezepelumab	5	5 (100.0)	0.01 (0.28)	-0.5	-0.05	0.14	0.15	0.3	-1.33 [-2.94, 0.29]
			Placebo	3	3 (100.0)	0.63 (0.71)	0.2	0.18	0.26	1.44	1.4	
		Week 24	Tezepelumab	5	5 (100.0)	0.19 (0.22)	-0.1	-0.02	0.27	0.34	0.4	-1.19 [-2.99, 0.60]
			Placebo	3	2 (66.7)	0.82 (1.08)	0.1	0.05	0.82	1.58	1.6	
		Week 36	Tezepelumab	5	5 (100.0)	-0.03 (0.54)	-0.8	-0.17	0.01	0.03	0.8	-0.93 [-2.46, 0.59]
			Placebo	3	3 (100.0)	0.48 (0.55)	0.0	0.04	0.30	1.10	1.1	
		Week 52	Tezepelumab	5	5 (100.0)	-0.11 (0.44)	-0.8	-0.07	-0.06	0.08	0.4	-0.65 [-2.13, 0.82]
			Placebo	3	3 (100.0)	0.21 (0.55)	-0.3	-0.31	0.15	0.78	0.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Central/Eastern Europe	Absolute values	Baseline	Tezepelumab	4	4 (100.0)	1.50 (0.24)	1.3	1.29	1.51	1.71	1.7	
			Placebo	4	4 (100.0)	1.29 (0.33)	0.8	1.10	1.44	1.49	1.5	
		Week 2	Tezepelumab	4	4 (100.0)	1.75 (0.50)	1.4	1.47	1.56	2.04	2.5	
			Placebo	4	4 (100.0)	1.23 (0.37)	0.8	0.94	1.23	1.52	1.7	
		Week 4	Tezepelumab	4	4 (100.0)	2.02 (0.97)	1.3	1.47	1.68	2.57	3.4	
			Placebo	4	4 (100.0)	1.21 (0.26)	0.9	1.03	1.26	1.39	1.5	
		Week 8	Tezepelumab	4	4 (100.0)	1.81 (0.74)	1.2	1.38	1.61	2.25	2.9	
			Placebo	4	4 (100.0)	1.28 (0.33)	0.8	1.08	1.39	1.48	1.5	
		Week 12	Tezepelumab	4	4 (100.0)	1.81 (0.87)	1.2	1.30	1.46	2.32	3.1	
			Placebo	4	4 (100.0)	1.28 (0.32)	0.9	1.08	1.34	1.49	1.6	
		Week 16	Tezepelumab	4	4 (100.0)	2.03 (0.86)	1.4	1.50	1.70	2.57	3.3	
			Placebo	4	4 (100.0)	1.28 (0.32)	0.9	1.09	1.32	1.48	1.6	
		Week 24	Tezepelumab	4	4 (100.0)	1.69 (0.71)	1.1	1.25	1.49	2.14	2.7	
			Placebo	4	4 (100.0)	1.35 (0.36)	0.8	1.10	1.43	1.59	1.7	
		Week 36	Tezepelumab	4	4 (100.0)	1.79 (0.69)	1.3	1.37	1.55	2.21	2.8	
			Placebo	4	4 (100.0)	1.38 (0.37)	0.9	1.15	1.43	1.62	1.8	
		Week 52	Tezepelumab	4	4 (100.0)	1.75 (0.70)	1.1	1.33	1.57	2.18	2.8	
			Placebo	4	4 (100.0)	1.30 (0.33)	0.9	1.05	1.38	1.55	1.6	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Central/Eastern Europe	Change from baseline	Week 2	Tezepelumab	4	4 (100.0)	0.25 (0.38)	-0.1	-0.01	0.18	0.52	0.8	1.01 [-0.49, 2.51]
			Placebo	4	4 (100.0)	-0.07 (0.24)	-0.4	-0.21	-0.01	0.07	0.2	
		Week 4	Tezepelumab	4	4 (100.0)	0.52 (0.83)	-0.0	-0.03	0.19	1.06	1.7	1.01 [-0.49, 2.51]
			Placebo	4	4 (100.0)	-0.09 (0.15)	-0.3	-0.18	-0.05	0.01	0.0	
		Week 8	Tezepelumab	4	4 (100.0)	0.31 (0.60)	-0.1	-0.11	0.11	0.73	1.2	0.77 [-0.68, 2.23]
			Placebo	4	4 (100.0)	-0.01 (0.05)	-0.1	-0.05	-0.01	0.02	0.1	
		Week 12	Tezepelumab	4	4 (100.0)	0.31 (0.75)	-0.3	-0.21	0.08	0.82	1.4	0.59 [-0.84, 2.01]
			Placebo	4	4 (100.0)	-0.01 (0.13)	-0.2	-0.10	0.02	0.09	0.1	
		Week 16	Tezepelumab	4	4 (100.0)	0.53 (0.70)	0.1	0.13	0.22	0.94	1.6	1.07 [-0.44, 2.58]
			Placebo	4	4 (100.0)	-0.01 (0.14)	-0.2	-0.12	0.00	0.10	0.1	
		Week 24	Tezepelumab	4	4 (100.0)	0.19 (0.54)	-0.2	-0.15	-0.02	0.54	1.0	0.36 [-1.04, 1.76]
			Placebo	4	4 (100.0)	0.05 (0.10)	-0.0	-0.01	0.02	0.12	0.2	
		Week 36	Tezepelumab	4	4 (100.0)	0.29 (0.55)	-0.1	-0.07	0.07	0.65	1.1	0.49 [-0.92, 1.91]
			Placebo	4	4 (100.0)	0.09 (0.15)	-0.1	-0.01	0.07	0.19	0.3	
		Week 52	Tezepelumab	4	4 (100.0)	0.25 (0.56)	-0.2	-0.15	0.09	0.65	1.0	0.59 [-0.83, 2.02]
			Placebo	4	4 (100.0)	0.01 (0.17)	-0.3	-0.10	0.07	0.11	0.1	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Asia Pacific	Absolute values	Baseline	Tezepelumab	13	13 (100.0)	1.69 (0.62)	0.4	1.44	1.74	2.13	2.8	
			Placebo	7	7 (100.0)	1.74 (0.23)	1.4	1.54	1.70	1.93	2.1	
		Week 2	Tezepelumab	13	13 (100.0)	1.66 (0.50)	0.6	1.29	1.59	2.03	2.4	
			Placebo	7	7 (100.0)	1.67 (0.21)	1.3	1.41	1.74	1.85	1.9	
		Week 4	Tezepelumab	13	13 (100.0)	1.71 (0.55)	0.7	1.44	1.64	2.13	2.5	
			Placebo	7	7 (100.0)	1.73 (0.19)	1.4	1.56	1.78	1.85	2.0	
		Week 8	Tezepelumab	13	12 (92.3)	1.69 (0.50)	0.6	1.43	1.65	2.08	2.4	
			Placebo	7	7 (100.0)	1.84 (0.31)	1.5	1.69	1.76	1.82	2.5	
		Week 12	Tezepelumab	13	12 (92.3)	1.67 (0.49)	0.6	1.47	1.59	2.08	2.4	
			Placebo	7	7 (100.0)	1.72 (0.24)	1.4	1.48	1.69	1.93	2.1	
		Week 16	Tezepelumab	13	13 (100.0)	1.73 (0.62)	0.6	1.37	1.67	2.26	2.6	
			Placebo	7	7 (100.0)	1.69 (0.10)	1.5	1.66	1.71	1.76	1.8	
		Week 24	Tezepelumab	13	13 (100.0)	1.76 (0.38)	1.1	1.61	1.76	1.89	2.4	
			Placebo	7	7 (100.0)	1.71 (0.30)	1.3	1.48	1.67	2.07	2.1	
		Week 36	Tezepelumab	13	13 (100.0)	1.71 (0.55)	0.9	1.33	1.54	2.12	2.8	
			Placebo	7	7 (100.0)	1.68 (0.20)	1.4	1.46	1.70	1.88	1.9	
		Week 52	Tezepelumab	13	13 (100.0)	1.71 (0.58)	0.8	1.43	1.60	2.11	2.9	
			Placebo	7	7 (100.0)	1.67 (0.11)	1.5	1.59	1.70	1.73	1.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Asia Pacific	Change from baseline	Week 2	Tezepelumab	13	13 (100.0)	-0.04 (0.24)	-0.6	-0.10	0.05	0.09	0.2	0.16 [-0.76, 1.08]
			Placebo	7	7 (100.0)	-0.07 (0.17)	-0.3	-0.26	-0.07	0.08	0.2	
		Week 4	Tezepelumab	13	13 (100.0)	0.02 (0.41)	-0.9	-0.13	0.12	0.27	0.6	0.08 [-0.84, 1.00]
			Placebo	7	7 (100.0)	-0.01 (0.16)	-0.3	-0.14	0.04	0.09	0.1	
		Week 8	Tezepelumab	13	12 (92.3)	0.02 (0.31)	-0.8	-0.06	0.15	0.23	0.3	-0.28 [-1.22, 0.66]
			Placebo	7	7 (100.0)	0.09 (0.18)	-0.2	-0.02	0.13	0.20	0.4	
		Week 12	Tezepelumab	13	12 (92.3)	0.02 (0.35)	-0.7	-0.09	0.08	0.16	0.7	0.14 [-0.79, 1.07]
			Placebo	7	7 (100.0)	-0.02 (0.04)	-0.1	-0.06	0.00	0.02	0.0	
		Week 16	Tezepelumab	13	13 (100.0)	0.04 (0.26)	-0.6	-0.13	0.08	0.22	0.4	0.39 [-0.54, 1.31]
			Placebo	7	7 (100.0)	-0.05 (0.21)	-0.5	-0.15	0.00	0.08	0.2	
		Week 24	Tezepelumab	13	13 (100.0)	0.07 (0.34)	-0.6	-0.07	0.02	0.16	0.7	0.32 [-0.61, 1.24]
			Placebo	7	7 (100.0)	-0.03 (0.27)	-0.4	-0.26	-0.04	0.09	0.4	
		Week 36	Tezepelumab	13	13 (100.0)	0.02 (0.37)	-0.7	-0.13	0.04	0.25	0.6	0.27 [-0.66, 1.19]
			Placebo	7	7 (100.0)	-0.06 (0.17)	-0.2	-0.19	-0.11	0.15	0.2	
		Week 52	Tezepelumab	13	13 (100.0)	0.02 (0.47)	-1.0	-0.07	0.00	0.35	0.7	0.23 [-0.69, 1.15]
			Placebo	7	7 (100.0)	-0.07 (0.24)	-0.5	-0.22	0.00	0.12	0.2	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Rest of the world	Absolute values	Baseline	Tezepelumab	7	7 (100.0)	1.51 (0.92)	0.6	0.83	1.23	2.02	3.3	
			Placebo	5	5 (100.0)	1.71 (0.31)	1.4	1.44	1.77	1.88	2.1	
		Week 2	Tezepelumab	7	6 (85.7)	1.56 (0.86)	0.7	0.90	1.43	1.94	2.9	
			Placebo	5	4 (80.0)	1.50 (0.31)	1.2	1.25	1.53	1.76	1.8	
		Week 4	Tezepelumab	7	7 (100.0)	1.53 (0.90)	0.7	0.74	1.53	1.94	3.3	
			Placebo	5	5 (100.0)	1.65 (0.28)	1.3	1.38	1.80	1.87	1.9	
		Week 8	Tezepelumab	7	6 (85.7)	1.36 (0.57)	0.7	0.88	1.32	1.90	2.0	
			Placebo	5	5 (100.0)	1.71 (0.33)	1.3	1.48	1.81	1.98	2.0	
		Week 12	Tezepelumab	7	7 (100.0)	1.55 (0.90)	0.7	0.81	1.44	1.83	3.3	
			Placebo	5	5 (100.0)	1.74 (0.45)	1.2	1.42	1.74	2.10	2.3	
		Week 16	Tezepelumab	7	6 (85.7)	1.47 (0.92)	0.6	0.92	1.20	1.85	3.1	
			Placebo	5	5 (100.0)	1.55 (0.49)	0.8	1.33	1.78	1.78	2.0	
		Week 24	Tezepelumab	7	6 (85.7)	1.30 (0.62)	0.6	0.82	1.24	1.92	2.0	
			Placebo	5	3 (60.0)	1.39 (0.46)	0.9	0.93	1.40	1.85	1.9	
		Week 36	Tezepelumab	7	5 (71.4)	1.15 (0.56)	0.5	0.85	0.91	1.65	1.8	
			Placebo	5	3 (60.0)	1.66 (0.25)	1.5	1.47	1.57	1.94	1.9	
		Week 52	Tezepelumab	7	5 (71.4)	1.30 (0.56)	0.9	0.89	0.90	1.87	2.0	
			Placebo	5	3 (60.0)	1.40 (0.31)	1.1	1.06	1.47	1.66	1.7	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Rest of the world	Change from baseline	Week 2	Tezepelumab	7	6 (85.7)	0.01 (0.20)	-0.3	-0.08	0.04	0.12	0.3	0.93 [-0.42, 2.27]
			Placebo	5	4 (80.0)	-0.16 (0.16)	-0.3	-0.30	-0.18	-0.03	0.0	
		Week 4	Tezepelumab	7	7 (100.0)	0.02 (0.23)	-0.4	-0.18	0.06	0.25	0.3	0.38 [-0.78, 1.54]
			Placebo	5	5 (100.0)	-0.06 (0.16)	-0.3	-0.13	0.02	0.03	0.1	
		Week 8	Tezepelumab	7	6 (85.7)	0.14 (0.18)	-0.0	-0.01	0.11	0.21	0.5	0.83 [-0.41, 2.08]
			Placebo	5	5 (100.0)	0.01 (0.12)	-0.2	-0.07	0.04	0.10	0.1	
		Week 12	Tezepelumab	7	7 (100.0)	0.04 (0.14)	-0.2	-0.11	0.07	0.14	0.2	0.03 [-1.12, 1.18]
			Placebo	5	5 (100.0)	0.03 (0.22)	-0.3	-0.03	0.00	0.07	0.4	
		Week 16	Tezepelumab	7	6 (85.7)	-0.08 (0.26)	-0.6	-0.15	-0.03	0.09	0.2	0.29 [-0.91, 1.48]
			Placebo	5	5 (100.0)	-0.16 (0.27)	-0.6	-0.10	-0.06	-0.02	0.0	
		Week 24	Tezepelumab	7	6 (85.7)	0.09 (0.18)	-0.1	-0.03	0.02	0.23	0.4	1.50 [-0.09, 3.09]
			Placebo	5	3 (60.0)	-0.24 (0.28)	-0.5	-0.51	-0.25	0.05	0.0	
		Week 36	Tezepelumab	7	5 (71.4)	-0.07 (0.20)	-0.4	-0.11	-0.07	0.08	0.1	-0.49 [-1.95, 0.97]
			Placebo	5	3 (60.0)	0.03 (0.19)	-0.2	-0.16	0.03	0.22	0.2	
		Week 52	Tezepelumab	7	5 (71.4)	0.09 (0.19)	-0.1	-0.02	0.06	0.27	0.3	1.01 [-0.53, 2.55]
			Placebo	5	3 (60.0)	-0.12 (0.25)	-0.4	-0.38	-0.11	0.12	0.1	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
< 150 cells/uL	Absolute values	Baseline	Tezepelumab	32	32 (100.0)	1.71 (0.71)	0.4	1.25	1.73	2.06	3.3	
			Placebo	22	22 (100.0)	1.76 (0.52)	0.8	1.49	1.75	2.11	2.8	
		Week 2	Tezepelumab	32	31 (96.9)	1.78 (0.68)	0.6	1.29	1.79	2.36	3.4	
			Placebo	22	18 (81.8)	1.74 (0.55)	0.8	1.38	1.73	1.97	2.8	
		Week 4	Tezepelumab	32	32 (100.0)	1.78 (0.77)	0.7	1.23	1.66	2.44	3.4	
			Placebo	22	22 (100.0)	1.76 (0.55)	0.9	1.43	1.73	1.99	3.0	
		Week 8	Tezepelumab	32	30 (93.8)	1.73 (0.65)	0.6	1.23	1.68	2.05	3.3	
			Placebo	22	22 (100.0)	1.76 (0.60)	0.8	1.41	1.77	1.98	2.8	
		Week 12	Tezepelumab	32	32 (100.0)	1.76 (0.73)	0.6	1.23	1.68	2.23	3.6	
			Placebo	22	21 (95.5)	1.76 (0.60)	0.9	1.43	1.61	2.14	3.0	
		Week 16	Tezepelumab	32	31 (96.9)	1.85 (0.77)	0.6	1.43	1.65	2.28	3.5	
			Placebo	22	21 (95.5)	1.75 (0.57)	0.9	1.41	1.71	1.90	3.0	
		Week 24	Tezepelumab	32	31 (96.9)	1.73 (0.64)	0.6	1.12	1.70	2.26	3.5	
			Placebo	22	20 (90.9)	1.77 (0.50)	0.8	1.49	1.71	2.09	2.7	
		Week 36	Tezepelumab	32	30 (93.8)	1.70 (0.66)	0.5	1.25	1.63	2.12	3.5	
			Placebo	22	19 (86.4)	1.82 (0.59)	0.9	1.41	1.78	2.36	3.0	
		Week 52	Tezepelumab	32	28 (87.5)	1.73 (0.65)	0.7	1.16	1.73	2.20	3.4	
			Placebo	22	19 (86.4)	1.77 (0.58)	0.9	1.49	1.68	2.15	2.9	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
< 150 cells/uL	Change from baseline	Week 2	Tezepelumab	32	31 (96.9)	0.06 (0.25)	-0.6	-0.02	0.08	0.15	0.8	0.41 [-0.18, 0.99]
			Placebo	22	18 (81.8)	-0.03 (0.20)	-0.4	-0.10	-0.06	0.04	0.5	
		Week 4	Tezepelumab	32	32 (100.0)	0.08 (0.42)	-0.9	-0.11	0.04	0.28	1.7	0.24 [-0.31, 0.78]
			Placebo	22	22 (100.0)	-0.01 (0.18)	-0.3	-0.07	0.02	0.09	0.4	
		Week 8	Tezepelumab	32	30 (93.8)	0.08 (0.34)	-0.8	-0.08	0.03	0.16	1.2	0.28 [-0.27, 0.83]
			Placebo	22	22 (100.0)	-0.00 (0.26)	-0.8	-0.06	0.02	0.10	0.5	
		Week 12	Tezepelumab	32	32 (100.0)	0.06 (0.34)	-0.7	-0.10	0.02	0.19	1.4	0.22 [-0.33, 0.78]
			Placebo	22	21 (95.5)	-0.01 (0.20)	-0.4	-0.07	-0.01	0.05	0.4	
		Week 16	Tezepelumab	32	31 (96.9)	0.12 (0.40)	-0.6	-0.07	0.12	0.28	1.6	0.44 [-0.12, 1.00]
			Placebo	22	21 (95.5)	-0.03 (0.24)	-0.6	-0.10	0.01	0.08	0.5	
		Week 24	Tezepelumab	32	31 (96.9)	0.07 (0.30)	-0.6	-0.10	0.00	0.22	1.0	0.29 [-0.27, 0.86]
			Placebo	22	20 (90.9)	-0.00 (0.18)	-0.5	-0.09	0.03	0.08	0.4	
		Week 36	Tezepelumab	32	30 (93.8)	0.03 (0.35)	-0.7	-0.12	0.01	0.21	1.1	-0.07 [-0.64, 0.51]
			Placebo	22	19 (86.4)	0.05 (0.19)	-0.3	-0.09	0.06	0.19	0.4	
		Week 52	Tezepelumab	32	28 (87.5)	0.05 (0.38)	-1.0	-0.07	0.03	0.23	1.0	0.03 [-0.55, 0.62]
			Placebo	22	19 (86.4)	0.04 (0.22)	-0.5	-0.07	0.08	0.13	0.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
150 - < 300 cells/uL	Absolute values	Baseline	Tezepelumab	23	23 (100.0)	1.93 (0.52)	1.0	1.48	2.02	2.39	2.7	
			Placebo	18	18 (100.0)	1.69 (0.55)	0.9	1.35	1.58	1.93	3.2	
		Week 2	Tezepelumab	23	22 (95.7)	1.97 (0.52)	1.0	1.58	1.99	2.38	2.9	
			Placebo	18	17 (94.4)	1.74 (0.77)	0.9	1.29	1.61	1.80	4.1	
		Week 4	Tezepelumab	23	23 (100.0)	1.95 (0.47)	1.1	1.64	2.00	2.25	2.8	
			Placebo	18	17 (94.4)	1.86 (0.91)	1.0	1.38	1.56	2.02	4.8	
		Week 8	Tezepelumab	23	23 (100.0)	2.01 (0.54)	1.2	1.58	1.92	2.51	2.8	
			Placebo	18	17 (94.4)	1.88 (0.84)	0.8	1.48	1.69	2.03	4.6	
		Week 12	Tezepelumab	23	22 (95.7)	1.99 (0.55)	1.1	1.55	1.96	2.41	3.0	
			Placebo	18	18 (100.0)	1.85 (0.83)	0.8	1.41	1.64	2.10	4.6	
		Week 16	Tezepelumab	23	23 (100.0)	1.98 (0.54)	1.1	1.49	1.91	2.41	3.0	
			Placebo	18	18 (100.0)	1.79 (0.86)	0.8	1.32	1.66	2.04	4.7	
		Week 24	Tezepelumab	23	23 (100.0)	1.98 (0.53)	1.1	1.61	1.91	2.43	2.9	
			Placebo	18	16 (88.9)	1.76 (0.96)	0.8	1.25	1.44	2.02	4.8	
		Week 36	Tezepelumab	23	23 (100.0)	2.00 (0.60)	1.1	1.51	1.85	2.52	3.1	
			Placebo	18	16 (88.9)	1.79 (0.80)	1.1	1.41	1.53	1.85	4.3	
		Week 52	Tezepelumab	23	23 (100.0)	1.97 (0.58)	1.0	1.54	1.97	2.39	3.1	
			Placebo	18	16 (88.9)	1.76 (0.78)	1.1	1.15	1.64	2.01	4.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
150 - < 300 cells/uL	Change from baseline	Week 2	Tezepelumab	23	22 (95.7)	0.02 (0.23)	-0.7	-0.01	0.03	0.09	0.5	-0.15 [-0.78, 0.49]
			Placebo	18	17 (94.4)	0.06 (0.28)	-0.3	-0.07	0.01	0.10	0.9	
		Week 4	Tezepelumab	23	23 (100.0)	0.03 (0.22)	-0.5	-0.08	0.01	0.15	0.6	-0.50 [-1.14, 0.14]
			Placebo	18	17 (94.4)	0.18 (0.41)	-0.3	0.01	0.10	0.28	1.6	
		Week 8	Tezepelumab	23	23 (100.0)	0.08 (0.22)	-0.5	-0.05	0.04	0.21	0.7	-0.25 [-0.88, 0.38]
			Placebo	18	17 (94.4)	0.16 (0.37)	-0.2	-0.07	0.11	0.20	1.4	
		Week 12	Tezepelumab	23	22 (95.7)	0.07 (0.23)	-0.3	-0.06	0.05	0.14	0.7	-0.32 [-0.95, 0.31]
			Placebo	18	18 (100.0)	0.16 (0.35)	-0.3	-0.03	0.06	0.26	1.4	
		Week 16	Tezepelumab	23	23 (100.0)	0.06 (0.20)	-0.5	-0.05	0.04	0.19	0.4	-0.15 [-0.76, 0.47]
			Placebo	18	18 (100.0)	0.10 (0.40)	-0.6	-0.06	0.02	0.19	1.4	
		Week 24	Tezepelumab	23	23 (100.0)	0.05 (0.24)	-0.3	-0.12	0.00	0.23	0.6	-0.01 [-0.65, 0.63]
			Placebo	18	16 (88.9)	0.06 (0.48)	-0.5	-0.26	0.04	0.10	1.6	
		Week 36	Tezepelumab	23	23 (100.0)	0.07 (0.32)	-0.8	-0.15	0.04	0.25	0.8	-0.18 [-0.82, 0.46]
			Placebo	18	16 (88.9)	0.13 (0.34)	-0.3	-0.10	0.05	0.31	1.1	
		Week 52	Tezepelumab	23	23 (100.0)	0.04 (0.32)	-0.8	-0.07	0.00	0.18	0.7	-0.11 [-0.75, 0.53]
			Placebo	18	16 (88.9)	0.07 (0.31)	-0.4	-0.16	0.04	0.20	0.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q1: < 140 cells/uL	Absolute values	Baseline	Tezepelumab	28	28 (100.0)	1.68 (0.69)	0.4	1.21	1.81	2.06	3.2	
			Placebo	22	22 (100.0)	1.76 (0.52)	0.8	1.49	1.75	2.11	2.8	
		Week 2	Tezepelumab	28	27 (96.4)	1.77 (0.69)	0.6	1.23	1.80	2.36	3.4	
			Placebo	22	18 (81.8)	1.74 (0.55)	0.8	1.38	1.73	1.97	2.8	
		Week 4	Tezepelumab	28	28 (100.0)	1.76 (0.77)	0.7	1.06	1.67	2.44	3.4	
			Placebo	22	22 (100.0)	1.76 (0.55)	0.9	1.43	1.73	1.99	3.0	
		Week 8	Tezepelumab	28	27 (96.4)	1.75 (0.69)	0.6	1.23	1.68	2.11	3.3	
			Placebo	22	22 (100.0)	1.76 (0.60)	0.8	1.41	1.77	1.98	2.8	
		Week 12	Tezepelumab	28	28 (100.0)	1.75 (0.72)	0.6	1.21	1.75	2.23	3.6	
			Placebo	22	21 (95.5)	1.76 (0.60)	0.9	1.43	1.61	2.14	3.0	
		Week 16	Tezepelumab	28	27 (96.4)	1.84 (0.78)	0.6	1.29	1.67	2.28	3.5	
			Placebo	22	21 (95.5)	1.75 (0.57)	0.9	1.41	1.71	1.90	3.0	
		Week 24	Tezepelumab	28	28 (100.0)	1.75 (0.68)	0.6	1.11	1.82	2.28	3.5	
			Placebo	22	20 (90.9)	1.77 (0.50)	0.8	1.49	1.71	2.09	2.7	
		Week 36	Tezepelumab	28	27 (96.4)	1.74 (0.68)	0.5	1.16	1.86	2.14	3.5	
			Placebo	22	19 (86.4)	1.82 (0.59)	0.9	1.41	1.78	2.36	3.0	
		Week 52	Tezepelumab	28	25 (89.3)	1.76 (0.68)	0.7	1.21	1.80	2.20	3.4	
			Placebo	22	19 (86.4)	1.77 (0.58)	0.9	1.49	1.68	2.15	2.9	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q1: < 140 cells/uL	Change from baseline	Week 2	Tezepelumab	28	27 (96.4)	0.07 (0.26)	-0.6	-0.02	0.09	0.17	0.8	0.45 [-0.15, 1.05]
			Placebo	22	18 (81.8)	-0.03 (0.20)	-0.4	-0.10	-0.06	0.04	0.5	
		Week 4	Tezepelumab	28	28 (100.0)	0.08 (0.45)	-0.9	-0.16	0.04	0.30	1.7	0.24 [-0.33, 0.80]
			Placebo	22	22 (100.0)	-0.01 (0.18)	-0.3	-0.07	0.02	0.09	0.4	
		Week 8	Tezepelumab	28	27 (96.4)	0.08 (0.36)	-0.8	-0.09	0.01	0.15	1.2	0.26 [-0.31, 0.82]
			Placebo	22	22 (100.0)	-0.00 (0.26)	-0.8	-0.06	0.02	0.10	0.5	
		Week 12	Tezepelumab	28	28 (100.0)	0.06 (0.36)	-0.7	-0.14	0.04	0.20	1.4	0.24 [-0.33, 0.80]
			Placebo	22	21 (95.5)	-0.01 (0.20)	-0.4	-0.07	-0.01	0.05	0.4	
		Week 16	Tezepelumab	28	27 (96.4)	0.14 (0.42)	-0.6	-0.07	0.16	0.29	1.6	0.47 [-0.11, 1.05]
			Placebo	22	21 (95.5)	-0.03 (0.24)	-0.6	-0.10	0.01	0.08	0.5	
		Week 24	Tezepelumab	28	28 (100.0)	0.07 (0.32)	-0.6	-0.10	0.00	0.24	1.0	0.27 [-0.31, 0.85]
			Placebo	22	20 (90.9)	-0.00 (0.18)	-0.5	-0.09	0.03	0.08	0.4	
		Week 36	Tezepelumab	28	27 (96.4)	0.05 (0.37)	-0.7	-0.12	0.03	0.22	1.1	-0.02 [-0.61, 0.57]
			Placebo	22	19 (86.4)	0.05 (0.19)	-0.3	-0.09	0.06	0.19	0.4	
		Week 52	Tezepelumab	28	25 (89.3)	0.06 (0.40)	-1.0	-0.06	0.06	0.24	1.0	0.06 [-0.54, 0.66]
			Placebo	22	19 (86.4)	0.04 (0.22)	-0.5	-0.07	0.08	0.13	0.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q2: 140 - < 250 cells/uL	Absolute values	Baseline	Tezepelumab	23	23 (100.0)	1.92 (0.57)	1.1	1.47	1.70	2.39	3.3	
			Placebo	11	11 (100.0)	1.66 (0.41)	0.9	1.36	1.70	1.93	2.3	
		Week 2	Tezepelumab	23	22 (95.7)	1.96 (0.57)	1.0	1.55	1.76	2.54	2.9	
			Placebo	11	10 (90.9)	1.64 (0.51)	0.9	1.29	1.66	1.76	2.6	
		Week 4	Tezepelumab	23	23 (100.0)	1.95 (0.57)	1.1	1.59	1.75	2.45	3.3	
			Placebo	11	10 (90.9)	1.75 (0.53)	1.0	1.38	1.65	2.02	2.7	
		Week 8	Tezepelumab	23	22 (95.7)	1.93 (0.53)	1.2	1.58	1.77	2.43	2.8	
			Placebo	11	11 (100.0)	1.72 (0.49)	0.8	1.48	1.69	1.81	2.7	
		Week 12	Tezepelumab	23	22 (95.7)	1.94 (0.64)	1.1	1.46	1.68	2.41	3.3	
			Placebo	11	11 (100.0)	1.72 (0.54)	0.8	1.42	1.66	1.93	2.7	
		Week 16	Tezepelumab	23	23 (100.0)	1.98 (0.58)	1.2	1.49	1.84	2.56	3.1	
			Placebo	11	11 (100.0)	1.60 (0.52)	0.8	1.26	1.68	1.78	2.6	
		Week 24	Tezepelumab	23	22 (95.7)	1.88 (0.53)	1.1	1.59	1.75	2.27	2.9	
			Placebo	11	9 (81.8)	1.56 (0.60)	0.8	1.29	1.46	1.67	2.7	
		Week 36	Tezepelumab	23	22 (95.7)	1.88 (0.60)	1.1	1.43	1.74	2.34	3.1	
			Placebo	11	9 (81.8)	1.63 (0.44)	1.2	1.46	1.49	1.59	2.7	
		Week 52	Tezepelumab	23	22 (95.7)	1.85 (0.59)	1.0	1.44	1.67	2.27	3.1	
			Placebo	11	11 (100.0)	1.62 (0.53)	1.1	1.14	1.62	1.73	2.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q2: 140 - < 250 cells/uL	Change from baseline	Week 2	Tezepelumab	23	22 (95.7)	0.02 (0.23)	-0.7	-0.01	0.04	0.09	0.5	0.06 [-0.68, 0.81]
			Placebo	11	10 (90.9)	0.01 (0.17)	-0.3	-0.07	0.02	0.10	0.3	
		Week 4	Tezepelumab	23	23 (100.0)	0.03 (0.15)	-0.3	-0.08	0.01	0.15	0.3	-0.55 [-1.31, 0.20]
			Placebo	11	10 (90.9)	0.12 (0.17)	-0.1	0.03	0.10	0.28	0.4	
		Week 8	Tezepelumab	23	22 (95.7)	0.07 (0.22)	-0.5	-0.05	0.04	0.19	0.7	0.06 [-0.66, 0.78]
			Placebo	11	11 (100.0)	0.06 (0.19)	-0.2	-0.12	0.04	0.20	0.4	
		Week 12	Tezepelumab	23	22 (95.7)	0.03 (0.18)	-0.3	-0.09	0.05	0.14	0.4	-0.14 [-0.86, 0.59]
			Placebo	11	11 (100.0)	0.06 (0.21)	-0.3	-0.05	0.00	0.26	0.4	
		Week 16	Tezepelumab	23	23 (100.0)	0.06 (0.19)	-0.5	-0.05	0.04	0.19	0.4	0.55 [-0.18, 1.28]
			Placebo	11	11 (100.0)	-0.05 (0.24)	-0.6	-0.15	0.00	0.02	0.3	
		Week 24	Tezepelumab	23	22 (95.7)	0.02 (0.19)	-0.3	-0.12	0.02	0.21	0.3	0.60 [-0.19, 1.39]
			Placebo	11	9 (81.8)	-0.11 (0.30)	-0.5	-0.37	-0.05	0.05	0.4	
		Week 36	Tezepelumab	23	22 (95.7)	0.02 (0.30)	-0.8	-0.15	0.03	0.14	0.6	-0.09 [-0.87, 0.69]
			Placebo	11	9 (81.8)	0.04 (0.25)	-0.3	-0.19	0.04	0.22	0.4	
		Week 52	Tezepelumab	23	22 (95.7)	-0.01 (0.30)	-0.8	-0.10	-0.01	0.13	0.7	0.09 [-0.64, 0.81]
			Placebo	11	11 (100.0)	-0.03 (0.25)	-0.4	-0.26	-0.02	0.15	0.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q3: 250 - < 430 cells/uL	Absolute values	Baseline	Tezepelumab	4	4 (100.0)	1.92 (0.62)	1.0	1.54	2.09	2.30	2.5	
			Placebo	7	7 (100.0)	1.74 (0.76)	1.1	1.11	1.45	2.10	3.2	
		Week 2	Tezepelumab	4	4 (100.0)	1.91 (0.43)	1.3	1.67	2.10	2.15	2.2	
			Placebo	7	7 (100.0)	1.87 (1.08)	1.0	1.02	1.46	2.31	4.1	
		Week 4	Tezepelumab	4	4 (100.0)	1.97 (0.23)	1.6	1.82	2.03	2.12	2.2	
			Placebo	7	7 (100.0)	2.02 (1.31)	1.1	1.10	1.56	2.35	4.8	
		Week 8	Tezepelumab	4	4 (100.0)	2.10 (0.57)	1.3	1.70	2.26	2.50	2.6	
			Placebo	7	6 (85.7)	2.18 (1.26)	1.2	1.40	1.78	2.30	4.6	
		Week 12	Tezepelumab	4	4 (100.0)	2.13 (0.31)	1.8	1.92	2.14	2.35	2.5	
			Placebo	7	7 (100.0)	2.06 (1.18)	1.3	1.31	1.47	2.25	4.6	
		Week 16	Tezepelumab	4	4 (100.0)	1.93 (0.59)	1.1	1.61	2.19	2.25	2.3	
			Placebo	7	7 (100.0)	2.08 (1.21)	1.2	1.32	1.64	2.28	4.7	
		Week 24	Tezepelumab	4	4 (100.0)	2.18 (0.40)	1.7	1.87	2.25	2.49	2.6	
			Placebo	7	7 (100.0)	2.01 (1.30)	1.1	1.21	1.42	2.25	4.8	
		Week 36	Tezepelumab	4	4 (100.0)	2.18 (0.69)	1.3	1.67	2.29	2.70	2.9	
			Placebo	7	7 (100.0)	1.98 (1.12)	1.1	1.14	1.75	2.26	4.3	
		Week 52	Tezepelumab	4	4 (100.0)	2.16 (0.47)	1.5	1.80	2.27	2.53	2.6	
			Placebo	7	5 (71.4)	2.05 (1.20)	1.1	1.15	1.68	2.29	4.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q3: 250 - < 430 cells/uL	Change from baseline	Week 2	Tezepelumab	4	4 (100.0)	-0.01 (0.23)	-0.3	-0.15	0.01	0.13	0.2	-0.42 [-1.66, 0.82]
			Placebo	7	7 (100.0)	0.13 (0.39)	-0.3	-0.09	0.01	0.46	0.9	
		Week 4	Tezepelumab	4	4 (100.0)	0.05 (0.45)	-0.5	-0.23	0.03	0.33	0.6	-0.41 [-1.66, 0.83]
			Placebo	7	7 (100.0)	0.28 (0.63)	-0.3	-0.01	0.08	0.50	1.6	
		Week 8	Tezepelumab	4	4 (100.0)	0.18 (0.24)	-0.1	-0.01	0.16	0.36	0.5	-0.34 [-1.62, 0.93]
			Placebo	7	6 (85.7)	0.33 (0.55)	-0.1	-0.05	0.14	0.45	1.4	
		Week 12	Tezepelumab	4	4 (100.0)	0.21 (0.34)	0.0	0.03	0.06	0.40	0.7	-0.25 [-1.48, 0.98]
			Placebo	7	7 (100.0)	0.32 (0.47)	0.0	0.02	0.20	0.40	1.4	
		Week 16	Tezepelumab	4	4 (100.0)	0.01 (0.18)	-0.3	-0.12	0.07	0.13	0.1	-0.80 [-2.08, 0.48]
			Placebo	7	7 (100.0)	0.35 (0.51)	-0.1	0.07	0.19	0.43	1.4	
		Week 24	Tezepelumab	4	4 (100.0)	0.26 (0.33)	-0.0	-0.01	0.22	0.53	0.6	-0.02 [-1.25, 1.20]
			Placebo	7	7 (100.0)	0.27 (0.61)	-0.3	-0.05	0.07	0.40	1.6	
		Week 36	Tezepelumab	4	4 (100.0)	0.26 (0.34)	0.0	0.03	0.15	0.50	0.8	0.04 [-1.19, 1.27]
			Placebo	7	7 (100.0)	0.25 (0.42)	-0.2	-0.03	0.08	0.41	1.1	
		Week 52	Tezepelumab	4	4 (100.0)	0.24 (0.23)	0.0	0.06	0.23	0.43	0.5	-0.23 [-1.55, 1.09]
			Placebo	7	5 (71.4)	0.31 (0.31)	0.0	0.04	0.23	0.44	0.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
< 25 ppb	Absolute values	Baseline	Tezepelumab	55	55 (100.0)	1.80 (0.64)	0.4	1.28	1.79	2.20	3.3	
			Placebo	40	40 (100.0)	1.73 (0.53)	0.8	1.40	1.70	2.07	3.2	
		Week 2	Tezepelumab	55	53 (96.4)	1.86 (0.62)	0.6	1.42	1.80	2.36	3.4	
			Placebo	40	35 (87.5)	1.74 (0.66)	0.8	1.34	1.71	1.97	4.1	
		Week 4	Tezepelumab	55	55 (100.0)	1.85 (0.66)	0.7	1.44	1.75	2.40	3.4	
			Placebo	40	39 (97.5)	1.80 (0.72)	0.9	1.38	1.69	2.02	4.8	
		Week 8	Tezepelumab	55	53 (96.4)	1.85 (0.62)	0.6	1.55	1.79	2.38	3.3	
			Placebo	40	39 (97.5)	1.81 (0.70)	0.8	1.41	1.74	2.03	4.6	
		Week 12	Tezepelumab	55	54 (98.2)	1.86 (0.67)	0.6	1.44	1.76	2.32	3.6	
			Placebo	40	39 (97.5)	1.80 (0.71)	0.8	1.41	1.62	2.14	4.6	
		Week 16	Tezepelumab	55	54 (98.2)	1.91 (0.68)	0.6	1.46	1.84	2.34	3.5	
			Placebo	40	39 (97.5)	1.77 (0.71)	0.8	1.33	1.68	2.04	4.7	
		Week 24	Tezepelumab	55	54 (98.2)	1.84 (0.61)	0.6	1.52	1.83	2.29	3.5	
			Placebo	40	36 (90.0)	1.76 (0.73)	0.8	1.38	1.63	2.09	4.8	
		Week 36	Tezepelumab	55	53 (96.4)	1.83 (0.65)	0.5	1.33	1.83	2.30	3.5	
			Placebo	40	35 (87.5)	1.81 (0.68)	0.9	1.41	1.69	1.94	4.3	
		Week 52	Tezepelumab	55	51 (92.7)	1.83 (0.63)	0.7	1.43	1.79	2.26	3.4	
			Placebo	40	35 (87.5)	1.76 (0.67)	0.9	1.24	1.66	2.15	4.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
< 25 ppb	Change from baseline	Week 2	Tezepelumab	55	53 (96.4)	0.05 (0.24)	-0.7	-0.01	0.05	0.15	0.8	0.14 [-0.29, 0.57]
			Placebo	40	35 (87.5)	0.01 (0.24)	-0.4	-0.09	-0.01	0.08	0.9	
		Week 4	Tezepelumab	55	55 (100.0)	0.05 (0.35)	-0.9	-0.09	0.04	0.17	1.7	-0.07 [-0.48, 0.34]
			Placebo	40	39 (97.5)	0.08 (0.31)	-0.3	-0.05	0.04	0.12	1.6	
		Week 8	Tezepelumab	55	53 (96.4)	0.08 (0.30)	-0.8	-0.07	0.04	0.19	1.2	0.06 [-0.36, 0.47]
			Placebo	40	39 (97.5)	0.07 (0.32)	-0.8	-0.07	0.04	0.18	1.4	
		Week 12	Tezepelumab	55	54 (98.2)	0.06 (0.29)	-0.7	-0.09	0.05	0.17	1.4	-0.03 [-0.44, 0.38]
			Placebo	40	39 (97.5)	0.07 (0.29)	-0.4	-0.06	0.02	0.20	1.4	
		Week 16	Tezepelumab	55	54 (98.2)	0.10 (0.33)	-0.6	-0.05	0.10	0.22	1.6	0.19 [-0.22, 0.60]
			Placebo	40	39 (97.5)	0.03 (0.33)	-0.6	-0.10	0.01	0.18	1.4	
		Week 24	Tezepelumab	55	54 (98.2)	0.07 (0.27)	-0.6	-0.11	0.00	0.22	1.0	0.14 [-0.29, 0.56]
			Placebo	40	36 (90.0)	0.02 (0.35)	-0.5	-0.11	0.03	0.09	1.6	
		Week 36	Tezepelumab	55	53 (96.4)	0.05 (0.34)	-0.8	-0.12	0.04	0.21	1.1	-0.12 [-0.55, 0.30]
			Placebo	40	35 (87.5)	0.09 (0.27)	-0.3	-0.09	0.06	0.29	1.1	
		Week 52	Tezepelumab	55	51 (92.7)	0.04 (0.35)	-1.0	-0.07	0.01	0.23	1.0	-0.03 [-0.46, 0.40]
			Placebo	40	35 (87.5)	0.05 (0.26)	-0.5	-0.08	0.06	0.15	0.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q1: < 16 ppb	Absolute values	Baseline	Tezepelumab	31	31 (100.0)	1.78 (0.61)	0.8	1.27	1.74	2.20	3.2	
			Placebo	26	26 (100.0)	1.73 (0.61)	0.8	1.39	1.64	2.10	3.2	
		Week 2	Tezepelumab	31	29 (93.5)	1.90 (0.64)	0.9	1.41	1.94	2.42	3.4	
			Placebo	26	21 (80.8)	1.74 (0.79)	0.8	1.15	1.61	2.11	4.1	
		Week 4	Tezepelumab	31	31 (100.0)	1.89 (0.70)	0.7	1.44	1.94	2.45	3.4	
			Placebo	26	25 (96.2)	1.85 (0.85)	0.9	1.31	1.73	2.20	4.8	
		Week 8	Tezepelumab	31	30 (96.8)	1.92 (0.65)	0.7	1.57	1.79	2.41	3.3	
			Placebo	26	25 (96.2)	1.84 (0.80)	0.8	1.40	1.76	2.03	4.6	
		Week 12	Tezepelumab	31	30 (96.8)	1.86 (0.69)	0.8	1.44	1.79	2.37	3.6	
			Placebo	26	25 (96.2)	1.86 (0.82)	0.8	1.31	1.69	2.25	4.6	
		Week 16	Tezepelumab	31	30 (96.8)	1.98 (0.70)	0.9	1.54	1.94	2.41	3.5	
			Placebo	26	25 (96.2)	1.81 (0.84)	0.8	1.31	1.68	2.10	4.7	
		Week 24	Tezepelumab	31	31 (100.0)	1.86 (0.62)	0.8	1.57	1.89	2.27	3.5	
			Placebo	26	22 (84.6)	1.83 (0.89)	0.8	1.21	1.60	2.21	4.8	
		Week 36	Tezepelumab	31	30 (96.8)	1.90 (0.70)	0.8	1.33	1.84	2.42	3.5	
			Placebo	26	23 (88.5)	1.89 (0.79)	0.9	1.41	1.75	2.36	4.3	
		Week 52	Tezepelumab	31	28 (90.3)	1.90 (0.69)	0.7	1.49	1.88	2.38	3.4	
			Placebo	26	22 (84.6)	1.75 (0.79)	0.9	1.14	1.60	2.15	4.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q1: < 16 ppb	Change from baseline	Week 2	Tezepelumab	31	29 (93.5)	0.09 (0.25)	-0.6	0.00	0.05	0.20	0.8	0.30 [-0.26, 0.87]
			Placebo	26	21 (80.8)	0.01 (0.28)	-0.4	-0.09	-0.01	0.06	0.9	
		Week 4	Tezepelumab	31	31 (100.0)	0.11 (0.39)	-0.6	-0.07	0.04	0.25	1.7	-0.04 [-0.56, 0.49]
			Placebo	26	25 (96.2)	0.12 (0.36)	-0.3	-0.02	0.07	0.12	1.6	
		Week 8	Tezepelumab	31	30 (96.8)	0.14 (0.29)	-0.3	-0.07	0.06	0.25	1.2	0.17 [-0.36, 0.71]
			Placebo	26	25 (96.2)	0.08 (0.33)	-0.5	-0.06	0.04	0.11	1.4	
		Week 12	Tezepelumab	31	30 (96.8)	0.09 (0.33)	-0.4	-0.03	0.05	0.17	1.4	-0.10 [-0.63, 0.43]
			Placebo	26	25 (96.2)	0.12 (0.31)	-0.3	-0.03	0.04	0.22	1.4	
		Week 16	Tezepelumab	31	30 (96.8)	0.18 (0.34)	-0.3	0.00	0.13	0.28	1.6	0.31 [-0.23, 0.84]
			Placebo	26	25 (96.2)	0.08 (0.36)	-0.6	-0.07	0.02	0.18	1.4	
		Week 24	Tezepelumab	31	31 (100.0)	0.07 (0.26)	-0.3	-0.10	0.00	0.21	1.0	-0.04 [-0.58, 0.51]
			Placebo	26	22 (84.6)	0.09 (0.41)	-0.5	-0.10	0.05	0.14	1.6	
		Week 36	Tezepelumab	31	30 (96.8)	0.10 (0.33)	-0.8	-0.07	0.07	0.24	1.1	-0.19 [-0.73, 0.36]
			Placebo	26	23 (88.5)	0.16 (0.28)	-0.3	-0.03	0.08	0.30	1.1	
		Week 52	Tezepelumab	31	28 (90.3)	0.09 (0.36)	-0.8	-0.03	0.01	0.25	1.0	0.05 [-0.51, 0.61]
			Placebo	26	22 (84.6)	0.07 (0.27)	-0.4	-0.06	0.07	0.15	0.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q2: 16 - < 30 ppb Absolute values		Baseline	Tezepelumab	24	24 (100.0)	1.82 (0.69)	0.4	1.35	1.85	2.29	3.3	
			Placebo	14	14 (100.0)	1.73 (0.35)	1.0	1.41	1.76	2.04	2.2	
		Week 2	Tezepelumab	24	24 (100.0)	1.81 (0.60)	0.6	1.49	1.76	2.21	2.9	
			Placebo	14	14 (100.0)	1.73 (0.42)	1.0	1.39	1.74	1.89	2.7	
		Week 4	Tezepelumab	24	24 (100.0)	1.81 (0.63)	0.7	1.51	1.70	2.12	3.3	
			Placebo	14	14 (100.0)	1.72 (0.42)	1.0	1.43	1.67	1.85	2.6	
		Week 8	Tezepelumab	24	23 (95.8)	1.77 (0.57)	0.6	1.30	1.79	2.05	2.8	
			Placebo	14	14 (100.0)	1.76 (0.52)	0.8	1.53	1.74	1.94	2.7	
		Week 12	Tezepelumab	24	24 (100.0)	1.84 (0.66)	0.6	1.39	1.75	2.28	3.3	
			Placebo	14	14 (100.0)	1.70 (0.44)	1.0	1.43	1.57	1.93	2.6	
		Week 16	Tezepelumab	24	24 (100.0)	1.81 (0.65)	0.6	1.38	1.66	2.27	3.1	
			Placebo	14	14 (100.0)	1.68 (0.40)	1.0	1.42	1.68	1.78	2.7	
		Week 24	Tezepelumab	24	23 (95.8)	1.81 (0.60)	0.6	1.18	1.71	2.35	2.9	
			Placebo	14	14 (100.0)	1.65 (0.33)	1.1	1.42	1.63	1.73	2.3	
		Week 36	Tezepelumab	24	23 (95.8)	1.74 (0.57)	0.5	1.25	1.77	2.12	2.9	
			Placebo	14	12 (85.7)	1.65 (0.37)	1.0	1.42	1.64	1.78	2.6	
		Week 52	Tezepelumab	24	23 (95.8)	1.75 (0.54)	0.8	1.37	1.75	2.21	2.8	
			Placebo	14	13 (92.9)	1.78 (0.43)	1.0	1.59	1.70	1.97	2.7	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q2: 16 - < 30 ppb	Change from baseline	Week 2	Tezepelumab	24	24 (100.0)	-0.01 (0.23)	-0.7	-0.09	0.03	0.09	0.5	-0.09 [-0.75, 0.57]
			Placebo	14	14 (100.0)	0.01 (0.18)	-0.3	-0.09	-0.03	0.08	0.5	
		Week 4	Tezepelumab	24	24 (100.0)	-0.01 (0.28)	-0.9	-0.14	0.03	0.14	0.6	-0.04 [-0.70, 0.62]
			Placebo	14	14 (100.0)	-0.00 (0.21)	-0.3	-0.14	0.02	0.09	0.4	
		Week 8	Tezepelumab	24	23 (95.8)	0.01 (0.29)	-0.8	-0.09	0.02	0.18	0.6	-0.07 [-0.74, 0.59]
			Placebo	14	14 (100.0)	0.03 (0.31)	-0.8	-0.10	0.09	0.19	0.5	
		Week 12	Tezepelumab	24	24 (100.0)	0.03 (0.25)	-0.7	-0.13	0.05	0.17	0.5	0.21 [-0.45, 0.87]
			Placebo	14	14 (100.0)	-0.02 (0.23)	-0.4	-0.09	-0.02	0.06	0.4	
		Week 16	Tezepelumab	24	24 (100.0)	-0.01 (0.28)	-0.6	-0.18	0.04	0.19	0.4	0.11 [-0.55, 0.77]
			Placebo	14	14 (100.0)	-0.04 (0.26)	-0.6	-0.10	-0.01	0.07	0.5	
		Week 24	Tezepelumab	24	23 (95.8)	0.05 (0.29)	-0.6	-0.18	0.00	0.27	0.7	0.49 [-0.18, 1.17]
			Placebo	14	14 (100.0)	-0.07 (0.19)	-0.5	-0.21	0.03	0.06	0.1	
		Week 36	Tezepelumab	24	23 (95.8)	-0.01 (0.34)	-0.7	-0.18	-0.05	0.16	0.8	0.10 [-0.60, 0.80]
			Placebo	14	12 (85.7)	-0.04 (0.20)	-0.3	-0.21	-0.08	0.09	0.4	
		Week 52	Tezepelumab	24	23 (95.8)	-0.01 (0.34)	-1.0	-0.15	0.01	0.18	0.7	-0.11 [-0.79, 0.57]
			Placebo	14	13 (92.9)	0.03 (0.26)	-0.5	-0.08	0.00	0.15	0.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q1: < 53.1 IU/ml	Absolute values	Baseline	Tezepelumab	41	41 (100.0)	1.72 (0.65)	0.4	1.27	1.69	2.10	3.3	
			Placebo	34	34 (100.0)	1.71 (0.47)	0.8	1.41	1.70	2.04	2.8	
		Week 2	Tezepelumab	41	39 (95.1)	1.75 (0.59)	0.6	1.29	1.70	2.06	2.9	
			Placebo	34	30 (88.2)	1.68 (0.50)	0.8	1.35	1.71	1.93	2.8	
		Week 4	Tezepelumab	41	41 (100.0)	1.73 (0.63)	0.7	1.32	1.67	2.06	3.3	
			Placebo	34	33 (97.1)	1.74 (0.51)	0.9	1.43	1.69	1.99	3.0	
		Week 8	Tezepelumab	41	39 (95.1)	1.71 (0.54)	0.6	1.43	1.67	2.05	2.8	
			Placebo	34	34 (100.0)	1.74 (0.52)	0.8	1.41	1.74	1.94	2.8	
		Week 12	Tezepelumab	41	40 (97.6)	1.72 (0.63)	0.6	1.31	1.63	2.09	3.3	
			Placebo	34	33 (97.1)	1.73 (0.53)	0.8	1.42	1.62	2.10	3.0	
		Week 16	Tezepelumab	41	40 (97.6)	1.78 (0.62)	0.6	1.45	1.66	2.24	3.1	
			Placebo	34	33 (97.1)	1.69 (0.53)	0.8	1.33	1.68	1.90	3.0	
		Week 24	Tezepelumab	41	40 (97.6)	1.72 (0.56)	0.6	1.29	1.71	2.08	2.9	
			Placebo	34	31 (91.2)	1.68 (0.49)	0.8	1.40	1.63	2.07	2.7	
		Week 36	Tezepelumab	41	39 (95.1)	1.71 (0.60)	0.5	1.25	1.61	2.14	3.1	
			Placebo	34	30 (88.2)	1.75 (0.50)	0.9	1.45	1.70	1.92	3.0	
		Week 52	Tezepelumab	41	38 (92.7)	1.74 (0.59)	0.7	1.37	1.68	2.12	3.1	
			Placebo	34	30 (88.2)	1.71 (0.52)	0.9	1.34	1.67	1.97	2.9	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q1: < 53.1 IU/ml	Change from baseline	Week 2	Tezepelumab	41	39 (95.1)	0.01 (0.23)	-0.7	-0.08	0.05	0.12	0.5	0.19 [-0.29, 0.66]
			Placebo	34	30 (88.2)	-0.03 (0.20)	-0.4	-0.10	-0.04	0.04	0.5	
		Week 4	Tezepelumab	41	41 (100.0)	0.01 (0.27)	-0.9	-0.09	0.00	0.15	0.6	-0.10 [-0.55, 0.36]
			Placebo	34	33 (97.1)	0.03 (0.20)	-0.3	-0.07	0.05	0.11	0.5	
		Week 8	Tezepelumab	41	39 (95.1)	0.04 (0.26)	-0.8	-0.08	0.02	0.18	0.7	0.04 [-0.42, 0.50]
			Placebo	34	34 (100.0)	0.03 (0.24)	-0.8	-0.07	0.02	0.13	0.5	
		Week 12	Tezepelumab	41	40 (97.6)	0.01 (0.22)	-0.7	-0.10	0.03	0.15	0.5	-0.01 [-0.47, 0.45]
			Placebo	34	33 (97.1)	0.01 (0.19)	-0.4	-0.06	0.00	0.06	0.4	
		Week 16	Tezepelumab	41	40 (97.6)	0.05 (0.26)	-0.6	-0.08	0.10	0.20	0.7	0.28 [-0.18, 0.75]
			Placebo	34	33 (97.1)	-0.02 (0.24)	-0.6	-0.10	0.01	0.08	0.5	
		Week 24	Tezepelumab	41	40 (97.6)	0.04 (0.24)	-0.6	-0.10	0.01	0.21	0.7	0.35 [-0.12, 0.82]
			Placebo	34	31 (91.2)	-0.04 (0.22)	-0.5	-0.21	0.03	0.09	0.4	
		Week 36	Tezepelumab	41	39 (95.1)	0.02 (0.29)	-0.7	-0.12	0.03	0.20	0.6	-0.12 [-0.60, 0.36]
			Placebo	34	30 (88.2)	0.05 (0.21)	-0.3	-0.11	0.05	0.22	0.4	
		Week 52	Tezepelumab	41	38 (92.7)	0.03 (0.32)	-1.0	-0.07	0.00	0.16	0.7	0.03 [-0.45, 0.51]
			Placebo	34	30 (88.2)	0.02 (0.23)	-0.5	-0.11	0.05	0.15	0.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q2: 53.1 - < 195.6 IU/ml	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	1.93 (0.67)	1.0	1.41	1.79	2.27	3.2	
			Placebo	4	4 (100.0)	1.69 (0.53)	1.1	1.28	1.69	2.10	2.3	
		Week 2	Tezepelumab	9	9 (100.0)	2.06 (0.68)	1.3	1.42	2.17	2.42	3.4	
			Placebo	4	3 (75.0)	1.76 (0.82)	1.0	1.01	1.65	2.63	2.6	
		Week 4	Tezepelumab	9	9 (100.0)	2.17 (0.81)	1.1	1.61	2.00	2.60	3.4	
			Placebo	4	4 (100.0)	1.78 (0.70)	1.1	1.27	1.68	2.30	2.7	
		Week 8	Tezepelumab	9	9 (100.0)	2.13 (0.77)	1.2	1.30	2.35	2.62	3.3	
			Placebo	4	3 (75.0)	2.07 (0.57)	1.5	1.54	1.98	2.68	2.7	
		Week 12	Tezepelumab	9	9 (100.0)	2.20 (0.79)	1.2	1.70	2.32	2.50	3.6	
			Placebo	4	4 (100.0)	1.96 (0.64)	1.3	1.45	1.93	2.48	2.7	
		Week 16	Tezepelumab	9	9 (100.0)	2.22 (0.93)	1.1	1.32	2.22	2.96	3.5	
			Placebo	4	4 (100.0)	1.83 (0.55)	1.3	1.48	1.71	2.19	2.6	
		Week 24	Tezepelumab	9	9 (100.0)	2.09 (0.76)	1.2	1.61	2.26	2.43	3.5	
			Placebo	4	3 (75.0)	1.78 (0.85)	1.1	1.12	1.49	2.74	2.7	
		Week 36	Tezepelumab	9	9 (100.0)	2.05 (0.80)	1.1	1.28	2.02	2.52	3.5	
			Placebo	4	3 (75.0)	1.76 (0.86)	1.1	1.14	1.41	2.74	2.7	
		Week 52	Tezepelumab	9	8 (88.9)	2.04 (0.84)	1.0	1.36	1.98	2.67	3.4	
			Placebo	4	3 (75.0)	1.82 (0.87)	1.1	1.10	1.57	2.79	2.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q2: 53.1 - < 195.6 IU/ml	Change from baseline	Week 2	Tezepelumab	9	9 (100.0)	0.13 (0.29)	-0.3	0.01	0.09	0.20	0.8	-0.04 [-1.34, 1.27]
			Placebo	4	3 (75.0)	0.14 (0.19)	-0.1	-0.05	0.16	0.32	0.3	
		Week 4	Tezepelumab	9	9 (100.0)	0.24 (0.64)	-0.5	-0.16	0.03	0.33	1.7	0.26 [-0.92, 1.44]
			Placebo	4	4 (100.0)	0.10 (0.20)	-0.0	-0.01	0.02	0.21	0.4	
		Week 8	Tezepelumab	9	9 (100.0)	0.20 (0.40)	-0.2	0.00	0.15	0.26	1.2	0.08 [-1.23, 1.38]
			Placebo	4	3 (75.0)	0.17 (0.17)	0.1	0.05	0.10	0.37	0.4	
		Week 12	Tezepelumab	9	9 (100.0)	0.28 (0.50)	-0.2	0.02	0.10	0.39	1.4	0.00 [-1.18, 1.18]
			Placebo	4	4 (100.0)	0.28 (0.13)	0.1	0.17	0.30	0.38	0.4	
		Week 16	Tezepelumab	9	9 (100.0)	0.29 (0.57)	-0.3	0.02	0.04	0.36	1.6	0.28 [-0.90, 1.47]
			Placebo	4	4 (100.0)	0.15 (0.18)	-0.1	0.02	0.20	0.28	0.3	
		Week 24	Tezepelumab	9	9 (100.0)	0.16 (0.41)	-0.2	-0.12	-0.01	0.29	1.0	0.00 [-1.30, 1.31]
			Placebo	4	3 (75.0)	0.16 (0.23)	0.0	0.00	0.06	0.43	0.4	
		Week 36	Tezepelumab	9	9 (100.0)	0.13 (0.40)	-0.2	-0.15	0.04	0.25	1.1	-0.04 [-1.35, 1.26]
			Placebo	4	3 (75.0)	0.14 (0.26)	-0.1	-0.08	0.08	0.43	0.4	
		Week 52	Tezepelumab	9	8 (88.9)	0.16 (0.44)	-0.3	-0.15	0.05	0.37	1.0	-0.10 [-1.43, 1.23]
			Placebo	4	3 (75.0)	0.20 (0.24)	0.0	0.04	0.08	0.48	0.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q4: >= 572.4 IU/ml	Absolute values	Baseline	Tezepelumab	5	5 (100.0)	2.23 (0.26)	2.0	2.02	2.12	2.39	2.6	
			Placebo	2	2 (100.0)	2.14 (1.55)	1.0	1.04	2.14	3.23	3.2	
		Week 2	Tezepelumab	5	5 (100.0)	2.38 (0.39)	1.9	2.13	2.38	2.54	2.9	
			Placebo	2	2 (100.0)	2.53 (2.21)	1.0	0.97	2.53	4.09	4.1	
		Week 4	Tezepelumab	5	5 (100.0)	2.32 (0.25)	2.1	2.17	2.24	2.45	2.7	
			Placebo	2	2 (100.0)	2.92 (2.71)	1.0	1.00	2.92	4.83	4.8	
		Week 8	Tezepelumab	5	5 (100.0)	2.47 (0.35)	1.9	2.43	2.59	2.68	2.8	
			Placebo	2	2 (100.0)	2.70 (2.70)	0.8	0.79	2.70	4.61	4.6	
		Week 12	Tezepelumab	5	5 (100.0)	2.34 (0.23)	2.2	2.20	2.21	2.39	2.7	
			Placebo	2	2 (100.0)	2.78 (2.55)	1.0	0.98	2.78	4.58	4.6	
		Week 16	Tezepelumab	5	5 (100.0)	2.35 (0.14)	2.2	2.27	2.31	2.39	2.6	
			Placebo	2	2 (100.0)	2.82 (2.62)	1.0	0.97	2.82	4.67	4.7	
		Week 24	Tezepelumab	5	5 (100.0)	2.31 (0.26)	1.9	2.27	2.29	2.55	2.6	
			Placebo	2	2 (100.0)	2.94 (2.64)	1.1	1.07	2.94	4.81	4.8	
		Week 36	Tezepelumab	5	5 (100.0)	2.36 (0.43)	1.9	1.97	2.50	2.59	2.9	
			Placebo	2	2 (100.0)	2.67 (2.35)	1.0	1.00	2.67	4.33	4.3	
		Week 52	Tezepelumab	5	5 (100.0)	2.22 (0.26)	1.8	2.20	2.26	2.39	2.5	
			Placebo	2	2 (100.0)	2.49 (2.16)	1.0	0.96	2.49	4.01	4.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q4: >= 572.4 IU/ml	Change from baseline	Week 2	Tezepelumab	5	5 (100.0)	0.15 (0.26)	-0.1	-0.01	0.01	0.31	0.5	-0.66 [-2.35, 1.03]
			Placebo	2	2 (100.0)	0.40 (0.66)	-0.1	-0.07	0.40	0.86	0.9	
		Week 4	Tezepelumab	5	5 (100.0)	0.09 (0.07)	0.0	0.05	0.06	0.07	0.2	-1.32 [-3.15, 0.51]
			Placebo	2	2 (100.0)	0.78 (1.16)	-0.0	-0.04	0.78	1.60	1.6	
		Week 8	Tezepelumab	5	5 (100.0)	0.23 (0.33)	-0.1	0.04	0.13	0.47	0.7	-0.56 [-2.24, 1.11]
			Placebo	2	2 (100.0)	0.57 (1.15)	-0.3	-0.25	0.57	1.38	1.4	
		Week 12	Tezepelumab	5	5 (100.0)	0.11 (0.21)	-0.2	0.08	0.10	0.19	0.4	-1.11 [-2.89, 0.67]
			Placebo	2	2 (100.0)	0.65 (1.00)	-0.1	-0.06	0.65	1.35	1.4	
		Week 16	Tezepelumab	5	5 (100.0)	0.11 (0.14)	-0.1	0.00	0.15	0.17	0.3	-1.16 [-2.95, 0.63]
			Placebo	2	2 (100.0)	0.69 (1.07)	-0.1	-0.07	0.69	1.44	1.4	
		Week 24	Tezepelumab	5	5 (100.0)	0.08 (0.25)	-0.1	-0.11	-0.07	0.27	0.4	-1.34 [-3.18, 0.50]
			Placebo	2	2 (100.0)	0.81 (1.10)	0.0	0.03	0.81	1.58	1.6	
		Week 36	Tezepelumab	5	5 (100.0)	0.12 (0.60)	-0.8	-0.05	0.11	0.57	0.8	-0.63 [-2.32, 1.05]
			Placebo	2	2 (100.0)	0.53 (0.81)	-0.0	-0.04	0.53	1.10	1.1	
		Week 52	Tezepelumab	5	5 (100.0)	-0.01 (0.47)	-0.8	0.00	0.18	0.24	0.4	-0.72 [-2.42, 0.98]
			Placebo	2	2 (100.0)	0.35 (0.61)	-0.1	-0.08	0.35	0.78	0.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Nasal polyps last 2 years												
Yes	Absolute values	Baseline	Tezepelumab	4	4 (100.0)	1.56 (0.68)	0.8	1.14	1.47	1.99	2.5	
			Placebo	3	3 (100.0)	2.07 (1.01)	1.4	1.44	1.54	3.23	3.2	
		Week 2	Tezepelumab	4	4 (100.0)	1.54 (0.51)	0.9	1.20	1.54	1.88	2.2	
			Placebo	3	3 (100.0)	2.32 (1.56)	1.2	1.15	1.71	4.09	4.1	
		Week 4	Tezepelumab	4	4 (100.0)	1.49 (0.46)	0.9	1.17	1.54	1.82	2.0	
			Placebo	3	3 (100.0)	2.61 (1.93)	1.3	1.31	1.69	4.83	4.8	
		Week 8	Tezepelumab	4	4 (100.0)	1.67 (0.59)	1.0	1.27	1.67	2.08	2.4	
			Placebo	3	3 (100.0)	2.54 (1.81)	1.3	1.27	1.74	4.61	4.6	
		Week 12	Tezepelumab	4	4 (100.0)	1.61 (0.66)	0.9	1.20	1.52	2.03	2.5	
			Placebo	3	3 (100.0)	2.42 (1.88)	1.2	1.19	1.48	4.58	4.6	
		Week 16	Tezepelumab	4	4 (100.0)	1.51 (0.54)	0.9	1.15	1.46	1.88	2.2	
			Placebo	3	3 (100.0)	2.41 (2.01)	0.8	0.81	1.76	4.67	4.7	
		Week 24	Tezepelumab	4	4 (100.0)	1.65 (0.64)	0.9	1.23	1.66	2.07	2.4	
			Placebo	3	3 (100.0)	2.46 (2.07)	0.9	0.93	1.63	4.81	4.8	
		Week 36	Tezepelumab	4	4 (100.0)	1.62 (0.67)	0.9	1.21	1.53	2.03	2.5	
			Placebo	3	3 (100.0)	2.50 (1.59)	1.5	1.47	1.69	4.33	4.3	
		Week 52	Tezepelumab	4	4 (100.0)	1.59 (0.71)	0.9	1.16	1.44	2.01	2.6	
			Placebo	3	3 (100.0)	2.27 (1.55)	1.1	1.06	1.73	4.01	4.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Nasal polyps last 2 years												
Yes	Change from baseline	Week 2	Tezepelumab	4	4 (100.0)	-0.02 (0.19)	-0.3	-0.14	0.07	0.09	0.1	-0.68 [-2.24, 0.87]
			Placebo	3	3 (100.0)	0.25 (0.58)	-0.3	-0.29	0.17	0.86	0.9	
		Week 4	Tezepelumab	4	4 (100.0)	-0.07 (0.28)	-0.5	-0.24	0.03	0.10	0.1	-0.97 [-2.59, 0.64]
			Placebo	3	3 (100.0)	0.54 (0.93)	-0.1	-0.13	0.15	1.60	1.6	
		Week 8	Tezepelumab	4	4 (100.0)	0.11 (0.14)	-0.1	0.02	0.14	0.20	0.3	-0.69 [-2.24, 0.87]
			Placebo	3	3 (100.0)	0.47 (0.81)	-0.2	-0.17	0.20	1.38	1.4	
		Week 12	Tezepelumab	4	4 (100.0)	0.05 (0.02)	0.0	0.04	0.05	0.06	0.1	-0.54 [-2.07, 0.99]
			Placebo	3	3 (100.0)	0.35 (0.87)	-0.3	-0.25	-0.06	1.35	1.4	
		Week 16	Tezepelumab	4	4 (100.0)	-0.05 (0.18)	-0.3	-0.19	-0.02	0.10	0.1	-0.59 [-2.13, 0.95]
			Placebo	3	3 (100.0)	0.34 (1.04)	-0.6	-0.63	0.22	1.44	1.4	
		Week 24	Tezepelumab	4	4 (100.0)	0.09 (0.12)	-0.0	-0.01	0.10	0.19	0.2	-0.44 [-1.96, 1.09]
			Placebo	3	3 (100.0)	0.39 (1.08)	-0.5	-0.51	0.09	1.58	1.6	
		Week 36	Tezepelumab	4	4 (100.0)	0.06 (0.02)	0.0	0.04	0.06	0.08	0.1	-0.99 [-2.61, 0.62]
			Placebo	3	3 (100.0)	0.43 (0.59)	0.0	0.03	0.15	1.10	1.1	
		Week 52	Tezepelumab	4	4 (100.0)	0.02 (0.07)	-0.1	-0.04	0.03	0.08	0.1	-0.47 [-1.99, 1.06]
			Placebo	3	3 (100.0)	0.20 (0.58)	-0.4	-0.38	0.19	0.78	0.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Nasal polyps last 2 years												
No	Absolute values	Baseline	Tezepelumab	51	51 (100.0)	1.82 (0.64)	0.4	1.28	1.87	2.20	3.3	
			Placebo	37	37 (100.0)	1.70 (0.48)	0.8	1.39	1.70	2.04	2.8	
		Week 2	Tezepelumab	51	49 (96.1)	1.89 (0.63)	0.6	1.42	1.86	2.38	3.4	
			Placebo	37	32 (86.5)	1.69 (0.53)	0.8	1.35	1.68	1.95	2.8	
		Week 4	Tezepelumab	51	51 (100.0)	1.88 (0.67)	0.7	1.53	1.83	2.45	3.4	
			Placebo	37	36 (97.3)	1.74 (0.54)	0.9	1.41	1.69	2.01	3.0	
		Week 8	Tezepelumab	51	49 (96.1)	1.87 (0.62)	0.6	1.55	1.85	2.38	3.3	
			Placebo	37	36 (97.3)	1.75 (0.55)	0.8	1.45	1.75	2.01	2.8	
		Week 12	Tezepelumab	51	50 (98.0)	1.87 (0.67)	0.6	1.44	1.80	2.32	3.6	
			Placebo	37	36 (97.3)	1.75 (0.55)	0.8	1.42	1.64	2.14	3.0	
		Week 16	Tezepelumab	51	50 (98.0)	1.94 (0.68)	0.6	1.49	1.85	2.39	3.5	
			Placebo	37	36 (97.3)	1.71 (0.52)	0.9	1.33	1.67	1.97	3.0	
		Week 24	Tezepelumab	51	50 (98.0)	1.85 (0.61)	0.6	1.52	1.88	2.29	3.5	
			Placebo	37	33 (89.2)	1.70 (0.51)	0.8	1.40	1.62	2.07	2.7	
		Week 36	Tezepelumab	51	49 (96.1)	1.85 (0.65)	0.5	1.33	1.85	2.30	3.5	
			Placebo	37	32 (86.5)	1.74 (0.54)	0.9	1.40	1.65	1.93	3.0	
		Week 52	Tezepelumab	51	47 (92.2)	1.85 (0.62)	0.7	1.48	1.80	2.26	3.4	
			Placebo	37	32 (86.5)	1.72 (0.56)	0.9	1.29	1.64	2.06	2.9	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Nasal polyps last 2 years												
No	Change from baseline	Week 2	Tezepelumab	51	49 (96.1)	0.05 (0.25)	-0.7	-0.01	0.05	0.15	0.8	0.27 [-0.18, 0.72]
			Placebo	37	32 (86.5)	-0.01 (0.19)	-0.4	-0.09	-0.03	0.05	0.5	
		Week 4	Tezepelumab	51	51 (100.0)	0.06 (0.35)	-0.9	-0.09	0.04	0.22	1.7	0.09 [-0.34, 0.52]
			Placebo	37	36 (97.3)	0.04 (0.20)	-0.3	-0.05	0.04	0.11	0.5	
		Week 8	Tezepelumab	51	49 (96.1)	0.08 (0.31)	-0.8	-0.07	0.04	0.19	1.2	0.17 [-0.26, 0.61]
			Placebo	37	36 (97.3)	0.03 (0.24)	-0.8	-0.07	0.04	0.13	0.5	
		Week 12	Tezepelumab	51	50 (98.0)	0.06 (0.31)	-0.7	-0.09	0.04	0.18	1.4	0.06 [-0.37, 0.49]
			Placebo	37	36 (97.3)	0.05 (0.20)	-0.4	-0.05	0.02	0.20	0.4	
		Week 16	Tezepelumab	51	50 (98.0)	0.11 (0.33)	-0.6	-0.04	0.12	0.25	1.6	0.34 [-0.09, 0.78]
			Placebo	37	36 (97.3)	0.01 (0.21)	-0.6	-0.08	0.01	0.12	0.5	
		Week 24	Tezepelumab	51	50 (98.0)	0.06 (0.28)	-0.6	-0.12	0.00	0.23	1.0	0.28 [-0.16, 0.72]
			Placebo	37	33 (89.2)	-0.01 (0.21)	-0.5	-0.10	0.03	0.07	0.4	
		Week 36	Tezepelumab	51	49 (96.1)	0.05 (0.35)	-0.8	-0.13	0.01	0.22	1.1	-0.02 [-0.47, 0.42]
			Placebo	37	32 (86.5)	0.06 (0.21)	-0.3	-0.10	0.05	0.26	0.4	
		Week 52	Tezepelumab	51	47 (92.2)	0.05 (0.36)	-1.0	-0.09	0.01	0.24	1.0	0.02 [-0.43, 0.47]
			Placebo	37	32 (86.5)	0.04 (0.22)	-0.5	-0.08	0.05	0.14	0.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Age (cat. N)				N<10 any level					NE

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Region (cat. N)				N<10 any level					NE

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline eosinophils (cat. N)									0.712
< 150 cells/uL	Week 2	Tezepelumab	32	31 (96.9)	0.06 (0.04)	(-0.02, 0.15)	0.10 (0.06)	(-0.03, 0.23)	0.121
		Placebo	22	18 (81.8)	-0.04 (0.05)	(-0.14, 0.06)			
	Week 4	Tezepelumab	32	32 (100.0)	0.07 (0.06)	(-0.05, 0.20)	0.07 (0.10)	(-0.12, 0.27)	0.438
		Placebo	22	22 (100.0)	-0.00 (0.07)	(-0.15, 0.15)			
	Week 8	Tezepelumab	32	30 (93.8)	0.07 (0.05)	(-0.04, 0.18)	0.07 (0.09)	(-0.11, 0.24)	0.443
		Placebo	22	22 (100.0)	0.00 (0.07)	(-0.13, 0.13)			
	Week 12	Tezepelumab	32	32 (100.0)	0.06 (0.05)	(-0.05, 0.16)	0.06 (0.08)	(-0.11, 0.22)	0.478
		Placebo	22	21 (95.5)	-0.00 (0.06)	(-0.13, 0.12)			
	Week 16	Tezepelumab	32	31 (96.9)	0.13 (0.06)	(0.01, 0.25)	0.15 (0.09)	(-0.04, 0.34)	0.116
		Placebo	22	21 (95.5)	-0.02 (0.07)	(-0.17, 0.13)			
	Week 24	Tezepelumab	32	31 (96.9)	0.07 (0.04)	(-0.02, 0.16)	0.06 (0.07)	(-0.08, 0.20)	0.391
		Placebo	22	20 (90.9)	0.01 (0.05)	(-0.10, 0.12)			
	Week 36	Tezepelumab	32	30 (93.8)	0.03 (0.05)	(-0.07, 0.14)	-0.03 (0.08)	(-0.19, 0.13)	0.711
		Placebo	22	19 (86.4)	0.07 (0.06)	(-0.06, 0.19)			
	Week 52	Tezepelumab	32	28 (87.5)	0.04 (0.06)	(-0.07, 0.15)	-0.01 (0.09)	(-0.18, 0.16)	0.913
		Placebo	22	19 (86.4)	0.05 (0.07)	(-0.08, 0.18)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
150 - < 300 cells/uL	Week 2	Tezepelumab	23	22 (95.7)	0.02 (0.05)	(-0.09, 0.12)	-0.05 (0.08)	(-0.21, 0.12)	0.572
		Placebo	18	17 (94.4)	0.06 (0.06)	(-0.06, 0.18)			
	Week 4	Tezepelumab	23	23 (100.0)	0.02 (0.07)	(-0.11, 0.15)	-0.16 (0.10)	(-0.36, 0.04)	0.118
		Placebo	18	17 (94.4)	0.18 (0.07)	(0.03, 0.33)			
	Week 8	Tezepelumab	23	23 (100.0)	0.08 (0.06)	(-0.04, 0.19)	-0.10 (0.09)	(-0.28, 0.09)	0.295
		Placebo	18	17 (94.4)	0.17 (0.07)	(0.04, 0.31)			
	Week 12	Tezepelumab	23	22 (95.7)	0.06 (0.06)	(-0.05, 0.18)	-0.11 (0.09)	(-0.29, 0.07)	0.222
		Placebo	18	18 (100.0)	0.17 (0.07)	(0.04, 0.31)			
	Week 16	Tezepelumab	23	23 (100.0)	0.05 (0.06)	(-0.08, 0.17)	-0.07 (0.09)	(-0.26, 0.13)	0.491
		Placebo	18	18 (100.0)	0.11 (0.07)	(-0.03, 0.26)			
	Week 24	Tezepelumab	23	23 (100.0)	0.05 (0.07)	(-0.10, 0.19)	-0.01 (0.11)	(-0.24, 0.21)	0.914
		Placebo	18	16 (88.9)	0.06 (0.08)	(-0.11, 0.22)			
	Week 36	Tezepelumab	23	23 (100.0)	0.06 (0.07)	(-0.07, 0.20)	-0.08 (0.10)	(-0.28, 0.13)	0.466
		Placebo	18	16 (88.9)	0.14 (0.08)	(-0.02, 0.29)			
	Week 52	Tezepelumab	23	23 (100.0)	0.03 (0.06)	(-0.10, 0.16)	-0.03 (0.10)	(-0.23, 0.16)	0.728
		Placebo	18	16 (88.9)	0.06 (0.07)	(-0.09, 0.21)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline eosinophils (cat. Q)									0.866
Q1: < 140 cells/uL	Week 2	Tezepelumab	28	27 (96.4)	0.07 (0.04)	(-0.02, 0.16)	0.11 (0.07)	(-0.03, 0.25)	0.114
		Placebo	22	18 (81.8)	-0.04 (0.05)	(-0.14, 0.07)			
	Week 4	Tezepelumab	28	28 (100.0)	0.07 (0.07)	(-0.06, 0.21)	0.07 (0.10)	(-0.13, 0.28)	0.467
		Placebo	22	22 (100.0)	-0.00 (0.08)	(-0.15, 0.15)			
	Week 8	Tezepelumab	28	27 (96.4)	0.06 (0.06)	(-0.06, 0.19)	0.06 (0.09)	(-0.12, 0.25)	0.477
		Placebo	22	22 (100.0)	0.00 (0.07)	(-0.13, 0.14)			
	Week 12	Tezepelumab	28	28 (100.0)	0.06 (0.06)	(-0.06, 0.17)	0.06 (0.09)	(-0.11, 0.24)	0.475
		Placebo	22	21 (95.5)	-0.00 (0.06)	(-0.13, 0.13)			
	Week 16	Tezepelumab	28	27 (96.4)	0.14 (0.07)	(0.01, 0.28)	0.17 (0.10)	(-0.04, 0.37)	0.107
		Placebo	22	21 (95.5)	-0.02 (0.08)	(-0.17, 0.13)			
	Week 24	Tezepelumab	28	28 (100.0)	0.07 (0.05)	(-0.03, 0.16)	0.06 (0.07)	(-0.09, 0.21)	0.451
		Placebo	22	20 (90.9)	0.01 (0.06)	(-0.10, 0.12)			
	Week 36	Tezepelumab	28	27 (96.4)	0.05 (0.06)	(-0.06, 0.16)	-0.01 (0.08)	(-0.19, 0.16)	0.863
		Placebo	22	19 (86.4)	0.06 (0.06)	(-0.06, 0.19)			
	Week 52	Tezepelumab	28	25 (89.3)	0.05 (0.06)	(-0.07, 0.17)	0.01 (0.09)	(-0.18, 0.19)	0.945
		Placebo	22	19 (86.4)	0.05 (0.07)	(-0.09, 0.19)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q2: 140 - < 250 cells/uL	Week 2	Tezepelumab	23	22 (95.7)	0.02 (0.04)	(-0.07, 0.11)	0.02 (0.08)	(-0.15, 0.18)	0.823
		Placebo	11	10 (90.9)	0.00 (0.07)	(-0.13, 0.14)			
	Week 4	Tezepelumab	23	23 (100.0)	0.03 (0.03)	(-0.04, 0.10)	-0.08 (0.06)	(-0.20, 0.05)	0.211
		Placebo	11	10 (90.9)	0.11 (0.05)	(0.00, 0.21)			
	Week 8	Tezepelumab	23	22 (95.7)	0.06 (0.05)	(-0.03, 0.15)	-0.01 (0.08)	(-0.17, 0.16)	0.950
		Placebo	11	11 (100.0)	0.07 (0.06)	(-0.07, 0.20)			
	Week 12	Tezepelumab	23	22 (95.7)	0.04 (0.04)	(-0.05, 0.12)	-0.03 (0.07)	(-0.17, 0.12)	0.692
		Placebo	11	11 (100.0)	0.06 (0.06)	(-0.05, 0.18)			
	Week 16	Tezepelumab	23	23 (100.0)	0.06 (0.04)	(-0.03, 0.15)	0.11 (0.08)	(-0.05, 0.27)	0.177
		Placebo	11	11 (100.0)	-0.05 (0.06)	(-0.18, 0.08)			
	Week 24	Tezepelumab	23	22 (95.7)	0.03 (0.05)	(-0.07, 0.12)	0.15 (0.09)	(-0.03, 0.32)	0.104
		Placebo	11	9 (81.8)	-0.12 (0.07)	(-0.27, 0.03)			
	Week 36	Tezepelumab	23	22 (95.7)	0.01 (0.06)	(-0.11, 0.13)	-0.04 (0.11)	(-0.26, 0.17)	0.676
		Placebo	11	9 (81.8)	0.06 (0.09)	(-0.12, 0.24)			
	Week 52	Tezepelumab	23	22 (95.7)	-0.01 (0.06)	(-0.13, 0.12)	0.02 (0.11)	(-0.19, 0.24)	0.841
		Placebo	11	11 (100.0)	-0.03 (0.09)	(-0.20, 0.15)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q3: 250 - < 430 cells/uL	Week 2	Tezepelumab	4	4 (100.0)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 4	Tezepelumab	4	4 (100.0)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 8	Tezepelumab	4	4 (100.0)	NE		NE		
		Placebo	7	6 (85.7)					
	Week 12	Tezepelumab	4	4 (100.0)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 16	Tezepelumab	4	4 (100.0)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 24	Tezepelumab	4	4 (100.0)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 36	Tezepelumab	4	4 (100.0)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 52	Tezepelumab	4	4 (100.0)	NE		NE		
		Placebo	7	5 (71.4)					

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline FENO (cat. N)				N<10 any level					NE

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline FENO (cat. Q)									0.738
Q1: < 16 ppb	Week 2	Tezepelumab	31	29 (93.5)	0.10 (0.05)	(0.00, 0.19)	0.11 (0.07)	(-0.03, 0.25)	0.120
		Placebo	26	21 (80.8)	-0.01 (0.05)	(-0.12, 0.09)			
	Week 4	Tezepelumab	31	31 (100.0)	0.11 (0.07)	(-0.03, 0.24)	-0.00 (0.10)	(-0.20, 0.20)	0.993
		Placebo	26	25 (96.2)	0.11 (0.07)	(-0.04, 0.26)			
	Week 8	Tezepelumab	31	30 (96.8)	0.13 (0.06)	(0.02, 0.24)	0.04 (0.08)	(-0.12, 0.21)	0.616
		Placebo	26	25 (96.2)	0.09 (0.06)	(-0.03, 0.21)			
	Week 12	Tezepelumab	31	30 (96.8)	0.09 (0.06)	(-0.02, 0.20)	-0.03 (0.08)	(-0.20, 0.14)	0.727
		Placebo	26	25 (96.2)	0.12 (0.06)	(-0.00, 0.24)			
	Week 16	Tezepelumab	31	30 (96.8)	0.19 (0.06)	(0.07, 0.31)	0.12 (0.09)	(-0.07, 0.30)	0.205
		Placebo	26	25 (96.2)	0.07 (0.07)	(-0.06, 0.21)			
	Week 24	Tezepelumab	31	31 (100.0)	0.07 (0.06)	(-0.04, 0.19)	-0.01 (0.09)	(-0.19, 0.16)	0.888
		Placebo	26	22 (84.6)	0.09 (0.07)	(-0.04, 0.22)			
	Week 36	Tezepelumab	31	30 (96.8)	0.10 (0.06)	(-0.01, 0.21)	-0.05 (0.08)	(-0.21, 0.12)	0.563
		Placebo	26	23 (88.5)	0.15 (0.06)	(0.03, 0.27)			
	Week 52	Tezepelumab	31	28 (90.3)	0.08 (0.06)	(-0.04, 0.19)	0.01 (0.08)	(-0.16, 0.18)	0.884
		Placebo	26	22 (84.6)	0.06 (0.06)	(-0.06, 0.19)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q2: 16 - < 30 ppb	Week 2	Tezepelumab	24	24 (100.0)	-0.01 (0.04)	(-0.09, 0.08)	-0.01 (0.07)	(-0.15, 0.13)	0.898
		Placebo	14	14 (100.0)	0.00 (0.05)	(-0.11, 0.11)			
	Week 4	Tezepelumab	24	24 (100.0)	-0.01 (0.05)	(-0.11, 0.09)	-0.00 (0.08)	(-0.17, 0.16)	0.996
		Placebo	14	14 (100.0)	-0.00 (0.06)	(-0.14, 0.13)			
	Week 8	Tezepelumab	24	23 (95.8)	0.01 (0.06)	(-0.11, 0.13)	-0.02 (0.10)	(-0.21, 0.18)	0.844
		Placebo	14	14 (100.0)	0.03 (0.08)	(-0.12, 0.19)			
	Week 12	Tezepelumab	24	24 (100.0)	0.03 (0.05)	(-0.07, 0.13)	0.06 (0.08)	(-0.10, 0.22)	0.456
		Placebo	14	14 (100.0)	-0.03 (0.06)	(-0.16, 0.10)			
	Week 16	Tezepelumab	24	24 (100.0)	-0.01 (0.05)	(-0.12, 0.10)	0.04 (0.09)	(-0.14, 0.22)	0.653
		Placebo	14	14 (100.0)	-0.05 (0.07)	(-0.19, 0.10)			
	Week 24	Tezepelumab	24	23 (95.8)	0.06 (0.05)	(-0.04, 0.17)	0.14 (0.08)	(-0.03, 0.31)	0.100
		Placebo	14	14 (100.0)	-0.08 (0.07)	(-0.21, 0.06)			
	Week 36	Tezepelumab	24	23 (95.8)	-0.01 (0.06)	(-0.13, 0.10)	0.03 (0.09)	(-0.16, 0.22)	0.775
		Placebo	14	12 (85.7)	-0.04 (0.08)	(-0.19, 0.11)			
	Week 52	Tezepelumab	24	23 (95.8)	-0.00 (0.06)	(-0.13, 0.12)	-0.03 (0.10)	(-0.23, 0.17)	0.767
		Placebo	14	13 (92.9)	0.02 (0.08)	(-0.13, 0.18)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Total serum IgE (cat. N)				N<10 any level					NE

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_IBSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Nasal polyps last 2 years				N<10 any level					NE

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABMH0: Course of FEV1 Pre-BD
DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
FEV1 Pre-BD	Baseline	Tezepelumab	54	54 (100.0)	1.78 (0.63)	0.4	1.28	1.77	2.20	3.3	
		Placebo	39	39 (100.0)	1.74 (0.53)	0.8	1.39	1.70	2.10	3.2	
	Week 2	Tezepelumab	54	52 (96.3)	1.84 (0.61)	0.6	1.42	1.80	2.33	3.4	
		Placebo	39	34 (87.2)	1.75 (0.66)	0.8	1.35	1.71	1.97	4.1	
	Week 4	Tezepelumab	54	54 (100.0)	1.84 (0.66)	0.7	1.44	1.74	2.25	3.4	
		Placebo	39	38 (97.4)	1.81 (0.73)	0.9	1.38	1.71	2.02	4.8	
	Week 8	Tezepelumab	54	52 (96.3)	1.84 (0.61)	0.6	1.49	1.77	2.37	3.3	
		Placebo	39	38 (97.4)	1.82 (0.71)	0.8	1.41	1.75	2.03	4.6	
	Week 12	Tezepelumab	54	53 (98.1)	1.84 (0.66)	0.6	1.44	1.75	2.28	3.6	
		Placebo	39	38 (97.4)	1.81 (0.71)	0.8	1.41	1.64	2.14	4.6	
	Week 16	Tezepelumab	54	53 (98.1)	1.89 (0.67)	0.6	1.46	1.83	2.31	3.5	
		Placebo	39	38 (97.4)	1.77 (0.72)	0.8	1.33	1.69	2.04	4.7	
	Week 24	Tezepelumab	54	53 (98.1)	1.82 (0.59)	0.6	1.52	1.79	2.27	3.5	
		Placebo	39	35 (89.7)	1.77 (0.74)	0.8	1.36	1.63	2.11	4.8	
	Week 36	Tezepelumab	54	52 (96.3)	1.81 (0.63)	0.5	1.31	1.80	2.25	3.5	
		Placebo	39	34 (87.2)	1.82 (0.69)	0.9	1.43	1.70	1.94	4.3	
	Week 52	Tezepelumab	54	50 (92.6)	1.81 (0.61)	0.7	1.43	1.77	2.21	3.4	
		Placebo	39	34 (87.2)	1.77 (0.68)	0.9	1.24	1.67	2.15	4.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABMH0: Course of FEV1 Pre-BD
DITTB - adult

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in FEV1 Pre-BD	Week 2	Tezepelumab	54	52 (96.3)	0.05 (0.24)	-0.7	-0.02	0.05	0.15	0.8	0.13 [-0.30, 0.56]
		Placebo	39	34 (87.2)	0.01 (0.25)	-0.4	-0.09	-0.01	0.08	0.9	
	Week 4	Tezepelumab	54	54 (100.0)	0.06 (0.35)	-0.9	-0.09	0.04	0.17	1.7	-0.06 [-0.48, 0.35]
		Placebo	39	38 (97.4)	0.08 (0.32)	-0.3	-0.05	0.04	0.12	1.6	
	Week 8	Tezepelumab	54	52 (96.3)	0.08 (0.30)	-0.8	-0.08	0.05	0.20	1.2	0.07 [-0.35, 0.48]
		Placebo	39	38 (97.4)	0.06 (0.32)	-0.8	-0.07	0.04	0.18	1.4	
	Week 12	Tezepelumab	54	53 (98.1)	0.06 (0.30)	-0.7	-0.09	0.05	0.17	1.4	-0.03 [-0.45, 0.39]
		Placebo	39	38 (97.4)	0.07 (0.29)	-0.4	-0.06	0.01	0.20	1.4	
	Week 16	Tezepelumab	54	53 (98.1)	0.10 (0.33)	-0.6	-0.05	0.10	0.22	1.6	0.20 [-0.22, 0.61]
		Placebo	39	38 (97.4)	0.03 (0.33)	-0.6	-0.10	0.01	0.18	1.4	
	Week 24	Tezepelumab	54	53 (98.1)	0.06 (0.27)	-0.6	-0.11	0.00	0.22	1.0	0.13 [-0.30, 0.56]
		Placebo	39	35 (89.7)	0.02 (0.35)	-0.5	-0.11	0.03	0.10	1.6	
	Week 36	Tezepelumab	54	52 (96.3)	0.04 (0.34)	-0.8	-0.12	0.04	0.21	1.1	-0.16 [-0.59, 0.28]
		Placebo	39	34 (87.2)	0.09 (0.27)	-0.3	-0.09	0.06	0.29	1.1	
	Week 52	Tezepelumab	54	50 (92.6)	0.04 (0.35)	-1.0	-0.07	0.01	0.18	1.0	-0.05 [-0.49, 0.38]
		Placebo	39	34 (87.2)	0.05 (0.26)	-0.5	-0.08	0.05	0.15	0.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABMC0: Change from baseline in FEV1 Pre-BD - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Tezepelumab	54	52 (96.3)	0.05 (0.03)	(-0.02, 0.12)	0.06 (0.05)	(-0.05, 0.16)	0.289
	Placebo	39	34 (87.2)	-0.00 (0.04)	(-0.08, 0.07)			
Week 4	Tezepelumab	54	54 (100.0)	0.06 (0.05)	(-0.03, 0.15)	-0.01 (0.07)	(-0.15, 0.13)	0.871
	Placebo	39	38 (97.4)	0.07 (0.05)	(-0.04, 0.18)			
Week 8	Tezepelumab	54	52 (96.3)	0.08 (0.04)	(-0.01, 0.16)	0.01 (0.06)	(-0.12, 0.14)	0.852
	Placebo	39	38 (97.4)	0.07 (0.05)	(-0.03, 0.16)			
Week 12	Tezepelumab	54	53 (98.1)	0.06 (0.04)	(-0.02, 0.15)	-0.00 (0.06)	(-0.13, 0.12)	0.949
	Placebo	39	38 (97.4)	0.07 (0.05)	(-0.03, 0.16)			
Week 16	Tezepelumab	54	53 (98.1)	0.10 (0.05)	(0.01, 0.19)	0.07 (0.07)	(-0.07, 0.21)	0.296
	Placebo	39	38 (97.4)	0.03 (0.05)	(-0.08, 0.14)			
Week 24	Tezepelumab	54	53 (98.1)	0.06 (0.04)	(-0.02, 0.15)	0.04 (0.06)	(-0.09, 0.17)	0.547
	Placebo	39	35 (89.7)	0.02 (0.05)	(-0.07, 0.12)			
Week 36	Tezepelumab	54	52 (96.3)	0.05 (0.04)	(-0.04, 0.13)	-0.04 (0.07)	(-0.17, 0.09)	0.511
	Placebo	39	34 (87.2)	0.09 (0.05)	(-0.01, 0.19)			
Week 52	Tezepelumab	54	50 (92.6)	0.04 (0.04)	(-0.05, 0.12)	-0.01 (0.07)	(-0.14, 0.12)	0.903
	Placebo	39	34 (87.2)	0.04 (0.05)	(-0.06, 0.14)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Figure NF2FAC_ABMG0: Course of FEV1 Pre-BD
DITTB - adult



Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source table: NT2FAC_ABMH0
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Absolute values	Baseline	Tezepelumab	18	18 (100.0)	2.03 (0.75)	0.6	1.47	2.07	2.62	3.3	
			Placebo	7	7 (100.0)	2.30 (0.48)	1.8	1.93	2.11	2.61	3.2	
		Week 2	Tezepelumab	18	18 (100.0)	2.07 (0.74)	0.7	1.55	2.03	2.66	3.4	
			Placebo	7	7 (100.0)	2.33 (0.85)	1.7	1.76	1.85	2.63	4.1	
		Week 4	Tezepelumab	18	18 (100.0)	2.13 (0.80)	0.7	1.61	2.12	2.69	3.4	
			Placebo	7	7 (100.0)	2.48 (1.13)	1.6	1.79	2.02	2.70	4.8	
		Week 8	Tezepelumab	18	17 (94.4)	2.06 (0.74)	0.7	1.63	1.92	2.59	3.3	
			Placebo	7	7 (100.0)	2.48 (1.11)	1.1	1.76	2.51	2.69	4.6	
		Week 12	Tezepelumab	18	18 (100.0)	2.17 (0.81)	0.7	1.62	2.21	2.72	3.6	
			Placebo	7	7 (100.0)	2.53 (1.02)	1.4	1.93	2.13	2.83	4.6	
		Week 16	Tezepelumab	18	18 (100.0)	2.11 (0.84)	0.6	1.54	2.23	2.61	3.5	
			Placebo	7	7 (100.0)	2.49 (1.06)	1.7	1.78	2.04	2.87	4.7	
		Week 24	Tezepelumab	18	17 (94.4)	2.09 (0.75)	0.6	1.61	2.29	2.55	3.5	
			Placebo	7	7 (100.0)	2.49 (1.12)	1.6	1.67	2.07	2.74	4.8	
		Week 36	Tezepelumab	18	17 (94.4)	1.99 (0.78)	0.5	1.51	1.97	2.50	3.5	
			Placebo	7	7 (100.0)	2.45 (0.97)	1.6	1.74	1.94	2.91	4.3	
		Week 52	Tezepelumab	18	17 (94.4)	2.01 (0.69)	0.9	1.60	2.19	2.39	3.4	
			Placebo	7	6 (85.7)	2.52 (0.88)	1.6	1.73	2.50	2.79	4.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Change from baseline	Week 2	Tezepelumab	18	18 (100.0)	0.04 (0.29)	-0.7	-0.02	0.05	0.12	0.8	0.04 [-0.83, 0.92]
			Placebo	7	7 (100.0)	0.03 (0.42)	-0.3	-0.26	-0.17	0.32	0.9	
		Week 4	Tezepelumab	18	18 (100.0)	0.10 (0.45)	-0.3	-0.13	0.04	0.08	1.7	-0.15 [-1.02, 0.73]
			Placebo	7	7 (100.0)	0.18 (0.68)	-0.3	-0.30	0.07	0.39	1.6	
		Week 8	Tezepelumab	18	17 (94.4)	0.11 (0.35)	-0.5	-0.08	0.08	0.19	1.2	-0.15 [-1.03, 0.73]
			Placebo	7	7 (100.0)	0.18 (0.66)	-0.8	-0.17	0.08	0.40	1.4	
		Week 12	Tezepelumab	18	18 (100.0)	0.14 (0.40)	-0.2	-0.17	0.09	0.19	1.4	-0.19 [-1.06, 0.69]
			Placebo	7	7 (100.0)	0.23 (0.55)	-0.4	0.00	0.02	0.39	1.4	
		Week 16	Tezepelumab	18	18 (100.0)	0.08 (0.43)	-0.5	-0.07	0.02	0.15	1.6	-0.23 [-1.11, 0.65]
			Placebo	7	7 (100.0)	0.19 (0.61)	-0.5	-0.15	0.01	0.29	1.4	
		Week 24	Tezepelumab	18	17 (94.4)	0.14 (0.34)	-0.4	-0.10	0.09	0.29	1.0	-0.11 [-0.99, 0.77]
			Placebo	7	7 (100.0)	0.19 (0.66)	-0.3	-0.25	-0.04	0.43	1.6	
		Week 36	Tezepelumab	18	17 (94.4)	0.03 (0.43)	-0.8	-0.13	-0.05	0.16	1.1	-0.26 [-1.15, 0.62]
			Placebo	7	7 (100.0)	0.15 (0.50)	-0.3	-0.19	-0.16	0.43	1.1	
		Week 52	Tezepelumab	18	17 (94.4)	0.05 (0.41)	-0.8	-0.15	0.00	0.24	1.0	-0.32 [-1.26, 0.62]
			Placebo	7	6 (85.7)	0.19 (0.47)	-0.5	-0.20	0.27	0.48	0.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Absolute values	Baseline	Tezepelumab	36	36 (100.0)	1.66 (0.53)	0.4	1.28	1.67	2.04	2.8	
			Placebo	32	32 (100.0)	1.61 (0.46)	0.8	1.36	1.57	1.88	2.8	
		Week 2	Tezepelumab	36	34 (94.4)	1.72 (0.51)	0.6	1.32	1.75	2.06	2.5	
			Placebo	32	27 (84.4)	1.60 (0.53)	0.8	1.15	1.59	1.93	2.8	
		Week 4	Tezepelumab	36	36 (100.0)	1.70 (0.54)	0.7	1.37	1.68	2.04	2.6	
			Placebo	32	31 (96.9)	1.66 (0.52)	0.9	1.31	1.57	1.90	3.0	
		Week 8	Tezepelumab	36	35 (97.2)	1.72 (0.51)	0.6	1.30	1.68	2.11	2.7	
			Placebo	32	31 (96.9)	1.67 (0.51)	0.8	1.40	1.69	1.94	2.8	
		Week 12	Tezepelumab	36	35 (97.2)	1.67 (0.51)	0.6	1.32	1.63	2.08	2.5	
			Placebo	32	31 (96.9)	1.65 (0.52)	0.8	1.31	1.60	1.82	3.0	
		Week 16	Tezepelumab	36	35 (97.2)	1.78 (0.55)	0.6	1.39	1.67	2.22	3.0	
			Placebo	32	31 (96.9)	1.61 (0.51)	0.8	1.31	1.64	1.78	3.0	
		Week 24	Tezepelumab	36	36 (100.0)	1.69 (0.46)	0.8	1.18	1.71	2.05	2.4	
			Placebo	32	28 (87.5)	1.59 (0.49)	0.8	1.25	1.50	2.05	2.7	
		Week 36	Tezepelumab	36	35 (97.2)	1.72 (0.53)	0.8	1.25	1.65	2.14	2.8	
			Placebo	32	27 (84.4)	1.65 (0.50)	0.9	1.38	1.57	1.81	3.0	
		Week 52	Tezepelumab	36	33 (91.7)	1.71 (0.54)	0.7	1.37	1.64	2.11	2.9	
			Placebo	32	28 (87.5)	1.61 (0.51)	0.9	1.15	1.61	1.82	2.9	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Change from baseline	Week 2	Tezepelumab	36	34 (94.4)	0.05 (0.22)	-0.6	0.00	0.05	0.15	0.5	0.18 [-0.33, 0.69]
			Placebo	32	27 (84.4)	0.01 (0.19)	-0.4	-0.07	0.00	0.08	0.5	
		Week 4	Tezepelumab	36	36 (100.0)	0.04 (0.29)	-0.9	-0.08	0.05	0.25	0.6	-0.08 [-0.56, 0.40]
			Placebo	32	31 (96.9)	0.06 (0.17)	-0.3	-0.04	0.04	0.12	0.5	
		Week 8	Tezepelumab	36	35 (97.2)	0.07 (0.28)	-0.8	-0.07	0.04	0.20	0.7	0.14 [-0.34, 0.62]
			Placebo	32	31 (96.9)	0.04 (0.20)	-0.5	-0.06	0.04	0.13	0.5	
		Week 12	Tezepelumab	36	35 (97.2)	0.02 (0.23)	-0.7	-0.05	0.04	0.17	0.5	-0.07 [-0.55, 0.41]
			Placebo	32	31 (96.9)	0.04 (0.19)	-0.4	-0.06	0.00	0.19	0.4	
		Week 16	Tezepelumab	36	35 (97.2)	0.11 (0.27)	-0.6	-0.02	0.14	0.28	0.7	0.43 [-0.06, 0.92]
			Placebo	32	31 (96.9)	-0.00 (0.24)	-0.6	-0.10	0.01	0.14	0.5	
		Week 24	Tezepelumab	36	36 (100.0)	0.03 (0.23)	-0.6	-0.12	0.00	0.18	0.7	0.20 [-0.30, 0.70]
			Placebo	32	28 (87.5)	-0.02 (0.22)	-0.5	-0.09	0.03	0.09	0.4	
		Week 36	Tezepelumab	36	35 (97.2)	0.05 (0.29)	-0.7	-0.12	0.04	0.21	0.6	-0.11 [-0.61, 0.39]
			Placebo	32	27 (84.4)	0.08 (0.19)	-0.3	-0.07	0.07	0.22	0.4	
		Week 52	Tezepelumab	36	33 (91.7)	0.03 (0.32)	-1.0	-0.06	0.01	0.11	0.7	0.02 [-0.48, 0.52]
			Placebo	32	28 (87.5)	0.02 (0.20)	-0.4	-0.08	0.04	0.13	0.5	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Absolute values	Baseline	Tezepelumab	45	45 (100.0)	1.83 (0.66)	0.4	1.41	1.87	2.20	3.3	
			Placebo	32	32 (100.0)	1.75 (0.56)	0.8	1.42	1.70	2.13	3.2	
		Week 2	Tezepelumab	45	44 (97.8)	1.89 (0.64)	0.6	1.48	1.93	2.39	3.4	
			Placebo	32	28 (87.5)	1.76 (0.71)	0.8	1.32	1.71	2.04	4.1	
		Week 4	Tezepelumab	45	45 (100.0)	1.90 (0.69)	0.7	1.61	1.98	2.40	3.4	
			Placebo	32	32 (100.0)	1.84 (0.77)	0.9	1.35	1.71	2.11	4.8	
		Week 8	Tezepelumab	45	43 (95.6)	1.87 (0.65)	0.6	1.43	1.90	2.40	3.3	
			Placebo	32	32 (100.0)	1.80 (0.76)	0.8	1.39	1.74	2.01	4.6	
		Week 12	Tezepelumab	45	44 (97.8)	1.91 (0.70)	0.6	1.46	1.95	2.37	3.6	
			Placebo	32	31 (96.9)	1.83 (0.78)	0.8	1.37	1.62	2.25	4.6	
		Week 16	Tezepelumab	45	45 (100.0)	1.95 (0.70)	0.6	1.52	1.91	2.34	3.5	
			Placebo	32	31 (96.9)	1.79 (0.78)	0.8	1.31	1.71	2.10	4.7	
		Week 24	Tezepelumab	45	44 (97.8)	1.87 (0.62)	0.6	1.58	1.90	2.31	3.5	
			Placebo	32	28 (87.5)	1.79 (0.80)	0.8	1.33	1.65	2.15	4.8	
		Week 36	Tezepelumab	45	44 (97.8)	1.84 (0.66)	0.5	1.31	1.88	2.31	3.5	
			Placebo	32	27 (84.4)	1.86 (0.75)	0.9	1.45	1.70	2.36	4.3	
		Week 52	Tezepelumab	45	42 (93.3)	1.86 (0.63)	0.7	1.54	1.92	2.26	3.4	
			Placebo	32	28 (87.5)	1.79 (0.73)	0.9	1.20	1.68	2.19	4.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Change from baseline	Week 2	Tezepelumab	45	44 (97.8)	0.05 (0.26)	-0.7	-0.05	0.06	0.18	0.8	0.19 [-0.29, 0.66]
			Placebo	32	28 (87.5)	0.00 (0.25)	-0.4	-0.09	-0.04	0.07	0.9	
		Week 4	Tezepelumab	45	45 (100.0)	0.08 (0.37)	-0.9	-0.07	0.05	0.22	1.7	-0.02 [-0.47, 0.43]
			Placebo	32	32 (100.0)	0.08 (0.33)	-0.3	-0.06	0.04	0.13	1.6	
		Week 8	Tezepelumab	45	43 (95.6)	0.08 (0.32)	-0.8	-0.08	0.04	0.19	1.2	0.11 [-0.35, 0.56]
			Placebo	32	32 (100.0)	0.05 (0.34)	-0.8	-0.08	0.02	0.13	1.4	
		Week 12	Tezepelumab	45	44 (97.8)	0.08 (0.32)	-0.7	-0.04	0.08	0.18	1.4	0.05 [-0.41, 0.51]
			Placebo	32	31 (96.9)	0.07 (0.31)	-0.4	-0.06	0.00	0.20	1.4	
		Week 16	Tezepelumab	45	45 (100.0)	0.12 (0.35)	-0.6	-0.02	0.14	0.28	1.6	0.27 [-0.19, 0.73]
			Placebo	32	31 (96.9)	0.03 (0.34)	-0.6	-0.10	0.01	0.18	1.4	
		Week 24	Tezepelumab	45	44 (97.8)	0.07 (0.28)	-0.6	-0.11	0.00	0.25	1.0	0.16 [-0.31, 0.64]
			Placebo	32	28 (87.5)	0.02 (0.38)	-0.5	-0.16	0.03	0.09	1.6	
		Week 36	Tezepelumab	45	44 (97.8)	0.05 (0.36)	-0.8	-0.15	0.04	0.23	1.1	-0.22 [-0.70, 0.26]
			Placebo	32	27 (84.4)	0.12 (0.28)	-0.3	-0.07	0.08	0.30	1.1	
		Week 52	Tezepelumab	45	42 (93.3)	0.05 (0.38)	-1.0	-0.06	0.07	0.24	1.0	-0.06 [-0.53, 0.42]
			Placebo	32	28 (87.5)	0.07 (0.25)	-0.4	-0.08	0.08	0.16	0.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	1.55 (0.40)	1.2	1.28	1.44	1.74	2.4	
			Placebo	7	7 (100.0)	1.66 (0.37)	1.1	1.35	1.85	1.89	2.1	
		Week 2	Tezepelumab	9	8 (88.9)	1.61 (0.37)	1.2	1.35	1.54	1.74	2.4	
			Placebo	7	6 (85.7)	1.69 (0.45)	1.0	1.39	1.75	1.93	2.3	
		Week 4	Tezepelumab	9	9 (100.0)	1.52 (0.42)	0.9	1.27	1.53	1.64	2.5	
			Placebo	7	6 (85.7)	1.68 (0.46)	1.1	1.43	1.63	1.99	2.4	
		Week 8	Tezepelumab	9	9 (100.0)	1.65 (0.35)	1.2	1.58	1.67	1.68	2.4	
			Placebo	7	6 (85.7)	1.92 (0.40)	1.5	1.54	1.81	2.30	2.5	
		Week 12	Tezepelumab	9	9 (100.0)	1.51 (0.31)	1.2	1.23	1.49	1.55	2.2	
			Placebo	7	7 (100.0)	1.75 (0.35)	1.3	1.41	1.73	2.13	2.3	
		Week 16	Tezepelumab	9	8 (88.9)	1.54 (0.39)	1.1	1.33	1.49	1.62	2.4	
			Placebo	7	7 (100.0)	1.70 (0.32)	1.3	1.42	1.66	1.90	2.3	
		Week 24	Tezepelumab	9	9 (100.0)	1.57 (0.35)	1.1	1.40	1.60	1.71	2.3	
			Placebo	7	7 (100.0)	1.70 (0.42)	1.1	1.42	1.51	2.07	2.3	
		Week 36	Tezepelumab	9	8 (88.9)	1.61 (0.42)	1.2	1.35	1.53	1.74	2.5	
			Placebo	7	7 (100.0)	1.64 (0.38)	1.1	1.38	1.59	1.92	2.3	
		Week 52	Tezepelumab	9	8 (88.9)	1.54 (0.42)	1.1	1.24	1.44	1.73	2.4	
			Placebo	7	6 (85.7)	1.67 (0.39)	1.1	1.57	1.62	1.83	2.3	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Change from baseline	Week 2	Tezepelumab	9	8 (88.9)	0.01 (0.10)	-0.2	-0.00	0.05	0.07	0.1	-0.30 [-1.36, 0.77]
			Placebo	7	6 (85.7)	0.07 (0.24)	-0.3	-0.05	0.04	0.16	0.5	
		Week 4	Tezepelumab	9	9 (100.0)	-0.03 (0.18)	-0.3	-0.13	-0.04	0.06	0.3	-0.40 [-1.45, 0.64]
			Placebo	7	6 (85.7)	0.06 (0.26)	-0.3	-0.03	0.04	0.10	0.5	
		Week 8	Tezepelumab	9	9 (100.0)	0.10 (0.21)	-0.2	-0.05	0.05	0.25	0.5	-0.26 [-1.30, 0.78]
			Placebo	7	6 (85.7)	0.16 (0.23)	-0.1	-0.03	0.12	0.40	0.4	
		Week 12	Tezepelumab	9	9 (100.0)	-0.04 (0.14)	-0.2	-0.17	-0.05	0.05	0.2	-0.81 [-1.84, 0.22]
			Placebo	7	7 (100.0)	0.09 (0.18)	-0.1	-0.07	0.06	0.22	0.4	
		Week 16	Tezepelumab	9	8 (88.9)	-0.05 (0.15)	-0.4	-0.13	-0.02	0.06	0.1	-0.40 [-1.42, 0.63]
			Placebo	7	7 (100.0)	0.04 (0.29)	-0.5	-0.20	0.07	0.26	0.4	
		Week 24	Tezepelumab	9	9 (100.0)	0.02 (0.22)	-0.4	-0.12	0.02	0.16	0.4	-0.09 [-1.08, 0.90]
			Placebo	7	7 (100.0)	0.04 (0.23)	-0.4	-0.04	0.06	0.13	0.4	
		Week 36	Tezepelumab	9	8 (88.9)	0.02 (0.10)	-0.1	-0.05	0.01	0.09	0.2	0.21 [-0.81, 1.22]
			Placebo	7	7 (100.0)	-0.02 (0.23)	-0.3	-0.19	-0.08	0.08	0.4	
		Week 52	Tezepelumab	9	8 (88.9)	-0.06 (0.09)	-0.2	-0.12	-0.05	0.00	0.1	-0.07 [-1.13, 0.99]
			Placebo	7	6 (85.7)	-0.04 (0.32)	-0.5	-0.26	-0.01	0.08	0.4	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Absolute values	Baseline	Tezepelumab	31	31 (100.0)	1.85 (0.65)	0.4	1.48	1.87	2.39	3.2	
			Placebo	26	26 (100.0)	1.77 (0.56)	0.8	1.44	1.80	2.10	3.2	
		Week 2	Tezepelumab	31	31 (100.0)	1.89 (0.64)	0.6	1.56	1.80	2.38	3.4	
			Placebo	26	23 (88.5)	1.75 (0.73)	0.8	1.29	1.71	1.93	4.1	
		Week 4	Tezepelumab	31	31 (100.0)	1.88 (0.68)	0.7	1.61	1.94	2.24	3.4	
			Placebo	26	25 (96.2)	1.87 (0.80)	0.9	1.46	1.78	2.02	4.8	
		Week 8	Tezepelumab	31	31 (100.0)	1.91 (0.67)	0.6	1.57	1.90	2.43	3.3	
			Placebo	26	25 (96.2)	1.88 (0.77)	0.8	1.53	1.76	2.03	4.6	
		Week 12	Tezepelumab	31	31 (100.0)	1.90 (0.71)	0.6	1.45	1.83	2.39	3.6	
			Placebo	26	26 (100.0)	1.86 (0.75)	0.8	1.43	1.71	2.14	4.6	
		Week 16	Tezepelumab	31	31 (100.0)	1.93 (0.71)	0.6	1.52	1.85	2.39	3.5	
			Placebo	26	26 (100.0)	1.83 (0.77)	0.8	1.42	1.74	2.04	4.7	
		Week 24	Tezepelumab	31	31 (100.0)	1.92 (0.63)	0.8	1.57	1.89	2.38	3.5	
			Placebo	26	23 (88.5)	1.79 (0.83)	0.8	1.29	1.63	2.11	4.8	
		Week 36	Tezepelumab	31	31 (100.0)	1.92 (0.69)	0.8	1.33	1.86	2.50	3.5	
			Placebo	26	24 (92.3)	1.85 (0.73)	0.9	1.45	1.72	2.10	4.3	
		Week 52	Tezepelumab	31	31 (100.0)	1.87 (0.68)	0.7	1.43	1.80	2.39	3.4	
			Placebo	26	22 (84.6)	1.79 (0.73)	0.9	1.15	1.69	2.15	4.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Change from baseline	Week 2	Tezepelumab	31	31 (100.0)	0.04 (0.29)	-0.7	-0.02	0.05	0.17	0.8	0.03 [-0.51, 0.57]
			Placebo	26	23 (88.5)	0.03 (0.27)	-0.3	-0.09	-0.01	0.06	0.9	
		Week 4	Tezepelumab	31	31 (100.0)	0.03 (0.41)	-0.9	-0.13	0.03	0.15	1.7	-0.20 [-0.73, 0.33]
			Placebo	26	25 (96.2)	0.11 (0.37)	-0.3	-0.01	0.09	0.12	1.6	
		Week 8	Tezepelumab	31	31 (100.0)	0.06 (0.35)	-0.8	-0.08	0.04	0.19	1.2	-0.07 [-0.59, 0.46]
			Placebo	26	25 (96.2)	0.08 (0.38)	-0.8	-0.07	0.04	0.20	1.4	
		Week 12	Tezepelumab	31	31 (100.0)	0.05 (0.36)	-0.7	-0.18	0.03	0.18	1.4	-0.13 [-0.65, 0.40]
			Placebo	26	26 (100.0)	0.09 (0.31)	-0.4	-0.04	0.01	0.20	1.4	
		Week 16	Tezepelumab	31	31 (100.0)	0.08 (0.37)	-0.6	-0.13	0.09	0.19	1.6	0.05 [-0.47, 0.57]
			Placebo	26	26 (100.0)	0.06 (0.37)	-0.6	-0.10	0.01	0.18	1.4	
		Week 24	Tezepelumab	31	31 (100.0)	0.07 (0.32)	-0.6	-0.12	0.02	0.29	1.0	0.15 [-0.39, 0.69]
			Placebo	26	23 (88.5)	0.02 (0.41)	-0.5	-0.25	-0.04	0.10	1.6	
		Week 36	Tezepelumab	31	31 (100.0)	0.07 (0.40)	-0.8	-0.13	0.03	0.29	1.1	-0.04 [-0.58, 0.49]
			Placebo	26	24 (92.3)	0.08 (0.29)	-0.3	-0.13	0.05	0.19	1.1	
		Week 52	Tezepelumab	31	31 (100.0)	0.02 (0.41)	-1.0	-0.09	0.00	0.18	1.0	-0.08 [-0.63, 0.46]
			Placebo	26	22 (84.6)	0.05 (0.30)	-0.5	-0.11	0.04	0.19	0.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Absolute values	Baseline	Tezepelumab	23	23 (100.0)	1.69 (0.61)	0.6	1.27	1.58	2.10	3.3	
			Placebo	13	13 (100.0)	1.68 (0.50)	0.9	1.39	1.59	2.04	2.6	
		Week 2	Tezepelumab	23	21 (91.3)	1.78 (0.59)	0.7	1.32	1.80	2.18	2.9	
			Placebo	13	11 (84.6)	1.75 (0.54)	1.0	1.35	1.65	2.26	2.6	
		Week 4	Tezepelumab	23	23 (100.0)	1.78 (0.66)	0.7	1.27	1.66	2.40	3.3	
			Placebo	13	13 (100.0)	1.70 (0.58)	1.0	1.32	1.57	1.85	2.7	
		Week 8	Tezepelumab	23	21 (91.3)	1.72 (0.50)	0.7	1.30	1.63	2.05	2.6	
			Placebo	13	13 (100.0)	1.71 (0.60)	0.8	1.41	1.59	1.94	2.7	
		Week 12	Tezepelumab	23	22 (95.7)	1.75 (0.60)	0.7	1.32	1.67	2.21	3.3	
			Placebo	13	12 (92.3)	1.71 (0.64)	0.9	1.34	1.57	2.14	2.8	
		Week 16	Tezepelumab	23	22 (95.7)	1.83 (0.63)	0.6	1.43	1.58	2.28	3.1	
			Placebo	13	12 (92.3)	1.66 (0.61)	0.9	1.32	1.52	1.95	2.9	
		Week 24	Tezepelumab	23	22 (95.7)	1.67 (0.52)	0.6	1.18	1.61	2.13	2.4	
			Placebo	13	12 (92.3)	1.72 (0.55)	1.0	1.38	1.63	1.96	2.7	
		Week 36	Tezepelumab	23	21 (91.3)	1.65 (0.49)	0.5	1.28	1.51	2.10	2.3	
			Placebo	13	10 (76.9)	1.76 (0.62)	1.0	1.41	1.64	1.81	2.9	
		Week 52	Tezepelumab	23	19 (82.6)	1.70 (0.47)	0.9	1.37	1.60	2.19	2.4	
			Placebo	13	12 (92.3)	1.74 (0.61)	1.0	1.36	1.58	2.14	2.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Change from baseline	Week 2	Tezepelumab	23	21 (91.3)	0.06 (0.15)	-0.3	0.01	0.07	0.12	0.4	0.46 [-0.28, 1.19]
			Placebo	13	11 (84.6)	-0.02 (0.19)	-0.4	-0.10	-0.01	0.10	0.3	
		Week 4	Tezepelumab	23	23 (100.0)	0.09 (0.24)	-0.4	-0.08	0.05	0.30	0.6	0.32 [-0.36, 1.00]
			Placebo	13	13 (100.0)	0.02 (0.20)	-0.3	-0.05	-0.02	0.07	0.4	
		Week 8	Tezepelumab	23	21 (91.3)	0.12 (0.20)	-0.1	-0.01	0.08	0.25	0.7	0.52 [-0.19, 1.22]
			Placebo	13	13 (100.0)	0.03 (0.15)	-0.3	-0.06	0.00	0.08	0.4	
		Week 12	Tezepelumab	23	22 (95.7)	0.08 (0.19)	-0.2	-0.05	0.05	0.15	0.7	0.26 [-0.45, 0.97]
			Placebo	13	12 (92.3)	0.02 (0.24)	-0.4	-0.13	0.01	0.17	0.4	
		Week 16	Tezepelumab	23	22 (95.7)	0.12 (0.28)	-0.6	0.01	0.11	0.28	0.7	0.57 [-0.15, 1.29]
			Placebo	13	12 (92.3)	-0.03 (0.24)	-0.6	-0.09	-0.03	0.08	0.3	
		Week 24	Tezepelumab	23	22 (95.7)	0.05 (0.20)	-0.2	-0.07	0.00	0.15	0.6	0.09 [-0.61, 0.79]
			Placebo	13	12 (92.3)	0.03 (0.21)	-0.5	-0.01	0.03	0.10	0.4	
		Week 36	Tezepelumab	23	21 (91.3)	0.01 (0.21)	-0.5	-0.11	0.04	0.20	0.4	-0.49 [-1.25, 0.28]
			Placebo	13	10 (76.9)	0.11 (0.22)	-0.2	-0.08	0.14	0.30	0.4	
		Week 52	Tezepelumab	23	19 (82.6)	0.06 (0.23)	-0.4	-0.05	0.08	0.24	0.5	0.03 [-0.69, 0.76]
			Placebo	13	12 (92.3)	0.05 (0.20)	-0.3	-0.08	0.10	0.14	0.5	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Absolute values	Baseline	Tezepelumab	33	33 (100.0)	1.89 (0.61)	0.8	1.41	1.90	2.27	3.3	
			Placebo	28	28 (100.0)	1.77 (0.60)	0.8	1.38	1.76	2.17	3.2	
		Week 2	Tezepelumab	33	32 (97.0)	2.00 (0.62)	0.9	1.55	1.96	2.51	3.4	
			Placebo	28	24 (85.7)	1.83 (0.75)	0.8	1.34	1.70	2.29	4.1	
		Week 4	Tezepelumab	33	33 (100.0)	1.98 (0.69)	0.7	1.61	1.99	2.46	3.4	
			Placebo	28	27 (96.4)	1.88 (0.84)	0.9	1.32	1.64	2.35	4.8	
		Week 8	Tezepelumab	33	32 (97.0)	1.97 (0.62)	0.7	1.58	1.94	2.52	3.3	
			Placebo	28	27 (96.4)	1.87 (0.80)	0.8	1.40	1.74	2.30	4.6	
		Week 12	Tezepelumab	33	33 (100.0)	1.96 (0.69)	0.8	1.44	2.06	2.37	3.6	
			Placebo	28	27 (96.4)	1.88 (0.81)	0.8	1.37	1.61	2.46	4.6	
		Week 16	Tezepelumab	33	32 (97.0)	2.07 (0.67)	0.9	1.53	2.10	2.48	3.5	
			Placebo	28	27 (96.4)	1.87 (0.81)	0.9	1.32	1.66	2.18	4.7	
		Week 24	Tezepelumab	33	32 (97.0)	1.90 (0.62)	0.8	1.46	1.93	2.31	3.5	
			Placebo	28	26 (92.9)	1.85 (0.81)	0.8	1.40	1.66	2.21	4.8	
		Week 36	Tezepelumab	33	31 (93.9)	1.92 (0.63)	0.8	1.44	1.86	2.34	3.5	
			Placebo	28	25 (89.3)	1.90 (0.78)	0.9	1.41	1.75	2.36	4.3	
		Week 52	Tezepelumab	33	29 (87.9)	1.90 (0.60)	0.7	1.54	1.87	2.26	3.4	
			Placebo	28	24 (85.7)	1.87 (0.77)	0.9	1.20	1.68	2.30	4.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Change from baseline	Week 2	Tezepelumab	33	32 (97.0)	0.09 (0.21)	-0.3	-0.00	0.05	0.17	0.8	0.14 [-0.39, 0.67]
			Placebo	28	24 (85.7)	0.05 (0.27)	-0.4	-0.08	0.00	0.13	0.9	
		Week 4	Tezepelumab	33	33 (100.0)	0.08 (0.34)	-0.4	-0.06	0.03	0.15	1.7	-0.09 [-0.60, 0.42]
			Placebo	28	27 (96.4)	0.11 (0.36)	-0.3	-0.05	0.07	0.24	1.6	
		Week 8	Tezepelumab	33	32 (97.0)	0.12 (0.30)	-0.2	-0.08	0.03	0.18	1.2	0.13 [-0.39, 0.64]
			Placebo	28	27 (96.4)	0.08 (0.37)	-0.8	-0.07	0.04	0.19	1.4	
		Week 12	Tezepelumab	33	33 (100.0)	0.07 (0.30)	-0.3	-0.09	0.00	0.19	1.4	-0.12 [-0.63, 0.39]
			Placebo	28	27 (96.4)	0.10 (0.33)	-0.4	-0.05	0.05	0.22	1.4	
		Week 16	Tezepelumab	33	32 (97.0)	0.15 (0.37)	-0.6	0.01	0.14	0.27	1.6	0.17 [-0.35, 0.68]
			Placebo	28	27 (96.4)	0.09 (0.35)	-0.6	-0.06	0.02	0.19	1.4	
		Week 24	Tezepelumab	33	32 (97.0)	0.05 (0.27)	-0.4	-0.13	-0.01	0.24	1.0	-0.03 [-0.54, 0.49]
			Placebo	28	26 (92.9)	0.06 (0.37)	-0.5	-0.10	0.03	0.10	1.6	
		Week 36	Tezepelumab	33	31 (93.9)	0.05 (0.35)	-0.8	-0.12	0.01	0.21	1.1	-0.25 [-0.78, 0.28]
			Placebo	28	25 (89.3)	0.13 (0.29)	-0.3	-0.07	0.08	0.30	1.1	
		Week 52	Tezepelumab	33	29 (87.9)	0.01 (0.31)	-0.8	-0.15	0.01	0.16	1.0	-0.38 [-0.92, 0.17]
			Placebo	28	24 (85.7)	0.12 (0.25)	-0.3	-0.02	0.09	0.20	0.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Absolute values	Baseline	Tezepelumab	4	4 (100.0)	1.93 (0.59)	1.3	1.43	1.98	2.43	2.5	
			Placebo	3	3 (100.0)	1.42 (0.37)	1.0	1.04	1.44	1.77	1.8	
		Week 2	Tezepelumab	4	3 (75.0)	1.90 (0.24)	1.7	1.72	1.80	2.17	2.2	
			Placebo	3	3 (100.0)	1.28 (0.39)	1.0	0.97	1.15	1.71	1.7	
		Week 4	Tezepelumab	4	4 (100.0)	1.91 (0.14)	1.8	1.79	1.92	2.03	2.1	
			Placebo	3	3 (100.0)	1.39 (0.44)	1.0	1.00	1.31	1.87	1.9	
		Week 8	Tezepelumab	4	4 (100.0)	1.93 (0.35)	1.6	1.70	1.89	2.16	2.4	
			Placebo	3	3 (100.0)	1.29 (0.51)	0.8	0.79	1.27	1.81	1.8	
		Week 12	Tezepelumab	4	4 (100.0)	2.10 (0.46)	1.6	1.70	2.13	2.50	2.5	
			Placebo	3	3 (100.0)	1.30 (0.39)	1.0	0.98	1.19	1.74	1.7	
		Week 16	Tezepelumab	4	4 (100.0)	1.82 (0.32)	1.5	1.57	1.78	2.07	2.2	
			Placebo	3	3 (100.0)	1.19 (0.52)	0.8	0.81	0.97	1.78	1.8	
		Week 24	Tezepelumab	4	4 (100.0)	2.10 (0.52)	1.6	1.66	2.07	2.54	2.6	
			Placebo	3	2 (66.7)	1.00 (0.10)	0.9	0.93	1.00	1.07	1.1	
		Week 36	Tezepelumab	4	4 (100.0)	2.01 (0.46)	1.4	1.67	2.05	2.36	2.5	
			Placebo	3	2 (66.7)	1.24 (0.33)	1.0	1.00	1.24	1.47	1.5	
		Week 52	Tezepelumab	4	4 (100.0)	2.11 (0.44)	1.6	1.77	2.14	2.44	2.6	
			Placebo	3	3 (100.0)	1.23 (0.38)	1.0	0.96	1.06	1.66	1.7	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Change from baseline	Week 2	Tezepelumab	4	3 (75.0)	-0.14 (0.61)	-0.7	-0.65	-0.31	0.53	0.5	-0.01 [-1.61, 1.59]
			Placebo	3	3 (100.0)	-0.14 (0.13)	-0.3	-0.29	-0.07	-0.06	-0.1	
		Week 4	Tezepelumab	4	4 (100.0)	-0.02 (0.47)	-0.5	-0.40	-0.07	0.37	0.6	0.02 [-1.47, 1.52]
			Placebo	3	3 (100.0)	-0.02 (0.12)	-0.1	-0.13	-0.04	0.10	0.1	
		Week 8	Tezepelumab	4	4 (100.0)	0.00 (0.43)	-0.5	-0.27	-0.06	0.28	0.6	0.38 [-1.13, 1.90]
			Placebo	3	3 (100.0)	-0.13 (0.15)	-0.3	-0.25	-0.17	0.04	0.0	
		Week 12	Tezepelumab	4	4 (100.0)	0.17 (0.22)	0.0	0.03	0.08	0.31	0.5	1.52 [-0.25, 3.29]
			Placebo	3	3 (100.0)	-0.11 (0.12)	-0.3	-0.25	-0.06	-0.03	-0.0	
		Week 16	Tezepelumab	4	4 (100.0)	-0.11 (0.36)	-0.5	-0.36	-0.17	0.14	0.4	0.35 [-1.17, 1.86]
			Placebo	3	3 (100.0)	-0.23 (0.35)	-0.6	-0.63	-0.07	0.01	0.0	
		Week 24	Tezepelumab	4	4 (100.0)	0.17 (0.22)	-0.0	-0.01	0.15	0.35	0.4	1.52 [-0.48, 3.52]
			Placebo	3	2 (66.7)	-0.24 (0.38)	-0.5	-0.51	-0.24	0.03	0.0	
		Week 36	Tezepelumab	4	4 (100.0)	0.09 (0.37)	-0.2	-0.16	-0.06	0.34	0.6	0.28 [-1.42, 1.99]
			Placebo	3	2 (66.7)	-0.01 (0.05)	-0.0	-0.04	-0.01	0.03	0.0	
		Week 52	Tezepelumab	4	4 (100.0)	0.18 (0.35)	-0.1	-0.04	0.05	0.40	0.7	1.26 [-0.43, 2.95]
			Placebo	3	3 (100.0)	-0.19 (0.17)	-0.4	-0.38	-0.11	-0.08	-0.1	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Absolute values	Baseline	Tezepelumab	15	15 (100.0)	1.57 (0.66)	0.4	1.03	1.50	2.13	2.8	
			Placebo	6	6 (100.0)	1.80 (0.20)	1.5	1.69	1.76	1.93	2.1	
		Week 2	Tezepelumab	15	15 (100.0)	1.54 (0.55)	0.6	1.23	1.55	2.03	2.4	
			Placebo	6	6 (100.0)	1.73 (0.17)	1.4	1.71	1.75	1.85	1.9	
		Week 4	Tezepelumab	15	15 (100.0)	1.58 (0.62)	0.7	0.92	1.61	2.13	2.5	
			Placebo	6	6 (100.0)	1.78 (0.15)	1.6	1.69	1.79	1.85	2.0	
		Week 8	Tezepelumab	15	14 (93.3)	1.56 (0.56)	0.6	1.23	1.61	2.00	2.4	
			Placebo	6	6 (100.0)	1.89 (0.31)	1.7	1.74	1.78	1.82	2.5	
		Week 12	Tezepelumab	15	14 (93.3)	1.55 (0.56)	0.6	1.19	1.55	2.06	2.4	
			Placebo	6	6 (100.0)	1.77 (0.23)	1.5	1.66	1.71	1.93	2.1	
		Week 16	Tezepelumab	15	15 (100.0)	1.60 (0.68)	0.6	1.05	1.55	2.26	2.6	
			Placebo	6	6 (100.0)	1.72 (0.04)	1.7	1.70	1.71	1.76	1.8	
		Week 24	Tezepelumab	15	15 (100.0)	1.62 (0.51)	0.6	1.12	1.71	1.89	2.4	
			Placebo	6	6 (100.0)	1.75 (0.30)	1.3	1.63	1.70	2.07	2.1	
		Week 36	Tezepelumab	15	15 (100.0)	1.58 (0.63)	0.5	1.16	1.51	2.12	2.8	
			Placebo	6	6 (100.0)	1.73 (0.16)	1.5	1.69	1.72	1.88	1.9	
		Week 52	Tezepelumab	15	15 (100.0)	1.60 (0.61)	0.8	1.09	1.54	2.11	2.9	
			Placebo	6	6 (100.0)	1.70 (0.08)	1.6	1.62	1.72	1.73	1.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Change from baseline	Week 2	Tezepelumab	15	15 (100.0)	-0.02 (0.23)	-0.6	-0.10	0.05	0.09	0.2	0.21 [-0.74, 1.16]
			Placebo	6	6 (100.0)	-0.07 (0.19)	-0.3	-0.26	-0.06	0.08	0.2	
		Week 4	Tezepelumab	15	15 (100.0)	0.01 (0.38)	-0.9	-0.18	0.08	0.27	0.6	0.07 [-0.88, 1.02]
			Placebo	6	6 (100.0)	-0.01 (0.18)	-0.3	-0.14	0.07	0.09	0.1	
		Week 8	Tezepelumab	15	14 (93.3)	0.02 (0.29)	-0.8	-0.05	0.11	0.20	0.3	-0.26 [-1.22, 0.70]
			Placebo	6	6 (100.0)	0.09 (0.20)	-0.2	-0.02	0.06	0.20	0.4	
		Week 12	Tezepelumab	15	14 (93.3)	0.02 (0.33)	-0.7	-0.11	0.08	0.15	0.7	0.16 [-0.80, 1.12]
			Placebo	6	6 (100.0)	-0.03 (0.04)	-0.1	-0.06	-0.02	0.00	0.0	
		Week 16	Tezepelumab	15	15 (100.0)	0.03 (0.24)	-0.6	-0.13	0.02	0.22	0.4	0.46 [-0.50, 1.41]
			Placebo	6	6 (100.0)	-0.08 (0.22)	-0.5	-0.15	-0.05	0.02	0.2	
		Week 24	Tezepelumab	15	15 (100.0)	0.05 (0.32)	-0.6	-0.10	0.00	0.16	0.7	0.32 [-0.63, 1.27]
			Placebo	6	6 (100.0)	-0.05 (0.29)	-0.4	-0.26	-0.06	0.09	0.4	
		Week 36	Tezepelumab	15	15 (100.0)	0.01 (0.34)	-0.7	-0.13	0.04	0.25	0.6	0.24 [-0.71, 1.19]
			Placebo	6	6 (100.0)	-0.07 (0.19)	-0.2	-0.19	-0.15	0.15	0.2	
		Week 52	Tezepelumab	15	15 (100.0)	0.03 (0.44)	-1.0	-0.07	0.00	0.35	0.7	0.34 [-0.62, 1.29]
			Placebo	6	6 (100.0)	-0.10 (0.25)	-0.5	-0.22	-0.10	0.12	0.2	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Absolute values	Baseline	Tezepelumab	2	2 (100.0)	1.26 (0.61)	0.8	0.83	1.26	1.69	1.7	
			Placebo	2	2 (100.0)	1.62 (0.37)	1.4	1.35	1.62	1.88	1.9	
		Week 2	Tezepelumab	2	2 (100.0)	1.43 (0.72)	0.9	0.92	1.43	1.94	1.9	
			Placebo	2	1 (50.0)	1.35	1.4	1.35	1.35	1.35	1.4	
		Week 4	Tezepelumab	2	2 (100.0)	1.42 (0.74)	0.9	0.89	1.42	1.94	1.9	
			Placebo	2	2 (100.0)	1.64 (0.37)	1.4	1.38	1.64	1.90	1.9	
		Week 8	Tezepelumab	2	2 (100.0)	1.43 (0.66)	1.0	0.96	1.43	1.90	1.9	
			Placebo	2	2 (100.0)	1.73 (0.35)	1.5	1.48	1.73	1.98	2.0	
		Week 12	Tezepelumab	2	2 (100.0)	1.37 (0.66)	0.9	0.90	1.37	1.83	1.8	
			Placebo	2	2 (100.0)	1.84 (0.59)	1.4	1.42	1.84	2.25	2.3	
		Week 16	Tezepelumab	2	2 (100.0)	1.39 (0.66)	0.9	0.92	1.39	1.85	1.9	
			Placebo	2	2 (100.0)	1.56 (0.32)	1.3	1.33	1.56	1.78	1.8	
		Week 24	Tezepelumab	2	2 (100.0)	1.39 (0.75)	0.9	0.86	1.39	1.92	1.9	
			Placebo	2	1 (50.0)	1.40	1.4	1.40	1.40	1.40	1.4	
		Week 36	Tezepelumab	2	2 (100.0)	1.37 (0.65)	0.9	0.91	1.37	1.83	1.8	
			Placebo	2	1 (50.0)	1.57	1.6	1.57	1.57	1.57	1.6	
		Week 52	Tezepelumab	2	2 (100.0)	1.43 (0.76)	0.9	0.89	1.43	1.97	2.0	
			Placebo	2	1 (50.0)	1.47	1.5	1.47	1.47	1.47	1.5	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Change from baseline	Week 2	Tezepelumab	2	2 (100.0)	0.17 (0.11)	0.1	0.09	0.17	0.25	0.3	NE
			Placebo	2	1 (50.0)	0.00	0.0	0.00	0.00	0.00	0.0	
		Week 4	Tezepelumab	2	2 (100.0)	0.16 (0.13)	0.1	0.06	0.16	0.25	0.3	1.37 [-1.01, 3.74]
			Placebo	2	2 (100.0)	0.02 (0.01)	0.0	0.02	0.02	0.03	0.0	
		Week 8	Tezepelumab	2	2 (100.0)	0.17 (0.06)	0.1	0.13	0.17	0.21	0.2	1.29 [-1.04, 3.62]
			Placebo	2	2 (100.0)	0.12 (0.02)	0.1	0.10	0.12	0.13	0.1	
		Week 12	Tezepelumab	2	2 (100.0)	0.11 (0.05)	0.1	0.07	0.11	0.14	0.1	-0.75 [-2.84, 1.35]
			Placebo	2	2 (100.0)	0.22 (0.21)	0.1	0.07	0.22	0.37	0.4	
		Week 16	Tezepelumab	2	2 (100.0)	0.13 (0.05)	0.1	0.09	0.13	0.16	0.2	3.48 [-0.45, 7.41]
			Placebo	2	2 (100.0)	-0.06 (0.06)	-0.1	-0.10	-0.06	-0.02	-0.0	
		Week 24	Tezepelumab	2	2 (100.0)	0.13 (0.14)	0.0	0.03	0.13	0.23	0.2	NE
			Placebo	2	1 (50.0)	0.05	0.0	0.05	0.05	0.05	0.0	
		Week 36	Tezepelumab	2	2 (100.0)	0.11 (0.04)	0.1	0.08	0.11	0.14	0.1	NE
			Placebo	2	1 (50.0)	0.22	0.2	0.22	0.22	0.22	0.2	
		Week 52	Tezepelumab	2	2 (100.0)	0.17 (0.16)	0.1	0.06	0.17	0.28	0.3	NE
			Placebo	2	1 (50.0)	0.12	0.1	0.12	0.12	0.12	0.1	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Absolute values	Baseline	Tezepelumab	11	11 (100.0)	2.02 (0.40)	1.4	1.65	2.02	2.39	2.6	
			Placebo	10	10 (100.0)	1.73 (0.64)	0.9	1.06	1.84	2.17	2.8	
		Week 2	Tezepelumab	11	11 (100.0)	2.10 (0.44)	1.4	1.70	2.17	2.47	2.7	
			Placebo	10	9 (90.0)	1.93 (0.69)	0.9	1.46	2.11	2.31	2.8	
		Week 4	Tezepelumab	11	11 (100.0)	2.06 (0.42)	1.4	1.65	2.07	2.45	2.6	
			Placebo	10	10 (100.0)	1.89 (0.73)	1.0	1.08	1.88	2.47	3.0	
		Week 8	Tezepelumab	11	11 (100.0)	2.06 (0.51)	1.2	1.58	2.11	2.53	2.7	
			Placebo	10	9 (90.0)	1.84 (0.81)	0.8	1.07	2.23	2.35	2.8	
		Week 12	Tezepelumab	11	11 (100.0)	2.01 (0.44)	1.2	1.62	2.18	2.39	2.5	
			Placebo	10	10 (100.0)	1.84 (0.75)	0.8	1.28	1.81	2.52	3.0	
		Week 16	Tezepelumab	11	11 (100.0)	2.08 (0.49)	1.2	1.63	2.22	2.34	3.0	
			Placebo	10	10 (100.0)	1.88 (0.70)	0.9	1.32	1.97	2.28	3.0	
		Week 24	Tezepelumab	11	11 (100.0)	1.99 (0.42)	1.2	1.61	2.26	2.30	2.4	
			Placebo	10	10 (100.0)	1.74 (0.63)	0.8	1.12	1.85	2.25	2.7	
		Week 36	Tezepelumab	11	11 (100.0)	2.00 (0.50)	1.2	1.53	2.10	2.50	2.6	
			Placebo	10	9 (90.0)	1.89 (0.67)	1.1	1.19	1.75	2.36	3.0	
		Week 52	Tezepelumab	11	10 (90.9)	1.99 (0.45)	1.2	1.64	2.20	2.26	2.6	
			Placebo	10	10 (100.0)	1.94 (0.69)	1.0	1.10	2.19	2.31	2.9	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Change from baseline	Week 2	Tezepelumab	11	11 (100.0)	0.08 (0.22)	-0.3	-0.01	0.05	0.15	0.5	-0.12 [-1.00, 0.76]
			Placebo	10	9 (90.0)	0.11 (0.22)	-0.1	-0.05	0.03	0.10	0.5	
		Week 4	Tezepelumab	11	11 (100.0)	0.04 (0.23)	-0.5	-0.06	0.05	0.22	0.3	-0.55 [-1.42, 0.32]
			Placebo	10	10 (100.0)	0.16 (0.22)	-0.3	0.03	0.16	0.31	0.5	
		Week 8	Tezepelumab	11	11 (100.0)	0.04 (0.25)	-0.2	-0.09	-0.06	0.04	0.7	0.01 [-0.87, 0.89]
			Placebo	10	9 (90.0)	0.03 (0.37)	-0.8	-0.06	0.04	0.19	0.5	
		Week 12	Tezepelumab	11	11 (100.0)	-0.01 (0.18)	-0.2	-0.18	-0.03	0.10	0.4	-0.56 [-1.43, 0.32]
			Placebo	10	10 (100.0)	0.11 (0.25)	-0.4	-0.03	0.12	0.33	0.4	
		Week 16	Tezepelumab	11	11 (100.0)	0.06 (0.28)	-0.3	-0.22	0.03	0.18	0.7	-0.39 [-1.26, 0.47]
			Placebo	10	10 (100.0)	0.15 (0.19)	-0.1	0.01	0.10	0.26	0.5	
		Week 24	Tezepelumab	11	11 (100.0)	-0.03 (0.16)	-0.2	-0.18	-0.05	0.10	0.3	-0.28 [-1.14, 0.58]
			Placebo	10	10 (100.0)	0.02 (0.17)	-0.2	-0.10	-0.01	0.06	0.4	
		Week 36	Tezepelumab	11	11 (100.0)	-0.02 (0.28)	-0.5	-0.18	-0.05	0.11	0.6	-0.93 [-1.86, 0.01]
			Placebo	10	9 (90.0)	0.21 (0.20)	-0.3	0.17	0.30	0.31	0.4	
		Week 52	Tezepelumab	11	10 (90.9)	-0.01 (0.20)	-0.4	-0.05	-0.01	0.10	0.2	-1.21 [-2.17, -0.24]
			Placebo	10	10 (100.0)	0.21 (0.17)	-0.0	0.10	0.16	0.40	0.5	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Absolute values	Baseline	Tezepelumab	19	19 (100.0)	1.87 (0.67)	0.8	1.28	1.90	2.52	3.2	
			Placebo	11	11 (100.0)	1.88 (0.70)	1.0	1.35	1.88	2.47	3.2	
		Week 2	Tezepelumab	19	18 (94.7)	1.93 (0.68)	0.9	1.32	1.89	2.52	3.4	
			Placebo	11	9 (81.8)	1.93 (1.00)	1.0	1.29	1.61	2.43	4.1	
		Week 4	Tezepelumab	19	19 (100.0)	1.88 (0.69)	0.7	1.19	1.99	2.46	3.2	
			Placebo	11	10 (90.9)	2.12 (1.13)	1.0	1.43	1.86	2.68	4.8	
		Week 8	Tezepelumab	19	19 (100.0)	1.96 (0.66)	0.7	1.55	1.92	2.51	3.3	
			Placebo	11	11 (100.0)	2.04 (1.02)	0.8	1.53	1.76	2.68	4.6	
		Week 12	Tezepelumab	19	19 (100.0)	1.95 (0.73)	0.8	1.32	2.06	2.41	3.6	
			Placebo	11	11 (100.0)	2.09 (1.02)	1.0	1.41	1.73	2.70	4.6	
		Week 16	Tezepelumab	19	19 (100.0)	1.99 (0.67)	0.9	1.49	1.91	2.57	3.5	
			Placebo	11	11 (100.0)	2.03 (1.05)	1.0	1.26	1.68	2.60	4.7	
		Week 24	Tezepelumab	19	19 (100.0)	1.94 (0.71)	0.8	1.18	1.94	2.55	3.5	
			Placebo	11	10 (90.9)	2.11 (1.11)	1.1	1.42	1.77	2.66	4.8	
		Week 36	Tezepelumab	19	19 (100.0)	1.94 (0.68)	0.8	1.43	1.90	2.34	3.5	
			Placebo	11	11 (100.0)	2.01 (1.00)	1.0	1.38	1.59	2.74	4.3	
		Week 52	Tezepelumab	19	18 (94.7)	1.94 (0.66)	0.7	1.57	1.98	2.30	3.4	
			Placebo	11	9 (81.8)	1.96 (1.02)	1.0	1.15	1.62	2.76	4.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Change from baseline	Week 2	Tezepelumab	19	18 (94.7)	0.05 (0.24)	-0.7	0.00	0.04	0.18	0.5	-0.24 [-1.04, 0.57]
			Placebo	11	9 (81.8)	0.11 (0.32)	-0.2	-0.07	0.04	0.16	0.9	
		Week 4	Tezepelumab	19	19 (100.0)	0.01 (0.20)	-0.3	-0.13	0.03	0.15	0.6	-0.69 [-1.48, 0.10]
			Placebo	11	10 (90.9)	0.24 (0.50)	-0.2	-0.01	0.09	0.28	1.6	
		Week 8	Tezepelumab	19	19 (100.0)	0.09 (0.27)	-0.5	-0.08	0.06	0.18	0.7	-0.18 [-0.92, 0.57]
			Placebo	11	11 (100.0)	0.15 (0.48)	-0.5	-0.12	0.11	0.30	1.4	
		Week 12	Tezepelumab	19	19 (100.0)	0.09 (0.20)	-0.2	-0.05	0.05	0.19	0.5	-0.39 [-1.14, 0.36]
			Placebo	11	11 (100.0)	0.20 (0.41)	-0.1	-0.06	0.06	0.26	1.4	
		Week 16	Tezepelumab	19	19 (100.0)	0.13 (0.26)	-0.5	0.01	0.15	0.28	0.7	-0.08 [-0.82, 0.67]
			Placebo	11	11 (100.0)	0.15 (0.47)	-0.3	-0.10	0.07	0.26	1.4	
		Week 24	Tezepelumab	19	19 (100.0)	0.08 (0.24)	-0.4	-0.10	0.02	0.29	0.4	-0.30 [-1.07, 0.47]
			Placebo	11	10 (90.9)	0.19 (0.54)	-0.4	0.03	0.08	0.13	1.6	
		Week 36	Tezepelumab	19	19 (100.0)	0.07 (0.33)	-0.8	-0.15	0.03	0.24	0.8	-0.17 [-0.92, 0.57]
			Placebo	11	11 (100.0)	0.13 (0.37)	-0.3	-0.07	0.03	0.30	1.1	
		Week 52	Tezepelumab	19	18 (94.7)	0.01 (0.31)	-0.8	-0.07	0.05	0.16	0.7	-0.20 [-1.00, 0.60]
			Placebo	11	9 (81.8)	0.08 (0.35)	-0.3	-0.08	-0.02	0.15	0.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Absolute values	Baseline	Tezepelumab	13	13 (100.0)	1.69 (0.62)	0.4	1.44	1.74	2.13	2.8	
			Placebo	9	9 (100.0)	1.79 (0.20)	1.5	1.69	1.70	1.93	2.1	
		Week 2	Tezepelumab	13	13 (100.0)	1.66 (0.50)	0.6	1.29	1.59	2.03	2.4	
			Placebo	9	8 (88.9)	1.74 (0.18)	1.4	1.65	1.75	1.87	2.0	
		Week 4	Tezepelumab	13	13 (100.0)	1.71 (0.55)	0.7	1.44	1.64	2.13	2.5	
			Placebo	9	9 (100.0)	1.74 (0.15)	1.6	1.64	1.76	1.79	2.0	
		Week 8	Tezepelumab	13	12 (92.3)	1.69 (0.50)	0.6	1.43	1.65	2.08	2.4	
			Placebo	9	9 (100.0)	1.84 (0.27)	1.6	1.74	1.76	1.82	2.5	
		Week 12	Tezepelumab	13	12 (92.3)	1.67 (0.49)	0.6	1.47	1.59	2.08	2.4	
			Placebo	9	8 (88.9)	1.72 (0.22)	1.5	1.57	1.68	1.83	2.1	
		Week 16	Tezepelumab	13	13 (100.0)	1.73 (0.62)	0.6	1.37	1.67	2.26	2.6	
			Placebo	9	8 (88.9)	1.67 (0.11)	1.4	1.66	1.71	1.74	1.8	
		Week 24	Tezepelumab	13	13 (100.0)	1.76 (0.38)	1.1	1.61	1.76	1.89	2.4	
			Placebo	9	8 (88.9)	1.72 (0.27)	1.3	1.60	1.70	1.90	2.1	
		Week 36	Tezepelumab	13	13 (100.0)	1.71 (0.55)	0.9	1.33	1.54	2.12	2.8	
			Placebo	9	7 (77.8)	1.74 (0.15)	1.5	1.69	1.74	1.88	1.9	
		Week 52	Tezepelumab	13	13 (100.0)	1.71 (0.58)	0.8	1.43	1.60	2.11	2.9	
			Placebo	9	8 (88.9)	1.73 (0.12)	1.6	1.65	1.72	1.77	2.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Change from baseline	Week 2	Tezepelumab	13	13 (100.0)	-0.04 (0.24)	-0.6	-0.10	0.05	0.09	0.2	0.18 [-0.70, 1.06]
			Placebo	9	8 (88.9)	-0.07 (0.16)	-0.3	-0.21	-0.08	0.06	0.2	
		Week 4	Tezepelumab	13	13 (100.0)	0.02 (0.41)	-0.9	-0.13	0.12	0.27	0.6	0.20 [-0.65, 1.05]
			Placebo	9	9 (100.0)	-0.05 (0.17)	-0.3	-0.14	-0.02	0.09	0.1	
		Week 8	Tezepelumab	13	12 (92.3)	0.02 (0.31)	-0.8	-0.06	0.15	0.23	0.3	-0.14 [-1.00, 0.73]
			Placebo	9	9 (100.0)	0.05 (0.17)	-0.2	-0.02	0.00	0.13	0.4	
		Week 12	Tezepelumab	13	12 (92.3)	0.02 (0.35)	-0.7	-0.09	0.08	0.16	0.7	0.40 [-0.51, 1.30]
			Placebo	9	8 (88.9)	-0.10 (0.15)	-0.4	-0.13	-0.05	0.00	0.0	
		Week 16	Tezepelumab	13	13 (100.0)	0.04 (0.26)	-0.6	-0.13	0.08	0.22	0.4	0.68 [-0.23, 1.59]
			Placebo	9	8 (88.9)	-0.14 (0.27)	-0.6	-0.30	-0.07	0.01	0.2	
		Week 24	Tezepelumab	13	13 (100.0)	0.07 (0.34)	-0.6	-0.07	0.02	0.16	0.7	0.50 [-0.40, 1.39]
			Placebo	9	8 (88.9)	-0.09 (0.29)	-0.5	-0.34	-0.06	0.06	0.4	
		Week 36	Tezepelumab	13	13 (100.0)	0.02 (0.37)	-0.7	-0.13	0.04	0.25	0.6	0.35 [-0.57, 1.28]
			Placebo	9	7 (77.8)	-0.09 (0.18)	-0.2	-0.23	-0.19	0.15	0.2	
		Week 52	Tezepelumab	13	13 (100.0)	0.02 (0.47)	-1.0	-0.07	0.00	0.35	0.7	0.26 [-0.62, 1.15]
			Placebo	9	8 (88.9)	-0.08 (0.22)	-0.5	-0.21	-0.04	0.06	0.2	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Absolute values	Baseline	Tezepelumab	11	11 (100.0)	1.51 (0.72)	0.6	0.92	1.31	1.72	3.3	
			Placebo	9	9 (100.0)	1.52 (0.37)	0.8	1.39	1.49	1.77	2.1	
		Week 2	Tezepelumab	11	10 (90.9)	1.64 (0.71)	0.7	0.92	1.56	1.94	2.9	
			Placebo	9	8 (88.9)	1.36 (0.35)	0.8	1.12	1.37	1.68	1.8	
		Week 4	Tezepelumab	11	11 (100.0)	1.71 (0.91)	0.7	0.89	1.66	1.94	3.4	
			Placebo	9	9 (100.0)	1.45 (0.35)	0.9	1.31	1.38	1.80	1.9	
		Week 8	Tezepelumab	11	10 (90.9)	1.54 (0.65)	0.7	0.96	1.61	1.90	2.9	
			Placebo	9	9 (100.0)	1.52 (0.39)	0.8	1.37	1.48	1.81	2.0	
		Week 12	Tezepelumab	11	11 (100.0)	1.64 (0.85)	0.7	0.90	1.44	1.83	3.3	
			Placebo	9	9 (100.0)	1.54 (0.44)	0.9	1.30	1.42	1.74	2.3	
		Week 16	Tezepelumab	11	10 (90.9)	1.70 (0.90)	0.6	0.94	1.51	1.85	3.3	
			Placebo	9	9 (100.0)	1.43 (0.42)	0.8	1.31	1.33	1.78	2.0	
		Week 24	Tezepelumab	11	10 (90.9)	1.46 (0.65)	0.6	0.86	1.49	1.92	2.7	
			Placebo	9	7 (77.8)	1.37 (0.37)	0.8	0.93	1.40	1.69	1.9	
		Week 36	Tezepelumab	11	9 (81.8)	1.43 (0.67)	0.5	0.91	1.48	1.65	2.8	
			Placebo	9	7 (77.8)	1.50 (0.33)	0.9	1.41	1.47	1.78	1.9	
		Week 52	Tezepelumab	11	9 (81.8)	1.50 (0.63)	0.9	0.90	1.54	1.87	2.8	
			Placebo	9	7 (77.8)	1.34 (0.30)	0.9	1.06	1.47	1.57	1.7	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Change from baseline	Week 2	Tezepelumab	11	10 (90.9)	0.11 (0.29)	-0.3	-0.08	0.09	0.25	0.8	0.87 [-0.11, 1.84]
			Placebo	9	8 (88.9)	-0.12 (0.19)	-0.4	-0.30	-0.04	-0.01	0.2	
		Week 4	Tezepelumab	11	11 (100.0)	0.20 (0.55)	-0.4	-0.04	0.06	0.30	1.7	0.64 [-0.26, 1.55]
			Placebo	9	9 (100.0)	-0.07 (0.14)	-0.3	-0.13	-0.03	0.03	0.1	
		Week 8	Tezepelumab	11	10 (90.9)	0.21 (0.38)	-0.1	-0.04	0.11	0.30	1.2	0.74 [-0.19, 1.67]
			Placebo	9	9 (100.0)	-0.00 (0.09)	-0.2	-0.07	-0.01	0.05	0.1	
		Week 12	Tezepelumab	11	11 (100.0)	0.14 (0.45)	-0.3	-0.11	0.07	0.21	1.4	0.34 [-0.54, 1.23]
			Placebo	9	9 (100.0)	0.01 (0.18)	-0.3	-0.03	0.00	0.07	0.4	
		Week 16	Tezepelumab	11	10 (90.9)	0.16 (0.55)	-0.6	-0.07	0.11	0.16	1.6	0.60 [-0.33, 1.52]
			Placebo	9	9 (100.0)	-0.09 (0.22)	-0.6	-0.10	-0.06	0.01	0.1	
		Week 24	Tezepelumab	11	10 (90.9)	0.13 (0.35)	-0.2	-0.10	0.02	0.23	1.0	0.65 [-0.34, 1.64]
			Placebo	9	7 (77.8)	-0.07 (0.24)	-0.5	-0.25	0.00	0.05	0.2	
		Week 36	Tezepelumab	11	9 (81.8)	0.09 (0.41)	-0.4	-0.09	-0.06	0.14	1.1	0.08 [-0.90, 1.07]
			Placebo	9	7 (77.8)	0.06 (0.16)	-0.2	-0.08	0.06	0.22	0.3	
		Week 52	Tezepelumab	11	9 (81.8)	0.16 (0.38)	-0.2	-0.10	0.06	0.27	1.0	0.67 [-0.35, 1.69]
			Placebo	9	7 (77.8)	-0.05 (0.20)	-0.4	-0.25	0.06	0.12	0.1	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
< 18.5 kg/m**2	Absolute values	Baseline	Tezepelumab	2	2 (100.0)	2.07 (1.07)	1.3	1.31	2.07	2.83	2.8	
		Week 2	Tezepelumab	2	2 (100.0)	1.89 (0.67)	1.4	1.41	1.89	2.36	2.4	
		Week 4	Tezepelumab	2	2 (100.0)	1.63 (0.50)	1.3	1.27	1.63	1.98	2.0	
		Week 8	Tezepelumab	2	2 (100.0)	1.81 (0.28)	1.6	1.61	1.81	2.00	2.0	
		Week 12	Tezepelumab	2	2 (100.0)	1.66 (0.62)	1.2	1.22	1.66	2.10	2.1	
		Week 16	Tezepelumab	2	2 (100.0)	1.85 (0.59)	1.4	1.43	1.85	2.26	2.3	
		Week 24	Tezepelumab	2	2 (100.0)	1.82 (0.59)	1.4	1.40	1.82	2.24	2.2	
		Week 36	Tezepelumab	2	2 (100.0)	1.69 (0.62)	1.3	1.25	1.69	2.12	2.1	
		Week 52	Tezepelumab	2	2 (100.0)	1.46 (0.49)	1.1	1.11	1.46	1.80	1.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
< 18.5 kg/m**2	Change from baseline	Week 2	Tezepelumab	2	2 (100.0)	-0.19 (0.40)	-0.5	-0.47	-0.19	0.10	0.1	NE
		Week 4	Tezepelumab	2	2 (100.0)	-0.45 (0.57)	-0.9	-0.85	-0.45	-0.04	-0.0	NE
		Week 8	Tezepelumab	2	2 (100.0)	-0.27 (0.80)	-0.8	-0.83	-0.27	0.30	0.3	NE
		Week 12	Tezepelumab	2	2 (100.0)	-0.41 (0.45)	-0.7	-0.73	-0.41	-0.09	-0.1	NE
		Week 16	Tezepelumab	2	2 (100.0)	-0.23 (0.49)	-0.6	-0.57	-0.23	0.12	0.1	NE
		Week 24	Tezepelumab	2	2 (100.0)	-0.25 (0.48)	-0.6	-0.59	-0.25	0.09	0.1	NE
		Week 36	Tezepelumab	2	2 (100.0)	-0.39 (0.46)	-0.7	-0.71	-0.39	-0.06	-0.1	NE
		Week 52	Tezepelumab	2	2 (100.0)	-0.62 (0.59)	-1.0	-1.03	-0.62	-0.20	-0.2	NE

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Absolute values	Baseline	Tezepelumab	11	11 (100.0)	1.65 (0.79)	0.4	1.03	1.74	2.20	3.2	
			Placebo	7	7 (100.0)	1.91 (0.25)	1.5	1.69	1.89	2.16	2.2	
		Week 2	Tezepelumab	11	10 (90.9)	1.67 (0.79)	0.6	1.04	1.74	2.03	3.4	
			Placebo	7	7 (100.0)	1.88 (0.27)	1.4	1.71	1.89	2.11	2.3	
		Week 4	Tezepelumab	11	11 (100.0)	1.70 (0.74)	0.7	1.06	1.64	2.13	3.2	
			Placebo	7	7 (100.0)	1.97 (0.28)	1.7	1.78	1.85	2.20	2.5	
		Week 8	Tezepelumab	11	10 (90.9)	1.69 (0.79)	0.6	1.18	1.68	2.15	3.3	
			Placebo	7	7 (100.0)	2.04 (0.31)	1.7	1.79	1.86	2.35	2.5	
		Week 12	Tezepelumab	11	11 (100.0)	1.77 (0.84)	0.6	1.08	1.73	2.37	3.6	
			Placebo	7	7 (100.0)	1.93 (0.36)	1.5	1.69	1.82	2.14	2.6	
		Week 16	Tezepelumab	11	10 (90.9)	1.77 (0.87)	0.6	1.05	1.62	2.22	3.5	
			Placebo	7	7 (100.0)	1.86 (0.21)	1.7	1.71	1.76	2.10	2.2	
		Week 24	Tezepelumab	11	11 (100.0)	1.75 (0.72)	0.8	1.12	1.67	1.89	3.5	
			Placebo	7	7 (100.0)	1.97 (0.21)	1.6	1.73	2.07	2.11	2.2	
		Week 36	Tezepelumab	11	10 (90.9)	1.87 (0.89)	0.9	1.15	1.74	2.52	3.5	
			Placebo	7	6 (85.7)	1.89 (0.25)	1.7	1.70	1.84	1.92	2.4	
		Week 52	Tezepelumab	11	10 (90.9)	1.92 (0.88)	0.8	1.22	1.73	2.58	3.4	
			Placebo	7	7 (100.0)	1.86 (0.27)	1.6	1.62	1.81	2.15	2.3	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Change from baseline	Week 2	Tezepelumab	11	10 (90.9)	-0.03 (0.19)	-0.3	-0.17	-0.06	0.17	0.2	0.02 [-0.94, 0.99]
			Placebo	7	7 (100.0)	-0.03 (0.18)	-0.3	-0.26	0.04	0.10	0.2	
		Week 4	Tezepelumab	11	11 (100.0)	0.05 (0.34)	-0.5	-0.18	-0.07	0.30	0.6	-0.03 [-0.98, 0.92]
			Placebo	7	7 (100.0)	0.06 (0.19)	-0.3	0.03	0.09	0.15	0.3	
		Week 8	Tezepelumab	11	10 (90.9)	0.06 (0.20)	-0.2	-0.07	0.00	0.20	0.5	-0.38 [-1.36, 0.59]
			Placebo	7	7 (100.0)	0.13 (0.15)	-0.0	-0.02	0.13	0.20	0.4	
		Week 12	Tezepelumab	11	11 (100.0)	0.12 (0.27)	-0.2	-0.11	0.10	0.21	0.7	0.39 [-0.57, 1.35]
			Placebo	7	7 (100.0)	0.02 (0.17)	-0.1	-0.07	-0.03	0.02	0.4	
		Week 16	Tezepelumab	11	10 (90.9)	0.08 (0.25)	-0.4	-0.04	0.11	0.25	0.4	0.55 [-0.44, 1.53]
			Placebo	7	7 (100.0)	-0.05 (0.20)	-0.5	-0.10	0.01	0.02	0.2	
		Week 24	Tezepelumab	11	11 (100.0)	0.10 (0.36)	-0.4	-0.10	-0.02	0.38	0.7	0.12 [-0.83, 1.06]
			Placebo	7	7 (100.0)	0.06 (0.18)	-0.1	-0.08	0.03	0.13	0.4	
		Week 36	Tezepelumab	11	10 (90.9)	0.18 (0.25)	-0.1	-0.04	0.15	0.36	0.6	0.68 [-0.36, 1.73]
			Placebo	7	6 (85.7)	0.02 (0.17)	-0.2	-0.11	0.03	0.19	0.2	
		Week 52	Tezepelumab	11	10 (90.9)	0.22 (0.28)	-0.1	-0.02	0.17	0.41	0.7	1.02 [-0.01, 2.05]
			Placebo	7	7 (100.0)	-0.05 (0.24)	-0.5	-0.22	-0.02	0.15	0.2	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	20	20 (100.0)	1.71 (0.67)	0.6	1.30	1.71	2.11	3.3	
			Placebo	14	14 (100.0)	1.86 (0.71)	0.9	1.39	1.77	2.47	3.2	
		Week 2	Tezepelumab	20	20 (100.0)	1.83 (0.66)	0.7	1.33	1.93	2.40	2.9	
			Placebo	14	11 (78.6)	1.94 (0.92)	0.9	1.38	1.59	2.43	4.1	
		Week 4	Tezepelumab	20	20 (100.0)	1.86 (0.82)	0.7	1.17	1.98	2.43	3.4	
			Placebo	14	13 (92.9)	2.03 (1.05)	1.0	1.32	1.64	2.35	4.8	
		Week 8	Tezepelumab	20	19 (95.0)	1.82 (0.67)	0.7	1.23	1.88	2.43	2.9	
			Placebo	14	14 (100.0)	1.94 (0.98)	0.8	1.37	1.75	2.30	4.6	
		Week 12	Tezepelumab	20	20 (100.0)	1.82 (0.75)	0.7	1.20	1.95	2.21	3.3	
			Placebo	14	14 (100.0)	1.98 (1.00)	0.8	1.37	1.63	2.46	4.6	
		Week 16	Tezepelumab	20	20 (100.0)	1.89 (0.77)	0.6	1.28	1.94	2.34	3.3	
			Placebo	14	14 (100.0)	1.95 (1.03)	0.8	1.33	1.67	2.28	4.7	
		Week 24	Tezepelumab	20	19 (95.0)	1.77 (0.66)	0.6	1.10	1.92	2.29	2.7	
			Placebo	14	14 (100.0)	1.90 (1.03)	0.8	1.36	1.62	2.25	4.8	
		Week 36	Tezepelumab	20	19 (95.0)	1.73 (0.67)	0.5	1.16	1.83	2.30	2.9	
			Placebo	14	13 (92.9)	2.06 (0.91)	1.2	1.45	1.75	2.40	4.3	
		Week 52	Tezepelumab	20	17 (85.0)	1.71 (0.62)	0.7	1.17	1.79	2.20	2.8	
			Placebo	14	11 (78.6)	1.96 (0.94)	1.0	1.06	1.68	2.76	4.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Change from baseline	Week 2	Tezepelumab	20	20 (100.0)	0.12 (0.21)	-0.3	0.01	0.09	0.17	0.8	0.25 [-0.49, 0.99]
			Placebo	14	11 (78.6)	0.05 (0.34)	-0.3	-0.18	0.01	0.06	0.9	
		Week 4	Tezepelumab	20	20 (100.0)	0.15 (0.40)	-0.3	0.01	0.06	0.14	1.7	-0.06 [-0.75, 0.64]
			Placebo	14	13 (92.9)	0.17 (0.47)	-0.3	-0.07	0.08	0.20	1.6	
		Week 8	Tezepelumab	20	19 (95.0)	0.19 (0.31)	-0.2	0.04	0.13	0.25	1.2	0.31 [-0.38, 1.00]
			Placebo	14	14 (100.0)	0.08 (0.43)	-0.5	-0.08	-0.03	0.08	1.4	
		Week 12	Tezepelumab	20	20 (100.0)	0.11 (0.32)	-0.2	0.01	0.06	0.13	1.4	-0.02 [-0.70, 0.67]
			Placebo	14	14 (100.0)	0.12 (0.39)	-0.3	-0.05	0.01	0.19	1.4	
		Week 16	Tezepelumab	20	20 (100.0)	0.18 (0.41)	-0.2	-0.06	0.11	0.17	1.6	0.20 [-0.49, 0.88]
			Placebo	14	14 (100.0)	0.09 (0.47)	-0.6	-0.06	0.02	0.19	1.4	
		Week 24	Tezepelumab	20	19 (95.0)	0.14 (0.27)	-0.2	-0.06	0.14	0.23	1.0	0.24 [-0.45, 0.93]
			Placebo	14	14 (100.0)	0.05 (0.50)	-0.5	-0.25	-0.04	0.07	1.6	
		Week 36	Tezepelumab	20	19 (95.0)	0.10 (0.36)	-0.8	-0.02	0.06	0.20	1.1	-0.25 [-0.96, 0.46]
			Placebo	14	13 (92.9)	0.19 (0.34)	-0.3	0.03	0.17	0.30	1.1	
		Week 52	Tezepelumab	20	17 (85.0)	0.08 (0.36)	-0.8	-0.06	0.06	0.24	1.0	-0.17 [-0.93, 0.59]
			Placebo	14	11 (78.6)	0.13 (0.31)	-0.4	-0.01	0.13	0.23	0.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	21	21 (100.0)	1.89 (0.47)	1.3	1.49	1.87	2.20	2.6	
			Placebo	18	18 (100.0)	1.58 (0.42)	0.8	1.35	1.54	1.88	2.3	
		Week 2	Tezepelumab	21	20 (95.2)	1.94 (0.48)	1.3	1.57	1.80	2.41	2.7	
			Placebo	18	16 (88.9)	1.56 (0.55)	0.8	1.05	1.63	1.75	2.7	
		Week 4	Tezepelumab	21	21 (100.0)	1.92 (0.47)	1.1	1.66	1.75	2.25	2.8	
			Placebo	18	18 (100.0)	1.60 (0.50)	0.9	1.20	1.56	1.87	2.7	
		Week 8	Tezepelumab	21	21 (100.0)	1.92 (0.50)	1.2	1.57	1.85	2.38	2.8	
			Placebo	18	17 (94.4)	1.63 (0.53)	0.8	1.41	1.65	1.81	2.7	
		Week 12	Tezepelumab	21	20 (95.2)	1.91 (0.50)	1.2	1.50	1.74	2.36	3.0	
			Placebo	18	17 (94.4)	1.63 (0.49)	0.9	1.31	1.60	1.74	2.7	
		Week 16	Tezepelumab	21	21 (100.0)	1.95 (0.50)	1.3	1.56	1.83	2.34	3.0	
			Placebo	18	17 (94.4)	1.59 (0.48)	0.9	1.31	1.63	1.78	2.7	
		Week 24	Tezepelumab	21	21 (100.0)	1.90 (0.49)	1.1	1.61	1.87	2.32	2.9	
			Placebo	18	14 (77.8)	1.53 (0.49)	0.8	1.21	1.48	1.67	2.7	
		Week 36	Tezepelumab	21	21 (100.0)	1.86 (0.46)	1.1	1.48	1.77	2.20	2.8	
			Placebo	18	15 (83.3)	1.58 (0.52)	0.9	1.14	1.49	1.78	2.7	
		Week 52	Tezepelumab	21	21 (100.0)	1.87 (0.46)	1.0	1.57	1.87	2.20	2.8	
			Placebo	18	16 (88.9)	1.60 (0.57)	0.9	1.15	1.52	1.85	2.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Change from baseline	Week 2	Tezepelumab	21	20 (95.2)	0.03 (0.28)	-0.7	-0.00	0.05	0.11	0.5	0.10 [-0.55, 0.76]
			Placebo	18	16 (88.9)	0.01 (0.21)	-0.4	-0.08	-0.06	0.10	0.5	
		Week 4	Tezepelumab	21	21 (100.0)	0.03 (0.26)	-0.6	-0.13	0.00	0.17	0.6	0.02 [-0.61, 0.65]
			Placebo	18	18 (100.0)	0.02 (0.20)	-0.3	-0.04	0.02	0.10	0.4	
		Week 8	Tezepelumab	21	21 (100.0)	0.03 (0.25)	-0.5	-0.09	-0.03	0.15	0.7	0.02 [-0.61, 0.66]
			Placebo	18	17 (94.4)	0.03 (0.28)	-0.8	-0.08	0.04	0.13	0.5	
		Week 12	Tezepelumab	21	20 (95.2)	0.03 (0.25)	-0.4	-0.18	0.01	0.22	0.5	-0.09 [-0.74, 0.56]
			Placebo	18	17 (94.4)	0.05 (0.24)	-0.4	-0.04	0.06	0.22	0.4	
		Week 16	Tezepelumab	21	21 (100.0)	0.06 (0.26)	-0.6	-0.02	0.04	0.28	0.4	0.18 [-0.46, 0.82]
			Placebo	18	17 (94.4)	0.02 (0.24)	-0.6	-0.10	0.01	0.14	0.5	
		Week 24	Tezepelumab	21	21 (100.0)	0.01 (0.19)	-0.2	-0.13	0.00	0.10	0.4	0.13 [-0.55, 0.81]
			Placebo	18	14 (77.8)	-0.02 (0.24)	-0.5	-0.21	0.04	0.10	0.4	
		Week 36	Tezepelumab	21	21 (100.0)	-0.03 (0.31)	-0.5	-0.18	-0.10	0.16	0.6	-0.24 [-0.91, 0.42]
			Placebo	18	15 (83.3)	0.03 (0.22)	-0.3	-0.19	0.04	0.22	0.4	
		Week 52	Tezepelumab	21	21 (100.0)	-0.02 (0.28)	-0.7	-0.10	-0.01	0.11	0.7	-0.24 [-0.89, 0.42]
			Placebo	18	16 (88.9)	0.04 (0.24)	-0.3	-0.10	0.02	0.10	0.5	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Absolute values	Baseline	Tezepelumab	32	32 (100.0)	1.71 (0.71)	0.4	1.25	1.73	2.06	3.3	
			Placebo	21	21 (100.0)	1.78 (0.52)	0.8	1.49	1.81	2.11	2.8	
		Week 2	Tezepelumab	32	31 (96.9)	1.78 (0.68)	0.6	1.29	1.79	2.36	3.4	
			Placebo	21	17 (81.0)	1.77 (0.56)	0.8	1.41	1.74	1.97	2.8	
		Week 4	Tezepelumab	32	32 (100.0)	1.78 (0.77)	0.7	1.23	1.66	2.44	3.4	
			Placebo	21	21 (100.0)	1.77 (0.56)	0.9	1.46	1.76	1.99	3.0	
		Week 8	Tezepelumab	32	30 (93.8)	1.73 (0.65)	0.6	1.23	1.68	2.05	3.3	
			Placebo	21	21 (100.0)	1.77 (0.61)	0.8	1.41	1.79	1.98	2.8	
		Week 12	Tezepelumab	32	32 (100.0)	1.76 (0.73)	0.6	1.23	1.68	2.23	3.6	
			Placebo	21	20 (95.2)	1.78 (0.61)	0.9	1.40	1.65	2.20	3.0	
		Week 16	Tezepelumab	32	31 (96.9)	1.85 (0.77)	0.6	1.43	1.65	2.28	3.5	
			Placebo	21	20 (95.2)	1.76 (0.59)	0.9	1.37	1.71	2.00	3.0	
		Week 24	Tezepelumab	32	31 (96.9)	1.73 (0.64)	0.6	1.12	1.70	2.26	3.5	
			Placebo	21	19 (90.5)	1.78 (0.51)	0.8	1.49	1.72	2.11	2.7	
		Week 36	Tezepelumab	32	30 (93.8)	1.70 (0.66)	0.5	1.25	1.63	2.12	3.5	
			Placebo	21	18 (85.7)	1.85 (0.60)	0.9	1.45	1.79	2.36	3.0	
		Week 52	Tezepelumab	32	28 (87.5)	1.73 (0.65)	0.7	1.16	1.73	2.20	3.4	
			Placebo	21	18 (85.7)	1.78 (0.59)	0.9	1.52	1.71	2.15	2.9	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Change from baseline	Week 2	Tezepelumab	32	31 (96.9)	0.06 (0.25)	-0.6	-0.02	0.08	0.15	0.8	0.39 [-0.20, 0.99]
			Placebo	21	17 (81.0)	-0.03 (0.21)	-0.4	-0.10	-0.06	0.04	0.5	
		Week 4	Tezepelumab	32	32 (100.0)	0.08 (0.42)	-0.9	-0.11	0.04	0.28	1.7	0.24 [-0.31, 0.79]
			Placebo	21	21 (100.0)	-0.01 (0.18)	-0.3	-0.07	0.02	0.09	0.4	
		Week 8	Tezepelumab	32	30 (93.8)	0.08 (0.34)	-0.8	-0.08	0.03	0.16	1.2	0.30 [-0.26, 0.86]
			Placebo	21	21 (100.0)	-0.01 (0.27)	-0.8	-0.06	0.00	0.08	0.5	
		Week 12	Tezepelumab	32	32 (100.0)	0.06 (0.34)	-0.7	-0.10	0.02	0.19	1.4	0.23 [-0.33, 0.79]
			Placebo	21	20 (95.2)	-0.01 (0.20)	-0.4	-0.08	-0.02	0.09	0.4	
		Week 16	Tezepelumab	32	31 (96.9)	0.12 (0.40)	-0.6	-0.07	0.12	0.28	1.6	0.45 [-0.12, 1.02]
			Placebo	21	20 (95.2)	-0.03 (0.24)	-0.6	-0.10	-0.01	0.10	0.5	
		Week 24	Tezepelumab	32	31 (96.9)	0.07 (0.30)	-0.6	-0.10	0.00	0.22	1.0	0.30 [-0.27, 0.88]
			Placebo	21	19 (90.5)	-0.01 (0.19)	-0.5	-0.10	0.03	0.09	0.4	
		Week 36	Tezepelumab	32	30 (93.8)	0.03 (0.35)	-0.7	-0.12	0.01	0.21	1.1	-0.08 [-0.66, 0.50]
			Placebo	21	18 (85.7)	0.06 (0.20)	-0.3	-0.09	0.07	0.19	0.4	
		Week 52	Tezepelumab	32	28 (87.5)	0.05 (0.38)	-1.0	-0.07	0.03	0.23	1.0	0.04 [-0.55, 0.63]
			Placebo	21	18 (85.7)	0.04 (0.22)	-0.5	-0.07	0.07	0.13	0.5	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Absolute values	Baseline	Tezepelumab	22	22 (100.0)	1.89 (0.50)	1.0	1.48	1.91	2.37	2.6	
			Placebo	18	18 (100.0)	1.69 (0.55)	0.9	1.35	1.58	1.93	3.2	
		Week 2	Tezepelumab	22	21 (95.5)	1.93 (0.51)	1.0	1.58	1.94	2.18	2.9	
			Placebo	18	17 (94.4)	1.74 (0.77)	0.9	1.29	1.61	1.80	4.1	
		Week 4	Tezepelumab	22	22 (100.0)	1.92 (0.46)	1.1	1.64	1.97	2.24	2.8	
			Placebo	18	17 (94.4)	1.86 (0.91)	1.0	1.38	1.56	2.02	4.8	
		Week 8	Tezepelumab	22	22 (100.0)	1.98 (0.53)	1.2	1.58	1.91	2.43	2.8	
			Placebo	18	17 (94.4)	1.88 (0.84)	0.8	1.48	1.69	2.03	4.6	
		Week 12	Tezepelumab	22	21 (95.5)	1.95 (0.54)	1.1	1.55	1.83	2.39	3.0	
			Placebo	18	18 (100.0)	1.85 (0.83)	0.8	1.41	1.64	2.10	4.6	
		Week 16	Tezepelumab	22	22 (100.0)	1.95 (0.53)	1.1	1.49	1.88	2.39	3.0	
			Placebo	18	18 (100.0)	1.79 (0.86)	0.8	1.32	1.66	2.04	4.7	
		Week 24	Tezepelumab	22	22 (100.0)	1.94 (0.50)	1.1	1.61	1.90	2.38	2.9	
			Placebo	18	16 (88.9)	1.76 (0.96)	0.8	1.25	1.44	2.02	4.8	
		Week 36	Tezepelumab	22	22 (100.0)	1.95 (0.57)	1.1	1.51	1.84	2.50	2.9	
			Placebo	18	16 (88.9)	1.79 (0.80)	1.1	1.41	1.53	1.85	4.3	
		Week 52	Tezepelumab	22	22 (100.0)	1.91 (0.54)	1.0	1.54	1.88	2.30	2.9	
			Placebo	18	16 (88.9)	1.76 (0.78)	1.1	1.15	1.64	2.01	4.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Change from baseline	Week 2	Tezepelumab	22	21 (95.5)	0.02 (0.24)	-0.7	-0.01	0.01	0.09	0.5	-0.15 [-0.79, 0.49]
			Placebo	18	17 (94.4)	0.06 (0.28)	-0.3	-0.07	0.01	0.10	0.9	
		Week 4	Tezepelumab	22	22 (100.0)	0.03 (0.22)	-0.5	-0.08	0.03	0.15	0.6	-0.48 [-1.12, 0.16]
			Placebo	18	17 (94.4)	0.18 (0.41)	-0.3	0.01	0.10	0.28	1.6	
		Week 8	Tezepelumab	22	22 (100.0)	0.09 (0.23)	-0.5	-0.05	0.05	0.21	0.7	-0.24 [-0.87, 0.40]
			Placebo	18	17 (94.4)	0.16 (0.37)	-0.2	-0.07	0.11	0.20	1.4	
		Week 12	Tezepelumab	22	21 (95.5)	0.07 (0.23)	-0.3	-0.06	0.05	0.14	0.7	-0.31 [-0.95, 0.32]
			Placebo	18	18 (100.0)	0.16 (0.35)	-0.3	-0.03	0.06	0.26	1.4	
		Week 16	Tezepelumab	22	22 (100.0)	0.06 (0.20)	-0.5	-0.05	0.07	0.19	0.4	-0.14 [-0.77, 0.48]
			Placebo	18	18 (100.0)	0.10 (0.40)	-0.6	-0.06	0.02	0.19	1.4	
		Week 24	Tezepelumab	22	22 (100.0)	0.05 (0.24)	-0.3	-0.12	-0.01	0.23	0.6	-0.03 [-0.67, 0.62]
			Placebo	18	16 (88.9)	0.06 (0.48)	-0.5	-0.26	0.04	0.10	1.6	
		Week 36	Tezepelumab	22	22 (100.0)	0.06 (0.32)	-0.8	-0.15	0.04	0.16	0.8	-0.22 [-0.87, 0.42]
			Placebo	18	16 (88.9)	0.13 (0.34)	-0.3	-0.10	0.05	0.31	1.1	
		Week 52	Tezepelumab	22	22 (100.0)	0.02 (0.31)	-0.8	-0.07	0.00	0.16	0.7	-0.16 [-0.81, 0.48]
			Placebo	18	16 (88.9)	0.07 (0.31)	-0.4	-0.16	0.04	0.20	0.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	32	32 (100.0)	1.66 (0.61)	0.4	1.25	1.71	2.17	2.6	
			Placebo	24	24 (100.0)	1.68 (0.47)	0.8	1.42	1.62	1.91	2.8	
		Week 2	Tezepelumab	32	31 (96.9)	1.77 (0.60)	0.6	1.29	1.80	2.29	2.7	
			Placebo	24	21 (87.5)	1.63 (0.55)	0.8	1.35	1.61	1.85	2.8	
		Week 4	Tezepelumab	32	32 (100.0)	1.77 (0.67)	0.7	1.23	1.67	2.33	3.4	
			Placebo	24	23 (95.8)	1.74 (0.55)	0.9	1.32	1.73	2.02	3.0	
		Week 8	Tezepelumab	32	32 (100.0)	1.78 (0.63)	0.6	1.26	1.77	2.37	2.9	
			Placebo	24	23 (95.8)	1.77 (0.53)	0.8	1.41	1.76	1.98	2.8	
		Week 12	Tezepelumab	32	31 (96.9)	1.74 (0.66)	0.6	1.22	1.70	2.32	3.1	
			Placebo	24	24 (100.0)	1.74 (0.55)	0.8	1.39	1.65	2.19	3.0	
		Week 16	Tezepelumab	32	31 (96.9)	1.81 (0.73)	0.6	1.29	1.70	2.41	3.3	
			Placebo	24	24 (100.0)	1.69 (0.52)	0.8	1.33	1.67	1.84	3.0	
		Week 24	Tezepelumab	32	32 (100.0)	1.75 (0.58)	0.6	1.18	1.71	2.28	2.9	
			Placebo	24	21 (87.5)	1.67 (0.52)	0.8	1.40	1.63	2.11	2.7	
		Week 36	Tezepelumab	32	31 (96.9)	1.74 (0.64)	0.5	1.23	1.65	2.30	2.8	
			Placebo	24	21 (87.5)	1.73 (0.49)	0.9	1.45	1.69	1.88	3.0	
		Week 52	Tezepelumab	32	30 (93.8)	1.74 (0.64)	0.7	1.17	1.73	2.20	2.9	
			Placebo	24	21 (87.5)	1.66 (0.53)	0.9	1.24	1.62	1.81	2.9	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Change from baseline	Week 2	Tezepelumab	32	31 (96.9)	0.09 (0.20)	-0.3	0.01	0.07	0.12	0.8	0.38 [-0.18, 0.94]
			Placebo	24	21 (87.5)	0.01 (0.22)	-0.4	-0.06	0.01	0.10	0.5	
		Week 4	Tezepelumab	32	32 (100.0)	0.10 (0.38)	-0.5	-0.08	0.05	0.22	1.7	0.10 [-0.44, 0.63]
			Placebo	24	23 (95.8)	0.07 (0.19)	-0.3	-0.03	0.09	0.15	0.5	
		Week 8	Tezepelumab	32	32 (100.0)	0.12 (0.26)	-0.2	-0.07	0.05	0.23	1.2	0.23 [-0.31, 0.77]
			Placebo	24	23 (95.8)	0.06 (0.23)	-0.5	-0.08	0.04	0.19	0.5	
		Week 12	Tezepelumab	32	31 (96.9)	0.09 (0.33)	-0.3	-0.09	0.02	0.19	1.4	0.10 [-0.43, 0.64]
			Placebo	24	24 (100.0)	0.06 (0.18)	-0.3	-0.04	0.02	0.16	0.4	
		Week 16	Tezepelumab	32	31 (96.9)	0.14 (0.36)	-0.6	-0.04	0.12	0.28	1.6	0.41 [-0.13, 0.94]
			Placebo	24	24 (100.0)	0.01 (0.25)	-0.6	-0.12	0.02	0.18	0.5	
		Week 24	Tezepelumab	32	32 (100.0)	0.09 (0.29)	-0.3	-0.12	0.00	0.21	1.0	0.36 [-0.20, 0.91]
			Placebo	24	21 (87.5)	-0.01 (0.22)	-0.5	-0.05	0.03	0.07	0.4	
		Week 36	Tezepelumab	32	31 (96.9)	0.06 (0.31)	-0.5	-0.13	0.03	0.20	1.1	-0.10 [-0.65, 0.45]
			Placebo	24	21 (87.5)	0.09 (0.19)	-0.3	-0.07	0.08	0.22	0.4	
		Week 52	Tezepelumab	32	30 (93.8)	0.08 (0.32)	-0.4	-0.09	0.01	0.16	1.0	0.23 [-0.33, 0.79]
			Placebo	24	21 (87.5)	0.01 (0.25)	-0.5	-0.20	0.08	0.15	0.5	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	22	22 (100.0)	1.95 (0.64)	0.9	1.48	1.93	2.37	3.3	
			Placebo	14	14 (100.0)	1.87 (0.63)	0.9	1.59	1.82	2.17	3.2	
		Week 2	Tezepelumab	22	21 (95.5)	1.95 (0.63)	0.9	1.55	1.86	2.36	3.4	
			Placebo	14	12 (85.7)	2.00 (0.82)	1.0	1.67	1.85	2.27	4.1	
		Week 4	Tezepelumab	22	22 (100.0)	1.94 (0.65)	0.7	1.64	1.96	2.24	3.3	
			Placebo	14	14 (100.0)	1.95 (0.98)	1.0	1.55	1.70	2.20	4.8	
		Week 8	Tezepelumab	22	20 (90.9)	1.92 (0.58)	0.9	1.58	1.78	2.27	3.3	
			Placebo	14	14 (100.0)	1.92 (0.98)	0.8	1.22	1.77	2.23	4.6	
		Week 12	Tezepelumab	22	22 (100.0)	1.98 (0.66)	0.8	1.62	1.95	2.21	3.6	
			Placebo	14	13 (92.9)	1.96 (0.98)	0.9	1.43	1.66	2.14	4.6	
		Week 16	Tezepelumab	22	22 (100.0)	2.00 (0.58)	0.9	1.56	1.88	2.27	3.5	
			Placebo	14	13 (92.9)	1.98 (0.99)	0.9	1.41	1.71	2.10	4.7	
		Week 24	Tezepelumab	22	21 (95.5)	1.91 (0.62)	0.8	1.61	1.89	2.27	3.5	
			Placebo	14	13 (92.9)	1.95 (1.01)	1.0	1.29	1.72	2.07	4.8	
		Week 36	Tezepelumab	22	21 (95.5)	1.91 (0.61)	0.9	1.51	1.85	2.20	3.5	
			Placebo	14	12 (85.7)	2.01 (0.96)	1.0	1.32	1.76	2.55	4.3	
		Week 52	Tezepelumab	22	20 (90.9)	1.91 (0.55)	0.9	1.58	1.80	2.28	3.4	
			Placebo	14	12 (85.7)	2.00 (0.88)	1.0	1.37	1.84	2.50	4.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Change from baseline	Week 2	Tezepelumab	22	21 (95.5)	-0.02 (0.30)	-0.7	-0.10	0.01	0.20	0.5	-0.15 [-0.86, 0.56]
			Placebo	14	12 (85.7)	0.03 (0.30)	-0.3	-0.09	-0.07	0.06	0.9	
		Week 4	Tezepelumab	22	22 (100.0)	-0.01 (0.30)	-0.9	-0.18	0.04	0.17	0.5	-0.25 [-0.93, 0.42]
			Placebo	14	14 (100.0)	0.09 (0.47)	-0.3	-0.14	-0.02	0.07	1.6	
		Week 8	Tezepelumab	22	20 (90.9)	0.03 (0.35)	-0.8	-0.13	0.05	0.17	0.7	-0.05 [-0.74, 0.63]
			Placebo	14	14 (100.0)	0.06 (0.45)	-0.8	-0.07	-0.01	0.08	1.4	
		Week 12	Tezepelumab	22	22 (100.0)	0.02 (0.25)	-0.7	-0.03	0.07	0.15	0.4	-0.15 [-0.84, 0.53]
			Placebo	14	13 (92.9)	0.08 (0.45)	-0.4	-0.09	-0.03	0.20	1.4	
		Week 16	Tezepelumab	22	22 (100.0)	0.04 (0.28)	-0.6	-0.09	0.09	0.19	0.7	-0.13 [-0.82, 0.56]
			Placebo	14	13 (92.9)	0.09 (0.46)	-0.6	-0.07	0.00	0.10	1.4	
		Week 24	Tezepelumab	22	21 (95.5)	0.02 (0.24)	-0.6	-0.10	0.00	0.23	0.4	-0.11 [-0.81, 0.58]
			Placebo	14	13 (92.9)	0.06 (0.51)	-0.5	-0.21	0.03	0.10	1.6	
		Week 36	Tezepelumab	22	21 (95.5)	0.02 (0.37)	-0.8	-0.12	0.04	0.22	0.8	-0.22 [-0.93, 0.49]
			Placebo	14	12 (85.7)	0.11 (0.39)	-0.3	-0.20	-0.04	0.30	1.1	
		Week 52	Tezepelumab	22	20 (90.9)	-0.03 (0.38)	-1.0	-0.05	0.01	0.23	0.4	-0.46 [-1.18, 0.27]
			Placebo	14	12 (85.7)	0.13 (0.28)	-0.2	-0.05	0.02	0.27	0.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Absolute values	Baseline	Tezepelumab	49	49 (100.0)	1.74 (0.64)	0.4	1.28	1.70	2.13	3.3	
			Placebo	37	37 (100.0)	1.72 (0.47)	0.8	1.44	1.70	2.04	2.8	
		Week 2	Tezepelumab	49	47 (95.9)	1.78 (0.61)	0.6	1.32	1.72	2.18	3.4	
			Placebo	37	32 (86.5)	1.70 (0.52)	0.8	1.37	1.71	1.95	2.8	
		Week 4	Tezepelumab	49	49 (100.0)	1.79 (0.67)	0.7	1.42	1.67	2.13	3.4	
			Placebo	37	36 (97.3)	1.75 (0.53)	0.9	1.41	1.71	2.01	3.0	
		Week 8	Tezepelumab	49	47 (95.9)	1.77 (0.60)	0.6	1.30	1.68	2.11	3.3	
			Placebo	37	36 (97.3)	1.77 (0.53)	0.8	1.45	1.75	2.01	2.8	
		Week 12	Tezepelumab	49	48 (98.0)	1.79 (0.67)	0.6	1.35	1.68	2.26	3.6	
			Placebo	37	36 (97.3)	1.76 (0.54)	0.8	1.42	1.64	2.14	3.0	
		Week 16	Tezepelumab	49	48 (98.0)	1.84 (0.69)	0.6	1.41	1.67	2.27	3.5	
			Placebo	37	36 (97.3)	1.72 (0.53)	0.8	1.33	1.69	1.97	3.0	
		Week 24	Tezepelumab	49	48 (98.0)	1.77 (0.59)	0.6	1.29	1.71	2.19	3.5	
			Placebo	37	33 (89.2)	1.70 (0.52)	0.8	1.40	1.63	2.07	2.7	
		Week 36	Tezepelumab	49	47 (95.9)	1.75 (0.62)	0.5	1.25	1.65	2.20	3.5	
			Placebo	37	32 (86.5)	1.77 (0.53)	0.9	1.44	1.70	1.93	3.0	
		Week 52	Tezepelumab	49	45 (91.8)	1.76 (0.62)	0.7	1.37	1.71	2.19	3.4	
			Placebo	37	32 (86.5)	1.73 (0.55)	0.9	1.29	1.67	2.06	2.9	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Change from baseline	Week 2	Tezepelumab	49	47 (95.9)	0.03 (0.24)	-0.7	-0.02	0.05	0.15	0.8	0.20 [-0.25, 0.65]
			Placebo	37	32 (86.5)	-0.01 (0.20)	-0.4	-0.09	-0.01	0.07	0.5	
		Week 4	Tezepelumab	49	49 (100.0)	0.05 (0.37)	-0.9	-0.13	0.01	0.17	1.7	0.05 [-0.38, 0.48]
			Placebo	37	36 (97.3)	0.04 (0.20)	-0.3	-0.06	0.04	0.12	0.5	
		Week 8	Tezepelumab	49	47 (95.9)	0.07 (0.29)	-0.8	-0.08	0.04	0.19	1.2	0.12 [-0.31, 0.55]
			Placebo	37	36 (97.3)	0.04 (0.24)	-0.8	-0.07	0.04	0.16	0.5	
		Week 12	Tezepelumab	49	48 (98.0)	0.06 (0.31)	-0.7	-0.09	0.04	0.16	1.4	0.07 [-0.36, 0.50]
			Placebo	37	36 (97.3)	0.04 (0.20)	-0.4	-0.06	0.01	0.20	0.4	
		Week 16	Tezepelumab	49	48 (98.0)	0.10 (0.34)	-0.6	-0.08	0.10	0.24	1.6	0.33 [-0.11, 0.76]
			Placebo	37	36 (97.3)	-0.00 (0.24)	-0.6	-0.10	0.01	0.16	0.5	
		Week 24	Tezepelumab	49	48 (98.0)	0.06 (0.28)	-0.6	-0.11	0.00	0.21	1.0	0.33 [-0.12, 0.77]
			Placebo	37	33 (89.2)	-0.02 (0.23)	-0.5	-0.11	0.03	0.09	0.4	
		Week 36	Tezepelumab	49	47 (95.9)	0.04 (0.31)	-0.7	-0.13	0.03	0.20	1.1	-0.11 [-0.56, 0.34]
			Placebo	37	32 (86.5)	0.06 (0.21)	-0.3	-0.10	0.06	0.26	0.4	
		Week 52	Tezepelumab	49	45 (91.8)	0.04 (0.34)	-1.0	-0.07	0.01	0.16	1.0	0.03 [-0.43, 0.48]
			Placebo	37	32 (86.5)	0.03 (0.24)	-0.5	-0.09	0.05	0.15	0.5	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Absolute values	Baseline	Tezepelumab	5	5 (100.0)	2.23 (0.26)	2.0	2.02	2.12	2.39	2.6	
			Placebo	2	2 (100.0)	2.14 (1.55)	1.0	1.04	2.14	3.23	3.2	
		Week 2	Tezepelumab	5	5 (100.0)	2.38 (0.39)	1.9	2.13	2.38	2.54	2.9	
			Placebo	2	2 (100.0)	2.53 (2.21)	1.0	0.97	2.53	4.09	4.1	
		Week 4	Tezepelumab	5	5 (100.0)	2.32 (0.25)	2.1	2.17	2.24	2.45	2.7	
			Placebo	2	2 (100.0)	2.92 (2.71)	1.0	1.00	2.92	4.83	4.8	
		Week 8	Tezepelumab	5	5 (100.0)	2.47 (0.35)	1.9	2.43	2.59	2.68	2.8	
			Placebo	2	2 (100.0)	2.70 (2.70)	0.8	0.79	2.70	4.61	4.6	
		Week 12	Tezepelumab	5	5 (100.0)	2.34 (0.23)	2.2	2.20	2.21	2.39	2.7	
			Placebo	2	2 (100.0)	2.78 (2.55)	1.0	0.98	2.78	4.58	4.6	
		Week 16	Tezepelumab	5	5 (100.0)	2.35 (0.14)	2.2	2.27	2.31	2.39	2.6	
			Placebo	2	2 (100.0)	2.82 (2.62)	1.0	0.97	2.82	4.67	4.7	
		Week 24	Tezepelumab	5	5 (100.0)	2.31 (0.26)	1.9	2.27	2.29	2.55	2.6	
			Placebo	2	2 (100.0)	2.94 (2.64)	1.1	1.07	2.94	4.81	4.8	
		Week 36	Tezepelumab	5	5 (100.0)	2.36 (0.43)	1.9	1.97	2.50	2.59	2.9	
			Placebo	2	2 (100.0)	2.67 (2.35)	1.0	1.00	2.67	4.33	4.3	
		Week 52	Tezepelumab	5	5 (100.0)	2.22 (0.26)	1.8	2.20	2.26	2.39	2.5	
			Placebo	2	2 (100.0)	2.49 (2.16)	1.0	0.96	2.49	4.01	4.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Change from baseline	Week 2	Tezepelumab	5	5 (100.0)	0.15 (0.26)	-0.1	-0.01	0.01	0.31	0.5	-0.66 [-2.35, 1.03]
			Placebo	2	2 (100.0)	0.40 (0.66)	-0.1	-0.07	0.40	0.86	0.9	
		Week 4	Tezepelumab	5	5 (100.0)	0.09 (0.07)	0.0	0.05	0.06	0.07	0.2	-1.32 [-3.15, 0.51]
			Placebo	2	2 (100.0)	0.78 (1.16)	-0.0	-0.04	0.78	1.60	1.6	
		Week 8	Tezepelumab	5	5 (100.0)	0.23 (0.33)	-0.1	0.04	0.13	0.47	0.7	-0.56 [-2.24, 1.11]
			Placebo	2	2 (100.0)	0.57 (1.15)	-0.3	-0.25	0.57	1.38	1.4	
		Week 12	Tezepelumab	5	5 (100.0)	0.11 (0.21)	-0.2	0.08	0.10	0.19	0.4	-1.11 [-2.89, 0.67]
			Placebo	2	2 (100.0)	0.65 (1.00)	-0.1	-0.06	0.65	1.35	1.4	
		Week 16	Tezepelumab	5	5 (100.0)	0.11 (0.14)	-0.1	0.00	0.15	0.17	0.3	-1.16 [-2.95, 0.63]
			Placebo	2	2 (100.0)	0.69 (1.07)	-0.1	-0.07	0.69	1.44	1.4	
		Week 24	Tezepelumab	5	5 (100.0)	0.08 (0.25)	-0.1	-0.11	-0.07	0.27	0.4	-1.34 [-3.18, 0.50]
			Placebo	2	2 (100.0)	0.81 (1.10)	0.0	0.03	0.81	1.58	1.6	
		Week 36	Tezepelumab	5	5 (100.0)	0.12 (0.60)	-0.8	-0.05	0.11	0.57	0.8	-0.63 [-2.32, 1.05]
			Placebo	2	2 (100.0)	0.53 (0.81)	-0.0	-0.04	0.53	1.10	1.1	
		Week 52	Tezepelumab	5	5 (100.0)	-0.01 (0.47)	-0.8	0.00	0.18	0.24	0.4	-0.72 [-2.42, 0.98]
			Placebo	2	2 (100.0)	0.35 (0.61)	-0.1	-0.08	0.35	0.78	0.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Absolute values	Baseline	Tezepelumab	8	8 (100.0)	1.67 (0.69)	0.4	1.22	1.88	2.08	2.6	
			Placebo	7	7 (100.0)	1.72 (0.45)	0.9	1.54	1.70	2.11	2.2	
		Week 2	Tezepelumab	8	8 (100.0)	1.75 (0.68)	0.6	1.35	1.83	2.05	2.9	
			Placebo	7	5 (71.4)	1.91 (0.22)	1.7	1.74	1.85	1.97	2.3	
		Week 4	Tezepelumab	8	8 (100.0)	1.86 (0.65)	0.7	1.52	1.86	2.37	2.7	
			Placebo	7	7 (100.0)	1.70 (0.41)	1.1	1.56	1.69	1.79	2.5	
		Week 8	Tezepelumab	8	7 (87.5)	1.70 (0.73)	0.6	1.21	1.79	2.38	2.8	
			Placebo	7	7 (100.0)	1.81 (0.55)	0.8	1.59	1.74	2.35	2.5	
		Week 12	Tezepelumab	8	7 (87.5)	1.76 (0.68)	0.6	1.21	1.75	2.21	2.7	
			Placebo	7	6 (85.7)	1.73 (0.56)	0.9	1.48	1.63	2.13	2.6	
		Week 16	Tezepelumab	8	8 (100.0)	1.76 (0.71)	0.6	1.12	2.01	2.30	2.6	
			Placebo	7	6 (85.7)	1.60 (0.42)	0.9	1.41	1.68	1.76	2.2	
		Week 24	Tezepelumab	8	8 (100.0)	1.81 (0.51)	1.1	1.40	1.78	2.21	2.6	
			Placebo	7	6 (85.7)	1.63 (0.45)	1.0	1.29	1.60	2.07	2.2	
		Week 36	Tezepelumab	8	8 (100.0)	1.68 (0.51)	0.9	1.26	1.78	2.09	2.3	
			Placebo	7	5 (71.4)	1.61 (0.30)	1.2	1.46	1.69	1.81	1.9	
		Week 52	Tezepelumab	8	8 (100.0)	1.72 (0.55)	0.8	1.36	1.77	2.18	2.4	
			Placebo	7	6 (85.7)	1.72 (0.43)	1.0	1.62	1.72	1.97	2.3	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	8	8 (100.0)	0.07 (0.15)	-0.1	-0.04	0.03	0.21	0.3	0.49 [-0.64, 1.63]
			Placebo	7	5 (71.4)	-0.00 (0.17)	-0.3	-0.07	0.04	0.10	0.2	
		Week 4	Tezepelumab	8	8 (100.0)	0.18 (0.27)	-0.2	0.03	0.09	0.40	0.6	0.77 [-0.29, 1.83]
			Placebo	7	7 (100.0)	-0.01 (0.24)	-0.3	-0.28	-0.02	0.20	0.3	
		Week 8	Tezepelumab	8	7 (87.5)	0.07 (0.19)	-0.2	-0.14	0.13	0.25	0.3	-0.09 [-1.14, 0.96]
			Placebo	7	7 (100.0)	0.09 (0.18)	-0.1	-0.06	0.00	0.20	0.4	
		Week 12	Tezepelumab	8	7 (87.5)	0.15 (0.29)	-0.2	-0.09	0.10	0.21	0.7	0.57 [-0.55, 1.69]
			Placebo	7	6 (85.7)	-0.01 (0.27)	-0.4	-0.06	-0.01	0.04	0.4	
		Week 16	Tezepelumab	8	8 (100.0)	0.08 (0.17)	-0.2	-0.02	0.11	0.21	0.3	0.88 [-0.23, 2.00]
			Placebo	7	6 (85.7)	-0.14 (0.33)	-0.6	-0.45	0.01	0.02	0.2	
		Week 24	Tezepelumab	8	8 (100.0)	0.13 (0.36)	-0.2	-0.13	-0.04	0.46	0.7	0.74 [-0.36, 1.84]
			Placebo	7	6 (85.7)	-0.11 (0.26)	-0.5	-0.41	-0.01	0.09	0.1	
		Week 36	Tezepelumab	8	8 (100.0)	0.01 (0.38)	-0.8	-0.13	0.01	0.30	0.4	0.14 [-0.98, 1.26]
			Placebo	7	5 (71.4)	-0.04 (0.25)	-0.2	-0.23	-0.19	0.15	0.3	
		Week 52	Tezepelumab	8	8 (100.0)	0.05 (0.44)	-0.8	-0.15	0.11	0.38	0.5	0.16 [-0.90, 1.23]
			Placebo	7	6 (85.7)	-0.02 (0.25)	-0.5	-0.07	0.07	0.15	0.2	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Absolute values	Baseline	Tezepelumab	46	46 (100.0)	1.80 (0.63)	0.6	1.28	1.73	2.20	3.3	
			Placebo	32	32 (100.0)	1.74 (0.55)	0.8	1.38	1.73	2.02	3.2	
		Week 2	Tezepelumab	46	44 (95.7)	1.86 (0.61)	0.7	1.45	1.80	2.37	3.4	
			Placebo	32	29 (90.6)	1.72 (0.71)	0.8	1.29	1.61	1.93	4.1	
		Week 4	Tezepelumab	46	46 (100.0)	1.84 (0.67)	0.7	1.44	1.74	2.24	3.4	
			Placebo	32	31 (96.9)	1.84 (0.78)	0.9	1.32	1.73	2.20	4.8	
		Week 8	Tezepelumab	46	45 (97.8)	1.86 (0.60)	0.7	1.57	1.75	2.35	3.3	
			Placebo	32	31 (96.9)	1.82 (0.75)	0.8	1.40	1.76	2.03	4.6	
		Week 12	Tezepelumab	46	46 (100.0)	1.85 (0.67)	0.7	1.44	1.75	2.32	3.6	
			Placebo	32	32 (100.0)	1.83 (0.74)	0.8	1.39	1.66	2.20	4.6	
		Week 16	Tezepelumab	46	45 (97.8)	1.91 (0.67)	0.6	1.49	1.70	2.31	3.5	
			Placebo	32	32 (100.0)	1.81 (0.76)	0.8	1.33	1.70	2.07	4.7	
		Week 24	Tezepelumab	46	45 (97.8)	1.82 (0.61)	0.6	1.52	1.79	2.27	3.5	
			Placebo	32	29 (90.6)	1.80 (0.79)	0.8	1.40	1.67	2.11	4.8	
		Week 36	Tezepelumab	46	44 (95.7)	1.83 (0.65)	0.5	1.38	1.80	2.32	3.5	
			Placebo	32	29 (90.6)	1.85 (0.73)	0.9	1.43	1.70	2.26	4.3	
		Week 52	Tezepelumab	46	42 (91.3)	1.83 (0.62)	0.7	1.43	1.78	2.21	3.4	
			Placebo	32	28 (87.5)	1.78 (0.73)	0.9	1.20	1.64	2.19	4.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Change from baseline	Week 2	Tezepelumab	46	44 (95.7)	0.04 (0.26)	-0.7	-0.02	0.05	0.14	0.8	0.09 [-0.38, 0.56]
			Placebo	32	29 (90.6)	0.02 (0.26)	-0.4	-0.09	-0.01	0.06	0.9	
		Week 4	Tezepelumab	46	46 (100.0)	0.04 (0.36)	-0.9	-0.13	0.02	0.17	1.7	-0.18 [-0.64, 0.27]
			Placebo	32	31 (96.9)	0.10 (0.33)	-0.3	-0.04	0.05	0.11	1.6	
		Week 8	Tezepelumab	46	45 (97.8)	0.09 (0.31)	-0.8	-0.07	0.04	0.18	1.2	0.08 [-0.37, 0.54]
			Placebo	32	31 (96.9)	0.06 (0.35)	-0.8	-0.08	0.04	0.13	1.4	
		Week 12	Tezepelumab	46	46 (100.0)	0.05 (0.30)	-0.7	-0.09	0.04	0.15	1.4	-0.13 [-0.58, 0.33]
			Placebo	32	32 (100.0)	0.09 (0.30)	-0.4	-0.06	0.01	0.21	1.4	
		Week 16	Tezepelumab	46	45 (97.8)	0.10 (0.35)	-0.6	-0.07	0.10	0.25	1.6	0.11 [-0.35, 0.56]
			Placebo	32	32 (100.0)	0.06 (0.33)	-0.6	-0.08	0.01	0.18	1.4	
		Week 24	Tezepelumab	46	45 (97.8)	0.05 (0.26)	-0.6	-0.11	0.00	0.21	1.0	0.00 [-0.47, 0.47]
			Placebo	32	29 (90.6)	0.05 (0.36)	-0.5	-0.10	0.03	0.10	1.6	
		Week 36	Tezepelumab	46	44 (95.7)	0.05 (0.33)	-0.7	-0.12	0.04	0.20	1.1	-0.21 [-0.68, 0.26]
			Placebo	32	29 (90.6)	0.12 (0.27)	-0.3	-0.07	0.07	0.29	1.1	
		Week 52	Tezepelumab	46	42 (91.3)	0.04 (0.34)	-1.0	-0.07	0.01	0.16	1.0	-0.10 [-0.58, 0.37]
			Placebo	32	28 (87.5)	0.07 (0.27)	-0.4	-0.10	0.05	0.16	0.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	15	15 (100.0)	1.80 (0.61)	0.6	1.41	1.96	2.20	2.6	
			Placebo	15	15 (100.0)	1.83 (0.41)	0.9	1.59	1.85	2.16	2.6	
		Week 2	Tezepelumab	15	15 (100.0)	1.85 (0.61)	0.7	1.29	1.86	2.38	2.7	
			Placebo	15	14 (93.3)	1.88 (0.47)	0.9	1.61	1.91	2.26	2.7	
		Week 4	Tezepelumab	15	15 (100.0)	1.88 (0.67)	0.7	1.42	2.07	2.48	2.8	
			Placebo	15	15 (100.0)	1.93 (0.46)	1.0	1.57	1.85	2.35	2.7	
		Week 8	Tezepelumab	15	14 (93.3)	1.92 (0.63)	0.7	1.57	1.84	2.43	2.8	
			Placebo	15	15 (100.0)	1.88 (0.53)	0.8	1.65	1.82	2.30	2.7	
		Week 12	Tezepelumab	15	14 (93.3)	1.86 (0.65)	0.7	1.45	1.91	2.32	3.0	
			Placebo	15	14 (93.3)	1.89 (0.53)	0.8	1.60	1.77	2.25	2.8	
		Week 16	Tezepelumab	15	15 (100.0)	1.92 (0.65)	0.6	1.55	2.18	2.39	3.0	
			Placebo	15	14 (93.3)	1.87 (0.53)	0.9	1.63	1.81	2.18	2.9	
		Week 24	Tezepelumab	15	15 (100.0)	1.84 (0.62)	0.6	1.61	1.89	2.29	2.9	
			Placebo	15	13 (86.7)	1.88 (0.47)	0.8	1.62	2.02	2.19	2.7	
		Week 36	Tezepelumab	15	15 (100.0)	1.81 (0.64)	0.5	1.28	1.97	2.32	2.8	
			Placebo	15	13 (86.7)	1.90 (0.49)	1.2	1.58	1.80	2.26	2.9	
		Week 52	Tezepelumab	15	14 (93.3)	1.90 (0.55)	0.9	1.54	2.15	2.26	2.8	
			Placebo	15	14 (93.3)	1.92 (0.52)	1.1	1.59	1.90	2.29	2.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	15	15 (100.0)	0.04 (0.23)	-0.6	-0.01	0.05	0.12	0.5	0.05 [-0.68, 0.77]
			Placebo	15	14 (93.3)	0.03 (0.22)	-0.3	-0.09	-0.01	0.10	0.5	
		Week 4	Tezepelumab	15	15 (100.0)	0.08 (0.29)	-0.6	-0.06	0.08	0.22	0.6	-0.08 [-0.80, 0.63]
			Placebo	15	15 (100.0)	0.10 (0.21)	-0.3	0.03	0.09	0.28	0.5	
		Week 8	Tezepelumab	15	14 (93.3)	0.12 (0.29)	-0.3	-0.09	0.11	0.25	0.7	0.25 [-0.48, 0.98]
			Placebo	15	15 (100.0)	0.05 (0.30)	-0.8	-0.08	0.06	0.20	0.5	
		Week 12	Tezepelumab	15	14 (93.3)	0.07 (0.30)	-0.4	-0.18	0.11	0.19	0.7	0.12 [-0.62, 0.86]
			Placebo	15	14 (93.3)	0.04 (0.26)	-0.4	-0.07	0.00	0.26	0.4	
		Week 16	Tezepelumab	15	15 (100.0)	0.11 (0.26)	-0.3	-0.07	0.08	0.29	0.7	0.34 [-0.40, 1.07]
			Placebo	15	14 (93.3)	0.02 (0.27)	-0.6	-0.10	0.01	0.18	0.5	
		Week 24	Tezepelumab	15	15 (100.0)	0.03 (0.23)	-0.2	-0.12	-0.03	0.15	0.6	0.13 [-0.61, 0.87]
			Placebo	15	13 (86.7)	0.00 (0.25)	-0.5	-0.10	0.03	0.10	0.4	
		Week 36	Tezepelumab	15	15 (100.0)	0.01 (0.30)	-0.5	-0.18	0.04	0.22	0.6	-0.25 [-1.00, 0.49]
			Placebo	15	13 (86.7)	0.08 (0.23)	-0.3	-0.11	0.07	0.30	0.4	
		Week 52	Tezepelumab	15	14 (93.3)	0.04 (0.32)	-0.7	-0.05	0.07	0.24	0.5	-0.12 [-0.87, 0.62]
			Placebo	15	14 (93.3)	0.07 (0.25)	-0.3	-0.07	0.05	0.17	0.5	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Absolute values	Baseline	Tezepelumab	39	39 (100.0)	1.77 (0.65)	0.4	1.28	1.70	2.20	3.3	
			Placebo	24	24 (100.0)	1.68 (0.60)	0.8	1.35	1.52	1.99	3.2	
		Week 2	Tezepelumab	39	37 (94.9)	1.84 (0.62)	0.6	1.48	1.79	2.17	3.4	
			Placebo	24	20 (83.3)	1.66 (0.77)	0.8	1.12	1.53	1.77	4.1	
		Week 4	Tezepelumab	39	39 (100.0)	1.82 (0.67)	0.7	1.44	1.73	2.13	3.4	
			Placebo	24	23 (95.8)	1.73 (0.86)	0.9	1.20	1.56	1.87	4.8	
		Week 8	Tezepelumab	39	38 (97.4)	1.81 (0.61)	0.6	1.43	1.72	2.11	3.3	
			Placebo	24	23 (95.8)	1.78 (0.82)	0.8	1.37	1.69	1.98	4.6	
		Week 12	Tezepelumab	39	39 (100.0)	1.83 (0.68)	0.6	1.38	1.73	2.28	3.6	
			Placebo	24	24 (100.0)	1.77 (0.81)	0.9	1.31	1.51	2.12	4.6	
		Week 16	Tezepelumab	39	38 (97.4)	1.88 (0.69)	0.6	1.43	1.69	2.27	3.5	
			Placebo	24	24 (100.0)	1.72 (0.81)	0.8	1.32	1.65	1.78	4.7	
		Week 24	Tezepelumab	39	38 (97.4)	1.81 (0.59)	0.8	1.40	1.74	2.26	3.5	
			Placebo	24	22 (91.7)	1.70 (0.86)	0.8	1.21	1.46	1.85	4.8	
		Week 36	Tezepelumab	39	37 (94.9)	1.81 (0.63)	0.8	1.43	1.77	2.20	3.5	
			Placebo	24	21 (87.5)	1.77 (0.79)	0.9	1.38	1.57	1.92	4.3	
		Week 52	Tezepelumab	39	36 (92.3)	1.77 (0.63)	0.7	1.40	1.73	2.16	3.4	
			Placebo	24	20 (83.3)	1.67 (0.76)	0.9	1.13	1.60	1.69	4.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Change from baseline	Week 2	Tezepelumab	39	37 (94.9)	0.05 (0.25)	-0.7	-0.02	0.05	0.15	0.8	0.18 [-0.37, 0.72]
			Placebo	24	20 (83.3)	-0.00 (0.27)	-0.4	-0.09	-0.01	0.04	0.9	
		Week 4	Tezepelumab	39	39 (100.0)	0.05 (0.38)	-0.9	-0.13	0.01	0.17	1.7	-0.04 [-0.55, 0.48]
			Placebo	24	23 (95.8)	0.06 (0.38)	-0.3	-0.13	0.01	0.11	1.6	
		Week 8	Tezepelumab	39	38 (97.4)	0.07 (0.30)	-0.8	-0.07	0.03	0.18	1.2	-0.01 [-0.53, 0.51]
			Placebo	24	23 (95.8)	0.07 (0.34)	-0.5	-0.07	0.04	0.13	1.4	
		Week 12	Tezepelumab	39	39 (100.0)	0.06 (0.30)	-0.7	-0.06	0.04	0.17	1.4	-0.10 [-0.61, 0.41]
			Placebo	24	24 (100.0)	0.09 (0.31)	-0.3	-0.05	0.02	0.16	1.4	
		Week 16	Tezepelumab	39	38 (97.4)	0.09 (0.36)	-0.6	-0.05	0.11	0.19	1.6	0.15 [-0.36, 0.66]
			Placebo	24	24 (100.0)	0.04 (0.37)	-0.6	-0.08	0.01	0.16	1.4	
		Week 24	Tezepelumab	39	38 (97.4)	0.08 (0.29)	-0.6	-0.10	0.02	0.23	1.0	0.12 [-0.41, 0.64]
			Placebo	24	22 (91.7)	0.04 (0.41)	-0.5	-0.11	0.03	0.09	1.6	
		Week 36	Tezepelumab	39	37 (94.9)	0.06 (0.35)	-0.8	-0.12	0.03	0.20	1.1	-0.13 [-0.67, 0.41]
			Placebo	24	21 (87.5)	0.10 (0.30)	-0.3	-0.07	0.06	0.22	1.1	
		Week 52	Tezepelumab	39	36 (92.3)	0.04 (0.37)	-1.0	-0.08	0.00	0.15	1.0	-0.01 [-0.56, 0.54]
			Placebo	24	20 (83.3)	0.04 (0.28)	-0.5	-0.10	0.05	0.13	0.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	13	13 (100.0)	1.83 (0.51)	0.9	1.47	1.96	2.13	2.6	
			Placebo	14	14 (100.0)	1.83 (0.43)	0.9	1.59	1.87	2.16	2.6	
		Week 2	Tezepelumab	13	13 (100.0)	1.87 (0.53)	1.1	1.42	1.86	2.29	2.7	
			Placebo	14	13 (92.9)	1.89 (0.49)	0.9	1.61	1.93	2.26	2.7	
		Week 4	Tezepelumab	13	13 (100.0)	1.91 (0.58)	0.7	1.59	2.07	2.45	2.6	
			Placebo	14	14 (100.0)	1.96 (0.47)	1.0	1.73	1.92	2.35	2.7	
		Week 8	Tezepelumab	13	12 (92.3)	1.94 (0.51)	1.2	1.58	1.84	2.41	2.7	
			Placebo	14	14 (100.0)	1.94 (0.50)	0.8	1.66	1.84	2.30	2.7	
		Week 12	Tezepelumab	13	12 (92.3)	1.85 (0.50)	0.9	1.54	1.91	2.27	2.4	
			Placebo	14	13 (92.9)	1.92 (0.53)	0.8	1.62	1.82	2.25	2.8	
		Week 16	Tezepelumab	13	13 (100.0)	1.94 (0.49)	1.1	1.60	2.18	2.34	2.5	
			Placebo	14	13 (92.9)	1.87 (0.55)	0.9	1.63	1.78	2.18	2.9	
		Week 24	Tezepelumab	13	13 (100.0)	1.85 (0.47)	0.8	1.61	1.89	2.27	2.4	
			Placebo	14	12 (85.7)	1.90 (0.48)	0.8	1.62	2.05	2.22	2.7	
		Week 36	Tezepelumab	13	13 (100.0)	1.84 (0.51)	1.1	1.33	1.97	2.20	2.6	
			Placebo	14	12 (85.7)	1.93 (0.50)	1.2	1.60	1.81	2.31	2.9	
		Week 52	Tezepelumab	13	12 (92.3)	1.92 (0.44)	1.2	1.57	2.15	2.24	2.4	
			Placebo	14	13 (92.9)	1.89 (0.54)	1.1	1.59	1.83	2.29	2.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	13	13 (100.0)	0.04 (0.25)	-0.6	-0.01	0.05	0.12	0.5	-0.02 [-0.79, 0.75]
			Placebo	14	13 (92.9)	0.04 (0.23)	-0.3	-0.07	0.04	0.10	0.5	
		Week 4	Tezepelumab	13	13 (100.0)	0.08 (0.31)	-0.6	-0.06	0.06	0.22	0.6	-0.21 [-0.97, 0.55]
			Placebo	14	14 (100.0)	0.13 (0.19)	-0.3	0.04	0.09	0.28	0.5	
		Week 8	Tezepelumab	13	12 (92.3)	0.12 (0.31)	-0.3	-0.12	0.09	0.26	0.7	0.05 [-0.72, 0.82]
			Placebo	14	14 (100.0)	0.11 (0.20)	-0.2	-0.03	0.07	0.20	0.5	
		Week 12	Tezepelumab	13	12 (92.3)	0.04 (0.30)	-0.4	-0.19	0.04	0.17	0.7	-0.12 [-0.91, 0.66]
			Placebo	14	13 (92.9)	0.08 (0.24)	-0.4	-0.05	0.00	0.26	0.4	
		Week 16	Tezepelumab	13	13 (100.0)	0.11 (0.27)	-0.3	0.00	0.08	0.28	0.7	0.31 [-0.46, 1.08]
			Placebo	14	13 (92.9)	0.03 (0.28)	-0.6	-0.10	0.01	0.18	0.5	
		Week 24	Tezepelumab	13	13 (100.0)	0.02 (0.24)	-0.2	-0.12	-0.06	0.14	0.6	-0.01 [-0.79, 0.78]
			Placebo	14	12 (85.7)	0.02 (0.25)	-0.5	-0.09	0.04	0.12	0.4	
		Week 36	Tezepelumab	13	13 (100.0)	0.01 (0.32)	-0.5	-0.18	0.04	0.22	0.6	-0.36 [-1.15, 0.43]
			Placebo	14	12 (85.7)	0.10 (0.22)	-0.2	-0.10	0.13	0.31	0.4	
		Week 52	Tezepelumab	13	12 (92.3)	0.01 (0.33)	-0.7	-0.15	0.00	0.21	0.5	-0.14 [-0.92, 0.65]
			Placebo	14	13 (92.9)	0.05 (0.24)	-0.3	-0.07	-0.02	0.15	0.5	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Absolute values	Baseline	Tezepelumab	41	41 (100.0)	1.77 (0.67)	0.4	1.28	1.70	2.20	3.3	
			Placebo	25	25 (100.0)	1.69 (0.58)	0.8	1.35	1.54	1.88	3.2	
		Week 2	Tezepelumab	41	39 (95.1)	1.83 (0.65)	0.6	1.41	1.79	2.36	3.4	
			Placebo	25	21 (84.0)	1.66 (0.75)	0.8	1.15	1.59	1.74	4.1	
		Week 4	Tezepelumab	41	41 (100.0)	1.82 (0.69)	0.7	1.44	1.73	2.13	3.4	
			Placebo	25	24 (96.0)	1.73 (0.84)	0.9	1.26	1.56	1.84	4.8	
		Week 8	Tezepelumab	41	40 (97.6)	1.80 (0.64)	0.6	1.37	1.72	2.13	3.3	
			Placebo	25	24 (96.0)	1.75 (0.81)	0.8	1.32	1.62	1.96	4.6	
		Week 12	Tezepelumab	41	41 (100.0)	1.84 (0.71)	0.6	1.38	1.73	2.28	3.6	
			Placebo	25	25 (100.0)	1.76 (0.80)	0.9	1.31	1.48	2.10	4.6	
		Week 16	Tezepelumab	41	40 (97.6)	1.87 (0.73)	0.6	1.41	1.69	2.28	3.5	
			Placebo	25	25 (100.0)	1.72 (0.80)	0.8	1.32	1.66	1.78	4.7	
		Week 24	Tezepelumab	41	40 (97.6)	1.81 (0.63)	0.6	1.29	1.74	2.28	3.5	
			Placebo	25	23 (92.0)	1.70 (0.84)	0.8	1.21	1.49	1.85	4.8	
		Week 36	Tezepelumab	41	39 (95.1)	1.80 (0.67)	0.5	1.25	1.77	2.30	3.5	
			Placebo	25	22 (88.0)	1.76 (0.78)	0.9	1.38	1.58	1.92	4.3	
		Week 52	Tezepelumab	41	38 (92.7)	1.77 (0.65)	0.7	1.37	1.73	2.20	3.4	
			Placebo	25	21 (84.0)	1.69 (0.75)	0.9	1.15	1.62	1.70	4.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Change from baseline	Week 2	Tezepelumab	41	39 (95.1)	0.05 (0.25)	-0.7	-0.02	0.05	0.15	0.8	0.21 [-0.32, 0.74]
			Placebo	25	21 (84.0)	-0.01 (0.26)	-0.4	-0.09	-0.01	0.04	0.9	
		Week 4	Tezepelumab	41	41 (100.0)	0.05 (0.37)	-0.9	-0.09	0.03	0.17	1.7	0.01 [-0.50, 0.51]
			Placebo	25	24 (96.0)	0.05 (0.37)	-0.3	-0.13	0.00	0.11	1.6	
		Week 8	Tezepelumab	41	40 (97.6)	0.07 (0.30)	-0.8	-0.07	0.05	0.18	1.2	0.11 [-0.40, 0.61]
			Placebo	25	24 (96.0)	0.04 (0.38)	-0.8	-0.08	0.02	0.12	1.4	
		Week 12	Tezepelumab	41	41 (100.0)	0.07 (0.30)	-0.7	-0.05	0.05	0.17	1.4	-0.00 [-0.50, 0.49]
			Placebo	25	25 (100.0)	0.07 (0.32)	-0.4	-0.06	0.02	0.12	1.4	
		Week 16	Tezepelumab	41	40 (97.6)	0.09 (0.35)	-0.6	-0.06	0.11	0.20	1.6	0.16 [-0.34, 0.66]
			Placebo	25	25 (100.0)	0.04 (0.36)	-0.6	-0.07	0.01	0.14	1.4	
		Week 24	Tezepelumab	41	40 (97.6)	0.08 (0.29)	-0.6	-0.10	0.02	0.25	1.0	0.16 [-0.36, 0.67]
			Placebo	25	23 (92.0)	0.03 (0.40)	-0.5	-0.21	0.03	0.09	1.6	
		Week 36	Tezepelumab	41	39 (95.1)	0.06 (0.35)	-0.8	-0.12	0.03	0.20	1.1	-0.09 [-0.61, 0.43]
			Placebo	25	22 (88.0)	0.09 (0.30)	-0.3	-0.08	0.05	0.22	1.1	
		Week 52	Tezepelumab	41	38 (92.7)	0.05 (0.36)	-1.0	-0.07	0.01	0.18	1.0	-0.03 [-0.57, 0.50]
			Placebo	25	21 (84.0)	0.06 (0.28)	-0.5	-0.08	0.06	0.13	0.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	19	19 (100.0)	1.87 (0.56)	0.8	1.47	1.87	2.20	2.8	
			Placebo	13	13 (100.0)	1.74 (0.47)	0.9	1.45	1.81	2.10	2.5	
		Week 2	Tezepelumab	19	18 (94.7)	1.96 (0.50)	0.9	1.59	1.96	2.36	2.7	
			Placebo	13	10 (76.9)	1.74 (0.42)	1.0	1.61	1.75	1.85	2.6	
		Week 4	Tezepelumab	19	19 (100.0)	2.02 (0.58)	0.8	1.61	2.02	2.46	3.4	
			Placebo	13	12 (92.3)	1.75 (0.47)	1.0	1.50	1.76	1.94	2.7	
		Week 8	Tezepelumab	19	18 (94.7)	1.95 (0.56)	0.7	1.67	1.95	2.38	2.9	
			Placebo	13	13 (100.0)	1.75 (0.53)	0.8	1.65	1.76	1.94	2.7	
		Week 12	Tezepelumab	19	18 (94.7)	1.98 (0.59)	0.8	1.55	2.06	2.37	3.1	
			Placebo	13	13 (100.0)	1.75 (0.52)	0.9	1.48	1.72	2.10	2.7	
		Week 16	Tezepelumab	19	18 (94.7)	2.03 (0.65)	0.9	1.55	2.17	2.41	3.3	
			Placebo	13	13 (100.0)	1.69 (0.45)	0.9	1.63	1.70	1.78	2.6	
		Week 24	Tezepelumab	19	19 (100.0)	1.98 (0.46)	1.1	1.67	1.92	2.29	2.9	
			Placebo	13	12 (92.3)	1.68 (0.49)	1.0	1.36	1.65	1.96	2.7	
		Week 36	Tezepelumab	19	18 (94.7)	1.97 (0.56)	0.8	1.54	2.08	2.32	2.8	
			Placebo	13	13 (100.0)	1.71 (0.47)	1.0	1.46	1.69	1.92	2.7	
		Week 52	Tezepelumab	19	18 (94.7)	1.98 (0.57)	0.7	1.60	2.02	2.27	2.9	
			Placebo	13	10 (76.9)	1.59 (0.52)	1.0	1.14	1.62	1.73	2.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	19	18 (94.7)	0.06 (0.24)	-0.5	-0.01	0.05	0.12	0.8	0.27 [-0.51, 1.04]
			Placebo	13	10 (76.9)	0.00 (0.20)	-0.3	-0.17	0.04	0.16	0.3	
		Week 4	Tezepelumab	19	19 (100.0)	0.16 (0.48)	-0.9	-0.06	0.12	0.25	1.7	0.33 [-0.40, 1.06]
			Placebo	13	12 (92.3)	0.02 (0.22)	-0.3	-0.15	0.06	0.18	0.4	
		Week 8	Tezepelumab	19	18 (94.7)	0.09 (0.38)	-0.8	-0.08	0.09	0.25	1.2	0.23 [-0.48, 0.95]
			Placebo	13	13 (100.0)	0.01 (0.26)	-0.5	-0.12	-0.02	0.20	0.4	
		Week 12	Tezepelumab	19	18 (94.7)	0.13 (0.43)	-0.7	-0.18	0.12	0.19	1.4	0.33 [-0.39, 1.05]
			Placebo	13	13 (100.0)	0.01 (0.13)	-0.1	-0.06	0.00	0.04	0.4	
		Week 16	Tezepelumab	19	18 (94.7)	0.13 (0.43)	-0.6	-0.04	0.13	0.22	1.6	0.50 [-0.23, 1.22]
			Placebo	13	13 (100.0)	-0.04 (0.21)	-0.5	-0.15	-0.06	0.07	0.3	
		Week 24	Tezepelumab	19	19 (100.0)	0.11 (0.36)	-0.6	-0.20	0.14	0.29	1.0	0.59 [-0.15, 1.33]
			Placebo	13	12 (92.3)	-0.08 (0.24)	-0.4	-0.26	-0.06	0.08	0.4	
		Week 36	Tezepelumab	19	18 (94.7)	0.07 (0.40)	-0.7	-0.13	0.04	0.24	1.1	0.28 [-0.44, 1.00]
			Placebo	13	13 (100.0)	-0.03 (0.21)	-0.3	-0.19	-0.07	0.04	0.4	
		Week 52	Tezepelumab	19	18 (94.7)	0.08 (0.46)	-1.0	-0.07	0.06	0.28	1.0	0.38 [-0.40, 1.16]
			Placebo	13	10 (76.9)	-0.08 (0.28)	-0.5	-0.26	-0.14	0.13	0.5	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Absolute values	Baseline	Tezepelumab	35	35 (100.0)	1.74 (0.67)	0.4	1.27	1.70	2.20	3.3	
			Placebo	26	26 (100.0)	1.74 (0.57)	0.8	1.39	1.69	2.04	3.2	
		Week 2	Tezepelumab	35	34 (97.1)	1.78 (0.67)	0.6	1.29	1.70	2.29	3.4	
			Placebo	26	24 (92.3)	1.76 (0.75)	0.8	1.22	1.62	2.18	4.1	
		Week 4	Tezepelumab	35	35 (100.0)	1.74 (0.69)	0.7	1.19	1.67	2.24	3.3	
			Placebo	26	26 (100.0)	1.84 (0.82)	0.9	1.32	1.61	2.20	4.8	
		Week 8	Tezepelumab	35	34 (97.1)	1.78 (0.63)	0.6	1.30	1.64	2.35	3.3	
			Placebo	26	25 (96.2)	1.86 (0.80)	0.8	1.40	1.74	2.23	4.6	
		Week 12	Tezepelumab	35	35 (100.0)	1.77 (0.70)	0.6	1.23	1.66	2.28	3.6	
			Placebo	26	25 (96.2)	1.85 (0.80)	0.8	1.37	1.61	2.25	4.6	
		Week 16	Tezepelumab	35	35 (100.0)	1.82 (0.68)	0.6	1.43	1.65	2.28	3.5	
			Placebo	26	25 (96.2)	1.82 (0.83)	0.8	1.32	1.66	2.10	4.7	
		Week 24	Tezepelumab	35	34 (97.1)	1.73 (0.64)	0.6	1.16	1.63	2.27	3.5	
			Placebo	26	23 (88.5)	1.81 (0.84)	0.8	1.36	1.62	2.19	4.8	
		Week 36	Tezepelumab	35	34 (97.1)	1.72 (0.65)	0.5	1.25	1.63	2.20	3.5	
			Placebo	26	21 (80.8)	1.89 (0.80)	0.9	1.43	1.75	2.26	4.3	
		Week 52	Tezepelumab	35	32 (91.4)	1.71 (0.61)	0.8	1.22	1.62	2.20	3.4	
			Placebo	26	24 (92.3)	1.85 (0.73)	0.9	1.29	1.68	2.26	4.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Change from baseline	Week 2	Tezepelumab	35	34 (97.1)	0.04 (0.25)	-0.7	-0.02	0.05	0.17	0.5	0.07 [-0.45, 0.59]
			Placebo	26	24 (92.3)	0.02 (0.27)	-0.4	-0.09	-0.03	0.05	0.9	
		Week 4	Tezepelumab	35	35 (100.0)	0.00 (0.25)	-0.6	-0.18	0.00	0.17	0.6	-0.33 [-0.84, 0.18]
			Placebo	26	26 (100.0)	0.10 (0.36)	-0.3	-0.03	0.04	0.11	1.6	
		Week 8	Tezepelumab	35	34 (97.1)	0.08 (0.25)	-0.5	-0.06	0.04	0.15	0.7	-0.03 [-0.55, 0.48]
			Placebo	26	25 (96.2)	0.09 (0.35)	-0.8	-0.03	0.05	0.13	1.4	
		Week 12	Tezepelumab	35	35 (100.0)	0.03 (0.20)	-0.4	-0.09	0.03	0.12	0.5	-0.27 [-0.79, 0.25]
			Placebo	26	25 (96.2)	0.10 (0.35)	-0.4	-0.05	0.05	0.22	1.4	
		Week 16	Tezepelumab	35	35 (100.0)	0.08 (0.27)	-0.6	-0.07	0.09	0.25	0.7	0.02 [-0.49, 0.54]
			Placebo	26	25 (96.2)	0.07 (0.38)	-0.6	-0.06	0.01	0.18	1.4	
		Week 24	Tezepelumab	35	34 (97.1)	0.04 (0.21)	-0.4	-0.11	-0.01	0.15	0.7	-0.13 [-0.66, 0.40]
			Placebo	26	23 (88.5)	0.07 (0.39)	-0.5	-0.05	0.04	0.10	1.6	
		Week 36	Tezepelumab	35	34 (97.1)	0.03 (0.31)	-0.8	-0.12	-0.01	0.20	0.8	-0.45 [-1.00, 0.10]
			Placebo	26	21 (80.8)	0.17 (0.28)	-0.3	0.03	0.17	0.30	1.1	
		Week 52	Tezepelumab	35	32 (91.4)	0.01 (0.28)	-0.8	-0.08	0.00	0.15	0.7	-0.36 [-0.89, 0.18]
			Placebo	26	24 (92.3)	0.11 (0.24)	-0.4	-0.02	0.09	0.16	0.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Sex									0.511
Male	Week 2	Tezepelumab	18	18 (100.0)	0.04 (0.08)	(-0.13, 0.20)	-0.00 (0.15)	(-0.31, 0.31)	0.986
		Placebo	7	7 (100.0)	0.04 (0.13)	(-0.23, 0.30)			
	Week 4	Tezepelumab	18	18 (100.0)	0.10 (0.12)	(-0.16, 0.36)	-0.09 (0.24)	(-0.58, 0.39)	0.694
		Placebo	7	7 (100.0)	0.19 (0.20)	(-0.22, 0.61)			
	Week 8	Tezepelumab	18	17 (94.4)	0.09 (0.11)	(-0.14, 0.32)	-0.10 (0.21)	(-0.52, 0.33)	0.637
		Placebo	7	7 (100.0)	0.19 (0.17)	(-0.17, 0.55)			
	Week 12	Tezepelumab	18	18 (100.0)	0.14 (0.11)	(-0.08, 0.36)	-0.10 (0.20)	(-0.52, 0.32)	0.628
		Placebo	7	7 (100.0)	0.24 (0.17)	(-0.12, 0.60)			
	Week 16	Tezepelumab	18	18 (100.0)	0.08 (0.12)	(-0.16, 0.32)	-0.13 (0.22)	(-0.58, 0.33)	0.570
		Placebo	7	7 (100.0)	0.20 (0.19)	(-0.18, 0.59)			
	Week 24	Tezepelumab	18	17 (94.4)	0.13 (0.11)	(-0.10, 0.35)	-0.07 (0.20)	(-0.50, 0.35)	0.721
		Placebo	7	7 (100.0)	0.20 (0.17)	(-0.16, 0.56)			
	Week 36	Tezepelumab	18	17 (94.4)	0.03 (0.11)	(-0.20, 0.25)	-0.14 (0.20)	(-0.55, 0.28)	0.505
		Placebo	7	7 (100.0)	0.16 (0.17)	(-0.19, 0.51)			
	Week 52	Tezepelumab	18	17 (94.4)	0.05 (0.10)	(-0.16, 0.25)	-0.09 (0.19)	(-0.48, 0.31)	0.651
		Placebo	7	6 (85.7)	0.13 (0.16)	(-0.20, 0.47)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Female	Week 2	Tezepelumab	36	34 (94.4)	0.06 (0.03)	(-0.01, 0.13)	0.07 (0.05)	(-0.03, 0.17)	0.188
		Placebo	32	27 (84.4)	-0.01 (0.04)	(-0.08, 0.07)			
	Week 4	Tezepelumab	36	36 (100.0)	0.04 (0.04)	(-0.04, 0.12)	-0.01 (0.06)	(-0.13, 0.11)	0.920
		Placebo	32	31 (96.9)	0.04 (0.04)	(-0.04, 0.13)			
	Week 8	Tezepelumab	36	35 (97.2)	0.07 (0.04)	(-0.01, 0.15)	0.03 (0.06)	(-0.08, 0.15)	0.595
		Placebo	32	31 (96.9)	0.04 (0.04)	(-0.04, 0.12)			
	Week 12	Tezepelumab	36	35 (97.2)	0.03 (0.04)	(-0.04, 0.10)	-0.01 (0.05)	(-0.11, 0.10)	0.893
		Placebo	32	31 (96.9)	0.03 (0.04)	(-0.04, 0.11)			
	Week 16	Tezepelumab	36	35 (97.2)	0.12 (0.04)	(0.03, 0.20)	0.12 (0.06)	(0.00, 0.25)	0.050 *
		Placebo	32	31 (96.9)	-0.01 (0.05)	(-0.10, 0.08)			
	Week 24	Tezepelumab	36	36 (100.0)	0.03 (0.04)	(-0.04, 0.10)	0.05 (0.05)	(-0.06, 0.15)	0.393
		Placebo	32	28 (87.5)	-0.01 (0.04)	(-0.09, 0.06)			
	Week 36	Tezepelumab	36	35 (97.2)	0.06 (0.04)	(-0.02, 0.14)	-0.02 (0.06)	(-0.14, 0.10)	0.728
		Placebo	32	27 (84.4)	0.08 (0.04)	(-0.01, 0.17)			
	Week 52	Tezepelumab	36	33 (91.7)	0.05 (0.04)	(-0.04, 0.14)	0.03 (0.07)	(-0.10, 0.16)	0.669
		Placebo	32	28 (87.5)	0.02 (0.05)	(-0.08, 0.12)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Age									0.681
< 65 years	Week 2	Tezepelumab	45	44 (97.8)	0.05 (0.04)	(-0.02, 0.13)	0.07 (0.06)	(-0.05, 0.19)	0.256
		Placebo	32	28 (87.5)	-0.02 (0.05)	(-0.11, 0.08)			
	Week 4	Tezepelumab	45	45 (100.0)	0.08 (0.05)	(-0.03, 0.18)	-0.00 (0.08)	(-0.17, 0.16)	0.955
		Placebo	32	32 (100.0)	0.08 (0.06)	(-0.05, 0.21)			
	Week 8	Tezepelumab	45	43 (95.6)	0.07 (0.05)	(-0.02, 0.17)	0.03 (0.08)	(-0.12, 0.18)	0.720
		Placebo	32	32 (100.0)	0.05 (0.06)	(-0.07, 0.16)			
	Week 12	Tezepelumab	45	44 (97.8)	0.09 (0.05)	(-0.01, 0.18)	0.02 (0.07)	(-0.12, 0.17)	0.767
		Placebo	32	31 (96.9)	0.06 (0.06)	(-0.05, 0.18)			
	Week 16	Tezepelumab	45	45 (100.0)	0.13 (0.05)	(0.02, 0.23)	0.10 (0.08)	(-0.06, 0.26)	0.229
		Placebo	32	31 (96.9)	0.03 (0.06)	(-0.10, 0.15)			
	Week 24	Tezepelumab	45	44 (97.8)	0.07 (0.05)	(-0.02, 0.17)	0.05 (0.08)	(-0.10, 0.20)	0.496
		Placebo	32	28 (87.5)	0.02 (0.06)	(-0.09, 0.14)			
	Week 36	Tezepelumab	45	44 (97.8)	0.05 (0.05)	(-0.05, 0.15)	-0.07 (0.08)	(-0.22, 0.08)	0.357
		Placebo	32	27 (84.4)	0.12 (0.06)	(0.00, 0.24)			
	Week 52	Tezepelumab	45	42 (93.3)	0.05 (0.05)	(-0.05, 0.15)	-0.01 (0.08)	(-0.17, 0.14)	0.852
		Placebo	32	28 (87.5)	0.06 (0.06)	(-0.05, 0.18)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 65 years	Week 2	Tezepelumab	9	8 (88.9)	0.03 (0.07)	(-0.13, 0.18)	-0.02 (0.10)	(-0.25, 0.21)	0.840
		Placebo	7	6 (85.7)	0.05 (0.08)	(-0.12, 0.22)			
	Week 4	Tezepelumab	9	9 (100.0)	-0.05 (0.09)	(-0.24, 0.14)	-0.06 (0.13)	(-0.35, 0.23)	0.654
		Placebo	7	6 (85.7)	0.01 (0.10)	(-0.21, 0.23)			
	Week 8	Tezepelumab	9	9 (100.0)	0.08 (0.08)	(-0.09, 0.25)	-0.09 (0.12)	(-0.35, 0.17)	0.440
		Placebo	7	6 (85.7)	0.17 (0.09)	(-0.02, 0.37)			
	Week 12	Tezepelumab	9	9 (100.0)	-0.07 (0.05)	(-0.18, 0.05)	-0.17 (0.08)	(-0.34, 0.00)	0.055
		Placebo	7	7 (100.0)	0.10 (0.06)	(-0.03, 0.23)			
	Week 16	Tezepelumab	9	8 (88.9)	-0.05 (0.07)	(-0.20, 0.11)	-0.10 (0.11)	(-0.34, 0.14)	0.374
		Placebo	7	7 (100.0)	0.05 (0.08)	(-0.12, 0.23)			
	Week 24	Tezepelumab	9	9 (100.0)	-0.01 (0.08)	(-0.17, 0.16)	-0.06 (0.12)	(-0.31, 0.19)	0.616
		Placebo	7	7 (100.0)	0.05 (0.09)	(-0.13, 0.24)			
	Week 36	Tezepelumab	9	8 (88.9)	0.03 (0.07)	(-0.13, 0.18)	0.03 (0.10)	(-0.21, 0.26)	0.799
		Placebo	7	7 (100.0)	-0.00 (0.08)	(-0.18, 0.17)			
	Week 52	Tezepelumab	9	8 (88.9)	-0.05 (0.08)	(-0.22, 0.12)	-0.03 (0.11)	(-0.28, 0.22)	0.816
		Placebo	7	6 (85.7)	-0.02 (0.08)	(-0.21, 0.16)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Exacerbations in the year before study									0.439
<= 2	Week 2	Tezepelumab	31	31 (100.0)	0.04 (0.05)	(-0.07, 0.14)	0.04 (0.08)	(-0.12, 0.19)	0.627
		Placebo	26	23 (88.5)	-0.00 (0.06)	(-0.12, 0.11)			
	Week 4	Tezepelumab	31	31 (100.0)	0.03 (0.07)	(-0.11, 0.17)	-0.06 (0.11)	(-0.27, 0.15)	0.547
		Placebo	26	25 (96.2)	0.10 (0.08)	(-0.06, 0.25)			
	Week 8	Tezepelumab	31	31 (100.0)	0.06 (0.07)	(-0.07, 0.19)	-0.02 (0.10)	(-0.22, 0.17)	0.802
		Placebo	26	25 (96.2)	0.09 (0.07)	(-0.06, 0.23)			
	Week 12	Tezepelumab	31	31 (100.0)	0.05 (0.06)	(-0.07, 0.18)	-0.04 (0.09)	(-0.22, 0.14)	0.661
		Placebo	26	26 (100.0)	0.09 (0.07)	(-0.04, 0.23)			
	Week 16	Tezepelumab	31	31 (100.0)	0.08 (0.07)	(-0.05, 0.21)	0.02 (0.10)	(-0.18, 0.22)	0.828
		Placebo	26	26 (100.0)	0.06 (0.07)	(-0.09, 0.21)			
	Week 24	Tezepelumab	31	31 (100.0)	0.07 (0.06)	(-0.05, 0.20)	0.05 (0.10)	(-0.14, 0.24)	0.589
		Placebo	26	23 (88.5)	0.02 (0.07)	(-0.12, 0.16)			
	Week 36	Tezepelumab	31	31 (100.0)	0.07 (0.06)	(-0.06, 0.20)	-0.01 (0.09)	(-0.20, 0.18)	0.909
		Placebo	26	24 (92.3)	0.08 (0.07)	(-0.06, 0.22)			
	Week 52	Tezepelumab	31	31 (100.0)	0.02 (0.06)	(-0.10, 0.15)	-0.02 (0.10)	(-0.21, 0.18)	0.861
		Placebo	26	22 (84.6)	0.04 (0.07)	(-0.10, 0.18)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
> 2	Week 2	Tezepelumab	23	21 (91.3)	0.07 (0.03)	(-0.00, 0.14)	0.09 (0.06)	(-0.03, 0.20)	0.151
		Placebo	13	11 (84.6)	-0.02 (0.05)	(-0.11, 0.08)			
	Week 4	Tezepelumab	23	23 (100.0)	0.09 (0.05)	(-0.01, 0.19)	0.07 (0.08)	(-0.09, 0.24)	0.376
		Placebo	13	13 (100.0)	0.02 (0.07)	(-0.11, 0.15)			
	Week 8	Tezepelumab	23	21 (91.3)	0.09 (0.04)	(0.01, 0.18)	0.07 (0.07)	(-0.08, 0.21)	0.344
		Placebo	13	13 (100.0)	0.03 (0.05)	(-0.09, 0.14)			
	Week 12	Tezepelumab	23	22 (95.7)	0.08 (0.04)	(-0.01, 0.17)	0.06 (0.07)	(-0.09, 0.21)	0.443
		Placebo	13	12 (92.3)	0.02 (0.06)	(-0.10, 0.14)			
	Week 16	Tezepelumab	23	22 (95.7)	0.14 (0.06)	(0.02, 0.25)	0.17 (0.09)	(-0.02, 0.36)	0.085
		Placebo	13	12 (92.3)	-0.03 (0.08)	(-0.19, 0.12)			
	Week 24	Tezepelumab	23	22 (95.7)	0.05 (0.04)	(-0.04, 0.13)	0.02 (0.07)	(-0.13, 0.16)	0.799
		Placebo	13	12 (92.3)	0.03 (0.06)	(-0.09, 0.15)			
	Week 36	Tezepelumab	23	21 (91.3)	0.02 (0.04)	(-0.07, 0.11)	-0.10 (0.08)	(-0.26, 0.06)	0.211
		Placebo	13	10 (76.9)	0.11 (0.06)	(-0.01, 0.24)			
	Week 52	Tezepelumab	23	19 (82.6)	0.05 (0.05)	(-0.04, 0.15)	0.00 (0.08)	(-0.15, 0.16)	0.962
		Placebo	13	12 (92.3)	0.05 (0.06)	(-0.07, 0.17)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Race				N<10 any level					NE

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Region									0.611
Europe	Week 2	Tezepelumab	11	11 (100.0)	0.08 (0.07)	(-0.06, 0.22)	-0.02 (0.10)	(-0.23, 0.19)	0.853
		Placebo	10	9 (90.0)	0.10 (0.07)	(-0.05, 0.25)			
	Week 4	Tezepelumab	11	11 (100.0)	0.04 (0.07)	(-0.11, 0.18)	-0.12 (0.10)	(-0.34, 0.09)	0.247
		Placebo	10	10 (100.0)	0.16 (0.07)	(0.01, 0.31)			
	Week 8	Tezepelumab	11	11 (100.0)	0.04 (0.09)	(-0.16, 0.23)	-0.02 (0.14)	(-0.30, 0.27)	0.905
		Placebo	10	9 (90.0)	0.06 (0.10)	(-0.15, 0.26)			
	Week 12	Tezepelumab	11	11 (100.0)	-0.01 (0.07)	(-0.15, 0.13)	-0.12 (0.10)	(-0.32, 0.09)	0.242
		Placebo	10	10 (100.0)	0.11 (0.07)	(-0.03, 0.26)			
	Week 16	Tezepelumab	11	11 (100.0)	0.06 (0.07)	(-0.10, 0.21)	-0.09 (0.11)	(-0.32, 0.13)	0.402
		Placebo	10	10 (100.0)	0.15 (0.08)	(-0.01, 0.31)			
	Week 24	Tezepelumab	11	11 (100.0)	-0.03 (0.05)	(-0.14, 0.08)	-0.05 (0.08)	(-0.21, 0.12)	0.565
		Placebo	10	10 (100.0)	0.02 (0.06)	(-0.10, 0.13)			
	Week 36	Tezepelumab	11	11 (100.0)	-0.02 (0.08)	(-0.18, 0.14)	-0.25 (0.11)	(-0.48, -0.01)	0.041 *
		Placebo	10	9 (90.0)	0.23 (0.08)	(0.06, 0.40)			
	Week 52	Tezepelumab	11	10 (90.9)	0.01 (0.06)	(-0.12, 0.13)	-0.20 (0.09)	(-0.39, -0.02)	0.032 *
		Placebo	10	10 (100.0)	0.21 (0.06)	(0.08, 0.34)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
America	Week 2	Tezepelumab	19	18 (94.7)	0.05 (0.06)	(-0.07, 0.18)	0.01 (0.11)	(-0.21, 0.22)	0.959
		Placebo	11	9 (81.8)	0.05 (0.08)	(-0.12, 0.22)			
	Week 4	Tezepelumab	19	19 (100.0)	0.01 (0.08)	(-0.14, 0.17)	-0.19 (0.13)	(-0.45, 0.07)	0.147
		Placebo	11	10 (90.9)	0.20 (0.10)	(-0.01, 0.41)			
	Week 8	Tezepelumab	19	19 (100.0)	0.09 (0.08)	(-0.08, 0.26)	-0.06 (0.14)	(-0.34, 0.22)	0.647
		Placebo	11	11 (100.0)	0.15 (0.11)	(-0.07, 0.37)			
	Week 12	Tezepelumab	19	19 (100.0)	0.09 (0.07)	(-0.05, 0.22)	-0.12 (0.11)	(-0.34, 0.11)	0.298
		Placebo	11	11 (100.0)	0.20 (0.09)	(0.03, 0.38)			
	Week 16	Tezepelumab	19	19 (100.0)	0.13 (0.08)	(-0.04, 0.29)	-0.03 (0.13)	(-0.29, 0.24)	0.845
		Placebo	11	11 (100.0)	0.15 (0.10)	(-0.06, 0.37)			
	Week 24	Tezepelumab	19	19 (100.0)	0.08 (0.08)	(-0.09, 0.24)	-0.11 (0.14)	(-0.39, 0.17)	0.418
		Placebo	11	10 (90.9)	0.19 (0.11)	(-0.03, 0.41)			
	Week 36	Tezepelumab	19	19 (100.0)	0.07 (0.08)	(-0.09, 0.24)	-0.06 (0.13)	(-0.33, 0.21)	0.656
		Placebo	11	11 (100.0)	0.13 (0.10)	(-0.08, 0.35)			
	Week 52	Tezepelumab	19	18 (94.7)	0.00 (0.07)	(-0.14, 0.15)	-0.07 (0.12)	(-0.31, 0.18)	0.591
		Placebo	11	9 (81.8)	0.07 (0.10)	(-0.13, 0.27)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Asia/Pacific	Week 2	Tezepelumab	13	13 (100.0)	-0.05 (0.05)	(-0.15, 0.05)	0.00 (0.08)	(-0.16, 0.17)	0.967
		Placebo	9	8 (88.9)	-0.05 (0.06)	(-0.18, 0.08)			
	Week 4	Tezepelumab	13	13 (100.0)	0.00 (0.08)	(-0.16, 0.17)	0.04 (0.13)	(-0.23, 0.30)	0.783
		Placebo	9	9 (100.0)	-0.03 (0.10)	(-0.23, 0.17)			
	Week 8	Tezepelumab	13	12 (92.3)	-0.02 (0.06)	(-0.15, 0.11)	-0.09 (0.10)	(-0.30, 0.11)	0.364
		Placebo	9	9 (100.0)	0.07 (0.07)	(-0.08, 0.23)			
	Week 12	Tezepelumab	13	12 (92.3)	0.02 (0.07)	(-0.12, 0.16)	0.09 (0.10)	(-0.12, 0.31)	0.377
		Placebo	9	8 (88.9)	-0.08 (0.08)	(-0.25, 0.09)			
	Week 16	Tezepelumab	13	13 (100.0)	0.03 (0.07)	(-0.13, 0.18)	0.15 (0.12)	(-0.10, 0.39)	0.238
		Placebo	9	8 (88.9)	-0.12 (0.09)	(-0.31, 0.08)			
	Week 24	Tezepelumab	13	13 (100.0)	0.06 (0.06)	(-0.08, 0.19)	0.13 (0.10)	(-0.09, 0.34)	0.233
		Placebo	9	8 (88.9)	-0.07 (0.08)	(-0.24, 0.10)			
	Week 36	Tezepelumab	13	13 (100.0)	0.01 (0.07)	(-0.15, 0.17)	0.07 (0.12)	(-0.19, 0.32)	0.597
		Placebo	9	7 (77.8)	-0.05 (0.10)	(-0.25, 0.14)			
	Week 52	Tezepelumab	13	13 (100.0)	0.01 (0.10)	(-0.19, 0.20)	0.07 (0.15)	(-0.25, 0.39)	0.654
		Placebo	9	8 (88.9)	-0.06 (0.12)	(-0.31, 0.18)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Rest of the world	Week 2	Tezepelumab	11	10 (90.9)	NE		NE		
		Placebo	9	8 (88.9)					
	Week 4	Tezepelumab	11	11 (100.0)	NE		NE		
		Placebo	9	9 (100.0)					
	Week 8	Tezepelumab	11	10 (90.9)	NE		NE		
		Placebo	9	9 (100.0)					
	Week 12	Tezepelumab	11	11 (100.0)	NE		NE		
		Placebo	9	9 (100.0)					
	Week 16	Tezepelumab	11	10 (90.9)	NE		NE		
		Placebo	9	9 (100.0)					
	Week 24	Tezepelumab	11	10 (90.9)	NE		NE		
		Placebo	9	7 (77.8)					
	Week 36	Tezepelumab	11	9 (81.8)	NE		NE		
		Placebo	9	7 (77.8)					
	Week 52	Tezepelumab	11	9 (81.8)	NE		NE		
		Placebo	9	7 (77.8)					

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
BMI				N<10 any level					NE

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline eosinophils - Low									0.731
< 150 cells/uL	Week 2	Tezepelumab	32	31 (96.9)	0.06 (0.04)	(-0.02, 0.15)	0.10 (0.07)	(-0.04, 0.23)	0.147
		Placebo	21	17 (81.0)	-0.03 (0.05)	(-0.14, 0.07)			
	Week 4	Tezepelumab	32	32 (100.0)	0.07 (0.06)	(-0.05, 0.20)	0.07 (0.10)	(-0.12, 0.27)	0.455
		Placebo	21	21 (100.0)	-0.00 (0.08)	(-0.15, 0.15)			
	Week 8	Tezepelumab	32	30 (93.8)	0.07 (0.06)	(-0.04, 0.18)	0.07 (0.09)	(-0.10, 0.25)	0.424
		Placebo	21	21 (100.0)	-0.00 (0.07)	(-0.14, 0.13)			
	Week 12	Tezepelumab	32	32 (100.0)	0.06 (0.05)	(-0.05, 0.16)	0.06 (0.08)	(-0.11, 0.23)	0.492
		Placebo	21	20 (95.2)	-0.00 (0.07)	(-0.13, 0.13)			
	Week 16	Tezepelumab	32	31 (96.9)	0.13 (0.06)	(0.01, 0.25)	0.15 (0.10)	(-0.04, 0.35)	0.118
		Placebo	21	20 (95.2)	-0.02 (0.08)	(-0.18, 0.13)			
	Week 24	Tezepelumab	32	31 (96.9)	0.07 (0.04)	(-0.02, 0.16)	0.06 (0.07)	(-0.08, 0.21)	0.396
		Placebo	21	19 (90.5)	0.01 (0.06)	(-0.10, 0.12)			
	Week 36	Tezepelumab	32	30 (93.8)	0.03 (0.05)	(-0.07, 0.14)	-0.04 (0.08)	(-0.20, 0.13)	0.650
		Placebo	21	18 (85.7)	0.07 (0.06)	(-0.06, 0.20)			
	Week 52	Tezepelumab	32	28 (87.5)	0.04 (0.06)	(-0.07, 0.15)	-0.01 (0.09)	(-0.19, 0.17)	0.904
		Placebo	21	18 (85.7)	0.05 (0.07)	(-0.09, 0.19)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 150 cells/uL	Week 2	Tezepelumab	22	21 (95.5)	0.02 (0.05)	(-0.09, 0.13)	-0.04 (0.08)	(-0.21, 0.13)	0.631
		Placebo	18	17 (94.4)	0.06 (0.06)	(-0.06, 0.18)			
	Week 4	Tezepelumab	22	22 (100.0)	0.03 (0.07)	(-0.11, 0.16)	-0.15 (0.10)	(-0.35, 0.06)	0.157
		Placebo	18	17 (94.4)	0.17 (0.08)	(0.02, 0.33)			
	Week 8	Tezepelumab	22	22 (100.0)	0.08 (0.06)	(-0.04, 0.21)	-0.08 (0.09)	(-0.27, 0.10)	0.363
		Placebo	18	17 (94.4)	0.17 (0.07)	(0.03, 0.30)			
	Week 12	Tezepelumab	22	21 (95.5)	0.07 (0.06)	(-0.06, 0.19)	-0.10 (0.09)	(-0.29, 0.08)	0.272
		Placebo	18	18 (100.0)	0.17 (0.07)	(0.03, 0.30)			
	Week 16	Tezepelumab	22	22 (100.0)	0.05 (0.06)	(-0.08, 0.18)	-0.06 (0.10)	(-0.25, 0.14)	0.558
		Placebo	18	18 (100.0)	0.11 (0.07)	(-0.04, 0.26)			
	Week 24	Tezepelumab	22	22 (100.0)	0.04 (0.07)	(-0.11, 0.19)	-0.01 (0.11)	(-0.24, 0.22)	0.910
		Placebo	18	16 (88.9)	0.05 (0.08)	(-0.12, 0.22)			
	Week 36	Tezepelumab	22	22 (100.0)	0.05 (0.07)	(-0.09, 0.19)	-0.08 (0.10)	(-0.29, 0.13)	0.429
		Placebo	18	16 (88.9)	0.14 (0.08)	(-0.02, 0.29)			
	Week 52	Tezepelumab	22	22 (100.0)	0.02 (0.07)	(-0.12, 0.15)	-0.04 (0.10)	(-0.24, 0.16)	0.668
		Placebo	18	16 (88.9)	0.06 (0.07)	(-0.09, 0.21)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline specific perennial FEIA status									0.255
All negative	Week 2	Tezepelumab	32	31 (96.9)	0.09 (0.04)	(0.02, 0.17)	0.10 (0.06)	(-0.01, 0.22)	0.079
		Placebo	24	21 (87.5)	-0.01 (0.04)	(-0.10, 0.08)			
	Week 4	Tezepelumab	32	32 (100.0)	0.10 (0.06)	(-0.01, 0.22)	0.04 (0.09)	(-0.13, 0.21)	0.639
		Placebo	24	23 (95.8)	0.06 (0.06)	(-0.07, 0.19)			
	Week 8	Tezepelumab	32	32 (100.0)	0.12 (0.04)	(0.03, 0.20)	0.05 (0.07)	(-0.08, 0.18)	0.456
		Placebo	24	23 (95.8)	0.07 (0.05)	(-0.04, 0.17)			
	Week 12	Tezepelumab	32	31 (96.9)	0.09 (0.05)	(-0.01, 0.19)	0.03 (0.07)	(-0.12, 0.18)	0.720
		Placebo	24	24 (100.0)	0.06 (0.06)	(-0.05, 0.18)			
	Week 16	Tezepelumab	32	31 (96.9)	0.14 (0.06)	(0.03, 0.26)	0.13 (0.09)	(-0.04, 0.31)	0.129
		Placebo	24	24 (100.0)	0.01 (0.07)	(-0.12, 0.14)			
	Week 24	Tezepelumab	32	32 (100.0)	0.09 (0.04)	(-0.00, 0.18)	0.09 (0.07)	(-0.05, 0.23)	0.212
		Placebo	24	21 (87.5)	0.00 (0.05)	(-0.11, 0.11)			
	Week 36	Tezepelumab	32	31 (96.9)	0.06 (0.05)	(-0.03, 0.16)	-0.03 (0.07)	(-0.18, 0.12)	0.678
		Placebo	24	21 (87.5)	0.09 (0.06)	(-0.02, 0.20)			
	Week 52	Tezepelumab	32	30 (93.8)	0.08 (0.05)	(-0.02, 0.18)	0.07 (0.08)	(-0.09, 0.22)	0.411
		Placebo	24	21 (87.5)	0.02 (0.06)	(-0.10, 0.14)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Any positive	Week 2	Tezepelumab	22	21 (95.5)	-0.01 (0.06)	(-0.14, 0.11)	-0.03 (0.10)	(-0.24, 0.18)	0.773
		Placebo	14	12 (85.7)	0.02 (0.08)	(-0.15, 0.18)			
	Week 4	Tezepelumab	22	22 (100.0)	-0.01 (0.08)	(-0.17, 0.15)	-0.10 (0.13)	(-0.36, 0.16)	0.444
		Placebo	14	14 (100.0)	0.09 (0.10)	(-0.12, 0.29)			
	Week 8	Tezepelumab	22	20 (90.9)	0.01 (0.08)	(-0.16, 0.18)	-0.05 (0.13)	(-0.32, 0.23)	0.734
		Placebo	14	14 (100.0)	0.06 (0.10)	(-0.15, 0.27)			
	Week 12	Tezepelumab	22	22 (100.0)	0.02 (0.07)	(-0.12, 0.16)	-0.05 (0.11)	(-0.28, 0.18)	0.667
		Placebo	14	13 (92.9)	0.07 (0.09)	(-0.11, 0.25)			
	Week 16	Tezepelumab	22	22 (100.0)	0.04 (0.08)	(-0.11, 0.20)	-0.05 (0.12)	(-0.29, 0.20)	0.715
		Placebo	14	13 (92.9)	0.09 (0.10)	(-0.11, 0.28)			
	Week 24	Tezepelumab	22	21 (95.5)	0.03 (0.08)	(-0.13, 0.18)	-0.04 (0.12)	(-0.29, 0.22)	0.775
		Placebo	14	13 (92.9)	0.06 (0.10)	(-0.14, 0.26)			
	Week 36	Tezepelumab	22	21 (95.5)	0.02 (0.08)	(-0.14, 0.18)	-0.08 (0.13)	(-0.34, 0.18)	0.537
		Placebo	14	12 (85.7)	0.10 (0.10)	(-0.11, 0.30)			
	Week 52	Tezepelumab	22	20 (90.9)	-0.04 (0.08)	(-0.19, 0.12)	-0.14 (0.12)	(-0.39, 0.11)	0.263
		Placebo	14	12 (85.7)	0.10 (0.10)	(-0.10, 0.30)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Total serum IgE				N<10 any level					NE

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
OCS at baseline									0.729
Yes	Week 2	Tezepelumab	8	8 (100.0)	NE		NE		
		Placebo	7	5 (71.4)					
	Week 4	Tezepelumab	8	8 (100.0)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 8	Tezepelumab	8	7 (87.5)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 12	Tezepelumab	8	7 (87.5)	NE		NE		
		Placebo	7	6 (85.7)					
	Week 16	Tezepelumab	8	8 (100.0)	NE		NE		
		Placebo	7	6 (85.7)					
	Week 24	Tezepelumab	8	8 (100.0)	NE		NE		
		Placebo	7	6 (85.7)					
	Week 36	Tezepelumab	8	8 (100.0)	NE		NE		
		Placebo	7	5 (71.4)					
	Week 52	Tezepelumab	8	8 (100.0)	NE		NE		
		Placebo	7	6 (85.7)					

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 2	Tezepelumab	46	44 (95.7)	0.05 (0.04)	(-0.03, 0.12)	0.05 (0.06)	(-0.07, 0.17)	0.436
		Placebo	32	29 (90.6)	-0.00 (0.05)	(-0.09, 0.09)			
	Week 4	Tezepelumab	46	46 (100.0)	0.04 (0.05)	(-0.07, 0.14)	-0.05 (0.08)	(-0.22, 0.11)	0.513
		Placebo	32	31 (96.9)	0.09 (0.06)	(-0.03, 0.21)			
	Week 8	Tezepelumab	46	45 (97.8)	0.08 (0.05)	(-0.01, 0.18)	0.02 (0.08)	(-0.13, 0.17)	0.773
		Placebo	32	31 (96.9)	0.06 (0.06)	(-0.05, 0.18)			
	Week 12	Tezepelumab	46	46 (100.0)	0.05 (0.04)	(-0.04, 0.14)	-0.04 (0.07)	(-0.17, 0.10)	0.598
		Placebo	32	32 (100.0)	0.09 (0.05)	(-0.02, 0.19)			
	Week 16	Tezepelumab	46	45 (97.8)	0.11 (0.05)	(0.00, 0.21)	0.04 (0.08)	(-0.12, 0.20)	0.589
		Placebo	32	32 (100.0)	0.06 (0.06)	(-0.06, 0.18)			
	Week 24	Tezepelumab	46	45 (97.8)	0.05 (0.04)	(-0.04, 0.14)	-0.00 (0.07)	(-0.14, 0.14)	0.967
		Placebo	32	29 (90.6)	0.05 (0.05)	(-0.05, 0.16)			
	Week 36	Tezepelumab	46	44 (95.7)	0.05 (0.05)	(-0.04, 0.14)	-0.06 (0.07)	(-0.20, 0.08)	0.404
		Placebo	32	29 (90.6)	0.11 (0.05)	(0.00, 0.22)			
	Week 52	Tezepelumab	46	42 (91.3)	0.03 (0.05)	(-0.06, 0.12)	-0.02 (0.07)	(-0.16, 0.12)	0.742
		Placebo	32	28 (87.5)	0.06 (0.05)	(-0.05, 0.17)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
LAMA use at baseline									0.457
Yes	Week 2	Tezepelumab	15	15 (100.0)	0.04 (0.06)	(-0.08, 0.16)	0.01 (0.08)	(-0.16, 0.18)	0.879
		Placebo	15	14 (93.3)	0.03 (0.06)	(-0.09, 0.15)			
	Week 4	Tezepelumab	15	15 (100.0)	0.08 (0.07)	(-0.05, 0.22)	-0.02 (0.09)	(-0.21, 0.17)	0.814
		Placebo	15	15 (100.0)	0.10 (0.07)	(-0.03, 0.24)			
	Week 8	Tezepelumab	15	14 (93.3)	0.10 (0.08)	(-0.05, 0.26)	0.05 (0.11)	(-0.17, 0.27)	0.628
		Placebo	15	15 (100.0)	0.05 (0.08)	(-0.10, 0.21)			
	Week 12	Tezepelumab	15	14 (93.3)	0.08 (0.07)	(-0.07, 0.22)	0.04 (0.10)	(-0.17, 0.25)	0.681
		Placebo	15	14 (93.3)	0.04 (0.07)	(-0.11, 0.18)			
	Week 16	Tezepelumab	15	15 (100.0)	0.11 (0.07)	(-0.03, 0.25)	0.09 (0.10)	(-0.11, 0.29)	0.364
		Placebo	15	14 (93.3)	0.02 (0.07)	(-0.12, 0.17)			
	Week 24	Tezepelumab	15	15 (100.0)	0.03 (0.06)	(-0.09, 0.16)	0.04 (0.09)	(-0.14, 0.22)	0.684
		Placebo	15	13 (86.7)	-0.00 (0.06)	(-0.13, 0.13)			
	Week 36	Tezepelumab	15	15 (100.0)	0.01 (0.07)	(-0.13, 0.15)	-0.08 (0.10)	(-0.28, 0.13)	0.454
		Placebo	15	13 (86.7)	0.08 (0.07)	(-0.06, 0.23)			
	Week 52	Tezepelumab	15	14 (93.3)	0.02 (0.07)	(-0.14, 0.17)	-0.05 (0.11)	(-0.27, 0.17)	0.644
		Placebo	15	14 (93.3)	0.07 (0.07)	(-0.09, 0.22)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 2	Tezepelumab	39	37 (94.9)	0.05 (0.04)	(-0.03, 0.14)	0.08 (0.07)	(-0.05, 0.22)	0.230
		Placebo	24	20 (83.3)	-0.03 (0.05)	(-0.13, 0.08)			
	Week 4	Tezepelumab	39	39 (100.0)	0.05 (0.06)	(-0.07, 0.17)	0.00 (0.10)	(-0.19, 0.20)	0.986
		Placebo	24	23 (95.8)	0.05 (0.08)	(-0.11, 0.20)			
	Week 8	Tezepelumab	39	38 (97.4)	0.07 (0.05)	(-0.04, 0.17)	-0.01 (0.08)	(-0.17, 0.16)	0.934
		Placebo	24	23 (95.8)	0.07 (0.07)	(-0.06, 0.20)			
	Week 12	Tezepelumab	39	39 (100.0)	0.06 (0.05)	(-0.04, 0.16)	-0.03 (0.08)	(-0.19, 0.13)	0.741
		Placebo	24	24 (100.0)	0.09 (0.06)	(-0.04, 0.21)			
	Week 16	Tezepelumab	39	38 (97.4)	0.10 (0.06)	(-0.02, 0.22)	0.06 (0.09)	(-0.12, 0.25)	0.500
		Placebo	24	24 (100.0)	0.03 (0.07)	(-0.11, 0.18)			
	Week 24	Tezepelumab	39	38 (97.4)	0.08 (0.05)	(-0.03, 0.18)	0.04 (0.09)	(-0.14, 0.21)	0.667
		Placebo	24	22 (91.7)	0.04 (0.07)	(-0.10, 0.18)			
	Week 36	Tezepelumab	39	37 (94.9)	0.07 (0.05)	(-0.04, 0.17)	-0.03 (0.09)	(-0.21, 0.14)	0.697
		Placebo	24	21 (87.5)	0.10 (0.07)	(-0.04, 0.24)			
	Week 52	Tezepelumab	39	36 (92.3)	0.04 (0.05)	(-0.06, 0.15)	0.02 (0.09)	(-0.16, 0.19)	0.842
		Placebo	24	20 (83.3)	0.02 (0.07)	(-0.11, 0.16)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Tiotropium use at baseline									0.436
Yes	Week 2	Tezepelumab	13	13 (100.0)	0.04 (0.07)	(-0.10, 0.18)	0.00 (0.09)	(-0.19, 0.20)	0.966
		Placebo	14	13 (92.9)	0.03 (0.07)	(-0.10, 0.17)			
	Week 4	Tezepelumab	13	13 (100.0)	0.08 (0.07)	(-0.07, 0.22)	-0.05 (0.10)	(-0.26, 0.15)	0.602
		Placebo	14	14 (100.0)	0.13 (0.07)	(-0.02, 0.27)			
	Week 8	Tezepelumab	13	12 (92.3)	0.10 (0.07)	(-0.05, 0.25)	-0.01 (0.10)	(-0.22, 0.20)	0.924
		Placebo	14	14 (100.0)	0.11 (0.07)	(-0.03, 0.25)			
	Week 12	Tezepelumab	13	12 (92.3)	0.05 (0.07)	(-0.11, 0.20)	-0.02 (0.10)	(-0.23, 0.20)	0.882
		Placebo	14	13 (92.9)	0.06 (0.07)	(-0.08, 0.21)			
	Week 16	Tezepelumab	13	13 (100.0)	0.11 (0.08)	(-0.05, 0.27)	0.09 (0.11)	(-0.13, 0.31)	0.390
		Placebo	14	13 (92.9)	0.02 (0.07)	(-0.14, 0.17)			
	Week 24	Tezepelumab	13	13 (100.0)	0.02 (0.07)	(-0.12, 0.15)	0.01 (0.09)	(-0.18, 0.20)	0.908
		Placebo	14	12 (85.7)	0.01 (0.07)	(-0.13, 0.14)			
	Week 36	Tezepelumab	13	13 (100.0)	0.00 (0.07)	(-0.15, 0.16)	-0.10 (0.11)	(-0.31, 0.12)	0.362
		Placebo	14	12 (85.7)	0.10 (0.07)	(-0.05, 0.25)			
	Week 52	Tezepelumab	13	12 (92.3)	-0.01 (0.08)	(-0.18, 0.16)	-0.04 (0.11)	(-0.28, 0.19)	0.695
		Placebo	14	13 (92.9)	0.03 (0.08)	(-0.13, 0.20)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 2	Tezepelumab	41	39 (95.1)	0.06 (0.04)	(-0.02, 0.13)	0.08 (0.06)	(-0.05, 0.21)	0.201
		Placebo	25	21 (84.0)	-0.03 (0.05)	(-0.13, 0.07)			
	Week 4	Tezepelumab	41	41 (100.0)	0.05 (0.06)	(-0.06, 0.17)	0.02 (0.09)	(-0.17, 0.21)	0.855
		Placebo	25	24 (96.0)	0.04 (0.07)	(-0.11, 0.18)			
	Week 8	Tezepelumab	41	40 (97.6)	0.07 (0.05)	(-0.03, 0.17)	0.03 (0.08)	(-0.14, 0.20)	0.713
		Placebo	25	24 (96.0)	0.04 (0.07)	(-0.09, 0.17)			
	Week 12	Tezepelumab	41	41 (100.0)	0.07 (0.05)	(-0.03, 0.17)	0.00 (0.08)	(-0.16, 0.16)	0.979
		Placebo	25	25 (100.0)	0.07 (0.06)	(-0.06, 0.19)			
	Week 16	Tezepelumab	41	40 (97.6)	0.10 (0.06)	(-0.01, 0.21)	0.07 (0.09)	(-0.12, 0.25)	0.472
		Placebo	25	25 (100.0)	0.03 (0.07)	(-0.11, 0.18)			
	Week 24	Tezepelumab	41	40 (97.6)	0.08 (0.05)	(-0.02, 0.18)	0.05 (0.08)	(-0.12, 0.22)	0.558
		Placebo	25	23 (92.0)	0.03 (0.07)	(-0.10, 0.16)			
	Week 36	Tezepelumab	41	39 (95.1)	0.06 (0.05)	(-0.04, 0.17)	-0.02 (0.08)	(-0.19, 0.15)	0.798
		Placebo	25	22 (88.0)	0.09 (0.07)	(-0.05, 0.22)			
	Week 52	Tezepelumab	41	38 (92.7)	0.05 (0.05)	(-0.05, 0.15)	0.00 (0.08)	(-0.16, 0.17)	0.964
		Placebo	25	21 (84.0)	0.04 (0.07)	(-0.09, 0.18)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Montelukast/ Cromoglicic acid use at baseline									0.307
Yes	Week 2	Tezepelumab	19	18 (94.7)	0.08 (0.05)	(-0.02, 0.18)	0.13 (0.08)	(-0.03, 0.29)	0.114
		Placebo	13	10 (76.9)	-0.05 (0.06)	(-0.17, 0.08)			
	Week 4	Tezepelumab	19	19 (100.0)	0.16 (0.09)	(-0.02, 0.34)	0.17 (0.14)	(-0.12, 0.45)	0.242
		Placebo	13	12 (92.3)	-0.01 (0.11)	(-0.23, 0.21)			
	Week 8	Tezepelumab	19	18 (94.7)	0.07 (0.08)	(-0.09, 0.23)	0.07 (0.12)	(-0.18, 0.31)	0.567
		Placebo	13	13 (100.0)	0.00 (0.09)	(-0.19, 0.19)			
	Week 12	Tezepelumab	19	18 (94.7)	0.13 (0.08)	(-0.02, 0.29)	0.13 (0.12)	(-0.11, 0.37)	0.285
		Placebo	13	13 (100.0)	0.00 (0.09)	(-0.18, 0.19)			
	Week 16	Tezepelumab	19	18 (94.7)	0.15 (0.08)	(-0.02, 0.31)	0.20 (0.13)	(-0.06, 0.45)	0.125
		Placebo	13	13 (100.0)	-0.05 (0.10)	(-0.25, 0.14)			
	Week 24	Tezepelumab	19	19 (100.0)	0.12 (0.07)	(-0.02, 0.26)	0.19 (0.11)	(-0.03, 0.41)	0.091
		Placebo	13	12 (92.3)	-0.07 (0.08)	(-0.24, 0.10)			
	Week 36	Tezepelumab	19	18 (94.7)	0.08 (0.07)	(-0.07, 0.23)	0.11 (0.11)	(-0.12, 0.35)	0.344
		Placebo	13	13 (100.0)	-0.04 (0.09)	(-0.22, 0.14)			
	Week 52	Tezepelumab	19	18 (94.7)	0.08 (0.09)	(-0.09, 0.26)	0.17 (0.14)	(-0.11, 0.45)	0.219
		Placebo	13	10 (76.9)	-0.09 (0.11)	(-0.31, 0.13)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 2	Tezepelumab	35	34 (97.1)	0.04 (0.04)	(-0.05, 0.12)	0.03 (0.07)	(-0.11, 0.16)	0.688
		Placebo	26	24 (92.3)	0.01 (0.05)	(-0.09, 0.11)			
	Week 4	Tezepelumab	35	35 (100.0)	0.00 (0.05)	(-0.10, 0.11)	-0.10 (0.08)	(-0.25, 0.06)	0.203
		Placebo	26	26 (100.0)	0.10 (0.06)	(-0.01, 0.22)			
	Week 8	Tezepelumab	35	34 (97.1)	0.08 (0.05)	(-0.02, 0.18)	-0.02 (0.08)	(-0.17, 0.14)	0.824
		Placebo	26	25 (96.2)	0.09 (0.06)	(-0.02, 0.21)			
	Week 12	Tezepelumab	35	35 (100.0)	0.03 (0.05)	(-0.06, 0.12)	-0.07 (0.07)	(-0.21, 0.07)	0.327
		Placebo	26	25 (96.2)	0.10 (0.05)	(-0.01, 0.20)			
	Week 16	Tezepelumab	35	35 (100.0)	0.08 (0.05)	(-0.03, 0.19)	0.01 (0.08)	(-0.15, 0.18)	0.892
		Placebo	26	25 (96.2)	0.07 (0.06)	(-0.06, 0.19)			
	Week 24	Tezepelumab	35	34 (97.1)	0.04 (0.05)	(-0.06, 0.14)	-0.03 (0.08)	(-0.19, 0.12)	0.667
		Placebo	26	23 (88.5)	0.07 (0.06)	(-0.05, 0.19)			
	Week 36	Tezepelumab	35	34 (97.1)	0.03 (0.05)	(-0.07, 0.13)	-0.13 (0.08)	(-0.28, 0.03)	0.108
		Placebo	26	21 (80.8)	0.16 (0.06)	(0.04, 0.28)			
	Week 52	Tezepelumab	35	32 (91.4)	0.01 (0.04)	(-0.08, 0.10)	-0.10 (0.07)	(-0.24, 0.04)	0.152
		Placebo	26	24 (92.3)	0.11 (0.05)	(0.00, 0.21)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Western Europe	Absolute values	Baseline	Tezepelumab	11	11 (100.0)	2.02 (0.40)	1.4	1.65	2.02	2.39	2.6	
			Placebo	13	13 (100.0)	1.74 (0.57)	0.9	1.45	1.83	2.16	2.8	
		Week 2	Tezepelumab	11	11 (100.0)	2.10 (0.44)	1.4	1.70	2.17	2.47	2.7	
			Placebo	13	11 (84.6)	1.90 (0.62)	0.9	1.46	1.97	2.31	2.8	
		Week 4	Tezepelumab	11	11 (100.0)	2.06 (0.42)	1.4	1.65	2.07	2.45	2.6	
			Placebo	13	13 (100.0)	1.84 (0.64)	1.0	1.55	1.64	2.35	3.0	
		Week 8	Tezepelumab	11	11 (100.0)	2.06 (0.51)	1.2	1.58	2.11	2.53	2.7	
			Placebo	13	12 (92.3)	1.82 (0.70)	0.8	1.24	1.84	2.33	2.8	
		Week 12	Tezepelumab	11	11 (100.0)	2.01 (0.44)	1.2	1.62	2.18	2.39	2.5	
			Placebo	13	12 (92.3)	1.79 (0.69)	0.8	1.36	1.57	2.39	3.0	
		Week 16	Tezepelumab	11	11 (100.0)	2.08 (0.49)	1.2	1.63	2.22	2.34	3.0	
			Placebo	13	12 (92.3)	1.82 (0.65)	0.9	1.37	1.75	2.23	3.0	
		Week 24	Tezepelumab	11	11 (100.0)	1.99 (0.42)	1.2	1.61	2.26	2.30	2.4	
			Placebo	13	12 (92.3)	1.73 (0.57)	0.8	1.26	1.67	2.22	2.7	
		Week 36	Tezepelumab	11	11 (100.0)	2.00 (0.50)	1.2	1.53	2.10	2.50	2.6	
			Placebo	13	10 (76.9)	1.88 (0.64)	1.1	1.19	1.78	2.36	3.0	
		Week 52	Tezepelumab	11	10 (90.9)	1.99 (0.45)	1.2	1.64	2.20	2.26	2.6	
			Placebo	13	12 (92.3)	1.92 (0.63)	1.0	1.39	2.06	2.30	2.9	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Western Europe	Change from baseline	Week 2	Tezepelumab	11	11 (100.0)	0.08 (0.22)	-0.3	-0.01	0.05	0.15	0.5	0.04 [-0.80, 0.87]
			Placebo	13	11 (84.6)	0.07 (0.21)	-0.1	-0.07	0.01	0.10	0.5	
		Week 4	Tezepelumab	11	11 (100.0)	0.04 (0.23)	-0.5	-0.06	0.05	0.22	0.3	-0.26 [-1.06, 0.55]
			Placebo	13	13 (100.0)	0.10 (0.23)	-0.3	-0.02	0.11	0.24	0.5	
		Week 8	Tezepelumab	11	11 (100.0)	0.04 (0.25)	-0.2	-0.09	-0.06	0.04	0.7	0.06 [-0.76, 0.88]
			Placebo	13	12 (92.3)	0.02 (0.32)	-0.8	-0.07	0.02	0.13	0.5	
		Week 12	Tezepelumab	11	11 (100.0)	-0.01 (0.18)	-0.2	-0.18	-0.03	0.10	0.4	-0.21 [-1.03, 0.61]
			Placebo	13	12 (92.3)	0.04 (0.28)	-0.4	-0.11	0.03	0.28	0.4	
		Week 16	Tezepelumab	11	11 (100.0)	0.06 (0.28)	-0.3	-0.22	0.03	0.18	0.7	-0.05 [-0.87, 0.77]
			Placebo	13	12 (92.3)	0.07 (0.28)	-0.6	-0.01	0.02	0.23	0.5	
		Week 24	Tezepelumab	11	11 (100.0)	-0.03 (0.16)	-0.2	-0.18	-0.05	0.10	0.3	-0.04 [-0.86, 0.78]
			Placebo	13	12 (92.3)	-0.02 (0.21)	-0.5	-0.11	-0.01	0.06	0.4	
		Week 36	Tezepelumab	11	11 (100.0)	-0.02 (0.28)	-0.5	-0.18	-0.05	0.11	0.6	-0.71 [-1.60, 0.17]
			Placebo	13	10 (76.9)	0.16 (0.23)	-0.3	0.08	0.25	0.31	0.4	
		Week 52	Tezepelumab	11	10 (90.9)	-0.01 (0.20)	-0.4	-0.05	-0.01	0.10	0.2	-0.95 [-1.84, -0.06]
			Placebo	13	12 (92.3)	0.17 (0.18)	-0.1	0.02	0.14	0.32	0.5	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
North America	Absolute values	Baseline	Tezepelumab	14	14 (100.0)	1.89 (0.65)	0.9	1.28	1.89	2.52	3.2	
			Placebo	8	8 (100.0)	1.68 (0.54)	1.0	1.23	1.62	2.10	2.5	
		Week 2	Tezepelumab	14	13 (92.9)	2.00 (0.64)	1.1	1.68	1.97	2.52	3.4	
			Placebo	8	6 (75.0)	1.54 (0.64)	1.0	1.02	1.34	1.93	2.6	
		Week 4	Tezepelumab	14	14 (100.0)	1.92 (0.68)	0.7	1.64	1.91	2.46	3.2	
			Placebo	8	7 (87.5)	1.71 (0.64)	1.0	1.10	1.46	2.32	2.7	
		Week 8	Tezepelumab	14	14 (100.0)	2.00 (0.59)	1.2	1.58	1.92	2.41	3.3	
			Placebo	8	8 (100.0)	1.68 (0.55)	0.8	1.38	1.71	1.90	2.7	
		Week 12	Tezepelumab	14	14 (100.0)	1.99 (0.71)	0.9	1.63	1.92	2.28	3.6	
			Placebo	8	8 (100.0)	1.75 (0.58)	1.0	1.36	1.68	2.14	2.7	
		Week 16	Tezepelumab	14	14 (100.0)	2.06 (0.68)	1.3	1.54	1.85	2.61	3.5	
			Placebo	8	8 (100.0)	1.65 (0.55)	1.0	1.24	1.55	2.03	2.6	
		Week 24	Tezepelumab	14	14 (100.0)	1.93 (0.70)	0.8	1.52	1.87	2.32	3.5	
			Placebo	8	8 (100.0)	1.71 (0.57)	1.1	1.32	1.49	2.12	2.7	
		Week 36	Tezepelumab	14	14 (100.0)	2.00 (0.64)	1.1	1.44	1.98	2.34	3.5	
			Placebo	8	8 (100.0)	1.68 (0.61)	1.0	1.23	1.51	2.10	2.7	
		Week 52	Tezepelumab	14	13 (92.9)	2.03 (0.63)	1.0	1.59	1.98	2.27	3.4	
			Placebo	8	6 (75.0)	1.62 (0.66)	1.0	1.15	1.48	1.83	2.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
North America	Change from baseline	Week 2	Tezepelumab	14	13 (92.9)	0.09 (0.17)	-0.2	0.01	0.04	0.18	0.5	0.36 [-0.61, 1.34]
			Placebo	8	6 (75.0)	0.03 (0.15)	-0.1	-0.07	-0.02	0.04	0.3	
		Week 4	Tezepelumab	14	14 (100.0)	0.03 (0.22)	-0.3	-0.13	0.02	0.15	0.6	-0.17 [-1.07, 0.74]
			Placebo	8	7 (87.5)	0.07 (0.17)	-0.2	-0.04	0.08	0.10	0.4	
		Week 8	Tezepelumab	14	14 (100.0)	0.11 (0.25)	-0.2	-0.05	0.08	0.18	0.7	0.41 [-0.47, 1.29]
			Placebo	8	8 (100.0)	0.00 (0.30)	-0.5	-0.18	0.04	0.24	0.4	
		Week 12	Tezepelumab	14	14 (100.0)	0.10 (0.24)	-0.2	-0.05	0.04	0.30	0.5	0.11 [-0.76, 0.98]
			Placebo	8	8 (100.0)	0.08 (0.19)	-0.1	-0.06	0.02	0.23	0.4	
		Week 16	Tezepelumab	14	14 (100.0)	0.17 (0.25)	-0.4	0.02	0.17	0.34	0.7	0.84 [-0.07, 1.75]
			Placebo	8	8 (100.0)	-0.03 (0.19)	-0.3	-0.15	-0.03	0.08	0.3	
		Week 24	Tezepelumab	14	14 (100.0)	0.04 (0.24)	-0.4	-0.12	0.01	0.29	0.4	0.03 [-0.83, 0.90]
			Placebo	8	8 (100.0)	0.03 (0.25)	-0.4	-0.12	0.08	0.12	0.4	
		Week 36	Tezepelumab	14	14 (100.0)	0.11 (0.24)	-0.3	-0.10	0.16	0.24	0.6	0.48 [-0.40, 1.36]
			Placebo	8	8 (100.0)	0.00 (0.20)	-0.3	-0.08	-0.04	0.05	0.4	
		Week 52	Tezepelumab	14	13 (92.9)	0.06 (0.26)	-0.3	-0.01	0.09	0.16	0.7	0.17 [-0.79, 1.14]
			Placebo	8	6 (75.0)	0.02 (0.25)	-0.3	-0.08	-0.04	0.04	0.5	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
South America	Absolute values	Baseline	Tezepelumab	5	5 (100.0)	1.80 (0.81)	0.8	1.14	2.12	2.37	2.6	
			Placebo	3	3 (100.0)	2.43 (0.90)	1.5	1.45	2.61	3.23	3.2	
		Week 2	Tezepelumab	5	5 (100.0)	1.75 (0.83)	0.9	1.04	1.72	2.13	2.9	
			Placebo	3	3 (100.0)	2.71 (1.26)	1.6	1.61	2.43	4.09	4.1	
		Week 4	Tezepelumab	5	5 (100.0)	1.76 (0.80)	0.8	1.06	2.06	2.17	2.7	
			Placebo	3	3 (100.0)	3.08 (1.59)	1.7	1.73	2.68	4.83	4.8	
		Week 8	Tezepelumab	5	5 (100.0)	1.82 (0.89)	0.7	1.18	1.92	2.59	2.8	
			Placebo	3	3 (100.0)	2.98 (1.50)	1.7	1.65	2.69	4.61	4.6	
		Week 12	Tezepelumab	5	5 (100.0)	1.85 (0.88)	0.8	1.08	2.20	2.49	2.7	
			Placebo	3	3 (100.0)	2.97 (1.54)	1.5	1.51	2.83	4.58	4.6	
		Week 16	Tezepelumab	5	5 (100.0)	1.81 (0.67)	0.9	1.39	1.91	2.27	2.6	
			Placebo	3	3 (100.0)	3.06 (1.53)	1.6	1.63	2.87	4.67	4.7	
		Week 24	Tezepelumab	5	5 (100.0)	1.99 (0.81)	1.1	1.12	2.55	2.55	2.6	
			Placebo	3	2 (66.7)	3.74 (1.52)	2.7	2.66	3.74	4.81	4.8	
		Week 36	Tezepelumab	5	5 (100.0)	1.77 (0.83)	0.8	1.15	1.85	2.20	2.9	
			Placebo	3	3 (100.0)	2.91 (1.42)	1.5	1.49	2.91	4.33	4.3	
		Week 52	Tezepelumab	5	5 (100.0)	1.70 (0.74)	0.7	1.22	1.79	2.30	2.5	
			Placebo	3	3 (100.0)	2.64 (1.44)	1.1	1.14	2.76	4.01	4.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
South America	Change from baseline	Week 2	Tezepelumab	5	5 (100.0)	-0.06 (0.37)	-0.7	-0.10	0.01	0.15	0.3	-0.79 [-2.28, 0.71]
			Placebo	3	3 (100.0)	0.28 (0.53)	-0.2	-0.18	0.16	0.86	0.9	
		Week 4	Tezepelumab	5	5 (100.0)	-0.05 (0.16)	-0.3	-0.08	0.04	0.05	0.1	-1.40 [-3.04, 0.23]
			Placebo	3	3 (100.0)	0.65 (0.83)	0.1	0.07	0.28	1.60	1.6	
		Week 8	Tezepelumab	5	5 (100.0)	0.02 (0.33)	-0.5	-0.08	0.04	0.13	0.5	-1.07 [-2.62, 0.48]
			Placebo	3	3 (100.0)	0.55 (0.72)	0.1	0.08	0.20	1.38	1.4	
		Week 12	Tezepelumab	5	5 (100.0)	0.05 (0.08)	-0.1	0.00	0.08	0.10	0.1	-1.21 [-2.79, 0.38]
			Placebo	3	3 (100.0)	0.54 (0.70)	0.1	0.06	0.22	1.35	1.4	
		Week 16	Tezepelumab	5	5 (100.0)	0.01 (0.28)	-0.5	-0.05	0.14	0.15	0.3	-1.33 [-2.94, 0.29]
			Placebo	3	3 (100.0)	0.63 (0.71)	0.2	0.18	0.26	1.44	1.4	
		Week 24	Tezepelumab	5	5 (100.0)	0.19 (0.22)	-0.1	-0.02	0.27	0.34	0.4	-1.19 [-2.99, 0.60]
			Placebo	3	2 (66.7)	0.82 (1.08)	0.1	0.05	0.82	1.58	1.6	
		Week 36	Tezepelumab	5	5 (100.0)	-0.03 (0.54)	-0.8	-0.17	0.01	0.03	0.8	-0.93 [-2.46, 0.59]
			Placebo	3	3 (100.0)	0.48 (0.55)	0.0	0.04	0.30	1.10	1.1	
		Week 52	Tezepelumab	5	5 (100.0)	-0.11 (0.44)	-0.8	-0.07	-0.06	0.08	0.4	-0.65 [-2.13, 0.82]
			Placebo	3	3 (100.0)	0.21 (0.55)	-0.3	-0.31	0.15	0.78	0.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Central/Eastern Europe	Absolute values	Baseline	Tezepelumab	4	4 (100.0)	1.50 (0.24)	1.3	1.29	1.51	1.71	1.7	
			Placebo	4	4 (100.0)	1.29 (0.33)	0.8	1.10	1.44	1.49	1.5	
		Week 2	Tezepelumab	4	4 (100.0)	1.75 (0.50)	1.4	1.47	1.56	2.04	2.5	
			Placebo	4	4 (100.0)	1.23 (0.37)	0.8	0.94	1.23	1.52	1.7	
		Week 4	Tezepelumab	4	4 (100.0)	2.02 (0.97)	1.3	1.47	1.68	2.57	3.4	
			Placebo	4	4 (100.0)	1.21 (0.26)	0.9	1.03	1.26	1.39	1.5	
		Week 8	Tezepelumab	4	4 (100.0)	1.81 (0.74)	1.2	1.38	1.61	2.25	2.9	
			Placebo	4	4 (100.0)	1.28 (0.33)	0.8	1.08	1.39	1.48	1.5	
		Week 12	Tezepelumab	4	4 (100.0)	1.81 (0.87)	1.2	1.30	1.46	2.32	3.1	
			Placebo	4	4 (100.0)	1.28 (0.32)	0.9	1.08	1.34	1.49	1.6	
		Week 16	Tezepelumab	4	4 (100.0)	2.03 (0.86)	1.4	1.50	1.70	2.57	3.3	
			Placebo	4	4 (100.0)	1.28 (0.32)	0.9	1.09	1.32	1.48	1.6	
		Week 24	Tezepelumab	4	4 (100.0)	1.69 (0.71)	1.1	1.25	1.49	2.14	2.7	
			Placebo	4	4 (100.0)	1.35 (0.36)	0.8	1.10	1.43	1.59	1.7	
		Week 36	Tezepelumab	4	4 (100.0)	1.79 (0.69)	1.3	1.37	1.55	2.21	2.8	
			Placebo	4	4 (100.0)	1.38 (0.37)	0.9	1.15	1.43	1.62	1.8	
		Week 52	Tezepelumab	4	4 (100.0)	1.75 (0.70)	1.1	1.33	1.57	2.18	2.8	
			Placebo	4	4 (100.0)	1.30 (0.33)	0.9	1.05	1.38	1.55	1.6	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Central/Eastern Europe	Change from baseline	Week 2	Tezepelumab	4	4 (100.0)	0.25 (0.38)	-0.1	-0.01	0.18	0.52	0.8	1.01 [-0.49, 2.51]
			Placebo	4	4 (100.0)	-0.07 (0.24)	-0.4	-0.21	-0.01	0.07	0.2	
		Week 4	Tezepelumab	4	4 (100.0)	0.52 (0.83)	-0.0	-0.03	0.19	1.06	1.7	1.01 [-0.49, 2.51]
			Placebo	4	4 (100.0)	-0.09 (0.15)	-0.3	-0.18	-0.05	0.01	0.0	
		Week 8	Tezepelumab	4	4 (100.0)	0.31 (0.60)	-0.1	-0.11	0.11	0.73	1.2	0.77 [-0.68, 2.23]
			Placebo	4	4 (100.0)	-0.01 (0.05)	-0.1	-0.05	-0.01	0.02	0.1	
		Week 12	Tezepelumab	4	4 (100.0)	0.31 (0.75)	-0.3	-0.21	0.08	0.82	1.4	0.59 [-0.84, 2.01]
			Placebo	4	4 (100.0)	-0.01 (0.13)	-0.2	-0.10	0.02	0.09	0.1	
		Week 16	Tezepelumab	4	4 (100.0)	0.53 (0.70)	0.1	0.13	0.22	0.94	1.6	1.07 [-0.44, 2.58]
			Placebo	4	4 (100.0)	-0.01 (0.14)	-0.2	-0.12	0.00	0.10	0.1	
		Week 24	Tezepelumab	4	4 (100.0)	0.19 (0.54)	-0.2	-0.15	-0.02	0.54	1.0	0.36 [-1.04, 1.76]
			Placebo	4	4 (100.0)	0.05 (0.10)	-0.0	-0.01	0.02	0.12	0.2	
		Week 36	Tezepelumab	4	4 (100.0)	0.29 (0.55)	-0.1	-0.07	0.07	0.65	1.1	0.49 [-0.92, 1.91]
			Placebo	4	4 (100.0)	0.09 (0.15)	-0.1	-0.01	0.07	0.19	0.3	
		Week 52	Tezepelumab	4	4 (100.0)	0.25 (0.56)	-0.2	-0.15	0.09	0.65	1.0	0.59 [-0.83, 2.02]
			Placebo	4	4 (100.0)	0.01 (0.17)	-0.3	-0.10	0.07	0.11	0.1	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Asia Pacific	Absolute values	Baseline	Tezepelumab	13	13 (100.0)	1.69 (0.62)	0.4	1.44	1.74	2.13	2.8	
			Placebo	6	6 (100.0)	1.80 (0.20)	1.5	1.69	1.76	1.93	2.1	
		Week 2	Tezepelumab	13	13 (100.0)	1.66 (0.50)	0.6	1.29	1.59	2.03	2.4	
			Placebo	6	6 (100.0)	1.73 (0.17)	1.4	1.71	1.75	1.85	1.9	
		Week 4	Tezepelumab	13	13 (100.0)	1.71 (0.55)	0.7	1.44	1.64	2.13	2.5	
			Placebo	6	6 (100.0)	1.78 (0.15)	1.6	1.69	1.79	1.85	2.0	
		Week 8	Tezepelumab	13	12 (92.3)	1.69 (0.50)	0.6	1.43	1.65	2.08	2.4	
			Placebo	6	6 (100.0)	1.89 (0.31)	1.7	1.74	1.78	1.82	2.5	
		Week 12	Tezepelumab	13	12 (92.3)	1.67 (0.49)	0.6	1.47	1.59	2.08	2.4	
			Placebo	6	6 (100.0)	1.77 (0.23)	1.5	1.66	1.71	1.93	2.1	
		Week 16	Tezepelumab	13	13 (100.0)	1.73 (0.62)	0.6	1.37	1.67	2.26	2.6	
			Placebo	6	6 (100.0)	1.72 (0.04)	1.7	1.70	1.71	1.76	1.8	
		Week 24	Tezepelumab	13	13 (100.0)	1.76 (0.38)	1.1	1.61	1.76	1.89	2.4	
			Placebo	6	6 (100.0)	1.75 (0.30)	1.3	1.63	1.70	2.07	2.1	
		Week 36	Tezepelumab	13	13 (100.0)	1.71 (0.55)	0.9	1.33	1.54	2.12	2.8	
			Placebo	6	6 (100.0)	1.73 (0.16)	1.5	1.69	1.72	1.88	1.9	
		Week 52	Tezepelumab	13	13 (100.0)	1.71 (0.58)	0.8	1.43	1.60	2.11	2.9	
			Placebo	6	6 (100.0)	1.70 (0.08)	1.6	1.62	1.72	1.73	1.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Asia Pacific	Change from baseline	Week 2	Tezepelumab	13	13 (100.0)	-0.04 (0.24)	-0.6	-0.10	0.05	0.09	0.2	0.15 [-0.82, 1.12]
			Placebo	6	6 (100.0)	-0.07 (0.19)	-0.3	-0.26	-0.06	0.08	0.2	
		Week 4	Tezepelumab	13	13 (100.0)	0.02 (0.41)	-0.9	-0.13	0.12	0.27	0.6	0.09 [-0.88, 1.06]
			Placebo	6	6 (100.0)	-0.01 (0.18)	-0.3	-0.14	0.07	0.09	0.1	
		Week 8	Tezepelumab	13	12 (92.3)	0.02 (0.31)	-0.8	-0.06	0.15	0.23	0.3	-0.25 [-1.23, 0.73]
			Placebo	6	6 (100.0)	0.09 (0.20)	-0.2	-0.02	0.06	0.20	0.4	
		Week 12	Tezepelumab	13	12 (92.3)	0.02 (0.35)	-0.7	-0.09	0.08	0.16	0.7	0.16 [-0.82, 1.15]
			Placebo	6	6 (100.0)	-0.03 (0.04)	-0.1	-0.06	-0.02	0.00	0.0	
		Week 16	Tezepelumab	13	13 (100.0)	0.04 (0.26)	-0.6	-0.13	0.08	0.22	0.4	0.47 [-0.51, 1.45]
			Placebo	6	6 (100.0)	-0.08 (0.22)	-0.5	-0.15	-0.05	0.02	0.2	
		Week 24	Tezepelumab	13	13 (100.0)	0.07 (0.34)	-0.6	-0.07	0.02	0.16	0.7	0.36 [-0.62, 1.33]
			Placebo	6	6 (100.0)	-0.05 (0.29)	-0.4	-0.26	-0.06	0.09	0.4	
		Week 36	Tezepelumab	13	13 (100.0)	0.02 (0.37)	-0.7	-0.13	0.04	0.25	0.6	0.27 [-0.70, 1.25]
			Placebo	6	6 (100.0)	-0.07 (0.19)	-0.2	-0.19	-0.15	0.15	0.2	
		Week 52	Tezepelumab	13	13 (100.0)	0.02 (0.47)	-1.0	-0.07	0.00	0.35	0.7	0.29 [-0.69, 1.26]
			Placebo	6	6 (100.0)	-0.10 (0.25)	-0.5	-0.22	-0.10	0.12	0.2	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Rest of the world	Absolute values	Baseline	Tezepelumab	7	7 (100.0)	1.51 (0.92)	0.6	0.83	1.23	2.02	3.3	
			Placebo	5	5 (100.0)	1.71 (0.31)	1.4	1.44	1.77	1.88	2.1	
		Week 2	Tezepelumab	7	6 (85.7)	1.56 (0.86)	0.7	0.90	1.43	1.94	2.9	
			Placebo	5	4 (80.0)	1.50 (0.31)	1.2	1.25	1.53	1.76	1.8	
		Week 4	Tezepelumab	7	7 (100.0)	1.53 (0.90)	0.7	0.74	1.53	1.94	3.3	
			Placebo	5	5 (100.0)	1.65 (0.28)	1.3	1.38	1.80	1.87	1.9	
		Week 8	Tezepelumab	7	6 (85.7)	1.36 (0.57)	0.7	0.88	1.32	1.90	2.0	
			Placebo	5	5 (100.0)	1.71 (0.33)	1.3	1.48	1.81	1.98	2.0	
		Week 12	Tezepelumab	7	7 (100.0)	1.55 (0.90)	0.7	0.81	1.44	1.83	3.3	
			Placebo	5	5 (100.0)	1.74 (0.45)	1.2	1.42	1.74	2.10	2.3	
		Week 16	Tezepelumab	7	6 (85.7)	1.47 (0.92)	0.6	0.92	1.20	1.85	3.1	
			Placebo	5	5 (100.0)	1.55 (0.49)	0.8	1.33	1.78	1.78	2.0	
		Week 24	Tezepelumab	7	6 (85.7)	1.30 (0.62)	0.6	0.82	1.24	1.92	2.0	
			Placebo	5	3 (60.0)	1.39 (0.46)	0.9	0.93	1.40	1.85	1.9	
		Week 36	Tezepelumab	7	5 (71.4)	1.15 (0.56)	0.5	0.85	0.91	1.65	1.8	
			Placebo	5	3 (60.0)	1.66 (0.25)	1.5	1.47	1.57	1.94	1.9	
		Week 52	Tezepelumab	7	5 (71.4)	1.30 (0.56)	0.9	0.89	0.90	1.87	2.0	
			Placebo	5	3 (60.0)	1.40 (0.31)	1.1	1.06	1.47	1.66	1.7	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. N)												
Rest of the world	Change from baseline	Week 2	Tezepelumab	7	6 (85.7)	0.01 (0.20)	-0.3	-0.08	0.04	0.12	0.3	0.93 [-0.42, 2.27]
			Placebo	5	4 (80.0)	-0.16 (0.16)	-0.3	-0.30	-0.18	-0.03	0.0	
		Week 4	Tezepelumab	7	7 (100.0)	0.02 (0.23)	-0.4	-0.18	0.06	0.25	0.3	0.38 [-0.78, 1.54]
			Placebo	5	5 (100.0)	-0.06 (0.16)	-0.3	-0.13	0.02	0.03	0.1	
		Week 8	Tezepelumab	7	6 (85.7)	0.14 (0.18)	-0.0	-0.01	0.11	0.21	0.5	0.83 [-0.41, 2.08]
			Placebo	5	5 (100.0)	0.01 (0.12)	-0.2	-0.07	0.04	0.10	0.1	
		Week 12	Tezepelumab	7	7 (100.0)	0.04 (0.14)	-0.2	-0.11	0.07	0.14	0.2	0.03 [-1.12, 1.18]
			Placebo	5	5 (100.0)	0.03 (0.22)	-0.3	-0.03	0.00	0.07	0.4	
		Week 16	Tezepelumab	7	6 (85.7)	-0.08 (0.26)	-0.6	-0.15	-0.03	0.09	0.2	0.29 [-0.91, 1.48]
			Placebo	5	5 (100.0)	-0.16 (0.27)	-0.6	-0.10	-0.06	-0.02	0.0	
		Week 24	Tezepelumab	7	6 (85.7)	0.09 (0.18)	-0.1	-0.03	0.02	0.23	0.4	1.50 [-0.09, 3.09]
			Placebo	5	3 (60.0)	-0.24 (0.28)	-0.5	-0.51	-0.25	0.05	0.0	
		Week 36	Tezepelumab	7	5 (71.4)	-0.07 (0.20)	-0.4	-0.11	-0.07	0.08	0.1	-0.49 [-1.95, 0.97]
			Placebo	5	3 (60.0)	0.03 (0.19)	-0.2	-0.16	0.03	0.22	0.2	
		Week 52	Tezepelumab	7	5 (71.4)	0.09 (0.19)	-0.1	-0.02	0.06	0.27	0.3	1.01 [-0.53, 2.55]
			Placebo	5	3 (60.0)	-0.12 (0.25)	-0.4	-0.38	-0.11	0.12	0.1	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
< 150 cells/uL	Absolute values	Baseline	Tezepelumab	32	32 (100.0)	1.71 (0.71)	0.4	1.25	1.73	2.06	3.3	
			Placebo	21	21 (100.0)	1.78 (0.52)	0.8	1.49	1.81	2.11	2.8	
		Week 2	Tezepelumab	32	31 (96.9)	1.78 (0.68)	0.6	1.29	1.79	2.36	3.4	
			Placebo	21	17 (81.0)	1.77 (0.56)	0.8	1.41	1.74	1.97	2.8	
		Week 4	Tezepelumab	32	32 (100.0)	1.78 (0.77)	0.7	1.23	1.66	2.44	3.4	
			Placebo	21	21 (100.0)	1.77 (0.56)	0.9	1.46	1.76	1.99	3.0	
		Week 8	Tezepelumab	32	30 (93.8)	1.73 (0.65)	0.6	1.23	1.68	2.05	3.3	
			Placebo	21	21 (100.0)	1.77 (0.61)	0.8	1.41	1.79	1.98	2.8	
		Week 12	Tezepelumab	32	32 (100.0)	1.76 (0.73)	0.6	1.23	1.68	2.23	3.6	
			Placebo	21	20 (95.2)	1.78 (0.61)	0.9	1.40	1.65	2.20	3.0	
		Week 16	Tezepelumab	32	31 (96.9)	1.85 (0.77)	0.6	1.43	1.65	2.28	3.5	
			Placebo	21	20 (95.2)	1.76 (0.59)	0.9	1.37	1.71	2.00	3.0	
		Week 24	Tezepelumab	32	31 (96.9)	1.73 (0.64)	0.6	1.12	1.70	2.26	3.5	
			Placebo	21	19 (90.5)	1.78 (0.51)	0.8	1.49	1.72	2.11	2.7	
		Week 36	Tezepelumab	32	30 (93.8)	1.70 (0.66)	0.5	1.25	1.63	2.12	3.5	
			Placebo	21	18 (85.7)	1.85 (0.60)	0.9	1.45	1.79	2.36	3.0	
		Week 52	Tezepelumab	32	28 (87.5)	1.73 (0.65)	0.7	1.16	1.73	2.20	3.4	
			Placebo	21	18 (85.7)	1.78 (0.59)	0.9	1.52	1.71	2.15	2.9	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
< 150 cells/uL	Change from baseline	Week 2	Tezepelumab	32	31 (96.9)	0.06 (0.25)	-0.6	-0.02	0.08	0.15	0.8	0.39 [-0.20, 0.99]
			Placebo	21	17 (81.0)	-0.03 (0.21)	-0.4	-0.10	-0.06	0.04	0.5	
		Week 4	Tezepelumab	32	32 (100.0)	0.08 (0.42)	-0.9	-0.11	0.04	0.28	1.7	0.24 [-0.31, 0.79]
			Placebo	21	21 (100.0)	-0.01 (0.18)	-0.3	-0.07	0.02	0.09	0.4	
		Week 8	Tezepelumab	32	30 (93.8)	0.08 (0.34)	-0.8	-0.08	0.03	0.16	1.2	0.30 [-0.26, 0.86]
			Placebo	21	21 (100.0)	-0.01 (0.27)	-0.8	-0.06	0.00	0.08	0.5	
		Week 12	Tezepelumab	32	32 (100.0)	0.06 (0.34)	-0.7	-0.10	0.02	0.19	1.4	0.23 [-0.33, 0.79]
			Placebo	21	20 (95.2)	-0.01 (0.20)	-0.4	-0.08	-0.02	0.09	0.4	
		Week 16	Tezepelumab	32	31 (96.9)	0.12 (0.40)	-0.6	-0.07	0.12	0.28	1.6	0.45 [-0.12, 1.02]
			Placebo	21	20 (95.2)	-0.03 (0.24)	-0.6	-0.10	-0.01	0.10	0.5	
		Week 24	Tezepelumab	32	31 (96.9)	0.07 (0.30)	-0.6	-0.10	0.00	0.22	1.0	0.30 [-0.27, 0.88]
			Placebo	21	19 (90.5)	-0.01 (0.19)	-0.5	-0.10	0.03	0.09	0.4	
		Week 36	Tezepelumab	32	30 (93.8)	0.03 (0.35)	-0.7	-0.12	0.01	0.21	1.1	-0.08 [-0.66, 0.50]
			Placebo	21	18 (85.7)	0.06 (0.20)	-0.3	-0.09	0.07	0.19	0.4	
		Week 52	Tezepelumab	32	28 (87.5)	0.05 (0.38)	-1.0	-0.07	0.03	0.23	1.0	0.04 [-0.55, 0.63]
			Placebo	21	18 (85.7)	0.04 (0.22)	-0.5	-0.07	0.07	0.13	0.5	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
150 - < 300 cells/uL	Absolute values	Baseline	Tezepelumab	22	22 (100.0)	1.89 (0.50)	1.0	1.48	1.91	2.37	2.6	
			Placebo	18	18 (100.0)	1.69 (0.55)	0.9	1.35	1.58	1.93	3.2	
		Week 2	Tezepelumab	22	21 (95.5)	1.93 (0.51)	1.0	1.58	1.94	2.18	2.9	
			Placebo	18	17 (94.4)	1.74 (0.77)	0.9	1.29	1.61	1.80	4.1	
		Week 4	Tezepelumab	22	22 (100.0)	1.92 (0.46)	1.1	1.64	1.97	2.24	2.8	
			Placebo	18	17 (94.4)	1.86 (0.91)	1.0	1.38	1.56	2.02	4.8	
		Week 8	Tezepelumab	22	22 (100.0)	1.98 (0.53)	1.2	1.58	1.91	2.43	2.8	
			Placebo	18	17 (94.4)	1.88 (0.84)	0.8	1.48	1.69	2.03	4.6	
		Week 12	Tezepelumab	22	21 (95.5)	1.95 (0.54)	1.1	1.55	1.83	2.39	3.0	
			Placebo	18	18 (100.0)	1.85 (0.83)	0.8	1.41	1.64	2.10	4.6	
		Week 16	Tezepelumab	22	22 (100.0)	1.95 (0.53)	1.1	1.49	1.88	2.39	3.0	
			Placebo	18	18 (100.0)	1.79 (0.86)	0.8	1.32	1.66	2.04	4.7	
		Week 24	Tezepelumab	22	22 (100.0)	1.94 (0.50)	1.1	1.61	1.90	2.38	2.9	
			Placebo	18	16 (88.9)	1.76 (0.96)	0.8	1.25	1.44	2.02	4.8	
		Week 36	Tezepelumab	22	22 (100.0)	1.95 (0.57)	1.1	1.51	1.84	2.50	2.9	
			Placebo	18	16 (88.9)	1.79 (0.80)	1.1	1.41	1.53	1.85	4.3	
		Week 52	Tezepelumab	22	22 (100.0)	1.91 (0.54)	1.0	1.54	1.88	2.30	2.9	
			Placebo	18	16 (88.9)	1.76 (0.78)	1.1	1.15	1.64	2.01	4.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. N)												
150 - < 300 cells/uL	Change from baseline	Week 2	Tezepelumab	22	21 (95.5)	0.02 (0.24)	-0.7	-0.01	0.01	0.09	0.5	-0.15 [-0.79, 0.49]
			Placebo	18	17 (94.4)	0.06 (0.28)	-0.3	-0.07	0.01	0.10	0.9	
		Week 4	Tezepelumab	22	22 (100.0)	0.03 (0.22)	-0.5	-0.08	0.03	0.15	0.6	-0.48 [-1.12, 0.16]
			Placebo	18	17 (94.4)	0.18 (0.41)	-0.3	0.01	0.10	0.28	1.6	
		Week 8	Tezepelumab	22	22 (100.0)	0.09 (0.23)	-0.5	-0.05	0.05	0.21	0.7	-0.24 [-0.87, 0.40]
			Placebo	18	17 (94.4)	0.16 (0.37)	-0.2	-0.07	0.11	0.20	1.4	
		Week 12	Tezepelumab	22	21 (95.5)	0.07 (0.23)	-0.3	-0.06	0.05	0.14	0.7	-0.31 [-0.95, 0.32]
			Placebo	18	18 (100.0)	0.16 (0.35)	-0.3	-0.03	0.06	0.26	1.4	
		Week 16	Tezepelumab	22	22 (100.0)	0.06 (0.20)	-0.5	-0.05	0.07	0.19	0.4	-0.14 [-0.77, 0.48]
			Placebo	18	18 (100.0)	0.10 (0.40)	-0.6	-0.06	0.02	0.19	1.4	
		Week 24	Tezepelumab	22	22 (100.0)	0.05 (0.24)	-0.3	-0.12	-0.01	0.23	0.6	-0.03 [-0.67, 0.62]
			Placebo	18	16 (88.9)	0.06 (0.48)	-0.5	-0.26	0.04	0.10	1.6	
		Week 36	Tezepelumab	22	22 (100.0)	0.06 (0.32)	-0.8	-0.15	0.04	0.16	0.8	-0.22 [-0.87, 0.42]
			Placebo	18	16 (88.9)	0.13 (0.34)	-0.3	-0.10	0.05	0.31	1.1	
		Week 52	Tezepelumab	22	22 (100.0)	0.02 (0.31)	-0.8	-0.07	0.00	0.16	0.7	-0.16 [-0.81, 0.48]
			Placebo	18	16 (88.9)	0.07 (0.31)	-0.4	-0.16	0.04	0.20	0.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q1: < 140 cells/uL	Absolute values	Baseline	Tezepelumab	28	28 (100.0)	1.68 (0.69)	0.4	1.21	1.81	2.06	3.2	
			Placebo	21	21 (100.0)	1.78 (0.52)	0.8	1.49	1.81	2.11	2.8	
		Week 2	Tezepelumab	28	27 (96.4)	1.77 (0.69)	0.6	1.23	1.80	2.36	3.4	
			Placebo	21	17 (81.0)	1.77 (0.56)	0.8	1.41	1.74	1.97	2.8	
		Week 4	Tezepelumab	28	28 (100.0)	1.76 (0.77)	0.7	1.06	1.67	2.44	3.4	
			Placebo	21	21 (100.0)	1.77 (0.56)	0.9	1.46	1.76	1.99	3.0	
		Week 8	Tezepelumab	28	27 (96.4)	1.75 (0.69)	0.6	1.23	1.68	2.11	3.3	
			Placebo	21	21 (100.0)	1.77 (0.61)	0.8	1.41	1.79	1.98	2.8	
		Week 12	Tezepelumab	28	28 (100.0)	1.75 (0.72)	0.6	1.21	1.75	2.23	3.6	
			Placebo	21	20 (95.2)	1.78 (0.61)	0.9	1.40	1.65	2.20	3.0	
		Week 16	Tezepelumab	28	27 (96.4)	1.84 (0.78)	0.6	1.29	1.67	2.28	3.5	
			Placebo	21	20 (95.2)	1.76 (0.59)	0.9	1.37	1.71	2.00	3.0	
		Week 24	Tezepelumab	28	28 (100.0)	1.75 (0.68)	0.6	1.11	1.82	2.28	3.5	
			Placebo	21	19 (90.5)	1.78 (0.51)	0.8	1.49	1.72	2.11	2.7	
		Week 36	Tezepelumab	28	27 (96.4)	1.74 (0.68)	0.5	1.16	1.86	2.14	3.5	
			Placebo	21	18 (85.7)	1.85 (0.60)	0.9	1.45	1.79	2.36	3.0	
		Week 52	Tezepelumab	28	25 (89.3)	1.76 (0.68)	0.7	1.21	1.80	2.20	3.4	
			Placebo	21	18 (85.7)	1.78 (0.59)	0.9	1.52	1.71	2.15	2.9	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q1: < 140 cells/uL	Change from baseline	Week 2	Tezepelumab	28	27 (96.4)	0.07 (0.26)	-0.6	-0.02	0.09	0.17	0.8	0.44 [-0.18, 1.05]
			Placebo	21	17 (81.0)	-0.03 (0.21)	-0.4	-0.10	-0.06	0.04	0.5	
		Week 4	Tezepelumab	28	28 (100.0)	0.08 (0.45)	-0.9	-0.16	0.04	0.30	1.7	0.24 [-0.33, 0.80]
			Placebo	21	21 (100.0)	-0.01 (0.18)	-0.3	-0.07	0.02	0.09	0.4	
		Week 8	Tezepelumab	28	27 (96.4)	0.08 (0.36)	-0.8	-0.09	0.01	0.15	1.2	0.27 [-0.30, 0.85]
			Placebo	21	21 (100.0)	-0.01 (0.27)	-0.8	-0.06	0.00	0.08	0.5	
		Week 12	Tezepelumab	28	28 (100.0)	0.06 (0.36)	-0.7	-0.14	0.04	0.20	1.4	0.24 [-0.34, 0.82]
			Placebo	21	20 (95.2)	-0.01 (0.20)	-0.4	-0.08	-0.02	0.09	0.4	
		Week 16	Tezepelumab	28	27 (96.4)	0.14 (0.42)	-0.6	-0.07	0.16	0.29	1.6	0.48 [-0.11, 1.06]
			Placebo	21	20 (95.2)	-0.03 (0.24)	-0.6	-0.10	-0.01	0.10	0.5	
		Week 24	Tezepelumab	28	28 (100.0)	0.07 (0.32)	-0.6	-0.10	0.00	0.24	1.0	0.28 [-0.30, 0.87]
			Placebo	21	19 (90.5)	-0.01 (0.19)	-0.5	-0.10	0.03	0.09	0.4	
		Week 36	Tezepelumab	28	27 (96.4)	0.05 (0.37)	-0.7	-0.12	0.03	0.22	1.1	-0.04 [-0.63, 0.56]
			Placebo	21	18 (85.7)	0.06 (0.20)	-0.3	-0.09	0.07	0.19	0.4	
		Week 52	Tezepelumab	28	25 (89.3)	0.06 (0.40)	-1.0	-0.06	0.06	0.24	1.0	0.07 [-0.54, 0.67]
			Placebo	21	18 (85.7)	0.04 (0.22)	-0.5	-0.07	0.07	0.13	0.5	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q2: 140 - < 250 cells/uL	Absolute values	Baseline	Tezepelumab	22	22 (100.0)	1.89 (0.56)	1.1	1.47	1.70	2.37	3.3	
			Placebo	11	11 (100.0)	1.66 (0.41)	0.9	1.36	1.70	1.93	2.3	
		Week 2	Tezepelumab	22	21 (95.5)	1.92 (0.55)	1.0	1.55	1.72	2.38	2.9	
			Placebo	11	10 (90.9)	1.64 (0.51)	0.9	1.29	1.66	1.76	2.6	
		Week 4	Tezepelumab	22	22 (100.0)	1.92 (0.56)	1.1	1.59	1.74	2.25	3.3	
			Placebo	11	10 (90.9)	1.75 (0.53)	1.0	1.38	1.65	2.02	2.7	
		Week 8	Tezepelumab	22	21 (95.5)	1.90 (0.51)	1.2	1.58	1.75	2.38	2.8	
			Placebo	11	11 (100.0)	1.72 (0.49)	0.8	1.48	1.69	1.81	2.7	
		Week 12	Tezepelumab	22	21 (95.5)	1.91 (0.63)	1.1	1.46	1.66	2.39	3.3	
			Placebo	11	11 (100.0)	1.72 (0.54)	0.8	1.42	1.66	1.93	2.7	
		Week 16	Tezepelumab	22	22 (100.0)	1.95 (0.57)	1.2	1.49	1.84	2.41	3.1	
			Placebo	11	11 (100.0)	1.60 (0.52)	0.8	1.26	1.68	1.78	2.6	
		Week 24	Tezepelumab	22	21 (95.5)	1.84 (0.49)	1.1	1.59	1.71	2.13	2.9	
			Placebo	11	9 (81.8)	1.56 (0.60)	0.8	1.29	1.46	1.67	2.7	
		Week 36	Tezepelumab	22	21 (95.5)	1.82 (0.55)	1.1	1.43	1.71	2.20	2.8	
			Placebo	11	9 (81.8)	1.63 (0.44)	1.2	1.46	1.49	1.59	2.7	
		Week 52	Tezepelumab	22	21 (95.5)	1.79 (0.54)	1.0	1.44	1.60	2.20	2.9	
			Placebo	11	11 (100.0)	1.62 (0.53)	1.1	1.14	1.62	1.73	2.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q2: 140 - < 250 cells/uL	Change from baseline	Week 2	Tezepelumab	22	21 (95.5)	0.02 (0.23)	-0.7	-0.01	0.04	0.09	0.5	0.06 [-0.70, 0.81]
			Placebo	11	10 (90.9)	0.01 (0.17)	-0.3	-0.07	0.02	0.10	0.3	
		Week 4	Tezepelumab	22	22 (100.0)	0.03 (0.15)	-0.3	-0.07	0.04	0.15	0.3	-0.52 [-1.28, 0.24]
			Placebo	11	10 (90.9)	0.12 (0.17)	-0.1	0.03	0.10	0.28	0.4	
		Week 8	Tezepelumab	22	21 (95.5)	0.08 (0.22)	-0.5	-0.05	0.04	0.19	0.7	0.07 [-0.66, 0.80]
			Placebo	11	11 (100.0)	0.06 (0.19)	-0.2	-0.12	0.04	0.20	0.4	
		Week 12	Tezepelumab	22	21 (95.5)	0.03 (0.18)	-0.3	-0.09	0.05	0.14	0.4	-0.14 [-0.87, 0.59]
			Placebo	11	11 (100.0)	0.06 (0.21)	-0.3	-0.05	0.00	0.26	0.4	
		Week 16	Tezepelumab	22	22 (100.0)	0.06 (0.20)	-0.5	-0.05	0.06	0.19	0.4	0.54 [-0.19, 1.28]
			Placebo	11	11 (100.0)	-0.05 (0.24)	-0.6	-0.15	0.00	0.02	0.3	
		Week 24	Tezepelumab	22	21 (95.5)	0.02 (0.19)	-0.3	-0.12	0.00	0.16	0.3	0.56 [-0.24, 1.35]
			Placebo	11	9 (81.8)	-0.11 (0.30)	-0.5	-0.37	-0.05	0.05	0.4	
		Week 36	Tezepelumab	22	21 (95.5)	-0.00 (0.29)	-0.8	-0.15	0.01	0.11	0.6	-0.15 [-0.94, 0.63]
			Placebo	11	9 (81.8)	0.04 (0.25)	-0.3	-0.19	0.04	0.22	0.4	
		Week 52	Tezepelumab	22	21 (95.5)	-0.03 (0.29)	-0.8	-0.10	-0.01	0.11	0.7	0.02 [-0.71, 0.75]
			Placebo	11	11 (100.0)	-0.03 (0.25)	-0.4	-0.26	-0.02	0.15	0.5	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q3: 250 - < 430 cells/uL	Absolute values	Baseline	Tezepelumab	4	4 (100.0)	1.92 (0.62)	1.0	1.54	2.09	2.30	2.5	
			Placebo	7	7 (100.0)	1.74 (0.76)	1.1	1.11	1.45	2.10	3.2	
		Week 2	Tezepelumab	4	4 (100.0)	1.91 (0.43)	1.3	1.67	2.10	2.15	2.2	
			Placebo	7	7 (100.0)	1.87 (1.08)	1.0	1.02	1.46	2.31	4.1	
		Week 4	Tezepelumab	4	4 (100.0)	1.97 (0.23)	1.6	1.82	2.03	2.12	2.2	
			Placebo	7	7 (100.0)	2.02 (1.31)	1.1	1.10	1.56	2.35	4.8	
		Week 8	Tezepelumab	4	4 (100.0)	2.10 (0.57)	1.3	1.70	2.26	2.50	2.6	
			Placebo	7	6 (85.7)	2.18 (1.26)	1.2	1.40	1.78	2.30	4.6	
		Week 12	Tezepelumab	4	4 (100.0)	2.13 (0.31)	1.8	1.92	2.14	2.35	2.5	
			Placebo	7	7 (100.0)	2.06 (1.18)	1.3	1.31	1.47	2.25	4.6	
		Week 16	Tezepelumab	4	4 (100.0)	1.93 (0.59)	1.1	1.61	2.19	2.25	2.3	
			Placebo	7	7 (100.0)	2.08 (1.21)	1.2	1.32	1.64	2.28	4.7	
		Week 24	Tezepelumab	4	4 (100.0)	2.18 (0.40)	1.7	1.87	2.25	2.49	2.6	
			Placebo	7	7 (100.0)	2.01 (1.30)	1.1	1.21	1.42	2.25	4.8	
		Week 36	Tezepelumab	4	4 (100.0)	2.18 (0.69)	1.3	1.67	2.29	2.70	2.9	
			Placebo	7	7 (100.0)	1.98 (1.12)	1.1	1.14	1.75	2.26	4.3	
		Week 52	Tezepelumab	4	4 (100.0)	2.16 (0.47)	1.5	1.80	2.27	2.53	2.6	
			Placebo	7	5 (71.4)	2.05 (1.20)	1.1	1.15	1.68	2.29	4.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. Q)												
Q3: 250 - < 430 cells/uL	Change from baseline	Week 2	Tezepelumab	4	4 (100.0)	-0.01 (0.23)	-0.3	-0.15	0.01	0.13	0.2	-0.42 [-1.66, 0.82]
			Placebo	7	7 (100.0)	0.13 (0.39)	-0.3	-0.09	0.01	0.46	0.9	
		Week 4	Tezepelumab	4	4 (100.0)	0.05 (0.45)	-0.5	-0.23	0.03	0.33	0.6	-0.41 [-1.66, 0.83]
			Placebo	7	7 (100.0)	0.28 (0.63)	-0.3	-0.01	0.08	0.50	1.6	
		Week 8	Tezepelumab	4	4 (100.0)	0.18 (0.24)	-0.1	-0.01	0.16	0.36	0.5	-0.34 [-1.62, 0.93]
			Placebo	7	6 (85.7)	0.33 (0.55)	-0.1	-0.05	0.14	0.45	1.4	
		Week 12	Tezepelumab	4	4 (100.0)	0.21 (0.34)	0.0	0.03	0.06	0.40	0.7	-0.25 [-1.48, 0.98]
			Placebo	7	7 (100.0)	0.32 (0.47)	0.0	0.02	0.20	0.40	1.4	
		Week 16	Tezepelumab	4	4 (100.0)	0.01 (0.18)	-0.3	-0.12	0.07	0.13	0.1	-0.80 [-2.08, 0.48]
			Placebo	7	7 (100.0)	0.35 (0.51)	-0.1	0.07	0.19	0.43	1.4	
		Week 24	Tezepelumab	4	4 (100.0)	0.26 (0.33)	-0.0	-0.01	0.22	0.53	0.6	-0.02 [-1.25, 1.20]
			Placebo	7	7 (100.0)	0.27 (0.61)	-0.3	-0.05	0.07	0.40	1.6	
		Week 36	Tezepelumab	4	4 (100.0)	0.26 (0.34)	0.0	0.03	0.15	0.50	0.8	0.04 [-1.19, 1.27]
			Placebo	7	7 (100.0)	0.25 (0.42)	-0.2	-0.03	0.08	0.41	1.1	
		Week 52	Tezepelumab	4	4 (100.0)	0.24 (0.23)	0.0	0.06	0.23	0.43	0.5	-0.23 [-1.55, 1.09]
			Placebo	7	5 (71.4)	0.31 (0.31)	0.0	0.04	0.23	0.44	0.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
< 25 ppb	Absolute values	Baseline	Tezepelumab	54	54 (100.0)	1.78 (0.63)	0.4	1.28	1.77	2.20	3.3	
			Placebo	39	39 (100.0)	1.74 (0.53)	0.8	1.39	1.70	2.10	3.2	
		Week 2	Tezepelumab	54	52 (96.3)	1.84 (0.61)	0.6	1.42	1.80	2.33	3.4	
			Placebo	39	34 (87.2)	1.75 (0.66)	0.8	1.35	1.71	1.97	4.1	
		Week 4	Tezepelumab	54	54 (100.0)	1.84 (0.66)	0.7	1.44	1.74	2.25	3.4	
			Placebo	39	38 (97.4)	1.81 (0.73)	0.9	1.38	1.71	2.02	4.8	
		Week 8	Tezepelumab	54	52 (96.3)	1.84 (0.61)	0.6	1.49	1.77	2.37	3.3	
			Placebo	39	38 (97.4)	1.82 (0.71)	0.8	1.41	1.75	2.03	4.6	
		Week 12	Tezepelumab	54	53 (98.1)	1.84 (0.66)	0.6	1.44	1.75	2.28	3.6	
			Placebo	39	38 (97.4)	1.81 (0.71)	0.8	1.41	1.64	2.14	4.6	
		Week 16	Tezepelumab	54	53 (98.1)	1.89 (0.67)	0.6	1.46	1.83	2.31	3.5	
			Placebo	39	38 (97.4)	1.77 (0.72)	0.8	1.33	1.69	2.04	4.7	
		Week 24	Tezepelumab	54	53 (98.1)	1.82 (0.59)	0.6	1.52	1.79	2.27	3.5	
			Placebo	39	35 (89.7)	1.77 (0.74)	0.8	1.36	1.63	2.11	4.8	
		Week 36	Tezepelumab	54	52 (96.3)	1.81 (0.63)	0.5	1.31	1.80	2.25	3.5	
			Placebo	39	34 (87.2)	1.82 (0.69)	0.9	1.43	1.70	1.94	4.3	
		Week 52	Tezepelumab	54	50 (92.6)	1.81 (0.61)	0.7	1.43	1.77	2.21	3.4	
			Placebo	39	34 (87.2)	1.77 (0.68)	0.9	1.24	1.67	2.15	4.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. N)												
< 25 ppb	Change from baseline	Week 2	Tezepelumab	54	52 (96.3)	0.05 (0.24)	-0.7	-0.02	0.05	0.15	0.8	0.13 [-0.30, 0.56]
			Placebo	39	34 (87.2)	0.01 (0.25)	-0.4	-0.09	-0.01	0.08	0.9	
		Week 4	Tezepelumab	54	54 (100.0)	0.06 (0.35)	-0.9	-0.09	0.04	0.17	1.7	-0.06 [-0.48, 0.35]
			Placebo	39	38 (97.4)	0.08 (0.32)	-0.3	-0.05	0.04	0.12	1.6	
		Week 8	Tezepelumab	54	52 (96.3)	0.08 (0.30)	-0.8	-0.08	0.05	0.20	1.2	0.07 [-0.35, 0.48]
			Placebo	39	38 (97.4)	0.06 (0.32)	-0.8	-0.07	0.04	0.18	1.4	
		Week 12	Tezepelumab	54	53 (98.1)	0.06 (0.30)	-0.7	-0.09	0.05	0.17	1.4	-0.03 [-0.45, 0.39]
			Placebo	39	38 (97.4)	0.07 (0.29)	-0.4	-0.06	0.01	0.20	1.4	
		Week 16	Tezepelumab	54	53 (98.1)	0.10 (0.33)	-0.6	-0.05	0.10	0.22	1.6	0.20 [-0.22, 0.61]
			Placebo	39	38 (97.4)	0.03 (0.33)	-0.6	-0.10	0.01	0.18	1.4	
		Week 24	Tezepelumab	54	53 (98.1)	0.06 (0.27)	-0.6	-0.11	0.00	0.22	1.0	0.13 [-0.30, 0.56]
			Placebo	39	35 (89.7)	0.02 (0.35)	-0.5	-0.11	0.03	0.10	1.6	
		Week 36	Tezepelumab	54	52 (96.3)	0.04 (0.34)	-0.8	-0.12	0.04	0.21	1.1	-0.16 [-0.59, 0.28]
			Placebo	39	34 (87.2)	0.09 (0.27)	-0.3	-0.09	0.06	0.29	1.1	
		Week 52	Tezepelumab	54	50 (92.6)	0.04 (0.35)	-1.0	-0.07	0.01	0.18	1.0	-0.05 [-0.49, 0.38]
			Placebo	39	34 (87.2)	0.05 (0.26)	-0.5	-0.08	0.05	0.15	0.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q1: < 16 ppb	Absolute values	Baseline	Tezepelumab	30	30 (100.0)	1.75 (0.59)	0.8	1.27	1.73	2.13	3.2	
			Placebo	26	26 (100.0)	1.73 (0.61)	0.8	1.39	1.64	2.10	3.2	
		Week 2	Tezepelumab	30	28 (93.3)	1.87 (0.64)	0.9	1.35	1.90	2.40	3.4	
			Placebo	26	21 (80.8)	1.74 (0.79)	0.8	1.15	1.61	2.11	4.1	
		Week 4	Tezepelumab	30	30 (100.0)	1.87 (0.70)	0.7	1.44	1.85	2.40	3.4	
			Placebo	26	25 (96.2)	1.85 (0.85)	0.9	1.31	1.73	2.20	4.8	
		Week 8	Tezepelumab	30	29 (96.7)	1.89 (0.64)	0.7	1.57	1.68	2.40	3.3	
			Placebo	26	25 (96.2)	1.84 (0.80)	0.8	1.40	1.76	2.03	4.6	
		Week 12	Tezepelumab	30	29 (96.7)	1.83 (0.68)	0.8	1.44	1.75	2.28	3.6	
			Placebo	26	25 (96.2)	1.86 (0.82)	0.8	1.31	1.69	2.25	4.6	
		Week 16	Tezepelumab	30	29 (96.7)	1.96 (0.69)	0.9	1.54	1.85	2.39	3.5	
			Placebo	26	25 (96.2)	1.81 (0.84)	0.8	1.31	1.68	2.10	4.7	
		Week 24	Tezepelumab	30	30 (100.0)	1.82 (0.60)	0.8	1.57	1.88	2.26	3.5	
			Placebo	26	22 (84.6)	1.83 (0.89)	0.8	1.21	1.60	2.21	4.8	
		Week 36	Tezepelumab	30	29 (96.7)	1.86 (0.67)	0.8	1.33	1.83	2.33	3.5	
			Placebo	26	23 (88.5)	1.89 (0.79)	0.9	1.41	1.75	2.36	4.3	
		Week 52	Tezepelumab	30	27 (90.0)	1.86 (0.67)	0.7	1.44	1.79	2.37	3.4	
			Placebo	26	22 (84.6)	1.75 (0.79)	0.9	1.14	1.60	2.15	4.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q1: < 16 ppb	Change from baseline	Week 2	Tezepelumab	30	28 (93.3)	0.09 (0.25)	-0.6	-0.01	0.07	0.22	0.8	0.30 [-0.27, 0.87]
			Placebo	26	21 (80.8)	0.01 (0.28)	-0.4	-0.09	-0.01	0.06	0.9	
		Week 4	Tezepelumab	30	30 (100.0)	0.11 (0.40)	-0.6	-0.04	0.05	0.25	1.7	-0.02 [-0.55, 0.51]
			Placebo	26	25 (96.2)	0.12 (0.36)	-0.3	-0.02	0.07	0.12	1.6	
		Week 8	Tezepelumab	30	29 (96.7)	0.14 (0.30)	-0.3	-0.07	0.06	0.25	1.2	0.19 [-0.35, 0.72]
			Placebo	26	25 (96.2)	0.08 (0.33)	-0.5	-0.06	0.04	0.11	1.4	
		Week 12	Tezepelumab	30	29 (96.7)	0.09 (0.33)	-0.4	-0.03	0.05	0.17	1.4	-0.09 [-0.63, 0.44]
			Placebo	26	25 (96.2)	0.12 (0.31)	-0.3	-0.03	0.04	0.22	1.4	
		Week 16	Tezepelumab	30	29 (96.7)	0.19 (0.35)	-0.3	0.00	0.14	0.28	1.6	0.32 [-0.22, 0.86]
			Placebo	26	25 (96.2)	0.08 (0.36)	-0.6	-0.07	0.02	0.18	1.4	
		Week 24	Tezepelumab	30	30 (100.0)	0.07 (0.26)	-0.3	-0.10	0.00	0.20	1.0	-0.05 [-0.60, 0.50]
			Placebo	26	22 (84.6)	0.09 (0.41)	-0.5	-0.10	0.05	0.14	1.6	
		Week 36	Tezepelumab	30	29 (96.7)	0.09 (0.33)	-0.8	-0.07	0.07	0.22	1.1	-0.22 [-0.77, 0.33]
			Placebo	26	23 (88.5)	0.16 (0.28)	-0.3	-0.03	0.08	0.30	1.1	
		Week 52	Tezepelumab	30	27 (90.0)	0.07 (0.36)	-0.8	-0.03	0.01	0.23	1.0	0.01 [-0.55, 0.58]
			Placebo	26	22 (84.6)	0.07 (0.27)	-0.4	-0.06	0.07	0.15	0.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q2: 16 - < 30 ppb Absolute values		Baseline	Tezepelumab	24	24 (100.0)	1.82 (0.69)	0.4	1.35	1.85	2.29	3.3	
			Placebo	13	13 (100.0)	1.75 (0.35)	1.0	1.54	1.81	2.04	2.2	
		Week 2	Tezepelumab	24	24 (100.0)	1.81 (0.60)	0.6	1.49	1.76	2.21	2.9	
			Placebo	13	13 (100.0)	1.76 (0.42)	1.0	1.59	1.74	1.89	2.7	
		Week 4	Tezepelumab	24	24 (100.0)	1.81 (0.63)	0.7	1.51	1.70	2.12	3.3	
			Placebo	13	13 (100.0)	1.75 (0.43)	1.0	1.55	1.69	1.85	2.6	
		Week 8	Tezepelumab	24	23 (95.8)	1.77 (0.57)	0.6	1.30	1.79	2.05	2.8	
			Placebo	13	13 (100.0)	1.78 (0.53)	0.8	1.53	1.74	1.94	2.7	
		Week 12	Tezepelumab	24	24 (100.0)	1.84 (0.66)	0.6	1.39	1.75	2.28	3.3	
			Placebo	13	13 (100.0)	1.72 (0.46)	1.0	1.43	1.60	1.93	2.6	
		Week 16	Tezepelumab	24	24 (100.0)	1.81 (0.65)	0.6	1.38	1.66	2.27	3.1	
			Placebo	13	13 (100.0)	1.70 (0.41)	1.0	1.42	1.70	1.78	2.7	
		Week 24	Tezepelumab	24	23 (95.8)	1.81 (0.60)	0.6	1.18	1.71	2.35	2.9	
			Placebo	13	13 (100.0)	1.66 (0.34)	1.1	1.42	1.63	1.73	2.3	
		Week 36	Tezepelumab	24	23 (95.8)	1.74 (0.57)	0.5	1.25	1.77	2.12	2.9	
			Placebo	13	11 (84.6)	1.67 (0.38)	1.0	1.46	1.69	1.81	2.6	
		Week 52	Tezepelumab	24	23 (95.8)	1.75 (0.54)	0.8	1.37	1.75	2.21	2.8	
			Placebo	13	12 (92.3)	1.80 (0.44)	1.0	1.61	1.72	2.10	2.7	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. Q)												
Q2: 16 - < 30 ppb	Change from baseline	Week 2	Tezepelumab	24	24 (100.0)	-0.01 (0.23)	-0.7	-0.09	0.03	0.09	0.5	-0.11 [-0.79, 0.56]
			Placebo	13	13 (100.0)	0.01 (0.19)	-0.3	-0.09	0.00	0.08	0.5	
		Week 4	Tezepelumab	24	24 (100.0)	-0.01 (0.28)	-0.9	-0.14	0.03	0.14	0.6	-0.03 [-0.71, 0.64]
			Placebo	13	13 (100.0)	-0.00 (0.22)	-0.3	-0.14	0.03	0.09	0.4	
		Week 8	Tezepelumab	24	23 (95.8)	0.01 (0.29)	-0.8	-0.09	0.02	0.18	0.6	-0.05 [-0.73, 0.63]
			Placebo	13	13 (100.0)	0.03 (0.32)	-0.8	-0.10	0.05	0.19	0.5	
		Week 12	Tezepelumab	24	24 (100.0)	0.03 (0.25)	-0.7	-0.13	0.05	0.17	0.5	0.22 [-0.45, 0.90]
			Placebo	13	13 (100.0)	-0.03 (0.24)	-0.4	-0.09	-0.04	0.06	0.4	
		Week 16	Tezepelumab	24	24 (100.0)	-0.01 (0.28)	-0.6	-0.18	0.04	0.19	0.4	0.14 [-0.53, 0.82]
			Placebo	13	13 (100.0)	-0.05 (0.27)	-0.6	-0.10	-0.02	0.02	0.5	
		Week 24	Tezepelumab	24	23 (95.8)	0.05 (0.29)	-0.6	-0.18	0.00	0.27	0.7	0.53 [-0.16, 1.22]
			Placebo	13	13 (100.0)	-0.09 (0.19)	-0.5	-0.21	0.03	0.05	0.1	
		Week 36	Tezepelumab	24	23 (95.8)	-0.01 (0.34)	-0.7	-0.18	-0.05	0.16	0.8	0.10 [-0.62, 0.82]
			Placebo	13	11 (84.6)	-0.04 (0.21)	-0.3	-0.23	-0.11	0.15	0.4	
		Week 52	Tezepelumab	24	23 (95.8)	-0.01 (0.34)	-1.0	-0.15	0.01	0.18	0.7	-0.09 [-0.79, 0.61]
			Placebo	13	12 (92.3)	0.02 (0.27)	-0.5	-0.14	-0.01	0.17	0.5	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q1: < 53.1 IU/ml	Absolute values	Baseline	Tezepelumab	40	40 (100.0)	1.69 (0.64)	0.4	1.27	1.67	2.08	3.3	
			Placebo	33	33 (100.0)	1.72 (0.47)	0.8	1.44	1.70	2.04	2.8	
		Week 2	Tezepelumab	40	38 (95.0)	1.72 (0.58)	0.6	1.29	1.70	2.03	2.9	
			Placebo	33	29 (87.9)	1.70 (0.50)	0.8	1.38	1.71	1.93	2.8	
		Week 4	Tezepelumab	40	40 (100.0)	1.70 (0.62)	0.7	1.30	1.67	2.06	3.3	
			Placebo	33	32 (97.0)	1.75 (0.51)	0.9	1.41	1.71	2.01	3.0	
		Week 8	Tezepelumab	40	38 (95.0)	1.68 (0.52)	0.6	1.43	1.67	2.01	2.8	
			Placebo	33	33 (100.0)	1.74 (0.53)	0.8	1.41	1.74	1.94	2.8	
		Week 12	Tezepelumab	40	39 (97.5)	1.69 (0.62)	0.6	1.23	1.62	2.08	3.3	
			Placebo	33	32 (97.0)	1.73 (0.54)	0.8	1.42	1.64	2.12	3.0	
		Week 16	Tezepelumab	40	39 (97.5)	1.76 (0.61)	0.6	1.43	1.65	2.22	3.1	
			Placebo	33	32 (97.0)	1.70 (0.53)	0.8	1.33	1.69	1.97	3.0	
		Week 24	Tezepelumab	40	39 (97.5)	1.69 (0.54)	0.6	1.18	1.70	2.07	2.9	
			Placebo	33	30 (90.9)	1.69 (0.49)	0.8	1.40	1.65	2.07	2.7	
		Week 36	Tezepelumab	40	38 (95.0)	1.68 (0.56)	0.5	1.25	1.61	2.12	2.8	
			Placebo	33	29 (87.9)	1.77 (0.50)	0.9	1.46	1.70	1.92	3.0	
		Week 52	Tezepelumab	40	37 (92.5)	1.70 (0.56)	0.7	1.37	1.64	2.11	2.9	
			Placebo	33	29 (87.9)	1.72 (0.53)	0.9	1.34	1.68	1.97	2.9	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q1: < 53.1 IU/ml	Change from baseline	Week 2	Tezepelumab	40	38 (95.0)	0.01 (0.23)	-0.7	-0.08	0.05	0.12	0.5	0.17 [-0.31, 0.66]
			Placebo	33	29 (87.9)	-0.03 (0.20)	-0.4	-0.10	-0.01	0.04	0.5	
		Week 4	Tezepelumab	40	40 (100.0)	0.01 (0.27)	-0.9	-0.11	0.01	0.16	0.6	-0.09 [-0.55, 0.38]
			Placebo	33	32 (97.0)	0.03 (0.20)	-0.3	-0.10	0.06	0.12	0.5	
		Week 8	Tezepelumab	40	38 (95.0)	0.04 (0.26)	-0.8	-0.08	0.02	0.18	0.7	0.05 [-0.41, 0.52]
			Placebo	33	33 (100.0)	0.02 (0.24)	-0.8	-0.07	0.00	0.13	0.5	
		Week 12	Tezepelumab	40	39 (97.5)	0.01 (0.23)	-0.7	-0.11	0.03	0.15	0.5	-0.01 [-0.48, 0.46]
			Placebo	33	32 (97.0)	0.01 (0.19)	-0.4	-0.06	0.00	0.06	0.4	
		Week 16	Tezepelumab	40	39 (97.5)	0.05 (0.26)	-0.6	-0.09	0.10	0.21	0.7	0.29 [-0.18, 0.76]
			Placebo	33	32 (97.0)	-0.02 (0.24)	-0.6	-0.10	0.01	0.08	0.5	
		Week 24	Tezepelumab	40	39 (97.5)	0.04 (0.24)	-0.6	-0.10	0.00	0.21	0.7	0.34 [-0.13, 0.82]
			Placebo	33	30 (90.9)	-0.04 (0.22)	-0.5	-0.21	0.00	0.09	0.4	
		Week 36	Tezepelumab	40	38 (95.0)	0.01 (0.28)	-0.7	-0.12	0.02	0.20	0.6	-0.17 [-0.65, 0.31]
			Placebo	33	29 (87.9)	0.06 (0.21)	-0.3	-0.11	0.06	0.22	0.4	
		Week 52	Tezepelumab	40	37 (92.5)	0.02 (0.31)	-1.0	-0.07	0.00	0.13	0.7	-0.00 [-0.49, 0.49]
			Placebo	33	29 (87.9)	0.02 (0.23)	-0.5	-0.11	0.04	0.15	0.5	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q2: 53.1 - < 195.6 IU/ml	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	1.93 (0.67)	1.0	1.41	1.79	2.27	3.2	
			Placebo	4	4 (100.0)	1.69 (0.53)	1.1	1.28	1.69	2.10	2.3	
		Week 2	Tezepelumab	9	9 (100.0)	2.06 (0.68)	1.3	1.42	2.17	2.42	3.4	
			Placebo	4	3 (75.0)	1.76 (0.82)	1.0	1.01	1.65	2.63	2.6	
		Week 4	Tezepelumab	9	9 (100.0)	2.17 (0.81)	1.1	1.61	2.00	2.60	3.4	
			Placebo	4	4 (100.0)	1.78 (0.70)	1.1	1.27	1.68	2.30	2.7	
		Week 8	Tezepelumab	9	9 (100.0)	2.13 (0.77)	1.2	1.30	2.35	2.62	3.3	
			Placebo	4	3 (75.0)	2.07 (0.57)	1.5	1.54	1.98	2.68	2.7	
		Week 12	Tezepelumab	9	9 (100.0)	2.20 (0.79)	1.2	1.70	2.32	2.50	3.6	
			Placebo	4	4 (100.0)	1.96 (0.64)	1.3	1.45	1.93	2.48	2.7	
		Week 16	Tezepelumab	9	9 (100.0)	2.22 (0.93)	1.1	1.32	2.22	2.96	3.5	
			Placebo	4	4 (100.0)	1.83 (0.55)	1.3	1.48	1.71	2.19	2.6	
		Week 24	Tezepelumab	9	9 (100.0)	2.09 (0.76)	1.2	1.61	2.26	2.43	3.5	
			Placebo	4	3 (75.0)	1.78 (0.85)	1.1	1.12	1.49	2.74	2.7	
		Week 36	Tezepelumab	9	9 (100.0)	2.05 (0.80)	1.1	1.28	2.02	2.52	3.5	
			Placebo	4	3 (75.0)	1.76 (0.86)	1.1	1.14	1.41	2.74	2.7	
		Week 52	Tezepelumab	9	8 (88.9)	2.04 (0.84)	1.0	1.36	1.98	2.67	3.4	
			Placebo	4	3 (75.0)	1.82 (0.87)	1.1	1.10	1.57	2.79	2.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q2: 53.1 - < 195.6 IU/ml	Change from baseline	Week 2	Tezepelumab	9	9 (100.0)	0.13 (0.29)	-0.3	0.01	0.09	0.20	0.8	-0.04 [-1.34, 1.27]
			Placebo	4	3 (75.0)	0.14 (0.19)	-0.1	-0.05	0.16	0.32	0.3	
		Week 4	Tezepelumab	9	9 (100.0)	0.24 (0.64)	-0.5	-0.16	0.03	0.33	1.7	0.26 [-0.92, 1.44]
			Placebo	4	4 (100.0)	0.10 (0.20)	-0.0	-0.01	0.02	0.21	0.4	
		Week 8	Tezepelumab	9	9 (100.0)	0.20 (0.40)	-0.2	0.00	0.15	0.26	1.2	0.08 [-1.23, 1.38]
			Placebo	4	3 (75.0)	0.17 (0.17)	0.1	0.05	0.10	0.37	0.4	
		Week 12	Tezepelumab	9	9 (100.0)	0.28 (0.50)	-0.2	0.02	0.10	0.39	1.4	0.00 [-1.18, 1.18]
			Placebo	4	4 (100.0)	0.28 (0.13)	0.1	0.17	0.30	0.38	0.4	
		Week 16	Tezepelumab	9	9 (100.0)	0.29 (0.57)	-0.3	0.02	0.04	0.36	1.6	0.28 [-0.90, 1.47]
			Placebo	4	4 (100.0)	0.15 (0.18)	-0.1	0.02	0.20	0.28	0.3	
		Week 24	Tezepelumab	9	9 (100.0)	0.16 (0.41)	-0.2	-0.12	-0.01	0.29	1.0	0.00 [-1.30, 1.31]
			Placebo	4	3 (75.0)	0.16 (0.23)	0.0	0.00	0.06	0.43	0.4	
		Week 36	Tezepelumab	9	9 (100.0)	0.13 (0.40)	-0.2	-0.15	0.04	0.25	1.1	-0.04 [-1.35, 1.26]
			Placebo	4	3 (75.0)	0.14 (0.26)	-0.1	-0.08	0.08	0.43	0.4	
		Week 52	Tezepelumab	9	8 (88.9)	0.16 (0.44)	-0.3	-0.15	0.05	0.37	1.0	-0.10 [-1.43, 1.23]
			Placebo	4	3 (75.0)	0.20 (0.24)	0.0	0.04	0.08	0.48	0.5	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q4: >= 572.4 IU/ml	Absolute values	Baseline	Tezepelumab	5	5 (100.0)	2.23 (0.26)	2.0	2.02	2.12	2.39	2.6	
			Placebo	2	2 (100.0)	2.14 (1.55)	1.0	1.04	2.14	3.23	3.2	
		Week 2	Tezepelumab	5	5 (100.0)	2.38 (0.39)	1.9	2.13	2.38	2.54	2.9	
			Placebo	2	2 (100.0)	2.53 (2.21)	1.0	0.97	2.53	4.09	4.1	
		Week 4	Tezepelumab	5	5 (100.0)	2.32 (0.25)	2.1	2.17	2.24	2.45	2.7	
			Placebo	2	2 (100.0)	2.92 (2.71)	1.0	1.00	2.92	4.83	4.8	
		Week 8	Tezepelumab	5	5 (100.0)	2.47 (0.35)	1.9	2.43	2.59	2.68	2.8	
			Placebo	2	2 (100.0)	2.70 (2.70)	0.8	0.79	2.70	4.61	4.6	
		Week 12	Tezepelumab	5	5 (100.0)	2.34 (0.23)	2.2	2.20	2.21	2.39	2.7	
			Placebo	2	2 (100.0)	2.78 (2.55)	1.0	0.98	2.78	4.58	4.6	
		Week 16	Tezepelumab	5	5 (100.0)	2.35 (0.14)	2.2	2.27	2.31	2.39	2.6	
			Placebo	2	2 (100.0)	2.82 (2.62)	1.0	0.97	2.82	4.67	4.7	
		Week 24	Tezepelumab	5	5 (100.0)	2.31 (0.26)	1.9	2.27	2.29	2.55	2.6	
			Placebo	2	2 (100.0)	2.94 (2.64)	1.1	1.07	2.94	4.81	4.8	
		Week 36	Tezepelumab	5	5 (100.0)	2.36 (0.43)	1.9	1.97	2.50	2.59	2.9	
			Placebo	2	2 (100.0)	2.67 (2.35)	1.0	1.00	2.67	4.33	4.3	
		Week 52	Tezepelumab	5	5 (100.0)	2.22 (0.26)	1.8	2.20	2.26	2.39	2.5	
			Placebo	2	2 (100.0)	2.49 (2.16)	1.0	0.96	2.49	4.01	4.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE (cat. N)												
Q4: >= 572.4 IU/ml	Change from baseline	Week 2	Tezepelumab	5	5 (100.0)	0.15 (0.26)	-0.1	-0.01	0.01	0.31	0.5	-0.66 [-2.35, 1.03]
			Placebo	2	2 (100.0)	0.40 (0.66)	-0.1	-0.07	0.40	0.86	0.9	
		Week 4	Tezepelumab	5	5 (100.0)	0.09 (0.07)	0.0	0.05	0.06	0.07	0.2	-1.32 [-3.15, 0.51]
			Placebo	2	2 (100.0)	0.78 (1.16)	-0.0	-0.04	0.78	1.60	1.6	
		Week 8	Tezepelumab	5	5 (100.0)	0.23 (0.33)	-0.1	0.04	0.13	0.47	0.7	-0.56 [-2.24, 1.11]
			Placebo	2	2 (100.0)	0.57 (1.15)	-0.3	-0.25	0.57	1.38	1.4	
		Week 12	Tezepelumab	5	5 (100.0)	0.11 (0.21)	-0.2	0.08	0.10	0.19	0.4	-1.11 [-2.89, 0.67]
			Placebo	2	2 (100.0)	0.65 (1.00)	-0.1	-0.06	0.65	1.35	1.4	
		Week 16	Tezepelumab	5	5 (100.0)	0.11 (0.14)	-0.1	0.00	0.15	0.17	0.3	-1.16 [-2.95, 0.63]
			Placebo	2	2 (100.0)	0.69 (1.07)	-0.1	-0.07	0.69	1.44	1.4	
		Week 24	Tezepelumab	5	5 (100.0)	0.08 (0.25)	-0.1	-0.11	-0.07	0.27	0.4	-1.34 [-3.18, 0.50]
			Placebo	2	2 (100.0)	0.81 (1.10)	0.0	0.03	0.81	1.58	1.6	
		Week 36	Tezepelumab	5	5 (100.0)	0.12 (0.60)	-0.8	-0.05	0.11	0.57	0.8	-0.63 [-2.32, 1.05]
			Placebo	2	2 (100.0)	0.53 (0.81)	-0.0	-0.04	0.53	1.10	1.1	
		Week 52	Tezepelumab	5	5 (100.0)	-0.01 (0.47)	-0.8	0.00	0.18	0.24	0.4	-0.72 [-2.42, 0.98]
			Placebo	2	2 (100.0)	0.35 (0.61)	-0.1	-0.08	0.35	0.78	0.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Nasal polyps last 2 years												
Yes	Absolute values	Baseline	Tezepelumab	4	4 (100.0)	1.56 (0.68)	0.8	1.14	1.47	1.99	2.5	
			Placebo	3	3 (100.0)	2.07 (1.01)	1.4	1.44	1.54	3.23	3.2	
		Week 2	Tezepelumab	4	4 (100.0)	1.54 (0.51)	0.9	1.20	1.54	1.88	2.2	
			Placebo	3	3 (100.0)	2.32 (1.56)	1.2	1.15	1.71	4.09	4.1	
		Week 4	Tezepelumab	4	4 (100.0)	1.49 (0.46)	0.9	1.17	1.54	1.82	2.0	
			Placebo	3	3 (100.0)	2.61 (1.93)	1.3	1.31	1.69	4.83	4.8	
		Week 8	Tezepelumab	4	4 (100.0)	1.67 (0.59)	1.0	1.27	1.67	2.08	2.4	
			Placebo	3	3 (100.0)	2.54 (1.81)	1.3	1.27	1.74	4.61	4.6	
		Week 12	Tezepelumab	4	4 (100.0)	1.61 (0.66)	0.9	1.20	1.52	2.03	2.5	
			Placebo	3	3 (100.0)	2.42 (1.88)	1.2	1.19	1.48	4.58	4.6	
		Week 16	Tezepelumab	4	4 (100.0)	1.51 (0.54)	0.9	1.15	1.46	1.88	2.2	
			Placebo	3	3 (100.0)	2.41 (2.01)	0.8	0.81	1.76	4.67	4.7	
		Week 24	Tezepelumab	4	4 (100.0)	1.65 (0.64)	0.9	1.23	1.66	2.07	2.4	
			Placebo	3	3 (100.0)	2.46 (2.07)	0.9	0.93	1.63	4.81	4.8	
		Week 36	Tezepelumab	4	4 (100.0)	1.62 (0.67)	0.9	1.21	1.53	2.03	2.5	
			Placebo	3	3 (100.0)	2.50 (1.59)	1.5	1.47	1.69	4.33	4.3	
		Week 52	Tezepelumab	4	4 (100.0)	1.59 (0.71)	0.9	1.16	1.44	2.01	2.6	
			Placebo	3	3 (100.0)	2.27 (1.55)	1.1	1.06	1.73	4.01	4.0	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Nasal polyps last 2 years												
Yes	Change from baseline	Week 2	Tezepelumab	4	4 (100.0)	-0.02 (0.19)	-0.3	-0.14	0.07	0.09	0.1	-0.68 [-2.24, 0.87]
			Placebo	3	3 (100.0)	0.25 (0.58)	-0.3	-0.29	0.17	0.86	0.9	
		Week 4	Tezepelumab	4	4 (100.0)	-0.07 (0.28)	-0.5	-0.24	0.03	0.10	0.1	-0.97 [-2.59, 0.64]
			Placebo	3	3 (100.0)	0.54 (0.93)	-0.1	-0.13	0.15	1.60	1.6	
		Week 8	Tezepelumab	4	4 (100.0)	0.11 (0.14)	-0.1	0.02	0.14	0.20	0.3	-0.69 [-2.24, 0.87]
			Placebo	3	3 (100.0)	0.47 (0.81)	-0.2	-0.17	0.20	1.38	1.4	
		Week 12	Tezepelumab	4	4 (100.0)	0.05 (0.02)	0.0	0.04	0.05	0.06	0.1	-0.54 [-2.07, 0.99]
			Placebo	3	3 (100.0)	0.35 (0.87)	-0.3	-0.25	-0.06	1.35	1.4	
		Week 16	Tezepelumab	4	4 (100.0)	-0.05 (0.18)	-0.3	-0.19	-0.02	0.10	0.1	-0.59 [-2.13, 0.95]
			Placebo	3	3 (100.0)	0.34 (1.04)	-0.6	-0.63	0.22	1.44	1.4	
		Week 24	Tezepelumab	4	4 (100.0)	0.09 (0.12)	-0.0	-0.01	0.10	0.19	0.2	-0.44 [-1.96, 1.09]
			Placebo	3	3 (100.0)	0.39 (1.08)	-0.5	-0.51	0.09	1.58	1.6	
		Week 36	Tezepelumab	4	4 (100.0)	0.06 (0.02)	0.0	0.04	0.06	0.08	0.1	-0.99 [-2.61, 0.62]
			Placebo	3	3 (100.0)	0.43 (0.59)	0.0	0.03	0.15	1.10	1.1	
		Week 52	Tezepelumab	4	4 (100.0)	0.02 (0.07)	-0.1	-0.04	0.03	0.08	0.1	-0.47 [-1.99, 1.06]
			Placebo	3	3 (100.0)	0.20 (0.58)	-0.4	-0.38	0.19	0.78	0.8	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Nasal polyps last 2 years												
No	Absolute values	Baseline	Tezepelumab	50	50 (100.0)	1.80 (0.63)	0.4	1.28	1.83	2.20	3.3	
			Placebo	36	36 (100.0)	1.71 (0.49)	0.8	1.38	1.74	2.07	2.8	
		Week 2	Tezepelumab	50	48 (96.0)	1.87 (0.62)	0.6	1.42	1.83	2.37	3.4	
			Placebo	36	31 (86.1)	1.70 (0.54)	0.8	1.35	1.71	1.97	2.8	
		Week 4	Tezepelumab	50	50 (100.0)	1.87 (0.67)	0.7	1.53	1.79	2.40	3.4	
			Placebo	36	35 (97.2)	1.74 (0.54)	0.9	1.38	1.73	2.02	3.0	
		Week 8	Tezepelumab	50	48 (96.0)	1.85 (0.62)	0.6	1.49	1.82	2.37	3.3	
			Placebo	36	35 (97.2)	1.76 (0.56)	0.8	1.41	1.76	2.03	2.8	
		Week 12	Tezepelumab	50	49 (98.0)	1.86 (0.67)	0.6	1.44	1.77	2.28	3.6	
			Placebo	36	35 (97.2)	1.76 (0.56)	0.8	1.41	1.66	2.14	3.0	
		Week 16	Tezepelumab	50	49 (98.0)	1.92 (0.68)	0.6	1.49	1.84	2.34	3.5	
			Placebo	36	35 (97.2)	1.72 (0.53)	0.9	1.33	1.68	2.04	3.0	
		Week 24	Tezepelumab	50	49 (98.0)	1.83 (0.59)	0.6	1.52	1.87	2.27	3.5	
			Placebo	36	32 (88.9)	1.70 (0.52)	0.8	1.38	1.65	2.09	2.7	
		Week 36	Tezepelumab	50	48 (96.0)	1.82 (0.63)	0.5	1.31	1.84	2.25	3.5	
			Placebo	36	31 (86.1)	1.75 (0.55)	0.9	1.41	1.70	1.94	3.0	
		Week 52	Tezepelumab	50	46 (92.0)	1.83 (0.60)	0.7	1.48	1.80	2.21	3.4	
			Placebo	36	31 (86.1)	1.72 (0.56)	0.9	1.24	1.66	2.15	2.9	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSHN: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTB - adult

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Nasal polyps last 2 years												
No	Change from baseline	Week 2	Tezepelumab	50	48 (96.0)	0.05 (0.25)	-0.7	-0.02	0.05	0.16	0.8	0.26 [-0.19, 0.71]
			Placebo	36	31 (86.1)	-0.01 (0.20)	-0.4	-0.09	-0.01	0.06	0.5	
		Week 4	Tezepelumab	50	50 (100.0)	0.07 (0.36)	-0.9	-0.09	0.04	0.22	1.7	0.10 [-0.34, 0.53]
			Placebo	36	35 (97.2)	0.04 (0.20)	-0.3	-0.05	0.04	0.11	0.5	
		Week 8	Tezepelumab	50	48 (96.0)	0.08 (0.31)	-0.8	-0.08	0.04	0.20	1.2	0.19 [-0.25, 0.62]
			Placebo	36	35 (97.2)	0.03 (0.24)	-0.8	-0.07	0.04	0.13	0.5	
		Week 12	Tezepelumab	50	49 (98.0)	0.06 (0.31)	-0.7	-0.09	0.04	0.18	1.4	0.06 [-0.38, 0.49]
			Placebo	36	35 (97.2)	0.05 (0.20)	-0.4	-0.05	0.02	0.20	0.4	
		Week 16	Tezepelumab	50	49 (98.0)	0.11 (0.34)	-0.6	-0.04	0.12	0.25	1.6	0.35 [-0.08, 0.79]
			Placebo	36	35 (97.2)	0.01 (0.22)	-0.6	-0.10	0.01	0.14	0.5	
		Week 24	Tezepelumab	50	49 (98.0)	0.06 (0.28)	-0.6	-0.12	0.00	0.23	1.0	0.28 [-0.17, 0.73]
			Placebo	36	32 (88.9)	-0.01 (0.22)	-0.5	-0.11	0.03	0.08	0.4	
		Week 36	Tezepelumab	50	48 (96.0)	0.04 (0.35)	-0.8	-0.14	0.01	0.22	1.1	-0.06 [-0.51, 0.39]
			Placebo	36	31 (86.1)	0.06 (0.21)	-0.3	-0.11	0.06	0.29	0.4	
		Week 52	Tezepelumab	50	46 (92.0)	0.04 (0.36)	-1.0	-0.09	0.01	0.23	1.0	-0.00 [-0.46, 0.45]
			Placebo	36	31 (86.1)	0.04 (0.23)	-0.5	-0.08	0.04	0.15	0.5	

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Region (cat. N)				N<10 any level					NE

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline eosinophils (cat. N)									0.731
< 150 cells/uL	Week 2	Tezepelumab	32	31 (96.9)	0.06 (0.04)	(-0.02, 0.15)	0.10 (0.07)	(-0.04, 0.23)	0.147
		Placebo	21	17 (81.0)	-0.03 (0.05)	(-0.14, 0.07)			
	Week 4	Tezepelumab	32	32 (100.0)	0.07 (0.06)	(-0.05, 0.20)	0.07 (0.10)	(-0.12, 0.27)	0.455
		Placebo	21	21 (100.0)	-0.00 (0.08)	(-0.15, 0.15)			
	Week 8	Tezepelumab	32	30 (93.8)	0.07 (0.06)	(-0.04, 0.18)	0.07 (0.09)	(-0.10, 0.25)	0.424
		Placebo	21	21 (100.0)	-0.00 (0.07)	(-0.14, 0.13)			
	Week 12	Tezepelumab	32	32 (100.0)	0.06 (0.05)	(-0.05, 0.16)	0.06 (0.08)	(-0.11, 0.23)	0.492
		Placebo	21	20 (95.2)	-0.00 (0.07)	(-0.13, 0.13)			
	Week 16	Tezepelumab	32	31 (96.9)	0.13 (0.06)	(0.01, 0.25)	0.15 (0.10)	(-0.04, 0.35)	0.118
		Placebo	21	20 (95.2)	-0.02 (0.08)	(-0.18, 0.13)			
	Week 24	Tezepelumab	32	31 (96.9)	0.07 (0.04)	(-0.02, 0.16)	0.06 (0.07)	(-0.08, 0.21)	0.396
		Placebo	21	19 (90.5)	0.01 (0.06)	(-0.10, 0.12)			
	Week 36	Tezepelumab	32	30 (93.8)	0.03 (0.05)	(-0.07, 0.14)	-0.04 (0.08)	(-0.20, 0.13)	0.650
		Placebo	21	18 (85.7)	0.07 (0.06)	(-0.06, 0.20)			
	Week 52	Tezepelumab	32	28 (87.5)	0.04 (0.06)	(-0.07, 0.15)	-0.01 (0.09)	(-0.19, 0.17)	0.904
		Placebo	21	18 (85.7)	0.05 (0.07)	(-0.09, 0.19)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
150 - < 300 cells/uL	Week 2	Tezepelumab	22	21 (95.5)	0.02 (0.05)	(-0.09, 0.13)	-0.04 (0.08)	(-0.21, 0.13)	0.631
		Placebo	18	17 (94.4)	0.06 (0.06)	(-0.06, 0.18)			
	Week 4	Tezepelumab	22	22 (100.0)	0.03 (0.07)	(-0.11, 0.16)	-0.15 (0.10)	(-0.35, 0.06)	0.157
		Placebo	18	17 (94.4)	0.17 (0.08)	(0.02, 0.33)			
	Week 8	Tezepelumab	22	22 (100.0)	0.08 (0.06)	(-0.04, 0.21)	-0.08 (0.09)	(-0.27, 0.10)	0.363
		Placebo	18	17 (94.4)	0.17 (0.07)	(0.03, 0.30)			
	Week 12	Tezepelumab	22	21 (95.5)	0.07 (0.06)	(-0.06, 0.19)	-0.10 (0.09)	(-0.29, 0.08)	0.272
		Placebo	18	18 (100.0)	0.17 (0.07)	(0.03, 0.30)			
	Week 16	Tezepelumab	22	22 (100.0)	0.05 (0.06)	(-0.08, 0.18)	-0.06 (0.10)	(-0.25, 0.14)	0.558
		Placebo	18	18 (100.0)	0.11 (0.07)	(-0.04, 0.26)			
	Week 24	Tezepelumab	22	22 (100.0)	0.04 (0.07)	(-0.11, 0.19)	-0.01 (0.11)	(-0.24, 0.22)	0.910
		Placebo	18	16 (88.9)	0.05 (0.08)	(-0.12, 0.22)			
	Week 36	Tezepelumab	22	22 (100.0)	0.05 (0.07)	(-0.09, 0.19)	-0.08 (0.10)	(-0.29, 0.13)	0.429
		Placebo	18	16 (88.9)	0.14 (0.08)	(-0.02, 0.29)			
	Week 52	Tezepelumab	22	22 (100.0)	0.02 (0.07)	(-0.12, 0.15)	-0.04 (0.10)	(-0.24, 0.16)	0.668
		Placebo	18	16 (88.9)	0.06 (0.07)	(-0.09, 0.21)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline eosinophils (cat. Q)									0.946
Q1: < 140 cells/uL	Week 2	Tezepelumab	28	27 (96.4)	0.07 (0.04)	(-0.02, 0.16)	0.11 (0.07)	(-0.04, 0.25)	0.138
		Placebo	21	17 (81.0)	-0.03 (0.05)	(-0.14, 0.08)			
	Week 4	Tezepelumab	28	28 (100.0)	0.07 (0.07)	(-0.07, 0.21)	0.07 (0.10)	(-0.14, 0.28)	0.483
		Placebo	21	21 (100.0)	-0.00 (0.08)	(-0.16, 0.16)			
	Week 8	Tezepelumab	28	27 (96.4)	0.06 (0.06)	(-0.06, 0.19)	0.07 (0.09)	(-0.12, 0.25)	0.458
		Placebo	21	21 (100.0)	-0.00 (0.07)	(-0.14, 0.13)			
	Week 12	Tezepelumab	28	28 (100.0)	0.06 (0.06)	(-0.06, 0.17)	0.06 (0.09)	(-0.12, 0.24)	0.489
		Placebo	21	20 (95.2)	-0.00 (0.07)	(-0.14, 0.13)			
	Week 16	Tezepelumab	28	27 (96.4)	0.14 (0.07)	(0.01, 0.28)	0.17 (0.10)	(-0.04, 0.38)	0.109
		Placebo	21	20 (95.2)	-0.03 (0.08)	(-0.18, 0.13)			
	Week 24	Tezepelumab	28	28 (100.0)	0.07 (0.05)	(-0.03, 0.16)	0.06 (0.08)	(-0.10, 0.21)	0.454
		Placebo	21	19 (90.5)	0.01 (0.06)	(-0.11, 0.12)			
	Week 36	Tezepelumab	28	27 (96.4)	0.05 (0.06)	(-0.06, 0.16)	-0.02 (0.09)	(-0.20, 0.15)	0.799
		Placebo	21	18 (85.7)	0.07 (0.07)	(-0.06, 0.20)			
	Week 52	Tezepelumab	28	25 (89.3)	0.05 (0.06)	(-0.07, 0.17)	0.00 (0.09)	(-0.18, 0.19)	0.960
		Placebo	21	18 (85.7)	0.05 (0.07)	(-0.10, 0.19)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q2: 140 - < 250 cells/uL	Week 2	Tezepelumab	22	21 (95.5)	0.02 (0.05)	(-0.08, 0.11)	0.02 (0.08)	(-0.15, 0.18)	0.841
		Placebo	11	10 (90.9)	0.00 (0.07)	(-0.13, 0.14)			
	Week 4	Tezepelumab	22	22 (100.0)	0.03 (0.03)	(-0.04, 0.10)	-0.07 (0.06)	(-0.20, 0.05)	0.252
		Placebo	11	10 (90.9)	0.10 (0.05)	(0.00, 0.21)			
	Week 8	Tezepelumab	22	21 (95.5)	0.06 (0.05)	(-0.03, 0.16)	-0.00 (0.08)	(-0.17, 0.16)	0.971
		Placebo	11	11 (100.0)	0.07 (0.07)	(-0.07, 0.20)			
	Week 12	Tezepelumab	22	21 (95.5)	0.03 (0.04)	(-0.05, 0.12)	-0.03 (0.07)	(-0.18, 0.12)	0.687
		Placebo	11	11 (100.0)	0.06 (0.06)	(-0.05, 0.18)			
	Week 16	Tezepelumab	22	22 (100.0)	0.06 (0.05)	(-0.03, 0.15)	0.11 (0.08)	(-0.05, 0.27)	0.182
		Placebo	11	11 (100.0)	-0.05 (0.06)	(-0.18, 0.08)			
	Week 24	Tezepelumab	22	21 (95.5)	0.02 (0.05)	(-0.08, 0.12)	0.13 (0.09)	(-0.05, 0.30)	0.159
		Placebo	11	9 (81.8)	-0.11 (0.07)	(-0.25, 0.04)			
	Week 36	Tezepelumab	22	21 (95.5)	-0.00 (0.06)	(-0.13, 0.12)	-0.06 (0.11)	(-0.28, 0.15)	0.550
		Placebo	11	9 (81.8)	0.06 (0.09)	(-0.12, 0.24)			
	Week 52	Tezepelumab	22	21 (95.5)	-0.03 (0.06)	(-0.15, 0.10)	0.00 (0.10)	(-0.21, 0.22)	0.973
		Placebo	11	11 (100.0)	-0.03 (0.08)	(-0.20, 0.14)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q3: 250 - < 430 cells/uL	Week 2	Tezepelumab	4	4 (100.0)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 4	Tezepelumab	4	4 (100.0)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 8	Tezepelumab	4	4 (100.0)	NE		NE		
		Placebo	7	6 (85.7)					
	Week 12	Tezepelumab	4	4 (100.0)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 16	Tezepelumab	4	4 (100.0)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 24	Tezepelumab	4	4 (100.0)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 36	Tezepelumab	4	4 (100.0)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 52	Tezepelumab	4	4 (100.0)	NE		NE		
		Placebo	7	5 (71.4)					

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline FENO (cat. N)				N<10 any level					NE

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline FENO (cat. Q)									0.792
Q1: < 16 ppb	Week 2	Tezepelumab	30	28 (93.3)	0.10 (0.05)	(0.00, 0.20)	0.11 (0.07)	(-0.03, 0.26)	0.117
		Placebo	26	21 (80.8)	-0.01 (0.05)	(-0.12, 0.09)			
	Week 4	Tezepelumab	30	30 (100.0)	0.11 (0.07)	(-0.03, 0.25)	0.01 (0.10)	(-0.20, 0.21)	0.947
		Placebo	26	25 (96.2)	0.11 (0.07)	(-0.04, 0.26)			
	Week 8	Tezepelumab	30	29 (96.7)	0.13 (0.06)	(0.02, 0.25)	0.05 (0.08)	(-0.12, 0.21)	0.581
		Placebo	26	25 (96.2)	0.09 (0.06)	(-0.03, 0.21)			
	Week 12	Tezepelumab	30	29 (96.7)	0.09 (0.06)	(-0.02, 0.21)	-0.03 (0.09)	(-0.20, 0.14)	0.754
		Placebo	26	25 (96.2)	0.12 (0.06)	(-0.01, 0.25)			
	Week 16	Tezepelumab	30	29 (96.7)	0.20 (0.06)	(0.07, 0.32)	0.12 (0.09)	(-0.06, 0.31)	0.191
		Placebo	26	25 (96.2)	0.07 (0.07)	(-0.07, 0.21)			
	Week 24	Tezepelumab	30	30 (100.0)	0.07 (0.06)	(-0.05, 0.19)	-0.02 (0.09)	(-0.19, 0.16)	0.853
		Placebo	26	22 (84.6)	0.09 (0.07)	(-0.05, 0.22)			
	Week 36	Tezepelumab	30	29 (96.7)	0.09 (0.06)	(-0.02, 0.21)	-0.06 (0.08)	(-0.22, 0.11)	0.501
		Placebo	26	23 (88.5)	0.15 (0.06)	(0.03, 0.27)			
	Week 52	Tezepelumab	30	27 (90.0)	0.07 (0.06)	(-0.05, 0.18)	0.00 (0.08)	(-0.17, 0.17)	0.968
		Placebo	26	22 (84.6)	0.06 (0.06)	(-0.06, 0.19)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Q2: 16 - < 30 ppb	Week 2	Tezepelumab	24	24 (100.0)	-0.01 (0.04)	(-0.09, 0.08)	-0.02 (0.07)	(-0.16, 0.12)	0.808
		Placebo	13	13 (100.0)	0.01 (0.06)	(-0.10, 0.12)			
	Week 4	Tezepelumab	24	24 (100.0)	-0.01 (0.05)	(-0.11, 0.10)	-0.00 (0.08)	(-0.17, 0.17)	0.988
		Placebo	13	13 (100.0)	-0.01 (0.07)	(-0.14, 0.13)			
	Week 8	Tezepelumab	24	23 (95.8)	0.01 (0.06)	(-0.11, 0.13)	-0.01 (0.10)	(-0.22, 0.19)	0.887
		Placebo	13	13 (100.0)	0.02 (0.08)	(-0.14, 0.19)			
	Week 12	Tezepelumab	24	24 (100.0)	0.03 (0.05)	(-0.07, 0.13)	0.06 (0.08)	(-0.11, 0.23)	0.459
		Placebo	13	13 (100.0)	-0.03 (0.07)	(-0.17, 0.10)			
	Week 16	Tezepelumab	24	24 (100.0)	-0.01 (0.05)	(-0.12, 0.10)	0.05 (0.09)	(-0.14, 0.23)	0.611
		Placebo	13	13 (100.0)	-0.05 (0.07)	(-0.20, 0.10)			
	Week 24	Tezepelumab	24	23 (95.8)	0.06 (0.05)	(-0.04, 0.17)	0.15 (0.09)	(-0.03, 0.33)	0.092
		Placebo	13	13 (100.0)	-0.09 (0.07)	(-0.23, 0.05)			
	Week 36	Tezepelumab	24	23 (95.8)	-0.01 (0.06)	(-0.13, 0.10)	0.02 (0.10)	(-0.18, 0.22)	0.815
		Placebo	13	11 (84.6)	-0.04 (0.08)	(-0.20, 0.13)			
	Week 52	Tezepelumab	24	23 (95.8)	-0.01 (0.06)	(-0.13, 0.12)	-0.03 (0.10)	(-0.23, 0.18)	0.795
		Placebo	13	12 (92.3)	0.02 (0.08)	(-0.15, 0.19)			

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Total serum IgE (cat. N)				N<10 any level					NE

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022

Table NT2FAC_ABSCN: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTB - adult

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Nasal polyps last 2 years				N<10 any level					NE

Note: DITTB - adult = Dossier Biomarker Intent-to-Treat - adult.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 01JUN2022